PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	O'Donovan, SM; Hourihane, JO; Murray, DM; Kenny, LC; Khashan, AS; Chaoimh, CN; Irvine, AD; Kiely, M				O'Donovan, Sinead M.; Hourihane, Jonathan O'B.; Murray, Deirdre M.; Kenny, Louise C.; Khashan, Ali S.; Chaoimh, Carol Ni; Irvine, Alan D.; Kiely, Mairead			Neonatal adiposity increases the risk of atopic dermatitis during the first year of life	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; eczema; infant; body composition; vitamin D; infant feeding	25-HYDROXYVITAMIN D LEVELS; VITAMIN-D SUPPLEMENTATION; FOOD ALLERGY DEVELOPMENT; BODY-MASS INDEX; PROSPECTIVE COHORT; PRIMARY PREVENTION; BIRTH COHORT; RANDOMIZED-TRIAL; CHILDREN; DISEASE	Background: Early nutrition and adiposity have been linked to atopic dermatitis (AD) development. Objective: We sought to describe risk factors for AD in the first year of life in infants participating in the Cork BASELINE birth cohort study (n = 1537). Methods: Prospective data on early-life events, infant feeding, and nutritional and environmental exposures were collected at 15 weeks' gestation, birth, and 2, 6, and 12 months of age. Body composition was assessed by using air displacement plethysmography at day 2 and 2 months. The primary outcome, persistent AD, was determined if the UK Working Party Diagnostic Criteria were satisfied at both 6 and 12 months. Results: At 6 and 12 months, the point prevalence of AD was 14.2% (99% CI, 10.5% to 17.8%) and 13.7% (99% CI, 10.3% to 17.6%), respectively; 7.5% (99% CI, 5.0% to 9.9%) of infants had AD at both 6 and 12 months of age. At hospital discharge, 35% of infants were exclusively breast-fed, decreasing to 14% by 2 months. Complementary feeding was commenced at a median of 19 weeks (interquartile range, 17-22 weeks; 19% at <17 weeks and 6% at >= 26 weeks). Median fat mass at day 2 was 0.35 kg (interquartile range, 0.25-0.48 kg). A parental history of atopic disease was self-reported by 43% of mothers and 34% of fathers. Risk factors for AD at 6 and 12 months were maternal atopy (adjusted odds ratio, 2.99; 99% CI, 1.35-6.59; P = .0004) and fat mass of the 80th percentile or greater at day 2 (adjusted odds ratio, 2.31; 99% CI, 1.02-2.25; P = .009). Conclusion: This is the first report of neonatal adiposity as a predictor of AD at 6 and 12 months of age in a well-characterized atopic disease-specific birth cohort.	[O'Donovan, Sinead M.; Chaoimh, Carol Ni; Kiely, Mairead] Natl Univ Ireland Univ Coll Cork, Sch Food & Nutr Sci, Vitamin Res Grp D, Cork, Ireland; [Hourihane, Jonathan O'B.; Murray, Deirdre M.] Natl Univ Ireland Univ Coll Cork, Dept Paediat & Child Hlth, Cork, Ireland; [Murray, Deirdre M.; Kenny, Louise C.; Khashan, Ali S.; Kiely, Mairead] Natl Univ Ireland Univ Coll Cork, Irish Ctr Fetal & Neonatal Translat Res, Cork, Ireland; [Kenny, Louise C.] Natl Univ Ireland Univ Coll Cork, Dept Obstet & Gynaecol, Cork, Ireland; [Khashan, Ali S.] Natl Univ Ireland Univ Coll Cork, Dept Epidemiol & Publ Hlth, Cork, Ireland; [Irvine, Alan D.] Trinity Coll Dublin, Dept Clin Med, Dublin, Ireland; [Irvine, Alan D.] Our Ladys Childrens Hosp, Dept Paediat Dermatol, Dublin, Ireland; [Irvine, Alan D.] Natl Childrens Res Ctr, Dublin, Ireland	University College Cork; University College Cork; University College Cork; University College Cork; University College Cork; Trinity College Dublin; National Children's Research Centre (NCRC); Our Ladys Children Hospital Crumlin; National Children's Research Centre (NCRC); Trinity College Dublin	Kiely, M (corresponding author), Natl Univ Ireland Univ Coll Cork, Food & Nutr Sci, Vitamin Res Grp D, Sch Food & Nutr Sci, Cork, Ireland.	m.kiely@ucc.ie	Kenny, Louise C/G-1112-2011; Irvine, Alan D/A-3982-2008; Kenny, Louise/X-6329-2019; Kiely, Mairead E/ABA-3235-2020; Kiely, Mairead/I-8269-2019	Kenny, Louise C/0000-0002-9011-759X; Irvine, Alan D/0000-0002-9048-2044; Kenny, Louise/0000-0002-9011-759X; Kiely, Mairead/0000-0003-0973-808X	National Children's Research Centre (NCRC); UK Food Standards Agency (FSA) [T07060]; Health Research Board of Ireland [CSA 02/2007]; INFANT Research Centre [12/RC/2272]; European Commission under the Seventh Framework (ODIN) [GA 613977]; European Commission under the Seventh Framework (iFAAM) [GA 312147]	National Children's Research Centre (NCRC); UK Food Standards Agency (FSA); Health Research Board of Ireland; INFANT Research Centre(Science Foundation Ireland); European Commission under the Seventh Framework (ODIN); European Commission under the Seventh Framework (iFAAM)	The National Children's Research Centre (NCRC) is the primary funding source for the ongoing Cork Babies After SCOPE: Evaluating the Longitudinal Impact Using Neurological and Nutritional Endpoints (BASELINE) birth cohort. Additional support came from the UK Food Standards Agency (FSA) (grant no. T07060). The SCOPE Ireland Study was funded by the Health Research Board of Ireland (CSA 02/2007). L.C.K., M.K., and D.M.M. are PIs in the Science Foundation Ireland funded INFANT Research Centre (grant no. 12/RC/2272). S.M.O'D. is supported by a grant to M.K. from the European Commission under the Seventh Framework (ODIN, GA 613977 Food-based Solutions for Optimal Vitamin D Nutrition and Health through the Life-cycle) and by a grant to M.K. and J.O'B.H. from the European Commission under the Seventh Framework (iFAAM; GA 312147 Integrated Approaches to Food Allergen and Allergy Risk Management).	Allan K, 2010, CLIN EXP ALLERGY, V40, P370, DOI 10.1111/j.1365-2222.2009.03413.x; Allen KJ, 2013, J ALLERGY CLIN IMMUN, V131, P1109, DOI 10.1016/j.jaci.2013.01.017; Back O, 2009, ACTA DERM-VENEREOL, V89, P28, DOI 10.2340/00015555-0541; Baiz N, 2014, J ALLERGY CLIN IMMUN, V133, P147, DOI 10.1016/j.jaci.2013.05.017; Barnes KC, 2010, J ALLERGY CLIN IMMUN, V125, P16, DOI 10.1016/j.jaci.2009.11.008; Benn CS, 2004, AM J EPIDEMIOL, V160, P217, DOI 10.1093/aje/kwh208; Bergmann RL, 2002, CLIN EXP ALLERGY, V32, P205, DOI 10.1046/j.1365-2222.2002.01274.x; Calder PC, 2013, CLIN EXP ALLERGY, V43, P700, DOI 10.1111/cea.12126; Camargo CA, 2014, J ALLERGY CLIN IMMUN, V134, P831, DOI 10.1016/j.jaci.2014.08.002; Camargo CA, 2011, PEDIATRICS, V127, pE180, DOI 10.1542/peds.2010-0442; Cashman KD, 2013, AM J CLIN NUTR, V97, P1235, DOI 10.3945/ajcn.112.057182; Central Statistics Office, CENS 2006 ED QUAL; Chappell LC, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f6398; Chen YC, 2013, OBES REV, V14, P222, DOI 10.1111/j.1467-789X.2012.01055.x; COLE TJ, 1992, STAT MED, V11, P1305, DOI 10.1002/sim.4780111005; Crider KS, 2013, AM J CLIN NUTR, V98, P1272, DOI 10.3945/ajcn.113.065623; Crume TL, 2011, J PEDIATR-US, V158, P941, DOI 10.1016/j.jpeds.2010.12.007; de Silva D, 2014, ALLERGY, V69, P581, DOI 10.1111/all.12334; Deckers IA, 2012, PLOS ONE, V7; Ellis KJ, 2007, AM J CLIN NUTR, V85, P90, DOI 10.1093/ajcn/85.1.90; Fleischer DM, 2013, J ALLER CL IMM-PRACT, V1, P29, DOI 10.1016/j.jaip.2012.09.003; Forno E, 2014, J ALLERGY CLIN IMMUN, V133, P1308, DOI 10.1016/j.jaci.2013.09.041; Gale CR, 2008, EUR J CLIN NUTR, V62, P68, DOI 10.1038/sj.ejcn.1602680; Grimshaw KEC, 2014, J ALLERGY CLIN IMMUN, V133, P511, DOI 10.1016/j.jaci.2013.05.035; Groom KM, 2009, OBSTET GYNECOL, V113, P332, DOI 10.1097/AOG.0b013e318195b223; Grulee CG, 1936, J PEDIATR-US, V9, P223, DOI 10.1016/S0022-3476(36)80058-4; Hypponen E, 2004, ANN NY ACAD SCI, V1037, P84, DOI 10.1196/annals.1337.013; Institute of Medicine, 2011, DIETARY REFERENCE IN; Irvine AD, 2011, NEW ENGL J MED, V365, P1315, DOI 10.1056/NEJMra1011040; Jones AP, 2012, PEDIATRICS, V130, pE1128, DOI 10.1542/peds.2012-1172; Keil T, 2010, ALLERGY, V65, P482, DOI 10.1111/j.1398-9995.2009.02171.x; Kramer MS, 2001, JAMA-J AM MED ASSOC, V285, P413, DOI 10.1001/jama.285.4.413; Kremmyda LS, 2011, CLIN REV ALLERG IMMU, V41, P36, DOI 10.1007/s12016-009-8186-2; Kusunoki T, 2008, PEDIAT ALLERG IMM-UK, V19, P527, DOI 10.1111/j.1399-3038.2007.00686.x; Liu PC, 2013, J ADV NURS, V69, P1446, DOI 10.1111/jan.12129; Lowe AJ, 2011, J ALLERGY CLIN IMMUN, V128, P360, DOI 10.1016/j.jaci.2010.05.006; Ma GS, 2004, AM J CLIN NUTR, V79, P653; Machura E, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/760691; McAleer MA, 2013, J ALLERGY CLIN IMMUN, V131, P280, DOI 10.1016/j.jaci.2012.12.668; Miyake Y, 2010, EUR RESPIR J, V35, P1228, DOI 10.1183/09031936.00100609; Modi N, 2011, PEDIATR RES, V70, P287, DOI 10.1203/PDR.0b013e318225f9b1; Suarez-Varela MM, 2010, J INVEST ALLERG CLIN, V20, P469; Muraro A, 2014, ALLERGY, V69, P590, DOI 10.1111/all.12398; Murray CS, 2011, CLIN EXP ALLERGY, V41, P78, DOI 10.1111/j.1365-2222.2010.03598.x; Nagel G, 2009, PEDIAT ALLERG IMM-UK, V20, P81, DOI 10.1111/j.1399-3038.2008.00740.x; North RA, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d1875; Nurmatov U, 2011, J ALLERGY CLIN IMMUN, V127, P724, DOI 10.1016/j.jaci.2010.11.001; O'Donovan S. M., 2014, INT J EPIDEMIOL, DOI 10.1093/ije/dyu157; O'Donovan SM, 2015, PUBLIC HEALTH NUTR, P1; Odhiambo JA, 2009, J ALLERGY CLIN IMMUN, V124, P1251, DOI 10.1016/j.jaci.2009.10.009; Page KA, 2014, J PEDIATR-US, V164, P807, DOI 10.1016/j.jpeds.2013.11.063; Peroni DG, 2011, BRIT J DERMATOL, V164, P1078, DOI 10.1111/j.1365-2133.2010.10147.x; Prescott Susan, 2011, Ann Nutr Metab, V59 Suppl 1, P28, DOI 10.1159/000334150; Rothers J, 2011, J ALLERGY CLIN IMMUN, V128, P1093, DOI 10.1016/j.jaci.2011.07.015; SAARINEN UM, 1995, LANCET, V346, P1065, DOI 10.1016/S0140-6736(95)91742-X; Sempos CT, 2012, SCAND J CLIN LAB INV, V72, P32, DOI 10.3109/00365513.2012.681935; Silverberg JI, 2014, DERMATITIS, V25, P172, DOI 10.1097/DER.0000000000000047; Silverberg JI, 2011, J ALLERGY CLIN IMMUN, V127, P1180, DOI 10.1016/j.jaci.2011.01.063; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Tarini BA, 2006, ARCH PEDIAT ADOL MED, V160, P502, DOI 10.1001/archpedi.160.5.502; Vahavihu K, 2010, BRIT J DERMATOL, V163, P321, DOI 10.1111/j.1365-2133.2010.09767.x; von Berg A, 2013, J ALLERGY CLIN IMMUN, V131, P1565, DOI 10.1016/j.jaci.2013.01.006; Weisse K, 2013, ALLERGY, V68, P220, DOI 10.1111/all.12081; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P383, DOI 10.1111/j.1365-2133.1994.tb08530.x; World Health Organization, 2006, WHO CHILD GROWTH STA, P312; Yang YW, 2009, BRIT J DERMATOL, V161, P373, DOI 10.1111/j.1365-2133.2009.09049.x; Yao TC, 2011, J ASTHMA, V48, P503, DOI 10.3109/02770903.2011.576743	67	24	25	2	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2016	137	1					108	117		10.1016/j.jaci.2015.05.035	http://dx.doi.org/10.1016/j.jaci.2015.05.035			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DA3UK	26194543				2022-12-18	WOS:000367724300001
J	Rochereau, N; Pavot, V; Verrier, B; Jospin, F; Ensinas, A; Genin, C; Corthesy, B; Paul, S				Rochereau, Nicolas; Pavot, Vincent; Verrier, Bernard; Jospin, Fabienne; Ensinas, Agathe; Genin, Christian; Corthesy, Blaise; Paul, Stephane			Delivery of antigen to nasal-associated lymphoid tissue microfold cells through secretory IgA targeting local dendritic cells confers protective immunity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Nasal vaccine strategy; secretory IgA; reverse transcytosis; microfold cells; nasal-associated lymphoid tissue; protection	MUCOSAL; IMMUNIZATION; VACCINATION; RESPONSES; COMPONENT	Background: Transmission of mucosal pathogens relies on their ability to bind to the surfaces of epithelial cells, to cross this thin barrier, and to gain access to target cells and tissues, leading to systemic infection. This implies that pathogen-specific immunity at mucosal sites is critical for the control of infectious agents using these routes to enter the body. Although mucosal delivery would ensure the best onset of protective immunity, most of the candidate vaccines are administered through the parenteral route. Objective: The present study evaluates the feasibility of delivering the chemically bound p24gag (referred to as p24 in the text) HIV antigen through secretory IgA (SIgA) in nasal mucosae in mice. Results: We show that SIgA interacts specifically with mucosal microfold cells present in the nasal-associated lymphoid tissue. p24-SIgA complexes are quickly taken up in the nasal cavity and selectively engulfed by mucosal dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin-positive dendritic cells. Nasal immunization with p24-SIgA elicits both a strong humoral and cellular immune response against p24 at the systemic and mucosal levels. This ensures effective protection against intranasal challenge with recombinant vaccinia virus encoding p24. Conclusion: This study represents the first example that underscores the remarkable potential of SIgA to serve as a carrier for a protein antigen in a mucosal vaccine approach targeting the nasal environment.	[Rochereau, Nicolas; Jospin, Fabienne; Ensinas, Agathe; Genin, Christian; Paul, Stephane] Univ Lyon, GIMAP EA3064, CIC Vaccinol 1408, St Etienne, France; [Pavot, Vincent; Verrier, Bernard] Univ Lyon, Inst Biol & Chim Prot LBTI, UMR CNRS 5305, Lyon, France; [Corthesy, Blaise] CHU Vaudois, R&D Lab, Div Immunol & Allergy, Ctr Labs Epalinges, Lausanne, Switzerland	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Paul, S (corresponding author), GIMAP, Fac Med Jacques Lisfranc, 15 Rue Ambroise Pare, F-42023 St Etienne, France.	stephane.paul@chu-st-etienne.fr	; verrier, bernard/J-4094-2017	Pavot, Vincent/0000-0002-7362-643X; paul, stephane/0000-0002-8830-4273; , rochereau/0000-0002-6522-895X; verrier, bernard/0000-0002-8478-7095	Region Rhone-Alpes; ANRS (France); ANRS [2013_1_14255]; Sidaction [AI19-3-01535]; Swiss Science Research Foundation [3100-156806]	Region Rhone-Alpes(Region Auvergne-Rhone-Alpes); ANRS (France)(ANRS); ANRS(ANRSFrench National Research Agency (ANR)); Sidaction; Swiss Science Research Foundation(Swiss National Science Foundation (SNSF))	N.R. was supported by postdoctoral fellowships from Region Rhone-Alpes and the ANRS (France). This work was financed by research grants from the ANRS (2013_1_14255) and Sidaction (AI19-3-01535). We would like to thank the staff of the "Unite Hospitalo-Universitaire d'experimentation animale'' technical platforms of IFR143 for help in sample analysis. B.C.'s laboratory is supported by grant no. 3100-156806 from the Swiss Science Research Foundation.	Alpar HO, 2001, ADV DRUG DELIVER REV, V51, P173, DOI 10.1016/S0169-409X(01)00166-1; Anonymous, 2009, Morbidity and Mortality Weekly Report, V58, P1100; Bomsel M, 2011, IMMUNITY, V34, P269, DOI 10.1016/j.immuni.2011.01.015; Brandtzaeg P, 2011, AM J RESP CRIT CARE, V183, P1595, DOI 10.1164/rccm.201011-1783OC; Brandtzaeg P, 2010, IMMUNOL INVEST, V39, P303, DOI 10.3109/08820131003680369; Carvalho LH, 2001, J IMMUNOL METHODS, V252, P207, DOI 10.1016/S0022-1759(01)00331-3; Childers NK, 2006, ORAL MICROBIOL IMMUN, V21, P309, DOI 10.1111/j.1399-302X.2006.00302.x; Chiu C, 2015, NAT IMMUNOL, V16, P18, DOI 10.1038/ni.3056; Cisney ED, 2012, JOVE-J VIS EXP, DOI 10.3791/3960; Czerkinsky C, 2012, CURR TOP MICROBIOL, V354, P1, DOI 10.1007/82_2010_112; Duc M, 2010, J BIOL CHEM, V285, P953, DOI 10.1074/jbc.M109.059220; Favre LI, 2003, J CHROMATOGR B, V786, P143, DOI 10.1016/S1570-0232(02)00723-7; Fiore AE, 2009, CURR TOP MICROBIOL, V333, P43, DOI 10.1007/978-3-540-92165-3_3; Fujimura Y, 2000, VIRCHOWS ARCH, V436, P560, DOI 10.1007/s004289900177; Haynes BF, 2014, SCIENCE, V344, P588, DOI 10.1126/science.1254990; Holmgren J, 2005, NAT MED, V11, pS45, DOI 10.1038/nm1213; Holmgren J, 2003, VACCINE, V21, pS89, DOI 10.1016/S0264-410X(03)00206-8; Jiang YH, 2014, PHARM RES-DORDR, V31, P2748, DOI 10.1007/s11095-014-1372-9; Kim SH, 2014, EXP MOL MED, V46, DOI 10.1038/emm.2013.165; Kiyono H, 2004, NAT REV IMMUNOL, V4, P699, DOI 10.1038/nri1439; Lefrancois L, 2001, Curr Protoc Immunol, VChapter 3, DOI 10.1002/0471142735.im0319s17; Lu L, 2011, J VIROL, V85, P10542, DOI 10.1128/JVI.05441-11; Lu XH, 2002, VACCINE, V20, P1019, DOI 10.1016/S0264-410X(01)00452-2; Mantis NJ, 2002, J IMMUNOL, V169, P1844, DOI 10.4049/jimmunol.169.4.1844; Mestecky J, 2010, J REPROD IMMUNOL, V85, P81, DOI 10.1016/j.jri.2010.02.003; Mohan T, 2014, IMMUNOL RES, V58, P139, DOI 10.1007/s12026-013-8428-5; Neutra MR, 2006, NAT REV IMMUNOL, V6, P148, DOI 10.1038/nri1777; Oleszycka E, 2014, CURR OPIN IMMUNOL, V28, P1, DOI 10.1016/j.coi.2013.12.007; Pavot V, 2013, J CONTROL RELEASE, V167, P60, DOI 10.1016/j.jconrel.2013.01.015; Pavot V, 2012, VACCINE, V30, P142, DOI 10.1016/j.vaccine.2011.11.003; Phalipon A, 2002, IMMUNITY, V17, P107, DOI 10.1016/S1074-7613(02)00341-2; Rey J, 2004, J IMMUNOL, V172, P3026, DOI 10.4049/jimmunol.172.5.3026; RINDISBACHER L, 1995, J BIOL CHEM, V270, P14220, DOI 10.1074/jbc.270.23.14220; Rochereau N, 2015, EUR J IMMUNOL, V45, P773, DOI 10.1002/eji.201444816; Rochereau N, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001658; Yamamoto M, 2012, CURR TOP MICROBIOL, V354, P39, DOI 10.1007/82_2011_134; Zhu JF, 2010, ANNU REV IMMUNOL, V28, P445, DOI 10.1146/annurev-immunol-030409-101212	37	24	25	2	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2016	137	1					214	+		10.1016/j.jaci.2015.07.042	http://dx.doi.org/10.1016/j.jaci.2015.07.042			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DA3UK	26414879				2022-12-18	WOS:000367724300013
J	Kubo, T; Wawrzyniak, P; Morita, H; Sugita, K; Wanke, K; Kast, JI; Altunbulakli, C; Ruckert, B; Jakiela, B; Sanak, M; Akdis, M; Akdis, CA				Kubo, Terufumi; Wawrzyniak, Paulina; Morita, Hideaki; Sugita, Kazunari; Wanke, Kerstin; Kast, Jeannette I.; Altunbulakli, Can; Rueckert, Beate; Jakiela, Bogdan; Sanak, Marek; Akdis, Muebeccel; Akdis, Cezmi A.			CpG-DNA enhances the tight junction integrity of the bronchial epithelial cell barrier	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							HYPERIMMUNOGLOBULIN-E SYNDROME; INFECTION JOBS SYNDROME; DISSEMINATED COCCIDIOIDOMYCOSIS; SIGNAL TRANSDUCER; CROHNS-DISEASE; PATIENT; HISTOPLASMOSIS; ASTHMA; CRYPTOCOCCOSIS; TRANSCRIPTION		[Kubo, Terufumi; Wawrzyniak, Paulina; Morita, Hideaki; Sugita, Kazunari; Wanke, Kerstin; Kast, Jeannette I.; Altunbulakli, Can; Rueckert, Beate; Akdis, Muebeccel; Akdis, Cezmi A.] Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, Davos, Switzerland; [Kubo, Terufumi; Wawrzyniak, Paulina; Morita, Hideaki; Sugita, Kazunari; Wanke, Kerstin; Kast, Jeannette I.; Altunbulakli, Can; Rueckert, Beate; Akdis, Muebeccel; Akdis, Cezmi A.] Christine Kuhne Ctr Allergy Res & Educ, Davos, Switzerland; [Jakiela, Bogdan; Sanak, Marek] Jagiellonian Univ, Dept Internal Med, Krakow, Poland	Swiss Institute of Allergy & Asthma Research; University of Zurich; Jagiellonian University	Kubo, T (corresponding author), Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, Davos, Switzerland.	akdisac@siaf.uzh.ch	Jakiela, Bogdan/CAA-1861-2022; Wawrzyniak, Paulina/AAD-7265-2020; Morita, Hideaki/S-2214-2016; Akdis, Cezmi/AAV-4844-2020; Wawrzyniak, Paulina/AAG-3548-2019; Morita, Hideaki/ADL-2008-2022; Sanak, Marek/AAV-1628-2021; Wawrzyniak, Paulina/HCG-8924-2022	Jakiela, Bogdan/0000-0003-0444-981X; Wawrzyniak, Paulina/0000-0001-9641-2103; Morita, Hideaki/0000-0003-0928-8322; Akdis, Cezmi/0000-0001-8020-019X; Sanak, Marek/0000-0001-7635-8103; Altunbulakli, Can/0000-0003-2264-7377				Akdis M, 2014, J ALLERGY CLIN IMMUN, V133, P621, DOI 10.1016/j.jaci.2013.12.1088; ALBERTIFLOR JJ, 1986, DIGESTION, V33, P176, DOI 10.1159/000199290; Beeh KM, 2013, J ALLERGY CLIN IMMUN, V131, P866, DOI 10.1016/j.jaci.2012.12.1561; CAPPELL MS, 1991, AM J GASTROENTEROL, V86, P119; De Benedetto Anna, 2011, J Allergy Clin Immunol, V127, P773, DOI 10.1016/j.jaci.2010.10.018; De Benedetto A, 2011, J ALLERGY CLIN IMMUN, V127, P773, DOI 10.1016/j.jaci.2010.10.018; Desai K, 1996, J ALLERGY CLIN IMMUN, V98, P1123, DOI 10.1016/S0091-6749(96)80202-8; Garn H, 2013, J ALLERGY CLIN IMMUN, V131, P1465, DOI 10.1016/j.jaci.2013.04.031; Garty BZ, 1995, PEDIAT ALLERG IMM-UK, V6, P175, DOI 10.1111/j.1399-3038.1995.tb00279.x; Georas SN, 2014, J ALLERGY CLIN IMMUN, V134, P509, DOI 10.1016/j.jaci.2014.05.049; Hardyman MA, 2013, J ALLERGY CLIN IMMUN, V132, P665, DOI 10.1016/j.jaci.2013.03.005; Huang YJ, 2015, J ALLERGY CLIN IMMUN, V135, P25, DOI 10.1016/j.jaci.2014.11.011; HUTTO JO, 1988, GASTROENTEROLOGY, V94, P808, DOI 10.1016/0016-5085(88)90257-0; JACOBS DH, 1984, GASTROENTEROLOGY, V87, P201; Kast JI, 2012, J ALLERGY CLIN IMMUN, V130, P544, DOI 10.1016/j.jaci.2012.04.044; Powers AE, 2009, PEDIATR INFECT DIS J, V28, P664, DOI 10.1097/INF.0b013e31819866ec; Rana C, 2013, INDIAN J GASTROENTER, V32, P64, DOI 10.1007/s12664-012-0275-0; Rezaee F, 2011, J ALLERGY CLIN IMMUN, V128, P1216, DOI 10.1016/j.jaci.2011.08.035; Robinson Wilson S, 2011, Clin Mol Allergy, V9, P14, DOI 10.1186/1476-7961-9-14; Sampaio EP, 2013, J ALLERGY CLIN IMMUN, V131, P1624, DOI 10.1016/j.jaci.2013.01.052; Soyka MB, 2012, J ALLERGY CLIN IMMUN, V130, P1087, DOI 10.1016/j.jaci.2012.05.052; Stanga SD, 2008, CLIN PEDIATR, V47, P959, DOI 10.1177/0009922808319788; Steiner SJ, 2009, PEDIATR INFECT DIS J, V28, P744, DOI 10.1097/INF.0b013e31819b65e0; van de Veen W, 2013, J ALLERGY CLIN IMMUN, V131, P1204, DOI 10.1016/j.jaci.2013.01.014; Vinh DC, 2011, CLIN INFECT DIS, V52, pE99, DOI 10.1093/cid/ciq215; Vinh DC, 2009, CLIN INFECT DIS, V49, pE62, DOI 10.1086/605532	26	24	25	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2015	136	5					1413	1416		10.1016/j.jaci.2015.05.006	http://dx.doi.org/10.1016/j.jaci.2015.05.006			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CW1YE	26100085	Green Submitted, Bronze			2022-12-18	WOS:000364787200037
J	Hamilton, RG				Hamilton, Robert G.			Clinical laboratories worldwide need to report IgE antibody results on clinical specimens as analytical results and not use differential positive thresholds	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									Johns Hopkins Univ, Sch Med, Dept Pathol & Med, Div Allergy & Clin Immunol, Baltimore, MD 21218 USA	Johns Hopkins University	Hamilton, RG (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pathol & Med, Div Allergy & Clin Immunol, Baltimore, MD 21218 USA.	rhamilt2@jhmi.edu						Diagnostic Immunology Resource Committee, 2014, SE B 2014 DIAGN ALL; Hamilton RG, 2015, QUALITY ASSURANCE CL; Linden CC, 2011, ANN ALLERG ASTHMA IM, V106, P153, DOI 10.1016/j.anai.2010.11.004; Scala G, 2015, J ALLERGY CLIN IMMUN, V135, P291, DOI 10.1016/j.jaci.2014.10.008; Stringari G, 2014, J ALLERGY CLIN IMMUN, V134, P75, DOI 10.1016/j.jaci.2014.01.042; Tripodi S, 2015, J ALLERGY CLIN IMMUN, V135, P292, DOI 10.1016/j.jaci.2014.10.009	6	24	24	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2015	136	3					811	+		10.1016/j.jaci.2015.03.002	http://dx.doi.org/10.1016/j.jaci.2015.03.002			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CQ9EA	25863980				2022-12-18	WOS:000360913300038
J	Kim, KW; Myers, RA; Lee, JH; Igartua, C; Lee, KE; Kim, YH; Kim, EJ; Yoon, D; Lee, JS; Hirota, T; Tamari, M; Takahashi, A; Kubo, M; Choi, JM; Kim, KE; Nicolae, DL; Ober, C; Sohn, MH				Kim, Kyung Won; Myers, Rachel A.; Lee, Ji Hyun; Igartua, Catherine; Lee, Kyung Eun; Kim, Yoon Hee; Kim, Eun-Jin; Yoon, Dankyu; Lee, Joo-Shil; Hirota, Tomomitsu; Tamari, Mayumi; Takahashi, Atsushi; Kubo, Michiaki; Choi, Je-Min; Kim, Kyu-Earn; Nicolae, Dan L.; Ober, Carole; Sohn, Myung Hyun			Genome-wide association study of recalcitrant atopic dermatitis in Korean children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Genome-wide association study; atopic dermatitis; allergic sensitization; IgE; severity; children	SUSCEPTIBILITY LOCI; GENE-EXPRESSION; ASTHMA; METAANALYSIS; FILAGGRIN; SENSITIZATION; DISEASES; ECZEMA; RISK; PROTOCADHERIN-1	Background: Atopic dermatitis (AD) is a heterogeneous chronic inflammatory skin disease. Most AD during infancy resolves during childhood, but moderate-to-severe AD with allergic sensitization is more likely to persist into adulthood and more often occurs with other allergic diseases. Objective: We sought to find susceptibility loci by performing the first genome-wide association study (GWAS) of AD in Korean children with recalcitrant AD, which was defined as moderate-to-severe AD with allergic sensitization. Methods: Our study included 246 children with recalcitrant AD and 551 adult control subjects with a negative history of both allergic disease and allergic sensitization. DNA from these subjects was genotyped; sets of common single nucleotide polymorphisms (SNPs) were imputed and used in the GWAS after quality control checks. Results: SNPs at a region on 13q21.31 were associated with recalcitrant AD at a genome-wide threshold of significance (P < 2.0 x 10(-8)). These associated SNPs are more than 1 Mb from the closest gene, protocadherin (PCDH)(9). SNPs at 4 additional loci had P values of less than 1 x 10(-6), including SNPs at or near the neuroblastoma amplified sequence (NBAS; 2p24.3), thymus-expressed molecule involved in selection (THEMIS; 6q22.33), GATA3 (10p14), and S-phase cyclin A-associated protein in the ER (SCAPER; 15q24.3) genes. Further analysis of total serum IgE levels suggested 13q21.31 might be primarily an IgE locus, and analyses of published data demonstrated that SNPs at the 15q24.3 region are expression quantitative trait loci for 2 nearby genes, ISL2 and proline-serine-threonine phosphatase interacting protein 1 (PSTPIP1), in immune cells. Conclusion: Our GWAS of recalcitrant AD identified new susceptibility regions containing genes involved in epithelial cell function and immune dysregulation, 2 key features of AD, and potentially extend our understanding of their role in pathogenesis.	[Kim, Kyung Won; Lee, Kyung Eun; Kim, Yoon Hee; Kim, Kyu-Earn; Sohn, Myung Hyun] Yonsei Univ, Coll Med, Dept Pediat, Severance Hosp,Inst Allergy,Brain Korea PLUS Proj, Seoul 120752, South Korea; [Kim, Kyung Won; Myers, Rachel A.; Igartua, Catherine; Nicolae, Dan L.; Ober, Carole] Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA; [Nicolae, Dan L.] Univ Chicago, Dept Med & Stat, Chicago, IL 60637 USA; [Lee, Ji Hyun] Yonsei Univ, Dept Oral Biol, Coll Dent, Seoul 120752, South Korea; [Kim, Eun-Jin; Yoon, Dankyu; Lee, Joo-Shil] Korea Natl Inst Hlth, Div Allergy & Chron Resp Dis, Ctr Biomed Sci, Osong, South Korea; [Hirota, Tomomitsu; Tamari, Mayumi] RIKEN, Lab Resp & Allerg Dis, Yokohama, Kanagawa, Japan; [Kubo, Michiaki] RIKEN, Lab Genotyping Dev, Ctr Integrat Med Sci, Yokohama, Kanagawa, Japan; [Takahashi, Atsushi] RIKEN, Lab Stat Anal, Ctr Integrat Med Sci, Tokyo, Japan; [Choi, Je-Min] Hanyang Univ, Dept Life Sci, Res Inst Nat Sci, Seoul 133791, South Korea	Yonsei University; Yonsei University Health System; University of Chicago; University of Chicago; Yonsei University; Yonsei University Health System; Korea Centers for Disease Control & Prevention (KCDC); Korea National Institute of Health (KNIH); Korea CDC Center for Biomedical Science; RIKEN; RIKEN; RIKEN; Hanyang University	Sohn, MH (corresponding author), Yonsei Univ, Coll Med, Dept Pediat, Inst Allergy, 50 Yonsei Ro, Seoul 120752, South Korea.	mhsohn@yuhs.ac	Kubo, Michiaki/N-7947-2015; rchnds, rchnds/D-7595-2016; Tamari, Mayumi/N-5378-2015	Kim, Kyung Won/0000-0003-4529-6135; Sohn, Myung Hyun/0000-0002-2478-487X; Choi, Je-Min/0000-0002-9482-710X; Nicolae, Dan/0000-0002-0918-4630; Ober, Carole/0000-0003-4626-9809; Kim, Yoon Hee/0000-0002-2149-8501	Korea Health Industry Development Institute (KHIDI) - Ministry of Health & Welfare, Republic of Korea [HI11C1404, HI14C0234, A092076]; National Research Foundation of Korea (NRF) grant - Korean Government (MSIP) [2007-0056092]; Korea Research Foundation Grant - Korean Government [KRF-2010-0025171]; National Institutes of Health [U19 AI095230, R01 HL085197]; Korean Genome Analysis Project [4845-301]; Korean Genome and Epidemiology Study [4851-302]; Korea Biobank Project [4851-307, KBP-2014-033]; Korea Center for Disease Control and Prevention, Republic of Korea; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL085197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI095230] Funding Source: NIH RePORTER	Korea Health Industry Development Institute (KHIDI) - Ministry of Health & Welfare, Republic of Korea; National Research Foundation of Korea (NRF) grant - Korean Government (MSIP); Korea Research Foundation Grant - Korean Government(National Research Foundation of KoreaKorean Government); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Korean Genome Analysis Project; Korean Genome and Epidemiology Study; Korea Biobank Project; Korea Center for Disease Control and Prevention, Republic of Korea; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) funded by the Ministry of Health & Welfare, Republic of Korea (grant no. HI11C1404, HI14C0234, and A092076), a National Research Foundation of Korea (NRF) grant funded by the Korean Government (MSIP; no. 2007-0056092), the Korea Research Foundation Grant funded by the Korean Government (KRF-2010-0025171), and National Institutes of Health grants U19 AI095230 and R01 HL085197 (to C.O.). This study included biospecimens and data from the Korean Genome Analysis Project (4845-301), the Korean Genome and Epidemiology Study (4851-302), and the Korea Biobank Project (4851-307, KBP-2014-033), which were supported by the Korea Center for Disease Control and Prevention, Republic of Korea.	Altshuler D, 2010, NATURE, V467, P1061, DOI 10.1038/nature09534; Barnes KC, 2010, J ALLERGY CLIN IMMUN, V125, P16, DOI 10.1016/j.jaci.2009.11.008; Bieber T, 2008, NEW ENGL J MED, V358, P1483, DOI 10.1056/NEJMra074081; Bonnelykke K, 2013, NAT GENET, V45, P902, DOI 10.1038/ng.2694; Chabod M, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002461; Ding J, 2010, AM J HUM GENET, V87, P779, DOI 10.1016/j.ajhg.2010.10.024; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; Eichenfield Lawrence F, 2003, J Am Acad Dermatol, V49, P1088, DOI 10.1016/S0190-9622(03)02539-8; Ellinghaus D, 2013, NAT GENET, V45, P808, DOI 10.1038/ng.2642; Esparza-Gordillo J, 2009, NAT GENET, V41, P596, DOI 10.1038/ng.347; Fairfax BP, 2014, SCIENCE, V343, P1118, DOI 10.1126/science.1246949; Fairfax BP, 2012, NAT GENET, V44, P502, DOI 10.1038/ng.2205; Ferreira MAR, 2011, LANCET, V378, P1006, DOI 10.1016/S0140-6736(11)60874-X; Fu G, 2014, TRENDS IMMUNOL, V35, P311, DOI 10.1016/j.it.2014.05.003; Garmhausen D, 2013, ALLERGY, V68, P498, DOI 10.1111/all.12112; Grundberg E, 2012, NAT GENET, V44, P1084, DOI 10.1038/ng.2394; Henderson J, 2008, J ALLERGY CLIN IMMUN, V121, P872, DOI 10.1016/j.jaci.2008.01.026; Hinds DA, 2013, NAT GENET, V45, P907, DOI 10.1038/ng.2686; Hirota T, 2012, NAT GENET, V44, P1222, DOI 10.1038/ng.2438; Hirota T, 2011, NAT GENET, V43, P893, DOI 10.1038/ng.887; Howie B, 2012, NAT GENET, V44, P955, DOI 10.1038/ng.2354; Hulpiau P, 2009, INT J BIOCHEM CELL B, V41, P349, DOI 10.1016/j.biocel.2008.09.027; Jostins L, 2012, NATURE, V491, P119, DOI 10.1038/nature11582; Kaneko S, 2007, J CANCER RES CLIN, V133, P185, DOI 10.1007/s00432-006-0156-y; Koning H, 2012, PEDIAT ALLERG IMM-UK, V23, P270, DOI 10.1111/j.1399-3038.2011.01201.x; Koppelman GH, 2009, AM J RESP CRIT CARE, V180, P929, DOI 10.1164/rccm.200810-1621OC; Levin AM, 2013, J ALLERGY CLIN IMMUN, V131, P1176, DOI 10.1016/j.jaci.2012.10.002; Lichtenstein P, 1997, ALLERGY, V52, P1079, DOI 10.1111/j.1398-9995.1997.tb00179.x; Lonsdale J, 2013, NAT GENET, V45, P580, DOI 10.1038/ng.2653; Maksimova N, 2010, J MED GENET, V47, P538, DOI 10.1136/jmg.2009.074815; McAleer MA, 2013, J ALLERGY CLIN IMMUN, V131, P280, DOI 10.1016/j.jaci.2012.12.668; Mortensen LJ, 2014, EUR RESPIR J, V43, P792, DOI 10.1183/09031936.00021613; Murphy A, 2010, HUM MOL GENET, V19, P4745, DOI 10.1093/hmg/ddq392; Nystad W, 2005, INT J EPIDEMIOL, V34, P1302, DOI 10.1093/ije/dyi061; Okada Y, 2014, NATURE, V506, P376, DOI 10.1038/nature12873; Padyukov L, 2011, ANN RHEUM DIS, V70, P259, DOI 10.1136/ard.2009.126821; Paternoster L, 2012, NAT GENET, V44, P187, DOI 10.1038/ng.1017; Pruim RJ, 2010, BIOINFORMATICS, V26, P2336, DOI 10.1093/bioinformatics/btq419; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Ramasamy A, 2011, J ALLERGY CLIN IMMUN, V128, P996, DOI 10.1016/j.jaci.2011.08.030; Reubsaet LL, 2014, ALLERGY, V69, P406, DOI 10.1111/all.12366; Ring J, 2012, J EUR ACAD DERMATOL, V26, P1176, DOI 10.1111/j.1468-3083.2012.04636.x; Sawcer S, 2011, NATURE, V476, P214, DOI 10.1038/nature10251; Smith EJ, 2010, CURR GENOMICS, V11, P519, DOI 10.2174/138920210793175921; STALDER JF, 1993, DERMATOLOGY, V186, P23, DOI 10.1159/000247298; Sun LD, 2011, NAT GENET, V43, P690, DOI 10.1038/ng.851; Thyssen JP, 2014, J ALLERGY CLIN IMMUN, V134, P792, DOI 10.1016/j.jaci.2014.06.014; Toncheva AA, 2012, PEDIAT ALLERG IMM-UK, V23, P636, DOI 10.1111/j.1399-3038.2012.01334.x; Tsang WY, 2007, J CELL BIOL, V178, P621, DOI 10.1083/jcb.200701166; van den Oord RAHM, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2433; Wang G, 2014, GENETICS, V196, P413, DOI 10.1534/genetics.113.157503; Weidinger S, 2013, HUM MOL GENET, V22, P4841, DOI 10.1093/hmg/ddt317; Weidinger S, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000166; Yatagai Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080941; Yoon D, 2012, BMB REP, V45, P305, DOI 10.5483/BMBRep.2012.45.5.305; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8	56	24	25	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2015	136	3					678	+		10.1016/j.jaci.2015.03.030	http://dx.doi.org/10.1016/j.jaci.2015.03.030			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CQ9EA	25935106	Bronze, Green Accepted			2022-12-18	WOS:000360913300020
J	de Wit, J; Jorritsma, T; Makuch, M; Remmerswaal, EBM; Bos, HK; Souwer, Y; Neefjes, J; ten Berge, IJM; van Ham, SM				de Wit, Jelle; Jorritsma, Tineke; Makuch, Mateusz; Remmerswaal, Ester B. M.; Bos, Hanny Klaasse; Souwer, Yuri; Neefjes, Jacques; ten Berge, Ineke J. M.; van Ham, S. Marieke			Human B cells promote T-cell plasticity to optimize antibody response by inducing coexpression of T(H)1/T-FH signatures	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						B cell; T-cell plasticity; IL-21; IFN-gamma; coexpression; T-bet; Bcl-6; antibody response; crosstalk	FOLLICULAR-HELPER-CELLS; ANTIGEN PRESENTATION; VIRAL-INFECTION; DENDRITIC CELLS; IFN-GAMMA; IN-VIVO; DIFFERENTIATION; SALMONELLA; MEMORY; IL-21	Background: B cells mediate humoral immunity against pathogens but also direct CD4(+) T-cell responses. Recent plasticity studies in mice have challenged the concept of strict fate commitment during CD4(+) T-cell differentiation into distinct subsets. Objective: We sought to elucidate the contribution of human antigen-primed B cells in CD4(+) T-cell responses that support humoral immunity. Methods: CD4(+) T-cell differentiation by primary human B cells was investigated in in vitro cocultures by using tetanus toxoid and Salmonella species as antigen models. T-cell differentiation was assessed by using intracellular cytokines and subset-specific transcription factors and markers. IgM and IgG formation was analyzed by means of ELISA. Results: Human B cells, but not dendritic cells, induce prominent and stable coexpression of T(H)1 and follicular helper T (T-FH) cell characteristics during priming and on antigen recall. T(H)1/T-FH cells coexpress the T(H)1 and T-FH effector cytokines IFN-gamma and IL-21 and the T-FH marker CXCR5, demonstrating that the coexpressed T(H)1 and T-FH subset-specifying transcription factors T-box transcription factor (T-bet) and B cell lymphoma 6 are both functionally active. B cell-derived IL-6 and IL-12 controlled respective expression of IL-21 and IFN-gamma, with IL-21 being key for humoral immunity. Conclusion: Human B cells exploit CD4(+) T-cell plasticity to create flexibility in the effector T-cell response. Induction of a T-cell subset coexpressing IL-21 and IFN-gamma might combine IL-21-mediated T-cell aid for antibody production while maintaining T(H)1 cytokine expression to support other cellular immune defenses.	[de Wit, Jelle; Jorritsma, Tineke; Makuch, Mateusz; Bos, Hanny Klaasse; Souwer, Yuri; van Ham, S. Marieke] Univ Amsterdam, Acad Med Ctr, Dept Immunopathol, Sanquin Blood Supply,Div Res, NL-1105 AZ Amsterdam, Netherlands; [de Wit, Jelle; Jorritsma, Tineke; Makuch, Mateusz; Bos, Hanny Klaasse; Souwer, Yuri; van Ham, S. Marieke] Univ Amsterdam, Acad Med Ctr, Landsteiner Lab, NL-1105 AZ Amsterdam, Netherlands; [Remmerswaal, Ester B. M.; ten Berge, Ineke J. M.] Univ Amsterdam, Acad Med Ctr, Dept Internal Med, Renal Transplant Unit, NL-1105 AZ Amsterdam, Netherlands; [Neefjes, Jacques] Netherlands Canc Inst, Div Cell Biol, Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Netherlands Cancer Institute	van Ham, SM (corresponding author), Plesmanlaan 125, NL-1066 CX Amsterdam, Netherlands.	m.vanham@sanquin.nl	Remmerswaal, Ester/ABF-3596-2020; de Wit, Jelle/W-7035-2019; Neefjes, Jacques J.C./H-8780-2017	Remmerswaal, Ester/0000-0003-4694-6048; de Wit, Jelle/0000-0003-2444-6050; Neefjes, Jacques J.C./0000-0001-6763-2211	Landsteiner Foundation for Blood Research [0533, 0816]; Sanquin Blood Supply PPOC [PPOC 09-032]	Landsteiner Foundation for Blood Research; Sanquin Blood Supply PPOC	Supported by grants from the Landsteiner Foundation for Blood Research (grants 0533 and 0816) and Sanquin Blood Supply PPOC (PPOC 09-032).	Avery DT, 2008, J IMMUNOL, V181, P1767, DOI 10.4049/jimmunol.181.3.1767; Barr TA, 2010, J IMMUNOL, V185, P2783, DOI 10.4049/jimmunol.1001431; Bouaziz JD, 2007, P NATL ACAD SCI USA, V104, P20878, DOI 10.1073/pnas.0709205105; Choi YS, 2013, J IMMUNOL, V190, P4014, DOI 10.4049/jimmunol.1202963; Choi YS, 2013, J IMMUNOL, V190, P3049, DOI 10.4049/jimmunol.1203032; Chtanova T, 2004, J IMMUNOL, V173, P68, DOI 10.4049/jimmunol.173.1.68; Crawford A, 2006, J IMMUNOL, V176, P3498, DOI 10.4049/jimmunol.176.6.3498; Crotty S, 2011, ANNU REV IMMUNOL, V29, P621, DOI 10.1146/annurev-immunol-031210-101400; Crotty S, 2010, NAT IMMUNOL, V11, P114, DOI 10.1038/ni.1837; de Wit J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013016; Deenick EK, 2011, IMMUNOLOGY, V134, P361, DOI 10.1111/j.1365-2567.2011.03487.x; Dienz O, 2009, J EXP MED, V206, P69, DOI 10.1084/jem.20081571; DiLillo DJ, 2010, J IMMUNOL, V184, P4006, DOI 10.4049/jimmunol.0903009; Eto D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017739; Good KL, 2006, J IMMUNOL, V177, P5236, DOI 10.4049/jimmunol.177.8.5236; Hale JS, 2013, IMMUNITY, V38, P805, DOI 10.1016/j.immuni.2013.02.020; Haynes NM, 2007, J IMMUNOL, V179, P5099, DOI 10.4049/jimmunol.179.8.5099; Hess J, 1996, J IMMUNOL, V156, P3321; JENKINS MK, 1990, J IMMUNOL, V144, P1585; Johnston RJ, 2009, SCIENCE, V325, P1006, DOI 10.1126/science.1175870; KAGAYA K, 1989, INFECT IMMUN, V57, P609, DOI 10.1128/IAI.57.2.609-615.1989; King IL, 2009, J EXP MED, V206, P1001, DOI 10.1084/jem.20090313; KURTJONES EA, 1988, J IMMUNOL, V140, P3773; Lee SK, 2012, IMMUNITY, V37, P880, DOI 10.1016/j.immuni.2012.10.010; Linterman MA, 2010, SEMIN IMMUNOPATHOL, V32, P183, DOI 10.1007/s00281-009-0194-z; Linterman MA, 2009, J EXP MED, V206, P561, DOI 10.1084/jem.20081886; Lu KT, 2011, IMMUNITY, V35, P622, DOI 10.1016/j.immuni.2011.07.015; Luthje K, 2012, NAT IMMUNOL, V13, P491, DOI 10.1038/ni.2261; Ma CS, 2012, BLOOD, V119, P3997, DOI 10.1182/blood-2011-11-392985; Ma CS, 2009, IMMUNOL CELL BIOL, V87, P590, DOI 10.1038/icb.2009.64; Macaulay AE, 1998, J IMMUNOL, V160, P1694; Mastroeni P, 2003, J MED MICROBIOL, V52, P453, DOI 10.1099/jmm.0.05173-0; Nakayamada S, 2011, IMMUNITY, V35, P919, DOI 10.1016/j.immuni.2011.11.012; Nurieva RI, 2008, IMMUNITY, V29, P138, DOI 10.1016/j.immuni.2008.05.009; Nurieva RI, 2009, SCIENCE, V325, P1001, DOI 10.1126/science.1176676; Oestreich KJ, 2012, NAT IMMUNOL, V13, P405, DOI 10.1038/ni.2242; Oestreich KJ, 2012, NAT REV IMMUNOL, V12, P799, DOI 10.1038/nri3321; Oestreich KJ, 2011, J EXP MED, V208, P1001, DOI 10.1084/jem.20102144; Onoda T, 2007, INT IMMUNOL, V19, P1191, DOI 10.1093/intimm/dxm090; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; ROUSSET F, 1991, J EXP MED, V173, P705, DOI 10.1084/jem.173.3.705; Sarra M, 2010, INFLAMM BOWEL DIS, V16, P1332, DOI 10.1002/ibd.21238; Schmitt N, 2009, IMMUNITY, V31, P158, DOI 10.1016/j.immuni.2009.04.016; Souwer Y, 2009, J IMMUNOL, V182, P7473, DOI 10.4049/jimmunol.0802831; Stockinger B, 1996, J EXP MED, V183, P891, DOI 10.1084/jem.183.3.891; Suto A, 2008, J EXP MED, V205, P1369, DOI 10.1084/jem.20072057; ten Brinke A, 2007, VACCINE, V25, P7145, DOI 10.1016/j.vaccine.2007.07.031; Toellner KM, 1998, J EXP MED, V187, P1193, DOI 10.1084/jem.187.8.1193; Vogelzang A, 2008, IMMUNITY, V29, P127, DOI 10.1016/j.immuni.2008.06.001; Wei L, 2007, J BIOL CHEM, V282, P34605, DOI 10.1074/jbc.M705100200; Yi JS, 2009, SCIENCE, V324, P1572, DOI 10.1126/science.1175194; Yu D, 2009, IMMUNITY, V31, P457, DOI 10.1016/j.immuni.2009.07.002; Zaretsky AG, 2009, J EXP MED, V206, P991, DOI 10.1084/jem.20090303; Zubler RH, 2001, SPRINGER SEMIN IMMUN, V23, P405, DOI 10.1007/s281-001-8167-7	54	24	24	1	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2015	135	4					1053	1060		10.1016/j.jaci.2014.08.012	http://dx.doi.org/10.1016/j.jaci.2014.08.012			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CF0MQ	25258142				2022-12-18	WOS:000352238600028
J	Song, Y; Liu, CD; Hui, YQ; Srivastava, K; Zhou, ZW; Chen, J; Miller, RL; Finkelman, FD; Li, XM				Song, Ying; Liu, Changda; Hui, Yiqun; Srivastava, Kamal; Zhou, Zhenwen; Chen, Jia; Miller, Rachel L.; Finkelman, Fred D.; Li, Xiu-Min			Maternal allergy increases susceptibility to offspring allergy in association with T(H)2-biased epigenetic alterations in a mouse model of peanut allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Peanut allergy; anaphylaxis mice; offspring; IgE; IL-4; DNA methylation	FOOD ALLERGY; HERBAL FORMULA-2; ENVIRONMENTAL EPIGENETICS; ANAPHYLACTIC REACTIONS; CELL RESPONSES; UP-REGULATION; MURINE MODEL; RISK-FACTORS; ASTHMA; TOLERANCE	Background: Although maternal atopy is a risk factor for the development of peanut allergy, this phenomenon has not been well characterized experimentally, and the mechanisms underlying offspring risk are unclear. Objective: We sought to determine whether offspring of mothers with peanut allergy (O-PAM mice) are more susceptible to peanut allergy than offspring of naive mothers (O-NM mice) in a murine model and, if so, whether the susceptibility is linked to T(H)2-biased epigenetic alterations. Methods: Five-week-old O-PAM and O-NM mice were intragastrically sensitized to and challenged with peanut. Serum peanut-specific IgE levels, plasma histamine levels, anaphylactic reactions, and splenocyte and MLN cell cytokine production were measured. DNA methylation levels of the Il4 gene promoter from splenocytes and MLN cells from sensitized offspring and splenocytes from unsensitized neonatal offspring were determined by means of pyrosequencing. Results: O-PAM mice exhibited 3-fold higher peanut-specific IgE levels after peanut sensitization, as well as 5-fold higher histamine levels and significantly higher anaphylactic symptom scores after challenge than O-NM mice (P < .05-.01). Cultured splenocytes and MLNs from O-PAM mice produced significantly more T(H)2 cytokines than cells from O-NM mice (P < .05-.01). Cells from O-PAM mice exhibited significantly reduced DNA methylation at CpG sites of the Il4 gene promoter than cells from O-NM mice. DNA methylation levels were inversely correlated with IL-4 and IgE production. O-PAM neonatal splenocyte hypomethylation of the Il4 gene promoter was also present. Conclusion: This study is the first to demonstrate that increased susceptibility to peanut allergy in O-PAM mice is associated with epigenetic alteration of the Il4 gene promoter. This finding might provide insight into preventing the development of early-life allergy.	[Song, Ying; Liu, Changda; Hui, Yiqun; Srivastava, Kamal; Zhou, Zhenwen; Chen, Jia; Li, Xiu-Min] Icahn Sch Med Mt Sinai, Dept Pediat, New York, NY 10029 USA; [Chen, Jia] Icahn Sch Med Mt Sinai, Dept Prevent Med, New York, NY 10029 USA; [Miller, Rachel L.] Columbia Univ, Dept Med, Div Pulm Allergy & Crit Care Med, New York, NY USA; [Miller, Rachel L.] Columbia Univ, Dept Pediat, Div Allergy & Immunol, New York, NY 10027 USA; [Miller, Rachel L.] Columbia Univ, Dept Environm Hlth Sci, New York, NY USA; [Finkelman, Fred D.] Univ Cincinnati, Coll Med, Div Immunol Allergy & Rheumatol, Cincinnati, OH 45221 USA; [Finkelman, Fred D.] Cincinnati Vet Affairs Med Ctr, Dept Med, Cincinnati, OH USA; [Finkelman, Fred D.] Cincinnati Childrens Hosp Med Ctr, Div Immunobiol, Cincinnati, OH 45229 USA; [Zhou, Zhenwen] Guangzhou Women & Childrens Med Ctr, Guangzhou, Guangdong, Peoples R China	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Columbia University; Columbia University; Columbia University; University System of Ohio; University of Cincinnati; US Department of Veterans Affairs; Veterans Health Administration (VHA); Cincinnati VA Medical Center; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Li, XM (corresponding author), Icahn Sch Med Mt Sinai, One Gustave L Levy Pl, New York, NY 10029 USA.	xiu-min.li@mssm.edu	li, xiu/GXV-1745-2022		National Institutes of Health/NCCAM Center for Complementary and Alternative Medicine [1R01AT001495-01A1, 2R01 AT001495-05A2]; Food Allergy Education and Research; Winston Wolkoff Fund for Integrative Medicine for Allergies and Wellness; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R01AT001495] Funding Source: NIH RePORTER	National Institutes of Health/NCCAM Center for Complementary and Alternative Medicine; Food Allergy Education and Research; Winston Wolkoff Fund for Integrative Medicine for Allergies and Wellness; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)	Supported by the National Institutes of Health/NCCAM Center for Complementary and Alternative Medicine grant nos. 1R01AT001495-01A1 and 2R01 AT001495-05A2, Food Allergy Education and Research, and the Winston Wolkoff Fund for Integrative Medicine for Allergies and Wellness.	[Anonymous], 2010, J ALLERGY CLIN IMMUN, V126, pS5, DOI 10.1016/j.jaci.2010.10.007; Beyer K, 2002, J ALLERGY CLIN IMMUN, V109, P707, DOI 10.1067/mai.2002.122503; Beyer KB, 2001, J ALLERGY CLIN IMMUN, V107, P1077, DOI 10.1067/mai.2001.115480; Bjorksten B, 2005, CURR OPIN ALLERGY CL, V5, P249, DOI 10.1097/01.all.0000168790.82206.17; Bock SA, 2007, J ALLERGY CLIN IMMUN, V119, P1016, DOI 10.1016/j.jaci.2006.12.622; Brandt EB, 2003, J CLIN INVEST, V112, P1666, DOI 10.1172/JCI19785; Brough HA, 2013, J ALLERGY CLIN IMMUN, V132, P623, DOI 10.1016/j.jaci.2013.02.035; Fernandez-Roig S, 2012, NUTR METAB, V9, DOI 10.1186/1743-7075-9-41; Fields PE, 2002, J IMMUNOL, V169, P647, DOI 10.4049/jimmunol.169.2.647; FINKELMAN FD, 1988, J IMMUNOL, V141, P2335; Finkelman FD, 2007, J ALLERGY CLIN IMMUN, V120, P506, DOI 10.1016/j.jaci.2007.07.033; Fleischer DM, 2005, J ALLERGY CLIN IMMUN, V116, P1087, DOI 10.1016/j.jaci.2005.09.002; Fleischer DM, 2004, J ALLERGY CLIN IMMUN, V114, P1195, DOI 10.1016/j.jaci.2004.08.035; Goldberg AD, 2007, CELL, V128, P635, DOI 10.1016/j.cell.2007.02.006; Greer FR, 2008, PEDIATRICS, V121, P183, DOI 10.1542/peds.2007-3022; Gupta RS, 2011, PEDIATRICS, V128, pE9, DOI 10.1542/peds.2011-0204; Hourihane JO, 1996, BRIT MED J, V313, P518, DOI 10.1136/bmj.313.7056.518; Institute of Laboratory Animal Resources Commission of Life Sciences NRC, 1996, GUIDE CARE USE LAB A; Janson PCJ, 2009, BBA-GEN SUBJECTS, V1790, P906, DOI 10.1016/j.bbagen.2008.12.003; Kuriakose JS, 2010, CLIN EXP ALLERGY, V40, P1602, DOI 10.1111/j.1365-2222.2010.03599.x; Lack G, 2003, NEW ENGL J MED, V348, P977, DOI 10.1056/NEJMoa013536; Lack G, 2012, J ALLERGY CLIN IMMUN, V129, P1187, DOI 10.1016/j.jaci.2012.02.036; Lee SM, 2011, AM J RESP CELL MOL, V44, P341, DOI 10.1165/rcmb.2010-0001OC; Lee YL, 1999, IMMUNOLOGY, V97, P232, DOI 10.1046/j.1365-2567.1999.00768.x; Li XM, 2000, J ALLERGY CLIN IMMUN, V106, P150, DOI 10.1067/mai.2000.107395; Liu J, 2008, TOXICOL SCI, V102, P76, DOI 10.1093/toxsci/kfm290; Lopez-Exposito I, 2011, FOOD RES INT, V44, P1649, DOI 10.1016/j.foodres.2011.04.047; Lopez-Exposito I, 2009, J ALLERGY CLIN IMMUN, V124, P1039, DOI 10.1016/j.jaci.2009.08.024; Lovinsky-Desir S, 2012, CURR ALLERGY ASTHM R, V12, P211, DOI 10.1007/s11882-012-0257-4; Luengo O, 2013, J ALLERGY THER S, VS3; Miller RL, 2008, AM J RESP CRIT CARE, V177, P567, DOI 10.1164/rccm.200710-1511PP; Morafo V, 2003, J ALLERGY CLIN IMMUN, V111, P1122, DOI 10.1067/mai.2003.1463; Niedzwiecki M, 2012, ALLERGY, V67, P904, DOI 10.1111/j.1398-9995.2012.02841.x; Pochard P, 2010, J ALLERGY CLIN IMMUN, V126, P92, DOI 10.1016/j.jaci.2010.04.003; Prescott S, 2011, CLIN EPIGENETICS, V2, P223, DOI 10.1007/s13148-011-0028-4; Prescott SL, 2009, CURR OPIN ALLERGY CL, V9, P417, DOI 10.1097/ACI.0b013e328330634f; Qu C, 2007, CLIN EXP ALLERGY, V37, P846, DOI 10.1111/j.1365-2222.2007.02718.x; Sampson HA, 2003, PEDIATRICS, V111, P1601; Schade RP, 2000, J ALLERGY CLIN IMMUN, V106, P1155, DOI 10.1067/mai.2000.110802; Shaw T, 2009, EMBO REP, V10, P881, DOI 10.1038/embor.2009.102; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, P1322, DOI 10.1016/j.jaci.2010.03.029; Srivastava K, 2011, CLIN EXP ALLERGY, V41, P582, DOI 10.1111/j.1365-2222.2010.03643.x; Srivastava KD, 2009, J ALLERGY CLIN IMMUN, V123, P443, DOI 10.1016/j.jaci.2008.12.1107; Srivastava KD, 2005, J ALLERGY CLIN IMMUN, V115, P171, DOI 10.1016/j.jaci.2004.10.003; Steinke JW, 2001, RESP RES, V2, P66, DOI 10.1186/rr40; Strait RT, 2002, J ALLERGY CLIN IMMUN, V109, P658, DOI 10.1067/mai.2002.123302; Tsujimura Y, 2008, IMMUNITY, V28, P581, DOI 10.1016/j.immuni.2008.02.008; Turcanu V, 2003, J CLIN INVEST, V111, P1065, DOI 10.1172/JCI200316142; Wilson CB, 2009, NAT REV IMMUNOL, V9, P91, DOI 10.1038/nri2487; Wilson MS, 2005, J EXP MED, V202, P1199, DOI 10.1084/jem.20042572	50	24	25	0	29	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2014	134	6					1339	+		10.1016/j.jaci.2014.08.034	http://dx.doi.org/10.1016/j.jaci.2014.08.034			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AW1UG	25441650	Green Accepted			2022-12-18	WOS:000346075400016
J	Schulten, V; Tripple, V; Sidney, J; Greenbaum, J; Frazier, A; Alam, R; Broide, D; Peters, B; Sette, A				Schulten, Veronique; Tripple, Victoria; Sidney, John; Greenbaum, Jason; Frazier, April; Alam, Rafeul; Broide, David; Peters, Bjoern; Sette, Alessandro			Association between specific timothy grass antigens and changes in T(H)1- and T(H)2-cell responses following specific immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						T cells; specific immunotherapy; timothy grass; cytokine	T-CELL TOLERANCE; PHL P 1; IMMUNE-RESPONSES; HELPER-CELLS; BEE VENOM; ALLERGEN; PEPTIDES; PREVALENCE; IGE; HYPOALLERGENS	Background: Different populations of T cells are involved in the pathogenesis of allergic diseases. Objective: We investigated changes in T-H-cell populations in patients with allergies after specific immunotherapy (SIT). Methods: PBMCs were isolated from patients with allergies who received SIT and those who did not (controls). We tested the ability of peptides from 93 timothy grass (TG) proteins to induce T-cell responses (cytokine production). We used ELISPOT and staining assays for intracellular cytokines to measure the production of IL-4, IL-5, IL-13, IFN-gamma, and IL-10. Results: Compared with PBMCs from controls, PBMCs from patients who received SIT produced lower levels of T(H)2 cytokines on incubation with several different TG peptides. These data were used to select 20 peptides to be tested in an independent cohort of 20 patients with allergies who received SIT and 20 controls. We again observed a significant decrease in the production of T(H)2 cytokines, and an increase in the production of the T(H)1 cytokine IFN-g, in PBMCs from the validation groups. These changes correlated with improved symptoms after SIT. Immunization with this selected pool of peptides (or their associated antigens) could protect a substantial proportion of the population from TG allergy. Conclusions: We observed a significant decrease in the production of T(H)2 cytokines by PBMCs from patients who received SIT for TG allergy compared to those who did not. These changes might be used to monitor response to therapy. The decrease occurred in response to antigens that elicit little (if any) IgE responses; these antigens might be developed for use in immunotherapy.	[Schulten, Veronique; Tripple, Victoria; Sidney, John; Greenbaum, Jason; Frazier, April; Peters, Bjoern; Sette, Alessandro] La Jolla Inst Allergy & Immunol, Div Vaccine Discovery, La Jolla, CA 92037 USA; [Alam, Rafeul] Natl Jewish Hlth, Dept Med, Denver, CO USA; [Broide, David] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA	La Jolla Institute for Immunology; National Jewish Health; University of California System; University of California San Diego	Sette, A (corresponding author), La Jolla Inst Allergy & Immunol, 9420 Athena Circle, La Jolla, CA 92037 USA.	alex@liai.org	Sette, Alessandro/AFO-8916-2022	Peters, Bjoern/0000-0002-8457-6693; Alam, Rafeul/0000-0001-8562-4207; Broide, David/0000-0001-8405-9090	National Institute of Allergy and Infectious Diseases; National Institutes of Health (NIH) [ULRR031980, UL1TR000100]; Department of Health and Human Services [HHSN272200700048C, U19 AI100275]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000100] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI102943, U19AI100275, R01AI091614] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Health and Human Services; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This project has been funded in whole or in part with federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), the Department of Health and Human Services (under contract no. HHSN272200700048C and U19 grant no. U19 AI100275). This project was partially supported by the NIH (grant ULRR031980 for years 1 and 2 of Clinical and Translational Science Award [CTSA] funding and grant no. UL1TR000100 for year 3 and beyond	Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; Alexander C, 2005, CLIN EXP ALLERGY, V35, P52, DOI 10.1111/j.1365-2222.2005.02143.x; Andersson K, 2003, INT ARCH ALLERGY IMM, V130, P87, DOI 10.1159/000069013; Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; Bauchau V, 2004, EUR RESPIR J, V24, P758, DOI 10.1183/09031936.04.00013904; Bohle B, 2007, J ALLERGY CLIN IMMUN, V120, P707, DOI 10.1016/j.jaci.2007.06.013; Bui HH, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-153; CORRIGAN CJ, 1992, IMMUNOL TODAY, V13, P501, DOI 10.1016/0167-5699(92)90026-4; Durham SR, 1996, J ALLERGY CLIN IMMUN, V97, P1356, DOI 10.1016/S0091-6749(96)70205-1; Ebner C, 1997, CLIN EXP ALLERGY, V27, P1007, DOI 10.1111/j.1365-2222.1997.tb01252.x; Fellrath JM, 2003, J ALLERGY CLIN IMMUN, V111, P854, DOI 10.1067/mai.2003.1337; Gabrielsson S, 2001, ALLERGY, V56, P293, DOI 10.1034/j.1398-9995.2001.00472.x; Gafvelin G, 2007, J BIOL CHEM, V282, P3778, DOI 10.1074/jbc.M607938200; Greenbaum J, 2011, IMMUNOGENETICS, V63, P325, DOI 10.1007/s00251-011-0513-0; JUTEL M, 1995, J IMMUNOL, V154, P4187; KAPSENBERG ML, 1992, CURR OPIN IMMUNOL, V4, P788, DOI 10.1016/0952-7915(92)90063-K; Marth K, 2013, J IMMUNOL, V190, P3068, DOI 10.4049/jimmunol.1202441; McKinney DM, 2013, IMMUNOGENETICS, V65, P357, DOI 10.1007/s00251-013-0684-y; Middleton D, 2003, TISSUE ANTIGENS, V61, P403, DOI 10.1034/j.1399-0039.2003.00062.x; Mobs C, 2012, J ALLERGY CLIN IMMUN, V130, P1108, DOI 10.1016/j.jaci.2012.07.056; Mobs C, 2010, J IMMUNOL, V184, P2194, DOI 10.4049/jimmunol.0901379; Moverare R, 2000, IMMUNOL LETT, V73, P51, DOI 10.1016/S0165-2478(00)00199-1; Muller U, 1998, J ALLERGY CLIN IMMUN, V101, P747, DOI 10.1016/S0091-6749(98)70402-6; Nandy A, 2005, BIOCHEM BIOPH RES CO, V337, P563, DOI 10.1016/j.bbrc.2005.09.087; Nathan RA, 2007, ALLERGY ASTHMA PROC, V28, P3, DOI 10.2500/aap.2007.28.2934; Oseroff C, 2010, J IMMUNOL, V185, P943, DOI 10.4049/jimmunol.1000405; Patel D, 2013, J ALLERGY CLIN IMMUN, V131, P103, DOI 10.1016/j.jaci.2012.07.028; Pene J, 1998, J ALLERGY CLIN IMMUN, V102, P571, DOI 10.1016/S0091-6749(98)70294-5; Romagnani S, 2004, IMMUNOLOGY, V112, P352, DOI 10.1111/j.1365-2567.2004.01925.x; ROMAGNANI S, 1994, CURR OPIN IMMUNOL, V6, P838, DOI 10.1016/0952-7915(94)90002-7; Saarne T, 2005, CLIN EXP ALLERGY, V35, P657, DOI 10.1111/j.1365-2222.2005.02234.x; Schulten V, 2013, P NATL ACAD SCI USA, V110, P3459, DOI 10.1073/pnas.1300512110; Vickery BP, 2013, J ALLERGY CLIN IMMUN, V131, pe1; Vickery BP, 2013, J ALLERGY CLIN IMMUN, V131, P128, DOI 10.1016/j.jaci.2012.10.048; von Mutius E, 1998, LANCET, V351, P862, DOI 10.1016/S0140-6736(97)10100-3; Vrtala S, 1996, J ALLERGY CLIN IMMUN, V97, P781, DOI 10.1016/S0091-6749(96)80156-4; Wang P, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-568; Wang P, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000048; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258	39	24	28	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2014	134	5					1076	1083		10.1016/j.jaci.2014.05.033	http://dx.doi.org/10.1016/j.jaci.2014.05.033			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AT4UN	25042980	Green Accepted			2022-12-18	WOS:000344938900012
J	Dubuis, E; Wortley, MA; Grace, MS; Maher, SA; Adcock, JJ; Birrell, MA; Belvisi, MG				Dubuis, Eric; Wortley, Michael A.; Grace, Megan S.; Maher, Sarah A.; Adcock, John J.; Birrell, Mark A.; Belvisi, Maria G.			Theophylline inhibits the cough reflex through a novel mechanism of action	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Sensory nerves; vagus; cough; ion channels; capsaicin	OBSTRUCTIVE PULMONARY-DISEASE; SENSORY NERVE ACTIVITY; GUINEA-PIGS; INTERMEDIATE-CONDUCTANCE; SELECTIVE INHIBITORS; POTASSIUM CHANNEL; CAPSAICIN COUGH; K+ CHANNEL; ASTHMA; SENSITIVITY	Background: Theophylline has been used in the treatment of asthma and chronic obstructive pulmonary disease for more than 80 years. In addition to bronchodilator and anti-inflammatory activity, clinical studies have suggested that theophylline acts as an antitussive agent. Cough is the most frequent reason for consultation with a family doctor, and treatment options are limited. Determining how theophylline inhibits cough might lead to the development of optimized compounds. Objective: We sought to investigate the inhibitory activity of theophylline on vagal sensory nerve activity and the cough reflex. Methods: Using a range of techniques, we investigated the effect of theophylline on human and guinea pig vagal sensory nerve activity in vitro and on the cough reflex in guinea pig challenge models. Results: Theophylline was antitussive in a guinea pig model, inhibited activation of single C-fiber afferents in vivo and depolarization of human and guinea pig vagus in vitro, and inhibited calcium influx in airway-specific neurons in vitro. A sequence of pharmacological studies on the isolated vagus and patch clamp and single-channel inside-out experiments showed that the effect of theophylline was due to an increase in the open probability of calcium-activated potassium channels. Finally, we demonstrated the antitussive activity of theophylline in a cigarette smoke exposure model that exhibited enhanced tussive responses to capsaicin. Conclusion: Theophylline inhibits capsaicin-induced cough under both normal and "disease" conditions by decreasing the excitability of sensory nerves through activation of small- and intermediate-conductance calcium-activated potassium channels. These findings could lead to the development of optimized antitussive compounds with a reduced side effect potential.	[Dubuis, Eric; Wortley, Michael A.; Grace, Megan S.; Maher, Sarah A.; Adcock, John J.; Birrell, Mark A.; Belvisi, Maria G.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Fac Med, London SW7 2AZ, England	Imperial College London	Belvisi, MG (corresponding author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Fac Med, Exhibit Rd, London SW7 2AZ, England.	m.belvisi@imperial.ac.uk	Grace, Megan/AAA-7285-2019	dubuis, eric/0000-0001-7658-4178; Wortley, Michael/0000-0001-8622-5339	Medical Research Council (MRC, UK) [G0800196, G0800195, MR/K020293/1]; MRC; Wellcome Trust [089301/Z/09/Z]; NIHR Respiratory Disease Biomedical Research Unit at the Royal Brompton and Harefield NHS Foundation Trust and Imperial College London; MRC [G0800196, G0800195, MR/K020293/1] Funding Source: UKRI; Medical Research Council [G1000758B, G1000758, MR/K020293/1, G0800195, G0800196] Funding Source: researchfish; Asthma UK [MRC-AsthmaUKCentre] Funding Source: researchfish	Medical Research Council (MRC, UK)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome TrustEuropean Commission); NIHR Respiratory Disease Biomedical Research Unit at the Royal Brompton and Harefield NHS Foundation Trust and Imperial College London; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Asthma UK	M.A.B., S.A.M., and M.S.G. were funded by project grants from the Medical Research Council (MRC, UK; M. A. B., G0800196; S. A. M. and M. S. G., G0800195 and MR/K020293/1). M. A. W. was supported by an MRC studentship. E. D. was funded by a Wellcome Trust project grant (089301/Z/09/Z). The human tissue experiments in this study were undertaken with the support of the NIHR Respiratory Disease Biomedical Research Unit at the Royal Brompton and Harefield NHS Foundation Trust and Imperial College London.	Adcock JJ, 2003, BRIT J PHARMACOL, V138, P407, DOI 10.1038/sj.bjp.0705056; Barnes PJ, 2013, AM J RESP CRIT CARE, V188, P901, DOI 10.1164/rccm.201302-0388PP; BARNES PJ, 1994, EUR RESPIR J, V7, P579, DOI 10.1183/09031936.94.07030579; Belvisi MG, 2008, BRIT J PHARMACOL, V155, P547, DOI 10.1038/bjp.2008.298; Birrell MA, 2002, BRIT J PHARMACOL, V136, P620, DOI 10.1038/sj.bjp.0704758; Birrell MA, 2009, AM J RESP CRIT CARE, V180, P1042, DOI 10.1164/rccm.200905-0665OC; Blanc FX, 2009, RESP MED, V103, P786, DOI 10.1016/j.rmed.2008.11.010; Boettger MK, 2002, BRAIN, V125, P252, DOI 10.1093/brain/awf026; BOSE B, 1987, EUR J PEDIATR, V146, P524, DOI 10.1007/BF00441609; CAZZOLA M, 1993, RESPIRATION, V60, P212; Cherry Donald K, 2003, Adv Data, P1; Chuaychoo B, 2006, J PHYSIOL-LONDON, V575, P481, DOI 10.1113/jphysiol.2006.109371; CORTIJO J, 1993, BRIT J PHARMACOL, V108, P562, DOI 10.1111/j.1476-5381.1993.tb12841.x; Cui J, 1997, J GEN PHYSIOL, V109, P647, DOI 10.1085/jgp.109.5.647; Culpitt SV, 2002, AM J RESP CRIT CARE, V165, P1371, DOI 10.1164/rccm.2105106; Dai SP, 2009, PHYSIOL REV, V89, P411, DOI 10.1152/physrev.00029.2007; Doherty MJ, 2000, THORAX, V55, P643, DOI 10.1136/thorax.55.8.643; Eltom S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024097; Faber ESL, 2003, NEUROSCIENTIST, V9, P181, DOI 10.1177/1073858403009003011; Freund-Michel VC, 2010, EUR RESPIR J, V35, P647, DOI 10.1183/09031936.00034009; Fujimura M, 2007, PULM PHARMACOL THER, V20, P543, DOI 10.1016/j.pupt.2006.05.004; Gerlach AC, 2000, J BIOL CHEM, V275, P585, DOI 10.1074/jbc.275.1.585; Gerlach AC, 2001, J BIOL CHEM, V276, P10963, DOI 10.1074/jbc.M007716200; Grace M, 2012, THORAX, V67, P891, DOI 10.1136/thoraxjnl-2011-201443; Haque RA, 2005, CHEST, V127, P1710, DOI 10.1378/chest.127.5.1710; HATZELMANN A, 1995, BRIT J PHARMACOL, V114, P821, DOI 10.1111/j.1476-5381.1995.tb13278.x; Irwin RS, 2006, CHEST, V129, p1S, DOI 10.1378/chest.129.1_suppl.1S; KIRSTEN DK, 1993, CHEST, V104, P1101, DOI 10.1378/chest.104.4.1101; KOGAN MD, 1994, JAMA-J AM MED ASSOC, V272, P1025, DOI 10.1001/jama.272.13.1025; LAUDE EA, 1993, PULM PHARMACOL, V6, P171, DOI 10.1006/pulp.1993.1023; Lim S, 2001, AM J RESP CRIT CARE, V164, P273, DOI 10.1164/ajrccm.164.2.2006043; Lu HJ, 2004, CHINESE MED J-PEKING, V117, P1620; Maher SA, 2009, AM J RESP CRIT CARE, V180, P923, DOI 10.1164/rccm.200903-0388OC; Mikus EG, 1997, ARZNEIMITTEL-FORSCH, V47, P395; Mokry J, 2011, BRATISL MED J, V112, P131; Mokry J, 2009, J PHYSIOL PHARMACOL, V60, P87; Mokry J, 2008, J PHYSIOL PHARMACOL, V59, P473; Mokry J, 2013, ADV EXP MED BIOL, V756, P57, DOI 10.1007/978-94-007-4549-0_8; OCONNELL F, 1994, AM J RESP CRIT CARE, V150, P374, DOI 10.1164/ajrccm.150.2.8049818; Patel HJ, 2003, BRIT J PHARMACOL, V140, P261, DOI 10.1038/sj.bjp.0705435; Ram FSF., 2002, COCHRANE DB SYST REV, V2002, pCD003902, DOI DOI 10.1002/14651858.CD003902; Riegel AC, 2008, NEURON, V57, P559, DOI 10.1016/j.neuron.2007.12.029; SAANO V, 1993, J PHARM PHARMACOL, V45, P799, DOI 10.1111/j.2042-7158.1993.tb05688.x; Schroder RL, 2000, PFLUG ARCH EUR J PHY, V440, P809, DOI 10.1007/s004240000364; Schroeder K, 2002, BRIT MED J, V324, P329, DOI 10.1136/bmj.324.7333.329; SCHUDT C, 1991, BIOCHEM PHARMACOL, V42, P153, DOI 10.1016/0006-2952(91)90694-Z; SMITH CA, 1991, EUR RESPIR J, V4, P1076; Usmani OS, 2004, FASEB J, V18, P231, DOI 10.1096/fj.04-1990fje; Weatherall KL, 2010, PROG NEUROBIOL, V91, P242, DOI 10.1016/j.pneurobio.2010.03.002; WIDDICOMBE JG, 1995, EUR RESPIR J, V8, P1193, DOI 10.1183/09031936.95.08071193; ZuWallack RL, 2001, CHEST, V119, P1661, DOI 10.1378/chest.119.6.1661	51	24	25	1	20	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2014	133	6					1588	1598		10.1016/j.jaci.2013.11.017	http://dx.doi.org/10.1016/j.jaci.2013.11.017			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AI2FI	24406072	hybrid, Green Published			2022-12-18	WOS:000336672500010
J	Lluis, A; Ballenberger, N; Illi, S; Schieck, M; Kabesch, M; Illig, T; Schleich, I; von Mutius, E; Schaub, B				Lluis, Anna; Ballenberger, Nikolaus; Illi, Sabina; Schieck, Maximilian; Kabesch, Michael; Illig, Thomas; Schleich, Isolde; von Mutius, Erika; Schaub, Bianca			Regulation of T(H)17 markers early in life through maternal farm exposure	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Cord blood; cytokines; farming; innate; single nucleotide polymorphism; T(H)17 cells; regulatory T cells	ROR-GAMMA-T; CHILDHOOD ASTHMA; CELL-DIFFERENTIATION; ATOPIC SENSITIZATION; MILK CONSUMPTION; RETINOIC ACID; MESSENGER-RNA; IGE LEVELS; IN-VIVO; ASSOCIATION	Background: Previous studies suggested that maternal farm exposure during pregnancy modulates early immune development toward an allergy-protective status potentially mediated by T(H)1 or regulatory T (Treg) cells. However, the underlying mechanisms might involve immune modulation of additional T-cell populations, such as T(H)17 cells, influenced by genetic predisposition. Objective: We examined the role of maternal farm exposure and genetic predisposition on T(H)17 cell responses to innate and adaptive immune stimulation in cord blood. Methods: Eighty-four pregnant mothers were recruited before delivery. Detailed questionnaires (60 nonfarming mother, 22 farming mothers, and 2 exclusions) assessed farming exposures. Cord blood was stimulated with lipid A, peptidoglycan (Ppg), or PHA. T(H)17 lineage (retinoic acid receptor-related orphan receptor C [RORC], retinoic acid receptor-related orphan receptor alpha [RORA], IL-23 receptor [IL23R], IL17, IL17F, and IL22) and Treg cell markers (forkhead box protein 3 [FOXP3], lymphocyte activation gene 3 [LAG3], and glucocorticoid-induced TNF receptor [GITR]) were assessed at the mRNA level. T(H)17/Treg/T(H)1/T(H)2 cytokines and 7 single nucleotide polymorphisms within the T(H)17 lineage (RORC, IL23R, and IL17) were examined. Results: T(H)17 lineage mRNA markers were expressed at birth at low concentrations independent of maternal farm exposure. A positive correlation between T(H)17 lineage markers and FOXP3 (mRNA) was observed on stimulation (nonfarming mothers: lipid A, Ppg, and PHA; farming mothers: Ppg and PHA), influenced by maternal farming. Specific single nucleotide polymorphisms within the T(H)17 lineage genes influenced gene expression of T(H)17 and Treg cell markers and cytokine secretion. Conclusions: Gene expression of T(H)17 lineage markers in cord blood was not influenced by maternal farming. Yet T(H)17 and Treg cell markers were positively correlated and influenced by maternal farm exposure. Our data suggest that prenatal exposures and genetic predisposition play a role during early T(H)17 immune maturation, potentially regulating the development of immune-mediated diseases, such as childhood asthma.	[Lluis, Anna; Ballenberger, Nikolaus; Illi, Sabina; Schleich, Isolde; von Mutius, Erika; Schaub, Bianca] Ludwig Maximilians Univ Munchen, Univ Childrens Hosp Munich, Dept Pulm & Allergy, Munich, Germany; [Schieck, Maximilian; Kabesch, Michael] Univ Childrens Hosp Regensburg KUNO, Dept Pediat Pneumol & Allergy, Regensburg, Germany; [Illig, Thomas] Helmholtz Ctr Munich, Inst Epidemiol, Neuherberg, Germany; [Illig, Thomas] Hannover Med Sch, Unified Biobank, Hannover, Germany	University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Hannover Medical School	Schaub, B (corresponding author), Dr von Haunersches Kinderspital, Univ Childrens Hosp Munich, Lindwurmstr 4, D-80337 Munich, Germany.	Bianca.Schaub@med.uni-muenchen.de	Kabesch, Michael/AAB-5701-2020; Schaub, Bianca/B-9935-2019; Schieck, Maximilian/D-4121-2013; Kabesch, Michael/GZM-1583-2022	Schaub, Bianca/0000-0003-1652-8873; Schieck, Maximilian/0000-0001-5878-0546; von Mutius, Erika/0000-0002-8893-4515	Marie Curie Early Stage Training; DFG [SFB TR22]	Marie Curie Early Stage Training(European Commission); DFG(German Research Foundation (DFG))	Supported by Marie Curie Early Stage Training ( to A. L.) and DFG: SFB TR22 ( to B. S. and A.L.).	Alfven T, 2006, ALLERGY, V61, P414, DOI 10.1111/j.1398-9995.2005.00939.x; Bai AP, 2009, J LEUKOCYTE BIOL, V86, P959, DOI 10.1189/jlb.0109006; Ballenberger N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046423; Bullens DMA, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-135; Chen JH, 2010, J CLIN IMMUNOL, V30, P539, DOI 10.1007/s10875-010-9391-8; Chen Y, 2011, IMMUNITY, V34, P409, DOI 10.1016/j.immuni.2011.02.011; Ciprandi G, 2009, ALLERGY, V64, P1375, DOI 10.1111/j.1398-9995.2009.02010.x; Cosmi L, 2011, ALLERGY, V66, P989, DOI 10.1111/j.1398-9995.2011.02576.x; Duerr RH, 2006, SCIENCE, V314, P1461, DOI 10.1126/science.1135245; Dzhagalov I, 2004, J IMMUNOL, V173, P2952, DOI 10.4049/jimmunol.173.5.2952; Ege MJ, 2011, NEW ENGL J MED, V364, P701, DOI 10.1056/NEJMoa1007302; Ege MJ, 2006, J ALLERGY CLIN IMMUN, V117, P817, DOI 10.1016/j.jaci.2005.12.1307; Eisenstein EM, 2009, PEDIATR RES, V65, p26R, DOI 10.1203/PDR.0b013e31819e76c7; Espinoza JL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026229; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; Gold MS, 2005, MED J AUSTRALIA, V182, P298, DOI 10.5694/j.1326-5377.2005.tb06707.x; Helsel DR, 2005, NONDETECTS DATA ANAL; Ichiyama K, 2008, J BIOL CHEM, V283, P17003, DOI 10.1074/jbc.M801286200; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kimura A, 2010, EUR J IMMUNOL, V40, P1830, DOI 10.1002/eji.201040391; Liu CA, 2003, J ALLERGY CLIN IMMUN, V112, P899, DOI 10.1016/j.jaci.2003.08.030; Liu J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013267; Lluis A, 2012, CURR OPIN ALLERGY CL, V12, P158, DOI 10.1097/ACI.0b013e32835109a8; Loss G, 2011, J ALLERGY CLIN IMMUN, V128, P766, DOI 10.1016/j.jaci.2011.07.048; McGeachy MJ, 2008, IMMUNITY, V28, P445, DOI 10.1016/j.immuni.2008.03.001; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; Moore MM, 2004, PEDIATRICS, V113, P468, DOI 10.1542/peds.113.3.468; Mucida D, 2007, SCIENCE, V317, P256, DOI 10.1126/science.1145697; Nolting J, 2009, J EXP MED, V206, P2131, DOI 10.1084/jem.20090639; OBRIEN PC, 1987, BIOMETRICS, V43, P169, DOI 10.2307/2531957; PRENTICE RL, 1978, BIOMETRIKA, V65, P167, DOI 10.1093/biomet/65.1.167; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Ratajczak P, 2010, BLOOD, V116, P1165, DOI 10.1182/blood-2009-12-255810; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Sakaguchi S, 2007, SCIENCE, V317, P627, DOI 10.1126/science.1142331; Schaub B, 2008, J ALLERGY CLIN IMMUN, V121, P1491, DOI 10.1016/j.jaci.2008.04.010; Schaub Bianca, 2009, J Allergy Clin Immunol, V123, P774, DOI 10.1016/j.jaci.2009.01.056; Schedel M, 2004, J ALLERGY CLIN IMMUN, V114, P1100, DOI 10.1016/j.jaci.2004.07.048; Schedel M, 2008, AM J RESP CRIT CARE, V177, P613, DOI 10.1164/rccm.200703-373OC; SCHIECK M, 2013, J ALLERGY CLIN IMMUN, P9542; Stockinger B, 2007, CURR OPIN IMMUNOL, V19, P281, DOI 10.1016/j.coi.2007.04.005; TOBIN J, 1958, ECONOMETRICA, V26, P24, DOI 10.2307/1907382; Toda M, 2003, J ALLERGY CLIN IMMUN, V111, P875, DOI 10.1067/mai.2003.1414; von Mutius E, 2010, NAT REV IMMUNOL, V10, P861, DOI 10.1038/nri2871; Voo KS, 2009, P NATL ACAD SCI USA, V106, P4793, DOI 10.1073/pnas.0900408106; Waser M, 2007, CLIN EXP ALLERGY, V37, P661, DOI 10.1111/j.1365-2222.2006.02640.x; Zhang FP, 2008, NAT IMMUNOL, V9, P1297, DOI 10.1038/ni.1663	47	24	29	0	20	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2014	133	3					864	871		10.1016/j.jaci.2013.09.030	http://dx.doi.org/10.1016/j.jaci.2013.09.030			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC3EK	24275363	Bronze			2022-12-18	WOS:000332397600031
J	Ballardini, N; Bergstrom, A; Bohme, M; van Hage, M; Hallner, E; Johansson, E; Soderhall, C; Kull, I; Wickman, M; Wahlgren, CF				Ballardini, Natalia; Bergstrom, Anna; Bohme, Maria; van Hage, Marianne; Hallner, Eva; Johansson, Emma; Soderhall, Cilla; Kull, Inger; Wickman, Magnus; Wahlgren, Carl-Fredrik			Infantile eczema: Prognosis and risk of asthma and rhinitis in preadolescence	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ATOPIC-DERMATITIS; BIRTH COHORT; AGE; ASSOCIATION		[Ballardini, Natalia; Bergstrom, Anna; Hallner, Eva; Wickman, Magnus] Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden; [Ballardini, Natalia; Wickman, Magnus] Soder Sjukhuset, Sachs Children & Youth Hosp, S-10064 Stockholm, Sweden; [Bohme, Maria; Johansson, Emma; Wahlgren, Carl-Fredrik] Karolinska Univ Hosp, Dermatol & Venereol Unit, Stockholm, Sweden; [van Hage, Marianne] Karolinska Univ Hosp, Clin Immunol & Allergy Unit, Dept Med Solna, Karolinska Inst, Stockholm, Sweden; [Soderhall, Cilla] Karolinska Inst, Dept Biosci & Nutr, S-10401 Stockholm, Sweden; [Kull, Inger] Soder Sjukhuset, Karolinska Inst, Dept Clin Sci & Educ, S-10064 Stockholm, Sweden	Karolinska Institutet; Sodersjukhuset Hospital; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska Institutet; Sodersjukhuset Hospital	Ballardini, N (corresponding author), Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden.	natalia.ballardini@ki.se	Söderhäll, Cilla/E-3940-2012; Johansson, Emma K/AAD-7193-2022; van Hage, Marianne/A-9678-2017; Johansson, Emma/AAY-3468-2021	Söderhäll, Cilla/0000-0002-8397-3080; Johansson, Emma K/0000-0002-3318-3910; van Hage, Marianne/0000-0003-3091-1596; Kull, Inger/0000-0001-6096-3771; Ballardini, Natalia/0000-0001-6759-346X				Ballardini N, 2012, ALLERGY, V67, P537, DOI 10.1111/j.1398-9995.2012.02786.x; Bohme M, 2002, ACTA DERM-VENEREOL, V82, P98, DOI 10.1080/00015550252948112; Burr ML, 2013, BRIT J DERMATOL, V168, P1339, DOI 10.1111/bjd.12216; Illi S, 2004, J ALLERGY CLIN IMMUN, V113, P925, DOI 10.1016/j.jaci.2004.01.778; Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591; Ricci G, 2006, J AM ACAD DERMATOL, V55, P765, DOI 10.1016/j.jaad.2006.04.064; Wickman M, 2002, PEDIATR ALLERGY IMMU, V13, P11, DOI 10.1034/j.1399-3038.13.s.15.10.x; Williams HC, 2005, NEW ENGL J MED, V352, P2314, DOI 10.1056/NEJMcp042803; Williams HC, 2000, CLIN EXP DERMATOL, V25, P522, DOI 10.1046/j.1365-2230.2000.00698.x	9	24	25	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2014	133	2					594	U512		10.1016/j.jaci.2013.08.054	http://dx.doi.org/10.1016/j.jaci.2013.08.054			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC3EF	24332221				2022-12-18	WOS:000332397100044
J	Leung, TF; Ko, FWS; Sy, HY; Tsui, SKW; Wong, GWK				Leung, Ting F.; Ko, Fanny W. S.; Sy, Hing Y.; Tsui, Stephen K. W.; Wong, Gary W. K.			Differences in asthma genetics between Chinese and other populations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						sthma; genetics; genome-wide association study; next-generation sequencing; susceptibility	SUSCEPTIBILITY LOCI; ASSOCIATION; ATOPY; MARKERS; RISK; CD14	Asthma is caused by complex gene-gene and gene-environment interactions. Most asthma genes are not replicable across populations, which is possibly because of differences in the epidemiology of these genes. Our case-control association and next-generation sequencing studies revealed substantial discrepancies in the frequencies of single nucleotide polymorphisms (SNPs) and haplotype blocks for asthma genes between Chinese and other populations. The minor allele frequencies for nearly half of our studied SNPs differed by 0.2 or greater between southern Chinese subjects in Hong Kong and European white populations, African populations, or both. Because genome-wide association studies for asthma have not been performed in Chinese subjects, we cannot tell whether the genomic findings of recent consortium-based genome-wide association studies are applicable to our population. In addition, our group performed Roche 454 pyrosequencing on a 100-kb area spanning each of 10 asthma loci in 24 healthy Hong Kong children. For the 17q21 locus, there was substantial variation in the haplotype structures that were constructed from 224 common SNPs among Hong Kong subjects and 6 ethnic groups under the 1000 Genomes Project. Sixteen mostly small haplotype blocks were formed in Hong Kong, whereas 6 haplotype blocks were identified in Han Chinese in Beijing and central European subjects and 11 and 19 blocks were identified in Puerto Rican and Yoruba African subjects. In conclusion, differences in allele frequencies of asthma genes and haplotype structures of asthma loci are found between Chinese subjects and other ethnic groups. These sequence variations must be considered during the selection of tagging SNPs for replicating genetic associations between populations.	[Leung, Ting F.; Sy, Hing Y.; Wong, Gary W. K.] Chinese Univ Hong Kong, Dept Pediat, Hong Kong, Hong Kong, Peoples R China; [Ko, Fanny W. S.] Chinese Univ Hong Kong, Dept Med & Therapeut, Hong Kong, Hong Kong, Peoples R China; [Tsui, Stephen K. W.] Chinese Univ Hong Kong, Sch Biomed Sci, Hong Kong, Hong Kong, Peoples R China	Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong	Wong, GWK (corresponding author), Prince Wales Hosp, Dept Pediat, 6-F,Clinical Sci Bldg, Shatin, Hong Kong, Peoples R China.	wingkinwong@cuhk.edu.hk	LEUNG, Ting Fan/E-7728-2013; Tsui, Stephen Kwok-Wing/E-4385-2015; Wong, Gary WK/AAY-9207-2020; Yee, SY Hing/ABA-5396-2020; Ko, Fanny W. S./B-8958-2016	LEUNG, Ting Fan/0000-0002-6469-1926; Tsui, Stephen Kwok-Wing/0000-0003-0686-4259; Wong, Gary WK/0000-0001-5939-812X; Ko, Fanny W. S./0000-0001-8454-0087; Sy, Hing Yee/0000-0002-0298-1696	Research Grants Council General Research Fund of the Hong Kong SAR Government [469908, 470909, 477110]; Research Committee Group Research Scheme [3110034, 3110060, 3110087]; Direct Grants for Research of Chinese University of Hong Kong [2010.2.049, 2011.1.058]	Research Grants Council General Research Fund of the Hong Kong SAR Government; Research Committee Group Research Scheme; Direct Grants for Research of Chinese University of Hong Kong	Supported by the Research Grants Council General Research Fund (469908, 470909, and 477110) of the Hong Kong SAR Government and the Research Committee Group Research Scheme (3110034, 3110060, and 3110087) and Direct Grants for Research (2010.2.049 and 2011.1.058) of Chinese University of Hong Kong.	Altshuler DM, 2012, NATURE, V491, P56, DOI 10.1038/nature11632; [Anonymous], 2004, NAT GENET S11, V36, pS1; Chan IHS, 2006, J ALLERGY CLIN IMMUN, V117, P127, DOI 10.1016/j.jaci.2005.09.031; Hirota T, 2011, NAT GENET, V43, P893, DOI 10.1038/ng.887; Leung TF, 2012, J ALLERGY CLIN IMMUN, V129, pAB137, DOI 10.1016/j.jaci.2011.12.460; Leung TF, 2009, ALLERGY, V64, P621, DOI 10.1111/j.1398-9995.2008.01873.x; Leung TF, 2004, J ALLERGY CLIN IMMUN, V114, P199, DOI 10.1016/j.jaci.2004.03.048; Leung TF, 2003, PEDIAT ALLERG IMM-UK, V14, P255, DOI 10.1034/j.1399-3038.2003.00048.x; Leung TF, 2009, PEDIAT ALLERG IMM-UK, V20, P556, DOI 10.1111/j.1399-3038.2008.00835.x; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Myers RA, 2012, J ALLERGY CLIN IMMUN, V130, P1294, DOI 10.1016/j.jaci.2012.07.054; Noguchi E, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002170; Simpson A, 2006, AM J RESP CRIT CARE, V174, P386, DOI 10.1164/rccm.200509-1380OC; Sy HY, 2010, PEDIATR PULM, V45, P890, DOI 10.1002/ppul.21242; Sy HY, 2012, PHARMACOGENET GENOM, V22, P517, DOI 10.1097/FPC.0b013e3283535d91	16	24	29	1	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2014	133	1					42	48		10.1016/j.jaci.2013.09.018	http://dx.doi.org/10.1016/j.jaci.2013.09.018			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	281MM	24188974				2022-12-18	WOS:000329105700006
J	Otsuka, A; Hanakawa, S; Miyachi, Y; Kabashima, K				Otsuka, Atsushi; Hanakawa, Sho; Miyachi, Yoshiki; Kabashima, Kenji			CD39: A new surface marker of mouse regulatory gamma delta T cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Otsuka, Atsushi; Hanakawa, Sho; Miyachi, Yoshiki; Kabashima, Kenji] Kyoto Univ, Grad Sch Med, Dept Dermatol, Kyoto, Japan	Kyoto University	Otsuka, A (corresponding author), Kyoto Univ, Grad Sch Med, Dept Dermatol, Kyoto, Japan.	kaba@kuhp.kyoto-u.ac.jp	Kabashima, Kenji/G-2521-2014	Kabashima, Kenji/0000-0002-0773-0554; Otsuka, Atsushi/0000-0001-7365-947X				Borsellino G, 2007, BLOOD, V110, P1225, DOI 10.1182/blood-2006-12-064527; Drobyski WR, 2000, J IMMUNOL, V165, P1634, DOI 10.4049/jimmunol.165.3.1634; Hao JL, 2010, CELL MOL IMMUNOL, V7, P409, DOI 10.1038/cmi.2010.50; Honda T, 2013, J INVEST DERMATOL, V133, P303, DOI 10.1038/jid.2012.284; Peng G, 2007, IMMUNITY, V27, P334, DOI 10.1016/j.immuni.2007.05.020; Ribot JC, 2009, NAT IMMUNOL, V10, P427, DOI 10.1038/ni.1717; Shibata K, 2008, J IMMUNOL, V181, P5940, DOI 10.4049/jimmunol.181.9.5940; Vantourout P, 2013, NAT REV IMMUNOL, V13, P88, DOI 10.1038/nri3384	8	24	24	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2013	132	6					1448	1451		10.1016/j.jaci.2013.05.037	http://dx.doi.org/10.1016/j.jaci.2013.05.037			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	259PG	23870672				2022-12-18	WOS:000327538200031
J	Elholm, G; Schlunssen, V; Doekes, G; Basinas, I; Bibby, BM; Hjort, C; Gronager, PM; Omland, O; Sigsgaard, T				Elholm, Grethe; Schluenssen, Vivi; Doekes, Gert; Basinas, Ioannis; Bibby, Bo Martin; Hjort, Charlotte; Gronager, Pernille Milvang; Omland, Oyvind; Sigsgaard, Torben			Become a farmer and avoid new allergic sensitization: Adult farming exposures protect against new-onset atopic sensitization	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							HAY-FEVER; PARAMETERS; ASTHMA		[Elholm, Grethe; Schluenssen, Vivi; Basinas, Ioannis; Sigsgaard, Torben] Aarhus Univ, Dept Publ Hlth, Sect Environm Occupat & Hlth, Aarhus, Denmark; [Doekes, Gert] Univ Utrecht, Inst Risk Assessment Sci, Div Environm Epidemiol, Utrecht, Netherlands; [Bibby, Bo Martin] Aarhus Univ, Dept Publ Hlth, Biostat Sect, Aarhus, Denmark; [Hjort, Charlotte] Reg Hosp Viborg, Dept Qual & Res, Viborg, Denmark; [Gronager, Pernille Milvang] ALK Abello, Res ALK Abello, Horsholm, Denmark; [Omland, Oyvind] Aarhus Univ Hosp, Clin Occupat Med, Aalborg Hosp, Aalborg, Denmark	Aarhus University; Utrecht University; Aarhus University; ALK-Abello AS; Aalborg University; Aalborg University Hospital; Aarhus University	Elholm, G (corresponding author), Aarhus Univ, Dept Publ Hlth, Sect Environm Occupat & Hlth, Aarhus, Denmark.	gelh@mil.au.dk	Elholm, Grethe/AAL-5758-2021; Sigsgaard, Torben/AAC-1292-2020	Elholm, Grethe/0000-0003-0318-4506; Sigsgaard, Torben/0000-0002-2043-7571; Basinas, Ioannis/0000-0001-7708-3017; Schlunssen, Vivi/0000-0003-4915-1734				Arbes SJ, 2013, CLIN EXP ALLERGY, V43, P544, DOI 10.1111/cea.12069; Basinas I, 2012, OCCUP ENVIRON MED, V69, P99, DOI 10.1136/oem.2011.065169; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28, DOI 10.1046/j.1365-2222.1999.00479.x; Ege MJ, 2011, NEW ENGL J MED, V364, P701, DOI 10.1056/NEJMoa1007302; Elholm Grethe, 2010, Clin Epidemiol, V2, P45; Genuneit J, 2011, PAEDIATR PERINAT EP, V25, P436, DOI 10.1111/j.1365-3016.2011.01223.x; GREENLAND S, 1991, STAT MED, V10, P1069, DOI 10.1002/sim.4780100707; HOSMER DW, 1992, EPIDEMIOLOGY, V3, P452, DOI 10.1097/00001648-199209000-00012; Kalilani Linda, 2006, Epidemiol Perspect Innov, V3, P5, DOI 10.1186/1742-5573-3-5; Le Moual N, 2008, AM J RESP CRIT CARE, V177, P4, DOI 10.1164/rccm.200703-415PP; LEE J, 1981, J CHRON DIS, V34, P415, DOI 10.1016/0021-9681(81)90040-0; Rothman KJ., 2008, MODERN EPIDEMIOLOGY, V3rd ed; Skrondal A, 2003, AM J EPIDEMIOL, V158, P251, DOI 10.1093/aje/kwg113; Smit LAM, 2010, INT ARCH ALLERGY IMM, V152, P151, DOI 10.1159/000265536; SMITH D, 1987, J CHRON DIS, V40, P827, DOI 10.1016/0021-9681(87)90138-X; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; von Mutius E, 2010, NAT REV IMMUNOL, V10, P861, DOI 10.1038/nri2871	17	24	24	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2013	132	5					1239	1241		10.1016/j.jaci.2013.07.003	http://dx.doi.org/10.1016/j.jaci.2013.07.003			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	242JH	23987793				2022-12-18	WOS:000326235600035
J	Bors, A; Csuka, D; Varga, L; Farkas, H; Tordai, A; Fust, G; Szilagyi, A				Bors, Andras; Csuka, Dorottya; Varga, Lilian; Farkas, Henriette; Tordai, Attila; Fuest, George; Szilagyi, Agnes			Less severe clinical manifestations in patients with hereditary angioedema with missense C1INH gene mutations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							INHIBITOR DEFICIENCY		[Bors, Andras; Tordai, Attila] Semmelweis Univ, Hungarian Natl Blood Transfus Serv, Lab Mol Diagnost, H-1085 Budapest, Hungary; [Csuka, Dorottya; Varga, Lilian; Farkas, Henriette; Fuest, George; Szilagyi, Agnes] Semmelweis Univ, Dept Internal Med 3, H-1085 Budapest, Hungary	Semmelweis University; Semmelweis University	Bors, A (corresponding author), Semmelweis Univ, Hungarian Natl Blood Transfus Serv, Lab Mol Diagnost, H-1085 Budapest, Hungary.	szilagi@kut.sote.hu	Csuka, Dorottya/F-2224-2010; Szilagyi, Agnes/F-2337-2010	Csuka, Dorottya/0000-0003-3610-9852; Szilagyi, Agnes/0000-0002-9769-3215; Farkas, Henriette/0000-0003-2929-1721; Varga, Lilian/0000-0002-5484-364X				Agostoni A, 2004, J ALLERGY CLIN IMMUN, V114, pS51, DOI 10.1016/j.jaci.2004.06.047; Bork K, 2006, AM J MED, V119, P267, DOI 10.1016/j.amjmed.2005.09.064; Calafell F, 2010, HUM MOL GENET, V19, P517, DOI 10.1093/hmg/ddp517; Cicardi M, 2010, INTERN EMERG MED, V5, P481, DOI 10.1007/s11739-010-0408-3; Kalmar L, 2003, HUM MUTAT, V22, DOI 10.1002/humu.9202; Kanaji T, 1998, BLOOD, V91, P2010, DOI 10.1182/blood.V91.6.2010.2010_2010_2014; de la Cruz RM, 2012, IMMUNOL LETT, V141, P158, DOI 10.1016/j.imlet.2011.07.011; Simonovic I, 2000, BBA-PROTEIN STRUCT M, V1481, P97, DOI 10.1016/S0167-4838(00)00115-1; VERPY E, 1995, J CLIN INVEST, V95, P350, DOI 10.1172/JCI117663	9	24	24	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2013	131	6					1708	1711		10.1016/j.jaci.2012.11.015	http://dx.doi.org/10.1016/j.jaci.2012.11.015			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	166CT	23265861				2022-12-18	WOS:000320532800037
J	Abos-Gracia, B; del Moral, MG; Lopez-Relano, J; Viana-Huete, V; Castro, L; Villalba, M; Martinez-Naves, E				Abos-Gracia, Beatriz; Gomez del Moral, Manuel; Lopez-Relano, Juan; Viana-Huete, Vanesa; Castro, Lourdes; Villalba, Mayte; Martinez-Naves, Eduardo			Olea europaea pollen lipids activate invariant natural killer T cells by upregulating CD1d expression on dendritic cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Pollen lipids; Olea europaea; dendritic cells; invariant natural killer T cells; CD1d; peroxisome proliferator-activated receptor gamma	NKT CELLS; AIRWAY INFLAMMATION; ASTHMA; HYPERREACTIVITY; RECOGNITION; RECEPTORS; CHILDREN; ALPHA; IL-4	Background: Invariant natural killer T (iNKT) cells recognize lipids presented by CD1d and have been implicated in the pathogenesis of allergic asthma. Recognition of plant pollen lipids by iNKT cells and their role in allergic responses are poorly defined. Objective: Our goal was to investigate whether iNKT cells can be activated by monocyte-derived dendritic cells (DCs) exposed to lipid antigens from Olea europaea. Methods: DCs generated in vitro were exposed to O europaea pollen grains or lipids isolated from them. Expression of lipid-presenting molecules (CD1), as well as maturation markers (HLA-DR, HLA-I, CD86, and CD80 molecules), on DCs was analyzed. iNKT cell activation after coculture with DCs was evaluated based on expansion, cytokine production, and cytotoxicity tests. Results: DCs upregulated CD1d and CD86 expression and downregulated CD1a expression after exposure to a whole extract of olive pollen lipids. CD1d and CD1a were regulated at the transcriptional level in a peroxisome proliferator-activated receptor g activation-dependent manner. Polar lipids, diacylglycerols, free fatty acids, and triacylglycerols isolated from pollen grains upregulate CD1d. The increase in CD1d expression on the DC cell surface induced by polar lipids was not regulated at the RNA level. iNKT cells efficiently recognize DCs treated with the different lipids isolated from olive pollen grains. Conclusions: Lipids from O europaea pollen upregulate CD1d and CD86 molecules on DCs, which are then able to activate iNKT cells through a CD1d-dependent pathway.	[Abos-Gracia, Beatriz; Lopez-Relano, Juan; Viana-Huete, Vanesa; Martinez-Naves, Eduardo] Univ Complutense, Fac Med, Unidad Inmunol, E-28040 Madrid, Spain; [Gomez del Moral, Manuel] Univ Complutense, Fac Med, Dept Biol Celular, E-28040 Madrid, Spain; [Castro, Lourdes; Villalba, Mayte] Univ Complutense, Fac Quim, Dept Bioquim & Biol Mol 1, E-28040 Madrid, Spain	Complutense University of Madrid; Complutense University of Madrid; Complutense University of Madrid	Martinez-Naves, E (corresponding author), Univ Complutense, Fac Med, Unidad Inmunol, Avda Complutense S-N, E-28040 Madrid, Spain.	emnaves@med.ucm.es	MARTINEZ-NAVES, EDUARDO/Y-6177-2019; Gomez del Moral, Manuel/ABB-4917-2021; Villalba, Mayte/K-5365-2014; Gomez, Manuel/Z-3787-2019; Villalba, María Teresa/AAW-1067-2020	Gomez, Manuel/0000-0002-0642-8142; Villalba, María Teresa/0000-0002-0042-9953; Lopez-Relano, Juan/0000-0001-9620-3299; VIANA HUETE, VANESA/0000-0001-8390-1346; MARTINEZ-NAVES, EDUARDO/0000-0001-8136-9042	Spanish Ministerio de Sanidad [FIS-PI080125]; Universidad Complutense de Madrid [920631]; Universidad Complutense de Madrid	Spanish Ministerio de Sanidad(Spanish Government); Universidad Complutense de Madrid; Universidad Complutense de Madrid	Supported by grants from Spanish Ministerio de Sanidad (reference FIS-PI080125) and Universidad Complutense de Madrid (reference 920631, to E.M.-N.). B.A.-G. is the recipient of a predoctoral fellowship from Universidad Complutense de Madrid.	Agea E, 2005, J EXP MED, V202, P295, DOI 10.1084/jem.20050773; Akbari O, 2006, ALLERGY, V61, P962, DOI 10.1111/j.1398-9995.2006.01124.x; Akbari O, 2003, NAT MED, V9, P582, DOI 10.1038/nm851; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; Bertorelli G, 2000, ALLERGY, V55, P449, DOI 10.1034/j.1398-9995.2000.055005449.x; Bratke K, 2007, NEW ENGL J MED, V357, P194; Brennan PJ, 2011, NAT IMMUNOL, V12, P1202, DOI 10.1038/ni.2143; Das J, 2006, NAT MED, V12, P1345, DOI 10.1038/nm1206-1345; Fokkens WJ, 1998, CLIN EXP ALLERGY, V28, P187; Godfrey DI, 2004, J CLIN INVEST, V114, P1379, DOI 10.1172/JCI200423594; Hamzaoui A, 2006, MEDIAT INFLAMM, V2006, DOI 10.1155/MI/2006/71214; Jahnsen FL, 2001, THORAX, V56, P823, DOI 10.1136/thorax.56.11.823; Kawano T, 1997, SCIENCE, V278, P1626, DOI 10.1126/science.278.5343.1626; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; Koh YI, 2010, INT ARCH ALLERGY IMM, V153, P239, DOI 10.1159/000314364; Kronenberg M, 2005, NATURE, V435, P598, DOI 10.1038/nature03725; Lisbonne M, 2003, J IMMUNOL, V171, P1637, DOI 10.4049/jimmunol.171.4.1637; Liu Y, 2006, J IMMUNOL METHODS, V312, P34, DOI 10.1016/j.jim.2006.02.009; Matangkasombut P, 2009, J ALLERGY CLIN IMMUN, V123, P1181, DOI 10.1016/j.jaci.2009.02.013; Mattner J, 2005, NATURE, V434, P525, DOI 10.1038/nature03408; Meyer EH, 2006, P NATL ACAD SCI USA, V103, P2782, DOI 10.1073/pnas.0510282103; Mutalithas K, 2007, J ALLERGY CLIN IMMUN, V119, P1274, DOI 10.1016/j.jaci.2007.02.021; Pham-Thi N, 2006, J ALLERGY CLIN IMMUN, V117, P217, DOI 10.1016/j.jaci.2005.09.052; Pham-Thi N, 2006, NEW ENGL J MED, V354, P2615; Pichavant M, 2008, J EXP MED, V205, P385, DOI 10.1084/jem.20071507; Raghuraman G, 2006, J IMMUNOL, V177, P7841, DOI 10.4049/jimmunol.177.11.7841; Reynolds C, 2009, J ALLERGY CLIN IMMUN, V124, P860, DOI 10.1016/j.jaci.2009.07.022; RODRIGUEZROSALES MP, 1990, REV ESP FISIOL, V46, P371; Russano AM, 2006, J ALLERGY CLIN IMMUN, V117, P1178, DOI 10.1016/j.jaci.2006.01.001; Skold M, 2003, INFECT IMMUN, V71, P5447, DOI 10.1128/IAI.71.10.5447-5455.2003; Szatmari I, 2006, J EXP MED, V203, P2351, DOI 10.1084/jem.20060141; Thomas SY, 2006, NEW ENGL J MED, V354, P2613; Thomas SY, 2007, J IMMUNOL, V179, P1901, DOI 10.4049/jimmunol.179.3.1901; Traidl-Hoffmann C, 2005, J EXP MED, V201, P627, DOI 10.1084/jem.20041065; Venkataswamy MM, 2010, SEMIN IMMUNOL, V22, P68, DOI 10.1016/j.smim.2009.10.003; Vijayanand P, 2007, NEW ENGL J MED, V356, P1410, DOI 10.1056/NEJMoa064691; Wingender G, 2011, J EXP MED, V208, P1151, DOI 10.1084/jem.20102229	37	24	25	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2013	131	5					1393	U221		10.1016/j.jaci.2012.11.014	http://dx.doi.org/10.1016/j.jaci.2012.11.014			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	144AU	23265858	Bronze			2022-12-18	WOS:000318912200017
J	Newcombe, PA; Sheffield, JK; Chang, AB				Newcombe, Peter A.; Sheffield, Jeanie K.; Chang, Anne B.			Parent cough-specific quality of life: Development and validation of a short form	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Quality of life; pediatric cough; psychometrics; minimally important difference	MINIMALLY IMPORTANT DIFFERENCES; CYSTIC FIBROSIS BRONCHIECTASIS; HEALTH-STATUS; QUESTIONNAIRE; CHILDREN; SCALES; RELIABILITY; VALIDITY; OUTCOMES; DISEASE	Background: Cough is a distressing symptom and has a significant effect on many children and their families. Quality-of-life (QOL) measures provide important outcome indicators for clinicians and aid in evaluating the efficacy of interventions. Objective: The aim of this study was to develop and validate a short cough-specific QOL questionnaire for pediatric use. Method: Two sources provided data to establish a shortened version of the Parent Cough-specific Quality of Life (PC-QOL) questionnaire. The first (n = 240, 137 boys; median age, 29 months [interquartile range, 14-64 months]) was used for development and cross-validation. Stepwise regression was used to select the reduced set of items, and analyses of reliability, validity, and minimally important differences determined psychometric strength and sensitivity to change. The second independent dataset (n = 320, 190 boys; median age, 39.5 months [interquartile range, 16-77 months]) was used as a confirmatory sample. Results: Forward-step regression identified 8 items that accounted for 95% of the variance in the full-scale PC-QOL questionnaire. This shortened version (PC-QOL-8) was internally consistent (Cronbach a = 0.84), had good test-retest reliability (intraclass correlation coefficient = 0.66), and demonstrated strong validity (significant correlations with a cough verbal category descriptor score, cough visual analog scale, and subscales of the Short Form-12 General Health scale, the Pediatric Quality of Life Inventory, and the Depression, Anxiety, and Stress Scale). The reduced scale was responsive to change, and a minimally important difference of 0.9 was suggested. These findings were confirmed with the second dataset. Conclusion: The PC-QOL-8 questionnaire is a short, reliable, and valid instrument for assessing the effect of a child's chronic cough. It demonstrated sensitivity to change, and its length and psychometric properties should enhance its potential uptake and routine use in clinical practice and research. (J Allergy Clin Immunol 2013; 131:1069-74.)	[Newcombe, Peter A.] Univ Queensland, Sch Social Work & Appl Human Sci, Brisbane, Qld 4072, Australia; [Newcombe, Peter A.; Sheffield, Jeanie K.] Univ Queensland, Sch Psychol, Brisbane, Qld 4072, Australia; [Chang, Anne B.] Royal Childrens Hosp, Queensland Childrens Resp Ctr, Brisbane, Qld, Australia; [Chang, Anne B.] Royal Childrens Hosp, Queensland Childrens Med Res Inst, Brisbane, Qld, Australia; [Chang, Anne B.] Menzies Sch Hlth Res, Child Hlth Div, Darwin, NT, Australia	University of Queensland; University of Queensland; Royal Children's Hospital Brisbane; Royal Children's Hospital Brisbane; Charles Darwin University; Menzies School of Health Research	Newcombe, PA (corresponding author), Univ Queensland, Sch Psychol, Brisbane, Qld 4072, Australia.	newc@psy.uq.edu.au	Newcombe, Peter/C-1480-2016; Chang, Anne/F-2066-2013	Newcombe, Peter/0000-0002-5969-396X; Chang, Anne/0000-0002-1331-3706	National Health and Medical Research Council (NHMRC) [490321, 545216]; Royal Children's Hospital Foundation; Queensland Children's Medical Research Institute [50004]	National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); Royal Children's Hospital Foundation; Queensland Children's Medical Research Institute	This work for the MSCAPE database was supported by the National Health and Medical Research Council (NHMRC, grant ID 490321). Salary support for A. B. C. to conduct this work was provided by the NHMRC (grant ID 545216). The views expressed in this publication are those of the authors and do not reflect the views of the NHMRC. The work for the PCS database was supported by the Royal Children's Hospital Foundation and the Queensland Children's Medical Research Institute (grant no. 50004).	Birring SS, 2003, THORAX, V58, P339, DOI 10.1136/thorax.58.4.339; Chang AB, 1998, EUR RESPIR J, V11, P462, DOI 10.1183/09031936.98.11020462; Chang AB, 1997, AM J RESP CRIT CARE, V155, P1935, DOI 10.1164/ajrccm.155.6.9196099; Chang AB, 2003, ARCH DIS CHILD, V88, P57, DOI 10.1136/adc.88.1.57; Chang AB, 2012, CHEST; Chang AB, 2011, EXPERT REV RESP MED, V5, P503, DOI [10.1586/ers.11.35, 10.1586/ERS.11.35]; Crawford JR, 2003, BRIT J CLIN PSYCHOL, V42, P111, DOI 10.1348/014466503321903544; de Vet HCW, 2010, J CLIN EPIDEMIOL, V63, P37, DOI 10.1016/j.jclinepi.2009.03.011; Higginson IJ, 2001, BRIT MED J, V322, P1297, DOI 10.1136/bmj.322.7297.1297; Irwin RS, 2006, CHEST, V129, p232S, DOI 10.1378/chest.129.1_suppl.232S; Jones PW, 2009, EUR RESPIR J, V34, P648, DOI 10.1183/09031936.00102509; JUNIPER EF, 1994, J CLIN EPIDEMIOL, V47, P81, DOI 10.1016/0895-4356(94)90036-1; JUNIPER EF, 1992, THORAX, V47, P76, DOI 10.1136/thx.47.2.76; Juniper EF, 1996, QUAL LIFE RES, V5, P35, DOI 10.1007/BF00435967; Kalpaklioglu AF, 2005, ANN ALLERG ASTHMA IM, V94, P581, DOI 10.1016/S1081-1206(10)61137-4; Kapur N, 2012, CHEST, V141, P1018, DOI 10.1378/chest.11-0679; KAZIS LE, 1989, MED CARE, V27, pS178, DOI 10.1097/00005650-198903001-00015; Landgraf JM, 2004, QUALITY LIFE PHARMAC, P793; Lemieux J, 2007, J CLIN EPIDEMIOL, V60, P448, DOI 10.1016/j.jclinepi.2006.08.006; Lovibond P.F, 1995, MANUAL DEPRESSION AN, Vsecond; Marchant JM, 2008, CHEST, V134, P303, DOI 10.1378/chest.07-2236; Morice AH, 2007, EUR RESPIR J, V29, P1256, DOI 10.1183/09031936.00101006; Murray MP, 2009, EUR RESPIR J, V34, P125, DOI 10.1183/09031936.00160508; Newcombe PA, 2008, CHEST, V133, P386, DOI 10.1378/chest.07-0888; Newcombe PA, 2011, CHEST, V139, P576, DOI 10.1378/chest.10-1476; Shikiar Richard, 2005, Health Qual Life Outcomes, V3, P36, DOI 10.1186/1477-7525-3-36; Solans M, 2008, VALUE HEALTH, V11, P742, DOI 10.1111/j.1524-4733.2007.00293.x; Tabachnick B. G., 2015, USING MULTIVARIATE S; Testa MA, 1996, NEW ENGL J MED, V334, P835, DOI 10.1056/NEJM199603283341306; Varni JW, 2001, MED CARE, V39, P800, DOI 10.1097/00005650-200108000-00006; Varni JW, 2004, J RHEUMATOL, V31, P2494; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; Wiebe S, 2003, J CLIN EPIDEMIOL, V56, P52, DOI 10.1016/S0895-4356(02)00537-1; Wyrwich Kathleen W, 2004, J Biopharm Stat, V14, P97, DOI 10.1081/BIP-120028508; Wyrwich KW, 2005, QUAL LIFE RES, V14, P285, DOI 10.1007/s11136-004-0705-2; Wyrwich KW, 2000, J EVAL CLIN PRACT, V6, P39, DOI 10.1046/j.1365-2753.2000.00238.x; Yost KJ, 2011, J CLIN EPIDEMIOL, V64, P507, DOI 10.1016/j.jclinepi.2010.11.018; Yost KJ, 2005, EVAL HEALTH PROF, V28, P172, DOI 10.1177/0163278705275340; Young Emma C, 2010, Ther Adv Respir Dis, V4, P49, DOI 10.1177/1753465809358249	39	24	24	1	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2013	131	4					1069	1074		10.1016/j.jaci.2012.10.004	http://dx.doi.org/10.1016/j.jaci.2012.10.004			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	120QT	23146374				2022-12-18	WOS:000317187200015
J	Al-Herz, W; Al-Mousa, H				Al-Herz, Waleed; Al-Mousa, Hamoud			Combined immunodeficiency: The Middle East experience	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Primary immunodeficiencies; combined; Middle East; consanguinity	AUTOSOMAL RECESSIVE FORM; MUTATIONS; GENE; CONSANGUINITY; DISORDERS	Previous reports about primary immunodeficiency disorders have shown variations in the frequency and distribution among populations from different ethnic and geographic backgrounds. In this review we describe peculiarities about combined immunodeficiencies (CIDs) in the Middle East. The frequency and type of genetic defects causing CIDs in this region differ in comparison with those in other populations because of the common practice of consanguineous marriage in the Middle East, which results in the relative increase in autosomal recessive diseases. We highlight some of the challenges in the awareness, diagnosis, and therapy of CIDs in the region and the research opportunities, especially those directed toward the identification of novel disease-causing genes. (J Allergy Clin Immunol 2013;131:658-60.)	[Al-Herz, Waleed] Kuwait Univ, Dept Pediat, Fac Med, Safat 13110, Kuwait; [Al-Herz, Waleed] Al Sabah Hosp, Dept Pediat, Allergy & Clin Immunol Unit, Kuwait, Kuwait; [Al-Mousa, Hamoud] King Faisal Specialist Hosp & Res Ctr, Dept Pediat, Riyadh 11211, Saudi Arabia; [Al-Mousa, Hamoud] King Faisal Specialist Hosp & Res Ctr, Dept Genet, Res Ctr, Riyadh 11211, Saudi Arabia; [Al-Mousa, Hamoud] Alfaisal Univ, Coll Med, Riyadh, Saudi Arabia	Kuwait University; Al Sabah Hospital; King Faisal Specialist Hospital & Research Center; King Faisal Specialist Hospital & Research Center; Alfaisal University	Al-Herz, W (corresponding author), Kuwait Univ, Dept Pediat, Fac Med, Safat 13110, Kuwait.	wemh@hotmail.com	Al-Mousa, Hamoud/AAS-4477-2020					Al-Ghonaium A, 2008, BONE MARROW TRANSPL, V42, pS53, DOI 10.1038/bmt.2008.115; Al-Herz W, 2011, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00054; Al-Herz W, 2011, INT ARCH ALLERGY IMM, V154, P76, DOI 10.1159/000319212; Boztug K, 2009, CURR OPIN IMMUNOL, V21, P472, DOI 10.1016/j.coi.2009.09.003; Chan K, 2011, MOL GENET METAB, V104, P383, DOI 10.1016/j.ymgme.2011.07.007; Ferrari S, 2001, P NATL ACAD SCI USA, V98, P12614, DOI 10.1073/pnas.221456898; Lee PPW, 2011, J CLIN IMMUNOL, V31, P281, DOI 10.1007/s10875-010-9489-z; Lipstein EA, 2010, PEDIATRICS, V125, pE1226, DOI 10.1542/peds.2009-1567; MACCHI P, 1995, NATURE, V377, P65, DOI 10.1038/377065a0; Morinishi Y, 2009, J PEDIATR-US, V155, P829, DOI 10.1016/j.jpeds.2009.05.026; Puck JM, 2012, J ALLERGY CLIN IMMUN, V129, P607, DOI 10.1016/j.jaci.2012.01.032; Revy P, 2000, CELL, V102, P565, DOI 10.1016/S0092-8674(00)00079-9; Rezaei N, 2006, AM J REPROD IMMUNOL, V56, P145, DOI 10.1111/j.1600-0897.2006.00409.x; Roscioli T, 2006, NAT GENET, V38, P620, DOI 10.1038/ng1780; Teebi AS, 2005, COMMUNITY GENET, V8, P21, DOI 10.1159/000083333; Yee A, 2008, PEDIAT ALLERG IMM-UK, V19, P298, DOI 10.1111/j.1399-3038.2007.00646.x; Zhang Q, 2009, NEW ENGL J MED, V361, P2046, DOI 10.1056/NEJMoa0905506; zur Stadt U, 2009, AM J HUM GENET, V85, P482, DOI 10.1016/j.ajhg.2009.09.005	18	24	24	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2013	131	3					658	660		10.1016/j.jaci.2012.11.033	http://dx.doi.org/10.1016/j.jaci.2012.11.033			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	098ZM	23321211				2022-12-18	WOS:000315587800004
J	Teraki, Y; Kawabe, M; Izaki, S				Teraki, Yuichi; Kawabe, Misaki; Izaki, Seiichi			Possible role of T(H)17 cells in the pathogenesis of Stevens-Johnson syndrome and toxic epidermal necrolysis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Teraki, Yuichi; Kawabe, Misaki; Izaki, Seiichi] Saitama Med Univ, Dept Dermatol, Saitama Med Ctr, Saitama, Japan	Saitama Medical University	Teraki, Y (corresponding author), Saitama Med Univ, Dept Dermatol, Saitama Med Ctr, Saitama, Japan.	teraki@saitama-med.ac.jp						Arakawa M, 2011, EXP DERMATOL, V20, P1022, DOI 10.1111/j.1600-0625.2011.01378.x; Borchers AT, 2008, AUTOIMMUN REV, V7, P598, DOI 10.1016/j.autrev.2008.06.004; Caproni M, 2006, BRIT J DERMATOL, V154, P319, DOI 10.1111/j.1365-2133.2005.07023.x; Downey A, 2012, J AM ACAD DERMATOL, V66, P995, DOI 10.1016/j.jaad.2011.09.029; Krueger JG, 2012, J ALLERGY CLIN IMMUN, V130, P145, DOI 10.1016/j.jaci.2012.04.024; Louten J, 2009, J ALLERGY CLIN IMMUN, V123, P1004, DOI 10.1016/j.jaci.2009.04.003; Mockenhaupt M, 2011, EXPERT REV CLIN IMMU, V7, P803, DOI [10.1586/eci.11.66, 10.1586/ECI.11.66]; Pennino D, 2010, J IMMUNOL, V184, P4880, DOI 10.4049/jimmunol.0901767; Teraki Y, 2003, J ALLERGY CLIN IMMUN, V112, P609, DOI 10.1037/mai.2003.1653	9	24	28	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2013	131	3					907	909		10.1016/j.jaci.2012.08.042	http://dx.doi.org/10.1016/j.jaci.2012.08.042			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	098ZM	23083672				2022-12-18	WOS:000315587800037
J	Myers, RA; Himes, BE; Gignoux, CR; Yang, JJ; Gauderman, WJ; Rebordosa, C; Xie, JM; Torgerson, DG; Levin, AM; Baurley, J; Graves, PE; Mathias, RA; Romieu, I; Roth, LA; Conti, D; Avila, L; Eng, C; Vora, H; LeNoir, MA; Soto-Quiros, M; Liu, JH; Celedon, JC; Farber, HJ; Kumar, R; Avila, PC; Meade, K; Serebrisky, D; Thyne, S; Rodriguez-Cintron, W; Rodriguez-Santana, JR; Borrell, LN; Lemanske, RF; Bleecker, ER; Meyers, DA; London, SJ; Barnes, KC; Raby, BA; Martinez, FD; Gilliland, FD; Williams, LK; Burchard, EG; Weiss, ST; Nicolae, DL; Ober, C				Myers, Rachel A.; Himes, Blanca E.; Gignoux, Christopher R.; Yang, James J.; Gauderman, W. James; Rebordosa, Cristina; Xie, Jianming; Torgerson, Dara G.; Levin, Albert M.; Baurley, James; Graves, Penelope E.; Mathias, Rasika A.; Romieu, Isabelle; Roth, Lindsey A.; Conti, David; Avila, Lydiana; Eng, Celeste; Vora, Hita; LeNoir, Michael A.; Soto-Quiros, Manuel; Liu, Jinghua; Celedon, Juan C.; Farber, Harold J.; Kumar, Rajesh; Avila, Pedro C.; Meade, Kelley; Serebrisky, Denise; Thyne, Shannon; Rodriguez-Cintron, William; Rodriguez-Santana, Jose R.; Borrell, Luisa N.; Lemanske, Robert F., Jr.; Bleecker, Eugene R.; Meyers, Deborah A.; London, Stephanie J.; Barnes, Kathleen C.; Raby, Benjamin A.; Martinez, Fernando D.; Gilliland, Frank D.; Williams, L. Keoki; Burchard, Esteban G.; Weiss, Scott T.; Nicolae, Dan L.; Ober, Carole			Further replication studies of the EVE Consortium meta-analysis identifies 2 asthma risk loci in European Americans	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; genetic risk factors; meta-analysis; KLK3	GENOME-WIDE ASSOCIATION; PROSTATE-SPECIFIC ANTIGEN; SUSCEPTIBILITY LOCI; INNATE IMMUNITY; VARIANTS; GENETICS; SCREEN; SEQUENCE	Background: Genome-wide association studies of asthma have implicated many genetic risk factors, with well-replicated associations at approximately 10 loci that account for only a small proportion of the genetic risk. Objectives: We aimed to identify additional asthma risk loci by performing an extensive replication study of the results from the EVE Consortium meta-analysis. Methods: We selected 3186 single nucleotide polymorphisms for replication based on the P values from the EVE Consortium meta-analysis. These single nucleotide polymorphisms were genotyped in ethnically diverse replication samples from 9 different studies, totaling 7202 cases, 6426 controls, and 507 case-parent trios. Association analyses were conducted within each participating study, and the resulting test statistics were combined in a meta-analysis. Results: Two novel associations were replicated in European Americans: rs1061477 in the KLK3 gene on chromosome 19 (combined odds ratio = 1.18; 95% CI, 1.10-1.25) and rs9570077 (combined odds ratio =1.20; 95% CI, 1.12-1.29) on chromosome 13q21. We could not replicate any additional associations in the African Americans or Latinos. Conclusions: This extended replication study identified 2 additional asthma risk loci in populations of European descent. The absence of additional loci for African Americans and Latinos highlights the difficulty in replicating associations in admixed populations. (J Allergy Clin Immunol 2012;130:1294-301.)	[Myers, Rachel A.; Xie, Jianming; Nicolae, Dan L.; Ober, Carole] Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA; [Himes, Blanca E.; Raby, Benjamin A.; Weiss, Scott T.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Channing Div Network Med, Boston, MA 02115 USA; [Gignoux, Christopher R.; Torgerson, Dara G.; Roth, Lindsey A.; Eng, Celeste; Burchard, Esteban G.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA; [Yang, James J.; Levin, Albert M.] Henry Ford Hlth Syst, Dept Publ Hlth Sci, Detroit, MI USA; [Gauderman, W. James; Baurley, James; Conti, David; Vora, Hita; Liu, Jinghua; Gilliland, Frank D.] Univ So Calif, Dept Preventat Med, Los Angeles, CA USA; [Rebordosa, Cristina; Graves, Penelope E.; Martinez, Fernando D.] Univ Arizona, Arizona Resp Ctr, Tucson, AZ USA; [Rebordosa, Cristina; Graves, Penelope E.; Martinez, Fernando D.] Univ Arizona, Inst BIO5, Tucson, AZ USA; [Xie, Jianming] Southeast Univ, Sch Biol Sci & Med Engn, Nanjing, Jiangsu, Peoples R China; [Mathias, Rasika A.; Barnes, Kathleen C.] Johns Hopkins Univ, Dept Med, Baltimore, MD USA; [Romieu, Isabelle] Inst Nacl Salud Publ, Mexico City, DF, Mexico; [Romieu, Isabelle] Int Agcy Res Canc, F-69372 Lyon, France; [Avila, Lydiana; Soto-Quiros, Manuel] Hosp Nacl Ninos Dr Carlos Saenz Herrera, San Jose, Costa Rica; [LeNoir, Michael A.] Bay Area Pediat, Oakland, CA USA; [Celedon, Juan C.] Univ Pittsburgh, Div Pediat Pulmonol, Pittsburgh, PA USA; [Farber, Harold J.] Baylor Coll Med, Dept Pediat, Sect Pulmonol, Houston, TX 77030 USA; [Kumar, Rajesh] Ann & Robert H Lurie Childrens Hosp Chicago, Div Allergy & Immunol, Chicago, IL USA; [Avila, Pedro C.] Northwestern Univ, Dept Med, Chicago, IL 60611 USA; [Meade, Kelley] Childrens Hosp Oakland, Oakland, CA USA; [Serebrisky, Denise] Albert Einstein Coll Med, Jacobi Med Ctr, Bronx, NY 10467 USA; [Serebrisky, Denise] Albert Einstein Coll Med, Dept Pediat, Bronx, NY 10467 USA; [Thyne, Shannon] Univ Calif San Francisco, Dept Pediat, San Francisco, CA USA; [Rodriguez-Cintron, William] Vet Affairs Med Ctr, San Juan, PR USA; [Rodriguez-Santana, Jose R.] Ctr Neumol Pediat, San Juan, PR USA; [Borrell, Luisa N.] CUNY Herbert H Lehman Coll, Dept Hlth Sci, New York, NY USA; [Lemanske, Robert F., Jr.] Univ Wisconsin, Dept Pediat, Madison, WI USA; [Bleecker, Eugene R.] Wake Forest Sch Med, Ctr Human Genom, Winston Salem, NC USA; [Meyers, Deborah A.; London, Stephanie J.] NIEHS, NIH, Dept Hlth & Human Serv, Res Triangle Pk, NC 27709 USA; [Williams, L. Keoki] Henry Ford Hlth Syst, Ctr Hlth Serv Res, Dept Internal Med, Detroit, MI USA; [Burchard, Esteban G.] Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA; [Nicolae, Dan L.] Univ Chicago, Dept Med, Chicago, IL 60637 USA; [Nicolae, Dan L.] Univ Chicago, Dept Stat, Chicago, IL 60637 USA	University of Chicago; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of California System; University of California San Francisco; Henry Ford Health System; Henry Ford Hospital; University of Southern California; University of Arizona; University of Arizona; Southeast University - China; Johns Hopkins University; Instituto Nacional de Salud Publica; World Health Organization; International Agency for Research on Cancer (IARC); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Baylor College of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland; Jacobi Medical Center; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); City University of New York (CUNY) System; Lehman College (CUNY); University of Wisconsin System; University of Wisconsin Madison; Wake Forest University; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Henry Ford Health System; Henry Ford Hospital; University of California System; University of California San Francisco; University of Chicago; University of Chicago	Ober, C (corresponding author), 920 E 58th St,CLSC Room 425, Chicago, IL 60637 USA.	ober@genetics.uchicago.edu	Avila, Lydiana/D-5638-2015; Raby, Benjamin/AAK-3866-2021; liu, jinghua/H-4516-2014; Borrell, Luisa N./G-8753-2018; London, Stephanie/C-3734-2019	Avila, Lydiana/0000-0002-9579-1591; Borrell, Luisa N./0000-0002-0560-4853; Galanter, Joshua/0000-0002-2561-6384; Ober, Carole/0000-0003-4626-9809; Nicolae, Dan/0000-0002-0918-4630; Kumar, Rajesh/0000-0002-1962-7108; London, Stephanie/0000-0003-4911-5290; Rebordosa, Cristina/0000-0002-8064-5997	National Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health (NIH); NIH; UpToDate; EMD China; American Academy of Pediatrics; University of California; NHLBI; Pharmaxis; Michigan Public Health Institute; Allegheny General Hospital; West Allegheny Health Systems, Inc; California Chapter 4; AAP; Colorado Allergy Society; Pennsylvania Allergy and Asthma Association; Harvard Pilgrim Health; California Society of Allergy; NYC Allergy Society; World Allergy Organization; American College of Chest Physicians; American Academy of Allergy, Asthma, Immunology; Elsevier; Abbott; Merck; National Institute of Allergy and Infectious Diseases; Office of the Director, National Institutes of Health (NIH); National Heart, Lung, and Blood Institute [HL087665, HL070831, HL072414, HL049596, HL064307, HL064313, HL075419, HL65899, HL083069, HL066289, HL101543, HL101651, HL079055, HL087699, HL49612, HL075417, HL04266, HL072433, HL061768, HL076647, HL087680, HL078885, HL088133, HL87665]; National Institute of Diabetes and Digestive and Kidney Diseases [DK064695]; National Institutes of Environmental Health Sciences [ES09606, ES018176, ES015903, ES007048, ES009581, R826708, RD831861, ES011627, ES015794]; Division of Intramural Research [Z01 ES049019]; National Center for Research Resources [RR03048, RR00188]; Environmental Protection Agency [83213901, R-826724]; American Asthma Foundation; Fund for Henry Ford Hospital; Mary Beryl Patch Turnbull Scholar Program; Flight Attendant Medical Research Institute (FAMRI); Robert Wood Johnson Foundation (RWJF); Amos Medical Faculty Development Award; Sandler Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL066289, RC2HL101543, U01HL075417, U10HL064313, P01HL083069, R01HL079055, R01HL087665, R01HL078885, R01HL087699, R01HL087680, U01HL065899, R01HL076647, R01HL061768, U01HL049612, U01HL075419, U01HL072433, RC2HL101651, U10HL064307, U01HL049596, R01HL088133, R01HL066289, R01HL072414, P01HL070831, K23HL004266] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041040, R01AI061774, R01AI079139, U19AI077439, R18AI044840, R01AI044840, U19AI070503] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK064695] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES009606, ZIAES049019, P01ES018176, P50ES015903, P30ES007048, P01ES009581, P01ES011627, P50ES018176] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); UpToDate; EMD China; American Academy of Pediatrics; University of California(University of California System); NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Pharmaxis; Michigan Public Health Institute; Allegheny General Hospital(General Electric); West Allegheny Health Systems, Inc; California Chapter 4; AAP; Colorado Allergy Society; Pennsylvania Allergy and Asthma Association; Harvard Pilgrim Health; California Society of Allergy; NYC Allergy Society; World Allergy Organization; American College of Chest Physicians(General Electric); American Academy of Allergy, Asthma, Immunology; Elsevier; Abbott(Abbott Laboratories); Merck(Merck & Company); National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Office of the Director, National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); National Institutes of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Division of Intramural Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Environmental Protection Agency(United States Environmental Protection Agency); American Asthma Foundation; Fund for Henry Ford Hospital; Mary Beryl Patch Turnbull Scholar Program; Flight Attendant Medical Research Institute (FAMRI); Robert Wood Johnson Foundation (RWJF)(Robert Wood Johnson Foundation (RWJF)); Amos Medical Faculty Development Award; Sandler Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	C. R. Gignoux has received grants and travel support from the National Heart, Lung, and Blood Institute (NHLBI) and has stock/ stock options in 23andMe, Inc. A. M. Levin has received grants and travel support from the National Institutes of Health (NIH) and is employed by Henry Ford Health System. R. A. Mathias has received grants from the NIH and the NHLBI and is employed by Johns Hopkins University. W. J. Gauderman, J. Baurley, L. A. Roth, D. Conti, R. Kumar, P. C. Avila, S. Thyne, J. R. Rodriguez-Santana, L. N. Borrell, F. D. Gilliland, E. G. Burchard, and D. L. Nicolae have received grants from the NIH. L. Avila has received payment for lectures, including service on speakers' bureaus, from Merck Sharpe Dohme and AstraZeneca. M. A. LeNoir receives payment for lectures, including service on speakers' bureaus, from Teva and GlaxoSmithKline. J. C. Celedon has received grants from the NIH, has consultant arrangements with Genentech, and receives royalties from UpToDate. H. J. Farber has received grants from the NIH, is employed by the Texas Children's Health Plan, has received payment for lectures from EMD China, has received payment for manuscript preparation from Web MD, has received travel expenses from the American Academy of Pediatrics, and has received honoraria for service as the Editor of Pediatric Allergy, Immunology, and Pulmonology from Mary Ann Liebert, Inc. D. Serebrisky has received grants from the NIH and has received payment for lectures, including service on speakers' bureaus, from Teva. W. Rodriguez-Cintron has received grants from the University of California, San Francisco. R. F. Lemankse, Jr has received travel support and fees for participation in review activities from the NIH; has consultant arrangements with Merck, Sepracor, SA Boney and Associates, LTD, GlaxoSmithKline, American Institute of Research, Genentech, Inc, Double Helix Development, Inc, and Boerhinger Ingelheim; is employed by the University of Wisconsin School of Medicine and Public Health; has received grants from the NHLBI and Pharmaxis; has received payment for lectures, including service on speakers' bureaus, from the Michigan Public Health Institute, Allegheny General Hospital, the American Academy of Pediatrics, West Allegheny Health Systems, Inc, California Chapter 4, AAP, the Colorado Allergy Society, the Pennsylvania Allergy and Asthma Association, Harvard Pilgrim Health, the California Society of Allergy, the NYC Allergy Society, the World Allergy Organization, and the American College of Chest Physicians; has received payment for manuscript preparation from the American Academy of Allergy, Asthma,& Immunology; and has received royalties from Elsevier and UpToDate. D. A. Meyers has received grants from the NHLBI. K. C. Barnes has received grants from the NIH and the NHLBI; has board membership with Genentech; has consultant arrangements with Sanofi-Aventis and Sirius Genomics; is employed by Johns Hopkins University; and has received payments for lectures, including service on speakers' bureaus, from the "Evolution and Diseases of Modern Environments" Symposium, the American Academy of Allergy, Asthma, & Immunology, the Cincinnati CHMC Allergy Conference, and the 50th Annual Swineford Allergy Conference. B. A. Raby has received grants from the NIH and has received royalties from UpToDate, Inc. F. D. Martinez has consultant arrangements with MedImmune, has received grants from the NIH, has received payment for lectures, including service on speakers' bureaus, from Abbott and Merck, and has received travel expenses from Abbott and Merck.; L. K. Williams has received grants from the National Institute of Allergy and Infectious Diseases and the NHLBI. C. Ober has received grants, travel support, fees for participation in review activities, and payment for lectures, including service on speakers' bureaus, from the NIH. The rest of the authors declare that they have no relevant conflicts of interest.; Supported by grants from the Office of the Director, National Institutes of Health (NIH) to C.O. and D.L.N.; the National Heart, Lung, and Blood Institute (HL101651 to C.O. and D.L.N.; HL087665 to D. L. N.; HL070831, HL072414, and HL049596 to C.O.; HL064307 and HL064313 to F. D. M.; HL075419, HL65899, HL083069, HL066289, HL087680, HL101543, and HL101651 to S. T. W.; HL079055 to L. K. W.; HL087699, HL49612, HL075417, HL04266, and HL072433 to K. C. B.; HL061768 and HL076647 to F. D. G.; HL087680 to W.J.G.; HL078885 and HL088133 to E. G. B.; and HL87665 to D. A. M.); the National Institutes of Allergy and Infectious Disease (AI070503 to C.O.; AI079139 and AI061774 to L. K. W.; AI50024, AI44840, and AI41040 to K. C. B.; and AI077439 to E. G. B.); the National Institute of Diabetes and Digestive and Kidney Diseases to L. K. W. (DK064695); the National Institutes of Environmental Health Sciences (ES09606, ES018176, and ES015903 to K. C. B.; ES007048, ES009581, R826708, RD831861, and ES011627 to F. D. G.; ES015794 to E. G. B.; and the Division of Intramural Research, Z01 ES049019 to S.J.L.); the National Center for Research Resources (RR03048 to K. C. B., RR00188 to H.J.F.); the Environmental Protection Agency (83213901 and R-826724 to K. C. B.); the American Asthma Foundation and the Fund for Henry Ford Hospital (to L. K. W.); Mary Beryl Patch Turnbull Scholar Program (to K. C. B.); and the Flight Attendant Medical Research Institute (FAMRI), Robert Wood Johnson Foundation (RWJF) Amos Medical Faculty Development Award, the American Asthma Foundation, and the Sandler Foundation (to E. G. B.).	Bochkov YA, 2010, MUCOSAL IMMUNOL, V3, P69, DOI 10.1038/mi.2009.109; Bustamante CD, 2011, NATURE, V475, P163, DOI 10.1038/475163a; Choudhry S, 2008, HUM GENET, V123, P455, DOI 10.1007/s00439-008-0495-7; DUFFY DL, 1990, AM REV RESPIR DIS, V142, P1351, DOI 10.1164/ajrccm/142.6_Pt_1.1351; Ferreira MAR, 2011, EUR J HUM GENET, V19, P458, DOI 10.1038/ejhg.2010.191; Finn Patricia W, 2009, Proc Am Thorac Soc, V6, P260, DOI 10.1513/pats.200807-064RM; Gamazon ER, 2010, BIOINFORMATICS, V26, P259, DOI 10.1093/bioinformatics/btp644; Gudbjartsson DF, 2009, NAT GENET, V41, P342, DOI 10.1038/ng.323; Hancock DB, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000623; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Himes BE, 2009, AM J HUM GENET, V84, P581, DOI 10.1016/j.ajhg.2009.04.006; Hirota T, 2011, NAT GENET, V43, P893, DOI 10.1038/ng.887; Hunninghake GM, 2010, ALLERGY, V65, P1566, DOI 10.1111/j.1398-9995.2010.02415.x; Johnson AD, 2008, BIOINFORMATICS, V24, P2938, DOI 10.1093/bioinformatics/btn564; Kodak JA, 2006, PROSTATE, V66, P1592, DOI 10.1002/pros.20414; Lawrence MG, 2010, ENDOCR REV, V31, P407, DOI 10.1210/er.2009-0034; Ledogar RJ, 2000, AM J PUBLIC HEALTH, V90, P929, DOI 10.2105/AJPH.90.6.929; Li XN, 2010, J ALLERGY CLIN IMMUN, V125, P328, DOI 10.1016/j.jaci.2009.11.018; Li Y, 2010, GENET EPIDEMIOL, V34, P816, DOI 10.1002/gepi.20533; Marchini J, 2004, NAT GENET, V36, P512, DOI 10.1038/ng1337; Marsh DG, 1997, NAT GENET, V15, P389; Masoli M, 2004, ALLERGY, V59, P469, DOI 10.1111/j.1398-9995.2004.00526.x; Mathias RA, 2010, J ALLERGY CLIN IMMUN, V125, P336, DOI 10.1016/j.jaci.2009.08.031; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Moorman Jeanne E., 2007, Morbidity and Mortality Weekly Report, V56, P1; Nicolae D, 2005, AM J HUM GENET, V76, P349, DOI 10.1086/427763; NIEMINEN MM, 1991, CHEST, V100, P70, DOI 10.1378/chest.100.1.70; Ober C, 2000, AM J HUM GENET, V67, P1154, DOI 10.1016/S0002-9297(07)62946-2; Ober C, 2011, IMMUNOL REV, V242, P10, DOI 10.1111/j.1600-065X.2011.01029.x; Saxena R, 2007, SCIENCE, V316, P1331, DOI 10.1126/science.1142358; Sleiman PMA, 2010, NEW ENGL J MED, V362, P36, DOI 10.1056/NEJMoa0901867; Torgerson DG, 2011, NAT GENET, V43, P887, DOI 10.1038/ng.888; Venanzi S, 2001, CLIN EXP ALLERGY, V31, P1220, DOI 10.1046/j.1365-2222.2001.01132.x; Xu JF, 2001, AM J HUM GENET, V68, P1437, DOI 10.1086/320589; Yang J, 2010, GENET EPIDEMIOL, V34, P254, DOI 10.1002/gepi.20456	36	24	24	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2012	130	6					1294	1301		10.1016/j.jaci.2012.07.054	http://dx.doi.org/10.1016/j.jaci.2012.07.054			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	044RP	23040885	Green Published, Green Accepted			2022-12-18	WOS:000311641100007
J	Mertes, PM; Demoly, P; Alperovitch, A; Bazin, A; Bienvenu, J; Caldani, C; Lamy, B; Laroche, D; des Floris, MFL; Py, JY; Rebibo, D; Willaert, B; Drouet, C; Carlier, M; Lienhart, A				Mertes, Paul Michel; Demoly, Pascal; Alperovitch, Annick; Bazin, Agnes; Bienvenu, Jacques; Caldani, Cyril; Lamy, Bernard; Laroche, Dominique; des Floris, Marie-Francoise Leconte; Py, Jean-Yves; Rebibo, Danielle; Willaert, Beatrice; Drouet, Christian; Carlier, Monique; Lienhart, Andre			Methylene blue-treated plasma: An increased allergy risk?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							FRESH-FROZEN PLASMA; FILTER; QUALITY		[Mertes, Paul Michel] CHU Nancy, Serv Anesth Reanimat Chirurg, INSERM, Grp Choc,Hop Cent,U911, Nancy, France; [Demoly, Pascal] Univ Hosp Montpellier, Hop Arnaud Villeneuve, INSERM, Dept Pneumol,U657, Montpellier, France; [Alperovitch, Annick] INSERM, U708, Paris, France; [Alperovitch, Annick] Univ Paris 06, Paris, France; [Bazin, Agnes] CHU Caen, Unite Hemovigilance, F-14000 Caen, France; [Bienvenu, Jacques] Univ Lyon, Lyon, France; [Bienvenu, Jacques] INSERM, U851, F-69008 Lyon, France; [Bienvenu, Jacques] Ctr Hosp Lyon Sud, Hosp Civils Lyon, Immunol Lab, F-69310 Pierre Benite, France; [Caldani, Cyril] Etab Francais Sang Alpes Mediterranee, St Laurent Du Var, France; [Lamy, Bernard] Agence Reg St Bourgogne, Direct Sante Publ, Dijon, France; [Lamy, Bernard] CHU Caen, Lab Hormonol, F-14000 Caen, France; [Laroche, Dominique] Univ Caen Basse Normandie, Sch Med, Caen, France; [des Floris, Marie-Francoise Leconte] Etab Francais Sang, Besancon, France; [Rebibo, Danielle] Etab Francais Sang, Direct Med, Orleans, France; [Willaert, Beatrice] Minist Travail Emploi & Sante, Paris, France; [Drouet, Christian] Univ Grenoble 1, CHU Grenoble, GREPI AGIM CNRS 3405, Grenoble, France; [Carlier, Monique] Afssaps, Haemovigilance Unit, St Denis, France; [Lienhart, Andre] Hop St Antoine, Dept Anesthesie Reanimat, F-75571 Paris, France	CHU de Nancy; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; CHU de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; CHU de Caen NORMANDIE; Universite de Caen Normandie; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Lyon; CHU de Caen NORMANDIE; Universite de Caen Normandie; Universite de Caen Normandie; Universite de Franche-Comte; CHU Grenoble Alpes; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite	Mertes, PM (corresponding author), CHU Nancy, Serv Anesth Reanimat Chirurg, INSERM, Grp Choc,Hop Cent,U911, Nancy, France.	pm.mertes@chu-nancy.fr	bienvenu, jacques/F-2917-2013; DROUET, Christian/AAE-5682-2020; Demoly, Pascal/Y-9938-2019; DROUET, Christian/J-8775-2019	DROUET, Christian/0000-0003-1318-4278; Demoly, Pascal/0000-0001-7827-7964; DROUET, Christian/0000-0003-1318-4278				Crettaz D, 2004, PROTEOMICS, V4, P881, DOI 10.1002/pmic.200300667; D'Alessandro A, 2010, ANAL BIOANAL CHEM, V398, P111, DOI 10.1007/s00216-010-3799-0; Hellstern P, 2008, TRANSFUS APHER SCI, V39, P69, DOI 10.1016/j.transci.2008.05.005; Iwama H, 2001, J CRIT CARE, V16, P74, DOI 10.1053/jcrc.2001.26296; Mertes PM, 2008, J ALLERGY CLIN IMMUN, V122, P348, DOI 10.1016/j.jaci.2008.04.040; Politis C, 2007, VOX SANG, V92, P319, DOI 10.1111/j.1423-0410.2007.00898.x; Salge-Bartels U, 2006, TRANSFUSION MED, V16, P266, DOI 10.1111/j.1365-3148.2006.00672.x; Steil L, 2008, TRANSFUSION, V48, P2356, DOI 10.1111/j.1537-2995.2008.01856.x	8	24	25	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2012	130	3					808	812		10.1016/j.jaci.2012.03.050	http://dx.doi.org/10.1016/j.jaci.2012.03.050			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	001LZ	22664163				2022-12-18	WOS:000308463500034
J	Manthei, DM; Jackson, DJ; Evans, MD; Gangnon, RE; Tisler, CJ; Gern, JE; Lemanske, RF; Denlinger, LC				Manthei, David M.; Jackson, Daniel J.; Evans, Michael D.; Gangnon, Ronald E.; Tisler, Christopher J.; Gern, James E.; Lemanske, Robert F., Jr.; Denlinger, Loren C.			Protection from asthma in a high-risk birth cohort by attenuated P2X(7) function	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; allergy; children; P2X(7); ATP	ALLERGIC AIRWAY INFLAMMATION; HUMAN DENDRITIC CELLS; DUST-MITE ALLERGEN; PORE FUNCTION; ATP RELEASE; EARLY-LIFE; RECEPTOR; RHINOVIRUS; ACTIVATION; INNATE	Background: Viral illnesses are important factors in both asthma inception and exacerbations, and allergic sensitization in early life further enhances asthma risk through unclear mechanisms. Cellular damage caused by infection or allergen inhalation increases ATP levels in the airways with subsequent purinergic receptor activation. The purinergic receptor P2X(7) can enhance airway leukocyte recruitment to the airways, and P2X(7) knockout mice display a reduced asthma-like phenotype. Objective: Based on the P2X(7) knockout mouse, we hypothesized that children with low P2X(7) function would have decreased rates of asthma. Methods: We used a functional assay to determine P2X(7) pore-producing capacity in whole-blood samples in a birth cohort at high risk for asthma development. The P2X(7) assay was validated with known loss-of-function alleles in human subjects. P2X(7) pore status categorization was used to assess asthma and allergy status in the cohort. Results: Attenuated P2X(7) function was associated with lower asthma rates at ages 6 and 8 years, and the greatest effects were observed in boys. Children with asthma at age 11 years who had low P2X(7) capacity had less severe disease in the previous year. Attenuated P2X(7) function was also associated with sensitization to fewer aeroallergens. Conclusion: P2X(7) functional capacity is associated with asthma risk or disease severity, and these relationships appear to be age related. (J Allergy Clin Immunol 2012; 130:496-502.)	[Manthei, David M.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI 53792 USA; [Jackson, Daniel J.; Tisler, Christopher J.; Gern, James E.; Lemanske, Robert F., Jr.] Univ Wisconsin, Dept Pediat, Madison, WI 53792 USA; [Evans, Michael D.; Gangnon, Ronald E.] Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI 53792 USA; [Gangnon, Ronald E.] Univ Wisconsin, Dept Populat Hlth Sci, Madison, WI 53792 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Denlinger, LC (corresponding author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, 600 Highland Ave,CSC MC Box 9988, Madison, WI 53792 USA.	lcd@medicine.wisc.edu		Gangnon, Ronald/0000-0003-2587-6714; Evans, Michael/0000-0001-7449-3993	National Institutes of Health [P01 HL070831, K23 HL081492]; Clinical and Translational Science Award (CTSA) through National Center for Research Resources (NCRR) [1UL1RR025011]; Clinical and Translational Science Award (CTSA) through the National Center for Advancing Translational Sciences (NCATS) [9U54TR000021]; Pharmaxis; Boehringer Ingelheim; GlaxoSmithKline; Biota; MedImmune; Theraclone; AstraZeneca; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000427] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025011] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL081492, P01HL070831] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008692] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Clinical and Translational Science Award (CTSA) through National Center for Research Resources (NCRR); Clinical and Translational Science Award (CTSA) through the National Center for Advancing Translational Sciences (NCATS); Pharmaxis; Boehringer Ingelheim(Boehringer Ingelheim); GlaxoSmithKline(GlaxoSmithKline); Biota; MedImmune(AstraZenecaMedimmune); Theraclone; AstraZeneca(AstraZeneca); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Supported by National Institutes of Health grants P01 HL070831 and K23 HL081492, and the project described was supported by the Clinical and Translational Science Award (CTSA) program, previously through the National Center for Research Resources (NCRR), grant 1UL1RR025011, and now through the National Center for Advancing Translational Sciences (NCATS), grant 9U54TR000021. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.; D. J. Jackson has received research support from Pharmaxis. J. E. Gern is a member of the Scientific Advisory Board of and has stock options with 3V Biosciences; has received one or more consulting fees from Boehringer Ingelheim, GlaxoSmithKline, Biota, MedImmune, and Theraclone; and has received one or more grants from AstraZeneca and GlaxoSmithKline. R. F. Lemanske, Jr, is a speaker for Merck, AstraZeneca, Doembecher Children's Hospital, Washington University, the Medicus Group, the Park Nicolet Institute, the American College of Allergy, Asthma & Immunology, the Los Angeles Allergy Society, the Michigan Allergy/Asthma Society, the Medical College of Wisconsin, the Fund for Medical Research and Education (Detroit), the Children's Hospital of Minnesota, the Toronto Allergy Society, the American Academy of Allergy, Asthma & Immunology, Beaumont Hospital (Detroit), the University of Illinois, the Canadian Society of Allergy and Clinical Immunology, New York Presbyterian, the Med Media Educational Group, Onpointe Medical Communications, the Medical University of South Carolina, Health Matters Communication, Bishop McCann, Donohue, Purohit, Miller, the Center for Health Care Education, the University of California-San Francisco, the American Thoracic Society, the University of Iowa, Indiana University, the American Lung Association of the Upper Midwest, Vanderbilt University, Rochester Children's Hospital, the Colorado Allergy Society, the Pennsylvania Allergy Society, Harvard Pilgrim Health Care, the California Allergy Society, the New York City Allergy Society, and the World Allergy Society; has consultant arrangements with AstraZeneca, Map Pharmaceuticals, Gray Consulting, Smith Research, the Merck Childhood Asthma Network, Novartis, Quintiles/Innovax, RC Horowitz & Co, International Meetings and Science, Scienomics, Scientific Therapeutics, Gray Consulting, Cognimed, SA Boney and Associates, GlaxoSmithKline, Double Helix Development, and Merck; is an author for UpToDate; and is a textbook editor for and receives royalties from Elsevier. The rest of the authors declare that they have no relevant conflicts of interest.	Baroni M, 2007, FASEB J, V21, P1926, DOI 10.1096/fj.06-7238com; Bizzintino J, 2011, EUR RESPIR J, V37, P1037, DOI 10.1183/09031936.00092410; Busse WW, 2010, LANCET, V376, P826, DOI 10.1016/S0140-6736(10)61380-3; Cappelli C, 2012, IMMUNOBIOLOGY, V217, P307, DOI 10.1016/j.imbio.2011.10.006; Celedon JC, 2007, J ALLERGY CLIN IMMUN, V120, P144, DOI 10.1016/j.jaci.2007.03.037; Chessell IP, 2005, PAIN, V114, P386, DOI 10.1016/j.pain.2005.01.002; Coutinho-Silva R, 1999, AM J PHYSIOL-CELL PH, V276, pC1139, DOI 10.1152/ajpcell.1999.276.5.C1139; Denlinger LC, 2005, J IMMUNOL, V174, P4424, DOI 10.4049/jimmunol.174.7.4424; Denlinger LC, 2006, CLIN CHEM, V52, P995, DOI 10.1373/clinchem.2005.065425; Denlinger LC, 2009, AM J RESP CRIT CARE, V179, P265, DOI 10.1164/rccm.200802-293OC; Forbes RL, 2012, THORAX, V67, P209, DOI 10.1136/thoraxjnl-2011-200708; Fuller SJ, 2009, PURINERG SIGNAL, V5, P257, DOI 10.1007/s11302-009-9136-4; Georas SN, 2010, CURR ALLERGY ASTHM R, V10, P92, DOI 10.1007/s11882-010-0090-6; Georgiou JG, 2005, J INVEST DERMATOL, V125, P482, DOI 10.1111/j.0022-202X.2005.23835.x; Gu BJ, 2000, AM J PHYSIOL-CELL PH, V279, pC1189, DOI 10.1152/ajpcell.2000.279.4.C1189; Guilbert Theresa W, 2010, Expert Rev Respir Med, V4, P71, DOI 10.1586/ers.09.60; Hammad H, 2009, NAT MED, V15, P410, DOI 10.1038/nm.1946; Holt PG, 2011, CHEST, V139, P1165, DOI 10.1378/chest.10-2397; Humphreys BD, 1998, J LEUKOCYTE BIOL, V64, P265, DOI 10.1002/jlb.64.2.265; Ichinohe T, 2010, NAT IMMUNOL, V11, P404, DOI 10.1038/ni.1861; Idzko M, 2007, NAT MED, V13, P913, DOI 10.1038/nm1617; Iwane MK, 2011, J INFECT DIS, V204, P1702, DOI 10.1093/infdis/jir634; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; Jackson DJ, 2012, AM J RESP CRIT CARE, V185, P281, DOI 10.1164/rccm.201104-0660OC; Khakh BS, 2006, NATURE, V442, P527, DOI 10.1038/nature04886; Kim JM, 2010, PROG MOL BIOL TRANSL, V92, P279, DOI 10.1016/S1877-1173(10)92011-5; Korpi-Steiner NL, 2008, CYTOM PART B-CLIN CY, V74B, P319, DOI 10.1002/cyto.b.20421; Labasi JM, 2002, J IMMUNOL, V168, P6436, DOI 10.4049/jimmunol.168.12.6436; Lemanske RF, 2002, PEDIAT ALLERG IMM-UK, V13, P38, DOI 10.1034/j.1399-3038.13.s.15.8.x; Loisel DA, 2011, J ALLERGY CLIN IMMUN, V128, P524, DOI 10.1016/j.jaci.2011.06.016; Lommatzsch M, 2010, AM J RESP CRIT CARE, V181, P928, DOI 10.1164/rccm.200910-1506OC; Lucattelli M, 2011, AM J RESP CELL MOL, V44, P423, DOI 10.1165/rcmb.2010-0038OC; Meng GX, 2009, IMMUNITY, V30, P860, DOI 10.1016/j.immuni.2009.04.012; Minnicozzi M, 2011, IMMUNOL REV, V242, P106, DOI 10.1111/j.1600-065X.2011.01025.x; Muller T, 2010, ALLERGY, V65, P1545, DOI 10.1111/j.1398-9995.2010.02426.x; Muller T, 2011, AM J RESP CELL MOL, V44, P456, DOI 10.1165/rcmb.2010-0129OC; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; Palmenberg AC, 2009, SCIENCE, V324, P55, DOI 10.1126/science.1165557; Papadopoulos NG, 2002, THORAX, V57, P328, DOI 10.1136/thorax.57.4.328; Possin ME, 2010, PEDIAT ALLERG IMM-UK, V21, P990, DOI 10.1111/j.1399-3038.2010.01041.x; Rathinam VAK, 2010, J CLIN IMMUNOL, V30, P632, DOI 10.1007/s10875-010-9431-4; Saunders BM, 2003, J IMMUNOL, V171, P5442, DOI 10.4049/jimmunol.171.10.5442; Schleimer RP, 2007, J ALLERGY CLIN IMMUN, V120, P1279, DOI 10.1016/j.jaci.2007.08.046; Schneider EM, 2011, J CELL COMMUN SIGNAL, V5, P145, DOI 10.1007/s12079-010-0113-z; Sluyter R, 2002, INT IMMUNOL, V14, P1415, DOI 10.1093/intimm/dxf111; Sly PD, 2008, LANCET, V372, P1100, DOI 10.1016/S0140-6736(08)61451-8; Sly PD, 2011, CURR OPIN ALLERGY CL, V11, P127, DOI 10.1097/ACI.0b013e32834487c6; Taylor JM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015784; Taylor SRJ, 2007, J IMMUNOL, V178, P3474, DOI 10.4049/jimmunol.178.6.3474; Thomas A, 2011, J ALLERGY CLIN IMMUN, V128, P915, DOI 10.1016/j.jaci.2011.07.014; van Rijt LS, 2011, AM J RESP CRIT CARE, V184, P303, DOI 10.1164/rccm.201101-0019OC; Vink NM, 2010, J ALLERGY CLIN IMMUN, V126, P498, DOI 10.1016/j.jaci.2010.06.018; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901; Weber FC, 2010, J EXP MED, V207, P2609, DOI 10.1084/jem.20092489; Wilhelm K, 2010, NAT MED, V16, P1434, DOI 10.1038/nm.2242; Willart MAM, 2009, CLIN EXP ALLERGY, V39, P12, DOI 10.1111/j.1365-2222.2008.03118.x; Willart Monique A. M., 2010, Allergology International, V59, P95, DOI 10.2332/allergolint.09-RAI-0162; Woehrle T, 2010, BLOOD, V116, P3475, DOI 10.1182/blood-2010-04-277707; Yin J, 2007, J CELL SCI, V120, P815, DOI 10.1242/jcs.03389	59	24	24	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2012	130	2					496	502		10.1016/j.jaci.2012.05.040	http://dx.doi.org/10.1016/j.jaci.2012.05.040			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	981WC	22743305	Green Accepted			2022-12-18	WOS:000307002200033
J	Pearson, MS; Tribolet, L; Cantacessi, C; Periago, MV; Valerio, MA; Jariwala, AR; Hotez, P; Diemert, D; Loukas, A; Bethony, J				Pearson, Mark S.; Tribolet, Leon; Cantacessi, Cinzia; Periago, Maria Victoria; Adela Valerio, Maria; Jariwala, Amar R.; Hotez, Peter; Diemert, David; Loukas, Alex; Bethony, Jeffrey			Molecular mechanisms of hookworm disease: Stealth, virulence, and vaccines	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Hookworms; virulence factors; immune modulation; vaccines; proteases; Ancylostoma secreted proteins	NEUTROPHIL INHIBITORY FACTOR; ADULT ANCYLOSTOMA-CANINUM; GLUTATHIONE-S-TRANSFERASE; SERINE-PROTEASE INHIBITOR; COAGULATION-FACTORS XA; D ASPARTIC PROTEASES; NECATOR-AMERICANUS; ANTICOAGULANT PEPTIDE; TISSUE INHIBITOR; INFECTIVE LARVAE	Hookworms produce a vast repertoire of structurally and functionally diverse molecules that mediate their long-term survival and pathogenesis within a human host. Many of these molecules are secreted by the parasite, after which they interact with critical components of host biology, including processes that are key to host survival. The most important of these interactions is the hookworm's interruption of nutrient acquisition by the host through its ingestion and digestion of host blood. This results in iron deficiency and eventually the microcytic hypochromic anemia or iron deficiency anemia that is the clinical hallmark of hookworm infection. Other molecular mechanisms of hookworm infection cause a systematic suppression of the host immune response to both the parasite and to bystander antigens (eg, vaccines or allergens). This is achieved by a series of molecules that assist the parasite in the stealthy evasion of the host immune response. This review will summarize the current knowledge of the molecular mechanisms used by hookworms to survive for extended periods in the human host (up to 7 years or longer) and examine the pivotal contributions of these molecular mechanisms to chronic hookworm parasitism and host clinical outcomes. (J Allergy Clin Immunol 2012;130:13-21.)	[Pearson, Mark S.; Tribolet, Leon; Cantacessi, Cinzia; Loukas, Alex] James Cook Univ, Ctr Biodiscovery & Mol Dev Therapeut, Cairns, Qld 4878, Australia; [Periago, Maria Victoria] Inst Rene Rachou, Belo Horizonte, MG, Brazil; [Adela Valerio, Maria] Univ Valencia, Dept Parasitol, Valencia, Spain; [Jariwala, Amar R.; Diemert, David; Bethony, Jeffrey] George Washington Univ, Dept Microbiol Immunol & Trop Med, Washington, DC 20037 USA; [Hotez, Peter] Baylor Coll Med, Natl Sch Trop Med, Dept Pediat & Mol Virol & Microbiol, Houston, TX 77030 USA; [Hotez, Peter] Sabin Vaccine Inst, Houston, TX USA; [Hotez, Peter] Texas Childrens Hosp, Ctr Vaccine Dev, Houston, TX 77030 USA	James Cook University; Fundacao Oswaldo Cruz; University of Valencia; George Washington University; Baylor College of Medicine; Baylor College of Medicine	Pearson, MS (corresponding author), James Cook Univ, Ctr Biodiscovery & Mol Dev Therapeut, Cairns, Qld 4878, Australia.	mark.pearson@jcu.edu.au; jbethony@gwu.edu	Periago, Maria Victoria/AAO-7914-2020; Diemert, David/AAQ-3353-2020; Pearson, Mark S/O-5636-2014; Periago, Maria/H-1054-2013; Loukas, Alex/B-7355-2014; Cantacessi, Cinzia/B-7356-2014; Valero, M. Adela/K-6718-2016; Periago, Maria Victoria/ABE-6384-2020; Valero, Maria Adela/AAA-1658-2020	Loukas, Alex/0000-0002-0896-8441; Cantacessi, Cinzia/0000-0001-6863-2950; Valero, M. Adela/0000-0003-1584-8330; Periago, Maria Victoria/0000-0002-1470-5146; Valero, Maria Adela/0000-0003-1584-8330; Diemert, David/0000-0002-2789-0512; Tribolet, Leon/0000-0002-2093-9678; Hotez, Peter/0000-0001-8770-1042; Pearson, Mark/0000-0002-0002-1544	Sabin Vaccine Institute; National Health and Medical Research Council; Government of The Netherlands	Sabin Vaccine Institute; National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Government of The Netherlands(Netherlands Government)	M. S. Pearson, A. Loukas, and J. Bethony have received research support from the Sabin Vaccine Institute. L. Tribolet has received research support from the Sabin Vaccine Institute and the National Health and Medical Research Council. P. Hotez is president of the Sabin Vaccine Institute. D. Diemert has received research support from the Sabin Vaccine Institute and the Government of The Netherlands. The rest of the authors declare that they have no relevant conflicts of interest.	Albonico M, 2004, INT J PARASITOL, V34, P1205, DOI 10.1016/j.ijpara.2004.08.001; ALBONICO M, 1995, T ROY SOC TROP MED H, V89, P538, DOI 10.1016/0035-9203(95)90101-9; Ascenzi P, 2003, CURR PROTEIN PEPT SC, V4, P231, DOI 10.2174/1389203033487180; Asojo OA, 2005, J MOL BIOL, V346, P801, DOI 10.1016/j.jmb.2004.12.023; Asojo OA, 2007, BMC STRUCT BIOL, V7, DOI 10.1186/1472-6807-7-42; BARNARD JW, 1995, J IMMUNOL, V155, P4876; BEAVER PC, 1988, AM J TROP MED HYG, V39, P369, DOI 10.4269/ajtmh.1988.39.369; Bethony J, 2005, FASEB J, V19, P1743, DOI 10.1096/fj.05-3936fje; Bethony JM, 2008, VACCINE, V26, P2408, DOI 10.1016/j.vaccine.2008.02.049; Bethony JM, 2011, IMMUNOL REV, V239, P237, DOI 10.1111/j.1600-065X.2010.00976.x; Bower MA, 2008, EXP PARASITOL, V118, P569, DOI 10.1016/j.exppara.2007.11.014; Brooker S, 2004, ADV PARASIT, V58, P197, DOI 10.1016/S0065-308X(04)58004-1; Brooker S, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000291; BROPHY PM, 1990, PARASITOLOGY, V100, P345, DOI 10.1017/S0031182000061369; BROPHY PM, 1992, INT J PARASITOL, V22, P1009, DOI 10.1016/0020-7519(92)90061-O; Brown A, 1999, AM J TROP MED HYG, V60, P840, DOI 10.4269/ajtmh.1999.60.840; Bungiro RD, 2004, INFECT IMMUN, V72, P2203, DOI 10.1128/IAI.72.4.2203-2213.2004; Bungiro Richard, 2011, Curr Infect Dis Rep, V13, P210, DOI 10.1007/s11908-011-0182-z; Caffrey CR, 2004, TRENDS PARASITOL, V20, P241, DOI 10.1016/j.pt.2004.03.004; Campbell AM, 2001, COMP BIOCHEM PHYS B, V128, P701, DOI 10.1016/S1096-4959(00)00360-2; Cantacessi C, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000684; CAPPELLO M, 1995, P NATL ACAD SCI USA, V92, P6152, DOI 10.1073/pnas.92.13.6152; Cappello M, 1996, MOL BIOCHEM PARASIT, V80, P113, DOI 10.1016/0166-6851(96)02658-8; CAPPELLO M, 1993, J INFECT DIS, V167, P1474, DOI 10.1093/infdis/167.6.1474; Chadderdon RC, 1999, J INFECT DIS, V179, P1235, DOI 10.1086/314724; Cho YS, 2007, J BIOL CHEM, V282, P23447, DOI 10.1074/jbc.M702950200; Chu D, 2004, INFECT IMMUN, V72, P2214, DOI 10.1128/IAI.72.4.2214-2221.2004; Costa AFDV, 2009, MOL CELL PROBE, V23, P298, DOI 10.1016/j.mcp.2009.07.004; Cuellar C, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000439; DARKE SJ, 1959, BRIT J NUTR, V13, P278, DOI 10.1079/BJN19590038; Datu BJD, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000130; Daveson AJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017366; Del Valle A, 2003, MOL BIOCHEM PARASIT, V129, P167, DOI 10.1016/S0166-6851(03)00121-X; Deng L, 2010, BIOCHEM BIOPH RES CO, V392, P155, DOI 10.1016/j.bbrc.2009.12.177; Don TA, 2007, PARASITOLOGY, V134, P427, DOI 10.1017/S003118200600148X; Don TA, 2004, INT J PARASITOL, V34, P1029, DOI 10.1016/j.ijpara.2004.04.013; Espino AM, 2004, J PARASITOL, V90, P876, DOI 10.1645/GE-215R; Feng JJ, 2007, MOL BIOCHEM PARASIT, V152, P132, DOI 10.1016/j.molbiopara.2007.01.001; Figueiredo CA, 2010, INFECT IMMUN, V78, P3160, DOI 10.1128/IAI.01228-09; Fitzsimmons CM, 2009, TRENDS PARASITOL, V25, P447, DOI 10.1016/j.pt.2009.07.004; Francis SE, 1997, ANNU REV MICROBIOL, V51, P97, DOI 10.1146/annurev.micro.51.1.97; Gan WQ, 2009, FEBS LETT, V583, P1976, DOI 10.1016/j.febslet.2009.05.009; Gaze S, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002520; Goud GN, 2005, VACCINE, V23, P4754, DOI 10.1016/j.vaccine.2005.04.040; Harrison LM, 2001, MOL BIOCHEM PARASIT, V115, P101, DOI 10.1016/S0166-6851(01)00276-6; Hawdon JM, 2003, J PARASITOL, V89, P402, DOI 10.1645/0022-3395(2003)089[0402:MCOANM]2.0.CO;2; Hawdon JM, 1996, J BIOL CHEM, V271, P6672, DOI 10.1074/jbc.271.12.6672; Hawdon JM, 1999, MOL BIOCHEM PARASIT, V99, P149, DOI 10.1016/S0166-6851(99)00011-0; Hecht O, 2004, J BIOL CHEM, V279, P17834, DOI 10.1074/jbc.M312978200; HOTEZ P, 1990, INFECT IMMUN, V58, P3883, DOI 10.1128/IAI.58.12.3883-3892.1990; Hotez PJ, 2008, EXPERT REV VACCINES, V7, P745, DOI 10.1586/14760584.7.6.745; Hotez PJ, 2010, NAT REV MICROBIOL, V8, P814, DOI 10.1038/nrmicro2438; HOTEZ PJ, 1992, INFECT IMMUN, V60, P1018, DOI 10.1128/IAI.60.3.1018-1023.1992; Hotez PJ, 2004, NEW ENGL J MED, V351, P799, DOI 10.1056/NEJMra032492; HOTEZ PJ, 1983, J EXP MED, V157, P1594, DOI 10.1084/jem.157.5.1594; Jiang DS, 2011, MOL BIOCHEM PARASIT, V177, P42, DOI 10.1016/j.molbiopara.2011.01.008; Jiang N, 1995, ANN NEUROL, V38, P935, DOI 10.1002/ana.410380615; Jin XA, 2011, PARASITOL RES, V108, P287, DOI 10.1007/s00436-010-2055-z; KALKOFEN UP, 1974, AM J TROP MED HYG, V23, P1046, DOI 10.4269/ajtmh.1974.23.1046; Kovalick GE, 2005, INSECT BIOCHEM MOLEC, V35, P825, DOI 10.1016/j.ibmb.2005.03.003; Kucera K, 2011, J MOL BIOL, V408, P9, DOI 10.1016/j.jmb.2011.02.033; Lee AYY, 2003, J INTERN MED, V254, P313, DOI 10.1046/j.1365-2796.2003.01224.x; Lee JY, 2002, BIOCHEM BIOPH RES CO, V296, P1238, DOI 10.1016/S0006-291X(02)02062-4; Loeb L, 1910, J INFECT DIS, V7, P625, DOI 10.1093/infdis/7.5.625; Cancado GGL, 2011, INFLAMM BOWEL DIS, V17, P2275, DOI 10.1002/ibd.21629; Loukas A, 2006, LANCET INFECT DIS, V6, P733, DOI 10.1016/S1473-3099(06)70630-2; Loukas A, 2011, OMICS, V15, P567, DOI 10.1089/omi.2010.0150; McSorley HJ, 2010, PARASITE IMMUNOL, V32, P549, DOI 10.1111/j.1365-3024.2010.01224.x; McSorley HJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024092; Medina C, 2006, J PHARMACOL EXP THER, V318, P933, DOI 10.1124/jpet.106.103465; Mieszczanek J, 2004, MOL BIOCHEM PARASIT, V137, P151, DOI 10.1016/j.molbiopara.2004.05.011; Mieszczanek J, 2004, MOL BIOCHEM PARASIT, V133, P319, DOI 10.1016/j.molbiopara.2003.10.015; Milstone AM, 2000, J BIOL CHEM, V275, P29391, DOI 10.1074/jbc.M002715200; MOYLE M, 1994, J BIOL CHEM, V269, P10008; MUCHOWSKI PJ, 1994, J BIOL CHEM, V269, P26419; Mulvenna J, 2009, MOL CELL PROTEOMICS, V8, P109, DOI 10.1074/mcp.M800206-MCP200; Nagano O, 2004, CANCER SCI, V95, P930, DOI 10.1111/j.1349-7006.2004.tb03179.x; Nagase H, 2006, CARDIOVASC RES, V69, P562, DOI 10.1016/j.cardiores.2005.12.002; Pearson MS, 2010, BIOL CHEM, V391, P901, DOI 10.1515/BC.2010.074; Pearson MS, 2009, FASEB J, V23, P3007, DOI 10.1096/fj.09-131433; Perally S, 2008, J PROTEOME RES, V7, P4557, DOI 10.1021/pr800395x; Ranjit N, 2006, INT J PARASITOL, V36, P701, DOI 10.1016/j.ijpara.2006.01.015; Ranjit N, 2009, J INFECT DIS, V199, P904, DOI 10.1086/597048; Ranjit N, 2008, MOL BIOCHEM PARASIT, V160, P90, DOI 10.1016/j.molbiopara.2008.04.008; Rebello SS, 1997, J PHARMACOL EXP THER, V283, P91; RIEU P, 1994, J CELL BIOL, V127, P2081, DOI 10.1083/jcb.127.6.2081; Ruyssers NE, 2009, INFLAMM BOWEL DIS, V15, P491, DOI 10.1002/ibd.20787; Schuller DJ, 2005, PROTEINS, V61, P1024, DOI 10.1002/prot.20649; Sen L, 2000, VACCINE, V18, P1096, DOI 10.1016/S0264-410X(99)00371-0; Smith JL, 2010, TROP MED INT HEALTH, V15, P776, DOI 10.1111/j.1365-3156.2010.02542.x; Stanssens P, 1996, P NATL ACAD SCI USA, V93, P2149, DOI 10.1073/pnas.93.5.2149; TANDON BN, 1966, BRIT MED J, V1, P714, DOI 10.1136/bmj.1.5489.714; Taylor MD, 2012, TRENDS IMMUNOL, V33, P181, DOI 10.1016/j.it.2012.01.001; Van Loon LC, 1999, PHYSIOL MOL PLANT P, V55, P85, DOI 10.1006/pmpp.1999.0213; Van Rossum AJ, 2004, INFECT IMMUN, V72, P2780, DOI 10.1128/IAI.72.5.2780-2790.2004; VETTER JCM, 1977, Z PARASITENKD, V53, P263, DOI 10.1007/BF00389942; VETTER JCM, 1977, Z PARASITENKD, V53, P255, DOI 10.1007/BF00389941; Wilkening G, 1998, J BIOL CHEM, V273, P30271, DOI 10.1074/jbc.273.46.30271; Williamson AL, 2006, INFECT IMMUN, V74, P961, DOI 10.1128/IAI.74.2.961-967.2006; Williamson AL, 2004, J BIOL CHEM, V279, P35950, DOI 10.1074/jbc.M405842200; Williamson AL, 2003, PARASITOLOGY, V126, P179, DOI 10.1017/S0031182002002706; Williamson AL, 2003, J INFECT DIS, V187, P484, DOI 10.1086/367708; Williamson AL, 2002, FASEB J, V16, P1458, DOI 10.1096/fj.02-0181fje; Willis C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025369; Xiao S, 2008, EXP PARASITOL, V118, P32, DOI 10.1016/j.exppara.2007.05.010; Yamazaki Y, 2003, ARCH BIOCHEM BIOPHYS, V412, P133, DOI 10.1016/S0003-9861(03)00028-6; Yazdanbakhsh M, 2002, SCIENCE, V296, P490, DOI 10.1126/science.296.5567.490; Zhan B, 2005, INFECT IMMUN, V73, P6903, DOI 10.1128/IAI.73.10.6903-6911.2005; Zhan B, 2003, INT J PARASITOL, V33, P897, DOI 10.1016/S0020-7519(03)00111-5; Zhan B, 2002, AM J TROP MED HYG, V66, P238, DOI 10.4269/ajtmh.2002.66.238; Zhan B, 2008, MOL BIOCHEM PARASIT, V162, P142, DOI 10.1016/j.molbiopara.2008.08.008; Zhan B, 2010, INFECT IMMUN, V78, P1552, DOI 10.1128/IAI.00848-09	112	24	28	0	29	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2012	130	1					13	21		10.1016/j.jaci.2012.05.029	http://dx.doi.org/10.1016/j.jaci.2012.05.029			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	977GN	22742835	Green Published			2022-12-18	WOS:000306644800002
J	Van Crombruggen, K; Holtappels, G; De Ruyck, N; Derycke, L; Tomassen, P; Bachert, C				Van Crombruggen, Koen; Holtappels, Gabriele; De Ruyck, Natalie; Derycke, Lara; Tomassen, Peter; Bachert, Claus			RAGE processing in chronic airway conditions: Involvement of Staphylococcus aureus and ECP	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Receptor for advanced glycation end products; eosinophil cationic protein; Staphylococcus aureus; airway inflammation	GLYCATION END-PRODUCTS; RECOGNITION RECEPTOR RAGE; SOLUBLE RECEPTOR; PULMONARY-FIBROSIS; LUNG INJURY; EXPRESSION; SRAGE; DIFFERENTIATION; ENTEROTOXINS; ACTIVATION	Background: The receptor for advanced glycation end products (RAGE) is a multiligand receptor that exists as a membrane-bound (mRAGE) form and a soluble (sRAGE) form. RAGE is reported to play a role in diverse pathologies including lower airway conditions, but the exact mechanism of action remains poorly understood. In the upper airways, the involvement of RAGE remains completely unexplored. Objective: To investigate the involvement of RAGE in the human upper airway conditions chronic rhinosinusitis without nasal polyps (CRSsNP) and chronic rhinosinusitis with nasal polyps (CRSwNP). Methods: Protein levels of sRAGE, mRAGE, IL-5, and eosinophil cationic protein (ECP) were quantitatively assessed in inflamed tissue of CRSsNP and CRSwNP patients. Nasal tissue of subjects without disease served as control. Ex vivo human sinonasal tissue stimulation assays were used to assess the effect of Staphylococcus aureus and ECP on sRAGE processing. Results: sRAGE protein levels were higher in CRSsNP tissue, whereas mRAGE protein levels were lower than in controls. In CRSwNP patients, both tissue sRAGE and mRAGE protein levels were reduced. Low tissue sRAGE protein concentrations were associated with high IL-5 and ECP protein levels. In vitro, S aureus induced the release of sRAGE from the tissue, while ECP was shown to be implicated in the breakdown of free sRAGE. Conclusions: We demonstrate for the first time that RAGE protein is highly expressed in human upper airways under normal physiology and that it is subject to differential processing in CRSsNP and CRSwNP, identifying S aureus and ECP as novel and crucial players in this process. (J Allergy Clin Immunol 2012;129:1515-21.)	[Van Crombruggen, Koen; Holtappels, Gabriele; De Ruyck, Natalie; Derycke, Lara; Tomassen, Peter; Bachert, Claus] Ghent Univ Hosp, Dept Otorhinolaryngol, Upper Airway Res Lab, B-9000 Ghent, Belgium	Ghent University; Ghent University Hospital	Van Crombruggen, K (corresponding author), Ghent Univ Hosp, Dept Otorhinolaryngol, Upper Airway Res Lab, De Pintelaan 185, B-9000 Ghent, Belgium.	koen.vancrombruggen@ugent.be	Tomassen, Peter/B-8013-2009; Bachert, Claus/J-8825-2012	Tomassen, Peter/0000-0002-0698-6574; 	Research Foundation Flanders (FWO) [G.0641.10]; Ghent University [01G01009]; Global Allergy and Asthma Research Network	Research Foundation Flanders (FWO)(FWO); Ghent University(Ghent University); Global Allergy and Asthma Research Network	This work was supported by funding from the Research Foundation Flanders (FWO; research project no. G.0641.10), and a Concerted Research Action project grant (grant no. 01G01009) from the Special Research Fund of Ghent University.; P. Tomassen received research support from the Global Allergy and Asthma Research Network and Ghent University. The rest of the authors declare that they have no relevant conflicts of interest.	Bachert C, 2010, CURR ALLERGY ASTHM R, V10, P194, DOI 10.1007/s11882-010-0096-0; Bachert C, 1997, J ALLERGY CLIN IMMUN, V99, P837, DOI 10.1016/S0091-6749(97)80019-X; Bachert C, 2010, J ALLERGY CLIN IMMUN, V126, P962, DOI 10.1016/j.jaci.2010.07.007; Bierhaus A, 2005, J MOL MED, V83, P876, DOI 10.1007/s00109-005-0688-7; Bopp C, 2008, CRIT CARE, V12, DOI 10.1186/cc6164; Bopp C, 2008, J SURG RES, V147, P79, DOI 10.1016/j.jss.2007.07.014; BRETT J, 1993, AM J PATHOL, V143, P1699; Chavakis T, 2003, J EXP MED, V198, P1507, DOI 10.1084/jem.20030800; Chen YL, 2008, J IMMUNOL, V181, P4272, DOI 10.4049/jimmunol.181.6.4272; Demling N, 2006, CELL TISSUE RES, V323, P475, DOI 10.1007/s00441-005-0069-0; Englert JM, 2008, AM J PATHOL, V172, P583, DOI 10.2353/ajpath.2008.070569; Englert JM, 2011, INT J CLIN EXP PATHO, V4, P241; Ferhani N, 2010, AM J RESP CRIT CARE, V181, P917, DOI 10.1164/rccm.200903-0340OC; Fokkens W, 2007, RHINOLOGY, P1; Hanford LE, 2004, J BIOL CHEM, V279, P50019, DOI 10.1074/jbc.M409782200; Hayashida A, 2009, AM J PATHOL, V174, P509, DOI 10.2353/ajpath.2009.080394; He M, 2007, AM J PHYSIOL-LUNG C, V293, pL1427, DOI 10.1152/ajplung.00075.2007; Hofmann MA, 1999, CELL, V97, P889, DOI 10.1016/S0092-8674(00)80801-6; Hudson BI, 2008, FASEB J, V22, P1572, DOI 10.1096/fj.07-9909com; Li XY, 2010, J ALLERGY CLIN IMMUN, V125, P1061, DOI 10.1016/j.jaci.2010.02.023; Liliensiek B, 2004, J CLIN INVEST, V113, P1641, DOI 10.1172/JCI200418704; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Meltzer Eli O, 2004, J Allergy Clin Immunol, V114, P155, DOI 10.1016/j.jaci.2004.09.029; Nakamura K, 2007, MOL MED, V13, P185, DOI 10.2119/2006-00090.Nakamura; Ohlmeier S, 2010, PROTEOM CLIN APPL, V4, P97, DOI 10.1002/prca.200900128; Park PW, 2004, J BIOL CHEM, V279, P251, DOI 10.1074/jbc.M308537200; Pullerits R, 2006, ARTHRITIS RHEUM, V54, P3898, DOI 10.1002/art.22217; Queisser MA, 2008, AM J RESP CELL MOL, V39, P337, DOI 10.1165/rcmb.2007-0244OC; Ramsgaard L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020132; Ramsgaard L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009604; Raucci A, 2008, FASEB J, V22, P3716, DOI 10.1096/fj.08-109033; Sakurai S, 2006, DIABETES RES CLIN PR, V73, P158, DOI 10.1016/j.diabres.2005.12.013; Schmidt AM, 2001, J CLIN INVEST, V108, P949, DOI 10.1172/JCI14002; Su X, 2009, AM J PHYSIOL-LUNG C, V297, pL1, DOI 10.1152/ajplung.90546.2008; Sukkar MB, 2012, EUR RESPIR J, V39, P721, DOI 10.1183/09031936.00022011; Taguchi A, 2000, NATURE, V405, P354, DOI 10.1038/35012626; Thomas Mike, 2008, Prim Care Respir J, V17, P79, DOI 10.3132/pcrj.2008.00029; Van Bruaene N, 2009, J ALLERGY CLIN IMMUN, V124, P253, DOI 10.1016/j.jaci.2009.04.013; Van Crombruggen K, 2011, N-S ARCH PHARMACOL, V383, P613, DOI 10.1007/s00210-011-0638-6; Van Zele T, 2006, ALLERGY, V61, P1280, DOI 10.1111/j.1398-9995.2006.01225.x; Van Zele T, 2004, J ALLERGY CLIN IMMUN, V114, P981, DOI 10.1016/j.jaci.2004.07.013; Wang YJ, 2010, J IMMUNOL, V185, P1822, DOI 10.4049/jimmunol.0903398; Watelet JB, 2004, ALLERGY, V59, P54, DOI 10.1046/j.1398-9995.2003.00364.x; Yamakawa N, 2011, AM J PHYSIOL-LUNG C, V300, pL516, DOI 10.1152/ajplung.00118.2010; Yan SS, 2003, NAT MED, V9, P287, DOI 10.1038/nm831; Zhang HY, 2008, AM J RESP CRIT CARE, V178, P356, DOI 10.1164/rccm.200707-1069OC; Zhang L, 2008, J BIOL CHEM, V283, P35507, DOI 10.1074/jbc.M806948200	47	24	25	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2012	129	6					1515	+		10.1016/j.jaci.2012.02.021	http://dx.doi.org/10.1016/j.jaci.2012.02.021			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	952BL	22460069				2022-12-18	WOS:000304764600011
J	Marashi, SM; Raeiszadeh, M; Enright, V; Tahami, F; Workman, S; Chee, R; Webster, AD; Milne, RSB; Emery, VC				Marashi, Sayed Mahdi; Raeiszadeh, Mohammed; Enright, Victoria; Tahami, Fariba; Workman, Sarita; Chee, Ronnie; Webster, A. David; Milne, Richard S. B.; Emery, Vincent C.			Influence of cytomegalovirus infection on immune cell phenotypes in patients with common variable immunodeficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Human cytomegalovirus; common variable immunodeficiency; programmed death 1; late effector T cell; CD27; CD28; polyfunctional T cell; inflammatory disease	CD8(+) T-CELLS; VIRUS-INFECTIONS; UPDATE; MANAGEMENT; FEATURES; DISEASE; SUBSET	Background: A subset of patients with common variable immunodeficiency (CVID) have debilitating inflammatory complications strongly associated with cytomegalovirus (CMV) infection and a hyperproliferative CMV-specific T-cell response. Objectives: We studied the T-cell response to CMV and the global effect of this virus on immune effector cell populations in patients with CVID. Methods: Antibody staining, peptide stimulation, and proliferation assays were used to profile CMV-specific T-cell function. Results: CMV infection drives the CD4/CD8 ratio inversion that is characteristic of CVID. The late effector CD8(+) T-cell subset is expanded in CMV-infected patients with CVID. This expansion is largely attributable to CMV-specific cells and correlates with inflammatory disease; within the CMV-specific population, the frequency of late effector cells correlates inversely with the frequency of cells expressing programmed death 1. Supernatants from proliferating CMV-specific CD8(+) cells from patients with inflammatory disease can confer proliferative potential on cells from patients with noninflammatory CVID and healthy subjects. Blocking experiments showed that this proliferation is mediated in part by IFN-gamma and TNF-alpha. Conclusions: These data strengthen the association of CMV with inflammatory pathology in patients with CVID, explain some of the well-known T-cell abnormalities associated with this condition, and provide a plausible mechanism for the documented therapeutic activity of anti-TNF-alpha and antiviral chemotherapy in managing CVID-associated inflammatory disease. (J Allergy Clin Immunol 2012;129:1349-56.)	[Marashi, Sayed Mahdi; Milne, Richard S. B.; Emery, Vincent C.] UCL, Med Res Council Ctr Med Mol Virol, Div Infect & Immun, Sch Med, London NW3 2QG, England; [Raeiszadeh, Mohammed; Workman, Sarita] UCL, Dept Immunol, Div Infect & Immun, Sch Med, London NW3 2QG, England; [Enright, Victoria; Tahami, Fariba; Chee, Ronnie; Webster, A. David] Royal Free Hosp NHS Trust, Dept Clin Immunol, London, England; [Marashi, Sayed Mahdi] Univ Tehran Med Sci, Virol Ctr, Sch Publ Hlth, Tehran, Iran	University of London; University College London; UCL Medical School; University of London; University College London; UCL Medical School; University of London; University College London; Tehran University of Medical Sciences	Emery, VC (corresponding author), UCL, Med Res Council Ctr Med Mol Virol, Div Infect & Immun, Sch Med, Royal Free Campus,Rowland Hill St, London NW3 2QG, England.	v.emery@ucl.ac.uk	Emery, Vincent C/G-8928-2013	Emery, Vincent C/0000-0001-5893-9756	Centre Grant from the Medical Research Council; Wellcome Trust; Primary Immunodeficiency Association; Tehran University of Medical Sciences; Iranian Ministry of Health	Centre Grant from the Medical Research Council; Wellcome Trust(Wellcome TrustEuropean Commission); Primary Immunodeficiency Association; Tehran University of Medical Sciences(Tehran University of Medical Sciences); Iranian Ministry of Health	The UCL MRC Centre for Medical Molecular Virology is funded by Centre Grant from the Medical Research Council. Part of this work was funded by a Wellcome Trust Grant (to V.C.E. and colleagues) and a grant from the Primary Immunodeficiency Association (to A.D.W.). S.M.M. received a scholarship from Tehran University of Medical Sciences and was supported by a PhD studentship from the Iranian Ministry of Health.	Appay V, 2002, NAT MED, V8, P379, DOI 10.1038/nm0402-379; Carbone J, 2006, Allergol Immunopathol (Madr), V34, P131, DOI 10.1157/13091037; Chapel H, 2003, CLIN EXP IMMUNOL, V132, P9, DOI 10.1046/j.1365-2249.2003.02110.x; Chapel H, 2009, BRIT J HAEMATOL, V145, P709, DOI 10.1111/j.1365-2141.2009.07669.x; Chua I, 2007, CLIN EXP IMMUNOL, V150, P306, DOI 10.1111/j.1365-2249.2007.03481.x; Cunningham-Rundles C, 1999, CLIN IMMUNOL, V92, P34, DOI 10.1006/clim.1999.4725; JAFFE JS, 1993, BLOOD, V82, P192, DOI 10.1182/blood.V82.1.192.bloodjournal821192; Klenerman P, 2005, NAT IMMUNOL, V6, P873, DOI 10.1038/ni1241; Marashi SM, 2011, J ALLERGY CLIN IMMUN, V127, P1385, DOI 10.1016/j.jaci.2011.04.001; Mocarski ES, 2002, TRENDS MICROBIOL, V10, P332, DOI 10.1016/S0966-842X(02)02393-4; Park MA, 2008, LANCET, V372, P489, DOI 10.1016/S0140-6736(08)61199-X; Qiu H, 2008, J EXP MED, V205, P19, DOI 10.1084/jem.20070201; Raeiszadeh M, 2006, CLIN EXP IMMUNOL, V146, P234, DOI 10.1111/j.1365-2249.2006.03209.x; Serrano D, 2000, CLIN IMMUNOL, V97, P248, DOI 10.1006/clim.2000.4941; Thatayatikom A, 2005, ANN ALLERG ASTHMA IM, V95, P293, DOI 10.1016/S1081-1206(10)61228-8; Wilkinson GWG, 2008, J CLIN VIROL, V41, P206, DOI 10.1016/j.jcv.2007.10.027; WRIGHT JJ, 1990, BLOOD, V76, P2046; Yong PFK, 2008, IMMUNOL ALLERGY CLIN, V28, P367, DOI 10.1016/j.iac.2008.01.001	18	24	24	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2012	129	5					1349	U234		10.1016/j.jaci.2012.02.011	http://dx.doi.org/10.1016/j.jaci.2012.02.011			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	934CG	22444511				2022-12-18	WOS:000303418000026
J	Yagil, Z; Erlich, TH; Ofir-Birin, Y; Tshori, S; Kay, G; Yekhtin, Z; Fisher, DE; Cheng, C; Wong, WSF; Hartmann, K; Razin, E; Nechushtan, H				Yagil, Zohar; Erlich, Tal Hadad; Ofir-Birin, Yifat; Tshori, Sagi; Kay, Gillian; Yekhtin, Zanna; Fisher, David E.; Cheng, Chang; Wong, W. S. Fred; Hartmann, Karin; Razin, Ehud; Nechushtan, Hovav			Transcription factor E3, a major regulator of mast cell-mediated allergic response	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; mast cells; degranulation; histamine; cytokine secretion; transcription factor E3 knockout mice	MOUSE MICROPHTHALMIA LOCUS; MUTANT MICE; OSTEOCLAST DEVELOPMENT; FACTOR FAMILY; KIT-LIGAND; TFE3; MITF; EXPRESSION; ACTIVATOR; PROTEIN	Background: Microphthalmia transcription factor, an MiT transcription family member closely related to transcription factor E3 (TFE3), is essential for mast cell development and survival. TFE3 was previously reported to play a role in the functions of B and T cells; however, its role in mast cells has not yet been explored. Objective: We sought to explore the role played by TFE3 in mast cell function. Methods: Mast cell numbers were evaluated by using toluidine blue staining. FACS analysis was used to determine percentages of Kit and Fc epsilon RI double-positive cells in the peritoneum of wildtype (WT) and TFE3 knockout (TFE3(-/-)) mice. Cytokine and inflammatory mediator secretion were measured in immunologically activated cultured mast cells derived from either knockout or WT mice. In vivo plasma histamine levels were measured after immunologic triggering of these mice. Results: No significant differences in mast cell numbers between WT and TFE3(-/-) mice were observed in the peritoneum, lung, and skin. However, TFE3(-/-) mice showed a marked decrease in the number of Kit(+) and Fc epsilon RI+ peritoneal and cultured mast cells. Surface expression levels of FceRI in TFE3(-/-) peritoneal mast cells was significantly lower than in control cells. Cultured mast cells derived from TFE3-/- mice showed a marked decrease in degranulation and mediator secretion. In vivo experiments showed that the level of plasma histamine in TFE3(-/-) mice after an allergic trigger was substantially less than that seen in WT mice. Conclusion: TFE3 is a novel regulator of mast cell functions and as such could emerge as a new target for the manipulation of allergic diseases. (J Allergy Clin Immunol 2012;129:1357-66.)	[Yagil, Zohar; Erlich, Tal Hadad; Ofir-Birin, Yifat; Kay, Gillian; Razin, Ehud] Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem & Mol Biol, Inst Med Res Israel Canada, IL-91010 Jerusalem, Israel; [Tshori, Sagi] Hadassah Hebrew Univ, Dept Nucl Med, Med Ctr, Jerusalem, Israel; [Yekhtin, Zanna] Hadassah Hebrew Univ, Dept Bone Marrow Transplantat & Canc Immunotherap, Med Ctr, Jerusalem, Israel; [Nechushtan, Hovav] Hadassah Hebrew Univ, Dept Oncol, Med Ctr, Jerusalem, Israel; [Fisher, David E.] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Cheng, Chang; Wong, W. S. Fred] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Pharmacol, Natl Univ Hlth Syst, Singapore 117595, Singapore; [Wong, W. S. Fred] Natl Univ Singapore, Program Immunol, Inst Life Sci, Singapore 117548, Singapore; [Hartmann, Karin] Univ Cologne, Dept Dermatol, Cologne, Germany	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hadassah University Medical Center; Hebrew University of Jerusalem; Hadassah University Medical Center; Hebrew University of Jerusalem; Hadassah University Medical Center; Harvard University; Massachusetts General Hospital; National University of Singapore; National University of Singapore; University of Cologne	Razin, E (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem & Mol Biol, Inst Med Res Israel Canada, IL-91010 Jerusalem, Israel.	ehudr@ekmd.huji.ac.il	Wong, Wai Shui Fred/D-8205-2013; Fisher, David/AAH-2878-2019; nechushtan, hovav/Z-3564-2019; Hartmann, Karin/N-4865-2015; Kay, Gillian/F-3474-2014	Hartmann, Karin/0000-0002-4595-8226; Kay, Gillian/0000-0003-0966-2388; Wong, Wai Shiu Fred/0000-0001-7010-3759; Erlich, Tal/0000-0003-0601-2574	United States Binational Science Foundation; Israeli Academy of Science; Deutsches Krebsforschungszentrum (DKFZ); Israel's Ministry of Science and Technology (MOST); German-Israeli Foundation for Scientific Research and Development; National Research Foundation of Singapore (HUJ-CREATE); Morasha Foundation; Canadian Friends of Hebrew University; Binational Science Foundation; Israel Science Foundation	United States Binational Science Foundation; Israeli Academy of Science; Deutsches Krebsforschungszentrum (DKFZ)(Helmholtz Association); Israel's Ministry of Science and Technology (MOST); German-Israeli Foundation for Scientific Research and Development(German-Israeli Foundation for Scientific Research and Development); National Research Foundation of Singapore (HUJ-CREATE); Morasha Foundation; Canadian Friends of Hebrew University; Binational Science Foundation(US-Israel Binational Science Foundation); Israel Science Foundation(Israel Science Foundation)	Supported by the United States Binational Science Foundation (E.R. and D.E.F.), the Israeli Academy of Science (E.R.), the Cooperation Program in Cancer Research of the Deutsches Krebsforschungszentrum (DKFZ) and Israel's Ministry of Science and Technology (MOST) (E.R.), the German-Israeli Foundation for Scientific Research and Development (K.H. and E.R.), the National Research Foundation of Singapore (HUJ-CREATE; E.R.), and the Morasha Foundation Fund (H.N.). Z.Y. was supported by the Canadian Friends of Hebrew University.; Z. Yagil, T. Hadad Erlich, Y. Ofir-Birin, and E. Razin receive research support from the Binational Science Foundation, the German-Israeli Foundation for Scientific Research and Development, and the Israel Science Foundation. K. Hartmann has consultant arrangements with Novartis Pharma, ALK-Abello, and Shire and receives research support from the German-Israeli Foundation for Scientific Research and Development. H. Nechushtan receives research support from the Israel Science Foundation. The rest of the authors declare that they have no relevant conflicts of interest.	ARTANDI SE, 1994, MOL CELL BIOL, V14, P7704, DOI 10.1128/MCB.14.12.7704; Gould HJ, 2008, NAT REV IMMUNOL, V8, P205, DOI 10.1038/nri2273; Hallsson JH, 2000, GENETICS, V155, P291; HEMESATH TJ, 1994, GENE DEV, V8, P2770, DOI 10.1101/gad.8.22.2770; Hershey CL, 2004, BONE, V34, P689, DOI 10.1016/j.bone.2003.08.014; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; Hong SB, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015793; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Huan CM, 2006, NAT IMMUNOL, V7, P1082, DOI 10.1038/ni1378; ISOZAKI K, 1994, AM J PATHOL, V145, P827; Kitamura Y, 2002, MOL IMMUNOL, V38, P1173, DOI 10.1016/S0161-5890(02)00058-5; Kitamura Y, 2002, INT ARCH ALLERGY IMM, V127, P106, DOI 10.1159/000048178; Kitamura Y, 2001, INT ARCH ALLERGY IMM, V124, P16, DOI 10.1159/000053657; Kitamura Y, 2006, IMMUNOL ALLERGY CLIN, V26, P387, DOI 10.1016/j.iac.2006.05.004; Lee YN, 2011, BLOOD, V117, P3629, DOI 10.1182/blood-2010-07-293548; Levy C, 2002, J BIOL CHEM, V277, P1962, DOI 10.1074/jbc.M109236200; Levy C, 2010, CELL, V141, P994, DOI 10.1016/j.cell.2010.05.004; Mansky KC, 2002, J LEUKOCYTE BIOL, V71, P304; MEKORI YA, 1993, J IMMUNOL, V151, P3775; Merrell K, 1997, MOL CELL BIOL, V17, P3335, DOI 10.1128/MCB.17.6.3335; Nechushtan H, 1997, BLOOD, V89, P2999, DOI 10.1182/blood.V89.8.2999; Razin E, 1999, J BIOL CHEM, V274, P34272, DOI 10.1074/jbc.274.48.34272; RAZIN E, 1981, P NATL ACAD SCI-BIOL, V78, P2559, DOI 10.1073/pnas.78.4.2559; RAZIN E, 1982, P NATL ACAD SCI-BIOL, V79, P4665, DOI 10.1073/pnas.79.15.4665; Schwarz T, 2010, BIOCHEM BIOPH RES CO, V394, P890, DOI 10.1016/j.bbrc.2010.03.034; Steingrimsson E, 2002, P NATL ACAD SCI USA, V99, P4477, DOI 10.1073/pnas.072071099; Takahashi K, 2001, EUR J IMMUNOL, V31, P590, DOI 10.1002/1521-4141(200102)31:2<590::AID-IMMU590>3.3.CO;2-4; Takemoto CM, 2002, J BIOL CHEM, V277, P30244, DOI 10.1074/jbc.M201441200; Tshori S, 2007, MOL CELL BIOL, V27, P3911, DOI 10.1128/MCB.01455-06; Tsicopoulos A, 2000, CLIN EXP ALLERGY, V30, P602; Verastegui C, 2000, MOL ENDOCRINOL, V14, P449, DOI 10.1210/me.14.3.449; Weilbaecher KN, 2001, MOL CELL, V8, P749, DOI 10.1016/S1097-2765(01)00360-4; Wu M, 2000, GENE DEV, V14, P301; Xu WD, 2000, EXP CELL RES, V255, P135, DOI 10.1006/excr.2000.4803; YEE NS, 1994, J EXP MED, V179, P1777, DOI 10.1084/jem.179.6.1777	35	24	24	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2012	129	5					1357	U249		10.1016/j.jaci.2011.11.051	http://dx.doi.org/10.1016/j.jaci.2011.11.051			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	934CG	22360977				2022-12-18	WOS:000303418000027
J	Touzot, F; Gaillard, L; Vasquez, N; Le Guen, T; Bertrand, Y; Bourhis, J; Leblanc, T; Fischer, A; Soulier, J; de Villartay, JP; Revy, P				Touzot, Fabien; Gaillard, Laetitia; Vasquez, Nadia; Le Guen, Tangui; Bertrand, Yves; Bourhis, Jean; Leblanc, Thierry; Fischer, Alain; Soulier, Jean; de Villartay, Jean-Pierre; Revy, Patrick			Heterogeneous telomere defects in patients with severe forms of dyskeratosis congenita	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Telomere; dyskeratosis congenita; Hoyeraal-Hreidarsson syndrome; senescence; immune deficiencies; bone marrow failure	HEMATOPOIETIC STEM-CELLS; CEREBELLAR HYPOPLASIA; CANCER; MUTATIONS; SHELTERIN; REPAIR; HAPLOINSUFFICIENCY; IMMUNODEFICIENCY; ANTICIPATION; CONTRIBUTES	Background: Telomeres represent the tips of linear chromosomes. In human subjects telomere maintenance deficiency leads to dyskeratosis congenita (DC), a rare genetic disorder characterized by progressive bone marrow failure, accelerated aging, and cancer predisposition. Hoyeraal-Hreidarsson syndrome (HH) is a severe variant of DC in which an early onset of bone marrow failure leading to combined immunodeficiency is associated with microcephaly, cerebellar hypoplasia, and growth retardation. Objectives: Limited information is available on the cellular and molecular phenotypes of cells from patients with HH. We analyzed fibroblasts and whole blood cells from 5 patients with HH, 3 of them of unknown molecular origin. Methods: Telomere length, cellular senescence rate, telomerase activity, telomeric aberration, and DNA repair pathways were investigated. Results: Although patients' cells exhibit dysfunctional telomeres, sharp differences in the telomeric aberrations and telomere lengths were noted among these patients. In some patients the dysfunctional telomere phenotype was unprecedented and associated with either normal telomere length or with telomeric aberrations akin to fragile telomeres. This result is of particular importance because the molecular diagnosis of these patients is primarily based on telomere length, which therefore misses a subset of patients with telomere dysfunction. Conclusion: These observations provide the notions that (1) various telomere defects can lead to similar clinical features, (2) telomere dysfunction in cells from patients with DC/HH is not always associated with short telomeres, and (3) additional factors, likely involved in telomere protection rather than in length regulation, are responsible for a subset of DC/HH. (J Allergy Clin Immunol 2012;129:473-82.)	[Touzot, Fabien; Gaillard, Laetitia; Le Guen, Tangui; Fischer, Alain; de Villartay, Jean-Pierre; Revy, Patrick] INSERM, U768, F-75015 Paris, France; [Touzot, Fabien; Gaillard, Laetitia; Le Guen, Tangui; Fischer, Alain; de Villartay, Jean-Pierre; Revy, Patrick] Univ Paris 05, Fac Med Rene Descartes, IFR94, Paris, France; [Touzot, Fabien; Fischer, Alain; de Villartay, Jean-Pierre] Hop Necker Enfants Malad, AP HP, Serv Immunol & Hematol Pediat, Paris, France; [Vasquez, Nadia; Soulier, Jean] Univ Paris 07, INSERM, U944, Inst Univ Hematol, Paris, France; [Bertrand, Yves] Inst Hematol & Oncol Pediat, Lyon, France; [Bertrand, Yves] Univ Lyon 1, F-69365 Lyon, France; [Bourhis, Jean] Inst Gustave Roussy, UPRES EA 27 10, Villejuif, France; [Leblanc, Thierry] Hop Robert Debre, AP HP, Serv Hematol Pediat, F-75019 Paris, France; [Touzot, Fabien; Gaillard, Laetitia; Le Guen, Tangui; Fischer, Alain; de Villartay, Jean-Pierre; Revy, Patrick] Fdn Imagine Paris, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; UNICANCER; Gustave Roussy; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite	Revy, P (corresponding author), INSERM, U768, 149 Rue Sevres, F-75015 Paris, France.	patrick.revy@inserm.fr	Revy, Patrick/H-8137-2017; Touzot, Fabien/T-7797-2018; de Villartay, jean pierre/H-9353-2017	Touzot, Fabien/0000-0002-0889-4905; de Villartay, jean pierre/0000-0001-5987-0463; Revy, Patrick/0000-0003-0758-8022	Institut National de la Sante et de la Recherche Medicale; Ligue Nationale contre le Cancer (Equipe Labellisee La Ligue); Association pour la Recherche sur le Cancer; Institut National du Cancer (INCa)/Canceropole Ile de France; DHOS (centre de Reference Maladies Rares "Aplasies medullaires constitutionnelles''); European Research Council; Fondation pour la Recherche Medicale; La Ligue; INSERM	Institut National de la Sante et de la Recherche Medicale(Institut National de la Sante et de la Recherche Medicale (Inserm)); Ligue Nationale contre le Cancer (Equipe Labellisee La Ligue)(Institut National du Cancer (INCA) France); Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); Institut National du Cancer (INCa)/Canceropole Ile de France(Institut National du Cancer (INCA) France); DHOS (centre de Reference Maladies Rares "Aplasies medullaires constitutionnelles''); European Research Council(European Research Council (ERC)European Commission); Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); La Ligue; INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission)	Supported by institutional grants from the Institut National de la Sante et de la Recherche Medicale, Ligue Nationale contre le Cancer (Equipe Labellisee La Ligue), Association pour la Recherche sur le Cancer, Institut National du Cancer (INCa)/Canceropole Ile de France, DHOS (centre de Reference Maladies Rares "Aplasies medullaires constitutionnelles''), and the European Research Council. F.T. received fellowships from the Fondation pour la Recherche Medicale, and T.L.G. received fellowships from La Ligue. P.R. is a scientist from the Centre National de la Recherche Scientifique (CNRS).; A. Fischer has received research support from the European Research Council and INSERM. The rest of the authors declare that they have no relevant conflicts of interest.	ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; Alter BP, 2009, BLOOD, V113, P6549, DOI 10.1182/blood-2008-12-192880; Armanios M, 2005, P NATL ACAD SCI USA, V102, P15960, DOI 10.1073/pnas.0508124102; Armanios M, 2009, AM J HUM GENET, V85, P823, DOI 10.1016/j.ajhg.2009.10.028; Arnoult N, 2008, CYTOGENET GENOME RES, V122, P229, DOI 10.1159/000167808; Atzmon G, 2010, P NATL ACAD SCI USA, V107, P1710, DOI 10.1073/pnas.0906191106; Bailey SM, 2001, SCIENCE, V293, P2462, DOI 10.1126/science.1062560; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; Blasco MA, 2005, EMBO J, V24, P1095, DOI 10.1038/sj.emboj.7600598; Blasco MA, 1998, CIBA F SYMP, V211, P160; Buck D, 2006, CELL, V124, P287, DOI 10.1016/j.cell.2005.12.030; Collado M, 2007, CELL, V130, P223, DOI 10.1016/j.cell.2007.07.003; Crabbe L, 2004, SCIENCE, V306, P1951, DOI 10.1126/science.1103619; d'Adda di Fagagna F, 2003, NATURE, V426, P194, DOI [10.1038/nature02118, DOI 10.1038/NATURE02118]; de Lange T, 2005, GENE DEV, V19, P2100, DOI 10.1101/gad.1346005; de Lange T, 2009, SCIENCE, V326, P948, DOI 10.1126/science.1170633; Gilson E, 2007, NAT REV MOL CELL BIO, V8, P825, DOI 10.1038/nrm2259; Goldman F, 2005, P NATL ACAD SCI USA, V102, P17119, DOI 10.1073/pnas.0505318102; Hao LY, 2005, CELL, V123, P1121, DOI 10.1016/j.cell.2005.11.020; HOYERAAL HM, 1970, ACTA PAEDIATR SCAND, V59, P185, DOI 10.1111/j.1651-2227.1970.tb08986.x; HREIDARSSON S, 1988, ACTA PAEDIATR SCAND, V77, P773, DOI 10.1111/j.1651-2227.1988.tb10751.x; Kim NW, 1997, NUCLEIC ACIDS RES, V25, P2595, DOI 10.1093/nar/25.13.2595; Kirwan M, 2011, BRIT J HAEMATOL, V153, P634, DOI 10.1111/j.1365-2141.2011.08679.x; Kirwan M, 2009, BBA-MOL BASIS DIS, V1792, P371, DOI 10.1016/j.bbadis.2009.01.010; Lansdorp PM, 2009, EMBO J, V28, P2532, DOI 10.1038/emboj.2009.172; Martinez P, 2009, GENE DEV, V23, P2060, DOI 10.1101/gad.543509; Mitchell JR, 1999, NATURE, V402, P551, DOI 10.1038/990141; Moser BA, 2009, EMBO J, V28, P810, DOI 10.1038/emboj.2009.31; Nijnik A, 2007, NATURE, V447, P686, DOI 10.1038/nature05875; O'Sullivan RJ, 2010, NAT REV MOL CELL BIO, V11, P171, DOI 10.1038/nrm2848; Ohga S, 1997, EUR J PEDIATR, V156, P80; Palm W, 2008, ANNU REV GENET, V42, P301, DOI 10.1146/annurev.genet.41.110306.130350; Pinto FO, 2009, HAEMATOL-HEMATOL J, V94, P487, DOI 10.3324/haematol.13592; Revy P, 2000, PEDIATRICS, V105, DOI 10.1542/peds.105.3.e39; Revy P, 2005, ADV IMMUNOL, V87, P237, DOI 10.1016/S0065-2776(05)87007-5; Rossi DJ, 2007, NATURE, V447, P725, DOI 10.1038/nature05862; Saharia A, 2008, CURR BIOL, V18, P496, DOI 10.1016/j.cub.2008.02.071; Savage SA, 2008, AM J HUM GENET, V82, P501, DOI 10.1016/j.ajhg.2007.10.004; Sfeir A, 2009, CELL, V138, P90, DOI 10.1016/j.cell.2009.06.021; Takai H, 2003, CURR BIOL, V13, P1549, DOI 10.1016/S0960-9822(03)00542-6; Tomas-Loba A, 2008, CELL, V135, P609, DOI 10.1016/j.cell.2008.09.034; Touzot F, 2010, P NATL ACAD SCI USA, V107, P10097, DOI 10.1073/pnas.0914918107; Vulliamy T, 2004, NAT GENET, V36, P447, DOI 10.1038/ng1346; Walne AJ, 2008, BLOOD, V112, P3594, DOI 10.1182/blood-2008-05-153445; Walne AJ, 2008, MECH AGEING DEV, V129, P48, DOI 10.1016/j.mad.2007.10.006; Walne AJ, 2010, HUM MOL GENET, V19, P4453, DOI 10.1093/hmg/ddq371; Wu P, 2010, MOL CELL, V39, P606, DOI 10.1016/j.molcel.2010.06.031; Zhong F, 2011, GENE DEV, V25, P11, DOI 10.1101/gad.2006411	48	24	24	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2012	129	2					473	U300		10.1016/j.jaci.2011.09.043	http://dx.doi.org/10.1016/j.jaci.2011.09.043			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	887TC	22078571	Bronze			2022-12-18	WOS:000299951700027
J	Pallikkuth, S; Kanthikeel, SP; Silva, SY; Fischl, M; Pahwa, R; Pahwa, S				Pallikkuth, Suresh; Kanthikeel, Sudheesh Pilakka; Silva, Sandra Y.; Fischl, Margaret; Pahwa, Rajendra; Pahwa, Savita			Innate immune defects correlate with failure of antibody responses to H1N1/09 vaccine in HIV-infected patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						2009 H1N1 vaccination and HIV; B-cell defect in HIV; BAFF-binding receptors and HIV; innate immune defect and HIV; T-independent humoral immune factors	MEMORY B-CELLS; TRANSMEMBRANE ACTIVATOR; DENDRITIC CELLS; BAFF; DISEASE; TACI; DIFFERENTIATION; SURVIVAL; SIGNALS; APRIL	Background: Mechanisms underlying the failure of influenza vaccine-induced antibody responses in HIV-infected persons are poorly understood. Objective: To investigate innate immune factors regulating B-cell function in HIV-infected persons and to correlate them with serologic responses to H1N1/09 vaccine. Methods: We evaluated immunologic characteristics of 17 HIV-infected patients and 8 healthy controls (HCs) at 0, 7, and 28 days (designated T0, T1, and T2) following a single 15-mu g dose of nonadjuvanted H1N1/09 influenza vaccine by using flow cytometry, ELISpot, and ELISA. All HCs and 9 patients (53%) seroconverted with >1:40 hemagglutination inhibition antibody titer at T2. Results: In vaccine responders and HCs, serum levels of BAFF (B cell-activating factor) and APRIL (a proliferation-inducing ligand) increased from T0 to T2 in conjunction with increases in frequencies of memory B cells. Concurrently, receptors for these factors showed changes, with increases in expression of TACI (transmembrane activator and calcium modulator and cyclophilin ligand interactor) and decreases in BAFF receptor in memory B cells. IL-2 secreting cells and IgG antibody-secreting cells increased at T2 in vaccine responders and HCs in ex vivo H1N1 antigen-stimulated cultures. These immunologic responses were not evident at T1 and were deficient in vaccine nonresponder patients at T2. At T0, vaccine nonresponders had lower frequencies of BAFF receptor and TACI-expressing memory B cells than did responders. Conclusion: Impaired memory B-cell responses, deficiencies in serum BAFF and APRIL, and alterations in their receptors on B cells were associated with failure of H1N1/09 influenza vaccine responses among virologically controlled HIV-infected patients. (J Allergy Clin Immunol 2011;128:1279-85.)	[Pallikkuth, Suresh; Kanthikeel, Sudheesh Pilakka; Silva, Sandra Y.; Pahwa, Savita] Univ Miami, Miller Sch Med, Dept Microbiol & Immunol, Miami, FL 33136 USA; [Fischl, Margaret] Univ Miami, Miller Sch Med, AIDS Clin Res Unit, Dept Med, Miami, FL 33136 USA; [Pahwa, Rajendra] Univ Miami, Miller Sch Med, Diabet Res Inst, Miami, FL 33136 USA	University of Miami; University of Miami; University of Miami	Pahwa, S (corresponding author), Univ Miami, Miller Sch Med, Dept Microbiol & Immunol, 1580 NW 10th Ave,BCRI 712, Miami, FL 33136 USA.	spahwa@med.miami.edu	Pahwa, Savita/AAA-4900-2019	Pahwa, Savita/0000-0002-4470-4216	NIH [A1077501]; International Maternal, Pediatric and Adolescent AIDS Clinical Trials Group (IMPAACT); National Institute of Allergy and Infectious Diseases (NIAID) [U01 AI068632]; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute of Mental Health (NIMH) [AI068632]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI068632, R01AI077501, P30AI073961, UM1AI068632] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); International Maternal, Pediatric and Adolescent AIDS Clinical Trials Group (IMPAACT); National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); National Institute of Mental Health (NIMH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by NIH grant A1077501 to S.P. and a specialty laboratory grant from International Maternal, Pediatric and Adolescent AIDS Clinical Trials Group (IMPAACT). Overall support for IMPAACT was provided by the National Institute of Allergy and Infectious Diseases (NIAID) (U01 AI068632), the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), and the National Institute of Mental Health (NIMH) (AI068632).	Avery DT, 2003, J CLIN INVEST, V112, P286, DOI 10.1172/JCI200318025; Benson MJ, 2007, CURR OPIN IMMUNOL, V19, P275, DOI 10.1016/j.coi.2007.04.009; Bickel M, 2010, AIDS, V24, pF31, DOI 10.1097/QAD.0b013e3283398da1; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; Buseyne F, 2005, J IMMUNOL METHODS, V298, P105, DOI 10.1016/j.jim.2005.01.003; Castigli E, 2005, J EXP MED, V201, P35, DOI 10.1084/jem.20032000; Castigli E, 2007, J ALLERGY CLIN IMMUN, V120, P885, DOI 10.1016/j.jaci.2007.06.012; Cerutti A, 2005, IMMUNOL CELL BIOL, V83, P554, DOI 10.1111/j.1440-1711.2005.01389.x; Crotty S, 2004, J IMMUNOL METHODS, V286, P111, DOI 10.1016/j.jim.2003.12.015; Darce JR, 2007, J IMMUNOL, V179, P7276, DOI 10.4049/jimmunol.179.11.7276; Elgueta R, 2010, IMMUNOL REV, V236, P139, DOI 10.1111/j.1600-065X.2010.00924.x; Ettinger R, 2007, J IMMUNOL, V178, P2872, DOI 10.4049/jimmunol.178.5.2872; Fontaine J, 2011, BLOOD, V117, P145, DOI 10.1182/blood-2010-08-301887; Gauld SB, 2002, SCIENCE, V296, P1641, DOI 10.1126/science.1071546; Geha Raif S, 2005, J Pediatr Gastroenterol Nutr, V40 Suppl 1, pS27, DOI 10.1097/00005176-200504001-00015; Good KL, 2006, J IMMUNOL, V177, P5236, DOI 10.4049/jimmunol.177.8.5236; Good-Jacobson KL, 2010, J IMMUNOL, V185, P3117, DOI 10.4049/jimmunol.1001155; Greenbaum JA, 2009, P NATL ACAD SCI USA, V106, P20365, DOI 10.1073/pnas.0911580106; Greenberg ME, 2009, NEW ENGL J MED, V361, P2405, DOI 10.1056/NEJMoa0907413; Napolitano L. M., 2009, Morbidity and Mortality Weekly Report, V58, P749; Hancock K, 2009, NEW ENGL J MED, V361, P1945, DOI 10.1056/NEJMoa0906453; He B, 2010, NAT IMMUNOL, V11, P836, DOI 10.1038/ni.1914; Ho J, 2011, AIDS, V25, P295, DOI 10.1097/QAD.0b013e328342328b; Klein MB, 2007, CLIN INFECT DIS, V45, P234, DOI 10.1086/518986; Kurosaki T, 2010, IMMUNOL REV, V237, P104, DOI 10.1111/j.1600-065X.2010.00939.x; Kurosaki T, 2010, ANNU REV IMMUNOL, V28, P21, DOI 10.1146/annurev.immunol.021908.132541; Litinskiy MB, 2002, NAT IMMUNOL, V3, P822, DOI 10.1038/ni829; Mackay F, 2004, CURR OPIN PHARMACOL, V4, P347, DOI 10.1016/j.coph.2004.02.009; Mackay F, 2003, ANNU REV IMMUNOL, V21, P231, DOI 10.1146/annurev.immunol.21.120601.141152; Mackay F, 2010, IMMUNOL REV, V237, P205, DOI 10.1111/j.1600-065X.2010.00944.x; Malaspina A, 2006, P NATL ACAD SCI USA, V103, P2262, DOI 10.1073/pnas.0511094103; Malaspina A, 2005, J INFECT DIS, V191, P1442, DOI 10.1086/429298; Mantchev GT, 2007, J IMMUNOL, V179, P2282, DOI 10.4049/jimmunol.179.4.2282; MINGARI MC, 1984, NATURE, V312, P641, DOI 10.1038/312641a0; Mohammadi J, 2009, J CLIN IMMUNOL, V29, P777, DOI 10.1007/s10875-009-9317-5; Moir S, 2008, J INFECT DIS, V197, P572, DOI 10.1086/526789; Moir S, 2009, NAT REV IMMUNOL, V9, P235, DOI 10.1038/nri2524; Moore PA, 1999, SCIENCE, V285, P260, DOI 10.1126/science.285.5425.260; North ME, 1996, CLIN EXP IMMUNOL, V105, P517, DOI 10.1046/j.1365-2249.1996.d01-795.x; O'Connor BP, 2004, J EXP MED, V199, P91, DOI 10.1084/jem.20031330; Pallikkuth S, 2011, J IMMUNOL, V186, P6173, DOI 10.4049/jimmunol.1100264; Plotkin SA, 2010, CLIN VACCINE IMMUNOL, V17, P1055, DOI 10.1128/CVI.00131-10; Poodt AEJ, 2009, CLIN EXP IMMUNOL, V156, P35, DOI 10.1111/j.1365-2249.2008.03863.x; Reed JL, 2009, J INFECT DIS, V199, P1128, DOI 10.1086/597386; Rodriguez B, 2003, AIDS, V17, P1983, DOI 10.1097/00002030-200309050-00018; Schneider P, 2005, CURR OPIN IMMUNOL, V17, P282, DOI 10.1016/j.coi.2005.04.005; Smith KGC, 1997, EMBO J, V16, P2996, DOI 10.1093/emboj/16.11.2996; Talbot HK, 2008, VACCINE, V26, P4057, DOI 10.1016/j.vaccine.2008.05.024; Tangye SG, 2006, SEMIN IMMUNOL, V18, P305, DOI 10.1016/j.smim.2006.04.004; Tebas P, 2010, AIDS, V24, P2187, DOI 10.1097/QAD.0b013e32833c6d5c; Yoshida T, 2010, IMMUNOL REV, V237, P117, DOI 10.1111/j.1600-065X.2010.00938.x; Zhang X, 2005, INT IMMUNOL, V17, P779, DOI 10.1093/intimm/dxh259	52	24	24	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2011	128	6					1279	1285		10.1016/j.jaci.2011.05.033	http://dx.doi.org/10.1016/j.jaci.2011.05.033			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	865WX	21752440	Green Accepted			2022-12-18	WOS:000298342700018
J	Fried, AJ; Rauter, I; Dillon, SR; Jabara, HH; Geha, RS				Fried, Ari J.; Rauter, Ingrid; Dillon, Stacey R.; Jabara, Haifa H.; Geha, Raif S.			Functional analysis of transmembrane activator and calcium-modulating cyclophilin ligand interactor (TACI) mutations associated with common variable immunodeficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							DEFICIENCY; VARIANTS		[Fried, Ari J.; Rauter, Ingrid; Jabara, Haifa H.; Geha, Raif S.] Harvard Univ, Sch Med, Div Immunol, Childrens Hosp Boston, Boston, MA 02115 USA; [Fried, Ari J.; Rauter, Ingrid; Jabara, Haifa H.; Geha, Raif S.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA USA; [Dillon, Stacey R.] ZymoGenetics Inc, Seattle, WA USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Zymogenet Inc.	Fried, AJ (corresponding author), Harvard Univ, Sch Med, Div Immunol, Childrens Hosp Boston, Boston, MA 02115 USA.	raif.geha@childrens.harvard.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI076210, U19AI031541, P01AI031541] Funding Source: NIH RePORTER; NIAID NIH HHS [U19 AI031541, P01 AI031541, P01 AI076210, P01 AI076210-02] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Castigli E, 2005, NAT GENET, V37, P829, DOI 10.1038/ng1601; Castigli E, 2007, NAT GENET, V39, P430, DOI 10.1038/ng0407-430; Cunningham-Rundles C, 2006, J IMMUNOL, V176, P1978, DOI 10.4049/jimmunol.176.3.1978; Garibyan L, 2007, J CLIN INVEST, V117, P1550, DOI 10.1172/JCI31023; Lee JJ, 2010, J ALLERGY CLIN IMMUN, V126, P1234, DOI 10.1016/j.jaci.2010.08.017; Pan-Hammarstrom Q, 2007, NAT GENET, V39, P429, DOI 10.1038/ng0407-429; Salzer U, 2005, NAT GENET, V37, P820, DOI 10.1038/ng1600; Salzer U, 2009, BLOOD, V113, P1967, DOI 10.1182/blood-2008-02-141937; Warnatz K, 2009, P NATL ACAD SCI USA, V106, P13945, DOI 10.1073/pnas.0903543106; Yu JE, 2009, J ALLERGY CLIN IMMUN, V124, P349, DOI 10.1016/j.jaci.2009.05.019	10	24	25	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2011	128	1					226	228		10.1016/j.jaci.2011.01.048	http://dx.doi.org/10.1016/j.jaci.2011.01.048			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	785RE	21419480	Green Accepted, Bronze			2022-12-18	WOS:000292245600035
J	Chua, I; Lagos, M; Charalambous, BM; Workman, S; Chee, R; Grimbacher, B				Chua, Ignatius; Lagos, Macarena; Charalambous, Bambos M.; Workman, Sarita; Chee, Ronnie; Grimbacher, Bodo			Pathogen-specific IgG antibody levels in immunodeficient patients receiving immunoglobulin replacement do not provide additional benefit to therapeutic management over total serum IgG	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							INFLUENZAE TYPE-B; CAPSULAR POLYSACCHARIDE		[Chua, Ignatius; Workman, Sarita; Chee, Ronnie; Grimbacher, Bodo] UCL, JMF Ctr Primary Immune Deficiency, London WC1E 6BT, England; [Charalambous, Bambos M.] UCL, Ctr Clin Microbiol, London WC1E 6BT, England; [Lagos, Macarena] Univ Valparaiso, Escuela Med, Valparaiso, Chile	University of London; University College London; University of London; University College London; Universidad de Valparaiso	Chua, I (corresponding author), UCL, JMF Ctr Primary Immune Deficiency, London WC1E 6BT, England.	b.grimbacher@ucl.ac.uk						ANDERSON P, 1984, J INFECT DIS, V149, P1034, DOI 10.1093/infdis/149.6.1034; Lucas M, 2010, J ALLERGY CLIN IMMUN, V125, P1354, DOI 10.1016/j.jaci.2010.02.040; RAMSAY M, 1991, BRIT MED J, V330, P1489; Schauer U, 2003, CLIN DIAGN LAB IMMUN, V10, P202, DOI 10.1128/CDLI.10.2.202-207.2003; Stead A, 2002, CLIN EXP IMMUNOL, V130, P325, DOI 10.1046/j.1365-2249.2002.01974.x	5	24	28	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2011	127	6					1410	1411		10.1016/j.jaci.2011.01.035	http://dx.doi.org/10.1016/j.jaci.2011.01.035			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	769WH	21376379	Bronze			2022-12-18	WOS:000291048500013
J	Sicherer, SH; Leung, DYM				Sicherer, Scott H.; Leung, Donald Y. M.			Advances in allergic skin disease, anaphylaxis, and hypersensitivity reactions to foods, drugs, and insects in 2010	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Dermatology; skin disease; urticaria; atopic dermatitis; anaphylaxis; allergy; hypersensitivity disorders; food; drug; insect venom	THYMIC STROMAL LYMPHOPOIETIN; ATOPIC-DERMATITIS; STAPHYLOCOCCUS-AUREUS; DENDRITIC CELLS; EGG ALLERGY; T-CELLS; MILK; FILAGGRIN; RISK; IDENTIFICATION	This review highlights some of the research advances in anaphylaxis; hypersensitivity reactions to foods, drugs, and insects; and allergic skin disease that were reported in the Journal in 2010. Key epidemiologic observations include an apparent increase in peanut allergy, with more than 1% of children affected, and increasing evidence that early food allergen exposure, rather than avoidance, might improve allergy outcomes. Advances in food allergy diagnosis include improved insights into prognosis and estimation of severity through component-resolved diagnostics and characterization of IgE binding to specific epitopes. Regarding treatment, oral and epicutaneous immunotherapy show promise. Studies of drug allergies show insights into pathophysiology, and studies on insect hypersensitivity reveal improved diagnostic methods. Genetic and functional studies have revealed the important role of epidermal differentiation products in the pathogenesis of atopic dermatitis. Cross-talk between the atopic immune response with the innate immune response have also been found to predispose to infection in patients with atopic dermatitis. New therapeutic approaches to control chronic urticaria have also been identified during the past year. (J Allergy Clin Immunol 2011;127:326-35.)	[Sicherer, Scott H.] Mt Sinai Hosp, Div Allergy Immunol, New York, NY 10029 USA; [Sicherer, Scott H.] Mt Sinai Sch Med, Elliot & Roslyn Jaffe Food Allergy Inst, Div Allergy & Immunol, Dept Pediat, New York, NY USA; [Leung, Donald Y. M.] Natl Jewish Hlth, Dept Pediat, Div Pediat Allergy Immunol, Denver, CO USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; National Jewish Health	Sicherer, SH (corresponding author), Mt Sinai Hosp, Div Allergy Immunol, Box 1198,1 Gustave L Levy Pl, New York, NY 10029 USA.	scott.sicherer@mssm.edu			National Institutes of Health/National Institute of Allergy and Infectious Diseases	National Institutes of Health/National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	S. H. Sicherer is a consultant for the Food Allergy Initiative and receives research support from the National Institutes of Health/National Institute of Allergy and Infectious Diseases. D. Y. M. Leung had declared that he has no conflict of interest.	Abonia JP, 2010, J ALLERGY CLIN IMMUN, V126, P140, DOI 10.1016/j.jaci.2010.04.009; Aceves SS, 2010, J ALLERGY CLIN IMMUN, V126, P1198, DOI 10.1016/j.jaci.2010.08.050; Akin C, 2010, J ALLERGY CLIN IMMUN, V126, P1099, DOI 10.1016/j.jaci.2010.08.035; Alvarez-Twose I, 2010, J ALLERGY CLIN IMMUN, V125, P1269, DOI 10.1016/j.jaci.2010.02.019; [Anonymous], 2010, J ALLERGY CLIN IMMUN, V126, pS5, DOI 10.1016/j.jaci.2010.10.007; Arellano FM, 2009, J ALLERGY CLIN IMMUN, V123, P1111, DOI 10.1016/j.jaci.2009.02.028; Arkwright PD, 2009, J ALLERGY CLIN IMMUN, V123, P510, DOI 10.1016/j.jaci.2008.11.043; Ayuso R, 2010, J ALLERGY CLIN IMMUN, V125, P1286, DOI 10.1016/j.jaci.2010.03.010; Barnes KC, 2010, J ALLERGY CLIN IMMUN, V125, P16, DOI 10.1016/j.jaci.2009.11.008; Beck LA, 2009, J ALLERGY CLIN IMMUN, V124, P260, DOI 10.1016/j.jaci.2009.05.020; Ben-Shoshan M, 2010, J ALLERGY CLIN IMMUN, V125, P1327, DOI 10.1016/j.jaci.2010.03.015; Blumchen K, 2010, J ALLERGY CLIN IMMUN, V126, P83, DOI 10.1016/j.jaci.2010.04.030; Boguniewicz M, 2010, J ALLERGY CLIN IMMUN, V125, P4, DOI 10.1016/j.jaci.2009.11.027; Broccardo CJ, 2011, J ALLERGY CLIN IMMUN, V127, P186, DOI 10.1016/j.jaci.2010.10.033; Broccardo CJ, 2009, J ALLERGY CLIN IMMUN, V124, P1113, DOI 10.1016/j.jaci.2009.07.057; Bublin M, 2010, J ALLERGY CLIN IMMUN, V125, P687, DOI 10.1016/j.jaci.2009.10.017; Caldwell JM, 2010, J ALLERGY CLIN IMMUN, V125, P879, DOI 10.1016/j.jaci.2010.01.038; Castrejon JL, 2010, J ALLERGY CLIN IMMUN, V125, P411, DOI 10.1016/j.jaci.2009.10.031; Crotty MP, 2010, J ALLERGY CLIN IMMUN, V125, P935, DOI 10.1016/j.jaci.2009.12.003; DeBrosse CW, 2010, J ALLERGY CLIN IMMUN, V126, P112, DOI 10.1016/j.jaci.2010.05.027; Dupont C, 2010, J ALLERGY CLIN IMMUN, V125, P1165, DOI 10.1016/j.jaci.2010.02.029; Fiocchi A, 2010, J ALLERGY CLIN IMMUN, V126, P1119, DOI 10.1016/j.jaci.2010.10.011; Ford LS, 2010, J ALLERGY CLIN IMMUN, V126, P384, DOI 10.1016/j.jaci.2010.05.034; Gagnon R, 2010, J ALLERGY CLIN IMMUN, V126, P317, DOI 10.1016/j.jaci.2010.05.037; Gandhi C, 2009, J ALLERGY CLIN IMMUN, V124, P1245, DOI 10.1016/j.jaci.2009.09.035; Gao PS, 2010, J ALLERGY CLIN IMMUN, V125, P1403, DOI 10.1016/j.jaci.2010.03.016; Gao PS, 2009, J ALLERGY CLIN IMMUN, V124, P507, DOI 10.1016/j.jaci.2009.07.034; Gonzalez-Perez A, 2010, J ALLERGY CLIN IMMUN, V125, P1098, DOI 10.1016/j.jaci.2010.02.009; Grigoryev DN, 2010, J ALLERGY CLIN IMMUN, V125, P153, DOI 10.1016/j.jaci.2009.10.024; Gros E, 2009, J ALLERGY CLIN IMMUN, V124, P753, DOI 10.1016/j.jaci.2009.07.004; Gruber C, 2010, J ALLERGY CLIN IMMUN, V126, P791, DOI 10.1016/j.jaci.2010.07.022; Guttman-Yassky E, 2009, J ALLERGY CLIN IMMUN, V124, P1235, DOI 10.1016/j.jaci.2009.09.031; Hamilton RG, 2010, J ALLERGY CLIN IMMUN, V126, P33, DOI 10.1016/j.jaci.2010.03.014; Harduar-Morano L, 2010, J ALLERGY CLIN IMMUN, V126, P98, DOI 10.1016/j.jaci.2010.04.017; Hatano Y, 2010, J ALLERGY CLIN IMMUN, V125, P160, DOI 10.1016/j.jaci.2009.06.049; Hochwallner H, 2010, J ALLERGY CLIN IMMUN, V125, P1279, DOI 10.1016/j.jaci.2010.03.007; Howell MD, 2009, J ALLERGY CLIN IMMUN, V124, pR7, DOI 10.1016/j.jaci.2009.07.012; Ilchmann A, 2010, J ALLERGY CLIN IMMUN, V125, P175, DOI 10.1016/j.jaci.2009.08.013; Jensen JM, 2009, J ALLERGY CLIN IMMUN, V123, P1124, DOI 10.1016/j.jaci.2009.03.032; Jin C, 2010, J ALLERGY CLIN IMMUN, V125, P184, DOI 10.1016/j.jaci.2009.08.037; Torres MJ, 2010, J ALLERGY CLIN IMMUN, V125, P502, DOI 10.1016/j.jaci.2009.11.032; Kasperkiewicz M, 2011, J ALLERGY CLIN IMMUN, V127, P267, DOI 10.1016/j.jaci.2010.07.042; Katz Y, 2010, J ALLERGY CLIN IMMUN, V126, P77, DOI 10.1016/j.jaci.2010.04.020; Kelso JM, 2010, J ALLERGY CLIN IMMUN, V125, P800, DOI 10.1016/j.jaci.2010.02.013; Kessel A, 2009, J ALLERGY CLIN IMMUN, V123, P970, DOI 10.1016/j.jaci.2009.01.065; Khan DA, 2010, J ALLERGY CLIN IMMUN, V125, pS126, DOI 10.1016/j.jaci.2009.10.028; Koplin JJ, 2010, J ALLERGY CLIN IMMUN, V126, P807, DOI 10.1016/j.jaci.2010.07.028; La Shell MS, 2010, J ALLERGY CLIN IMMUN, V125, P1294, DOI 10.1016/j.jaci.2010.02.041; Leung DYM, 2009, J ALLERGY CLIN IMMUN, V124, P494, DOI 10.1016/j.jaci.2009.07.041; Li JT, 2010, J ALLERGY CLIN IMMUN, V125, P1412, DOI 10.1016/j.jaci.2010.03.009; Lieberman P, 2010, J ALLERGY CLIN IMMUN, V126, P477, DOI 10.1016/j.jaci.2010.06.022; Liu AH, 2010, J ALLERGY CLIN IMMUN, V126, P798, DOI 10.1016/j.jaci.2010.07.026; Magerl M, 2010, J ALLERGY CLIN IMMUN, V126, P665, DOI 10.1016/j.jaci.2010.05.047; Meyer N, 2010, J ALLERGY CLIN IMMUN, V125, P858, DOI 10.1016/j.jaci.2010.01.016; Miajlovic H, 2010, J ALLERGY CLIN IMMUN, V126, P1184, DOI 10.1016/j.jaci.2010.09.015; Mittermann I, 2010, J ALLERGY CLIN IMMUN, V125, P1300, DOI 10.1016/j.jaci.2010.03.017; Nicolaou N, 2010, J ALLERGY CLIN IMMUN, V125, P191, DOI 10.1016/j.jaci.2009.10.008; Niebuhr M, 2010, J ALLERGY CLIN IMMUN, V126, P1176, DOI 10.1016/j.jaci.2010.07.041; Niedoszytko M, 2010, J ALLERGY CLIN IMMUN, V125, P1092, DOI 10.1016/j.jaci.2010.01.021; Nograles KE, 2010, J ALLERGY CLIN IMMUN, V125, P744, DOI 10.1016/j.jaci.2009.12.934; Nograles KE, 2009, J ALLERGY CLIN IMMUN, V123, P1244, DOI 10.1016/j.jaci.2009.03.041; Novak N, 2010, J ALLERGY CLIN IMMUN, V125, P50, DOI 10.1016/j.jaci.2009.11.019; O'Regan GM, 2010, J ALLERGY CLIN IMMUN, V126, P574, DOI 10.1016/j.jaci.2010.04.038; Oyoshi MK, 2010, J ALLERGY CLIN IMMUN, V126, P976, DOI 10.1016/j.jaci.2010.08.041; Oyoshi MK, 2009, J ALLERGY CLIN IMMUN, V124, P485, DOI 10.1016/j.jaci.2009.05.042; Peters AS, 2010, J ALLERGY CLIN IMMUN, V126, P590, DOI 10.1016/j.jaci.2010.06.020; Pincus M, 2010, J ALLERGY CLIN IMMUN, V125, P273, DOI 10.1016/j.jaci.2009.10.057; Pochard P, 2010, J ALLERGY CLIN IMMUN, V126, P92, DOI 10.1016/j.jaci.2010.04.003; Romano A, 2010, J ALLERGY CLIN IMMUN, V126, P994, DOI 10.1016/j.jaci.2010.06.052; Rudders SA, 2010, J ALLERGY CLIN IMMUN, V126, P385, DOI 10.1016/j.jaci.2010.05.018; Rueff F, 2010, J ALLERGY CLIN IMMUN, V126, P105, DOI 10.1016/j.jaci.2010.04.025; Salfeld P, 2009, J ALLERGY CLIN IMMUN, V124, P170, DOI 10.1016/j.jaci.2009.02.038; Sanchez-Morillas L, 2010, J ALLERGY CLIN IMMUN, V126, P177, DOI 10.1016/j.jaci.2010.03.012; Savage JH, 2010, J ALLERGY CLIN IMMUN, V125, P683, DOI 10.1016/j.jaci.2009.12.994; Savilahti EM, 2010, J ALLERGY CLIN IMMUN, V125, P1315, DOI 10.1016/j.jaci.2010.03.025; Schimke LF, 2010, J ALLERGY CLIN IMMUN, V126, P611, DOI 10.1016/j.jaci.2010.06.029; Schlievert PM, 2010, J ALLERGY CLIN IMMUN, V125, P39, DOI 10.1016/j.jaci.2009.10.039; Schneider L, 2010, J ALLERGY CLIN IMMUN, V126, P1306, DOI 10.1016/j.jaci.2010.08.010; Schouten B, 2010, J ALLERGY CLIN IMMUN, V125, P1308, DOI 10.1016/j.jaci.2010.02.039; Searing DA, 2010, J ALLERGY CLIN IMMUN, V125, P995, DOI 10.1016/j.jaci.2010.03.008; Shek LPC, 2010, J ALLERGY CLIN IMMUN, V126, P324, DOI 10.1016/j.jaci.2010.06.003; Sherrill JD, 2010, J ALLERGY CLIN IMMUN, V126, P160, DOI 10.1016/j.jaci.2010.04.037; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V126, P1191, DOI 10.1016/j.jaci.2010.08.036; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, P1322, DOI 10.1016/j.jaci.2010.03.029; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, pS116, DOI 10.1016/j.jaci.2009.08.028; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, P1077, DOI 10.1016/j.jaci.2010.02.038; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, P85, DOI 10.1016/j.jaci.2009.11.031; Siebenhaar F, 2009, J ALLERGY CLIN IMMUN, V123, P672, DOI 10.1016/j.jaci.2008.12.008; Silverberg JI, 2010, J ALLERGY CLIN IMMUN, V126, P300, DOI 10.1016/j.jaci.2010.05.041; Simons FER, 2010, J ALLERGY CLIN IMMUN, V125, pS161, DOI 10.1016/j.jaci.2009.12.981; Simons FER, 2010, J ALLERGY CLIN IMMUN, V125, P419, DOI 10.1016/j.jaci.2009.10.056; Song Y, 2010, J ALLERGY CLIN IMMUN, V126, P1208, DOI 10.1016/j.jaci.2010.09.013; Sonkoly E, 2010, J ALLERGY CLIN IMMUN, V126, P581, DOI 10.1016/j.jaci.2010.05.045; Staevska M, 2010, J ALLERGY CLIN IMMUN, V125, P676, DOI 10.1016/j.jaci.2009.11.047; Stutius LM, 2010, J ALLERGY CLIN IMMUN, V125, P938, DOI 10.1016/j.jaci.2009.12.982; Sugita K, 2010, J ALLERGY CLIN IMMUN, V126, DOI 10.1016/j.jaci.2010.06.004; Tartibi HM, 2010, J ALLERGY CLIN IMMUN, V126, P664, DOI 10.1016/j.jaci.2010.06.014; Thorp WA, 2010, J ALLERGY CLIN IMMUN, V126, DOI 10.1016/j.jaci.2010.04.040; Thyagarajan A, 2010, J ALLERGY CLIN IMMUN, V126, P31, DOI 10.1016/j.jaci.2010.05.012; Travers JB, 2010, J ALLERGY CLIN IMMUN, V125, P146, DOI 10.1016/j.jaci.2009.09.052; van Nieuwaal NHG, 2010, J ALLERGY CLIN IMMUN, V125, P1391, DOI 10.1016/j.jaci.2010.01.057; Vassallo MF, 2010, J ALLERGY CLIN IMMUN, V126, P217, DOI 10.1016/j.jaci.2010.06.011; Vereda A, 2010, J ALLERGY CLIN IMMUN, V126, P596, DOI 10.1016/j.jaci.2010.06.023; Villalta D, 2010, J ALLERGY CLIN IMMUN, V125, P1158, DOI 10.1016/j.jaci.2010.01.043; Vu AT, 2010, J ALLERGY CLIN IMMUN, V126, P985, DOI 10.1016/j.jaci.2010.09.002; Waibel KH, 2010, J ALLERGY CLIN IMMUN, V125, P749, DOI 10.1016/j.jaci.2009.12.015; Waibel KH, 2010, J ALLERGY CLIN IMMUN, V125, P490, DOI 10.1016/j.jaci.2009.11.007; Wang J, 2010, J ALLERGY CLIN IMMUN, V125, P695, DOI 10.1016/j.jaci.2009.12.017; Wang MQ, 2010, J ALLERGY CLIN IMMUN, V126, P306, DOI 10.1016/j.jaci.2010.05.017; Wu WH, 2010, J ALLERGY CLIN IMMUN, V126, P290, DOI 10.1016/j.jaci.2010.05.024; Yang AC, 2010, J ALLERGY CLIN IMMUN, V125, P872, DOI 10.1016/j.jaci.2009.11.043	111	24	25	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2011	127	2					326	335		10.1016/j.jaci.2010.11.024	http://dx.doi.org/10.1016/j.jaci.2010.11.024			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	714KH	21190728				2022-12-18	WOS:000286808000003
J	Fitzpatrick, AM; Teague, WG				Fitzpatrick, Anne M.; Teague, W. Gerald		Natl Heart Lung Blood Inst	Progressive airflow limitation is a feature of children with severe asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CHILDHOOD ASTHMA; POPULATION; ADULTHOOD; LUNG; NUCLEOTIDE; AMERICA; PROGRAM; HUMANS; COHORT; AGE		[Fitzpatrick, Anne M.] Emory Univ, Dept Pediat, Sch Med, Atlanta, GA 30322 USA; [Teague, W. Gerald] Univ Virginia, Sch Med, Dept Pediat, Charlottesville, VA 22908 USA	Emory University; University of Virginia	Fitzpatrick, AM (corresponding author), Emory Univ, Dept Pediat, Sch Med, Atlanta, GA 30322 USA.	anne.fitzpatrick@emory.edu		Fitzpatrick, Anne/0000-0002-2933-5926	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [KL2TR000455, UL1TR000454, TL1TR000456] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [TL1RR025010, UL1RR025008, KL2RR025009] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069170] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCH [R01NR012021] Funding Source: NIH RePORTER; NCATS NIH HHS [TL1 TR000456, UL1 TR000454, KL2 TR000455] Funding Source: Medline; NCRR NIH HHS [UL1 RR025008-03, TL1 RR025010, KL2 RR025009, UL1 RR025008] Funding Source: Medline; NHLBI NIH HHS [R01 HL069170, R01HL069170, U10 HL109250, R01 HL069170-07] Funding Source: Medline; NINR NIH HHS [R01 NR012021-01, R01NR012021, R01 NR012021] Funding Source: Medline	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); NCATS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))		BANDELT HJ, 1995, GENETICS, V141, P743; Covar RA, 2004, AM J RESP CRIT CARE, V170, P234, DOI 10.1164/rccm.200308-1174OC; Covar RA, 2010, J ALLERGY CLIN IMMUN, V125, P359, DOI 10.1016/j.jaci.2009.10.037; Fagundes NJR, 2008, AM J HUM GENET, V82, P583, DOI 10.1016/j.ajhg.2007.11.013; Fitzpatrick AM, 2006, J ALLERGY CLIN IMMUN, V118, P1218, DOI 10.1016/j.jaci.2006.08.019; Goebel T, 2008, SCIENCE, V319, P1497, DOI 10.1126/science.1153569; Kitchen A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001596; Moore WC, 2007, J ALLERGY CLIN IMMUN, V119, P405, DOI 10.1016/j.jaci.2006.11.639; Nachman MW, 2000, GENETICS, V156, P297; Rasmussen F, 2002, AM J RESP CRIT CARE, V165, P1480, DOI 10.1164/rccm.2108009; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; Strunk RC, 2006, J ALLERGY CLIN IMMUN, V118, P1040, DOI 10.1016/j.jaci.2006.07.053; Tamm E, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000829; Tang H, 2002, GENETICS, V161, P447; WANG XB, 1993, PEDIATR PULM, V15, P75, DOI 10.1002/ppul.1950150204; Wolfe R, 2000, AM J RESP CRIT CARE, V162, P2177, DOI 10.1164/ajrccm.162.6.9812019	16	24	24	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2011	127	1					282	284		10.1016/j.jaci.2010.10.036	http://dx.doi.org/10.1016/j.jaci.2010.10.036			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	702SY	21211661	Green Accepted, Bronze			2022-12-18	WOS:000285917300046
J	Houliston, L; Nolan, R; Noble, V; Pascoe, E; Hobday, J; Loh, R; Mallon, D				Houliston, Louise; Nolan, Richard; Noble, Valerie; Pascoe, Elaine; Hobday, John; Loh, Richard; Mallon, Dominic			Honeybee venom immunotherapy in children using a 50-mu g maintenance dose	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ALLERGY; STINGS		[Houliston, Louise; Nolan, Richard; Noble, Valerie; Pascoe, Elaine; Hobday, John; Loh, Richard; Mallon, Dominic] Princess Margaret Hosp Children, Subiaco, WA, Australia; [Nolan, Richard] Fremantle Hosp, Dept Immunol, Fremantle, WA, Australia; [Loh, Richard; Mallon, Dominic] Univ Western Australia, Nedlands, WA 6009, Australia	University of Western Australia; University of Western Australia	Houliston, L (corresponding author), Princess Margaret Hosp Children, Subiaco, WA, Australia.	rnolan@respiratorywest.com.au		Pascoe, Elaine/0000-0003-1653-5803				Golden DBK, 2010, CURR OPIN ALLERGY CL, V10, P337, DOI 10.1097/ACI.0b013e32833bc0ba; Golden DBK, 2004, NEW ENGL J MED, V351, P668, DOI 10.1056/NEJMoa022952; Golden DBK, 1998, J ALLERGY CLIN IMMUN, V101, P298, DOI 10.1016/S0091-6749(98)70239-8; GOLDEN DBK, 1981, J ALLERGY CLIN IMMUN, V67, P370, DOI 10.1016/0091-6749(81)90082-8; Lerch E, 1998, J ALLERGY CLIN IMMUN, V101, P606, DOI 10.1016/S0091-6749(98)70167-8; MULLER U, 1991, J ALLERGY CLIN IMMUN, V87, P702, DOI 10.1016/0091-6749(91)90392-2; MULLER U, 1992, J ALLERGY CLIN IMMUN, V89, P529, DOI 10.1016/0091-6749(92)90319-W; REISMAN RE, 1992, J ALLERGY CLIN IMMUN, V89, P1189, DOI 10.1016/0091-6749(92)90304-K; URBANEK R, 1985, J PEDIATR-US, V107, P367, DOI 10.1016/S0022-3476(85)80508-4	9	24	24	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2011	127	1					98	99		10.1016/j.jaci.2010.07.031	http://dx.doi.org/10.1016/j.jaci.2010.07.031			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	702SY	20864150				2022-12-18	WOS:000285917300014
J	Sugita, K; Tohyama, M; Watanabe, H; Otsuka, A; Nakajima, S; Iijima, M; Hashimoto, K; Tokura, Y; Miyachi, Y; Kabashima, K				Sugita, Kazunari; Tohyama, Mikiko; Watanabe, Hideaki; Otsuka, Atsushi; Nakajima, Saeko; Iijima, Masafumi; Hashimoto, Koji; Tokura, Yoshiki; Miyachi, Yoshiki; Kabashima, Kenji			Fluctuation of blood and skin plasmacytoid dendritic cells in drug-induced hypersensitivity syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							LUPUS-ERYTHEMATOSUS; INTERFERON; TISSUE		[Sugita, Kazunari; Tokura, Yoshiki] Univ Occupat & Environm Hlth, Dept Dermatol, Kitakyushu, Fukuoka 807, Japan; [Tohyama, Mikiko; Hashimoto, Koji] Ehime Univ, Sch Med, Dept Dermatol, Toon, Ehime, Japan; [Watanabe, Hideaki; Iijima, Masafumi] Showa Univ, Sch Med, Dept Dermatol, Tokyo 142, Japan; [Otsuka, Atsushi; Nakajima, Saeko; Miyachi, Yoshiki; Kabashima, Kenji] Kyoto Univ, Dept Dermatol, Grad Sch Med, Kyoto, Japan	University of Occupational & Environmental Health - Japan; Ehime University; Showa University; Kyoto University	Sugita, K (corresponding author), Univ Occupat & Environm Hlth, Dept Dermatol, Kitakyushu, Fukuoka 807, Japan.	kaba@kuhp.kyoto-u.ac.jp	Nakajima, Saeko/AAB-1577-2021; Kabashima, Kenji/G-2521-2014	Otsuka, Atsushi/0000-0001-7365-947X; Kabashima, Kenji/0000-0002-0773-0554; Nakajima, Saeko/0000-0003-0831-1447				Banchereau J, 2006, IMMUNITY, V25, P383, DOI 10.1016/j.immuni.2006.08.010; Colonna M, 2004, NAT IMMUNOL, V5, P1219, DOI 10.1038/ni1141; FACCHETTI F, 1988, J PATHOL, V155, P295, DOI 10.1002/path.1711550404; Farkas L, 2001, AM J PATHOL, V159, P237, DOI 10.1016/S0002-9440(10)61689-6; Kano Y, 2004, ARCH DERMATOL, V140, P183, DOI 10.1001/archderm.140.2.183; Olweus J, 1997, P NATL ACAD SCI USA, V94, P12551, DOI 10.1073/pnas.94.23.12551; Park JJ, 2010, ACTA DERM-VENEREOL, V90, P305, DOI 10.2340/00015555-0827; Sekine N, 2001, JAMA-J AM MED ASSOC, V285, P1153, DOI 10.1001/jama.285.9.1153; Shiohara T, 2007, CLIN REV ALLERG IMMU, V33, P124, DOI 10.1007/s12016-007-8010-9; Siegal FP, 1999, SCIENCE, V284, P1835, DOI 10.1126/science.284.5421.1835; Sontheimer RD, 2009, J INVEST DERMATOL, V129, P1088, DOI [10.1038/jid.2009.42, 10.1038/sj.jid.2009.42]; Watanabe T, 2009, J DERMATOL SCI, V54, P134, DOI 10.1016/j.jdermsci.2008.12.014	12	24	25	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2010	126	2								10.1016/j.jaci.2010.06.004	http://dx.doi.org/10.1016/j.jaci.2010.06.004			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	642IL	20624646				2022-12-18	WOS:000281203800037
J	Nino, G; Hu, AH; Grunstein, JS; Grunstein, MM				Nino, Gustavo; Hu, Aihua; Grunstein, Judith S.; Grunstein, Michael M.			Mechanism of glucocorticoid protection of airway smooth muscle from proasthmatic effects of long-acting beta(2)-adrenoceptor agonist exposure	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; salmeterol; homologous beta(2)-adrenergic receptor desensitization; airway smooth muscle; phosphodiesterase; ERK1/2 phosphotylation siRNA; MAPK phosphatase 1	KINASE PHOSPHATASE-1; PROTEIN-KINASE; UP-REGULATION; EXPRESSION; HYPERRESPONSIVENESS; PHOSPHODIESTERASE-4; SALMETEROL; ALLERGEN; ASTHMA; DESENSITIZATION	Background: Chronic use of long-acting beta(2)-adrenergic receptor agonists (LABAs), resulting in beta(2)-adrenergic receptor desensitization, has been associated with increased asthma morbidity. When LABAs are used in combination with inhaled glucocorticoids, however, asthma control is improved, raising the following question: Do glucocorticoids inhibit the proasthmatic mechanism that mediates altered contractility in LABA-exposed airway smooth muscle (ASM)? Objective: This study aimed to identify the potential protective role and mechanism of action of glucocorticoids in mitigating the effects of prolonged LABA exposure on ASM constrictor and relaxation responsiveness. Methods: Cultured human ASM cells and isolated rabbit ASM tissues were examined for induced changes in agonist-mediated cyclic adenosine monophosphate accumulation, constrictor and relaxation responsiveness, and expression of specific glucocorticoid-regulated molecules after 24-hour exposure to the LABA salmeterol in the absence and presence of dexamethasone. Results: Salmeterol-exposed ASM exhibited impaired cyclic adenosine monophosphate and relaxation responses to isoproterenol and increased acetylcholine-induced contractility. These proasthmatic effects of prolonged LABA exposure were attributed to upregulated phosphodiesterase 4 (PDE4) activity and were ablated by pretreatment with dexamethasone. Further studies demonstrated that (1) dexamethasone suppressed activation of the mitogen-activated protein kinases extracellular signal-regulated kinases 1 and 2 (ERK1/2), which upregulate PDE4 expression in salmeterol-exposed ASM; and (2) the inhibitory actions of dexamethasone on salmeterol-induced ERK1/2 activation and resultant PDE4-mediated changes in ASM responsiveness were prevented by gene silencing or pharmacologic inhibition of dexamethasone-induced expression of mitogen-activated protein kinase phosphatase 1, an endogenous deactivator of ERK1/2 signaling. Conclusion: Glucocorticoids prevent the adverse proasthmatic effects of prolonged LABA exposure on airway responsiveness as a result of glucocorticoid-induced upregulation of mitogen-activated protein kinase phosphatase 1, which inhibits proasthmatic ERK1/2 signaling in the LABA-exposed ASM. (J Allergy Clin Immunol 2010;125:1020-7.)	[Grunstein, Michael M.] Univ Penn, Childrens Hosp Philadelphia, Res Inst, Div Pulm Med,Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Grunstein, MM (corresponding author), Univ Penn, Childrens Hosp Philadelphia, Res Inst, Div Pulm Med,Sch Med, Abramson Res Bldg,34th St & Civ Ctr Blvd, Philadelphia, PA 19104 USA.	grunstein@email.chop.edu			NIH [HL-031467, HL-061038, HL097739]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031467, R01HL097739, R01HL061038] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by NIH grants HL-031467, HL-061038. and HL097739.	Abraham SM, 2006, BIOCHEM SOC T, V34, P1018, DOI 10.1042/BST0341018; Barnes PJ, 1998, CLIN SCI, V94, P557, DOI 10.1042/cs0940557; Bateman E, 2008, ANN INTERN MED, V149, P33, DOI 10.7326/0003-4819-149-1-200807010-00229; Beasley R, 1999, J ALLERGY CLIN IMMUN, V104, pS18, DOI 10.1016/S0091-6749(99)70270-8; Beltman J, 1996, J BIOL CHEM, V271, P27018, DOI 10.1074/jbc.271.43.27018; Billington CK, 2008, AM J RESP CELL MOL, V38, P1, DOI 10.1165/rcmb.2007-0171OC; Burgess JK, 2008, J CELL PHYSIOL, V216, P673, DOI 10.1002/jcp.21450; Chapman RW, 2007, EUR J PHARMACOL, V571, P215, DOI 10.1016/j.ejphar.2007.05.074; CHEUNG D, 1992, NEW ENGL J MED, V327, P1198, DOI 10.1056/NEJM199210223271703; Cooper PR, 2008, J ALLERGY CLIN IMMUN, V122, P734, DOI 10.1016/j.jaci.2008.07.040; Duan W, 2004, J IMMUNOL, V172, P7053, DOI 10.4049/jimmunol.172.11.7053; Giembycz MA, 2008, BRIT J PHARMACOL, V153, P1090, DOI 10.1038/sj.bjp.0707627; Giembycz MA, 2006, EUR RESPIR J, V27, P1286, DOI 10.1183/09031936.06.00112605; Grunstein MM, 2005, J ALLERGY CLIN IMMUN, V116, P94, DOI 10.1016/j.jaci.2005.03.046; Hakonarson H, 2001, AM J RESP CELL MOL, V25, P761, DOI 10.1165/ajrcmb.25.6.4628; Hansen G, 2000, P NATL ACAD SCI USA, V97, P6751, DOI 10.1073/pnas.97.12.6751; Hauck RW, 1997, BRIT J PHARMACOL, V121, P1523, DOI 10.1038/sj.bjp.0701289; Hirst SJ, 1998, AM J RESP CRIT CARE, V158, pS201, DOI 10.1164/ajrccm.158.supplement_2.13tac190; Houslay MD, 2003, BIOCHEM SOC T, V31, P1186; Hu AH, 2008, AM J PHYSIOL-LUNG C, V294, pL1055, DOI 10.1152/ajplung.00021.2008; Issa R, 2007, J IMMUNOL, V178, P7366, DOI 10.4049/jimmunol.178.11.7366; Kanehiro A, 2001, AM J RESP CRIT CARE, V163, P173, DOI 10.1164/ajrccm.163.1.2001118; Kang BN, 2008, AM J PHYSIOL-LUNG C, V295, pL186, DOI 10.1152/ajplung.00352.2007; Kassel O, 2001, EMBO J, V20, P7108, DOI 10.1093/emboj/20.24.7108; Kips JC, 2000, AM J RESP CRIT CARE, V161, P996, DOI 10.1164/ajrccm.161.3.9812056; Liu HG, 2000, J BIOL CHEM, V275, P26615, DOI 10.1074/jbc.M001634200; Mak JCW, 2002, BRIT J PHARMACOL, V135, P987, DOI 10.1038/sj.bjp.0704545; Mehats C, 2003, FASEB J, V17, P1831, DOI 10.1096/fj.03-0274com; Nelson HS, 2006, CHEST, V129, P15, DOI 10.1378/chest.129.1.15; Ni CM, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007949; Nino G, 2009, AM J PHYSIOL-LUNG C, V297, pL746, DOI 10.1152/ajplung.00079.2009; NOGUCHI T, 1993, MOL CELL BIOL, V13, P5195, DOI 10.1128/MCB.13.9.5195; Ohnishi H, 2009, J ALLERGY CLIN IMMUN, V123, P249, DOI 10.1016/j.jaci.2008.10.054; Panettieri Reynold A Jr, 2004, Proc Am Thorac Soc, V1, P231, DOI 10.1513/pats.200402-021MS; Pauwels RA, 1997, NEW ENGL J MED, V337, P1405, DOI 10.1056/NEJM199711133372001; Penn RB, 1998, AM J RESP CELL MOL, V19, P338, DOI 10.1165/ajrcmb.19.2.3025; Shan XY, 2006, AM J PHYSIOL-LUNG C, V291, pL324, DOI 10.1152/ajplung.00056.2006; Shore SA, 2003, RESP PHYSIOL NEUROBI, V137, P179, DOI 10.1016/S1569-9048(03)00146-0; Sun JG, 2006, LIFE SCI, V79, P2077, DOI 10.1016/j.lfs.2006.07.001; Tang HF, 2005, AM J RESP CRIT CARE, V171, P823, DOI 10.1164/rccm.200406-771OC; van Schalkwyk E, 2005, J ALLERGY CLIN IMMUN, V116, P292, DOI 10.1016/j.jaci.2005.04.023; Woolcock A, 1996, AM J RESP CRIT CARE, V153, P1481, DOI 10.1164/ajrccm.153.5.8630590	42	24	26	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2010	125	5					1020	1027		10.1016/j.jaci.2010.02.007	http://dx.doi.org/10.1016/j.jaci.2010.02.007			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	596LO	20392484	Green Accepted			2022-12-18	WOS:000277686700010
J	Asosingh, K; Hanson, JD; Cheng, G; Aronica, MA; Erzurum, SC				Asosingh, Kewal; Hanson, Jodi D.; Cheng, Georgiana; Aronica, Mark A.; Erzurum, Serpil C.			Allergen-induced, eotaxin-rich, proangiogenic bone marrow progenitors: A blood-borne cellular envoy for lung eosinophilia	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Eosinophils; allergy; airway inflammation; angiogenesis; bone marrow; eotaxin	GUINEA-PIG MODEL; TISSUE EOSINOPHILIA; ENDOTHELIAL-CELLS; NEOVASCULARIZATION CAPACITY; AIRWAY HYPERRESPONSIVENESS; ANGIOGENIC PROPERTIES; BRONCHIAL BIOPSIES; CHEMOKINE EOTAXIN; T-CELLS; ASTHMA	Background: Eosinophilic inflammation is closely related to angiogenesis in asthmatic airway remodeling. In ovalbumin (OVA) sensitized mice bone marrow derived, proangiogenic endothelial progenitor cells (EPCs) are rapidly recruited into the lungs after OVA aerosol challenge and promptly followed by mobilization and recruitment of eosinophils. Objective: We hypothesized that bone marrow derived EPCs initiate the recruitment of eosinophils through expression of the eosinophil chemoattractant eotaxin-1. Methods: EPCs were isolated from an OVA murine model of allergic airway inflammation and from asthmatic patients. Endothelial and smooth muscle cells were isolated from mice. Eotaxin-1 expression was analyzed by means of immunofluorescence, real-time PCR, or ELISA. In vivo recruitment of eosinophils by EPCs was analyzed in mice. Results: Circulating EPCs of asthmatic patients had higher levels of eotaxin-1 compared with those seen in control subjects. In the murine model OVA allergen exposure augmented eotaxin-1 mRNA and protein levels in EPCs. The EPCs from OVA-sensitized and OVA-challenged mice released high levels of eotaxin-1 on contact with lung endothelial cells from sensitized and challenged mice but not from control animals and not on contact with cardiac or hepatic endothelial cells from sensitized and challenged mice. Intranasal administration of the eotaxin-rich media overlying cultures of EPCs caused recruitment into the lungs, confirming functional chemoattractant activity. Conclusions: Bone marrow derived EPCs are early responders to environmental allergen exposures and initiate a parallel switch to a proangiogenic and proeosinophilic environment in the lungs of asthmatic patients. (J Allergy Clin Immunol 2010;125:918-25.)	[Asosingh, Kewal; Hanson, Jodi D.; Cheng, Georgiana; Aronica, Mark A.; Erzurum, Serpil C.] Cleveland Clin, Lerner Res Inst, Dept Pathobiol, Cleveland, OH 44195 USA; [Aronica, Mark A.; Erzurum, Serpil C.] Cleveland Clin, Resp Inst, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation	Asosingh, K (corresponding author), Cleveland Clin, Lerner Res Inst, Dept Pathobiol, NC22,9500 Euclid Ave, Cleveland, OH 44195 USA.	asosink@ccf.org; erzurus@ccf.org			National Institutes of Health [HL60917, HL69170, AI70649, HL081064, AI067816, HL04449]; National Center for Research Resources [UL1 RR024989]; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR018390, UL1RR024989] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL081064, RC1HL099303, R37HL060917, K08HL004449, R01HL060917, R01HL070649, R01HL069170] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI067816] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by grants from the National Institutes of Health (HL60917, HL69170, AI70649, HL081064. AI067816, and HL04449) and UL1 RR024989 from the National Center for Research Resources.	Aronica MA, 2004, J ALLERGY CLIN IMMUN, V114, P1441, DOI 10.1016/j.jaci.2004.08.025; Aronica MA, 2004, AM J RESP CRIT CARE, V169, P587, DOI 10.1164/rccm.200301-100OC; Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Asosingh K, 2007, J IMMUNOL, V178, P6482, DOI 10.4049/jimmunol.178.10.6482; Blanchard C, 2006, J CLIN INVEST, V116, P536, DOI 10.1172/JCI26679; Brown JR, 1998, CLIN EXP IMMUNOL, V114, P137; Campbell EM, 1998, J IMMUNOL, V161, P7047; Chavakis E, 2005, J EXP MED, V201, P63, DOI 10.1084/jem.20041402; DUNNILL MS, 1960, J CLIN PATHOL, V13, P27, DOI 10.1136/jcp.13.1.27; Fazel S, 2006, J CLIN INVEST, V116, P1865, DOI 10.1172/JCI27019; Fulkerson PC, 2006, P NATL ACAD SCI USA, V103, P16418, DOI 10.1073/pnas.0607863103; GarciaZepeda EA, 1996, NAT MED, V2, P449, DOI 10.1038/nm0496-449; Gonzalo JA, 1996, IMMUNITY, V4, P1, DOI 10.1016/S1074-7613(00)80293-9; Gonzalo JA, 1998, J EXP MED, V188, P157, DOI 10.1084/jem.188.1.157; Grimaldi JC, 1999, J LEUKOCYTE BIOL, V65, P846, DOI 10.1002/jlb.65.6.846; Hill JM, 2003, NEW ENGL J MED, V348, P593, DOI 10.1056/NEJMoa022287; Hirschi KK, 2008, ARTERIOSCL THROM VAS, V28, P1584, DOI 10.1161/ATVBAHA.107.155960; Humbles AA, 1997, J EXP MED, V186, P601, DOI 10.1084/jem.186.4.601; Jacobsen EA, 2007, CURR ALLERGY ASTHM R, V7, P18, DOI 10.1007/s11882-007-0026-y; Jin DK, 2006, NAT MED, V12, P557, DOI 10.1038/nm1400; JOSE PJ, 1994, J EXP MED, V179, P881, DOI 10.1084/jem.179.3.881; Justice JP, 2003, AM J PHYSIOL-LUNG C, V284, pL169, DOI 10.1152/ajplung.00260.2002; Kalka C, 2000, CIRC RES, V86, P1198, DOI 10.1161/01.RES.86.12.1198; Kerbel Robert S, 2008, Proc Natl Acad Sci U S A, V105, pE55, DOI 10.1073/pnas.0804876105; Komiya A, 2003, CELL IMMUNOL, V225, P91, DOI 10.1016/j.cellimm.2003.10.001; KUWANO K, 1993, AM REV RESPIR DIS, V148, P1220, DOI 10.1164/ajrccm/148.5.1220; Lee CG, 2004, NAT MED, V10, P1095, DOI 10.1038/nm1105; Lee JJ, 2004, SCIENCE, V305, P1773, DOI 10.1126/science.1099472; Li X, 1997, AM J RESP CRIT CARE, V156, P229, DOI 10.1164/ajrccm.156.1.9607066; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Marsboom G, 2008, STEM CELLS, V26, P1017, DOI 10.1634/stemcells.2007-0562; Mould AW, 1997, J CLIN INVEST, V99, P1064, DOI 10.1172/JCI119234; *NAT ASTHM ED PREV, 1997, NAT I HLTH PUBL; Ochkur SI, 2007, J IMMUNOL, V178, P7879, DOI 10.4049/jimmunol.178.12.7879; Oynebraten I, 2004, BLOOD, V104, P314, DOI 10.1182/blood-2003-08-2891; Palframan RT, 1998, BLOOD, V91, P2240, DOI 10.1182/blood.V91.7.2240.2240_2240_2248; Pascual RM, 2005, J ALLERGY CLIN IMMUN, V116, P477, DOI 10.1016/j.jaci.2005.07.011; Pearson JD, 2009, J THROMB HAEMOST, V7, P255, DOI 10.1111/j.1538-7836.2008.03214.x; Ponath PD, 1996, J CLIN INVEST, V97, P604, DOI 10.1172/JCI118456; Pope SM, 2005, J BIOL CHEM, V280, P13952, DOI 10.1074/jbc.M406037200; Prater DN, 2007, LEUKEMIA, V21, P1141, DOI 10.1038/sj.leu.2404676; Qin GJ, 2006, J EXP MED, V203, P153, DOI 10.1084/jem.20050459; Ritter MR, 2006, J CLIN INVEST, V116, P3266, DOI 10.1172/JCI29683; Rossig L, 2005, J EXP MED, V201, P1825, DOI 10.1084/jem.20042097; Rothenberg ME, 2006, ANNU REV IMMUNOL, V24, P147, DOI 10.1146/annurev.immunol.24.021605.090720; Rothenberg ME, 1999, AM J RESP CELL MOL, V21, P291, DOI 10.1165/ajrcmb.21.3.f160; Rothenberg ME, 1997, J EXP MED, V185, P785, DOI 10.1084/jem.185.4.785; Salvato G, 2001, THORAX, V56, P902, DOI 10.1136/thorax.56.12.902; Shantsila E, 2008, J AM COLL CARDIOL, V51, P669, DOI 10.1016/j.jacc.2007.09.057; Sieveking DP, 2008, J AM COLL CARDIOL, V51, P660, DOI 10.1016/j.jacc.2007.09.059; Smit JJ, 2006, EUR J PHARMACOL, V533, P277, DOI 10.1016/j.ejphar.2005.12.064; Stellos K, 2008, CIRCULATION, V117, P206, DOI 10.1161/CIRCULATIONAHA.107.714691; Tenscher K, 1996, BLOOD, V88, P3195, DOI 10.1182/blood.V88.8.3195.bloodjournal8883195; Urbich C, 2004, CIRC RES, V95, P343, DOI 10.1161/01.RES.0000137877.89448.78; Urbich C, 2003, CIRCULATION, V108, P2511, DOI 10.1161/01.CIR.0000096483.29777.50; Vrugt B, 2000, EUR RESPIR J, V15, P1014, DOI 10.1034/j.1399-3003.2000.01507.x; Yang Y, 1998, BLOOD, V92, P3912, DOI 10.1182/blood.V92.10.3912.422k23_3912_3923; Ying S, 1999, J IMMUNOL, V163, P6321; Ying S, 1997, EUR J IMMUNOL, V27, P3507, DOI 10.1002/eji.1830271252; Zacchigna S, 2008, J CLIN INVEST, V118, P2062, DOI 10.1172/JCI32832	60	24	25	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2010	125	4					918	925		10.1016/j.jaci.2010.01.017	http://dx.doi.org/10.1016/j.jaci.2010.01.017			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	584XP	20227754	Green Accepted			2022-12-18	WOS:000276787900019
J	Bohme, M; Kull, I; Bergstrom, A; Wickman, M; Nordvall, L; Pershagen, G; Wahlgren, CF				Bohme, Maria; Kull, Inger; Bergstrom, Anna; Wickman, Magnus; Nordvall, Lennart; Pershagen, Goran; Wahlgren, Carl-Fredrik			Parental smoking increases the risk for eczema with sensitization in 4-year-old children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							TOBACCO-SMOKE; MATERNAL SMOKING; EXPOSURE; RESPONSES; ALLERGENS; LIFE		[Bohme, Maria; Wahlgren, Carl-Fredrik] Karolinska Univ Hosp Solna, Dermatol & Venereol Unit, Dept Med, Karolinska Inst, Stockholm, Sweden; [Kull, Inger; Bergstrom, Anna; Wickman, Magnus; Pershagen, Goran] Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden; [Kull, Inger; Wickman, Magnus] Karolinska Inst, Ctr Allergy Res, Stockholm, Sweden; [Wickman, Magnus] Karolinska Inst, Sachs Childrens Hosp, Stockholm, Sweden; [Nordvall, Lennart] Uppsala Univ, Dept Womens & Childrens Hlth, Uppsala, Sweden	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Uppsala University	Bohme, M (corresponding author), Karolinska Univ Hosp Solna, Dermatol & Venereol Unit, Dept Med, Karolinska Inst, Stockholm, Sweden.	Maria.Bohme@ki.se		Kull, Inger/0000-0001-6096-3771; Pershagen, Goran/0000-0002-9701-1130				Bohme M, 2002, ACTA DERM-VENEREOL, V82, P98, DOI 10.1080/00015550252948112; Devereux G, 2002, CLIN EXP ALLERGY, V32, P43, DOI 10.1046/j.0022-0477.2001.01267.x; Gehring U, 2006, OCCUP ENVIRON MED, V63, P766, DOI 10.1136/oem.2006.027151; Hjern A, 2001, CLIN EXP ALLERGY, V31, P908, DOI 10.1046/j.1365-2222.2001.01096.x; Kramer U, 2004, BRIT J DERMATOL, V150, P111, DOI 10.1111/j.1365-2133.2004.05710.x; Kulig M, 1999, ALLERGY, V54, P220, DOI 10.1034/j.1398-9995.1999.00753.x; MAGNUSSON CGM, 1986, J ALLERGY CLIN IMMUN, V78, P898, DOI 10.1016/0091-6749(86)90237-X; Magnusson LL, 2005, CLIN EXP ALLERGY, V35, P1550, DOI 10.1111/j.1365-2222.2005.02374.x; Murray CS, 2004, PEDIATR PULM, V37, P492, DOI 10.1002/ppul.20019; Noakes PS, 2003, ALLERGY, V58, P1053, DOI 10.1034/j.1398-9995.2003.00290.x; Wickman M, 2002, PEDIATR ALLERGY IMMU, V13, P11, DOI 10.1034/j.1399-3038.13.s.15.10.x	11	24	26	1	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2010	125	4					941	943		10.1016/j.jaci.2009.12.997	http://dx.doi.org/10.1016/j.jaci.2009.12.997			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	584XP	20227755	Bronze			2022-12-18	WOS:000276787900024
J	Grigoryev, DN; Howell, MD; Watkins, TN; Chen, YC; Cheadle, C; Boguniewicz, M; Barnes, KC; Leung, DYM				Grigoryev, Dmitry N.; Howell, Michael D.; Watkins, Tonya N.; Chen, Yu-Chi; Cheadle, Chris; Boguniewicz, Mark; Barnes, Kathleen C.; Leung, Donald Y. M.			Vaccinia virus-specific molecular signature in atopic dermatitis skin	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Eczema vaccinatum; vaccinia virus; atopic dermatitis; genomics	INNATE IMMUNE-RESPONSE; ALPHA(1)-ACID GLYCOPROTEIN; ANTIMICROBIAL PEPTIDES; GENES; IDENTIFICATION; EXPRESSION; DEFICIENCY; PROTEINS; CONTACT; NLRS	Background: Eczema vaccinatum (EV), a disseminated viral skin infection, is a life-threatening complication of vaccinia virus (VV) inoculation in patients with atopic dermatitis (AD) and is thought to be associated with a defective innate immune response. However, the precise mechanism or mechanisms and key factor or factors of EV are unknown. Objective: Given that patients with psoriasis, another inflammatory skin disorder, are not susceptible to EV, we compared the global transcriptional response of skin to VV in healthy subjects, patients with psoriasis, and patients with AD, focusing on AD-specific genes. We hypothesized that differences in the transcriptional response to VV between patients with AD and patients with psoriasis or healthy subjects would identify a defective pathway or pathways that might be associated with the development of EV. Methods: Gene expression profiling of sham-treated and VV treated unaffected skin explants from patients with AD (n = 12), patients with psoriasis (n = 12), or healthy subjects (n = 13) were generated with U133_Plus2 (54,613 probe sets) GeneChips and analyzed with the GCOS_1.4/SAM_2.1/MAPPFinder_2.0 pipeline. Results: Sixty-seven genes were significantly affected by VV in AD skin but not in psoriatic and healthy skin. Genes associated with defense response, response to wounding, and immune response were the most affected by VV in AD skin. All genes in these ontologies were downregulated, including the innate immunity genes leukotriene B-4 receptor (LTB4R), orosomucoid 1 (ORM1), coagulation factor II (thrombin) receptor (F2R), complement component 9 (C9), and LPS-binding protein (LBP). These findings were confirmed by means of real-time PCR and validated by means of PubMatrix analysis. ORM1, Toll-like receptor 4 (TLR4), and NLR family pyrin domain containing 1 (NLRP1) genes were also linked to AD severity. Conclusion: This study identified groups of innate immunity genes that are associated with the aberrant response of AD skin to VV and represent potential targets for EV pathogenesis. (J Allergy Clin Immunol 2010;125:153-9.)	[Leung, Donald Y. M.] Natl Jewish Hlth, Dept Pediat, Div Pediat Allergy & Clin Immunol, Denver, CO 80206 USA; [Grigoryev, Dmitry N.; Watkins, Tonya N.; Chen, Yu-Chi; Cheadle, Chris; Barnes, Kathleen C.] Johns Hopkins Univ, Div Allergy & Clin Immunol, Baltimore, MD USA	National Jewish Health; Johns Hopkins University	Leung, DYM (corresponding author), Natl Jewish Hlth, Dept Pediat, Div Pediat Allergy & Clin Immunol, 1400 Jackson St,Room K926I, Denver, CO 80206 USA.	leungd@njhealth.org	Grigoryev, Dmitry/C-9422-2015	Grigoryev, Dmitry/0000-0002-1849-1763	National Institutes of Health/National Institute of Allergy and Infectious Diseases [N01 AI40029]; Mary Beryl Patch Turnbull Scholar Program; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000051, UL1RR025780] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI040029] Funding Source: NIH RePORTER	National Institutes of Health/National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Mary Beryl Patch Turnbull Scholar Program; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the Atopic Dermatitis and Vaccinia Network (National Institutes of Health/National Institute of Allergy and Infectious Diseases contract N01 AI40029). K. C. B. was supported in part by the Mary Beryl Patch Turnbull Scholar Program.	Beck LA, 2009, J ALLERGY CLIN IMMUN, V124, P260, DOI 10.1016/j.jaci.2009.05.020; Becker KG, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-61; Biljan D, 2009, COLLEGIUM ANTROPOL, V33, P83; Buckley JA, 2001, WATER ENVIRON RES, V73, P575, DOI 10.2175/106143001X139641; De Benedetto A, 2009, J INVEST DERMATOL, V129, P14, DOI 10.1038/jid.2008.259; Dorschner RA, 2001, J INVEST DERMATOL, V117, P91, DOI 10.1046/j.1523-1747.2001.01340.x; FAN CH, 1995, HUM HERED, V45, P117, DOI 10.1159/000154269; Gao L, 2007, CURR OPIN ALLERGY CL, V7, P459, DOI 10.1097/ACI.0b013e3282f1fb9a; Grigoryev DN, 2008, TRANSL RES, V151, P197, DOI 10.1016/j.trsl.2007.12.010; Grigoryev DN, 2007, MOL CELL PROBE, V21, P134, DOI 10.1016/j.mcp.2006.09.002; Grigoryev DN, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-62; Grigoryev DN, 2004, CRIT CARE, V8, P440, DOI 10.1186/cc2901; Hassoun HT, 2007, AM J PHYSIOL-RENAL, V293, pF30, DOI 10.1152/ajprenal.00023.2007; Hochepied T, 2000, J BIOL CHEM, V275, P14903, DOI 10.1074/jbc.275.20.14903; Howell MD, 2006, IMMUNITY, V24, P341, DOI 10.1016/j.immuni.2006.02.006; Howell MD, 2004, J IMMUNOL, V172, P1763, DOI 10.4049/jimmunol.172.3.1763; Ichikawa E, 2001, BRIT J DERMATOL, V144, P1080, DOI 10.1046/j.1365-2133.2001.04204.x; Kim BE, 2007, J ALLERGY CLIN IMMUN, V119, P457, DOI 10.1016/j.jaci.2006.10.005; Kufer TA, 2005, TRENDS MICROBIOL, V13, P381, DOI 10.1016/j.tim.2005.06.004; Larsson O, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-129; LIUTOV AG, 1992, PATOL FIZIOL EKSP TE, V1, P37; Longhi MP, 2005, J IMMUNOL, V175, P7098, DOI 10.4049/jimmunol.175.11.7098; Ma SF, 2005, AM J PHYSIOL-LUNG C, V289, pL468, DOI 10.1152/ajplung.00109.2005; Macaluso F, 2007, EXP DERMATOL, V16, P692, DOI 10.1111/j.1600-0625.2007.00589.x; Martinon F, 2005, TRENDS IMMUNOL, V26, P447, DOI 10.1016/j.it.2005.06.004; Melo NCV, 2009, HEMODIAL INT, V13, P38, DOI 10.1111/j.1542-4758.2009.00346.x; Muchitsch EM, 1996, ARCH INT PHARMACOD T, V331, P313; Nomura L, 2003, J ALLERGY CLIN IMMUN, V112, P1195, DOI 10.1016/j.jaci.2003.08.049; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; Ong PY, 2002, J INVEST DERMATOL, V119, P1463, DOI 10.1046/j.1523-1747.2002.19624.x; Saaf AM, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004017; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Vora S, 2008, CLIN INFECT DIS, V46, P1555, DOI 10.1086/587668; Wei CM, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-87; Wu H, 2009, ALLERGY, V64, P629, DOI 10.1111/j.1398-9995.2008.01912.x	36	24	24	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2010	125	1					153	159		10.1016/j.jaci.2009.10.024	http://dx.doi.org/10.1016/j.jaci.2009.10.024			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	544MG	20109744	Green Accepted			2022-12-18	WOS:000273660500018
J	Sandig, H; McDonald, J; Gilmour, J; Arno, M; Lee, TH; Cousins, DJ				Sandig, Hilary; McDonald, Joanne; Gilmour, Jane; Arno, Matthew; Lee, Tak H.; Cousins, David J.			Fibronectin is a T(H)1-specific molecule in human subjects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						T(H)1 cell; fibronectin; opsonization; Toll-like receptor 4; integrin; monocyte	MULTIPLE-SCLEROSIS LESIONS; EXTRA DOMAIN-A; EIIIA SEGMENT; CELL-DIFFERENTIATION; EXTRACELLULAR-MATRIX; EXPRESSION; PROTEIN; RAT; MYCOBACTERIA; RECOGNITION	Background: T(H)1 cell-mediated immunity is essential for host defense against a variety of intracellular pathogens, such as mycobacteria, salmonella, and Leishmania species. A major T(H)1-mediated effector mechanism involves the IFN-gamma-induced killing of the pathogen by infected macrophages. Objectives: The range of known T(H)1-specific effector molecules is limited, especially in human subjects. We sought to identify novel effector molecules that might be involved in T(H)1-mediated pathogen clearance. Methods: We performed microarray-based analysis of human T(H)1 and T(H)2 cells to identify T(H)1-specific molecules. These analyses identified the extracellular matrix molecule fibronectin as a highly expressed T(H)1-specific molecule. We examined the expression of fibronectin in a variety of human cell types by using real-time RT-PCR, ELISA, and Western blotting. We also studied the role of fibronectin in modulating monocyte phenotype using in vitro culture. Results: We show that human T(H)1 cells constitutively express and secrete fibronectin after in vitro differentiation from naive precursors. Furthermore, we demonstrate that ex vivo human T(H)1 cells selectively express fibronectin when compared with T(H)2 cells. The predominant isoform of fibronectin expressed by T(H)1 cells contains additional domains of the protein responsible for alpha 4 beta 1 integrin binding and activation of Toll-like receptor 4. We show that treatment of monocytes with T(H)1 cell-derived fibronectin induces expression of the proinflammatory cytokine IL-6 while inhibiting IL-10 expression. Conclusions: Because fibronectin also plays a major role in the attachment and opsonization of numerous intracellular pathogens, we propose that it might be a critical molecule produced by T(H)1 cells involved in pathogen eradication. (J Allergy Clin Immunol 2009;124:528-35.)	[Sandig, Hilary; McDonald, Joanne; Gilmour, Jane; Lee, Tak H.; Cousins, David J.] Guys Hosp, Kings Coll London, Div Asthma Allergy & Lung Biol, MRC, London SE1 9RT, England; [Sandig, Hilary; McDonald, Joanne; Gilmour, Jane; Lee, Tak H.; Cousins, David J.] Guys Hosp, Kings Coll London, Asthma UK Ctr Allerg Mech Asthma, London SE1 9RT, England; [Arno, Matthew] Kings Coll London, Sch Biomed & Hlth Sci, Genom Ctr, London WC2R 2LS, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of London; King's College London	Cousins, DJ (corresponding author), Guys Hosp, Kings Coll London, Div Asthma Allergy & Lung Biol, MRC, 5th Floor Tower Wing, London SE1 9RT, England.	david.cousins@kcl.ac.uk	Lee, Tak/AAA-9526-2020	Lee, Tak/0000-0002-7554-4059; Cousins, David/0000-0003-3821-9596	Medical Research Council [G9536930]; Asthma UK; Guy's & St Thomas' Charity; Friends of Guy's Hospital; Medical Research Council; Department of Health through the National Institute for Health Research (NIHR); MRC [G9536930] Funding Source: UKRI; Medical Research Council [G0400503B] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Asthma UK; Guy's & St Thomas' Charity; Friends of Guy's Hospital; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Department of Health through the National Institute for Health Research (NIHR)(National Institute for Health Research (NIHR)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	Supported by grants from the Medical Research Council (G9536930), Asthma UK, Guy's & St Thomas' Charity, and the Friends of Guy's Hospital. J.M. is supported by a Medical Research Council PhD studentship. The authors also acknowledge financial support from the Department of Health through the National Institute for Health Research (NIHR) comprehensive Biomedical Research Centre award to Guy's and St Thomas' NHS Foundation Trust in partnership with King's College London.	Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Alexander J, 1999, J CELL SCI, V112, P2993; Ansel KM, 2006, ANNU REV IMMUNOL, V24, P607, DOI 10.1146/annurev.immunol.23.021704.115821; Clissi B, 2000, J IMMUNOL, V164, P3292, DOI 10.4049/jimmunol.164.6.3292; Coito AJ, 1997, AM J PATHOL, V150, P1757; Cousins DJ, 2002, J IMMUNOL, V169, P2498, DOI 10.4049/jimmunol.169.5.2498; FFRENCHCONSTANT C, 1989, J CELL BIOL, V109, P903, DOI 10.1083/jcb.109.2.903; Finlay BB, 1997, SCIENCE, V276, P718, DOI 10.1126/science.276.5313.718; Gilmour J, 2007, J ALLERGY CLIN IMMUN, V120, P56, DOI 10.1016/j.jaci.2007.03.033; GUAN JL, 1990, CELL, V60, P53, DOI 10.1016/0092-8674(90)90715-Q; Hauck CR, 2006, CURR OPIN MICROBIOL, V9, P5, DOI 10.1016/j.mib.2005.12.002; HINO K, 1995, ARTHRITIS RHEUM-US, V38, P678, DOI 10.1002/art.1780380516; JARNAGIN WR, 1994, J CELL BIOL, V127, P2037, DOI 10.1083/jcb.127.6.2037; Johansson Staffan, 1997, Frontiers in Bioscience (online), V2, pD126; Kagan JC, 2006, CELL, V125, P943, DOI 10.1016/j.cell.2006.03.047; KUHN C, 1989, AM REV RESPIR DIS, V140, P1693, DOI 10.1164/ajrccm/140.6.1693; Laitinen A, 1997, AM J RESP CRIT CARE, V156, P951, DOI 10.1164/ajrccm.156.3.9610084; Lasarte JJ, 2007, J IMMUNOL, V178, P748, DOI 10.4049/jimmunol.178.2.748; Liao YF, 2002, J BIOL CHEM, V277, P14467, DOI 10.1074/jbc.M201100200; Lu BF, 2004, P NATL ACAD SCI USA, V101, P3023, DOI 10.1073/pnas.0307743100; McGeachy MJ, 2008, IMMUNITY, V28, P445, DOI 10.1016/j.immuni.2008.03.001; Monney L, 2002, NATURE, V415, P536, DOI 10.1038/415536a; MOULD AP, 1991, J BIOL CHEM, V266, P3579; Muro AF, 2003, J CELL BIOL, V162, P149, DOI 10.1083/jcb.200212079; Murphy KM, 2002, NAT REV IMMUNOL, V2, P933, DOI 10.1038/nri954; O'Garra A, 2004, ADV IMMUNOL, V83, P133; Okamura Y, 2001, J BIOL CHEM, V276, P10229, DOI 10.1074/jbc.M100099200; Ottenhoff THM, 2002, NAT GENET, V32, P97, DOI 10.1038/ng0902-97; Pankov R, 2002, J CELL SCI, V115, P3861, DOI 10.1242/jcs.00059; Peters JH, 2001, ARTHRITIS RHEUM, V44, P2572, DOI 10.1002/1529-0131(200111)44:11<2572::AID-ART438>3.0.CO;2-Y; Rogge L, 2000, NAT GENET, V25, P96, DOI 10.1038/75671; Schorey JS, 1996, MOL MICROBIOL, V21, P321, DOI 10.1046/j.1365-2958.1996.6381353.x; Schwarz-Linek U, 2003, NATURE, V423, P177, DOI 10.1038/nature01589; SOBEL RA, 1989, AM J PATHOL, V135, P161; Sobel RA, 1998, J NEUROPATH EXP NEUR, V57, P205, DOI 10.1097/00005072-199803000-00001; Szabo SJ, 2003, ANNU REV IMMUNOL, V21, P713, DOI 10.1146/annurev.immunol.21.120601.140942; Tan MH, 2004, BLOOD, V104, P11, DOI 10.1182/blood-2003-09-3363; Ting KM, 2000, J INVEST DERMATOL, V114, P706, DOI 10.1046/j.1523-1747.2000.00871.x; Underhill DM, 2002, ANNU REV IMMUNOL, V20, P825, DOI 10.1146/annurev.immunol.20.103001.114744; VUENTO M, 1979, BIOCHEM J, V183, P331, DOI 10.1042/bj1830331	40	24	25	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2009	124	3					528	U205		10.1016/j.jaci.2009.04.036	http://dx.doi.org/10.1016/j.jaci.2009.04.036			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	552TG	19541353	Green Submitted			2022-12-18	WOS:000274315900019
J	Brenner, B; Corbridge, T; Kazzi, A				Brenner, Barry; Corbridge, Thomas; Kazzi, Antoine			Intubation and mechanical ventilation of the asthmatic patient in respiratory failure	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Acute asthma; asthma exacerbation; emergency department; mechanical ventilation; respiratory failure; respiratory arrest; intubation; orotracheal intubation; nasotracheal intubation	TRACHEAL INTUBATION; INTENSIVE-CARE; MANAGEMENT; BRONCHOCONSTRICTION; RESISTANCE; MYOPATHY; HYPERINFLATION; MORBIDITY; MORTALITY; INCREASE		[Brenner, Barry] Univ Hosp, Dept Emergency Med, Case Med Ctr, Case Western Reserve Sch Med, Cleveland, OH 44106 USA; [Corbridge, Thomas] Northwestern Univ, Feinberg Sch Med, Div Pulm & Crit Care Med, Chicago, IL 60611 USA; [Kazzi, Antoine] Amer Univ Beirut, Dept Emergency Med, Beirut, Lebanon	Case Western Reserve University; University Hospitals of Cleveland; Northwestern University; Feinberg School of Medicine; American University of Beirut	Brenner, B (corresponding author), Univ Hosp, Dept Emergency Med, Case Med Ctr, Case Western Reserve Sch Med, 11100 Euclid Ave, Cleveland, OH 44106 USA.							Abramson M, 2000, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001740; Adams BK, 2003, EMERG MED CLIN N AM, V21, P315, DOI 10.1016/S0733-8627(03)00015-4; Amato MBP, 1998, NEW ENGL J MED, V338, P347, DOI 10.1056/NEJM199802053380602; Behbehani NA, 1999, CHEST, V115, P1627; BELLOMO R, 1994, CHEST, V105, P891, DOI 10.1378/chest.105.3.891; Boussarsar M, 2002, INTENS CARE MED, V28, P406, DOI 10.1007/s00134-001-1178-1; BRAMAN SS, 1990, JAMA-J AM MED ASSOC, V264, P366, DOI 10.1001/jama.264.3.366; Brown RH, 1999, ANESTHESIOLOGY, V90, P822, DOI 10.1097/00000542-199903000-00025; Carroll N, 1996, EUR RESPIR J, V9, P709, DOI 10.1183/09031936.96.09040709; Conti G, 2002, CAN J ANAESTH, V49, P718, DOI 10.1007/BF03017452; CORBRIDGE T, 2005, TXB CRITICAL CARE, P587; CORBRIDGE TC, 1995, AM J RESP CRIT CARE, V151, P1296, DOI 10.1164/ajrccm.151.5.7735578; Corne S, 1997, AM J RESP CRIT CARE, V156, P304, DOI 10.1164/ajrccm.156.1.9607031; Dhand R, 1997, AM J RESP CRIT CARE, V156, P3, DOI 10.1164/ajrccm.156.1.9610025; DOUGLASS JA, 1992, AM REV RESPIR DIS, V146, P517, DOI 10.1164/ajrccm/146.2.517; El-Orbany MI, 2004, ANESTH ANALG, V98, P1680, DOI 10.1213/01.ANE.0000112315.58441.50; *ENV PROT AG, ASTHM FACTS; GAMMON RB, 1992, CHEST, V102, P568, DOI 10.1378/chest.102.2.568; Groeben H, 2002, ANESTHESIOLOGY, V97, P1445, DOI 10.1097/00000542-200212000-00016; HALL JB, 1990, MED CLIN N AM, V74, P779, DOI 10.1016/S0025-7125(16)30552-1; Kam PCA, 2007, ANAESTHESIA, V62, P690, DOI 10.1111/j.1365-2044.2007.05055.x; KOHN MS, 1999, CL ALLER IM, V13, P419; Leatherman J, 1996, CRIT CARE MED, V24, P541, DOI 10.1097/00003246-199603000-00028; LEATHERMAN J, 1994, CLIN CHEST MED, V15, P453; LHOMMEDIEU CS, 1987, ANN EMERG MED, V16, P568, DOI 10.1016/S0196-0644(87)80688-1; Lougheed MD, 2006, CHEST, V130, P1072, DOI 10.1378/chest.130.4.1072; MADISON JM, 2003, IRWIN RIPPES INTENSI, P509; Maslow AD, 2000, ANESTHESIOLOGY, V93, P1198, DOI 10.1097/00000542-200011000-00011; MAYO P, 1999, CL ALLER IM, V13, P469; McFadden ER, 2003, AM J RESP CRIT CARE, V168, P740, DOI 10.1164/rccm.200208-902SO; MOUNTAIN RD, 1990, CHEST, V98, P651, DOI 10.1378/chest.98.3.651; Nee PA, 2008, EMERG MED J, V25, P98, DOI 10.1136/emj.2005.030635; Oddo M, 2006, INTENS CARE MED, V32, P501, DOI 10.1007/s00134-005-0045-x; PANACEK EA, 1999, EMERGENCY ASTHMA; Papiris S, 2002, CRIT CARE, V6, P30; Reddy Venu Gopal, 2005, Middle East Journal of Anesthesiology, V18, P293; Saitoh Yuhji, 2002, J Anesth, V16, P102, DOI 10.1007/s005400200002; Scalfaro P, 2001, ANESTH ANALG, V93, P898, DOI 10.1097/00000539-200110000-00019; Schatz M, 2009, J ALLERGY CLIN IMMUN, V124, pS1, DOI 10.1016/j.jaci.2009.05.001; Shankar V, 2006, INTENS CARE MED, V32, P927, DOI 10.1007/s00134-006-0163-0; Shapiro JM, 2001, CHEST, V120, P1439, DOI 10.1378/chest.120.5.1439; Silvanus MT, 2004, ANESTHESIOLOGY, V100, P1052, DOI 10.1097/00000542-200405000-00004; Tobin MJ, 2001, NEW ENGL J MED, V344, P1986, DOI 10.1056/NEJM200106283442606; TUXEN DV, 1994, AM J RESP CRIT CARE, V150, P870, DOI 10.1164/ajrccm.150.3.8087364; TUXEN DV, 1987, AM REV RESPIR DIS, V136, P872, DOI 10.1164/ajrccm/136.4.872; Weg JG, 1998, NEW ENGL J MED, V338, P341, DOI 10.1056/NEJM199802053380601; WILLIAMS TJ, 1992, AM REV RESPIR DIS, V146, P607, DOI 10.1164/ajrccm/146.3.607; WILLIAMS TJ, 1988, AM REV RESPIR DIS, V137, P460, DOI 10.1164/ajrccm/137.2.460; Wu RSC, 2000, BRIT J ANAESTH, V84, P358, DOI 10.1093/oxfordjournals.bja.a013440; ZIMMERMAN JL, 1993, CRIT CARE MED, V21, P1727, DOI 10.1097/00003246-199311000-00023	50	24	27	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2009	124	2		S			S19	S28		10.1016/j.jaci.2009.05.008	http://dx.doi.org/10.1016/j.jaci.2009.05.008			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	482CE	19647132				2022-12-18	WOS:000268860500004
J	Gruchalla, RS; Sampson, HA; Matsui, E; David, G; Gergen, PJ; Calatroni, A; Brown, M; Liu, AH; Bloomberg, GR; Chmiel, JF; Kumar, R; Lamm, C; Smartt, E; Sorkness, CA; Steinbach, SF; Stone, KD; Szefler, SJ; Busse, WW				Gruchalla, Rebecca S.; Sampson, Hugh A.; Matsui, Elizabeth; David, Gloria; Gergen, Peter J.; Calatroni, Agustin; Brown, Mark; Liu, Andrew H.; Bloomberg, Gordon R.; Chmiel, James F.; Kumar, Rajesh; Lamm, Carin; Smartt, Ernestine; Sorkness, Christine A.; Steinbach, Suzanne F.; Stone, Kelly D.; Szefler, Stanley J.; Busse, William W.			Asthma morbidity among inner-city adolescents receiving guidelines-based therapy: Role of predictors in the setting of high adherence	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; exhaled nitric oxide; inner-city; allergic sensitization; airway inflammation; asthma severity	EXHALED NITRIC-OXIDE; EOSINOPHILIC AIRWAY INFLAMMATION; CHILDREN; SPUTUM; EXACERBATIONS; EXPOSURE; ALLERGEN; MARKERS; ADULTS; RISK	Background: With the expanding effort to provide guidelines-based therapy to adolescents with asthma, attention must be directed to evaluating which factors predict future asthma control when guidelines-based management is applied. Objective: We evaluated the role of fraction of exhaled nitric oxide in parts per billion, markers of allergic sensitization, airway inflammation, and measures of asthma severity in determining future risk of asthma symptoms and exacerbations in adolescents and young adults participating in the Asthma Control Evaluation study. Methods: Five hundred forty-six inner-city residents, ages 12 through 20 years, with persistent asthma were extensively evaluated at study entry for predictors of future symptoms and exacerbations over the subsequent 46 weeks, during which guidelines-based, optimal asthma management was offered. Baseline measurements included fraction of exhaled nitric oxide in parts per billion, total IgE, allergen-specific IgE, allergen skin test reactivity, asthma symptoms, lung function, peripheral blood eosinophils, and, for a subset, airway hyperresponsiveness and sputum eosinophils. Results: The baseline characteristics we examined accounted for only a small portion of the variance for future maximum symptom days and exacerbations-11.4% and 12.6%, respectively. Future exacerbations were somewhat predicted by asthma symptoms, albuterol use, previous exacerbations, and lung function, whereas maximum symptom days were predicted, also to a modest extent, by symptoms, albuterol use, and previous exacerbations, but not lung function. Conclusion: Our findings demonstrate that the usual predictors of future disease activity have little predictive power when applied to a highly adherent population with persistent asthma that is receiving guidelines-based care. Thus, new predictors need to be identified that will be able to measure the continued fluctuation of disease that persists in highly adherent, well-treated populations such as the one studied. (J Allergy Clin Immunol 2009;124:213-21.)	[Gruchalla, Rebecca S.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA; [Sampson, Hugh A.] Mt Sinai Sch Med, New York, NY USA; [Matsui, Elizabeth] Johns Hopkins Univ, Sch Med, Baltimore, MD USA; [David, Gloria; Calatroni, Agustin] Rho Inc, Chapel Hill, NC USA; [Gergen, Peter J.; Smartt, Ernestine] NIAID, Div Allergy Immunol & Transplantat, NIH, Bethesda, MD USA; [Brown, Mark] Univ Arizona, Coll Med, Tucson, AZ 85721 USA; [Liu, Andrew H.; Szefler, Stanley J.] Natl Jewish Hlth, Denver, CO USA; [Liu, Andrew H.] Univ Colorado, Hlth Sci Ctr, Boulder, CO 80309 USA; [Bloomberg, Gordon R.] Washington Univ, St Louis, MO USA; [Chmiel, James F.] Case Western Reserve Univ, Sch Med, Cleveland, OH USA; [Kumar, Rajesh] Childrens Mem Hosp, Chicago, IL 60614 USA; [Lamm, Carin] Columbia Univ, Coll Phys & Surg, New York, NY USA; [Steinbach, Suzanne F.] Boston Univ, Sch Med, Boston, MA 02215 USA; [Stone, Kelly D.] Childrens Natl Med Ctr, Washington, DC 20010 USA; [Szefler, Stanley J.] Univ Colorado, Denver Sch Med, Boulder, CO 80309 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; Icahn School of Medicine at Mount Sinai; Johns Hopkins University; Rho; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Arizona; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Boulder; Washington University (WUSTL); Case Western Reserve University; Ann & Robert H. Lurie Children's Hospital of Chicago; Columbia University; Boston University; Children's National Health System; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Boulder	Gruchalla, RS (corresponding author), Univ Texas SW Med Ctr Dallas, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Rebecca.Gruchalla@utsouthwestern.edu	Brown, Mark/M-1382-2019	Kumar, Rajesh/0000-0002-1962-7108; Matsui, Elizabeth/0000-0001-8134-5593; Brown, Mark A/0000-0002-4458-6563	National Institute of Allergy and Infectious Diseases, National Institutes of Health [NO1-Al-25496, NO1-Al-25482]; National Center for Research Resources, National Institutes of Health [RR00052, M01 RR00533, M01RR0071, 5UL1RR024992-02, 5M01RR020359-04]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000448] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000533, M01RR000052, UL1RR024992, M01RR020359, M01RR000071] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI025496] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Center for Research Resources, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported in whole or in part with federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, under contracts NO1-Al-25496 and NO1-Al-25482 and from the National Center for Research Resources, National Institutes of Health, under grants RR00052, M01 RR00533, M01RR0071. 5UL1RR024992-02, and 5M01RR020359-04.	Adams RJ, 2000, THORAX, V55, P566, DOI 10.1136/thorax.55.7.566; [Anonymous], 1999, Am J Respir Crit Care Med, V160, P2104; [Anonymous], 2007, EXPERT PANEL REPORT; Belessis Y, 2004, PEDIATR PULM, V37, P201, DOI 10.1002/ppul.10443; Berlyne GS, 2000, J ALLERGY CLIN IMMUN, V106, P638, DOI 10.1067/mai.2000.109622; Berry MA, 2005, CLIN EXP ALLERGY, V35, P1175, DOI 10.1111/j.1365-2222.2005.02314.x; Busse WW, 2007, J ALLERGY CLIN IMMUN, V120, P1012, DOI 10.1016/j.jaci.2007.09.016; Chan-Yeung M, 1999, AM J RESP CRIT CARE, V159, P1434, DOI 10.1164/ajrccm.159.5.9807007; Connolly CK, 1998, RESP MED, V92, P1274, DOI 10.1016/S0954-6111(98)90228-1; Covar RA, 2003, J PEDIATR-US, V142, P469, DOI 10.1067/mpd.2003.187; Deykin A, 2005, J ALLERGY CLIN IMMUN, V115, P720, DOI 10.1016/j.jaci.2004.12.1129; Djukanovic R, 2004, AM J RESP CRIT CARE, V170, P583, DOI 10.1164/rccm.200312-1651OC; Eisner MD, 2005, ANN ALLERG ASTHMA IM, V94, P566, DOI 10.1016/S1081-1206(10)61135-0; Evans R, 1999, J PEDIATR-US, V135, P332, DOI 10.1016/S0022-3476(99)70130-7; Fahy JV, 2001, AM J RESP CRIT CARE, V163, P1470, DOI 10.1164/ajrccm.163.6.9901105; Gelb AF, 2006, CHEST, V129, P1492, DOI 10.1378/chest.129.6.1492; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Gromping U, 2007, AM STAT, V61, P139, DOI 10.1198/000313007X188252; Gromping U, 2006, J STAT SOFTW, V17, DOI 10.18637/jss.v017.i01; Gruchalla RS, 2005, J ALLERGY CLIN IMMUN, V115, P478, DOI 10.1016/j.jaci.2004.12.006; Harkins MS, 2004, J ASTHMA, V41, P471, DOI 10.1081/JAS-120033990; Jatakanon A, 1998, THORAX, V53, P91, DOI 10.1136/thx.53.2.91; Jones SL, 2001, AM J RESP CRIT CARE, V164, P738, DOI 10.1164/ajrccm.164.5.2012125; Kwong KYC, 2008, ANN ALLERG ASTHMA IM, V101, P144, DOI 10.1016/S1081-1206(10)60202-5; Lex C, 2007, PEDIATR PULM, V42, P298, DOI 10.1002/ppul.20570; Lex C, 2006, AM J RESP CRIT CARE, V174, P1286, DOI 10.1164/rccm.200603-352OC; Mattes J, 1999, EUR RESPIR J, V13, P1391, DOI 10.1183/09031936.99.13613969; Miller MK, 2007, RESP MED, V101, P481, DOI 10.1016/j.rmed.2006.07.005; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Morgan WJ, 2004, NEW ENGL J MED, V351, P1068, DOI 10.1056/NEJMoa032097; Payne DNR, 2001, AM J RESP CRIT CARE, V164, P1376, DOI 10.1164/ajrccm.164.8.2101145; Pharoah PDP, 2008, NEW ENGL J MED, V358, P2796, DOI 10.1056/NEJMsa0708739; Pijnenburg MW, 2005, THORAX, V60, P215, DOI 10.1136/thx.2004.023374; R Development Core Team, 2007, R LANG ENV STAT COMP; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Silkoff PE, 2004, J ALLERGY CLIN IMMUN, V114, P1241, DOI 10.1016/j.jaci.2004.08.042; Silkoff PE, 1997, AM J RESP CRIT CARE, V155, P260, DOI 10.1164/ajrccm.155.1.9001322; SPORIK R, 1993, CLIN EXP ALLERGY, V23, P740, DOI 10.1111/j.1365-2222.1993.tb00361.x; Strunk RC, 2003, J ALLERGY CLIN IMMUN, V112, P883, DOI 10.1016/j.jaci.2003.08.014; Sullivan SD, 2007, ALLERGY, V62, P655, DOI 10.1111/j.1398-9995.2007.01383.x; Szefler S, 2008, LANCET, V372, P1065, DOI 10.1016/S0140-6736(08)61448-8; Zacharasiewicz A, 2005, AM J RESP CRIT CARE, V171, P1077, DOI 10.1164/rccm.200409-1242OC	42	24	24	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2009	124	2					213	221		10.1016/j.jaci.2009.05.036	http://dx.doi.org/10.1016/j.jaci.2009.05.036			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	482CD	19615730	Green Accepted			2022-12-18	WOS:000268860400006
J	Phillips, JF; Lockey, RF				Phillips, Joshua F.; Lockey, Richard F.			Exotic pet allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Exotic pets; indoor pets; rhinitis; environment; allergen	HAMSTER BITES; SENSITIZATION; ANAPHYLAXIS; IGUANA		[Phillips, Joshua F.; Lockey, Richard F.] Univ S Florida, Coll Med, James A Haley Vet Affairs Med Ctr, Div Allergy & Clin Immunol,Dept Internal Med, Tampa, FL 33612 USA	State University System of Florida; University of South Florida; US Department of Veterans Affairs; Veterans Health Administration (VHA); James A. Haley Veterans Hospital	Phillips, JF (corresponding author), Univ S Florida, Coll Med, James A Haley Vet Affairs Med Ctr, Div Allergy & Clin Immunol,Dept Internal Med, 13000 Bruce B Downs Blvd 111D, Tampa, FL 33612 USA.	jfphillips76@gmail.com						Berto JM, 2002, ALLERGY, V57, P155, DOI 10.1046/j.0105-4538.2001.00001.x; Codina R, 2001, J ALLERGY CLIN IMMUN, V107, P927, DOI 10.1067/mai.2001.114704; Kelso JM, 2000, J ALLERGY CLIN IMMUN, V106, P369; Levine EG, 2003, ARCH DERMATOL, V139, P1658; Liccardi G, 2006, INT ARCH ALLERGY IMM, V141, P295, DOI 10.1159/000095435; Lim DL, 2004, CLIN EXP ALLERGY, V34, P1122, DOI 10.1111/j.1365-2222.2004.01992.x; MCGIVERN D, 1985, CLIN ALLERGY, V15, P163, DOI 10.1111/j.1365-2222.1985.tb02269.x; Morgan MS, 2007, ANN ALLERG ASTHMA IM, V98, P258, DOI 10.1016/S1081-1206(10)60715-6; Niitsuma T, 2003, ALLERGY, V58, P1081, DOI 10.1034/j.1398-9995.2003.00242.x; Nugent J. S., 2003, Journal of Allergy and Clinical Immunology, V111, pS324, DOI 10.1016/S0091-6749(03)81183-1; Passer CC, 2004, ANN ALLERG ASTHMA IM, V93, P402, DOI 10.1016/S1081-1206(10)61401-9; Phipatanakul Wanda, 2002, Curr Allergy Asthma Rep, V2, P412, DOI 10.1007/s11882-002-0075-1; Miguel-Moncin MMS, 2006, J INVEST ALLERG CLIN, V16, P212; Sesztak-Greinecker G, 2005, HAUTARZT, V56, P1156, DOI 10.1007/s00105-004-0886-1; Spitzauer S, 1999, INT ARCH ALLERGY IMM, V120, P259, DOI 10.1159/000024278; *US FISH WILDL SER, 2008, REP AN IMP US 2005 2	16	24	24	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2009	123	2					513	515		10.1016/j.jaci.2008.09.019	http://dx.doi.org/10.1016/j.jaci.2008.09.019			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	409GU	18980777	Bronze			2022-12-18	WOS:000263495000041
J	Frischmeyer-Guerrerio, PA; Wisniewski, J; Wood, RA; Nowak-Wegrzyn, A				Frischmeyer-Guerrerio, Pamela A.; Wisniewski, Julia; Wood, Robert A.; Nowak-Wegrzyn, Anna			Manifestations and long-term outcome of food allergy in children after solid organ transplantation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							TACROLIMUS IMMUNOSUPPRESSION; LIVER-TRANSPLANTATION; RECIPIENTS		[Frischmeyer-Guerrerio, Pamela A.; Wood, Robert A.] Johns Hopkins Univ, Sch Med, Dept Pediat, Div Allergy & Immunol, Baltimore, MD 21205 USA; [Wisniewski, Julia; Nowak-Wegrzyn, Anna] Mt Sinai Sch Med, Dept Pediat, Jaffe Food Allergy Inst, Div Allergy & Immunol, New York, NY USA	Johns Hopkins University; Icahn School of Medicine at Mount Sinai	Frischmeyer-Guerrerio, PA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pediat, Div Allergy & Immunol, Baltimore, MD 21205 USA.	pguerrerio@jhmi.edu	Guerrerio, Pamela/S-9360-2019	Nowak-Wegrzyn, Anna/0000-0002-0960-9854				Dehlink E, 2006, PEDIATRICS, V118, pE764, DOI 10.1542/peds.2006-0370; Gabe SM, 1998, GASTROENTEROLOGY, V115, P67, DOI 10.1016/S0016-5085(98)70366-X; Guidi R, 2007, PEDIATR TRANSPLANT, V11, P1, DOI 10.1111/j.1399-3046.2006.00578.x; Lee JH, 2007, PEDIATR TRANSPLANT, V11, P518, DOI 10.1111/j.1399-3046.2007.00693.x; Legendre C, 1997, NEW ENGL J MED, V337, P822, DOI 10.1056/NEJM199709183371204; LEVY Y, 2007, PEDIAT TRANSPLA 1230; Lykavieris P, 2003, TRANSPLANTATION, V75, P152, DOI 10.1097/00007890-200301150-00027; Nowak-Wegrzyn AH, 2001, J ALLERGY CLIN IMMUN, V108, P146; Phan TG, 2003, ARCH INTERN MED, V163, P237, DOI 10.1001/archinte.163.2.237	9	24	25	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2008	122	5					1031	1033		10.1016/j.jaci.2008.08.032	http://dx.doi.org/10.1016/j.jaci.2008.08.032			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	372ZF	18922566				2022-12-18	WOS:000260940100026
J	Hur, GY; Choi, GS; Sheen, SS; Lee, HY; Park, HJ; Choi, SJ; Ye, YM; Park, HS				Hur, Gyu-Young; Choi, Gil-Soon; Sheen, Seung-Soo; Lee, Hyun-Young; Park, Han-Jung; Choi, Sung-Jin; Ye, Young-Min; Park, Hae-Sim			Serum ferritin and transferrin levels as serologic markers of methylene diphenyl diisocyanate-induced occupational asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						MDI; occupational asthma; ferritin; transferrin; proteome	IRON HOMEOSTASIS; HYPOTRANSFERRINEMIC MICE; ALBUMIN CONJUGATE; ASSOCIATION; ANTIBODIES; PROTEINS; EXPOSURE; PROTEOME; GELSOLIN; WORKERS	Background: Although methylene diphenyl diisocyanate (MDI) may induce occupational asthma in the workplace, the pathogenic mechanisms are unclear. Objectives: By using bronchoalveolar lavage fluid, we sought to identify proteins that were differentially expressed between subjects with MDI-induced occupational asthma (MDI-OA) and asymptomatic exposed controls (AECs). Methods: To find proteins that were differentially expressed between the MDI-OA and AEC groups, 2-dimensional electrophoresis was performed by using bronchoalveolar lavage fluid obtained from subjects after MDI-specitic inhalation challenge. The selected protein spots were then identified by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. The clinical relevance of the differentially expressed spots was compared by ELISA using sera from the MDI-OA/eosinophilic bronchitis, AEC, and unexposed healthy control groups. Receiver operating characteristic curves were then plotted, and the sensitivity and specificity were determined. Results: Twenty-three protein spots were identified that distinguished the subjects with MDI-OA from those in the AEC group. Among them, ferritin expression was downregulated whereas transferrin expression was upregulated in subjects with MDI-OA compared with AEC; these results were validated by ELISA using sera from the MDI-OA/EB and AEC groups. To identify subjects with MDI-OA, the optimal serum cutoff levels were 69.84 ng/mL for ferritin and 2.48 mu g/mL for transferrin. When these 2 parameters were combined, the sensitivity was 71.43% and the specificity was 85.71%. Conclusion: Serum ferritin and transferrin levels are associated with the phenotype of MDI-OA.	[Hur, Gyu-Young; Choi, Gil-Soon; Lee, Hyun-Young; Park, Han-Jung; Choi, Sung-Jin; Ye, Young-Min; Park, Hae-Sim] Ajou Univ, Sch Med, Dept Allergy & Rheumatol, Suwon 443721, South Korea; [Sheen, Seung-Soo] Ajou Univ, Sch Med, Dept Pulm & Crit Care Med, Suwon 443721, South Korea	Ajou University; Ajou University	Park, HS (corresponding author), Ajou Univ, Sch Med, Dept Allergy & Rheumatol, San 5, Suwon 443721, South Korea.	hspark@ajou.ac.kr	Sheen, Seungsoo/AAB-4963-2021; Park, Hae-Sim/S-7974-2019	Ye, Young-Min/0000-0002-7517-1715; Park, Hae-Sim/0000-0003-2614-0303	Ministry of Health and Welfare, Republic of Korea [A050571]	Ministry of Health and Welfare, Republic of Korea(Ministry of Health & Welfare (MOHW), Republic of Korea)	Supported by a grant from the Korean Health 21 R&D Project of the Ministry of Health and Welfare, Republic of Korea (A050571).	Breuer W, 1997, FEBS LETT, V403, P213, DOI 10.1016/S0014-5793(97)00056-2; BROGAN TD, 1975, THORAX, V30, P72, DOI 10.1136/thx.30.1.72; Candiano G, 2005, AM J RESP CRIT CARE, V172, P1090, DOI 10.1164/rccm.200409-1185OC; CARTIER A, 1989, J ALLERGY CLIN IMMUN, V84, P507, DOI 10.1016/0091-6749(89)90364-3; Cho YM, 2003, PROTEOMICS, V3, P1883, DOI 10.1002/pmic.200300562; Choi BK, 2003, PROTEOMICS, V3, P1955, DOI 10.1002/pmic.200300558; Choi JH, 2004, ANN ALLERG ASTHMA IM, V93, P293, DOI 10.1016/S1081-1206(10)61504-9; Connelly KG, 1997, AM J RESP CRIT CARE, V155, P21, DOI 10.1164/ajrccm.155.1.9001283; Crameri R, 2005, ALLERGY, V60, P1227, DOI 10.1111/j.1398-9995.2005.00873.x; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; Elms J, 2001, TOXICOL IN VITRO, V15, P631, DOI 10.1016/S0887-2333(01)00078-9; Ghio AJ, 2006, BIOL RES, V39, P67, DOI 10.4067/S0716-97602006000100008; Ghio AJ, 2003, CRIT CARE MED, V31, P395, DOI 10.1097/01.CCM.0000050284.35609.97; Ghio AJ, 2000, AM J PHYSIOL-LUNG C, V278, pL1051, DOI 10.1152/ajplung.2000.278.5.L1051; Ghio AJ, 2008, AM J RESP CELL MOL, V38, P715, DOI 10.1165/rcmb.2007-0179OC; Grube Eberhard, 2008, Int J Med Sci, V5, P50; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Houtman R, 2003, PROTEOMICS, V3, P2008, DOI 10.1002/pmic.200300469; Hur GY, 2008, CLIN EXP ALLERGY, V38, P586, DOI 10.1111/j.1365-2222.2008.02935.x; Hur GY, 2008, RESP MED, V102, P548, DOI 10.1016/j.rmed.2007.11.015; Kim SH, 2006, FEBS LETT, V580, P1883, DOI 10.1016/j.febslet.2006.02.052; Kourie JI, 2000, PROG BIOPHYS MOL BIO, V73, P91, DOI 10.1016/S0079-6107(00)00003-1; Lagan AL, 2008, CHEST, V133, P1302, DOI 10.1378/chest.07-1117; Lee SH, 2006, AM J RESP CRIT CARE, V173, P370, DOI 10.1164/rccm.200505-740OC; Mapp CE, 2005, AM J RESP CRIT CARE, V172, P280, DOI 10.1164/rccm.200311-1575SO; Mapp CE, 2001, OCCUP ENVIRON MED, V58, P354, DOI 10.1136/oem.58.5.354; Murphy VE, 2006, RESPIROLOGY, V11, P41, DOI 10.1111/j.1440-1843.2006.00782.x; Park HS, 1999, J ALLERGY CLIN IMMUN, V104, P847, DOI 10.1016/S0091-6749(99)70297-6; Park HS, 2002, CLIN EXP ALLERGY, V32, P198, DOI 10.1046/j.1365-2222.2002.01290.x; Park HS, 2002, CLIN EXP ALLERGY, V32, P551, DOI 10.1046/j.0954-7894.2002.01349.x; Poon AH, 2004, AM J RESP CRIT CARE, V170, P967, DOI 10.1164/rccm.200403-412oc; Quirce S, 2004, CURR OPIN ALLERGY CL, V4, P87, DOI 10.1097/01.all.0000123963.96233.92; Raby BA, 2004, AM J RESP CRIT CARE, V170, P1057, DOI 10.1164/rccm.200404-447OC; Reid DW, 2007, EUR RESPIR J, V30, P286, DOI 10.1183/09031936.00154006; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Spinardi L., 2007, V45, P55; Turi JL, 2004, FREE RADICAL BIO MED, V36, P850, DOI 10.1016/j.freeradbiomed.2003.12.008; Vollmert C, 2004, CLIN EXP ALLERGY, V34, P1841, DOI 10.1111/j.1365-2222.2004.02047.x; Vural H, 2000, J TRACE ELEM MED BIO, V14, P88, DOI 10.1016/S0946-672X(00)80036-X; Wittke A, 2004, J IMMUNOL, V173, P3432, DOI 10.4049/jimmunol.173.5.3432; Wu J, 2005, IEEE T MOBILE COMPUT, V4, P259, DOI 10.1109/TMC.2005.40; Yang FM, 1999, AM J PHYSIOL-LUNG C, V277, pL1214, DOI 10.1152/ajplung.1999.277.6.L1214; Ye YM, 2006, J ALLERGY CLIN IMMUN, V118, P885, DOI 10.1016/j.jaci.2006.06.026; ZAMMITTABONA M, 1983, AM REV RESPIR DIS, V128, P226	44	24	24	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2008	122	4					774	780		10.1016/j.jaci.2008.07.034	http://dx.doi.org/10.1016/j.jaci.2008.07.034			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	359LU	19014769	Green Submitted			2022-12-18	WOS:000259989000024
J	Broide, D				Broide, David			New perspectives on mechanisms underlying chronic allergic inflammation and asthma in 2007	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review							OBSTRUCTIVE PULMONARY-DISEASE; AIRWAY HYPERRESPONSIVENESS; BRONCHODILATOR RESPONSE; INCREASED EXPRESSION; EPITHELIAL-CELLS; GENE-EXPRESSION; IGE LEVELS; EARLY-LIFE; DUST-MITE; IN-VIVO	This review summarizes selected articles appearing from January to December 2007 in the Journal of Allergy and Clinical Immunology. Articles were chosen that related to advances in mechanisms of chronic allergic inflammation and asthma, including those describing gene association studies, mast cells, IgE, eosinophils, cytokines, the inception of allergy, airway remodeling, preclinical therapeutic targets, and virally induced asthma.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Broide, D (corresponding author), Univ Calif San Diego, Dept Med, Biomed Sci Bldg,Room 5090,9500 Gilman Dr, La Jolla, CA 92093 USA.	dbroide@ucsd.edu		Broide, David/0000-0001-8405-9090				Adedoyin J, 2007, J ALLERGY CLIN IMMUN, V119, P640, DOI 10.1016/j.jaci.2006.11.637; Adlerberth I, 2007, J ALLERGY CLIN IMMUN, V120, P343, DOI 10.1016/j.jaci.2007.05.018; Ballantyne SJ, 2007, J ALLERGY CLIN IMMUN, V120, P1324, DOI 10.1016/j.jaci.2007.07.051; Balzar S, 2007, J ALLERGY CLIN IMMUN, V119, P855, DOI 10.1016/j.jaci.2006.12.642; Bergeron C, 2007, J ALLERGY CLIN IMMUN, V119, P391, DOI 10.1016/j.jaci.2006.10.030; Bieli C, 2007, J ALLERGY CLIN IMMUN, V120, P1308, DOI 10.1016/j.jaci.2007.07.034; Blanchard C, 2007, J ALLERGY CLIN IMMUN, V120, P1292, DOI 10.1016/j.jaci.2007.10.024; Borger P, 2007, J ALLERGY CLIN IMMUN, V119, P98, DOI 10.1016/j.jaci.2006.07.056; Carter MC, 2007, J ALLERGY CLIN IMMUN, V119, P1550, DOI 10.1016/j.jaci.2007.03.032; Crestani E, 2007, J ALLERGY CLIN IMMUN, V120, P820, DOI 10.1016/j.jaci.2007.05.033; Daines MO, 2007, J ALLERGY CLIN IMMUN, V119, P375, DOI 10.1016/j.jaci.2006.09.039; Dharajiya N, 2007, J ALLERGY CLIN IMMUN, V119, P646, DOI 10.1016/j.jaci.2006.11.634; Dijkstra D, 2007, J ALLERGY CLIN IMMUN, V120, P300, DOI 10.1016/j.jaci.2007.03.024; Eddleston J, 2007, J ALLERGY CLIN IMMUN, V119, P115, DOI 10.1016/j.jaci.2006.08.027; Ermers MJJ, 2007, J ALLERGY CLIN IMMUN, V119, P1086, DOI 10.1016/j.jaci.2006.12.655; Erwin EA, 2007, J ALLERGY CLIN IMMUN, V119, P359, DOI 10.1016/j.jaci.2006.12.648; Esnault S, 2007, J ALLERGY CLIN IMMUN, V120, P1082, DOI 10.1016/j.jaci.2007.06.024; Foley SC, 2007, J ALLERGY CLIN IMMUN, V119, P863, DOI 10.1016/j.jaci.2006.12.665; Foroughi S, 2007, J ALLERGY CLIN IMMUN, V120, P594, DOI 10.1016/j.jaci.2007.06.015; Fujiwara M, 2007, J ALLERGY CLIN IMMUN, V119, P662, DOI 10.1016/j.jaci.2006.12.643; Gao L, 2007, J ALLERGY CLIN IMMUN, V119, P1111, DOI 10.1016/j.jaci.2007.03.019; Gieras A, 2007, J ALLERGY CLIN IMMUN, V119, P384, DOI 10.1016/j.jaci.2006.09.034; Godot V, 2007, J ALLERGY CLIN IMMUN, V120, P827, DOI 10.1016/j.jaci.2007.05.046; Goleva E, 2007, J ALLERGY CLIN IMMUN, V120, P1065, DOI 10.1016/j.jaci.2007.07.042; Gutermuth J, 2007, J ALLERGY CLIN IMMUN, V120, P293, DOI 10.1016/j.jaci.2007.03.017; Hunninghake GM, 2007, J ALLERGY CLIN IMMUN, V120, P84, DOI 10.1016/j.jaci.2007.04.032; Hunninghake GM, 2007, J ALLERGY CLIN IMMUN, V119, P654, DOI 10.1016/j.jaci.2006.12.609; Johansson S, 2007, J ALLERGY CLIN IMMUN, V120, P308, DOI 10.1016/j.jaci.2007.03.021; Kanters D, 2007, J ALLERGY CLIN IMMUN, V120, P1073, DOI 10.1016/j.jaci.2007.06.021; Kawaguchi M, 2007, J ALLERGY CLIN IMMUN, V119, P1408, DOI 10.1016/j.jaci.2007.02.036; Kiss A, 2007, J ALLERGY CLIN IMMUN, V120, P334, DOI 10.1016/j.jaci.2007.04.025; Koehm S, 2007, J ALLERGY CLIN IMMUN, V120, P570, DOI 10.1016/j.jaci.2007.04.037; Kunzmann S, 2007, J ALLERGY CLIN IMMUN, V119, P1398, DOI 10.1016/j.jaci.2007.02.018; Kusel MMH, 2007, J ALLERGY CLIN IMMUN, V119, P1105, DOI 10.1016/j.jaci.2006.12.669; Kwatia MA, 2007, J ALLERGY CLIN IMMUN, V119, P838, DOI 10.1016/j.jaci.2006.12.614; Lee JH, 2007, J ALLERGY CLIN IMMUN, V120, P1110, DOI 10.1016/j.jaci.2007.08.041; Lee KS, 2007, J ALLERGY CLIN IMMUN, V119, P141, DOI 10.1016/j.jaci.2006.09.001; Loza MJ, 2007, J ALLERGY CLIN IMMUN, V120, P578, DOI 10.1016/j.jaci.2007.05.019; MacGlashan DW, 2007, J ALLERGY CLIN IMMUN, V119, P626, DOI 10.1016/j.jaci.2006.09.040; Meliton AY, 2007, J ALLERGY CLIN IMMUN, V120, P1316, DOI 10.1016/j.jaci.2007.07.038; Metz-Favre C, 2007, J ALLERGY CLIN IMMUN, V120, P315, DOI 10.1016/j.jaci.2007.03.046; Miller M, 2007, J ALLERGY CLIN IMMUN, V120, P1118, DOI 10.1016/j.jaci.2007.08.045; Moore WC, 2007, J ALLERGY CLIN IMMUN, V119, P405, DOI 10.1016/j.jaci.2006.11.639; Munitz A, 2007, J ALLERGY CLIN IMMUN, V119, P1382, DOI 10.1016/j.jaci.2007.01.031; Palmer CNA, 2007, J ALLERGY CLIN IMMUN, V120, P64, DOI 10.1016/j.jaci.2007.04.001; Pegorier S, 2007, J ALLERGY CLIN IMMUN, V120, P1301, DOI 10.1016/j.jaci.2007.09.023; Platts-Mills TAE, 2007, J ALLERGY CLIN IMMUN, V120, P1058, DOI 10.1016/j.jaci.2007.06.032; Raby BA, 2007, J ALLERGY CLIN IMMUN, V120, P351, DOI 10.1016/j.jaci.2007.05.029; Ramsey CD, 2007, J ALLERGY CLIN IMMUN, V119, P150, DOI 10.1016/j.jaci.2006.09.012; Rogers AJ, 2007, J ALLERGY CLIN IMMUN, V120, P1332, DOI 10.1016/j.jaci.2007.09.037; Schulz F, 2007, J ALLERGY CLIN IMMUN, V120, P1097, DOI 10.1016/j.jaci.2007.07.065; Siddiqui S, 2007, J ALLERGY CLIN IMMUN, V120, P813, DOI 10.1016/j.jaci.2007.05.028; Siebenhaar F, 2007, J ALLERGY CLIN IMMUN, V120, P213, DOI 10.1016/j.jaci.2007.05.011; Southam DS, 2007, J ALLERGY CLIN IMMUN, V119, P848, DOI 10.1016/j.jaci.2006.12.623; Stern DA, 2007, J ALLERGY CLIN IMMUN, V120, P835, DOI 10.1016/j.jaci.2007.05.050; Stern DA, 2007, J ALLERGY CLIN IMMUN, V119, P351, DOI 10.1016/j.jaci.2006.10.013; Ueta M, 2007, J ALLERGY CLIN IMMUN, V120, P476, DOI 10.1016/j.jaci.2007.04.024; Valenta R, 2007, J ALLERGY CLIN IMMUN, V119, P826, DOI 10.1016/j.jaci.2007.01.025; Wark PAB, 2007, J ALLERGY CLIN IMMUN, V120, P586, DOI 10.1016/j.jaci.2007.04.046; Weber-Chrysochoou C, 2007, J ALLERGY CLIN IMMUN, V120, P286, DOI 10.1016/j.jaci.2007.06.034; Yang KD, 2007, J ALLERGY CLIN IMMUN, V120, P842, DOI 10.1016/j.jaci.2007.07.009; Yang Z, 2007, J ALLERGY CLIN IMMUN, V119, P106, DOI 10.1016/j.jaci.2006.08.021; Yoshisue H, 2007, J ALLERGY CLIN IMMUN, V119, P132, DOI 10.1016/j.jaci.2006.08.028; Zanini A, 2007, J ALLERGY CLIN IMMUN, V120, P329, DOI 10.1016/j.jaci.2007.04.021	64	24	24	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2008	122	3					475	480		10.1016/j.jaci.2008.06.025	http://dx.doi.org/10.1016/j.jaci.2008.06.025			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	348TW	18694589				2022-12-18	WOS:000259234000005
J	Guo, J; Lin, X; Williams, MA; Hamid, Q; Georas, SN				Guo, Jia; Lin, Xin; Williams, Marc A.; Hamid, Qutayba; Georas, Steve N.			Yin-Yang 1 regulates effector cytokine gene expression and T(H)2 immune responses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						T lymphocyte; cytokine gene regulation; transcription factors; allergic inflammation; asthma	TRANSCRIPTION FACTOR YY1; ACTIVATED T-CELLS; NUCLEAR FACTOR; FACTOR YIN-YANG-1; GAMMA PROMOTER; IFN-GAMMA; MECHANISMS; INFLAMMATION; ELEMENT; BINDING	Background: The transcription factor Yin-Yang 1 (YY-1) binds to the promoter regions of several T-cell cytokine genes, but the expression and contribution of this factor to cytokine gene expression and T-cell activation in vivo is not clear. Objective: We sought to better define the role of YY-1 in T-cell gene regulation and allergic immune responses. Methods: We studied cytokine gene expression in T lymphocytes isolated from wild-type mice and heterozygous littermates bearing 1 targeted yy-1 allele (yy-1(+/-) mice). T cells were stimulated with anti-T-cell receptor (anti-TCR) plus CD28 antibodies or with peptide antigen plus antigen-presenting cells by using newly generated yy-1(+/-) TCR transgenic mice. We also studied ovalbumin-driven allergic immune responses in a mouse model of asthma and YY-1 expression in lung tissue from human asthmatic subjects. Results: CD4(+) T cells from yy-1(+/-) mice secreted significantly less IL-4 and IFN-gamma compared with wild-type littermates after TCR-dependent activation, whereas IL-2 production was not significantly affected. Both airway inflammation and recall splenocyte IL-4 production were inhibited in yy-1(+/-) mice, as was antigen-driven T-cell proliferation. YY-1 expression was higher in airway biopsy specimens from asthmatic compared with control subjects. Conclusion: These data indicate that YY-1 regulates T-cell cytokine gene expression and allergic immune responses in a gene dose-dependent manner.	[Guo, Jia; Lin, Xin; Williams, Marc A.; Georas, Steve N.] Univ Rochester, Div Pulm & Crit Care Med, Med Ctr, Rochester, NY USA; [Hamid, Qutayba] McGill Univ, Meakins Christie Labs, Montreal, PQ, Canada	University of Rochester; McGill University	Georas, SN (corresponding author), 601 Elmwood Ave,Box 692, Rochester, NY USA.	Steve_Georas@urmc.rochester.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073952] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01HL073952, R01 HL073952] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Affar E, 2006, MOL CELL BIOL, V26, P3565, DOI 10.1128/MCB.26.9.3565-3581.2006; Agarwal S, 1999, J ALLERGY CLIN IMMUN, V103, P990, DOI 10.1016/S0091-6749(99)70168-5; [Anonymous], 1987, Am Rev Respir Dis, V136, P1066; Barnden MJ, 1998, IMMUNOL CELL BIOL, V76, P34, DOI 10.1046/j.1440-1711.1998.00709.x; Ben-Sasson SZ, 2001, J IMMUNOL, V166, P112, DOI 10.4049/jimmunol.166.1.112; Bergeron C, 2007, J ALLERGY CLIN IMMUN, V119, P391, DOI 10.1016/j.jaci.2006.10.030; Bird JJ, 1998, IMMUNITY, V9, P229, DOI 10.1016/S1074-7613(00)80605-6; BRUHN KW, 1993, P NATL ACAD SCI USA, V90, P9707, DOI 10.1073/pnas.90.20.9707; Cai Y, 2007, NAT STRUCT MOL BIOL, V14, P872, DOI 10.1038/nsmb1276; Cameron L, 2006, J IMMUNOL, V177, P8633, DOI 10.4049/jimmunol.177.12.8633; Cohn L, 2004, ANNU REV IMMUNOL, V22, P789, DOI 10.1146/annurev.immunol.22.012703.104716; Cunningham JT, 2007, NATURE, V450, P736, DOI 10.1038/nature06322; DAVYDOV IV, 1995, J IMMUNOL, V155, P5273; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; Do Kim J, 2006, GENOME RES, V16, P901, DOI 10.1101/gr.5091406; Donohoe ME, 1999, MOL CELL BIOL, V19, P7237; Dorado B, 2002, J IMMUNOL, V169, P3030, DOI 10.4049/jimmunol.169.6.3030; Fields PE, 2004, IMMUNITY, V21, P865, DOI 10.1016/j.immuni.2004.10.015; Finotto S, 2001, J EXP MED, V193, P1247, DOI 10.1084/jem.193.11.1247; Garban HJ, 2001, J IMMUNOL, V167, P75, DOI 10.4049/jimmunol.167.1.75; Georas S, 2000, LEUKEMIA, V14, P629, DOI 10.1038/sj.leu.2401712; Georas Steve N, 2004, Proc Am Thorac Soc, V1, P215, DOI 10.1513/pats.200402-004MS; Gordon S, 2006, ONCOGENE, V25, P1125, DOI 10.1038/sj.onc.1209080; Guo J, 2001, J BIOL CHEM, V276, P48871, DOI 10.1074/jbc.M101592200; He Y, 2007, NEURON, V55, P217, DOI 10.1016/j.neuron.2007.06.029; Hiromura M, 2003, J BIOL CHEM, V278, P14046, DOI 10.1074/jbc.M300789200; HO AM, 1994, J BIOL CHEM, V269, P28181; Ho IC, 2002, CELL, V109, pS109, DOI 10.1016/S0092-8674(02)00705-5; Hobbs K, 1998, AM J RESP CRIT CARE, V158, P1958, DOI 10.1164/ajrccm.158.6.9804011; Kalayci O, 2003, AM J RESP CELL MOL, V29, P750, DOI 10.1165/rcmb.2003-0024OC; Kuperman D, 1998, J EXP MED, V187, P939, DOI 10.1084/jem.187.6.939; Laouar Y, 2000, IMMUNITY, V13, P291, DOI 10.1016/S1074-7613(00)00029-7; Lee GR, 2006, IMMUNITY, V24, P369, DOI 10.1016/j.immuni.2006.03.007; Li BY, 1999, EMBO J, V18, P420, DOI 10.1093/emboj/18.2.420; Liu HF, 2007, GENE DEV, V21, P1179, DOI 10.1101/gad.1529307; LIWEBER M, 1994, J IMMUNOL, V153, P4122; Lorente M, 2006, MECH DEVELOP, V123, P312, DOI 10.1016/j.mod.2006.02.003; Mordvinov VA, 1999, J ALLERGY CLIN IMMUN, V103, P1125, DOI 10.1016/S0091-6749(99)70188-0; *NAT ASTHM ED PREV, 1997, EXP PAN REP GUID DIA; PFEUFFER I, 1994, J IMMUNOL, V153, P5572; Richter A, 1999, J EXP MED, V190, P1439, DOI 10.1084/jem.190.10.1439; ROONEY JW, 1994, EMBO J, V13, P625, DOI 10.1002/j.1460-2075.1994.tb06300.x; Santiago FS, 2001, J BIOL CHEM, V276, P41143, DOI 10.1074/jbc.M104913200; Schwenger GTF, 1999, J ALLERGY CLIN IMMUN, V104, P820, DOI 10.1016/S0091-6749(99)70293-9; Shi Y, 1997, BBA-REV CANCER, V1332, pF49, DOI 10.1016/S0304-419X(96)00044-3; Silverman ES, 2004, AM J RESP CRIT CARE, V169, P214, DOI 10.1164/rccm.200307-973OC; Soutto M, 2002, J IMMUNOL, V169, P4205, DOI 10.4049/jimmunol.169.8.4205; Spilianakis CG, 2005, NATURE, V435, P637, DOI 10.1038/nature03574; Sui GC, 2004, CELL, V117, P859, DOI 10.1016/j.cell.2004.06.004; Sweetser MT, 1998, J BIOL CHEM, V273, P34775, DOI 10.1074/jbc.273.52.34775; SZABO SJ, 1995, IMMUNITY, V2, P665, DOI 10.1016/1074-7613(95)90011-X; Thomas MJ, 1999, GENE, V236, P197, DOI 10.1016/S0378-1119(99)00261-9; Valapour M, 2002, J ALLERGY CLIN IMMUN, V109, P238, DOI 10.1067/mai.2002.121145; Wilkinson FH, 2006, P NATL ACAD SCI USA, V103, P19296, DOI 10.1073/pnas.0603564103; Yao YL, 2001, MOL CELL BIOL, V21, P5979, DOI 10.1128/MCB.21.17.5979-5991.2001; Ye JP, 1996, MOL CELL BIOL, V16, P4744; YE JP, 1994, J BIOL CHEM, V269, P25728; Zhang DH, 1999, IMMUNITY, V11, P473, DOI 10.1016/S1074-7613(00)80122-3	58	24	27	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2008	122	1					195	201		10.1016/j.jaci.2008.03.012	http://dx.doi.org/10.1016/j.jaci.2008.03.012			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	325RD	18423564	Green Accepted			2022-12-18	WOS:000257605100031
J	Park, HW; Park, CH; Park, SH; Park, JY; Park, HS; Yang, HJ; Ahn, KA; Kim, KH; Oh, JW; Kim, KE; Pyun, BY; Lee, HB; Min, KU				Park, Heung-Woo; Park, Chang-Han; Park, Su-Hwa; Park, Jun Young; Park, Hyun Sun; Yang, Hyeon Jong; Ahn, Kang-Ato; Kim, Kyu-Han; Oh, Jae-Won; Kim, Kyu-Earn; Pyun, Bok-Yang; Lee, Ha-Baik; Min, Kyung-Up			Dermatologic adverse reactions to 7 common food additives in patients with allergic diseases: A double-blind, placebo-controlled study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ATOPIC-DERMATITIS; URTICARIA		[Park, Heung-Woo; Park, Chang-Han; Min, Kyung-Up] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 151, South Korea; [Park, Heung-Woo; Park, Chang-Han; Min, Kyung-Up] Seoul Natl Univ, Coll Med, Inst Allergy & Clin Immunol, Seoul 151, South Korea; [Park, Hyun Sun; Kim, Kyu-Han; Kim, Kyu-Earn] Seoul Natl Univ, Coll Med, Dept Dermatol, Seoul 151, South Korea; [Park, Su-Hwa; Ahn, Kang-Ato] Sungkyunkwan Univ, Sch Med, Dept Pediat, Seoul, South Korea; [Park, Jun Young] Yonsei Univ, Coll Med, Dept Pediat, Seoul, South Korea; [Yang, Hyeon Jong; Pyun, Bok-Yang] Soonchunhyang Univ, Coll Med, Dept Pediat, Seoul, South Korea; [Oh, Jae-Won; Lee, Ha-Baik] Hanyang Univ, Coll Med, Dept Pediat, Seoul 133791, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Sungkyunkwan University (SKKU); Yonsei University; Yonsei University Health System; Soonchunhyang University; Hanyang University	Park, HW (corresponding author), Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 151, South Korea.	drmin@snu.ae.kr	Min, Kyung-Up/J-5468-2012; Park, Heung-Woo/AAW-7690-2020; Kim, Kyu Han/E-7814-2012	Park, Heung-Woo/0000-0002-6970-3228; Park, Hyunsun/0000-0003-1338-654X				Di Lorenzo G, 2005, INT ARCH ALLERGY IMM, V138, P235, DOI 10.1159/000088724; FUGLSANG G, 1994, ALLERGY, V49, P31, DOI 10.1111/j.1398-9995.1994.tb00770.x; HANNUKSELA M, 1986, INT J DERMATOL, V25, P178, DOI 10.1111/j.1365-4362.1986.tb02212.x; LEE JO, 2000, ANN REP KFDA, V4, P119; Nettis E, 2004, BRIT J DERMATOL, V151, P898, DOI 10.1111/j.1365-2133.2004.06095.x; Nettis E, 2003, CLIN EXP ALLERGY, V33, P1725, DOI 10.1111/j.1365-2222.2003.01825.x; RAJKA G, 1989, ACTA DERM-VENEREOL, P13; VANBEVER HP, 1989, ALLERGY, V44, P588; Worm M, 2000, CLIN EXP ALLERGY, V30, P407, DOI 10.1046/j.1365-2222.2000.00722.x	9	24	24	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2008	121	4					1059	1061		10.1016/j.jaci.2007.12.1162	http://dx.doi.org/10.1016/j.jaci.2007.12.1162			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	286YY	18325576				2022-12-18	WOS:000254884000040
J	Schmechel, D; Green, BJ; Blachere, FM; Janotka, E; Beezhold, DH				Schmechel, Detlef; Green, Brett J.; Blachere, Francoise M.; Janotka, Erika; Beezhold, Donald H.			Analytical bias of cross-reactive polyclonal antibodies for environmental immunoassays of Alternaria alternata	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						fungi; polyclonal antibodies; Alternaria; ELISA	IN-HOUSE DUST; RESIDENTIAL CHARACTERISTICS; MONOCLONAL-ANTIBODIES; HOME CHARACTERISTICS; FUNGAL ALLERGENS; US HOMES; AIRBORNE; ASTHMA; DUSTBORNE; SYMPTOMS	Background: Alternaria alternata is recognized as an important aeroallergen indoors and outdoors, and exposure to the fungus has been identified as a risk factor for asthma. Two recent publications concluded that 95% to 99% of American homes contained detectable amounts of Alternaria antigens when analyzed with a polyclonal antibody (pAb)-based ELISA. Objectives: We investigated the cross-reactivity of the commercially available pAbs that were used in those studies. Methods: Reactivity to 24 fungal species commonly found in indoor environments was analyzed by inhibition ELISA by using solid-phase A alternata antigen. The pAbs were also tested by immunoblotting and halogen immunoassay for a subgroup of fungi. Results: Spores of 7 fungi including species of Alternaria, Ulocladium, Stemphylium, Epicoccum, Drechslera, and Exserohilum strongly inhibited the binding of the pAbs when tested by ELISA. Six other fungi reacted in the ELISA at a lower level, and 11 fungal species including several Penicillium, Aspergillus, Fusarium, and Cladosporium species failed to show inhibition. The immunoblots and the halogen immunoassay staining confirmed the cross-reactivity patterns of the ELISA. Conclusion: The pAbs against A alternata were found to crossreact broadly with related and nonrelated fungi. The prevalence data previously reported for A alternata should be considered to be fungal-reactive rather than A alternata-specific.	[Schmechel, Detlef; Green, Brett J.; Blachere, Francoise M.; Janotka, Erika; Beezhold, Donald H.] NIOSH, Allergy & Clin Immunol Branch, Morgantown, WV 26505 USA	Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH)	Schmechel, D (corresponding author), NIOSH, Allergy & Clin Immunol Branch, 1095 Willowdale Rd, Morgantown, WV 26505 USA.	DSchmechel@cdc.gov		Beezhold, Donald/0000-0001-5543-5747	NIEHS NIH HHS [Y1-ES-0001] Funding Source: Medline	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AGARWAL MK, 1982, J ALLERGY CLIN IMMUN, V70, P437, DOI 10.1016/0091-6749(82)90006-9; Barnes C, 2006, ANN ALLERG ASTHMA IM, V97, P350, DOI 10.1016/S1081-1206(10)60800-9; Beguin H., 1995, Aerobiologia, V11, P3, DOI 10.1007/BF02136138; Bisht V, 2002, ANN ALLERG ASTHMA IM, V89, P285, DOI 10.1016/S1081-1206(10)61956-4; Bowyer P, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-251; Bush RK, 2004, J ALLERGY CLIN IMMUN, V113, P227, DOI 10.1016/j.jaci.2003.11.023; Chew GL, 2003, ALLERGY, V58, P13, DOI 10.1034/j.1398-9995.2003.00013.x; Cho SH, 2006, SCI TOTAL ENVIRON, V371, P31, DOI 10.1016/j.scitotenv.2006.09.001; de Ana SG, 2006, J INVEST ALLERG CLIN, V16, P357; Green BJ, 2003, J ALLERGY CLIN IMMUN, V111, P285, DOI 10.1067/mai.2003.57; Green BJ, 2006, ANAL BIOCHEM, V354, P151, DOI 10.1016/j.ab.2006.03.035; Gupta R, 2002, ALLERGY, V57, P636, DOI 10.1034/j.1398-9995.2002.03331.x; Hicks JB, 2005, J OCCUP ENVIRON HYG, V2, P481, DOI 10.1080/15459620500252860; HOFFMAN DR, 1979, J ALLERGY CLIN IMMUN, V63, P213; Hong SG, 2005, FUNGAL GENET BIOL, V42, P119, DOI 10.1016/j.fgb.2004.10.009; HORNER WE, 1995, CLIN MICROBIOL REV, V8, P161, DOI 10.1128/CMR.8.2.161; Horner WE, 2004, APPL ENVIRON MICROB, V70, P6394, DOI 10.1128/AEM.70.11.6394-6400.2004; KOCH A, 1995, ALLERGOLOGIE, V18, P501; Kodsueb R, 2006, MYCOLOGIA, V98, P571, DOI 10.3852/mycologia.98.4.571; Levetin E, 2006, AEROBIOLOGIA, V22, P3, DOI 10.1007/s10453-005-9012-9; LICORISH K, 1985, J ALLERGY CLIN IMMUN, V76, P819, DOI 10.1016/0091-6749(85)90755-9; LIN HH, 1987, J FOOD SCI, V52, P1089, DOI 10.1111/j.1365-2621.1987.tb14282.x; Mitakakis TZ, 2001, J ALLERGY CLIN IMMUN, V107, P388, DOI 10.1067/mai.2001.112602; Ponikau JU, 2006, CLIN REV ALLERG IMMU, V30, P187, DOI 10.1385/CRIAI:30:3:187; Saenz-de-Santamaria M, 2006, MYCOSES, V49, P91, DOI 10.1111/j.1439-0507.2006.01195.x; Salo PM, 2006, J ALLERGY CLIN IMMUN, V118, P892, DOI 10.1016/j.jaci.2006.07.037; Salo PM, 2005, J ALLERGY CLIN IMMUN, V116, P623, DOI 10.1016/j.jaci.2005.05.030; Schmechel D, 2006, J IMMUNOL METHODS, V309, P150, DOI 10.1016/j.jim.2005.12.001; Schmechel D, 2005, INDOOR AIR, V15, P11, DOI 10.1111/j.1600-0668.2005.00340.x; Schmechel D, 1997, FOOD AGR IMMUNOL, V9, P219, DOI 10.1080/09540109709354952; SCHMECHEL D, 2005, BIOAERSOL FUNGI BACT, P366; TEE RD, 1987, J ALLERGY CLIN IMMUN, V79, P627, DOI 10.1016/S0091-6749(87)80159-8; Trout DB, 2004, ANN ALLERG ASTHMA IM, V92, P483, DOI 10.1016/S1081-1206(10)61754-1; VERHOEFF AP, 1994, ALLERGY, V49, P540, DOI 10.1111/j.1398-9995.1994.tb01126.x; VERMA J, 1995, ALLERGY, V50, P811, DOI 10.1111/j.1398-9995.1995.tb05054.x; Vesper SJ, 2006, J OCCUP ENVIRON MED, V48, P852, DOI 10.1097/01.jom.0000224736.52780.2f; Vijay Hari M, 2004, Clin Allergy Immunol, V18, P223; WICKMAN M, 1992, J ALLERGY CLIN IMMUN, V89, P752, DOI 10.1016/0091-6749(92)90384-E; WOOD RA, 1988, AM REV RESPIR DIS, V137, P358, DOI 10.1164/ajrccm/137.2.358; Zureik M, 2002, BMJ-BRIT MED J, V325, P411, DOI 10.1136/bmj.325.7361.411	40	24	24	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2008	121	3					763	768		10.1016/j.jaci.2007.09.046	http://dx.doi.org/10.1016/j.jaci.2007.09.046			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	273GR	18036643				2022-12-18	WOS:000253918900035
J	Huebner, M; Kim, DY; Ewart, S; Karmaus, W; Sadeghnejad, A; Arshad, SH				Huebner, Marianne; Kim, Dong-Yun; Ewart, Susan; Karmaus, Wilfried; Sadeghnejad, Alireza; Arshad, Syed H.			Patterns of GATA3 and IL13 gene polymorphisms associated with childhood rhinitis and atopy in a birth cohort	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						rhinitis; allergic rhinitis; atopy; GATA3; IL13; genetic association; gene-gene interactions	MULTIFACTOR DIMENSIONALITY REDUCTION; SNP-SNP INTERACTIONS; TOTAL IGE; ASTHMA; IL-13; CHILDREN; EPIDEMIOLOGY; ENVIRONMENT; POPULATION; PREVALENCE	Background: GATA3 activates transcription of the T(H)2 cytokines, including IL13, an important step in the allergic inflammatory pathway. Objective: We sought to identify associations of single nucleotide polymorphisms of the genes GATA3 and IL13 and their interactions with rhinitis and allergic sensitization during childhood. Methods: We performed genetic association studies in a cohort of children (n = 923) who have been evaluated for the development of rhinitis and allergic sensitization by means of skin prick tests (SPTs) at age 10 years. Pyrosequencing was used to genotype 7 polymorphisms from GATA3 and 5 from IL13. A novel model-selection procedure combining logistic regression models and classification was used to study the contributions of the polymorphisms and their interactions. Results: Combinations of polymorphisms and their interactions increase the risk for rhinitis and allergic sensitization at age 10 years. A model with rs1058240, rs379568, and rs4143094 (GATA3) and rs1800925 (IL13) and their interactions was selected to predict rhinitis and positive SPT responses. rs1058240 was associated with rhinitis and allergic rhinitis (P < .05), and the gene-gene interaction rs1058240:rs1800925 was associated with rhinitis (P = .043). The odds ratios for 4 genotype combinations were significant for rhinitis or SPTs (P < .044). Conclusion: Gene-gene interaction between GATA3 and IL13 polymorphisms can influence the risk of childhood rhinitis. Our study suggests that set associations of polymorphisms are important in studying genetic associations for complex phenotypes, such as rhinitis and atopy.	[Huebner, Marianne] Michigan State Univ, Dept Stat & Probabil, E Lansing, MI 48823 USA; [Kim, Dong-Yun] Virginia Tech, Dept Stat, Blacksburg, VA USA; [Ewart, Susan] Michigan State Univ, Dept Large Anim Clin Sci, Coll Vet Med, E Lansing, MI 48823 USA; [Karmaus, Wilfried] Univ S Carolina, Arnold Sch Publ Hlth, Columbia, SC 29208 USA; [Sadeghnejad, Alireza] Wake Forest Univ, Winston Salem, NC 27109 USA; [Arshad, Syed H.] Univ Southampton, Southampton SO9 5NH, Hants, England	Michigan State University; Virginia Polytechnic Institute & State University; Michigan State University; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; Wake Forest University; University of Southampton	Huebner, M (corresponding author), Michigan State Univ, Dept Stat & Probabil, A-422 Wells Halls, E Lansing, MI 48823 USA.	huebner@msu.edu	Huebner, Marianne/AAA-6882-2020	Huebner, Marianne/0000-0002-9694-9231	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI061471] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705; Arshad SH, 2001, PEDIATRICS, V108, part. no., DOI 10.1542/peds.108.2.e33; Arshad SH, 2002, ACTA PAEDIATR, V91, P1334; Battle NC, 2007, AM J RESP CRIT CARE, V175, P881, DOI 10.1164/rccm.200607-992OC; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Breiman L, 2001, MACH LEARN, V45, P5, DOI 10.1023/A:1010933404324; Bureau A, 2005, GENET EPIDEMIOL, V28, P171, DOI 10.1002/gepi.20041; Chan IHS, 2006, J ALLERGY CLIN IMMUN, V117, P127, DOI 10.1016/j.jaci.2005.09.031; DeMeo DL, 2002, GENET EPIDEMIOL, V23, P335, DOI 10.1002/gepi.10182; Efron B., 1994, INTRO BOOTSTRAP; Ewart SL, 2000, AM J RESP CELL MOL, V23, P537, DOI 10.1165/ajrcmb.23.4.4199; Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424; Goodman JE, 2006, INT J CANCER, V118, P1790, DOI 10.1002/ijc.21523; Graves PE, 2000, J ALLERGY CLIN IMMUN, V105, P506, DOI 10.1067/mai.2000.104940; Hahn LW, 2003, BIOINFORMATICS, V19, P376, DOI 10.1093/bioinformatics/btf869; Heinzmann A, 2000, HUM MOL GENET, V9, P549, DOI 10.1093/hmg/9.4.549; Howard TD, 2001, AM J RESP CELL MOL, V25, P377, DOI 10.1165/ajrcmb.25.3.4483; Howard TD, 2002, AM J HUM GENET, V70, P230, DOI 10.1086/338242; Hummelshoj T, 2003, EUR J IMMUNOGENET, V30, P355, DOI 10.1046/j.1365-2370.2003.00416.x; Hunninghake GM, 2007, J ALLERGY CLIN IMMUN, V120, P84, DOI 10.1016/j.jaci.2007.04.032; Kim HB, 2006, J HUM GENET, V51, P1055, DOI 10.1007/s10038-006-0061-x; Koeppen-Schomerus G, 2001, ARCH DIS CHILD, V85, P398, DOI 10.1136/adc.85.5.398; Kurukulaaratchy RJ, 2003, EUR RESPIR J, V22, P767, DOI 10.1183/09031936.03.00005903; Kurukulaaratchy RJ, 2002, RESP MED, V96, P163, DOI 10.1053/rmed.2001.1236; Latvala J, 2005, BMJ-BRIT MED J, V330, P1186, DOI 10.1136/bmj.38448.603924.AE; Lundback B, 1998, CLIN EXP ALLERGY, V28, P3; Onay VU, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-114; Powe DG, 2006, CLIN EXP ALLERGY, V36, P1367, DOI 10.1111/j.1365-2222.2006.02593.x; Pykalainen M, 2005, J ALLERGY CLIN IMMUN, V115, P80, DOI 10.1016/j.jaci.2004.10.006; Ritchie MD, 2003, GENET EPIDEMIOL, V24, P150, DOI 10.1002/gepi.10218; Vercelli D, 2002, CURR OPIN ALLERGY CL, V2, P389, DOI 10.1097/00130832-200210000-00004; Wang M, 2003, HUM GENET, V113, P387, DOI 10.1007/s00439-003-1001-x; *WORLD ALL ORG, COMB ALL RHIN ASTHM; WRIGHT AL, 1994, PEDIATRICS, V94, P895	34	24	26	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2008	121	2					408	414		10.1016/j.jaci.2007.09.020	http://dx.doi.org/10.1016/j.jaci.2007.09.020			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	265CX	18037162	Green Accepted			2022-12-18	WOS:000253337800020
J	Gernez, Y; Tirouvanziam, R; Nguyen, KD; Herzenberg, LA; Krensky, AM; Nadeau, KC				Gernez, Yael; Tirouvanziam, Rabindra; Nguyen, Khoa D.; Herzenberg, Leonard A.; Krensky, Alan M.; Nadeau, Kari C.			Altered phosphorylated signal transducer and activator of transcription profile of CD4(+)CD161(+) T cells in asthma: Modulation by allergic status and oral corticosteroids	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; atopy; fluorescence-activated cell sorting; immune polarization	FLOW-CYTOMETRY; AIRWAY INFLAMMATION; PERIPHERAL-BLOOD; HUMAN NKR-P1A; MECHANISMS; CD161; IL-4; NK; EXPRESSION; PATHWAYS	Background: Asthma is a complex immunologic disorder linked to altered cytokine signaling. Objective: We tested whether asthmatic patients showed any change in cytokine-dependent signal transducer and activator of transcription (STAT) levels, focusing on the central/effector-memory CD4(+)CD161(+) subset, which represents 15% to 25% of circulating T cells. Methods: We quantified intracellular levels of active phosphorylated STAT (phospho-STAT) 1, 3, 5, and 6 by means of flow cytometry, without any activation or expansion. Results: Baseline phospho-STAT1 and phospho-STAT6 levels were increased in CD4(+)CD161(+) T cells from asthmatic patients compared with those from healthy control subjects (by 10- and 8-fold, respectively). This asthma-associated alteration was both subset specific because no change was seen in CD4(+)CD161(-)CD25(+) (regulatory T cells) and CD4(+)CD161(-)CD25(-) subsets and isoform specific because phospho-STAT5 and phospho-STAT3 levels were unchanged. Among asthmatic patients, phospho-STAT1 and phospho-STAT6 levels correlated negatively with each other, suggesting antagonistic regulation. Oral corticosteroid (OCS) treatment significantly decreased phospho-STAT6 and IL-4 levels but not phospho-STAT1 levels. Disease parameters showing significant correlations with phospho-STAT1, phospho-STAT6, or both included age at onset, plasma IgE levels, and levels of the T(H)2 cytokines IL-4 and IL-10 and the T(H)1 cytokine IL-2. Overall, combined phospho-STAT1 and phospho-STAT6 measurements showed excellent predictive value for identifying (1) asthmatic patients versus healthy control subjects, (2) allergic versus nonallergic asthmatic patients, and (3) asthmatic patients taking versus those not taking OCSs. Conclusion: Baseline changes in phospho-STAT1 and phospho-STAT6 levels in blood CD4(+)CD161(+) T cells identify asthmatic patients and mirror their allergic status and response to OCSs. Clinical implications: These results confirm the pathologic importance of activated STAT1 and STAT6 in asthma and suggest their potential use as clinical biomarkers.	[Tirouvanziam, Rabindra] Beckman Ctr B013, Stanford, CA 94305 USA; [Gernez, Yael; Herzenberg, Leonard A.] Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA; [Tirouvanziam, Rabindra; Nguyen, Khoa D.; Nadeau, Kari C.] Stanford Univ, Sch Med, Dept Pediat, Stanford, CA 94305 USA; [Krensky, Alan M.] NIH, Bethesda, MD USA	Stanford University; Stanford University; National Institutes of Health (NIH) - USA	Tirouvanziam, R (corresponding author), Beckman Ctr B013, Stanford, CA 94305 USA.	tirouvan@stanford.edu	Tirouvanziam, Rabindra/E-8981-2010	Nguyen, Khoa/0000-0002-6720-2470	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK035008] Funding Source: NIH RePORTER; NIDDK NIH HHS [R37 DK035008-23] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adcock IM, 2006, EUR J PHARMACOL, V533, P118, DOI 10.1016/j.ejphar.2005.12.054; [Anonymous], 1987, AM REV RESPIR DIS, V136, P225; Barnes PJ, 2003, ANN INTERN MED, V139, P359, DOI 10.7326/0003-4819-139-5_Part_1-200309020-00012; Baumgarth N, 2000, J IMMUNOL METHODS, V243, P77, DOI 10.1016/S0022-1759(00)00229-5; Bel EH, 2004, CURR OPIN PULM MED, V10, P44, DOI 10.1097/00063198-200401000-00008; Bousquet J, 2000, CLIN EXP ALLERGY, V30, P2; Buhl R, 2005, CURR OPIN PULM MED, V11, P27; Chanez P, 2007, J ALLERGY CLIN IMMUN, V119, P1337, DOI 10.1016/j.jaci.2006.11.702; Chatila TA, 2004, TRENDS MOL MED, V10, P493, DOI 10.1016/j.molmed.2004.08.004; Chen WG, 2007, J ALLERGY CLIN IMMUN, V119, P529, DOI 10.1016/j.jaci.2007.01.004; Christodoulopoulos P, 2001, J ALLERGY CLIN IMMUN, V107, P586, DOI 10.1067/mai.2001.114883; Cohn L, 2004, ANNU REV IMMUNOL, V22, P789, DOI 10.1146/annurev.immunol.22.012703.104716; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; Deykin A, 2006, J ALLERGY CLIN IMMUN, V118, P565, DOI 10.1016/j.jaci.2006.06.007; Efthimiou P, 2006, ANN RHEUM DIS, V65, P564, DOI 10.1136/ard.2005.042143; Gulbins E, 2003, ONCOGENE, V22, P7070, DOI 10.1038/sj.onc.1207146; Herzenberg LA, 2006, NAT IMMUNOL, V7, P681, DOI 10.1038/ni0706-681; Ho LP, 2007, NEW ENGL J MED, V356, P1466, DOI 10.1056/NEJMe078014; Horne R, 2006, CHEST, V130, p65S, DOI 10.1378/chest.130.1_suppl.65S; Iliopoulou EG, 2006, CLIN CANCER RES, V12, P6901, DOI 10.1158/1078-0432.CCR-06-0977; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; LANIER LL, 1994, J IMMUNOL, V153, P2417; Loza MJ, 2002, EUR J IMMUNOL, V32, P3453, DOI 10.1002/1521-4141(200212)32:12<3453::AID-IMMU3453>3.0.CO;2-D; Miller RL, 1998, J ALLERGY CLIN IMMUN, V102, P503, DOI 10.1016/S0091-6749(98)70141-1; O'Byrne PM, 2006, CHEST, V130, P244, DOI 10.1378/chest.130.1.244; PARRILLO JE, 1979, ANNU REV PHARMACOL, V19, P179, DOI 10.1146/annurev.pa.19.040179.001143; Perez OD, 2006, IMMUNOL REV, V210, P208, DOI 10.1111/j.0105-2896.2006.00364.x; Pernis AB, 2002, J CLIN INVEST, V109, P1279, DOI 10.1172/JCI200215786; Pozo D, 2006, J IMMUNOL, V176, P2397, DOI 10.4049/jimmunol.176.4.2397; Ratthe C, 2007, J LEUKOCYTE BIOL, V81, P1287, DOI 10.1189/jlb.0306209; Robertson JM, 2006, IMMUNOL REV, V211, P49, DOI 10.1111/j.0105-2896.2006.00383.x; Shi HZ, 2004, CLIN IMMUNOL, V113, P172, DOI 10.1016/j.clim.2004.06.009; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; Shirai T, 2006, J ALLERGY CLIN IMMUN, V118, P622, DOI 10.1016/j.jaci.2006.05.005; So EY, 2002, FEBS LETT, V518, P53, DOI 10.1016/S0014-5793(02)02635-2; Takahashi T, 2006, J IMMUNOL, V176, P211, DOI 10.4049/jimmunol.176.1.211; Tirouvanziam R, 2006, DRUG NEWS PERSPECT, V19, P609, DOI 10.1358/dnp.2006.19.10.1068008; Umetsu DT, 2006, IMMUNOL REV, V212, P238, DOI 10.1111/j.0105-2896.2006.00413.x; Wang IM, 2004, MOL IMMUNOL, V41, P873, DOI 10.1016/j.molimm.2004.04.027; Wurtz O, 2004, INT IMMUNOL, V16, P501, DOI 10.1093/intimm/dxh050; Yu CR, 2004, J IMMUNOL, V173, P737, DOI 10.4049/jimmunol.173.2.737; Zimmermann N, 2004, J IMMUNOL, V172, P1815, DOI 10.4049/jimmunol.172.3.1815	42	24	26	1	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2007	120	6					1441	1448		10.1016/j.jaci.2007.08.012	http://dx.doi.org/10.1016/j.jaci.2007.08.012			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	241JX	17919711	Green Accepted			2022-12-18	WOS:000251653800029
J	Soeria-Atmadja, D; Onell, A; Kober, A; Matsson, P; Gustafsson, MG; Hammerling, U				Soeria-Atmadja, Daniel; Oenell, Annica; Kober, Anita; Matsson, Per; Gustafsson, Mats G.; Hammerling, Ulf			Multivariate statistical analysis of large-scale IgE antibody measurements reveals allergen extract relationships in sensitized individuals	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IgE reactivity; allergens; multivariate data analysis; clustering algorithms	HOUSE-DUST-MITE; CROSS-REACTIVE ALLERGENS; FOOD ALLERGENS; BINDING; RECOMBINANT; DIAGNOSIS; IDENTIFICATION; PREDICTION; PEPTIDES; PROTEINS	Background: Many allergenic sources are reportedly cross-reactive because of protein structural similarities. Although several aggregations are well characterized, no holistic mapping of IgE reactivity has hitherto been reported. Objective: The aim of this study was to disclose relevant associations within a large set of allergen preparations, as revealed by specific IgE antibody levels in blood sera of multireactive human donors. Methods: A dataset of recorded IgE antibody serum concentrations of 1011 nonidentifiable multireactive individuals (devoid of clinical records) to 89 allergen extracts was compiled for in silico analysis. Various algorithms were used to identify specific multivariate dependencies between the IgE antibody levels. Results: Exhaustive cluster analysis demonstrates that IgE antibody responses to the 89 extracts can be aggregated into 12 stable formations. These clusters hold both well-known relationships, unexpected patterns, and unknown patterns, the latter categories being exemplified by the coclustering of wasp and certain seafood and a clear differentiation among pollen allergens. Conclusion: Identified relationships within several well-known groups of cross-reactive allergen extracts confirm the applicability of dedicated multivariate data analysis within the allergology field. Moreover, some of the unexpected IgE reactivity associations in sensitized human subjects might help in identifying new relationships with potential importance to allergy. Clinical implications: Although clinical implications from this study should be validated in subsequent investigations with documentation on symptoms included, we believe this seminal approach is a key step toward the development of new analysis tools for interpretation of allergy data generated by using high-throughput recording systems.	[Soeria-Atmadja, Daniel; Hammerling, Ulf] Natl Food Adm Toxicol Lab, Div Toxicol, SE-75126 Uppsala, Sweden; [Gustafsson, Mats G.] Uppsala Univ, Dept Engn Sci, SE-75121 Uppsala, Sweden; [Soeria-Atmadja, Daniel; Gustafsson, Mats G.] Univ Uppsala Hosp, Dept Med Sci, Uppsala, Sweden; [Oenell, Annica; Kober, Anita; Matsson, Per] Phadia AB, Res & Dev, Uppsala, Sweden	Uppsala University; Uppsala University; Uppsala University Hospital; Thermo Fisher Scientific; Phadia	Hammerling, U (corresponding author), Natl Food Adm Toxicol Lab, Div Toxicol, POB 622, SE-75126 Uppsala, Sweden.	mg@angstrom.uu.se; ulfh@slv.se						Aalberse RC, 2000, J ALLERGY CLIN IMMUN, V106, P228, DOI 10.1067/mai.2000.108434; Aalberse RC, 2001, ALLERGY, V56, P478, DOI 10.1034/j.1398-9995.2001.056006478.x; AKI T, 1995, J ALLERGY CLIN IMMUN, V96, P74, DOI 10.1016/S0091-6749(95)70035-8; Asero R, 2007, MOL NUTR FOOD RES, V51, P135, DOI 10.1002/mnfr.200600132; Bjorklund AK, 2005, BIOINFORMATICS, V21, P39, DOI 10.1093/bioinformatics/bth477; Botros HG, 1996, IMMUNOLOGY, V88, P340, DOI 10.1046/j.1365-2567.1996.d01-669.x; Bowyer P, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-251; Breiteneder H, 2006, MOL NUTR FOOD RES, V50, P628, DOI 10.1002/mnfr.200500274; Brusic Vladimir, 2006, Inflammation & Allergy Drug Targets, V5, P35, DOI 10.2174/187152806775269277; Burastero SE, 2004, INT ARCH ALLERGY IMM, V135, P296, DOI 10.1159/000082323; Cui J, 2007, MOL IMMUNOL, V44, P514, DOI 10.1016/j.molimm.2006.02.010; Fahlbusch B, 2003, ALLERGY, V58, P629, DOI 10.1034/j.1398-9995.2003.00177.x; Ferreira F, 2004, ALLERGY, V59, P243, DOI 10.1046/j.1398-9995.2003.00407.x; Foetisch K, 2003, J ALLERGY CLIN IMMUN, V111, P889, DOI 10.1067/mai.2003.173; Gendel SM, 2006, MOL NUTR FOOD RES, V50, P633, DOI 10.1002/mnfr.200500271; Hales BJ, 2006, J ALLERGY CLIN IMMUN, V118, P361, DOI 10.1016/j.jaci.2006.04.001; Hastie T, 2009, ELEMENTS STAT LEARNI; Hemmer W, 2004, CLIN EXP ALLERGY, V34, P460, DOI 10.1111/j.1365-2222.2004.01897.x; Hemmer W, 2001, J ALLERGY CLIN IMMUN, V108, P1045, DOI 10.1067/mai.2001.120013; Jenkins JA, 2005, J ALLERGY CLIN IMMUN, V115, P163, DOI 10.1016/j.jaci.2004.10.026; Lidholm J, 2006, CURR OPIN ALLERGY CL, V6, P234, DOI 10.1097/01.all.0000225166.90768.d6; Mari A, 1999, J ALLERGY CLIN IMMUN, V103, P1005, DOI 10.1016/S0091-6749(99)70171-5; Mari A, 2005, INT ARCH ALLERGY IMM, V138, P88, DOI 10.1159/000087848; Mari A, 2003, CLIN EXP ALLERGY, V33, P1419, DOI 10.1046/j.1365-2222.2003.01773.x; Mothes N, 2006, CLIN CHEM LAB MED, V44, P125, DOI 10.1515/CCLM.2006.024; Pittner G, 2004, CLIN EXP ALLERGY, V34, P597, DOI 10.1111/j.1365-2222.2004.1930.x; Poulsen LK, 2001, ALLERGY, V56, P39, DOI 10.1034/j.1398-9995.2001.00912.x; PUROHIT A, 2007, ALLERG IMMUNOL PARIS, V39, P85; Radauer C, 2006, J ALLERGY CLIN IMMUN, V117, P141, DOI 10.1016/j.jaci.2005.09.010; ROUSSEEUW PJ, 1987, J COMPUT APPL MATH, V20, P53, DOI 10.1016/0377-0427(87)90125-7; Sicherer SH, 2001, J ALLERGY CLIN IMMUN, V108, P881, DOI 10.1067/mai.2001.118515; Simon-Nobbe B, 2000, J ALLERGY CLIN IMMUN, V106, P887, DOI 10.1067/mai.2000.110799; Smith AM, 2001, INT ARCH ALLERGY IMM, V124, P61, DOI 10.1159/000053669; Soeria-Atmadja D, 2006, NUCLEIC ACIDS RES, V34, P3779, DOI 10.1093/nar/gkl467; Stadler MB, 2003, FASEB J, V17, P1141, DOI 10.1096/fj.02-1052fje; Taylor SL, 2006, MOL NUTR FOOD RES, V50, P604, DOI 10.1002/mnfr.200500275; Thomas WR, 2002, INT ARCH ALLERGY IMM, V129, P1, DOI 10.1159/000065179; Van Do T, 2005, J ALLERGY CLIN IMMUN, V116, P1314, DOI 10.1016/j.jaci.2005.07.033; Vieths S, 2002, ANN NY ACAD SCI, V964, P47; Virtanen T, 2001, ALLERGY, V56, P48, DOI 10.1034/j.1398-9995.2001.00915.x; Wilson IBH, 1998, GLYCOBIOLOGY, V8, P651, DOI 10.1093/glycob/8.7.651; Wohrl S, 2006, ALLERGY, V61, P633, DOI 10.1111/j.1398-9995.2006.01078.x	42	24	25	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2007	120	6					1433	1440		10.1016/j.jaci.2007.07.021	http://dx.doi.org/10.1016/j.jaci.2007.07.021			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	241JX	17825892				2022-12-18	WOS:000251653800028
J	Wood, PR; Smith, B; O'Donnell, L; Galbreath, AD; Lara, M; Forkner, E; Peters, JI				Wood, Pamela Runge; Smith, Brad; O'Donnell, Louise; Galbreath, Autumn Dawn; Lara, Marielena; Forkner, Emma; Peters, Jay I.			Quantifying asthma symptoms in adults: The Lara Asthma Symptom Scale	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						health status indicators; asthma symptoms; quality of life; Hispanic Americans; psychometrics; severity of illness index; questionnaire; asthma; outcome assessment	QUALITY-OF-LIFE; END-POINTS; VALIDATION; QUESTIONNAIRE; RELIABILITY; SEVERITY; VALIDITY	Background: Accurate assessment of asthma symptoms is critical in research and clinical settings. A multidimensional asthma control questionnaire could provide more accurate information about asthma symptoms than global assessments, which often overestimate asthma control. Objective: We sought to evaluate the efficacy of the Lara Asthma Symptom Scale (LASS) in adults with persistent asthma. Methods: Participants were 18 to 64 years of age with persistent asthma. Data were collected at baseline, 6 months, and 12 months. We described the construct and predictive validity of the LASS by comparing it with measures of pulmonary function (FEV1), asthma-specific quality of life (Juniper's Asthma Quality of Life Questionnaire [AQLQ]), and health care use (emergency department [ED] visits and hospitalizations). Results: Three hundred eighty-three participants provided baseline data. The LASS had high internal consistency reliability (Cronbach alpha = .84). LASS scores correlated significantly with baseline measures of FEV1 (-0.20, P = .0002), AQLQ (-0.68, P < .0001), ED visits (0.17, P = .002), and hospitalizations (0.15, P = .008). Baseline LASS scores were associated significantly with ED visits (P = .03) and hospitalizations (P = .04) over the subsequent 12 months. Change in LASS scores over time correlated significantly with changes in FEV1 (-0.22, P = .001) and AQLQ (-0.70, P < .001). Conclusions: The LASS demonstrated good internal consistency, excellent validity based on concurrent criterion validity and longitudinal predictive validity, and good discriminatory properties in a heterogeneous sample of adults with persistent asthma. Clinical implications: This study validates a simple multidimensional asthma questionnaire as a clinical tool in the assessment of asthma control in adults.	[Wood, Pamela Runge; O'Donnell, Louise] Univ Texas Hlth Sci Ctr San Antonio, Dept Pediat, San Antonio, TX 78229 USA; [O'Donnell, Louise] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA; [Galbreath, Autumn Dawn; Peters, Jay I.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA; [Smith, Brad; Forkner, Emma] Altarum Inst, San Antonio, TX USA; [Galbreath, Autumn Dawn] Texas Transplant Inst, San Antonio, TX USA; [Lara, Marielena] Rand Hlth, Santa Monica, CA USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; RAND Corporation	Wood, PR (corresponding author), UTHSCSA MS7808, Dept Pediat, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	woodp@uthscsa.edu						[Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; Bateman ED, 2004, AM J RESP CRIT CARE, V170, P836, DOI 10.1164/rccm.200401-033OC; Bukstein D, 2006, J ALLERGY CLIN IMMUN, V118, pS1, DOI 10.1016/j.jaci.2006.08.002; Centers for Disease Control and Prevention (CDC), 2004, MMWR-MORBID MORTAL W, V53, P145; Fuhlbrigge AL, 2004, CURR OPIN PULM MED, V10, P1, DOI 10.1097/00063198-200401000-00002; Fuhlbrigge AL, 2002, AM J RESP CRIT CARE, V166, P1044, DOI 10.1164/rccm.2107057; GALBREATH AD, 2007, AM J RESP CRIT CARE, V175, pA59; *GINA, 2006, GINA REP GLOB STRAT; Graham LM, 2006, CHEST, V130, p13S, DOI 10.1378/chest.130.1_suppl.13S; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179, DOI 10.1164/ajrccm.159.1.9712108; Juniper EF, 2005, RESP MED, V99, P553, DOI 10.1016/j.rmed.2004.10.008; Juniper EF, 2004, EUR RESPIR J, V23, P287, DOI 10.1183/09031936.04.00064204; JUNIPER EF, 1994, J CLIN EPIDEMIOL, V47, P81, DOI 10.1016/0895-4356(94)90036-1; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; Juniper EF, 1999, CHEST, V115, P1265, DOI 10.1378/chest.115.5.1265; Juniper EF, 2001, EUR RESPIR J, V18, P38, DOI 10.1183/09031936.01.00088301; Lara M, 2000, MED CARE, V38, P342, DOI 10.1097/00005650-200003000-00011; Leidy NK, 1998, AM J RESP CRIT CARE, V158, P1082, DOI 10.1164/ajrccm.158.4.9708130; Liu AH, 2007, J ALLERGY CLIN IMMUN, V119, P817, DOI 10.1016/j.jaci.2006.12.662; Moy ML, 2001, AM J RESP CRIT CARE, V163, P924, DOI 10.1164/ajrccm.163.4.2008014; Nathan RA, 2004, J ALLERGY CLIN IMMUN, V113, P59, DOI 10.1016/j.jaci.2003.09.008; National Heart Lung and Blood Institute Division of blood diseases and resources, 2002, NIH PUBL; Osborne ML, 1999, CHEST, V115, P85, DOI 10.1378/chest.115.1.85; Pellegrino R, 2005, EUR RESPIR J, V26, P948, DOI 10.1183/09031936.05.00035205; Pinnock H, 2005, J CLIN EPIDEMIOL, V58, P809, DOI 10.1016/j.jclinepi.2005.01.010; Schatz M, 2006, J ALLERGY CLIN IMMUN, V117, P549, DOI 10.1016/j.jaci.2006.01.011; Schatz M, 2005, J ALLERGY CLIN IMMUN, V115, P1049, DOI 10.1016/j.jaci.2005.02.008; Schatz M, 2007, J ALLERGY CLIN IMMUN, V119, P336, DOI 10.1016/j.jaci.2006.08.042; Schmier JK, 2007, ANN ALLERG ASTHMA IM, V98, P245, DOI 10.1016/S1081-1206(10)60713-2; Shingo S, 2001, EUR RESPIR J, V17, P220, DOI 10.1183/09031936.01.17202200; Skinner Elizabeth A, 2004, Dis Manag, V7, P305, DOI 10.1089/dis.2004.7.305; Vermeire PA, 2002, RESP MED, V96, P142, DOI 10.1053/rmed.2001.1241; Vollmer WM, 1999, AM J RESP CRIT CARE, V160, P1647, DOI 10.1164/ajrccm.160.5.9902098; Zorc JJ, 2006, J ASTHMA, V43, P753, DOI 10.1080/02770900601031615	34	24	25	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2007	120	6					1368	1372		10.1016/j.jaci.2007.09.025	http://dx.doi.org/10.1016/j.jaci.2007.09.025			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	241JX	17981316				2022-12-18	WOS:000251653800018
J	Allen, LC; Kepley, CL; Saxon, A; Zhang, K				Allen, Lisa Chan; Kepley, Christopher L.; Saxon, Andrew; Zhang, Ke			Modifications to an Fc gamma-Fc epsilon fusion protein alter its effectiveness in the inhibition of Fc epsilon RI-mediated functions	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						GE2; IgE; IgG; Fc epsilon RI; Fc gamma RIIb; allergy	AFFINITY IGE RECEPTOR; MONOCLONAL-ANTIBODY; PROMOTER HAPLOTYPE; DENDRITIC CELLS; EXPRESSION; RESPONSES; COAGGREGATION; AUTOIMMUNITY; BINDING; PHASE	Background: GE2, a human bifunctional Fc gamma-Fc epsilon fusion protein cross-links Fc gamma RIIb and Fc epsilon RI on human mast cells and basophils and results in inhibition of Fc epsilon RI-mediated functions. Objective: Three modified Fc gamma-Fc epsilon: (GE) proteins were compared with GE2 for their effect on inhibition of Fc epsilon RI-mediated cellular responses. Methods: GE2 was modified to potentially improve its therapeutic efficacy by increasing binding to Fc gamma RIIb (GE S mutant) and decreasing binding to Fc gamma RIII (GE H mutant) or reversing the Fc gamma and Fc epsilon domains and removing nonhuman linker sequences (E2G). These proteins were tested for their ability to bind a basophil-like cell line, block Fc epsilon RI-mediated degranulation in human basophils, and inhibit passive cutaneous anaphylaxis in human Fc epsilon RI alpha-transgenic mice. Results: All 4 GE proteins bound cells that express Fc epsilon RI and Fc gamma RIIb, although the original GE2 retained the strongest ability to bind to these cells. E2G was as effective as GE2 in its ability to inhibit anti-Fel d 1 IgE-mediated histamine release from human basophils and block passive cutaneous anaphylaxis reactions. The GE S and GE H mutants were less effective. Conclusion: Optimization of GE2 as an inhibitor of Fc epsilon RI-mediated functions showed that effectiveness was maintained when potentially immunogenic linker sequences were removed and Ig domain positions were reversed, but specific residue changes within the IgG C(H)2 domain aimed at enhancing GE2's inhibitory function by increasing Fc gamma RII binding or additionally decreasing Fc gamma RIII binding were not beneficial. Clinical implications: GE2 and E2G molecules are effective inhibitors of Fc epsilon RI-mediated degranulation and are of interest.	Univ Calif Los Angeles, David Geffen Sch Med, Div Clin Immunol Allergy, Hart & Louise Lyon Lab, Los Angeles, CA 90095 USA; Virginia Commonwealth Univ, Hlth Syst, Richmond, VA 23284 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Virginia Commonwealth University	Zhang, K (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Div Clin Immunol Allergy, Hart & Louise Lyon Lab, Los Angeles, CA 90095 USA.	kzhang@mednet.ucla.edu			NIAID NIH HHS [AI-15251] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI015251, R01AI015251] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arbes SJ, 2005, J ALLERGY CLIN IMMUN, V116, P377, DOI 10.1016/j.jaci.2005.05.017; Aydar Y, 2003, J IMMUNOL, V171, P5975, DOI 10.4049/jimmunol.171.11.5975; Blom T, 1996, SCAND J IMMUNOL, V44, P54, DOI 10.1046/j.1365-3083.1996.d01-84.x; BLOM T, 1992, EUR J IMMUNOL, V22, P2025, DOI 10.1002/eji.1830220811; DAERON M, 1995, J CLIN INVEST, V95, P577, DOI 10.1172/JCI117701; Dombrowicz D, 1996, J IMMUNOL, V157, P1645; Fahy JV, 1997, AM J RESP CRIT CARE, V155, P1828, DOI 10.1164/ajrccm.155.6.9196082; GOSSELIN EJ, 1990, J IMMUNOL, V144, P1817; Kepley CL, 2000, J ALLERGY CLIN IMMUN, V106, P337, DOI 10.1067/mai.2000.107931; Kepley CL, 2004, J BIOL CHEM, V279, P35139, DOI 10.1074/jbc.M404318200; Kepley CL, 2003, CLIN IMMUNOL, V108, P89, DOI 10.1016/S1521-6616(03)00155-4; Metes D, 1998, BLOOD, V91, P2369, DOI 10.1182/blood.V91.7.2369.2369_2369_2380; Ong YE, 2005, J ALLERGY CLIN IMMUN, V116, P558, DOI 10.1016/j.jaci.2005.05.035; ROSENFELD SI, 1987, J IMMUNOL, V138, P2869; Saxon A, 2004, CURR OPIN ALLERGY CL, V4, P563, DOI 10.1097/00130832-200412000-00015; Shields RL, 2001, J BIOL CHEM, V276, P6591, DOI 10.1074/jbc.M009483200; Su KH, 2004, J IMMUNOL, V172, P7192, DOI 10.4049/jimmunol.172.11.7192; Su KH, 2004, J IMMUNOL, V172, P7186, DOI 10.4049/jimmunol.172.11.7186; Yamada T, 2003, J BIOL CHEM, V278, P32818, DOI 10.1074/jbc.M304590200; Zhang K, 2004, J ALLERGY CLIN IMMUN, V114, P321, DOI 10.1016/j.jaci.2004.03.058; Zhu DC, 2002, NAT MED, V8, P518, DOI 10.1038/nm0502-518	21	24	25	1	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2007	120	2					462	468		10.1016/j.jaci.2007.04.019	http://dx.doi.org/10.1016/j.jaci.2007.04.019			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	198VF	17543377				2022-12-18	WOS:000248654900036
J	Hsu, SC; Tsai, TH; Kawasaki, H; Chen, CH; Plunkett, B; Lee, RT; Lee, YC; Huang, SK				Hsu, Shih-Chang; Tsai, Tsung-Hsien; Kawasaki, Hirokazu; Chen, Chien-Ho; Plunkett, Beverly; Lee, Reiko T.; Lee, Yuan C.; Huang, Shau-Ku			Antigen coupled with Lewis-x trisaccharides elicits potent immune responses in mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						dendritic cells; C-type lectin receptor; Lewis-x trisaccharides	C-TYPE LECTIN; TOLL-LIKE RECEPTORS; T-CELL RESPONSES; DENDRITIC CELLS; DC-SIGN; INDUCTION; MOUSE; PATHOGENS; PROTEINS; BINDING	Background: Glycoproteins containing Lewis-x (Le(x)) trisaccharides are often associated with the host's adaptive T(H)2-type immunity, but the mechanisms underlying the T(H)2-biased response are at present unclear. Objective: The modulatory effect of Le(x) or its glycoconjugates on IgE/T(H)2 responses was investigated. Methods: The levels of serum antibodies and cytokines were analyzed by means of ELISA, RT-PCR, or both. Results: In C3H mice Le(x) coupled with BSA (Le(x)-BSA) elicited higher levels of specific IgE and IgG1, but not IgG2a, which were associated with increased levels of splenic T(H)2 cytokines when compared with those seen in BSA-sensitized mice. In BALB/c mice sensitized with Le(x)-BSA or Le(x) mixed with ovalbumin, significantly increased levels of specific IgE and IgG2a antibodies were found concomitant with reduced levels of serum IL-12p70. These effects were attenuated in IL-12-deficient BALB/c mice. Le(x) and an isomer, Le(y), but not other isomers, inhibited the production of LPS-induced IL-12p70, associated with a significant reduction of nuclear NF-kappa B, in bone marrow-derived dendritic cells from BALB/c mice, suggesting that Lex-induced suppression of IL-12p70 results in an enhanced TH2 response. The addition of mannan, a known ligand for dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin, abrogated the suppressive effect of Le(x) trisaccharides. Conclusion: These results provide evidence for a potential role of Le(x) trisaccharides in shaping the immune responses through, at least in part, its suppressive effect on IL-12p70 production. Considering the relative ubiquity of glycoproteins with Le(x) or similar oligosaccharides, including plant-derived (or food-derived) allergens, these findings might have a broad implication. Clinical implications: The adjuvant activity of Le(x) trisaccharides might aid in vaccine design and might be important in determining the allergenicity of proteins containing this or other similar structures.	Johns Hopkins Asthma & Allergy Ctr, Baltimore, MD 21224 USA; Taipei Med Univ, Dept Dermatol, Taipei, Taiwan; Taipei Municipal Wan Fang Hosp, Taipei, Taiwan; Taipei Med Univ, Dept Med Technol, Taipei, Taiwan; Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins Medicine; Taipei Medical University; Taipei Municipal WanFang Hospital; Taipei Medical University; Johns Hopkins University	Huang, SK (corresponding author), Johns Hopkins Asthma & Allergy Ctr, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.	skhuang@jhmi.edu	Hsu, Shih-Chang/I-4277-2012; Huang, Shau-Ku/F-5509-2010	Hsu, Shih-Chang/0000-0003-1010-1182; 	NIAID NIH HHS [R01 AI-052468] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052468] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Atochina O, 2005, CLIN DIAGN LAB IMMUN, V12, P1041, DOI 10.1128/CDLI.12.9.1041-1049.2005; Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Barends M, 2003, J MED VIROL, V69, P156, DOI 10.1002/jmv.10252; Cambi A, 2003, CURR OPIN CELL BIOL, V15, P539, DOI 10.1016/j.ceb.2003.08.004; Delayre-Orthez C, 2004, CLIN EXP ALLERGY, V34, P1789, DOI 10.1111/j.1365-2222.2004.02082.x; Esche C, 1999, J INVEST DERMATOL, V113, P1028, DOI 10.1046/j.1523-1747.1999.00779.x; Fotisch K, 2001, GLYCOCONJUGATE J, V18, P373, DOI 10.1023/A:1014860030380; Galustian C, 2004, INT IMMUNOL, V16, P853, DOI 10.1093/intimm/dxh089; Gantner BN, 2003, J EXP MED, V197, P1107, DOI 10.1084/jem.20021787; Geijtenbeek TBH, 2004, ANNU REV IMMUNOL, V22, P33, DOI 10.1146/annurev.immunol.22.012703.104558; Geijtenbeek TBH, 2003, J EXP MED, V197, P7, DOI 10.1084/jem.20021229; Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7; Guo Y, 2004, NAT STRUCT MOL BIOL, V11, P591, DOI 10.1038/nsmb784; Hilton J, 1997, FOOD CHEM TOXICOL, V35, P1209, DOI 10.1016/S0278-6915(97)00119-1; Jankovic D, 2002, IMMUNITY, V16, P429, DOI 10.1016/S1074-7613(02)00278-9; Li XM, 1998, J IMMUNOL, V160, P1378; Lutz MB, 1999, J IMMUNOL METHODS, V223, P77, DOI 10.1016/S0022-1759(98)00204-X; Markowe LA, 2002, J COMMUNITY APPL SOC, V12, P223, DOI 10.1002/casp.674; McGreal EP, 2005, CURR OPIN IMMUNOL, V17, P18, DOI 10.1016/j.coi.2004.12.001; Moser M, 2000, NAT IMMUNOL, V1, P199, DOI 10.1038/79734; Okano M, 2001, J IMMUNOL, V167, P442, DOI 10.4049/jimmunol.167.1.442; Park CG, 2001, INT IMMUNOL, V13, P1283, DOI 10.1093/intimm/13.10.1283; Powlesland AS, 2006, J BIOL CHEM, V281, P20440, DOI 10.1074/jbc.M601925200; Staudacher E, 1999, BBA-GEN SUBJECTS, V1473, P216, DOI 10.1016/S0304-4165(99)00181-6; Tacken PJ, 2005, BLOOD, V106, P1278, DOI 10.1182/blood-2005-01-0318; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; TRINCHIERI G, 1995, ANNU REV IMMUNOL, V13, P251, DOI 10.1146/annurev.iy.13.040195.001343; van Kooyk Y, 2004, CURR OPIN IMMUNOL, V16, P488, DOI 10.1016/j.coi.2004.05.010; van Kooyk Y, 2003, NAT REV IMMUNOL, V3, P697, DOI 10.1038/nri1182; van Ree R, 2000, J BIOL CHEM, V275, P11451, DOI 10.1074/jbc.275.15.11451; VELUPILLAI P, 1994, P NATL ACAD SCI USA, V91, P18, DOI 10.1073/pnas.91.1.18	32	24	24	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2007	119	6					1522	1528		10.1016/j.jaci.2007.01.034	http://dx.doi.org/10.1016/j.jaci.2007.01.034			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	178PO	17353042	Bronze			2022-12-18	WOS:000247232800031
J	Thompson, EE; Pan, L; Ostrovnaya, I; Weiss, LA; Gern, JE; Lemanske, RF; Nicolae, DL; Ober, C				Thompson, Emma E.; Pan, Lin; Ostrovnaya, Irina; Weiss, Lauren A.; Gern, James E.; Lemanske, Robert F., Jr.; Nicolae, Dan L.; Ober, Carole			Integrin beta 3 genotype influences asthma and allergy phenotypes in the first 6 years of life	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; allergy; noncoding variation; integrin; viral respiratory illness	SINGLE-NUCLEOTIDE POLYMORPHISM; GENE-ENVIRONMENT INTERACTIONS; SERUM IGE LEVELS; HAPLOTYPE RECONSTRUCTION; 3'-UNTRANSLATED REGION; CELL-MIGRATION; SUSCEPTIBILITY; EXPRESSION; ATOPY; ASSOCIATION	Background: The integrin beta 3 gene (ITGB3) encodes a subunit of the platelet and monocyte-specific fibrinogen receptor and the widely expressed vitronectin receptor, which have diverse roles in cell migration, adhesion, and signaling. Previous work from our laboratory reported associations between single nucleotide polymorphisms (SNPs) in ITGB3 and asthma and allergic sensitization in 4 populations. Objective: To examine whether SNPs in ITGB3 are associated with the development of asthma and allergic phenotypes in early life. Methods: We typed 13 SNPs in 206 children participating in a birth cohort study and tested for associations with asthma and allergy phenotypes in the first 6 years of life. Results: Our study revealed significant associations between SNPs in ITGB3 and asthma, wheezing, and IgE levels, suggesting an early role for this gene in the development of asthma and allergy. In particular, SNPs at the 3' end of the gene were significantly associated with IgE levels beginning at 1 year of age, whereas a SNP in intron I showed significant interaction effects with viral respiratory illness in infancy on asthma susceptibility. Conclusion: Our results suggest that genetic variation in ITGB3 contributes to asthma susceptibility and allergic sensitization, and that the effects of this gene begin early in life. Similar to our earlier study, different SNPs in the gene are associated with asthma and IgE. Clinical implications: ITGB3 may play an important role in the development of asthma and allergy and may represent a potential therapeutic target for the treatment of these disorders.	Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA; Univ Chicago, Dept Stat, Chicago, IL 60637 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA; Univ Wisconsin, Dept Med, Madison, WI USA; Univ Wisconsin, Dept Pediat, Madison, WI USA	University of Chicago; University of Chicago; University of Chicago; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Thompson, EE (corresponding author), 920 E 58th St, Chicago, IL 60637 USA.	eethomps@uchicago.edu		Ober, Carole/0000-0003-4626-9809; Nicolae, Dan/0000-0002-0918-4630	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL070831, T32HL007605] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL70831, T32 HL007605] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bazan-Socha S, 2006, CLIN EXP ALLERGY, V36, P1184, DOI 10.1111/j.1365-2222.2006.02540.x; Bosse Y, 2007, ANNU REV MED, V58, P171, DOI 10.1146/annurev.med.58.071105.111738; Bourgain C, 2003, AM J HUM GENET, V73, P612, DOI 10.1086/378208; Carlson CS, 2004, AM J HUM GENET, V74, P106, DOI 10.1086/381000; Chan A, 2006, GENES IMMUN, V7, P169, DOI 10.1038/sj.gene.6364287; Clop A, 2006, NAT GENET, V38, P813, DOI 10.1038/ng1810; Donfack J, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-145; Eder W, 2005, J ALLERGY CLIN IMMUN, V116, P601, DOI 10.1016/j.jaci.2005.05.003; GEM JE, 2004, J ALLERGY CLIN IMMUN, V113, P307; Gern JE, 2006, J ALLERGY CLIN IMMUN, V117, P72, DOI 10.1016/j.jaci.2005.10.002; Goto Y, 2001, CLIN CANCER RES, V7, P1952; Groneberg DA, 2004, EXP LUNG RES, V30, P223, DOI 10.1080/01902140490276320; Hansen G, 2000, J CLIN INVEST, V105, P61, DOI 10.1172/JCI7589; Hirota T, 2005, J ALLERGY CLIN IMMUN, V116, P789, DOI 10.1016/j.jaci.2005.06.010; Hoffjan S, 2005, AM J HUM GENET, V76, P696, DOI 10.1086/429418; Hoffjan S, 2004, J ALLERGY CLIN IMMUN, V113, P511, DOI 10.1016/j.jaci.2003.10.044; Huang DR, 2000, J NEUROIMMUNOL, V105, P69, DOI 10.1016/S0165-5728(00)00191-0; Huang J, 2005, MOL BIOL CELL, V16, P4982, DOI 10.1091/mbc.E05-03-0258; Kurz T, 2006, J ALLERGY CLIN IMMUN, V118, P396, DOI 10.1016/j.jaci.2006.04.036; Lemanske RF, 2002, PEDIAT ALLERG IMM-UK, V13, P38, DOI 10.1034/j.1399-3038.13.s.15.8.x; Lemanske RF, 2005, J ALLERGY CLIN IMMUN, V116, P571, DOI 10.1016/j.jaci.2005.06.024; Martinez FD, 2005, IMMUNOL ALLERGY CLIN, V25, P709, DOI 10.1016/j.iac.2005.09.001; Nakao A, 2002, J ALLERGY CLIN IMMUN, V110, P873, DOI 10.1067/mai.2002.129236; Neaville WA, 2003, J ALLERGY CLIN IMMUN, V112, P740, DOI 10.1016/S0091-6749(03)01868-2; Nguyen TTB, 2005, AM J RESP CRIT CARE, V171, P217, DOI 10.1164/rccm.200408-1046OC; Ober C, 2000, AM J HUM GENET, V67, P1154, DOI 10.1016/S0002-9297(07)62946-2; Ober C, 2006, GENES IMMUN, V7, P95, DOI 10.1038/sj.gene.6364284; Ober C, 2005, J ALLERGY CLIN IMMUN, V116, P274, DOI 10.1016/j.jaci.2005.04.039; Ober C, 2000, AM J HUM GENET, V66, P517, DOI 10.1086/302781; Ober C, 2005, CURR OPIN IMMUNOL, V17, P670, DOI 10.1016/j.coi.2005.09.009; Redington AE, 1997, AM J RESP CRIT CARE, V156, P642, DOI 10.1164/ajrccm.156.2.9605065; Reynolds LE, 2005, NAT MED, V11, P167, DOI 10.1038/nm1165; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Stephens M, 2003, AM J HUM GENET, V73, P1162, DOI 10.1086/379378; Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501; Thompson RD, 2000, J IMMUNOL, V165, P426, DOI 10.4049/jimmunol.165.1.426; Van Eerdewegh P, 2002, NATURE, V418, P426, DOI 10.1038/nature00878; VERCELLI D, 1989, J EXP MED, V169, P1295, DOI 10.1084/jem.169.4.1295; Vercelli D, 2006, J ALLERGY CLIN IMMUN, V117, P1303, DOI 10.1016/j.jaci.2006.03.030; Vijayan KV, 2005, J BIOL CHEM, V280, P21756, DOI 10.1074/jbc.M500872200; Villette S, 2002, BLOOD CELL MOL DIS, V29, P174, DOI 10.1006/bcmd.2002.0556; Weiss LA, 2005, AM J RESP CRIT CARE, V172, P67, DOI 10.1164/rccm.200411-1555OC; Weiss LA, 2006, EUR J HUM GENET, V14, P923, DOI 10.1038/sj.ejhg.5201644; Weiss LA, 2006, HUM GENET, V120, P93, DOI 10.1007/s00439-006-0196-z; Williams LK, 2006, J ALLERGY CLIN IMMUN, V118, P851, DOI 10.1016/j.jaci.2006.07.007; Woltmann G, 2000, BLOOD, V95, P3146; Zambelli-Weiner A, 2005, J ALLERGY CLIN IMMUN, V115, P1203, DOI 10.1016/j.jaci.2005.03.001	47	24	25	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2007	119	6					1423	1429		10.1016/j.jaci.2007.03.029	http://dx.doi.org/10.1016/j.jaci.2007.03.029			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	178PO	17556058				2022-12-18	WOS:000247232800018
J	Freyschmidt, EJ; Mathias, CB; MacArthur, DH; Laouar, A; Narasimhaswamy, M; Weih, F; Oettgen, HC				Freyschmidt, Eva-Jasmin; Mathias, Clinton B.; MacArthur, Daniel H.; Laouar, Amale; Narasimhaswamy, Manjunath; Weih, Falk; Oettgen, Hans C.			Skin inflammation in RelB(-/-) mice leads to defective immunity and impaired clearance of vaccinia virus	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eczema vaccination; allergy; vaccinia virus; smallpox vaccination; viral response; cytotoxic T cells; THI/T(H)2 cells	RESPIRATORY SYNCYTIAL VIRUS; INTERFERON-GAMMA RECEPTOR; NITRIC-OXIDE-SYNTHASE; ATOPIC-DERMATITIS; SMALLPOX VACCINATION; TARGETED DISRUPTION; TRANSGENIC MICE; T-CELLS; IN-VIVO; INTERLEUKIN-4	Background: Atopic dermatitis (AD) is an inflammatory skin disorder occurring in genetically predisposed individuals with a systemic T(H)2 bias. Atopic dermatitis patients exposed to the smallpox vaccine, vaccinia virus (VV), occasionally develop eczema vaccinatum (EV), an overwhelming and potentially lethal systemic infection with VV. Objective: To establish a marine model of EV and examine the effects of skin inflammation on VV immunity. Methods: The skin of ReIB-/- mice, like that of chronic AD lesions in humans, exhibits thickening, eosinophilic infiltration, hyperkeratosis, and acanthosis. RelB(-/-) and wild-type (WT) control mice were infected with VV via skin scarification. Viral spread, cytokine levels, IgG2a responses and VV-specific T cells were measured. Results: Cutaneously VV-infected RelB(-/-), but not WT mice, exhibited weight loss, markedly impaired systemic clearance of the virus and increased contiguous propagation from the inoculation site. This was associated with a dramatically impaired generation of IFN-gamma-producing CD8(+) vaccinia-specific T cells along with decreased secretion of IFN-gamma by VV-stimulated splenocytes. The T(H)2 cytokines-IL-4, IL-5, IL-13, and IL-10-on the other hand, were overproduced. When infected intraperitoneally, RelB(-/-) mice generated robust T cell responses with good IFN-gamma production. Conclusion: Allergic inflammation in RelB(-/-) mice is associated with dysregulated immunity to VV encountered via the skin. We speculate that susceptibility of AD patients to overwhelming vaccinia virus infection is similarly related to ineffective T cell responses. Clinical implications: The susceptibility of patients with AD to EV following cutaneous contact with VV is related to ineffective antiviral immune responses.	Harvard Univ, Childrens Hosp, Sch Med, Dept Pediat,Div Immunol, Boston, MA 02115 USA; Harvard Univ, Sch Med, CBR Inst Biomed Res, Boston, MA 02115 USA; Fritz Lipmann Inst, Res Grp Immunol, Jena, Germany	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Leibniz Institut fur Alternsforschung - Fritz-Lipmann-Institut (FLI)	Oettgen, HC (corresponding author), Harvard Univ, Childrens Hosp, Sch Med, Dept Pediat,Div Immunol, 300 Longwood Ave, Boston, MA 02115 USA.	hans.oettgen@childrens.harvard.edu	Laouar, Amale/AAO-2903-2020	Mathias, Clinton/0000-0002-0223-4842				Asahi K, 1999, J DERMATOL SCI, V21, P49, DOI 10.1016/S0923-1811(99)00013-4; Aung S, 1999, J VIROL, V73, P8944, DOI 10.1128/JVI.73.11.8944-8949.1999; Barton D, 2000, EUR J IMMUNOL, V30, P2323, DOI 10.1002/1521-4141(2000)30:8<2323::AID-IMMU2323>3.0.CO;2-H; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; Chan LS, 2001, J INVEST DERMATOL, V117, P977, DOI 10.1046/j.0022-202x.2001.01484.x; Corn RA, 2005, J IMMUNOL, V175, P2102, DOI 10.4049/jimmunol.175.4.2102; EARL PL, 1998, PREPARATION CELL CUL; Engler RJM, 2002, J ALLERGY CLIN IMMUN, V110, P357, DOI 10.1067/mai.2002.128052; Fischer JE, 1997, J VIROL, V71, P8672, DOI 10.1128/JVI.71.11.8672-8677.1997; GREWE M, 1994, LANCET, V343, P25, DOI 10.1016/S0140-6736(94)90879-6; Grossmann M, 1999, INT J BIOCHEM CELL B, V31, P1209, DOI 10.1016/S1357-2725(99)00068-0; Howell MD, 2006, IMMUNITY, V24, P341, DOI 10.1016/j.immuni.2006.02.006; HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301; Johnson TR, 2001, J GEN VIROL, V82, P2107, DOI 10.1099/0022-1317-82-9-2107; Karupiah G, 1998, J VIROL, V72, P7703, DOI 10.1128/JVI.72.9.7703-7706.1998; KARUPIAH G, 1993, SCIENCE, V261, P1445, DOI 10.1126/science.7690156; Konishi H, 2002, P NATL ACAD SCI USA, V99, P11340, DOI 10.1073/pnas.152337799; LANE JM, 1970, J INFECT DIS, V122, P303, DOI 10.1093/infdis/122.4.303; LEUNG DYM, 1983, J ALLERGY CLIN IMMUN, V71, P47, DOI 10.1016/0091-6749(83)90546-8; Lu BF, 1998, P NATL ACAD SCI USA, V95, P8233, DOI 10.1073/pnas.95.14.8233; Matsuda H, 1997, INT IMMUNOL, V9, P461, DOI 10.1093/intimm/9.3.461; Matsui M, 2005, J VIROL, V79, P12798, DOI 10.1128/JVI.79.20.12798-12806.2005; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; Schmid P, 2001, ALLERGY, V56, P841, DOI 10.1034/j.1398-9995.2001.00144.x; Sharma DP, 1996, J VIROL, V70, P7103, DOI 10.1128/JVI.70.10.7103-7107.1996; SHER A, 1992, ANNU REV IMMUNOL, V10, P385, DOI 10.1146/annurev.iy.10.040192.002125; Spergel JM, 1998, J CLIN INVEST, V101, P1614, DOI 10.1172/JCI1647; TEPPER RI, 1990, CELL, V62, P457, DOI 10.1016/0092-8674(90)90011-3; TSICOPOULOS A, 1994, J ALLERGY CLIN IMMUN, V94, P764, DOI 10.1016/0091-6749(94)90185-6; Tsukuba T, 2003, J BIOCHEM, V134, P893, DOI 10.1093/jb/mvg216; van den Broek M, 2000, J IMMUNOL, V164, P371, DOI 10.4049/jimmunol.164.1.371; Weih F, 1997, J IMMUNOL, V158, P5211; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6; Wollenberg A, 2004, CURR OPIN ALLERGY CL, V4, P271, DOI 10.1097/01.all.0000136758.66442.28	34	24	26	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2007	119	3					671	679		10.1016/j.jaci.2006.12.645	http://dx.doi.org/10.1016/j.jaci.2006.12.645			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	146HL	17336617				2022-12-18	WOS:000244925000021
J	Vancheri, C; Gili, E; Failla, M; Mastruzzo, C; Salinaro, ET; LoFurno, D; Pistorio, MP; La Rosa, C; Caruso, M; Crimi, N				Vancheri, C; Gili, E; Failla, M; Mastruzzo, C; Salinaro, ET; LoFurno, D; Pistorio, MP; La Rosa, C; Caruso, M; Crimi, N			Bradykinin differentiates human lung fibroblasts to a myofibroblast phenotype via the B2 receptor	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						remodeling; lung fibrosis; alpha-SMA; MAPK	SMOOTH MUSCLE ACTIN; GROWTH-FACTOR-BETA; MECHANISMS; EXPRESSION; RELEASE; ASTHMA; HYPERRESPONSIVENESS; PROLIFERATION; PHARMACOLOGY; INFLAMMATION	Background: The identification of factors mediating the transition of lung fibroblasts into myofibroblasts is considered fundamental in the comprehension of abnormal reparative processes. Bradykinin, a mediator known for its proinflammatory action, is able to induce cytokine production and contractility in fibroblast cultures. Objectives: In this study the ability of bradykinin to drive fibroblast into a myofibroblast phenotype at the cellular and molecular level was evaluated. Methods: alpha-Smooth muscle actin (alpha-SMA) expression and TGF-beta in bradykinin stimulated fibroblasts were tested by means of flow cytometry, Western blot, and RT-PCR. Cell proliferation and collagen production were evaluated by the colorimetric methylthiazol tetrazolium assay and sirius red assay, respectively. Which bradykinin receptor mediates the expression of alpha-SMA was evaluated using selective B1 and B2 blocking agents. Furthermore, the effect of bradykinin on extracellular signal-regulated kinase 1/2 phosphorylation was explored. Results: Bradykinin caused in lung fibroblasts a significant increase in alpha-SMA at the cellular and molecular level. The B2 receptor was held responsible for this effect because a specific receptor antagonist had entirely blocked this effect. Bradykinin was able to induce fibroblast proliferation and collagen production. Bradykinin significantly activated mitogen-activated protein kinase pathway by phosphorylating extracellular signal-regulated kinase 1/2, whereas PD98059, a specific inhibitor, was able to block myofibroblast induction. Although bradykinin induced an increase of TGF-beta on fibroblasts, the blockage of this cytokine did not alter alpha-SMA expression. Conclusion: The data support the hypothesis that bradykinin may be involved in bronchial remodeling and lung fibrosis beyond its well recognized proinflammatory activity, also suggesting a new potential therapeutic strategy to control altered reparatory processes.	Univ Catania, Dept Internal & Specialist Med, Sect Resp Dis, I-95125 Catania, Italy	University of Catania	Vancheri, C (corresponding author), Univ Catania, Dept Internal & Specialist Med, Sect Resp Dis, Via Passo Gravina 187, I-95125 Catania, Italy.	vancheri@unict.it	Furno, Debora Lo/P-1667-2019; Crimi, Nunzio/AAL-2994-2020; Caruso, Massimo/P-4161-2016; Caruso, Massimo/G-6604-2012; VANCHERI, Carlo/K-9417-2016	Furno, Debora Lo/0000-0002-1971-8990; Crimi, Nunzio/0000-0002-8591-4535; Caruso, Massimo/0000-0002-4412-2080; Caruso, Massimo/0000-0002-4412-2080; VANCHERI, Carlo/0000-0002-5120-9926				ABRAHAM WM, 1991, AM REV RESPIR DIS, V143, P787, DOI 10.1164/ajrccm/143.4_Pt_1.787; Aliev G., 2001, Journal of Submicroscopic Cytology and Pathology, V33, P141; BREWSTER CEP, 1990, AM J RESP CELL MOL, V3, P507, DOI 10.1165/ajrcmb/3.5.507; CHONCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156; CHRISTIANSEN SC, 1987, J CLIN INVEST, V79, P188, DOI 10.1172/JCI112782; FINE A, 1987, J BIOL CHEM, V262, P3897; Folkerts G, 2000, AM J RESP CRIT CARE, V161, P1666, DOI 10.1164/ajrccm.161.5.9710002; Gizycki MJ, 1997, AM J RESP CELL MOL, V16, P664, DOI 10.1165/ajrcmb.16.6.9191468; HALL JM, 1992, PHARMACOL THERAPEUT, V56, P131, DOI 10.1016/0163-7258(92)90016-S; JORDANA M, 1988, AM REV RESPIR DIS, V137, P579, DOI 10.1164/ajrccm/137.3.579; Kaplan AP, 2002, J ALLERGY CLIN IMMUN, V109, P195, DOI 10.1067/mai.2002.121316; Karlsson JA, 1996, PULM PHARMACOL THER, V9, P315, DOI 10.1006/pulp.1996.0041; KHALIL N, 1989, J EXP MED, V170, P727, DOI 10.1084/jem.170.3.727; Koyama S, 2000, AM J RESP CELL MOL, V22, P75, DOI 10.1165/ajrcmb.22.1.3752; Mio T, 2001, AM J PHYSIOL-LUNG C, V281, pL164, DOI 10.1152/ajplung.2001.281.1.L164; MITCHELL J, 1989, LAB INVEST, V60, P643; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NAKAJIMA N, 1994, AM J RESP CRIT CARE, V149, P694, DOI 10.1164/ajrccm.149.3.7509704; PAEGELOW I, 1995, INFLAMM RES, V44, P306, DOI 10.1007/BF02032574; Pan ZK, 1996, J CLIN INVEST, V98, P2042, DOI 10.1172/JCI119009; PROUD D, 1988, ANNU REV IMMUNOL, V6, P49, DOI 10.1146/annurev.iy.06.040188.000405; REGOLI D, 1980, PHARMACOL REV, V32, P1; Ricciardolo FLM, 2001, AM J MED, V111, P18, DOI 10.1016/S0002-9343(01)00816-6; ROLFE MW, 1991, AM J RESP CELL MOL, V5, P493, DOI 10.1165/ajrcmb/5.5.493; Sato E, 2000, J ALLERGY CLIN IMMUN, V106, P117, DOI 10.1067/mai.2000.107400; SOLER M, 1990, Pulmonary Pharmacology, V3, P9, DOI 10.1016/0952-0600(90)90003-2; Van Schoor J, 2000, EUR RESPIR J, V16, P514, DOI 10.1034/j.1399-3003.2000.016003514.x; Zhang HY, 1996, AM J PATHOL, V148, P527	28	24	27	0	4	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2005	116	6					1242	1248		10.1016/j.jaci.2005.09.025	http://dx.doi.org/10.1016/j.jaci.2005.09.025			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IJ	16337452				2022-12-18	WOS:000235687000011
J	Chinen, J; Shearer, WT				Chinen, J; Shearer, WT			Basic and clinical immunology	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						immunoregulation; HIV; immunodeficiency; innate immunity; complement	PRIMARY IMMUNODEFICIENCY DISEASES; COMMON VARIABLE IMMUNODEFICIENCY; ESSENTIAL MODULATOR MUTATION; IMMUNE-RESPONSE; T-CELLS; HEREDITARY ANGIOEDEMA; ECTODERMAL DYSPLASIA; DIGEORGE-SYNDROME; GENE-THERAPY; MAST-CELLS	The authors selected articles published in the literature from January 2004 through December 2004 that were relevant to the areas of basic and clinical immunology. Several articles explored the development of T(H)1 or T(H)2 response and the role of the monocyte-T cell interaction. Others were articles describing the action of drugs commonly used in asthma to inhibit cytokine responses and the anti-inflammatory role of nonimmune pulmonary cells present in the lung. Several reports show how dendritic cells are being developed as vehicles for DNA vaccines aimed at stimulating cellular responses, an advance of great importance for HIV researchers working on vaccines, who are concerned about the different ways HIV evades the immune response. Other publications described Toll-like receptors in diverse cells, including mast cells and CD4(+) T cells, for the recognition of viruses and bacteria. In the area of clinical immunology, an updated classification for primary immunodeficiencies with more than 100 identified genes responsible for these diseases and the report on the second clinical trial of gene therapy for X-linked severe combined immunodeficiency syndrome were published. Significant advances included the clinical prognosis in common variable immunodeficiency for patients presenting with lung pathology, the safety of live vaccines in partial DiGeorge syndrome, the report of patients with complete DiGeorge syndrome with the presence of peripheral blood T cells, the clinical spectrum of patients with NF-kappa B essential modifier (NEMO) gene deficiency, the publication of a consensus algorithm for the management of hereditary angioedema, and the report of immune restoration syndrome in pediatric HIV infection.	NHGRI, Genet & Mol Biol Branch, NIH, Bethesda, MD 20892 USA; Texas Childrens Hosp, Dept Allergy & Immunol, Houston, TX 77030 USA; Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Chinen, J (corresponding author), NHGRI, Genet & Mol Biol Branch, NIH, 10 Ctr Dr,MSC 1611,Bldg 10-CRC Room 6-3340, Bethesda, MD 20892 USA.	jchinen@mail.nih.gov		Shearer, William/0000-0002-2483-2130				Bates CA, 2004, J ALLERGY CLIN IMMUN, V114, P415, DOI 10.1016/j.jaci.2004.05.057; Bowen T, 2004, J ALLERGY CLIN IMMUN, V114, P629, DOI 10.1016/j.jaci.2004.06.043; Cavazzana-Calvo Marina, 2005, Annu Rev Med, V56, P585, DOI 10.1146/annurev.med.56.090203.104142; Chinen J, 2004, J ALLERGY CLIN IMMUN, V114, P934, DOI 10.1016/j.jaci.2004.07.045; Chinen J, 2004, J ALLERGY CLIN IMMUN, V113, P595, DOI 10.1016/j.jaci.2004.01.765; Cunningham-Rundles C, 2004, J ALLERGY CLIN IMMUN, V113, P747, DOI 10.1016/j.jaci.2004.01.761; Depta JPH, 2004, J ALLERGY CLIN IMMUN, V113, P519, DOI 10.1016/j.jaci.2003.11.030; Dorak MT, 2004, LANCET, V363, P2137, DOI 10.1016/S0140-6736(04)16505-7; Draenert R, 2004, J EXP MED, V199, P905, DOI 10.1084/jem.20031982; Etzioni A, 2004, PEDIATR RES, V56, P519, DOI 10.1203/01.PDR.0000139318.65842.4A; Farkas L, 2004, J ALLERGY CLIN IMMUN, V114, P436, DOI 10.1016/j.jaci.2004.04.035; Flo TH, 2004, NATURE, V432, P917, DOI 10.1038/nature03104; Frank MM, 2004, J ALLERGY CLIN IMMUN, V114, P626, DOI 10.1016/j.jaci.2004.06.035; Gardulf A, 2004, J ALLERGY CLIN IMMUN, V114, P936, DOI 10.1016/j.jaci.2004.06.053; Gaspar HB, 2004, LANCET, V364, P2181, DOI 10.1016/S0140-6736(04)17590-9; Gelman AE, 2004, J IMMUNOL, V172, P6065, DOI 10.4049/jimmunol.172.10.6065; Goleva E, 2004, J ALLERGY CLIN IMMUN, V114, P183, DOI 10.1016/j.jaci.2004.04.001; Hajoui O, 2004, J ALLERGY CLIN IMMUN, V114, P657, DOI 10.1016/j.jaci.2004.05.034; Hanania NA, 2004, J ALLERGY CLIN IMMUN, V113, P717, DOI 10.1016/j.jaci.2003.12.584; Henness S, 2004, J ALLERGY CLIN IMMUN, V114, P958, DOI 10.1016/j.jaci.2004.06.023; Hoffjan S, 2004, J ALLERGY CLIN IMMUN, V113, P511, DOI 10.1016/j.jaci.2003.10.044; Holzelova E, 2004, NEW ENGL J MED, V351, P1409, DOI 10.1056/NEJMoa040036; Hung CH, 2004, J ALLERGY CLIN IMMUN, V114, P664, DOI 10.1016/j.jaci.2004.05.042; Jilek S, 2004, J ALLERGY CLIN IMMUN, V114, P943, DOI 10.1016/j.jaci.2004.05.065; Karagiannidis C, 2004, J ALLERGY CLIN IMMUN, V114, P1425, DOI 10.1016/j.jaci.2004.07.014; Kawaguchi M, 2004, J ALLERGY CLIN IMMUN, V114, P444, DOI 10.1016/j.jaci.2004.03.047; Klostermann B, 2004, J ALLERGY CLIN IMMUN, V113, P327, DOI 10.1016/j.jaci.2003.10.067; Kulka M, 2004, J ALLERGY CLIN IMMUN, V114, P174, DOI 10.1016/j.jaci.2004.03.049; Lametschwandtner G, 2004, J ALLERGY CLIN IMMUN, V113, P987, DOI 10.1016/j.jaci.2004.02.004; Leslie AJ, 2004, NAT MED, V10, P282, DOI 10.1038/nm992; Ludwig-Portugall I, 2004, J ALLERGY CLIN IMMUN, V114, P951, DOI 10.1016/j.jaci.2004.06.013; Luo ZH, 2004, J ALLERGY CLIN IMMUN, V114, P726, DOI 10.1016/j.jaci.2004.07.049; Markert ML, 2004, J ALLERGY CLIN IMMUN, V113, P734, DOI 10.1016/j.jaci.2004.01.766; Marshall JS, 2004, J ALLERGY CLIN IMMUN, V114, P21, DOI 10.1016/j.jaci.2004.04.045; Moir S, 2004, J EXP MED, V200, P587, DOI 10.1084/jem.20032236; Moylett EH, 2004, CLIN IMMUNOL, V112, P106, DOI 10.1016/j.clim.2004.02.008; Nakajima T, 2004, J ALLERGY CLIN IMMUN, V113, P528, DOI 10.1016/j.jaci.2003.12.036; Nassif A, 2004, J ALLERGY CLIN IMMUN, V114, P1209, DOI 10.1016/j.jaci.2004.07.047; Ng B, 2004, J ALLERGY CLIN IMMUN, V114, P1463, DOI 10.1016/j.jaci.2004.09.006; Niehues T, 2004, J ALLERGY CLIN IMMUN, V114, P1456, DOI 10.1016/j.jaci.2004.08.047; Notarangelo L, 2004, J ALLERGY CLIN IMMUN, V114, P677, DOI 10.1016/j.jaci.2004.06.044; O'Hagan DT, 2004, IMMUNOL REV, V199, P191, DOI 10.1111/j.0105-2896.2004.00153.x; Orange JS, 2004, J ALLERGY CLIN IMMUN, V114, P650, DOI 10.1016/j.jaci.2004.06.052; Orange JS, 2004, J ALLERGY CLIN IMMUN, V113, P725, DOI 10.1016/j.jaci.2004.01.762; Pace E, 2004, J ALLERGY CLIN IMMUN, V114, P1216, DOI 10.1016/j.jaci.2004.07.052; Rakoff-Nahoum S, 2004, CELL, V118, P229, DOI 10.1016/j.cell.2004.07.002; Salzer U, 2004, CLIN IMMUNOL, V113, P234, DOI 10.1016/j.clim.2004.07.002; Spiegelberg HL, 2002, CURR OPIN MOL THER, V4, P64; Sullivan KE, 2004, CURR OPIN ALLERGY CL, V4, P505, DOI 10.1097/00130832-200412000-00006; Tangsinmankong N, 2004, J ALLERGY CLIN IMMUN, V113, P742, DOI 10.1016/j.jaci.2004.01.768; Upham JW, 2004, J ALLERGY CLIN IMMUN, V114, P1202, DOI 10.1016/j.jaci.2004.06.051; Wen L, 2004, J ALLERGY CLIN IMMUN, V113, P585, DOI 10.1016/j.jaci.2004.02.003; Winchester R, 2004, JAIDS-J ACQ IMM DEF, V36, P659, DOI 10.1097/00126334-200406010-00002; Wittmann M, 2004, J ALLERGY CLIN IMMUN, V114, P965, DOI 10.1016/j.jaci.2004.06.033	54	24	31	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2005	116	2					411	418		10.1016/j.jaci.2005.05.010	http://dx.doi.org/10.1016/j.jaci.2005.05.010			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017ID	16083798	Bronze			2022-12-18	WOS:000235686400026
J	Ameredes, BT; Calhoun, WJ				Ameredes, BT; Calhoun, WJ			Modulation of GM-CSF release by enantiomers of beta-agonists in human airway smooth muscle	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						albuterol; beta-receptors; cAMP; formoterol; inverse agonist; levalbuterol; propranolol; racemic	(S)-ALBUTEROL INCREASES; ADRENERGIC AGONISTS; CELLS; ASTHMA; BETA(2)-ADRENOCEPTOR; ALBUTEROL; CYTOKINE; HYPERRESPONSIVENESS; GLUCOCORTICOIDS; TRANSCRIPTION	Background: beta(2)-Adrenergic receptor agonists can reduce the release of GM-CSF by human airway smooth muscle cells (HASMCs). These effects are considered anti-inflammatory and are ascribed to the activity of the (R)-enantiomer within the racemate of the agonist. However, the effect of the (S)enantiomer on GM-CSF release, once thought to be inert, has not been extensively explored. Objective: We hypothesized that the (S)-enantiomer may counter the effects of the (R)-enantiomer, potentially increasing GM-CSF release. Therefore, the effects of administration of individual and combined enantiomers on GM-CSF release were examined. Methods: Cultured HASMCs were stimulated with IL-1 beta, TNF-alpha, and IFN-gamma and treated with (R)-enantiomers and (S)-enantiomers of albuterol and formoterol, with and without propranolol and ICI-118,551, and in combination with dexamethasone. GM-CSF in the resulting conditioned media was assessed by ELISA. Results: (R)-enantiomers significantly reduced GM-CSF release by as much as 41% (P < .05), which was reversible with propranolol. In contrast, (S)-enantiomers significantly increased GM-CSF release by as much as 34% (P < .05) over release with no drug, and by 25% to 40% (P < .05) when added with (R)-enantiomers. The decremental effect of dexamethasone was amplified by (R)-enantiomers but inhibited by (S)-enantiomers. Both propranolol and ICI-118,551 alone increased GM-CSF release in a concentration-dependent fashion, similar to (S)-enantiomers. Conclusion: We conclude that GM-CSF release by HASMC is downregulated by (R)-enantiomers and enhanced by (S)-enantiomers. The reversal of (R)-enantiomer and dexamethasone effects by the (S)-enantiomer suggests suppression of their anti-inflammatory effects, perhaps through an antagonistic mechanism similar to propranolol.	Univ Pittsburgh, Sch Med,Div Pulm Allergy & Crit Care Med, Montefiore Univ Hosp, Asthma Allergy & Airway Res Ctr, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; UPMC Presbyterian	Ameredes, BT (corresponding author), Univ Pittsburgh, Sch Med,Div Pulm Allergy & Crit Care Med, Montefiore Univ Hosp, Asthma Allergy & Airway Res Ctr, 628NW,3459 5th Ave, Pittsburgh, PA 15213 USA.	ameredesbt@upmc.edu		Calhoun, William/0000-0001-7075-712X				Agrawal DK, 2004, J ALLERGY CLIN IMMUN, V113, P503, DOI 10.1016/j.jaci.2003.12.039; ANDERSON GP, 1993, LIFE SCI, V52, P2145, DOI 10.1016/0024-3205(93)90729-M; Atabai K, 2002, INTENS CARE MED, V28, P705, DOI 10.1007/s00134-002-1282-x; Baker JG, 2003, MOL PHARMACOL, V64, P1357, DOI 10.1124/mol.64.6.1357; Baramki D, 2002, J ALLERGY CLIN IMMUN, V109, P449, DOI 10.1067/mai.2002.122159; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BROIDE DH, 1992, J ALLERGY CLIN IMMUN, V89, P958, DOI 10.1016/0091-6749(92)90218-Q; CHIDIAC P, 1994, MOL PHARMACOL, V45, P490; Cho SH, 2001, INT ARCH ALLERGY IMM, V124, P478, DOI 10.1159/000053783; Currie GP, 2003, BRIT J CLIN PHARMACO, V56, P11, DOI 10.1046/j.1365-2125.2003.01831.x; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; Dhand R, 1999, AM J RESP CRIT CARE, V160, P1136, DOI 10.1164/ajrccm.160.4.9812074; Elias JA, 1997, AM J PHYSIOL-LUNG C, V273, pL648, DOI 10.1152/ajplung.1997.273.3.L648; Endo T, 1997, PULM PHARMACOL THER, V10, P81, DOI 10.1006/pupt.1997.0078; Farmer P, 2000, AM J PHYSIOL-LUNG C, V279, pL675, DOI 10.1152/ajplung.2000.279.4.L675; Gerthoffer WT, 2003, RESP PHYSIOL NEUROBI, V137, P237, DOI 10.1016/S1569-9048(03)00150-2; Gumbhir-Shah K, 1998, J CLIN PHARMACOL, V38, P1096; Hallsworth MP, 1998, AM J RESP CELL MOL, V19, P910, DOI 10.1165/ajrcmb.19.6.3275; Hallsworth MP, 2001, AM J RESP CRIT CARE, V164, P688, DOI 10.1164/ajrccm.164.4.2011004; Handley D, 1999, J ALLERGY CLIN IMMUN, V104, pS69, DOI 10.1016/S0091-6749(99)70276-9; Handley DA, 2002, PULM PHARMACOL THER, V15, P135, DOI 10.1006/pupt.2001.0327; HARTLEY D, 1971, J MED CHEM, V14, P895, DOI 10.1021/jm00291a036; Hirst SJ, 1996, EUR RESPIR J, V9, P808, DOI 10.1183/09031936.96.09040808; Izeboud CA, 2000, N-S ARCH PHARMACOL, V362, P184, DOI 10.1007/s002100000281; KERREBIJN KF, 1990, LUNG, V168, P142, DOI 10.1007/BF02718127; Kleinert H, 1996, MOL PHARMACOL, V49, P15; Lazzeri N, 2001, AM J RESP CELL MOL, V24, P44, DOI 10.1165/ajrcmb.24.1.4027; Ma DM, 1999, MOL PHARMACOL, V55, P50, DOI 10.1124/mol.55.1.50; MAZZONI L, 1994, PULM PHARMACOL, V7, P367, DOI 10.1006/pulp.1994.1043; Milligan G, 1997, TRENDS PHARMACOL SCI, V18, P468, DOI 10.1016/S0165-6147(97)90685-4; Mitra S, 1998, MOL PHARMACOL, V53, P347, DOI 10.1124/mol.53.3.347; Nelson HS, 1998, J ALLERGY CLIN IMMUN, V102, P943, DOI 10.1016/S0091-6749(98)70332-X; Newman SP, 1984, AEROSOLS LUNG, P197; Nielson CP, 1998, AM J RESP CRIT CARE, V157, P184, DOI 10.1164/ajrccm.157.1.9704070; *NIH, 1997, NAT ASTHM ED PREV PR; PANETTIERI RA, 1989, AM J PHYSIOL, V256, pC329, DOI 10.1152/ajpcell.1989.256.2.C329; Pascual RM, 2001, AM J PHYSIOL-LUNG C, V281, pL1425, DOI 10.1152/ajplung.2001.281.6.L1425; Penn RB, 1996, CLIN REV ALLERG IMMU, V14, P37, DOI 10.1007/BF02772201; Roth M, 2002, LANCET, V360, P1293, DOI 10.1016/S0140-6736(02)11319-5; Saunders MA, 1997, BRIT J PHARMACOL, V120, P545, DOI 10.1038/sj.bjp.0700998; SEARS MR, 1994, DRUG SAFETY, V11, P259, DOI 10.2165/00002018-199411040-00005; Shore SA, 2003, RESP PHYSIOL NEUROBI, V137, P179, DOI 10.1016/S1569-9048(03)00146-0; SLEIGH MA, 1988, AM REV RESPIR DIS, V137, P726, DOI 10.1164/ajrccm/137.3.726; Stevens PA, 1998, BRIT J PHARMACOL, V123, P335, DOI 10.1038/sj.bjp.0701600; TAYLOR DR, 1993, THORAX, V48, P134, DOI 10.1136/thx.48.2.134; TOMLINSON PR, 1995, BIOCHEM PHARMACOL, V49, P1809, DOI 10.1016/0006-2952(94)00532-Q; Umino T, 2000, AM J RESP CELL MOL, V22, P702, DOI 10.1165/ajrcmb.22.6.3806; Volcheck GW, 1998, J ALLERGY CLIN IMMUN, V101, pS35; Ye RD, 2000, AM J PHYSIOL-LUNG C, V279, pL615, DOI 10.1152/ajplung.2000.279.4.L615; Zhang XY, 1998, AM J PHYSIOL-LUNG C, V274, pL32, DOI 10.1152/ajplung.1998.274.1.L32	50	24	26	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2005	116	1					65	72		10.1016/j.jaci.2005.03.007	http://dx.doi.org/10.1016/j.jaci.2005.03.007			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IC	15990776				2022-12-18	WOS:000235686300011
J	Busse, PJ; Wang, JJ; Halm, EA				Busse, PJ; Wang, JJ; Halm, EA			Allergen sensitization evaluation and allergen avoidance education in an inner-city adult cohort with persistent asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; adult; education; allergen evaluation	INDOOR ALLERGENS; MANAGEMENT GUIDELINES; SPECIALTY CARE; RISK-FACTORS; EXPOSURE; CHILDREN; INTERVENTION; SENSITIVITY; SEVERITY; ALTITUDE	Background: Asthma morbidity, mortality, and health services utilization are highest among inner-city populations. The National Asthma Education and Prevention Program Expert Panel recommends that all patients with moderate and severe persistent asthma be evaluated for sensitization to environmental allergens. Objective: This study examined whether a cohort of inner-city adults hospitalized with asthma had been evaluated for allergen sensitization, received avoidance counseling, and followed through on these recommendations. Methods: One hundred sixty-nine eligible patients who were part of a prospective cohort of all adults hospitalized in an inner-city hospital over a consecutive 12-month period completed a questionnaire to assess allergen sensitization evaluation, avoidance education, and adherence. Results: Overall, 60% of patients had ever been evaluated for allergen sensitization. Among those who were evaluated, 94.0% were sensitized to at least one antigen: 91.5% to dust mites, 90.5% to outdoor allergens, 77.9% to cats, 69.5% to dogs, 68.4% to molds, and 61% to cockroaches. Approximately half of the patients sensitized to dust mite (55.1%) or mold (52.8%) were given any avoidance-abatement advice. Patient adherence to this advice was highly variable. Allergen sensitization evaluation was more likely among women (odds ratio, 3.05; CI, 1.64-8.64) and those who use oral steroids most or all of the time (odds ratio, 7.14; CI, 2.25-22.56) and less likely among smokers (odds ratio, 0.26; CI, 0.11-0.61). Conclusion: In this population of inner-city adults hospitalized with asthma, the quality of allergen sensitization evaluation, avoidance education, and patient adherence with these recommendations was suboptimal.	Mt Sinai Sch Med, Dept Clin Immunol, New York, NY 10029 USA; Mt Sinai Sch Med, Dept Hlth Policy, New York, NY 10029 USA; Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Busse, PJ (corresponding author), Mt Sinai Sch Med, Dept Clin Immunol, 1425 Madison Ave, New York, NY 10029 USA.	paula.busse@mssm.edu			AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS009973] Funding Source: NIH RePORTER; AHRQ HHS [R01 HS09973] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Cabana MD, 2004, J ALLERGY CLIN IMMUN, V114, P352, DOI 10.1016/j.jaci.2004.04.047; CALHOUN WJ, 1993, AM REV RESPIR DIS, V147, P1465, DOI 10.1164/ajrccm/147.6_Pt_1.1465; Callahan KA, 2003, ANN ALLERG ASTHMA IM, V90, P302, DOI 10.1016/S1081-1206(10)61798-X; CARR W, 1992, AM J PUBLIC HEALTH, V82, P59, DOI 10.2105/AJPH.82.1.59; Chew GL, 1999, ALLERGY, V54, P1058, DOI 10.1034/j.1398-9995.1999.00003.x; COLDITZ GA, 1986, AM J EPIDEMIOL, V123, P894, DOI 10.1093/oxfordjournals.aje.a114319; Custovic A, 1998, THORAX, V53, P63, DOI 10.1136/thx.53.1.63; de Blay F, 2003, ALLERGY, V58, P27, DOI 10.1034/j.1398-9995.2003.23674.x; DENSONLINO JM, 1993, ANN ALLERGY, V71, P130; Diette GB, 2001, PEDIATRICS, V108, P432, DOI 10.1542/peds.108.2.432; Doerschug KC, 1999, AM J RESP CRIT CARE, V159, P1735, DOI 10.1164/ajrccm.159.6.9809051; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573, DOI 10.1164/ajrccm/147.3.573; Kitch BT, 2000, ENVIRON HEALTH PERSP, V108, P301, DOI 10.2307/3454347; KM SL, 1998, ASTHMA HOSP MORTALIT; Legorreta AP, 1998, ARCH INTERN MED, V158, P457, DOI 10.1001/archinte.158.5.457; Leone FT, 1999, RESP MED, V93, P788, DOI 10.1016/S0954-6111(99)90263-9; Meng YY, 1999, J EVAL CLIN PRACT, V5, P213, DOI 10.1046/j.1365-2753.1999.00177.x; Moore WC, 2001, J ALLERGY CLIN IMMUN, V108, P908, DOI 10.1067/mai.2001.119413; Morgan WJ, 2004, NEW ENGL J MED, V351, P1068, DOI 10.1056/NEJMoa032097; *NAT ASTHM ED PREV, 1997, NAT I HLTH NAT HEART; Nelson HS, 2000, J ALLERGY CLIN IMMUN, V105, pS628, DOI 10.1067/mai.2000.106154; PERONI DG, 1994, AM J RESP CRIT CARE, V149, P1442, DOI 10.1164/ajrccm.149.6.8004296; Platts-Mills TAE, 2000, J ALLERGY CLIN IMMUN, V106, P787, DOI 10.1067/mai.2000.110548; PLATTSMILLS TAE, 1982, LANCET, V2, P675; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Sarpong SB, 1998, ANN ALLERG ASTHMA IM, V80, P303, DOI 10.1016/S1081-1206(10)62973-0; Sicherer SH, 2004, J ALLERGY CLIN IMMUN, V114, P159, DOI 10.1016/j.jaci.2004.04.018; Stevenson LA, 2001, J ALLERGY CLIN IMMUN, V108, P747, DOI 10.1067/mai.2001.119410; Tunnicliffe WS, 1999, EUR RESPIR J, V13, P654, DOI 10.1183/09031936.99.13365499; *UN HOSP FUND STAF, NEW YORK CIT COMM HL; VERVLOET D, 1982, J ALLERGY CLIN IMMUN, V69, P290, DOI 10.1016/S0091-6749(82)80006-7; Wu AW, 2001, ARCH INTERN MED, V161, P2554, DOI 10.1001/archinte.161.21.2554	32	24	24	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2005	116	1					146	152		10.1016/j.jaci.2005.03.031	http://dx.doi.org/10.1016/j.jaci.2005.03.031			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IC	15990788	Bronze			2022-12-18	WOS:000235686300023
J	Kim, C; Feldman, HI; Joffe, M; Tenhave, T; Boston, R; Apter, AJ				Kim, C; Feldman, HI; Joffe, M; Tenhave, T; Boston, R; Apter, AJ			Influences of earlier adherence and symptoms on current symptoms: A marginal structural models analysis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; adherence; marginal structural models; biostatistics; time-varying analysis; symptoms; inhaled corticosteroids	MEDICATION ADHERENCE; INHALED STEROIDS; ASTHMA; EPIDEMIOLOGY; PERCEPTION; PATTERNS	Background: The morbidity and mortality associated with asthma are suspected to be a result, in part, of poor adherence to inhaled corticosteroid regimens. One influence on adherence may be the perception of symptoms. Because symptoms and adherence affect each other over time, a conventional statistical approach for studying these relationships may provide biased results. Objective: To understand the influence of previous asthma symptoms and previous adherence on current symptoms. Methods: A total of 76 adults, mean age 48 years 15 years, with moderate or severe persistent asthma underwent 6 weeks of electronic monitoring of their use of inhaled corticosteroids and completed a daily symptom diary. We estimated the effect or earlier adherence on final symptoms by using marginal structural models, estimated by using a weighted estimation technique. Results: Morning was better than evening adherence, which declined over the observation period. The variability of adherence appeared to increase over the observation period. In addition, earlier adherence predicted current adherence more strongly than earlier symptoms predicted current adherence. There was no overall significant relationship between cumulative adherence and final symptoms. Conclusion: These data indicate that accurately determining past adherence will help identify patients to target to improve. future adherence. These analyses are important for their understanding time-varying measures in the clinical setting.	Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA; Univ Penn, Dept Med, Div Pulm Allergy & Crit Care Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania	Apter, AJ (corresponding author), Hosp Univ Penn, 3600 Spruce St,829 Gates Bldg, Philadelphia, PA 19104 USA.	apter@mail.med.upenn.edu			NCRR NIH HHS [M01 RR 00040] Funding Source: Medline; NHLBI NIH HHS [HL 04337-01] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000040] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL004337] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Apter AJ, 1997, J ALLERGY CLIN IMMUN, V99, P605, DOI 10.1016/S0091-6749(97)70020-4; Apter AJ, 1998, AM J RESP CRIT CARE, V157, P1810, DOI 10.1164/ajrccm.157.6.9712007; Apter AJ, 2003, J ALLERGY CLIN IMMUN, V111, P1219, DOI 10.1067/mai.2003.1479; Bodnar LM, 2004, AM J EPIDEMIOL, V159, P926, DOI 10.1093/aje/kwh131; Chu HW, 1998, AM J RESP CRIT CARE, V158, P1936, DOI 10.1164/ajrccm.158.6.9712073; Colice GL, 1999, AM J RESP CRIT CARE, V160, P1962, DOI 10.1164/ajrccm.160.6.9902112; Diette GB, 1999, ARCH INTERN MED, V159, P2697, DOI 10.1001/archinte.159.22.2697; DOLCE JJ, 1991, CHEST, V99, P837, DOI 10.1378/chest.99.4.837; MAWHINNEY H, 1991, ANN ALLERGY, V66, P294; MCFADDEN ER, 1973, NEW ENGL J MED, V288, P221, DOI 10.1056/NEJM197302012880501; MORISKY DE, 1986, MED CARE, V24, P67, DOI 10.1097/00005650-198601000-00007; *NAT I HLTH NAT HE, 2002, PUBL NAT I HLTH NAT; *NAT I HLTH NAT HE, 1997, PUBL NAT I HLTH NAT; Onyirimba F, 2003, ANN ALLERG ASTHMA IM, V90, P411, DOI 10.1016/S1081-1206(10)61825-X; Panzer SE, 2003, J ALLERGY CLIN IMMUN, V111, P308, DOI 10.1067/mai.2003.65; Robins JM, 2000, EPIDEMIOLOGY, V11, P550, DOI 10.1097/00001648-200009000-00011; RUBINFELD AR, 1976, LANCET, V1, P882; SHERBOURNE CD, 1991, SOC SCI MED, V32, P705, DOI 10.1016/0277-9536(91)90150-B	18	24	26	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2005	115	4					810	814		10.1016/j.jaci.2004.11.032	http://dx.doi.org/10.1016/j.jaci.2004.11.032			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	916GM	15806003	Bronze			2022-12-18	WOS:000228373400022
J	Vargas, PA; Simpson, PM; Wheeler, JG; Goel, R; Feild, CR; Tilford, JM; Jones, SM				Vargas, PA; Simpson, PM; Wheeler, JG; Goel, R; Feild, CR; Tilford, JM; Jones, SM			Characteristics of children with asthma who are enrolled in a Head Start program	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						preschool aged; asthma; minority; low-income; African American; Head Start; environmental tobacco exposure; allergy; atopy; Arkansas	ENVIRONMENTAL TOBACCO-SMOKE; INNER-CITY CHILDREN; INHALED CORTICOSTEROIDS; CHILDHOOD ASTHMA; EXPOSURE; BUDESONIDE; BETA-2-AGONIST; TERBUTALINE; PREVENTION; NICOTINE	Background: Asthma is an increasing public health concern that disproportionally affects children. In 1998, the Centers for Disease Control identified children aged 0 to 4 years as the "driving force" behind climbing rates of asthma-related emergency department visits and hospitalizations. Despite the significant asthma burden in preschool children, few studies characterize this population. Objective: This study identifies and characterizes children at risk for asthma who are enrolled in a local Head Start program. Methods: Caregivers of 368 children aged 3 to 5 years who were identified by using an asthma survey were recruited. Data were collected on demographics, health care use and access, medication use, symptoms, and trigger exposure. Exposure to tobacco smoke was determined by urinary cotinine and allergen sensitization by skin prick test. Results: At baseline, 64% of the children had more than 1 emergency department visit for asthma in their lifetime, whereas 31% had more than 1 visit in the previous 6 months. Caretakers reported smoking in 37% of households with cotinine exceeding 20 ng/mg in 27% of the sample. Twenty-one percent reported symptoms consistent with intermittent asthma, and 79% reported symptoms consistent with persistent asthma. Forty-five percent of the children reported nighttime symptoms more than 1 night per week. Seventy-one percent had positive test results for more than 1 allergen, and 42% had positive test results for more than 3 allergens. Only 32% of children with persistent asthma had both rescue and controller medications. Conclusion: Children with asthma enrolled in a Head Start program have significant environmental tobacco smoke exposure, are highly atopic and symptomatic, and do not receive appropriate medication treatment. Overall, children in the study had poor asthma control. This high-risk group could benefit from case management programs.	Arkansas Childrens Hosp, Ctr Appl Res & Evaluat, Little Rock, AR 72202 USA; Univ Arkansas Med Sci, Dept Pediat, Little Rock, AR 72205 USA	Arkansas Children's Hospital; University of Arkansas System; University of Arkansas Medical Sciences	Vargas, PA (corresponding author), Arkansas Childrens Hosp, Ctr Appl Res & Evaluat, 800 Marshall St,Slot 512-26, Little Rock, AR 72202 USA.	VargasPerlaA@uams.edu		Vargas, Perla/0000-0003-2852-3922	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [U18HS011062] Funding Source: NIH RePORTER	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Blais L, 1998, THORAX, V53, P1025, DOI 10.1136/thx.53.12.1025; Blais L, 1998, AM J RESP CRIT CARE, V158, P126, DOI 10.1164/ajrccm.158.1.9707107; CHILMONCZYK BA, 1993, NEW ENGL J MED, V328, P1665, DOI 10.1056/NEJM199306103282303; Cornelius MD, 2003, NICOTINE TOB RES, V5, P333, DOI 10.1080/1462220031000094141; FOSARELLI P, 1985, American Journal of Preventive Medicine, V1, P23; Goodman DC, 1998, PEDIATRICS, V101, P208, DOI 10.1542/peds.101.2.208; GREENBERG RA, 1984, NEW ENGL J MED, V310, P1075, DOI 10.1056/NEJM198404263101703; HAAHTELA T, 1994, NEW ENGL J MED, V331, P700, DOI 10.1056/NEJM199409153311103; HAAHTELA T, 1991, NEW ENGL J MED, V325, P388, DOI 10.1056/NEJM199108083250603; Haahtela T, 1998, CLIN EXP ALLERGY, V28, P133; HALFON N, 1993, PEDIATRICS, V91, P56; Jones CA, 2004, CHEST, V125, P924, DOI 10.1378/chest.125.3.924; Kattan M, 1997, PEDIATR PULM, V24, P253, DOI 10.1002/(SICI)1099-0496(199710)24:4<253::AID-PPUL4>3.0.CO;2-L; Konig P, 2002, PEDIATR PULM, V33, P307, DOI 10.1002/ppul.10090; Ladebauche P, 2001, Pediatr Nurs, V27, P396; LAITINEN LA, 1992, J ALLERGY CLIN IMMUN, V90, P32, DOI 10.1016/S0091-6749(06)80008-4; Lang DM, 1997, ARCH INTERN MED, V157, P1193, DOI 10.1001/archinte.157.11.1193; MALVEAUX FJ, 1993, J ASTHMA, V30, P431, DOI 10.3109/02770909309056751; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; McGill KA, 1998, PEDIATRICS, V102, P77, DOI 10.1542/peds.102.1.77; *NAT ASTHM ED PREV, 1997, NIH PUBL; *NAT CTR HLTH STAT, 1996, US VIT STAT; Perez-Stable EJ, 1998, JAMA-J AM MED ASSOC, V280, P152, DOI 10.1001/jama.280.2.152; Public Health Service guidelines for the management of health-care worker exposures to HIV and recommendations for postexposure prophylaxis. Centers for Disease Control and Prevention, 1998, MMWR RECOMMENDATIONS, V47, P1; *STAT PACK SAS I I, 2004, SAS 9 1; WEITZMAN M, 1990, AM J DIS CHILD, V144, P1189, DOI 10.1001/archpedi.1990.02150350021016; Winkelstein ML, 1997, ANN ALLERG ASTHMA IM, V78, P419, DOI 10.1016/S1081-1206(10)63206-1; WOOD DL, 1990, PEDIATRICS, V86, P666; Wood RA, 2002, JAMA-J AM MED ASSOC, V288, P745, DOI 10.1001/jama.288.6.745; ZIGLER E, 1997, PROJECT HEAD START L	30	24	25	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2004	114	3					499	504		10.1016/j.jaci.2004.05.025	http://dx.doi.org/10.1016/j.jaci.2004.05.025			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	853AX	15356547				2022-12-18	WOS:000223799600004
J	Lynn, J; Knight, AK; Kamoun, M; Levinson, AI				Lynn, J; Knight, AK; Kamoun, M; Levinson, AI			A 55-year-old man with hypogammaglobulinemia, lymphopenia, and unrelenting cutaneous warts	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						warts; lymphangiectasia; hypogammaglobulinemia; hypoalbuminemia; lymphopenia; CD4(+)CD45RA(+) T cells	PROTEIN-LOSING ENTEROPATHY; COMMON VARIABLE IMMUNODEFICIENCY; CHRONIC LYMPHOCYTIC-LEUKEMIA; INTESTINAL LYMPHANGIECTASIA; CONSTRICTIVE PERICARDITIS; MONOCLONAL GAMMOPATHY; SELECTIVE LOSS; LONG-TERM; T-CELLS; LYMPHOMA	A 55-year-old white man with a history of hypertension, fibromyalgia, and colonic polyps presented with unrelenting plantar warts on his hands and feet for the past 4 years. He was otherwise healthy and without a history of recurrent infections. Physical examination was unremarkable except for extensive warts on his hands and feet. Pertinent laboratory findings included hypoalbuminemia, hypogammaglobulinemia, and lymphopenia most severely affecting CD4(+) T cells. Testing for HIV infection was negative. This clinical and laboratory presentation suggested a combined Immoral and cellular immunodeficiency syndrome that could be best explained by loss of lymphocytes, immunoglobulins, and other serum proteins. Additional immunologic testing revealed a marked reduction in peripheral blood naive (CD4(+)CD45RA(+)) T cells. A 24-hour stool collection showed a markedly elevated a,antitrypsin level. These findings were most consistent with the diagnosis of intestinal lymphangiectasia, a type of protein-losing enteropathy associated with hypoalbuminemia, hypogammaglobulinemia, and lymphopenia, characterized by a preferential loss of naive CD4(+) T cells into the gastrointestinal tract. This case illustrates the importance of considering intestinal loss of immunoglobulins and lymphocytes in the differential diagnosis of the adult patient who presents with laboratory evidence of a combined humoral and cellular immunodeficiency. It also underscores the diagnostic utility of the clinical immunology laboratory and how flow cytometry, in particular, can contribute to an understanding of pathogenic mechanisms.	Univ Penn, Sch Med, Pulm Allergy & Crit Care Div, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pathol & Lab Med, Allergy & Immunol Sect, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Levinson, AI (corresponding author), Univ Penn, Sch Med, Pulm Allergy & Crit Care Div, 1014 BRB2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.	frog@mail.med.upenn.edu						BAC DJ, 1995, LANCET, V345, P1639, DOI 10.1016/S0140-6736(95)90145-0; BLAESE RM, 1971, J CLIN INVEST, V50, P2331, DOI 10.1172/JCI106731; Bouhnik Y, 2000, GUT, V47, P296, DOI 10.1136/gut.47.2.296; Brentjens MH, 2002, DERMATOL CLIN, V20, P315, DOI 10.1016/S0733-8635(01)00028-6; BRODER S, 1981, GASTROENTEROLOGY, V80, P166; CHEW CK, 1966, CAN MED ASSOC J, V95, P1183; CUNNINGHAMRUNDLES S, 1981, J CLIN IMMUNOL, V1, P65, DOI 10.1007/BF00915478; FLORENT C, 1981, GASTROENTEROLOGY, V81, P777; Fuss IJ, 1998, EUR J IMMUNOL, V28, P4275, DOI 10.1002/(SICI)1521-4141(199812)28:12<4275::AID-IMMU4275>3.0.CO;2-P; Hernandez PA, 2003, NAT GENET, V34, P70, DOI 10.1038/ng1149; KONDRATENKO I, 1997, CLIN EXP IMMUNOL, V108, P93; Kyle RA, 2002, NEW ENGL J MED, V346, P564, DOI 10.1056/NEJMoa01133202; MALACRIDA V, 1987, J CLIN PATHOL, V40, P793, DOI 10.1136/jcp.40.7.793; MULLER C, 1991, DIGEST DIS SCI, V36, P116, DOI 10.1007/BF01300099; NELSON DL, 1975, J PEDIATR-US, V86, P548, DOI 10.1016/S0022-3476(75)80145-4; Ossandon A, 2002, LUPUS, V11, P465, DOI 10.1191/0961203302lu233xx; Pangalis GA, 1999, SEMIN HEMATOL, V36, P104; ROZMAN C, 1988, CANCER-AM CANCER SOC, V61, P279, DOI 10.1002/1097-0142(19880115)61:2<279::AID-CNCR2820610215>3.0.CO;2-4; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; STAGG AJ, 1994, CLIN EXP IMMUNOL, V96, P48; STROBER W, 1967, J CLIN INVEST, V46, P1643, DOI 10.1172/JCI105656; Tarr PE, 2001, MEDICINE, V80, P123, DOI 10.1097/00005792-200103000-00005; THOMAS DW, 1981, GASTROENTEROLOGY, V80, P776; TIFT WL, 1975, ARCH DIS CHILD, V50, P269, DOI 10.1136/adc.50.4.269; WALDMANN TA, 1972, J CLIN INVEST, V51, P2162, DOI 10.1172/JCI107023; WILKINSON P, 1965, NEW ENGL J MED, V273, P1178, DOI 10.1056/NEJM196511252732202; WOCHNER RD, 1966, J CLIN INVEST, V45, P321, DOI 10.1172/JCI105346; YAMAMOTO H, 1989, CLIN EXP IMMUNOL, V75, P196	28	24	25	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2004	114	2					409	414		10.1016/j.jaci.2004.02.033	http://dx.doi.org/10.1016/j.jaci.2004.02.033			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	847OU	15316525				2022-12-18	WOS:000223405600032
J	Goleva, E; Dunlap, A; Leung, DYM				Goleva, E; Dunlap, A; Leung, DYM			Differential control of T(H)2 versus T(H)2 cell responses by the combination of low-dose steroids with beta(2)-adrenergic agonists	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							SMOOTH-MUSCLE-CELLS; GLUCOCORTICOID-RECEPTOR; AIRWAY INFLAMMATION; CYTOKINE PRODUCTION; SALMETEROL; ASTHMA; BETA(2)-AGONISTS; CORTICOSTEROIDS; PHOSPHODIESTERASE-4; PHARMACOKINETICS	Background: Combination treatment with steroids and long-acting beta(2)-agonists provides greater asthma control than simply increasing the dose of steroids. Objective: Although the effects of combination treatment with steroids and long-acting beta(2)-agonists have been attributed to their anti-inflammatory and bronchodilator effects, the ability of this combination to act synergistically on T cells has not been explored. Methods: PBMCs from control subjects and allergic asthmatic patients were stimulated with PHA in the presence of low doses of fluticasone propionate (FP) with or without salmeterol for 72 hours. The inhibition of T-cell proliferation, cytokine production, and glucocorticoid receptor translocation was measured. Results: Both groups showed a similar degree of inhibition of PHA-induced T-cell proliferation with FP (inhibitory concentration of 50% approximate to 10(-9) mol/L) alone. Use of lower concentrations of FP (10(-12) to 10(-11) mol/L) in combination with salmeterol (10(-10) to 10(-7) mol/L) in control subjects provided similar inhibition of proliferation. This combination treatment was associated with significantly greater glucocorticoid receptor translocation into the cell nucleus compared with that seen with FP alone (10(-12) mol/L; P<.01). In contrast, FP-salmeterol failed to act synergistically in asthmatic patients. The 2-drug combination significantly inhibited production of TNF-alpha and IFN-gamma in both groups (P<.05) but failed to inhibit T(H)2 cytokine (IL-5 and IL-13) production by PBMCs from asthmatic patients. Because allergic inflammation is associated with increased levels of cellular phosphodiesterases that might degrade salmeterol-induced cyclic adenosine monophosphate, rolipram (10(-6) mol/ L), a phosphodiesterase 4 inhibitor, was added to the FP-salmeterol combination. This triple combination of drugs enhanced inhibitory activity of low-dose steroids on T-cell proliferation in asthmatic patients and inhibited IL-13 production. Conclusion: These data suggest that beta(2)-agonists in combination with low doses of steroids can suppress T-cell proliferation and TO cytokine production from healthy individuals, but suppression of T cells with a combination of FP and salmeterol in asthmatic patients requires inhibition of phosphodiesterases.	Natl Jewish Med & Res ctr, Dept Pediat, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Dept Pediat, Denver, CO 80262 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Leung, DYM (corresponding author), Natl Jewish Med & Res ctr, Dept Pediat, 1400 Jackson St,Room K926i, Denver, CO 80206 USA.	leungd@njc.org			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036577] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL36577] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Agnello D, 2003, J CLIN IMMUNOL, V23, P147, DOI 10.1023/A:1023381027062; Allen David B, 2003, J Allergy Clin Immunol, V112, pS1, DOI 10.1016/S0091-6749(03)01859-1; Anstead MI, 1998, AM J RESP CRIT CARE, V157, P990, DOI 10.1164/ajrccm.157.3.9704071; Baramki D, 2002, J ALLERGY CLIN IMMUN, V109, P449, DOI 10.1067/mai.2002.122159; Barnes PJ, 2002, EUR RESPIR J, V19, P182, DOI 10.1183/09031936.02.00283202; Bodwell JE, 1998, J STEROID BIOCHEM, V65, P91, DOI 10.1016/S0960-0760(97)00185-4; Eickelberg O, 1999, J BIOL CHEM, V274, P1005, DOI 10.1074/jbc.274.2.1005; Giembycz MA, 1996, TRENDS PHARMACOL SCI, V17, P331, DOI 10.1016/0165-6147(96)10039-0; Goleva E, 2002, J IMMUNOL, V169, P5934, DOI 10.4049/jimmunol.169.10.5934; Handley D A, 2000, Curr Opin Pulm Med, V6, P43, DOI 10.1097/00063198-200001000-00009; Holen E, 1998, APMIS, V106, P849, DOI 10.1111/j.1699-0463.1998.tb00231.x; Houslay MD, 2003, BIOCHEM J, V370, P1, DOI 10.1042/BJ20021698; Johnson M, 1998, AM J RESP CRIT CARE, V158, pS146, DOI 10.1164/ajrccm.158.supplement_2.13tac110; Kanehiro A, 2001, AM J RESP CRIT CARE, V163, P173, DOI 10.1164/ajrccm.163.1.2001118; KRAUSE W, 1990, EUR J CLIN PHARMACOL, V38, P71, DOI 10.1007/BF00314807; Leung DYM, 2003, J ALLERGY CLIN IMMUN, V111, P3, DOI 10.1067/mai.2003.97; Liggett Stephen B., 2002, Journal of Allergy and Clinical Immunology, V110, pS223, DOI 10.1067/mai.2002.129945; MANCHEE GR, 1993, DRUG METAB DISPOS, V21, P1022; Martin RJ, 2002, AM J RESP CRIT CARE, V165, P1377, DOI 10.1164/rccm.2105013; Moniotte S, 2001, J MOL CELL CARDIOL, V33, P2121, DOI 10.1006/jmcc.2001.1475; Moore RH, 1998, CHEST, V113, P1095, DOI 10.1378/chest.113.4.1095; Nelson HS, 2001, J ALLERGY CLIN IMMUN, V107, P397, DOI 10.1067/mai.2001.112939; Oddera S, 1998, RESPIRATION, V65, P199, DOI 10.1159/000029260; Pang LH, 2000, AM J RESP CELL MOL, V23, P79, DOI 10.1165/ajrcmb.23.1.3985; Pelaia G, 2003, LIFE SCI, V72, P1549, DOI 10.1016/S0024-3205(02)02446-3; Romagnani S, 2002, MOL IMMUNOL, V38, P881, DOI 10.1016/S0161-5890(02)00013-5; Roth M, 2002, LANCET, V360, P1293, DOI 10.1016/S0140-6736(02)11319-5; Sanders VM, 1997, J IMMUNOL, V158, P4200; Santamaria LF, 1999, J INVEST DERMATOL, V113, P82, DOI 10.1046/j.1523-1747.1999.00639.x; SEKUT L, 1995, CLIN EXP IMMUNOL, V99, P461; Szefler SJ, 2002, J ALLERGY CLIN IMMUN, V109, P410, DOI 10.1067/mai.2002.122635; Thorsson L, 2001, BRIT J CLIN PHARMACO, V52, P529, DOI 10.1046/j.0306-5251.2001.01493.x; Wahle M, 2001, CYTOKINE, V16, P205, DOI 10.1006/cyto.2001.0965; Wallin A, 2003, J ALLERGY CLIN IMMUN, V112, P72, DOI 10.1067/mai.2003.1518; Wang Z, 2002, J BIOL CHEM, V277, P26573, DOI 10.1074/jbc.M110530200; Yamamoto J, 2000, J LEUKOCYTE BIOL, V68, P568	36	24	28	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2004	114	1					183	191		10.1016/j.jaci.2004.04.001	http://dx.doi.org/10.1016/j.jaci.2004.04.001			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	836DA	15241363				2022-12-18	WOS:000222534300027
J	Arlian, LG; Vyszenski-Moher, DL; Morgan, MS				Arlian, LG; Vyszenski-Moher, DL; Morgan, MS			Mite and mite allergen removal during machine washing of laundry	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						dust mites; bleach; sodium hypochlorite; washing; Dermatophagoides farinae; allergen; detergent; laundry	HOUSE-DUST MITE; DERMATOPHAGOIDES-PTERONYSSINUS; ASTHMA; CHILDREN; TEMPERATURE; EXPOSURE	Background: Few studies have investigated live house dust mite and mite allergen removal from clothing and bedding by washing machines. No studies have investigated the transfer of mites from infested to uninfested clothing and bedding during washing. Objective: The purpose of this study was to wash different types of clothing and bedding in residential washing machines to determine the live Dermatophagoides farinae mite and allergen removal and the mite transfer from mite-infested items to mite-free items. Methods: Clothing and bedding items were machine washed in 6- and 8-lb loads in warm (36degreesC-38degreesC) or cold (22degreesC-27degreesC) water with and without recommended concentrations of laundry detergent and sodium hypochlorite bleach. Live mites and allergen present in washed versus unwashed and washed mite-infested versus washed mite-free items were compared. Results: Washing clothing and bedding in water alone, detergent, or detergent plus bleach removed 60% to 83% of the live mites. Washing removed more mites from some items than from others. When mite-infested items were washed with identical sets of mite-free items, many live mites were transferred to the previously mite-free items. Overall, 84% of Der f 1 was removed from items washed in water alone or in detergent and 98%. from items washed in detergent plus bleach. Conclusions: Washing clothing and bedding in cold or warm water with detergent or detergent plus bleach removed most allergen and a significant (P < .05) portion of live mites. Repeated washing is required to further reduce mite levels. Live mites were transferred from mite-infested to mite-free items during washing.	Wright State Univ, Dept Biol Sci, Dayton, OH 45435 USA	Wright State University Dayton	Arlian, LG (corresponding author), Wright State Univ, Dept Biol Sci, Dayton, OH 45435 USA.							ANDERSEN A, 1989, ALLERGY, V44, P396, DOI 10.1111/j.1398-9995.1989.tb04170.x; Arlian LG, 2001, J ALLERGY CLIN IMMUN, V107, pS406, DOI 10.1067/mai.2001.113670; *ASTM COMM, 1998, ANN BOOK ASTM STAND; Bischoff ERC, 1998, CLIN EXP ALLERGY, V28, P60, DOI 10.1046/j.1365-2222.1998.00192.x; Carswell F, 1996, CLIN EXP ALLERGY, V26, P386, DOI 10.1111/j.1365-2222.1996.tb00554.x; Chen P, 2001, CLIN EXP ALLERGY, V31, P1086, DOI 10.1046/j.1365-2222.2001.01127.x; Custovic A, 1998, THORAX, V53, P63, DOI 10.1136/thx.53.1.63; Custovic A, 1996, J ALLERGY CLIN IMMUN, V98, P64, DOI 10.1016/S0091-6749(96)70227-0; EHNERT B, 1992, J ALLERGY CLIN IMMUN, V90, P135, DOI 10.1016/S0091-6749(06)80024-2; Frederick JM, 1997, EUR RESPIR J, V10, P361, DOI 10.1183/09031936.97.10020361; MCDONALD LG, 1992, J ALLERGY CLIN IMMUN, V90, P599, DOI 10.1016/0091-6749(92)90132-L; MCDONALD LG, 1993, J ALLERGY CLIN IMMUN, V92, P771, DOI 10.1016/0091-6749(93)90022-8; Neal JS, 2002, ANN ALLERG ASTHMA IM, V88, P410, DOI 10.1016/S1081-1206(10)62373-3; Tovey ER, 2001, J ALLERGY CLIN IMMUN, V108, P369, DOI 10.1067/mai.2001.117799; Vanlaar CH, 2000, J ALLERGY CLIN IMMUN, V105, P1130, DOI 10.1067/mai.2000.106213; Vyszenski-Moher DL, 2002, ANN ALLERG ASTHMA IM, V88, P578, DOI 10.1016/S1081-1206(10)61889-3	16	24	25	1	12	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2003	111	6					1269	1273		10.1067/mai.2003.1547	http://dx.doi.org/10.1067/mai.2003.1547			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	688FZ	12789228				2022-12-18	WOS:000183424700016
J	Bager, P; Westergaard, T; Rostgaard, K; Nielsen, NM; Melbye, M; Aaby, P				Bager, P; Westergaard, T; Rostgaard, K; Nielsen, NM; Melbye, M; Aaby, P			Smallpox vaccination and risk of allergy and asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; allergic rhinitis; asthma; atopy; epidemiology; risk factors; smallpox vaccine; vaccination	ATOPY; ANTIBODIES; POPULATION; INFECTION; RESPONSES; SYMPTOMS; ECZEMA; AGE	Background: It has been proposed that childhood vaccinations may influence the development of allergy. Atopy and allergic diseases have increased after routine smallpox vaccination was stopped in the 1970s. Objective: we examined whether administration of smallpox vaccination during childhood was associated with a decreased risk of atopy, allergic rhinitis, and asthma. Methods: The occurrence of atopy, allergic rhinitis, and asthma was studied in nearly 2000 women participating in a national birth cohort study. Detailed information on smallpox vaccination was available from school health records. Atopic status was assessed serologically by a specific response to 11 common inhalant allergens by using serum samples obtained from the women during the period 1997 to 2001. Information on allergic rhinitis and asthma was available from telephone interviews. Results: we found no association between having been vaccinated against smallpox in childhood and risk of atopy or allergic rhinitis. Smallpox vaccination was associated with a slightly decreased risk of asthma. There was no association between age at smallpox vaccination and risk of atopy, allergic rhinitis, or asthma. Adjusting for birth cohort, sibship size, age of the woman's mother at birth, and social class in childhood did not change these results. Conclusion: Our findings do not suggest that childhood vaccination against smallpox, even if given early in life, influences the development of atopy or allergic rhinitis. The association with asthma should be interpreted with caution and needs further study.	Statens Serum Inst, Danish Epidemiol Sci Ctr, Dept Epidemiol Res, DK-2300 Copenhagen S, Denmark	Aarhus University; Statens Serum Institut	Westergaard, T (corresponding author), Statens Serum Inst, Danish Epidemiol Sci Ctr, Dept Epidemiol Res, 5 Artillerivej, DK-2300 Copenhagen S, Denmark.			Aaby, Peter/0000-0001-8331-1389; Rostgaard, Klaus/0000-0001-6220-9414; Bager, Peter/0000-0002-3577-8459; melbye, mads/0000-0001-8264-6785				Aaby P, 2000, CLIN EXP ALLERGY, V30, P644, DOI 10.1046/j.1365-2222.2000.00803.x; ANDERSEN E, 1981, ACTA NEUROL SCAND, V63, P131; Bicknell WJ, 2002, NEW ENGL J MED, V346, P1323, DOI 10.1056/NEJMsb020357; BREMAN JG, 1980, NEW ENGL J MED, V303, P1263, DOI 10.1056/NEJM198011273032204; Butland BK, 1997, BRIT MED J, V315, P717, DOI 10.1136/bmj.315.7110.717; Demkowicz WE, 1996, J VIROL, V70, P2627, DOI 10.1128/JVI.70.4.2627-2631.1996; Drazen JM, 2002, NEW ENGL J MED, V346, P1262, DOI 10.1056/NEJM2e020038; ELAD B, 1990, J INFECT DIS, V161, P446, DOI 10.1093/infdis/161.3.446; Enevoldsen B, 1980, Ugeskr Laeger, V142, P544; Ennis FA, 2002, J INFECT DIS, V185, P1657, DOI 10.1086/340517; ERIKSSON G, 1966, ACTA MED SCAND, VS, P147; Farooqi IS, 1998, THORAX, V53, P927, DOI 10.1136/thx.53.11.927; Fauci AS, 2002, NEW ENGL J MED, V346, P1319, DOI 10.1056/NEJM200204253461711; Frey SE, 2002, NEW ENGL J MED, V346, P1265, DOI 10.1056/NEJMoa020534; Frey SE, 2002, NEW ENGL J MED, V346, P1275, DOI 10.1056/NEJMoa013431; Gruber C, 2001, PEDIAT ALLERG IMM-UK, V12, P296, DOI 10.1034/j.1399-3038.2001.1r046.x; Hjortshoj A, 1974, Ugeskr Laeger, V136, P1448; Jefferson T, 1998, BRIT MED J, V317, P159, DOI 10.1136/bmj.317.7152.159; Larsen FS, 1996, J AM ACAD DERMATOL, V34, P760, DOI 10.1016/S0190-9622(96)90009-2; Linneberg A, 1999, ALLERGY, V54, P1194, DOI 10.1034/j.1398-9995.1999.00180.x; Moses AE, 2002, NEW ENGL J MED, V346, P1287, DOI 10.1056/NEJMicm010892; NINAN TK, 1992, BRIT MED J, V304, P873, DOI 10.1136/bmj.304.6831.873; ODENT MR, 1994, JAMA-J AM MED ASSOC, V272, P592, DOI 10.1001/jama.1994.03520080034035; Olsen J, 2001, SCAND J PUBLIC HEALT, V29, P300, DOI 10.1177/14034948010290040201; Paganelli R, 1998, ALLERGY, V53, P763; Strachan DP, 1997, J ALLERGY CLIN IMMUN, V99, P6, DOI 10.1016/S0091-6749(97)81038-X; Ulrik CS, 2000, ANN ALLERG ASTHMA IM, V85, P293, DOI 10.1016/S1081-1206(10)62532-X; WITTIG HJ, 1978, ANN ALLERGY, V41, P84; Yazdanbakhsh M, 2002, SCIENCE, V296, P490, DOI 10.1126/science.296.5567.490	29	24	24	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2003	111	6					1227	1231		10.1067/mai.2003.1483	http://dx.doi.org/10.1067/mai.2003.1483			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	688FZ	12789221	Bronze			2022-12-18	WOS:000183424700009
J	Caplan, EL; Ford, JL; Young, PF; Ownby, DR				Caplan, EL; Ford, JL; Young, PF; Ownby, DR			Fire ants represent an important risk for anaphylaxis among residents of an endemic region	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						fire ant hypersensitivity; immunoglobulin E; anaphylaxis	WHOLE-BODY EXTRACTS; VENOM-SPECIFIC IGE; SOLENOPSIS-INVICTA; HYPERSENSITIVITY; HYMENOPTERA; STINGS; ALLERGENS; ASSAY; BEE	Background: Imported fire ants (IFA) represent a potential anaphylactic risk to IFA-sensitized individuals. Objective: We examined the prevalence of allergic sensitization to IFA, yellow jacket venom (YJV), and peanut in an adult population from an IFA-infested region, Augusta, Georgia. Methods: Specific IgE to IFA, YJV, and peanut were determined by using the Pharmacia UniCAP assay in 200 random blood donors from an Augusta blood bank. These results were compared with specific IgE to identical allergens in a random sample of blood donors from Oklahoma City, Oklahoma (OKC), a nonendemic region for IFA. Results: Prevalence of IFA-specific IgE (17%) in the Augusta population was significantly higher than to YJV (10%, P = .04) or peanut (7.5%, P = .004). The majority of individuals who had significant IgE to IFA (greater than or equal to0.35 kIU/L) did not have IgE to YJV (24/34 = 71%). YJV caused significantly more inhibition of IgE binding to a YJV solid phase than to an IFA solid phase when the 10 dual-positive sera were analyzed (58% vs 11%, P = .005). The prevalence of IFA-specific IgE in adults from Augusta was higher than in OKC (17% vs 2%, P = .0002). YJV-specific IgE was also more prevalent in Augusta compared with OKC (10% vs 6.0%, P = .04), whereas no difference was demonstrated for peanut-specific IgE (7.5% vs 6.5%, P = .6). Conclusions: Allergic specific IgE to IFA is 1.7 times more common in adults living in an endemic area than specific IgE for other allergens associated with potentially fatal anaphylaxis. This suggests that IFA may pose the greatest risk of anaphylaxis for adults residing in IFA-endemic regions.	Med Coll Georgia, Sect Allergy & Immunol, Dept Pediat, Augusta, GA 30912 USA	University System of Georgia; Augusta University	Caplan, EL (corresponding author), Med Coll Georgia, Sect Allergy & Immunol, Dept Pediat, BG 1019, Augusta, GA 30912 USA.							ADAMS CT, 1981, J MED ENTOMOL, V18, P378, DOI 10.1093/jmedent/18.5.378; DESHAZO RD, 1984, J ALLERGY CLIN IMMUN, V74, P841, DOI 10.1016/0091-6749(84)90188-X; DESHAZO RD, 1990, NEW ENGL J MED, V323, P462, DOI 10.1056/NEJM199008163230707; FEGER TA, 1995, J ALLERGY CLIN IMMUN, V96, P182, DOI 10.1016/S0091-6749(95)70006-4; Ford JL, 1997, J ALLERGY CLIN IMMUN, V100, P425, DOI 10.1016/S0091-6749(97)70259-8; FREEMAN TM, 1992, J ALLERGY CLIN IMMUN, V90, P210, DOI 10.1016/0091-6749(92)90073-B; GOLDEN DBK, 1989, JAMA-J AM MED ASSOC, V262, P240, DOI 10.1001/jama.262.2.240; HOFFMAN DR, 1988, J ALLERGY CLIN IMMUN, V82, P828, DOI 10.1016/0091-6749(88)90085-1; HOFFMAN DR, 1991, ANN ALLERGY, V66, P29; Kemp SF, 2000, J ALLERGY CLIN IMMUN, V105, P683, DOI 10.1067/mai.2000.105707; PONDER RD, 1994, ANN ALLERGY, V72, P329; Prahlow JA, 1998, AM J FOREN MED PATH, V19, P137, DOI 10.1097/00000433-199806000-00007; RHOADES RB, 1989, J ALLERGY CLIN IMMUN, V84, P159, DOI 10.1016/0091-6749(89)90319-9; Stafford CT, 1996, ANN ALLERG ASTHMA IM, V77, P87, DOI 10.1016/S1081-1206(10)63493-X; STAFFORD CT, 1992, J ALLERGY CLIN IMMUN, V90, P653, DOI 10.1016/0091-6749(92)90139-S; STUCKEY M, 1982, LANCET, V2, P41; TRACY JM, 1995, J ALLERGY CLIN IMMUN, V95, P824, DOI 10.1016/S0091-6749(95)70125-7; TRIPLETT RF, 1976, SOUTHERN MED J, V69, P258, DOI 10.1097/00007611-197603000-00002	18	24	27	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2003	111	6					1274	1277		10.1067/mai.2003.1453	http://dx.doi.org/10.1067/mai.2003.1453			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	688FZ	12789229				2022-12-18	WOS:000183424700017
J	Lee, DKC; Bates, CE; Currie, GP; Lipworth, BJ				Lee, DKC; Bates, CE; Currie, GP; Lipworth, BJ			Comparative in vivo bioactivity of modern H-1-antihistamines on AMP challenge in atopic asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						H-1-antihistamines; desloratadine; fexofenadine; levocetirizine; adenosine monophosphate	ADENOSINE-MONOPHOSPHATE; AIRWAY INFLAMMATION; CLINICAL-EFFICACY; DESLORATADINE; LEVOCETIRIZINE; HISTAMINE; FEXOFENADINE; 5'-MONOPHOSPHATE; RESPONSIVENESS; METHACHOLINE	Background: Modern H-1-antihistamines differ in their in vitro binding affinity, but their comparative in vivo bioactivity in asthmatic airways is unknown. Objectives: We compared clinically recommended doses of 3 H-1-antihistamines on airway hyperresponsiveness to AMP challenge (the primary outcome variable). Methods: Sixteen atopic patients with mild-to-moderate asthma of whom 10 were receiving inhaled corticosteroid therapy (all had positive results to house dust mite on skin prick testing) were randomized in a double-blind, placebo-controlled, cross-over fashion to receive single doses of 5 mg of desloratadine, 180 mg of fexofenadine hydrochloride (FEX), 5 mg of levocetirizine dihydrochloride (LEV), or placebo, with AMP challenge performed 12 hours after dosing. Results: All H-1-antihistamines demonstrated significantly greater (P < .05) geometric mean +/- SEM AMP PC20 values compared with that of placebo (86 +/- 29 mg/mL): desloratadine, 189 +/- 54 mg/mL; FEX, 176 +/- 57 mg/mL; and LEV, 163 +/- 48 mg/mL. Prechallenge forced expiratory flow at 25% to 75% of maximal lung volume (percent predicted) but not FEV1 was significantly higher (P < .05) for all H-1-antihistamines compared with that of placebo (53% +/- 4%): desloratadine, 62% +/- 4%; FEX, 62% +/- 4%; and LEV, 59% +/- 3%. There were no significant differences in either AMP PC20 or lung function values among the H-1-antihistamines. Conclusion: Single doses of H-1-antihistamines improved airway hyperresponsiveness and small-airways caliber to a similar degree. Data for in vitro binding affinity do not therefore translate into commensurate differences in in vivo bioactivity at clinically recommended doses.	Univ Dundee, Ninewells Hosp & Med Sch, Asthma & Allergy Res Grp, Dundee DD1 9SY, Scotland	University of Dundee	Lipworth, BJ (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Asthma & Allergy Res Grp, Dundee DD1 9SY, Scotland.			Currie, Graeme P/0000-0002-5711-9147				Agrawal DK, 2001, EXPERT OPIN INV DRUG, V10, P547, DOI 10.1517/13543784.10.3.547; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; ANTHES JC, 2000, ALLERGY, V55, P277; Arnold R, 2002, ALLERGY, V57, P146; Bachert C, 2002, ALLERGY, V57, P145; Bachert C, 2001, ALLERGY, V56, P14, DOI 10.1034/j.1398-9995.2001.00102.x; Biller H, 2002, ALLERGY, V57, P146; Brannan JD, 2001, AM J RESP CRIT CARE, V163, P1420, DOI 10.1164/ajrccm.163.6.2006019; Clough GF, 2001, ALLERGY, V56, P985, DOI 10.1034/j.1398-9995.2001.00204.x; CURRIE GP, 2002, AM J RESP CRIT CA S8, V165, pB40; De Meer G, 2002, AM J RESP CRIT CARE, V165, P327, DOI 10.1164/ajrccm.165.3.2104066; Fowler SJ, 2000, AM J RESP CRIT CARE, V162, P1318, DOI 10.1164/ajrccm.162.4.9912103; Geha RS, 2001, J ALLERGY CLIN IMMUN, V107, P752, DOI 10.1067/mai.2001.114239; Henz BM, 2001, ALLERGY, V56, P7, DOI 10.1034/j.1398-9995.2001.00101.x; Hoda U, 2002, ALLERGY, V57, P146; Howarth P. H., 2002, Clinical and Experimental Allergy Reviews, V2, P18, DOI 10.1046/j.1472-9725.2002.00030.x; Larsen JS, 2001, PHARMACOTHERAPY, V21, p28S, DOI 10.1592/phco.21.4.28S.34264; Leurs R, 2002, CLIN EXP ALLERGY, V32, P489, DOI 10.1046/j.0954-7894.2002.01314.x; RAFFERTY P, 1987, INT ARCH ALLER A IMM, V82, P292, DOI 10.1159/000234210; Tan KS, 1997, THORAX, V52, P608, DOI 10.1136/thx.52.7.608; Van den Berge M, 2001, AM J RESP CRIT CARE, V164, P1127, DOI 10.1164/ajrccm.164.7.2102135; Van dn Berge M, 2001, AM J RESP CRIT CARE, V163, P1546, DOI 10.1164/ajrccm.163.7.2010145; Waldman SA, 2002, ANN ALLERG ASTHMA IM, V89, P7, DOI 10.1016/S1081-1206(10)61904-7; Wang DY, 2001, ALLERGY, V56, P339, DOI 10.1034/j.1398-9995.2001.00775.x; Wilson AM, 2002, CLIN EXP ALLERGY, V32, P1504, DOI 10.1046/j.1365-2745.2002.01509.x; Ying S, 2002, ALLERGY, V57, P145	26	24	25	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2003	111	2					337	341		10.1067/mai.2003.32	http://dx.doi.org/10.1067/mai.2003.32			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	644WF	12589354				2022-12-18	WOS:000180942700018
J	Creticos, PS; Adams, WR; Petty, BG; Lewis, LD; Singh, GJP; Khattignavong, AP; Molzon, JA; Martinez, MN; Lietman, PS; Williams, RL				Creticos, PS; Adams, WR; Petty, BG; Lewis, LD; Singh, GJP; Khattignavong, AP; Molzon, JA; Martinez, MN; Lietman, PS; Williams, RL			A methacholine challenge dose-response study for development of a pharmacodynamic bioequivalence methodology for albuterol metered-dose inhalers	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; albuterol metered-dose inhaler; bioequivalence; dose-response; methacholine challenge	IN-VIVO BIOEQUIVALENCE; INHALATION; HISTAMINE; PHARMACOKINETICS; METAPROTERENOL; BIOASSAY	Background: With the expiration of the patent on albuterol metered-dose inhalers (MDIs) in 1989, methods to assess in vivo bioequivalence of generic formulations required investigation. Objective: In an effort to develop a sensitive method to document bioequivalence, bronchoprovocation with methacholine chloride was used to assess the dose-response relationship of albuterol as delivered by MDI. Sensitivity was assessed in terms of magnitudes of ED50, the estimated albuterol dose required to achieve 50% of the fitted maximal value of the pharmacodynamic effect above baseline, and change in response as a function of dose, with emphasis on 1 and 2 actuations. Methods: On separate study days, 15 nonsmokers with mild asthma received randomized nominal albuterol doses of 0 to 576 mug by using specially manufactured MDI canisters. FEV1 was measured 15 minutes after MDI dosing. Serially increasing doses of methacholine were administered, and FEV1 was measured after each methacholine dose until a 20% decrease in FEV1 (PD20) was achieved. Results: Mean PD20 values after use of each of the albuterol-containing MDIs were significantly greater than either mean screening or mean placebo PD20 values (P < .05). Mean responses and most individual subject responses to 1 and 2 actuations (90 and 180 mug) of albuterol MDI were within the sensitive region of the dose-response curve. The mean estimated ED50 value on the basis of nonlinear mixed effect modeling was 119.2 mug (range, 33.3-337.1 mug), with an intersubject percentage coefficient of variation of 69.0%. Conclusions: The methacholine bronchoprovocation model is safe and useful in the study of albuterol MDI dose-response in Asthmatic subjects. Bronchoprovocation studies may be used for determination of bioequivalence of multisource albuterol MDI products.	Johns Hopkins Univ, Sch Med, Dept Med, Div Clin Immunol, Baltimore, MD 21205 USA; US FDA, Ctr Drug Evaluat & Res, Off Pharmaceut Sci, Off Gener Drugs, Rockville, MD 20857 USA; Johns Hopkins Sch Med, Dept Med, Div Clin Pharmacol, Baltimore, MD USA	Johns Hopkins University; US Food & Drug Administration (FDA); Johns Hopkins University; Johns Hopkins Medicine	Creticos, PS (corresponding author), Johns Hopkins Asthma & Allergy Ctr, 5501 Bayview Circle, Baltimore, MD 21224 USA.							AHMED T, 1990, RESPIRATORY DRUG DEL, P207; AHRENS RC, 1984, AM REV RESPIR DIS, V129, P903; AHRENS RC, 1987, J ALLERGY CLIN IMMUN, V79, P876, DOI 10.1016/0091-6749(87)90235-1; Ahrens RC, 1999, AM J RESP CRIT CARE, V160, P1238, DOI 10.1164/ajrccm.160.4.9806101; [Anonymous], 1987, AM REV RESPIR DIS, V136, P1285; BARNES PJ, 1983, BRIT J CLIN PHARMACO, V15, P677, DOI 10.1111/j.1365-2125.1983.tb01549.x; BLAKE KV, 1992, CHEST, V101, P309, DOI 10.1378/chest.101.2.309; *BRONCH COMM, 1985, AM AC ALL IMM TECHN, P1; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CRETICOS PS, 1991, ALLERGEN IMMUNOTHERA, P119; *CTR DRUG EV RES F, 1993, M GEN DRUGS ADV COMM, pI291; DUNNETT CW, 1955, J AM STAT ASSOC, V50, P1096, DOI 10.2307/2281208; Ette EI, 1998, ANN PHARMACOTHER, V32, P818, DOI 10.1345/aph.17304; Geoffroy P, 1999, ANN ALLERG ASTHMA IM, V82, P377, DOI 10.1016/S1081-1206(10)63287-5; GOMENI R, 1994, ANTICANCER RES, V14, P2321; GONDA I, 1985, INT J PHARM, V27, P99, DOI 10.1016/0378-5173(85)90189-9; HEIMER D, 1980, J ALLERGY CLIN IMMUN, V66, P75, DOI 10.1016/0091-6749(80)90141-4; HOLFORD NHG, 1981, CLIN PHARMACOKINET, V6, P429, DOI 10.2165/00003088-198106060-00002; HOLFORD NHG, 1990, MKMODEL PHARM MODELI; HOOPER J, 1993, M GEN DRUGS ADV COMM; JUNIPER EF, 1978, THORAX, V33, P705, DOI 10.1136/thx.33.6.705; KINOWSKI JM, 1995, CLIN DRUG INVEST, V9, P260, DOI 10.2165/00044011-199509050-00003; KOOPMANS LH, 1964, BIOMETRIKA, V51, P25, DOI 10.1093/biomet/51.1-2.25; LIGHT RW, 1977, CHEST, V72, P512, DOI 10.1378/chest.72.4.512; MORRIS JF, 1971, AM REV RESPIR DIS, V103, P57; NELSON HS, 1983, J ALLERGY CLIN IMMUN, V72, P371, DOI 10.1016/0091-6749(83)90502-X; NEWMAN SP, 1982, INT J PHARM, V11, P337, DOI 10.1016/0378-5173(82)90084-9; *NIH NAT ASTHM ED, 1991, NIH PUBL; Parameswaran KN, 1999, AM J RESP CRIT CARE, V160, P354, DOI 10.1164/ajrccm.160.1.9812035; QUESSY SN, 1991, J ASTHMA, V28, P323, DOI 10.3109/02770909109089459; *SCI SOFTW, 1992, PCNONLIN VERS 4 0 SO; *SIMED SA, 1996, P PHARM VERS 1 4 PRO; Singh GJP, 1999, CLIN PHARMACOL THER, V66, P346, DOI 10.1053/cp.1999.v66.a101209; Stewart BA, 2000, CHEST, V117, P714, DOI 10.1378/chest.117.3.714; TEMPLE RJ, 1994, COMMUN STAT THEORY, V23, P499, DOI 10.1080/03610929408831269; WILLIAMS R, 1993, M GEN DRUGS ADV COMM, P247; Wong A G, 1998, Can Respir J, V5, P119	37	24	25	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2002	110	5					713	720		10.1067/mai.2002.129036	http://dx.doi.org/10.1067/mai.2002.129036			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	612NN	12417879				2022-12-18	WOS:000179082500005
J	Anderson, SD; Brannan, JD				Anderson, SD; Brannan, JD			Exercise-induced asthma: Is there still a case for histamine?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						exercise-induced asthma; leukotrienes; osmolarity; water loss	INDUCED BRONCHOCONSTRICTION; MAST-CELLS; SENSITIVITY; MONTELUKAST; TERFENADINE; ACTIVATION; BASOPHILS; RELEASE		Royal Prince Alfred Hosp, Dept Resp Med, Camperdown, NSW 2050, Australia	University of Sydney	Anderson, SD (corresponding author), Royal Prince Alfred Hosp, Dept Resp Med, E11S,Missenden Rd, Camperdown, NSW 2050, Australia.			Anderson, Sandra/0000-0002-6308-8770; Brannan, John/0000-0001-7243-7998				Anderson SD, 2000, J ALLERGY CLIN IMMUN, V106, P453, DOI 10.1067/mai.2000.109822; ANDERSON SD, 1982, EUR J RESPIR DIS, V63, P459; Anderson SD, 1996, J ALLERGY CLIN IMMUN, V98, pS124, DOI 10.1016/S0091-6749(96)80140-0; ANDERSON SD, 1992, THORAX, V47, P748, DOI 10.1136/thx.47.9.748; Anderson SD, 2001, MED SCI SPORT EXER, V33, P893, DOI 10.1097/00005768-200106000-00007; Baki A, 2002, ARCH DIS CHILD, V86, P38, DOI 10.1136/adc.86.1.38; BARNES NC, 1984, THORAX, V39, P500, DOI 10.1136/thx.39.7.500; BOUSQUET J, 1988, J ALLERGY CLIN IMMUN, V82, P881, DOI 10.1016/0091-6749(88)90094-2; Brannan JD, 2001, AM J RESP CRIT CARE, V163, P1420, DOI 10.1164/ajrccm.163.6.2006019; BRANNAN JD, 2001, EUR RESPIR J, V18, pS102; Crampette L, 1996, ALLERGY, V51, P346, DOI 10.1111/j.1398-9995.1996.tb00098.x; Dahlen B, 2002, J ALLERGY CLIN IMMUN, V109, P789, DOI 10.1067/mai.2002.123306; EGGLESTON PA, 1987, AM REV RESPIR DIS, V135, P1043; EGGLESTON PA, 1984, AM REV RESPIR DIS, V130, P86; FINNERTY JP, 1990, EUR RESPIR J, V3, P540; Gibson PG, 2001, AM J RESP CRIT CARE, V163, P32, DOI 10.1164/ajrccm.163.1.9807061; JEFFERY PK, 1992, AM REV RESPIR DIS, V145, P890, DOI 10.1164/ajrccm/145.4_Pt_1.890; Kivity S, 2000, RESP MED, V94, P1200, DOI 10.1053/rmed.2000.0951; Leff JA, 1998, NEW ENGL J MED, V339, P147, DOI 10.1056/NEJM199807163390302; MOLONEY ED, 2001, EUR RESP S33, V18, pS79; O'Sullivan S, 1998, EUR RESPIR J, V12, P345, DOI 10.1183/09031936.98.12020345	21	24	25	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2002	109	5					771	773		10.1067/mai.2002.123644	http://dx.doi.org/10.1067/mai.2002.123644			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	553QW	11994697				2022-12-18	WOS:000175687800003
J	Kim, SH; Oh, SY; Oh, HB; Kim, YK; Cho, SH; Kim, YY; Min, KU				Kim, SH; Oh, SY; Oh, HB; Kim, YK; Cho, SH; Kim, YY; Min, KU			Association of beta(2)-adrenoreceptor polymorphisms with nocturnal cough among atopic subjects but not with atopy and nonspecific bronchial hyperresponsiveness	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						beta(2)-adrenoreceptor; asthma phenotype; polymorphism; nocturnal cough	BETA(2)-ADRENERGIC RECEPTOR; AIRWAY HYPERRESPONSIVENESS; GENETIC POLYMORPHISMS; IGE LEVELS; ASTHMA; REACTIVITY; RESPONSIVENESS; SUSCEPTIBILITY; METHACHOLINE; POPULATION	Background: The reports from in vitro studies that beta(2)-adrenergic receptor (B2AR) polymorphisms are associated with agonist-promoted downregulation have evoked considerable research interest for the roles of these polymorphisms to the pathogenesis of asthma. Objective: We sought to evaluate the association between asthma phenotypes and B2AR polymorphisms at 2 sites (Arg16 --> Gly16 and Gln27 --> Glu27) in the general population. Methods: Four hundred forte unrelated Korean adults were randomly selected, and asthma phenotypes were determined with a questionnaire, immunoassay, skin prick testing, and methacholine bronchial provocation testing. Genotypes of B2AR polymorphisms were determined with PCR-based methods. Results: No significant association was found between B2AR alleles and haplotypes and total IgE levels, skin test responses to aeroallergens, and bronchial responsiveness to methacholine, Among the atopic subjects, however, numbers of both Arg16 alleles and Arg16-Gln27 haplotypes were negatively associated with nocturnal cough, and in contrast, Gly16-Gln27 was positively associated with it. Conclusion: B2AR polymorphisms may play an important role in the expression of nocturnal cough in atopic subjects but not in the expression of atop and bronchial hyperresponsiveness in a general population.	Seoul Natl Univ, Coll Med, Dept Internal Med, Chongno Gu, Seoul 110744, South Korea; Seoul Natl Univ, Med Res Ctr, Inst Allergy & Clin Immunol, Seoul, South Korea; Seoul Natl Univ Hosp, Clin Res Inst, Seoul 110744, South Korea; Univ Ulsan, Coll Med, Dept Clin Pathol, Seoul, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Seoul National University Hospital; University of Ulsan	Min, KU (corresponding author), Seoul Natl Univ, Coll Med, Dept Internal Med, Chongno Gu, 28 Yongon Dong, Seoul 110744, South Korea.		Min, Kyung-Up/J-5468-2012; Cho, Sang Heon/J-2793-2012					CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P534; COCKCROFT DW, 1988, ANN ALLERGY, V60, P465; COCKCROFT DW, 1990, AM REV RESPIR DIS, V142, P497, DOI 10.1164/ajrccm/142.3.497; D'Amato M, 1998, AM J RESP CRIT CARE, V158, P1968, DOI 10.1164/ajrccm.158.6.9804126; DAHL R, 1991, EUR RESPIR REV, V1, P272; Dewar JC, 1997, J ALLERGY CLIN IMMUN, V100, P261, DOI 10.1016/S0091-6749(97)70234-3; DUFFY DL, 1993, THORAX, V48, P1021, DOI 10.1136/thx.48.10.1021; FERRIS BG, 1978, AM REV RESPIR DIS S, V118, P10; GREEN SA, 1993, J BIOL CHEM, V268, P23116; GREEN SA, 1995, AM J RESP CELL MOL, V13, P25, DOI 10.1165/ajrcmb.13.1.7598936; HALL IP, 1995, LANCET, V345, P1213, DOI 10.1016/S0140-6736(95)91994-5; Holloway JW, 2000, CLIN EXP ALLERGY, V30, P1097; IND PW, 1989, AM REV RESPIR DIS, V139, P1390, DOI 10.1164/ajrccm/139.6.1390; JOSEPHS LK, 1989, AM REV RESPIR DIS, V140, P350, DOI 10.1164/ajrccm/140.2.350; Kim YK, 1999, J ALLERGY CLIN IMMUN, V104, P618, DOI 10.1016/S0091-6749(99)70333-7; Kim YK, 1999, J ALLERGY CLIN IMMUN, V104, P311, DOI 10.1016/S0091-6749(99)70372-6; Koh YY, 1998, J ALLERGY CLIN IMMUN, V102, P921, DOI 10.1016/S0091-6749(98)70329-X; LIGGETT SB, 1997, J RESP CRIT CARE MED, V156, pS156; Martinez FD, 1997, J CLIN INVEST, V100, P3184, DOI 10.1172/JCI119874; POSTMA DS, 1995, NEW ENGL J MED, V333, P894, DOI 10.1056/NEJM199510053331402; Ramsay CE, 1999, CLIN EXP ALLERGY, V29, P1195; REIHAUS E, 1995, AM J RESP CELL MOL B, V8, P334; RHONDEN KJ, 1988, J APPL PHYSIOL, V65, P700; Summerhill E, 2000, AM J RESP CRIT CARE, V162, P599, DOI 10.1164/ajrccm.162.2.9910108; Tan S, 1997, LANCET, V350, P995, DOI 10.1016/S0140-6736(97)03211-X; TOWNLEY RG, 1986, J ALLERGY CLIN IMMUN, V77, P101, DOI 10.1016/0091-6749(86)90330-1; TURKI J, 1995, J CLIN INVEST, V95, P1635, DOI 10.1172/JCI117838; Ulbrecht M, 2000, AM J RESP CRIT CARE, V161, P469, DOI 10.1164/ajrccm.161.2.9902072; Weir TD, 1998, AM J RESP CRIT CARE, V158, P787, DOI 10.1164/ajrccm.158.3.9801035	29	24	25	0	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2002	109	4					630	635		10.1067/mai.2002.122842	http://dx.doi.org/10.1067/mai.2002.122842			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	543YZ	11941312				2022-12-18	WOS:000175132600010
J	Grimm, V; Rakoski, J; Ring, J				Grimm, V; Rakoski, J; Ring, J			Urticaria and angioedema induced by COX-2 inhibitors	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									Tech Univ Munich, GSF, Div Environm Dermatol & Allergy, D-8000 Munich, Germany; Tech Univ Munich, Dept Dermatol, D-8000 Munich, Germany	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich; Technical University of Munich	Grimm, V (corresponding author), Tech Univ Munich, GSF, Div Environm Dermatol & Allergy, D-8000 Munich, Germany.		Ring, Johannes/GLN-4341-2022	Ring, Johannes/0000-0001-8236-3152				Dahlen B, 2001, NEW ENGL J MED, V344, P142, DOI 10.1056/NEJM200101113440215; Knox A, 2000, THORAX, V55, pS1, DOI 10.1136/thorax.55.suppl_2.S1; SPECTOR SL, 1979, J ALLERGY CLIN IMMUN, V64, P500, DOI 10.1016/0091-6749(79)90059-9; Szczeklik A, 2001, CLIN EXP ALLERGY, V31, P219, DOI 10.1046/j.1365-2222.2001.01075.x; Yoshida S, 2000, J ALLERGY CLIN IMMUN, V106, P1201, DOI 10.1067/mai.2000.110926	5	24	24	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2002	109	2					370	370		10.1067/mai.2002.121315	http://dx.doi.org/10.1067/mai.2002.121315			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	528EZ	11842312				2022-12-18	WOS:000174232600027
J	Renz, H; von Mutius, E; Illi, S; Wolkers, F; Hirsch, T; Weiland, SK				Renz, H; von Mutius, E; Illi, S; Wolkers, F; Hirsch, T; Weiland, SK			T(H)1/T(H)2 immune response profiles differ between atopic children in eastern and western Germany	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						T(H)1/T(H)2 phenotype; allergy; asthma	T-CELLS; PREVALENCE; STIMULATION; DERMATITIS; ASTHMA; IGE	Background: Lower prevalence rates for childhood respiratory allergies have been reported in eastern Germany than in western Germany. Objective: Because allergic phenotypes are thought to be associated with an unbalanced T(H)1/T(H)2 T cell effector response, a cross-sectional investigation was carried out as part of the German ISAAC Phase 11 study to determine whether T(H)1/T(H)2 capacity might have developed in different directions during the separation between the 2 parts of the country. Methods: In a community-based random sample of 9- to 11-year-old (n = 6399) and 5- to 7-year-old (n = 6202) children in eastern and western Germany, the prevalence of atopy was assessed. Heparinized blood samples were collected from a subgroup of children stratified according to the number of older siblings. T(H)1 and T(H)2 cytokine productivity was determined after stimulation with phorbol ester plus ionomycin. Results: Individuals who grew up in eastern Germany had a marked bias toward T(H)0 responsiveness (>60%), regardless of whether they were atopic. In contrast, the children of western Germany, particularly when they were atopic, showed T(H)2 polarization. Conclusions: This is the first epidemiologic survey to demonstrate regional differences in the T(H)1/T(H)2 response pattern and their relation to atopic disease between regions.	Univ Marburg Hosp, Dept Clin Chem & Mol Diagnost, D-35033 Marburg, Germany; Univ Munich, Childrens Hosp, D-8000 Munich, Germany; Tech Univ Dresden, Childrens Clin, D-8027 Dresden, Germany; Univ Ulm, Dept Epidemiol, D-89069 Ulm, Germany	University of Munich; Technische Universitat Dresden; Ulm University	Renz, H (corresponding author), Univ Marburg Hosp, Dept Clin Chem & Mol Diagnost, Baldingerstr, D-35033 Marburg, Germany.			von Mutius, Erika/0000-0002-8893-4515				Behrendt H, 1993, ALLERGO J, V2, P31; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; HAMID Q, 1994, J CLIN INVEST, V94, P870, DOI 10.1172/JCI117408; Heinrich J, 1998, ALLERGY, V53, P89, DOI 10.1111/j.1398-9995.1998.tb03779.x; Herz U, 1998, INT ARCH ALLERGY IMM, V115, P179, DOI 10.1159/000023899; Humbert M, 1999, IMMUNOL TODAY, V20, P528, DOI 10.1016/S0167-5699(99)01535-2; Meissner N, 1997, CLIN EXP ALLERGY, V27, P1402, DOI 10.1111/j.1365-2222.1997.tb02984.x; Murphy E, 1996, J EXP MED, V183, P901, DOI 10.1084/jem.183.3.901; Nasert S, 1996, J IMMUNOL, V157, P441; Nowak D, 1996, EUR RESPIR J, V9, P2541, DOI 10.1183/09031936.96.09122541; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; von Mutius E, 2000, J ALLERGY CLIN IMMUN, V105, P9, DOI 10.1016/S0091-6749(00)90171-4; VONMUTIUS E, 1994, AM J RESP CRIT CARE, V149, P358, DOI 10.1164/ajrccm.149.2.8306030; VONMUTIUS E, 1994, BRIT MED J, V308, P692, DOI 10.1136/bmj.308.6930.692; Weiland SK, 1999, EUR RESPIR J, V14, P862, DOI 10.1034/j.1399-3003.1999.14d23.x	15	24	24	0	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2002	109	2					338	342		10.1067/mai.2002.121459	http://dx.doi.org/10.1067/mai.2002.121459			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	528EZ	11842306	Bronze			2022-12-18	WOS:000174232600021
J	Schade, RR; Van Ieperen-Van Dijk, AG; Versluis, C; Van Reijsen, FC; Kimpen, JLL; Bruijnzeel-Koomen, CAFM; Knol, EF; Van Hoffen, E				Schade, RR; Van Ieperen-Van Dijk, AG; Versluis, C; Van Reijsen, FC; Kimpen, JLL; Bruijnzeel-Koomen, CAFM; Knol, EF; Van Hoffen, E			Cell-surface expression of CD25, CD26, and CD30 by allergen-specificT cells is intrinsically different in cow's milk allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic dermatitis; Tcell clone; cow's milk; CD25; CD26; CD30; food allergy; infants; human; T(H)1/T(H)2 cells	INTERFERON-GAMMA PRODUCTION; BLOOD MONONUCLEAR-CELLS; ATOPIC-DERMATITIS; T-CELLS; PERIPHERAL-BLOOD; TH2 CELLS; FOOD HYPERSENSITIVITY; ADENOSINE-DEAMINASE; IMMUNE-RESPONSE; SERUM LEVELS	Background: The release of T(H)2 cytokines by food-specific T cells is thought to be important in the etiology of food allergy. It has been suggested that the activation state of food-specific T cells also plays a significant role, but this has not yet been studied at the single-cell level. Objective: Differences in the expression of cell-surface markers by cow's milk protein (CMP)-specific T cells between infants with and without cow's milk allergy (CMA) were evaluated at the clonal level. In addition, expression after the spontaneous development of tolerance of cow's milk in infants with CMA was analyzed. Methods: We established CMP-specific T-cell clones (TCCs) from blood of infants with CMA and atopic dermatitis, from atopic controls with atopic dermatitis but without CMA, and from nonatopic controls. In addition, we established TCCs from infants with CMA after they had spontaneously developed tolerance to cow's milk. Expression levels of CD25, CD26, and CD30 by each TCC were analyzed by use of now cytometry. Results: Cow's milk protein-specific T cells from infants with CMA expressed much higher levels of CD25 and CD30 than CMP-specific T cells from infants without CMA. Expression of CD26 was much lower than in normal controls. After development of tolerance for cow's milk, expression of CD25 and CD30 was decreased, whereas the expression of CD26 was increased to normal levels. Conclusion: Antigen-specific T cells from patients with food allergy display an increased expression of cell-surface markers of activation compared with cells of patients without food 1 allergy. This suggests an intrinsically stronger food-specific T-cell response in food-allergic patients, and points to the key role of food-specific T cells in the pathogenesis of food allergy.	Univ Utrecht, Med Ctr, Dept Dermatol Allergol G02124, NL-3508 GA Utrecht, Netherlands; Univ Utrecht, Med Ctr, Dept Gen Pediat & Infect Dis, NL-3508 GA Utrecht, Netherlands	Utrecht University; Utrecht University	Van Hoffen, E (corresponding author), Univ Utrecht, Med Ctr, Dept Dermatol Allergol G02124, POB 85-500, NL-3508 GA Utrecht, Netherlands.			Knol, Edward/0000-0001-7368-9820				ABERNATHYCARVER KJ, 1995, J CLIN INVEST, V95, P913, DOI 10.1172/JCI117743; Akdis M, 1997, J IMMUNOL, V159, P4611; ALZONA M, 1994, J IMMUNOL, V153, P2861; Andre F, 1996, ALLERGY, V51, P350; Annunziato F, 1998, EUR CYTOKINE NETW, V9, P12; Bengtsson A, 2001, ALLERGY, V56, P593, DOI 10.1034/j.1398-9995.2001.00137.x; Bengtsson A, 1997, CLIN EXP IMMUNOL, V109, P533, DOI 10.1046/j.1365-2249.1997.4731373.x; Bengtsson A, 1995, J LEUKOCYTE BIOL, V58, P683, DOI 10.1002/jlb.58.6.683; BOCK SA, 1987, PEDIATRICS, V79, P683; Bonno M, 1996, J ALLERGY CLIN IMMUN, V97, P680, DOI 10.1016/S0091-6749(96)70314-7; Burks AW, 1998, J PEDIATR-US, V132, P132, DOI 10.1016/S0022-3476(98)70498-6; Campbell DE, 1998, PEDIAT ALLERG IMM-UK, V9, P68, DOI 10.1111/j.1399-3038.1998.tb00306.x; Caproni M, 1997, ALLERGY, V52, P1063, DOI 10.1111/j.1398-9995.1997.tb00177.x; De Meester I, 1999, IMMUNOL TODAY, V20, P367, DOI 10.1016/S0167-5699(99)01486-3; DELPRETE G, 1995, J EXP MED, V182, P1655, DOI 10.1084/jem.182.6.1655; DELPRETE G, 1995, FASEB J, V9, P81, DOI 10.1096/fasebj.9.1.7821763; Esnault S, 1996, CLIN EXP IMMUNOL, V106, P67, DOI 10.1046/j.1365-2249.1996.d01-823.x; Franco R, 1998, IMMUNOL REV, V161, P27, DOI 10.1111/j.1600-065X.1998.tb01569.x; Grewe M, 1998, IMMUNOL TODAY, V19, P359, DOI 10.1016/S0167-5699(98)01285-7; Hamann D, 1996, J IMMUNOL, V156, P1387; HILL DJ, 1986, J PEDIATR-US, V109, P270, DOI 10.1016/S0022-3476(86)80384-5; Hoffman KM, 1997, J ALLERGY CLIN IMMUN, V99, P360, DOI 10.1016/S0091-6749(97)70054-X; Horie R, 1998, SEMIN IMMUNOL, V10, P457, DOI 10.1006/smim.1998.0156; KAMEOKA J, 1993, SCIENCE, V261, P466, DOI 10.1126/science.8101391; KONDO N, 1990, J ALLERGY CLIN IMMUN, V86, P253, DOI 10.1016/S0091-6749(05)80073-9; Morimoto C, 1998, IMMUNOL REV, V161, P55, DOI 10.1111/j.1600-065X.1998.tb01571.x; Noma T, 1996, CLIN EXP ALLERGY, V26, P1298, DOI 10.1111/j.1365-2222.1996.tb00527.x; PLAUT M, 1990, J IMMUNOL, V144, P4497; Sampson HA, 1997, JAMA-J AM MED ASSOC, V278, P1888, DOI 10.1001/jama.278.22.1888; Scala E, 1998, J IMMUNOL, V161, P489; Schade RP, 2000, J ALLERGY CLIN IMMUN, V106, P1155, DOI 10.1067/mai.2000.110802; SCHEELTOELLNER D, 1995, LAB INVEST, V73, P685; Shi HZ, 1999, J ALLERGY CLIN IMMUN, V103, P388, DOI 10.1016/S0091-6749(99)70461-6; Spinozzi F, 1997, SCAND J IMMUNOL, V45, P417, DOI 10.1046/j.1365-3083.1997.d01-416.x; Suomalainen H, 1994, Pediatr Allergy Immunol, V5, P20, DOI 10.1111/j.1399-3038.1994.tb00214.x; Suomalainen H, 1993, Pediatr Allergy Immunol, V4, P203, DOI 10.1111/j.1399-3038.1993.tb00092.x; Theze J, 1996, IMMUNOL TODAY, V17, P481, DOI 10.1016/0167-5699(96)10057-C; VANREIJSEN FC, 1992, J ALLERGY CLIN IMMUN, V90, P184, DOI 10.1016/0091-6749(92)90070-I; WALKER C, 1993, CLIN EXP ALLERGY, V23, P145, DOI 10.1111/j.1365-2222.1993.tb00310.x; Werfel T, 1996, CLIN EXP ALLERGY, V26, P1380, DOI 10.1111/j.1365-2222.1996.tb00539.x; Willheim M, 1997, J ALLERGY CLIN IMMUN, V100, P348, DOI 10.1016/S0091-6749(97)70248-3	41	24	24	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2002	109	2					357	362		10.1067/mai.2002.121457	http://dx.doi.org/10.1067/mai.2002.121457			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	528EZ	11842309				2022-12-18	WOS:000174232600024
J	Spahn, JD; Szefler, SJ				Spahn, JD; Szefler, SJ			Childhood asthma: New insights into management	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						bronchodilators; childhood asthma; Childhood Asthma Management Program; cromolyn; inhaled corticosteroids; long-term control therapy; theophylline	BUDESONIDE INHALATION SUSPENSION; LONG-TERM TREATMENT; INHALED CORTICOSTEROIDS; PERSISTENT ASTHMA; YOUNG-CHILDREN; ANTIINFLAMMATORY TREATMENT; AIRWAY INFLAMMATION; PULMONARY-FUNCTION; DOUBLE-BLIND; GENE	Recently, a concerted effort has been made to reverse the trend of increasing asthma mortality and morbidity. One additional strategy might be to recognize patients at risk for persistent asthma and to intervene early. This review summarizes new information on asthma pathogenesis that has helped shape a new direction in managing childhood asthma. At the core is the recognition that asthma is a chronic inflammatory disease. Subsequently, inhaled steroids, the most potent anti-inflammatory asthma medications, have emerged as the cornerstone of the management of persistent asthma. The recent report of the National Heart, Lung, and Blood Institute's Childhood Asthma Management Program provides a comprehensive "profile of performance" for 3 treatment choices for the management of persistent asthma. This study answers questions regarding the benefits and shortcomings of the medications evaluated and prompts a closer evaluation of the long-term effects of other treatment strategies, including medications currently being developed. Although intervention with inhaled steroids offers new opportunities to control the development of asthma, one must be cognizant of potential risks in early and long-term therapeutic intervention. This review provides a perspective on our present knowledge, the rationale for early intervention, and opportunities for more aggressive therapy, as well as speculation on how ongoing clinical research will continue to play a role in advancing asthma care and moving toward a "cure" for this fife-threatening disease.	Natl Jewish Med & Res Ctr, Dept Pediat, Immunopharmacol Lab, Div Allergy & Immunol, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Dept Pediat, Boulder, CO 80309 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Boulder, CO 80309 USA; Natl Jewish Med & Res Ctr, Dept Pediat, Div Clin Pharmacol, Denver, CO 80206 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Boulder; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Boulder; National Jewish Health	Szefler, SJ (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, Immunopharmacol Lab, Div Allergy & Immunol, 1400 Jackson St, Denver, CO 80206 USA.				NCRR NIH HHS [5 M01 RR00051] Funding Source: Medline; NHLBI NIH HHS [HL36577, 1NO1-HR-16048, HL 51834] Funding Source: Medline; NICHD NIH HHS [1U01-HD37237] Funding Source: Medline; DIVISION OF LUNG DISEASES [N01HR016048] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U01HD037237] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000051] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036577, U10HL051834] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); DIVISION OF LUNG DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Agertoft L, 2000, NEW ENGL J MED, V343, P1064, DOI 10.1056/NEJM200010123431502; AGERTOFT L, 1994, RESP MED, V88, P373, DOI 10.1016/0954-6111(94)90044-2; Annett RD, 2000, J ALLERGY CLIN IMMUN, V105, P717, DOI 10.1067/mai.2000.105226; Baker JW, 1999, PEDIATRICS, V103, P414, DOI 10.1542/peds.103.2.414; Bender BG, 2000, ARCH PEDIAT ADOL MED, V154, P706, DOI 10.1001/archpedi.154.7.706; Burney P, 1997, AM J RESP CRIT CARE, V156, P1773; Castro-Rodriguez JA, 2000, AM J RESP CRIT CARE, V162, P1403, DOI 10.1164/ajrccm.162.4.9912111; Cherniack R, 1999, CONTROL CLIN TRIALS, V20, P91; *CHILDH ASTHM MAN, 2000, NEW ENGLAND J MED, V0343; Cumming RG, 1997, NEW ENGL J MED, V337, P8, DOI 10.1056/NEJM199707033370102; Donahue JG, 1997, JAMA-J AM MED ASSOC, V277, P887, DOI 10.1001/jama.277.11.887; Garbe E, 1998, JAMA-J AM MED ASSOC, V280, P539, DOI 10.1001/jama.280.6.539; GARDINER PV, 1994, AM J RESP CRIT CARE, V150, P1006, DOI 10.1164/ajrccm.150.4.7921429; GONZALEZ FJ, 1994, CLIN PHARMACOKINET, V26, P59, DOI 10.2165/00003088-199426010-00005; Hamid QA, 2000, J ALLERGY CLIN IMMUN, V105, P20, DOI 10.1016/S0091-6749(00)90172-6; In KH, 1997, J CLIN INVEST, V99, P1130, DOI 10.1172/JCI119241; Jaffar ZH, 1996, EUR RESPIR J, V9, P456, DOI 10.1183/09031936.96.09030456; Kearns Gregory L., 1995, Current Opinion in Pediatrics, V7, P220, DOI 10.1097/00008480-199504000-00018; Kemp JP, 1999, ANN ALLERG ASTHMA IM, V83, P231, DOI 10.1016/S1081-1206(10)62646-4; KIDNEY J, 1995, AM J RESP CRIT CARE, V151, P1907, DOI 10.1164/ajrccm.151.6.7767539; Laitinen A, 1997, AM J RESP CRIT CARE, V156, P951, DOI 10.1164/ajrccm.156.3.9610084; LAITINEN LA, 1992, J ALLERGY CLIN IMMUN, V90, P32, DOI 10.1016/S0091-6749(06)80008-4; Lee T, 1996, AM J RESP CRIT CARE, V154, pS1, DOI 10.1164/ajrccm/154.2_Pt_2.S1; Leeder JS, 1997, PEDIATR CLIN N AM, V44, P55, DOI 10.1016/S0031-3955(05)70463-6; LEUNG DYM, 1995, J EXP MED, V181, P33, DOI 10.1084/jem.181.1.33; Matz J, 2001, J ALLERGY CLIN IMMUN, V107, P783, DOI 10.1067/mai.2001.114709; MAY DG, 1994, J CLIN PHARMACOL, V34, P881, DOI 10.1002/j.1552-4604.1994.tb04001.x; *NAT I HLTH, 1995, GLOB IN ASTHM GLOB S; *NAT I HLTH, 1997, NAT ASTHM ED PREV PR; Nelson HS, 1999, J ALLERGY CLIN IMMUN, V104, pS77, DOI 10.1016/S0091-6749(99)70277-0; Nelson HS, 2000, J ALLERGY CLIN IMMUN, V106, P1088, DOI 10.1067/mai.2000.110920; Nelson HS, 1999, J ALLERGY CLIN IMMUN, V104, P775, DOI 10.1016/S0091-6749(99)70287-3; Olivieri D, 1997, AM J RESP CRIT CARE, V155, P1864, DOI 10.1164/ajrccm.155.6.9196087; POSTMA DS, 1995, NEW ENGL J MED, V333, P894, DOI 10.1056/NEJM199510053331402; RASMUSSEN JB, 1992, J ALLERGY CLIN IMMUN, V90, P193, DOI 10.1016/0091-6749(92)90071-9; REIHSAUS E, 1993, AM J RESP CELL MOL, V8, P334, DOI 10.1165/ajrcmb/8.3.334; Robinson DS, 2001, LANCET, V357, P2007, DOI 10.1016/S0140-6736(00)05113-8; Shapiro G, 1998, J ALLERGY CLIN IMMUN, V102, P789, DOI 10.1016/S0091-6749(98)70019-3; Spahn JD, 2000, LUNG BIOL HEALTH DIS, V145, P1; Suissa S, 2001, J ALLERGY CLIN IMMUN, V107, P937, DOI 10.1067/mai.2001.115653; Szefler SJ, 1998, J ALLERGY CLIN IMMUN, V102, pS23, DOI 10.1016/S0091-6749(98)70003-X; Szefler SJ, 2000, J ALLERGY CLIN IMMUN, V106, pS115; Szefler SJ, 1999, J ALLERGY CLIN IMMUN, V104, pS159, DOI 10.1016/S0091-6749(99)70056-4; Tanner JM., 1983, ASSESSMENT SKELETAL; TRIGG CJ, 1994, AM J RESP CRIT CARE, V150, P17, DOI 10.1164/ajrccm.150.1.8025745; Vanden Burgt JA, 2000, J ALLERGY CLIN IMMUN, V106, P1210, DOI 10.1067/mai.2000.111582; Wanner A, 1997, AM J RESP CRIT CARE, V156, pS67; Warner JO, 1998, PEDIATR PULM, V25, P1; Wennergren G, 1996, J ALLERGY CLIN IMMUN, V97, P742, DOI 10.1016/S0091-6749(96)80150-3; Wenzel SE, 1997, AM J RESP CRIT CARE, V156, P737, DOI 10.1164/ajrccm.156.3.9610046; Zeiger RS, 1999, J ALLERGY CLIN IMMUN, V103, P376, DOI 10.1016/S0091-6749(99)70460-4	51	24	25	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2002	109	1					3	13		10.1067/mai.2002.120756	http://dx.doi.org/10.1067/mai.2002.120756			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	519RM	11799358	Bronze			2022-12-18	WOS:000173739300001
J	Zhu, YK; Liu, XD; Wang, HJ; Kohyama, T; Wen, FQ; Skold, CM; Rennard, SI				Zhu, YK; Liu, XD; Wang, HJ; Kohyama, T; Wen, FQ; Skold, CM; Rennard, SI			Interactions between monocytes and smooth-muscle cells can lead to extracellular matrix degradation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						smooth-muscle cells; monocytes; elastase; collagen degradation; matrix metalloproteinases	TUMOR-NECROSIS-FACTOR; HUMAN SYNOVIAL-CELLS; FIBROBLAST PROLIFERATION; PROSTAGLANDIN PRODUCTION; STIMULATES COLLAGENASE; ASTHMA; METALLOPROTEINASES; INTERLEUKIN-1; CONTRACTION; GROWTH	Background: Chronic infiltration of the airway wall with inflammatory cells characterizes both asthma and chronic, bronchitis. Remodeling of the airway wall is also a feature of both diseases. Objective: We hypothesized that collagen degradation may take place during coculture of monocytes with smooth-muscle cells (SMCs) and that this degradation might be altered by agents that modify the inflammatory regimen. Methods: Monocytes (4.5 x 10(5)/mL) were cast into collagen gels containing human airway SMCs (4.5 x 105/mL) and released into serum-free Dulbecco's modified Eagle's medium containing neutrophil elastase. Collagen content was quantified as total insoluble hydroxyproline on day 5. Zymography and immunoblotting were used to detect matrix metalloproteinases. Results: Monocytes cocultured with SMCs in 3-dimensional native type I collagen gels produced TNF-alpha and lL-1 beta and resulted in collagen degradation (30.5 vs 17.9 mg per gel) through inducing matrix metalloproteinase 1, 2, and 9 by means of SMCs. PGE(2) was significantly increased in coculture (0.9 vs 10.5 ng/mL). Indomethacin (1 mu mol/L) completely inhibited PGE2 production but augmented collagen degradation (17.9 vs 2.3 mug per gel), and this was blocked by the addition of exogenous PGE(2). Dexamethasone also inhibited collagen degradation in coculture. Conclusion: The current study supports the concept that interactions among cells present in the airway inflammatory milieu that characterize airway disease can lead to alterations in tissue structure and suggests mechanisms by which therapeutic strategies can be designed to modify tissue remodeling.	Univ Nebraska, Med Ctr, Nebraska Med Ctr 985125, Omaha, NE 68198 USA; Jincheng Hosp, Dept Resp Dis, Lanzhou, Peoples R China; Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada; Karolinska Inst, Dept Med, Stockholm, Sweden	University of Nebraska System; University of Nebraska Medical Center; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Karolinska Institutet	Rennard, SI (corresponding author), Univ Nebraska, Med Ctr, Nebraska Med Ctr 985125, 600 S 42nd St, Omaha, NE 68198 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064088] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL64088] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BELL E, 1979, P NATL ACAD SCI USA, V76, P1274, DOI 10.1073/pnas.76.3.1274; BERGMAN I, 1963, ANAL CHEM, V35, P1961, DOI 10.1021/ac60205a053; BEZDICEK P, 1997, LUNG SCI FDN, P859; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; DAYER JM, 1985, J EXP MED, V162, P2163, DOI 10.1084/jem.162.6.2163; DAYER JM, 1986, J CLIN INVEST, V77, P645, DOI 10.1172/JCI112350; EDWARDS CA, 1980, CLIN CHIM ACTA, V104, P161, DOI 10.1016/0009-8981(80)90192-8; ELIAS JA, 1988, AM REV RESPIR DIS, V138, P1595, DOI 10.1164/ajrccm/138.6.1595; ELIAS JA, 1985, J LEUKOCYTE BIOL, V37, P15, DOI 10.1002/jlb.37.1.15; ELSDALE T, 1972, J CELL BIOL, V54, P626, DOI 10.1083/jcb.54.3.626; FLETCHER C, 1976, NATURAL HIST CHRONIC, P1; GRINNELL F, 1994, J CELL BIOL, V124, P401, DOI 10.1083/jcb.124.4.401; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P1745, DOI 10.1164/ajrccm/140.6.1745; KELLY D, 1990, CYTOTECHNOLOGY, V4, P227, DOI 10.1007/BF00563783; KLEINER DE, 1994, ANAL BIOCHEM, V218, P325, DOI 10.1006/abio.1994.1186; KORN JH, 1980, J CLIN INVEST, V65, P543, DOI 10.1172/JCI109698; Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703; LEFEBVRE V, 1991, BIOCHIM BIOPHYS ACTA, V1094, P8, DOI 10.1016/0167-4889(91)90020-X; Li L, 1998, BBA-MOL CELL RES, V1405, P110, DOI 10.1016/S0167-4889(98)00091-3; Mio T, 1996, IN VITRO CELL DEV-AN, V32, P427; Niewoehner DE, 1998, TXB PULMONARY DIS, P823; PANETTIERI RA, 1989, AM J PHYSIOL, V256, pC329, DOI 10.1152/ajpcell.1989.256.2.C329; PEAT JK, 1987, EUR J RESPIR DIS, V70, P171; RENNARD S, 1997, EUR RESPIR REV, V7, P206; Rennard SI, 1996, J ALLERGY CLIN IMMUN, V98, pS278, DOI 10.1016/S0091-6749(96)70076-3; ROCHE WR, 1989, LANCET, V1, P520; Shapiro SD, 1998, CURR OPIN CELL BIOL, V10, P602, DOI 10.1016/S0955-0674(98)80035-5; SHAPIRO SD, 1995, J BIOL CHEM, V270, P6351, DOI 10.1074/jbc.270.11.6351; Skold CM, 2000, AM J PHYSIOL-LUNG C, V279, pL667, DOI 10.1152/ajplung.2000.279.4.L667; WAGNER EM, 1990, AM REV RESPIR DIS, V141, P584, DOI 10.1164/ajrccm/141.3.584; WAHL LM, 1984, CELL IMMUNOL, V85, P373, DOI 10.1016/0008-8749(84)90251-X; WOESSNER JF, 1988, MATRIX METALLOPROTEI, P1; Zhang YH, 1998, J IMMUNOL, V161, P3071	33	24	25	1	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2001	108	6					989	996		10.1067/mai.2001.120193	http://dx.doi.org/10.1067/mai.2001.120193			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	505WK	11742278				2022-12-18	WOS:000172938400016
J	Okano, M; Kino, K; Takishita, T; Hattori, H; Ogawa, T; Yoshino, T; Yokoyama, M; Nishizaki, K				Okano, M; Kino, K; Takishita, T; Hattori, H; Ogawa, T; Yoshino, T; Yokoyama, M; Nishizaki, K			Roles of carbohydrates on Cry j 1, the major allergen of Japanese cedar pollen, in specific T-cell responses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergen; carbohydrate; Cry j 1; T cell; clones; T(H)2; mannose receptor	CRYPTOMERIA-JAPONICA POLLEN; BEE-VENOM ALLERGEN; DER-P-II; MANNOSE RECEPTOR; DERMATOPHAGOIDES-PTERONYSSINUS; MYCOBACTERIUM-TUBERCULOSIS; IN-VIVO; ANTIGEN; IGE; COMPLEX	Background: Carbohydrates expressed on allergens are known to be important for allergenicity. However, little is known about whether the carbohydrates drive the T(H)2 response. Objective: We sought to determine a role for carbohydrates expressed on Cry j 1, which is the major allergen of Cryptomeria japonica pollen and causes the most prevalent pollinosis in Japan, in in vitro cellular responses. Methods: Carbohydrates on Cry j 1 were destroyed by periodate-oxidation under mild conditions. Proliferative responses and cytokine productions against native, periodate-treated, and mock-treated Cry j 1 were compared in peripheral blood mononuclear cells, Cry j 1-specific T-cell lines, and clones from patients with Japanese cedar pollinosis. Results: We found that peripheral blood mononuclear cells from patients with Japanese cedar pollinosis displayed a significant decrease in proliferation and IL-5 production in response to periodate-treated Cry j 1 in comparison with native and mock-treated Cry j 1. Decreased proliferative responses against periodate-treated Cry j 1 were also seen in polyclonal T-cell lines, and the responses showed a heterogeneity. In addition, Cry j 1-specific CD4+ T-cell clones also displayed a significant decrease in proliferation and IL-4 and IL-5 production-but not IFN-gamma production-in comparison with the control antigens. However, most of the clones showed decreased but positive proliferative responses against periodate-treated Cry j 1. Blockade or the mannose receptor had no effect on cellular responses. Conclusion: The results suggest that carbohydrates on Cry j 1 play a major role in promoting Cry j 1-specific T(H)2 response in vitro, though they are not major targets as T-cell epitopes.	Okayama Univ, Sch Med, Dept Otolaryngol, Okayama 7008558, Japan; Okayama Univ, Sch Med, Dept Pathol, Okayama 7008558, Japan; Meiji Inst Hlth, Odawara, Kanagawa, Japan	Okayama University; Okayama University	Okano, M (corresponding author), Okayama Univ, Sch Med, Dept Otolaryngol, 2-5-1 Shikata Cho, Okayama 7008558, Japan.							Batanero E, 1996, J ALLERGY CLIN IMMUN, V97, P1264, DOI 10.1016/S0091-6749(96)70194-X; Corinti S, 1997, J EXP MED, V186, P899, DOI 10.1084/jem.186.6.899; Currie AJ, 2000, J IMMUNOL, V164, P3878, DOI 10.4049/jimmunol.164.7.3878; Dormann D, 1997, INT ARCH ALLERGY IMM, V114, P272, DOI 10.1159/000237679; DUDLER T, 1995, EUR J IMMUNOL, V25, P538, DOI 10.1002/eji.1830250235; EZEKOWITZ RAB, 1991, NATURE, V351, P155, DOI 10.1038/351155a0; Grakoui A, 1999, J IMMUNOL, V162, P1923; HASHIMOTO M, 1995, CLIN EXP ALLERGY, V25, P848, DOI 10.1111/j.1365-2222.1995.tb00027.x; Horn C, 1999, J BIOL CHEM, V274, P32023, DOI 10.1074/jbc.274.45.32023; Ikagawa S, 1996, J ALLERGY CLIN IMMUN, V97, P53, DOI 10.1016/S0091-6749(96)70283-X; KAHN S, 1995, J EXP MED, V182, P1243, DOI 10.1084/jem.182.5.1243; Nishihata S, 1999, Arerugi, V48, P597; Ogawa H, 1996, GLYCOCONJUGATE J, V13, P555, DOI 10.1007/BF00731443; OHTA M, 1991, ARCH BIOCHEM BIOPHYS, V290, P474, DOI 10.1016/0003-9861(91)90569-5; Okano M, 1999, ALLERGY, V54, P811, DOI 10.1034/j.1398-9995.1999.00096.x; OKANO M, 1994, ALLERGY, V49, P436, DOI 10.1111/j.1398-9995.1994.tb00836.x; Okano M, 1996, ALLERGY, V51, P29, DOI 10.1111/j.1398-9995.1996.tb04546.x; Okano M, 1999, J IMMUNOL, V163, P6712; Romain F, 1999, INFECT IMMUN, V67, P5567, DOI 10.1128/IAI.67.11.5567-5572.1999; SCHENK S, 1994, EUR J BIOCHEM, V224, P717, DOI 10.1111/j.1432-1033.1994.00717.x; SONE T, 1994, BIOCHEM BIOPH RES CO, V199, P619, DOI 10.1006/bbrc.1994.1273; Sone T, 1998, J IMMUNOL, V161, P448; Sone T, 1999, INT ARCH ALLERGY IMM, V119, P185, DOI 10.1159/000024194; STAHL PD, 1992, CURR OPIN IMMUNOL, V4, P49, DOI 10.1016/0952-7915(92)90123-V; Stahl PD, 1998, CURR OPIN IMMUNOL, V10, P50, DOI 10.1016/S0952-7915(98)80031-9; Su SN, 1996, J ALLERGY CLIN IMMUN, V98, P486, DOI 10.1016/S0091-6749(96)70080-5; Tanaka H, 2000, J EXP MED, V192, P405, DOI 10.1084/jem.192.3.405; Till S, 1997, J ALLERGY CLIN IMMUN, V99, P563, DOI 10.1016/S0091-6749(97)70085-X; van Ree R, 2000, J BIOL CHEM, V275, P11451, DOI 10.1074/jbc.275.15.11451; Wurtzen PA, 1999, J ALLERGY CLIN IMMUN, V104, P115, DOI 10.1016/S0091-6749(99)70122-3; YANAGIHARA Y, 1994, INT ARCH ALLERGY IMM, V105, P162, DOI 10.1159/000236819; YASUEDA H, 1983, J ALLERGY CLIN IMMUN, V71, P77, DOI 10.1016/0091-6749(83)90550-X	32	24	25	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2001	108	1					101	108						8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	458AN	11447389				2022-12-18	WOS:000170171200014
J	Light, WC				Light, WC			Insect sting fatality 9 years after venom treatment (venom allergy, fatality)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									Laurel Asthma & Allergy Associates, Latrobe, PA 15650 USA		Light, WC (corresponding author), Laurel Asthma & Allergy Associates, 1100 Ligonier St, Latrobe, PA 15650 USA.							Graft DF, 1998, J ALLERGY CLIN IMMUN, V101, P573, DOI 10.1016/S0091-6749(98)70161-7	1	24	25	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2001	107	5					925	925		10.1067/mai.2001.114985	http://dx.doi.org/10.1067/mai.2001.114985			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	434JX	11344365				2022-12-18	WOS:000168812300026
J	McEuen, AR; Calafat, J; Compton, SJ; Easom, NJW; Buckley, MG; Knol, EF; Walls, AF				McEuen, AR; Calafat, J; Compton, SJ; Easom, NJW; Buckley, MG; Knol, EF; Walls, AF			Mass, charge, and subcellular localization of a unique secretory product identified by the basophil-specific antibody BB1	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						basophil; CD63; tryptase; immunoelectron microscopy; flow cytometry; isoelectric focusing; gel filtration chromatography	MONOCLONAL-ANTIBODY; CELL TRYPTASE; NASAL-MUCOSA; SKIN; LUNG; EOSINOPHILS; LEUKOCYTES; BLOOD; DIFFERENTIATION; PURIFICATION	Background: BB1 is a basophil-specific mAb (Lab Invest 1999;79:27-38). The Identity of the corresponding antigen has not been determined, but it gives a granular appearance on staining and is secreted on activation of basophils. Objective: We sought to further characterize the basophil-specific antigen identified by BB1. Methods: Intracellular localization was determined by flow cytometry and by immunogold labeling and electron microscopy. Physical chemical properties were investigated by gel filtration chromatography and preparative isoelectric focusing. Results: In flow cytometry, permeabilization of cells increased immunofluorescence 100-fold, confirming the predominantly intracellular localization of the antigen. It was further localized to the secretory granules by immunoelectron microscopy. Double labeling with a CD63-specific antibody demonstrated selective binding of BB1 to the granule matrix. Gel filtration chromatography indicated that the antigen is secreted as a complex of approximately 5 x 10(6)d, which was well resolved from the 210-kd supramolecular complex containing tryptase. The antigen was degraded by pronase. Isoelectric focusing indicated a highly basic protein with an isoelectric point of 9.6. Conclusion: With its granule localization, release on cell activation, and unique properties, the antigen identified by BB1 could be a novel mediator of allergic disease. We propose the name basogranulin for this novel basophil-specific protein.	Southampton Gen Hosp, Immunopharmacol Grp, Southampton SO16 6YD, Hants, England; Netherlands Canc Inst, Dept Cell Biol, Amsterdam, Netherlands; Univ Utrecht, Med Ctr, Dept Dermatol Allergol, Utrecht, Netherlands	University of Southampton; Netherlands Cancer Institute; Utrecht University	McEuen, AR (corresponding author), Southampton Gen Hosp, Immunopharmacol Grp, Mail Point 837,Tremona Rd, Southampton SO16 6YD, Hants, England.			Walls, Andrew/0000-0003-4803-4595; Knol, Edward/0000-0001-7368-9820				BODGER MP, 1987, BRIT J HAEMATOL, V67, P281, DOI 10.1111/j.1365-2141.1987.tb02348.x; BODGER MP, 1987, BLOOD, V69, P1414; Calafat J, 1997, BLOOD, V90, P1255, DOI 10.1182/blood.V90.3.1255.1255_1255_1266; Calafat J, 1997, EUR J HAEMATOL, V58, P56; Cameron L, 2000, J IMMUNOL, V164, P1538, DOI 10.4049/jimmunol.164.3.1538; CASTELLS MC, 1987, J IMMUNOL, V138, P2184; CHURCH MK, 1997, ALLERGY ALLERGIC DIS, V1, P149; DEBOER M, 1986, J IMMUNOL, V136, P3447; DENBURG JA, 1992, BLOOD, V79, P846; Dvorak AM, 1998, INT REV CYTOL, V180, P87; Fahy O, 2001, AM J PATHOL, V158, P1053, DOI 10.1016/S0002-9440(10)64052-7; FUKUDA T, 1987, BLOOD, V70, P612; GILBERT HS, 1975, BLOOD, V46, P279; GOLDSTEIN SM, 1992, J IMMUNOL, V148, P2475; HASTIE R, 1974, LAB INVEST, V31, P223; Irani AMA, 1998, J ALLERGY CLIN IMMUN, V101, P354, DOI 10.1016/S0091-6749(98)70248-9; Kepley CL, 1998, J LEUKOCYTE BIOL, V64, P474, DOI 10.1002/jlb.64.4.474; KEPLEY CL, 1995, J IMMUNOL, V154, P6548; KleinJan A, 2000, J ALLERGY CLIN IMMUN, V106, P677, DOI 10.1067/mai.2000.109621; KNOL EF, 1991, J ALLERGY CLIN IMMUN, V88, P328, DOI 10.1016/0091-6749(91)90094-5; Knol EF, 1996, EUR RESPIR J, V9, pS126; Lindstedt KA, 1998, BBA-GEN SUBJECTS, V1425, P617, DOI 10.1016/S0304-4165(98)00115-9; Liou W, 1996, HISTOCHEM CELL BIOL, V106, P41, DOI 10.1007/BF02473201; Macfarlane AJ, 2000, J ALLERGY CLIN IMMUN, V105, P99, DOI 10.1016/S0091-6749(00)90184-2; MACGLASHAN DW, 2000, ASTHMA RHINITIS, P339; Maecker HT, 1997, FASEB J, V11, P428, DOI 10.1096/fasebj.11.6.9194523; McEuen AR, 1996, BIOCHEM PHARMACOL, V52, P331, DOI 10.1016/0006-2952(96)00211-0; McEuen AR, 1999, LAB INVEST, V79, P27; NIEUWENHUIS HK, 1987, BLOOD, V70, P838; NILSSON G, 1993, IMMUNOLOGY, V79, P325; NOLTE H, 1987, ALLERGY, V42, P366, DOI 10.1111/j.1398-9995.1987.tb02223.x; Pemberton AD, 2000, CLIN EXP ALLERGY, V30, P818, DOI 10.1046/j.1365-2222.2000.00831.x; ROBERTS EM, 2000, AM J RESP CRIT CARE, V161, pA467; ROTTEM M, 2000, ASTHMA RHINITIS, P245; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; VALENT P, 1990, INT ARCH ALLER A IMM, V91, P198, DOI 10.1159/000235115; VISCHER UM, 1993, BLOOD, V82, P1184, DOI 10.1182/blood.V82.4.1184.1184; WALLS AF, 1990, CLIN EXP ALLERGY, V20, P581, DOI 10.1111/j.1365-2222.1990.tb03153.x; WILLHEIM M, 1995, J IMMUNOL METHODS, V182, P115, DOI 10.1016/0022-1759(95)00034-8; Yeh KW, 1999, AM J RESP CRIT CARE, V159, pA329; Ying S, 1999, J IMMUNOL, V163, P3976	41	24	26	0	5	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2001	107	5					842	848		10.1067/mai.2001.114650	http://dx.doi.org/10.1067/mai.2001.114650			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	434JX	11344351				2022-12-18	WOS:000168812300012
J	Emonet, S; Pasche-Koo, F; Perin-Minisini, MJ; Hauser, C				Emonet, S; Pasche-Koo, F; Perin-Minisini, MJ; Hauser, C			Anaphylaxis to oxybenzone, a frequent constituent of sunscreens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									Univ Geneva, Sch Med, Div Immunol & Allergy, Allergy Unit, CH-1211 Geneva, Switzerland; Univ Geneva, Sch Med, Dept Dermatol, CH-1211 Geneva, Switzerland	University of Geneva; University of Geneva	Emonet, S (corresponding author), Univ Geneva, Sch Med, Div Immunol & Allergy, Allergy Unit, CH-1211 Geneva, Switzerland.							Hayden CGJ, 1997, LANCET, V350, P863, DOI 10.1016/S0140-6736(05)62032-6; JEANMOUGIN M, 1994, NOUV DERMATOL, V13, P372; RAMSAY DL, 1972, ARCH DERMATOL, V105, P906, DOI 10.1001/archderm.105.6.906; RIETSCHEL RL, 1995, FISHERS CONTACT DERM, P531	4	24	24	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2001	107	3					556	557		10.1067/mai.2001.112430	http://dx.doi.org/10.1067/mai.2001.112430			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	416RE	11240962				2022-12-18	WOS:000167793300023
J	Tachimoto, H; Hudson, SA; Bochner, BS				Tachimoto, H; Hudson, SA; Bochner, BS			Acquisition and alteration of adhesion molecules during cultured human mast cell differentiation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						mast cells; adhesion; adhesion molecules; integrins; maturation; differentiation; stem cells; matrix proteins; fibronectin.; laminin; vitronectin	INTEGRIN GENE PROMOTER; FC-EPSILON-RI; BLOOD MONONUCLEAR-CELLS; COLONY-FORMING CELL; FETAL LIVER-CELLS; RECOMBINANT HUMAN; HUMAN BASOPHILS; BONE-MARROW; IN-VITRO; CYTOKINE PRODUCTION	Background: Mature human mast cells express several types of adhesion molecules on their surface. Interactions between extracellular matrix (ECM) and adhesion molecules may be important for the migration and localization of mast cells and their precursors in tissues. Little is known about the regulation of adhesion molecules on mast cells during their differentiation. Objectives: To clarify the evolution of adhesion phenotype and function, we examined the expression of adhesion molecules during cultured human mast cell (CHMC) differentiation and tested adhesion of mature CHMCs to various ECM proteins. Methods: CHMCs were obtained by culturing human cord blood-derived CD34(+) cells in the presence of stem cell factor and IL-6. Indirect immunofluorescence and now cytometry was used to study cell surface expression of adhesion molecules and other markers. Mature CHMCs were tested for adhesion molecule function with immobilized matrix proteins. Results: At 1 week of culture, cells expressed CD11a, CD18, CD29, CD49d, and CD49e. At 14 weeks of culture, more mature CHMCs expressed CD11b, CD11c, CD29, CD49b, CD49c, CD49d, CD49e, CD51, CD61, and CD54 and weakly expressed CD18 and CD11a. CD11c, CD51, and CD61 appeared de novo by 4 weeks of culture, whereas CD49b and CD49e appeared by 8 weeks. CD29 decreased at 4 weeks but returned to the identical levels of 1-week-old cells by 8 weeks. Compared with levels at week 1, the levels of CD11a, CD18, CD49d, and CD49e at 4 weeks and beyond decreased during culture. Expression of CD49a, CD49f, and alphad integrin was never detectable during CHMC differentiation. Fourteen-week-old CHMCs significantly adhered to the leucine-aspartic acid-valine-containing connecting segment 1 fragment of fibronectin, the 120-kd argine-glycine-aspartic acid-containing fragment of fibronectin, vitronectin, and laminin through specific integrins. Conclusion: Expression of integrins and CD54 is differentially regulated during CHMC differentiation, and mature CHMCs can adhere to many ECM proteins. These changes may facilitate emigration from the bone marrow into the circulation and ultimately contribute to the tissue homing and localization pattern seen with mature mast cells.	Johns Hopkins Univ, Sch Med, Dept Med, Div Clin Immunol, Baltimore, MD 21205 USA	Johns Hopkins University	Bochner, BS (corresponding author), Johns Hopkins Asthma & Allergy Ctr, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.				NIAID NIH HHS [AI41472] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI041472, R01AI041472] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adkinson NF, 1980, MEASUREMENT TOTAL SE; AGIS H, 1993, J IMMUNOL, V151, P4221; Anderson KL, 1998, BLOOD, V91, P3702, DOI 10.1182/blood.V91.10.3702; COLUMBO M, 1995, J IMMUNOL, V154, P6058; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; DERCKSEN MW, 1995, BLOOD, V85, P3319; DONAHUE JP, 1994, BBA-GENE STRUCT EXPR, V1219, P228, DOI 10.1016/0167-4781(94)90278-X; EBISAWA M, 1995, J ALLERGY CLIN IMMUN, V95, P219; Ghannadan M, 1998, J INVEST DERMATOL, V111, P689, DOI 10.1046/j.1523-1747.1998.00359.x; GUO CB, 1992, BLOOD, V79, P708; HAMAWY MM, 1992, J IMMUNOL, V149, P615; HAMAWY MM, 1993, J BIOL CHEM, V268, P5227; HENKEL G, 1994, P NATL ACAD SCI USA, V91, P7737, DOI 10.1073/pnas.91.16.7737; Inamura N, 1998, J IMMUNOL, V160, P4026; IRANI AMA, 1992, BLOOD, V80, P3009; ISHIZAKA K, 1970, IMMUNOCHEMISTRY, V7, P687, DOI 10.1016/0019-2791(70)90175-8; Kambe M, 1998, BBA-GENE STRUCT EXPR, V1395, P209, DOI 10.1016/S0167-4781(97)00152-8; Kim LT, 1998, J SURG RES, V76, P185, DOI 10.1006/jsre.1998.5331; KITAMURA Y, 1981, NATURE, V291, P159, DOI 10.1038/291159a0; KITAMURA Y, 1979, NATURE, V281, P154, DOI 10.1038/281154a0; KOVACH NL, 1995, BLOOD, V85, P159, DOI 10.1182/blood.V85.1.159.bloodjournal851159; Kruger-Krasagakes S, 1999, IMMUNOLOGY, V98, P253; Larouche K, 1996, DNA CELL BIOL, V15, P779, DOI 10.1089/dna.1996.15.779; LopezRodriguez C, 1997, EUR J IMMUNOL, V27, P1843, DOI 10.1002/eji.1830270804; MacGlashan D, 1998, BLOOD, V91, P1633, DOI 10.1182/blood.V91.5.1633.1633_1633_1643; McKinlay LH, 1998, J IMMUNOL, V161, P4098; MITSUI H, 1993, P NATL ACAD SCI USA, V90, P735, DOI 10.1073/pnas.90.2.735; Ochi H, 1999, J EXP MED, V190, P267, DOI 10.1084/jem.190.2.267; Oda N, 1999, J CELL PHYSIOL, V178, P121, DOI 10.1002/(SICI)1097-4652(199902)178:2<121::AID-JCP1>3.3.CO;2-6; Rodewald HR, 1996, SCIENCE, V271, P818, DOI 10.1126/science.271.5250.818; ROSEN GD, 1994, J BIOL CHEM, V269, P15652; ROSEN GD, 1991, P NATL ACAD SCI USA, V88, P4094, DOI 10.1073/pnas.88.10.4094; Rosenkranz AR, 1998, J IMMUNOL, V161, P6463; SAELAND S, 1992, EXP HEMATOL, V20, P24; Saito H, 1996, J IMMUNOL, V157, P343; SHAW S, 1995, LEUKOCYTE TYPING, V5, P16; SHIMIZU Y, 1995, BLOOD, V86, P930; Shimizu YJ, 1996, J IMMUNOL, V156, P3443; SIRAGANIAN RP, 1975, J IMMUNOL METHODS, V7, P283, DOI 10.1016/0022-1759(75)90025-3; SPERR WR, 1992, ANN HEMATOL, V65, P10, DOI 10.1007/BF01715119; SUBAUSTE MC, 1995, J CLIN INVEST, V96, P549, DOI 10.1172/JCI118067; Tachimoto H, 2000, J ALLERGY CLIN IMMUN, V106, P141, DOI 10.1067/mai.2000.107043; Tachimoto H, 1997, INT ARCH ALLERGY IMM, V113, P293, DOI 10.1159/000237578; Toru H, 1997, BLOOD, V89, P3296, DOI 10.1182/blood.V89.9.3296; Tsuji T, 1999, J BIOCHEM, V125, P1183, DOI 10.1093/oxfordjournals.jbchem.a022402; VALENT P, 1992, ADV IMMUNOL, V52, P333, DOI 10.1016/S0065-2776(08)60879-2; VALENT P, 1992, BLOOD, V80, P2237; VALENT P, 1989, BLOOD, V73, P1778; Wimazal F, 1999, TISSUE ANTIGENS, V54, P499, DOI 10.1034/j.1399-0039.1999.540507.x; Yuan Q, 1998, J IMMUNOL, V161, P5143; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U; ZUTTER MM, 1995, BLOOD, V86, P3006	52	24	25	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2001	107	2					302	309		10.1067/mai.2001.111930	http://dx.doi.org/10.1067/mai.2001.111930			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	403YV	11174197				2022-12-18	WOS:000167071400017
J	Zeibecoglou, K; Ying, S; Meng, Q; Poulter, LW; Robinson, DS; Kay, AB				Zeibecoglou, K; Ying, S; Meng, Q; Poulter, LW; Robinson, DS; Kay, AB			Macrophage subpopulations and macrophage-derived cytokines in sputum of atopic and nonatopic asthmatic subjects and atopic and normal control subjects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; atopy; macrophage; IL-10; IL-12	MESSENGER-RNA EXPRESSION; STIMULATORY FACTOR INTERLEUKIN-12; T-CELL SUBSETS; BRONCHOALVEOLAR LAVAGE; BRONCHIAL BIOPSIES; AIRWAY HYPERRESPONSIVENESS; PULMONARY SARCOIDOSIS; ALVEOLAR MACROPHAGES; INTRINSIC ASTHMA; PERIPHERAL-BLOOD	Background: Previous studies have shown a prominent macrophage signal in the bronchial mucosa from nonatopic (intrinsic) compared with atopic (extrinsic) asthmatic subjects. This observation might have represented an expansion of a proinflammatory macrophage population or a homeostatic mechanism to decrease T(H)2-type inflammation. Objective: The aim of the study was to investigate the numbers of macrophages and macrophage subpopulations and the expression of IL-10 and IL-12 in sputum from asthmatic and control subjects. Methods: Eight atopic asthmatic (AA) subjects, 10 nonatopic asthmatic (NAA) subjects, 6 atopic control (AC) subjects, and 7 normal control (NC) subjects underwent sputum induction. Macrophages were enumerated by using Romanowsky stain and immunocytochemistry (CD68), RFD1 (interdigitating cell marker) and RFD7 (mature phagocyte marker) mAbs were used for immunocytochemical phenotyping, whereas IL-10 and IL-12 messenger (m)RNA was examined with in situ hybridization by using S-35-labeled riboprobes. The phenotype of cells expressing IL-10 or IL-12 mRNA was examined by simultaneous in situ hybridization and immunostaining. Results: No differences in the numbers of CD68(+) macrophages and RFD1(+), RFD7(+), and RFD1(+)/RFD7(+) subpopulations were found between AA, NAA, AC, and NC subjects. However, the numbers of IL-10 and IL-12 mRNA(+) cells were increased in AA subjects compared with NAA, AC, and NC subjects (P < .05), No other differences were found among the groups. Most of the IL-10 and IL-12 mRNA(+) cells in sputum from asthmatic subjects were macrophages (>80%), with less than 10% of mRNA colocalizing to epithelial cells. Conclusions: Sputum macrophage numbers, unlike tissue macrophages, as previously reported, were not elevated in NAA subjects. Increased IL-10 and IL-12 expression in atopic asthma may indicate the existence of a homeostatic mechanism to decrease lung inflammation. The lack of such cytokines in intrinsic asthma may predispose to bronchial inflammation in these subjects.	Univ London Imperial Coll Sci Technol & Med, London, England; Natl Heart & Lung Inst, London, England; Royal Free Hosp, Sch Med, London NW3 2QG, England	Imperial College London; Imperial College London; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	Zeibecoglou, K (corresponding author), Univ London Imperial Coll Sci Technol & Med, London, England.							BENTLEY AM, 1992, AM REV RESPIR DIS, V146, P500, DOI 10.1164/ajrccm/146.2.500; Borish L, 1996, J ALLERGY CLIN IMMUN, V97, P1288, DOI 10.1016/S0091-6749(96)70197-5; CAMPBELL DA, 1986, THORAX, V41, P429, DOI 10.1136/thx.41.6.429; DANDREA A, 1992, J EXP MED, V176, P1387, DOI 10.1084/jem.176.5.1387; DELPRETE G, 1993, J IMMUNOL, V150, P353; ENK AH, 1994, J EXP MED, V179, P1397, DOI 10.1084/jem.179.4.1397; Folkard SG, 1997, EUR RESPIR J, V10, P2097, DOI 10.1183/09031936.97.10092097; GAVETT SH, 1995, J EXP MED, V182, P1527, DOI 10.1084/jem.182.5.1527; Goerdt S, 1999, IMMUNITY, V10, P137, DOI 10.1016/S1074-7613(00)80014-X; GOSSET P, 1992, AM REV RESPIR DIS, V146, P768, DOI 10.1164/ajrccm/146.3.768; Guler ML, 1996, SCIENCE, V271, P984, DOI 10.1126/science.271.5251.984; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; Hamid QA, 1997, J ALLERGY CLIN IMMUN, V99, P254, DOI 10.1016/S0091-6749(97)70106-4; Humbert M, 1997, AM J RESP CELL MOL, V16, P1; Humbert M, 1996, AM J RESP CRIT CARE, V154, P1497, DOI 10.1164/ajrccm.154.5.8912771; Hutter C, 1992, FEMS Microbiol Immunol, V5, P309; *INT COMM STAND HA, 1984, BRIT J HAEMATOL, V57, P507; JANOSSY G, 1986, J IMMUNOL, V136, P4354; Koning H, 1997, CYTOKINE, V9, P427, DOI 10.1006/cyto.1996.0185; Kotsimbos ATC, 1997, J ALLERGY CLIN IMMUN, V99, P666, DOI 10.1016/S0091-6749(97)70029-0; Magnan A, 1998, ALLERGY, V53, P1092, DOI 10.1111/j.1398-9995.1998.tb03821.x; MANETTI R, 1993, J EXP MED, V177, P1199, DOI 10.1084/jem.177.4.1199; MASON DY, 1978, J CLIN PATHOL, V31, P454, DOI 10.1136/jcp.31.5.454; Naseer T, 1997, AM J RESP CRIT CARE, V155, P845, DOI 10.1164/ajrccm.155.3.9117015; Olivenstein R, 1999, J ALLERGY CLIN IMMUN, V103, P238, DOI 10.1016/S0091-6749(99)70497-5; PIN I, 1992, AM REV RESPIR DIS, V145, P1265, DOI 10.1164/ajrccm/145.6.1265; Poulter LW, 1996, IMMUNOBIOLOGY, V195, P574, DOI 10.1016/S0171-2985(96)80023-4; POULTER LW, 1992, EUR RESPIR J, V5, P182; POULTER LW, 1986, SCAND J IMMUNOL, V24, P351; PUNNONEN J, 1993, J IMMUNOL, V151, P1280; ROBINSON DS, 1993, J ALLERGY CLIN IMMUN, V92, P397, DOI 10.1016/0091-6749(93)90118-Y; Robinson DS, 1996, AM J RESP CELL MOL, V14, P113, DOI 10.1165/ajrcmb.14.2.8630259; Sanchez-Guerrero I, 1997, Allergol Immunopathol (Madr), V25, P98; SPITERI MA, 1989, EUR RESPIR J, V2, P218; SPITERI MA, 1988, CLIN EXP IMMUNOL, V74, P359; TANG MLK, 1995, CLIN EXP ALLERGY, V25, P515, DOI 10.1111/j.1365-2222.1995.tb01088.x; WALKER C, 1991, J IMMUNOL, V146, P1829; WALKER C, 1992, AM REV RESPIR DIS, V146, P109, DOI 10.1164/ajrccm/146.1.109; YING S, 1995, AM J RESP CELL MOL, V12, P477, DOI 10.1165/ajrcmb.12.5.7742012; Ying S, 1997, J IMMUNOL, V158, P3539; Ying S, 1997, EUR J IMMUNOL, V27, P3507, DOI 10.1002/eji.1830271252	41	24	24	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2000	106	4					697	704		10.1067/mai.2000.109824	http://dx.doi.org/10.1067/mai.2000.109824			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	365ZP	11031340				2022-12-18	WOS:000089980600013
J	Dessanges, JF; Prefaut, C; Taytard, A; Matran, R; Naya, I; Compagnon, A; Dinh-Xuan, AT				Dessanges, JF; Prefaut, C; Taytard, A; Matran, R; Naya, I; Compagnon, A; Dinh-Xuan, AT			The effect of zafirlukast on repetitive exercise-induced bronchoconstriction: The possible role of leukotrienes in exercise-induced refractoriness	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						exercise-induced asthma; exercise-induced refractoriness; leukotriene-receptor antagonists; zafirlukast	INDUCED ASTHMA; RECEPTOR ANTAGONIST; INDUCED BRONCHOSPASM; PHARMACOLOGY; MONTELUKAST; ICI-204,219; INHIBITION; STIMULUS	Background: Single doses of zafirlukast attenuate exercise-induced bronchoconstriction (EIB), but previous studies have not measured zafirlukast's effects after regular dosing or its duration of effect beyond 4 hours. Objective: The purpose of this study was to assess the effects of zafirlukast 20 mg and 80 mg twice daily compared with placebo on exercise challenges performed at 2 and 8 hours after the last dose of regular administration. Methods: Twenty-four adult patients with stable asthma taking beta(2)-agonists, inhaled corticosteroids, or both received treatment with zafirlukast (20 mg and 80 mg) and placebo. The patients were treated twice daily for 14 days in a randomized, double-blind, 3-way cross-over fashion, with a 7-day washout period between each treatment. Exercise challenges were performed at 2 and 8 hours after the morning dose on day 14, FEV1 was measured before exercise and at set intervals after exercise until it returned to within 7% of its baseline value, Results: Both zafirlukast treatments significantly reduced EIB, as measured by the area under the FEV, time curve after the 2-hour (P < .001) and 8-hour (P < .001) exercise challenges and maximum fan in FEV1 at the 2-hour challenge (P < .001), The comparison at 8 hours between treatments was affected by the unexpected finding that EIB was less in the placebo group after the 2-hour challenge than after the 2-hour challenge, as measured by the within-group change in the maximum fall in FEV1 (P < .001) and the area under the FEV1 time curve (P = .0023), Conclusion: Regular zafirlukast treatment protects against EIB for at least 8 hours after regular dosing, A refractory period, which may be caused by exercise-induced leukotriene release, may last for up to 6 hours after the initial response to exercise.	CHU Cochin Port Royal, Serv Physiol Explorat Fonctionnelles, AP HP, F-75679 Paris 14, France; Hop Arnaud Villeneuve, Montpellier, France; Hop Haut Leveque, Pessac, France; Hop Cardiol, F-59037 Lille, France; Zeneca Pharma, Cergy, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Universite de Montpellier; CHU de Montpellier; CHU Bordeaux; Universite de Lille - ISITE; CHU Lille	Dinh-Xuan, AT (corresponding author), CHU Cochin Port Royal, Serv Physiol Explorat Fonctionnelles, AP HP, 27 Rue Fg St Jacques, F-75679 Paris 14, France.		DINH-XUAN, Anh Tuan/A-9691-2008	DINH-XUAN, Anh Tuan/0000-0001-8651-5176				Adkins JC, 1998, DRUGS, V55, P121, DOI 10.2165/00003495-199855010-00008; ANDERSON SD, 1985, EUR J RESPIR DIS, V67, P20; ANDERSON SD, 1989, ALLERGY PROC, V10, P215, DOI 10.2500/108854189778960054; BJORNSDOTTIR US, 1993, IMMUNOL ALLERGY CLIN, V13, P861; Bronsky EA, 1997, CLIN PHARMACOL THER, V62, P556, DOI 10.1016/S0009-9236(97)90051-5; CHANYEUNG MM, 1971, AM REV RESPIR DIS, V104, P915; DINH XUAN AT, 1989, EUR RESPIR J, V2, P409; EDMUNDS AT, 1978, AM REV RESPIR DIS, V117, P247; FINNERTY JP, 1992, AM REV RESPIR DIS, V145, P746, DOI 10.1164/ajrccm/145.4_Pt_1.746; Inman MD, 1996, AM J RESP CRIT CARE, V153, P65, DOI 10.1164/ajrccm.153.1.8542164; JAMES L, 1976, J ALLERGY CLIN IMMUN, V57, P408, DOI 10.1016/0091-6749(76)90055-5; KEMP JP, 1994, AM J RESP CRIT CARE, V150, P1612, DOI 10.1164/ajrccm.150.6.7952623; KRELL RD, 1990, AM REV RESPIR DIS, V141, P978, DOI 10.1164/ajrccm/141.4_Pt_1.978; LEFT JA, 1998, NEW ENGL J MED, V339, P147; LOCKHART A, 1992, AM REV RESPIR DIS, V146, pS19, DOI 10.1164/ajrccm/146.5_Pt_2.S19; MAKKER HK, 1993, AM REV RESPIR DIS, V147, P1413, DOI 10.1164/ajrccm/147.6_Pt_1.1413; MANNING PJ, 1993, AM REV RESPIR DIS, V148, P950, DOI 10.1164/ajrccm/148.4_Pt_1.950; MANNING PJ, 1990, NEW ENGL J MED, V323, P1736, DOI 10.1056/NEJM199012203232504; MCFADDEN ER, 1986, J CLIN INVEST, V78, P18, DOI 10.1172/JCI112549; MELILLO E, 1994, AM J RESP CRIT CARE, V149, P1138, DOI 10.1164/ajrccm.149.5.8173753; Meltzer SS, 1996, AM J RESP CRIT CARE, V153, P931, DOI 10.1164/ajrccm.153.3.8630575; OBYRNE PM, 1997, SRS A LEUKOTRIENES, P255; Pearlman DS, 1999, J PEDIATR-US, V134, P273, DOI 10.1016/S0022-3476(99)70449-X; RAMAGE L, 1994, RESP MED, V88, P363, DOI 10.1016/0954-6111(94)90042-6; Reiss TF, 1997, THORAX, V52, P1030, DOI 10.1136/thx.52.12.1030; ROBUSCHI M, 1992, AM REV RESPIR DIS, V145, P1285, DOI 10.1164/ajrccm/145.6.1285	26	24	26	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1999	104	6					1155	1161		10.1016/S0091-6749(99)70007-2	http://dx.doi.org/10.1016/S0091-6749(99)70007-2			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	266FD	10588995				2022-12-18	WOS:000084289200006
J	Jacobson, JD; Ansari, MA; Mansfield, ME; McArthur, CP; Clement, LT				Jacobson, JD; Ansari, MA; Mansfield, ME; McArthur, CP; Clement, LT			Gonadotropin-releasing hormone increases CD4+-lymphocyte numbers in an animal model of immunodeficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						immunodeficiency; gonadotropin-releasing hormone; CD4+ T lymphocytes; autoimmunity; immunoglobulins	HUMORAL IMMUNE-RESPONSES; RECENT THYMIC EMIGRANTS; BB RAT; LYMPHOCYTE COUNTS; LHRH RECEPTORS; MESSENGER-RNA; G-PROTEINS; EXPRESSION; ANTAGONIST; POTENT	Background: Gonadotropin-releasing hormone (GnRH) possesses immunostimulatory properties. We have previously demonstrated that GnRH antagonists decrease lymphocyte numbers in an animal model of autoimmune disease. We speculated that the converse might be true, that GnRH administration would increase lymphocyte numbers or alter lymphocyte subsets in an immunodeficiency state. Objective: Our purpose was to test the hypothesis that GnRH agonist would increase IgG and CD4 counts in a rat model of immunodeficiency independently of gonadal steroids. Methods: We used diabetes-prone (DP) BE rats. This model has been characterized to have an AIDS-like lymphocyte profile, with lymphopenia and depressed CD4 counts. Ovariectomized female DP rats were randomized to receive subcutaneous injections with GnRH or vehicle 6 times meekly. DR rats were ovariectomized and treated with vehicle as controls. We performed flow cytometric analysis and complete blood cell counts at baseline, 3.5 weeks, and 7 weeks of treatment. We also measured total serum IgG and luteinizing hormone levels. Results: GnRH administration significantly increased total serum IgG levels in DP rats compared with vehicle. The percentages of CD4(+) cells in blood were also significantly increased in the GnRH-treated group compared with the vehicle-treated group and compared with baseline. Similarly, the absolute numbers of CD4(+) positive T cells were increased over controls at 7 weeks. The effects of GnRH were specific for the CD4 subset because there were no significant differences in numbers of CD8(+) positive cells between the 2 treatment groups. Conclusion: GnRH shows potential utility as an immunostimulatory agent in immunodeficient states manifesting diminished numbers of immunocompetent CD4(+) T lymphocytes.	Univ Missouri, Sch Dent, Kansas City, MO USA; Univ So Calif, Med Ctr, Div Allergy Immunol, Los Angeles, CA USA; Univ Missouri, Childrens Mercy Hosp, Endocrinol Sect, Sch Med, Kansas City, MO 64108 USA	University of Missouri System; University of Missouri Kansas City; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of Southern California; Children's Mercy Hospital; University of Missouri System; University of Missouri Kansas City	Jacobson, JD (corresponding author), Univ Missouri, Childrens Mercy Hosp, Endocrinol Sect, Sch Med, 2401 Gillham Rd, Kansas City, MO 64108 USA.			McArthur, Carole/0000-0002-9286-8362	NIAMS NIH HHS [1R29 AR43152] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR043152] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AZAD N, 1993, ENDOCRINOLOGY, V133, P215, DOI 10.1210/en.133.1.215; BAGATELL CJ, 1989, J CLIN ENDOCR METAB, V69, P43, DOI 10.1210/jcem-69-1-43; BATTICANE N, 1991, ENDOCRINOLOGY, V129, P277, DOI 10.1210/endo-129-1-277; BELVISI L, 1993, J ENDOCRINOL INVEST, V16, P889, DOI 10.1007/BF03348951; BLALOCK JE, 1985, J IMMUNOL, V135, pS858; Chen HF, 1999, J CLIN ENDOCR METAB, V84, P743, DOI 10.1210/jc.84.2.743; Deschaux P, 1986, Boll Soc Ital Biol Sper, V62, P763; DOBS AS, 1988, AM J MED, V84, P611, DOI 10.1016/0002-9343(88)90144-1; ELDER ME, 1983, J IMMUNOL, V130, P1723; EMANUELE NV, 1990, ENDOCRINOLOGY, V126, P2482, DOI 10.1210/endo-126-5-2482; FRASER GR, 1963, BRIT MED J, P1284, DOI 10.1136/bmj.1.5340.1284; HAWES BE, 1993, CLIN CHEM, V39, P325; HAWES BE, 1992, ENDOCRINOLOGY, V130, P2465, DOI 10.1210/en.130.5.2465; Iwakoshi NN, 1998, J IMMUNOL, V160, P5838; JACOBSON JD, 1994, ENDOCRINOLOGY, V134, P2516, DOI 10.1210/en.134.6.2516; Jacobson JD, 1998, NEUROENDOCRINOLOGY, V67, P117, DOI 10.1159/000054306; JACOBSON JD, 1999, IN PRESS ENDOCRINOLO; LIKE AA, 1983, DIABETES, V32, pA51; LIKE AA, 1986, J IMMUNOL, V136, P3254; MAIER CC, 1992, CELL MOL NEUROBIOL, V12, P447, DOI 10.1007/BF00711545; MARCHETTI B, 1989, ENDOCRINOLOGY, V125, P1037, DOI 10.1210/endo-125-2-1037; McDougall B, 1997, SCAND J IMMUNOL, V45, P103, DOI 10.1046/j.1365-3083.1997.d01-374.x; MORALE MC, 1991, ENDOCRINOLOGY, V128, P1073, DOI 10.1210/endo-128-2-1073; NAJI A, 1983, J IMMUNOL, V130, P2168; NISWENDER GD, 1968, P SOC EXP BIOL MED, V128, P807; Ramanathan S, 1998, J IMMUNOL, V160, P5757; Saravolatz L, 1996, CLIN INFECT DIS, V22, P513, DOI 10.1093/clinids/22.3.513; SCOTT J, 1987, DIABETOLOGIA, V30, P774; TENOVER JS, 1990, J CLIN ENDOCR METAB, V71, P881, DOI 10.1210/jcem-71-4-881; Weesner GD, 1997, LIFE SCI, V61, P1643, DOI 10.1016/S0024-3205(97)00769-8; WILDER RL, 1995, ANNU REV IMMUNOL, V13, P307; WILLIAMS ED, 1964, NEW ENGL J MED, V270, P805, DOI 10.1056/NEJM196404162701601; YALE JF, 1984, CLIN EXP IMMUNOL, V57, P1; YALE JF, 1985, DIABETES, V34, P955, DOI 10.2337/diabetes.34.10.955	34	24	28	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1999	104	3	1				653	658		10.1016/S0091-6749(99)70338-6	http://dx.doi.org/10.1016/S0091-6749(99)70338-6			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	241EP	10482842				2022-12-18	WOS:000082870000030
J	Ylitalo, L; Makinen-Kiljunen, S; Turjanmaa, K; Palosuo, T; Reunala, T				Ylitalo, L; Makinen-Kiljunen, S; Turjanmaa, K; Palosuo, T; Reunala, T			Cow's milk casein, a hidden allergen in natural rubber latex gloves	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						latex gloves; cow's milk allergy; casein; latex allergy testing	SKIN PRICK TEST; MEDICAL GLOVES; FOOD ALLERGY; CHILDREN; INFANTS	Background: We have previously noted that one natural rubber latex (NRL) glove brand used for skin prick testing in the diagnosis of NRL allergy contained cow's milk casein. Objective: We sought to examine whether other commonly marketed NRL glove brands contain cow's milk casein, Methods: The casein content of 30 NRL glove extracts (1:5 wt/vol) was measured by RAST inhibition and by rocket immunoelectrophoresis and rocket radioimmunoelectrophoresis by using casein-specific rabbit antiserum, a serum pool from patients with cow's milk allergy, and radiolabeled antihuman IgE, The NRL allergen content was measured by ELISA inhibition. Results: The casein content of the glove used in NRL allergy screening (Triflex, Baxter) was rather high (ie, about 400 mu g/g of glove). Its total protein content was 1000 mu g/g of glove. Rocket radioimmunoelectrophoresis detected distinct amounts of casein in 8, minimal amounts in 7, and no casein in the remaining 15 NRL glove brands. Conclusions: Several brands of NRL gloves were found to contain casein, implying that extracts prepared from such gloves can cause false-positive skin prick test reactions when diagnosing NRL allergy. The use of casein as a stabilizer in glove manufacture without appropriate labeling should be stopped because it can also cause contact urticaria syndrome in individuals with cow's milk allergy.	Tampere Univ Hosp, Dept Dermatol, FIN-33521 Tampere, Finland; Univ Helsinki, Cent Hosp, Hosp Skin & Allerg Dis, Helsinki, Finland; Natl Publ Hlth Inst, Helsinki, Finland; Univ Tampere, Sch Med, Tampere, Finland	Tampere University; Tampere University Hospital; University of Helsinki; Helsinki University Central Hospital; Finland National Institute for Health & Welfare; Tampere University	Ylitalo, L (corresponding author), Tampere Univ Hosp, Dept Dermatol, POB 2000, FIN-33521 Tampere, Finland.							ALENIUS H, 1994, ANN ALLERGY, V73, P315; Beezhold D, 1996, J ALLERGY CLIN IMMUN, V98, P1097, DOI 10.1016/S0091-6749(96)80197-7; BLACKLEY DC, 1966, HIGHER POLYM LATICES, V1, P119; CONDESALAZAR L, 1993, J AM ACAD DERMATOL, V29, P176, DOI 10.1016/0190-9622(93)70163-N; Hamann CP, 1993, AM J CONTACT DERMATI, V4, P4, DOI DOI 10.1097/01634989-199303000-00003; HEESE A, 1991, J AM ACAD DERMATOL, V25, P831, DOI 10.1016/S0190-9622(08)80977-2; Isolauri E, 1996, J ALLERGY CLIN IMMUN, V97, P9, DOI 10.1016/S0091-6749(96)70277-4; LECKS HI, 1980, JAMA-J AM MED ASSOC, V244, P1560, DOI 10.1001/jama.244.14.1560; Liebke C, 1996, PEDIATR ALLERGY IMMU, V7, P103, DOI 10.1111/j.1399-3038.1996.tb00115.x; Liss GM, 1997, OCCUP ENVIRON MED, V54, P335, DOI 10.1136/oem.54.5.335; MAKINENKILJUNEN S, 1992, J ALLERGY CLIN IMMUN, V90, P230, DOI 10.1016/0091-6749(92)90076-E; MAKINENKILJUNEN S, 1993, LANCET, V342, P863, DOI 10.1016/0140-6736(93)92721-5; Palosuo T, 1998, ALLERGY, V53, P59, DOI 10.1111/j.1398-9995.1998.tb03774.x; PALOSUO T, 1996, PUBLICATIONS NATL AG, V2, P1; Sampson HA, 1997, JAMA-J AM MED ASSOC, V278, P1888, DOI 10.1001/jama.278.22.1888; SCHRANDER JJP, 1993, EUR J PEDIATR, V152, P640, DOI 10.1007/BF01955238; SUBRAMANIAN A, 1995, IMMUNOLOGY ALLERGY C, P1; SUSSMAN GL, 1995, ANN INTERN MED, V122, P43, DOI 10.7326/0003-4819-122-1-199501010-00007; TURJANMAA K, 1988, CONTACT DERMATITIS, V19, P362, DOI 10.1111/j.1600-0536.1988.tb02953.x; Turjanmaa K, 1997, ALLERGY, V52, P41, DOI 10.1111/j.1398-9995.1997.tb02544.x; Turjanmaa K, 1996, ALLERGY, V51, P593, DOI 10.1111/j.1398-9995.1996.tb04678.x; TURJANMAA K, 1995, LATEX ALLERGY, P71; VANDENPLAS O, 1995, AM J RESP CRIT CARE, V151, P54, DOI 10.1164/ajrccm.151.1.7812572; Warshaw EM, 1998, J AM ACAD DERMATOL, V39, P1, DOI 10.1016/S0190-9622(98)70397-4; Ylitalo L, 1997, J ALLERGY CLIN IMMUN, V100, P606, DOI 10.1016/S0091-6749(97)70163-5; YUNGINGER JW, 1994, J ALLERGY CLIN IMMUN, V93, P836, DOI 10.1016/0091-6749(94)90374-3	26	24	24	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1999	104	1					177	180		10.1016/S0091-6749(99)70131-4	http://dx.doi.org/10.1016/S0091-6749(99)70131-4			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	221QZ	10400857				2022-12-18	WOS:000081738900027
J	Ringsberg, KC; Akerlind, I				Ringsberg, KC; Akerlind, I			Presence of hyperventilation in patients with asthma-like symptoms but negative asthma test responses: Provocation with voluntary hyperventilation and mental stress	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; asthma-like; hyperventilation; hyperventilation syndrome; mental stress	DIAGNOSIS; CHALLENGES; DISORDERS	Background: A group of patients reporting asthma-like symptoms but with negative asthma tests has been identified. Objective: The objective of this study was to determine whether hyperventilation might explain these symptoms and whether the tests could be used as diagnostic tools. Methods: A hyperventilation provocation test (HVPT), a mental stress test, and the Word Color Conflict Test (WCCT) were performed on 10 patients with asthma-like symptoms, 10 patients with asthma, and 10 healthy subjects. End-tidal PCO2 (PETCO2) was recorded 10 minutes after the HVPT and during the WCCT Blood pressure, heart rate, and respiratory rate were also studied. The Nijmegen symptom questionnaire was used in the assessment of symptoms. Results: After the HVPT, the PETCO2 values recovered most slowly in the study group, the difference being significant compared with the healthy group (P < .01), During the WCCT, the study group had the lowest PETCO2 values at the 10- and 15-minute measurements, the difference again being significant compared with the healthy group (P < .05). The study group more often experienced symptoms before the test than the group with asthma (P < .05) and the healthy group (P < .001). The study group recognized significantly more symptoms previously experienced during the HVPT than the group with asthma (P < .05) and the healthy group (P < .01) and during the WCCT than the healthy group (P < .05). The study group showed a negative correlation between the PETCO2 level and the number of symptoms after the HVPT at 8 (r = -0-72; P < .05) and 10 minutes (r = -0.76; P < .05) and after the WCCT (r = -0.59; P < .05). Blood pressure, heart rate, and respiratory rate shelved small differences between the groups. Conclusion: Patients with asthma-like symptoms may experience hyperventilation when provoked. Mental stress might be 1 trigger factor. The HVPT and WCCT can be used as diagnostic instruments.	Linkoping Univ, Dept Hlth & Environm, Div Prevent & Social Med & Publ Hlth Sci, S-58185 Linkoping, Sweden; Cty Ostergotland, Primary Hlth Care Res & Dev Unit, Norrkoping, Sweden	Linkoping University; City Council Ostergotland	Ringsberg, KC (corresponding author), Linkoping Univ, Dept Hlth & Environm, Div Prevent & Social Med & Publ Hlth Sci, S-58185 Linkoping, Sweden.							BASS C, 1985, BRIT MED J, V290, P1387, DOI 10.1136/bmj.290.6479.1387; Bass C, 1997, J PSYCHOSOM RES, V42, P421, DOI 10.1016/S0022-3999(96)00365-0; BRADLEY JV, 1968, DISTRIBUTION FREE ST, P68; BRASHEAR RE, 1983, LUNG, V161, P257, DOI 10.1007/BF02713872; COLLINS A, 1978, J HUM STRESS, V4, P43, DOI 10.1080/0097840X.1978.9934986; COMPERNOLLE T, 1979, PSYCHOSOMATICS, V20, P612; DEMETER SL, 1986, AM J MED, V81, P989, DOI 10.1016/0002-9343(86)90393-1; FOLGERING H, 1978, B EUR PHYSIOPATH RES, V14, P503; FRANKENHAEUSER M, 1968, PSYCHOSOM MED, V30, P109, DOI 10.1097/00006842-196801000-00010; GARDNER W, 1990, J ROY SOC MED, V83, P755, DOI 10.1177/014107689008301201; GARDNER WN, 1989, BRIT J HOSP MED, V41, P73; Gardner WN, 1996, CHEST, V109, P516, DOI 10.1378/chest.109.2.516; GARDNER WN, 1986, LANCET, V2, P826; GROSSMAN P, 1984, J PSYCHOSOM RES, V28, P97, DOI 10.1016/0022-3999(84)90001-1; Guttmann E, 1940, Br Med J, V2, P736; Hardonk H., 1979, HDB CLIN NEUROLOGY, V38, P309; HORNSVELD H, 1990, J PSYCHOSOM RES, V34, P687, DOI 10.1016/0022-3999(90)90113-I; Hornsveld HK, 1996, LANCET, V348, P154, DOI 10.1016/S0140-6736(96)02024-7; Jacobsen E, 1974, PROGR RELAXATION PHY; Lavietes MH, 1996, INT J BEHAV MED, V3, P70, DOI 10.1207/s15327558ijbm0301_6; Lewis T, 1916, BRIT MED J, V1916, P517, DOI 10.1136/bmj.2.2911.517; Leznoff A, 1997, J ALLERGY CLIN IMMUN, V99, P438, DOI 10.1016/S0091-6749(97)70067-8; LINDSAY S, 1991, J PSYCHOSOM RES, V35, P155, DOI 10.1016/0022-3999(91)90070-5; LOWHAGEN O, 1983, EUR J RESPIR DIS, V64, P466; MAGARIAN GJ, 1982, MEDICINE, V61, P219, DOI 10.1097/00005792-198207000-00002; MCFADDEN ER, 1968, NEW ENGL J MED, V278, P1027, DOI 10.1056/NEJM196805092781901; Millqvist E, 1996, ALLERGY, V51, P434, DOI 10.1111/j.1398-9995.1996.tb00156.x; MORGAN WP, 1983, AM IND HYG ASSOC J, V44, P685; *NIH, 1992, PUBL NIH, P1; ODEN A, 1975, ANN STAT, V3, P518, DOI 10.1214/aos/1176343082; PAUL O, 1987, BRIT HEART J, V58, P306; RAFFERTY GF, 1992, RESP MED, V86, P335, DOI 10.1016/S0954-6111(06)80033-8; RINGSBERG KC, 1993, INTEGR PHYS BEH SCI, V28, P358, DOI 10.1007/BF02690933; Ringsberg KC, 1997, ALLERGY, V52, P532, DOI 10.1111/j.1398-9995.1997.tb02596.x; Ringsberg KC, 1997, SCAND J CARING SCI, V11, P103, DOI 10.1111/j.1471-6712.1997.tb00440.x; ROLL M, 1990, J INTERN MED, V228, P223, DOI 10.1111/j.1365-2796.1990.tb00222.x; SALTZMAN HA, 1963, NEW ENGL J MED, V268, P1431, DOI 10.1056/NEJM196306272682602; SMITH CW, 1985, POSTGRAD MED, V78, P73, DOI 10.1080/00325481.1985.11699084; Soley MH, 1938, AM J MED SCI, V196, P840, DOI 10.1097/00000441-193812000-00010; UNESTHAL LE, 1991, SJALUKONTROLL GENOM; VANDIXHOORN J, 1985, J PSYCHOSOM RES, V29, P199, DOI 10.1016/0022-3999(85)90042-X; VANDOORN P, 1982, B EUR PHYSIOPATH RES, V18, P829; VANSTEENKISTE J, 1991, ACTA CLIN BELG, V46, P142, DOI 10.1080/17843286.1991.11718157; VANSTEENKISTE J, 1991, EUR RESPIR J, V4, P393; White PD, 1942, J AMER MED ASSOC, V118, P270, DOI 10.1001/jama.1942.02830040008003	45	24	24	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1999	103	4					601	608		10.1016/S0091-6749(99)70231-9	http://dx.doi.org/10.1016/S0091-6749(99)70231-9			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	186HY	10200008				2022-12-18	WOS:000079723900011
J	Taniguchi, K; Fujisawa, T; Ihara, T; Kamiya, H				Taniguchi, K; Fujisawa, T; Ihara, T; Kamiya, H			Gelatin-induced T-cell activation in children with nonanaphylactic-type reactions to vaccines containing gelatin	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						vaccine; gelatin; adverse reaction; delayed-type hypersensitivity; memory T lymphocyte; CD25; CD45RO	SENSITIVE ATOPIC-DERMATITIS; VARICELLA-ZOSTER VIRUS; LYMPHOCYTES; IGE; EXPRESSION; ANTIGEN; MEASLES; MUMPS	Background: Many cases of anaphylactic or nonanaphylactic reactions have been reported to measles-mumps-rubella vaccine or its component vaccines that contain gelatin as a stabilizer. Increased levels of specific IgE antibodies to gelatin have been reported in children with anaphylactic reactions. However, IgE is not increased in cases of nonanaphylactic reaction, and the mechanisms of the reaction are still controversial. Objective: The study was aimed to elucidate the relationship between nonanaphylactic reaction and gelatin. Methods: We investigated in vitro induction of activated memory helper T cells (CD4(+)CD25(+)CD45RO(+) cells) in response to gelatin in children with nonanaphylactic reactions to vaccines containing gelatin. Results: In patients with delayed-type sensitivity to gelatin confirmed with a positive skin test response, CD4(+)CD25(+)CD45RO(+) cells were significantly more strongly induced in culture containing gelatin than in control cultures. However, there was no significant difference between cultures with gelatin and those with control solvent in patients without reactions after vaccination. Of 76 patients with nonanaphylactic reactions after immunization with vaccine containing gelatin, 61 had an increased lymphocyte stimulation index to gelatin versus control children. Conclusion: These results suggest the possibility that nonanaphylactic reactions to gelatin-containing vaccine in Japan might be mediated by delayed hypersensitivity reactions against gelatin.	Mie Natl Hosp, Dept Pediat, Mie, Japan		Taniguchi, K (corresponding author), Natl Inst Infect Dis, Infect Dis Surveillanve Ctr, Shinjuku Ku, Toyama 1-23-1, Tokyo 162, Japan.							AGATA H, 1992, ARCH DIS CHILD, V67, P280, DOI 10.1136/adc.67.3.280; AGATA H, 1993, J ALLERGY CLIN IMMUN, V91, P668, DOI 10.1016/0091-6749(93)90273-I; BOS JD, 1993, IMMUNOL TODAY, V14, P75, DOI 10.1016/0167-5699(93)90062-P; FREW AJ, 1988, J IMMUNOL, V141, P4158; ITO M, 1992, J INFECT DIS, V165, P158, DOI 10.1093/infdis/165.1.158; KELSO JM, 1993, J ALLERGY CLIN IMMUN, V91, P867, DOI 10.1016/0091-6749(93)90344-F; KONDO N, 1993, J ALLERGY CLIN IMMUN, V91, P658, DOI 10.1016/0091-6749(93)90272-H; KUMAGAI T, 1996, REPORTS IMMUNIZATION, P341; MIZUTANI KI, 1995, CLIN DIAGN LAB IMMUN, V2, P381, DOI 10.1128/CDLI.2.3.381-384.1995; Noma T, 1996, J ALLERGY CLIN IMMUN, V98, P816, DOI 10.1016/S0091-6749(96)70131-8; PICKER LJ, 1991, NATURE, V349, P796, DOI 10.1038/349796a0; SAKAGUCHI M, 1995, J ALLERGY CLIN IMMUN, V96, P563, DOI 10.1016/S0091-6749(95)70304-7; WERFEL S, 1995, J ALLERGY CLIN IMMUN, V96, P57, DOI 10.1016/S0091-6749(95)70033-1; YAMANAKA T, 1996, REPORTS IMMUNIZATION, P346	14	24	25	1	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1998	102	6	1				1028	1032		10.1016/S0091-6749(98)70342-2	http://dx.doi.org/10.1016/S0091-6749(98)70342-2			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	150XE	9847445	Bronze			2022-12-18	WOS:000077690700022
J	Bank, I; Reshef, A; Beniaminov, M; Rosenthal, E; Rechavi, G; Monselise, Y				Bank, I; Reshef, A; Beniaminov, M; Rosenthal, E; Rechavi, G; Monselise, Y			Role of gamma/delta T cells in a patient with CD4(+)CD3(-) lymphocytosis, hypereosinophilia, and high levels of IgE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						hypereosinophilic syndrome; gamma delta T cells; CD4(+) T cells; IL-4; IFN-gamma	B-CELLS; GAMMA; RECEPTOR; INTERLEUKIN-5; LYMPHOMA; EXPRESSION; TH1; DIFFERENTIATION; EOSINOPHILIA; FREQUENCY	Background: CD4(+)CD3(-) T cells have previously been shown to play a pathogenic role in the hypereosinophilic syndrome by secreting IL-5 and IL-4. Objectives: The goal of this study was to study the role of CD4+CD3- and other T-cell subsets in a patient with eosinophilia, dermatitis, and a high level of IgE (100,000 IU/mL) in the serum. Methods: We isolated PBMCs and performed flow cytometry, cell cultures, and in vitro assays of Ig, Lymphokine production, and cell-mediated cytotoxicity, Results: Flow cytometric and immunohistochemical analysis of the PBMCs revealed a major population (consisting of approximately 85% of the CD4(+) T cells) that lacked expression of CD3 and T-cell receptors on the cell surface (CD4(+)CD3(-)T cells), but did express CD3 peptides in the cytoplasm. Activation of the PBMCs in vitro resulted in a 100-fold greater than normal release of IL-4, whereas IFN-gamma production was less than normal, suggesting a predominantly type 2 helper functional phenotype of the CD4+CD3- T cells. Importantly, both CD4(-)CD8(low) V delta 1(+) T-cell receptor gamma delta(+) and CD4(+)CD3(-) T cells were cultured from the PBMCs, The former secreted IFN-gamma exclusively, whereas the latter secreted both IL-4 and IFN-gamma. Furthermore, only the T-cell receptor gamma delta(+) lymphocytes were cytotoxic to autologous B-lymphoblastoid cells and specifically inhibited IgE production in cultures of autologous polyclonally stimulated PBMCs, Conclusions: The results suggest that CDloq V delta 1(+) T cell receptor gamma delta(+) clones functionally counteract IgE-inducing effects of type 2 CD4+CD3- helper cells in this patient with hypereosinophilic syndrome.	Chaim Sheba Med Ctr, Dept Med, Sackler Sch Med, IL-52621 Tel Hashomer, Israel; Chaim Sheba Med Ctr, Dept Allergy & Immunol, Sackler Sch Med, IL-52621 Tel Hashomer, Israel; Chaim Sheba Med Ctr, Dept Hematol, Sackler Sch Med, IL-52621 Tel Hashomer, Israel; Chaim Sheba Med Ctr, Immunoregulat Lab, Sackler Sch Med, IL-52621 Tel Hashomer, Israel	Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine	Bank, I (corresponding author), Chaim Sheba Med Ctr, Dept Med, Sackler Sch Med, IL-52621 Tel Hashomer, Israel.		Bank, I./I-7153-2012; Reshef, Avner/AAL-3638-2020	Reshef, Avner/0000-0002-3324-7072				BANK I, 1992, BLOOD, V81, P3157; BORISH L, 1993, J ALLERGY CLIN IMMUN, V92, P123, DOI 10.1016/0091-6749(93)90046-I; BORISH L, 1997, J ALLERGY CLIN IMMUN, V99, P160; Brugnoni D, 1996, BLOOD, V87, P1416, DOI 10.1182/blood.V87.4.1416.bloodjournal8741416; Chen KS, 1996, CLIN EXP ALLERGY, V26, P295; COGAN E, 1994, NEW ENGL J MED, V330, P535, DOI 10.1056/NEJM199402243300804; Corry DB, 1996, J EXP MED, V183, P109, DOI 10.1084/jem.183.1.109; FISCHER MB, 1995, J INVEST DERMATOL, V104, P537, DOI 10.1111/1523-1747.ep12606046; GASCAN H, 1992, EUR J IMMUNOL, V22, P1133, DOI 10.1002/eji.1830220505; GOODMAN T, 1988, NATURE, V333, P855, DOI 10.1038/333855a0; HACKER G, 1995, IMMUNOLOGY, V84, P105; HACKER G, 1992, J IMMUNOL, V149, P3984; Hyjek EM, 1997, J IMMUNOL, V158, P464; Kaufmann SHE, 1996, P NATL ACAD SCI USA, V93, P2272, DOI 10.1073/pnas.93.6.2272; KIM CJ, 1991, CANCER, V67, P1064, DOI 10.1002/1097-0142(19910215)67:4<1064::AID-CNCR2820670433>3.0.CO;2-P; KRAFT DL, 1993, J EXP MED, V178, P265, DOI 10.1084/jem.178.1.265; MAGGI E, 1992, J IMMUNOL, V148, P2142; MAMICHOUAIB F, 1991, J IMMUNOL, V147, P2864; MCMENAMIN C, 1994, SCIENCE, V265, P1869, DOI 10.1126/science.7916481; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; MURATA K, 1992, CANCER, V69, P966, DOI 10.1002/1097-0142(19920215)69:4&lt;966::AID-CNCR2820690422&gt;3.0.CO;2-H; OKADA A, 1988, J EXP MED, V168, P1481, DOI 10.1084/jem.168.4.1481; Paul WE, 1997, CIBA F SYMP, V204, P208; QIAN DP, 1993, P NATL ACAD SCI USA, V90, P11875, DOI 10.1073/pnas.90.24.11875; RAGHAVACHAR A, 1987, J IMMUNOL, V139, P3753; RIZZO LV, 1995, EUR J IMMUNOL, V25, P708, DOI 10.1002/eji.1830250312; Romagnani S, 1996, CLIN IMMUNOL IMMUNOP, V80, P225, DOI 10.1006/clin.1996.0118; SAMOSZUK M, 1993, AM J HEMATOL, V42, P402, DOI 10.1002/ajh.2830420416; Schandene L, 1996, J CLIN INVEST, V97, P309, DOI 10.1172/JCI118417; SCREZENMEIER H, 1993, EXP HEMATOL, V21, P358; Soderstrom K, 1996, J IMMUNOL, V156, P2331; SODERSTROM K, 1994, J IMMUNOL, V152, P6017; Spinozzi F, 1996, ANN INTERN MED, V124, P223, DOI 10.7326/0003-4819-124-2-199601150-00005; TANAKA Y, 1995, NATURE, V375, P155, DOI 10.1038/375155a0; WELLER PF, 1994, BLOOD, V83, P2759, DOI 10.1182/blood.V83.10.2759.2759; Wen L, 1996, J EXP MED, V183, P2271, DOI 10.1084/jem.183.5.2271; WRIGHT A, 1989, J EXP MED, V169, P1557, DOI 10.1084/jem.169.5.1557	37	24	24	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1998	102	4	1				621	630		10.1016/S0091-6749(98)70279-9	http://dx.doi.org/10.1016/S0091-6749(98)70279-9			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	131XK	9802371	Bronze			2022-12-18	WOS:000076600400013
J	Szefler, SJ; Nelson, HS				Szefler, SJ; Nelson, HS			Alternative agents for anti-inflammatory treatment of asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						glucocorticoids; cromolyn; nedocromil; theophylline; leukotriene; zileuton; zafirlukast; montelukast; beclomethasone; budesonide	LONG-TERM TREATMENT; NEDOCROMIL SODIUM; BECLOMETHASONE DIPROPIONATE; CROMOLYN SODIUM; BRONCHIAL HYPERRESPONSIVENESS; INHALED CORTICOSTEROIDS; CONTROLLED TRIAL; MODERATE ASTHMA; INDUCED BRONCHOCONSTRICTION; 5-LIPOXYGENASE INHIBITION	Recent guidelines for the management of asthma have emphasized the role of inflammation in persistent asthma, Medications with anti-inflammatory properties are recommended as the primary long-term-control medications. Of the available choices of long-term-control medications, inhaled corticosteroids are the preferred medication, A literature review of the available studies supports this recommendation of inhaled corticosteroids as the preferred agents for long-term control, Other long-term-control medications-specifically nedocromil, theophylline, and leukotriene modifiers, but not cromolyn-can supplement the beneficial effect of inhaled corticosteroids on pulmonary function and symptom control. Long-acting beta(2)-adrenergic agonists can also provide an additive clinical benefit to inhaled corticosteroids on symptom control and pulmonary function, but they do not provide additional antiinflammatory effect, Extended long-term studies of each of the long-term-control medications with anti-inflammatory actions are needed to assess their specific effect on airway remodeling and on the natural history of asthma.	Natl Jewish Med & Res Ctr, Dept Pediat, Div Clin Pharmacol & Allergy & Immunol, Denver, CO 80206 USA; Natl Jewish Med & Res Ctr, Dept Med, Div Clin Pharmacol & Allergy & Immunol, Denver, CO 80206 USA	National Jewish Health; National Jewish Health	Szefler, SJ (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, Div Clin Pharmacol & Allergy & Immunol, Room J209,1400 Jackson St, Denver, CO 80206 USA.							BARNES PJ, 1994, EUR RESPIR J, V7, P579, DOI 10.1183/09031936.94.07030579; BEL EH, 1990, AM REV RESPIR DIS, V141, P21, DOI 10.1164/ajrccm/141.1.21; Bissonnette EY, 1997, J ALLERGY CLIN IMMUN, V100, P825, DOI 10.1016/S0091-6749(97)70280-X; BLUMENTHAL MN, 1988, J ALLERGY CLIN IMMUN, V81, P681, DOI 10.1016/0091-6749(88)91038-X; BOULET LP, 1990, RESP MED, V84, P317, DOI 10.1016/S0954-6111(08)80060-1; CALHOUN WJ, 1995, AM J RESP CRIT CARE, V151, pA42; Campbell MJ, 1997, BRIT MED J, V314, P1439, DOI 10.1136/bmj.314.7092.1439; Chervinsky P., 1997, European Respiratory Journal Supplement, V10, p439S; COCKCROFT DW, 1987, J ALLERGY CLIN IMMUN, V79, P734, DOI 10.1016/0091-6749(87)90204-1; DAWOOD AG, 1977, CLIN ALLERGY, V7, P161, DOI 10.1111/j.1365-2222.1977.tb01437.x; Diamant Z, 1997, AM J RESP CRIT CARE, V155, P1247, DOI 10.1164/ajrccm.155.4.9105062; DJUKANOVIC R, 1995, EUR RESPIR J, V8, P831; Donahue JG, 1997, JAMA-J AM MED ASSOC, V277, P887, DOI 10.1001/jama.277.11.887; DUTOIT JI, 1987, AM REV RESPIR DIS, V136, P1174, DOI 10.1164/ajrccm/136.5.1174; EIGEN H, 1987, J ALLERGY CLIN IMMUN, V80, P612, DOI 10.1016/0091-6749(87)90016-9; ERNST P, 1992, JAMA-J AM MED ASSOC, V268, P3462, DOI 10.1001/jama.268.24.3462; Evans DJ, 1997, NEW ENGL J MED, V337, P1412, DOI 10.1056/NEJM199711133372002; FAURSCHOU P, 1994, ALLERGY, V49, P659, DOI 10.1111/j.1398-9995.1994.tb00136.x; FINDLAY SR, 1992, J ALLERGY CLIN IMMUN, V89, P1040, DOI 10.1016/0091-6749(92)90227-S; FISCHER AR, 1995, AM J RESP CRIT CARE, V152, P1203, DOI 10.1164/ajrccm.152.4.7551371; FRANCIS RS, 1984, CLIN ALLERGY, V14, P537, DOI 10.1111/j.1365-2222.1984.tb02241.x; FYANS PG, 1986, CLIN ALLERGY, V16, P505, DOI 10.1111/j.1365-2222.1986.tb01988.x; Galant SP, 1996, ANN ALLERG ASTHMA IM, V77, P112, DOI 10.1016/S1081-1206(10)63496-5; GARDINER PV, 1994, AM J RESP CRIT CARE, V150, P1006, DOI 10.1164/ajrccm.150.4.7921429; GOLDIN JG, 1988, THORAX, V43, P982, DOI 10.1136/thx.43.12.982; GOTTLIEB DJ, 1995, CHEST, V108, P28, DOI 10.1378/chest.108.1.28; GREENING AP, 1994, LANCET, V344, P219, DOI 10.1016/S0140-6736(94)92996-3; HARPER GD, 1990, RESP MED, V84, P463, DOI 10.1016/S0954-6111(08)80110-2; HENDERSON WR, 1994, ANN INTERN MED, V121, P684, DOI 10.7326/0003-4819-121-9-199411010-00010; HILLER EJ, 1975, BRIT J DIS CHEST, V69, P103; Holgate ST, 1996, J ALLERGY CLIN IMMUN, V98, P1, DOI 10.1016/S0091-6749(96)70220-8; Hoshino M, 1997, EUR RESPIR J, V10, P858; IND PW, 1998, AM J RESP CRIT CARE, V157, pA415; Kane GC, 1996, J ALLERGY CLIN IMMUN, V97, P646, DOI 10.1016/S0091-6749(96)70310-X; KIDNEY J, 1995, AM J RESP CRIT CARE, V151, P1907, DOI 10.1164/ajrccm.151.6.7767539; Knorr B. A., 1997, European Respiratory Journal Supplement, V10, p219S; KRAEMER R, 1987, ACTA PAEDIATR SCAND, V76, P119, DOI 10.1111/j.1651-2227.1987.tb10426.x; Kraft M, 1997, CHEST, V111, P1249, DOI 10.1378/chest.111.5.1249; Laitinen L. A., 1997, European Respiratory Journal Supplement, V10, p419S; LAITINEN LA, 1993, LANCET, V341, P989, DOI 10.1016/0140-6736(93)91073-U; LAL S, 1993, CHEST, V104, P438, DOI 10.1378/chest.104.2.438; LEUNG KBP, 1986, EUR J RESPIR DIS, V69, P223; Liu MC, 1996, J ALLERGY CLIN IMMUN, V98, P859, DOI 10.1016/S0091-6749(96)80002-9; LOWHAGEN O, 1984, Respiration, V46, P105; LOWHAGEN O, 1985, J ALLERGY CLIN IMMUN, V75, P460, DOI 10.1016/S0091-6749(85)80018-X; Marin JM, 1996, J ALLERGY CLIN IMMUN, V97, P602, DOI 10.1016/S0091-6749(96)70305-6; MITCHELL J, 1976, BRIT MED J, V2, P457; MOLEMA J, 1989, EUR RESPIR J, V2, P308; *N AM TIL STUD GRO, 1990, CHEST, V97, P1299; NASSIF EG, 1981, NEW ENGL J MED, V304, P71, DOI 10.1056/NEJM198101083040202; *NAT ASTHM ED PREV, 1991, NIH NAT HEART LUNG B; *NAT ASTHM ED PREV, 1997, NIH NAT HEART LUNG B; Nayak AS, 1998, J ALLERGY CLIN IMMUN, V101, pS233; NG SH, 1977, POSTGRAD MED J, V53, P315, DOI 10.1136/pgmj.53.620.315; OHICKEY SP, 1994, RESP MED, V88, P499, DOI 10.1016/S0954-6111(05)80330-0; OREFICE U, 1992, RESPIRATION, V59, P97; Pauwels RA, 1997, NEW ENGL J MED, V337, P1405, DOI 10.1056/NEJM199711133372001; PETTY TL, 1989, AM REV RESPIR DIS, V139, P694, DOI 10.1164/ajrccm/139.3.694; PRICE JF, 1995, RESP MED, V89, P363, DOI 10.1016/0954-6111(95)90009-8; RASMUSSEN JB, 1992, J ALLERGY CLIN IMMUN, V90, P193, DOI 10.1016/0091-6749(92)90071-9; RASMUSSEN JB, 1992, ALLERGY, V47, P604, DOI 10.1111/j.1398-9995.1992.tb02382.x; REBUCK AS, 1990, J ALLERGY CLIN IMMUN, V85, P612, DOI 10.1016/0091-6749(90)90101-9; Reed CE, 1998, J ALLERGY CLIN IMMUN, V101, P14, DOI 10.1016/S0091-6749(98)70187-3; Reiss T. F., 1997, European Respiratory Journal Supplement, V10, p437S; SARSFIELD JK, 1977, PRACTITIONER, V218, P128; Schwartz HJ, 1996, CHEST, V109, P945, DOI 10.1378/chest.109.4.945; SHAPIRO GG, 1991, J ALLERGY CLIN IMMUN, V88, P742, DOI 10.1016/0091-6749(91)90181-M; Simons FER, 1997, NEW ENGL J MED, V337, P1659, DOI 10.1056/NEJM199712043372304; SULLIVAN PJ, 1993, LANCET, V343, P1006; SVENDSEN UG, 1989, J ALLERGY CLIN IMMUN, V84, P224, DOI 10.1016/0091-6749(89)90329-1; SVENDSEN UG, 1991, EUR RESPIR J, V4, P992; SVENDSEN UG, 1987, J ALLERGY CLIN IMMUN, V80, P68; Tamaoki J, 1997, AM J RESP CRIT CARE, V155, P1235, DOI 10.1164/ajrccm.155.4.9105060; TAYLOR IK, 1991, LANCET, V337, P690, DOI 10.1016/0140-6736(91)90277-V; TOOGOOD JH, 1981, J ALLERGY CLIN IMMUN, V67, P317, DOI 10.1016/0091-6749(81)90028-2; Verberne AAPH, 1997, AM J RESP CRIT CARE, V156, P688, DOI 10.1164/ajrccm.156.3.9611067; Vollmer WM, 1997, ARCH INTERN MED, V157, P1201, DOI 10.1001/archinte.157.11.1201; WARD AJM, 1993, AM REV RESPIR DIS, V147, P518, DOI 10.1164/ajrccm/147.3.518; Wennergren G, 1996, J ALLERGY CLIN IMMUN, V97, P742, DOI 10.1016/S0091-6749(96)80150-3; Wenzel S, 1997, AM J RESP CRIT CARE, V155, pA203; WENZEL SE, 1995, AM J RESP CRIT CARE, V152, P897, DOI 10.1164/ajrccm.152.3.7663802; Westbroek J., 1997, European Respiratory Journal Supplement, V10, p243S; WONG CS, 1993, CLIN EXP ALLERGY, V23, P370, DOI 10.1111/j.1365-2222.1993.tb00341.x; Woolcock A, 1996, AM J RESP CRIT CARE, V153, P1481, DOI 10.1164/ajrccm.153.5.8630590; Yates DH, 1997, EUR RESPIR J, V10, P1483, DOI 10.1183/09031936.97.10071483	85	24	25	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1998	102	4	2				S23	S35		10.1016/S0091-6749(98)70003-X	http://dx.doi.org/10.1016/S0091-6749(98)70003-X			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	133CT	9798721				2022-12-18	WOS:000076669400005
J	Iacovacci, P; Afferni, C; Barletta, B; Tinghino, R; Di Felice, G; Pini, C; Mari, A				Iacovacci, P; Afferni, C; Barletta, B; Tinghino, R; Di Felice, G; Pini, C; Mari, A			Juniperus oxycedrus: A new allergenic pollen from the cupressaceae family	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Cupressaceae; cypress; juniper; allergen characterization; cross-reactivity; fall-to-winter pollinosis	CROSS-REACTIVITY; JAPANESE CEDAR; CYPRESS; SEMPERVIRENS; IDENTIFICATION; POLLINOSIS; IGE; ARIZONICA; FRANCE; SOUTH	Background: Cupressaceae allergy is a worldwide pollinosis caused by several species. Some species in limited geographic areas pollinate in fall and winter. Juniperus oxycedrus matches these features. Objective: We sought to define the immunochemical, allergologic, and environmental aspects of J. oxycedrus pollen. Methods: Pollen extract from J, oxycedrus was prepared and characterized by biochemical analysis and human specific IgE binding by means of ELISA and immunoblotting, A 3-year phenological study was conducted to define the pollinating period of J. oxycedrus. Forty consecutive patients allergic to cypress were recruited in two areas and divided into two groups according to their exposure to J, oxycedrus pollen, Clinical evaluation, skin prick tests, and specific IgE determination with J. oxycedrus, J, ashei, and Cupressus arizonica extracts were carried out on both groups. Results: J. oxycedrus pollen extract was obtained, and it shotted specific IgE binding and wide cross-reactivity with other Cupressaceae species. The extract caused a positive skin test response in all the patients tested, with about 80% of them having detectable specific IgE. Symptoms related to J. oxycedrus pollen exposure were recorded in 72% of the directly exposed patients and occasionally in 9% of the nonexposed patients. In the Mediterranean coastal area considered, J, oxycedrus was the first Cupressaceae species that started to pollinate at the beginning of November and ended in the first part of December, Conclusions: J. oxycedrus represents a newly characterized pollen species of the Cupressaceae family that cross-reacts with other members of the same family. Subjects with cypress allergy have in vivo and in vitro positive test responses for J. oxycedrus and can show symptoms when exposed to its pollen. Finally, the most important feature of J. oxycedrus is its early pollinating period in southern Europe (Italy), causing a further extension of the cypress pollen season in areas where other Cupressaceae species are present.	Ist Super Sanita, Dept Immunol, I-00161 Rome, Italy	Istituto Superiore di Sanita (ISS)	Mari, A (corresponding author), Ist Super Sanita, Dept Immunol, Viale Regina Elena 299, I-00161 Rome, Italy.		BARLETTA, BIANCA/B-9980-2016; AFFERNI, CLAUDIA/B-9978-2016; Di Felice, Gabriella/B-9985-2016	AFFERNI, CLAUDIA/0000-0002-8567-7365; Di Felice, Gabriella/0000-0001-7387-9683				ARRIGONI P V, 1977, Webbia, V31, P1; Barletta B, 1996, J ALLERGY CLIN IMMUN, V98, P797, DOI 10.1016/S0091-6749(96)70129-X; BASS D, 1991, MED J AUSTRALIA, V155, P572, DOI 10.5694/j.1326-5377.1991.tb93901.x; Batanero E, 1996, J ALLERGY CLIN IMMUN, V97, P1264, DOI 10.1016/S0091-6749(96)70194-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHOLTZ GA, 1985, ANN ALLERGY, V55, P805; Caballero T, 1996, CLIN EXP ALLERGY, V26, P197, DOI 10.1111/j.1365-2222.1996.tb00080.x; CAIAFFA MF, 1993, ANN ALLERGY, V71, P45; CARAMIELLO R, 1991, AEROBIOLOGIA, V7, P181; CHARPIN D, 1993, CLIN EXP ALLERGY, V23, P435, DOI 10.1111/j.1365-2222.1993.tb00350.x; Chaw SM, 1997, MOL BIOL EVOL, V14, P56, DOI 10.1093/oxfordjournals.molbev.a025702; Cimignoli E., 1992, Aerobiologia, V8, P465, DOI 10.1007/BF02272917; DAYAN YB, 1995, CLIN EXP ALLERGY, V25, P456, DOI 10.1111/j.1365-2222.1995.tb01077.x; DIFELICE G, 1994, J ALLERGY CLIN IMMUN, V94, P547, DOI 10.1016/0091-6749(94)90212-7; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; *EUR PHARM, 1997, ALL PROD EUR PHARM; FORD SA, 1991, INT ARCH ALLER A IMM, V95, P178, DOI 10.1159/000235426; GOETZ DW, 1995, ANN ALLERG ASTHMA IM, V75, P256; Guerin B, 1996, INT ARCH ALLERGY IMM, V110, P91, DOI 10.1159/000237317; ITO H, 1995, ANN ALLERG ASTHMA IM, V74, P299; Mari A, 1996, J ALLERGY CLIN IMMUN, V98, P21, DOI 10.1016/S0091-6749(96)70222-1; Mari A, 1997, ALLERGY, V52, P355, DOI 10.1111/j.1398-9995.1997.tb01008.x; MARI A, 1997, J ALLERGY CLIN IMM S, V99, P156; Midoro-Horiuti T, 1992, Acta Paediatr Jpn, V34, P501; MODOROHORIUTI T, 1992, JPN J ALLERGOL, V41, P1459; Nakagawa H., 1996, Rhinology (Utrecht), V34, P201; Ogawa H, 1996, GLYCOCONJUGATE J, V13, P555, DOI 10.1007/BF00731443; ORBMAN D, 1945, S AFR MED J, V19, P142; PANZANI R, 1986, ANN ALLERGY, V56, P460; PANZANI R, 1986, ANN ALLERGY, V57, P26; PHAM NH, 1994, CLIN EXP ALLERGY, V24, P558, DOI 10.1111/j.1365-2222.1994.tb00953.x; PIGNATTI S, 1982, FLORA ITALIA, P81; Potter PC, 1996, CLIN EXP ALLERGY, V26, P1347, DOI 10.1046/j.1365-2222.1996.d01-293.x; RAMIREZ DA, 1984, J ALLERGY CLIN IMMUN, V73, P88, DOI 10.1016/0091-6749(84)90489-5; REID MJ, 1992, J ALLERGY CLIN IMMUN, V89, P593, DOI 10.1016/0091-6749(92)90327-X; Vieths S., 1994, Food and Agricultural Immunology, V6, P453, DOI 10.1080/09540109409354857; Waisel Y., 1997, AEROBIOLOGIA, V13, P127, DOI DOI 10.1007/BF02694429; WOLF A. FORD, 1948, ANN ALLERGY, V6, P431; YOO TJ, 1975, ANN ALLERGY, V34, P87; ZERBONI R, 1988, AEROBIOLOGIA, V4, P27	40	24	25	2	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1998	101	6	1				755	761		10.1016/S0091-6749(98)70304-5	http://dx.doi.org/10.1016/S0091-6749(98)70304-5			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZW470	9648702	Bronze			2022-12-18	WOS:000074414200008
J	Chu, TJ; Warren, MS				Chu, TJ; Warren, MS			Zafirlukast (ACCOLATE (R)) in the treatment of chronic idiopathic urticaria - A case series	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract									Zeneca, Wilmington, DE USA										0	24	24	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1998	101	1	2			641	S155	S155						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YW339					2022-12-18	WOS:000071924800641
J	Small, P; Houle, PA; Day, JH; Briscoe, M; Gold, M; Brodarec, I; Pong, AH; Mandl, M; Spenard, J; Phillips, R; Furlan, M				Small, P; Houle, PA; Day, JH; Briscoe, M; Gold, M; Brodarec, I; Pong, AH; Mandl, M; Spenard, J; Phillips, R; Furlan, M			A comparison of triamcinolone acetonide nasal aerosol spray and fluticasone propionate aqueous solution spray in the treatment of spring allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						triamcinolone acetonide; fluticasone propionate; aerosol; solution; rhinitis; seasonal; spring		Background: Many nasal corticosteroids with different potencies and formulations are available, but they have all been proven safe and effective. The clinical relevance, if any, of these differences is not gel completely established. Objective: We sought to compare the efficacy, safety, and patients' acceptance of triamcinolone acetonide aerosol spray and fluticasone propionate aqueous solution in the treatment of spring allergic rhinitis. Methods: After a drug-free baseline evaluation, patients with rhinitis were randomized to receive either a triamcinolone aerosol spray of 110 mu g in each nostril once daily (n = 117) or a fluticasone solution spray of 100 mu g in each nostril once daily (n = 116) in a single-blind, parallel-group study. The Rhinitis Index Score (sum of scores of symptoms on a scale from 0 to 3) was evaluated daily, in the morning before drug administration, for 21 days. The efficacy of each treatment was assessed by the mean reduction from baseline in the Rhinitis Index Score and in individual symptom scores. Patients' acceptance of the study drugs was also monitored by a daily questionnaire. Results: Reductions of the Rhinitis Index Score (mean +/- SEM) were 4.20 +/- 0.21 and 4.60 +/- 0.21 for triamcinolone and fluticasone, respectively (p = 0.23). There were no statistically significant differences between the drugs in the reduction of any of the individual symptoms. Patients expressed statistically significant differences between the drugs regarding acceptance; different properties of the aerosol and the solution were appreciated differently. Conclusions: This study shows that triamcinolone acetonide aerosol and fluticasone propionate solution sprays are both clinically equally effective, safe, and well tolerated for the treatment of spring pollen allergic rhinitis.	SIR MORTIMER B DAVIS JEWISH HOSP,MONTREAL,PQ H3T 1E2,CANADA; KINGSTON GEN HOSP,KINGSTON,ON K7L 2V7,CANADA; UNIV MONTREAL,DEPT PHARMACOL,MONTREAL,PQ H3C 3J7,CANADA; RHONE POULENC RORER CANADA INC,MONTREAL,PQ,CANADA	McGill University; Queens University - Canada; Universite de Montreal								Day JH, 1996, J ALLERGY CLIN IMMUN, V97, P1050, DOI 10.1016/S0091-6749(96)70257-9; MABRY RL, 1992, SOUTH MED J, V85, P149, DOI 10.1097/00007611-199202000-00008; MELTZER EO, 1990, J ALLERGY CLIN IMMUN, V86, P221, DOI 10.1016/S0091-6749(05)80069-7; SIEGEL SC, 1988, J ALLERGY CLIN IMMUN, V81, P984, DOI 10.1016/0091-6749(88)90166-2; STORMS WW, 1991, J RESPIR DIS S, V12, P539; TINKLEMAN D, 1990, ANN ALLERGY, V6412, P234; 1996, FLONASE PRODUCT MONO; 1996, NASACORT PRODUCT MON	8	24	26	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1997	100	5					592	595		10.1016/S0091-6749(97)70160-X	http://dx.doi.org/10.1016/S0091-6749(97)70160-X			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YG202	9389286				2022-12-18	WOS:A1997YG20200003
J	Zweiman, B; Getsy, J; Kalenian, M; Lane, A; Schwartz, LB; Doty, R; Lanza, D				Zweiman, B; Getsy, J; Kalenian, M; Lane, A; Schwartz, LB; Doty, R; Lanza, D			Nasal airway changes assessed by acoustic rhinometry and mediator release during immediate and late reactions to allergen challenge	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						acoustic rhinometry; late phase; allergic reaction; inflammatory responses	INFLAMMATORY MEDIATORS; RHINITIS; ANTIGEN; PHASE; OBSTRUCTION; RESISTANCE; SECRETIONS; GEOMETRY; CELLS; FLOW	Background: We have found that acoustic rhinometry is a reliable means of assessing nasal airway caliber changes during the immediate reaction to nasal allergen challenge of sensitive subjects. Comparison of such changes with symptoms and patterns of mediator release could help in the understanding of mechanisms of immediate and late-phase reactions after allergen challenge and their clinical relevance. Methods: Nasal minimal cross-sectional area (MCA) was assessed sequentially for 6 hours after two blinded challenges in random order with pollen antigens and buffer diluent in five sensitive human subjects. Comparisons were made with: (1) symptom scores; (2) olfaction changes; and (3) nasal secretion levels of histamine, tryptase, leukotriene C-4, serum albumin (a marker of vascular permeability), lactoferrin (a marker of local glandular secretion), and inflammatory cells in nasal scrapings. Results: In four of five subjects there was a significantly greater decrease in MCA after antigen challenge than after diluent challenge, correlating with the degree of subjective nasal congestion. In two of these four subjects there was a prominent second late-phase decrease in MCA at 3 to 5 hours, whereas the MCA was persistently decreased in an additional subject with accompanying subjective congestion. No significant decrease in olfactory acuity occurred. Levels were significantly higher in nasal secretions obtained after antigen challenge than in those obtained after buffer challenge with histamine (9 +/- 2.7 ng/ml vs 1.2 +/- 0.5 ng/ml; p = 0.04); tryptase (95 +/- 83 ng/ml vs 3 +/- 0.9 ng/ml; p = 0.02), leukotriene C-4 (5293 +/- 1385 ng/ml vs 578 +/- 183 ng/ml; p = 0.02), and albumin (123 +/- 9 ng/ml vs 19 +/- 1.6 ng/ml; p = 0.005) but not with lactoferrin (4.6 +/- 1.2 ng/ml vs 4.1 +/- 28 ng/ml; p = not significant). Granulocyte exudation was seen after antigen challenge but not after buffer diluent challenge. However, there was not a precise correlation between decreases in MCA with changes iii levels of these mediators in individual subjects. Conclusions: Acoustic rhinometry can quantitatively assess congestion during immediate and late-phase reactions after nasal challenge without significant correlation to the degree of individual inflammatory events assessed.	UNIV PENN,SCH MED,DEPT OTORHINOLARYNGOL,PHILADELPHIA,PA 19104; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DIV RHEUMATOL ALLERGY & IMMUNOL,RICHMOND,VA 23298	University of Pennsylvania; Virginia Commonwealth University	Zweiman, B (corresponding author), UNIV PENN,SCH MED,DEPT MED,ALLERGY & IMMUNOL DIV,512 JOHNSON PAVIL,PHILADELPHIA,PA 19104, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI014332, R01AI020487] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI 14332, R01 AI 20487] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		COLE P, 1989, CLIN OTOLARYNGOL, V14, P177, DOI 10.1111/j.1365-2273.1989.tb00357.x; DOTY RL, 1989, OTOLARYNG CLIN N AM, V22, P397; DVORACEK JE, 1984, J ALLERGY CLIN IMMUN, V73, P363, DOI 10.1016/0091-6749(84)90409-3; FOUKE JM, 1992, J LAB CLIN MED, V19, P371; GEORGITIS JW, 1991, INT ARCH ALLER A IMM, V96, P231, DOI 10.1159/000235500; GLEESON MJ, 1986, CLIN OTOLARYNGOL, V11, P99, DOI 10.1111/j.1365-2273.1986.tb00114.x; Godthelp T, 1996, J ALLERGY CLIN IMMUN, V97, P800, DOI 10.1016/S0091-6749(96)80158-8; GRYMER L F, 1991, Rhinology (Utrecht), V29, P35; HILBERG O, 1989, J APPL PHYSIOL, V66, P295, DOI 10.1152/jappl.1989.66.1.295; ILIOPOULOS O, 1990, J ALLERGY CLIN IMMUN, V86, P851, DOI 10.1016/S0091-6749(05)80146-0; ILIOPOULOS O, 1992, J IMMUNOL, V148, P2223; JACKSON AC, 1977, J APPL PHYSIOL, V43, P523, DOI 10.1152/jappl.1977.43.3.523; JONES AS, 1989, J LARYNGOL OTOL, V103, P909, DOI 10.1017/S0022215100110485; LAI VWS, 1993, ENT J, V72, P397; Lane AP, 1996, ANN OTO RHINOL LARYN, V105, P811; MAYHEW TM, 1993, CLIN OTOLARYNGOL, V18, P220; Meltzer EO, 1988, AM J RHINOL, V2, P47, DOI DOI 10.2500/105065888781693212; Naclerio RM, 1996, J ALLERGY CLIN IMMUN, V98, P721, DOI 10.1016/S0091-6749(96)70118-5; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; PASTORELLO EA, 1994, J ALLERGY CLIN IMMUN, V93, P85, DOI 10.1016/0091-6749(94)90236-4; RAPHAEL GD, 1991, J ALLERGY CLIN IMMUN, V88, P33, DOI 10.1016/0091-6749(91)90298-3; RASP G, 1993, LARYNGO RHINO OTOL, V72, P125, DOI 10.1055/s-2007-997869; SANDHAM A, 1988, Rhinology (Utrecht), V26, P191; SCHWARTZ LB, 1994, J CLIN IMMUNOL, V14, P190, DOI 10.1007/BF01533368; WANG D, 1995, CLIN OTOLARYNGOL, V20, P368, DOI 10.1111/j.1365-2273.1995.tb00063.x; ZWEIMAN B, 1990, J IMMUNOL, V144, P3953; ZWEIMAN B, 1997, IN PRESS J ALLERGY C	27	24	23	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1997	100	5					624	631		10.1016/S0091-6749(97)70166-0	http://dx.doi.org/10.1016/S0091-6749(97)70166-0			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YG202	9389292	hybrid			2022-12-18	WOS:A1997YG20200009
J	GodnicCvar, J; Susani, M; Breiteneder, H; Berger, A; Havelec, L; Waldhor, T; Hirschwehr, R; Valenta, R; Scheiner, O; Rudiger, H; Kraft, D; Ebner, C				GodnicCvar, J; Susani, M; Breiteneder, H; Berger, A; Havelec, L; Waldhor, T; Hirschwehr, R; Valenta, R; Scheiner, O; Rudiger, H; Kraft, D; Ebner, C			Recombinant Bet v 1, the major birch pollen allergen, induces hypersensitivity reactions equal to those induced by natural Bet v 1 in the airways of patients allergic to tree pollen	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						type I allergy; recombinant allergen; bet v 1; bronchial asthma; provocation test	BRONCHIAL PROVOCATION TESTS; T-CELL CLONES; IMMUNOCHEMICAL CHARACTERIZATION; STANDARDIZATION; EXTRACTS; IDENTIFICATION; IMMUNOTHERAPY; VERRUCOSA; DIAGNOSIS; ALDER	Background: Atopic allergens produced by recombinant DNA methods are promising tools for diagnosis and therapy of Type I allergy. To evaluate the immunologic properties of these molecules, it is necessary to compare them with natural allergens in vitro and in ave. Objective: The study was carried out to determine whether the potency of recombinant Bet v 1 (rBet v 1) is comparable to that of natural Bet v 1 (nBet v 1) in inducing allergic reactions in the nose and bronchi. Methods: Thirteen patients allergic to birch pollen with bronchial asthma and/or rhinitis were investigated. Skin prick tests and nasal and bronchial challenges were performed with rBet v 1 and nBet v 1. Results: In patients allergic to birch pollen, both allergens induced comparable skin reactions. In subjects with rhinitis rBet v 1 was equally potent in inducing nasal reactions (mean PD(+60)NR +/- SD, 10.48 +/- 17.42 mu g vs 7.98 +/- 8.9 mu g, p > 0.05). In patients with asthma, rBet v 1 was equally potent in inducing bronchial reactions (PD(20)FEV(1), 0.81 +/- 1.74 mu g vs 0.62 +/- 1.44 mu g, p > 0.05) as nBet v 1. Conclusion: No significant differences were observed between natural and recombinant allergen. We conclude that allergens produced by recombinant techniques can induce typical allergic reactions in important target organs of Type I allergy: the nose and bronchi.	ADV BIOL SYST INC,SALZBURG,AUSTRIA; UNIV VIENNA,INST GEN & EXPT PATHOL,A-1090 VIENNA,AUSTRIA; UNIV VIENNA,INST MED STAT & DOCUMENTAT,A-1090 VIENNA,AUSTRIA	University of Vienna; University of Vienna	GodnicCvar, J (corresponding author), UNIV VIENNA,CLIN INTERNAL MED 4,DEPT OCCUPAT MED,WAHRINGER GURTEL 18-20,A-1090 VIENNA,AUSTRIA.			Valenta, Rudolf/0000-0001-5944-3365				BOUSQUET J, 1991, J ALLERGY CLIN IMMUN, V88, P43, DOI 10.1016/0091-6749(91)90299-4; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; DEHAUT P, 1983, THORAX, V38, P316; DREBORG S, 1992, ALLERGY, V47, P418, DOI 10.1111/j.1398-9995.1992.tb02082.x; EBNER C, 1993, J IMMUNOL, V150, P1047; EBNER C, 1995, J ALLERGY CLIN IMMUN, V95, P962, DOI 10.1016/S0091-6749(95)70096-X; EBNER C, 1993, MOL IMMUNOL, V30, P1323, DOI 10.1016/0161-5890(93)90093-Q; FERREIRA FD, 1993, J BIOL CHEM, V268, P19574; Ferreira FD, 1996, J ALLERGY CLIN IMMUN, V97, P95, DOI 10.1016/S0091-6749(96)70287-7; IPSEN H, 1985, ALLERGY, V40, P510, DOI 10.1111/j.1398-9995.1985.tb00259.x; IPSEN H, 1983, J ALLERGY CLIN IMMUN, V72, P150, DOI 10.1016/0091-6749(83)90523-7; JAROLIM E, 1989, ALLERGY, V44, P385, DOI 10.1111/j.1398-9995.1989.tb04169.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MELILLO G, 1991, ALLERGY, V46, P321, DOI 10.1111/j.1398-9995.1991.tb00594.x; Pauli G, 1996, J ALLERGY CLIN IMMUN, V97, P1100, DOI 10.1016/S0091-6749(96)70264-6; PEPYS J, 1975, AM REV RESPIR DIS, V112, P829; PLAVEC D, 1994, ANN ALLERGY, V72, P321; REED CE, 1989, J ALLERGY CLIN IMMUN, V84, P4, DOI 10.1016/0091-6749(89)90171-1; SCHEINER O, 1995, ALLERGY, V50, P384, DOI 10.1111/j.1398-9995.1995.tb01167.x; SECRIST H, 1993, J EXP MED, V178, P2123, DOI 10.1084/jem.178.6.2123; STEWART GA, 1989, EPITOPES ATOPIC ALLE, P83; VALENTA R, 1991, J ALLERGY CLIN IMMUN, V88, P889, DOI 10.1016/0091-6749(91)90245-J; VANWIJK GR, 1987, CLIN ALLERGY, V7, P563	24	24	24	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1997	99	3					354	359		10.1016/S0091-6749(97)70053-8	http://dx.doi.org/10.1016/S0091-6749(97)70053-8			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WM422	9058691				2022-12-18	WOS:A1997WM42200012
J	Polosa, R; Magri, S; Vancheri, C; Armato, F; Santonocito, G; Mistretta, A; Crimi, N				Polosa, R; Magri, S; Vancheri, C; Armato, F; Santonocito, G; Mistretta, A; Crimi, N			Time course of changes in adenosine 5'-monophosphate airway responsiveness with inhaled heparin in allergic asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma bronchoconstriction; adenosine; heparin	LUNG MAST-CELLS; INOSITOL TRISPHOSPHATE RECEPTOR; VASCULAR SMOOTH-MUSCLE; ANTIGEN-INDUCED AIRWAY; BRONCHOCONSTRICTOR RESPONSE; IPRATROPIUM BROMIDE; HISTAMINE-RELEASE; ORAL TERFENADINE; CALCIUM RELEASE; INHIBITION	Background: Recent studies have shown that inhaled heparin exerts a protective effect against various bronchoconstrictor stimuli in asthma, possible through an inhibition of mast cell activation. Objective: Because adenosine 5'-monophosphate (AMP) elicits bronchoconstriction by augmenting mast cell mediator release, we have investigated the effect of inhaled heparin (15,000 units USP/ml, 4 mi) on the bronchoconstrictor response to this agonist and to methacholine in a randomized, double-blind, placebo-controlled study of 10 subjects with asthma. We also carried out a separate randomized, double-blind study in seven additional volunteers with asthma to examine in more detail the time-course of change in bronchial reactivity to inhaled AMP after treatment with nebulized heparin. Results: Inhaled heparin significantly increased the provocative concentration of AMP causing a 20% decrease in forced expiratory volume in 1 second (PC(20)FEV(1)-AMP) from the postplacebo treatment value of 22.3 mg/ml (range, 5.7 to 68.9 mg/ml) to 48.1 mg/ml (range, 5.1 196.8 mg/ml) (p < 0.01). When compared with placebo, inhaled heparin failed to alter the airway responsiveness to methacholine; the mean (range) PC20 methacholine values were 1.00 mg/ml (0.44 to 4.76 mg/ml) and 1.08 mg/ml (0.46 to 5.08 mg/ml), respectively. After placebo administration, the PC20 AMP values at 15, 60, and 180 minutes did not differ significantly from each other; their geometric mean (range) values were 26.1 mg/ml (5.9 to 85.8 mg/ml), 26.6 mg/ml (6.3 to 87.8 mg/ml), and 24.9 mg/ml (5.2 to 80.2 mg/ml), respectively. When compared with placebo, the PC20 values for AMP after administration of inhaled heparin were significantly increased up to 57.3 mg/ml (14.7 to 176.0 mg/ml) and to 52.7 mg/ml (13.9 to 90.8 mg/ml) at 15 minutes and 60 minutes, respectively. At 180 minutes, inhaled heparin failed to affect AMP airway responsiveness; the PC20 AMP was not significantly different from that of placebo, with a value of 30.6 mg/ml (4.8 to 93.3 mg/ml). Conclusion: Heparin administered by inhalation is effective in attenuating the airway response to AMP but not to methacholine. The time course of change in bronchial reactivity to AMP has a peak effect at 15 minutes and lasts up to 60 minutes. It is possible that the mechanism(s) underlying the protective effects of inhaled heparin in asthma may be related to an inhibitory modulation of mast cell activation.			Polosa, R (corresponding author), UNIV CATANIA,IST MALATTIE APPARATO RESP,VIA PASS GRAVINA 187,I-95125 CATANIA,ITALY.		Crimi, Nunzio/AAL-2994-2020; VANCHERI, Carlo/K-9417-2016	Crimi, Nunzio/0000-0002-8591-4535; VANCHERI, Carlo/0000-0002-5120-9926				AHMED T, 1992, AM REV RESPIR DIS, V145, P566, DOI 10.1164/ajrccm/145.3.566; AHMED T, 1994, J APPL PHYSIOL, V76, P893, DOI 10.1152/jappl.1994.76.2.893; AHMED T, 1993, NEW ENGL J MED, V329, P90, DOI 10.1056/NEJM199307083290204; AHMED T, 1993, J APPL PHYSIOL, V74, P1492, DOI 10.1152/jappl.1993.74.4.1492; BERGENDORFF A, 1973, ACTA PHYSIOL SCAND, V87, P213, DOI 10.1111/j.1748-1716.1973.tb05383.x; BERNSTEIN IL, 1988, J ALLERGY CLIN IMMUN, V82, P487, DOI 10.1016/0091-6749(88)90958-X; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BOWLER SD, 1993, AM REV RESPIR DIS, V147, P160, DOI 10.1164/ajrccm/147.1.160; CASTELLOT JJ, 1985, J CELL PHYSIOL, V124, P21, DOI 10.1002/jcp.1041240105; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CRIMI N, 1995, EUR RESPIR J, V8, P905; CUSHLEY MJ, 1983, BRIT J CLIN PHARMACO, V15, P161, DOI 10.1111/j.1365-2125.1983.tb01481.x; DAMATO G, 1989, J ALLERGY CLIN IMMUN, V83, P116, DOI 10.1016/0091-6749(89)90485-5; DOLOWITZ D A, 1960, Laryngoscope, V70, P873; FRYER AD, 1992, J CLIN INVEST, V90, P2292, DOI 10.1172/JCI116116; GHOSH TK, 1988, J BIOL CHEM, V263, P11075; GUSTAFSSON LE, 1986, EUR J PHARMACOL, V120, P179, DOI 10.1016/0014-2999(86)90538-8; HOLGATE ST, 1993, BRONCHIAL ASTHMA MEC, P253; HOWARTH PH, 1985, AM REV RESPIR DIS, V132, P986; HUGHES PJ, 1984, BIOCHEM PHARMACOL, V33, P3847, DOI 10.1016/0006-2952(84)90050-9; ILLES P, 1995, ADENOSINE AND ADENINE NUCLEOTIDES: FROM MOLECULAR BIOLOGY TO INTEGRATIVE PHYSIOLOGY, P77; JAQUES LB, 1979, PHARMACOL REV, V31, P99; KOBAYASHI S, 1988, BIOCHEM BIOPH RES CO, V153, P625, DOI 10.1016/S0006-291X(88)81141-0; LEE TH, 1983, LANCET, V1, P520; LEWIS RA, 1984, DRUGS LUNG, P63; LUCIO J, 1992, J APPL PHYSIOL, V73, P1093, DOI 10.1152/jappl.1992.73.3.1093; PAGE CP, 1991, LANCET, V337, P717, DOI 10.1016/0140-6736(91)90289-2; PAVORD I, 1995, AM J RESP CRIT CAR 2, V151, pA130; PEACHELL PT, 1988, AM REV RESPIR DIS, V138, P1143, DOI 10.1164/ajrccm/138.5.1143; PENNER R, 1988, NATURE, V334, P499, DOI 10.1038/334499a0; PENNER R, 1988, P NATL ACAD SCI USA, V85, P9856, DOI 10.1073/pnas.85.24.9856; PHILLIPS GD, 1987, THORAX, V42, P939, DOI 10.1136/thx.42.12.939; POLOSA R, 1990, EUR RESPIR J, V3, P665; POLOSA R, 1991, J ALLERGY CLIN IMMUN, V87, P939, DOI 10.1016/0091-6749(91)90415-K; POLOSA R, 1995, AM J RESP CRIT CARE, V151, P624; POLOSA R, 1992, EUR RESPIR J, V5, P700; SAYAMA S, 1987, J BIOL CHEM, V262, P6808; SCHWARTZ LB, 1986, J BIOL CHEM, V261, P7372; STEINBERG TH, 1990, AM J RESP CELL MOL, V2, P127, DOI 10.1165/ajrcmb/2.2.127; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; TASAKA K, 1987, AGENTS ACTIONS, V20, P157, DOI 10.1007/BF02074656; TONES MA, 1989, FEBS LETT, V252, P105, DOI 10.1016/0014-5793(89)80898-1; WORLEY PF, 1987, J BIOL CHEM, V262, P12132; WRIGHT TC, 1985, J CELL PHYSIOL, V125, P499, DOI 10.1002/jcp.1041250320; [No title captured]	45	24	24	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1997	99	3					338	344		10.1016/S0091-6749(97)70051-4	http://dx.doi.org/10.1016/S0091-6749(97)70051-4			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WM422	9058689	Bronze			2022-12-18	WOS:A1997WM42200010
J	Greineder, DK				Greineder, DK			Risk management in allergen immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergen immunotherapy; fatal reaction; precautions; risk factors; risk management; systemic reaction	SYSTEMIC REACTIONS; POLLEN EXTRACTS; FATALITIES; SAFETY	The major risk of allergen immunotherapy is the development of systemic anaphylactic reactions. The reported frequency of systemic reactions after allergen immunotherapy varies from <1% in patients receiving conventional immunotherapy to >39% in patients receiving rush immunotherapy. Fatal and systemic reactions to allergen immunotherapy have similar characteristics. The onset of both types of reaction occurs <30 minutes after injection in approximately 70% of patients. The most common risk factor for fatal and systemic reactions to allergen immunotherapy include a history of asthma, increasing allergen dose, high allergen sensitivity, previous systemic reaction, and injection during an active allergen season. On the basis of findings for several studies, precautions during allergen immunotherapy have been recommended. In addition, several interventions, including premedication with antihistamines or corticosteroids, measurement of peak flow before injection, and access to an antihistamine or injectable epinephrine after an allergen injection, have been suggested as measures to prevent reactions to and improve the safety of allergen immunotherapy. However, additional studies are necessary before these regimens are implemented routinely in allergen immunotherapy protocols.			Greineder, DK (corresponding author), HARVARD UNIV,COMMUNITY HLTH PLAN,KENMORE CTR,2 FENWAY PL,BOSTON,MA 02215, USA.							BUKANTZ SC, 1991, ALLERGEN IMMUNOTHERA, P233; Committee on the Safety of Medicines (CSM), 1986, BMJ-BRIT MED J, V293, P948; DUBUSKE LM, 1992, IMMUNOL ALLERGY CLIN, V12, P145; GREENBERG MA, 1986, J ALLERGY CLIN IMMUN, V77, P865, DOI 10.1016/0091-6749(86)90385-4; HEJJAOUI A, 1990, J ALLERGY CLIN IMMUN, V85, P473, DOI 10.1016/0091-6749(90)90157-Y; HEPNER M, 1987, J ALLERGY CLIN IMMUN, V79, P133; HEPNER MJ, 1990, J ALLERGY CLIN IMMUN, V86, P407, DOI 10.1016/S0091-6749(05)80105-8; JAMES LP, 1964, NEW ENGL J MED, V270, P597, DOI 10.1056/NEJM196403192701202; Lamson R, 1924, JAMA-J AM MED ASSOC, V82, P1090; LAMSON RW, 1929, JAMA-J AM MED ASSOC, V93, P1975; LEVINE MI, 1979, J ALLERGY CLIN IMMUN, V63, P209; LOCKEY RF, 1987, J ALLERGY CLIN IMMUN, V79, P660, DOI 10.1016/S0091-6749(87)80164-1; MATLOFF SM, 1993, ALLERGY PROC, V14, P347, DOI 10.2500/108854193778774001; NELSON BL, 1986, ANN ALLERGY, V56, P331; OSTERBALLE O, 1982, ALLERGY, V37, P553, DOI 10.1111/j.1398-9995.1982.tb02340.x; RANDS DA, 1980, BRIT MED J, V281, P854, DOI 10.1136/bmj.281.6244.854; RAWLINS MD, 1988, ARBEITEN P ERHLICH I, V82, P147; REID MJ, 1993, J ALLERGY CLIN IMMUN, V92, P6, DOI 10.1016/0091-6749(93)90030-J; RIECKENBERG MR, 1990, ANN ALLERGY, V64, P364; VANARSDEL PP, 1957, J ALLERGY, V28, P251, DOI 10.1016/0021-8707(57)90130-2; Vance BM, 1942, ARCH PATHOL, V34, P849; VANMETRE T, 1993, ALLERGY PRINCIPLES P; VERVLOET D, 1980, CLIN ALLERGY, V10, P59, DOI 10.1111/j.1365-2222.1980.tb02080.x; *WHO INT UN IMM SO, 1989, LANCET, V1, P259	24	24	25	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1996	98	6	3	S			S330	S334		10.1016/S0091-6749(96)80119-9	http://dx.doi.org/10.1016/S0091-6749(96)80119-9			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WC448	8977545				2022-12-18	WOS:A1996WC44800007
J	Pawankar, R; Ra, CS				Pawankar, R; Ra, CS			Heterogeneity of mast cells and T cells in the nasal mucosa	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						perennial allergic rhinitis; mast cells; mucosal lymphocytes; gamma delta T cells; adhesion molecules; T-H2 cytokines	ALLERGEN-INDUCED RHINITIS; EPIDERMAL LANGERHANS CELLS; HIGH-AFFINITY RECEPTOR; FC-EPSILON-RI; LYMPHOCYTE SUBSETS; BASOPHILIC CELLS; MESSENGER-RNA; IGE RECEPTOR; HUMAN NOSE; ACTIVATION	Allergic diseases like atopic rhinitis, bronchial asthma, and urticaria are prevalent and on the rise. The need to better understand the pathophysiology of these diseases is therefore crucial to the development of newer and more effective modes of treatment. We hypothesized that in inflammatory diseases like allergic rhinitis and asthma characterized by profound local clinical manifestations and inflammation of the relevant mucosae, the most important immunopathological findings must occur locally. Although studies on the cellular elements and mediators in the peripheral blood compartment may provide useful information, they may not accurately reflect events occurring within the target organ itself. Even in the normal mucosa there is a resident population of lymphocytes and mast cells. Taking perennial allergic rhinitis (PAR) and chronic infective rhinitis (CIR) as representative chronic airway inflammatory diseases we investigated the phenotypic and functional characteristics of most cell and lymphocytes in the nasal mucosa of patients with PAR CIR during the natural course of the disease. We further compared the characteristics of lymphocytes in the nasal mucosa with that in the peripheral blood compartment. our results demonstrated heterogeneity of mast cells and T cells in the nasal mucosa. Furthermore, the mucosal changes at the site of allergic inflammation were characterized by an increase in the proportion of CD4(+) CD45RO(+) T cells (memory cells); oligoclonal expansion and activation of V gamma 1/V delta 1(+) T cells; and increased number of Fc epsilon RI(+) cells; an increased proportion of T-H2- type cytokine expressing mast cells and lymphocytes and of very late antigen-4 and very late antigen-5 expressing nasal mast cells, independent of alterations in CIR; and autologous peripheral blood. these findings strongly suggest heterogeneity of lymphocytes and mast cells in the nasal mucosa based on the underlying inflammatory disease, and compartmentalization of inflammatory cells in the nasal mucosa and peripheral blood.	JUNTENDO UNIV, SCH MED, DEPT IMMUNOL, BUNKYO KU, TOKYO 113, JAPAN	Juntendo University								Barnes PJ, 1996, J ALLERGY CLIN IMMUN, V97, P159, DOI 10.1016/S0091-6749(96)80216-8; BASCOM R, 1988, AM REV RESPIR DIS, V138, P406, DOI 10.1164/ajrccm/138.2.406; BIEBER T, 1992, J EXP MED, V175, P1285, DOI 10.1084/jem.175.5.1285; BRADDING P, 1995, J IMMUNOL, V155, P297; BRADDING P, 1993, J IMMUNOL, V151, P3853; CASTELLS M, 1988, J ALLERGY CLIN IMMUN, V82, P348, DOI 10.1016/0091-6749(88)90005-X; COHAN VL, 1989, MAST CELL BASOPHIL D, P149; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DENBURG JA, 1985, J ALLERGY CLIN IMMUN, V76, P466, DOI 10.1016/0091-6749(85)90728-6; ENERBACK L, 1986, INT ARCH ALLER A IMM, V80, P44, DOI 10.1159/000234024; ENERBACK L, 1966, ACTA PATHOL MIC SC, V66, P289, DOI 10.1111/apm.1966.66.3.289; FERRICK DA, 1995, NATURE, V373, P255, DOI 10.1038/373255a0; FOKKENS WJ, 1992, CLIN EXP ALLERGY, V22, P701, DOI 10.1111/j.1365-2222.1992.tb00194.x; GALLI SJ, 1990, LAB INVEST, V62, P5; GALLI SJ, 1991, CURR OPIN IMMUNOL, V3, P865, DOI 10.1016/S0952-7915(05)80005-6; GALLI SJ, 1987, FED PROC, V46, P1345; GALLI SJ, 1988, ALLERGY PRINCIPLES P, P106; GOUNNI AS, 1994, NATURE, V367, P183, DOI 10.1038/367183a0; GUO CB, 1992, BLOOD, V79, P708; HOLGATE ST, 1988, ALLERGY PRINCIPLES P, P135; HORNER AA, 1995, J EXP MED, V181, P1239, DOI 10.1084/jem.181.3.1239; IRANI AA, 1986, P NATL ACAD SCI USA, V83, P4464, DOI 10.1073/pnas.83.12.4464; Ishizaka T, 1988, ALLERGY PRINCIPLES P, P71; JANEWAY CA, 1988, IMMUNOL TODAY, V9, P73, DOI 10.1016/0167-5699(88)91267-4; KITAMURA Y, 1989, ANNU REV IMMUNOL, V7, P59, DOI 10.1146/annurev.iy.07.040189.000423; KIYONO H, 1994, HDB MUCOSAL IMMUNOLO, P159; KLEMENTSSON H, 1991, ACTA OTO-LARYNGOL, V111, P776, DOI 10.3109/00016489109138412; KLEMENTSSON H, 1990, CLIN EXP ALLERGY, V20, P539, DOI 10.1111/j.1365-2222.1990.tb03147.x; LEE BJ, 1994, J ALLERGY CLIN IMMUN, V93, P183; LIM MC, 1995, AM J RESP CRIT CARE, V148, P2223; MOLLER A, 1993, J IMMUNOL, V151, P3261; MONTEFORT S, 1992, AM J RESP CELL MOL, V7, P393, DOI 10.1165/ajrcmb/7.4.393; MYGIND N, 1987, ACTA OTO-LARYNGOL, V103, P363; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; NISHIMOTO K, 1988, ACTA OTO-LARYNGOL, V106, P291, DOI 10.3109/00016488809106439; Nishiyama C, 1995, MOL IMMUNOL, V32, P1021, DOI 10.1016/0161-5890(95)00091-7; NISHIYAMA C, 1993, ARCH ALLERGY APPL IM, V105, P62; OKUDA M, 1977, ARCH OTO-RHINO-LARYN, V214, P283, DOI 10.1007/BF00457469; OKUDA M, 1985, ANN ALLERGY, V54, P152; OKUDA M, 1985, ANN ALLERGY, V54, P69; OKUDA M, 1987, IMMUNOBIOLOGY HISTOP, P317; OTSUKA H, 1985, J ALLERGY CLIN IMMUN, V76, P695, DOI 10.1016/0091-6749(85)90673-6; OTSUKA H, 1995, ARERUGI, V44, P847; PATELLA V, 1995, J IMMUNOL, V154, P2855; PAWANKAR R, 1996, JPN J ALLERY IMMUNOL, V14, P92; Pawankar RU, 1996, AM J RESP CRIT CARE, V153, P1655, DOI 10.1164/ajrccm.153.5.8630617; PAWANKAR RU, 1995, AM J RESP CRIT CARE, V152, P2059, DOI 10.1164/ajrccm.152.6.8520776; PAWANKAR RU, 1995, AM J RESP CRIT CARE, V152, P2049, DOI 10.1164/ajrccm.152.6.8520775; PROUD D, 1992, J ALLERGY CLIN IMMUN, V89, P1098, DOI 10.1016/0091-6749(92)90293-B; RA C, 1993, INT IMMUNOL, V5, P47, DOI 10.1093/intimm/5.1.47; RA CS, 1994, J ALLERGY CLIN IMMUN, V94, P625, DOI 10.1016/0091-6749(94)90139-2; RUST CJJ, 1990, NATURE, V346, P572, DOI 10.1038/346572a0; SANDERS ME, 1988, IMMUNOL TODAY, V9, P195, DOI 10.1016/0167-5699(88)91212-1; SCHULMAN ES, 1983, J IMMUNOL, V131, P1936; Seki H, 1992, JPN J OTOLARYNGOL, V95, P1012; SPITS H, 1991, J IMMUNOL, V147, P1180; STOOP AE, 1989, J ALLERGY CLIN IMMUN, V84, P734, DOI 10.1016/0091-6749(89)90302-3; VARNEY VA, 1992, AM REV RESPIR DIS, V146, P170, DOI 10.1164/ajrccm/146.1.170; WANG B, 1992, J EXP MED, V175, P1353, DOI 10.1084/jem.175.5.1353; WINTHER B, 1987, ARCH OTOLARYNGOL, V113, P59; WLODZIMIERZ P, 1992, J IMMUNOL, P3503; YANAGIHARA Y, 1994, J CLIN INVEST, V94, P2162, DOI 10.1172/JCI117574; YGITA H, 1993, MOL BASIS IMMUNE RES, P59; YING S, 1994, IMMUNOLOGY, V82, P200; YING S, 1993, AM J RESP CELL MOL, V9, P356, DOI 10.1165/ajrcmb/9.4.356	66	24	25	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1996	98	6	2	S			S248	S262		10.1016/S0091-6749(96)70073-8	http://dx.doi.org/10.1016/S0091-6749(96)70073-8			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WC447	8977534				2022-12-18	WOS:A1996WC44700011
J	Lane, SJ; Lee, TH				Lane, SJ; Lee, TH			Section 3: Mechanisms of symptomatology - Mast cell effector mechanisms	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						aspirin-sensitive asthma; cysteinyl leukotrienes; hyperosmolar stimuli; mast cell	EXERCISE-INDUCED ASTHMA; ASPIRIN-SENSITIVE ASTHMATICS; INDUCED BRONCHOCONSTRICTION; URINARY LEUKOTRIENE-E4; HISTAMINE-RELEASE; ARACHIDONIC-ACID; AIRWAY RESPONSIVENESS; LYSINE-ASPIRIN; TERFENADINE; INHIBITION	Several lines of evidence support the central role of the cysteinyl leukotrienes in aspirin-sensitive asthma, although their cellular source is unknown. The two most likely cells are the mast cell and eosinophil. Compared with aspirin-tolerant patients with asthma, patients with aspirin-sensitive asthma have been found to have a greater infiltration of mast cells and eosinophils in bronchial biopsy samples, although proportions of activated eosinophils were similar. Findings that support the involvement of mast cells include elevated serum histamine and tryptase levels after aspirin challenge in sensitive subjects, in line with a decrease in lung function and increased histamine and leukotriene C-4 levels in nasal secretions; release of high-molecular-weight neutrophil chemotactic factor into serum after challenge; and prevention of aspirin-induced bronchoconstriction by pretreatment with cromolyn sodium or nedocromil sodium. These agents are also effective in protecting against bronchoconstriction induced by hyperosmolar stimuli, a challenge that is not associated with increased leukotriene E(4) responsiveness but that is followed by increased release of histamine and prostaglandin D-2 into bronchoalveolar lavage fluid. Antihistamines are poorly effective at inhibiting aspirin-induced bronchoconstriction but have been shown to attenuate the bronchoconstrictor response to hyperosmolar challenge. The main effector mechanism in hyperosmolar-induced bronchoconstriction appears to be mast cell activation and histamine release.	GUYS HOSP,DEPT ALLERGY & RESP MED,LONDON SE1 9RT,ENGLAND	Guy's & St Thomas' NHS Foundation Trust				Lee, Tak/0000-0002-7554-4059				ARM JP, 1990, AM REV RESPIR DIS, V142, P1112, DOI 10.1164/ajrccm/142.5.1112; ARM JP, 1989, AM REV RESPIR DIS, V140, P148, DOI 10.1164/ajrccm/140.1.148; ATLURU D, 1986, BIOCHEM BIOPH RES CO, V135, P670, DOI 10.1016/0006-291X(86)90045-8; BELCHER NG, 1988, AM REV RESPIR DIS, V137, P1026, DOI 10.1164/ajrccm/137.5.1026; BOSSO JV, 1991, J ALLERGY CLIN IMMUN, V88, P830, DOI 10.1016/0091-6749(91)90238-J; CHRISTIE PE, 1992, AM REV RESPIR DIS, V146, P1531, DOI 10.1164/ajrccm/146.6.1531; CHRISTIE PE, 1991, AM REV RESPIR DIS, V143, P1025, DOI 10.1164/ajrccm/143.5_Pt_1.1025; CHRISTIE PE, 1993, EUR RESPIR J, V6, P1468; CHRISTIE PE, 1991, AM REV RESPIR DIS, V144, P957, DOI 10.1164/ajrccm/144.4.957; CLEE MD, 1984, BRIT J DIS CHEST, V78, P180, DOI 10.1016/0007-0971(84)90120-7; DAHLEN B, 1993, EUR RESPIR J, V6, P1018; EGGLESTON PA, 1984, AM REV RESPIR DIS, V130, P86; FERRERI NR, 1988, AM REV RESPIR DIS, V137, P847, DOI 10.1164/ajrccm/137.4.847; FINNERTY JP, 1989, AM REV RESPIR DIS, V140, P593, DOI 10.1164/ajrccm/140.3.593; FISCHER AR, 1994, J ALLERGY CLIN IMMUN, V94, P1046, DOI 10.1016/0091-6749(94)90123-6; FREED AN, 1987, J APPL PHYSIOL, V62, P574, DOI 10.1152/jappl.1987.62.2.574; GOETZL EJ, 1981, BIOCHEM BIOPH RES CO, V101, P344, DOI 10.1016/0006-291X(81)91266-3; GOLDYNE ME, 1987, PROSTAGLANDINS, V34, P783, DOI 10.1016/0090-6980(87)90060-8; GRAVELYN TR, 1988, AM REV RESPIR DIS, V137, P641, DOI 10.1164/ajrccm/137.3.641; Imokawa S, 1992, Arerugi, V41, P1515; ISRAEL E, 1993, AM REV RESPIR DIS, V148, P1447, DOI 10.1164/ajrccm/148.6_Pt_1.1447; JUERGENS UR, 1992, J ALLERGY CLIN IMMUN, V90, P636, DOI 10.1016/0091-6749(92)90137-Q; MACFARLANE PI, 1989, RESP MED, V83, P19, DOI 10.1016/S0954-6111(89)80055-1; MAGNUSSEN H, 1988, CHEST, V93, P937, DOI 10.1378/chest.93.5.937; MARTELLI NA, 1977, THORAX, V32, P684, DOI 10.1136/thx.32.6.684; MAXWELL DL, 1993, EUR RESPIR J, V6, P1145; Nasser S. M. Shuaib, 1994, Thorax, V49, P749, DOI 10.1136/thx.49.8.749; Nasser SMS, 1996, AM J RESP CRIT CARE, V153, P90, DOI 10.1164/ajrccm.153.1.8542168; ODLANDER B, 1988, BIOCHEM BIOPH RES CO, V153, P203, DOI 10.1016/S0006-291X(88)81209-9; OHICKEY SP, 1988, EUR RESPIR J, V1, P913; OHICKEY SP, 1989, THORAX, V44, P850; ORTOLANI C, 1987, ANN ALLERGY, V59, P106; PATEL KR, 1984, BRIT MED J, V288, P1496, DOI 10.1136/bmj.288.6429.1496; ROBUSCHI M, 1994, AM J RESP CRIT CARE, V149, pA1054; SAMTER M, 1968, ANN INTERN MED, V68, P975, DOI 10.7326/0003-4819-68-5-975; SLADEK K, 1994, AM J RESP CRIT CARE, V149, P940, DOI 10.1164/ajrccm.149.4.8143059; SMITH CM, 1992, EUR RESPIR J, V5, P693; Szmidt M, 1991, Pneumonol Alergol Pol, V59, P16; Yamashita T, 1989, Rhinol Suppl, V8, P15; Yoshimi R, 1993, Nihon Jibiinkoka Gakkai Kaiho, V96, P1922	40	24	25	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1996	98	5	2	S			S67	S71		10.1016/S0091-6749(96)80131-X	http://dx.doi.org/10.1016/S0091-6749(96)80131-X			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VW140	8939179				2022-12-18	WOS:A1996VW14000013
J	SHAH, TJ; KNOWLES, WO; MCGEADY, SJ				SHAH, TJ; KNOWLES, WO; MCGEADY, SJ			HEREDITARY ANGIOEDEMA WITH RECURRENT ABDOMINAL-PAIN AND ASCITES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note							INHIBITOR; DEFICIENCY		THOMAS JEFFERSON UNIV,PHILADELPHIA,PA 19107	Jefferson University								ARREAZA EE, 1988, ANN ALLERGY, V61, P69; ATKINSON J P, 1979, Annals of Allergy, V42, P348; FRANK MM, 1976, ANN INTERN MED, V84, P580, DOI 10.7326/0003-4819-84-5-580; GORDON EM, 1980, J LAB CLIN MED, V96, P762; MARENAH CB, 1983, BRIT MED J, V286, P786, DOI 10.1136/bmj.286.6367.786; SHEFFER AL, 1985, J ALLERGY CLIN IMMUN, V75, P640, DOI 10.1016/0091-6749(85)90087-9; WEINSTOCK LB, 1987, GASTROENTEROLOGY, V93, P1116, DOI 10.1016/0016-5085(87)90576-2	7	24	24	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1995	96	2					259	261		10.1016/S0091-6749(95)70017-X	http://dx.doi.org/10.1016/S0091-6749(95)70017-X			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RQ001	7636064	Bronze			2022-12-18	WOS:A1995RQ00100017
J	AMIRAV, I; GOREN, A; KRAVITZ, RM; PAWLOWSKI, NA				AMIRAV, I; GOREN, A; KRAVITZ, RM; PAWLOWSKI, NA			PHYSICIAN-TARGETED PROGRAM ON INHALED THERAPY FOR CHILDHOOD ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ASTHMA; ASTHMA EDUCATION; INHALED THERAPY; METERED-DOSE INHALER	METERED-DOSE INHALERS; CANISTER NEBULIZERS; INHALATION; AEROSOL; MEDICATIONS; EDUCATION; DEVICES; MISUSE; DEATHS; CARE	Background: Inhaled medications are the mainstay of asthma therapy but significant deficiencies exist in the knowledge and skills of physicians regarding use of metered-dose inhalers (MDI) and spacer devices. Objective: We developed, implemented and evaluated the effects of a physician-targeted educational program on inhaled therapy in a group of pediatric residents in our institution. Methods: Patient-directed instruction sheets on aerosol therapy were developed on the basis of literature review and expert guidelines. These sewed to establish a consistent foundation for the educational curriculum. The program was delivered through one-on-two teaching sessions (45 minutes). Residents were provided with a summary of theoretical and practical information and with devices for practice (a placebo MDI, InspirEase and AeroChamber holding chambers, and the AeroChamber device with mask). Each session included review of an educational monograph, demonstration of proper technique, and practice with the different devices. The program was evaluated by a randomized-control design. Assessment of practical skills included number of correct steps for the use of MDI (maximum score, 7), InspirEase (maximum, 7) and AeroChamber (maximum, 6). Theoretical knowledge was assessed with 25 multiple-choice questions. Results: Pretest scores in the experimental group (n = 24) were 3.7 of 7, 1.9 of 7, and 0.3 of 6 steps correct for MDI, InspirEase, and AeroChamber devices, respectively): and 13 of 25 for the theoretical knowledge assessment. The control group (n = 26) had similar pretest scores. After the program the experimental group significantly improved in all parameters: 6.3 of 7, 5.9 of 7, and 4.5 of 6 steps correct for MDI, InspirEase, and AeroChamber devices, respectively, and 18 of 25 questions correct (p < 0.01 for all parameters). Conclusions: Implementation of a simple educational program among pediatric residents can significantly increase their skills in the use of inhalational therapy.	CHILDRENS HOSP PHILADELPHIA, DIV GEN PEDIAT, PHILADELPHIA, PA 19104 USA; CHILDRENS HOSP PHILADELPHIA, DIV PULM MED, PHILADELPHIA, PA 19104 USA; CHILDRENS HOSP PHILADELPHIA, DIV ALLERGY IMMUNOL, PHILADELPHIA, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia			Amirav, Israel/I-9286-2019	Amirav, Israel/0000-0002-6917-5285				ALTMAN LK, 1993, NY TIMES        0420, pC3; AMIRAV I, IN PRESS J ALLERGY C; APPEL D, 1982, J FAM PRACTICE, V14, P1135; BAUMAN A, 1990, J ASTHMA, V27, P385, DOI 10.3109/02770909009073355; BENATAR SR, 1986, NEW ENGL J MED, V314, P423, DOI 10.1056/NEJM198602133140706; BIRKHEAD G, 1989, J ALLERGY CLIN IMMUN, V84, P484, DOI 10.1016/0091-6749(89)90361-8; BLOOMBERG GR, 1992, PEDIATR CLIN N AM, V39, P1225; BUIST AS, 1989, J ALLERGY CLIN IMMUN, V84, P275, DOI 10.1016/0091-6749(89)90408-9; BURTON AJ, 1984, BRIT MED J, V288, P1650, DOI 10.1136/bmj.288.6431.1650-a; DEBLAQUIERE P, 1989, AM REV RESPIR DIS, V140, P910, DOI 10.1164/ajrccm/140.4.910; DOLOVICH M, 1981, CHEST, V80, P834; EASON J, 1987, BRIT MED J, V294, P1255, DOI 10.1136/bmj.294.6582.1255; EPSTEIN SW, 1979, CAN MED ASSOC J, V120, P813; GOLDFINGER SE, 1982, NEW ENGL J MED, V306, P540, DOI 10.1056/NEJM198203043060910; GREENBERG LW, 1991, PATIENT EDUC COUNS, V17, P3, DOI 10.1016/0738-3991(91)90046-8; GUIDRY GG, 1992, CHEST, V101, P31, DOI 10.1378/chest.101.1.31; HEMSTREET MP, 1991, AM J ASTHMA ALLERGY, V4, P145; KELLING JS, 1983, CHEST, V83, P612, DOI 10.1378/chest.83.4.612; LEE HS, 1983, CLIN PEDIATR, V22, P440; LEVISON H, 1985, J PEDIATR-US, V107, P662, DOI 10.1016/S0022-3476(85)80389-9; MAS JC, 1992, AM J DIS CHILD, V146, P783, DOI 10.1001/archpedi.1992.02160190013003; MUNT PW, 1979, CAN MED ASSOC J, V120, P781; NEWHOUSE MT, 1986, NEW ENGL J MED, V315, P870, DOI 10.1056/NEJM198610023151406; NEWMAN SP, 1981, EUR J RESPIR DIS, V62, P3; SAUNDERS KB, 1965, BRIT MED J, V1, P1037, DOI 10.1136/bmj.1.5441.1037; SHIM C, 1980, AM J MED, V69, P891, DOI 10.1016/S0002-9343(80)80016-7; SLY PD, 1991, J PAEDIATR CHILD H, V27, P7, DOI 10.1111/j.1440-1754.1991.tb00337.x; TAL A, 1987, ISRAEL J MED SCI, V23, P168; WEISS KB, 1992, NEW ENGL J MED, V326, P862, DOI 10.1056/NEJM199203263261304; 1992, NIH923091 US DAP HLT; 1991, NIH913042 US DEP HLT	31	24	25	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1995	95	4					818	823		10.1016/S0091-6749(95)70124-9	http://dx.doi.org/10.1016/S0091-6749(95)70124-9			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QT468	7722161				2022-12-18	WOS:A1995QT46800006
J	SHORPOSNER, G; MIGUEZBURBANO, MJ; LU, Y; FEASTER, D; FLETCHER, M; SAUBERLICH, H; BAUM, MK				SHORPOSNER, G; MIGUEZBURBANO, MJ; LU, Y; FEASTER, D; FLETCHER, M; SAUBERLICH, H; BAUM, MK			ELEVATED IGE LEVEL IN RELATIONSHIP TO NUTRITIONAL-STATUS AND IMMUNE PARAMETERS IN EARLY HUMAN IMMUNODEFICIENCY VIRUS-1 DISEASE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IGE; HUMAN IMMUNODEFICIENCY VIRUS-1 INFECTION; VITAMIN E; NUTRITIONAL STATUS	ARACHIDONIC-ACID METABOLISM; HIV-INFECTION; VITAMIN-E; OXIDATIVE STRESS; IMMUNOGLOBULIN-E; MONOCYTES; MICRONUTRIENTS; ABNORMALITIES; PROGRESSION; MACROPHAGES	Elevation of IgE has been associated with T-cell dysregulation and with the occurrence of opportunistic infections in patients with acquired immunodeficiency syndrome. The precise cause of IgE overproduction during the early stages of human immunodeficiency virus (HIV)-1 disease, however, has not been established. In light of reports demonstrating that IgE production may be affected by vitamin E levels in an animal model, we evaluated nutritional status in relationship to plasma IgE levels and immune parameters in 100 asymptomatic HIV-1-seropositive and 42 HIV-1-seronegative homosexual men. Approximately 18% of the HIV-1-seropositive population demonstrated biochemical evidence of plasma vitamin E deficiency (<5 mu g/ml). Subsequent analysis of available samples indicated a dramatic elevation of IgE levels (308 +/- 112 IU/ml) in vitamin E-deficient seropositive subjects (n = 9) as compared with age and CD4-matched HIV-1-seropositive persons with adequate vitamin E levels (n = 16, 118.1 +/- 41.1 IU/ml) and significantly lower levels (59.5 +/- 15.7 IU/ml) in HIV-1-seronegative men (n = 20, p = 0.01). This effect, which was independent of CD4 cell count, did not appear to be influenced by atopic or gastrointestinal parasitic disease. The low plasma vitamin E levels were related at least in part to dietary intake (r = 0.552, p = 0.01), suggesting that supplementation may be warranted in HIV-1-infected persons in whom vitamin E deficiency develops. Analysis of covariance revealed a strong relationship between IgE levels and CD8 cell counts (p < 0.006), and between IgE level and vitamin E deficiency (p < 0.039). Although nutritional deficiency is unlikely to be the principal cause of immunoglobulin dysregulation in HIV infection, these results demonstrate that vitamin E deficiency may play a contributory role in IgE elevation during the early stages of disease.	UNIV MIAMI, SCH MED, CTR BIOPSYCHOSOCIAL STUDY AIDS, MIAMI, FL USA; UNIV ALABAMA, DEPT NUTR SCI, DIV EXPTL NUTR, BIRMINGHAM, AL 35294 USA	University of Miami; University of Alabama System; University of Alabama Birmingham	SHORPOSNER, G (corresponding author), UNIV MIAMI, SCH MED, DEPT EPIDEMIOL & PUBL HLTH, POB 01609 R-669, MIAMI, FL 33101 USA.		Feaster, Daniel/I-6079-2013		FOGARTY INTERNATIONAL CENTER [D43TW000017] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R03MH042555] Funding Source: NIH RePORTER; FIC NIH HHS [D43-TW00017-5] Funding Source: Medline; NIMH NIH HHS [1-P50-MH42555] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BAHNA SL, 1978, J ALLERGY CLIN IMMUN, V62, P167, DOI 10.1016/0091-6749(78)90102-1; BARUCHEL S, 1992, J LEUKOCYTE BIOL, V52, P111, DOI 10.1002/jlb.52.1.111; BAUM MK, 1992, ANN NY ACAD SCI, V669, P165; BEACH RS, 1992, AIDS, V6, P701, DOI 10.1097/00002030-199207000-00013; BENDICH A, 1990, ADV EXP MED BIOL, V262, P35; BENDICH A, 1990, ANN NY ACAD SCI, V587, P168, DOI 10.1111/j.1749-6632.1990.tb00144.x; BIERI JG, 1979, AM J CLIN NUTR, V32, P2143, DOI 10.1093/ajcn/32.10.2143; BOGDEN JD, 1990, ANN NY ACAD SCI, V587, P189, DOI 10.1111/j.1749-6632.1990.tb00146.x; BUCKLEY RH, 1975, J CLIN INVEST, V55, P157, DOI 10.1172/JCI107906; BUCKLEY RH, 1978, IMMUNOL REV, V41, P288, DOI 10.1111/j.1600-065X.1978.tb01469.x; CARR A, 1991, J CLIN IMMUNOL, V11, P55, DOI 10.1007/BF00917741; DIAZSANCHEZ D, 1993, IMMUNOLOGY, V78, P226; FERNANDEZCRUZ E, 1989, AIDS, V3, P91, DOI 10.1097/00002030-198902000-00007; FOLEY P, 1992, IMMUNOLOGY, V75, P391; GOGU SR, 1989, BIOCHEM BIOPH RES CO, V165, P401, DOI 10.1016/0006-291X(89)91084-X; GOLDFARB AA, 1961, NEW YORK STATE J MED, V61, P2721; GRUCHALLA RS, 1991, J ALLERGY CLIN IMMUN, V88, P784, DOI 10.1016/0091-6749(91)90186-R; IDA S, 1983, J GEN VIROL, V64, P533, DOI 10.1099/0022-1317-64-3-533; INAGAKI N, 1984, J PHARMACOBIO-DYNAM, V7, P70; ISRAELBIET D, 1992, J ALLERGY CLIN IMMUN, V89, P68, DOI 10.1016/S0091-6749(05)80042-9; MAGGI E, 1989, J RIC CLIN LAB, V9, P45; MALKOWSKAZWIERZ W, 1991, J ARCH IMMUNOL THER, V39, P109; MEYDANI SM, NUTRITIONAL MODULATI; MEYDANI SN, 1990, AM J CLIN NUTR, V52, P557, DOI 10.1093/ajcn/52.3.557; MEYDANI SN, 1990, ANN NY ACAD SCI, V587, P196, DOI 10.1111/j.1749-6632.1990.tb00147.x; MIGUEZBURBANO MJ, 1993, EXP BIOL, V1, P2901; NIELSEN SL, 1988, J CLIN MICROBIOL, V26, P654, DOI 10.1128/JCM.26.4.654-661.1988; PAPADOPULOSELEOPULOS E, 1992, RES IMMUNOL, V143, P145, DOI 10.1016/S0923-2494(92)80156-F; PEDERSEN M, 1991, ALLERGY, V46, P206, DOI 10.1111/j.1398-9995.1991.tb00572.x; PENTLAND AP, 1992, J BIOL CHEM, V267, P15578; PINON JM, 1990, J CLIN MICROBIOL, V28, P1739, DOI 10.1128/JCM.28.8.1739-1743.1990; RAMIS I, 1991, J CHROMATOGR, V557, P507, DOI 10.1016/S0021-9673(01)87159-4; SAKAMOTO W, 1991, PROSTAG LEUKOTR ESS, V44, P89, DOI 10.1016/0952-3278(91)90188-B; SAKAMOTO W, 1991, BIOCHIM BIOPHYS ACTA, V1074, P251, DOI 10.1016/0304-4165(91)90160-I; SCHWARTZMAN WA, 1991, AM J MED, V90, P595, DOI 10.1016/S0002-9343(05)80011-7; SHORPOSNER G, 1992, J IMMUNOL INFECT DIS, V4, P209; WALDMANN TA, 1972, J IMMUNOL, V109, P304; WOLF R, 1991, ANN ALLERGY, V66, P421; WRIGHT DN, 1990, J ALLERGY CLIN IMMUN, V85, P445, DOI 10.1016/0091-6749(90)90154-V	39	24	27	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1995	95	4					886	892		10.1016/S0091-6749(95)70133-8	http://dx.doi.org/10.1016/S0091-6749(95)70133-8			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QT468	7722170				2022-12-18	WOS:A1995QT46800015
J	VENAILLE, TJ; MENDIS, AHW; PHILLIPS, MJ; THOMPSON, PJ; ROBINSON, BWS				VENAILLE, TJ; MENDIS, AHW; PHILLIPS, MJ; THOMPSON, PJ; ROBINSON, BWS			ROLE OF NEUTROPHILS IN MEDIATING HUMAN EPITHELIAL-CELL DETACHMENT FROM NATIVE BASEMENT-MEMBRANE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						NEUTROPHILS; BASEMENT MEMBRANE; HUMAN EPITHELIAL CELLS; ASTHMA	PULMONARY INFLAMMATORY INJURY; PHORBOL ESTERS; PROTEIN-KINASE; RELEASE; DAMAGE; OXIDANTS; DISEASE; ASTHMA; CONSTITUENTS; DEGRADATION	Epithelial cell detachment from underlying basement membrane is a feature of diseases of many organs In the lungs it is seen in disorders as diverse as bronchiectasis, allograft rejection, and asthma. The potential for different leukocytes to induce this change is not clear. In asthma both eosinophils and neutrophils are found in affected tissues, but the capacity of each of these types of cells to induce detachment of native epithelial cells from basement membrane requires clarification. Although eosinophils damage rather than detach human epithelial cells, the effects of neutrophils on epithelial cells naturally attached to basement membrane have not previously been described Using the human amnion in vitro model, we rested the hypothesis that neutrophils have the capacity to detach intact human epithelial cells from basement membrane. The data indicate that increasing concentrations of neutrophils are able to detach epithelial cells from their underlying basement membrane. Detachment was increased when the neutrophils were activated in situ with tetradecanoyl phorbol acetate and after longer incubation periods. Platelet activating factor and opsonized zymosan showed similar boosting effects, whereas activated complement and formyl-methyl-leucyl-phenylalanine did not. Physical contact of the neutrophils with the epithelial cells was required to induced detachment. Detachment could be inhibited by glutathione and by soybean trypsin inhibitor, an inhibition pattern similar to cathepsin G and trypsin, but not collagenase in this system. We conclude that neutrophils are capable of detaching human epithelial cells from basement membrane, which in part involves the release of chymotrypsin-like serine proteases, probably in conjunction with oxidants, and that this detachment can be inhibited.	UNIV WESTERN AUSTRALIA,QUEEN ELIZABETH II MED CTR,DEPT MED,NEDLANDS,WA 6009,AUSTRALIA; SIR CHARLES GAIRDNER HOSP,QUEEN ELIZABETH II MED CTR,DEPT RESP MED,NEDLANDS,WA 6009,AUSTRALIA	University of Western Australia; University of Western Australia			Robinson, Bruce/N-1900-2014					AYARS GH, 1984, AM REV RESPIR DIS, V130, P964; BARKER AF, 1988, AM REV RESPIR DIS, V137, P969, DOI 10.1164/ajrccm/137.4.969; BECKER EL, 1974, J IMMUNOL, V112, P2047; BOUCHER R C, 1988, American Review of Respiratory Disease, V138, pS41; BOXER LA, 1988, HEMATOL ONCOL CLIN N, V2, P101; BREUER R, 1989, AM REV RESPIR DIS, V139, P779, DOI 10.1164/ajrccm/139.3.779; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; FRIGAS E, 1986, J ALLERGY CLIN IMMUN, V77, P527, DOI 10.1016/0091-6749(86)90341-6; GAY JC, 1988, BLOOD, V71, P159; GLANVILLE AR, 1987, ANN INTERN MED, V107, P300, DOI 10.7326/0003-4819-107-2-300; HENSON PM, 1971, J IMMUNOL, V107, P1535; HOGG JC, 1984, AM REV RESPIR DIS, V129, P207; IIJIMA H, 1987, AM REV RESPIR DIS, V136, P922, DOI 10.1164/ajrccm/136.4.922; JANUSZ MJ, 1991, J IMMUNOL, V146, P3922; LACKIE JM, 1988, J CELL SCI, V89, P449; LAITINEN LA, 1985, AM REV RESPIR DIS, V131, P599, DOI 10.1164/arrd.1985.131.4.599; MARTIN GR, 1987, ANNU REV CELL BIOL, V3, P57, DOI 10.1146/annurev.cellbio.3.1.57; MENDIS AHW, 1990, IMMUNOL CELL BIOL, V68, P95, DOI 10.1038/icb.1990.14; O'SHEA JJ, 1985, J IMMUNOL, V134, P2580; OBYRNE PM, 1986, CHEST, V90, P575, DOI 10.1378/chest.90.4.575; REVAK SD, 1985, J CLIN INVEST, V76, P1182, DOI 10.1172/JCI112074; RINALDO JE, 1987, TISSUE CELL, V19, P599, DOI 10.1016/0040-8166(87)90067-X; ROBINSON BWS, 1992, EXP LUNG RES, V18, P583, DOI 10.3109/01902149209031696; ROBINSON JM, 1985, J CELL BIOL, V101, P1052, DOI 10.1083/jcb.101.3.1052; SCHRAUFSTATTER IU, 1984, J CLIN INVEST, V73, P1175, DOI 10.1172/JCI111303; SMOLEN JE, 1981, BIOCHIM BIOPHYS ACTA, V672, P197, DOI 10.1016/0304-4165(81)90393-7; TAYLOR B, 1962, THORAX, V157, P69; TIMPL R, 1979, J BIOL CHEM, V254, P9933; VENAILLE TJ, 1989, IMMUNOL CELL BIOL, V67, P359, DOI 10.1038/icb.1989.52; VISSERS MCM, 1985, BLOOD, V66, P161; WACHTFOGEL YT, 1988, J CLIN INVEST, V81, P1310, DOI 10.1172/JCI113456; WARD PA, 1986, J ALLERGY CLIN IMMUN, V78, P373, DOI 10.1016/0091-6749(86)90020-5; WELLER PF, 1983, IMMUNOBIOLOGY EOSINO, P145; WILLEY IC, 1985, AM REV RESPIR DIS S, V131	34	24	24	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1995	95	2					597	606		10.1016/S0091-6749(95)70322-5	http://dx.doi.org/10.1016/S0091-6749(95)70322-5			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QH697	7852673				2022-12-18	WOS:A1995QH69700012
J	LOH, RKS; JABARA, HH; REN, CL; FU, SM; GEHA, RS				LOH, RKS; JABARA, HH; REN, CL; FU, SM; GEHA, RS			ROLE OF PROTEIN-TYROSINE KINASES IN CD40 INTERLEUKIN-4-MEDIATED ISOTYPE SWITCHING TO IGE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						PROTEIN TYROSINE KINASE; IGE; DELETIONAL SWITCH RECOMBINATION; INTERLEUKIN-4; ANTI-CD40	HUMAN B-CELLS; X-LINKED IMMUNODEFICIENCY; CD40 LIGAND; HYPER-IGM; DEFECTIVE EXPRESSION; EPSILON-TRANSCRIPTS; T-CELLS; INTERLEUKIN-4; INDUCTION; ACTIVATION	The B-cell antigen CD40 transduces signals, which synergize with interleukin (IL)-4 to induce IgE synthesis in human B cells. IL-4 induces epsilon germline transcription but not mature epsilon transcripts or IgE protein synthesis in B cells. Addition of anti-CD40 monoclonal antibody to IL-4-heated B cells results in deletional S mu L-- > S epsilon switch recombination, expression of mature epsilon transcripts, and IgE synthesis and secretion. Because both IL-4 and anti-CD40 induce protein tyrosine phosphorylation in B cells, we investigated the role of protein tyrosine kinase in IL-4/CD40-mediated IgE synthesis. The protein tyrosine kinase inhibitors genistein and herbimycin A, but nor the protein kinase C inhibitor 1-(5-isoquinolinesulfonyl)-2-methylpiperazine (H7) or the protein kinase A inhibitor N-2-guanidinoethyl-5-isoquinolinesulfonamide, inhibited IgE synthesis in B cells stimulated with IL-4 and CD40. Genestein and herbimycin, but not H7, inhibited IL-C-driven epsilon germline transcription in B cells. Both genestein and herbimycin, but not H7, inhibited CD40-mediated IgE synthesis in B cells pretreated for 4 days with IL-4 to allow optimal expression of epsilon germline transcripts. Inhibition of IgE synthesis in these cultures was accompanied by inhibition of S mu--> S epsilon deletional switch recombination as assayed by nested polymerase chain reactions. These results suggest that activation of protein tyrosine kinase plays an important role in both the IL-4 and the CD40 signalling pathways that lead to IgE isotype switching in B cells.	HARVARD UNIV,CHILDRENS HOSP,SCH MED,DIV IMMUNOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115; UNIV VIRGINIA,DEPT MED,DIV RHEUMATOL,CHARLOTTESVILLE,VA; UNIV VIRGINIA,DEPT MICROBIOL,CHARLOTTESVILLE,VA 22908	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; University of Virginia; University of Virginia				Fu, Shu Man/0000-0001-5158-3494	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031136, U01AI031541] Funding Source: NIH RePORTER; NIAID NIH HHS [1RO1AI31136-01A1, 1UO1AI31541-01] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLEN RC, 1993, SCIENCE, V259, P990, DOI 10.1126/science.7679801; ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; ARUFFO A, 1993, CELL, V72, P291, DOI 10.1016/0092-8674(93)90668-G; CLARK EA, 1990, J IMMUNOL, V145, P1400; DISANTO JP, 1993, NATURE, V361, P541, DOI 10.1038/361541a0; FANSLOW WC, 1992, J IMMUNOL, V149, P655; FULEIHAN R, 1993, P NATL ACAD SCI USA, V90, P2170, DOI 10.1073/pnas.90.6.2170; GAUCHAT JF, 1990, J EXP MED, V172, P463, DOI 10.1084/jem.172.2.463; GRUBER MF, 1989, J IMMUNOL, V142, P4144; JABARA HH, 1990, J EXP MED, V172, P1861, DOI 10.1084/jem.172.6.1861; JABARA HH, 1990, J IMMUNOL, V145, P3468; KORTHAUER U, 1993, NATURE, V361, P539, DOI 10.1038/361539a0; MIRESLUIS AR, 1991, J BIOL CHEM, V266, P18113; MOURAD W, 1989, J EXP MED, V170, P2011, DOI 10.1084/jem.170.6.2011; NOELLE RJ, 1992, P NATL ACAD SCI USA, V89, P6550, DOI 10.1073/pnas.89.14.6550; REN CL, 1994, J EXP MED, V179, P673, DOI 10.1084/jem.179.2.673; SHAPIRA SK, 1992, J EXP MED, V175, P289, DOI 10.1084/jem.175.1.289; UCKUN FM, 1991, J BIOL CHEM, V266, P17478; UMETSU DT, 1985, J EXP MED, V162, P202, DOI 10.1084/jem.162.1.202; VERCELLI D, 1989, J EXP MED, V169, P1295, DOI 10.1084/jem.169.4.1295; VERCELLI D, 1989, EUR J IMMUNOL, V19, P1419, DOI 10.1002/eji.1830190811; WANG L, 1993, J CELL BIOCH S, V17, P119; ZHANG K, 1991, J IMMUNOL, V146, P1836	23	24	26	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1994	94	4					784	792		10.1016/0091-6749(94)90187-2	http://dx.doi.org/10.1016/0091-6749(94)90187-2			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PM273	7523475	Bronze			2022-12-18	WOS:A1994PM27300018
J	JUNIPER, EF; GUYATT, GH; FERRIE, PJ; KING, DR				JUNIPER, EF; GUYATT, GH; FERRIE, PJ; KING, DR			SODIUM CROMOGLYCATE EYE DROPS - REGULAR VERSUS AS NEEDED USE IN THE TREATMENT OF SEASONAL ALLERGIC CONJUNCTIVITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ALLERGIC CONJUNCTIVITIS; SODIUM CROMOGLYCATE; QUALITY OF LIFE	BECLOMETHASONE DIPROPIONATE; INDUCED RHINITIS; CROMOLYN SODIUM; RHINOCONJUNCTIVITIS	Objective: The objective of this study was to compare the efficacy and side effects of sodium cromoglycate eye drops (Opticrom 2%) used regularly versus as needed in the treatment of seasonal (ragweed) allergic conjunctivitis. Methods: A randomized, unblinded, parallel group comparison was performed during the 6 week of the ragweed pollen season. Sixty-two adults with ragweed pollen-induced conjunctivitis were recruited for the study from previous ragweed studies and notices in the local media. Two drops of sodium cromoglycate were placed in each eye either four times daily (regular treatment group) or when needed, up to four times daily (prn group), from 1 week before and throughout the ragweed pollen season. Uncontrolled eye symptoms were treated with terfenadine 60 mg as needed, up to 120 mg daily. Subjects kept daily diaries for symptoms and medication requirements throughout the 6 weeks of treatment. The Rhinoconjunctivitis Quality of Life Questionnaire was administered and adverse experiences were reported after 1, 3, and 6 week of treatment. Results: Diary eye symptoms were similar in the two treatment groups, but quality of life was better in the regular treatment group. There was a trend for the prn group to require more terfenadine for uncontrolled eye symptoms. Conclusions: There may be some additional therapeutic benefit from using sodium cromoglycate rye drops regularly throughout the ragweed pollen season.	MCMASTER UNIV,DEPT MED,HAMILTON,ON,CANADA	McMaster University	JUNIPER, EF (corresponding author), MCMASTER UNIV,MED CTR,DEPT CLIN EPIDEMIOL & BIOSTAT,1200 MAIN ST W,HAMILTON L8N 3Z5,ON,CANADA.							COCKCROFT DW, 1987, J ALLERGY CLIN IMMUN, V79, P734, DOI 10.1016/0091-6749(87)90204-1; FRIDAY GA, 1983, AM J OPHTHALMOL, V95, P169, DOI 10.1016/0002-9394(83)90010-7; GREENBAUM J, 1977, J ALLERGY CLIN IMMUN, V59, P437, DOI 10.1016/0091-6749(77)90006-9; JUNIPER EF, 1981, CLIN ALLERGY, V11, P61, DOI 10.1111/j.1365-2222.1981.tb01567.x; JUNIPER EF, 1993, J ALLERGY CLIN IMMUN, V92, P66, DOI 10.1016/0091-6749(93)90039-I; JUNIPER EF, 1994, J CLIN EPIDEMIOL, V47, P81, DOI 10.1016/0895-4356(94)90036-1; JUNIPER EF, 1990, J ALLERGY CLIN IMMUN, V86, P380, DOI 10.1016/S0091-6749(05)80101-0; JUNIPER EF, 1991, CLIN EXP ALLERGY, V21, P77, DOI 10.1111/j.1365-2222.1991.tb00807.x; KRAY KT, 1985, J ALLERGY CLIN IMMUN, V76, P623, DOI 10.1016/0091-6749(85)90785-7; LINDSAYMILLER ACM, 1979, CLIN ALLERGY, V9, P271, DOI 10.1111/j.1365-2222.1979.tb01553.x; NIZAMI RM, 1981, ANN ALLERGY, V47, P5; SIMONLICHT IF, 1982, ANN ALLERGY, V49, P220; VANZIELEGHEM MA, 1987, J ALLERGY CLIN IMMUN, V79, P887, DOI 10.1016/0091-6749(87)90237-5	13	24	27	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1994	94	1					36	43		10.1016/0091-6749(94)90069-8	http://dx.doi.org/10.1016/0091-6749(94)90069-8			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NX393	8027497				2022-12-18	WOS:A1994NX39300006
J	GIRGISGABARDO, A; KANAI, N; DENBURG, JA; HARGREAVE, FE; JORDANA, M; DOLOVICH, J				GIRGISGABARDO, A; KANAI, N; DENBURG, JA; HARGREAVE, FE; JORDANA, M; DOLOVICH, J			IMMUNOCYTOCHEMICAL DETECTION OF GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR AND EOSINOPHIL CATIONIC PROTEIN IN SPUTUM CELLS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note							MESSENGER-RNA; EXPRESSION		MCMASTER UNIV,DEPT MED,MOLEC VIROL & IMMUNOL PROGRAM,HAMILTON,ON,CANADA; ST JOSEPHS HOSP,FIRESTONE REG CHEST & ALLERGY UNIT,HAMILTON,ON,CANADA	McMaster University; McGill University; McMaster University								BROIDE DH, 1992, J CLIN INVEST, V90, P1414, DOI 10.1172/JCI116008; GIBSON PG, 1989, THORAX, V44, P693, DOI 10.1136/thx.44.9.693; LEE MT, 1990, J LEUKOCYTE BIOL, V47, P275, DOI 10.1002/jlb.47.3.275; MASON DY, 1978, J CLIN PATHOL, V31, P454, DOI 10.1136/jcp.31.5.454; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; MOQBEL R, 1991, J EXP MED, V174, P749, DOI 10.1084/jem.174.3.749; SANDER B, 1991, IMMUNOL REV, V119, P65, DOI 10.1111/j.1600-065X.1991.tb00578.x	7	24	24	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1994	93	5					945	947		10.1016/0091-6749(94)90390-5	http://dx.doi.org/10.1016/0091-6749(94)90390-5			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NL919	8182238	Bronze			2022-12-18	WOS:A1994NL91900021
J	RAZIUDDIN, S; MIR, NA; ELAWAD, ME; TELMESANI, AW; ALJANADI, M				RAZIUDDIN, S; MIR, NA; ELAWAD, ME; TELMESANI, AW; ALJANADI, M			GAMMA-DELTA T-LYMPHOCYTES AND PROINFLAMMATORY CYTOKINES IN BACTERIAL-MENINGITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						BACTERIAL MENINGITIS; CYTOKINES; ALPHA-BETA T CELLS; GAMMA-DELTA T CELLS; T-CELL RECEPTOR; INTERLEUKIN-6; TUMOR NECROSIS FACTOR-ALPHA; INTERFERON-GAMMA	TUMOR NECROSIS FACTOR; CELL RECEPTOR; SEPTIC SHOCK; INTERLEUKIN-6; SPECIFICITY; ASSOCIATION; INFECTION; CACHECTIN; SUBSET; SERUM	Background: Patients with bacterial meningitis have a T-cell defect and impaired cytokine production. Methods: The phenotype and percentage of circulating alpha beta and gamma delta T-cell receptor-bearing lymphocytes were determined from patients with bacterialmeningitis (Haemophilis influenzae, Streptococcus pneumoniae, and Neisseria meningitidis), patients with bacterial infection but without meningitis, and healthy control subjects by a monoclonal antibody staining method. The in vitro production of cytokines, interleukins (IL-2, IL-6), interferon-gamma and tumor necrosis factor-alpha was measured by the bioassay or ELISAs. Results: The percentage of circulating gamma delta T cells with a CD3 + CD4 + CD8 - phenotype was significantly (p < 0.001) increased in all patients with bacterial meningitis compared with patients with bacterial infection and healthy control subjects. The CD3 + gamma delta T cells from patients with meningitis produced highly elevated levels of two proinflammatory cytokines, tumor necrosis factor-alpha and IL-6. However, interferon-gamma production was enhanced by CD3 + alpha beta T cells. Conclusion: The increased percentage of circulating T-cell receptor gamma delta T cells and their in vitro production of tumor necrosis factor-alpha and IL-6 cytokines may play an important role in the pathogenesis and inflammatory response in bacterial meningitis.	KING SAUD UNIV,COLL MED,DEPT PEDIAT,ABHA,SAUDI ARABIA; KING SAUD UNIV,COLL MED,DEPT INTERNAL MED,ABHA,SAUDI ARABIA; ASIR CENT HOSP,ABHA,SAUDI ARABIA	King Saud University; King Saud University; Assir Central Hospital	RAZIUDDIN, S (corresponding author), KING SAUD UNIV,COLL MED,DEPT CLIN IMMUNOL,POB 641,ABHA,SAUDI ARABIA.							ARDITI M, 1990, J INFECT DIS, V162, P139, DOI 10.1093/infdis/162.1.139; AZUBUIKE JC, 1990, ANN SAUDI MED, V10, P145, DOI 10.5144/0256-4947.1990.145; BARNES PF, 1992, J INFECT DIS, V165, P506, DOI 10.1093/infdis/165.3.506; BEUTLER B, 1987, NEW ENGL J MED, V316, P379; BORN WK, 1991, FASEB J, V5, P2699, DOI 10.1096/fasebj.5.12.1717333; CANNON JG, 1990, J INFECT DIS, V161, P79, DOI 10.1093/infdis/161.1.79; DEMARIA A, 1992, J INFECT DIS, V165, P917, DOI 10.1093/infdis/165.5.917; DEPAOLI P, 1990, J INFECT DIS, V161, P1013, DOI 10.1093/infdis/161.5.1013; HAREGEWOIN A, 1989, NATURE, V340, P309, DOI 10.1038/340309a0; JANEWAY CA, 1988, IMMUNOL TODAY, V9, P73, DOI 10.1016/0167-5699(88)91267-4; KUMAR EV, 1991, CLIN INTENSIVE CARE, V2, P4; MORETTA L, 1991, IMMUNOL REV, V120, P117; RAULET DH, 1989, ANNU REV IMMUNOL, V7, P175, DOI 10.1146/annurev.iy.07.040189.001135; RAZIUDDIN S, 1992, EUR J IMMUNOL, V22, P1143, DOI 10.1002/eji.1830220506; RAZIUDDIN S, 1991, J ALLERGY CLIN IMMUN, V87, P1115, DOI 10.1016/0091-6749(91)92157-V; TSUJIMOTO M, 1986, J IMMUNOL, V136, P2441; VANSNICK J, 1990, ANNU REV IMMUNOL, V8, P253, DOI 10.1146/annurev.immunol.8.1.253; WAAGE A, 1989, J EXP MED, V169, P333, DOI 10.1084/jem.169.1.333; WAAGE A, 1987, LANCET, V1, P355	19	24	24	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1994	93	4					793	798		10.1016/0091-6749(94)90260-7	http://dx.doi.org/10.1016/0091-6749(94)90260-7			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NH497	8163789	Bronze			2022-12-18	WOS:A1994NH49700013
J	DODGE, R; BURROWS, B; LEBOWITZ, MD; CLINE, MG				DODGE, R; BURROWS, B; LEBOWITZ, MD; CLINE, MG			ANTECEDENT FEATURES OF CHILDREN IN WHOM ASTHMA DEVELOPS DURING THE 2ND DECADE OF LIFE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ASTHMA; RISK; CHILDREN; ALLERGY	GENERAL-POPULATION SAMPLE; SKIN-TEST REACTIVITY; CHRONIC-BRONCHITIS; PREVALENCE; DISEASE; IGE	In this report we compare 36 subjects in whom asthma was first diagnosed between the ages of 10 and 20 with 297 control subjects. All subjects were studied at age 5 to 9. Among the subjects who acquired a new diagnosis of asthma (NDA), the diagnosis was usually preceded by lower respiratory tract symptoms (31 of the 36 subjects had respiratory symptoms or a diagnosis of rhinitis or chronic bronchitis before asthma developed). Among those tested, more of those with NDA had positive allergy skin test results (56.5%) before diagnosis than control subjects (29.6%; p < 0.05), and the subjects with NDA had higher levels of serum IgE than control subjects (mean log serum IgE = 2.27 in subjects with NDA, 1.76 in control subjects; p < 0.05). Pulmonary function tests revealed no significant differences in the groups before diagnosis. Using logistic regression, we determined that wheezing, cough, a diagnosis of chronic bronchitis, and a positive allergy skin test result were independent risk factors for asthma. When combinations of variables were used, subjects with wheezing and a positive allergy skin test result, cough and a positive test result, and also those with a prior diagnosis of chronic bronchitis alone were at highest risk of a subsequent diagnosis of asthma.	UNIV ARIZONA,COLL MED,CTR RESP SCI,TUCSON,AZ 85721	University of Arizona					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014136] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-14136] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARBEE RA, 1976, ANN INTERN MED, V84, P129, DOI 10.7326/0003-4819-84-2-129; BARBEE RA, 1981, J ALLERGY CLIN IMMUN, V68, P106, DOI 10.1016/0091-6749(81)90167-6; BURROWS B, 1976, ANN INTERN MED, V84, P134, DOI 10.7326/0003-4819-84-2-134; BURROWS B, 1991, J ALLERGY CLIN IMMUN, V88, P870, DOI 10.1016/0091-6749(91)90243-H; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; BURROWS B, 1975, AM REV RESPIR DIS, V112, P365; CHANYEUNG M, 1987, J ALLERGY CLIN IMMUN, V79, P792, DOI 10.1016/0091-6749(87)90212-0; DODGE RR, 1980, AM REV RESPIR DIS, V122, P567; FLEISS JL, 1981, STATISTICAL METHODS, P165; KNUDSON RJ, 1983, AM REV RESPIR DIS, V127, P725; LEBOWITZ MD, 1975, AM J EPIDEMIOL, V102, P137, DOI 10.1093/oxfordjournals.aje.a112141; LEBOWITZ MD, 1989, AM REV RESPIR DIS, V140, pS35, DOI 10.1164/ajrccm/140.3_Pt_2.S35; MARTIN AJ, 1980, BRIT MED J, V280, P1397, DOI 10.1136/bmj.280.6229.1397; MORGAN WJ, 1984, PEDIATR CLIN N AM, V31, P851; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P153	15	24	24	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1993	92	5					744	749		10.1016/0091-6749(93)90018-B	http://dx.doi.org/10.1016/0091-6749(93)90018-B			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MG982	8227866				2022-12-18	WOS:A1993MG98200016
J	MCDONALD, LG; TOVEY, E				MCDONALD, LG; TOVEY, E			THE EFFECTIVENESS OF BENZYL BENZOATE AND SOME ESSENTIAL PLANT OILS AS LAUNDRY ADDITIVES FOR KILLING HOUSE-DUST MITES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note									UNIV SYDNEY,DEPT MED,SYDNEY,NSW 2006,AUSTRALIA	University of Sydney			Tovey, Euan R/G-8604-2017	Tovey, Euan R/0000-0002-1802-7266				LAU S, 1989, J ALLERGY CLIN IMMUN, V84, P818; MCDONALD LG, 1992, J ALLERGY CLIN IMMUN, V90, P599, DOI 10.1016/0091-6749(92)90132-L; WATANABE F, 1989, Shoyakugaku Zasshi, V43, P163	3	24	24	0	8	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1993	92	5					771	772		10.1016/0091-6749(93)90022-8	http://dx.doi.org/10.1016/0091-6749(93)90022-8			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MG982	8227869	Bronze			2022-12-18	WOS:A1993MG98200020
J	FRIEDMAN, BS; SANTIAGO, ML; BERKEBILE, C; METCALFE, DD				FRIEDMAN, BS; SANTIAGO, ML; BERKEBILE, C; METCALFE, DD			COMPARISON OF AZELASTINE AND CHLORPHENIRAMINE IN THE TREATMENT OF MASTOCYTOSIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						MASTOCYTOSIS; ANTIHISTAMINES; MAST CELLS; HISTAMINE; CLINICAL TRIAL	ALLERGIC HISTAMINE-RELEASE; PERITONEAL MAST-CELLS; SYSTEMIC MASTOCYTOSIS; DOUBLE-BLIND; INHIBITION; ANTIHISTAMINES; EFFICACY; TRIAL; DRUGS	Background: Azelastine, a novel antiallergic medication, was compared with chlorpheniramine maleate for efficacy and safety in the treatment of systemic mastocytosis. Methods: Fifteen subjects with mastocytosis participated in a double-blind, randomized, three-period, crossover trial, which compared an azelastine regimen of 4 mg or 8 mg every 12 hours with a chlorpheniramine regimen of 12 mg every 12 hours. Response to therapy was assessed by daily symptom scores, extinction dilution skin tests, plasma histamine levels, and global evaluations. Results: Subjects' mean wheal area responses provoked by histamine or morphine sulfate were significantly lowered by azelastine when compared with chlorpheniramine. Plasma histamine levels in subjects receiving azelastine or chlorpheniramine were not significantly different. There were no significant differences between azelastine and chlorpheniramine in individual symptom scores or global evaluations except that azelastine at both doses significantly relieved pruritus and at 4 mg significantly relieved abdominal pain and that chlorpheniramine was associated with less fatigue in comparison to azelastine at 8 mg. Conclusions: It thus appears that azelastine is superior to chlorpheniramine in suppressing skin responses to histamine and morphine sulfate and in suppressing pruritus in patients with mastocytosis. However, when all parameters are considered, neither drug is clearly superior for the treatment of patients with mastocytosis.	NIAID,CLIN INVEST LAB,MAST CELL PHYSIOL SECT,BLDG 10,ROOM 11C210,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)								ATKINS P, 1985, J ALLERGY CLIN IMMUN, V75, P167, DOI 10.1016/0091-6749(85)90385-9; CHAND N, 1983, EUR J PHARMACOL, V96, P227, DOI 10.1016/0014-2999(83)90311-4; CHAND N, 1985, AGENTS ACTIONS, V16, P318, DOI 10.1007/BF01982866; CHURCH MK, 1980, BRIT J PHARMACOL, V69, P663, DOI 10.1111/j.1476-5381.1980.tb07919.x; DIAMANTIS W, 1974, J ALLERGY CLIN IMMUN, V73, P184; DYER J, 1982, J ALLERGY CLIN IMMUN, V70, P82, DOI 10.1016/0091-6749(82)90233-0; FRIDMAN BS, 1989, AM J MED, V87, P649; FRIEDMAN BS, 1989, 5TH INT S NEW YORK, P163; FRIERI M, 1985, AM J MED, V78, P9, DOI 10.1016/0002-9343(85)90454-1; KEFFER JM, 1989, J ALLERGY CLIN IMMUN, V83, P595, DOI 10.1016/0091-6749(89)90071-7; LICHTENSTEIN LM, 1975, J PHARMACOL EXP THER, V192, P441; LITTLE M, 1988, J ALLERGY CLIN IMMUN, V81, P278, DOI 10.1016/0091-6749(88)90676-8; OLLIER S, 1986, J ALLERGY CLIN IMMUN, V78, P358, DOI 10.1016/S0091-6749(86)80090-2; WEILER JM, 1988, J ALLERGY CLIN IMMUN, V82, P801, DOI 10.1016/0091-6749(88)90082-6	14	24	25	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1993	92	4					520	526		10.1016/0091-6749(93)90076-R	http://dx.doi.org/10.1016/0091-6749(93)90076-R			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MC590	8104966				2022-12-18	WOS:A1993MC59000004
J	WONG, BJO; HARGREAVE, FE				WONG, BJO; HARGREAVE, FE			BIOEQUIVALENCE OF METERED-DOSE INHALED MEDICATIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							SODIUM CROMOGLYCATE; ASTHMATIC RESPONSES; DRY AIR; SALBUTAMOL; ALBUTEROL; AEROSOLS; ALLERGEN; HYPERVENTILATION; BIOAVAILABILITY; BRONCHODILATOR		MCMASTER UNIV,ASTHMA RES GRP,HAMILTON L8S 4L8,ONTARIO,CANADA	McMaster University								ADAMS WP, 1991, JUN P REG ISS AER DE; AHRENS RC, 1991, ANN ALLERGY, V67, P296; Anderson S.D., 1985, AIRWAY RESPONSIVENES, P51; ARMITAGE P, 1971, STATISTICAL METHODS; BAKKE OM, 1984, HOSP FORMUL, V19, P411; BERNSTEIN IL, 1986, J ALLERGY CLIN IMMUN, V78, P489, DOI 10.1016/0091-6749(86)90093-X; BRITTON J, 1988, THORAX, V43, P300, DOI 10.1136/thx.43.4.300; CHHABRA SK, 1987, J ASTHMA, V24, P215, DOI 10.3109/02770908709070942; COCKCROFT DW, 1987, J ALLERGY CLIN IMMUN, V79, P734, DOI 10.1016/0091-6749(87)90204-1; CRANE J, 1989, THORAX, V44, P136, DOI 10.1136/thx.44.2.136; CYR TD, 1991, PHARMACEUT RES, V8, P658, DOI 10.1023/A:1015825311750; Feinstein AR, 1987, CLINIMETRICS, P141, DOI DOI 10.2307/J.CTT1XP3VBC.13; GUYATT G, 1987, J CHRON DIS, V40, P171, DOI 10.1016/0021-9681(87)90069-5; JOHANSSON SA, 1982, EUROPEAN ACADEMY ALL, V2, P709; JUNIPER EF, 1986, J ALLERGY CLIN IMMUN, V78, P387, DOI 10.1016/0091-6749(86)90022-9; JUNIPER EF, 1987, CLIN ALLERGY, V17, P523, DOI 10.1111/j.1365-2222.1987.tb02048.x; KIRSHNER B, 1985, J CHRON DIS, V38, P27, DOI 10.1016/0021-9681(85)90005-0; MCGILVERAY IJ, 1990, J PHARM SCI, V79, P945, DOI 10.1002/jps.2600791022; MORROW PE, 1974, AM REV RESPIR DIS, V110, P88; NELSON HS, 1986, J ALLERGY CLIN IMMUN, V77, P771, DOI 10.1016/0091-6749(86)90372-6; NEWHOUSE MT, 1986, NEW ENGL J MED, V315, P870, DOI 10.1056/NEJM198610023151406; NEWMAN SP, 1991, ACTA THERAP, V17, P49; PARKKALI L, 1983, CURR THER RES CLIN E, V33, P539; PHILLIPS G D, 1988, American Review of Respiratory Disease, V137, P29; PHILLIPS GD, 1990, J ALLERGY CLIN IMMUN, V85, P755, DOI 10.1016/0091-6749(90)90195-A; SPINO M, 1989, CAN MED ASSOC J, V141, P883; STREINER DL, 1989, HLTH MEASUREMENT SCA, P79; SVEDSEN UG, 1987, J ALLERGY CLIN IMMUN, V80, P68; TOOGOOD JH, 1984, AM REV RESPIR DIS, V129, P723, DOI 10.1164/arrd.1984.129.5.723; TWENTYMAN OP, 1991, AM REV RESPIR DIS, V144, P782, DOI 10.1164/ajrccm/144.4.782; ULMANN A, 1988, THORAX, V43, P674; VIDGREN P, 1991, PHARMAZIE, V46, P41; WONG BJ, 1992, AM REV RESPIR DIS, V146, P1156, DOI 10.1164/ajrccm/146.5_Pt_1.1156; WONG CS, 1990, LANCET, V336, P1396, DOI 10.1016/0140-6736(90)93099-B; ZAINUDIN BMZ, 1990, THORAX, V45, P469, DOI 10.1136/thx.45.6.469	35	24	25	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1993	92	3					373	379		10.1016/0091-6749(93)90115-V	http://dx.doi.org/10.1016/0091-6749(93)90115-V			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LX309	8360387				2022-12-18	WOS:A1993LX30900002
J	POLOSA, R; RAJAKULASINGAM, K; PROSPERINI, G; CHURCH, MK; HOLGATE, ST				POLOSA, R; RAJAKULASINGAM, K; PROSPERINI, G; CHURCH, MK; HOLGATE, ST			RELATIVE POTENCIES AND TIME-COURSE OF CHANGES IN ADENOSINE 5'-MONOPHOSPHATE AIRWAY RESPONSIVENESS WITH INHALED FUROSEMIDE AND BUMETANIDE IN ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ASTHMA; BRONCHOCONSTRICTION; ADENOSINE; FUROSEMIDE; BUMETANIDE	METHACHOLINE-INDUCED BRONCHOCONSTRICTION; DEPENDENT HISTAMINE-RELEASE; SODIUM METABISULFITE; MEDIATED MECHANISM; ORAL TERFENADINE; ATOPIC ASTHMA; FRUSEMIDE; INHIBITION; DIURETICS; PROSTAGLANDIN-E2	A randomized, double-blind placebo-controlled study was conducted to compare the effects of two chemically unrelated ''loop'' diuretics, furosemide (40 mg) and bumetanide (2 mg) on the bronchoconstrictor response to inhaled adenosine 5'-monophosphate (AMP) in 12 subjects with asthma. In eight additional volunteers with asthma, we also carried out a separate randomized, double-blind study to examine in more detail the tune course of change in bronchial reactivity to inhaled AMP after administration of nebulized furosemide and bumetanide Inhaled loop diuretics significantly increased the provocative concentration of AMP causing a 20% fall in forced expiratory volume in 1 second (FEV1) from the value of 21.2 mg/ml (range, 2.5 to 96.9 mg/ml) after placebo administration to 83.4 mg/ml (range, 11.3 to 345.0 mg/ml) (p < 0.01) and 33.8 mg/ml (range, 4. 7 to 120.9 mg/ml) (p < 0.05) after administration of furosemide and bumetanide, respectively. After placebo administration, the provocative concentration of AMP causing a 20% fall in FEV1 (PC20 AMP) at 10, 30, and 120 minutes did not differ significantly, their geometric mean (range) values were 578 mg/ml (10.9 to 341.0 mg/ml), 55.0 mg/ml (13.2 to 304.1 mg/ml), and 52.8 mg/ml (14.4 to 252.2 mg/ml), respectively When compared with placebo, inhaled furosemide significantly reduced the airway responsiveness to AMP at all time points; the PC20 AMP values at 10, 30, and 120 minutes were 154.6 mg/ml (29.4 to 658.7 mg/ml) (p < 0.01), 142.6 mg/ml (25.5 to 639.9 mg/ml) (p < 0.01), and 103.9 mg/ml (12.5 to 605.5 mg/ml) (p < 0.05), respectively. The PC20 values for AMP after pretreatment with bumetanide were significantly increased up to 110. 2 mg/ml (25.9 to 639. 0 mg/ml) (p < 0. 01) and to 92. 0 mg/ml (21.6 to 531.7 mg/ml) (p < 0. 05) at 10 and 30 minutes, respectively. At 120 minutes, inhaled bumetanide failed to affect AMP airway responsiveness, the PC20 AMP was not significantly different from that of placebo, with a value of 71.5 mg/ml (22.6 to 318.0 mg/ml). We conclude that comparable equidiuretic doses of furosemide and bumetanide are effective in attenuating the airway response to AMP, with furosemide being approximately 2.5 times more potent than bumetanide (p < 0. 01). The time course of change in bronchial reactivity to AMP is similar for both drugs with a peak effect at 10 minutes. It is possible that the mechanism(s) underlying the protective effects of inhaled loop diuretics in asthma may be distinct from those responsible for their diuretic properties.	UNIV CATANIA,IST MALATTIE APPARATO RESP,I-95124 CATANIA,ITALY	University of Catania	POLOSA, R (corresponding author), SOUTHAMPTON GEN HOSP,CTR BLOCK,LEVEL D,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND.							ALI J, 1984, J APPL PHYSIOL, V57, P160, DOI 10.1152/jappl.1984.57.1.160; ALTMAN DG, 1986, LANCET, V8, P307; ALTOUNYAN REC, 1986, EUR J RESPIR DIS, V69, P277; BIANCO S, 1988, LANCET, V2, P252; BIANCO S, 1989, NEW ENGL J MED, V321, P1069, DOI 10.1056/NEJM198910193211602; BIANCO S, 1980, EUR J RESPIR DIS S, V106, P81; BOURLAND WA, 1977, J PHARMACOL EXP THER, V202, P221; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CHURCH MK, 1983, BRIT J PHARMACOL, V80, P719, DOI 10.1111/j.1476-5381.1983.tb10063.x; CSETE ME, 1991, AM REV RESPIR DIS, V144, P59, DOI 10.1164/ajrccm/144.1.59; CUSHLEY MJ, 1983, BRIT J CLIN PHARMACO, V15, P161, DOI 10.1111/j.1365-2125.1983.tb01481.x; ELWOOD W, 1991, AM REV RESPIR DIS, V143, P1340, DOI 10.1164/ajrccm/143.6.1340; FOY JM, 1984, BRIT J PHARMACOL, V82, P165, DOI 10.1111/j.1476-5381.1984.tb16455.x; FRIZZELL RA, 1979, AM J PHYSIOL, V236, pF1, DOI 10.1152/ajprenal.1979.236.1.F1; GERKENS JF, 1984, BRIT J PHARMACOL, V83, P363, DOI 10.1111/j.1476-5381.1984.tb16496.x; Goldberg M, 1973, HDB PHYSL 8, P1003; GREGER R, 1981, PFLUG ARCH EUR J PHY, V390, P38, DOI 10.1007/BF00582708; GRUBBE RE, 1990, J ALLERGY CLIN IMMUN, V85, P881, DOI 10.1016/0091-6749(90)90072-C; HARDY CC, 1988, J APPL PHYSIOL, V64, P1567, DOI 10.1152/jappl.1988.64.4.1567; HERBERT S C, 1981, American Journal of Physiology, V241, pF412; HUGHES PJ, 1984, BIOCHEM PHARMACOL, V33, P3847, DOI 10.1016/0006-2952(84)90050-9; LANT A, 1985, DRUGS, V29, P57, DOI 10.2165/00003495-198529010-00003; LEWIS RA, 1984, DRUGS LUNG, P63; MARQUARDT DL, 1978, J IMMUNOL, V120, P871; NICHOL GM, 1990, AM REV RESPIR DIS, V142, P576, DOI 10.1164/ajrccm/142.3.576; OCONNOR BJ, 1991, AM REV RESPIR DIS, V143, P1329, DOI 10.1164/ajrccm/143.6.1329; Oliw E, 1979, Acta Physiol Scand Suppl, V461, P1; PASSMORE AP, 1989, BRIT J CLIN PHARMACO, V27, P305, DOI 10.1111/j.1365-2125.1989.tb05370.x; PAVORD I, 1991, THORAX, V46, P751; PAVORD I D, 1991, American Review of Respiratory Disease, V143, pA210; PAVORD ID, 1991, THORAX, V46, P633, DOI 10.1136/thx.46.9.633; PHILLIPS GD, 1987, THORAX, V42, P939, DOI 10.1136/thx.42.12.939; POLOSA R, 1990, EUR RESPIR J, V3, P665; POLOSA R, 1991, J ALLERGY CLIN IMMUN, V87, P939, DOI 10.1016/0091-6749(91)90415-K; POLOSA R, 1992, EUR RESPIR J, V5, P700; POLOSA R, 1990, EUR RESPIR J, V3, P1235; POLOSA R, 1990, AIRWAY SMOOTH MUSCLE, P133; RAFFERTY P, 1987, AM REV RESPIR DIS, V136, P369, DOI 10.1164/ajrccm/136.2.369; ROBUSCHI M, 1989, Pulmonary Pharmacology, V1, P187, DOI 10.1016/S0952-0600(89)80016-X; SCHERER B, 1979, CLIN SCI MOL MED, V56, P77, DOI 10.1042/cs0560077; SCHULMAN ES, 1982, J APPL PHYSIOL, V53, P589, DOI 10.1152/jappl.1982.53.3.589; SMITH AP, 1975, CLIN SCI MOL MED, V48, P421, DOI 10.1042/cs0480421; STONE KJ, 1976, PROSTAGLANDINS, V12, P197, DOI 10.1016/0090-6980(76)90115-5; STRUYKERBOUDIER HAJ, 1983, CLIN EXP HYPERTENS A, V5, P209, DOI 10.3109/10641968309048822; SZCZEKLIK A, 1978, PHARMACOL RES COMMUN, V10, P545, DOI 10.1016/S0031-6989(78)80053-8; TEMPLE DM, 1990, NEW ENGL J MED, V324, P131; VAGHI A, 1990, EUR RESPIR J S10, V3, pS93; VENTRESCA PG, 1990, AM REV RESPIR DIS, V142, P143, DOI 10.1164/ajrccm/142.1.143; WEBER PC, 1977, EUR J PHARMACOL, V41, P329, DOI 10.1016/0014-2999(77)90326-0	49	24	27	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1993	92	2					288	297		10.1016/0091-6749(93)90172-C	http://dx.doi.org/10.1016/0091-6749(93)90172-C			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LT469	8349939				2022-12-18	WOS:A1993LT46900009
J	IACOBELLI, AM; MCCULLOUGH, JA; OWNBY, DR				IACOBELLI, AM; MCCULLOUGH, JA; OWNBY, DR			THE PREVALENCE OF LATEX ALLERGYIN HIGH-RISK MEDICAL PERSONNEL	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	24	24	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1993	91	1	2				216	216						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KK431					2022-12-18	WOS:A1993KK43100302
J	POLMAR, SH				POLMAR, SH			THE ROLE OF THE IMMUNOLOGIST IN SINUS DISEASE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	SYMP ON MECHANISMS, DIAGNOSIS, AND TREATMENT OF SINUSITIS IN CHILDREN AND ADULTS	JAN 24-25, 1992	SCOTTSDALE, AZ	ALLEN & HANBURYS		IMMUNODEFICIENCY; IMMUNOGLOBULIN; AGAMMAGLOBULINEMIA; IGG SUBCLASS DEFICIENCY; IMMUNOGLOBULIN REPLACEMENT THERAPY; ETHMOIDECTOMY; ENDOSCOPIC SURGERY; SINUSITIS	CAPSULAR POLYSACCHARIDE ANTIGEN; CHILDREN	The clinical immunologist is playing an increasingly important role in the evaluation and management of sinus disease. Although most patients with sinus disease are not immunodeficient, a significant proportion of patients with chronic sinusitis unresponsive to medical and/or surgical therapy may have an immunodeficiency. Most immunodeficient patients for whom sinusitis is a major clinical problem tend to be those with humoral immunodeficiency diseases. The role of immunoglobulin replacement therapy is well established for patients with global immunoglobulin and antibody deficiencies (e.g., X-linked agammaglobulinemia and common variable immunodeficiency) and may be helpful in controlling refractory sinusitis in patients with more selective immunoglobulin deficiencies (e.g., IgG subclass deficiency and selective antibody deficiencies), but efficacy in these conditions remains to be established by controlled studies. Many immunodeficient patients have a history of repeated sinus surgery before the recognition of their immune defect. Even in immunodeficient patients treated with antibiotics and immunoglobulin replacement therapy, functional endoscopic sinus surgery is successful in only half of the patients.			POLMAR, SH (corresponding author), CHILDRENS HOSP MED CTR,DIV IMMUNOL,FEGAN 6,300 LONGWOOD AVE,BOSTON,MA 02115, USA.							Eibl M M, 1989, Immunodefic Rev, V1 Suppl, P1; FURUKAWA CT, 1983, PEDIATRICS, V71, P133; GOLDENHERSH MJ, 1990, J ALLERGY CLIN IMMUN, V85, P1030, DOI 10.1016/0091-6749(90)90047-8; LUSK RP, 1991, ARCH OTOLARYNGOL, V117, P60; POLMAR SH, IN PRESS PEDIATRIC S; RACHELEFSKY GS, 1988, PEDIATR CLIN N AM, V35, P1091; RACHELEFSKY GS, 1984, PEDIATRICS, V73, P526; RACHELEFSKY GS, 1980, MANAGEMENT UPPER RES; SHAPIRO GG, 1988, J ALLERGY CLIN IMMUN, V81, P1025, DOI 10.1016/0091-6749(88)90173-X; SHAPIRO GG, 1991, PEDIATRICS, V87, P311; SILK HJ, 1990, ANN ALLERGY, V64, P21; TINKELMAN DG, 1989, AM J DIS CHILD, V143, P938, DOI 10.1001/archpedi.1989.02150200098025; UMETSU DT, 1985, NEW ENGL J MED, V313, P1247, DOI 10.1056/NEJM198511143132002	13	24	25	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1992	90	3	2	S			511	515		10.1016/0091-6749(92)90176-3	http://dx.doi.org/10.1016/0091-6749(92)90176-3			5	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JP521	1527342				2022-12-18	WOS:A1992JP52100017
J	FEISS, G; MORRIS, R; ROM, D; MANSFIELD, L; DOCKHORN, R; ELLIS, E; SMITH, JA; TOBEY, RE				FEISS, G; MORRIS, R; ROM, D; MANSFIELD, L; DOCKHORN, R; ELLIS, E; SMITH, JA; TOBEY, RE			A COMPARATIVE-STUDY OF THE EFFECTS OF INTRANASAL TRIAMCINOLONE ACETONIDE AEROSOL (ITAA) AND PREDNISONE ON ADRENOCORTICAL FUNCTION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						INTRANASAL TRIAMCINOLONE ACETONIDE; PREDNISONE; ADRENOCORTICAL FUNCTION; ALLERGIC RHINITIS	PITUITARY-ADRENAL-FUNCTION; BECLOMETHASONE DIPROPIONATE; ALLERGIC RHINITIS; CHILDREN; ASTHMA; CORTICOSTEROIDS; BUDESONIDE; ACTH	A comparison of adrenocortical function before and after treatment with either intranasal triamcinolone acetonide aerosol (ITAA), prednisone, or placebo was done. Sixty-two male subjects with allergic rhinitis were treated for 6 weeks with either ITAA (220 or 440-mu-g/day), oral prednisone (10 mg/day), or placebo in double-blind, parallel-group fashion. Adrenocortical function was assessed by 6-hour cosyntropin stimulation before and at the end of the treatment period. The placebo-treated and two ITAA-treated groups produced no changes in adrenocortical function with treatment, and the ITAA-treated groups were not different from the placebo-treated group with mean +/- SEM changes in stimulated plasma cortisol (micrograms per deciliter) as follows: placebo, 2.68 +/- 1.77; ITAA 220-mu-g, -2.69 +/- 1.18; ITAA 440-mu-g, -2.96 +/- 1.81. The prednisone-treated group had a mean reduction in adrenocortical function (mean +/- SEM change in stimulated plasma cortisol of -19.8 +/- 1.77-mu-g/dl) that was significant (p < 0.0001) compared with that of the placebo-treated group. The results of this study indicate that 6 weeks of treatment with 220-mu-g/day or 440-mu-g/day of ITAA has no effect on adrenocortical function, but prednisone, at a dosage of 10 mg/day for 6 weeks, produces partial adrenocortical suppression.	NEMOURS CHILDRENS CLIN,JACKSONVILLE,FL; ALLERGY & ASTHMA SPECIALISTS,MINNEAPOLIS,MN; EL PASO INST MED RES & DEV,EL PASO,TX; INT MED TECH CONSULTANTS INC,LENEXA,KS		FEISS, G (corresponding author), RHONE POULENC RORER CENT RES,POB 1200,500 ARCOLA RD,COLLEGEVILLE,PA 19426, USA.							DROSZCZ W, 1980, ANN ALLERGY, V44, P174; DROSZCZ W, 1979, ANN ALLERGY, V42, P41; FRASER CG, 1952, JAMA-J AM MED ASSOC, V149, P1542, DOI 10.1001/jama.1952.72930340001009; GREIG WR, 1966, J ENDOCRINOL, V34, P411, DOI 10.1677/joe.0.0340411; HARRIS DM, 1974, CLIN ALLERGY, V4, P291, DOI 10.1111/j.1365-2222.1974.tb01387.x; LAW C, 1980, LANCET, V1, P942; LINDHOLM J, 1978, J CLIN ENDOCR METAB, V47, P272, DOI 10.1210/jcem-47-2-272; MAYNARD DE, 1966, ANN INTERN MED, V64, P552, DOI 10.7326/0003-4819-64-3-552; MCGILL PE, 1967, ANN RHEUM DIS, V26, P123, DOI 10.1136/ard.26.2.123; MELLIS CM, 1977, THORAX, V32, P29, DOI 10.1136/thx.32.1.29; MELTZER EO, 1990, J ALLERGY CLIN IMMUN, V86, P221, DOI 10.1016/S0091-6749(05)80069-7; MORRIS HG, 1971, J PEDIATR-US, V79, P480, DOI 10.1016/S0022-3476(71)80163-4; NELSON J, 1978, AM J MED SCI, V27, P165; PEDERSEN S, 1988, EUR RESPIR J, V1, P433; SALASSA RM, 1953, JAMA-J AM MED ASSOC, V152, P1509, DOI 10.1001/jama.1953.03690160009004; SHERMAN B, 1982, J ALLERGY CLIN IMMUN, V67, P208; SHORE SC, 1977, ARCH DIS CHILD, V52, P486, DOI 10.1136/adc.52.6.486; SMALL P, 1982, ANN ALLERGY, V49, P127; SPECKART PF, 1971, ARCH INTERN MED, V128, P761, DOI 10.1001/archinte.128.5.761; SPRINGER C, 1987, ARCH DIS CHILD, V62, P815, DOI 10.1136/adc.62.8.815; STORMS W, 1991, ANN ALLERGY, V66, P329; STREETEN DHP, 1984, ENDOCR REV, V5, P371, DOI 10.1210/edrv-5-3-371; TRUHAN AP, 1989, ANN ALLERGY, V62, P375; WOOD JB, 1965, LANCET, V1, P243; WYATT R, 1978, NEW ENGL J MED, V299, P1387, DOI 10.1056/NEJM197812212992504; 1991, PHYSICIANS DESK REFE, P2205	26	24	24	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1992	89	6					1151	1156		10.1016/0091-6749(92)90299-H	http://dx.doi.org/10.1016/0091-6749(92)90299-H			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HZ748	1607550				2022-12-18	WOS:A1992HZ74800010
J	ISRAEL, E; DRAZEN, J; PEARLMAN, H; COHN, J; RUBIN, P				ISRAEL, E; DRAZEN, J; PEARLMAN, H; COHN, J; RUBIN, P			A DOUBLE-BLIND MULTICENTER STUDY OF ZILEUTON, A POTENT 5-LIPOXYGENASE (5-LO) INHIBITOR VERSUS PLACEBO IN THE TREATMENT OF SPONTANEOUS ASTHMA IN ADULTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	24	24	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1992	89	1	2				236	236						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HB760					2022-12-18	WOS:A1992HB76000320
J	ZWETCHKENBAUM, JF; SKUFCA, R; NELSON, HS				ZWETCHKENBAUM, JF; SKUFCA, R; NELSON, HS			AN EXAMINATION OF FOOD HYPERSENSITIVITY AS A CAUSE OF INCREASED BRONCHIAL RESPONSIVENESS TO INHALED METHACHOLINE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						FOOD HYPERSENSITIVITY; METHACHOLINE; BRONCHIAL RESPONSIVENESS	ASTHMATIC-CHILDREN; CHALLENGE; ALLERGY	To determine if food challenges could alter bronchial hyperresponsiveness, methacholine challenges were performed before and 24 hours after double-blind, placebo-controlled food challenges on 11 subjects with asthma with a history of food-induced asthma and positive skin prick tests to the suspect food. An equal number of patients demonstrated increased methacholine sensitivity after food and placebo challenges. Thus, we could not find evidence that allergic reactions to food induced bronchial hyperresponsiveness.	NATL JEWISH CTR IMMUNOL & RESP MED,1400 JACKSON ST,DENVER,CO 80206	National Jewish Health								BOCK SA, 1977, CLIN ALLERGY, V7, P375, DOI 10.1111/j.1365-2222.1977.tb01466.x; BOUSQUET J, 1988, ANN ALLERGY, V61, P70; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; DURHAM SR, 1988, J ALLERGY CLIN IMMUN, V82, P764, DOI 10.1016/0091-6749(88)90077-2; KIDD JM, 1983, J ALLERGY CLIN IMMUN, V71, P407, DOI 10.1016/0091-6749(83)90070-2; MAY CD, 1976, J ALLERGY CLIN IMMUN, V58, P500, DOI 10.1016/0091-6749(76)90194-9; NOVEMBRE E, 1988, J ALLERGY CLIN IMMUN, V81, P1059, DOI 10.1016/0091-6749(88)90181-9; ONORATO J, 1986, J ALLERGY CLIN IMMUN, V78, P1139, DOI 10.1016/0091-6749(86)90263-0; WILSON N, 1982, BRIT MED J, V284, P1226, DOI 10.1136/bmj.284.6324.1226; WILSON NM, 1988, ANN ALLERGY, V61, P75	10	24	25	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1991	88	3	1				360	364		10.1016/0091-6749(91)90098-9	http://dx.doi.org/10.1016/0091-6749(91)90098-9			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GG126	1890264				2022-12-18	WOS:A1991GG12600030
J	MASSEY, WA; LICHTENSTEIN, LM				MASSEY, WA; LICHTENSTEIN, LM			THE EFFECTS OF ANTIHISTAMINES BEYOND H1 ANTAGONISM IN ALLERGIC INFLAMMATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article								Antigen and cold dry air were used to challenge the upper and lower airways, skin, and conjunctiva. In each of these four systems an immediate and late-phase reaction to antigen is well characterized. Although the pattern of mediator release is different in these four areas, the degree of infiltration of basophils and eosinophils in the late-phase reaction appears to be constant. Of a number of drugs that can influence these mediators and cell responses, the steroids represent a typical mode of action. Steroids block the late-phase response and ablate the eosinophil and basophil infiltration. Although the effects of antihistamines appear to be similar, they do not appear to be caused by H1 antagonism; the mechanism of their action is unknown. This discussion will focus on these non-H1 antagonist effects of antihistamines in four challenge models, particularly the upper airways and skin.	JOHNS HOPKINS UNIV, GOOD SAMARITAN HOSP, SCH MED, JOHNS HOPKINS ASTHMA & ALLERGY CTR, BALTIMORE, MD 21224 USA	Johns Hopkins University; Johns Hopkins Medicine					NIAID NIH HHS [AI 07290, AI 08270] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI008270, R01AI008270] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMS GK, 1979, J IMMUNOL, V122, P555; BAUMGARTEN CR, 1986, J IMMUNOL, V137, P1323; BAUMGARTEN CR, 1986, J IMMUNOL, V137, P977; BAUMGARTEN CR, 1985, J CLIN INVEST, V76, P191, DOI 10.1172/JCI111945; BOCHNER BS, 1989, PROGRESS IN ALLERGY AND CLINICAL IMMUNOLOGY, P12; Bovet D, 1944, CR SOC BIOL, V138, P99; CHARLESWORTH EN, 1989, J ALLERGY CLIN IMMUN, V83, P905, DOI 10.1016/0091-6749(89)90104-8; CHENG HC, 1982, DRUG DEVELOP RES, V2, P181, DOI 10.1002/ddr.430020208; CRETICOS PS, 1984, NEW ENGL J MED, V310, P1626, DOI 10.1056/NEJM198406213102502; DOBBINS DE, 1981, MICROVASC RES, V21, P343, DOI 10.1016/0026-2862(81)90017-0; Halpern BN, 1942, ARCH INT PHARMACOD T, V68, P339; HARVEY RP, 1980, J ALLERGY CLIN IMMUN, V65, P136, DOI 10.1016/0091-6749(80)90198-0; ILIOPOULOS O, 1989, J ALLERGY CLIN IMMUN, V83, P236; IMANARI T, 1976, DHEW NIH76791 PUBL, P205; LANDAU SW, 1951, J ALLERGY, V22, P19, DOI 10.1016/0021-8707(51)90127-X; LEPREVOST C, 1988, INT ARCH ALLER A IMM, V87, P9, DOI 10.1159/000234641; LICHTENSTEIN LM, 1975, J PHARMACOL EXP THER, V192, P441; LOEW ER, 1946, J PHARMACOL EXP THER, V86, P229; MOTA I, 1960, BRIT J PHARM CHEMOTH, V15, P396, DOI 10.1111/j.1476-5381.1960.tb01262.x; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; NACLERIO RM, 1989, LARYNGOSCOPE, V99, P596; SCHILD HO, 1951, LANCET, V261, P376; SCHULMAN ES, 1981, AM REV RESPIR DIS, V124, P402; SCHWARTZ JC, 1981, TRENDS PHARMACOL SCI, V2, P122, DOI 10.1016/0165-6147(81)90285-6; SIRAGANIAN R, 1974, ANAL BIOCHEM, V57, P283; TASAKA K, 1986, ANN ALLERGY, V56, P464; TOGIAS A, 1987, J ALLERGY CLIN IMMUN, V79, P599, DOI 10.1016/S0091-6749(87)80155-0; TOGIAS AG, 1986, JAMA-J AM MED ASSOC, V255, P225, DOI 10.1001/jama.255.2.225; TRZECIAKOWSKI JP, 1988, ALLERGY PRINCIPLES P, V1, P715; VALENTINE MD, 1975, EVALUATION GASTROINT, P227; YONKMAN FF, 1946, J PHARMACOL EXP THER, V87, P256	31	24	26	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1990	86	6	2	S			1019	1024		10.1016/S0091-6749(05)80247-7	http://dx.doi.org/10.1016/S0091-6749(05)80247-7			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ER131	1979797				2022-12-18	WOS:A1990ER13100006
J	DEZUBIRIA, A; HORNER, WE; LEHRER, SB				DEZUBIRIA, A; HORNER, WE; LEHRER, SB			EVIDENCE FOR CROSS-REACTIVE ALLERGENS AMONG BASIDIOMYCETES - IMMUNOPRINT-INHIBITION STUDIES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									TULANE UNIV,MED CTR,SCH MED,DEPT MED,CLIN IMMUNOL SECT,NEW ORLEANS,LA 70112	Tulane University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007376] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020331] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 07376] Funding Source: Medline; NIAID NIH HHS [AI 20331] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMS KF, 1964, ACTA ALLERGOL, V19, P11, DOI 10.1111/j.1398-9995.1964.tb03220.x; BROWN HM, 1978, CLIN ALLERGY, V8, P599, DOI 10.1111/j.1365-2222.1978.tb01514.x; BURGE HA, 1989, IMMUNOL ALLERGY CLIN, V9, P307; BUTCHER BT, 1987, J ALLERGY CLIN IMMUN, V80, P803, DOI 10.1016/S0091-6749(87)80269-5; DAVIS WE, 1988, CLIN ALLERGY, V18, P261, DOI 10.1111/j.1365-2222.1988.tb02868.x; DEMEULEMESTER C, 1987, ELECTROPHORESIS, V8, P71, DOI 10.1002/elps.1150080113; GREGORY PH, 1957, J GEN MICROBIOL, V17, P135, DOI 10.1099/00221287-17-1-135; HASNAIN SM, 1985, NEW ZEAL MED J, V98, P342; HASNAIN SM, 1985, NEW ZEAL MED J, V98, P393; HORNER WE, 1988, J ALLERGY CLIN IMMUN, V82, P978, DOI 10.1016/0091-6749(88)90134-0; HORNER WE, 1989, J ALLERGY CLIN IMMUN, V83, P784, DOI 10.1016/0091-6749(89)90015-8; HYDE H. A., 1960, ACTA ALLERGOL, V15, P159; IBANEZ MD, 1988, J ALLERGY CLIN IMMUN, V82, P787, DOI 10.1016/0091-6749(88)90080-2; KENDRICK B, 1985, 5TH KINGDOM, P317; LEHRER SB, 1986, J ALLERGY CLIN IMMUN, V78, P478, DOI 10.1016/0091-6749(86)90036-9; MCDONALD MS, 1980, CLIN ALLERGY, V10, P211, DOI 10.1111/j.1365-2222.1980.tb02099.x; ONEIL CE, 1988, INT ARCH ALLER A IMM, V85, P161, DOI 10.1159/000234496; PADY SM, 1967, J ALLERGY, V39, P302, DOI 10.1016/0021-8707(67)90094-9; RANTIO-LEHTIMAKI A, 1977, Grana, V16, P163; ROYES VIJ, 1987, GRANA, V26, P151, DOI 10.1080/00173138709429944; SALVAGGIO J, 1971, J ALLERGY CLIN IMMUN, V48, P96, DOI 10.1016/0091-6749(71)90091-1; SPRENGER JD, 1988, J ALLERGY CLIN IMMUN, V82, P1076, DOI 10.1016/0091-6749(88)90146-7; TARLO SM, 1979, J ALLERGY CLIN IMMUN, V64, P43, DOI 10.1016/0091-6749(79)90082-4	23	24	24	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1990	86	1					26	33						8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DQ688	2196301	Bronze			2022-12-18	WOS:A1990DQ68800005
J	SIMONS, KJ; MARTIN, TJ; WATSON, WTA; SIMONS, FER				SIMONS, KJ; MARTIN, TJ; WATSON, WTA; SIMONS, FER			PHARMACOKINETICS AND PHARMACODYNAMICS OF TERFENADINE AND CHLORPHENIRAMINE IN THE ELDERLY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV MANITOBA,FAC PHARM,HLTH SCI CLIN RES CTR,WINNIPEG R3T 2N2,MANITOBA,CANADA; UNIV MANITOBA,FAC MED,WINNIPEG R3T 2N2,MANITOBA,CANADA; UNIV MANITOBA,FAC SCI,WINNIPEG R3T 2N2,MANITOBA,CANADA	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Manitoba; University of Manitoba								[Anonymous], 1980, PRINCIPLES PROCEDURE; COOK CE, 1980, J PHARM SCI, V69, P1419, DOI 10.1002/jps.2600691218; EVERITT DE, 1986, ARCH INTERN MED, V146, P2393, DOI 10.1001/archinte.146.12.2393; GARTEIZ DA, 1982, ARZNEIMITTEL-FORSCH, V32-2, P1185; GENDREAUREID L, 1986, J ALLERGY CLIN IMMUN, V77, P335, DOI 10.1016/S0091-6749(86)80114-2; Gibaldi M, 1982, PHARMACOKINETICS; GOLDBERG PB, 1983, MED CLIN N AM, V67, P315; HOLFORD NHG, 1981, CLIN PHARMACOKINET, V6, P429, DOI 10.2165/00003088-198106060-00002; HUANG SM, 1982, EUR J CLIN PHARMACOL, V22, P359, DOI 10.1007/BF00548406; KOTZAN JA, 1982, J PHARM SCI, V71, P919, DOI 10.1002/jps.2600710820; LOI CM, 1988, PHARMACOL THERAPEUT, V36, P131, DOI 10.1016/0163-7258(88)90115-5; MCEVOY GK, 1989, AM HOSPITAL FORMULAR, P2; MONTAMAT SC, 1989, NEW ENGL J MED, V321, P303; OKERHOLM RA, 1981, BIOPHARM DRUG DISPOS, V2, P185, DOI 10.1002/bdd.2510020211; ROEHRS TA, 1984, SLEEP, V7, P137, DOI 10.1093/sleep/7.2.137; SHEPHERD AMM, 1986, DRUG STUDIES ELDERLY, P49; SHUMAKER RC, 1986, DRUG METAB REV, V17, P331, DOI 10.3109/03602538608998295; SIMONS FER, 1987, J ALLERGY CLIN IMMUN, V80, P884; SIMONS FER, 1982, J ALLERGY CLIN IMMUN, V69, P376, DOI 10.1016/0091-6749(82)90149-X; SIMONS FER, 1988, J ALLERGY CLIN IMMUN, V82, P1068; SIMONS KJ, 1989, CLIN PHARMACOL THER, V45, P9, DOI 10.1038/clpt.1989.2; SKASSABROCIEK W, 1987, J ALLERGY CLIN IMMUN, V80, P711, DOI 10.1016/0091-6749(87)90292-2; THOMPSON JA, 1981, J PHARM SCI-US, V70, P1284, DOI 10.1002/jps.2600701127; VALLNER JJ, 1979, CURR THER RES CLIN E, V26, P449; YACOBI A, 1980, J PHARM SCI, V69, P1077, DOI 10.1002/jps.2600690924	25	24	27	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1990	85	3					540	547		10.1016/0091-6749(90)90091-H	http://dx.doi.org/10.1016/0091-6749(90)90091-H			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CU668	2107240				2022-12-18	WOS:A1990CU66800002
J	GRIECO, MH				GRIECO, MH			IMMUNOGLOBULINS AND HYPERSENSITIVITY IN HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material											GRIECO, MH (corresponding author), ST LUKES ROOSEVELT HOSP CTR, 428 W 59TH ST, NEW YORK, NY 10019 USA.							AMIEL C, 1988, 4TH P INT AIDS C STO, P172; BOND MW, 1987, J IMMUNOL, V139, P3691; BUCHNESS MR, 1988, NEW ENGL J MED, V318, P1183, DOI 10.1056/NEJM198805053181807; CARINI C, 1988, 4TH P INT AIDS C STO, P188; COFFMAN RL, 1987, J IMMUNOL, V139, P3685; CURRAN JW, 1988, SCIENCE, V239, P610, DOI 10.1126/science.3340847; FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274; FLING JA, 1988, J ALLERGY CLIN IMMUN, V82, P965, DOI 10.1016/0091-6749(88)90132-7; GOTTLIEB MS, 1985, LANCET, V1, P1389; GREENBERGER PA, 1987, J ALLERGY CLIN IMMUN, V79, P484, DOI 10.1016/0091-6749(87)90366-6; HOSTETTLER C, 1987, DRUG INTEL CLIN PHAR, V21, P875, DOI 10.1177/106002808702101104; LEFRERE JJ, 1988, LANCET, V1, P1220; LIU KJ, 1988, SCIENCE, V240, P1333; LOWENSTEIN W, 1988, 4TH P INT AIDS C STO, P188; MIADONNA A, 1988, J ALLERGY CLIN IMMUN, V81, P227, DOI 10.1016/0091-6749(88)90470-8; MOSMANN TR, 1987, IMMUNOL TODAY, V8, P223, DOI 10.1016/0167-5699(87)90171-X; MOSS AR, 1988, 4TH P INT AIDS C STO, P294; PARKIN JM, 1987, BRIT MED J, V294, P1185, DOI 10.1136/bmj.294.6581.1185; PEDERSON M, 1988, 4 INT C AIDS STOCKH, P189; PENE J, 1988, J IMMUNOL, V141, P1218; POLK BF, 1987, NEW ENGL J MED, V316, P61, DOI 10.1056/NEJM198701083160201; QUIRINO T, 1988, 4TH P INT AIDS C STO, P194; RIETMEIJER CAM, 1988, ARCH DERMATOL, V124, P490, DOI 10.1001/archderm.124.4.490; RING J, 1988, J ALLERGY CLIN IMMUN, V81, P216, DOI 10.1016/0091-6749(88)90427-7; SCHWARTZ ND, 1986, ARCH INTERN MED, V146, P2059, DOI 10.1001/archinte.146.10.2059; SOTOAGUILAR MC, 1988, J ALLERGY CLIN IMMUN, V81, P619, DOI 10.1016/0091-6749(88)91030-5; TOBACK AC, 1986, J AM ACAD DERMATOL, V15, P1056, DOI 10.1016/S0190-9622(86)80316-4; WRIGHT DN, 1988, J ALLERGY CLIN IMMUN, V81, P216, DOI 10.1016/0091-6749(88)90426-5	28	24	24	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1989	84	1					1	4		10.1016/0091-6749(89)90170-X	http://dx.doi.org/10.1016/0091-6749(89)90170-X			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AG120	2666481				2022-12-18	WOS:A1989AG12000001
J	KEFFER, JM; BRESSLER, RB; WRIGHT, R; KALINER, MA; METCALFE, DD				KEFFER, JM; BRESSLER, RB; WRIGHT, R; KALINER, MA; METCALFE, DD			ANALYSIS OF THE WHEAL-AND-FLARE REACTIONS THAT FOLLOW THE INTRADERMAL INJECTION OF HISTAMINE AND MORPHINE IN ADULTS WITH RECURRENT, UNEXPLAINED ANAPHYLAXIS AND SYSTEMIC MASTOCYTOSIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											KEFFER, JM (corresponding author), NIAID, CLIN INVEST LAB, ALLERG DIS SECT, BLDG 10, ROOM 11N228, BETHESDA, MD 20892 USA.							BOXER M, 1987, ARCH INTERN MED, V147, P269, DOI 10.1001/archinte.147.2.269; CASALE TB, 1984, J ALLERGY CLIN IMMUN, V73, P775, DOI 10.1016/0091-6749(84)90447-0; COHEN RW, 1986, J ALLERGY CLIN IMMUN, V77, P802, DOI 10.1016/0091-6749(86)90377-5; FRIERI M, 1985, AM J MED, V78, P9, DOI 10.1016/0002-9343(85)90454-1; GARRIGA MM, 1988, J ALLERGY CLIN IMMUN, V82, P425, DOI 10.1016/0091-6749(88)90015-2; KALINER M, 1982, J ALLERGY CLIN IMMUN, V69, P283, DOI 10.1016/S0091-6749(82)80005-5; KALINER M, 1981, J ALLERGY CLIN IMMUN, V68, P365, DOI 10.1016/0091-6749(81)90134-2; KRAUSE LB, 1985, BRIT J CLIN PHARMACO, V20, P486, DOI 10.1111/j.1365-2125.1985.tb05103.x; LIEBERMAN P, 1979, ARCH INTERN MED, V139, P1032, DOI 10.1001/archinte.139.9.1032; MEGGS WJ, 1985, J ALLERGY CLIN IMMUN, V76, P840, DOI 10.1016/0091-6749(85)90758-4; Mood A. M, 1950, INTRO THEORY STATIST, P394; NATBONY SF, 1983, J ALLERGY CLIN IMMUN, V71, P177, DOI 10.1016/0091-6749(83)90096-9; OWNBY DR, 1982, J ALLERGY CLIN IMMUN, V69, P536, DOI 10.1016/0091-6749(82)90180-4; PARWARESCH MR, 1985, PATHOL RES PRACT, V179, P439, DOI 10.1016/S0344-0338(85)80184-9; ROSENBAUM RC, 1984, J NUCL MED, V25, P859; SALE SR, 1981, JAMA-J AM MED ASSOC, V246, P2336, DOI 10.1001/jama.246.20.2336; SIEGEL S, 1956, NONPARAMETRIC STAT, P202; SIMES RJ, 1986, BIOMETRIKA, V73, P751, DOI 10.2307/2336545; THOMPSON WR, 1947, BACTERIOL REV, V11, P115, DOI 10.1128/MMBR.11.2.115-145.1947; TURKELTAUB PC, 1986, CLIN REV ALLERG, V4, P371	20	24	25	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1989	83	3					595	601		10.1016/0091-6749(89)90071-7	http://dx.doi.org/10.1016/0091-6749(89)90071-7			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	T8596	2926081	Bronze			2022-12-18	WOS:A1989T859600005
J	NORDVALL, SL; JOHANSSON, SGO; LEDFORD, DK; LOCKEY, RF				NORDVALL, SL; JOHANSSON, SGO; LEDFORD, DK; LOCKEY, RF			ALLERGENS OF THE IMPORTED FIRE ANT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									KAROLINSKA HOSP,DEPT CLIN IMMUNOL,S-10401 STOCKHOLM 60,SWEDEN; DEPT INTERNAL MED,DIV ALLERGY & IMMUNOL,TAMPA,FL	Karolinska Institutet; Karolinska University Hospital	NORDVALL, SL (corresponding author), KAROLINSKA INST,ST GORANS CHILDRENS HOSP,DEPT PEDIAT,BOX 12500,S-11281 STOCKHOLM,SWEDEN.							AALBERSE RC, 1981, J ALLERGY CLIN IMMUN, V68, P356, DOI 10.1016/0091-6749(81)90133-0; AAS K, 1978, ALLERGY, V33, P3, DOI 10.1111/j.1398-9995.1978.tb01501.x; AUKRUST L, 1977, SCAND J IMMUNOL, V6, P1093; AUKRUST L, 1980, ALLERGY, V35, P206, DOI 10.1111/j.1398-9995.1980.tb01747.x; BAER H, 1977, ANN ALLERGY, V38, P378; BATTEIGER B, 1982, J IMMUNOL METHODS, V55, P297, DOI 10.1016/0022-1759(82)90089-8; BENNICH H, 1970, VOX SANG, V19, P1, DOI 10.1111/j.1423-0410.1970.tb01490.x; ERICKSON PF, 1982, J IMMUNOL METHODS, V51, P241, DOI 10.1016/0022-1759(82)90263-0; HARBOE N, 1973, Scandinavian Journal of Immunology, V2, P161; JOHANSSON SG, 1971, INT ARCH ALLER A IMM, V41, P443, DOI 10.1159/000230538; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARSH DG, 1975, ANTIGENS, V3, P271; PAULL BR, 1983, J ALLERGY CLIN IMMUN, V71, P448, DOI 10.1016/0091-6749(83)90460-8; RHOADES RB, 1978, ANN ALLERGY, V40, P100; STROM GB, 1980, J ALLERGY CLIN IMMUN, V65, P202; SUTTON R, 1982, J IMMUNOL METHODS, V52, P183, DOI 10.1016/0022-1759(82)90044-8; UHLIN T, 1983, INT ARCH ALLER A IMM, V70, P213, DOI 10.1159/000233326; WEEKE B, 1973, SCAND J IMMUNOL, V2, P47, DOI 10.1111/j.1365-3083.1973.tb03778.x; WEEKE B, 1973, SCAND J IMMUNOL, V2, P149, DOI 10.1111/j.1365-3083.1973.tb03796.x; WIDE L, 1967, LANCET, V2, P1105	20	24	24	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1988	82	4					567	576		10.1016/0091-6749(88)90966-9	http://dx.doi.org/10.1016/0091-6749(88)90966-9			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	Q6399	3171000	Bronze			2022-12-18	WOS:A1988Q639900006
J	OLSSON, P; HAMMARLUND, A; PIPKORN, U				OLSSON, P; HAMMARLUND, A; PIPKORN, U			WHEAL-AND-FLARE REACTIONS INDUCED BY ALLERGEN AND HISTAMINE - EVALUATION OF BLOOD-FLOW WITH LASER DOPPLER FLOWMETRY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV LUND HOSP,DEPT OTORHINOLARYNGOL,S-22185 LUND,SWEDEN	Lund University; Skane University Hospital								AHN H, 1985, GASTROENTEROLOGY, V88, P951, DOI 10.1016/S0016-5085(85)80013-5; ANDERSSON M, 1987, J ALLERGY CLIN IMMUN, V79, P345, DOI 10.1016/0091-6749(87)90153-9; BISGAARD H, 1984, J INVEST DERMATOL, V83, P184, DOI 10.1111/1523-1747.ep12263541; BISGAARD H, 1986, CLIN ALLERGY, V16, P289, DOI 10.1111/j.1365-2222.1986.tb01960.x; BONNER R, 1981, APPL OPTICS, V20, P2097, DOI 10.1364/AO.20.002097; CERVIN A, 1988, ACTA OTO-LARYNGOL, V105, P350, DOI 10.3109/00016488809097018; DREBORG S, 1986, J ALLERGY CLIN IMMUN, V77, P233; HAGERMARK O, 1978, J INVEST DERMATOL, V71, P233, DOI 10.1111/1523-1747.ep12515092; JULIUSSON S, 1987, CLIN ALLERGY, V17, P301, DOI 10.1111/j.1365-2222.1987.tb02018.x; KJELLMAN NIM, IN PRESS ALLERGY; MYGIND N, 1986, ESSENTIAL ALLERGY, P119; OLSSON P, 1986, ACTA OTO-LARYNGOL, V102, P106, DOI 10.3109/00016488609108653; OLSSON P, 1985, ACTA OTO-LARYNGOL, V99, P133, DOI 10.3109/00016488509119155; PETERS SP, 1982, AM REV RESPIR DIS, V126, P1034; Roddie IC, 1983, HDB PHYSL CARDIOVASC, P285; ROOK A, 1978, TXB DERMATOLOGY, P425; RYAN TJ, 1973, PHYSL PATHOPHYSIOLOG, P752; SERUP J, 1985, ALLERGY, V40, P233, DOI 10.1111/j.1398-9995.1985.tb00226.x; STABERG B, 1984, ARCH DERMATOL, V120, P741, DOI 10.1001/archderm.120.6.741; TENLAND T, 1982, THESIS U LINKOPING L	20	24	25	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1988	82	2					291	295		10.1016/0091-6749(88)91014-7	http://dx.doi.org/10.1016/0091-6749(88)91014-7			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	P8741	2969931				2022-12-18	WOS:A1988P874100024
J	MARRIE, TJ; JOHNSON, S; DURANT, H				MARRIE, TJ; JOHNSON, S; DURANT, H			CELL-MEDIATED-IMMUNITY OF HEALTHY ADULT NOVA SCOTIANS IN VARIOUS AGE-GROUPS COMPARED WITH NURSING-HOME AND HOSPITALIZED SENIOR CITIZENS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									DALHOUSIE UNIV,DEPT MED,HALIFAX B3H 4H2,NS,CANADA; DALHOUSIE UNIV,DEPT MICROBIOL,HALIFAX B3H 4H2,NS,CANADA	Dalhousie University; Dalhousie University	MARRIE, TJ (corresponding author), VICTORIA GEN HOSP,ROOM 4090 ACC,1278 TOWER RD,HALIFAX B3H 2Y9,NS,CANADA.							CHANDRA RK, 1983, LANCET, V1, P688; CHRISTOU NV, 1983, INFECT SURG, V3, P692; COHN JR, 1983, J AM GERIATR SOC, V31, P261, DOI 10.1111/j.1532-5415.1983.tb04867.x; COHN JR, 1983, J AM GERIATR SOC, V31, P808, DOI 10.1111/j.1532-5415.1983.tb03404.x; GIRARD JP, 1977, CLIN EXP IMMUNOL, V27, P85; GROSSMAN J, 1975, J ALLERGY CLIN IMMUN, V55, P268, DOI 10.1016/0091-6749(75)90146-3; KNIKER WT, 1984, ANN ALLERGY, V52, P75; MACLEAN LD, 1975, ANN SURG, V182, P207, DOI 10.1097/00000658-197509000-00004; MCCULLAGH P, 1983, BINARY DATA, P72; MURASKO DM, 1986, AM J MED, V81, P612, DOI 10.1016/0002-9343(86)90546-2; RIBOLI EB, 1984, CAN J SURG, V27, P60; ROBERTST.IC, 1974, LANCET, V2, P368; YUNIS EJ, 1976, J AM GERIATR SOC, V24, P258, DOI 10.1111/j.1532-5415.1976.tb03301.x; 1983, I MERIEUX INSTRUCTIO	14	24	24	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1988	81	5	1				836	843		10.1016/0091-6749(88)90939-6	http://dx.doi.org/10.1016/0091-6749(88)90939-6			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	N7036	3372906				2022-12-18	WOS:A1988N703600011
J	MAHAUTHAMAN, R; HOWELL, CJ; SPUR, BW; YOULTEN, LJF; CLARK, TJH; LESSOF, MH; LEE, TH				MAHAUTHAMAN, R; HOWELL, CJ; SPUR, BW; YOULTEN, LJF; CLARK, TJH; LESSOF, MH; LEE, TH			THE GENERATION AND CELLULAR-DISTRIBUTION OF LEUKOTRIENE-C4 IN HUMAN EOSINOPHILS STIMULATED BY UNOPSONIZED ZYMOSAN AND GLUCAN PARTICLES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									GUYS HOSP,UNITED MED & DENT SCH GUYS & ST THOMASS HOSP,DEPT MED,LONDON SE1 9RT,ENGLAND; GUYS HOSP,UNITED MED & DENT SCH GUYS & ST THOMASS HOSP,DEPT RESP MED,LONDON SE1 9RT,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London			Lee, Tak/AAA-9526-2020	Lee, Tak/0000-0002-7554-4059; Spur, Bernd/0000-0002-7581-4741				AUSTWICK PKC, 1981, FUNGI ACTINOMYCETES, P396; BACH MK, 1984, ARCH BIOCHEM BIOPHYS, V230, P455, DOI 10.1016/0003-9861(84)90426-0; BACON JSD, 1969, BIOCHEM J, V114, P557, DOI 10.1042/bj1140557; BARTNICK.S, 1968, ANNU REV MICROBIOL, V22, P87, DOI 10.1146/annurev.mi.22.100168.000511; BORGEAT P, 1984, J ALLERGY CLIN IMMUN, V74, P310, DOI 10.1016/0091-6749(84)90122-2; CLANCY RM, 1983, P NATL ACAD SCI-BIOL, V80, P7200, DOI 10.1073/pnas.80.23.7200; COREY EJ, 1980, TETRAHEDRON LETT, V21, P3143, DOI 10.1016/S0040-4039(00)77430-2; COREY EJ, 1980, J AM CHEM SOC, V102, P1436, DOI 10.1021/ja00524a045; CRETICOS PS, 1984, NEW ENGL J MED, V310, P1626, DOI 10.1056/NEJM198406213102502; CZOP JK, 1985, P NATL ACAD SCI USA, V82, P2751, DOI 10.1073/pnas.82.9.2751; CZOP JK, 1985, J IMMUNOL, V134, P2588; CZOP JK, 1980, J IMMUNOL, V125, P124; CZOP JK, 1978, J IMMUNOL, V120, P1132; DICARLO FJ, 1957, SCIENCE, V127, P756; DRAZEN JM, 1980, P NATL ACAD SCI-BIOL, V77, P4354, DOI 10.1073/pnas.77.7.4354; HENDERSON WR, 1984, IMMUNOLOGY, V51, P679; JORG A, 1982, J EXP MED, V155, P390, DOI 10.1084/jem.155.2.390; LEE CW, 1983, J BIOL CHEM, V258, P5004; LEWIS RA, 1984, J CLIN INVEST, V73, P889, DOI 10.1172/JCI111312; MANNERS DJ, 1973, BIOCHEM J, V135, P19, DOI 10.1042/bj1350019; MANNERS DJ, 1973, BIOCHEM J, V135, P31, DOI 10.1042/bj1350031; OWEN WF, 1987, J IMMUNOL, V138, P532; ROBERTS RL, 1985, BLOOD, V65, P433; ROKACH J, 1984, PROSTA LEUKOTR MED, V13, P21, DOI 10.1016/0262-1746(84)90098-2; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SHAW RJ, 1984, CLIN EXP IMMUNOL, V56, P716; SHAW RJ, 1985, NATURE, V316, P150, DOI 10.1038/316150a0; VADAS MA, 1979, J IMMUNOL, V122, P1228; WELLER PF, 1983, P NATL ACAD SCI-BIOL, V80, P7626, DOI 10.1073/pnas.80.24.7626; WILLIAMS JD, 1985, J IMMUNOL, V134, P2624; WILLIAMS JD, 1984, J IMMUNOL, V132, P3034; WILLIAMS JD, 1986, IMMUNOLOGY, V58, P117	32	24	24	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1988	81	4					696	705		10.1016/0091-6749(88)91041-X	http://dx.doi.org/10.1016/0091-6749(88)91041-X			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	N0650	3128590	Bronze			2022-12-18	WOS:A1988N065000010
J	BECKER, AB; CHUNG, KF; MCDONALD, DM; FRICK, OL; GOLD, WM				BECKER, AB; CHUNG, KF; MCDONALD, DM; FRICK, OL; GOLD, WM			CUTANEOUS ALLERGIC RESPONSE IN ATOPIC DOGS - RELATIONSHIP OF CELLULAR AND HISTAMINE RESPONSES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,BOX 0130,1327-M,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT ANAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PEDIAT,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco			Chung, Kian Fan/I-8456-2019; Chung, Kian Fan/B-1872-2012	Chung, Kian Fan/0000-0001-7101-1426; Chung, Kian Fan/0000-0001-7101-1426	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL024136] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015233] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-24136] Funding Source: Medline; NIAID NIH HHS [R01 AI15233] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BASRAN GS, 1984, CLIN ALLERGY, V14, P75, DOI 10.1111/j.1365-2222.1984.tb02193.x; BECKER AB, 1985, ANAT REC, V213, P477, DOI 10.1002/ar.1092130402; BECKER AB, 1986, J ALLERGY CLIN IMMUN, V78, P937, DOI 10.1016/0091-6749(86)90243-5; BJORK J, 1982, INFLAMMATION, V6, P189, DOI 10.1007/BF00916243; BORGEAT P, 1979, P NATL ACAD SCI USA, V76, P2148, DOI 10.1073/pnas.76.5.2148; CENTER DM, 1983, J ALLERGY CLIN IMMUN, V71, P29, DOI 10.1016/0091-6749(83)90543-2; CHUNG KF, 1985, J APPL PHYSIOL, V58, P1347, DOI 10.1152/jappl.1985.58.4.1347; COCKCROFT DW, 1983, LANCET, V2, P253; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; ELIAS HM, 1983, CONTINUING ED SERIES, P75; ENERBACK L, 1966, ACTA PATHOL MIC SC, V66, P289, DOI 10.1111/apm.1966.66.3.289; EZEAMUZIE IC, 1983, AGENTS ACTIONS, V13, P222, DOI 10.1007/BF01967337; FILLEY WV, 1982, LANCET, V2, P11; FRICK OL, 1983, AM J VET RES, V44, P440; FRIGAS E, 1981, MAYO CLIN PROC, V56, P345; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P160, DOI 10.1016/0091-6749(82)90037-9; GOMORI G, 1953, J HISTOCHEM CYTOCHEM, V1, P469, DOI 10.1177/1.6.469; HIGGS GA, 1983, BRIT J PHARMACOL, V79, P863, DOI 10.1111/j.1476-5381.1983.tb10530.x; HUMPHREY DM, 1982, LAB INVEST, V46, P422; KALINER MM, 1984, J ALLERGY CLIN IMMUN, V73, P311, DOI 10.1016/0091-6749(84)90401-9; LEDER L-D, 1979, American Journal of Dermatopathology, V1, P39; LEE TC, 1984, J BIOL CHEM, V259, P5526; LEMANSKE RF, 1983, J IMMUNOL, V131, P929; LEMANSKE RF, 1983, J IMMUNOL, V130, P2837; LEUNG DYM, 1983, J ALLERGY CLIN IMMUN, V71, P47, DOI 10.1016/0091-6749(83)90546-8; MCMANUS JFA, 1960, STAINING METHODS HIS, P65; ODONNELL MC, 1983, J EXP MED, V157, P1981, DOI 10.1084/jem.157.6.1981; PAGE CP, 1985, AGENTS ACTIONS, V16, P30, DOI 10.1007/BF01999636; PINCKARD RN, 1981, INT ARCH ALLER A IMM, V66, P127; SCHULMAN ES, 1985, AM REV RESPIR DIS, V131, P230; SMOLEN AJ, 1983, J NEUROCYTOL, V12, P739, DOI 10.1007/BF01258148; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; THUESON DO, 1979, J IMMUNOL, V123, P626; WELLER PF, 1983, P NATL ACAD SCI-BIOL, V80, P7626, DOI 10.1073/pnas.80.24.7626; ZHEUTLIN LM, 1984, J IMMUNOL, V133, P2180	35	24	24	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1988	81	2					441	448		10.1016/0091-6749(88)90914-1	http://dx.doi.org/10.1016/0091-6749(88)90914-1			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	M0993	2448359				2022-12-18	WOS:A1988M099300012
J	SLAVIN, RG; ZILLIOX, AP; SAMUELS, LD				SLAVIN, RG; ZILLIOX, AP; SAMUELS, LD			IS THERE SUCH AN ENTITY AS ALLERGIC SINUSITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	24	24	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1988	81	1					284	284		10.1016/0091-6749(88)90700-2	http://dx.doi.org/10.1016/0091-6749(88)90700-2			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	M0274					2022-12-18	WOS:A1988M027400487
J	HOPP, RJ; WEISS, SJ; NAIR, NM; BEWTRA, AK; TOWNLEY, RG				HOPP, RJ; WEISS, SJ; NAIR, NM; BEWTRA, AK; TOWNLEY, RG			INTERPRETATION OF THE RESULTS OF METHACHOLINE INHALATION CHALLENGE TESTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CREIGHTON UNIV, SCH MED, CTR ALLERG DIS, OMAHA, NE 68178 USA	Creighton University			Hopp, Russell/K-4578-2019					CARTIER A, 1983, J APPL PHYSIOL, V54, P821, DOI 10.1152/jappl.1983.54.3.821; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; COCKCROFT DW, 1983, CHEST, V84, P505, DOI 10.1378/chest.84.4.505; HARGREAVE FE, 1981, J ALLERGY CLIN IMMUN, V68, P347, DOI 10.1016/0091-6749(81)90132-9; HENDRICK DJ, 1986, AM REV RESPIR DIS, V133, P600; HOPP RJ, 1984, J ALLERGY CLIN IMMUN, V73, P265, DOI 10.1016/S0091-6749(84)80018-4; HOPP RJ, 1986, AM REV RESPIR DIS, V134, P994, DOI 10.1164/arrd.1986.134.5.994; HOPP RJ, 1984, J ALLERGY CLIN IMMUN, V74, P154, DOI 10.1016/0091-6749(84)90279-3; LABRALCO J M, 1984, Journal of Allergy and Clinical Immunology, V73, P124; LANG DM, 1987, J ALLERGY CLIN IMMUN, V79, P533, DOI 10.1016/0091-6749(87)90372-1; MALO JL, 1983, AM REV RESPIR DIS, V128, P8, DOI 10.1164/arrd.1983.128.1.8; MENDENHALL W, 1979, MATH STATISTICS APPL, P326; MENEELY GR, 1962, AM REV RESPIR DIS, V85, P762; NETER J, 1985, APPLIED LINEAR STATI, P67; NIE NH, 1975, STATISTICAL PACKAGE, P320; RYAN G, 1982, THORAX, V37, P423, DOI 10.1136/thx.37.6.423; SHAPIRO GG, 1982, J ALLERGY CLIN IMMUN, V69, P365, DOI 10.1016/0091-6749(82)90147-6; STERK PJ, 1985, AM REV RESPIR DIS, V132, P865; TATTERSFIELD AE, 1981, THORAX, V36, P561, DOI 10.1136/thx.36.8.561; TOWNLEY RG, 1975, J ALLERGY CLIN IMMUN, V56, P427, DOI 10.1016/0091-6749(75)90061-5; TOWNLEY RG, 1979, J ALLERGY CLIN IMMUN, V64, P569, DOI 10.1016/0091-6749(79)90014-9; WEISS S, 1986, J ALLERGY CLIN IMMUN, V77, P154; WOOLCOCK AJ, 1984, AM REV RESPIR DIS, V130, P71	23	24	24	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1987	80	6					821	830		10.1016/S0091-6749(87)80272-5	http://dx.doi.org/10.1016/S0091-6749(87)80272-5			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	L5020	3320161	Bronze			2022-12-18	WOS:A1987L502000009
J	SIMONS, FER; WATSON, WTA; SIMONS, KJ				SIMONS, FER; WATSON, WTA; SIMONS, KJ			THE PHARMACOKINETICS AND PHARMACODYNAMICS OF TERFENADINE IN CHILDREN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV MANITOBA,FAC MED,DEPT PEDIAT & CHILD HLTH,ALLERGY & CLIN IMMUNOL SECT,WINNIPEG R3T 2N2,MANITOBA,CANADA; UNIV MANITOBA,FAC PHARM,WINNIPEG R3T 2N2,MANITOBA,CANADA	University of Manitoba; University of Manitoba								[Anonymous], 1980, PRINCIPLES PROCEDURE; CONNELL JT, 1985, PHARMACOTHERAPY, V5, P201; COOK CE, 1980, J PHARM SCI, V69, P1419, DOI 10.1002/jps.2600691218; GARTEIZ DA, 1982, ARZNEIMITTEL-FORSCH, V32-2, P1185; GENDREAUREID L, 1986, J ALLERGY CLIN IMMUN, V77, P335, DOI 10.1016/S0091-6749(86)80114-2; GIBALDI M, 1982, PHARMACOKINETICS, P17; GUILL MF, 1986, J ALLERGY CLIN IMMUN, V78, P4, DOI 10.1016/0091-6749(86)90107-7; HOWARTH PH, 1984, THORAX, V39, P668, DOI 10.1136/thx.39.9.668; HUTHER KJ, 1977, EUR J CLIN PHARMACOL, V12, P195, DOI 10.1007/BF00609860; KAGAN G, 1980, J INT MED RES, V8, P404, DOI 10.1177/030006058000800607; KEMP JP, 1985, ANN ALLERGY, V54, P502; LOCKHART JDF, 1983, PRACTITIONER, V227, P1313; MURPHYOCONNOR JC, 1984, J INT MED RES, V12, P333, DOI 10.1177/030006058401200603; OKERHOLM RA, 1981, BIOPHARM DRUG DISPOS, V2, P185, DOI 10.1002/bdd.2510020211; REINBERG A, 1978, EUR J CLIN PHARMACOL, V14, P245, DOI 10.1007/BF00560457; RICHARDS DM, 1984, DRUGS, V28, P38, DOI 10.2165/00003495-198428010-00003; SIMONS FER, 1984, J ALLERGY CLIN IMMUN, V73, P69, DOI 10.1016/0091-6749(84)90486-X; SIMONS FER, 1982, J ALLERGY CLIN IMMUN, V69, P376, DOI 10.1016/0091-6749(82)90149-X; SIMONS FER, 1982, J ALLERGY CLIN IMMUN, V70, P458, DOI 10.1016/0091-6749(82)90009-4; SIMONS FER, 1983, PEDIATR CLIN N AM, V30, P899; SIMONS FER, 1984, J PEDIATR-US, V104, P123; SIMONS KJ, 1986, J ALLERGY CLIN IMMUN, V77, P326, DOI 10.1016/S0091-6749(86)80112-9; SORKIN EM, 1985, DRUGS, V29, P34, DOI 10.2165/00003495-198529010-00002; STRICKER BHC, 1986, BRIT MED J, V293, P536, DOI 10.1136/bmj.293.6546.536; TAUDORF E, 1985, ALLERGY, V40, P344, DOI 10.1111/j.1398-9995.1985.tb00245.x; THOMPSON JA, 1981, J PHARM SCI-US, V70, P1284, DOI 10.1002/jps.2600701127	26	24	27	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1987	80	6					884	890						7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	L5020	2891738				2022-12-18	WOS:A1987L502000018
J	EVANS, R				EVANS, R			RECENT OBSERVATIONS REFLECTING INCREASES IN MORTALITY FROM ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JOHNS HOPKINS MED INST,DEPT IMMUNOL & INFECT DIS,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins Medicine	EVANS, R (corresponding author), JOHNS HOPKINS MED INST,DEPT MED,615 N WOLFE ST,ROOM 4023,BALTIMORE,MD 21205, USA.				NHLBI NIH HHS [EDC-2 5 R01 HL30532-03] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030532] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		EVANS R, IN PRESS CHEST; MARKHAM D, 1986, J ALLERGY CLIN IMMUN, V77, P161; MULLALLY DI, 1985, J ALLERGY CLIN IMMUN, V75, P197, DOI 10.1016/0091-6749(85)90505-6; PAULOZZI LJ, 1986, ANN ALLERGY, V56, P392; SLY RM, 1984, ANN ALLERGY, V53, P20; STABLEFORTH DE, 1985, ASTHMA DEATHS UK INT	6	24	24	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1987	80	3	2	S			377	379		10.1016/0091-6749(87)90053-4	http://dx.doi.org/10.1016/0091-6749(87)90053-4			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	K1037	3624688				2022-12-18	WOS:A1987K103700005
J	FAIRLEY, D; BATCHELDER, GL				FAIRLEY, D; BATCHELDER, GL			A STUDY OF OAK-POLLEN PRODUCTION AND PHENOLOGY IN NORTHERN CALIFORNIA - PREDICTION OF ANNUAL VARIATION IN POLLEN COUNTS BASED ON GEOGRAPHIC AND METEROROLOGIC FACTORS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									POLLEN RES ASSOC INC,BEVERLY,MA		FAIRLEY, D (corresponding author), OHIO STATE UNIV,DEPT STAT,COLUMBUS,OH 43210, USA.							Barbour M. G., 1977, Terrestrial vegetation of California.; BOYER WD, 1973, ECOLOGY, V54, P420, DOI 10.2307/1934351; DURHAM OC, 1946, J ALLERGY, V17, P70, DOI 10.1016/0021-8707(46)90024-X; EBELL LF, 1964, DEP FOREST PUBLICATI, V1036, P30; Faegri K., 1964, TXB POLLEN ANAL, VSegunda Edn; FAIRLEY D, 1982, THESIS STANFORD; FARNHAM JE, 1982, N ENGL SOC ALLERGY P, V3, P320; GREGORY PH, 1973, MICROBIOLOGY ATMOSPH, P377; GRIFFIN JR, 1972, DISTRIBUTION FOREST, P114; HOWELL JT, 1970, MARIN FLORA, P114; HYDE HA, 1952, NEW PHYTOL, V51, P281, DOI 10.1111/j.1469-8137.1952.tb06137.x; Kozlowski T.T., 1971, GROWTH DEV TREES, V2, P514; KUCHLER AW, 1977, TERRESTRIAL VEGETATI, P1002; Lewis W.H., 1983, AIRBORNE ALLERGENIC, P254; MUNZ PA, 1965, CALIFORNIA FLORA, P1681; POHL F, 1937, BEIH BOT CENTRALBL, V56, P366; RAYNOR GS, 1970, J ALLERGY, V45, P329, DOI 10.1016/0021-8707(70)90041-9; SHARP WM, 1961, ECOLOGY, V42, P365, DOI 10.2307/1932087; SHELDON JM, 1967, MANUAL CLIN ALLERGY, P550; SOLOMON AM, 1979, AEROBIOLOGY ECOLOGIC, P386; Thomas JH., 1961, FLORA SANTA CRUZ MOU; THOMAS JT, 1958, FLORA SAN FRANCISCO, P157; ZENGER V, 1985, ANN ALLERGY, V55, P289	23	24	26	2	7	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1986	78	2					300	307		10.1016/S0091-6749(86)80080-X	http://dx.doi.org/10.1016/S0091-6749(86)80080-X			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	D7261	3734282	Bronze			2022-12-18	WOS:A1986D726100010
J	REED, CE				REED, CE			WHAT WE DO AND DO NOT KNOW ABOUT MOLD ALLERGY AND ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material											REED, CE (corresponding author), MAYO CLIN & MAYO FDN,DIV INTERNAL MED & ALLERG DIS,200 1ST ST SW,ROCHESTER,MN 55901, USA.							AGARWAL MK, 1984, J ALLERGY CLIN IMMUN, V74, P687, DOI 10.1016/0091-6749(84)90231-8; AGARWAL MK, 1981, J ALLERGY CLIN IMMUN, V68, P194, DOI 10.1016/0091-6749(81)90183-4; BURGE HA, 1982, J ALLERGY CLIN IMMUN, V70, P101, DOI 10.1016/0091-6749(82)90236-6; HABENICHT HA, 1984, J ALLERGY CLIN IMMUN, V74, P64, DOI 10.1016/0091-6749(84)90088-5; LICORISH K, 1985, J ALLERGY CLIN IMMUN, V76, P819, DOI 10.1016/0091-6749(85)90755-9; LONGBOTTOM JL, 1964, J PATHOL BACTERIOL, V88, P141, DOI 10.1002/path.1700880119; LOWENSTEIN H, 1977, INT ARCH ALLER A IMM, V55, P1, DOI 10.1159/000231900; Pratt Henry N., 1942, JOUR ALLERGY, V13, P227, DOI 10.1016/S0021-8707(42)90161-8; PRATT HENRY N., 1941, JOUR ALLERGY, V12, P431, DOI 10.1016/S0021-8707(41)90218-6; REED C, 1978, J ALLERGY CLIN IMMUN, V61, P227, DOI 10.1016/0091-6749(78)90189-6; SALVAGGIO J, 1971, J ALLERGY CLIN IMMUN, V48, P96, DOI 10.1016/0091-6749(71)90091-1; SALVAGGIO J, 1981, J ALLERGY CLIN IMMUN, V68, P327, DOI 10.1016/0091-6749(81)90131-7; SOLOMON WR, 1984, MOULD ALLERGY, P41; SOLOMON WR, 1980, J ALLERGY CLIN IMMUN, V65, P308; YUNGINGER JW, 1980, J ALLERGY CLIN IMMUN, V66, P138, DOI 10.1016/0091-6749(80)90061-5; YUNGINGER JW, 1976, J ALLERGY CLIN IMMUN, V58, P405, DOI 10.1016/0091-6749(76)90121-4	16	24	24	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1985	76	6					773	775		10.1016/0091-6749(85)90746-8	http://dx.doi.org/10.1016/0091-6749(85)90746-8			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AWX93	4067126				2022-12-18	WOS:A1985AWX9300002
J	BERNSTEIN, IL				BERNSTEIN, IL			CROMOLYN SODIUM IN THE TREATMENT OF ASTHMA - COMING OF AGE IN THE UNITED-STATES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											BERNSTEIN, IL (corresponding author), UNIV CINCINNATI, MED CTR, DEPT MED, DIV IMMUNOL, 231 BETHESDA AVE, CINCINNATI, OH 45267 USA.							ALTOUNYAN REC, 1980, CLIN ALLERGY, V10, P481, DOI 10.1111/j.1365-2222.1980.tb02162.x; ALTOUNYAN REC, 1970, DISODIUM CROMOGLYCAT, P47; ARCHER CB, 1985, AGENTS ACTIONS, V16, P6, DOI 10.1007/BF01999625; ATKINS PC, 1978, J ALLERGY CLIN IMMUN, V62, P149, DOI 10.1016/0091-6749(78)90099-4; BASRAN GS, 1984, BRIT J DIS CHEST, V78, P254, DOI 10.1016/0007-0971(84)90137-2; BENDOV I, 1983, AM REV RESPIR DIS, V127, P113, DOI 10.1164/arrd.1983.127.1.113; BENDOV I, 1984, ISRAEL J MED SCI, V20, P130; BERNSTEIN IL, 1981, J ALLERGY CLIN IMMUN, V68, P247; BROOKS CD, 1984, J ALLERGY CLIN IMMUN, V73, P584, DOI 10.1016/0091-6749(84)90515-3; BROWN K, 1982, 11TH P INT C ALL CLI; BUCKLEY JM, 1980, OCT P ANN M AM AC PE; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; COLLIER JG, 1984, BRIT J PHARMACOL, V81, P113, DOI 10.1111/j.1476-5381.1984.tb10750.x; COX JSG, 1967, NATURE, V216, P1328, DOI 10.1038/2161328a0; DEAL EC, 1980, J CLIN INVEST, V65, P659, DOI 10.1172/JCI109711; DIAZ P, 1984, J ALLERGY CLIN IMMUN, V74, P41, DOI 10.1016/0091-6749(84)90085-X; DICKSON W, 1979, MAST CELL ITS ROLE H, P343; DICKSON W, 1970, DISODIUM CROMOGLYCAT, P105; EDMUNDS AT, 1980, BRIT MED J, V281, P842, DOI 10.1136/bmj.281.6244.842; ENGSTROM I, 1977, SCAND J RESPIR DIS, P49; FULLER RW, 1983, CLIN SCI, V64, pP13; FURUKAWA CT, 1984, PEDIATRICS, V74, P453; HAMBLETON G, 1977, LANCET, V1, P381; HARRIES MG, 1981, LANCET, V1, P5; JOHNSON HG, 1983, ALLERGY PRINCIPLES P, V1, P613; JONES RM, 1983, BRIT J DIS CHEST, V77, P362, DOI 10.1016/0007-0971(83)90071-2; LATIMER KM, 1984, THORAX, V39, P277, DOI 10.1136/thx.39.4.277; LEE TH, 1984, AM REV RESPIR DIS, V129, P409; LEE TH, 1983, NEW ENGL J MED, V308, P1502, DOI 10.1056/NEJM198306233082504; LEITCH AG, 1984, ALLERGY, V39, P211, DOI 10.1111/j.1398-9995.1984.tb02626.x; LOWHAGEN O, 1985, J ALLERGY CLIN IMMUN, V75, P460, DOI 10.1016/S0091-6749(85)80018-X; MACDONALD TH, 1979, J INT MED RES, V7, P87; MAZUREK N, 1982, EMBO J, V1, P585, DOI 10.1002/j.1460-2075.1982.tb01212.x; NEWTH CJL, 1982, AUST NZ J MED, V12, P232, DOI 10.1111/j.1445-5994.1982.tb02467.x; NUMEROSO R, 1983, RESPIRATION, V44, P109, DOI 10.1159/000194536; PATEL KR, 1982, THORAX, V37, P663, DOI 10.1136/thx.37.9.663; PEPYS J, 1968, LANCET, V2, P134; PRENNER BM, 1982, ANN ALLERGY, V48, P254; RICHARDS IM, 1982, INT C BRONCHIAL HYPE, P29; RYO UY, 1976, JAMA-J AM MED ASSOC, V236, P927; SELCOW JE, 1983, ANN ALLERGY, V50, P13; SIMON R, 1984, Journal of Allergy and Clinical Immunology, V73, P136; SOUHRADA M, 1984, SCIENCE, V225, P723, DOI 10.1126/science.6087455; THEOHARIDES TC, 1980, SCIENCE, V207, P80, DOI 10.1126/science.6153130; WANNER A, 1979, AM J MED, V67, P477, DOI 10.1016/0002-9343(79)90797-6; WEINER P, 1984, ANN ALLERGY, V53, P186	46	24	24	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	2					381	388		10.1016/0091-6749(85)90658-X	http://dx.doi.org/10.1016/0091-6749(85)90658-X			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	APE89	3926853				2022-12-18	WOS:A1985APE8900022
J	GRAFFLONNEVIG, V; HEDLIN, G				GRAFFLONNEVIG, V; HEDLIN, G			THE EFFECT OF KETOTIFEN ON BRONCHIAL HYPERREACTIVITY IN CHILDHOOD ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									KAROLINSKA INST,HUDDINGE HOSP,PEDIAT CLIN,S-14104 HUDDINGE,SWEDEN	Karolinska Institutet	GRAFFLONNEVIG, V (corresponding author), SACHS CHILDREN HOSP,ALLERGOL SECT,SACHSGATAN 1,S-11669 STOCKHOLM,SWEDEN.							BEUMER HM, 1979, RESPIRATION, V37, P271, DOI 10.1159/000194038; BJURE J, 1963, ACTA PAEDIATR, V52, P232, DOI 10.1111/j.1651-2227.1963.tb03775.x; COCKCROFT DW, 1978, CLIN ALLERGY, V8, P361, DOI 10.1111/j.1365-2222.1978.tb00471.x; CSERHATI E, 1981, RESPIRATION S1, V42, P73; GIRARD JP, 1981, CLIN ALLERGY, V11, P449, DOI 10.1111/j.1365-2222.1981.tb01618.x; GRAFFLONNEVIG V, 1980, ALLERGY, V35, P341, DOI 10.1111/j.1398-9995.1980.tb01776.x; Kennedy G.R, 1982, RES CLIN FORUMS, V4, P17; KENNEDY JD, 1980, BRIT MED J, V281, P1458, DOI 10.1136/bmj.281.6253.1458; KLEIN G, 1981, RESPIRATION, V41, P128, DOI 10.1159/000194369; LILJA G, 1983, ALLERGY, V38, P31, DOI 10.1111/j.1398-9995.1983.tb00853.x; MARTIN U, 1978, ARZNEIMITTELFORSCH, V28-1, P770; Martin U, 1977, Monogr Allergy, V12, P145; MATTSON K, 1979, CLIN ALLERGY, V9, P495, DOI 10.1111/j.1365-2222.1979.tb02514.x; MATTSON K, 1979, CLIN ALLERGY, V9, P411, DOI 10.1111/j.1365-2222.1979.tb02500.x; MURRAY AB, 1981, J ALLERGY CLIN IMMUN, V68, P119, DOI 10.1016/0091-6749(81)90169-X; Ney UM, 1982, RES CLIN FORUMS, V4, P9; WARNER JO, 1982, CLIN ALLERGY, V12, P21; WUETHRICH B, 1978, INT J CLIN PHARM BI, V16, P424	18	24	24	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	1					59	63		10.1016/0091-6749(85)90805-X	http://dx.doi.org/10.1016/0091-6749(85)90805-X			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AMV84	3891826				2022-12-18	WOS:A1985AMV8400008
J	SIEGEL, SC; KATZ, RM; RACHELEFSKY, GS; BRANDON, ML; BORGEN, LA				SIEGEL, SC; KATZ, RM; RACHELEFSKY, GS; BRANDON, ML; BORGEN, LA			A PLACEBO-CONTROLLED TRIAL OF PROCATEROL - A NEW LONG-ACTING ORAL BETA-2-AGONIST IN BRONCHIAL-ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ALLERGY MED CLIN, LOS ANGELES, CA USA; ALLERGY MED GRP SAN DIEGO INC, SAN DIEGO, CA USA; WARNER LAMBERT PARKE DAVIS, PHARMACEUT RES, CLIN RES DEPT, ANN ARBOR, MI 48105 USA	Pfizer								[Anonymous], 1979, AM REV RESPIR DIS, V119, P831; AVERY WG, 1981, ANN ALLERGY, V47, P410; CAMPBELL AB, 1976, J PEDIATR-US, V89, P1020; CHERVINSKY P, 1978, ANN ALLERGY, V40, P189; DWYER JM, 1981, ANN ALLERGY, V47, P375; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; HYATT RE, 1958, J APPL PHYSIOL, V13, P331, DOI 10.1152/jappl.1958.13.3.331; KAMBUROFF P L, 1970, British Journal of Diseases of the Chest, V64, P46, DOI 10.1016/S0007-0971(70)80048-1; KREUKNIET J, 1971, SCAND J RESPIR DIS, V52, P137; LARSSON S, 1977, SCAND J RESPIR DIS, V58, P5; LARSSON S, 1977, J ALLERGY CLIN IMMUN, V59, P93, DOI 10.1016/0091-6749(77)90209-3; LEGGE JS, 1971, BRIT MED J, V1, P637, DOI 10.1136/bmj.1.5750.637; MARANETRA N, 1973, MED J AUSTRALIA, V1, P988, DOI 10.5694/j.1326-5377.1973.tb110855.x; NATHAN S P, 1979, Chest, V76, P384, DOI 10.1378/chest.76.4.384; NORN S, 1980, ALLERGY, V35, P549, DOI 10.1111/j.1398-9995.1980.tb01804.x; PATERSON JW, 1979, AM REV RESPIR DIS, V120, P1149; RACHELEFSKY GS, 1982, PEDIATRICS, V69, P397; SVEDMYR NLV, 1976, CHEST, V69, P479, DOI 10.1378/chest.69.4.479; TAKAYANAGI I, 1977, J PHARM PHARMACOL, V29, P187, DOI 10.1111/j.2042-7158.1977.tb11284.x; WOLFE JD, 1978, NEW ENGL J MED, V298, P363, DOI 10.1056/NEJM197802162980703; YOSHIZAKI S, 1976, J MED CHEM, V19, P1138, DOI 10.1021/jm00231a011; ZANETTI CL, 1982, J CLIN PHARMACOL, V22, P250, DOI 10.1002/j.1552-4604.1982.tb02669.x	22	24	25	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	75	6					698	705		10.1016/0091-6749(85)90096-X	http://dx.doi.org/10.1016/0091-6749(85)90096-X			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ALA84	2861219				2022-12-18	WOS:A1985ALA8400011
J	WEINBERGER, M; HENDELES, L				WEINBERGER, M; HENDELES, L			THEOPHYLLINE USE - AN OVERVIEW	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV FLORIDA,PEDIAT PHARMACOKINET CONSULTAT SERV,GAINESVILLE,FL 32611	State University System of Florida; University of Florida	WEINBERGER, M (corresponding author), UNIV IOWA,HOSP & CLIN,JCP,DEPT PEDIAT,DIV PEDIAT ALLERGY & PULM,IOWA CITY,IA 52242, USA.		Weinberger, Miles/H-6743-2019		NCRR NIH HHS [RR-59] Funding Source: Medline; NIAID NIH HHS [AI-16141-01] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CAMPBELL IA, 1979, CURR MED RES OPIN, V6, P85, DOI 10.1185/03007997909115914; DUSDIEKER L, 1982, J PEDIATR-US, V101, P281; FREIMAN JA, 1978, NEW ENGL J MED, V299, P690, DOI 10.1056/NEJM197809282991304; FURUKAWA CT, 1984, PEDIATRICS, V74, P453; HAMBLETON G, 1977, LANCET, V1, P381; HENDELES L, 1984, CLIN PHARMACOKINET, V9, P95, DOI 10.2165/00003088-198409020-00001; HENDELES L, 1983, PHARMACOTHERAPY, V3, P2; HENDELES L, 1983, IMMUNOL ALLERGY PRAC, V5, P300; JOAD J, 1985, J ALLERGY CLIN IMMUN, V75, P113, DOI 10.1016/0091-6749(85)90170-8; NASSIF EG, 1981, J PEDIATR-US, V98, P158; NASSIF EG, 1981, NEW ENGL J MED, V304, P71, DOI 10.1056/NEJM198101083040202; SARRAZIN E, 1980, J PEDIATR-US, V97, P825, DOI 10.1016/S0022-3476(80)80280-0; SHAPIRO GG, 1981, PEDIATRICS, V67, P508; WEINBERG.MM, 1974, J PEDIATR-US, V84, P421; WEINBERGER M, 1975, CLIN PHARMACOL THER, V17, P585; WEINBERGER M, 1984, J ALLERGY CLIN IMMUN, V73, P525, DOI 10.1016/0091-6749(84)90505-0; WEINBERGER M, 1983, NEW ENGL J MED, V308, P760, DOI 10.1056/NEJM198303313081306; WEINBERGER M, 1978, J PEDIATR-US, V92, P1, DOI 10.1016/S0022-3476(78)80058-4; WOLFE JD, 1978, NEW ENGL J MED, V298, P363, DOI 10.1056/NEJM197802162980703	19	24	24	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	2					277	284		10.1016/0091-6749(85)90642-6	http://dx.doi.org/10.1016/0091-6749(85)90642-6			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	APE89	2862172	Bronze			2022-12-18	WOS:A1985APE8900006
J	BIERMAN, CW				BIERMAN, CW			A COMPARISON OF LATE REACTIONS TO ANTIGEN AND EXERCISE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV WASHINGTON,SCH MED,DEPT PEDIAT,SEATTLE,WA 98195	University of Washington; University of Washington Seattle	BIERMAN, CW (corresponding author), CHILDRENS ORTHOPED HOSP & MED CTR,DIV ALLERGY,SEATTLE,WA 98105, USA.							ATKINS PC, 1977, ANN INTERN MED, V86, P415, DOI 10.7326/0003-4819-86-4-415; BIERMAN CW, 1980, J ALLERGY CLIN IMMUN, V65, P206; BOOIJ-NOORD H, 1972, Clinical Allergy, V2, P43, DOI 10.1111/j.1365-2222.1972.tb01267.x; BOOIJNOORD H, 1971, J ALLERGY CLIN IMMUN, V48, P344, DOI 10.1016/0091-6749(71)90080-7; BOULET LP, 1983, J ALLERGY CLIN IMMUN, V71, P399, DOI 10.1016/0091-6749(83)90069-6; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; COCKCROFT DW, 1983, LANCET, V2, P253; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; FELDMAN CH, 1982, AM REV RESPIR DIS, V125, P195; HARGREAVE FE, 1974, CAN MED ASSOC J, V110, P415; HARGREAVE FE, 1980, AIRWAY REACTIVITY ME, P145; HERXHEIMER H, 1952, INT ARCH ALLER A IMM, V3, P323, DOI 10.1159/000227979; KAY AB, 1982, J ALLERGY CLIN IMMUN, V70, P317, DOI 10.1016/0091-6749(82)90019-7; LEE TH, 1982, J ALLERGY CLIN IMMUN, V70, P73, DOI 10.1016/0091-6749(82)90232-9; LEE TH, 1983, NEW ENGL J MED, V308, P1502, DOI 10.1056/NEJM198306233082504; NAGY L, 1982, NEW ENGL J MED, V306, P497, DOI 10.1056/NEJM198203043060901; PAPAGEORGIOU N, 1983, LANCET, V2, P1220; Pepys J, 1973, Clin Allergy, V3, P1, DOI 10.1111/j.1365-2222.1973.tb01304.x; ROBERTSON DG, 1974, J ALLERGY CLIN IMMUN, V54, P244, DOI 10.1016/0091-6749(74)90067-0; SCHENKEL E, 1982, J ALLERGY CLIN IMMUN, V70, P321, DOI 10.1016/0091-6749(82)90020-3; VANLOOKERENCAMP.JG, 1969, SCAND J RESPIR DIS, V50, P76	22	24	24	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	5					654	659		10.1016/0091-6749(84)90300-2	http://dx.doi.org/10.1016/0091-6749(84)90300-2			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SS046	6201523				2022-12-18	WOS:A1984SS04600007
J	KEYZER, JJ; KAUFFMAN, HF; DEMONCHY, JGR; KEYZERUDDING, JJ; DEVRIES, K				KEYZER, JJ; KAUFFMAN, HF; DEMONCHY, JGR; KEYZERUDDING, JJ; DEVRIES, K			URINARY N-TAU-METHYLHISTAMINE DURING EARLY AND LATE ALLERGEN-INDUCED BRONCHIAL-OBSTRUCTIVE REACTIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									STATE UNIV GRONINGEN HOSP, CENT LAB CLIN CHEM, 9713 EZ GRONINGEN, NETHERLANDS; STATE UNIV GRONINGEN HOSP, DEPT ALLERGOL, INTERNAL MED CLIN, 9713 EZ GRONINGEN, NETHERLANDS; DEPT CHRON OBSTRUCT LUNG DIS, HAREN, NETHERLANDS	University of Groningen; University of Groningen								ALLEN DH, 1979, CHEST, V75, P235; AUSTEN KF, 1975, AM REV RESPIR DIS, V112, P423; BOOYNOORD H, 1971, J ALLERGY CLIN IMMUN, V48, P344; BOOYNOORD H, 1972, CLIN ALLERGY, V2, P43; BOUSHEY HA, 1980, AM REV RESPIR DIS, V121, P389; BROWN MJ, 1982, J ALLERGY CLIN IMMUN, V69, P20, DOI 10.1016/0091-6749(82)90082-3; CHASSON A L, 1960, Tech Bull Regist Med Technol, V30, P207; COCKCROFT DW, 1979, AM REV RESPIR DIS, V120, P1053; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; FAIRFAX AJ, 1983, CLIN EXP IMMUNOL, V52, P393; FINDLAY SR, 1980, AM REV RESPIR DIS, V122, P53; GLEICH GJ, 1980, J ALLERGY CLIN IMMUN, V66, P295, DOI 10.1016/0091-6749(80)90024-X; GOKEMEYER JDM, 1976, THESIS GRONINGEN; GRANERUS G, 1980, ALLERGY, V35, P31, DOI 10.1111/j.1398-9995.1980.tb01714.x; IND PW, 1982, AGENTS ACTIONS, V12, P12, DOI 10.1007/BF01965099; IND PW, 1983, CLIN ALLERGY, V13, P61, DOI 10.1111/j.1365-2222.1983.tb02568.x; KAUFFMAN HF, 1983, CLIN ALLERGY, V13, P219, DOI 10.1111/j.1365-2222.1983.tb02591.x; KEYZER JJ, 1983, NEW ENGL J MED, V309, P1603, DOI 10.1056/NEJM198312293092603; KEYZER JJ, 1981, CLIN CHIM ACTA, V113, P165, DOI 10.1016/0009-8981(81)90150-9; KEYZER JJ, 1983, J CHROMATOGR, V275, P261, DOI 10.1016/S0378-4347(00)84373-X; KEYZER JJ, 1984, DIAGN IMAG CLIN MED, V53, P67; KEYZER JJ, AGENTS ACTIONS; Lee T H, 1983, Agents Actions Suppl, V13, P273; LEE TH, 1983, NEW ENGL J MED, V308, P1502, DOI 10.1056/NEJM198306233082504; LICHTENSTEIN ML, 1977, ASTHMA PHYSL IMMUNOP; LILJA B, 1960, J ALLERGY, V31, P492, DOI 10.1016/0021-8707(60)90083-6; LILJA B, 1961, BRIT J PHARM CHEMOTH, V16, P203, DOI 10.1111/j.1476-5381.1961.tb00314.x; LOWHAGEN O, 1980, ALLERGY, V35, P521, DOI 10.1111/j.1398-9995.1980.tb01799.x; MARTIN GL, 1980, J ALLERGY CLIN IMMUN, V66, P204, DOI 10.1016/0091-6749(80)90040-8; MEURS H, 1982, J ALLERGY CLIN IMMUN, V70, P272, DOI 10.1016/0091-6749(82)90063-X; NAGY L, 1982, NEW ENGL J MED, V306, P497, DOI 10.1056/NEJM198203043060901; NARASBHAT K, 1976, J ALLERGY CLIN IMMUN, V58, P647, DOI 10.1016/0091-6749(76)90176-7; NEIJENS HJ, 1979, J ALLERGY CLIN IMMUN, V64, P507, DOI 10.1016/0091-6749(79)90060-5; PEPYS J, 1975, AM REV RESPIR DIS, V112, P829; VANLOOKERENCAMP.JG, 1969, SCAND J RESPIR DIS, V50, P76; WARNER JO, 1976, ARCH DIS CHILD, V51, P905, DOI 10.1136/adc.51.12.905	36	24	24	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	3					240	245		10.1016/0091-6749(84)90252-5	http://dx.doi.org/10.1016/0091-6749(84)90252-5			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TJ808	6470358				2022-12-18	WOS:A1984TJ80800004
J	MARCUS, AJ; SAFIER, LB; BROEKMAN, MJ; ULLMAN, HL; ISLAM, N; SORRELL, TC; SERHAN, CN; WEISSMANN, G; OGLESBY, TD; GORMAN, RR				MARCUS, AJ; SAFIER, LB; BROEKMAN, MJ; ULLMAN, HL; ISLAM, N; SORRELL, TC; SERHAN, CN; WEISSMANN, G; OGLESBY, TD; GORMAN, RR			PRODUCTION OF METABOLIC PRODUCTS OF ARACHIDONIC-ACID DURING CELL-CELL INTERACTIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CORNELL UNIV,MED CTR,COLL MED,DEPT MED,DIV HEMATOL ONCOL,NEW YORK,NY 10021; NYU,SCH MED,DEPT MED,DIV RHEUMATOL,NEW YORK,NY 10003; UPJOHN CO,DEPT EXPTL SCI,KALAMAZOO,MI 49001	Cornell University; New York University; Pfizer	MARCUS, AJ (corresponding author), VET ADM MED CTR,DEPT MED,DIV HEMATOL ONCOL,NEW YORK,NY 10010, USA.		Sorrell, Tania/AAZ-5286-2020; Weissmann, Gerald/N-5273-2015	Weissmann, Gerald/0000-0002-4285-4552; Sorrell, Tania/0000-0001-9460-0960	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL029034, P50HL018828] Funding Source: NIH RePORTER; NCRR NIH HHS [RR 05396] Funding Source: Medline; NHLBI NIH HHS [HL 18828-08, HL 29034] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		MARCUS AJ, 1984, P NATL ACAD SCI-BIOL, V81, P903, DOI 10.1073/pnas.81.3.903; MARCUS AJ, 1978, J LIPID RES, V19, P793; MARCUS AJ, 1983, STROKE, V14, P475, DOI 10.1161/01.STR.14.4.475; MARCUS AJ, 1980, J CLIN INVEST, V66, P979, DOI 10.1172/JCI109967; MARCUS AJ, 1982, BIOCHEM BIOPH RES CO, V109, P130, DOI 10.1016/0006-291X(82)91575-3; MARCUS AJ, 1983, METHODS HAEMATOLOGY, V8, P126; MARX JL, 1983, SCIENCE, V221, P1362, DOI 10.1126/science.6604316; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011	8	24	24	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	3					338	342		10.1016/0091-6749(84)90126-X	http://dx.doi.org/10.1016/0091-6749(84)90126-X			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TQ633	6088611	Bronze			2022-12-18	WOS:A1984TQ63300006
J	NORMAN, PS; KING, TP; ALEXANDER, JF; KAGEYSOBOTKA, A; LICHTENSTEIN, LM				NORMAN, PS; KING, TP; ALEXANDER, JF; KAGEYSOBOTKA, A; LICHTENSTEIN, LM			IMMUNOLOGICAL RESPONSES TO CONJUGATES OF ANTIGEN-E IN PATIENTS WITH RAGWEED HAY-FEVER	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ROCKEFELLER UNIV,NEW YORK,NY 10021	Rockefeller University	NORMAN, PS (corresponding author), JOHNS HOPKINS UNIV,GOOD SAMARITAN HOSP,DEPT MED,DIV CLIN IMMUNOL,BALTIMORE,MD 21239, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI017021] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 08466, AI 17021, AI 10506] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABUCHOWSKI A, 1977, J BIOL CHEM, V252, P357; CHIORAZZI N, 1976, P NATL ACAD SCI USA, V73, P2091, DOI 10.1073/pnas.73.6.2091; HAMILTON RG, 1979, J IMMUNOL, V122, P1073; KATZ DH, 1971, J EXP MED, V134, P201, DOI 10.1084/jem.134.1.201; KING TP, 1981, INT ARCH ALLER A IMM, V66, P439, DOI 10.1159/000232852; KING TP, 1981, ARCH BIOCHEM BIOPHYS, V212, P127, DOI 10.1016/0003-9861(81)90351-9; KING TP, 1979, J EXP MED, V149, P42; KING TP, 1980, INT J PEPT PROTEIN R, V15, P147; LEE WY, 1977, NATURE, V267, P618, DOI 10.1038/267618a0; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; LIU FT, 1979, P NATL ACAD SCI USA, V76, P1430, DOI 10.1073/pnas.76.3.1430; MAY CD, 1970, J ALLERGY, V46, P12, DOI 10.1016/0021-8707(70)90056-0; NORMAN PS, 1982, PROG ALLERGY, V32, P318; NORMAN PS, 1980, J ALLERGY CLIN IMMUN, V66, P336, DOI 10.1016/0091-6749(80)90030-5; NORMAN PS, 1965, J ALLERGY, V36, P284, DOI 10.1016/0021-8707(65)90087-0; SCHELLENBERG RR, 1975, J IMMUNOL, V115, P1577; SEHON AH, 1982, PROG ALLERGY, V32, P161; SIRAGANIAN RP, 1974, ANAL BIOCHEM, V57, P383, DOI 10.1016/0003-2697(74)90093-1; SOBOTKA AK, 1978, J IMMUNOL, V121, P2477; SOBOTKA AK, 1976, J IMMUNOL, V117, P84; WIE SI, 1981, INT ARCH ALLER A IMM, V64, P84, DOI 10.1159/000232678	21	24	25	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	6					782	789		10.1016/0091-6749(84)90448-2	http://dx.doi.org/10.1016/0091-6749(84)90448-2			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SV829	6725790				2022-12-18	WOS:A1984SV82900004
J	CORN, M				CORN, M			ASSESSMENT AND CONTROL OF ENVIRONMENTAL EXPOSURE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											CORN, M (corresponding author), JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DIV ENVIRONM HLTH ENGN,BALTIMORE,MD 21205, USA.							CORN M, 1979, AM IND HYG ASSOC J, V40, P47, DOI 10.1080/15298667991429318; CORN M, 1971, Environmental Letters, V1, P29; CORN M, 1976, AIR POLLUTION, V1, P77; CORN M, 1981, CHEST S, V79, P91; CORN M, 1981, RECENT ADV OCCUPATIO, P200; CORN M, 1978, AM LABORATORY    JUL; CORN M, ENG CONTROLS OCCUPAT; HAMMAD Y, 1981, OCCUPATIONAL LUNG DI, P291; LARSEN R I, 1969, Journal of the Air Pollution Control Association, V19, P24; LAWANGA S, 1978, B WHO, V56, P713; LEIDEL NA, 1977, US DHEW NIOSH77173 P; LIPPMAN M, 1971, INHALED PARTICLES, V3; LIPPMAN M, 1978, AIR SAMPLING INSTRUM; LIPPMANN M, 1970, AM IND HYG ASSOC J, V31, P138, DOI 10.1080/0002889708506223; LIPPMANN M., 1962, HEALTH PHYS, V8, P155, DOI 10.1097/00004032-196204000-00010; Lynch J. R., 1979, PATTYS IND HYGIENE T, VIII, P217; Mercer T, 2012, AEROSOL TECHNOLOGY H; MILLER FJ, 1979, JAPCA J AIR WASTE MA, V29, P610, DOI 10.1080/00022470.1979.10470831; MUIR DCF, 1972, CLINICAL ASPECTS INH, pCH1; PETERSEN JE, 1973, IND ENV ITS CONTROL, pCH25; Stern A.C., 1976, AIR POLLUTION; 1966, HLTH PHYS, V12, P181; 1981, AM IND HYG ASS J, V42, P64; 1982, AM C GOVT IND HYGIEN; 1983, USDOL OSHA48FR7473 P	25	24	24	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	72	3					231	241		10.1016/0091-6749(83)90026-X	http://dx.doi.org/10.1016/0091-6749(83)90026-X			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RH938	6886257	Bronze			2022-12-18	WOS:A1983RH93800002
J	EVANS, R				EVANS, R			VARIABILITY IN THE MEASUREMENT OF SPECIFIC IMMUNOGLOBULIN-E ANTIBODY BY THE RAST PROCEDURE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material											EVANS, R (corresponding author), WALTER REED ARMY MED CTR,ALLERGY CLIN IMMUNOL SERV,WASHINGTON,DC 20012, USA.							LUNDKVIST U, 1975, ADV DIAGNOSIS ALLERG, P85; NALEBUFF DJ, 1979, CONT ED FAM PHYSICIA, V10, P64; ZEISS CR, 1981, J ALLERGY CLIN IMMUN, V67, P105, DOI 10.1016/0091-6749(81)90004-X	3	24	24	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	69	2					245	252		10.1016/0091-6749(82)90106-3	http://dx.doi.org/10.1016/0091-6749(82)90106-3			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NC581	7056955				2022-12-18	WOS:A1982NC58100012
J	STROBER, W				STROBER, W			THE REGULATION OF MUCOSAL IMMUNE-SYSTEM	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											STROBER, W (corresponding author), NCI,METAB BRANCH,IMMUNOPHYSIOL SECT,BETHESDA,MD 20205, USA.							BLOCH KJ, 1973, J IMMUNOL, V110, P197; CANTOR HM, 1967, NATURE, V215, P744, DOI 10.1038/215744a0; CHALLACOMBE SJ, 1980, J EXP MED, V152, P1459, DOI 10.1084/jem.152.6.1459; CHALON MP, 1979, EUR J IMMUNOL, V9, P747, DOI 10.1002/eji.1830091002; CUNNINGHAMRUNDLES C, 1978, P NATL ACAD SCI USA, V75, P3387, DOI 10.1073/pnas.75.7.3387; DURKIN HG, 1981, J EXP MED, V154, P640, DOI 10.1084/jem.154.3.640; ELSON CO, 1981, GASTROENTEROLOGY, V80, P1513; GERMAIN RN, 1981, SCAND J IMMUNOL, V13, P1, DOI 10.1111/j.1365-3083.1981.tb00104.x; HIRASHIMA M, 1980, J IMMUNOL, V125, P1442; KAGNOFF MF, 1978, CELL IMMUNOL, V40, P186, DOI 10.1016/0008-8749(78)90326-X; KAWANISHI H, 1982, J IMMUNOL        AUG; MCGHEE JR, 1980, J IMMUNOL, V124, P1603; NGAN J, 1978, J IMMUNOL, V120, P861; RICHMAN LK, 1981, J IMMUNOL, V126, P2079; RICHMAN LK, 1979, J IMMUNOL, V123, P2602; SOOTHILL JF, 1976, CLIN ALLERGY, V6, P305, DOI 10.1111/j.1365-2222.1976.tb01911.x; SUEMURA M, 1980, J IMMUNOL, V125, P148; SUEMURA M, 1979, J IMMUNOL, V123, P918; WALKER WA, 1981, IMMUNOL TODAY, V2, P30, DOI 10.1016/0167-5699(81)90032-3	19	24	24	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	70	4					225	230		10.1016/0091-6749(82)90057-4	http://dx.doi.org/10.1016/0091-6749(82)90057-4			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PL151	6214574				2022-12-18	WOS:A1982PL15100001
J	EPSTEIN, WL; BYERS, VS; BAER, H				EPSTEIN, WL; BYERS, VS; BAER, H			INDUCTION OF PERSISTENT TOLERANCE TO URUSHIOL IN HUMANS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									BUR BIOL,BETHESDA,MD		EPSTEIN, WL (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT DERMATOL,SAN FRANCISCO,CA 94143, USA.				NIAID NIH HHS [AI-12947] Funding Source: Medline; PHS HHS [43-68-632, 223-77-1201] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BAER H, 1963, SCIENCE, V140, P1211, DOI 10.1126/science.140.3572.1211; BALDWIN WH, UNPUBLISHED; BOWSER RT, 1963, J IMMUNOL, V91, P791; BYERS, 1979, J CLIN INVESTIGATION, V64, P1437; Clarke J. R., 1942, JOUR ALLERGY, V13, P599, DOI 10.1016/S0021-8707(42)90073-X; EPSTEIN WL, 1974, CUTIS, V13, P544; EPSTEIN WL, 1974, ARCH DERMATOL, V109, P356, DOI 10.1001/archderm.109.3.356; EPSTEIN WL, 1956, JAMA-J AM MED ASSOC, V162, P95, DOI 10.1001/jama.1956.02970190011003; FORSTROM L, 1980, CONTACT DERMATITIS, V6, P241, DOI 10.1111/j.1600-0536.1980.tb04922.x; KLIGMAN AM, 1958, ARCH DERMATOL, V78, P47, DOI 10.1001/archderm.1958.01560070051008; LOWNEY ED, 1973, J INVEST DERMATOL, V61, P90, DOI 10.1111/1523-1747.ep12675416; SIMON CA, 1937, J INVEST DERMATOL, V2, P143; Spain WC, 1922, J IMMUNOL, V7, P179; SUGAI T, 1979, CONTACT DERMATITIS, V5, P383, DOI 10.1111/j.1600-0536.1979.tb04910.x	14	24	26	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	68	1					20	25		10.1016/0091-6749(81)90118-4	http://dx.doi.org/10.1016/0091-6749(81)90118-4			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LY101	7240596				2022-12-18	WOS:A1981LY10100004
J	SPECTOR, SL; LOTAN, A; ENGLISH, G; PHILPOT, I				SPECTOR, SL; LOTAN, A; ENGLISH, G; PHILPOT, I			COMPARISON BETWEEN TRANS-ILLUMINATION AND THE ROENTGENOGRAM IN DIAGNOSING PARA-NASAL SINUS DISEASE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											SPECTOR, SL (corresponding author), NATL JEWISH HOSP & RES CTR,DENVER,CO 80206, USA.							BALLANTYNE J C, 1949, J Laryngol Otol, V63, P337, DOI 10.1017/S0022215100046557; BERMAN SZ, 1974, J ALLERGY CLIN IMMUN, V53, P311, DOI 10.1016/0091-6749(74)90111-0; BOOTH BH, 1972, ALLERGIC DISEASES DI, P72; BURTOFF S, 1947, ARCH OTOLARYNGOL, V45, P516; FASCENELLI FW, 1969, ARCH OTOLARYNGOL, V90, P98; MCNEILL AR, 1963, J LARYNGOL OTOL, V77, P1009; SMITH MEN, 1961, J LARYNGOL OTOL, V75, P93; SOLOMON WR, 1967, MANUAL CLIN ALLERGY, P40; SPECTOR SL, 1976, OTOLARYNGOLOGY TXB, P291; VUROINEN P, 1962, J LARYNGOL, V76, P359	10	24	24	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	67	1					22	26		10.1016/0091-6749(81)90040-3	http://dx.doi.org/10.1016/0091-6749(81)90040-3			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KZ173	7451769				2022-12-18	WOS:A1981KZ17300005
J	SEHON, AH; LEE, WY				SEHON, AH; LEE, WY			SUPPRESSION OF IMMUNOGLOBULIN-E ANTIBODIES WITH MODIFIED ALLERGENS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											SEHON, AH (corresponding author), UNIV MANITOBA,FAC MED,DEPT IMMUNOL,MRC,ALLERGY RES GRP,WINNIPEG R3E 0W3,MANITOBA,CANADA.								0	24	24	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	64	4					242	250		10.1016/0091-6749(79)90139-8	http://dx.doi.org/10.1016/0091-6749(79)90139-8			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HQ469	479475				2022-12-18	WOS:A1979HQ46900003
J	WELSH, PW; YUNGINGER, JW; TANI, DG; TOUSSAINT, NF; LARSON, LA; BOURNE, WM; GLEICH, GJ				WELSH, PW; YUNGINGER, JW; TANI, DG; TOUSSAINT, NF; LARSON, LA; BOURNE, WM; GLEICH, GJ			TOPICAL OCULAR ADMINISTRATION OF CROMOLYN SODIUM FOR TREATMENT IN SEASONAL RAGWEED CONJUNCTIVITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MAYO CLIN & MAYO FDN,DEPT INTERNAL MED,ROCHESTER,MN 55901; MAYO CLIN & MAYO FDN,DEPT OPHTHALMOL,ROCHESTER,MN 55901; MAYO CLIN & MAYO FDN,DEPT IMMUNOL,ROCHESTER,MN 55901; UNIV MINNESOTA,MAYO GRAD SCH MED,ROCHESTER,MN 55901	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; University of Minnesota System; University of Minnesota Rochester	WELSH, PW (corresponding author), MAYO CLIN & MAYO FDN,DEPT PEDIAT,ALLERG DIS RES LAB,ROCHESTER,MN 55901, USA.							DIXON WJ, 1969, INTRO STATISTICAL AN, P341; EASTY D L, 1972, Clinical Allergy, V2, P99, DOI 10.1111/j.1365-2222.1972.tb01274.x; GLEICH GJ, 1977, J ALLERGY CLIN IMMUN, V60, P188, DOI 10.1016/0091-6749(77)90123-3; GREENBAUM J, 1977, J ALLERGY CLIN IMMUN, V59, P437, DOI 10.1016/0091-6749(77)90006-9; KAZDAN JJ, 1976, CAN J OPHTHALMOL, V11, P300; LEIFERMAN KM, 1975, J ALLERGY CLIN IMMUN, V56, P481, DOI 10.1016/0091-6749(75)90066-4; OGDEN EC, 1967, J ALLERGY, V40, P1, DOI 10.1016/0021-8707(67)90053-6; RICHARDSON KT, 1975, S GLAUCOMA MEMBRANE, P50; WELSH PW, 1977, J ALLERGY CLIN IMMUN, V60, P104, DOI 10.1016/0091-6749(77)90034-3	9	24	24	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	64	3					209	215		10.1016/0091-6749(79)90097-6	http://dx.doi.org/10.1016/0091-6749(79)90097-6			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HL221	112137	Bronze			2022-12-18	WOS:A1979HL22100009
J	ANDERSON, CT; ROUMIANTZEFF, M; KNIKER, WT				ANDERSON, CT; ROUMIANTZEFF, M; KNIKER, WT			MULTITEST SYSTEM FOR ASSAY OF DELAYED CUTANEOUS HYPERSENSITIVITY (DCH) TO UBIQUITOUS ANTIGENS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	24	24	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	61	3					167	167		10.1016/0091-6749(78)90367-6	http://dx.doi.org/10.1016/0091-6749(78)90367-6			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ES173					2022-12-18	WOS:A1978ES17300128
J	BACAL, E; PATTERSON, R				BACAL, E; PATTERSON, R			LONG-TERM EFFECTS OF BECLOMETHASONE DIPROPIONATE ON PREDNISONE DOSAGE IN CORTICOSTEROID-DEPENDENT ASTHMATIC	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NORTHWESTERN UNIV,SCH MED,DEPT MED,ALLERGY IMMUNOL SECT,CHICAGO,IL 60611	Northwestern University								AXELROD L, 1976, MEDICINE, V55, P39, DOI 10.1097/00005792-197601000-00003; BROWN HM, 1972, BRIT MED J, V1, P585, DOI 10.1136/bmj.1.5800.585; CAMERON SJ, 1973, BRIT MED J, V4, P205, DOI 10.1136/bmj.4.5886.205; CLARK TJH, 1972, LANCET, V1, P1361; COOPER BJ, 1976, J ALLERGY CLIN IMMUN, V58, P635, DOI 10.1016/0091-6749(76)90175-5; DAVIES G, 1977, ANN INTERN MED, V86, P549, DOI 10.7326/0003-4819-86-5-549; DICKSON W, 1973, ARCH DIS CHILD, V48, P671, DOI 10.1136/adc.48.9.671; GADDIE J, 1973, LANCET, V1, P691; GODFREY S, 1974, ARCH DIS CHILD, V49, P591, DOI 10.1136/adc.49.8.591; HODSON ME, 1974, AM REV RESPIR DIS, V110, P403; LAL S, 1972, BMJ-BRIT MED J, V3, P314, DOI 10.1136/bmj.3.5822.314; LOVERA J, 1976, J ALLERGY CLIN IMMUN, V57, P112, DOI 10.1016/0091-6749(76)90030-0; MABERLY DJ, 1973, BRIT MED J, V1, P778, DOI 10.1136/bmj.1.5856.778; TOOGOOD JH, 1977, J ALLERGY CLIN IMMUN, V59, P298, DOI 10.1016/0091-6749(77)90051-3; VOGT F, 1976, J ALLERGY CLIN IMMUN, V58, P316, DOI 10.1016/0091-6749(76)90137-8	15	24	24	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	62	2					72	75		10.1016/0091-6749(78)90081-7	http://dx.doi.org/10.1016/0091-6749(78)90081-7			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FL835	670607				2022-12-18	WOS:A1978FL83500001
J	LEHRER, SB; WILSON, MR; SALVAGGIO, JE				LEHRER, SB; WILSON, MR; SALVAGGIO, JE			IMMUNOGENIC PROPERTIES OF TOBACCO-SMOKE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											LEHRER, SB (corresponding author), TULANE MED CTR,CLIN IMMUNOL SECT,1700 PERDIDO ST,NEW ORLEANS,LA 70111, USA.							BECKER CG, 1976, P NATL ACAD SCI USA, V73, P1712, DOI 10.1073/pnas.73.5.1712; HARKAVY J, 1968, ANN ALLERGY, V26, P447; KELLER KF, 1976, J ALLERGY CLIN IMMUN, V57, P278, DOI 10.1016/0091-6749(76)90047-6; LEHRER SB, 1978, FED PROC, V37, P1456; MCDOUGALL JC, 1976, J ALLERGY CLIN IMMUN, V57, P237; SAVEL H, 1970, ARCH ENVIRON HEALTH, V21, P146, DOI 10.1080/00039896.1970.10667212; SLAVIN RG, 1972, ALLERGIC DISEASE DIA, P500; SPEER F, 1968, ARCH ENVIRON HEALTH, V16, P443, DOI 10.1080/00039896.1968.10665084; TAYLOR G, 1974, ENV TOBACCO SMOKE EF, P50; ZUSSMAN BM, 1974, J ASTHMA RES, V11, P159, DOI 10.3109/02770907409100294	10	24	24	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	62	6					368	370		10.1016/0091-6749(78)90138-0	http://dx.doi.org/10.1016/0091-6749(78)90138-0			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GA292	81845				2022-12-18	WOS:A1978GA29200009
J	DESHAZO, RD; LEVINSON, AI; BOEHM, T; EVANS, R; WARD, G				DESHAZO, RD; LEVINSON, AI; BOEHM, T; EVANS, R; WARD, G			SEVERE PERSISTENT BIPHASIC LOCAL (IMMEDIATE AND LATE) SKIN REACTIONS TO INSULIN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									WALTER REED ARMY INST RES, ALLERGY & CLIN IMMUNOL SERV, WASHINGTON, DC 20012 USA; WALTER REED ARMY INST RES, ENDOCRINOL SERV, WASHINGTON, DC 20012 USA	United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR)								DOLGER H, 1952, MED CLIN N AM, P783, DOI 10.1016/S0025-7125(16)35145-8; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; GALLOWAY JA, 1975, ENDOCRINOLOGY DIABET; HANAUER L, 1961, DIABETES, V10, P105, DOI 10.2337/diab.10.2.105; LAMKIN N, 1976, J ALLERGY CLIN IMMUN, V58, P213, DOI 10.1016/0091-6749(76)90157-3; LEVINSON AI, 1974, CELL IMMUNOL, V14, P321, DOI 10.1016/0008-8749(74)90216-0; LIEBERMAN P, 1971, J AMER MED ASSOC, V215, P1106; MAY CD, 1970, J ALLERGY, V46, P12, DOI 10.1016/0021-8707(70)90056-0; MINARS N, 1975, J ALLERGY CLIN IMMUN, V56, P411, DOI 10.1016/0091-6749(75)90135-9; PALEY RG, 1952, DIABETES, V1, P22, DOI 10.2337/diab.1.1.22; PALMER DF, 1972, HSM728102 DHEW PUBL; Wright P H, 1966, Diabetologia, V2, P178, DOI 10.1007/BF01222068	12	24	25	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	59	2					161	164		10.1016/0091-6749(77)90219-6	http://dx.doi.org/10.1016/0091-6749(77)90219-6			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CV622	319142				2022-12-18	WOS:A1977CV62200011
J	SCHWARTZ, RH; VANESS, JD; JOHNSTONE, DE; DREYFUSS, EM; ABRISHAMI, MA; CHAI, H				SCHWARTZ, RH; VANESS, JD; JOHNSTONE, DE; DREYFUSS, EM; ABRISHAMI, MA; CHAI, H			ALPHA-1 ANTITRYPSIN IN CHILDHOOD ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV ROCHESTER,SCH MED & DENT,DEPT PEDIAT,ROCHESTER,NY 14627; CHILDRENS ASTHMA RES INST & HOSP,DENVER,CO 80204	University of Rochester								ARNAUD P, 1976, CLIN RES, V24, pA488; ASCOLI M, 1903, BERL KLIN WSCHR, V40, P391; ERIKSSON S, 1965, ACTA MED SCAND     S, V177, P432; FAGERHOL MK, 1969, ACTA ALLERGOL, V24, P107, DOI 10.1111/j.1398-9995.1969.tb03760.x; FAGERHOL MK, 1967, CLIN CHIM ACTA, V16, P199, DOI 10.1016/0009-8981(67)90181-7; HALL WJ, 1976, J CLIN INVEST, V58, P1069, DOI 10.1172/JCI108558; KATZ RM, 1976, J ALLERGY CLIN IMMUN, V57, P41, DOI 10.1016/0091-6749(76)90077-4; KUEPPERS F, 1974, AM REV RESPIR DIS, V110, P176; LAURELL CB, 1968, SCAND J CLIN LAB INV, V21, P337, DOI 10.3109/00365516809077003; LAURELL CB, 1966, ANAL BIOCHEM, V15, P45, DOI 10.1016/0003-2697(66)90246-6; MITTMAN C, 1974, AM REV RESPIR DIS, V109, P295; ROWLEY PT, 1974, HUM HERED, V24, P472, DOI 10.1159/000152685; SZCZEKLIK A, 1974, AM REV RESPIR DIS, V109, P487; TALAMO RC, 1975, PEDIATRICS, V56, P91; VANCE JE, TO BE PUBLISHED; WILLIAMS H, 1969, BRIT MED J, V4, P321, DOI 10.1136/bmj.4.5679.321	16	24	24	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	59	1					31	34		10.1016/0091-6749(77)90173-7	http://dx.doi.org/10.1016/0091-6749(77)90173-7			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CS828	299861				2022-12-18	WOS:A1977CS82800005
J	SEVEL, D; WEINBERG, EG; VANNIEKERK, CH				SEVEL, D; WEINBERG, EG; VANNIEKERK, CH			LENTICULAR COMPLICATIONS OF LONG-TERM STEROID-THERAPY IN CHILDREN WITH ASTHMA AND ECZEMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CAPE TOWN,DEPT OPHTHALMOL,CAPE TOWN 7900,SOUTH AFRICA; GROOTE SCHUUR HOSP,DEPT OPHTHALMOL,CAPE TOWN,SOUTH AFRICA; RED CROSS WAR MEM CHILDRENS HOSP,PAEDIAT ALLERGY CLIN,CAPE TOWN,SOUTH AFRICA; UNIV CAPE TOWN,DEPT PAEDIAT & CHILD HLTH,CAPE TOWN 7900,SOUTH AFRICA	University of Cape Town; University of Cape Town; University of Cape Town								BETTMAN JW, 1968, AM J OPHTHALMOL, V65, P581, DOI 10.1016/0002-9394(68)93880-4; BLACK RL, 1960, JAMA-J AM MED ASSOC, V174, P166, DOI 10.1001/jama.1960.63030020005014; BRAVER DA, 1967, ARCH OPHTHALMOL-CHIC, V77, P161; BURDE RM, 1970, J AMER MED ASSOC, V213, P2075, DOI 10.1001/jama.213.12.2075; COX J S G, 1971, British Journal of Diseases of the Chest, V65, P189, DOI 10.1016/0007-0971(71)90028-3; CRONIN TP, 1964, ARCH OPHTHALMOL-CHIC, V72, P198; Duke-Elder S., 1969, SYSTEM OPHTHALMOLOGY, VXI, P637; DUNAND P, 1975, J ALLERGY CLIN IMMUN, V55, P123; ENGSTROM I, 1971, ACTA ALLERGOL, V26, P90, DOI 10.1111/j.1398-9995.1971.tb01284.x; GILES CL, 1962, JAMA-J AM MED ASSOC, V182, P719, DOI 10.1001/jama.1962.03050460011003; HARRIS JE, 1962, EXP EYE RES, V1, P372, DOI 10.1016/S0014-4835(62)80027-X; HAVRE DC, 1965, ARCH OPHTHALMOL-CHIC, V73, P818; LEIBOLD JE, 1963, JAMA-J AM MED ASSOC, V185, P448, DOI 10.1001/jama.1963.03060060046017; Morrow-Brown H., 1972, BRIT MED J, V1, P585; OGLESBY RB, 1961, ARCH OPHTHALMOL-CHIC, V66, P625, DOI 10.1001/archopht.1961.00960010627005; OGLESBY RB, 1961, ARCH OPHTHALMOL-CHIC, V66, P97; READ J, 1969, MED J AUSTRALIA, V1, P566, DOI 10.5694/j.1326-5377.1969.tb92293.x; SALLMANN LV, 1960, AM J OPHTHALMOL, V50, P1147; SUNDMARK E, 1966, ACTA OPHTHALMOL, V44, P291; WIESINGER H, 1963, INVEST OPHTH VISUAL, V2, P294; WOOD DC, 1967, AM J OPHTHALMOL, V63, P841, DOI 10.1016/0002-9394(67)91314-1; YUGE, 1962, FOLIA OPHTHALMOL JAP, V13, P64	22	24	24	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	60	4					215	217		10.1016/0091-6749(77)90132-4	http://dx.doi.org/10.1016/0091-6749(77)90132-4			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DX458	409750				2022-12-18	WOS:A1977DX45800002
J	TWAROG, FJ; WEINSTEIN, SF; KHAW, KT; STRIEDER, DJ; COLTEN, HR				TWAROG, FJ; WEINSTEIN, SF; KHAW, KT; STRIEDER, DJ; COLTEN, HR			HYPERSENSITIVITY TO PANCREATIC EXTRACTS IN PARENTS OF PATIENTS WITH CYSTIC-FIBROSIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CHILDRENS HOSP MED CTR,DEPT MED,DIV ALLERGY,BOSTON,MA 02115; CHILDRENS HOSP MED CTR,DEPT MED,DIV PULM,BOSTON,MA 02115; CHILDRENS HOSP MED CTR,INA SUE PERLMUTTER CYST FIBROSIS CTR,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,DEPT PEDIAT,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University								AXEN R, 1971, EUR J BIOCHEM, V18, P351; BERGNER A, 1975, PEDIATRICS, V55, P814; CHASE MW, 1946, P SOC EXP BIOL MED, V61, P257; CHASE MW, 1959, IMMUNOLOGIC UNRESPON, P507; COLTEN HR, 1975, NEW ENGL J MED, V292, P1050, DOI 10.1056/NEJM197505152922003; COOK CD, 1961, J PEDIATR, V59, P820; COUNAHAN R, 1975, ARCH DIS CHILD, V50, P477, DOI 10.1136/adc.50.6.477; DAVID MF, 1975, J ALLERGY CLIN IMMUN, V55, P135; DOLAN TF, 1974, AM REV RESPIR DIS, V110, P812; DOLOVICH J, 1972, J ALLERGY CLIN IMMUN, V49, P43, DOI 10.1016/0091-6749(72)90122-4; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; FRANZ T, 1971, J ALLERGY, V47, P170, DOI 10.1016/S0091-6749(71)80295-6; FREEDMAN S, 1975, J APPL PHYSIOL, V38, P974, DOI 10.1152/jappl.1975.38.6.974; HILL D, 1975, MED J AUSTRALIA, V2, P553, DOI 10.5694/j.1326-5377.1975.tb106057.x; KULCZYCKI L, 1961, JAMA-J AM MED ASSOC, V175, P358, DOI 10.1001/jama.1961.03040050014004; LITTMAN A, 1969, NEW ENGL J MED, V281, P201, DOI 10.1056/NEJM196907242810406; MAY CD, 1970, J ALLERGY, V46, P12, DOI 10.1016/0021-8707(70)90056-0; MURRAY AB, 1963, J PEDIATR-US, V62, P186, DOI 10.1016/S0022-3476(63)80390-X; Pepys J, 1973, Clin Allergy, V3, P1, DOI 10.1111/j.1365-2222.1973.tb01304.x; PEPYS J, 1975, AM REV RESPIR DIS, V112, P829; PEPYS J, 1973, Clinical Allergy, V3, P143, DOI 10.1111/j.1365-2222.1973.tb01318.x; RACHELEFSKY GS, 1975, AM J DIS CHILD, V128, P355; ROBERTSON DG, 1974, J ALLERGY CLIN IMMUN, V54, P244, DOI 10.1016/0091-6749(74)90067-0; SPITZ E, 1972, J ALLERGY CLIN IMMUN, V49, P337, DOI 10.1016/0091-6749(72)90132-7; WARREN CPW, 1975, CLIN ALLERGY, V1, P1; WATT A, 1973, Clinical Allergy, V3, P133, DOI 10.1111/j.1365-2222.1973.tb01317.x; ZETTERSTROM O, 1974, CLIN ALLERGY, V4, P273, DOI 10.1111/j.1365-2222.1974.tb01385.x	27	24	24	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	59	1					35	40		10.1016/0091-6749(77)90174-9	http://dx.doi.org/10.1016/0091-6749(77)90174-9			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CS828	64483				2022-12-18	WOS:A1977CS82800006
J	GLOVSKY, MM; BRAUNWALD, J; OPELZ, G; ALENTY, A				GLOVSKY, MM; BRAUNWALD, J; OPELZ, G; ALENTY, A			HYPERSENSITIVITY TO PROCARBAZINE ASSOCIATED WITH ANGIOEDEMA, URTICARIA, AND LOW SERUM COMPLEMENT ACTIVITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CALIF,SCH MED,DEPT SURG,LOS ANGELES,CA; KAISER FDN HOSP,DEPT ALLERGY & CLIN IMMUNOL,4900 SUNSET BLVD,LOS ANGELES,CA 90027; KAISER FDN HOSP,RES LAB,SO CALIF PERMANENTE MED GRP,LOS ANGELES,CA 90027; KAISER FDN HOSP,DEPT INTERN MED,LOS ANGELES,CA 90027	University of California System; University of California Los Angeles; Kaiser Permanente; Kaiser Permanente; Southern California Permanente Medical Group (SCPMG); Permanente Medical Groups; Kaiser Permanente								ATKINSON JP, 1973, FED P, V32, P992; COCHRANE CG, 1973, ADV IMMUNOL, P16; DIXON FJ, 1958, ARCH PATHOL, V65, P18; GIGLI I, 1968, J IMMUNOL, V100, P1154; GLOVSKY M, 1970, J IMMUNOL, V104, P1072; GLOVSKY MM, 1968, J IMMUNOL, V100, P979; JONES SE, 1972, CANCER-AM CANCER SOC, V29, P498, DOI 10.1002/1097-0142(197202)29:2<498::AID-CNCR2820290240>3.0.CO;2-O; LEPOW IH, 1970, AM J PATHOL, V61, P13; LOKICH JJ, 1972, CLIN PHARMACOL THER, V13, P573; MARTZ G, 1963, CANC CHEMOTHER REP, V33, P5; Pillemer L, 1941, J IMMUNOL, V40, P89; RATNOFF OD, 1967, J EXP MED, V125, P337, DOI 10.1084/jem.125.2.337; REED DJ, 1975, HDB EXPTL PHARMACOLO, P747; RUDDY S, 1967, J IMMUNOL, V99, P1162; SENGAR DPS, 1971, TRANSPLANTATION, V11, P260, DOI 10.1097/00007890-197103000-00004; SIEGEL J, 1974, J EXP MED, V140, P631, DOI 10.1084/jem.140.3.631; STOLINSKY DC, 1970, CANCER-AM CANCER SOC, V26, P984, DOI 10.1002/1097-0142(197011)26:5<984::AID-CNCR2820260504>3.0.CO;2-E; TANNENBA.H, 1974, J ALLERGY CLIN IMMUN, V53, P96; TODD IDH, 1965, BMJ-BRIT MED J, V1, P628, DOI 10.1136/bmj.1.5435.628; VYAS GN, 1968, LANCET, V2, P312; WARD PA, 1971, J CLIN INVEST, V50, P606, DOI 10.1172/JCI106531	21	24	24	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	57	2					134	140		10.1016/0091-6749(76)90032-4	http://dx.doi.org/10.1016/0091-6749(76)90032-4			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	BE952	1249347				2022-12-18	WOS:A1976BE95200005
J	LESSOF, MH; SOBOTKA, AK; LICHTENSTEIN, LM				LESSOF, MH; SOBOTKA, AK; LICHTENSTEIN, LM			PROTECTION AGAINST ANAPHYLAXIS IN HYMENOPTERA-SENSITIVE PATIENTS BY PASSIVE-IMMUNIZATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	24	24	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	57	3					246	247						2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	BJ240					2022-12-18	WOS:A1976BJ24000140
J	NAIR, BC; NAIR, C; DENNE, S; WYPYCH, J; ARBESMAN, CE; ELLIOTT, WB				NAIR, BC; NAIR, C; DENNE, S; WYPYCH, J; ARBESMAN, CE; ELLIOTT, WB			IMMUNOLOGICAL COMPARISON OF PHOSPHOLIPASES-A PRESENT IN HYMENOPTERA INSECT VENOMS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SUNY BUFFALO,DEPT BIOCHEM,BUFFALO,NY 14207; SUNY BUFFALO,DEPT MED,BUFFALO,NY 14207; SUNY BUFFALO,DEPT MICROBIOL,BUFFALO,NY 14207; SUNY BUFFALO,CTR IMMUNOL,BUFFALO,NY 14207; BUFFALO GEN HOSP,CTR ALLERGY RES,BUFFALO,NY	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Buffalo General Medical Center								ARBESMAN CE, 1966, J ALLERGY, V38, P1, DOI 10.1016/0021-8707(66)90067-0; ARBESMAN CE, 1965, J ALLERGY, V26, P147; BARKER SA, 1966, CLIN CHIM ACTA, V13, P582, DOI 10.1016/0009-8981(66)90162-8; BARNARD JH, 1973, J ALLERGY CLIN IMMUN, V52, P259, DOI 10.1016/0091-6749(73)90044-4; Barr S E, 1967, Med Ann Dist Columbia, V36, P395; BARR SE, 1971, ANN ALLERGY, V29, P49; BAUGH AT, 1965, ANN ALLERGY, V23, P430; BENTON AW, 1963, SCIENCE, V142, P228, DOI 10.1126/science.142.3589.228; BROWN H, 1969, J ALLERGY, V44, P146, DOI 10.1016/0021-8707(69)90138-5; CHARAVEGASARN CC, 1974, 30TH AM AC ALL ANN M, V2; DAY JM, 1962, ARCH NEUROL-CHICAGO, V7, P184, DOI 10.1001/archneur.1962.04210030022003; DEHAAS GH, 1968, BIOCHIM BIOPHYS ACTA, V159, P103, DOI 10.1016/0005-2744(68)90248-9; ETTER R L, 1961, Ind Med Surg, V30, P213; FISCHL J, 1972, ACTA PHARMACOL TOX, V31, P65, DOI 10.1111/j.1600-0773.1972.tb00698.x; FOGEL BJ, 1967, AM J DIS CHILD, V114, P325, DOI 10.1001/archpedi.1967.02090240139016; FOUBERT EL, 1958, J ALLERGY, V29, P13, DOI 10.1016/0021-8707(58)90050-9; Habermann E, 1968, Ergeb Physiol, V60, P220; Habermann E, 1974, Pharm Unserer Zeit, V3, P145; HABERMANN E, 1956, NATURE, V178, P1349, DOI 10.1038/1781349a0; Heremans J., 1960, GLOBULINES SERIQUES; HOFFMAN DR, 1975, J ALLERGY CLIN IMMUN, V55, P73; ILEA V, 1975, J ALLERGY CLIN IMMUN, V55, P74; JONAS W, 1963, Dapim Refuiim, V22, P353; KAPLINSKY E, 1974, TOXICON, V12, P69, DOI 10.1016/0041-0101(74)90101-9; LANGLOIS C, 1966, J ALLERGY, V37, P359, DOI 10.1016/0021-8707(66)90135-3; LICHTENSTEIN LM, 1974, NEW ENGL J MED, V290, P1223, DOI 10.1056/NEJM197405302902204; LOVELESS MARY HEWITT, 1956, ANN ALLERGY, V14, P347; MOHAMMED AH, 1961, NATURE, V189, P837, DOI 10.1038/189837b0; MUNJAL D, 1972, TOXICON, V10, P367, DOI 10.1016/0041-0101(72)90060-8; MUNJAL D, 1971, TOXICON, V9, P229, DOI 10.1016/0041-0101(71)90074-2; NAIR BC, 1975, TOXICON, V13, P453, DOI 10.1016/0041-0101(75)90174-9; OCONNOR R, 1964, ANN ALLERGY, V22, P385; OCONNOR R, 1965, ANN ALLERGY, V23, P151; OCONNOR R, 1964, SCIENCE, V145, P132; PARRISH HM, 1963, AM J MED SCI, V245, P129; SAELINGER CB, 1974, INT ARCH ALLER A IMM, V46, P28, DOI 10.1159/000231110; SCHARTZ HJ, 1970, J ALLERGY, V45, P87; SETTIPANE GA, 1971, ACTA ALLERGOL, V26, P121, DOI 10.1111/j.1398-9995.1971.tb01288.x; SHEPHERD GW, 1974, PREP BIOCHEM, V4, P71, DOI 10.1080/00327487408068187; SHIPOLIN.RA, 1971, EUR J BIOCHEM, V20, P459, DOI 10.1111/j.1432-1033.1971.tb01414.x; SHIVPURI DN, 1971, ANN ALLERGY, V29, P588; SHULMAN S, 1966, J IMMUNOL, V96, P29; SHULMAN S, 1966, J ALLERGY, V37, P350, DOI 10.1016/0021-8707(66)90134-1; SOBOTKA A, 1974, J ALLERGY CLIN IMMUN, V53, P103; SOBOTKA AK, 1974, J ALLERGY CLIN IMMUN, V53, P170, DOI 10.1016/0091-6749(74)90005-0; SOBOTKA AK, 1975, J ALLERGY CLIN IMMUN, V55, P73; VICK JA, 1972, AM BEE J         NOV, P414; YOCUM MW, 1973, J ALLERGY CLIN IMMUN, V52, P265, DOI 10.1016/0091-6749(73)90045-6; [No title captured]	49	24	24	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	58	1					101	109		10.1016/0091-6749(76)90111-1	http://dx.doi.org/10.1016/0091-6749(76)90111-1			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	BX742	947973				2022-12-18	WOS:A1976BX74200011
J	FLAHERTY, DK; MURRAY, HD; REED, CE				FLAHERTY, DK; MURRAY, HD; REED, CE			CROSS REACTIONS TO ANTIGENS CAUSING HYPERSENSITIVITY PNEUMONITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV WISCONSIN,SCH MED,DEPT MED,MADISON,WI 53706; UNIV WISCONSIN HOSP,SCH MED,DEPT PREVENT MED,ALLERGY SECT,1300 UNIV AVE,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison								EDWARDS JH, 1971, MED LAB TECHNOL, V28, P172; HOEHNE JH, 1973, CHEST, V63, P171; KAWAI T, 1972, J ALLERGY CLIN IMMUN, V49, P134; PEPYS J, 1969, MONOGRAPHS ALLERGY, V4; PORTER RR, 1959, BIOCHEM J, V73, P119, DOI 10.1042/bj0730119; REED CE, 1972, POSTGRAD MED, V51, P120, DOI 10.1080/00325481.1972.11698134; WILLIAMS J. V., 1963, THORAX, V18, P182, DOI 10.1136/thx.18.2.182	7	24	24	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1974	53	6					329	335		10.1016/0091-6749(74)90116-X	http://dx.doi.org/10.1016/0091-6749(74)90116-X			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	T2239	4208068				2022-12-18	WOS:A1974T223900002
J	WONG, D; LOPAPA, AF; HADDAD, ZH				WONG, D; LOPAPA, AF; HADDAD, ZH			IMMEDIATE HYPERSENSITIVITY REACTION TO AMINOPHYLLINE - REPORT OF A CASE WITH IMMUNOLOGIC CONFIRMATION BY AN IN-VITRO PROCEDURE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note																		AMKRAUT AA, 1963, J IMMUNOL, V91, P644; BAER RL, 1959, ARCH DERMATOL, V79, P647, DOI 10.1001/archderm.1959.01560180021006; FRICK OL, 1968, IMMUNOLOGY, V14, P563; GREEN JF, 1970, J IMMUNOL, V104, P863; HADDAD Z, IN PRESS; KOROTZER J, 1970, J ALLERGY, V45, P126; KOROTZER JL, 1971, IMMUNOLOGY, V20, P545; LICHTENS.LM, 1968, SCIENCE, V161, P902, DOI 10.1126/science.161.3844.902; LICHTENSTEIN LM, 1969, J IMMUNOL, V103, P866; MCKEE M, 1957, NEW ENGL J MED, V256, P956, DOI 10.1056/NEJM195705162562015; ORANGE RP, 1968, P SOC EXP BIOL MED, V129, P836; PERELMUTTER L, 1969, LANCET, V1, P1269; PERELMUTTER L, 1970, INT ARCH ALLER A IMM, V39, P27, DOI 10.1159/000230331; TAS J., 1958, ACTA ALLERGOL, V12, P39, DOI 10.1111/j.1398-9995.1958.tb04018.x	14	24	24	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1971	48	3					165	&		10.1016/0091-6749(71)90012-1	http://dx.doi.org/10.1016/0091-6749(71)90012-1			0	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	K3234	5284941	Bronze			2022-12-18	WOS:A1971K323400006
J	Adir, Y; Humbert, M; Saliba, W				Adir, Yochai; Humbert, Marc; Saliba, Walid			COVID-19 risk and outcomes in adult asthmatic patients treated with biologics or systemic corticosteroids: Nationwide real-world evidence	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						COVID-19; asthma; systemic corticosteroids; biologics		Background: Managing severe asthma during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic is challenging, particularly due to safety concerns regarding the use of systemic corticosteroids and biologics. Objectives: We sought to determine the association between biologics or systemic corticosteroids use and PCR positivity for SARS-CoV-2 and coronavirus disease 2019 (COVID-19) outcomes among asthmatic patients. Methods: We used the computerized database of Clalit Health Services, the largest health care provider in Israel, to identify all asthmatic adult patients who underwent PCR testing for SARSCoV-2, between March 1, 2020, and December 7, 2020. A cohort approach was used to assess the association between biologics use and steroids treatment and COVID-19 severity and 90-day mortality. Results: Overall, 8,242 of 80,602 tested asthmatic patients had positive PCR testing result for SARS-CoV-2. Both biologics and systemic corticosteroids were not associated with increased risk of SARS-CoV-2 infection. Multivariate analyses revealed that biologics were not associated with a significantly increased risk of moderate to severe COVID-19, nor with the composite end point of moderate to severe COVID-19 or all-cause mortality within 90 days. Chronic systemic corticosteroid use was associated with significantly increased risk of all tested outcome. Recent (within the previous 120 days) systemic corticosteroid use, but not former use, was significantly associated with increased risk of both moderate to severe COVID-19 and the composite of moderate to severe COVID-19 or all-cause mortality. Conclusions: Biologics approved for asthma and systemic corticosteroids are not associated with increased risk of SARS-CoV-2 infection. In contrast, systemic corticosteroids are an independent risk factor for worst COVID-19 severity and all-cause mortality. Our findings underscore the risk of recent or current exposure to systemic corticosteroids in asthmatic patients infected with SARS-CoV-2. (J Allergy Clin Immunol 2021;148:361-7.)	[Adir, Yochai] Fac Med Techn Inst Technol, Pulm Div, Lady Davis Carmel Med Ctr, Haifa, Israel; [Adir, Yochai; Saliba, Walid] Techn Israel Inst Technol, Ruth & Bruce Rappaport Fac Med, Haifa, Israel; [Humbert, Marc] Univ Paris Saclay, Le Kremlin Bicetre, France; [Humbert, Marc] Assistance Publ Hopitaux Paris AP HP, Dept Resp & Intens Care Med, Hopital Bicetre, Le Kremlin Bicetre, France; [Humbert, Marc] INSERM, Hopital Marie Lannelongue, UMRS 999, Le Plessis Robinson, France; [Saliba, Walid] Dept Commun Med & Epidemiol, Lady Davis Carmel Med Ctr, Haifa, Israel	Clalit Health Services; Carmel Medical Center; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Clalit Health Services; Carmel Medical Center	Adir, Y (corresponding author), Lady Davis Carmel Med Ctr, Pulm Div, 7 Michal St, Haifa, Israel.	adir-sh@zahav.net.il	Humbert, Marc/ABD-5112-2021					Beurnier A, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.01875-2020; Bloom CI, 2021, LANCET RESP MED, V9, P699, DOI 10.1016/S2213-2600(21)00013-8; Busse WW, 2010, LANCET, V376, P826, DOI 10.1016/S0140-6736(10)61380-3; Chhiba KD, 2020, J ALLERGY CLIN IMMUN, V146, P307, DOI 10.1016/j.jaci.2020.06.010; Choi HG, 2021, ALLERGY, V76, P921, DOI 10.1111/all.14675; Choi YJ, 2021, EUR RESPIR J, V57, DOI 10.1183/13993003.02226-2020; Du YZ, 2020, AM J RESP CRIT CARE, V201, P1372, DOI 10.1164/rccm.202003-0543OC; Ferastraoaru D, 2021, J ALLER CL IMM-PRACT, V9, P1152, DOI 10.1016/j.jaip.2020.12.045; Global INitiative for Asthma, 2020, GLOB STRAT ASTHM MAN; Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1545, DOI 10.1001/jama.2020.4031; Green I., 2021, J ALLER CL IMM-PRACT, V9, P684, DOI DOI 10.1016/j.jaip.2020.11.020; Hanon S, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.02857-2020; Heffler E, 2021, ALLERGY, V76, P887, DOI 10.1111/all.14532; Izquierdo JL, 2021, EUR RESPIR J, V57, DOI 10.1183/13993003.03142-2020; Lindsley AW, 2020, J ALLERGY CLIN IMMUN, V146, P1, DOI 10.1016/j.jaci.2020.04.021; Lovinsky-Desir S, 2020, J ALLERGY CLIN IMMUN, V146, P1027, DOI 10.1016/j.jaci.2020.07.026; Maes T, 2020, AM J RESP CRIT CARE, V202, P900, DOI 10.1164/rccm.202006-2129LE; Morais-Almeida M, 2020, WORLD ALLERGY ORGAN, V13, DOI 10.1016/j.waojou.2020.100126; Preis M, 2017, BLOOD, V129, P1210, DOI 10.1182/blood-2016-09-742262; Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI 10.1001/jama.2020.7681; Sajuthi SP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18781-2; Saliba W, 2019, DIABETES CARE, V42, P682, DOI 10.2337/dc18-2472; Satia I, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0228544; Schultze A, 2020, LANCET RESP MED, V8, P1106, DOI 10.1016/S2213-2600(20)30415-X; Taioli E., 2020, CHEST, V194, P2019; Terry PD, 2021, AM J RESP CRIT CARE, V203, P893, DOI 10.1164/rccm.202008-3266OC; Williamson EJ, 2020, NATURE, V584, P430, DOI 10.1038/s41586-020-2521-4; World Health Organization, 2020, CLIN MAN COVID 19; Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648; Yang JC, 2021, IEEE T INTELL TRANSP, V22, P3742, DOI 10.1109/TITS.2020.3023788; Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238; Zhu JY, 2020, J MED VIROL, V92, P1902, DOI [10.1002/jmv.25884, 10.1002/jmv.26085]; Zhu ZZ, 2020, J ALLERGY CLIN IMMUN, V146, P327, DOI 10.1016/j.jaci.2020.06.001	33	23	24	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2021	148	2					361	+		10.1016/j.jaci.2021.06.006	http://dx.doi.org/10.1016/j.jaci.2021.06.006		AUG 2021	20	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TZ7BX	34144110	Green Published, Bronze			2022-12-18	WOS:000684625700014
J	Raita, Y; Camargo, CA; Bochkov, YA; Celedon, JC; Gern, JE; Mansbach, JM; Rhee, EP; Freishtat, RJ; Hasegawa, K				Raita, Yoshihiko; Camargo, Carlos A., Jr.; Bochkov, Yury A.; Celedon, Juan C.; Gern, James E.; Mansbach, Jonathan M.; Rhee, Eugene P.; Freishtat, Robert J.; Hasegawa, Kohei			Integrated-omics endotyping of infants with rhinovirus bronchiolitis and risk of childhood asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Integrated-omics; microbiome; metabolome; cytokines; endotyping; bronchiolitis; asthma	RESPIRATORY SYNCYTIAL VIRUS; DISEASE SEVERITY; MICROBIOTA; INFECTION; ASSOCIATION; PREVENTION; PROFILES; PATTERNS; CHILDREN; AIRWAY	Background: Young children with rhinovirus (RV) infection-particularly bronchiolitis-are at high risk for developing childhood asthma. Emerging evidence suggests clinical heterogeneity within RV bronchiolitis. However, little is known about these biologically distinct subgroups (endotypes) and their relations with asthma risk. Objective: We aimed to identify RV bronchiolitis endotypes and examine their longitudinal relations with asthma risk. Methods: As part of a multicenter prospective cohort study of infants (age <12 months) hospitalized for bronchiolitis, we integrated clinical, RV species (RV-A, RV-B, and RV-C), nasopharyngeal microbiome (16S rRNA gene sequencing), cytokine, and metabolome (liquid chromatography tandem mass spectrometry) data collected at hospitalization. We then applied network and clustering approaches to identify bronchiolitis endotypes. We also examined their longitudinal association with risks of developing recurrent wheeze by age 3 years and asthma by age 5 years. Results: Of 122 infants hospitalized for RV bronchiolitis (median age, 4 months), we identified 4 distinct endotypes-mainly characterized by RV species, microbiome, and type 2 cytokine (T2) response: endotype A, virus(RV-C)microbiome(mixed) T2low; endotype B, virus(RV-A)microbiome(Haemophilus)T2(low); endotype C, virus(RSV/RV)microbiome(Streptococcus)T2(low); and endotype D, virus(RV-C)microbiome(Moraxella)T2(high). Compared with endotype A infants, endotype D infants had a significantly higher rate of recurrent wheeze (33% vs 64%; hazard ratio, 2.23; 95% CI, 1.00-4.96; P = .049) and a higher risk for developing asthma (28% vs 59%; odds ratio, 3.74: 95% CI, 1.21-12.6; P = .03). Conclusions: Integrated-omics analysis identified biologically meaningful RV bronchiolitis endotypes in infants, such as one characterized by RV-C infection, Moraxella-dominant microbiota, and high T2 cytokine response, at higher risk for developing recurrent wheeze and asthma. This study should facilitate further research toward validating our inferences.	[Raita, Yoshihiko; Camargo, Carlos A., Jr.; Hasegawa, Kohei] Harvard Med Sch, Dept Emergency Med, Massachusetts Gen Hosp, 125 Nashua St,Ste 920, Boston, MA 02114 USA; [Bochkov, Yury A.; Gern, James E.] Univ Wisconsin, Dept Pediat, Sch Med & Publ Hlth, Madison, WI USA; [Celedon, Juan C.] Univ Pittsburgh, Dept Pediat, Div Pulm, UPMC Childrens Hosp Pittsburgh, Pittsburgh, PA 15260 USA; [Gern, James E.] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI USA; [Mansbach, Jonathan M.] Harvard Med Sch, Boston Childrens Hosp, Dept Pediat, Boston, MA 02115 USA; [Rhee, Eugene P.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Med, Div Nephrol, Boston, MA 02115 USA; [Rhee, Eugene P.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Med, Endocrine Unit, Boston, MA 02115 USA; [Freishtat, Robert J.] Childrens Natl Hosp, Div Emergency Med, Washington, DC USA; [Freishtat, Robert J.] George Washington Univ, Sch Med & Hlth Sci, Dept Pediat, Washington, DC 20052 USA; [Freishtat, Robert J.] George Washington Univ, Sch Med & Hlth Sci, Dept Genom & Precis Med, Washington, DC 20052 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; University of Wisconsin System; University of Wisconsin Madison; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Wisconsin System; University of Wisconsin Madison; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Children's National Health System; George Washington University; George Washington University	Raita, Y (corresponding author), Harvard Med Sch, Dept Emergency Med, Massachusetts Gen Hosp, 125 Nashua St,Ste 920, Boston, MA 02114 USA.	yraita1@mgh.harvard.edu	Camargo, Carlos A./C-2145-2008	Camargo, Carlos A./0000-0002-5071-7654; Raita, Yoshihiko/0000-0002-5805-9369	National Institutes of Health [U01 AI-087881, R01 AI-114552, R01 AI-108588, R01 AI-134940, R21 HL-129909, UG3/UH3 OD-023253]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This study was supported by grants from the National Institutes of Health (grant nos. U01 AI-087881, R01 AI-114552, R01 AI-108588, R01 AI-134940, R21 HL-129909, and UG3/UH3 OD-023253). The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The funding organizations were not involved in the collection, management, or analysis of the data; preparation or approval of the manuscript; or decision to submit the manuscript for publication.	Abreo A, 2018, CLIN TRANSL MED, V7, DOI 10.1186/s40169-018-0195-4; Altman MC, 2020, J ALLERGY CLIN IMMUN, V145, P1332, DOI 10.1016/j.jaci.2019.12.904; Bacharier LB, 2012, J ALLERGY CLIN IMMUN, V130, P91, DOI 10.1016/j.jaci.2012.02.010; Bisgaard H, 2007, NEW ENGL J MED, V357, P1487, DOI 10.1056/NEJMoa052632; Bochkov YA, 2016, CURR ALLERGY ASTHM R, V16, DOI 10.1007/s11882-016-0608-7; Bochkov YA, 2014, J CLIN MICROBIOL, V52, P2461, DOI 10.1128/JCM.00075-14; Camargo CA, 2011, PEDIATRICS, V127, pE180, DOI 10.1542/peds.2010-0442; Castro M, 2008, J ALLERGY CLIN IMMUN, V122, P726, DOI 10.1016/j.jaci.2008.07.010; Dumas O, 2019, J ALLERGY CLIN IMMUN, V143, P1371, DOI 10.1016/j.jaci.2018.08.043; Dumas O, 2016, THORAX, V71, P712, DOI 10.1136/thoraxjnl-2016-208535; Edgar RC, 2013, NAT METHODS, V10, P996, DOI [10.1038/NMETH.2604, 10.1038/nmeth.2604]; Edgar RC, 2010, BIOINFORMATICS, V26, P2460, DOI 10.1093/bioinformatics/btq461; Feldman AS, 2015, AM J RESP CRIT CARE, V191, P34, DOI 10.1164/rccm.201405-0901PP; Fujiogi M, 2019, PEDIATRICS, V144, DOI 10.1542/peds.2019-2614; Hasegawa K, 2017, ALLERGY, V72, P1796, DOI 10.1111/all.13160; Hasegawa K, 2019, JAMA PEDIATR, V173, P544, DOI 10.1001/jamapediatrics.2019.0384; Hasegawa K, 2019, ALLERGY, V74, P1374, DOI 10.1111/all.13723; Hasegawa K, 2016, EUR RESPIR J, V48, P1329, DOI 10.1183/13993003.00152-2016; Hasegawa K, 2015, J INFECT DIS, V211, P1550, DOI 10.1093/infdis/jiu658; Karppinen S, 2020, CLIN INFECT DIS; Kelly RS, 2019, EUR RESPIR J, V54, DOI 10.1183/13993003.00761-2019; Kelly RS, 2018, CHEST, V154, P335, DOI 10.1016/j.chest.2018.05.038; Kotaniemi-Syrjanen A, 2003, J ALLERGY CLIN IMMUN, V111, P66, DOI 10.1067/mai.2003.33; Leek JT, 2012, BIOINFORMATICS, V28, P882, DOI 10.1093/bioinformatics/bts034; Marsh RL, 2016, MICROBIOME, V4, DOI 10.1186/s40168-016-0182-1; McCauley K, 2019, J ALLERGY CLIN IMMUN, V144, P1187, DOI 10.1016/j.jaci.2019.05.035; Methe BA, 2012, NATURE, V486, P215, DOI 10.1038/nature11209; Mikalsen IB, 2012, PEDIAT ALLERG IMM-UK, V23, P391, DOI 10.1111/j.1399-3038.2012.01283.x; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; Panda L, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09869-9; Poole A, 2014, J ALLERGY CLIN IMMUN, V133, P670, DOI 10.1016/j.jaci.2013.11.025; PowerSoil&REG;, POWERSOIL DNA IS KIT; Quast C, 2013, NUCLEIC ACIDS RES, V41, pD590, DOI 10.1093/nar/gks1219; Ralston SL, 2014, PEDIATRICS, V134, pE1474, DOI 10.1542/peds.2014-2742; Reijonen TM, 2000, PEDIATRICS, V106, P1406, DOI 10.1542/peds.106.6.1406; Rosas-Salazar C, 2016, J INFECT DIS, V214, P1924, DOI 10.1093/infdis/jiw456; Sigurs N, 2010, THORAX, V65, P1045, DOI 10.1136/thx.2009.121582; Sikazwe CT, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11111038; Stewart CJ, 2017, AM J RESP CRIT CARE, V196, P882, DOI 10.1164/rccm.201701-0071OC; Sturgill Jamie L., 2018, Advances in Biological Regulation, V70, P74, DOI 10.1016/j.jbior.2018.09.001; Teo SM, 2018, CELL HOST MICROBE, V24, P341, DOI 10.1016/j.chom.2018.08.005; Toivonen L, 2019, THORAX, V74, P592, DOI 10.1136/thoraxjnl-2018-212629; Toivonen L, 2019, J ALLERGY CLIN IMMUN, V143, P1925, DOI 10.1016/j.jaci.2018.12.1004; Turi KN, 2018, AM J RESP CRIT CARE, V198, P1064, DOI 10.1164/rccm.201711-2348OC; van den Berg RA, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-142; Vrtis R, 2018, J ALLERGY CLIN IMMUN, V141, P822, DOI 10.1016/j.jaci.2017.09.027; Wang B, 2014, NAT METHODS, V11, P333, DOI [10.1038/NMETH.2810, 10.1038/nmeth.2810]; Zhang YM, 2019, AM J RESP CRIT CARE, V199, P478, DOI 10.1164/rccm.201803-0438OC; Zhou YJ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13698-x; Zhu ZZ, 2019, EXPERT REV RESP MED, V13, P1135, DOI 10.1080/17476348.2019.1674650	50	23	25	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2021	147	6					2108	2117		10.1016/j.jaci.2020.11.002	http://dx.doi.org/10.1016/j.jaci.2020.11.002		JUN 2021	10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SM7YB	33197460	Green Accepted			2022-12-18	WOS:000657814800016
J	Giannetti, MP; Akin, C; Hufdhi, R; Hamilton, MJ; Weller, E; van Anrooij, B; Lyons, JJ; Hornick, JL; Pinkus, G; Castells, M; Pozdnyakova, O				Giannetti, Matthew P.; Akin, Cem; Hufdhi, Raied; Hamilton, Matthew J.; Weller, Emily; Anrooij, Bjorn van; Lyons, Jonathan J.; Hornick, Jason L.; Pinkus, Geraldine; Castells, Mariana; Pozdnyakova, Olga			Patients with mast cell activation symptoms and elevated baseline serum tryptase level have unique bone marrow morphology	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Mastocytosis; MC activation syndrome; hereditary a-tryptasemia; tryptase; mast cell morphology; bone marrow biopsy	MASTOCYTOSIS; DISORDER	Background: Patients with mast cell (MC) activation symptoms and elevated baseline serum tryptase level (MCAS-T) may not necessarily have a clonal MC disorder. Many are diagnosed with hereditary a-tryptasemia (HaT), a genetic trait characterized by autosomal dominant inheritance of multiple copies of TPSAB1 encoding a-tryptase and increased risk for severe anaphylaxis. Objective: The aim of our study was to identify and characterize bone marrow MC histopathologic features specific for MCAS-T. Methods: A total of 43 patients with MCAS-T underwent evaluation, including bone marrow biopsy, for a MC disorder. The results of the work-up for clonal MC disorders such as systemic mastocytosis and monoclonal MC activation syndrome were negative. Bone marrow MC histopathology was reviewed to identify characteristic features of MCAS-T. A subgroup of patients was available for tryptase genotyping. Results: Patients with MCAS-T showed unique morphologic and histologic features when compared with controls. MCs were larger (P < .01), hypogranular (P < .01), frequently detected in paratrabecular (P < .05) and perivascular (P < .01) locations, and associated with bone marrow eosinophilia (P < .01). A total of 10 patients who were available for tryptase genotyping were all confirmed to have HaT. This subgroup was representative of the larger MCAS-T cohort. Conclusion: We report unique bone marrow MC phenotypic and histopathologic changes in patients with MCAS-T. These morphologic changes are associated with an elevated tryptase level that has been confirmed to be caused by HaT in all patients available for testing. (J Allergy Clin Immunol 2021;147:1497-501.)	[Giannetti, Matthew P.; Weller, Emily; Castells, Mariana] Brigham & Womens Hosp, Div Allergy & Clin Immunol, 60 Fenwood Rd,Hale Bldg Transformat Med,5th Floor, Boston, MA 02132 USA; [Hamilton, Matthew J.] Brigham & Womens Hosp, Div Gastroenterol Endoscopy & Hepatol, 75 Francis St, Boston, MA 02115 USA; [Hornick, Jason L.; Pinkus, Geraldine; Pozdnyakova, Olga] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA; [Giannetti, Matthew P.; Hamilton, Matthew J.; Hornick, Jason L.; Pinkus, Geraldine; Castells, Mariana; Pozdnyakova, Olga] Harvard Med Sch, Boston, MA 02115 USA; [Akin, Cem; Hamilton, Matthew J.] Univ Michigan, Div Allergy & Immunol, Ann Arbor, MI 48109 USA; [Hufdhi, Raied] Univ Toledo, Dept Med, 2801 W Bancroft St, Toledo, OH 43606 USA; [Anrooij, Bjorn van] Univ Groningen, Univ Med Ctr Groningen, Dept Allergol, Groningen, Netherlands; [Lyons, Jonathan J.] NIAID, Lab Allerg Dis, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Michigan System; University of Michigan; University System of Ohio; University of Toledo; University of Groningen; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Giannetti, MP (corresponding author), Brigham & Womens Hosp, Div Allergy & Clin Immunol, 60 Fenwood Rd,Hale Bldg Transformat Med,5th Floor, Boston, MA 02132 USA.	mgiannetti@bwh.harvard.edu			Division of Intramural Research of the National Institute of Allergy and Infectious Diseases, National Institutes of Health	Division of Intramural Research of the National Institute of Allergy and Infectious Diseases, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported in part by the Division of Intramural Research of the National Institute of Allergy and Infectious Diseases, National Institutes of Health. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does the mention of trade names, commercial products, or organizations imply endorsement by the US Government.	Akin C, 2010, J ALLERGY CLIN IMMUN, V126, P1099, DOI 10.1016/j.jaci.2010.08.035; Bibi S, 2014, IMMUNOL ALLERGY CLIN, V34, P239, DOI 10.1016/j.iac.2014.01.009; Carter MC, 2018, J ALLERGY CLIN IMMUN, V141, P180, DOI 10.1016/j.jaci.2017.05.036; Galli SJ, 2012, NAT MED, V18, P693, DOI 10.1038/nm.2755; Gotlib J, 2013, BLOOD, V121, P2393, DOI 10.1182/blood-2012-09-458521; Greiner G, 2021, BLOOD, V137, P238, DOI 10.1182/blood.2020006157; Hamilton MJ, 2011, J ALLERGY CLIN IMMUN, V128, P147, DOI 10.1016/j.jaci.2011.04.037; Hartmann K, 2016, J ALLERGY CLIN IMMUN, V137, P35, DOI 10.1016/j.jaci.2015.08.034; Lyons JJ, 2021, J ALLERGY CLIN IMMUN, V147, P622, DOI 10.1016/j.jaci.2020.06.035; Lyons JJ, 2018, IMMUNOL ALLERGY CLIN, V38, P483, DOI 10.1016/j.iac.2018.04.003; Lyons JJ, 2016, NAT GENET, V48, P1564, DOI 10.1038/ng.3696; Lyons JJ, 2014, J ALLERGY CLIN IMMUN, V133, P1471, DOI 10.1016/j.jaci.2013.11.039; Olivera A, 2018, J ALLERGY CLIN IMMUN, V142, P381, DOI 10.1016/j.jaci.2018.01.034; Plum T, 2020, IMMUNITY, V52, P404, DOI 10.1016/j.immuni.2020.01.012; Le QT, 2019, J EXP MED, V216, P2348, DOI 10.1084/jem.20190701; Roberts RE, 2022, J STRATEG MARK, V30, P606, DOI 10.1080/0965254X.2020.1823457; Theoharides TC, 2015, NEW ENGL J MED, V373, P163, DOI 10.1056/NEJMra1409760; Valent P, 2017, BLOOD, V129, P1420, DOI 10.1182/blood-2016-09-731893; Valent P, 2012, INT ARCH ALLERGY IMM, V157, P215, DOI 10.1159/000328760	19	23	23	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2021	147	4					1497	+		10.1016/j.jaci.2020.11.017	http://dx.doi.org/10.1016/j.jaci.2020.11.017		APR 2021	6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RX3VK	33248113	Green Published			2022-12-18	WOS:000647154500014
J	Patrick, MT; Zhang, HH; Wasikowski, R; Prens, EP; Weidinger, S; Gudjonsson, JE; Elder, JT; He, K; Tsoi, LC				Patrick, Matthew T.; Zhang, Haihan; Wasikowski, Rachael; Prens, Errol P.; Weidinger, Stephan; Gudjonsson, Johann E.; Elder, James T.; He, Kevin; Tsoi, Lam C.			Associations between COVID-19 and skin conditions identified through epidemiology and genomic studies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						COVID-19; SARS-CoV-2; skin conditions; psoriasis; atopic dermatitis; epidemiology; genetics; gene expression	RHEUMATOID-ARTHRITIS; EPITHELIAL-CELLS; INCREASED RISK; PSORIASIS; EXPRESSION; DISEASE; VIRUS; INFECTIONS; PATHOGENESIS; CORONAVIRUS	Background: Coronavirus disease 2019 (COVID-19) is commonly associated with skin manifestations, and may also exacerbate existing skin diseases, yet the relationship between COVID-19 and skin diseases remains unclear. Objective: By investigating this relationship through a multiomics approach, we sought to ascertain whether patients with skin conditions are more susceptible to COVID-19. Methods: We conducted an epidemiological study and then compared gene expression across 9 different inflammatory skin conditions and severe acute respiratory syndrome coronavirus 2-infected bronchial epithelial cell lines, and then performed a genome-wide association study transdisease meta-analysis between COVID-19 susceptibility and 2 skin diseases (psoriasis and atopic dermatitis). Results: Skin conditions, including psoriasis and atopic dermatitis, increase the risk of COVID-19 (odds ratio, 1.55; P = 1.4 x 10(-9)) but decrease the risk of mechanical ventilation (odds ratio, 0.22; P = 8.5 x 10(-5)). We observed significant overlap in gene expression between the infected normal bronchial epithelial cells and inflammatory skin diseases, such as psoriasis and atopic dermatitis. For genes that are commonly induced in both the severe acute respiratory syndrome coronavirus 2 infection and skin diseases, there are 4 S100 family members located in the epidermal differentiation complex, and we also identified the "IL-17 signaling pathway" (P = 4.9 x 10(-77)) as one of the most significantly enriched pathways. Furthermore, a shared genome-wide significant locus in the epidermal differentiation complex was identified between psoriasis and severe acute respiratory syndrome coronavirus 2 infection, with the lead marker being a significant expression quantitative trait locus for S100A12 (P = 3.3 x 10(-7)). Conclusions: Together our findings suggest association between inflammatory skin conditions and higher risk of COVID-19, but with less severe course, and highlight shared components involved in anti-COVID-19 immune response.	[Patrick, Matthew T.; Wasikowski, Rachael; Gudjonsson, Johann E.; Elder, James T.; Tsoi, Lam C.] Univ Michigan, Sch Med, Dept Dermatol, Ann Arbor, MI USA; [Zhang, Haihan; He, Kevin; Tsoi, Lam C.] Univ Michigan, Dept Biostat, Ctr Stat Genet, Ann Arbor, MI 48109 USA; [Prens, Errol P.] Erasmus MC, Dept Dermatol, Rotterdam, Netherlands; [Weidinger, Stephan] Univ Hosp Schleswig Holstein, Dept Dermatol & Allergy, Campus Kiel, Kiel, Germany; [Elder, James T.] Ann Arbor Vet Affairs Hosp, Ann Arbor, MI USA; [Tsoi, Lam C.] Univ Michigan, Dept Computat Med & Bioinformat, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Erasmus University Rotterdam; Erasmus MC; University of Kiel; Schleswig Holstein University Hospital; University of Michigan System; University of Michigan	Patrick, MT; Tsoi, LC (corresponding author), Univ Michigan, Dept Dermatol, 7421 Med Sci Bldg I,1301 E Catherine St, Ann Arbor, MI 48109 USA.	mattpat@med.umich.edu; alextsoi@med.umich.edu		Tsoi, Lam Cheung/0000-0003-1627-5722; Patrick, Matthew/0000-0002-6174-9002	Arthritis National Research Foundation; National Psoriasis Foundation; National Institutes of Health [R01AR042742, R01AR050511, R01AR054966, R01AR063611, R01AR065183, K01AR072129, K08AR060802, R01AR06907]; Dermatology Foundation; Precision Health Scholars Award from the University of Michigan; Dawn and Dudley Holmes Foundation; Babcock Memorial Trust; Taubman Medical Research Institute as the Frances and Kenneth Eisenberg Emerging; National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) [UM-SBDRC 1P30AR075043]; Taubman Institute Innovation Project; Ann Arbor Veterans Affairs Hospital; National Psoriasis Foundation's Psoriasis Prevention Initiative	Arthritis National Research Foundation(National Research Foundation of Korea); National Psoriasis Foundation; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Dermatology Foundation; Precision Health Scholars Award from the University of Michigan; Dawn and Dudley Holmes Foundation; Babcock Memorial Trust; Taubman Medical Research Institute as the Frances and Kenneth Eisenberg Emerging; National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Taubman Institute Innovation Project; Ann Arbor Veterans Affairs Hospital; National Psoriasis Foundation's Psoriasis Prevention Initiative	This work was supported by the Arthritis National Research Foundation and the National Psoriasis Foundation (L.C.T. and M.T.P.) , National Psoriasis Foundation's Psoriasis Prevention Initiative (L.C.T. and J.E.G.) , and awards from the National Institutes of Health (grant nos. R01AR042742, R01AR050511, R01AR054966, R01AR063611, and R01AR065183 to J.T.E. and grant no. K01AR072129 to L.C.T.) . L.C.T. was also supported by the Dermatology Foundation, and M.T.P. was supported by a Precision Health Scholars Award from the University of Michigan. L.C.T., J.E.G., and J.T.E. are supported by the Dawn and Dudley Holmes Foundation and the Babcock Memorial Trust. J.E.G. was supported by the National Institutes of Health (grant nos. K08AR060802 and R01AR06907) and the Taubman Medical Research Institute as the Frances and Kenneth Eisenberg Emerging Scholar. L.C.T. and J.E.G. are also supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS; grant no. UM-SBDRC 1P30AR075043) and the Taubman Institute Innovation Project. J.T.E. is supported by the Ann Arbor Veterans Affairs Hospital.	Aguet F, 2020, SCIENCE, V369, P1318, DOI 10.1126/science.aaz1776; Ahouach B, 2020, BRIT J DERMATOL, V183, pE31, DOI 10.1111/bjd.19168; Amatore F, 2020, J EUR ACAD DERMATOL, V34, pE304, DOI 10.1111/jdv.16528; Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; [Anonymous], 2020, COVID 19 FREQUENTLY; [Anonymous], 2020, EVIDENCE USED UPDATE; [Anonymous], 2020, COVID 19 INFORM; Ardlie KG, 2015, SCIENCE, V348, P648, DOI 10.1126/science.1262110; Armstrong SD, 2020, TISSUE SPECIFIC TOLE; Atkinson SK, 2016, BMJ OPEN RESPIR RES, V3, DOI 10.1136/bmjresp-2015-000118; Balogh EA, 2020, J DERMATOL TREAT, V31, P327, DOI 10.1080/09546634.2020.1753996; Baniandres-Rodriguez O, 2021, J AM ACAD DERMATOL, V84, P513, DOI 10.1016/j.jaad.2020.10.046; Bhattacharjee S, 2012, AM J HUM GENET, V90, P821, DOI 10.1016/j.ajhg.2012.03.015; Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026; Blauvelt A, 2018, CLIN REV ALLERG IMMU, V55, P379, DOI 10.1007/s12016-018-8702-3; Bothra A, 2020, J EUR ACAD DERMATOL, V34, pE549, DOI 10.1111/jdv.16692; Buhl T, 2015, J INVEST DERMATOL, V135, P2198, DOI 10.1038/jid.2015.141; Caputo V, 2020, J EUR ACAD DERMATOL, V34, pE579, DOI 10.1111/jdv.16737; Centers for Disease Control and Prevention, 2020, SYMPT COR COVID 19; Chessa C, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.01155; Chu H, 2020, CLIN INFECT DIS, V71, P1400, DOI 10.1093/cid/ciaa410; Clough E, 2016, METHODS MOL BIOL, V1418, P93, DOI 10.1007/978-1-4939-3578-9_5; Colmenero I, 2020, BRIT J DERMATOL, V183, P729, DOI 10.1111/bjd.19327; Covid 19 Host Genetics Initiative, 2020, EUR J HUM GENET, V28, P715, DOI 10.1038/s41431-020-0636-6; Cronin JG, 2008, BRIT J DERMATOL, V159, P113, DOI 10.1111/j.1365-2133.2008.08627.x; De Giorgi V, 2020, J AM ACAD DERMATOL, V83, P674, DOI 10.1016/j.jaad.2020.05.073; Di Paola M, 2017, MBIO, V8, DOI 10.1128/mBio.02073-17; Diaz-Guimaraens B, 2020, JAMA DERMATOL, V156, P820, DOI 10.1001/jamadermatol.2020.1741; Diner BA, 2015, MOL CELL PROTEOMICS, V14, P2341, DOI 10.1074/mcp.M114.047068; Dinnon KH, 2020, NATURE, V586, P560, DOI 10.1038/s41586-020-2708-8; Dobin A, 2016, METHODS MOL BIOL, V1415, P245, DOI 10.1007/978-1-4939-3572-7_13; dos Santos JC, 2018, SEMIN IMMUNOL, V38, P15, DOI 10.1016/j.smim.2018.02.010; Droitcourt C, 2021, J AM ACAD DERMATOL, V84, P290, DOI 10.1016/j.jaad.2020.07.111; Duncan P, 2020, GUARDIAN; Elgarhy LH, 2020, CLIN DERMATOL, V38, P762, DOI 10.1016/j.clindermatol.2020.06.004; Ellinghaus D, 2020, NEW ENGL J MED, V383, P1522, DOI 10.1056/NEJMoa2020283; Eyerich S, 2018, TRENDS IMMUNOL, V39, P315, DOI 10.1016/j.it.2018.02.004; Fahmy DH, 2020, J EUR ACAD DERMATOL, V34, P1388, DOI 10.1111/jdv.16545; Florindo HF, 2020, NAT NANOTECHNOL, V15, P630, DOI 10.1038/s41565-020-0732-3; Freeman EE, 2020, J AM ACAD DERMATOL, V83, pE261, DOI 10.1016/j.jaad.2020.06.050; Casas CG, 2020, BRIT J DERMATOL, V183, P71, DOI 10.1111/bjd.19163; Gardien KLM, 2016, BURNS, V42, P1455, DOI 10.1016/j.burns.2016.04.018; Gaunt TR, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0926-z; Gianfrancesco M, 2021, ANN RHEUM DIS, V80, DOI 10.1136/annrheumdis-2020-218328; Gianfrancesco MA, 2020, LANCET RHEUMATOL, V2, pE250, DOI 10.1016/S2665-9913(20)30095-3; Gisondi P, 2020, BRIT J DERMATOL, V183, P373, DOI 10.1111/bjd.19158; Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015; Gu T, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.25197; Guarneri C, 2020, J EUR ACAD DERMATOL, V34, pE449, DOI 10.1111/jdv.16669; Gudjonsson JE, 2003, BRIT J DERMATOL, V149, P530, DOI 10.1046/j.1365-2133.2003.05552.x; Gudjonsson JE, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.139930; Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570; Hawkes JE, 2018, J IMMUNOL, V201, P1605, DOI 10.4049/jimmunol.1800013; Herman A, 2020, JAMA DERMATOL, V156, P998, DOI 10.1001/jamadermatol.2020.2368; Heron Melonie, 2019, Natl Vital Stat Rep, V68, P1; Illumina, 2014, RNA EXPRESS; Jabbari A, 2016, EBIOMEDICINE, V7, P240, DOI 10.1016/j.ebiom.2016.03.036; Jabbari A, 2014, J INVEST DERMATOL, V134, P87, DOI 10.1038/jid.2013.269; Kaiser H, 2019, DERMATOLOGY, V235, P478, DOI 10.1159/000502138; Kanehisa M, 2019, NUCLEIC ACIDS RES, V47, pD590, DOI 10.1093/nar/gky962; Kanehisa M, 2017, NUCLEIC ACIDS RES, V45, pD353, DOI 10.1093/nar/gkw1092; Kanitakis J, 2020, J AM ACAD DERMATOL, V83, P870, DOI 10.1016/j.jaad.2020.05.145; Kao LT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0116077; Kim D, 2019, NAT BIOTECHNOL, V37, P907, DOI 10.1038/s41587-019-0201-4; Kolivras Athanassios, 2020, JAAD Case Rep, V6, P489, DOI 10.1016/j.jdcr.2020.04.011; Kuleshov MV, 2016, NUCLEIC ACIDS RES, V44, pW90, DOI 10.1093/nar/gkw377; Kunz M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01807; Kutlu O, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13509; Lamers MM, 2020, SCIENCE, V369, P50, DOI 10.1126/science.abc1669; Langan SM, 2017, J INVEST DERMATOL, V137, P1375, DOI 10.1016/j.jid.2017.01.030; Le Bert N, 2020, NATURE, V584, P457, DOI 10.1038/s41586-020-2550-z; Lebwohl M, 2020, J AM ACAD DERMATOL, V82, P1217, DOI 10.1016/j.jaad.2020.03.031; Leuchten N, 2018, LUPUS, V27, P1431, DOI 10.1177/0961203318776093; Li BS, 2014, J INVEST DERMATOL, V134, P1828, DOI 10.1038/jid.2014.28; Li X, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145221; Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Lowes MA, 2014, ANNU REV IMMUNOL, V32, P227, DOI 10.1146/annurev-immunol-032713-120225; Ma WT, 2019, OPEN BIOL, V9, DOI 10.1098/rsob.190109; Mageau A, 2019, AUTOIMMUN REV, V18, P733, DOI 10.1016/j.autrev.2019.05.011; Magro C, 2020, TRANSL RES, V220, P1, DOI 10.1016/j.trsl.2020.04.007; Mahieu R, 2020, J EUR ACAD DERMATOL, V34, pE546, DOI 10.1111/jdv.16688; Mahil SK, 2020, BRIT J DERMATOL, V183, P404, DOI 10.1111/bjd.19161; Mahil SK, 2021, J ALLERGY CLIN IMMUN, V147, P60, DOI 10.1016/j.jaci.2020.10.007; Marzano AV, 2020, BRIT J DERMATOL, V183, P431, DOI 10.1111/bjd.19264; Mathieu Regine J, 2020, JAAD Case Rep, V6, P1360, DOI 10.1016/j.jdcr.2020.10.013; Monin L, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a028522; Motooka D, 2020, GENERATION HUMAN BRO, V2020; Munoz-Fontela C, 2020, NATURE, V586, P509, DOI 10.1038/s41586-020-2787-6; Ng CY, 2017, BRIT J DERMATOL, V177, P967, DOI 10.1111/bjd.15366; Ogdie A, 2017, ANN RHEUM DIS, V76, P1481, DOI 10.1136/annrheumdis-2017-211109; Onishi RM, 2010, IMMUNOLOGY, V129, P311, DOI 10.1111/j.1365-2567.2009.03240.x; Othumpangat S, 2016, VIROLOGY, V487, P85, DOI 10.1016/j.virol.2015.10.005; Ozaras R, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13632; Park A, 2020, CELL HOST MICROBE, V27, P870, DOI 10.1016/j.chom.2020.05.008; Paternoster L, 2015, NAT GENET, V47, P1449, DOI 10.1038/ng.3424; Patrick MT, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06672-6; Pividori M, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aba2083; Plichta JK, 2014, CRIT CARE MED, V42, pE420, DOI 10.1097/CCM.0000000000000309; Radzikowska U, 2020, ALLERGY, V75, P2829, DOI 10.1111/all.14429; Rajgor DD, 2020, LANCET INFECT DIS, V20, P776, DOI 10.1016/S1473-3099(20)30244-9; Recalcati S, 2020, J EUR ACAD DERMATOL, V34, pE346, DOI 10.1111/jdv.16533; Recalcati S, 2020, J EUR ACAD DERMATOL, V34, pE212, DOI 10.1111/jdv.16387; Rehbinder EM, 2020, J ALLER CL IMM-PRACT, V8, P664, DOI 10.1016/j.jaip.2019.09.014; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Rojas A, 2020, INFLAMM RES, V69, P641, DOI 10.1007/s00011-020-01353-x; Sanche S, 2020, EMERG INFECT DIS, V26, P1470, DOI 10.3201/eid2607.200282; Sanchez A, 2020, JAMA DERMATOL, V156, P819, DOI 10.1001/jamadermatol.2020.1704; Santonja C, 2020, BRIT J DERMATOL, V183, P778, DOI 10.1111/bjd.19338; Sette A, 2020, NAT REV IMMUNOL, V20, P457, DOI 10.1038/s41577-020-0389-z; Silverberg JI, 2015, J ALLERGY CLIN IMMUN, V135, P721, DOI 10.1016/j.jaci.2014.11.023; Singh M, 2020, J EUR ACAD DERMATOL, V34, pE378, DOI 10.1111/jdv.16628; Smits J, 2017, J INVEST DERMATOL, V137, pS212, DOI 10.1016/j.jid.2017.06.003; Sodhi CP, 2019, J IMMUNOL, V203, P3000, DOI 10.4049/jimmunol.1900579; Song J, 2021, ALLERGY, V76, P483, DOI 10.1111/all.14517; Sorensen LN, 2008, J IMMUNOL, V181, P8604, DOI 10.4049/jimmunol.181.12.8604; Stinco G, 2012, BRIT J DERMATOL, V167, P926, DOI 10.1111/j.1365-2133.2012.11043.x; Sun Y, 2017, SEMIN CELL DEV BIOL, V62, P170, DOI 10.1016/j.semcdb.2016.09.005; Swindell WR, 2017, J INVEST DERMATOL, V137, pS111, DOI 10.1186/s13073-017-0415-3; Syed MN, 2020, J AM ACAD DERMATOL, V83, P1523, DOI 10.1016/j.jaad.2020.06.1014; Takeshita J, 2018, J INVEST DERMATOL, V138, P1726, DOI 10.1016/j.jid.2018.01.039; Takeuchi O, 2000, J IMMUNOL, V165, P5392, DOI 10.4049/jimmunol.165.10.5392; Talantov D, 2005, CLIN CANCER RES, V11, P7234, DOI 10.1158/1078-0432.CCR-05-0683; Tang BM, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.02098-2016; Tao J, 2020, BRIT J DERMATOL, V182, P1477, DOI 10.1111/bjd.19011; Toyoda Y, 2014, ARTHRITIS RHEUMATOL, V66, P560, DOI 10.1002/art.38263; Trivedi NR, 2006, J INVEST DERMATOL, V126, P1071, DOI 10.1038/sj.jid.5700213; Tsoi LC, 2020, J ALLERGY CLIN IMMUN, V145, P1406, DOI 10.1016/j.jaci.2019.11.047; Tsoi LC, 2019, J INVEST DERMATOL, V139, P1480, DOI 10.1016/j.jid.2018.12.018; Tsoi LC, 2012, NAT GENET, V44, P1341, DOI 10.1038/ng.2467; Ungprasert P, 2017, J EUR ACAD DERMATOL, V31, P857, DOI 10.1111/jdv.14051; Verma AH, 2018, J IMMUNOL, V201, P627, DOI 10.4049/jimmunol.1800515; Wakkee M, 2011, J AM ACAD DERMATOL, V65, P1135, DOI 10.1016/j.jaad.2010.08.036; Wan J, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f5961; Wan MT, 2020, J AM ACAD DERMATOL, V83, P677, DOI 10.1016/j.jaad.2020.05.035; Wan MT, 2018, J AM ACAD DERMATOL, V78, P315, DOI 10.1016/j.jaad.2017.10.050; Wang QQ, 2021, MOL PSYCHIATR, V26, P30, DOI 10.1038/s41380-020-00880-7; Wang TB, 2020, LANCET, V395, pE52, DOI 10.1016/S0140-6736(20)30558-4; WHO, 2022, COVID 19 WEEKLY EPID; Salinas TRW, 2020, RESPIROLOGY, V25, P797, DOI 10.1111/resp.13875; Wilder-Smith A, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa020; Williamson EJ, 2020, NATURE, V584, P430, DOI 10.1038/s41586-020-2521-4; Woetzel D, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4526; Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]; Xu H, 2020, INT J ORAL SCI, V12, DOI [10.1038/s41368-020-0074-x, 10.1038/s41368-020-0074-X]; Xue XT, 2021, J INVEST DERMATOL, V141, P206, DOI 10.1016/j.jid.2020.05.087; Yang Y, 2016, INT J CLIN EXP MED, V9, P7986; Ye L, 2014, J INVEST DERMATOL, V134, P2843, DOI 10.1038/jid.2014.205; Ye Q, 2020, J INFECTION, V80, P607, DOI 10.1016/j.jinf.2020.03.037; Yiu ZZN, 2021, BRIT J DERMATOL, V184, P78, DOI 10.1111/bjd.19052; Zeng B, 2018, UNRAVELING POLYGENIC; Zhang B, 2020, J EUR ACAD DERMATOL, V34, pE434, DOI 10.1111/jdv.16573; Zhang XW, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8080807; Zhong M, 2020, BIORXIV; Zhou BY, 2010, P NATL ACAD SCI USA, V107, P9923, DOI 10.1073/pnas.1002757107; Zhu JG, 2007, BLOOD, V109, P619, DOI 10.1182/blood-2006-06-027136	156	23	24	1	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2021	147	3					857	+		10.1016/j.jaci.2021.01.006	http://dx.doi.org/10.1016/j.jaci.2021.01.006		MAR 2021	20	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RA9TV	33485957	Green Published, Bronze			2022-12-18	WOS:000631762400007
J	Lin, B; Berard, R; Al Rasheed, A; Aladba, B; Kranzusch, PJ; Henderlight, M; Grom, A; Kahle, D; Torreggiani, S; Aue, AG; Mitchell, J; de Jesus, AA; Schulert, GS; Goldbach-Mansky, R				Lin, Bin; Berard, Roberta; Al Rasheed, Abdulrahman; Aladba, Buthaina; Kranzusch, Philip J.; Henderlight, Maggie; Grom, Alexi; Kahle, Dana; Torreggiani, Sofia; Aue, Alexander G.; Mitchell, Jacob; de Jesus, Adriana A.; Schulert, Grant S.; Goldbach-Mansky, Raphaela			A novel STING1 variant causes a recessive form of STING-associated vasculopathy with onset in infancy (SAVI)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							CYCLIC GMP-AMP; DNA SENSOR; 2ND-MESSENGER; DINUCLEOTIDE		[Lin, Bin; Kahle, Dana; Torreggiani, Sofia; Aue, Alexander G.; Mitchell, Jacob; de Jesus, Adriana A.; Goldbach-Mansky, Raphaela] NIAID, Translat Autoinflammatory Dis Sect, Lab Clin Immunol & Microbiol, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Berard, Roberta] Western Univ, Dept Pediat, London, ON, Canada; [Al Rasheed, Abdulrahman] King Abdullah Specialized Children Hosp, Div Rheumatol, Dept Pediat, King Abdulaziz Med City, King, WI, Saudi Arabia; [Aladba, Buthaina] Sidra Med & Res Ctr, Div Rheumatol, Dept Pediat Med, Doha, Qatar; [Kranzusch, Philip J.] Harvard Med Sch, Dept Microbiol, Boston, MA 02115 USA; [Kranzusch, Philip J.] Dana Farber Canc Inst, Dept Canc Immunol & Virol, Boston, MA 02115 USA; [Henderlight, Maggie; Grom, Alexi; Schulert, Grant S.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA; [Henderlight, Maggie; Grom, Alexi; Schulert, Grant S.] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Western University (University of Western Ontario); Sidra Medical & Research Center; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Goldbach-Mansky, R (corresponding author), NIAID, Translat Autoinflammatory Dis Sect, Lab Clin Immunol & Microbiol, 9000 Rockville Pike, Bethesda, MD 20892 USA.	goldbacr@mail.nih.gov	Berard, Roberta/HGA-8473-2022; Lin, Bin/W-6461-2019	Lin, Bin/0000-0002-8032-937X; Berard, Roberta/0000-0003-2780-0617; Mitchell, Jacob/0000-0002-5370-9692	Intramural Research Program of the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases; NIH, National Institute of Arthritis, Musculoskeletal and Skin Diseases [K08 AR072075]; Cincinnati Children's Research Foundation	Intramural Research Program of the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases; NIH, National Institute of Arthritis, Musculoskeletal and Skin Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Cincinnati Children's Research Foundation	This research was supported by the Intramural Research Program of the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (to R.G.-M.); grant K08 AR072075 (to G.S.S.) from NIH, National Institute of Arthritis, Musculoskeletal and Skin Diseases; and an Academic Research and Clinical (ARC) grant from Cincinnati Children's Research Foundation (to A.G. and G.S.S.).	Ablasser A, 2019, SCIENCE, V363, P1055, DOI 10.1126/science.aat8657; Ablasser A, 2013, NATURE, V498, P380, DOI 10.1038/nature12306; Diner EJ, 2013, CELL REP, V3, P1355, DOI 10.1016/j.celrep.2013.05.009; Ergun SL, 2019, CELL, V178, P290, DOI 10.1016/j.cell.2019.05.036; Gao P, 2013, CELL, V153, P1094, DOI 10.1016/j.cell.2013.04.046; Ishikawa H, 2009, NATURE, V461, P788, DOI 10.1038/nature08476; Jeremiah N, 2014, J CLIN INVEST, V124, P5516, DOI 10.1172/JCI79100; Kim H, 2018, J INTERF CYTOK RES, V38, P171, DOI 10.1089/jir.2017.0127; Konno H, 2018, CELL REP, V23, P1112, DOI 10.1016/j.celrep.2018.03.115; Liu Y, 2014, NEW ENGL J MED, V371, P507, DOI 10.1056/NEJMoa1312625; Melki I, 2017, J ALLERGY CLIN IMMUN, V140, P543, DOI 10.1016/j.jaci.2016.10.031; Pokatayev V, 2020, NAT IMMUNOL, V21, P158, DOI 10.1038/s41590-019-0569-9; Shang GJ, 2019, NATURE, V567, P389, DOI 10.1038/s41586-019-0998-5; Srikanth S, 2019, NAT IMMUNOL, V20, P152, DOI 10.1038/s41590-018-0287-8; Sun LJ, 2013, SCIENCE, V339, P786, DOI 10.1126/science.1232458; Zhang CG, 2019, NATURE, V567, P394, DOI 10.1038/s41586-019-1000-2; Zhang X, 2013, MOL CELL, V51, P226, DOI 10.1016/j.molcel.2013.05.022	17	23	23	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2020	146	5					1204	+		10.1016/j.jaci.2020.06.032	http://dx.doi.org/10.1016/j.jaci.2020.06.032			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	OP5VH	32673614	Green Published, hybrid, Green Accepted			2022-12-18	WOS:000588153700023
J	Kracht, M; Muller-Ladner, U; Schmitz, ML				Kracht, Michael; Mueller-Ladner, Ulf; Schmitz, M. Lienhard			Mutual regulation of metabolic processes and proinflammatory NF-kappa B signaling	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						NF-kappa B; metabolism; cancer; inflammation	KINASE IKK-EPSILON; THERAPEUTIC TARGETS; ENERGY HOMEOSTASIS; INSULIN-RESISTANCE; GENE-EXPRESSION; BETA-CELLS; ACTIVATION; ALPHA; INFLAMMATION; TBK1	The nuclear factor kappa B (NF-kappa B) signaling system, a key regulator of immunologic processes, also affects a plethora of metabolic changes associated with inflammation and the immune response. NF-kappa B-regulating signaling cascades, in concert with NF-kappa B-mediated transcriptional events, control the metabolism at several levels. NF-kappa B modulates apical components of metabolic processes including metabolic hormones such as insulin and glucagon, the cellular master switches 5' AMP-activated protein kinase and mTOR, and also numerous metabolic enzymes and their respective regulators. Vice versa, metabolic enzymes and their products also exert multilevel control of NF-kappa B activity, thereby creating a highly connected regulatory network. These insights have resulted in the identification of the noncanonical I kappa B kinase kinases I kappa B kinase 3 and TBK1, which are upregulated by overnutrition, and may therefore be suitable potential therapeutic targets for metabolic syndromes. An inhibitor interfering with the activity of both kinases reduces obesity-related metabolic dysfunctions in mouse models and the encouraging results from a recent clinical trial indicate that targeting these NF-kappa B pathway components improves glucose homeostasis in a subset of patients with type 2 diabetes.	[Kracht, Michael] Justus Liebig Univ, Rudolf Buchheim Inst Pharmacol, Giessen, Germany; [Mueller-Ladner, Ulf] Justus Liebig Univ, Dept Rheumatol & Clin Immunol, Campus Kerckhoff, Bad Nauheim, Germany; [Schmitz, M. Lienhard] Justus Liebig Univ, Inst Biochem, Friedrichstr 24, D-35392 Giessen, Germany	Justus Liebig University Giessen; Justus Liebig University Giessen	Schmitz, ML (corresponding author), Justus Liebig Univ, Inst Biochem, Friedrichstr 24, D-35392 Giessen, Germany.	lienhard.schmitz@biochemie.med.uni-giessen.de	Schmitz, M. Lienhard/D-9328-2017	Schmitz, M. Lienhard/0000-0002-6984-7192	Deutsche Forschungsgemeinscha.t (German Research Foundation) [KR1143/9-2, KFO309, 284237345, TRR81/3, 183582903, SFB1213, 268555672, SFB1021, 197785619, GRK 2573, 416910386]; Excellence Cluster Cardio-Pulmonary Institute (EXC 2026: CardioPulmonary Institute) [390649896]; DZL/UGMLC program; German Ministry of Education and Research of the research consortia Molekulare Charakterisierung der Remission von Arthritis (MASCARA); MESINFLAME	Deutsche Forschungsgemeinscha.t (German Research Foundation)(German Research Foundation (DFG)); Excellence Cluster Cardio-Pulmonary Institute (EXC 2026: CardioPulmonary Institute); DZL/UGMLC program; German Ministry of Education and Research of the research consortia Molekulare Charakterisierung der Remission von Arthritis (MASCARA); MESINFLAME	This work is supported by the following grants from the Deutsche Forschungsgemeinscha.t (German Research Foundation): KR1143/9-2 (KFO309, P3 to M.K.; project 284237345), TRR81/3 (A07 to M.L.S.; B02 to M.K.; project 183582903), SFB1213 (B03 to M.K. and M.L.S.; project 268555672), SFB1021 (C01 to M.L.S.; C02 to M.K.; Z03 to M.K.; project 197785619), and GRK 2573 (RP4 to M.L.S.; RP5 to M.K.; project 416910386). Work in the laboratories of M.K. is also supported by the Excellence Cluster Cardio-Pulmonary Institute (EXC 2026: CardioPulmonary Institute, project 390649896) and the DZL/UGMLC program. The work of U.M.-L. is supported by grants of the German Ministry of Education and Research of the research consortia Molekulare Charakterisierung der Remission von Arthritis (MASCARA), project TP1, and MESINFLAME, project TP3.	ALKALAY I, 1995, P NATL ACAD SCI USA, V92, P10599, DOI 10.1073/pnas.92.23.10599; Arkan MC, 2005, NAT MED, V11, P191, DOI 10.1038/nm1185; Bakkar N, 2012, J CELL BIOL, V196, P497, DOI 10.1083/jcb.201108118; BEUTLER B, 1985, J EXP MED, V161, P984, DOI 10.1084/jem.161.5.984; Bodine SC, 2014, AM J PHYSIOL-ENDOC M, V307, pE469, DOI 10.1152/ajpendo.00204.2014; Bonizzi G, 2004, EMBO J, V23, P4202, DOI 10.1038/sj.emboj.7600391; Buss H, 2004, J BIOL CHEM, V279, P55633, DOI 10.1074/jbc.M409825200; Cai DS, 2004, CELL, V119, P285, DOI 10.1016/j.cell.2004.09.027; Cai DS, 2005, NAT MED, V11, P183, DOI 10.1038/nm1166; Calzado MA, 2007, CURR MED CHEM, V14, P367, DOI 10.2174/092986707779941113; Chiang SH, 2009, CELL, V138, P961, DOI 10.1016/j.cell.2009.06.046; Christ A, 2019, IMMUNITY, V51, P794, DOI 10.1016/j.immuni.2019.09.020; Clark K, 2011, P NATL ACAD SCI USA, V108, P17093, DOI 10.1073/pnas.1114194108; Clark K, 2009, J BIOL CHEM, V284, P14136, DOI 10.1074/jbc.M109.000414; Cogswell PC, 2003, J BIOL CHEM, V278, P2963, DOI 10.1074/jbc.M209995200; Condon KJ, 2019, J CELL SCI, V132, DOI 10.1242/jcs.222570; Dan HC, 2008, GENE DEV, V22, P1490, DOI 10.1101/gad.1662308; Durand JK, 2018, CELLS-BASEL, V7, DOI 10.3390/cells7090139; Eldor R, 2006, P NATL ACAD SCI USA, V103, P5072, DOI 10.1073/pnas.0508166103; Fitzgerald KA, 2020, CELL, V180, P1044, DOI 10.1016/j.cell.2020.02.041; Ganeshan K, 2014, ANNU REV IMMUNOL, V32, P609, DOI 10.1146/annurev-immunol-032713-120236; GRUBER PJ, 1994, NUCLEIC ACIDS RES, V22, P2417, DOI 10.1093/nar/22.12.2417; Haeusler RA, 2018, NAT REV MOL CELL BIO, V19, P31, DOI 10.1038/nrm.2017.89; Hamilton KS, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005169; Hayden MS, 2012, GENE DEV, V26, P203, DOI 10.1101/gad.183434.111; Hoesel B, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-86; Hoffmann A, 2002, SCIENCE, V298, P1241, DOI 10.1126/science.1071914; Ivanova IG, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20192101; Johnson RF, 2011, CANCER RES, V71, P5588, DOI 10.1158/0008-5472.CAN-10-4252; Jurida L, 2015, CELL REP, V10, P726, DOI 10.1016/j.celrep.2015.01.001; Kang YP, 2018, EXP MOL MED, V50, DOI 10.1038/s12276-018-0027-z; Kawauchi K, 2008, NAT CELL BIOL, V10, P611, DOI 10.1038/ncb1724; Kawauchi K, 2009, P NATL ACAD SCI USA, V106, P3431, DOI 10.1073/pnas.0813210106; Kempe S, 2005, NUCLEIC ACIDS RES, V33, P5308, DOI 10.1093/nar/gki836; Klaeschen AS, 2016, EXPERT REV CLIN PHAR, V9, P567, DOI 10.1586/17512433.2016.1145543; Kretzmann NA, 2008, INFLAMM BOWEL DIS, V14, P1504, DOI 10.1002/ibd.20543; Lawrence T, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001651; Lesueur C, 2012, BIOCHIMIE, V94, P806, DOI 10.1016/j.biochi.2011.11.012; Li H, 2008, J MOL MED, V86, P1113, DOI 10.1007/s00109-008-0373-8; Li YP, 1999, ANTIOXID REDOX SIGN, V1, P97, DOI 10.1089/ars.1999.1.1-97; Lima FD, 2013, EUR J NUTR, V52, P1343, DOI 10.1007/s00394-012-0443-0; Little RD, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06581-6; Liu T, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.23; Londhe P, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00104; Lu H, 2015, BMC GASTROENTEROL, V15, DOI 10.1186/s12876-015-0325-z; Luengo A, 2017, CELL CHEM BIOL, V24, P1161, DOI 10.1016/j.chembiol.2017.08.028; Ma CB, 2019, MOL CELLS, V42, P628, DOI 10.14348/molcells.2019.0038; Ma XL, 2012, P NATL ACAD SCI USA, V109, P9378, DOI 10.1073/pnas.1121552109; Marchlik E, 2010, J LEUKOCYTE BIOL, V88, P1171, DOI 10.1189/jlb.0210071; Mattioli I, 2006, J BIOL CHEM, V281, P6175, DOI 10.1074/jbc.M508045200; Mauro C, 2011, NAT CELL BIOL, V13, P1272, DOI 10.1038/ncb2324; Mayr-Buro C, 2019, CANCERS, V11, DOI 10.3390/cancers11081199; Muroi M, 2008, J LEUKOCYTE BIOL, V83, P702, DOI 10.1189/jlb.0907629; Myers DR, 2019, IMMUNOL REV, V291, P134, DOI 10.1111/imr.12796; Nazio F, 2013, NAT CELL BIOL, V15, P406, DOI 10.1038/ncb2708; Norlin S, 2005, DIABETES, V54, P125, DOI 10.2337/diabetes.54.1.125; Oeckinghaus A, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a000034; Oral EA, 2017, CELL METAB, V26, P157, DOI 10.1016/j.cmet.2017.06.006; Patel MN, 2015, P NATL ACAD SCI USA, V112, P506, DOI 10.1073/pnas.1414536112; Peltzer N, 2018, NATURE, V557, P112, DOI 10.1038/s41586-018-0064-8; Perkins ND, 2007, NAT REV MOL CELL BIO, V8, P49, DOI 10.1038/nrm2083; Perkins ND, 2012, NAT REV CANCER, V12, P121, DOI 10.1038/nrc3204; Puzio-Kuter Anna M, 2011, Genes Cancer, V2, P385, DOI 10.1177/1947601911409738; Rehman KK, 2003, J BIOL CHEM, V278, P9862, DOI 10.1074/jbc.M207700200; Reid MA, 2016, GENE DEV, V30, P1837, DOI 10.1101/gad.287235.116; Reilly SM, 2013, NAT MED, V19, P313, DOI 10.1038/nm.3082; Renner F, 2010, MOL CELL, V37, P503, DOI 10.1016/j.molcel.2010.01.018; Renner F, 2009, TRENDS BIOCHEM SCI, V34, P128, DOI 10.1016/j.tibs.2008.12.003; Riedlinger T, 2019, FASEB J, V33, P4188, DOI 10.1096/fj.201801638R; Riedlinger T, 2018, BIOMEDICINES, V6, DOI 10.3390/biomedicines6010036; Riedlinger T, 2017, BBA-MOL CELL RES, V1864, P1785, DOI 10.1016/j.bbamcr.2017.07.005; Santacatterina F, 2017, J TRANSL MED, V15, DOI 10.1186/s12967-017-1136-5; Saul VV, 2019, ISCIENCE, V19, P527, DOI 10.1016/j.isci.2019.08.001; Schmitz ML, 2018, BIOMEDICINES, V6, DOI 10.3390/biomedicines6020058; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; Semenza GL, 2011, COLD SH Q B, V76, P347, DOI 10.1101/sqb.2011.76.010678; Senegas A, 2015, CELL MOL LIFE SCI, V72, P1275, DOI 10.1007/s00018-014-1793-y; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Shi CS, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000751; Shi JH, 2015, MOL IMMUNOL, V68, P546, DOI 10.1016/j.molimm.2015.07.024; Shoelson SE, 2006, J CLIN INVEST, V116, P1793, DOI 10.1172/JCI29069; Singleton KD, 2008, BIOCHEM BIOPH RES CO, V373, P445, DOI 10.1016/j.bbrc.2008.06.057; Smith AC, 2019, NUCLEIC ACIDS RES, V47, pD1225, DOI 10.1093/nar/gky1072; Solaini G, 2010, BBA-BIOENERGETICS, V1797, P1171, DOI 10.1016/j.bbabio.2010.02.011; Stone OA, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06406-8; Suliman HB, 2010, J CELL SCI, V123, P2565, DOI 10.1242/jcs.064089; Suto T, 2020, J AUTOIMMUN, V110, DOI 10.1016/j.jaut.2019.102373; Szklarczyk D, 2017, NUCLEIC ACIDS RES, V45, pD362, DOI 10.1093/nar/gkw937; Tang Y, 2018, J BIOL CHEM, V293, P7578, DOI 10.1074/jbc.RA118.002727; Tenoever BR, 2007, SCIENCE, V315, P1274, DOI 10.1126/science.1136567; Tokunaga F, 2009, NAT CELL BIOL, V11, P123, DOI 10.1038/ncb1821; Van Beek M, 2012, CELL REP, V1, P444, DOI 10.1016/j.celrep.2012.04.006; Vander Heiden MG, 2017, CELL, V168, DOI 10.1016/j.cell.2016.12.039; Verstrepen L, 2014, BIOCHEM PHARMACOL, V92, P519, DOI 10.1016/j.bcp.2014.10.017; Wang XJ, 2019, MOL CELL, V76, P148, DOI 10.1016/j.molcel.2019.07.007; Wang XW, 2006, P NATL ACAD SCI USA, V103, P4204, DOI 10.1073/pnas.0507044103; WARBURG O, 1956, SCIENCE, V124, P269; Weiterer SS, 2020, EMBO J, V39, DOI 10.15252/embj.2019101533; Wellen KE, 2005, J CLIN INVEST, V115, P1111, DOI 10.1172/JCI200525102; Williams LM, 2020, DEV COMP IMMUNOL, V104, DOI 10.1016/j.dci.2019.103559; Wu H, 2003, BIOESSAYS, V25, P1096, DOI 10.1002/bies.10352; Wunderlich FT, 2008, P NATL ACAD SCI USA, V105, P1297, DOI 10.1073/pnas.0707849104; Xiao GT, 2004, J BIOL CHEM, V279, P30099, DOI 10.1074/jbc.M401428200; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159; Zha XJ, 2015, CANCER LETT, V359, P97, DOI 10.1016/j.canlet.2015.01.001; Zhang Q, 2017, CELL, V168, P37, DOI 10.1016/j.cell.2016.12.012; Zhang WS, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12351-x; Zhang XQ, 2008, CELL, V135, P61, DOI 10.1016/j.cell.2008.07.043; Zhao P, 2018, CELL, V172, P731, DOI 10.1016/j.cell.2018.01.007; Zhong ZY, 2016, CELL, V164, P896, DOI 10.1016/j.cell.2015.12.057	110	23	24	1	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2020	146	4					694	705		10.1016/j.jaci.2020.07.027	http://dx.doi.org/10.1016/j.jaci.2020.07.027			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	OH2JO	32771559	hybrid			2022-12-18	WOS:000582395800002
J	Peter, HH; Ochs, HD; Cunningham-Rundles, C; Vinh, DC; Kiessling, P; Greve, B; Jolles, S				Peter, Hans-Hartmut; Ochs, Hans D.; Cunningham-Rundles, Charlotte; Vinh, Donald C.; Kiessling, Peter; Greve, Bernhard; Jolles, Stephen			Targeting FcRn for immunomodulation: Benefits, risks, and practical considerations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						FcRn; neonatal Fc receptor; immunoglobulin; IgG; albumin; hypogammaglobulinemia; autoantibody; antibody-mediated autoimmunity; FcRn inhibitors; infection risk	TERM INTENSIVE PLASMAPHERESIS; REDUCED IMMUNOGLOBULIN LEVELS; SYSTEMIC-LUPUS-ERYTHEMATOSUS; THERAPEUTIC PLASMA-EXCHANGE; PROTEIN-LOSING ENTEROPATHY; SERUM IMMUNOGLOBULINS; INFECTIOUS COMPLICATIONS; MYCOPHENOLATE-MOFETIL; AMERICAN SOCIETY; HUMORAL IMMUNITY	The neonatal fragment crystallizable (Fc) receptor (FcRn) functions as a recycling mechanism to prevent degradation and extend the half-life of IgG and albumin in the circulation. Several FcRn inhibitors selectively targeting IgG recycling are now moving rapidly toward clinical practice in neurology and hematology. These molecules accelerate the destruction of IgG, reducing pathogenic IgG and IgG immune complexes, with no anticipated effects on IgA, IgM, IgE, complement, plasma cells, B cells, or other cells of the innate or adaptive immune systems. FcRn inhibitors have potential for future use in a much wider variety of antibody-mediated autoimmune diseases. Given the imminent clinical use, potential for broader utility, and novel mechanism of action of FcRn inhibitors, here we review data from 4 main sources: (a) currently available activity, safety, and mechanism-of-action data from clinical trials of FcRn inhibitors; (b) other procedures and treatments that also remove IgG (plasma donation, plasma exchange, immunoadsorption); (c) diseases resulting in loss of IgG; and (d) primary immunodeficiencies with potential mechanistic similarities to those induced by FcRn inhibitors. These data have been evaluated to provide practical considerations for the assessment, monitoring, and reduction of any potential infection risk associated with FcRn inhibition, in addition to highlighting areas for future research.	[Peter, Hans-Hartmut] Freiburg Univ Hosp, Ctr Chron Immunodeficiency, Freiburg, Germany; [Ochs, Hans D.] Univ Washington, Seattle Childrens Res Inst, Seattle, WA 98195 USA; [Ochs, Hans D.] Univ Washington, Dept Pediat, Seattle, WA 98195 USA; [Cunningham-Rundles, Charlotte] Icahn Sch Med Mt Sinai, Dept Med, Div Clin Immunol, New York, NY 10029 USA; [Vinh, Donald C.] McGill Univ, Dept Med, Div Infect Dis, Hlth Ctr, Montreal, PQ, Canada; [Vinh, Donald C.] McGill Univ, Hlth Ctr, Dept Med Microbiol, Montreal, PQ, Canada; [Vinh, Donald C.] McGill Univ, Hlth Ctr, Res Inst, Infect Dis & Immun Global Hlth Program, Montreal, PQ, Canada; [Kiessling, Peter; Greve, Bernhard] UCB Pharma, Monheim, Germany; [Jolles, Stephen] Univ Hosp Wales, Immunodeficiency Ctr Wales, Cardiff CF14 4XW, Wales	University of Freiburg; Seattle Children's Hospital; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Icahn School of Medicine at Mount Sinai; McGill University; McGill University; McGill University; UCB Pharma SA; Cardiff University	Jolles, S (corresponding author), Univ Hosp Wales, Immunodeficiency Ctr Wales, Cardiff CF14 4XW, Wales.	jollessr@cardiff.ac.uk		VINH, DONALD/0000-0003-1347-7767; Jolles, Stephen/0000-0002-7394-6804	UCB Pharma; Good Publications Practice (GPP3) guidelines	UCB Pharma(UCB Pharma SA); Good Publications Practice (GPP3) guidelines	Medical writing support was provided by Sarah Feaver, PhD, on behalf of iMed Comms, an Ashfield Company, part of UDG Healthcare plc, and funded by UCB Pharma in accordance with Good Publications Practice (GPP3) guidelines (http://www.ismpp.org/gpp3).The authors acknowledge Linda Feighery, PhD, CMPP, and Veronica Porkess, PhD, CMPP, of UCB Pharma for publication and editorial support. The article was reviewed and approved for publication by all authors and the sponsor.	AARLI JA, 1976, ACTA NEUROL SCAND, V54, P423, DOI 10.1111/j.1600-0404.1976.tb04374.x; Abe S, 1998, PSYCHIAT CLIN NEUROS, V52, P115, DOI 10.1111/j.1440-1819.1998.tb00983.x; Al Sinani S, 2012, WORLD J GASTROENTERO, V18, P6333, DOI 10.3748/wjg.v18.i43.6333; Ameratunga R, 2013, CLIN EXP IMMUNOL, V174, P203, DOI 10.1111/cei.12178; Ardeniz O, 2015, J ALLERGY CLIN IMMUN, V136, P392, DOI 10.1016/j.jaci.2014.12.1937; Ashrafi MR, 2010, IRAN J PEDIATR, V20, P269; Afonso AFB, 2016, BIOMOLECULES, V6, DOI 10.3390/biom6010015; Barmettler S, 2018, JAMA NETW OPEN, V1, DOI 10.1001/jamanetworkopen.2018.4169; Bazzi C, 2000, KIDNEY INT, V58, P1732, DOI 10.1046/j.1523-1755.2000.00334.x; Bechtloff S, 2005, VOX SANG, V88, P189, DOI 10.1111/j.1423-0410.2005.00632.x; Behzad M, 2012, BRIT J DERMATOL, V166, P844, DOI 10.1111/j.1365-2133.2011.10732.x; Blumberg LJ, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aax9586; BODENHEIMER HC, 1985, GASTROENTEROLOGY, V88, P412, DOI 10.1016/0016-5085(85)90500-1; Bonanni P, 2017, HUM VACC IMMUNOTHER, V13, P359, DOI 10.1080/21645515.2017.1264797; Braamskamp MJAM, 2010, EUR J PEDIATR, V169, P1179, DOI 10.1007/s00431-010-1235-2; Bril V, 2019, NEUROLOGY, V92; Bril V, 2019, NEUROLOGY, V92; Brodsky RA, 2019, NEW ENGL J MED, V381, P647, DOI 10.1056/NEJMcp1900554; Burkhardt T, 2017, TRANSFUS APHER SCI, V56, P417, DOI 10.1016/j.transci.2017.04.001; Cacoub P, 2015, AM J MED, V128, P950, DOI 10.1016/j.amjmed.2015.02.017; Carbone J, 2008, TRANSPL INFECT DIS, V10, P396, DOI 10.1111/j.1399-3062.2008.00329.x; Celiksoy MH, 2014, ANN ALLERG ASTHMA IM, V113, P467, DOI 10.1016/j.anai.2014.06.025; Chaturvedi S, 2018, BLOOD, V131, P1172, DOI 10.1182/blood-2017-09-742353; Chen XF, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004544; Chen YM, 2015, J BIOL CHEM, V290, P23826, DOI 10.1074/jbc.M115.668061; Cines DB, 2009, BLOOD, V113, P6511, DOI 10.1182/blood-2009-01-129155; Clowse MEB, 2017, ARTHRITIS RHEUMATOL, V69, P362, DOI 10.1002/art.39856; Conigliaro P, 2017, ISR MED ASSOC J, V19, P406; Consoli F. L., 2012, KIDNEY INT, V2, P139, DOI DOI 10.1038/kisup.2012.9; Copland AP, 2017, PRACT GASTROENTEROL, V41, P22; Cortese I, 2011, NEUROLOGY, V76, P294, DOI 10.1212/WNL.0b013e318207b1f6; DEBRE M, 1993, LANCET, V342, P945, DOI 10.1016/0140-6736(93)92000-J; Dechavanne C, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002403; Dechavanne C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046097; Durandy A, 2006, CURR OPIN RHEUMATOL, V18, P369, DOI 10.1097/01.bor.0000231905.12172.b5; E37, OL EPAR SUMM PROD CH; Elkon K, 2008, NAT CLIN PRACT RHEUM, V4, P491, DOI 10.1038/ncprheum0895; Farmer DG, 2013, TRANSPLANTATION, V95, P1154, DOI 10.1097/TP.0b013e3182869d05; Fassbinder T, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075-015-0603-8; FDA Center for Biologics Research, 2019, INF IMM GLOB HUM PRO; Filion CA, 2019, J ALLER CL IMM-PRACT, V7, P1277, DOI 10.1016/j.jaip.2018.12.004; FLESLAND O, 1990, Tidsskrift for den Norske Laegeforening, V110, P1936; Frangoul H, 2013, BONE MARROW TRANSPL, V48, P1456, DOI 10.1038/bmt.2013.76; Frerichs KA, 2020, HAEMATOLOGICA, V105, pE302, DOI 10.3324/haematol.2019.231860; Gafter-Gvili A, 2016, LEUKEMIA LYMPHOMA, V57, P512, DOI 10.3109/10428194.2015.1110748; Galldiks N, 2011, EUR NEUROL, V66, P183, DOI 10.1159/000331011; Gilhus NE, 2019, NAT REV DIS PRIMERS, V5, DOI 10.1038/s41572-019-0079-y; Glaesener S, 2014, ARTHRITIS RHEUMATOL, V66, P2590, DOI 10.1002/art.38736; Go T, 2004, SEIZURE-EUR J EPILEP, V13, P187, DOI 10.1016/S1059-1311(03)00086-4; Goldfarb NS, 2001, TRANSPLANTATION, V71, P242, DOI 10.1097/00007890-200101270-00013; Greco A, 2015, AUTOIMMUN REV, V14, P246, DOI 10.1016/j.autrev.2014.11.006; Grevys A, 2015, J IMMUNOL, V194, P5497, DOI 10.4049/jimmunol.1401218; GRIFFIN GD, 1982, CANCER RES, V42, P4505; Gudelja I, 2018, CELL IMMUNOL, V333, P65, DOI 10.1016/j.cellimm.2018.07.009; Gupta S, 2012, SCAND J IMMUNOL, V75, P329, DOI 10.1111/j.1365-3083.2011.02653.x; Gupta S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01056; Guptill JT, 2016, AUTOIMMUNITY, V49, P472, DOI 10.1080/08916934.2016.1214823; Hamblin AD, 2008, BRIT MED BULL, V87, P49, DOI 10.1093/bmb/ldn034; HANSBROUGH JF, 1988, PEDIATR INFECT DIS J, V7, pS49; Hartung Hans-Peter, 2010, Ther Adv Neurol Disord, V3, P205, DOI 10.1177/1756285610371146; Hedge D, 2000, ARCH DIS CHILD, V82, P234, DOI 10.1136/adc.82.3.234; Hodkinson JP, 2017, J CLIN IMMUNOL, V37, P329, DOI 10.1007/s10875-017-0381-y; HOOFNAGLE JH, 1986, GASTROENTEROLOGY, V91, P1327, DOI 10.1016/0016-5085(86)90183-6; Hoskote AU, 2012, PEDIATR CRIT CARE ME, V13, P535, DOI 10.1097/PCC.0b013e318241793d; Hostoffer R, 2005, J ALLERGY CLIN IMMUN, V115, P160, DOI [DOI 10.1016/J.JACI.2004.12.652, 10.1016/j.jaci.2004.12.652]; Howard JF, 2019, NEUROLOGY, V92, pE2661, DOI 10.1212/WNL.0000000000007600; Hull RP, 2008, BMJ-BRIT MED J, V336, P1185, DOI 10.1136/bmj.39576.709711.80; Hunter ZR, 2010, HAEMATOL-HEMATOL J, V95, P470, DOI 10.3324/haematol.2009.010348; Jaeger E, 2019, HEMATOL ONCOL, V37, P505; Kamisawa T, 2015, LANCET, V385, P1460, DOI 10.1016/S0140-6736(14)60720-0; Kasperkiewicz M, 2012, BRIT J DERMATOL, V166, P154, DOI 10.1111/j.1365-2133.2011.10585.x; KAYSEN GA, 1990, AM J NEPHROL, V10, P36, DOI 10.1159/000168192; Kelesidis T, 2010, CLIN IMMUNOL, V135, P347, DOI 10.1016/j.clim.2010.01.006; Kemper MJ, 2003, CLIN NEPHROL, V60, P242; Kiessling P, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aan1208; Kim J, 2007, CLIN IMMUNOL, V122, P146, DOI 10.1016/j.clim.2006.09.001; Kim YM, 2018, J HUM GENET, V63, P383, DOI 10.1038/s10038-017-0386-7; Kronbichler A, 2019, AUTOIMMUN REV, V18, P510, DOI 10.1016/j.autrev.2019.03.004; Kronbichler A, 2016, AUTOIMMUN REV, V15, P38, DOI 10.1016/j.autrev.2015.08.010; KRUSMANN W, 1988, STRAHLENTHER ONKOL, V164, P323; KU G, 1973, BRIT MED J, V4, P702, DOI 10.1136/bmj.4.5894.702; Lalan S, 2017, PEDIATR NEPHROL, V32, P503, DOI 10.1007/s00467-016-3487-1; Laub R, 2010, VOX SANG, V99, P220, DOI 10.1111/j.1423-0410.2010.01345.x; LEE AH, 1993, SEMIN ARTHRITIS RHEU, V22, P252, DOI 10.1016/0049-0172(93)80073-O; Lee J, 2012, INT IMMUNOPHARMACOL, V12, P42, DOI 10.1016/j.intimp.2011.10.007; Lefranc Marie-Paule, 2012, Methods Mol Biol, V882, P635, DOI 10.1007/978-1-61779-842-9_34; Lehmann HC, 2006, ARCH NEUROL-CHICAGO, V63, P930, DOI 10.1001/archneur.63.7.930; Levitt DG, 2017, CLIN EXP GASTROENTER, V10, P147, DOI 10.2147/CEG.S136803; LEVY J, 1972, J CLIN INVEST, V51, P2233, DOI 10.1172/JCI107031; Li M, 2019, J HUM GENET, V64, P265, DOI 10.1038/s10038-018-0552-6; Lieker I, 2017, J CLIN APHERESIS, V32, P486, DOI 10.1002/jca.21546; Ling LE, 2019, CLIN PHARMACOL THER, V105, P1031, DOI 10.1002/cpt.1276; LORBER A, 1978, ARTHRITIS RHEUM, V21, P785, DOI 10.1002/art.1780210708; LORINI R, 1983, THYMUS, V5, P61; Maccioni L, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5172-8; McWilliams LM, 2015, J ALLER CL IMM-PRACT, V3, P585, DOI 10.1016/j.jaip.2015.01.026; Mikulska M, 2018, CLIN MICROBIOL INFEC, V24, pS71, DOI 10.1016/j.cmi.2018.02.003; MLADENOVIC V, 1995, ARTHRITIS RHEUM-US, V38, P1595, DOI 10.1002/art.1780381111; Mohn N, 2020, NEUROL-NEUROIMMUNOL, V7, DOI 10.1212/NXI.0000000000000654; Morrison VA, 2009, CLIN LYMPHOMA MYELOM, V9, P365, DOI 10.3816/CLM.2009.n.071; Morsheimer MM, 2016, J ALLER CL IMM-PRACT, V4, P491, DOI 10.1016/j.jaip.2015.11.034; MUFTI GJ, 1986, BRIT J HAEMATOL, V63, P143, DOI 10.1111/j.1365-2141.1986.tb07504.x; Nagelkerke SQ, 2015, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00674; Newland AC, 2020, AM J HEMATOL, V95, P178, DOI 10.1002/ajh.25680; NHS medical data solutions services, 2018, 8 NAT IMM DAT REP 20; Nieters A., 2017, INT J RESPIR MED, V2, P6; Nieters A, 2019, SLEEP, V42, DOI 10.1093/sleep/zsz098; Onda M, 2014, J IMMUNOL, V193, P48, DOI 10.4049/jimmunol.1400063; Ozen A, 2017, NEW ENGL J MED, V377, P52, DOI 10.1056/NEJMoa1615887; Padmanabhan A, 2019, J CLIN APHERESIS, V34, P171, DOI 10.1002/jca.21705; Patel DD, 2020, J ALLERGY CLIN IMMUN, P2020; Patel SY, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00033; Perez EE, 2017, J ALLERGY CLIN IMMUN, V139, pS1, DOI 10.1016/j.jaci.2016.09.023; Perez-Persona E, 2007, BLOOD, V110, P2586, DOI 10.1182/blood-2007-05-088443; Ponsford M, 2019, BRIT J PSYCHIAT, V214, P83, DOI 10.1192/bjp.2018.152; Pyzik M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01540; Rajala HLM, 2017, J CANCER RES CLIN, V143, P1543, DOI 10.1007/s00432-017-2378-6; Ritter ML, 2009, TRANSPL INFECT DIS, V11, P290, DOI 10.1111/j.1399-3062.2009.00407.x; ROBAK T, 2019, BLOOD S, V134, DOI DOI 10.1182/blood-2019-129839; Robak T, BLOOD ADV; Roggenbuck JJ, 2018, ANN TRANSL MED, V6, DOI 10.21037/atm.2018.07.34; Sadat MA, 2014, NEW ENGL J MED, V370, P1615, DOI 10.1056/NEJMoa1302846; Sand KMK, 2015, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00682; Sarmiento E, 2005, TRANSPL P, V37, P4046, DOI 10.1016/j.transproceed.2005.09.153; Sasson SC, 2019, J MED CASE REP, V13, DOI 10.1186/s13256-019-2285-3; Schmaldienst S, 2001, RHEUMATOLOGY, V40, P513, DOI 10.1093/rheumatology/40.5.513; Schulzki T, 2006, VOX SANG, V91, P162, DOI 10.1111/j.1423-0410.2006.00794.x; Schwenger V, 2010, NEPHROL DIAL TRANSPL, V25, P2407, DOI 10.1093/ndt/gfq264; Sepulveda A, 2018, LANCET GASTROENTEROL, V3, P518, DOI 10.1016/S2468-1253(18)30140-7; Shock A, 2020, J ALLERY CLIN IMMUNO; Som S, 2012, TRANSFUSION, V52; Som S, 2012, TRANSFUSION, V52, P2525, DOI 10.1111/j.1537-2995.2012.03646.x; Sorrig R, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188988; Stapleton NM, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1608; Steegmann JL, 2003, HAEMATOLOGICA, V88, P762; Stohl W, 2012, ARTHRITIS RHEUM-US, V64, P2328, DOI 10.1002/art.34400; Strengers PFW, 2016, TRANSFUSION, V56, P3133, DOI 10.1111/trf.13913; Sun C, 2015, BLOOD, V126, P2213, DOI 10.1182/blood-2015-04-639203; Svalheim S, 2013, ACTA NEUROL SCAND, V127, P11, DOI 10.1111/ane.12044; Tamburello A, 2019, CLINICS PRACT, V9, P51, DOI 10.4081/cp.2019.1112; Thevarajan I, 2020, NAT MED, V26, P453, DOI 10.1038/s41591-020-0819-2; Thiel J, 2017, J ALLER CL IMM-PRACT, V5, P1556, DOI 10.1016/j.jaip.2017.07.027; Thiel J, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075-017-1306-0; Tran-Mi B, 2004, VOX SANG, V86, P189, DOI 10.1111/j.0042-9007.2004.00408.x; Ueda M, 2018, BLOOD REV, V32, P106, DOI 10.1016/j.blre.2017.09.003; Ulrichts P, 2018, J CLIN INVEST, V128, P4372, DOI 10.1172/JCI97911; Venhoff N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037626; Versprille LJFW, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16234743; WALDMANN TA, 1990, J CLIN INVEST, V86, P2093, DOI 10.1172/JCI114947; Winkelstein JA, 2006, MEDICINE, V85, P193, DOI 10.1097/01.md.0000229482.27398.ad; Winters JL, 2012, HEMATOL-AM SOC HEMAT, P7, DOI 10.1182/asheducation-2012.1.7; Wirsum C, 2016, J CLIN IMMUNOL, V36, P406, DOI 10.1007/s10875-016-0264-7; Wong GK, 2013, CLIN EXP IMMUNOL, V172, P63, DOI 10.1111/cei.12039; Yanez L, 2019, HEMASPHERE, V3, DOI 10.1097/HS9.0000000000000186; Yel L, 2010, J CLIN IMMUNOL, V30, P10, DOI 10.1007/s10875-009-9357-x; Zugmaier G, 2014, BLOOD CANCER J, V4, DOI 10.1038/bcj.2014.64	156	23	24	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2020	146	3					479	+		10.1016/j.jaci.2020.07.016	http://dx.doi.org/10.1016/j.jaci.2020.07.016			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NO0HS	32896308	hybrid, Green Published, Green Accepted			2022-12-18	WOS:000569168900002
J	Hartmann, K; Gotlib, J; Akin, C; Hermine, O; Awan, FT; Hexner, E; Mauro, MJ; Menssen, HD; Redhu, S; Knoll, S; Sotlar, K; George, TI; Horny, HP; Valent, P; Reiter, A; Kluin-Nelemans, HC				Hartmann, Karin; Gotlib, Jason; Akin, Cem; Hermine, Olivier; Awan, Farrukh T.; Hexner, Elizabeth; Mauro, Michael J.; Menssen, Hans D.; Redhu, Suman; Knoll, Stefanie; Sotlar, Karl; George, Tracy I.; Horny, Hans-Peter; Valent, Peter; Reiter, Andreas; Kluin-Nelemans, Hanneke C.			Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Advanced systemic mastocytosis; KIT mutation; mastocytosis; mediator symptoms; midostaurin; quality of life; tryptase; skin lesions of mastocytosis	RESPONSE CRITERIA; ASSESSMENT SCALE; CANCER-PATIENTS; CLASSIFICATION; EFFICACY; SAFETY; RELIABILITY; PREVALENCE; VALIDATION; ACTIVATION	Background: Advanced systemic mastocytosis (advSM) is characterized by presence of the KIT D816V mutation and pathologic accumulation of neoplastic mast cells (MCs) in various tissues, leading to severe symptoms and organ damage (eg, cytopenias, liver dysfunction, portal hypertension, malabsorption, and weight loss). Treatment with midostaurin, an orally active multikinase/KIT inhibitor now approved for advSM in the United States and the European Union, resulted in a high rate of response accompanied by reduced MC infiltration of the bone marrow and lowered serum tryptase level. Objective: We aimed to determine whether midostaurin improves health-related quality of life (QOL) and MC mediator related symptoms in patients with advSM. Methods: In 116 patients with systemic mastocytosis (89 patients with advSM fulfilling the strict inclusion criteria of the D2201 study [ClinicalTrials.gov identifier NCT00782067]), QOL and symptom burden were assessed during treatment with midostaurin by using the 12-Item Short-Form Health Survey (SF-12) and the Memorial Symptom Assessment Scale patient reported questionnaires, respectively. MC mediator related symptoms were evaluated by using a specific physician-reported questionnaire Results: Over the first 6 cycles of treatment with midostaurin (ie, 6 months), patients experienced significant improvements in total SF-12 and Memorial Symptom Assessment Scale scores, as well as in subscores of each instrument. These improvements were durable during 36 months of follow-up. Similarly, we found substantial improvements (67%-100%) in all MC mediator related symptoms. Conclusion: QOL and MC mediator related symptoms significantly improve with midostaurin treatment in patients with advSM (ClinicalTrials.gov identifier, NCT00782067).	[Hartmann, Karin] Univ Basel, Dept Dermatol, Div Allergy, Petersgraben 4, CH-4031 Basel, Switzerland; [Hartmann, Karin] Univ Basel, Dept Biomed, Basel, Switzerland; [Gotlib, Jason] Stanford Univ, Sch Med, Stanford, CA 94305 USA; [Akin, Cem] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA; [Hermine, Olivier] Univ Paris 05, Inst Imagine, Ctr Reference Mastocytoses, Paris, France; [Awan, Farrukh T.] Univ Texas Southwestern Med Ctr Dallas, Harold C Simmons Comprehens Canc Ctr, Dallas, TX 75390 USA; [Hexner, Elizabeth] Univ Penn, Philadelphia, PA 19104 USA; [Mauro, Michael J.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA; [Menssen, Hans D.; Redhu, Suman] Novartis Pharma AG, Basel, Switzerland; [Knoll, Stefanie] Novartis Pharmaceut, E Hanover, NJ USA; [Sotlar, Karl] Paracelsus Med Univ Salzburg, Inst Pathol, Salzburg, Austria; [George, Tracy I.] Univ Utah, Salt Lake City, UT USA; [George, Tracy I.] ARUP Labs, Salt Lake City, UT USA; [Horny, Hans-Peter] Ludwig Maximilian Univ Munich, Munich, Germany; [Valent, Peter] Med Univ Vienna, Dept Internal Med 1, Div Hematol & Hemostaseol, Vienna, Austria; [Valent, Peter] Med Univ Vienna, Ludwig Boltzmann Cluster Oncol, Vienna, Austria; [Reiter, Andreas] Heidelberg Univ, Univ Hosp Mannheim, Dept Hematol & Oncol, Mannheim, Germany; [Kluin-Nelemans, Hanneke C.] Univ Groningen, Univ Med Ctr Groningen, Dept Hematol, Groningen, Netherlands	University of Basel; University of Basel; Stanford University; Harvard University; Brigham & Women's Hospital; UDICE-French Research Universities; Universite Paris Cite; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Pennsylvania; Memorial Sloan Kettering Cancer Center; Novartis; Novartis; Paracelsus Private Medical University; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; ARUP Laboratories; University of Munich; Medical University of Vienna; Ludwig Boltzmann Institute; Medical University of Vienna; Ruprecht Karls University Heidelberg; University of Groningen	Hartmann, K (corresponding author), Univ Basel, Dept Dermatol, Div Allergy, Petersgraben 4, CH-4031 Basel, Switzerland.	karin.hartmann@usb.ch	Hartmann, Karin/N-4865-2015; George, Tracy I./GRY-0951-2022; Valent, Peter/B-8533-2016; Hermine, Olivier/Q-7072-2018	Hartmann, Karin/0000-0002-4595-8226; Valent, Peter/0000-0003-0456-5095; 	German Research Council (Deutsche Forschungsgemeinschaft) [HA 2393/6-1]; University of Basel; Charles and Ann Johnson Foundation; Austrian Science Fund [SFB F4704]	German Research Council (Deutsche Forschungsgemeinschaft)(German Research Foundation (DFG)); University of Basel; Charles and Ann Johnson Foundation; Austrian Science Fund(Austrian Science Fund (FWF))	K.H. was supported by the German Research Council (Deutsche Forschungsgemeinschaft, project HA 2393/6-1) and intramural funding of the University of Basel. J.G. was supported by the Charles and Ann Johnson Foundation. A research grant from the Austrian Science Fund (project SFB F4704) was provided to P.V.	Arber DA, 2016, BLOOD, V127, P2391, DOI 10.1182/blood-2016-03-643544; Barete S, 2015, BLOOD, V126, P1009, DOI 10.1182/blood-2014-12-614743; Castells M, 2002, INT ARCH ALLERGY IMM, V127, P147, DOI 10.1159/000048188; Chang Victor T, 2004, Expert Rev Pharmacoecon Outcomes Res, V4, P171, DOI 10.1586/14737167.4.2.171; Chang VT, 2004, J CLIN ONCOL, V22, p795S; Cohen SS, 2014, BRIT J HAEMATOL, V166, P521, DOI 10.1111/bjh.12916; DeAngelo DJ, 2018, LEUKEMIA, V32, P470, DOI 10.1038/leu.2017.234; Deshields T, 2014, SUPPORT CARE CANCER, V22, P1089, DOI 10.1007/s00520-013-2049-3; Gotlib J, 2016, NEW ENGL J MED, V374, P2530, DOI 10.1056/NEJMoa1513098; Gotlib J, 2013, BLOOD, V121, P2393, DOI 10.1182/blood-2012-09-458521; Gruson B, 2013, BRIT J HAEMATOL, V161, P434, DOI 10.1111/bjh.12265; Hartmann K, 2016, J ALLERGY CLIN IMMUN, V137, P35, DOI 10.1016/j.jaci.2015.08.034; Horny HP, 2007, PATHOBIOLOGY, V74, P121, DOI 10.1159/000101711; Kenzik KM, 2015, CANCER-AM CANCER SOC, V121, P2831, DOI 10.1002/cncr.29415; Kluin-Nelemans HC, 2003, BLOOD, V102, P4270, DOI 10.1182/blood-2003-05-1699; KLUINNELEMANS HC, 1992, NEW ENGL J MED, V326, P619, DOI 10.1056/NEJM199202273260907; Kosinski M, 1995, SF 12 SCORE SF 12 PH; Krauth MT, 2009, CLIN EXP ALLERGY, V39, P1711, DOI 10.1111/j.1365-2222.2009.03353.x; Lim KH, 2009, BLOOD, V113, P5727, DOI 10.1182/blood-2009-02-205237; Pardanani A, 2010, EUR J HAEMATOL, V84, P371, DOI 10.1111/j.1600-0609.2010.01407.x; Pardanani A, 2016, AM J HEMATOL, V91, P1147, DOI 10.1002/ajh.24553; Paul C, 2010, AM J HEMATOL, V85, P921, DOI 10.1002/ajh.21894; Peter B, 2016, LEUKEMIA, V30, P464, DOI 10.1038/leu.2015.242; Pettersson G, 2014, SUPPORT CARE CANCER, V22, P1171, DOI 10.1007/s00520-013-2069-z; PORTENOY RK, 1994, EUR J CANCER, V30A, P1326, DOI 10.1016/0959-8049(94)90182-1; Scherber R, 2011, BLOOD, V118, P401, DOI 10.1182/blood-2011-01-328955; Siebenhaar F, 2016, ALLERGY, V71, P869, DOI 10.1111/all.12842; Sperr WR, 2002, INT ARCH ALLERGY IMM, V128, P136, DOI 10.1159/000059404; Valent P, 2007, EUR J CLIN INVEST, V37, P435, DOI 10.1111/j.1365-2362.2007.01807.x; Valent P, 2017, ANN ONCOL, V28, P2367, DOI 10.1093/annonc/mdx290; Valent P, 2001, LEUKEMIA RES, V25, P603, DOI 10.1016/S0145-2126(01)00038-8; Valent P, 2017, BLOOD, V129, P1420, DOI 10.1182/blood-2016-09-731893; Valent P, 2017, CANCER RES, V77, P1261, DOI 10.1158/0008-5472.CAN-16-2234; van Anrooij B, 2016, ALLERGY, V71, P1585, DOI 10.1111/all.12920; van Anrooij B, 2018, J ALLERGY CLIN IMMUN, V142, P1006, DOI 10.1016/j.jaci.2018.06.003; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003	36	23	23	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2020	146	2					356	+		10.1016/j.jaci.2020.03.044	http://dx.doi.org/10.1016/j.jaci.2020.03.044			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MZ0TA	32437738	hybrid, Green Published			2022-12-18	WOS:000558835000026
J	Do, AN; Watson, CT; Cohain, AT; Griffin, RS; Grishin, A; Wood, RA; Burks, AW; Jones, SM; Scurlock, A; Leung, DYM; Sampson, HA; Sicherer, SH; Sharp, AJ; Schadt, EE; Bunyavanich, S				Do, Anh N.; Watson, Corey T.; Cohain, Ariella T.; Griffin, Robert S.; Grishin, Alexander; Wood, Robert A.; Burks, A. Wesley; Jones, Stacie M.; Scurlock, Amy; Leung, Donald Y. M.; Sampson, Hugh A.; Sicherer, Scott H.; Sharp, Andrew J.; Schadt, Eric E.; Bunyavanich, Supinda			Dual transcriptomic and epigenomic study of reaction severity in peanut-allergic children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food allergy; peanut allergy; reaction severity; transcriptome; epigenome; integrated network; causal mediation	FOOD ALLERGY; GENE; EXPRESSION; IGE; ANAPHYLAXIS; ACTIVATION; CHALLENGES; RECEPTORS; UPDATE; ASTHMA	Background: Unexpected allergic reactions to peanut are the most common cause of fatal food-related anaphylaxis. Mechanisms underlying the variable severity of peanut-allergic reactions remain unclear. Objectives: We sought to expand mechanistic understanding of reaction severity in peanut allergy. Methods: We performed an integrated transcriptomic and epigenomic study of peanut-allergic children as they reacted in vivo during double-blind, placebo-controlled peanut challenges. We integrated whole-blood transcriptome and CD41 T-cell epigenome profiles to identify molecular signatures of reaction severity (ie, how severely a peanut-allergic child reacts when exposed to peanut). A threshold-weighted reaction severity score was calculated for each subject based on symptoms experienced during peanut challenge and the eliciting dose. Through linear mixed effects modeling, network construction, and causal mediation analysis, we identified genes, CpGs, and their interactions that mediate reaction severity. Findings were replicated in an independent cohort. Results: We identified 318 genes with changes in expression during the course of reaction associated with reaction severity, and 203 CpG sites with differential DNA methylation associated with reaction severity. After replicating these findings in an independent cohort, we constructed interaction networks with the identified peanut severity genes and CpGs. These analyses and leukocyte deconvolution highlighted neutrophil-mediated immunity. We identified NFKBIA and ARG1 as hubs in the networks and 3 groups of interacting key node CpGs and peanut severity genes encompassing immune response, chemotaxis, and regulation of macroautophagy. In addition, we found that gene expression of PHACTR1 and ZNF121 causally mediates the association between methylation at corresponding CpGs and reaction severity, suggesting that methylation may serve as an anchor upon which gene expression modulates reaction severity. Conclusions: Our findings enhance current mechanistic understanding of the genetic and epigenetic architecture of reaction severity in peanut allergy.	[Do, Anh N.; Watson, Corey T.; Cohain, Ariella T.; Sharp, Andrew J.; Schadt, Eric E.; Bunyavanich, Supinda] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA; [Watson, Corey T.] Univ Louisville, Sch Med, Dept Biochem & Mol Genet, Louisville, KY 40292 USA; [Griffin, Robert S.] Hosp Special Surg, Dept Anesthesia, 535 E 70th St, New York, NY 10021 USA; [Grishin, Alexander; Sampson, Hugh A.; Sicherer, Scott H.; Bunyavanich, Supinda] Icahn Sch Med Mt Sinai, Dept Pediat, Div Allergy & Immunol, New York, NY 10029 USA; [Wood, Robert A.] Johns Hopkins Univ, Dept Pediat, Baltimore, MD 21218 USA; [Burks, A. Wesley] Univ N Carolina, Dept Pediat, Chapel Hill, NC 27515 USA; [Jones, Stacie M.; Scurlock, Amy] Univ Arkansas Med Sci, Dept Pediat, Little Rock, AR 72205 USA; [Jones, Stacie M.; Scurlock, Amy] Arkansas Childrens Hosp, 800 Marshall St, Little Rock, AR 72202 USA; [Leung, Donald Y. M.] Natl Jewish Hlth, Dept Pediat, Denver, CO USA	Icahn School of Medicine at Mount Sinai; University of Louisville; Icahn School of Medicine at Mount Sinai; Johns Hopkins University; University of North Carolina; University of North Carolina Chapel Hill; University of Arkansas System; University of Arkansas Medical Sciences; Arkansas Children's Hospital; National Jewish Health	Bunyavanich, S (corresponding author), Icahn Sch Med Mt Sinai, 1425 Madison Ave,1498, New York, NY 10029 USA.	supinda@post.harvard.edu			National Institutes of Health [R01AI118833, U19AI136053, U19AI066738, U01AI066560]; Mindich Child Health and Development Institute at Mount Sinai [UL1 TR-002535]; Mount Sinai [UL1 TR-000067]; University of Arkansas [UL1 TR-000039]; University of North Carolina [UL1 TR-000083]; National Center for Research Resources, a component of the National Institutes of Health [UL1 TR-000424]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI136053] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Mindich Child Health and Development Institute at Mount Sinai; Mount Sinai; University of Arkansas; University of North Carolina; National Center for Research Resources, a component of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This study was supported by the National Institutes of Health (grant nos. R01AI118833, U19AI136053, U19AI066738, and U01AI066560) and the Mindich Child Health and Development Institute at Mount Sinai. The project was also supported by National Jewish (grant no. UL1 TR-002535), Mount Sinai (grant no. UL1 TR-000067), University of Arkansas (grant no. UL1 TR-000039), University of North Carolina (grant no. UL1 TR-000083), and Johns Hopkins (grant no. UL1 TR-000424) from the National Center for Research Resources, a component of the National Institutes of Health. The funding bodies had no role in the collection, analysis, or interpretation of data, or the writing of the manuscript.	Arias K, 2011, J ALLERGY CLIN IMMUN, V127, P1552, DOI 10.1016/j.jaci.2011.03.044; Ariffin JK, 2016, J LEUKOCYTE BIOL, V100, P155, DOI 10.1189/jlb.2AB0815-339R; Asai Y, 2018, J ALLERGY CLIN IMMUN, V141, P991, DOI 10.1016/j.jaci.2017.09.015; Bogdan C, 2015, TRENDS IMMUNOL, V36, P161, DOI 10.1016/j.it.2015.01.003; Bunyavanich S., 2014, J ALLERGY CLIN IMMUN, V134, P2011; Flinn A, 2013, CURR ALLERGY ASTHM R, V13, P645, DOI 10.1007/s11882-013-0369-5; Flinterman AE, 2008, J ALLERGY CLIN IMMUN, V121, P737, DOI 10.1016/j.jaci.2007.11.039; Herwig R, 2016, NAT PROTOC, V11, P1889, DOI 10.1038/nprot.2016.117; Hong XM, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7304; Jaffe AE, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-2-r31; Jonsson F, 2011, J CLIN INVEST, V121, P1484, DOI 10.1172/JCI45232; Johnstone IM, 2009, PHILOS T R SOC A, V367, P4237, DOI 10.1098/rsta.2009.0159; Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230; Kosoy R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163831; Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559; Lawrence T, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001651; Lewis SA, 2005, CLIN EXP ALLERGY, V35, P767, DOI 10.1111/j.1365-2222.2005.02252.x; Ling MF, 2016, ANN AM THORAC SOC, V13, pS25, DOI 10.1513/AnnalsATS.201507-431MG; Litonjua AA, 2008, AM J RESP CRIT CARE, V178, P688, DOI 10.1164/rccm.200709-1363OC; Luo A, 2018, FEBS OPEN BIO, V8, P1943, DOI 10.1002/2211-5463.12530; Martino DJ, 2012, ALLERGY, V67, P191, DOI 10.1111/j.1398-9995.2011.02737.x; Martino D, 2014, EPIGENETICS-US, V9, P998, DOI 10.4161/epi.28945; McGowan EC, 2013, J ALLERGY CLIN IMMUN, V132, P1216, DOI 10.1016/j.jaci.2013.07.018; Monticelli LA, 2016, NAT IMMUNOL, V17, P656, DOI 10.1038/ni.3421; Munoz-Cano R, 2016, J INVEST ALLERG CLIN, V26, P73, DOI 10.18176/jiaci.0046; Munoz-Cano R, 2016, J ALLERGY CLIN IMMUN, V137, P137, DOI 10.1016/j.jaci.2015.05.042; National Institute of Allergy and Infectious Diseases, 2010, FOOD ALL QUICK FACTS; Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/NMETH.3337, 10.1038/nmeth.3337]; Nimmerjahn F, 2008, NAT REV IMMUNOL, V8, P34, DOI 10.1038/nri2206; Ogino K, 2013, INFLAMMATION, V36, P141, DOI 10.1007/s10753-012-9529-3; Paparo L, 2016, CLIN EPIGENETICS, V8, DOI 10.1186/s13148-016-0252-z; Pettersson ME, 2018, ALLERGY, V73, P1532, DOI 10.1111/all.13423; Polloni L, 2017, ALLERGY, V72, P1054, DOI 10.1111/all.13097; Reber LL, 2013, J ALLERGY CLIN IMMUN, V132, P881, DOI 10.1016/j.jaci.2013.06.008; Reschen ME, 2016, ATHEROSCLEROSIS, V250, P95, DOI 10.1016/j.atherosclerosis.2016.04.025; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Rolinck-Werninghaus C, 2012, ALLERGY, V67, P951, DOI 10.1111/j.1398-9995.2012.02838.x; */* S   5, 2010, J ALLERGY CLIN IMM S, V126, pS, DOI DOI 10.1016/J.JACI.2010.10.007; Sampson HA, 2012, J ALLERGY CLIN IMMUN, V130, P1260, DOI 10.1016/j.jaci.2012.10.017; Saulnier N, 2012, EUR REV MED PHARMACO, V16, P1197; Schuliga M, 2015, BIOMOLECULES, V5, P1266, DOI 10.3390/biom5031266; Shaker MS, 2017, CURR OPIN PEDIATR, V29, P497, DOI 10.1097/MOP.0000000000000509; Sicherer SH, 2018, J ALLERGY CLIN IMMUN, V141, P41, DOI 10.1016/j.jaci.2017.11.003; Sicherer SH, 2000, J ALLERGY CLIN IMMUN, V106, P53, DOI [10.1067/mai.2000.108105, 10.1067/mai.2000.110158]; Song Y, 2015, ANN ALLERG ASTHMA IM, V114, P319, DOI 10.1016/j.anai.2015.01.006; Supek F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021800; Syed A, 2014, J ALLERGY CLIN IMMUN, V133, P500, DOI 10.1016/j.jaci.2013.12.1037; Turner PJ, 2016, ALLERGY, V71, P1241, DOI 10.1111/all.12924; Uppal K, 2018, BIOINFORMATICS, V34, P701, DOI 10.1093/bioinformatics/btx656; van Egmond M, 2015, IMMUNOL REV, V268, P311, DOI 10.1111/imr.12333; van Iterson M, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-016-1131-9; Wainstein BK, 2010, PEDIAT ALLERG IMM-UK, V21, P603, DOI 10.1111/j.1399-3038.2010.01063.x; Watson CT, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-02188-7	53	23	23	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2020	145	4					1219	1230		10.1016/j.jaci.2019.10.040	http://dx.doi.org/10.1016/j.jaci.2019.10.040			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LA0FR	31838046	Green Accepted			2022-12-18	WOS:000523633400018
J	Pomes, A; Glesner, J; Calatroni, A; Visness, CM; Wood, RA; O'Connor, GT; Kattan, M; Bacharier, LB; Wheatley, LM; Gem, JE; Busse, WW; Wood, R; Matsui, E; Lederman, H; Witter, F; Leimenstoll, S; Scott, D; Cootauco, M; Jones, P; O'Connor, G; Cruikshank, W; Sandel, M; Lee-Parritz, A; Jordan, C; Gjerasi, E; Price-Johnson, P; Gagalis, L; Wang, L; Gonzalez, N; Tuzova, M; Gold, D; Wright, R; Kaftan, M; Lamm, C; Whitney, N; Yaniv, P; Pierce, M; Sampson, H; Sperling, R; Rivers, N; Bloomberg, G; Bacharier, L; Sadovsky, Y; Tesson, E; Koerkenmeier, C; Sharp, R; Ray, K; Durrange, J; Bauer, I; Freie, A; Morgan, V; Visness, C; Zook, P; Yaeger, M; Martin, J; Calatroni, A; Jaffee, K; Taylor, W; Budrevich, R; Mitchell, H; Busse, W; Gem, J; Heinritz, P; Sorkness, C; Hernandez, K; Bochkov, Y; Grindle, K; Dresen, A; Pappas, T; Renneberg, M; Stoffel, B; Gergen, P; Togias, A; Smartt, E; Thompson, K				Pomes, Anna; Glesner, Jill; Calatroni, Agustin; Visness, Cindy M.; Wood, Robert A.; O'Connor, George T.; Kattan, Meyer; Bacharier, Leonard B.; Wheatley, Lisa M.; Gem, James E.; Busse, William W.; Wood, R.; Matsui, E.; Lederman, H.; Witter, F.; Leimenstoll, S.; Scott, D.; Cootauco, M.; Jones, P.; O'Connor, G.; Cruikshank, W.; Sandel, M.; Lee-Parritz, A.; Jordan, C.; Gjerasi, E.; Price-Johnson, P.; Gagalis, L.; Wang, L.; Gonzalez, N.; Tuzova, M.; Gold, D.; Wright, R.; Kaftan, M.; Lamm, C.; Whitney, N.; Yaniv, P.; Pierce, M.; Sampson, H.; Sperling, R.; Rivers, N.; Bloomberg, G.; Bacharier, L.; Sadovsky, Y.; Tesson, E.; Koerkenmeier, C.; Sharp, R.; Ray, K.; Durrange, J.; Bauer, I; Freie, A.; Morgan, V; Visness, C.; Zook, P.; Yaeger, M.; Martin, J.; Calatroni, A.; Jaffee, K.; Taylor, W.; Budrevich, R.; Mitchell, H.; Busse, W.; Gem, J.; Heinritz, P.; Sorkness, C.; Hernandez, K.; Bochkov, Y.; Grindle, K.; Dresen, A.; Pappas, T.; Renneberg, M.; Stoffel, B.; Gergen, P.; Togias, A.; Smartt, E.; Thompson, K.		NIAD Funded Inner-City Asthma Cons	Cockroach allergen component analysis of children with or without asthma and rhinitis in an inner-city birth cohort	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Cockroach allergy; cockroach allergen components; asthma; rhinitis; diagnosis; immunotherapy	GLUTATHIONE-S-TRANSFERASE; GERMAN-COCKROACH; BLATTELLA-GERMANICA; BINDING PROTEINS; MITE ALLERGEN; IGE; SENSITIZATION; RESPONSES; SEVERITY; EXPOSURE	Background: Cockroach is one of the most important sources of indoor allergens and can lead to IgE sensitization and development of rhinitis and asthma. Objective: We sought to perform a cockroach allergen component analysis to determine the allergens and antibody levels and patterns of sensitization associated with asthma and rhinitis. Methods: Antibody (IgE, IgG, and IgG(4)) levels to total cockroach and 8 cockroach allergens were determined in 2 groups of cockroach-sensitized 10-year-old children with (n = 19) or without (n = 28) asthma and rhinitis. Allergen-specific antibody levels were measured in streptavidin ImmunoCAPs loaded with each of the recombinant allergens from groups 1, 2, 4, 5, 6, 7, 9, and 11, and total cockroach-specific IgE levels were measured with the i6 ImmunoCAP. Results: IgE antibody levels to cockroach allergens and extract, but not IgG or IgG(4) antibody levels, differed between subjects with and without asthma and rhinitis. Specifically, recognition of more cockroach allergens with higher allergen-specific IgE levels was associated with disease. Variable patterns of sensitization with no immunodominant allergens were found in both groups. There was a good correlation between the sum of allergen-specific IgE and total cockroach IgE levels (r = 0.86, P < .001). Conclusions: Component analysis of 8 cockroach allergens revealed significant differences in IgE reactivity associated with the presence of asthma and rhinitis. Allergen-specific IgE titers and sensitization profiles were associated with asthma and rhinitis.	[Pomes, Anna; Glesner, Jill] Indoor Biotechnol Inc, Basic Res, Charlottesville, VA 22903 USA; [Calatroni, Agustin; Visness, Cindy M.] Rho Fed Syst Div, Chapel Hill, NC USA; [Wood, Robert A.] Johns Hopkins Univ, Dept Pediat, Baltimore, MD 21218 USA; [Wood, Robert A.] Johns Hopkins Univ, Dept Allergy & Immunol, Baltimore, MD 21218 USA; [O'Connor, George T.] Boston Univ, Sch Med, Dept Medicne, Boston, MA 02118 USA; [Kattan, Meyer] Columbia Univ, Dept Pediat, New York, NY 10027 USA; [Bacharier, Leonard B.] Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; [Wheatley, Lisa M.] NIAID, Div Allergy Immunol & Transplantat, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Gem, James E.; Busse, William W.] Univ Wisconsin, Dept Pediat, Madison, WI USA; [Gem, James E.; Busse, William W.] Univ Wisconsin, Dept Med, Madison, WI USA; [Wood, R.; Matsui, E.; Lederman, H.; Witter, F.; Leimenstoll, S.; Scott, D.; Cootauco, M.; Jones, P.] Johns Hopkins Univ, Baltimore, MD USA; [O'Connor, G.; Cruikshank, W.; Sandel, M.; Lee-Parritz, A.; Jordan, C.; Gjerasi, E.; Price-Johnson, P.; Gagalis, L.; Wang, L.; Gonzalez, N.; Tuzova, M.] Boston Univ, Sch Med, Boston, MA 02118 USA; [Gold, D.; Wright, R.] Harvard Med Sch, Boston, MA 02115 USA; [Kaftan, M.; Lamm, C.; Whitney, N.; Yaniv, P.; Pierce, M.] Columbia Univ, New York, NY USA; [Sampson, H.; Sperling, R.; Rivers, N.] Mt Sinai Sch Med, New York, NY USA; [Bloomberg, G.; Bacharier, L.; Sadovsky, Y.; Tesson, E.; Koerkenmeier, C.; Sharp, R.; Ray, K.; Durrange, J.; Bauer, I; Freie, A.; Morgan, V] Washington Univ, Sch Med, St Louis, MO USA; [Visness, C.; Zook, P.; Yaeger, M.; Martin, J.; Calatroni, A.; Jaffee, K.; Taylor, W.; Budrevich, R.; Mitchell, H.] Rho Inc, Stat & Clin Coordinating Ctr, Chapel Hill, NC USA; [Busse, W.; Gem, J.; Heinritz, P.; Sorkness, C.; Hernandez, K.; Bochkov, Y.; Grindle, K.; Dresen, A.; Pappas, T.; Renneberg, M.; Stoffel, B.; Gergen, P.] Univ Wisconsin, Sci Coordinat & Adm Ctr, Madison, WI USA; [Gergen, P.; Togias, A.; Smartt, E.; Thompson, K.] NIAID, 9000 Rockville Pike, Bethesda, MD 20892 USA	INDOOR Biotechnologies; Johns Hopkins University; Johns Hopkins University; Boston University; Columbia University; Washington University (WUSTL); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Johns Hopkins University; Boston University; Harvard University; Harvard Medical School; Columbia University; Icahn School of Medicine at Mount Sinai; Washington University (WUSTL); Rho; University of Wisconsin System; University of Wisconsin Madison; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Pomes, A (corresponding author), Indoor Biotechnol Inc, 700 Harris St, Charlottesville, VA 22903 USA.	apomes@inbio.com	Pomés, Anna/H-7010-2019	Pomés, Anna/0000-0002-8729-1829; Calatroni, Agustin/0000-0002-1738-5176; Bacharier, Leonard/0000-0003-0432-2704	National Institute of Allergy and Infectious Diseases/National Institutes of Health (NIH) [NO1-AI-25496, NO1-AI-25482, HHSN272200900052C, HHSN272201000052I, 1UM1AI114271-01, UM2AI117870]; National Center for Research Resources/NIH [RR00052, M01RR00533, 1UL1RR025771, M01RR00071, 1UL1RR024156, 5UL1RR024992-02]; National Center for the Advancement of Translational Research/NIH [UL1TR001079, UL1TR000040]; National Institute of Allergy and Infectious Diseases of the NIH [R01AI077653]	National Institute of Allergy and Infectious Diseases/National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Center for Research Resources/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Center for the Advancement of Translational Research/NIH; National Institute of Allergy and Infectious Diseases of the NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by federal funds from the National Institute of Allergy and Infectious Diseases/National Institutes of Health (NIH) under contract numbers NO1-AI-25496, NO1-AI-25482, HHSN272200900052C, and HHSN272201000052I and cooperative agreements 1UM1AI114271-01 and UM2AI117870. Additional support was provided by the National Center for Research Resources/NIH under grants RR00052, M01RR00533, 1UL1RR025771, M01RR00071, 1UL1RR024156, and 5UL1RR024992-02 and the National Center for the Advancement of Translational Research/NIH under grants UL1TR001079 and UL1TR000040. Research was also supported by the National Institute of Allergy and Infectious Diseases of the NIH under award number R01AI077653 (to A. P.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Aalberse RC, 2000, AM J RESP CRIT CARE, V162, pS124, DOI 10.1164/ajrccm.162.supplement_2.ras-14; Arruda LK, 1997, J BIOL CHEM, V272, P20907, DOI 10.1074/jbc.272.33.20907; Arruda LK, 1995, J BIOL CHEM, V270, P31196, DOI 10.1074/jbc.270.52.31196; ARRUDA LK, 1995, J BIOL CHEM, V270, P19563, DOI 10.1074/jbc.270.33.19563; Bacharier LB, 2019, AM J RESP CRIT CARE, V199, P71, DOI 10.1164/rccm.201801-0190OC; Becker S, 2016, INT ARCH ALLERGY IMM, V170, P132, DOI 10.1159/000447694; Chuang JG, 2010, PROTEOMICS, V10, P3854, DOI 10.1002/pmic.201000348; Fan Y, 2005, INSECT MOL BIOL, V14, P45, DOI 10.1111/j.1365-2583.2004.00530.x; Fang Y, 2015, ALLERGY, V70, P1674, DOI 10.1111/all.12766; Gern James E, 2009, BMC Pulm Med, V9, P17, DOI 10.1186/1471-2466-9-17; Glesner J, 2019, J ALLERGY CLIN IMMUN, V143, P1474, DOI 10.1016/j.jaci.2018.07.036; Gromping U, 2006, J STAT SOFTW, V17, DOI 10.18637/jss.v017.i01; Gronlund H, 2008, CLIN EXP ALLERGY, V38, P1275, DOI 10.1111/j.1365-2222.2008.03003.x; Gustchina A, 2005, J MOL BIOL, V348, P433, DOI 10.1016/j.jmb.2005.02.062; Hindley J, 2006, J ALLERGY CLIN IMMUN, V117, P1389, DOI 10.1016/j.jaci.2006.02.017; Jeong KY, 2003, ALLERGY, V58, P1059, DOI 10.1034/j.1398-9995.2003.00167.x; Jeong KY, 2013, INT ARCH ALLERGY IMM, V161, P315, DOI 10.1159/000347034; Lee MF, 2012, ANN ALLERG ASTHMA IM, V108, P243, DOI 10.1016/j.anai.2012.01.014; Mittermann I, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156077; Mueller GA, 2016, CLIN EXP ALLERGY, V46, P365, DOI 10.1111/cea.12680; Mueller GA, 2015, J ALLERGY CLIN IMMUN, V136, P1369, DOI 10.1016/j.jaci.2015.03.015; Mueller GA, 2013, J ALLERGY CLIN IMMUN, V132, P1420, DOI 10.1016/j.jaci.2013.06.014; O'Connor GT, 2018, J ALLERGY CLIN IMMUN, V141, P1468, DOI 10.1016/j.jaci.2017.06.040; Patterson ML, 2002, CLIN EXP ALLERGY, V32, P721, DOI 10.1046/j.1365-2222.2002.01397.x; Pauli G, 2008, J ALLERGY CLIN IMMUN, V122, P951, DOI 10.1016/j.jaci.2008.09.017; Pomes A, 1998, J BIOL CHEM, V273, P30801, DOI 10.1074/jbc.273.46.30801; Pomes A, 2002, AM J RESP CRIT CARE, V165, P391, DOI 10.1164/ajrccm.165.3.2104027; Resch Y, 2015, J ALLERGY CLIN IMMUN, V136, P1083, DOI 10.1016/j.jaci.2015.03.024; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Satinover SM, 2005, J ALLERGY CLIN IMMUN, V115, P803, DOI 10.1016/j.jaci.2005.01.018; Slater JE, 2007, CLIN EXP ALLERGY, V37, P1033, DOI 10.1111/j.1365-2222.2007.02751.x; Togias A, 1997, INT ARCH ALLERGY IMM, V113, P87, DOI 10.1159/000237515; Wood RA, 2014, J ALLERGY CLIN IMMUN, V133, P846, DOI 10.1016/j.jaci.2013.08.047; Yang JJ, 2008, J ALLERGY CLIN IMMUN, V122, P820, DOI 10.1016/j.jaci.2008.07.044	34	23	23	2	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2019	144	4					935	944		10.1016/j.jaci.2019.05.036	http://dx.doi.org/10.1016/j.jaci.2019.05.036			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JB8FZ	31201891	Green Accepted, Bronze			2022-12-18	WOS:000488803900010
J	Czarnowicki, T; He, H; Leonard, A; Kim, HJ; Kameyama, N; Pavel, AB; Li, R; Estrada, Y; Wen, HC; Kimmel, GW; Kim, HJ; Chima, M; Lebwohl, M; Krueger, JG; Guttman-Yassky, E				Czarnowicki, Tali; He, Helen; Leonard, Alexandra; Kim, Hyun Je; Kameyama, Naoya; Pavel, Ana B.; Li, Randall; Estrada, Yeriel; Wen, Huei-Chi; Kimmel, Grace W.; Kim, Hee J.; Chima, Margot; Lebwohl, Mark; Krueger, James G.; Guttman-Yassky, Emma			Blood endotyping distinguishes the profile of vitiligo from that of other inflammatory and autoimmune skin diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Vitiligo; atopic dermatitis; psoriasis; alopecia areata; T(H)1; T(H)2; T(H)17; T(H)22; regulatory T; biomarkers; endotypes	REGULATORY T-CELLS; NON-SEGMENTAL VITILIGO; ATOPIC-DERMATITIS; ALOPECIA-AREATA; IFN-GAMMA; GENERALIZED VITILIGO; IMMUNE-RESPONSE; MOUSE MODEL; HELPER 17; MELANOCYTES	Background: Peripheral blood skin-homing/cutaneous lymphocyte antigen (CLA)(+) T cells emerge as biomarkers of cutaneous immune activation in patients with inflammatory skin diseases (atopic dermatitis [AD] and alopecia areata [AA]). However, blood phenotyping across these subsets is not yet available in patients with vitiligo. Objective: We sought to measure cytokine production by circulating skin-homing (CLA(+)) versus systemic (CLA(-)) "polar'' CD4(+)/CD8(+) ratio and activated T-cell subsets in patients with vitiligo compared with patients with AA, AD, or psoriasis and control subjects. Methods: Flow cytometry was used to measure levels of the cytokines IFN-gamma, IL-13, IL-9, IL-17, and IL-22 in CD4(+)/CD8(+) T cells in the blood of 19 patients with moderate-to-severe nonsegmental/generalized vitiligo, moderate-to-severe AA (n = 32), psoriasis (n = 24), or AD (n = 43) and control subjects (n = 30). Unsupervised clustering differentiated subjects into groups based on cellular frequencies. Results: Patients with Vitiligo showed the highest CLA(+)/CLA(-) T(H)1/type 1 cytotoxic T-cell polarization, with parallel T(H)2/T(H)9/T(H)17/T(H)22 level increases to levels often greater than those seen in patients with AA, AD, or psoriasis (P < .05). Total regulatory T-cell counts were lower in patients with vitiligo than in control subjects and patients with AD or psoriasis (P < .001). Vitiligo severity correlated with levels of multiple cytokines (P < .1), whereas duration was linked with IFN-gamma and IL-17 levels (P < .04). Patients and control subjects grouped into separate clusters based on blood biomarkers. Conclusions: Vitiligo is characterized by a multicytokine polarization among circulating skin-homing and systemic subsets, which differentiates it from other inflammatory/autoimmune skin diseases. Future targeted therapies should delineate the relative contribution of each cytokine axis to disease perpetuation.	[Czarnowicki, Tali; He, Helen; Leonard, Alexandra; Kim, Hyun Je; Kameyama, Naoya; Pavel, Ana B.; Li, Randall; Estrada, Yeriel; Wen, Huei-Chi; Kimmel, Grace W.; Kim, Hee J.; Chima, Margot; Lebwohl, Mark; Guttman-Yassky, Emma] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY 10029 USA; [Czarnowicki, Tali; He, Helen; Leonard, Alexandra; Kim, Hyun Je; Kameyama, Naoya; Pavel, Ana B.; Li, Randall; Estrada, Yeriel; Wen, Huei-Chi; Kimmel, Grace W.; Kim, Hee J.; Chima, Margot; Lebwohl, Mark; Guttman-Yassky, Emma] Icahn Sch Med Mt Sinai, Inst Immunol, New York, NY 10029 USA; [Czarnowicki, Tali; Krueger, James G.] Rockefeller Univ, Lab Investigative Dermatol, 1230 York Ave, New York, NY 10021 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Rockefeller University	Guttman-Yassky, E (corresponding author), Mt Sinai Med Ctr, Icahn Sch Med, Dept Dermatol, 5 E 98th St, New York, NY 10029 USA.	emma.guttman@mountsinai.org	Wen, Huei-Chi/ABD-7417-2021	, Ana Brandusa/0000-0002-8155-8553	Abbvie; Celgene; Eli Lilly; Janssen; MedImmune/AstraZeneca; Novartis; Pfizer; Regeneron; Vitae; Glenmark; Galderma; Asana; Innovaderm; Dermira; UCB; Amgen; Lilly; Merck; Kadmon; Boehringer; Kyowa; BMS; Serono; Biogen Idec; Delenex; Sanofi; Baxter; Paraxel; Xenoport; Kineta	Abbvie(AbbVie); Celgene(Bristol-Myers SquibbCelgene Corporation); Eli Lilly(Eli Lilly); Janssen(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); MedImmune/AstraZeneca(AstraZeneca); Novartis(Novartis); Pfizer(Pfizer); Regeneron(Regeneron); Vitae; Glenmark; Galderma; Asana; Innovaderm; Dermira; UCB(UCB Pharma SA); Amgen(Amgen); Lilly(Eli Lilly); Merck(Merck & Company); Kadmon; Boehringer(Boehringer Ingelheim); Kyowa; BMS(Bristol-Myers Squibb); Serono(Merck & Company); Biogen Idec(Biogen); Delenex; Sanofi; Baxter; Paraxel; Xenoport; Kineta	E.G.-Y. is an employee of Mount Sinai and has received research funds (grants paid to the institution) from Abbvie, Celgene, Eli Lilly, Janssen, MedImmune/AstraZeneca, Novartis, Pfizer, Regeneron, Vitae, Glenmark, Galderma, Asana, Innovaderm, Dermira, and UCB. E.G.-Y. is also a consultant for Sanofi Aventis, Regeneron, Stiefel/GlaxoSmithKline, MedImmune, Celgene, Anacor, AnaptysBio, Dermira, Galderma, Glenmark, Novartis, Pfizer, Vitae, Leo Pharma, Abbvie, Eli Lilly, Kyowa, Mitsubishi Tanabe, Asana Biosciences, and Promius. J.G.K. has received research support (grants paid to his institution) and/or personal fees from Pfizer, Amgen, Janssen, Lilly, Merck, Novartis, Kadmon, Dermira, Boehringer, Innovaderm, Kyowa, BMS, Serono, Biogen Idec, Delenex, AbbVie, Sanofi, Baxter, Paraxel, Xenoport, and Kineta.	Abou Elela M, 2013, EUR J DERMATOL, V23, P350, DOI 10.1684/ejd.2013.2023; Antonelli A, 2015, ANN TRANSL MED, V3, DOI 10.3978/j.issn.2305-5839.2015.03.02; Basak PY, 2009, J AM ACAD DERMATOL, V60, P256, DOI 10.1016/j.jaad.2008.09.048; Bassiouny DA, 2011, CLIN EXP DERMATOL, V36, P292, DOI 10.1111/j.1365-2230.2010.03972.x; Bertolotti A, 2014, PIGM CELL MELANOMA R, V27, P398, DOI 10.1111/pcmr.12219; BRENNER W, 1979, DERMATOLOGICA, V159, P356, DOI 10.1159/000250627; Cavalie M, 2015, J INVEST DERMATOL, V135, P970, DOI 10.1038/jid.2014.527; Chhabra S, 2016, CLIN EXP DERMATOL, V41, P806, DOI 10.1111/ced.12845; Choi H, 2013, J INVEST DERMATOL, V133, P528, DOI 10.1038/jid.2012.331; Czarnowicki T, 2018, ALLERGY, V73, P713, DOI 10.1111/all.13346; Czarnowicki T, 2017, ALLERGY, V72, P366, DOI 10.1111/all.13080; Czarnowicki T, 2015, J ALLERGY CLIN IMMUN, V136, P941, DOI 10.1016/j.jaci.2015.05.049; Czarnowicki T, 2015, J ALLERGY CLIN IMMUN, V136, P208, DOI 10.1016/j.jaci.2015.03.032; Czarnowicki T, 2015, J ALLERGY CLIN IMMUN, V136, P104, DOI 10.1016/j.jaci.2015.01.020; Das PK, 2001, TRENDS IMMUNOL, V22, P130, DOI 10.1016/S1471-4906(00)01844-5; Deng YX, 2017, HUM IMMUNOL, V78, P120, DOI 10.1016/j.humimm.2016.12.010; Dong C, 2003, J AUTOIMMUN, V21, P255, DOI 10.1016/S0896-8411(03)00119-7; Dong J, 2017, ONCOTARGET, V8; Drucker AM, 2017, ALLERGY, V72, P831, DOI 10.1111/all.13128; Dwivedi M, 2013, PIGM CELL MELANOMA R, V26, DOI 10.1111/pcmr.12105; Eby JM, 2014, PIGM CELL MELANOMA R, V27, P1075, DOI 10.1111/pcmr.12284; Frisoli ML, 2017, J ALLERGY CLIN IMMUN, V140, P654, DOI 10.1016/j.jaci.2017.07.011; Gittler JK, 2012, J ALLERGY CLIN IMMUN, V130, P1344, DOI 10.1016/j.jaci.2012.07.012; Guttman-Yassky E, 2018, J AM ACAD DERMATOL, V78, P872, DOI 10.1016/j.jaad.2018.01.016; Hamzavi I, 2004, ARCH DERMATOL, V140, P677, DOI 10.1001/archderm.140.6.677; Harris John E, 2015, Acta Derm Venereol, V95, P643; Harris JE, 2013, EXP DERMATOL, V22, P785, DOI 10.1111/exd.12264; Harris JE, 2012, J INVEST DERMATOL, V132, P1869, DOI 10.1038/jid.2011.463; Hegab DS, 2015, DERMAT RES PRACT, V2015, DOI 10.1155/2015/145409; Hegazy RA, 2014, EXP DERMATOL, V23, P283, DOI 10.1111/exd.12369; HOWITZ J, 1977, ARCH DERMATOL, V113, P47, DOI 10.1001/archderm.113.1.47; Jandus C, 2008, ARTHRITIS RHEUM, V58, P2307, DOI 10.1002/art.23655; Jimbow K, 2001, BRIT J DERMATOL, V144, P55, DOI 10.1046/j.1365-2133.2001.03952.x; Joshipura D, 2018, J AM ACAD DERMATOL, V78, P1205, DOI 10.1016/j.jaad.2018.02.023; Kakourou T, 2005, J AM ACAD DERMATOL, V53, P220, DOI 10.1016/j.jaad.2005.03.032; Kaminishi K, 2002, J DERMATOL SCI, V29, P19, DOI 10.1016/S0923-1811(01)00174-8; Kawakami T, 2011, DERMAT RES PRACT, V2011, DOI 10.1155/2011/750342; Khan R, 2012, J AM ACAD DERMATOL, V66, P510, DOI 10.1016/j.jaad.2011.07.018; Klarquist J, 2010, PIGM CELL MELANOMA R, V23, P276, DOI 10.1111/j.1755-148X.2010.00688.x; Komen L, 2015, BRIT J DERMATOL, V172, P437, DOI 10.1111/bjd.13432; Kotobuki Y, 2012, PIGM CELL MELANOMA R, V25, DOI 10.1111/j.1755-148X.2011.00945.x; Kuriyama S, 2015, J DERMATOL, V42, P215, DOI 10.1111/1346-8138.12746; Le Poole I Caroline, 2017, J Investig Dermatol Symp Proc, V18, pS38, DOI 10.1016/j.jisp.2016.10.023; Li Y, 2016, ONCOTARGET, V7, P71001, DOI 10.18632/oncotarget.11681; Lin M, 2014, EUR J DERMATOL, V24, P676, DOI 10.1684/ejd.2014.2436; Liu LY, 2017, J AM ACAD DERMATOL, V77, P675, DOI 10.1016/j.jaad.2017.05.043; Long SA, 2011, J IMMUNOL, V187, P2061, DOI 10.4049/jimmunol.1003224; Ma L, 2014, CLIN EXP IMMUNOL, V175, P25, DOI 10.1111/cei.12198; Malakouti M, 2015, J DERMATOL TREAT, V26, P41, DOI 10.3109/09546634.2013.879093; Martin DA, 2013, J INVEST DERMATOL, V133, P17, DOI 10.1038/jid.2012.194; McHugh RS, 2002, J ALLERGY CLIN IMMUN, V110, P693, DOI 10.1067/mai.2002.129339; Miao X., 2018, SCI REP, V8, P1; Mittereder N, 2016, J IMMUNOL, V197, P491, DOI 10.4049/jimmunol.1502241; Mohan GC, 2015, JAMA DERMATOL, V151, P522, DOI 10.1001/jamadermatol.2014.3324; Natarajan VT, 2014, P NATL ACAD SCI USA, V111, P2301, DOI 10.1073/pnas.1304988111; Nelson MH, 2015, J IMMUNOL, V194, P1737, DOI 10.4049/jimmunol.1401082; Niu Q, 2012, RHEUMATOL INT, V32, P2731, DOI 10.1007/s00296-011-1984-x; Nurieva RI, 2005, CLIN IMMUNOL, V115, P19, DOI 10.1016/j.clim.2005.02.010; Pan HF, 2013, CYTOKINE GROWTH F R, V24, P51, DOI 10.1016/j.cytogfr.2012.07.002; Paulos CM, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000448; PICKER LJ, 1990, AM J PATHOL, V136, P1053; Rashighi M, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007811; Richard J.B., 2018, SAINT MAURICE SANTE, P10; Rodrigues M, 2017, J AM ACAD DERMATOL, V77, P1, DOI 10.1016/j.jaad.2016.10.048; Rodrigues M, 2017, J AM ACAD DERMATOL, V77, P17, DOI 10.1016/j.jaad.2016.11.010; Rork JF, 2016, CURR OPIN PEDIATR, V28, P463, DOI 10.1097/MOP.0000000000000375; Rothstein B, 2017, J AM ACAD DERMATOL, V76, P1054, DOI 10.1016/j.jaad.2017.02.049; Sallusto F, 2004, ANNU REV IMMUNOL, V22, P745, DOI 10.1146/annurev.immunol.22.012703.104702; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; Samson M, 2012, ARTHRITIS RHEUM-US, V64, P2499, DOI 10.1002/art.34477; Shen CB, 2016, FRONT GENET, V7, DOI 10.3389/fgene.2016.00003; Silverberg JI, 2013, JAMA DERMATOL, V149, P983, DOI 10.1001/jamadermatol.2013.4228; Singh RK, 2016, AUTOIMMUN REV, V15, P397, DOI 10.1016/j.autrev.2016.01.004; Singh TP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0051752; Son J, 2014, PIGM CELL MELANOMA R, V27, DOI 10.1111/pcmr.12190; Strassner JP, 2016, CURR OPIN IMMUNOL, V43, P81, DOI 10.1016/j.coi.2016.09.008; Sushama S, 2019, J COSMET DERMATOL-US, V18, P337, DOI 10.1111/jocd.12517; Tabarkiewicz J, 2015, ARCH IMMUNOL THER EX, V63, P435, DOI 10.1007/s00005-015-0344-z; Tafuri A, 2001, NATURE, V409, P105, DOI 10.1038/35051113; Taieb A, 2007, PIGM CELL RES, V20, P27, DOI 10.1111/j.1600-0749.2006.00355.x; Taieb A, 2009, NEW ENGL J MED, V360, P160, DOI 10.1056/NEJMcp0804388; Tembhre MK, 2015, BRIT J DERMATOL, V172, P940, DOI 10.1111/bjd.13511; Tesciuba AG, 2008, J IMMUNOL, V181, P1019, DOI 10.4049/jimmunol.181.2.1019; van den Boorn JG, 2009, J INVEST DERMATOL, V129, P2220, DOI 10.1038/jid.2009.32; van den Wijngaard R, 2000, LAB INVEST, V80, P1299, DOI 10.1038/labinvest.3780138; Vocanson M, 2010, J ALLERGY CLIN IMMUN, V126, P280, DOI 10.1016/j.jaci.2010.05.022; Wang C, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0018907, 10.1371/journal.pone.0025832]; Wang XX, 2016, BRIT J DERMATOL, V174, P1318, DOI 10.1111/bjd.14416; Wankowicz-Kalinska A, 2003, LAB INVEST, V83, P683, DOI 10.1097/01.LAB.0000069521.42488.1B; Wolk K, 2009, J MOL MED, V87, P523, DOI 10.1007/s00109-009-0457-0; Woodland DL, 2009, NAT REV IMMUNOL, V9, P153, DOI 10.1038/nri2496; Yang LL, 2015, ACTA DERM-VENEREOL, V95, P664, DOI 10.2340/00015555-2080; Zhou J, 2018, FASEB J, V32, P4899, DOI 10.1096/fj.201701242RR; Zhou L, 2015, PIGM CELL MELANOMA R, V28, DOI 10.1111/pcmr.12355	94	23	23	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2019	143	6					2095	2107		10.1016/j.jaci.2018.11.031	http://dx.doi.org/10.1016/j.jaci.2018.11.031			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IB2QG	30576756	Bronze			2022-12-18	WOS:000470113200015
J	Dudeck, J; Froebel, J; Kotrba, J; Lehmann, CHK; Dudziak, D; Speier, S; Nedospasov, SA; Schraven, B; Dudeck, A				Dudeck, Jan; Froebel, Julia; Kotrba, Johanna; Lehmann, Christian H. K.; Dudziak, Diana; Speier, Stephan; Nedospasov, Sergei A.; Schraven, Burkhart; Dudeck, Anne			Engulfment of mast cell secretory granules on skin inflammation boosts dendritic cell migration and priming efficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Mast cells; dendritic cells; adaptive immune response; T-cell response; skin inflammation	TUMOR-NECROSIS-FACTOR; T-CELLS; NEUTROPHIL RECRUITMENT; CROSS-PRESENTATION; LANGERHANS CELLS; TNF; RESPONSES; HISTAMINE; HYPERTROPHY; MODULATION	Background: Mast cells (MCs) are best known as key effector cells of allergic reactions, but they also play an important role in host defense against pathogens. Despite increasing evidence for a critical effect of MCs on adaptive immunity, the underlying mechanisms are poorly understood. Objective: Here we monitored MC intercellular communication with dendritic cells (DCs), MC activation, and degranulation and tracked the fate of exocytosed mast cell granules (MCGs) during skin inflammation. Methods: Using a strategy to stain intracellular MCGs in vivo, we tracked the MCG fate after skin inflammation-induced MC degranulation. Furthermore, exogenous MCGs were applied to MC-deficient mice by means of intradermal injection. MCG effects on DC functionality and adaptive immune responses in vivo were assessed by combining intravital multiphoton microscopy with flow cytometry and functional assays. Results: We demonstrate that dermal DCs engulf the intact granules exocytosed by MCs on skin inflammation. Subsequently, the engulfed MCGs are actively shuttled to skin-draining lymph nodes and finally degraded inside DCs within the lymphoid tissue. Most importantly, MCG uptake promotes DC maturation and migration to skin-draining lymph nodes, partially through MCderived TNF, and boosts their T-cell priming efficiency. Surprisingly, exogenous MCGs alone are sufficient to induce a prominent DC activation and T-cell response. Conclusion: Our study highlights a unique feature of peripheral MCs to affect lymphoid tissue-borne adaptive immunity over distance by modifying DC functionality through delivery of granule-stored mediators.	[Dudeck, Jan; Froebel, Julia; Kotrba, Johanna; Schraven, Burkhart; Dudeck, Anne] Otto von Guericke Univ, Inst Mol & Clin Immunol, Fac Med, Leipziger Str 44, D-39120 Magdeburg, Germany; [Dudeck, Jan; Froebel, Julia; Kotrba, Johanna; Schraven, Burkhart; Dudeck, Anne] Otto von Guericke Univ, Hlth Campus Immunol Infectiol & Inflammat, Magdeburg, Germany; [Lehmann, Christian H. K.; Dudziak, Diana] Friedrich Alexander Univ Erlangen Nurnberg, Dept Dermatol, Lab Dendrit Cell Biol, Univ Hosp Erlangen, Erlangen, Germany; [Speier, Stephan] Tech Univ Dresden, Helmholtz Zentrum Munchen, PLID, Univ Clin Carl Gustav Carus, Munich, Germany; [Speier, Stephan] German Ctr Diabet Res DZD, Munich, Germany; [Speier, Stephan] Tech Univ Dresden, DFG Ctr Regenerat Therapies Dresden CRTD, Fac Med, Munich, Germany; [Nedospasov, Sergei A.] Engelhardt Inst Mol Biol, Moscow, Russia; [Nedospasov, Sergei A.] Lomonosov Moscow State Univ, Moscow, Russia	Otto von Guericke University; Otto von Guericke University; University of Erlangen Nuremberg; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technische Universitat Dresden; Technische Universitat Dresden; Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS; Lomonosov Moscow State University	Dudeck, A (corresponding author), Otto von Guericke Univ, Inst Mol & Clin Immunol, Fac Med, Leipziger Str 44, D-39120 Magdeburg, Germany.; Dudeck, A (corresponding author), Otto von Guericke Univ, Hlth Campus Immunol Infectiol & Inflammat, Magdeburg, Germany.	anne.dudeck@med.ovgu.de	Dudeck, Anne/ABB-3498-2020; Lehmann, Christian H.K./R-1684-2019; Speier, Stephan/E-8525-2010; Dudziak, Diana/B-2432-2017	Dudeck, Anne/0000-0002-1311-9620; Lehmann, Christian H.K./0000-0001-5927-9761; Speier, Stephan/0000-0002-4561-7085; Dudziak, Diana/0000-0001-9358-134X; Kotrba, Johanna/0000-0002-2113-5284	German Research Foundation (DFG) [DU1172/2, DU1172/3, CRC854]; DFG [CRC1181-TPA7]; EFI-Initiative BIG-Thera; Interdisciplinary Center for Clinical Research [IZKF-A65, IZKF-J54]; Russian Science Foundation [14-50-00060]	German Research Foundation (DFG)(German Research Foundation (DFG)); DFG(German Research Foundation (DFG)); EFI-Initiative BIG-Thera; Interdisciplinary Center for Clinical Research; Russian Science Foundation(Russian Science Foundation (RSF))	Supported by grants from the German Research Foundation (DFG; grants DU1172/2 [Priority Program 1468], DU1172/3 [Priority Program 1394], and CRC854 project A28N; to A.D.). D.D. was funded by the DFG (CRC1181-TPA7) and the EFI-Initiative BIG-Thera. D. D. and C.H.K.L. were funded by the Interdisciplinary Center for Clinical Research (IZKF-A65 and IZKF-J54). S.A.N. was supported by grant 14-50-00060 from the Russian Science Foundation.	Abraham SN, 2010, NAT REV IMMUNOL, V10, P440, DOI 10.1038/nri2782; Amaral MM, 2007, J IMMUNOL, V179, P3425, DOI 10.4049/jimmunol.179.6.3425; Bedoui S, 2009, NAT IMMUNOL, V10, P488, DOI 10.1038/ni.1724; Biedermann T, 2000, J EXP MED, V192, P1441, DOI 10.1084/jem.192.10.1441; Bryce PJ, 2004, IMMUNITY, V20, P381, DOI 10.1016/S1074-7613(04)00080-9; Caron G, 2001, J IMMUNOL, V166, P6000, DOI 10.4049/jimmunol.166.10.6000; Chan CY, 2012, CURR OPIN MICROBIOL, V15, P78, DOI 10.1016/j.mib.2011.10.007; Choi HW, 2016, IMMUNITY, V45, P1258, DOI 10.1016/j.immuni.2016.11.003; Dawicki W, 2010, J IMMUNOL, V184, P2116, DOI 10.4049/jimmunol.0803894; De Filippo K, 2013, BLOOD, V121, P4930, DOI 10.1182/blood-2013-02-486217; Dudeck A, 2011, IMMUNITY, V34, P973, DOI 10.1016/j.immuni.2011.03.028; Dudeck A, 2011, EUR J IMMUNOL, V41, P1883, DOI 10.1002/eji.201040994; Dudeck J, 2017, J EXP MED, V214, P3791, DOI 10.1084/jem.20160783; Dudeck J, 2015, CELL REP, V13, P399, DOI 10.1016/j.celrep.2015.08.078; Dudziak D, 2007, SCIENCE, V315, P107, DOI 10.1126/science.1136080; Dwyer DF, 2016, NAT IMMUNOL, V17, P878, DOI 10.1038/ni.3445; Echtenacher B, 1996, NATURE, V381, P75, DOI 10.1038/381075a0; Edelson BT, 2010, J EXP MED, V207, P823, DOI 10.1084/jem.20091627; Frossi B, 2018, IMMUNOL REV, V282, P35, DOI 10.1111/imr.12636; Galli SJ, 2000, CURR BIOL, V10, pR93, DOI 10.1016/S0960-9822(00)00322-5; Gaudenzio N, 2016, J CLIN INVEST, V126, P3981, DOI 10.1172/JCI85538; Gregory GD, 2005, EUR J IMMUNOL, V35, P3478, DOI 10.1002/eji.200535271; Gri G, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00120; Grivennikov SI, 2005, IMMUNITY, V22, P93, DOI 10.1016/j.immuni.2004.11.016; Heib V, 2007, BLOOD, V110, P946, DOI 10.1182/blood-2006-07-036889; Jawdat DM, 2004, J IMMUNOL, V173, P5275, DOI 10.4049/jimmunol.173.8.5275; Jawdat DM, 2006, J IMMUNOL, V177, P1755, DOI 10.4049/jimmunol.177.3.1755; Johnzon CF, 2016, AM J PATHOL, V186, P4, DOI 10.1016/j.ajpath.2015.06.024; Joulia R, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7174; Jung S, 2002, IMMUNITY, V17, P211, DOI 10.1016/S1074-7613(02)00365-5; Kitawaki T, 2006, INT IMMUNOL, V18, P1789, DOI 10.1093/intimm/dxl113; Kneilling M, 2009, BLOOD, V114, P1696, DOI 10.1182/blood-2008-11-187682; Krystel-Whittemore M, 2016, FRONT IMMUNOL, V6, P1, DOI 10.3389/fimmu.2015.00620; Kunder CA, 2009, J EXP MED, V206, P2455, DOI 10.1084/jem.20090805; Luche H, 2007, EUR J IMMUNOL, V37, P43, DOI 10.1002/eji.200636745; Malaviya R, 1996, NATURE, V381, P77, DOI 10.1038/381077a0; Mazzoni A, 2001, J CLIN INVEST, V108, P1865, DOI 10.1172/JCI200113930; Mazzoni A, 2006, J IMMUNOL, V177, P3577, DOI 10.4049/jimmunol.177.6.3577; McLachlan JB, 2008, NAT MED, V14, P536, DOI 10.1038/nm1757; McLachlan JB, 2003, NAT IMMUNOL, V4, P1199, DOI 10.1038/ni1005; Metcalfe DD, 1997, PHYSIOL REV, V77, P1033, DOI 10.1152/physrev.1997.77.4.1033; Miller JC, 2012, NAT IMMUNOL, V13, P888, DOI 10.1038/ni.2370; Otsuka A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025538; Reber LL, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.92900; Scholten J, 2008, TRANSGENIC RES, V17, P307, DOI 10.1007/s11248-007-9153-4; Shelburne CP, 2009, CELL HOST MICROBE, V6, P331, DOI 10.1016/j.chom.2009.09.004; Skokos D, 2003, J IMMUNOL, V170, P3037, DOI 10.4049/jimmunol.170.6.3037; Suto H, 2006, J IMMUNOL, V176, P4102, DOI 10.4049/jimmunol.176.7.4102; THARP MD, 1985, J HISTOCHEM CYTOCHEM, V33, P27, DOI 10.1177/33.1.2578142; Voehringer D, 2008, J IMMUNOL, V180, P4742, DOI 10.4049/jimmunol.180.7.4742; Wernersson S, 2014, NAT REV IMMUNOL, V14, P478, DOI 10.1038/nri3690	51	23	24	1	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2019	143	5					1849	+		10.1016/j.jaci.2018.08.052	http://dx.doi.org/10.1016/j.jaci.2018.08.052			20	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HW6FP	30339853	Bronze			2022-12-18	WOS:000466784600021
J	Sawada, Y; Tong, Y; Barangi, M; Hata, T; Williams, MR; Nakatsuji, T; Gallo, RL				Sawada, Yu; Tong, Yun; Barangi, Mariam; Hata, Tissa; Williams, Michael R.; Nakatsuji, Teruaki; Gallo, Richard L.			Dilute bleach baths used for treatment of atopic dermatitis are not antimicrobial in vitro	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							SKIN		[Sawada, Yu; Tong, Yun; Barangi, Mariam; Hata, Tissa; Williams, Michael R.; Nakatsuji, Teruaki; Gallo, Richard L.] Univ Calif San Diego, Dept Dermatol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Gallo, RL (corresponding author), Univ Calif San Diego, Dept Dermatol, La Jolla, CA 92093 USA.	rgallo@ucsd.edu	Gallo, Richard L/A-8931-2009	Gallo, Richard L/0000-0002-1401-7861; Tong, Yun/0000-0003-2003-1843	Atopic Dermatitis Disease Network (ADRN) [U19 AI117673]; National Institutes of Health [R01AR06781]; JSPS Overseas Research Fellowship	Atopic Dermatitis Disease Network (ADRN); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); JSPS Overseas Research Fellowship	R.L.G., T.H., and T.N. are supported by the Atopic Dermatitis Disease Network (ADRN; U19 AI117673). R.L.G., T.N., and M.R.W. are also supported by the National Institutes of Health (R01AR06781). Y.S. is supported by a JSPS Overseas Research Fellowship.	Chopra R, 2017, ANN ALLERG ASTHMA IM, V119, P435, DOI 10.1016/j.anai.2017.08.289; ENG RHK, 1991, ANTIMICROB AGENTS CH, V35, P1824, DOI 10.1128/AAC.35.9.1824; Eriksson S, 2017, BRIT J DERMATOL, V177, P513, DOI 10.1111/bjd.15410; Fritz SA, 2011, INFECT CONT HOSP EP, V32, P872, DOI 10.1086/661285; Huang JT, 2009, PEDIATRICS, V123, pE808, DOI 10.1542/peds.2008-2217; Leung TH, 2013, J CLIN INVEST, V123, P5361, DOI 10.1172/JCI70895; Liu HY, 2017, CELL HOST MICROBE, V22, P653, DOI 10.1016/j.chom.2017.10.006; Nakagawa S, 2017, CELL HOST MICROBE, V22, P667, DOI 10.1016/j.chom.2017.10.008; Williams MR, 2017, CELL HOST MICROBE, V22, P579, DOI 10.1016/j.chom.2017.10.015	9	23	23	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2019	143	5					1946	1948		10.1016/j.jaci.2019.01.009	http://dx.doi.org/10.1016/j.jaci.2019.01.009			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HW6FP	30677478	Bronze, Green Accepted			2022-12-18	WOS:000466784600035
J	Han, JK; Bachert, C; Desrosiers, M; Laidlaw, TM; Hopkins, C; Fokkens, WJ; Paggiaro, P; Cho, SH; Olze, H; Greos, LS; Zhang, M; Fan, CP; Draikiwicz, S; Amin, N; Kamat, S; Khan, A; Pirozzi, G; Graham, NMH; Ruddy, M; Staudinger, H; Mannent, LP				Han, Joseph K.; Bachert, Claus; Desrosiers, Martin; Laidlaw, Tanya M.; Hopkins, Claire; Fokkens, Wytske J.; Paggiaro, Pierluigi; Cho, Seong Ho; Olze, Heidi; Greos, Leon S.; Zhang, Mei; Fan, Chunpeng; Draikiwicz, Steven; Amin, Nikhil; Kamat, Siddhesh; Khan, Asif; Pirozzi, Gianluca; Graham, Neil M. H.; Ruddy, Marcella; Staudinger, Heribert; Mannent, Leda P.			Efficacy and Safety of Dupilumab in Patients with Chronic Rhinosinusitis with Nasal Polyps: Results from the Randomized Phase 3 Sinus-24 Study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract	Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology (AAAAI)	FEB 22-25, 2019	San Francisco, CA	Amer Acad Allergy, Asthma & Immunol					[Han, Joseph K.] Eastern Virginia Med Sch, Div Allergy, Norfolk, VA 23501 USA; [Bachert, Claus] Upper Airways Res Lab, Fac Med, Ghent, Belgium; [Bachert, Claus] Karolinska Inst, CLINTEC, Stockholm, Sweden; [Desrosiers, Martin] CRCHUM, Montreal, PQ, Canada; [Laidlaw, Tanya M.] Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, 75 Francis St, Boston, MA 02115 USA; [Hopkins, Claire] Guys & St Thomas Hosp, Dept ENT, London, England; [Fokkens, Wytske J.] Acad Med Ctr, Amsterdam, Netherlands; [Paggiaro, Pierluigi] Univ Pisa, Dept Surg Med Mol Biol & Crit Care, Pisa, Italy; [Cho, Seong Ho] Univ S Florida, Morsani Coll Med, Allergy & Immunol, Tampa, FL USA; [Olze, Heidi] Charite Univ Med Berlin, Dept Otorhinolaryngol Head & Neck Surg, Berlin, Germany; [Greos, Leon S.] Colorado Allergy & Asthma Ctr PC, Centennial, CO USA; [Zhang, Mei; Fan, Chunpeng; Draikiwicz, Steven; Pirozzi, Gianluca; Staudinger, Heribert] Sanofi, Bridgewater, MA USA; [Amin, Nikhil; Kamat, Siddhesh; Graham, Neil M. H.; Ruddy, Marcella] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA; [Khan, Asif; Mannent, Leda P.] Sanofi, Chilly Mazarin, France	Eastern Virginia Medical School; Karolinska Institutet; Universite de Montreal; Harvard University; Brigham & Women's Hospital; Guy's & St Thomas' NHS Foundation Trust; University of Amsterdam; Academic Medical Center Amsterdam; University of Pisa; State University System of Florida; University of South Florida; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Sanofi-Aventis; Regeneron; Sanofi-Aventis; Sanofi France			Khan, Asif H./T-6551-2017; Fokkens, Wytske WJ/ABF-2185-2020; Bachert, Claus/J-8825-2012	Khan, Asif H./0000-0001-9158-0116; 					0	23	23	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2019	143	2		S		L4	AB422	AB422		10.1016/j.jaci.2018.12.948	http://dx.doi.org/10.1016/j.jaci.2018.12.948			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	HK2VO		Bronze			2022-12-18	WOS:000457771200933
J	Berland, A; Rosain, J; Kaltenbach, S; Allain, V; Mahlaoui, N; Melki, I; Fievet, A; d'Enghien, CD; Ouachee-Chardin, M; Perrin, L; Auger, N; Cipe, FE; Finocchi, A; Dogu, F; Suarez, F; Moshous, D; Leblanc, T; Belot, A; Fieschi, C; Boutboul, D; Malphettes, M; Galicier, L; Oksenhendler, E; Blanche, S; Fischer, A; Revy, P; Stoppa-Lyonnet, D; Picard, C; de Villartay, JP				Berland, Aurelie; Rosain, Jeremie; Kaltenbach, Sophie; Allain, Vincent; Mahlaoui, Nizar; Melki, Isabelle; Fievet, Alice; d'Enghien, Catherine Dubois; Ouachee-Chardin, Marie; Perrin, Laurence; Auger, Nathalie; Cipe, Funda Erol; Finocchi, Andrea; Dogu, Figen; Suarez, Felipe; Moshous, Despina; Leblanc, Thierry; Belot, Alexandre; Fieschi, Claire; Boutboul, David; Malphettes, Marion; Galicier, Lionel; Oksenhendler, Eric; Blanche, Stephane; Fischer, Alain; Revy, Patrick; Stoppa-Lyonnet, Dominique; Picard, Capucine; de Villartay, Jean-Pierre			PROMIDIS alpha: A T-cell receptor a signature associated with immunodeficiencies caused by V(D)J recombination defects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Primary immunodeficiency; V(D)J recombination; T-cell receptor alpha repertoire; ataxia telangiectasia; DNA repair; next-generation sequencing	DNA-LIGASE IV; REPERTOIRE; MECHANISMS	Background: V(D)J recombination ensures the diversity of the adaptive immune system. Although its complete defect causes severe combined immunodeficiency (ie, T-B- severe combined immunodeficiency), its suboptimal activity is associated with a broad spectrum of immune manifestations, such as late-onset combined immunodeficiency and autoimmunity. The earliest molecular diagnosis of these patients is required to adopt the best therapy strategy, particularly when it involves a myeloablative conditioning regimen for hematopoietic stem cell transplantation. Objective: We aimed at developing biomarkers based on analysis of the T-cell receptor (TCR) alpha repertoire to assist in the diagnosis of patients with primary immunodeficiencies with V(D) J recombination and DNA repair deficiencies. Methods: We used flow cytometric (fluorescence-activated cell sorting) analysis to quantify TCR-V alpha 7.2-expressing T lymphocytes in peripheral blood and developed PROMIDIS alpha, a multiplex RT-PCR/next-generation sequencing assay, to evaluate a subset of the TCR alpha repertoire in T lymphocytes. Results: The combined fluorescence-activated cell sorting and PROMIDISa analyses revealed specific signatures in patients with V(D) J recombination-defective primary immunodeficiencies or ataxia telangiectasia/Nijmegen breakage syndromes. Conclusion: Analysis of the TCR alpha repertoire is particularly appropriate in a prospective way to identify patients with partial immune defects caused by suboptimal V(D) J recombination activity, a DNA repair defect, or both. It also constitutes a valuable tool for the retrospective in vivo functional validation of variants identified through exome or panel sequencing. Its broader implementation might be of interest to assist early diagnosis of patients presenting with hypomorphic DNA repair defects inclined to experience acute toxicity during prehematopoietic stem cell transplantation conditioning.	[Berland, Aurelie; Kaltenbach, Sophie; Moshous, Despina; Revy, Patrick; de Villartay, Jean-Pierre] INSERM, UMR1163, Lab Genome Dynam Immune Syst, Paris, France; [Berland, Aurelie; Rosain, Jeremie; Kaltenbach, Sophie; Mahlaoui, Nizar; Moshous, Despina; Fischer, Alain; Revy, Patrick; Picard, Capucine; de Villartay, Jean-Pierre] Univ Paris 05, Sorbonne Paris Cite, Inst Imagine, Paris, France; [Rosain, Jeremie; Allain, Vincent; Fischer, Alain; Picard, Capucine] Necker Enfants Malad Hosp, APHP, Study Ctr Primary Immunodeficiencies, Paris, France; [Mahlaoui, Nizar; Melki, Isabelle; Moshous, Despina; Blanche, Stephane] Necker Enfants Malad Univ Hosp, AP HP, Pediat Immunohaematol & Rheumatol Unit, Paris, France; [Melki, Isabelle] Hop Robert Debre, APHP, Gen Pediat Infect Dis & Internal Med Dept, Paris, France; [Fievet, Alice; Stoppa-Lyonnet, Dominique] Inst Curie, INSERM, U830, Paris, France; [Fievet, Alice; d'Enghien, Catherine Dubois; Stoppa-Lyonnet, Dominique] Inst Curie, Serv Genet, Paris, France; [Ouachee-Chardin, Marie; Leblanc, Thierry] Robert Debre APHP, Dept Pediat Hematol, Paris, France; [Perrin, Laurence] Robert Debre Hosp, APHP, Dept Genet, Paris, France; [Auger, Nathalie] Inst Gustave Roussy, Dept Biopathol, Villejuif, France; [Cipe, Funda Erol] Kanuni Sultan Suleyman Res & Training Hosp, Dept Pediat Allergy Immunol, Istanbul, Turkey; [Finocchi, Andrea] Bambino Gesu Pediat Hosp, Univ Dept Pediat, DPUO, Rome, Italy; [Finocchi, Andrea] Univ Tor Vergata, Sch Med, Rome, Italy; [Dogu, Figen] Ankara Univ, Sch Med, Dept Pediat Immunol & Allergy, Ankara, Turkey; [Suarez, Felipe] Necker Enfants Malad Univ Hosp, APHP, Dept Haematol, Paris, France; [Belot, Alexandre] Hosp Civils Lyon, Hop Femme Mere Enfant, Pediat Rheumatol Nephrol & Dermatol Dept, Lyon, France; [Fieschi, Claire; Boutboul, David; Malphettes, Marion; Galicier, Lionel; Oksenhendler, Eric] Hop St Louis, APHP, Dept Clin Immunol, Paris, France; [Fischer, Alain] INSERM, UMR1163, Paris, France; [Fischer, Alain] Coll France, Paris, France; [Stoppa-Lyonnet, Dominique] Univ Paris 05, Sorbonne Paris Cite, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite; UNICANCER; Gustave Roussy; Istanbul Kanuni Sultan Suleyman Training & Research Hospital; IRCCS Bambino Gesu; University of Rome Tor Vergata; Ankara University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; CHU Lyon; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; College de France; UDICE-French Research Universities; Universite Paris Cite	de Villartay, JP (corresponding author), Inst Imagine, INSERM, UMR1163, Equipe Labellisee Ligue Canc, 24 Bd Montparnasse, F-75015 Paris, France.	devillartay@gmail.com	MAHLAOUI, Nizar/AAH-6103-2020; de Villartay, jean pierre/H-9353-2017; Dogu, Figen/AAI-1316-2020; Finocchi, Andrea/K-5926-2016; Revy, Patrick/H-8137-2017; Moshous, Despina/B-7507-2017; Fiévet, Alice/K-4749-2019; Belot, Alexandre/C-7378-2013	MAHLAOUI, Nizar/0000-0002-0030-8094; de Villartay, jean pierre/0000-0001-5987-0463; Dogu, Figen/0000-0002-7869-4941; Finocchi, Andrea/0000-0003-0958-8536; Moshous, Despina/0000-0001-6719-3693; Fiévet, Alice/0000-0003-2096-8708; Belot, Alexandre/0000-0003-4902-5332; Revy, Patrick/0000-0003-0758-8022; Rosain, Jeremie/0000-0002-2822-161X	INSERM; Agence National de la Recherche [ANR-13-PRTS-0004]; La Ligue Nationale contre le Cancer (Equipe Labellisee LA LIGUE); AT-Europe Foundation	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Agence National de la Recherche(French National Research Agency (ANR)); La Ligue Nationale contre le Cancer (Equipe Labellisee LA LIGUE); AT-Europe Foundation	Supported by institutional grants from INSERM and the Agence National de la Recherche (ANR-13-PRTS-0004) and by grants from La Ligue Nationale contre le Cancer (Equipe Labellisee LA LIGUE 2017) and the AT-Europe Foundation.	Alt FW, 2013, CELL, V152, P417, DOI 10.1016/j.cell.2013.01.007; Bednarski JJ, 2012, ADV IMMUNOL, V116, P175, DOI 10.1016/B978-0-12-394300-2.00006-5; BRANDLE D, 1992, P NATL ACAD SCI USA, V89, P9529, DOI 10.1073/pnas.89.20.9529; Cipe FE, 2014, CASE REP PEDIAT, V2014, DOI 10.1155/2014/614238; Dard R, 2017, PEDIAT ALLERG IMM-UK, V28, P298, DOI 10.1111/pai.12694; de Villartay JP, 2003, NAT REV IMMUNOL, V3, P962, DOI 10.1038/nri1247; DEVILLARTAY JP, 1988, NATURE, V335, P170, DOI 10.1038/335170a0; Eberhard JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111323; Gatti R, 1993, ATAXIA TELANGIECTASI; Griffith LM, 2016, J ALLERGY CLIN IMMUN, V138, P375, DOI 10.1016/j.jaci.2016.01.051; Grimaldi D, 2014, INTENS CARE MED, V40, P192, DOI 10.1007/s00134-013-3163-x; Guo J, 2002, NAT IMMUNOL, V3, P469, DOI 10.1038/ni791; Han A, 2014, NAT BIOTECHNOL, V32, P684, DOI 10.1038/nbt.2938; Kassambara A., PRACTICAL GUIDE CLUS; Le S, 2008, J STAT SOFTW, V25, P1, DOI 10.18637/jss.v025.i01; Lee YN, 2016, SCI IMMUNOL, V1, DOI 10.1126/sciimmunol.aah6109; Magalhaes I, 2015, J CLIN INVEST, V125, P1752, DOI 10.1172/JCI78941; Martin E, 2009, PLOS BIOL, V7, P525, DOI 10.1371/journal.pbio.1000054; Mauvieux L, 2001, EUR J IMMUNOL, V31, P2080, DOI 10.1002/1521-4141(200107)31:7<2080::AID-IMMU2080>3.3.CO;2-8; Neven B, 2017, CLIN INFECT DIS, V64, P83, DOI 10.1093/cid/ciw675; Notarangelo LD, 2016, NAT REV IMMUNOL, V16, P234, DOI 10.1038/nri.2016.28; Okada S, 2015, SCIENCE, V349, P606, DOI 10.1126/science.aaa4282; PLOWMAN PN, 1990, BRIT J RADIOL, V63, P624, DOI 10.1259/0007-1285-63-752-624; Riballo E, 1999, CURR BIOL, V9, P699, DOI 10.1016/S0960-9822(99)80311-X; Rowe JH, 2017, J ALLERGY CLIN IMMUN, V140, P1739, DOI 10.1016/j.jaci.2017.08.001; Schatz DG, 2011, ANNU REV GENET, V45, P167, DOI 10.1146/annurev-genet-110410-132552; Schuetz C, 2014, BLOOD, V123, P281, DOI 10.1182/blood-2013-01-476432; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; Vera G, 2013, MOL CELL BIOL, V33, P701, DOI 10.1128/MCB.01057-12; Yu XM, 2014, J ALLERGY CLIN IMMUN, V133, P1109, DOI 10.1016/j.jaci.2013.11.018; Yu YX, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkv1016; Zhu YY, 2001, BIOTECHNIQUES, V30, P892, DOI 10.2144/01304pf02	33	23	23	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2019	143	1					325	+		10.1016/j.jaci.2018.05.028	http://dx.doi.org/10.1016/j.jaci.2018.05.028			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HG4BD	29906526	Green Published, Bronze			2022-12-18	WOS:000454918300036
J	Song, T; Pavel, AB; Wen, HC; Malik, K; Estrada, Y; Gonzalez, J; Hashim, PW; Nia, JK; Baum, D; Kimmel, G; Singer, GK; Krueger, JG; Guttman-Yassky, E				Song, Teresa; Pavel, Ana B.; Wen, Huei-Chi; Malik, Kunal; Estrada, Yeriel; Gonzalez, Juana; Hashim, Peter W.; Nia, John K.; Baum, Danielle; Kimmel, Grace; Singer, Giselle K.; Krueger, James G.; Guttman-Yassky, Emma			An integrated model of alopecia areata biomarkers highlights both T(H)1 and T(H)2 upregulation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									[Song, Teresa; Pavel, Ana B.; Wen, Huei-Chi; Malik, Kunal; Estrada, Yeriel; Hashim, Peter W.; Nia, John K.; Baum, Danielle; Kimmel, Grace; Singer, Giselle K.; Guttman-Yassky, Emma] Icahn Sch Med Mt Sinai, Dept Dermatol, Lab Inflammatory Skin Dis, New York, NY 10029 USA; [Song, Teresa; Malik, Kunal] SUNY Downstate, Coll Med, New York, NY USA; [Gonzalez, Juana; Krueger, James G.] Rockefeller Univ, Lab Invest Dermatol, 1230 York Ave, New York, NY 10021 USA	Icahn School of Medicine at Mount Sinai; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; Rockefeller University	Guttman-Yassky, E (corresponding author), Icahn Sch Med Mt Sinai, Dept Dermatol, Lab Inflammatory Skin Dis, New York, NY 10029 USA.	emma.guttman@mountsinai.org	Wen, Huei-Chi/ABD-7417-2021	Hashim, Peter/0000-0003-4904-2183	Pfizer; Amgen; Janssen; Lilly; Merck; Novartis; Kadmon; Dermira; Boehringer; Innovaderm; Kyowa; BMS; Serono; BiogenIdec; Delenex; AbbVie; Sanofi; Baxter; Paraxel; Xenoport; Kineta; Celgene; Eli Lilly; Medimmune/Astra Zeneca; Regeneron; Vitae; Glenmark; Galderma; Asana; UCB	Pfizer(Pfizer); Amgen(Amgen); Janssen(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); Lilly(Eli Lilly); Merck(Merck & Company); Novartis(Novartis); Kadmon; Dermira; Boehringer(Boehringer Ingelheim); Innovaderm; Kyowa; BMS(Bristol-Myers Squibb); Serono(Merck & Company); BiogenIdec(Biogen); Delenex; AbbVie(AbbVie); Sanofi; Baxter; Paraxel; Xenoport; Kineta; Celgene(Bristol-Myers SquibbCelgene Corporation); Eli Lilly(Eli Lilly); Medimmune/Astra Zeneca(AstraZeneca); Regeneron(Regeneron); Vitae; Glenmark; Galderma; Asana; UCB(UCB Pharma SA)	J. G. Krueger has received research support (grants paid to his institution) and/or personal fees from Pfizer, Amgen, Janssen, Lilly, Merck, Novartis, Kadmon, Dermira, Boehringer, Innovaderm, Kyowa, BMS, Serono, BiogenIdec, Delenex, AbbVie, Sanofi, Baxter, Paraxel, Xenoport, and Kineta. E. Guttman-Yassky is an employee of Mount Sinai and has received research funds (grants paid to the institution) from: Abbvie, Celgene, Eli Lilly, Janssen, Medimmune/Astra Zeneca, Novartis, Pfizer, Regeneron, Vitae, Glenmark, Galderma, Asana, Innovaderm, Dermira, and UCB and is also a consultant for Sanofi Aventis, Regeneron, Stiefel/GlaxoSmithKline, MedImmune, Celgene, Anacor, AnaptysBio, Dermira, Galderma, Glenmark, Novartis, Pfizer, Vitae, Leo Pharma, Abbvie, Eli Lilly, Kyowa, Mitsubishi Tanabe, Asana Biosciences, and Promius. The rest of the authors declare that they have no relevant conflicts of interest.	Czarnowicki T, 2018, ALLERGY, V73, P713, DOI 10.1111/all.13346; Dainichi T, 2017, J DERMATOL SCI, V86, P3, DOI 10.1016/j.jdermsci.2016.10.004; Inui S, 2013, J DERMATOL, V40, P881, DOI 10.1111/1346-8138.12273; Kuwano Y, 2007, BRIT J DERMATOL, V157, P466, DOI 10.1111/j.1365-2133.2007.07943.x; Renert-Yuval Y, 2017, ADV THER, V34, P1594, DOI 10.1007/s12325-017-0542-7; Suarez-Farinas M, 2015, J ALLERGY CLIN IMMUN, V136, P1277, DOI 10.1016/j.jaci.2015.06.032; Tembhre MK, 2013, BRIT J DERMATOL, V169, P543, DOI 10.1111/bjd.12396; Ungar B, 2017, J INVEST DERMATOL, V137, P603, DOI 10.1016/j.jid.2016.09.037; Xing LZ, 2014, NAT MED, V20, P1043, DOI 10.1038/nm.3645	9	23	23	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2018	142	5					1631	+		10.1016/j.jaci.2018.06.029	http://dx.doi.org/10.1016/j.jaci.2018.06.029			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GZ5BL	29981808	Bronze			2022-12-18	WOS:000449429800025
J	Godar, M; Deswarte, K; Vergote, K; Saunders, M; de Haard, H; Hammad, H; Blanchetot, C; Lambrecht, BN				Godar, Marie; Deswarte, Kim; Vergote, Karl; Saunders, Michael; de Haard, Hans; Hammad, Hamida; Blanchetot, Christophe; Lambrecht, Bart N.			A bispecific antibody strategy to target multiple type 2 cytokines in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; bispecific antibody; bronchial hyperreactivity; goblet cell metaplasia; house dust mite; IL-4 receptor alpha; IL-5	HOUSE-DUST MITES; EOSINOPHILIC ASTHMA; AIRWAY EPITHELIUM; T-CELLS; INTERLEUKIN (IL)-13; ALLERGIC-ASTHMA; INFLAMMATION; MEPOLIZUMAB; IMMUNITY; IL-4	Background: Asthma is a chronic inflammatory airway disease in which innate and adaptive immune cells act together to cause eosinophilic inflammation, goblet cell metaplasia (GCM), and bronchial hyperreactivity (BHR). In clinical trials using biologicals against IL-4 receptor (IL-4R) alpha or IL-5, only a subset of patients with moderate-to-severe asthma responded favorably, suggesting that distinct pathophysiologic mechanisms are at play in subgroups of patients called endotypes. However, the effect of multiple cytokine blockade using bispecific antibodies has not been tested. Objective: We sought to target simultaneously the IL-4, IL-13, and IL-5 signaling pathways with a novel IL-4R alpha/IL-5-bispecific antibody in a murine house dust mite (HDM) model of asthma. Methods: Two mAbs neutralizing IL-4R alpha and IL-5 were generated by using a llama-based antibody platform. Their heavy and light chains were then cotransfected in mammalian cells, resulting in a heterogeneous antibody mixture from which the bispecific antibody was isolated by using a dual anti-idiotypic purification process. C57BL/6J mice were finally sensitized and challenged to HDM extracts and treated during challenge with the antibodies. Results: We successfully generated and characterized the monospecific and bispecific antibodies targeting IL-4R alpha and IL-5. The monospecific antibodies could suppress eosinophilia, IgE synthesis, or both, whereas only the IL-4R alpha/IL-5-bispecific antibody and the combination of monospecific antibodies additionally inhibited GCM and BHR. Conclusion: Type 2 cytokines act synergistically to cause GCM and BHR in HDM-exposed mice. These preclinical results show the feasibility of generating bispecific antibodies that target multiple cytokine signaling pathways as superior inhibitors of asthma features, including the difficult-to-treat GCM.	[Godar, Marie; Saunders, Michael; de Haard, Hans; Blanchetot, Christophe] Argenx BVBA, Ind Pk Zwijnaarde 7, B-9052 Zwijnaarde, Belgium; [Godar, Marie; Deswarte, Kim; Vergote, Karl; Hammad, Hamida; Lambrecht, Bart N.] VIB UGent Ctr Inflammat Res, B-9000 Ghent, Belgium; [Godar, Marie; Deswarte, Kim; Vergote, Karl; Hammad, Hamida; Lambrecht, Bart N.] Univ Ghent, Dept Internal Med, B-9000 Ghent, Belgium; [Lambrecht, Bart N.] Erasmus MC, Dept Pulm Med, Rotterdam, Netherlands	Flanders Institute for Biotechnology (VIB); Ghent University; Ghent University; Erasmus University Rotterdam; Erasmus MC	Blanchetot, C (corresponding author), Argenx BVBA, Ind Pk Zwijnaarde 7, B-9052 Zwijnaarde, Belgium.; Lambrecht, BN (corresponding author), VIB UGent Ctr Inflammat Res, B-9000 Ghent, Belgium.; Lambrecht, BN (corresponding author), Univ Ghent, Dept Internal Med, B-9000 Ghent, Belgium.	CBlanchetot@argenx.com; bart.lambrecht@ugent.be	Hammad, Hamida/J-9391-2015; Lambrecht, Bart N/K-2484-2014	Hammad, Hamida/0000-0003-3762-8603; Lambrecht, Bart N/0000-0003-4376-6834; Deswarte, Kim/0000-0002-9761-6973	Agentschap voor Innovatie door Wetenschap en Technologie (IWT) [IWT130849]; EOS Excellence of Science award (FWO) [G0G2318N]	Agentschap voor Innovatie door Wetenschap en Technologie (IWT)(Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT)); EOS Excellence of Science award (FWO)	Supported by the Agentschap voor Innovatie door Wetenschap en Technologie (IWT, grant no. IWT130849) and by an EOS Excellence of Science award (FWO, project no. G0G2318N).	Anderson GP, 2008, LANCET, V372, P1107, DOI 10.1016/S0140-6736(08)61452-X; Basilico C, 2014, J CLIN INVEST, V124, P3172, DOI 10.1172/JCI72316; Bel EH, 2014, NEW ENGL J MED, V371, P1189, DOI 10.1056/NEJMoa1403291; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BRUSSELLE GG, 1994, CLIN EXP ALLERGY, V24, P73, DOI 10.1111/j.1365-2222.1994.tb00920.x; Brusselle Guy, 2017, ERJ Open Res, V3, DOI 10.1183/23120541.00004-2017; Calderon MA, 2015, J ALLERGY CLIN IMMUN, V136, P38, DOI 10.1016/j.jaci.2014.10.012; Castro M, 2015, LANCET RESP MED, V3, P355, DOI [10.1016/S2213-2600(15)00042-9, 10.1016/S2213-2600(15)00119-8]; Chao DT, 2009, IMMUNOL INVEST, V38, P76, DOI 10.1080/08820130802608238; Chen G, 2014, AM J RESP CRIT CARE, V189, P301, DOI 10.1164/rccm.201306-1181OC; Chen G, 2009, J CLIN INVEST, V119, P2914, DOI 10.1172/JCI39731; Choy DF, 2011, J IMMUNOL, V186, P1861, DOI 10.4049/jimmunol.1002568; Coquet JM, 2015, IMMUNITY, V43, P318, DOI 10.1016/j.immuni.2015.07.015; de Haard HJ, 1999, J BIOL CHEM, V274, P18218, DOI 10.1074/jbc.274.26.18218; De Haard HJW, 2005, J BACTERIOL, V187, P4531, DOI 10.1128/JB.187.13.4531-4541.2005; Deckers J, 2017, J ALLERGY CLIN IMMUN, V140, P1364, DOI 10.1016/j.jaci.2016.12.970; Dullaers M, 2017, J ALLERGY CLIN IMMUN, V140, P76, DOI 10.1016/j.jaci.2016.09.020; Fahy JV, 2015, NAT REV IMMUNOL, V15, P57, DOI 10.1038/nri3786; Fahy JV, 2010, NEW ENGL J MED, V363, P2233, DOI 10.1056/NEJMra0910061; Godar M, 2018, MABS-AUSTIN, V10, P34, DOI 10.1080/19420862.2017.1392425; Godar M, 2016, SCI REP-UK, V6, DOI 10.1038/srep31621; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; Hammad H, 2015, IMMUNITY, V43, P29, DOI 10.1016/j.immuni.2015.07.007; Hammad H, 2010, J EXP MED, V207, P2097, DOI 10.1084/jem.20101563; Hansbro PM, 2011, BRIT J PHARMACOL, V163, P81, DOI 10.1111/j.1476-5381.2011.01219.x; Hoogenboom Hennie R, 2002, Methods Mol Biol, V178, P1; Jacobsen EA, 2015, ALLERGY, V70, P1148, DOI 10.1111/all.12655; Jacobsen EA, 2014, CLIN EXP ALLERGY, V44, P1119, DOI 10.1111/cea.12358; Klarenbeek A, 2015, MABS-AUSTIN, V7, P693, DOI 10.1080/19420862.2015.1046648; Kontermann RE, 2012, MABS-AUSTIN, V4, P182, DOI 10.4161/mabs.4.2.19000; Lambrecht BN, 2017, NAT IMMUNOL, V18, P1076, DOI 10.1038/ni.3829; Lambrecht BN, 2015, NAT IMMUNOL, V16, P45, DOI 10.1038/ni.3049; Lambrecht BN, 2014, J ALLERGY CLIN IMMUN, V134, P499, DOI 10.1016/j.jaci.2014.06.036; Lambrecht BN, 2012, NAT MED, V18, P684, DOI 10.1038/nm.2737; Lloyd CM, 2010, NAT REV IMMUNOL, V10, P838, DOI 10.1038/nri2870; MACARDLE PJ, 1995, IMMUNOL CELL BIOL, V73, P165, DOI 10.1038/icb.1995.26; Mattes J, 2002, J EXP MED, V195, P1433, DOI 10.1084/jem.20020009; Merchant AM, 1998, NAT BIOTECHNOL, V16, P677, DOI 10.1038/nbt0798-677; Nair P, 2009, NEW ENGL J MED, V360, P985, DOI 10.1056/NEJMoa0805435; Ortega HG, 2014, NEW ENGL J MED, V371, P1198, DOI 10.1056/NEJMoa1403290; Park KS, 2007, J CLIN INVEST, V117, P978, DOI 10.1172/JCI29176; Ridgway JBB, 1996, PROTEIN ENG, V9, P617, DOI 10.1093/protein/9.7.617; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Roovers RC, 2007, CANCER IMMUNOL IMMUN, V56, P303, DOI 10.1007/s00262-006-0180-4; Schuijs MJ, 2015, SCIENCE, V349, P1106, DOI 10.1126/science.aac6623; Walsh CJ, 2016, CLIN EXP ALLERGY, V46, P1291, DOI 10.1111/cea.12762; Wang YH, 2010, J EXP MED, V207, P2479, DOI 10.1084/jem.20101376; Webb DC, 2003, EUR J IMMUNOL, V33, P3377, DOI 10.1002/eji.200324178; Wenzel S, 2013, NEW ENGL J MED, V368, P2455, DOI 10.1056/NEJMoa1304048; Wenzel SE, 2012, NAT MED, V18, P716, DOI 10.1038/nm.2678; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC	53	23	25	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2018	142	4					1185	+		10.1016/j.jaci.2018.06.002	http://dx.doi.org/10.1016/j.jaci.2018.06.002			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GV7RG	29890236	Bronze, Green Accepted, Green Published			2022-12-18	WOS:000446327300018
J	Valent, P; Akin, C; Bonadonna, P; Hartmann, K; Broesby-Olsen, S; Brockow, K; Butterfield, JH; Reiter, A; Gotlib, J; Castells, M; Milner, JD; Carter, MC; Komarow, H; Radia, D; Pardanani, A; Sotlar, K; Triggiani, M; Horny, HP; Arock, M; Schwartz, LB; Metcalfe, DD				Valent, Peter; Akin, Cem; Bonadonna, Patrizia; Hartmann, Karin; Broesby-Olsen, Sigurd; Brockow, Knut; Butterfield, Joseph H.; Reiter, Andreas; Gotlib, Jason; Castells, Mariana; Milner, Joshua D.; Carter, Melody C.; Komarow, Hirsh; Radia, Deepti; Pardanani, Animesh; Sotlar, Karl; Triggiani, Massimo; Horny, Hans -Peter; Arock, Michel; Schwartz, Lawrence B.; Metcalfe, Dean D.			Mast cell activation syndrome: Importance of consensus criteria and call for research	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							SERUM TRYPTASE; DISORDERS		[Valent, Peter] Med Univ Vienna, Div Haematol, Dept Internal Med 1, Vienna, Austria; [Akin, Cem] Univ Michigan, Div Allergy & Clin Immunol, Ann Arbor, MI 48109 USA; [Bonadonna, Patrizia] Verona Univ Hosp, Allergy Unit, Verona, Italy; [Hartmann, Karin] Univ Lubeck, Dept Dermatol, Lubeck, Germany; [Broesby-Olsen, Sigurd] Odense Univ Hosp, Dept Dermatol, Odense, Denmark; [Broesby-Olsen, Sigurd] Odense Univ Hosp, Allergy Ctr, Odense, Denmark; [Brockow, Knut] Tech Univ Munich, Dept Dermatol & Allergy Biederstein, Munich, Germany; [Butterfield, Joseph H.] Mayo Clin, Div Allerg Dis, Rochester, MN USA; [Reiter, Andreas] Heidelberg Univ, Univ Med Mannheim, Med Klin 3, Mannheim, Germany; [Gotlib, Jason] Stanford Univ, Sch Med, Stanford Canc Inst, Stanford, CA 94305 USA; [Castells, Mariana] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Div Allergy & Immunol, Boston, MA USA; [Milner, Joshua D.; Carter, Melody C.; Komarow, Hirsh; Metcalfe, Dean D.] NIAID, Lab Allerg Dis, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Radia, Deepti] Guys & St Thomas NHS Fdn Trust, Guys Hosp, Dept Haematol, London, England; [Pardanani, Animesh] Mayo Clin, Div Hematol, Rochester, MN USA; [Sotlar, Karl] Paracelsus Med Univ Salzburg, Inst Pathol, Salzburg, Austria; [Triggiani, Massimo] Univ Salerno, Div Allergy & Clin Immunol, Salerno, Italy; [Horny, Hans -Peter] Ludwig Maximilians Univ Munchen, Inst Pathol, Munich, Germany; [Arock, Michel] Ecole Normale Super, LBPA CNRS UMR8113, Cachan, France; [Schwartz, Lawrence B.] Virginia Commonwealth Univ, Dept Internal Med, Div Rheumatol Allergy & Immunol, Richmond, VA USA	Medical University of Vienna; University of Michigan System; University of Michigan; University of Verona; Azienda Ospedaliera Universitaria Integrata Verona; University of Lubeck; University of Southern Denmark; Odense University Hospital; University of Southern Denmark; Odense University Hospital; Technical University of Munich; Mayo Clinic; Ruprecht Karls University Heidelberg; Stanford Cancer Institute; Stanford University; Harvard University; Brigham & Women's Hospital; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Guy's & St Thomas' NHS Foundation Trust; Mayo Clinic; Paracelsus Private Medical University; University of Salerno; University of Munich; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Saclay; Virginia Commonwealth University	Valent, P (corresponding author), Med Univ Vienna, Div Haematol, Dept Internal Med 1, Vienna, Austria.	peter.valent@meduniwien.ac.at	Hartmann, Karin/N-4865-2015; Test, PV/U-9451-2019; Triggiani, Massimo/K-8271-2016; Test, Test/Y-7921-2019; Valent, Peter/B-8533-2016; Gamperl, Susi/V-2715-2019	Hartmann, Karin/0000-0002-4595-8226; Triggiani, Massimo/0000-0001-7318-2093; Valent, Peter/0000-0003-0456-5095; Gamperl, Susi/0000-0003-0456-5095	Austrian Science Funds (FWF) [F4701-B20, F4704-B20]; Division of Intramural Research, National Institute of Allergy and Infectious Diseases; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI001091, ZIAAI000249, ZIAAI001183] Funding Source: NIH RePORTER	Austrian Science Funds (FWF)(Austrian Science Fund (FWF)); Division of Intramural Research, National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported in part by the Austrian Science Funds (FWF) projects F4701-B20 and F4704-B20 and by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases.	Akin C, 2007, BLOOD, V110, P2331, DOI 10.1182/blood-2006-06-028100; Akin C, 2017, J ALLERGY CLIN IMMUN, V140, P349, DOI 10.1016/j.jaci.2017.06.007; Akin C, 2010, J ALLERGY CLIN IMMUN, V126, P1099, DOI 10.1016/j.jaci.2010.08.035; Baretto RL, 2017, ALLERGY, V72, P2031, DOI 10.1111/all.13226; Carter MC, 2018, J ALLERGY CLIN IMMUN, V141, P180, DOI 10.1016/j.jaci.2017.05.036; Lortholary O, 2017, LANCET, V389, P612, DOI 10.1016/S0140-6736(16)31403-9; Lyons JJ, 2016, NAT GENET, V48, P1564, DOI 10.1038/ng.3696; Ravi A, 2014, J ALLER CL IMM-PRACT, V2, P775, DOI 10.1016/j.jaip.2014.06.011; Schwartz LB, 1995, J CLIN INVEST, V96, P2702, DOI 10.1172/JCI118337; Valent P, 2012, INT ARCH ALLERGY IMM, V157, P215, DOI 10.1159/000328760	10	23	23	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2018	142	3					1008	+		10.1016/j.jaci.2018.06.004	http://dx.doi.org/10.1016/j.jaci.2018.06.004			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GS5RJ	29928922	Green Accepted, Green Submitted, Bronze			2022-12-18	WOS:000443726500041
J	Qian, X; Aboushousha, R; van de Wetering, C; Chia, SB; Amiel, E; Schneider, RW; van der Velden, JLJ; Lahue, KG; Hoagland, DA; Casey, DT; Daphtary, N; Ather, JL; Randall, MJ; Aliyeva, M; Black, KE; Chapman, DG; Lundblad, LKA; McMillan, DH; Dixon, AE; Anathy, V; Irvin, CG; Poynter, ME; Wouters, EFM; Vacek, PM; Henket, M; Schleich, F; Louis, R; van der Vliet, A; Janssen-Heininger, YMW				Qian, Xi; Aboushousha, Reem; van de Wetering, Cheryl; Chia, Shi B.; Amiel, Eyal; Schneider, Robert W.; van der Velden, Jos L. J.; Lahue, Karolyn G.; Hoagland, Daisy A.; Casey, Dylan T.; Daphtary, Nirav; Ather, Jennifer L.; Randall, Matthew J.; Aliyeva, Minara; Black, Kendall E.; Chapman, David G.; Lundblad, Lennart K. A.; McMillan, David H.; Dixon, Anne E.; Anathy, Vikas; Irvin, Charles G.; Poynter, Matthew E.; Wouters, Emiel F. M.; Vacek, Pamela M.; Henket, Monique; Schleich, Florence; Louis, Renaud; van der Vliet, Albert; Janssen-Heininger, Yvonne M. W.			IL-1/inhibitory kappa B kinase epsilon-induced glycolysis augment epithelial effector function and promote allergic airways disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; house dust mite; glycolysis; IL-1; inhibitor of kappa B kinase epsilon; lactate; lactate dehydrogenase A	HOUSE-DUST MITE; ACTIVATION PROMOTES; CELL ACTIVATION; MURINE MODEL; INFLAMMATION; LACTATE; ASTHMA; IL-1; METABOLISM; RESPONSES	Background: Emerging studies suggest that enhanced glycolysis accompanies inflammatory responses. Virtually nothing is known about the relevance of glycolysis in patients with allergic asthma. Objectives: We sought to determine whether glycolysis is altered in patients with allergic asthma and to address its importance in the pathogenesis of allergic asthma. Methods: We examined alterations in glycolysis in sputum samples from asthmatic patients and primary human nasal cells and used murine models of allergic asthma, as well as primary mouse tracheal epithelial cells, to evaluate the relevance of glycolysis. Results: In a murine model of allergic asthma, glycolysis was induced in the lungs in an IL-1-dependent manner. Furthermore, administration of IL-1 beta into the airways stimulated lactate production and expression of glycolytic enzymes, with notable expression of lactate dehydrogenase A occurring in the airway epithelium. Indeed, exposure of mouse tracheal epithelial cells to IL-1 beta or IL-1 alpha resulted in increased glycolytic flux, glucose use, expression of glycolysis genes, and lactate production. Enhanced glycolysis was required for IL-1 beta- or IL-1 alpha-mediated proinflammatory responses and the stimulatory effects of IL-1 beta on house dust mite (HDM)-induced release of thymic stromal lymphopoietin and GM-CSF from tracheal epithelial cells. Inhibitor of kappa B kinase epsilon was downstream of HDM or IL-1 beta and required for HDM-induced glycolysis and pathogenesis of allergic airways disease. Small interfering RNA ablation of lactate dehydrogenase A attenuated HDM-induced increases in lactate levels and attenuated HDM-induced disease. Primary nasal epithelial cells from asthmatic patients intrinsically produced more lactate compared with cells from healthy subjects. Lactate content was significantly higher in sputum supernatants from asthmatic patients, notably those with greater than 61% neutrophils. A positive correlation was observed between sputum lactate and IL-1 beta levels, and lactate content correlated negatively with lung function. Conclusions: Collectively, these findings demonstrate that IL-1 beta/inhibitory kappa B kinase epsilon signaling plays an important role in HDM-induced glycolysis and pathogenesis of allergic airways disease.	[Qian, Xi; Aboushousha, Reem; Chia, Shi B.; Schneider, Robert W.; van der Velden, Jos L. J.; Lahue, Karolyn G.; Hoagland, Daisy A.; Casey, Dylan T.; McMillan, David H.; Anathy, Vikas; van der Vliet, Albert; Janssen-Heininger, Yvonne M. W.] Univ Vermont, Coll Med, Dept Pathol & Lab Med, Burlington, VT USA; [Daphtary, Nirav; Ather, Jennifer L.; Randall, Matthew J.; Aliyeva, Minara; Black, Kendall E.; Chapman, David G.; Lundblad, Lennart K. A.; Dixon, Anne E.; Irvin, Charles G.; Poynter, Matthew E.] Univ Vermont, Coll Med, Dept Med, Burlington, VT 05405 USA; [Vacek, Pamela M.] Univ Vermont, Coll Med, Med Biostat Unit, Burlington, VT USA; [van de Wetering, Cheryl; Wouters, Emiel F. M.] Maastricht Univ, Med Ctr, Dept Pulmonol, Maastricht, Netherlands; [Amiel, Eyal] Univ Vermont, Coll Nursing & Hlth Sci, Dept Med Lab & Radiat, Burlington, VT USA; [Henket, Monique; Schleich, Florence; Louis, Renaud] CHU Sart TilmanB35, Dept Resp Med, Liege, Belgium; [Chapman, David G.] Univ Sydney, Sydney Med Sch, Woolcock Inst Med Res, Sydney, NSW, Australia	University of Vermont; University of Vermont; University of Vermont; Maastricht University; University of Vermont; University of Sydney; Woolcock Institute of Medical Research	Janssen-Heininger, YMW (corresponding author), Univ Vermont, Dept Pathol & Lab Med, HSRF Bldg,Room 216A, Burlington, VT 05405 USA.	yvonne.janssen@uvm.edu	Hoagland, Daisy/AAT-4774-2021; Wouters, Emiel/ABD-6200-2021	Casey, Dylan/0000-0002-6634-0708; Ather, Jennifer/0000-0003-0484-5599; Aboushousha, Reem/0000-0003-2284-2180; Poynter, Matthew/0000-0002-7578-4570; Randall, Matthew/0000-0003-3840-8952; Lundblad, Lennart/0000-0002-1749-8242; Chapman, David/0000-0002-8211-1817	National Institutes of Health (NIH) [R01 HL060014, HL079331, R35 HL135828, R01 HL122383, R01 HL085646, ES021476, HL130847, R01 HL133920]; NIH/National Institute of Allergy and Infectious Diseases [1R21AI112804]; NIH/National Center for Research Resources [P30 GM103532]; VLC CoBRE [P30GM103532]; VCIID CoBRE [P20GM103496]; UVM College of Nursing and Health Sciences Start-up Funds; GlaxoSmithKline; Novartis; Chiesi; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL076122, R01HL138708, R01HL122383, R01HL079331, R01HL060014, R35HL135828, R01HL085646, R01HL130847, R01HL133920, R01HL137268] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI112804] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES021476] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P30GM103532, P20GM103496] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R21AG055325] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH/National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIH/National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); VLC CoBRE; VCIID CoBRE; UVM College of Nursing and Health Sciences Start-up Funds; GlaxoSmithKline(GlaxoSmithKline); Novartis(Novartis); Chiesi(Chiesi Pharmaceuticals Inc); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Supported National Institutes of Health (NIH) grants R01 HL060014 and HL079331; R35 HL135828 (to Y.M.W.J.-H.), R01 HL122383 (to V.A.), R01 HL085646, and ES021476 (to A.v.d.V.); HL130847 (to A.E.D.); R01 HL133920 (M.E.P. and A.E.D.); and NIH/National Institute of Allergy and Infectious Diseases 1R21AI112804 and NIH/National Center for Research Resources P30 GM103532 (to L.K.A.L.), as well as VLC CoBRE: P30GM103532 and VCIID CoBRE: P20GM103496 (M.E.P.), UVM College of Nursing and Health Sciences Start-up Funds (to E.A.), and research grants from GlaxoSmithKline (to R.L.), Novartis (to R.L.), and Chiesi (to R.L. and E.F.M.W.).	Alcorn JF, 2008, J CELL SCI, V121, P1036, DOI 10.1242/jcs.019455; Anathy V, 2014, AM J RESP CRIT CARE, V189, P463, DOI 10.1164/rccm.201310-1905OC; Ather JL, 2015, CLIN EXP ALLERGY, V45, P1245, DOI 10.1111/cea.12491; Ather JL, 2011, AM J RESP CELL MOL, V44, P631, DOI 10.1165/rcmb.2010-0106OC; Baggstrom MQ, 2011, J THORAC ONCOL, V6, P1757, DOI 10.1097/JTO.0b013e31822e2941; Broide DH, 2000, BLOOD, V95, P263; Colegio OR, 2014, NATURE, V513, P559, DOI 10.1038/nature13490; Delvaux M, 2004, THORAX, V59, P111, DOI 10.1136/thorax.2003.011130; Dixon AE, 2009, CHEST, V136, P1324, DOI 10.1378/chest.08-1983; Dodda V, 2011, CHEST, V140, p183A; Doherty JR, 2013, J CLIN INVEST, V123, P3685, DOI 10.1172/JCI69741; Donnelly RP, 2014, J IMMUNOL, V193, P4477, DOI 10.4049/jimmunol.1401558; Doughty CA, 2006, BLOOD, V107, P4458, DOI 10.1182/blood-2005-12-4788; Erle DJ, 2014, J CELL BIOL, V205, P621, DOI 10.1083/jcb.201401050; Everts B, 2014, NAT IMMUNOL, V15, P323, DOI 10.1038/ni.2833; Fahy JV, 2015, NAT REV IMMUNOL, V15, P57, DOI 10.1038/nri3786; Garlanda C, 2013, IMMUNITY, V39, P1003, DOI 10.1016/j.immuni.2013.11.010; Gauthier M, 2015, AM J RESP CRIT CARE, V192, P660, DOI 10.1164/rccm.201504-0763PP; Gulen MF, 2012, IMMUNITY, V37, P800, DOI 10.1016/j.immuni.2012.08.019; Haas R, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002202; Hoffman SM, 2016, J ALLERGY CLIN IMMUN, V137, P822, DOI 10.1016/j.jaci.2015.08.018; Hotamisligil GS, 2006, NATURE, V444, P860, DOI 10.1038/nature05485; Jantsch J, 2008, J IMMUNOL, V180, P4697, DOI 10.4049/jimmunol.180.7.4697; Johnson VJ, 2005, J ALLERGY CLIN IMMUN, V116, P851, DOI 10.1016/j.jaci.2005.07.008; Kim RY, 2017, AM J RESP CRIT CARE, V196, P283, DOI 10.1164/rccm.201609-1830OC; Kouzaki H, 2011, J IMMUNOL, V186, P4375, DOI 10.4049/jimmunol.1003020; Krawczyk CM, 2010, BLOOD, V115, P4742, DOI 10.1182/blood-2009-10-249540; Leppanen O, 2006, ATHEROSCLEROSIS, V188, P323, DOI 10.1016/j.atherosclerosis.2005.11.017; Lewis LM, 2014, CHEST, V145, P53, DOI 10.1378/chest.13-0930; Liu WM, 2017, J ALLERGY CLIN IMMUN, V139, P1548, DOI 10.1016/j.jaci.2016.08.032; Maes T, 2016, J ALLERGY CLIN IMMUN, V137, P1433, DOI 10.1016/j.jaci.2016.02.018; Manise M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058388; Michalek RD, 2011, J IMMUNOL, V186, P3299, DOI 10.4049/jimmunol.1003613; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Moon JS, 2015, CELL REP, V12, P102, DOI 10.1016/j.celrep.2015.05.046; Moorman Jeanne E, 2012, Vital Health Stat 3, P1; Muller L, 2013, JOVE-J VIS EXP, DOI 10.3791/50646; Nakae S, 2003, INT IMMUNOL, V15, P483, DOI 10.1093/intimm/dxg054; Nathan C, 2010, CELL, V140, P871, DOI 10.1016/j.cell.2010.02.029; O'Neill LAJ, 2016, NAT REV IMMUNOL, V16, P553, DOI 10.1038/nri.2016.70; Ostroukhova M, 2012, AM J PHYSIOL-LUNG C, V302, pL300, DOI 10.1152/ajplung.00221.2011; Pantano C, 2008, AM J RESP CRIT CARE, V177, P959, DOI 10.1164/rccm.200707-1096OC; Park MJ, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/631384; Pauwels NS, 2011, EUR RESPIR J, V38, P1019, DOI 10.1183/09031936.00158110; Peebles RS, 2017, J ALLERGY CLIN IMMUN, V139, P1788, DOI 10.1016/j.jaci.2017.03.018; Peng M, 2016, SCIENCE, V354, P481, DOI 10.1126/science.aaf6284; Polanski R, 2014, CLIN CANCER RES, V20, P926, DOI 10.1158/1078-0432.CCR-13-2270; Pugin J, 1996, AM J RESP CRIT CARE, V153, P1850, DOI 10.1164/ajrccm.153.6.8665045; Rajamaki K, 2013, J BIOL CHEM, V288, P13410, DOI 10.1074/jbc.M112.426254; Reilly SM, 2013, NAT MED, V19, P313, DOI 10.1038/nm.3082; Riesenfeld Erik, 2012, J Allergy Ther, V1, P1; Rodrigo GJ, 2005, EMERG MED J, V22, P404, DOI 10.1136/emj.2003.012039; Rogliani P, 2015, PULM PHARMACOL THER, V31, P15, DOI 10.1016/j.pupt.2015.01.005; Schmitz N, 2003, EUR J IMMUNOL, V33, P991, DOI 10.1002/eji.200323801; Shirai T, 2016, J EXP MED, V213, P337, DOI 10.1084/jem.20150900; Taneja N, 2004, AM J PHYSIOL-CELL PH, V287, pC548, DOI 10.1152/ajpcell.00126.2003; Tomioka S, 2002, J APPL PHYSIOL, V93, P263, DOI 10.1152/japplphysiol.01129.2001; Tully JE, 2013, J IMMUNOL, V191, P5811, DOI 10.4049/jimmunol.1301329; Tully JE, 2012, AM J RESP CELL MOL, V47, P497, DOI 10.1165/rcmb.2012-0014OC; Van Tassell BW, 2010, J CARDIOVASC PHARM, V55, P117, DOI 10.1097/FJC.0b013e3181c87e53; Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014; Whelan R, 2004, EUR RESPIR J, V24, P559, DOI 10.1183/09031936.04.00133803; WIKEHOOLEY JL, 1984, RADIOTHER ONCOL, V2, P343, DOI 10.1016/S0167-8140(84)80077-8; Willart MAM, 2012, J EXP MED, V209, P1505, DOI 10.1084/jem.20112691; WU R, 1982, IN VITRO CELL DEV B, V18, P800	65	23	23	4	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2018	142	2					435	+		10.1016/j.jaci.2017.08.043	http://dx.doi.org/10.1016/j.jaci.2017.08.043			26	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GP2LN	29108965	Green Submitted, Green Accepted, Bronze			2022-12-18	WOS:000440664400013
J	Stokholm, J; Chawes, BL; Vissing, N; Bonnelykke, K; Bisgaard, H				Stokholm, Jakob; Chawes, Bo L.; Vissing, Nadja; Bonnelykke, Klaus; Bisgaard, Hans			Cat exposure in early life decreases asthma risk from the 17q21 high-risk variant	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						MeSH; asthma; cats; dogs; human orosomucoid-like 3 gene protein; gene-environment interaction	ENVIRONMENTAL DETERMINANTS; BACTERIAL-COLONIZATION; CHILDHOOD ASTHMA; ONSET; PETS; BRONCHIOLITIS; ALLERGENS; SYMPTOMS; DISEASES; ORMDL3	Background: Early-life exposure to cats and dogs has shown diverging associations with childhood asthma risk, and gene-environment interaction is one possible explanation. Objectives: We investigated interactions between cat and dog exposure and single nucleotide polymorphism rs7216389 variants in the chromosome 17q21 locus, the strongest known genetic risk factor for childhood asthma. Methods: Genotyping was performed in 377 children from the at-risk Copenhagen Prospective Studies on Asthma in Childhood(2000). The primary end point was the development of asthma until age 12 years. The secondary end point was the number of episodes with pneumonia and bronchiolitis from 0 to 3 years of age. Exposures included cat and dog ownership from birth and cat and dog allergen levels in bedding at age 1 year. Replication was performed in the unselected COPSAC(2010) cohort with follow-up until 5 years of age. Results: Cat and/or dog exposure from birth was associated with a lower prevalence of asthma among children with the rs7216389 high-risk TT genotype (adjusted hazard ratio, 0.16; 95% CI, 0.04-0.71; P = .015), with no effect in those with the CC/CT genotype (adjusted P = .283), demonstrating interaction between cat and dog exposure and the rs7216389 genotype (adjusted P = .044). Cat allergen levels were inversely associated with asthma development in children with the TT genotype (adjusted hazard ratio, 0.83; 95% CI, 0.71-0.97; P = .022), supporting the cat-rs7216389 genotype interaction (adjusted P = .008). Dog allergen exposure did not show such interaction. Furthermore, the TT genotype was associated with higher risk of pneumonia and bronchiolitis, and this increased risk was likewise decreased in children exposed to cat. Replication showed similar effects on asthma risk. Conclusion: The observed gene-environment interaction suggests a role of early-life exposure, especially to cat, for attenuating the risk of childhood asthma, pneumonia, and bronchiolitis in genetically susceptible subjects.	[Stokholm, Jakob; Chawes, Bo L.; Vissing, Nadja; Bonnelykke, Klaus; Bisgaard, Hans] Univ Copenhagen, Herlev & Gentofte Hosp, Copenhagen Prospect Studies Asthma Childhood, COPSAC, Copenhagen, Denmark; [Stokholm, Jakob] Naestved Hosp, Dept Pediat, Naestved, Denmark	University of Copenhagen; Naestved Hospital	Bisgaard, H (corresponding author), Univ Copenhagen, Herlev & Gentofte Hosp, Copenhagen Prospect Studies Asthma Childhood, COPSAC, Ledreborg Alle 34, DK-2820 Gentofte, Denmark.	bisgaard@copsac.com	Bisgaard, Hans/N-4761-2016	Bisgaard, Hans/0000-0003-4131-7592; Bonnelykke, Klaus/0000-0003-2003-1018; Stokholm, Jakob/0000-0003-4989-9769; Chawes, Bo/0000-0001-6846-6243	Chiesi Pharmaceuticals; Boehringer Ingelheim; Lundbeck Foundation; Novo Nordisk Foundation; Danish Ministry of Health; Danish Strategic Research Foundation; Lundbeck Foundation [R163-2013-16235] Funding Source: researchfish	Chiesi Pharmaceuticals(Chiesi Pharmaceuticals Inc); Boehringer Ingelheim(Boehringer Ingelheim); Lundbeck Foundation(Lundbeckfonden); Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Danish Ministry of Health; Danish Strategic Research Foundation(Danske Strategiske Forskningsrad (DSF)); Lundbeck Foundation(Lundbeckfonden)	H. Bisgaard received consultancy fees from Chiesi Pharmaceuticals and Boehringer Ingelheim, and his institution received grants from the Lundbeck Foundation, Novo Nordisk Foundation, Danish Ministry of Health, and Danish Strategic Research Foundation for other works. The rest of the authors declare that they have no relevant conflicts of interest.	Apelberg BJ, 2001, J ALLERGY CLIN IMMUN, V107, P455, DOI 10.1067/mai.2001.113240; Bisgaard H, 2004, ANN ALLERG ASTHMA IM, V93, P381, DOI 10.1016/S1081-1206(10)61398-1; Bisgaard H, 2013, CLIN EXP ALLERGY, V43, P1384, DOI 10.1111/cea.12213; Bisgaard H, 2006, NEW ENGL J MED, V354, P1998, DOI 10.1056/NEJMoa054692; Bisgaard H, 2008, PLOS MED, V5, DOI 10.1371/journal.pmed.0050131; Bisgaard H, 2007, NEW ENGL J MED, V357, P1487, DOI 10.1056/NEJMoa052632; Bisgaard H, 2009, AM J RESP CRIT CARE, V179, P179, DOI 10.1164/rccm.200809-1436OC; Bonnelykke K, 2014, NAT GENET, V46, P51, DOI 10.1038/ng.2830; Bouzigon E, 2008, NEW ENGL J MED, V359, P1985, DOI 10.1056/NEJMoa0806604; Brauner EV, 2012, GENES IMMUN, V13, P94, DOI 10.1038/gene.2011.51; Caliskan M, 2013, NEW ENGL J MED, V368, P1398, DOI 10.1056/NEJMoa1211592; Carlsen KCL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043214; Chawes BLK, 2012, J ALLERGY CLIN IMMUN, V130, P354, DOI 10.1016/j.jaci.2012.04.045; Dunn RR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064133; Eder W, 2006, NEW ENGL J MED, V355, P2226, DOI 10.1056/NEJMra054308; Flory JH, 2009, J ALLERGY CLIN IMMUN, V124, P605, DOI 10.1016/j.jaci.2009.05.047; Jirtle RL, 2007, NAT REV GENET, V8, P253, DOI 10.1038/nrg2045; Kim JL, 2005, INDOOR AIR, V15, P170, DOI 10.1111/j.1600-0668.2005.00334.x; Kocevar VS, 2004, CHEST, V125, P1680, DOI 10.1378/chest.125.5.1680; Kreiner-Moller E, 2015, ALLERGY, V70, P107, DOI 10.1111/all.12537; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; Lombardi E, 2010, PEDIATR ALLERGY IMMU, V21, P268, DOI 10.1111/j.1399-3038.2009.00910.x; Loss GJ, 2016, AM J RESP CRIT CARE, V193, P889, DOI 10.1164/rccm.201507-1493OC; Medjo B, 2013, PEDIATR INT, V55, P133, DOI 10.1111/ped.12071; Michel S, 2013, ALLERGY, V68, P355, DOI 10.1111/all.12097; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; Nafstad P, 2001, ALLERGY, V56, P307, DOI 10.1034/j.1398-9995.2001.00881.x; Ono JG, 2014, PEDIATR RES, V75, P165, DOI 10.1038/pr.2013.186; Prescott SL, 2013, J ALLERGY CLIN IMMUN, V131, P23, DOI 10.1016/j.jaci.2012.11.019; Stokholm J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046226; Team R.C, 2015, R LANG ENV STAT COMP; Vissing NH, 2013, AM J RESP CRIT CARE, V188, P1246, DOI 10.1164/rccm.201302-0215OC	32	23	23	4	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2018	141	5					1598	1606		10.1016/j.jaci.2017.07.044	http://dx.doi.org/10.1016/j.jaci.2017.07.044			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GF7KX	29102067	Bronze			2022-12-18	WOS:000432148200008
J	Silkoff, PE; Flavin, S; Gordon, R; Loza, MJ; Sterk, PJ; Lutter, R; Diamant, Z; Turner, RB; Lipworth, BJ; Proud, D; Singh, D; Eich, A; Backer, V; Gern, JE; Herzmann, C; Halperin, SA; Mensinga, TT; Del Vecchio, AM; Branigan, P; San Mateo, L; Baribaud, F; Barnathan, ES; Johnston, SL				Silkoff, Philip E.; Flavin, Susan; Gordon, Robert; Loza, Mathew J.; Sterk, Peter J.; Lutter, Rene; Diamant, Zuzana; Turner, Ronald B.; Lipworth, Brian J.; Proud, David; Singh, Dave; Eich, Andreas; Backer, Vibeke; Gern, James E.; Herzmann, Christian; Halperin, Scott A.; Mensinga, Tjeert T.; Del Vecchio, Alfred M.; Branigan, Patrick; San Mateo, Lani; Baribaud, Frederic; Barnathan, Elliot S.; Johnston, Sebastian L.			Toll-like receptor 3 blockade in rhinovirus-induced experimental asthma exacerbations: A randomized controlled study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; viral infection; inflammation; Toll-like receptor 3	IN-VIVO; INFECTION; MICE; INFLAMMATION; CYTOKINE; ANTIBODY; CELLS	Background: Human rhinoviruses (HRVs) commonly precipitate asthma exacerbations. Toll-like receptor 3, an innate pattern recognition receptor, is triggered by HRV, driving inflammation that can worsen asthma. Objective: We sought to evaluate an inhibitory mAb to Toll-like receptor 3, CNTO3157, on experimental HRV-16 inoculation in healthy subjects and asthmatic patients. Methods: In this double-blind, multicenter, randomized, parallel-group study in North America and Europe, healthy subjects and patients with mild-to-moderate stable asthma received single or multiple doses of CNTO3157 or placebo, respectively, and were then inoculated with HRV-16 within 72 hours. All subjects were monitored for respiratory symptoms, lung function, and nasal viral load. The primary end point was maximal decrease in FEV1 during 10 days after inoculation. Results: In asthmatic patients (n = 63) CNTO3157 provided no protection against FEV1 decrease (least squares mean: CNTO3157 [n = 30] = -7.08% [SE, 8.15%]; placebo [n = 25] = -5.98% [SE, 8.56%]) or symptoms after inoculation. In healthy subjects (n = 12) CNTO3157 versus placebo significantly attenuated upper (P =.03) and lower (P =.02) airway symptom scores, with area-under-the-curve increases of 9.1 (15.1) versus 34.9 (17.6) and 13.0 (18.4) versus 50.4 (25.9) for the CNTO3157 (n = 8) and placebo (n = 4) groups, respectively, after inoculation. All of the severe and 4 of the nonserious asthma exacerbations occurred while receiving CNTO3157. Conclusion: In summary, CNTO3157 was ineffective in attenuating the effect of HRV-16 challenge on lung function, asthma control, and symptoms in asthmatic patients but suppressed cold symptoms in healthy subjects. Other approaches, including blockade of multiple pathways or antiviral agents, need to be sought for this high unmet medical need.	[Silkoff, Philip E.; Flavin, Susan; Gordon, Robert; Loza, Mathew J.; Del Vecchio, Alfred M.; Branigan, Patrick; San Mateo, Lani; Baribaud, Frederic; Barnathan, Elliot S.] Janssen Res & Dev LLC, Spring House, PA USA; [Sterk, Peter J.] Univ Amsterdam, Acad Med Ctr, Dept Resp Med F5 259, K0-150, Amsterdam, Netherlands; [Lutter, Rene] Univ Amsterdam, Acad Med Ctr, Dept Resp Med, K0-150, Amsterdam, Netherlands; [Lutter, Rene] Univ Amsterdam, Acad Med Ctr, Dept Expt Immunol, K0-150, Amsterdam, Netherlands; [Diamant, Zuzana] Skane Univ Hosp, Inst Clin Sci, Dept Resp Med & Allergol, Lund, Sweden; [Diamant, Zuzana; Mensinga, Tjeert T.] QPS Netherlands, Groningen, Netherlands; [Turner, Ronald B.] Univ Virginia, Sch Med, Dept Pediat, Charlottesville, VA 22908 USA; [Lipworth, Brian J.] Univ Dundee, Ninewells Hosp, Scottish Ctr Resp Res, Dundee, Scotland; [Lipworth, Brian J.] Univ Dundee, Med Sch, Dundee, Scotland; [Proud, David] Univ Calgary, Cumming Sch Med, Snyder Inst Chron Dis, Dept Physiol & Pharmacol, Calgary, AB, Canada; [Singh, Dave] Univ Manchester, Univ Hosp South Manchester Fdn Trust, Ctr Resp Med & Allergy, Med Evaluat Unit, Manchester, Lancs, England; [Eich, Andreas] IKF Pneumol Frankfurt, Clin Res Ctr Resp Dis, Frankfurt, Germany; [Backer, Vibeke] Dept Resp Med, Copenhagen, Denmark; [Gern, James E.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA; [Herzmann, Christian] Res Ctr Borstel, Ctr Clin Studies, Sulfeld, Germany; [Halperin, Scott A.] Dalhousie Univ, Canadian Ctr Vaccinol, Halifax, NS, Canada; [Halperin, Scott A.] IWK Hlth Ctr, Halifax, NS, Canada; [Johnston, Sebastian L.] Imperial Coll London, Natl Heart & Lung Inst, Airway Dis Infect Sect, London, England	Johnson & Johnson; Johnson & Johnson USA; Janssen Biotech Inc; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Lund University; Skane University Hospital; University of Virginia; University of Dundee; University of Dundee; University of Calgary; University of Manchester; Wythenshawe Hospital NHS Foundation Trust; University of Wisconsin System; University of Wisconsin Madison; Dalhousie University; Dalhousie University; Imperial College London	Silkoff, PE (corresponding author), 715 Bryn Mawr Ave, Penn Valley, PA 19072 USA.	philsilkoff@gmail.com	Johnston, Sebastian Lennox/I-2423-2012; Backer, Vibeke/AAQ-9379-2021; Singh, Dave/AAH-4342-2020; Sterk, P.J./AAK-8175-2020	Johnston, Sebastian Lennox/0000-0003-3009-9200; Singh, Dave/0000-0001-8918-7075; Gordon, Robert/0000-0001-9703-6584; Halperin, Scott/0000-0003-0525-589X; Loza, Matthew/0000-0002-8609-118X	Janssen R&D, Spring House, Pa; Medical Research Council [G1000758] Funding Source: researchfish; National Institute for Health Research [NF-SI-0514-10092] Funding Source: researchfish; Asthma UK [CH11SJ, MRC-AsthmaUKCentre, MRC-Asthma UK Centre] Funding Source: researchfish	Janssen R&D, Spring House, Pa; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR)); Asthma UK	Supported by Janssen R&D, Spring House, Pa.	Adura PT, 2014, EUR RESPIR J, V43, P1186, DOI 10.1183/09031936.00141713; Bardin PG, 2000, EUR RESPIR J, V16, P980, DOI 10.1183/09031936.00.16598000; Beale J, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009124; Bunting RA, 2011, CELL IMMUNOL, V267, P9, DOI 10.1016/j.cellimm.2010.10.008; Calven J, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0645-3; Del Vecchio AM, 2015, PULM PHARMACOL THER, V30, P32, DOI 10.1016/j.pupt.2014.10.005; Djukanovic R, 2014, AM J RESP CRIT CARE, V190, P145, DOI 10.1164/rccm.201312-2235OC; Duffy KE, 2007, CELL IMMUNOL, V248, P103, DOI 10.1016/j.cellimm.2007.10.002; Faber TE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034364; Gern JE, 1997, AM J RESP CRIT CARE, V155, P1159, DOI 10.1164/ajrccm.155.3.9117003; Gielen V, 2015, J ALLERGY CLIN IMMUN, V136, P177, DOI 10.1016/j.jaci.2014.11.039; HALPERIN SA, 1985, AM REV RESPIR DIS, V132, P976; Jackson DJ, 2015, J ALLERGY CLIN IMMUN, V136, P497, DOI 10.1016/j.jaci.2015.01.028; Jackson DJ, 2014, AM J RESP CRIT CARE, V190, P1373, DOI 10.1164/rccm.201406-1039OC; JACKSON GG, 1958, ARCH INTERN MED, V101, P267, DOI 10.1001/archinte.1958.00260140099015; Juniper EF, 1999, CHEST, V115, P1265, DOI 10.1378/chest.115.5.1265; Kennedy JL, 2012, CURR OPIN VIROL, V2, P287, DOI 10.1016/j.coviro.2012.03.008; Le Goffic R, 2006, PLOS PATHOG, V2, P526, DOI 10.1371/journal.ppat.0020053; Leung YHC, 2014, J GEN VIROL, V95, P1870, DOI 10.1099/vir.0.066258-0; Majde JA, 2010, BRAIN BEHAV IMMUN, V24, P306, DOI 10.1016/j.bbi.2009.10.011; McCartney S, 2009, J EXP MED, V206, P2967, DOI 10.1084/jem.20091181; McCartney SA, 2009, IMMUNOL REV, V227, P87, DOI 10.1111/j.1600-065X.2008.00726.x; Meltzer EO, 2011, J ALLERGY CLIN IMMUN, V127, P167, DOI 10.1016/j.jaci.2010.08.042; Message SD, 2008, P NATL ACAD SCI USA, V105, P13562, DOI 10.1073/pnas.0804181105; Papadopoulos NG, 2000, J INFECT DIS, V181, P1875, DOI 10.1086/315513; Wang Q, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002070; Wang Q, 2009, J IMMUNOL, V183, P6989, DOI 10.4049/jimmunol.0901386; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901; Wark PAB, 2007, J ALLERGY CLIN IMMUN, V120, P586, DOI 10.1016/j.jaci.2007.04.046; Yin H, 2012, CLIN EXP IMMUNOL, V170, P1, DOI 10.1111/j.1365-2249.2012.04629.x; Yin H, 2011, CLIN EXP IMMUNOL, V164, P248, DOI 10.1111/j.1365-2249.2011.04326.x; Zhang SY, 2007, SCIENCE, V317, P1522, DOI 10.1126/science.1139522	32	23	23	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2018	141	4					1220	1230		10.1016/j.jaci.2017.06.027	http://dx.doi.org/10.1016/j.jaci.2017.06.027			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GB6QV	28734844	Green Submitted, Bronze, Green Published			2022-12-18	WOS:000429197800008
J	Wypych, TP; Marzi, R; Wu, GF; Lanzavecchia, A; Sallusto, F				Wypych, Tomasz Piotr; Marzi, Roberta; Wu, Gregory F.; Lanzavecchia, Antonio; Sallusto, Federica			Role of B cells in T-H cell responses in a mouse model of asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Mouse model of asthma; house dust mite; B cells; antigen presentation; initiation of allergic response; maintenance of allergic response	HOUSE-DUST MITE; ANTIGEN-PRESENTING CELLS; DENDRITIC CELLS; DEFICIENT MICE; IN-VIVO; AIRWAY HYPERRESPONSIVENESS; MEDIATED-IMMUNITY; TYPE-2 IMMUNITY; LYMPHOCYTES; ALLERGEN	Background: The importance of B lymphocytes to present antigens for antibody production is well documented. In contrast, very little is known about their capacity to influence CD4(+) T-cell activation during a primary or secondary response to allergens. Objective: Using mouse models of asthma, we investigated the role of B cells as antigen-presenting cells in priming and maintenance of T-H cell responses. Methods: Mice were immunized through the intranasal route with house dust mite (HDM) extract derived from Dermatophagoides pteronyssinus. B cells were depleted in HDM-sensitized animals to investigate the importance of B cells in maintenance of the allergic response. B cells were depleted before HDM sensitization to investigate the role of B cells in T-cell priming; furthermore, HDM sensitization was performed in mice with MHC class II expression restricted to the B-cell lineage. Results: We found that B cells serve as potent antigen-presenting cells ex vivo and restimulate in vivo-primed HDM-specific T-H cells. HDM antigens were taken up by B cells independently of B-cell receptor specificity, indicating that HDM uptake and antigen presentation to CD4(+) T cells is not restricted to rare B cells carrying HDM-specific B cell receptors. B-cell depletion before HDM challenge in HDM-sensitized mice resulted in a dramatic reduction of allergic response, indicating the role of B cells in amplification of T(H)2 responses. In contrast, HDM sensitization of mice in which MHC class II expression was restricted to B cells revealed the inability of these cells to prime T(H)2 responses but highlighted their unexpected role in priming T(H)1 and T(H)17 responses. Conclusion: Collectively, these data reveal new mechanisms leading to initiation and exacerbation of the allergic response that might have implications for designing new therapeutic strategies to combat HDM allergy.	[Wypych, Tomasz Piotr; Marzi, Roberta; Lanzavecchia, Antonio; Sallusto, Federica] Univ Svizzera Italiana, Inst Res Biomed, Via Vincenzo Vela 6, CH-6500 Bellinzona, Switzerland; [Wypych, Tomasz Piotr] Univ Bern, Grad Sch Cellular & Biomed Sci, Bern, Switzerland; [Wu, Gregory F.] Washington Univ, Dept Neurol, St Louis, MO USA; [Lanzavecchia, Antonio] Swiss Fed Inst Technol, Inst Microbiol, Zurich, Switzerland	Universita della Svizzera Italiana; University of Bern; Washington University (WUSTL); Swiss Federal Institutes of Technology Domain; ETH Zurich	Wypych, TP; Sallusto, F (corresponding author), Univ Svizzera Italiana, Inst Res Biomed, Via Vincenzo Vela 6, CH-6500 Bellinzona, Switzerland.	tomasz.wypych@chuv.ch; federica.sallusto@irb.usi.ch	Wypych, Tomasz/AAY-9069-2020	Wypych, Tomasz/0000-0003-0558-7923; Sallusto, Federica/0000-0003-3750-2752	Swiss National Science Foundation [PDAMP3_137087, PDFMP3_137127]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS083678] Funding Source: NIH RePORTER	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was in part funded by the Swiss National Science Foundation (grant n. PDAMP3_137087 and grant n. PDFMP3_137127).	Archambault AS, 2013, J IMMUNOL, V191, P545, DOI 10.4049/jimmunol.1201598; Ballesteros-Tato A, 2016, IMMUNITY, V44, P259, DOI 10.1016/j.immuni.2015.11.017; Barnett LG, 2014, J IMMUNOL, V192, P3607, DOI 10.4049/jimmunol.1301284; Baumgarth N, 2000, P NATL ACAD SCI USA, V97, P4766, DOI 10.1073/pnas.97.9.4766; Baumgarth N, 2011, NAT REV IMMUNOL, V11, P34, DOI 10.1038/nri2901; Becattini S, 2015, SCIENCE, V347, P400, DOI 10.1126/science.1260668; Beier KC, 2004, J ALLERGY CLIN IMMUN, V114, P775, DOI 10.1016/j.jaci.2004.06.024; Birrell MA, 2010, EUR RESPIR J, V36, P1220, DOI 10.1183/09031936.00069110; Constant SL, 1999, J IMMUNOL, V162, P5695; Coquet JM, 2015, IMMUNITY, V43, P318, DOI 10.1016/j.immuni.2015.07.015; Cross AH, 2006, J NEUROIMMUNOL, V180, P63, DOI 10.1016/j.jneuroim.2006.06.029; Dullaers M, 2017, J ALLERGY CLIN IMMUN, V140, P76, DOI 10.1016/j.jaci.2016.09.020; Dwyer DF, 2014, J IMMUNOL, V193, P529, DOI 10.4049/jimmunol.1303247; EPSTEIN MM, 1995, J EXP MED, V182, P915, DOI 10.1084/jem.182.4.915; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; Hamelmann E, 1999, AM J RESP CELL MOL, V21, P480, DOI 10.1165/ajrcmb.21.4.3659; Hammad H, 2015, IMMUNITY, V43, P29, DOI 10.1016/j.immuni.2015.07.007; Hondowicz BD, 2016, IMMUNITY, V44, P155, DOI 10.1016/j.immuni.2015.11.004; Kavanaugh A, 2008, ANN RHEUM DIS, V67, P402, DOI 10.1136/ard.2007.074229; Khaltaev N, 2007, GLOBAL SURVEILLANCE; Korsgren M, 1997, J EXP MED, V185, P885, DOI 10.1084/jem.185.5.885; Lambrecht Bart N, 2014, Ann Am Thorac Soc, V11 Suppl 5, pS236, DOI 10.1513/AnnalsATS.201405-218AW; Leon B, 2014, J IMMUNOL, V193, P1531, DOI 10.4049/jimmunol.1400149; Leon B, 2012, NAT IMMUNOL, V13, P681, DOI 10.1038/ni.2309; Lindell DM, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003129; Looney RJ, 2004, ARTHRITIS RHEUM, V50, P2580, DOI 10.1002/art.20430; Lund FE, 2008, CURR OPIN IMMUNOL, V20, P332, DOI 10.1016/j.coi.2008.03.003; MacLean JA, 1999, AM J RESP CELL MOL, V20, P379, DOI 10.1165/ajrcmb.20.3.3291; Ngo VN, 2001, J EXP MED, V194, P1649, DOI 10.1084/jem.194.11.1649; Plantinga M, 2013, IMMUNITY, V38, P322, DOI 10.1016/j.immuni.2012.10.016; Rauch PJ, 2012, SCIENCE, V335, P597, DOI 10.1126/science.1215173; Rodriguez-Pinto D, 2005, EUR J IMMUNOL, V35, P1097, DOI 10.1002/eji.200425732; RONCHESE F, 1993, J EXP MED, V177, P679, DOI 10.1084/jem.177.3.679; Shulzhenko N, 2011, NAT MED, V17, P1585, DOI 10.1038/nm.2505; Simon D, 2008, J ALLERGY CLIN IMMUN, V121, P122, DOI 10.1016/j.jaci.2007.11.016; Stone KD, 2010, J ALLERGY CLIN IMMUN, V125, pS73, DOI 10.1016/j.jaci.2009.11.017; SUNSHINE GH, 1991, J EXP MED, V174, P1653, DOI 10.1084/jem.174.6.1653; Swedin L, 2010, INT ARCH ALLERGY IMM, V153, P249, DOI 10.1159/000314365; Topham DJ, 1996, J IMMUNOL, V157, P2947; van Rijt LS, 2005, J EXP MED, V201, P981, DOI 10.1084/jem.20042311	40	23	25	1	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2018	141	4					1395	1410		10.1016/j.jaci.2017.09.001	http://dx.doi.org/10.1016/j.jaci.2017.09.001			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GB6QV	28889953	Green Accepted, Bronze			2022-12-18	WOS:000429197800025
J	Lugogo, N; Green, CL; Agada, N; Zhang, SY; Meghdadpour, S; Zhou, R; Yang, SY; Anstrom, KJ; Anstrom, J; Martin, R; Lemanske, RF; Boushey, H; Lazarus, SC; Wasserman, SI; Castro, M; Calhoun, W; Peters, SP; DiMango, E; Chinchilli, V; Kunselman, S; King, TS; Icitovic, N; Kraft, M				Lugogo, Njira; Green, Cynthia L.; Agada, Noah; Zhang, Siyi; Meghdadpour, Susanne; Zhou, Run; Yang, Siyun; Anstrom, Kevin J.; Israel, Elliot; Martin, Richard; Lemanske, Robert F., Jr.; Boushey, Homer; Lazarus, Stephen C.; Wasserman, Stephen I.; Castro, Mario; Calhoun, William; Peters, Stephen P.; DiMango, Emily; Chinchilli, Vernon; Kunselman, Susan; King, Tonya S.; Icitovic, Nikolina; Kraft, Monica			Obesity's effect on asthma extends to diagnostic criteria	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; obesity; eosinophils; inflammatory markers; fraction of exhaled nitric oxide	EXHALED NITRIC-OXIDE; TO-MODERATE ASTHMA; EOSINOPHILIC INFLAMMATION; ALLERGIC-ASTHMA; AIRWAY INFLAMMATION; OBESE INDIVIDUALS; SPUTUM EOSINOPHIL; CONTROLLED-TRIAL; PREDICT; ADULTS	Background: The use of inflammatory biomarkers to delineate the type of lung inflammation present in asthmatic subjects is increasingly common. However, the effect of obesity on these markers is unknown. Objectives: We aimed to determine the effect of obesity on conventional markers of inflammation in asthmatic subjects. Methods: We performed secondary analysis of data from 652 subjects previously enrolled in 2 Asthma Clinical Research Network trials. We performed linear correlations between biomarkers and logistic regression analysis to determine the predictive value of IgE levels, blood eosinophil counts, and fraction of exhaled nitric oxide values in relationship to sputum eosinophil counts (> 2%), as well as to determine whether cut points existed that would maximize the sensitivity and specificity for predicting sputum eosinophilia in the 3 weight groups. Results: Overall, statistically significant but relatively weak correlations were observed among all 4 markers of inflammation. Within obese subjects, the only significant correlation found was between IgE levels and blood eosinophil counts (r = 0.33, P<.001); furthermore, all other correlations between inflammatory markers were approximately 0, including correlations with sputum eosinophil counts. In addition, the predictive value of each biomarker alone or in combination was poor in obese subjects. In fact, in obese subjects none of the biomarkers of inflammation significantly predicted the presence of high sputum eosinophil counts. Obese asthmatic subjects have lower cut points for IgE levels (268 IU), fraction of exhaled nitric oxide values (14.5 ppb), and blood eosinophil counts (96 cells/mu L) than all other groups. Conclusions: In obese asthmatic subjects conventional biomarkers of inflammation are poorly predictive of eosinophilic airway inflammation. As such, biomarkers currently used to delineate eosinophilic inflammation in asthmatic subjects should be approached with caution in these subjects.	[Lugogo, Njira] Univ Michigan, Dept Med, Div Pulm & Crit Care Med, Ann Arbor, MI 48109 USA; [Green, Cynthia L.; Zhang, Siyi; Zhou, Run; Yang, Siyun; Anstrom, Kevin J.] Duke Univ, Dept Biostat & BioInformat, Durham, NC USA; [Agada, Noah] Riley Childrens Hosp, Div Pediat Allergy & Immunol, Dept Pediat Pulmonol, Indianapolis, IN USA; [Agada, Noah] Eli Lilly & Co, Indianapolis, IN 46285 USA; [Meghdadpour, Susanne] Duke Univ, Dept Pediat, Div Allergy Immunol Pulm & Sleep Med, Durham, NC 27706 USA; [Israel, Elliot] Brigham & Womens Hosp, Dept Med, Div Pulm & Crit Care Med, 75 Francis St, Boston, MA 02115 USA; [Israel, Elliot] Harvard Med Sch, Boston, MA USA; [Martin, Richard] Natl Jewish Hlth, Dept Med, Denver, CO USA; [Martin, Richard] Univ Colorado, Denver, CO 80202 USA; [Lemanske, Robert F., Jr.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pediat & Med, Madison, WI 53706 USA; [Boushey, Homer; Lazarus, Stephen C.] Univ Calif San Francisco, Dept Med, Div Pulm Crit Care Allergy & Sleep Med, San Francisco, CA USA; [Wasserman, Stephen I.] Univ Calif San Diego, Dept Med, Div Rheumatol Allergy & Immunol, San Diego, CA 92103 USA; [Castro, Mario] Washington Univ, Dept Med, Div Pulm & Crit Care Med, St Louis, MO USA; [Calhoun, William] Univ Texas Med Branch, Div Pulm Crit Care & Sleep, Galveston, TX 77555 USA; [Calhoun, William] Univ Texas Med Branch, Dept Internal Med, Div Allergy & Clin Immunol, Galveston, TX 77555 USA; [Peters, Stephen P.] Wake Forest Univ, Dept Internal Med, Sect Pulm Crit Care Allergy & Immunol Dis, Winston Salem, NC 27109 USA; [DiMango, Emily] Columbia Univ, Dept Med, Div Pulm Allergy & Crit Care Med, New York, NY USA; [Chinchilli, Vernon; Kunselman, Susan; King, Tonya S.] Penn State Coll Med, Dept Publ Hlth Serv, Div Biostat, Hershey, PA USA; [Icitovic, Nikolina] Icahn Sch Med Mt Sinai, Dept Environm Med & Publ Hlth, New York, NY 10029 USA; [Kraft, Monica] Univ Arizona, Dept Med, Tucson, AZ USA	University of Michigan System; University of Michigan; Duke University; James Whitcomb Riley Hospital Children; Eli Lilly; Duke University; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; National Jewish Health; University of Colorado System; University of Colorado Denver; University of Wisconsin System; University of Wisconsin Madison; University of California System; University of California San Francisco; University of California System; University of California San Diego; Washington University (WUSTL); University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; Wake Forest University; Columbia University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Icahn School of Medicine at Mount Sinai; University of Arizona	Lugogo, N (corresponding author), Univ Michigan, Dept Med, Div Pulm & Crit Care Med, Ann Arbor, MI 48109 USA.	nlugogo@umich.edu		Agada, Noah/0000-0001-6991-5995; Calhoun, William/0000-0001-7075-712X	National Heart, Lung, and Blood Institute (NHLBI)/National Institutes of Health (NIH) Asthma Research Network [U10 HL074225, U10 HL074227, U10 HL074231, U10 HL074204, U10 HL074212, U10 HL074073, U10 HL074206, U10 HL074208, U10 HL07421]; NIH training grant [5 T32 AI 007062-36]; NHLBI Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U10HL074208, U10HL074231, U10HL074225, U10HL074227, U10HL074204, U10HL074218, U10HL074206, U10HL074073, U10HL074212, U10HL098107] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007062] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006694] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute (NHLBI)/National Institutes of Health (NIH) Asthma Research Network; NIH training grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NHLBI Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported by the National Heart, Lung, and Blood Institute (NHLBI)/National Institutes of Health (NIH) Asthma Research Network grants U10 HL074225, U10 HL074227, U10 HL074231, U10 HL074204, U10 HL074212, U10 HL074073, U10 HL074206, U10 HL074208, and U10 HL07421. NIH training grant #5 T32 AI 007062-36 and NHLBI Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC).	Agrawal A, 2011, AM J RESP CELL MOL, V44, P270, DOI 10.1165/rcmb.2010-0141TR; Bacci E, 2006, CHEST, V129, P565, DOI 10.1378/chest.129.3.565; Bacci E, 2012, RESPIROLOGY, V17, P1199, DOI 10.1111/j.1440-1843.2012.02242.x; BAIGELMAN W, 1983, AM J MED, V75, P929, DOI 10.1016/0002-9343(83)90871-9; Beuther DA, 2007, AM J RESP CRIT CARE, V175, P661, DOI 10.1164/rccm.200611-1717OC; Bobolea I, 2015, ALLERGY, V70, P540, DOI 10.1111/all.12580; Boulet LP, 2008, CLIN INVEST MED, V31, pE386, DOI 10.25011/cim.v31i6.4926; Bousquet J, 2004, CHEST, V125, P1378, DOI 10.1378/chest.125.4.1378; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; Brightling Christopher E, 2005, Treat Respir Med, V4, P309, DOI 10.2165/00151829-200504050-00002; Calhoun WJ, 2012, JAMA-J AM MED ASSOC, V308, P987, DOI 10.1001/2012.jama.10893; Calixto MC, 2010, BRIT J PHARMACOL, V159, P617, DOI 10.1111/j.1476-5381.2009.00560.x; Castro M, 2014, LANCET RESP MED, V2, P879, DOI 10.1016/S2213-2600(14)70201-2; Ciprandi G, 2014, ALLERGY ASTHMA PROC, V35, pE62, DOI 10.2500/aap.2014.35.3773; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; Desai D, 2013, AM J RESP CRIT CARE, V188, P657, DOI 10.1164/rccm.201208-1470OC; Deykin A, 2005, J ALLERGY CLIN IMMUN, V115, P720, DOI 10.1016/j.jaci.2004.12.1129; Dweik RA, 2011, AM J RESP CRIT CARE, V184, P602, DOI 10.1164/rccm.9120-11ST; Fitzpatrick S, 2012, CLIN EXP ALLERGY, V42, P747, DOI 10.1111/j.1365-2222.2011.03863.x; Hanania NA, 2013, AM J RESP CRIT CARE, V187, P804, DOI 10.1164/rccm.201208-1414OC; Hastie AT, 2013, J ALLERGY CLIN IMMUN, V132, P72, DOI 10.1016/j.jaci.2013.03.044; Holguin F, 2013, AM J RESP CRIT CARE, V187, P153, DOI 10.1164/rccm.201207-1270OC; Holguin F, 2011, J ALLERGY CLIN IMMUN, V127, P1486, DOI 10.1016/j.jaci.2011.03.036; Holguin F, 2010, J APPL PHYSIOL, V108, P754, DOI 10.1152/japplphysiol.00702.2009; Jia GQ, 2012, J ALLERGY CLIN IMMUN, V130, P647, DOI 10.1016/j.jaci.2012.06.025; Kato H, 2011, INT ARCH ALLERGY IMM, V155, P335, DOI 10.1159/000321195; Kharitonov SA, 1996, AM J RESP CRIT CARE, V153, P454, DOI 10.1164/ajrccm.153.1.8542158; Kim SH, 2014, ALLERGY ASTHMA IMMUN, V6, P189, DOI 10.4168/aair.2014.6.3.189; Komakula S, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-32; Lambrecht BN, 2015, NAT IMMUNOL, V16, P45, DOI 10.1038/ni.3049; Lemiere C, 2006, J ALLERGY CLIN IMMUN, V118, P1033, DOI 10.1016/j.jaci.2006.08.003; Maniscalco M, 2015, OBES RES CLIN PRACT, V9, P603, DOI 10.1016/j.orcp.2015.03.004; Marijsse GS, 2014, AM J RESP CRIT CARE, V189, P1284, DOI 10.1164/rccm.201311-2011LE; Massanari M, 2010, RESP MED, V104, P188, DOI 10.1016/j.rmed.2009.09.011; McGrath KW, 2012, AM J RESP CRIT CARE, V185, P612, DOI 10.1164/rccm.201109-1640OC; Meijer RJ, 2002, CLIN EXP ALLERGY, V32, P1096, DOI 10.1046/j.1365-2222.2002.01412.x; Michalek RD, 2011, J IMMUNOL, V186, P3299, DOI 10.4049/jimmunol.1003613; Michils A, 2008, EUR RESPIR J, V31, P539, DOI 10.1183/09031936.00020407; Ortega Hector, 2014, Ann Am Thorac Soc, V11, P1011, DOI 10.1513/AnnalsATS.201312-454OC; Pascoe S, 2015, LANCET RESP MED, V3, P435, DOI 10.1016/S2213-2600(15)00106-X; Pavord ID, 2012, LANCET, V380, P651, DOI 10.1016/S0140-6736(12)60988-X; Peters MC, 2014, J ALLERGY CLIN IMMUN, V133, P388, DOI 10.1016/j.jaci.2013.07.036; Peters SP, 2010, NEW ENGL J MED, V363, P1715, DOI 10.1056/NEJMoa1008770; Peters-Golden M, 2006, EUR RESPIR J, V27, P495, DOI 10.1183/09031936.06.00077205; Petsky HL, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005603.pub2; Sutherland ER, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036631; Takeda M, 2012, INT ARCH ALLERGY IMM, V158, P87, DOI 10.1159/000337799; van der Wiel E, 2014, AM J RESP CRIT CARE, V189, P1281, DOI 10.1164/rccm.201310-1841LE; Visness CM, 2009, J ALLERGY CLIN IMMUN, V123; Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC; ZHANG Y, 2014, AM J RESP CRIT CARE, V189	51	23	23	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2018	141	3					1096	1104		10.1016/j.jaci.2017.04.047	http://dx.doi.org/10.1016/j.jaci.2017.04.047			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FY6PR	28624608	Bronze, Green Accepted			2022-12-18	WOS:000426974800029
J	Epp, A; Hobusch, J; Bartsch, YC; Petry, J; Lilienthal, GM; Koeleman, CAM; Eschweiler, S; Mobs, C; Hall, A; Morris, SC; Braumann, D; Engellenner, C; Bitterling, J; Rahmoller, J; Leliavski, A; Thurmann, R; Collin, M; Moremen, KW; Strait, RT; Blanchard, V; Petersen, A; Gemoll, T; Habermann, JK; Petersen, F; Nandy, A; Kahlert, H; Hertl, M; Wuhrer, M; Pfutzner, W; Jappe, U; Finkelman, FD; Ehlers, M				Epp, Alexandra; Hobusch, Juliane; Bartsch, Yannic C.; Petry, Janina; Lilienthal, Gina-Maria; Koeleman, Carolien A. M.; Eschweiler, Simon; Moebs, Christian; Hall, Ashley; Morris, Suzanne C.; Braumann, Dominique; Engellenner, Christine; Bitterling, Josephine; Rahmoeller, Johann; Leliavski, Alexei; Thurmann, Robina; Collin, Mattias; Moremen, Kelley W.; Strait, Richard T.; Blanchard, Veronique; Petersen, Arnd; Gemoll, Timo; Habermann, Jens K.; Petersen, Frank; Nandy, Andreas; Kahlert, Helga; Hertl, Michael; Wuhrer, Manfred; Pfuetzner, Wolfgang; Jappe, Uta; Finkelman, Fred D.; Ehlers, Marc			Sialylation of IgG antibodies inhibits IgG-mediated allergic reactions	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							ANAPHYLAXIS; ACTIVATION		[Epp, Alexandra; Hobusch, Juliane; Bartsch, Yannic C.; Petry, Janina; Lilienthal, Gina-Maria; Eschweiler, Simon; Braumann, Dominique; Bitterling, Josephine; Rahmoeller, Johann; Leliavski, Alexei; Thurmann, Robina; Ehlers, Marc] Univ Lubeck, Labs Immunol & Antibody Glycan Anal, Inst Nutr Med, Lubeck, Germany; [Epp, Alexandra; Hobusch, Juliane; Bartsch, Yannic C.; Petry, Janina; Lilienthal, Gina-Maria; Eschweiler, Simon; Braumann, Dominique; Bitterling, Josephine; Rahmoeller, Johann; Leliavski, Alexei; Thurmann, Robina; Gemoll, Timo; Habermann, Jens K.; Ehlers, Marc] Univ Med Ctr Schleswig Holstein, Lubeck, Germany; [Koeleman, Carolien A. M.; Wuhrer, Manfred] Leiden Univ, Med Ctr, Ctr Prote & Metabol, Leiden, Netherlands; [Moebs, Christian; Hertl, Michael; Pfuetzner, Wolfgang] Philipps Univ Marburg, Dept Dermatol & Allergol, Marburg, Germany; [Hall, Ashley; Strait, Richard T.] Cincinnati Childrens Hosp Med Ctr, Div Emergency Med, Cincinnati, OH 45229 USA; [Finkelman, Fred D.] Cincinnati Childrens Hosp Med Ctr, Div Immunobiol, Cincinnati, OH 45229 USA; [Hall, Ashley; Strait, Richard T.] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH USA; [Morris, Suzanne C.; Finkelman, Fred D.] Univ Cincinnati, Coll Med, Dept Med, Div Immunol Allergy & Rheumatol, Cincinnati, OH USA; [Braumann, Dominique; Blanchard, Veronique] Charite, Lab Glycodesign & Glycoanalyt, Inst Lab Med Clin Chem & Pathobiochem, Berlin, Germany; [Engellenner, Christine; Petersen, Frank] Leibniz Ctr Med & Biosci, Res Ctr Borstel, Div Biochem Immunol, Borstel, Germany; [Rahmoeller, Johann] Univ Med Ctr Schleswig Holstein, Dept Anesthesiol & Intens Care, Lubeck, Germany; [Collin, Mattias] Lund Univ, Div Infect Med, Dept Clin Sci, Lund, Sweden; [Moremen, Kelley W.] Univ Georgia, Complex Carbohydrate Res Ctr, Athens, GA 30602 USA; [Petersen, Arnd; Jappe, Uta] German Ctr Lung Res DZL, Res Ctr Borstel, Div Clin & Mol Allergol, Airway Res Ctr North ARCN, Borstel, Germany; [Gemoll, Timo; Habermann, Jens K.] Univ Lubeck, Sect Translat Surg Oncol & Biobanking, Dept Surg, Lubeck, Germany; [Nandy, Andreas; Kahlert, Helga] Allergopharma GmbH & Co KG, Res & Preclin Dev, Darmstadt, Germany; [Jappe, Uta] Univ Lubeck, Dept Internal Med, Interdisciplinary Allergy Outpatient Clin, Lubeck, Germany; [Finkelman, Fred D.] Cincinnati Vet Affairs Med Ctr, Dept Med, Cincinnati, OH USA	University of Lubeck; University of Kiel; Schleswig Holstein University Hospital; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Philipps University Marburg; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Forschungszentrum Borstel; University of Kiel; Schleswig Holstein University Hospital; Lund University; University System of Georgia; University of Georgia; Forschungszentrum Borstel; University of Lubeck; Allergopharma; University of Lubeck; US Department of Veterans Affairs; Veterans Health Administration (VHA); Cincinnati VA Medical Center	Ehlers, M (corresponding author), Univ Lubeck, Labs Immunol & Antibody Glycan Anal, Inst Nutr Med, Lubeck, Germany.; Ehlers, M (corresponding author), Univ Med Ctr Schleswig Holstein, Lubeck, Germany.	marc.ehlers@uk-sh.de	Ehlers, Marc/C-9441-2011; Moremen, Kelley/AAD-4661-2019; Habermann, Jens K/E-2968-2010; Wuhrer, Manfred/ABE-9168-2020; Habermann, Jens/AAA-5149-2020; Collin, Mattias/C-6398-2009; Gemoll, Timo/P-6547-2019; Leliavski, Alexei/N-9333-2017	Ehlers, Marc/0000-0002-5383-8603; Wuhrer, Manfred/0000-0002-0814-4995; Collin, Mattias/0000-0002-6166-7410; Blanchard, Veronique/0000-0002-5980-6450; Eschweiler, Simon/0000-0002-6379-8588; Mobs, Christian/0000-0002-5197-7669; Leliavski, Alexei/0000-0003-0279-9226; Braumann, Dominique/0000-0001-9987-0257	German Research foundation [EH 221/8-1, 1911, GRK 1727, CRU 303, 306, iGRK1911, MO 2076/3-1, HE 1602/10-1, PF 344/3-1, SFB/TR22]; Else-Kroner-Fresenius Foundation [2014_A91]; U.S. Department of Veterans Affairs Merit Award; National Institutes of Health [R01 AI072040, GM103390, GM107012]; Food Allergy Research and Education (FARE); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI072040] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P41GM103390, P01GM107012] Funding Source: NIH RePORTER	German Research foundation(German Research Foundation (DFG)); Else-Kroner-Fresenius Foundation; U.S. Department of Veterans Affairs Merit Award(US Department of Veterans Affairs); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Food Allergy Research and Education (FARE); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Supported by the German Research foundation (grants nos. EH 221/8-1, International Research Training Group [iGRK] 1911, GRK 1727, CRU 303 and Excellence cluster 306 to M.E., iGRK1911 to F.D.F., as well as MO 2076/3-1, HE 1602/10-1, PF 344/3-1 and SFB/TR22 to C.M, M.H. and W.P.), the Else-Kroner-Fresenius Foundation (2014_A91 to M.E.), the U.S. Department of Veterans Affairs Merit Award to F.D.F., the National Institutes of Health (R01 AI072040 to F.D.F., as well as GM103390 and GM107012 to K.W.M.), and the Food Allergy Research and Education (FARE; to F.D.F.).	Akdis CA, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa7390; Beutier H, 2017, J ALLERGY CLIN IMMUN, V139, P269, DOI 10.1016/j.jaci.2016.03.028; Collin M, 2013, EXP DERMATOL, V22, P511, DOI 10.1111/exd.12171; Finkelman FD, 2016, J ALLERGY CLIN IMMUN, V137, P1674, DOI 10.1016/j.jaci.2016.02.015; Hess C, 2013, J CLIN INVEST, V123, P3788, DOI 10.1172/JCI65938; Mobs C, 2012, J ALLERGY CLIN IMMUN, V130, P1108, DOI 10.1016/j.jaci.2012.07.056; Oefner CM, 2012, J ALLERGY CLIN IMMUN, V129, P1647, DOI 10.1016/j.jaci.2012.02.037; Pincetic A, 2014, NAT IMMUNOL, V15, P707, DOI 10.1038/ni.2939; Strait RT, 2006, J CLIN INVEST, V116, P833, DOI 10.1172/JCI25575	9	23	24	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2018	141	1					399	402		10.1016/j.jaci.2017.06.021	http://dx.doi.org/10.1016/j.jaci.2017.06.021			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FR8GH	28728998	Green Submitted, Green Accepted, Bronze			2022-12-18	WOS:000419312200045
J	Leitao, FS; Ra, SW; Mattman, A; Schellenberg, RS; Fishbane, N; Criner, GJ; Woodruff, PG; Lazarus, SC; Albert, R; Connett, JE; Han, MK; Martinez, FJ; Leung, JM; Man, SFP; Aaron, SD; Reed, RM; Sin, DD				Leitao Filho, Fernando Sergio; Ra, Seung Won; Mattman, Andre; Schellenberg, Robert S.; Fishbane, Nick; Criner, Gerard J.; Woodruff, Prescott G.; Lazarus, Stephen C.; Albert, Richard; Connett, John E.; Han, Meilan K.; Martinez, Fernando J.; Leung, Janice M.; Man, S. F. Paul; Aaron, Shawn D.; Reed, Robert M.; Sin, Don D.			Serum IgGand risk of exacerbations and hospitalizations in chronic obstructive pulmonary disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							RECURRENT RESPIRATORY-INFECTIONS; PREVENTION; DEFICIENCY; CHILDREN; ADULTS; VALUES; COPD		[Leitao Filho, Fernando Sergio; Ra, Seung Won; Schellenberg, Robert S.; Fishbane, Nick; Leung, Janice M.; Man, S. F. Paul; Sin, Don D.] Univ British Columbia, Ctr Heart Lung Innovat, St Pauls Hosp, Vancouver, BC, Canada; [Leitao Filho, Fernando Sergio; Ra, Seung Won; Schellenberg, Robert S.; Fishbane, Nick; Leung, Janice M.; Man, S. F. Paul; Sin, Don D.] Univ British Columbia, Dept Med, Div Resp Med, Vancouver, BC, Canada; [Leitao Filho, Fernando Sergio] Univ Fortaleza, UNIFOR, Fortaleza, Ceara, Brazil; [Ra, Seung Won] Univ Ulsan, Coll Med, Ulsan Univ Hosp, Ulsan, South Korea; [Mattman, Andre] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC, Canada; [Criner, Gerard J.] Temple Univ, Dept Thorac Med & Surg, Lewis Katz Sch Med, Philadelphia, PA 19122 USA; [Woodruff, Prescott G.; Lazarus, Stephen C.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA; [Albert, Richard] Univ Colorado, Pulm Sci & Crit Care Med, Denver, CO 80202 USA; [Connett, John E.] Univ Minnesota, Sch Publ Hlth, Minneapolis, MN USA; [Han, Meilan K.] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; [Martinez, Fernando J.] Cornell Univ, Joan & Sanford I Weill Dept Med, Weill Cornell Med Coll, New York, NY 10021 USA; [Aaron, Shawn D.] Univ Ottawa, Dept Med, Ottawa, ON, Canada; [Reed, Robert M.] Univ Maryland, Sch Med, Div Pulm & Crit Care Med, Baltimore, MD 21201 USA	St. Paul's Hospital; University of British Columbia; University of Saskatchewan; University of British Columbia; Universidade Fortaleza; University of Ulsan; Ulsan University Hospital; University of British Columbia; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of California System; University of California San Francisco; University of Colorado System; University of Colorado Denver; University of Minnesota System; University of Minnesota Twin Cities; University of Michigan System; University of Michigan; Cornell University; University of Ottawa; University System of Maryland; University of Maryland Baltimore	Sin, DD (corresponding author), Univ British Columbia, Ctr Heart Lung Innovat, St Pauls Hosp, Vancouver, BC, Canada.; Sin, DD (corresponding author), Univ British Columbia, Dept Med, Div Resp Med, Vancouver, BC, Canada.	don.sin@hli.ubc.ca	Sin, Don/AAC-2219-2021; Won, Seung/AAN-5240-2021; Ra, Seung Won/M-9946-2018; Fishbane, Nick/GYE-0318-2022	Won, Seung/0000-0002-2458-8414; Ra, Seung Won/0000-0002-2458-8414; Fishbane, Nick/0000-0003-4316-1341	BC Lung Association; Canadian Respiratory Research Network; Flight Attendants Medical Research Institute; US National Heart, Blood and Lung Institute	BC Lung Association; Canadian Respiratory Research Network; Flight Attendants Medical Research Institute; US National Heart, Blood and Lung Institute	This work was supported by the BC Lung Association, the Canadian Respiratory Research Network, and the Flight Attendants Medical Research Institute. The MACRO and STATCOPE trials were funded by the US National Heart, Blood and Lung Institute.	Agarwal S, 2007, ANN ALLERG ASTHMA IM, V99, P281, DOI 10.1016/S1081-1206(10)60665-5; Albert RK, 2011, NEW ENGL J MED, V365, P689, DOI 10.1056/NEJMoa1104623; Criner GJ, 2014, NEW ENGL J MED, V370, P2201, DOI 10.1056/NEJMoa1403086; Dati F, 1996, EUR J CLIN CHEM CLIN, V34, P517; Liu L., 2014, TREND TESTS COUNTS P; Niewoehner DE, 2005, ANN INTERN MED, V143, P317, DOI 10.7326/0003-4819-143-5-200509060-00007; Ozkan H, 2005, J INVEST ALLERG CLIN, V15, P69; POPA V, 1993, ANN ALLERGY, V70, P418; Qvarfordt I, 2001, THORAX, V56, P445, DOI 10.1136/thorax.56.6.445; Schauer U, 2003, CLIN CHEM, V49, P1924, DOI 10.1373/clinchem.2003.022350; Takahashi T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040570; Vestbo J, 2013, AM J RESP CRIT CARE, V187, P347, DOI 10.1164/rccm.201204-0596PP; Yerkovich ST, 2012, BMC PULM MED, V12, DOI 10.1186/1471-2466-12-37	13	23	23	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2017	140	4					1164	+		10.1016/j.jaci.2017.01.046	http://dx.doi.org/10.1016/j.jaci.2017.01.046			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FI7JL	28456620				2022-12-18	WOS:000412172900033
J	Marciano, BE; Allen, ES; Conry-Cantilena, C; Kristosturyan, E; Klein, HG; Fleisher, TA; Holland, SM; Malech, HL; Rosenzweig, SD				Marciano, Beatriz E.; Allen, Elisabeth S.; Conry-Cantilena, Cathy; Kristosturyan, Ervand; Klein, Harvey G.; Fleisher, Thomas A.; Holland, Steven M.; Malech, Harry L.; Rosenzweig, Sergio D.			Granulocyte transfusions in patients with chronic granulomatous disease and refractory infections: The NIH experience	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Marciano, Beatriz E.; Kristosturyan, Ervand; Holland, Steven M.] NIAID, Lab Clin Infect Dis, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Allen, Elisabeth S.; Conry-Cantilena, Cathy; Klein, Harvey G.] NIH, Dept Transfus Med, Ctr Clin, Bethesda, MD 20892 USA; [Fleisher, Thomas A.; Rosenzweig, Sergio D.] NIH, Serv Immunol, Dept Lab Med, Ctr Clin, Bldg 10, Bethesda, MD 20892 USA; [Malech, Harry L.] NIAID, Host Def Lab, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Rosenzweig, Sergio D.] NIAID, Primary Immunodeficiency Clin, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Rosenzweig, SD (corresponding author), NIH, Serv Immunol, Dept Lab Med, Ctr Clin, Bldg 10, Bethesda, MD 20892 USA.; Rosenzweig, SD (corresponding author), NIAID, Primary Immunodeficiency Clin, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.	srosenzweig@cc.nih.gov		Malech, Harry/0000-0001-5874-5775	Intramural Research Program of the National Institutes of Health Clinical Center and the National Institutes of Allergy and Infectious Diseases; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000644, ZIAAI000991, ZIAAI001122, ZIAAI000988] Funding Source: NIH RePORTER; CLINICAL CENTER [ZIACL010304] Funding Source: NIH RePORTER	Intramural Research Program of the National Institutes of Health Clinical Center and the National Institutes of Allergy and Infectious Diseases; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); CLINICAL CENTER	This work was supported by the Intramural Research Program of the National Institutes of Health Clinical Center and the National Institutes of Allergy and Infectious Diseases.	Allen D, 2015, EXPERT REV ANTI-INFE, V13, P787, DOI 10.1586/14787210.2015.1032939; Holland SM, 2013, HEMATOL ONCOL CLIN N, V27, P89, DOI 10.1016/j.hoc.2012.11.002; Ikinciogullari A, 2005, THER APHER DIAL, V9, P137, DOI 10.1111/j.1774-9987.2005.00227.x; Kuhns DB, 2010, NEW ENGL J MED, V363, P2600, DOI 10.1056/NEJMoa1007097; Parta M, 2015, J CLIN IMMUNOL, V35, P675, DOI 10.1007/s10875-015-0204-y; Price TH, 2015, BLOOD, V126, P2153, DOI 10.1182/blood-2015-05-645986; Stanworth SJ, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005339; Stroncek DF, 1996, TRANSFUSION, V36, P1009, DOI 10.1046/j.1537-2995.1996.36111297091747.x; Yoshihara S, 2016, CURR OPIN HEMATOL, V23, P55, DOI 10.1097/MOH.0000000000000203	9	23	24	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2017	140	2					622	+		10.1016/j.jaci.2017.02.026	http://dx.doi.org/10.1016/j.jaci.2017.02.026			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FC5BK	28342916	Green Accepted, Bronze			2022-12-18	WOS:000406855500047
J	Van Gerven, L; Alpizar, YA; Steelant, B; Callebaut, I; Krohn, IK; Wouters, M; Vermeulen, F; Boeckxstaens, G; Talavera, K; Hellings, PW				Van Gerven, Laura; Alpizar, Yeranddy A.; Steelant, Brecht; Callebaut, Ina; Krohn, Inge Kortekaas; Wouters, Mira; Vermeulen, Francois; Boeckxstaens, Guy; Talavera, Karel; Hellings, Peter W.			Enhanced chemosensory sensitivity in patients with idiopathic rhinitis and its reversal by nasal capsaicin treatment	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Capsaicin; idiopathic rhinitis; nonallergic rhinitis; nasal hyperreactivity; nasal mucosal potential; TRPV1; TRPA1; treatment	NONALLERGIC RHINITIS; DOUBLE-BLIND; HYPERREACTIVITY; TRPV1; RESPONSES; SPRAY	Background: The therapeutic action of capsaicin treatment in patients with idiopathic rhinitis (IR) is based on ablation of the transient receptor potential cation channel subfamily V, receptor 1 (TRPV1)-substance P nociceptive signaling pathway. However, the functional consequences of capsaicin treatment on nasal nerve activation and the association between the reduction in nasal hyperreactivity (NHR) and response to capsaicin treatment remain unknown. Objective: We sought to study the effects of capsaicin nasal spray on the afferent innervation of the nasal mucosa by monitoring trigeminal nerve activity in patients with IR and healthy control (HC) subjects. Methods: A double-blind, placebo-controlled randomized trial with capsaicin nasal spray was performed involving 33 patients with IR and 12 HC subjects. Before and at 4, 12, and 26 weeks after treatment, nasal mucosal potentials (NMPs) were measured while exposing the nasal mucosa of patients with IR and HC subjects to aerosols with increasing doses of the chemical irritants allyl isothiocyanate (AITC; also known as mustard oil) or capsaicin. The threshold for each compound was determined for each subject. The results of the NMP measurements were evaluated in parallel with the therapeutic response, visual analog scale scores for nasal symptoms, self-reported NHR, and mRNA expression of PGP9.5; TRPV1; transient receptor potential cation channel subfamily A, receptor 1 (TRPA1); TRPV4; transient receptor potential cation channel subfamily M, member 8 (TRPM8); and nerve growth factor (NGF) in nasal biopsy specimens. Results: AITC turned out to be the best stimulus because the coughing induced by capsaicin interfered with measurements. At baseline, the threshold for evoking changes in NMPs based on AITC was significantly lower for patients with IR compared with HC subjects (P = .0423). Capsaicin treatment of IR patients increased the threshold for the response to AITC at 4 and 12 weeks compared with placebo (P = .0406 and P = .0325, respectively), which returned to baseline by week 26 (P = .0611). This increase correlated with changes in visual analog scale major symptom (P = .0004) and total symptom (P = .0018) scores. IR patients with self-reported NHR at baseline showed a trend to being better responders to capsaicin treatment compared with patients with IR but without NHR (P = .10). Conclusion: The lower threshold for AITC based on NMPs in patients with IR compared with HC subjects and the increased threshold for AITC after capsaicin treatment in patients with IR demonstrate the crucial role of TRPA1 and TRPV1 in IR pathophysiology. The strong correlation between the increase in AITC threshold in patients with IR and symptom reduction after capsaicin treatment demonstrates the clinical relevance of these findings.	[Van Gerven, Laura; Callebaut, Ina; Hellings, Peter W.] Univ Hosp Leuven, Clin Div Otorhinolaryngol Head & Neck Surg, Leuven, Belgium; [Van Gerven, Laura; Steelant, Brecht; Krohn, Inge Kortekaas; Hellings, Peter W.] Univ Hosp Leuven, Cyst Fibrosis Reference Ctr, Leuven, Belgium; [Alpizar, Yeranddy A.; Talavera, Karel] Katholieke Univ Leuven, Lab Clin Immunol, Dept Microbiol & Immunol, Leuven, Belgium; [Wouters, Mira; Boeckxstaens, Guy] Katholieke Univ Leuven, Lab Ion Channel Res & TRP Res Platform Leuven TRP, Dept Cellular & Mol Med, Leuven, Belgium; [Vermeulen, Francois] Katholieke Univ Leuven, Translat Res Ctr Gastrointestinal Disorders TARGI, Leuven, Belgium; [Hellings, Peter W.] Univ Ghent, Dept Otorhinolaryngol, Ghent, Belgium; [Hellings, Peter W.] Acad Med Ctr, Dept Otorhinolaryngol, Amsterdam, Netherlands	KU Leuven; University Hospital Leuven; KU Leuven; University Hospital Leuven; KU Leuven; KU Leuven; KU Leuven; Ghent University; University of Amsterdam; Academic Medical Center Amsterdam	Hellings, PW (corresponding author), Univ Hosp Leuven, Kapucijnenvoer 33, B-3000 Leuven, Belgium.	Peter.Hellings@uzleuven.be	Boeckxstaens, Guy/AAP-2502-2020; Van Gerven, Laura/ABG-5800-2021; Steelant, Brecht/H-8335-2018; Hellings, Peter W/I-4068-2018	Van Gerven, Laura/0000-0002-5325-7956; Steelant, Brecht/0000-0002-0358-9362; Hellings, Peter W/0000-0001-6898-688X; VERMEULEN, Francois/0000-0003-2303-2470; Kortekaas Krohn, Inge/0000-0003-3649-1131; Alpizar, Yeranddy A/0000-0003-1959-5393; Callebaut, Ina/0000-0002-6666-6783	Agency for Innovation by Science and Technology in Flanders, Belgium (IWT); Postdoctoral Mandate of the KU Leuven; Odysseus program, FWO [G.0905.07]; Fund for Scientific Research Flanders, Belgium (FWO); Belgian Federal Government [IUAP P6/28]; FWO [G076513N]; Research Council of the KU Leuven [GOA/14/011]; Research Council of the KU Leuven (PF-TRPLe)	Agency for Innovation by Science and Technology in Flanders, Belgium (IWT)(Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT)); Postdoctoral Mandate of the KU Leuven; Odysseus program, FWO(FWO); Fund for Scientific Research Flanders, Belgium (FWO)(FWO); Belgian Federal Government; FWO(FWO); Research Council of the KU Leuven(KU Leuven); Research Council of the KU Leuven (PF-TRPLe)	L.V.G. is supported by a grant of the Agency for Innovation by Science and Technology in Flanders, Belgium (IWT). Y.A.A. was supported by a Postdoctoral Mandate of the KU Leuven and is currently a postdoctoral researcher of the Fund for Scientific Research (FWO) Flanders, Belgium. M.W. is a postdoctoral researcher of the Fund for Scientific Research (FWO) Flanders, Belgium. G.B. is supported by a governmental grant (Odysseus program, G.0905.07, FWO). P.W.H. is a recipient of a senior researcher fellowship from the Fund for Scientific Research Flanders, Belgium (FWO). This work was also supported by grants from the Belgian Federal Government (IUAP P6/28), the FWO (G076513N), and the Research Council of the KU Leuven (GOA/14/011 and PF-TRPLe).	Alenmyr L, 2011, CLIN PHYSIOL FUNCT I, V31, P435, DOI 10.1111/j.1475-097X.2011.01039.x; Alpizar YA, 2014, PFLUG ARCH EUR J PHY, V466, P507, DOI 10.1007/s00424-013-1334-9; Baraniuk JN, 2009, ANN NY ACAD SCI, V1170, P604, DOI 10.1111/j.1749-6632.2009.04481.x; Blom HM, 1997, J ALLERGY CLIN IMMUN, V100, P739, DOI 10.1016/S0091-6749(97)70267-7; Bousquet J, 2008, ALLERGY, V63, P842, DOI 10.1111/j.1398-9995.2008.01715.x; Everaerts W, 2011, CURR BIOL, V21, P316, DOI 10.1016/j.cub.2011.01.031; Gees M, 2013, MOL PHARMACOL, V84, P325, DOI 10.1124/mol.113.085548; Gevorgyan A, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010591.pub2; Hummel T., 1998, Rhinology (Utrecht), V36, P168; Jacobs R, 2009, ALLERGY ASTHMA PROC, V30, P120, DOI 10.2500/aap.2009.30.3206; LACROIX JS, 1991, CLIN EXP ALLERGY, V21, P595, DOI 10.1111/j.1365-2222.1991.tb00852.x; Laudien JH, 2008, NEUROIMAGE, V41, P1426, DOI 10.1016/j.neuroimage.2008.03.046; Lundblad L, 2001, ACTA OTO-LARYNGOL, V121, P505, DOI 10.1080/000164801300366679; Meusel T, 2010, PAIN, V151, P516, DOI 10.1016/j.pain.2010.08.013; Naehrlich L, 2014, J CYST FIBROS, V13, P24, DOI 10.1016/j.jcf.2013.08.006; Rombaux P, 2012, RHINOLOGY, V50, P13, DOI 10.4193/Rhino11.126; Scheibe M, 2008, LARYNGOSCOPE, V118, P152, DOI 10.1097/MLG.0b013e318156599d; Segboer CL, 2013, ALLERGY, V68, P1427, DOI 10.1111/all.12255; THURAUF N, 1993, BRAIN RES, V629, P293, DOI 10.1016/0006-8993(93)91333-N; Van Gerven L, 2012, RHINOLOGY, V50, P227, DOI [10.4193/Rhino11.152, 10.4193/Rhino.11.152]; Van Gerven L, 2014, J ALLERGY CLIN IMMUN, V133, P1332, DOI 10.1016/j.jaci.2013.08.026; Van Rijswijk JB, 2003, ALLERGY, V58, P754, DOI 10.1034/j.1398-9995.2003.00203.x; van Wijk R. Gerth, 1999, Rhinology (Utrecht), V37, P50	23	23	23	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2017	140	2					437	+		10.1016/j.jaci.2017.03.014	http://dx.doi.org/10.1016/j.jaci.2017.03.014			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FC5BK	28389389	Bronze			2022-12-18	WOS:000406855500016
J	Jabbal, S; Poli, G; Lipworth, B				Jabbal, Sunny; Poli, Gianluigi; Lipworth, Brian			Does size really matter?: Relationship of particle size to lung deposition and exhaled fraction	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							IMPULSE OSCILLOMETRY; PERSISTENT ASTHMA; INFLAMMATION		[Jabbal, Sunny; Lipworth, Brian] Ninewells Hosp & Med Sch, Scottish Ctr Resp Res, Dundee, Scotland; [Poli, Gianluigi] Chiesi Farmaceut SpA, Global Clin Dev, Parma, Italy	University of Dundee; Chiesi Pharmaceuticals Inc	Lipworth, B (corresponding author), Ninewells Hosp & Med Sch, Scottish Ctr Resp Res, Dundee, Scotland.	b.j.lipworth@dundee.ac.uk		Jabbal, Sunny/0000-0002-9604-9807; Lipworth, Brian/0000-0002-8140-2014	Chiesi; Teva; Meda; Boerhinger; Chiesi Farmaceutici	Chiesi(Chiesi Pharmaceuticals Inc); Teva(Teva Pharmaceutical Industries); Meda; Boerhinger(Boehringer Ingelheim); Chiesi Farmaceutici(Chiesi Pharmaceuticals Inc)	B. Lipworth receives grant support from Chiesi, Teva, and Meda; serves as consultant for Chiesi, Sandos, and Cipla; and receives speaker fees from Chiesi, Teva, and Boerhinger. G. Poli is an employee of Chiesi Farmaceutici. S. Jabbal receives grant support from Chiesi Farmaceutici.	De Backer W, 2010, J AEROSOL MED PULM D, V23, P137, DOI 10.1089/jamp.2009.0772; Hauber HP, 2003, J ALLERGY CLIN IMMUN, V112, P58, DOI 10.1067/mai.2003.1612; Jabbal S, 2016, J ALLERGY CLIN IMMUN, V138, P601, DOI 10.1016/j.jaci.2015.12.1336; Kraft M, 1996, AM J RESP CRIT CARE, V154, P1505, DOI 10.1164/ajrccm.154.5.8912772; Lipworth B, 2014, LANCET RESP MED, V2, P497, DOI 10.1016/S2213-2600(14)70103-1; Manoharan A, 2016, J ALLERGY CLIN IMMUN, V137, P727, DOI 10.1016/j.jaci.2015.06.012; Manoharan A, 2014, EUR RESPIR J, V44, P1353, DOI 10.1183/09031936.00082314; Nicolini G, 2010, ALLERGY ASTHMA PROC, V31, pE85, DOI 10.2500/aap.2010.31.3367; Usmani OS, 2005, AM J RESP CRIT CARE, V172, P1497, DOI 10.1164/rccm.200410-1414OC; Usmani OS, 2003, J APPL PHYSIOL, V95, P2106, DOI 10.1152/japplphysiol.00525.2003	10	23	25	1	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2017	139	6					2013	+		10.1016/j.jaci.2016.11.036	http://dx.doi.org/10.1016/j.jaci.2016.11.036			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EW7VG	28087325	Green Submitted, Bronze			2022-12-18	WOS:000402724600041
J	Herberth, G; Pierzchalski, A; Feltens, R; Bauer, M; Roder, S; Olek, S; Hinz, D; Borte, M; von Bergen, M; Lehmann, I				Herberth, Gunda; Pierzchalski, Arkadiusz; Feltens, Ralph; Bauer, Mario; Roeder, Stefan; Olek, Sven; Hinz, Denise; Borte, Michael; von Bergen, Martin; Lehmann, Irina		LINA Study Grp	Prenatal phthalate exposure associates with low regulatory T-cell numbers and atopic dermatitis in early childhood: Results from the LINA mother-child study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							BISPHENOL-A; EXPRESSION; ASTHMA; ORMDL3; BLOOD; SPHINGOSINE-1-PHOSPHATE; INFLAMMATION; COHORT; MOUSE; FOXP3		[Herberth, Gunda; Bauer, Mario; Hinz, Denise; Lehmann, Irina] UFZ Helmholtz Ctr Environm Res Leipzig, Dept Environm Immunol, Leipzig, Germany; [Pierzchalski, Arkadiusz; Feltens, Ralph; von Bergen, Martin] UFZ Helmholtz Ctr Environm Res Leipzig, Dept Mol Syst Biol, Leipzig, Germany; [Roeder, Stefan] UFZ Helmholtz Ctr Environm Res Leipzig, Core Facil Studies, Leipzig, Germany; [Olek, Sven] Epiontis GmbH, Ivana Tuerbachova Lab Epigenet, Berlin, Germany; [Hinz, Denise] La Jolla Inst Allergy & Immunol, Div Vaccine Discovery, La Jolla, CA USA; [Borte, Michael] Univ Leipzig, Acad Teaching Hosp, Childrens Hosp, Municipal Hosp St Georg, Leipzig, Germany; [von Bergen, Martin] Univ Leipzig, Inst Biochem, Leipzig, Germany; [von Bergen, Martin] Aalborg Univ, Dept Chem & Biosci, Aalborg, Denmark	Helmholtz Association; Helmholtz Center for Environmental Research (UFZ); Helmholtz Association; Helmholtz Center for Environmental Research (UFZ); Helmholtz Association; Helmholtz Center for Environmental Research (UFZ); Epiontis GmbH; La Jolla Institute for Immunology; Leipzig University; Leipzig University; Aalborg University	Herberth, G (corresponding author), UFZ Helmholtz Ctr Environm Res Leipzig, Dept Environm Immunol, Leipzig, Germany.	gunda.herberth@ufz.de; irina.lehmann@ufz.de	von Bergen, Martin/D-7960-2011; Bauer, Mario/AAZ-7540-2021	von Bergen, Martin/0000-0003-2732-2977; Herberth, Gunda/0000-0003-0212-3509; Lehmann, Irina/0000-0001-8875-5587	Helmholtz institutional funding (Helmholtz Centre for Environmental Research - UFZ)	Helmholtz institutional funding (Helmholtz Centre for Environmental Research - UFZ)	The LINA study was supported by Helmholtz institutional funding (Helmholtz Centre for Environmental Research - UFZ).	Ammit AJ, 2001, FASEB J, V15, P1212, DOI 10.1096/fj.00-0742fje; Carreras-Sureda A, 2013, HUM MOL GENET, V22, P519, DOI 10.1093/hmg/dds450; Feltens R, 2015, J CHROMATOGR SEP TEC, V6, P290, DOI DOI 10.4172/2157-7064.1000290; Gascon M, 2015, J ALLERGY CLIN IMMUN, V135, P370, DOI 10.1016/j.jaci.2014.09.030; Gude DR, 2008, FASEB J, V22, P2629, DOI 10.1096/fj.08-107169; Ha SG, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3479; Herberth G, 2014, J ALLERGY CLIN IMMUN, V133, P543, DOI 10.1016/j.jaci.2013.06.036; Hinz D, 2012, ALLERGY, V67, P380, DOI 10.1111/j.1398-9995.2011.02767.x; Hojjati MR, 2005, BBA-MOL CELL BIOL L, V1737, P44, DOI 10.1016/j.bbalip.2005.08.006; Just AC, 2012, ENVIRON HEALTH PERSP, V120, P1475, DOI 10.1289/ehp.1104544; Levy BD, 2013, NEW ENGL J MED, V369, P976, DOI 10.1056/NEJMcibr1306864; Miller M, 2014, J IMMUNOL, V192, P3475, DOI 10.4049/jimmunol.1303047; Miller M, 2012, P NATL ACAD SCI USA, V109, P16648, DOI 10.1073/pnas.1204151109; Nishiuma T, 2008, AM J PHYSIOL-LUNG C, V294, pL1085, DOI 10.1152/ajplung.00445.2007; Oyeniran C, 2015, J ALLERGY CLIN IMMUN, V136, P1035, DOI 10.1016/j.jaci.2015.02.031; Rogers JA, 2013, MOL IMMUNOL, V53, P421, DOI 10.1016/j.molimm.2012.09.013; Roviezzo F, 2010, AM J RESP CELL MOL, V42, P572, DOI 10.1165/rcmb.2009-0108OC; Siow D, 2015, J LIPID RES, V56, P898, DOI 10.1194/jlr.M057539; Sun XG, 2010, J ALLERGY CLIN IMMUN, V126, P241, DOI 10.1016/j.jaci.2010.04.036; Wang IJ, 2014, ENVIRON INT, V62, P48, DOI 10.1016/j.envint.2013.09.002; Warshauer JT, 2015, DIABETES-METAB RES, V31, P734, DOI 10.1002/dmrr.2662; Weigert A, 2009, IMMUNOBIOLOGY, V214, P748, DOI 10.1016/j.imbio.2009.06.003; Whyatt RM, 2014, J ALLERGY CLIN IMMUN, V134, P1195, DOI 10.1016/j.jaci.2014.07.027; Wieczorek G, 2009, CANCER RES, V69, P599, DOI 10.1158/0008-5472.CAN-08-2361	24	23	23	2	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2017	139	4					1376	1379		10.1016/j.jaci.2016.09.034	http://dx.doi.org/10.1016/j.jaci.2016.09.034			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ER4LR	27826096	hybrid, Green Published			2022-12-18	WOS:000398771800034
J	Joetham, A; Schedel, M; O'Connor, BP; Kim, S; Takeda, K; Abbott, J; Gelfand, EW				Joetham, Anthony; Schedel, Michaela; O'Connor, Brian P.; Kim, Soohyun; Takeda, Katsuyuki; Abbott, Jordan; Gelfand, Erwin W.			Inducible and naturally occurring regulatory T cells enhance lung allergic responses through divergent transcriptional pathways	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Inducible and naturally occurring regulatory T cells; suppression; enhancement; asthma; IL-17; IL-13	AIRWAY HYPERRESPONSIVENESS; CUTTING EDGE; INDUCTION; FOXP3; INFLAMMATION; IL-13; SPECIFICITY; ACTIVATION; GENERATION; PLASTICITY	Background: Regulatory T cells attenuate development of asthma in wild-type (WT) mice, with both naturally occurring regulatory T (nTreg) cells and inducible regulatory T (iTreg) cells exhibiting suppressive activity. When transferred into CD8-deficient (CD8(-/-)) recipients, both cell types enhanced development of allergen-induced airway hyperresponsiveness. Objective: We sought to determine whether the pathways leading to enhancement of lung allergic responses by transferred nTreg and iTreg cells differed. Methods: nTreg cells (CD4(+)CD25(+)) were isolated from WT mice and iTreg cells were generated from WT CD4(+)CD25(-) T cells after activation in the presence of TGF-beta and transferred into sensitized CD8(-/-) recipients before challenge. Development of airway hyperresponsiveness, cytokine levels, and airway inflammation were monitored. Results: Transfer of nTreg cells enhanced lung allergic responses, as did transfer of iTreg cells. Although anti-IL-13 reduced nTreg cell-mediated enhancement, it was ineffective in iTreg cell-mediated enhancement; conversely, anti-IL-17, but not anti-IL-13, attenuated the enhancement by iTreg cells. Recovered iTreg cells from the lungs of CD8(-/-) recipients were capable of IL-17 production and expressed high levels of signature genes of the T(H)17 pathway, ROR gamma t and Il17, whereas reduced expression of the Treg cell key transcription factor forkhead box p3 (Foxp3) was observed. In vitro exogenous IL-6-induced IL-17 production in iTreg cells, and in vivo conversion of transferred iTreg cells was dependent on recipient IL-6. Conclusions: iTreg cells, similar to nTreg cells, exhibit functional plasticity and can be converted from suppressor cells to pathogenic effector cells, enhancing lung allergic responses, but these effects were mediated through different pathways.	[Joetham, Anthony; Schedel, Michaela; Kim, Soohyun; Takeda, Katsuyuki; Abbott, Jordan; Gelfand, Erwin W.] Natl Jewish Health, Div Cell Biol, Dept Pediat, Denver, CO USA; [O'Connor, Brian P.] Natl Jewish Health, Ctr Genes Environm & Hlth, Denver, CO USA		Gelfand, EW (corresponding author), Natl Jewish Hlth, Dept Pediat, 1400 Jackson St, Denver, CO 80206 USA.	gelfande@njhealth.org	Abbott, Jordan K/P-2509-2016; Schedel, Michaela/B-3065-2019	Abbott, Jordan K/0000-0001-6334-5266; Schedel, Michaela/0000-0001-8465-2986	National Institutes of Health (NIH) [AI-77609]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI077609, R56AI077609] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health (NIH) grant AI-77609. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Heart, Lung, and Blood Institute or the NIH.	Akbari O, 2002, NAT MED, V8, P1024, DOI 10.1038/nm745; Arazi A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008447; Basu R, 2015, NAT IMMUNOL, V16, P286, DOI 10.1038/ni.3099; Bennett CL, 2001, NAT GENET, V27, P20, DOI 10.1038/83713; Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152; Clark LB, 1999, J IMMUNOL, V162, P2546; Dakhama A, 2005, J IMMUNOL, V175, P1876, DOI 10.4049/jimmunol.175.3.1876; Doganci A, 2005, J CLIN INVEST, V115, P313, DOI 10.1172/JCI200522433; Dominitzki S, 2007, J IMMUNOL, V179, P2041, DOI 10.4049/jimmunol.179.4.2041; Evans DJ, 1996, THORAX, V51, P1178, DOI 10.1136/thx.51.12.1178; Fantini MC, 2007, NAT PROTOC, V2, P1789, DOI 10.1038/nprot.2007.258; Huang H, 2013, J IMMUNOL, V191, P1136, DOI 10.4049/jimmunol.1201899; Ingram JL, 2012, J ALLERGY CLIN IMMUN, V130, P829, DOI 10.1016/j.jaci.2012.06.034; Ito K, 2008, AM J RESP CELL MOL, V39, P543, DOI 10.1165/rcmb.2008-0028OC; Joetham A, 2008, J IMMUNOL, V180, P7117, DOI 10.4049/jimmunol.180.11.7117; Joetham A, 2007, P NATL ACAD SCI USA, V104, P15057, DOI 10.1073/pnas.0706765104; Joetham A, 2007, J IMMUNOL, V178, P1433, DOI 10.4049/jimmunol.178.3.1433; Joetham A, 2014, J IMMUNOL, V193, P2238, DOI 10.4049/jimmunol.1400604; Joetham A, 2012, J BIOL CHEM, V287, P17100, DOI 10.1074/jbc.M111.316943; Joetham A, 2011, J IMMUNOL, V186, P113, DOI 10.4049/jimmunol.1001663; Joetham A, 2009, J IMMUNOL, V183, P1821, DOI 10.4049/jimmunol.0900303; Kimura A, 2007, P NATL ACAD SCI USA, V104, P12099, DOI 10.1073/pnas.0705268104; Laan M, 1999, J IMMUNOL, V162, P2347; Mcgee HS, 2009, AM J RESP CRIT CARE, V180, P211, DOI 10.1164/rccm.200809-1505OC; Presser K, 2008, J IMMUNOL, V181, P7751, DOI 10.4049/jimmunol.181.11.7751; Ray A, 2010, MUCOSAL IMMUNOL, V3, P216, DOI 10.1038/mi.2010.4; Selvaraj RK, 2007, J IMMUNOL, V178, P7667, DOI 10.4049/jimmunol.178.12.7667; Taube C, 2004, AM J RESP CELL MOL, V30, P837, DOI 10.1165/rcmb.2003-0395OC; Taube C, 2002, J IMMUNOL, V169, P6482, DOI 10.4049/jimmunol.169.11.6482; Thornton AM, 2000, J IMMUNOL, V164, P183, DOI 10.4049/jimmunol.164.1.183; Tomkinson A, 2001, AM J RESP CRIT CARE, V163, P721, DOI 10.1164/ajrccm.163.3.2005010; Valzasina B, 2005, BLOOD, V105, P2845, DOI 10.1182/blood-2004-07-2959; Wan SG, 2007, J IMMUNOL, V178, P271, DOI 10.4049/jimmunol.178.1.271; Wan YSY, 2007, NATURE, V445, P766, DOI 10.1038/nature05479; Wenzel SE, 1997, AM J RESP CRIT CARE, V156, P737, DOI 10.1164/ajrccm.156.3.9610046; Wilson RH, 2009, AM J RESP CRIT CARE, V180, P720, DOI 10.1164/rccm.200904-0573OC; Xu LL, 2007, J IMMUNOL, V178, P6725, DOI 10.4049/jimmunol.178.11.6725; Zhou XY, 2009, NAT IMMUNOL, V10, P1000, DOI 10.1038/ni.1774	39	23	23	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2017	139	4					1331	1342		10.1016/j.jaci.2016.06.051	http://dx.doi.org/10.1016/j.jaci.2016.06.051			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ER4LR	27542981	Green Accepted, Bronze			2022-12-18	WOS:000398771800028
J	Cahill, KN; Johns, CB; Cui, J; Wickner, P; Bates, DW; Laidlaw, TM; Beeler, PE				Cahill, Katherine N.; Johns, Christina B.; Cui, Jing; Wickner, Paige; Bates, David W.; Laidlaw, Tanya M.; Beeler, Patrick E.			Automated identification of an aspirin-exacerbated respiratory disease cohort	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Aspirin-exacerbated respiratory disease; electronic health record; asthma; nasal polyps; nonsteroidal anti-inflammatory drugs; chronic rhinosinusitis; structured query language; clinical decision support	RHINOSINUSITIS-ASTHMA; DESENSITIZATION; ALGORITHM; VALIDATION; SAFETY	Background: Aspirin-exacerbated respiratory disease (AERD) is characterized by 3 clinical features: asthma, nasal polyposis, and respiratory reactions to cyclooxygenase-1 inhibitors (nonsteroidal anti-inflammatory drugs). Electronic health records (EHRs) contain information on each feature of this triad. Objective: We sought to determine whether an informatics algorithm applied to the EHR could electronically identify patients with AERD. Methods: We developed an informatics algorithm to search the EHRs of patients aged 18 years and older from the Partners Healthcare system over a 10-year period (2004-2014). Charts with search terms for asthma, nasal polyps, and record of respiratory (cohort A) or unspecified (cohort B) reactions to nonsteroidal anti-inflammatory drugs were identified as "possible AERD.'' Two clinical experts reviewed all charts to confirm a diagnosis of "clinical AERD'' and classify cases as "diagnosed AERD'' or "undiagnosed AERD'' on the basis of physician-documented AERD-specific terms in patient notes. Results: Our algorithm identified 731" possible AERD'' cases, of which 638 were not in our AERD patient registry. Chart review of cohorts A (n 5 511) and B (n 5 127) demonstrated a positive predictive value of 78.4% for "clinical AERD,'' which rose to 88.7% when unspecified reactions were excluded. Of those with clinical AERD, 12.4% had no mention of AERD by any treating caregiver and were classified as "undiagnosed AERD.'' "Undiagnosed AERD'' cases were less likely than "diagnosed AERD'' cases to have been seen by an allergist/immunologist (38.7% vs 93.2%; P <.0001). Conclusions: An informatics algorithm can successfully identify both known and previously undiagnosed cases of AERD with a high positive predictive value. Involvement of an allergist/immunologist significantly increases the likelihood of an AERD diagnosis.	[Cahill, Katherine N.; Cui, Jing; Wickner, Paige; Bates, David W.; Laidlaw, Tanya M.; Beeler, Patrick E.] Harvard Med Sch, Dept Med, Boston, MA USA; [Cahill, Katherine N.; Johns, Christina B.; Cui, Jing; Wickner, Paige; Laidlaw, Tanya M.] Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, 75 Francis St, Boston, MA 02115 USA; [Bates, David W.; Beeler, Patrick E.] Brigham & Womens Hosp, Div Gen Internal Med & Primary Care, 75 Francis St, Boston, MA 02115 USA; [Beeler, Patrick E.] Univ Zurich Hosp, Res Ctr Med Informat, Zurich, Switzerland; [Beeler, Patrick E.] Univ Zurich, Zurich, Switzerland	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; University of Zurich; University Zurich Hospital; University of Zurich	Cahill, KN (corresponding author), Brigham & Womens Hosp, 1 Jimmy Fund Way,Smith Bldg,Rm 626B, Boston, MA 02115 USA.	kncahill@partners.org	Beeler, Patrick E/A-6143-2016; Beeler, Patrick/AAM-5461-2020; Bates, David/AAE-7283-2019	Beeler, Patrick E/0000-0002-6097-2480; Beeler, Patrick/0000-0002-6097-2480; Cahill, Katherine/0000-0002-8549-1835; Johns, Christina/0000-0002-0541-040X	National Institutes of Health (NIH) [NIH K23 HL111113, NIH K23 AI118804-01]; Swiss National Science Foundation [P2BSP3_148619]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL128241, K23HL111113] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K23AI118804] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by the National Institutes of Health (NIH) (grant nos. NIH K23 HL111113 and NIH K23 AI118804-01), the Swiss National Science Foundation (grant no. P2BSP3_148619 to P.E.B.), departmental funds, and generous contributions from the Vinik and Kaye Families.	Berges-Gimeno MP, 2002, ANN ALLERG ASTHMA IM, V89, P474, DOI 10.1016/S1081-1206(10)62084-4; Bochenek G, 2015, RESP MED, V109, P588, DOI 10.1016/j.rmed.2015.02.015; Bochenek G, 2014, J ALLERGY CLIN IMMUN, V133, P98, DOI 10.1016/j.jaci.2013.07.004; Carroll RJ, 2012, J AM MED INFORM ASSN, V19, pE162, DOI 10.1136/amiajnl-2011-000583; Centers for Disease Control and Prevention, 2013, ASTHM DAT STAT SURV; Cho I, 2015, INT J MED INFORM, V84, P694, DOI 10.1016/j.ijmedinf.2015.05.011; Dahlen B, 1998, AM J RESP CRIT CARE, V157, P1187, DOI 10.1164/ajrccm.157.4.9707089; Galanter WL, 2010, INT J MED INFORM, V79, P332, DOI 10.1016/j.ijmedinf.2008.05.005; Ibrahim C, 2014, ALLERGY ASTHMA CL IM, V10, DOI 10.1186/s13223-014-0064-7; Kowalski ML, 2013, ALLERGY, V68, P1219, DOI 10.1111/all.12260; Lee-Sarwar K, 2015, J ALLER CL IMM-PRACT, V3, P449, DOI 10.1016/j.jaip.2015.01.007; Nalichowski Ruth, 2006, AMIA Annu Symp Proc, P1044; Newton KM, 2013, J AM MED INFORM ASSN, V20, pE147, DOI 10.1136/amiajnl-2012-000896; Nigwekar SU, 2014, J GEN INTERN MED, V29, pS924, DOI 10.1007/s11606-014-2910-1; Overby CL, 2013, J AM MED INFORM ASSN, V20, pE243, DOI 10.1136/amiajnl-2013-001930; Phansalkar S, 2012, J AM MED INFORM ASSN, V19, P735, DOI 10.1136/amiajnl-2011-000612; PLESKOW WW, 1983, J ALLERGY CLIN IMMUN, V71, P574, DOI 10.1016/0091-6749(83)90439-6; Rajan JP, 2015, J ALLERGY CLIN IMMUN, V135, P676, DOI 10.1016/j.jaci.2014.08.020; Seidling HM, 2011, J AM MED INFORM ASSN, V18, P479, DOI 10.1136/amiajnl-2010-000039; Shaker M, 2008, J ALLERGY CLIN IMMUN, V121, P81, DOI 10.1016/j.jaci.2007.06.047; Stevenson DD, 1996, J ALLERGY CLIN IMMUN, V98, P751, DOI 10.1016/S0091-6749(96)70123-9; Stevenson DD, 2006, J ALLERGY CLIN IMMUN, V118, P773, DOI 10.1016/j.jaci.2006.07.024; Stevenson DD, 2006, J ALLERGY CLIN IMMUN, V118, P801, DOI 10.1016/j.jaci.2006.06.019; Swierczynska-Krepa M, 2014, J ALLERGY CLIN IMMUN, V134, P883, DOI 10.1016/j.jaci.2014.02.041; Ta V, 2015, J ALLER CL IMM-PRACT, V3, P711, DOI 10.1016/j.jaip.2015.03.001; Van der Sijs H, 2006, J AM MED INFORM ASSN, V13, P138, DOI 10.1197/jamia.M1809; White AA, 2005, ANN ALLERG ASTHMA IM, V95, P330, DOI 10.1016/S1081-1206(10)61150-7; Xi N, 2015, CAN FAM PHYSICIAN, V61, pE474; Zalis M, 2010, J AM COLL RADIOL, V7, P625, DOI 10.1016/j.jacr.2010.03.011; Zimmerman CR, 2009, AM J HEALTH-SYST PH, V66, P671, DOI 10.2146/ajhp070645	30	23	23	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2017	139	3					819	+		10.1016/j.jaci.2016.05.048	http://dx.doi.org/10.1016/j.jaci.2016.05.048			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	EP3QC	27567328	Green Accepted, Bronze			2022-12-18	WOS:000397295800014
J	Mosteller, M; Hosking, L; Murphy, K; Shen, JD; Song, KJ; Nelson, M; Ghosh, S				Mosteller, Michael; Hosking, Louise; Murphy, Kay; Shen, Judong; Song, Kijoung; Nelson, Matthew; Ghosh, Soumitra			No evidence of large genetic effects on steroid response in asthma patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Steroid response; asthma; fluticasone; genome-wide association studies; inhaled corticosteroids; pharmacogenetics	GENOME-WIDE ASSOCIATION; IMPROVED LUNG-FUNCTION; INHALED CORTICOSTEROIDS; RESEARCH-PROGRAM; GLCCI1; TESTS; IMPROVEMENT; IMPUTATION; ADULTS; TBX21	Background: Inhaled corticosteroids (ICSs) are considered the most effective anti-inflammatory therapy for asthma control and management; however, there is substantial treatment response variability. Objective: We sought to identify genetic markers of ICS response by conducting the largest pharmacogenetic investigation to date in 2672 ICS-treated patients with asthma. Methods: Genotyping and imputation was performed in fluticasone furoate (FF) or fluticasone propionate-treated patients with asthma from 3 phase IIB and 4 phase IIIA randomized, double-blind, placebo-controlled, parallel group, multicenter studies. The primary end point analyzed was change in trough FEV1 (Delta FEV1) from baseline to 8 to 12 weeks of treatment. Results: More than 9.8 million common genetic variants (minor allele frequency >= 1%) were analyzed to test for association with DFEV1. No genetic variant met the prespecified threshold for statistical significance. Conclusions: This study provides no evidence to confirmpreviously reported associations between candidate genetic variants and ICS response (Delta FEV1) in patients with asthma. In addition, no variant satisfied the criterion for genome-wide significance in our study. Common genetic variants are therefore unlikely to prove useful as predictive biomarkers of ICS response in patients with asthma.	[Mosteller, Michael; Hosking, Louise; Murphy, Kay] GSK, Stevenage, Herts, England; [Shen, Judong] GSK, Res Triangle Pk, NC USA; [Song, Kijoung; Nelson, Matthew; Ghosh, Soumitra] GSK, Upper Merion, PA USA; [Mosteller, Michael] PAREXEL Int, Res Triangle Pk, NC USA; [Shen, Judong] Merck & Co Inc, Rahway, NJ USA	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; Parexel International; Merck & Company	Hosking, L (corresponding author), GSK, Med Res Ctr, Gunnels Wood Rd, Stevenage SG1 2NY, Herts, England.	louise.k.hosking@gsk.com			GSK [116935]	GSK(GlaxoSmithKline)	This study was funded by GSK (study no. 116935).	Altshuler DM, 2012, NATURE, V491, P56, DOI 10.1038/nature11632; Aulchenko YS, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-134; Bhakta Nirav R, 2013, Clin Transl Allergy, V3, P24, DOI 10.1186/2045-7022-3-24; Cho SH, 2012, PHARMACOGENET GENOM, V22, P327, DOI 10.1097/FPC.0b013e32834ef849; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; GOODMAN SN, 1992, STAT MED, V11, P875, DOI 10.1002/sim.4780110705; Halsey LG, 2015, NAT METHODS, V12, P179, DOI 10.1038/nmeth.3288; Hawkins GA, 2009, J ALLERGY CLIN IMMUN, V123, P1376, DOI 10.1016/j.jaci.2009.01.049; Hosking L, 2014, J ALLERGY CLIN IMMUN, V133, P587, DOI 10.1016/j.jaci.2013.08.024; Howie B, 2012, NAT GENET, V44, P955, DOI 10.1038/ng.2354; John S, 2011, NAT GENET, V43, P264, DOI 10.1038/ng.759; Kutalik Z, 2011, BIOSTATISTICS, V12, P1, DOI 10.1093/biostatistics/kxq039; Lee S, 2012, BIOSTATISTICS, V13, P762, DOI 10.1093/biostatistics/kxs014; Li J, 2005, HEREDITY, V95, P221, DOI 10.1038/sj.hdy.6800717; Li MX, 2012, HUM GENET, V131, P747, DOI 10.1007/s00439-011-1118-2; Lopert A, 2013, SCI REP-UK, V3, DOI 10.1038/srep02915; Manichaikul A, 2010, BIOINFORMATICS, V26, P2867, DOI 10.1093/bioinformatics/btq559; Masoli M, 2004, ALLERGY, V59, P469, DOI 10.1111/j.1398-9995.2004.00526.x; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Moore Wendy C, 2013, Ann Am Thorac Soc, V10 Suppl, pS118, DOI 10.1513/AnnalsATS.201309-307AW; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; Mougey EB, 2013, PHARMACOGENOMICS J, V13, P242, DOI 10.1038/tpj.2012.5; Park HW, 2014, J ALLERGY CLIN IMMUN, V133, P664, DOI 10.1016/j.jaci.2013.12.1042; Pavord ID, 2012, LANCET, V380, P651, DOI 10.1016/S0140-6736(12)60988-X; Reddy TE, 2012, MOL CELL BIOL, V32, P3756, DOI 10.1128/MCB.00062-12; Rossios C, 2011, EUR J PHARMACOL, V670, P244, DOI 10.1016/j.ejphar.2011.08.022; Tantisira KG, 2008, PHARMACOGENET GENOM, V18, P733, DOI 10.1097/FPC.0b013e3282fe6ebf; Tantisira KG, 2012, AM J RESP CRIT CARE, V185, P1286, DOI 10.1164/rccm.201111-2061OC; Tantisira KG, 2011, NEW ENGL J MED, V365, P1173, DOI 10.1056/NEJMoa0911353; Tantisira KG, 2004, HUM MOL GENET, V13, P1353, DOI 10.1093/hmg/ddh149; Tantisira KG, 2004, P NATL ACAD SCI USA, V101, P18099, DOI 10.1073/pnas.0408532102; Vijverberg SJH, 2014, PHARMACOGENOMICS, V15, P799, DOI [10.2217/PGS.14.37, 10.2217/pgs.14.37]; Weiss ST, 2012, J ALLERGY CLIN IMMUN, V129, P327, DOI 10.1016/j.jaci.2011.12.971; Wigginton JE, 2005, AM J HUM GENET, V76, P887, DOI 10.1086/429864; Willer CJ, 2010, BIOINFORMATICS, V26, P2190, DOI 10.1093/bioinformatics/btq340; Yang JA, 2011, AM J HUM GENET, V88, P76, DOI 10.1016/j.ajhg.2010.11.011; Yang JA, 2010, NAT GENET, V42, P565, DOI 10.1038/ng.608	37	23	23	1	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2017	139	3					797	+		10.1016/j.jaci.2016.05.032	http://dx.doi.org/10.1016/j.jaci.2016.05.032			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EP3QC	27523435				2022-12-18	WOS:000397295800011
J	Bacchelli, C; Moretti, FA; Carmo, M; Adams, S; Stanescu, HC; Pearce, K; Madkaikar, M; Gilmour, KC; Nicholas, AK; Woods, CG; Kleta, R; Beales, PL; Qasim, W; Gaspar, HB				Bacchelli, Chiara; Moretti, Federico A.; Carmo, Marlene; Adams, Stuart; Stanescu, Horia C.; Pearce, Kerra; Madkaikar, Manisha; Gilmour, Kimberly C.; Nicholas, Adeline K.; Woods, C. Geoffrey; Kleta, Robert; Beales, Phil L.; Qasim, Waseem; Gaspar, H. Bobby			Mutations in linker for activation of T cells (LAT) lead to a novel form of severe combined immunodeficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Severe combined immunodeficiency; linker for activation of T cells; immunodeficiency; T-cell receptor signaling; genetic defect; T lymphopenia	ANTIGEN RECEPTOR COMPLEX; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; CD3-EPSILON GENE; ADAPTER PROTEIN; EXPRESSION; DEFICIENCY; DISEASE; DEATH; MICE	Background: Signaling through the T-cell receptor (TCR) is critical for T-cell development and function. Linker for activation of T cells (LAT) is a transmembrane adaptor signaling molecule that is part of the TCR complex and essential for T-cell development, as demonstrated by LAT-deficient mice, which show a complete lack of peripheral T cells. Objective: We describe a pedigree affected by a severe combined immunodeficiency phenotype with absent T cells and normal B-cell and natural killer cell numbers. A novel homozygous frameshift mutation in the gene encoding for LAT was identified in this kindred. Methods: Genetic, molecular, and functional analyses were used to identify and characterize the LAT defect. Clinical and immunologic analysis of patients was also performed and reported. Results: Homozygosity mapping was used to identify potential defective genes. Sanger sequencing of the LAT gene showed a mutation that resulted in a premature stop codon and protein truncation leading to complete loss of function and loss of expression of LAT in the affected family members. We also demonstrate loss of LAT expression and lack of TCR signaling restoration in LAT-deficient cell lines reconstituted with a synthetic LAT gene bearing this severe combined immunodeficiency mutation. Conclusion: For the first time, the results of this study show that inherited LAT deficiency should be considered in patients with combined immunodeficiency with T-cell abnormalities.	[Bacchelli, Chiara; Pearce, Kerra; Beales, Phil L.] UCL Inst Child Hlth, Genet & Genom Med, London, England; [Moretti, Federico A.; Carmo, Marlene; Madkaikar, Manisha; Gilmour, Kimberly C.; Qasim, Waseem; Gaspar, H. Bobby] UCL Inst Child Hlth, Infect Immun Inflammat & Physiol Med, London, England; [Adams, Stuart] Great Ormond St Hosp NHS Trust, Bone Marrow Transplantat, London, England; [Gilmour, Kimberly C.; Qasim, Waseem; Gaspar, H. Bobby] Great Ormond St Hosp NHS Trust, Dept Clin Immunol, London, England; [Stanescu, Horia C.; Kleta, Robert] UCL, Royal Free Hosp, Ctr Nephrol, London, England; [Madkaikar, Manisha] Natl Inst Immunohematol, ICMR, Dept Pediat Immunol & Leukocyte Biol, Mumbai, Maharashtra, India; [Nicholas, Adeline K.; Woods, C. Geoffrey] Univ Cambridge, Dept Med Genet, Cambridge, England	University of London; University College London; University of London; University College London; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; Indian Council of Medical Research (ICMR); ICMR - National Institute of Immunohaemotology (NIIH); University of Cambridge	Gaspar, HB (corresponding author), UCL Inst Child Hlth, Mol & Cellular Immunol Sect, Infect Immun Inflammat & Physiol Med, 30 Guilford St, London WC1N 1EH, England.	h.gaspar@ucl.ac.uk		Madkaikar, Manisha/0000-0001-6380-3116; Moretti, Federico Andrea/0000-0003-3187-3683; QASIM, WASEEM/0000-0001-8353-4494; Nicholas, Adeline/0000-0002-7124-629X	Great Ormond Street Hospital Children's Charity; National Institute of Health Research Biomedical Research Centre at Great Ormond Street Hospital; University College London; Biotechnology and Biological Sciences Research Council [BB/M020991/1] Funding Source: researchfish; Medical Research Council [G0801843] Funding Source: researchfish; National Institute for Health Research [RP-2014-05-007, NF-SI-0513-10008] Funding Source: researchfish; Great Ormond Street Hospital Childrens Charity [V1296] Funding Source: researchfish; The British Council [216377911] Funding Source: researchfish; BBSRC [BB/M020991/1] Funding Source: UKRI; MRC [G0801843] Funding Source: UKRI	Great Ormond Street Hospital Children's Charity; National Institute of Health Research Biomedical Research Centre at Great Ormond Street Hospital; University College London(General Electric); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR)); Great Ormond Street Hospital Childrens Charity; The British Council; BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	H.B.G. is supported by the Great Ormond Street Hospital Children's Charity. This study was supported by the National Institute of Health Research Biomedical Research Centre at Great Ormond Street Hospital and University College London.	Abraham RT, 2004, NAT REV IMMUNOL, V4, P301, DOI 10.1038/nri1330; Bartelt RR, 2013, WIRES SYST BIOL MED, V5, P101, DOI 10.1002/wsbm.1194; Bousfiha A, 2015, J CLIN IMMUNOL, V35, P727, DOI 10.1007/s10875-015-0198-5; Carr IM, 2009, HUM MUTAT, V30, P960, DOI 10.1002/humu.20974; Chuck MI, 2010, J IMMUNOL, V184, P2476, DOI 10.4049/jimmunol.0902876; Dadi HK, 2003, NEW ENGL J MED, V349, P1821, DOI 10.1056/NEJMoa031178; DAMBROSIO D, 1994, EUR J IMMUNOL, V24, P616, DOI 10.1002/eji.1830240319; Dave VP, 1997, EMBO J, V16, P1360, DOI 10.1093/emboj/16.6.1360; de Saint Basile G, 2004, J CLIN INVEST, V114, P1512, DOI 10.1172/JCI200422588; Facchetti F, 1999, AM J PATHOL, V154, P1037, DOI 10.1016/S0002-9440(10)65356-4; Finco TS, 1998, IMMUNITY, V9, P617, DOI 10.1016/S1074-7613(00)80659-7; Fischer A, 2005, IMMUNOL REV, V203, P98, DOI 10.1111/j.0105-2896.2005.00223.x; Fischer A, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.61; Garcia-Blesa A, 2013, BIOCHEM J, V450, P511, DOI 10.1042/BJ20121135; GOLDSMITH MA, 1988, P NATL ACAD SCI USA, V85, P8613, DOI 10.1073/pnas.85.22.8613; GOLDSMITH MA, 1987, P NATL ACAD SCI USA, V84, P6879, DOI 10.1073/pnas.84.19.6879; Houtman JCD, 2005, FEBS J, V272, P5426, DOI 10.1111/j.1742-4658.2005.04972.x; Huang DCS, 1999, P NATL ACAD SCI USA, V96, P14871, DOI 10.1073/pnas.96.26.14871; Klossowicz M, 2013, J IMMUNOL METHODS, V389, P9, DOI 10.1016/j.jim.2012.12.004; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Kung C, 2000, NAT MED, V6, P343; Kwan A, 2014, JAMA-J AM MED ASSOC, V312, P729, DOI 10.1001/jama.2014.9132; LEDEIST F, 1991, EUR J IMMUNOL, V21, P1641, DOI 10.1002/eji.1830210709; Li-Weber M, 2002, CELL DEATH DIFFER, V9, P101, DOI 10.1038/sj.cdd.4400984; LOVE PE, 1993, SCIENCE, V261, P918, DOI 10.1126/science.7688481; MALISSEN M, 1993, EMBO J, V12, P4347, DOI 10.1002/j.1460-2075.1993.tb06119.x; MALISSEN M, 1995, EMBO J, V14, P4641, DOI 10.1002/j.1460-2075.1995.tb00146.x; Montiel-Equihua CA, 2012, MOL THER, V20, P1400, DOI 10.1038/mt.2012.50; Munoz P, 2003, J BIOL CHEM, V278, P50791, DOI 10.1074/jbc.M308034200; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Rieux-Laucat F, 2006, NEW ENGL J MED, V354, P1913, DOI 10.1056/NEJMoa053750; Roberts JL, 2007, BLOOD, V109, P3198, DOI 10.1182/blood-2006-08-043166; Rouquette-Jazdanian AK, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131823; Shen SD, 2009, J IMMUNOL, V182, P5596, DOI 10.4049/jimmunol.0803170; Snow AL, 2010, IMMUNOL REV, V236, P68, DOI 10.1111/j.1600-065X.2010.00917.x; Sommers CL, 2002, SCIENCE, V296, P2040, DOI 10.1126/science.1069066; SOUDAIS C, 1993, NAT GENET, V3, P77, DOI 10.1038/ng0193-77; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; Tchilian EZ, 2001, J IMMUNOL, V166, P1308, DOI 10.4049/jimmunol.166.2.1308; WEISS A, 1984, J EXP MED, V160, P1284, DOI 10.1084/jem.160.5.1284; Williams BL, 1998, MOL CELL BIOL, V18, P1388, DOI 10.1128/MCB.18.3.1388; Zhang WG, 1999, IMMUNITY, V10, P323, DOI 10.1016/S1074-7613(00)80032-1; Zhang WG, 1999, INT IMMUNOL, V11, P943, DOI 10.1093/intimm/11.6.943; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8	44	23	24	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2017	139	2					634	+		10.1016/j.jaci.2016.05.036	http://dx.doi.org/10.1016/j.jaci.2016.05.036			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EO9IM	27522155	Bronze, Green Submitted			2022-12-18	WOS:000397002400029
J	Keller, B; Cseresnyes, Z; Stumpf, I; Wehr, C; Fliegauf, M; Bulashevska, A; Usadel, S; Grimbacher, B; Rizzi, M; Eibel, H; Niesner, R; Warnatz, K				Keller, Baerbel; Cseresnyes, Zoltan; Stumpf, Ina; Wehr, Claudia; Fliegauf, Manfred; Bulashevska, Alla; Usadel, Susanne; Grimbacher, Bodo; Rizzi, Marta; Eibel, Hermann; Niesner, Raluca; Warnatz, Klaus			Disturbed canonical nuclear factor of kappa light chain signaling in B cells of patients with common variable immunodeficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Common variable immunodeficiency; B cells; CD21(low) B cells; canonical nuclear factor of kappa light chain; signaling; B-cell receptor; Toll-like receptor 9; CD40; HIV	MEMORY B; NONSENSE MUTATION; GERMINAL-CENTERS; 11 CARD11; RECEPTOR; DEFICIENCY; TRANSCRIPTION; MAINTENANCE; INDIVIDUALS; PATHWAY	Background: Most patients with common variable immunodeficiency (CVID) present with severely reduced switched memory B-cell counts, and some display an increase of CD21 (low) B-cell counts (CVID 21low), whereas others do not (CVID 21norm). Altered B-cell receptor (BCR) signaling might contribute to the defective memory formation observed in patients with CVID. Objective: We sought to investigate canonical nuclear factor of kappa light chain (NF-kappa B) signaling in B cells from patients with CVID as a central pathway in B-cell differentiation. Methods: Degradation of inhibitor of kappa B alpha (I kappa B alpha) and p65 phosphorylation, nuclear translocation of p65, and regulation of target genes and cell function were investigated after different modes of B-cell stimulation. Results: BCR-mediated canonical NF-kappa B signaling was impaired in all mature naive CVID-derived B cells. This impairment was more profound in naive B cells from CVID 21low patients than CVID 21norm patients and most pronounced in CD21 (low) B cells. The signaling defect translated into reduced induction of Bcl-xL and I kappa B alpha, 2 bona fide target genes of the canonical NF-kappa B pathway. CD40 ligand-and Toll-like receptor 9-mediated signaling were less strongly altered. Signaling in CD21 (low) B cells but not CD21 (+) B cells of patients with HIV was similarly affected. Conclusion: Combined with the previous description of disturbed Ca (2+) signaling, the discovery of NF-kappa B signaling defects, especially in CVID 21low patients, suggests a broad underlying signaling defect affecting especially BCR-derived signals. Given the immune phenotype of monogenic defects affecting Ca (2+) and NF-kappa B signaling, the latter is more likely to contribute to the humoral deficiency. The strongly disturbed BCR signaling of CD21 (low) B cells is characteristic for this cell type and independent of the underlying disease.	[Keller, Baerbel; Stumpf, Ina; Wehr, Claudia; Fliegauf, Manfred; Bulashevska, Alla; Grimbacher, Bodo; Rizzi, Marta; Eibel, Hermann; Warnatz, Klaus] Univ Med Ctr, Ctr Chron Immunodeficiency, Breisacherstr 115, D-79106 Freiburg, Germany; [Keller, Baerbel; Stumpf, Ina; Wehr, Claudia; Fliegauf, Manfred; Bulashevska, Alla; Grimbacher, Bodo; Rizzi, Marta; Eibel, Hermann; Warnatz, Klaus] Univ Freiburg, Breisacherstr 115, D-79106 Freiburg, Germany; [Cseresnyes, Zoltan; Niesner, Raluca] Leibniz Inst, German Rheumatism Res Ctr, JIMI imaging Network & Biophys Analyt, Berlin, Germany; [Usadel, Susanne] Univ Med Ctr Freiburg, Div Infect Dis, Dept Internal Med, Infektiologikum Freiburg, Freiburg, Germany; [Grimbacher, Bodo] UCL, Inst Immun & Transplantat, London WC1E 6BT, England	University of Freiburg; University of Freiburg; Deutsches Rheuma-Forschungszentrum (DRFZ); University of Freiburg; University of London; University College London	Warnatz, K (corresponding author), Univ Med Ctr, Ctr Chron Immunodeficiency, Breisacherstr 115, D-79106 Freiburg, Germany.; Warnatz, K (corresponding author), Univ Freiburg, Breisacherstr 115, D-79106 Freiburg, Germany.	klaus.warnatz@uniklinik-freiburg.de	Rizzi, Marta/ABE-7264-2020; Warnatz, Klaus/AAD-3464-2022; Bulashevska, Alla/C-4910-2019; Cseresnyes, Zoltan/AAG-4266-2020; Wehr, Claudia/AAZ-5758-2021	Wehr, Claudia/0000-0002-5037-6175; Rizzi, Marta/0000-0002-5153-6089; Cseresnyes, Zoltan/0000-0002-6574-2588	German Federal Ministry of Education and Research [BMBF 01EO1303]; Deutsche Forschungsgemeinschaft [TRR130]; Margarete von Wrangell Habilitation Program'' by the Ministry of Sciences, Research and Arts in Baden Wurttemberg; European Social Fund	German Federal Ministry of Education and Research(Federal Ministry of Education & Research (BMBF)); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Margarete von Wrangell Habilitation Program'' by the Ministry of Sciences, Research and Arts in Baden Wurttemberg; European Social Fund(European Social Fund (ESF))	Supported by the German Federal Ministry of Education and Research (BMBF 01EO1303) and the Deutsche Forschungsgemeinschaft TRR130. M.R. was supported by Margarete von Wrangell Habilitation Program'' by the Ministry of Sciences, Research and Arts in Baden Wurttemberg and the European Social Fund.	Basso K, 2015, NAT REV IMMUNOL, V15, P172, DOI 10.1038/nri3814; Bendall HH, 1999, MOL IMMUNOL, V36, P187, DOI 10.1016/S0161-5890(99)00031-0; Burns SO, 2014, J ALLERGY CLIN IMMUN, V134, P215, DOI 10.1016/j.jaci.2013.12.1093; Charles ED, 2011, BLOOD, V117, P5425, DOI 10.1182/blood-2010-10-312942; Chen K, 2013, AM J HUM GENET, V93, P812, DOI 10.1016/j.ajhg.2013.09.009; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Chinen J, 2015, J ALLERGY CLIN IMMUN, V135, P1132, DOI 10.1016/j.jaci.2015.02.037; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; CROSS SL, 1989, SCIENCE, V244, P466, DOI 10.1126/science.2497520; Cunningham-Rundles C, 2012, HEMATOL-AM SOC HEMAT, P301, DOI 10.1182/asheducation-2012.1.301; Damdinsuren B, 2010, IMMUNITY, V32, P355, DOI 10.1016/j.immuni.2010.02.013; Feske S, 2006, NATURE, V441, P179, DOI 10.1038/nature04702; Feske S, 2011, ANN NY ACAD SCI, V1238, P74, DOI 10.1111/j.1749-6632.2011.06240.x; Fliegauf M, 2015, AM J HUM GENET, V97, P389, DOI 10.1016/j.ajhg.2015.07.008; Foerster C, 2010, J IMMUNOL, V184, P7305, DOI 10.4049/jimmunol.1000434; Gerondakis S, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000182; Goetz CA, 2008, IMMUNOL RES, V41, P233, DOI 10.1007/s12026-008-8033-1; Greil J, 2013, J ALLERGY CLIN IMMUN, V131, P1376, DOI 10.1016/j.jaci.2013.02.012; Grossmann M, 2000, EMBO J, V19, P6351, DOI 10.1093/emboj/19.23.6351; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; Gugasyan R, 2000, IMMUNOL REV, V176, P134; Heise N, 2014, J EXP MED, V211, P2103, DOI 10.1084/jem.20132613; Holodick NE, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00457; Isnardi I, 2010, BLOOD, V115, P5026, DOI 10.1182/blood-2009-09-243071; Jolles S, 2013, J ALLER CL IMM-PRACT, V1, P545, DOI 10.1016/j.jaip.2013.09.015; Kaileh M, 2012, IMMUNOL REV, V246, P254, DOI 10.1111/j.1600-065X.2012.01106.x; Klein U, 2015, CURR OPIN HEMATOL, V22, P379, DOI 10.1097/MOH.0000000000000160; Liu YW, 2014, J CLIN IMMUNOL, V34, P686, DOI 10.1007/s10875-014-0064-x; Torres JM, 2014, J CLIN INVEST, V124, P5239, DOI 10.1172/JCI77493; Moir S, 2008, J EXP MED, V205, P1797, DOI 10.1084/jem.20072683; Moir S, 2013, IMMUNOL REV, V254, P207, DOI 10.1111/imr.12067; MORRIS DL, 1993, J EXP MED, V177, P857, DOI 10.1084/jem.177.3.857; Mouillot G, 2010, J CLIN IMMUNOL, V30, P746, DOI 10.1007/s10875-010-9424-3; Mousallem T, 2014, BLOOD, V124, P2046, DOI 10.1182/blood-2014-04-571265; Ochtrop MLG, 2011, BLOOD, V118, P309, DOI 10.1182/blood-2010-11-321695; Oeckinghaus A, 2011, NAT IMMUNOL, V12, P695, DOI 10.1038/ni.2065; Pannicke U, 2013, NEW ENGL J MED, V369, P2504, DOI 10.1056/NEJMoa1309199; Pasparakis M, 2002, J EXP MED, V196, P743, DOI 10.1084/jem.20020907; Rakhmanov M, 2010, BLOOD, V116, P3682, DOI 10.1182/blood-2010-05-285585; Rakhmanov M, 2009, P NATL ACAD SCI USA, V106, P13451, DOI 10.1073/pnas.0901984106; Salzer U, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar4032; Shaffer AL, 2001, IMMUNITY, V15, P375, DOI 10.1016/S1074-7613(01)00194-7; Shlomchik MJ, 2012, IMMUNOL REV, V247, P52, DOI 10.1111/j.1600-065X.2012.01124.x; Stepensky P, 2013, J ALLERGY CLIN IMMUN, V131, P477, DOI 10.1016/j.jaci.2012.11.050; Takemori T, 2014, EUR J IMMUNOL, V44, P1258, DOI 10.1002/eji.201343716; Turvey SE, 2014, J ALLERGY CLIN IMMUN, V134, P276, DOI 10.1016/j.jaci.2014.06.015; Warnatz K, 2002, BLOOD, V99, P1544, DOI 10.1182/blood.V99.5.1544; Wehr C, 2004, CLIN IMMUNOL, V113, P161, DOI 10.1016/j.clim.2004.05.010; Wehr C, 2008, BLOOD, V111, P77, DOI 10.1182/blood-2007-06-091744; Weiss GE, 2009, J IMMUNOL, V183, P2176, DOI 10.4049/jimmunol.0901297	50	23	23	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2017	139	1					220	+		10.1016/j.jaci.2016.04.043	http://dx.doi.org/10.1016/j.jaci.2016.04.043			20	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EK5WM	27461466				2022-12-18	WOS:000393996800024
J	Imbert, S; Bresler, P; Boissonnas, A; Gauthier, L; Souchet, L; Uzunov, M; Leblond, V; Mazier, D; Nguyen, S; Fekkar, A				Imbert, Sebastien; Bresler, Priscillia; Boissonnas, Alexandre; Gauthier, Lauraine; Souchet, Laetitia; Uzunov, Madalina; Leblond, Veronique; Mazier, Dominique; Nguyen, Stephanie; Fekkar, Arnaud			Calcineurin inhibitors impair neutrophil activity against Aspergillus fumigatus in allogeneic hematopoietic stem cell transplant recipients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Innate immunity; calcineurin inhibitor; invasive fungal infection; immune reconstitution; transplantation	INVASIVE MOLD INFECTIONS; CYCLOSPORINE-A; PULMONARY ASPERGILLOSIS; IMMUNOSUPPRESSION; POLYMORPHISMS; RAPAMYCIN; SURVIVAL; DISEASE; FK506; MICE	Background: Neutrophils are key effectors against the widely distributed mold Aspergillus fumigatus, which is a major threat for immunocompromised patients, including allogeneic hematopoietic stem cell transplant (HSCT) recipients. Yet little is known about neutrophil activity over time after cell transplantation, especially regarding A fumigatus. Objective: We aimed at assessing the activity of neutrophils on A fumigatus in allogeneic HSCT recipients at different posttransplantation time points. Methods: We performed a longitudinal study involving 37 patients undergoing HSCT, drawing blood samples at engraftment and at 2, 6, and 10 months after the HSCT. Posttransplantation neutrophil activity in the recipients was compared with that of the respective donors. Neutrophil/A fumigatus coculture, flow cytometry, and video microscopy were used to assess neutrophil inhibition of fungal growth, cell/fungus interactions, reactive oxygen species production, major surface molecule expression, and neutrophil extracellular trap (NET) formation. Results: The ability of neutrophils to interfere with Aspergillus species hyphal growth was impaired after HSCT. The administration of calcineurin inhibitors appeared to play an important role in this impairment. We also observed that post-HSCT neutrophils produced less NETs, which was correlated with increased fungal growth. Tapering immunosuppression led to the recuperation of inhibition capacity 10 months after HSCT. Conclusion: In HSCT recipients neutrophil-driven innate immunity to fungi is altered in the early posttransplantation period (between recovery from neutropenia and up to 6 months). This alteration is at least partly related to administration of calcineurin inhibitors and diminution of NETs production.	[Imbert, Sebastien; Gauthier, Lauraine; Mazier, Dominique; Fekkar, Arnaud] Grp Hosp La Pitie Salpetriere, AP HP, Serv Parasitol Mycol, Paris, France; [Bresler, Priscillia; Boissonnas, Alexandre; Leblond, Veronique; Mazier, Dominique; Nguyen, Stephanie; Fekkar, Arnaud] Univ Paris 04, Univ Paris 06, INSERM U1135, Ctr Immunol & Malad Infect CIMI Paris,CNRS ERL 82, Paris, France; [Souchet, Laetitia; Uzunov, Madalina; Leblond, Veronique; Nguyen, Stephanie] Grp Hosp La Pitie Salpetriere, AP HP, Serv Hematol, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite	Fekkar, A (corresponding author), Hop La Pitie Salpetriere, Lab Parasitol Mycol, Pavillon Laveran,Blvd Hop, F-75013 Paris, France.	arnaud.fekkar@aphp.fr	Fekkar, Arnaud/P-2803-2017; Boissonnas, Alexandre/A-2801-2016; Imbert, Sebastien/AAC-2492-2020	Boissonnas, Alexandre/0000-0002-7770-7210; Imbert, Sebastien/0000-0003-4187-0806	Agence de Biomedecine; Aviesan	Agence de Biomedecine; Aviesan	Supported by the Agence de Biomedecine and Aviesan.	Aramburu J, 1999, SCIENCE, V285, P2129, DOI 10.1126/science.285.5436.2129; BERENGUER J, 1995, AM J RESP CRIT CARE, V152, P1079, DOI 10.1164/ajrccm.152.3.7663787; Bianchi M, 2009, BLOOD, V114, P2619, DOI 10.1182/blood-2009-05-221606; Bochud PY, 2008, NEW ENGL J MED, V359, P1766, DOI 10.1056/NEJMoa0802629; Caroli A, 2000, AM J GASTROENTEROL, V95, P3016, DOI 10.1111/j.1572-0241.2000.03239.x; Choi SW, 2014, NAT REV CLIN ONCOL, V11, P536, DOI 10.1038/nrclinonc.2014.102; Cunha C, 2014, MYCOPATHOLOGIA, V178, P387, DOI 10.1007/s11046-014-9796-7; De Pauw B, 2008, CLIN INFECT DIS, V46, P1813, DOI 10.1086/588660; DUCKER TP, 1992, J LEUKOCYTE BIOL, V52, P11, DOI 10.1002/jlb.52.1.11; Garcia-Vidal C, 2008, CLIN INFECT DIS, V47, P1041, DOI 10.1086/591969; Greenblatt MB, 2010, J EXP MED, V207, P923, DOI 10.1084/jem.20092531; Gupta AK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097088; He H, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.533; High KP, 1997, J INFECT DIS, V175, P222, DOI 10.1093/infdis/175.1.222; Kolaczkowska E, 2013, NAT REV IMMUNOL, V13, P159, DOI 10.1038/nri3399; Leal SM, 2012, J CLIN INVEST, V122, P2482, DOI 10.1172/JCI63239; McCormick A, 2010, MICROBES INFECT, V12, P928, DOI 10.1016/j.micinf.2010.06.009; McInturff AM, 2012, BLOOD, V120, P3118, DOI 10.1182/blood-2012-01-405993; Nawada R, 1996, J CLIN MICROBIOL, V34, P1433, DOI 10.1128/JCM.34.6.1433-1439.1996; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; Pang KAP, 2012, J INFECTION, V64, P424, DOI 10.1016/j.jinf.2011.12.015; Papayannopoulos V, 2010, J CELL BIOL, V191, P677, DOI 10.1083/jcb.201006052; Philippe B, 2003, INFECT IMMUN, V71, P3034, DOI 10.1128/IAI.71.6.3034-3042.2003; Ramaprasad C, 2010, LEUKEMIA LYMPHOMA, V51, P756, DOI 10.3109/10428191003695678; ROILIDES E, 1994, ANTIMICROB AGENTS CH, V38, P2883, DOI 10.1128/AAC.38.12.2883; Sachewsky N, 2014, DIS MODEL MECH, V7, P953, DOI 10.1242/dmm.014480; Samaniego M, 2006, NAT CLIN PRACT NEPHR, V2, P688, DOI 10.1038/ncpneph0343; SCHAFFNER A, 1982, J CLIN INVEST, V69, P617, DOI 10.1172/JCI110489; SHIBASAKI F, 1995, J CELL BIOL, V131, P735, DOI 10.1083/jcb.131.3.735; Sieber M, 2009, CELL COMMUN SIGNAL, V7, DOI 10.1186/1478-811X-7-25; Stuehler C, 2015, J INFECT DIS, V212, P959, DOI 10.1093/infdis/jiv143; Tourneur E, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003152; Winston DJ, 2011, BIOL BLOOD MARROW TR, V17, P507, DOI 10.1016/j.bbmt.2010.04.017; Wojtowicz A, 2015, J INFECT DIS, V211, P1646, DOI 10.1093/infdis/jiu636	34	23	23	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2016	138	3					860	868		10.1016/j.jaci.2016.02.026	http://dx.doi.org/10.1016/j.jaci.2016.02.026			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DY9ZM	27132218	Bronze, Green Submitted			2022-12-18	WOS:000385496000022
J	Horak, F; Puri, KD; Steiner, BH; Holes, L; Xing, G; Zieglmayer, P; Zieglmayer, R; Lemell, P; Yu, A				Horak, Friedrich; Puri, Kamal D.; Steiner, Bart H.; Holes, Leanne; Xing, Guan; Zieglmayer, Petra; Zieglmayer, Rene; Lemell, Patrick; Yu, Albert			Randomized phase 1 study of the phosphatidylinositol 3-kinase delta inhibitor idelalisib in patients with allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Phosphatidylinositol 3-kinase; p110 delta; grass pollen; allergen challenge chamber; Vienna Challenge Chamber; idelalisib; GS-1101; CCL17; CCL22; allergic rhinitis	MACROPHAGE-DERIVED CHEMOKINE; ACTIVATION-REGULATED CHEMOKINE; VIENNA-CHALLENGE-CHAMBER; PHOSPHOINOSITIDE 3-KINASE; AIRWAY INFLAMMATION; ATOPIC-DERMATITIS; B-CELL; P110-DELTA; PLASMA; RESPONSES	Background: Phosphatidylinositol 3-kinase p110 delta isoform (PI3K p110 delta) activity is essential for mast cell activation, suggesting that inhibition of PI3K p110 delta might be useful in treating allergic diseases. Objective: We sought to determine the effect of the PI3K p110 delta-selective inhibitor idelalisib on allergic responses. Methods: This phase 1 randomized, double-blind, placebo-controlled, 2 -period crossover study was conducted with the Vienna Challenge Chamber. Grass pollen-induced allergic symptoms were documented during screening. Eligible subjects received idelalisib (100 mg twice daily) or placebo for 7 days, with allergen challenge on day 7. After a 2 -week washout period, subjects received the alternate treatment and repeated allergen challenge. Study measures included safety, nasal and nonnasal symptoms, nasal airflow, nasal secretions, basophil activation, and plasma cytokine levels. Results: Forty-one patients with allergic rhinitis received idelalisib/placebo (n = 21) or placebo/idelalisib (n = 20). Idelalisib treatment was well tolerated. Mean total nasal symptom scores were lower during the combined idelalisib treatment periods compared with placebo (treatment difference [idelalisib - placebo], -1.78; 95% CI, -2.53 to -1.03; P < .001). Statistically significant differences were also observed for the combined treatment periods for total symptom scores, nasal airflow, nasal secretion weight, and nasal congestion scores. The percentage of ex vivo activated basophils (CD63(+)/CCR3(+) cells; after stimulation with grass pollen) was substantially lower for idelalisib-treated compared with placebo-treated subjects. Plasma CCL17 and CCL22 levels were reduced after idelalisib treatment. Conclusion: Idelalisib treatment was well tolerated in patients with allergic rhinitis and appears to reduce allergic responses clinically and immunologically after an environmental allergen challenge.	[Horak, Friedrich; Zieglmayer, Petra; Zieglmayer, Rene; Lemell, Patrick] Vienna Challenge Chamber, Vienna, Austria; [Puri, Kamal D.; Steiner, Bart H.; Holes, Leanne; Xing, Guan; Yu, Albert] Gilead Sci, Seattle, WA USA	Gilead Sciences	Puri, KD (corresponding author), Celgene Corp, 10300 Campus Point Dr,Suite 100, San Diego, CA 92121 USA.	kpuri@Celgene.com	Zieglmayer, Petra/AAG-1006-2020		Gilead Sciences	Gilead Sciences(Gilead Sciences)	We thank Taylor Technology (Princeton, NJ), PRA International (Assen, The Netherlands), and PSI (St Petersburg, Russia) for their assistance conducting this study and Dr David Gossage for critical review of the manuscript. Medical writing assistance was provided by Kate Loughney and Timothy J. DiChiara under the sponsorship of Gilead Sciences.	Ali K, 2004, NATURE, V431, P1007, DOI 10.1038/nature02991; Ali K, 2008, J IMMUNOL, V180, P2538, DOI 10.4049/jimmunol.180.4.2538; Bochner BS, 2003, J ALLERGY CLIN IMMUN, V112, P930, DOI 10.1016/j.jaci.2003.08.012; Bonecchi R, 1998, J EXP MED, V187, P129, DOI 10.1084/jem.187.1.129; Broide DH, 2001, J ALLERGY CLIN IMMUN, V108, pS65, DOI 10.1067/mai.2001.116436; Eberlein B, 2010, CLIN EXP ALLERGY, V40, P411, DOI 10.1111/j.1365-2222.2009.03426.x; Fujisawa T, 2002, J ALLERGY CLIN IMMUN, V110, P139, DOI 10.1067/mai.2002.126079; Furman RR, 2014, NEW ENGL J MED, V370, P997, DOI 10.1056/NEJMoa1315226; Gopal AK, 2014, NEW ENGL J MED, V370, P1008, DOI 10.1056/NEJMoa1314583; Horak F, 2006, CURR MED RES OPIN, V22, P151, DOI 10.1185/030079906X80305; Horak F, 2010, INFLAMM RES, V59, P391, DOI 10.1007/s00011-009-0117-4; Howarth PH, 2000, ALLERGY, V55, P7, DOI 10.1034/j.1398-9995.2000.00802.x; Imai T, 1997, J BIOL CHEM, V272, P15036, DOI 10.1074/jbc.272.23.15036; Imai T, 1999, INT IMMUNOL, V11, P81, DOI 10.1093/intimm/11.1.81; KOCH GG, 1972, BIOMETRICS, V28, P577, DOI 10.2307/2556170; Lannutti BJ, 2011, BLOOD, V117, P591, DOI 10.1182/blood-2010-03-275305; Lee KS, 2006, FASEB J, V20, P455, DOI 10.1096/fj.05-5045com; Leung TF, 2004, CLIN EXP ALLERGY, V34, P786, DOI 10.1111/j.1365-2222.2004.1951.x; Leung TF, 2003, PEDIATR ALLERGY IMMU, V14, P296, DOI 10.1034/j.1399-3038.2003.00052.x; Leung TF, 2003, EUR RESPIR J, V21, P616, DOI 10.1183/09031936.03.00083303; Leung TF, 2002, J ALLERGY CLIN IMMUN, V110, P404, DOI 10.1067/mai.2002.126378; Nashed BF, 2007, EUR J IMMUNOL, V37, P416, DOI 10.1002/eji.200636401; Okkenhaug K, 2003, NAT REV IMMUNOL, V3, P317, DOI 10.1038/nri1056; Okkenhaug K, 2002, SCIENCE, V297, P1031; Okkenhaug K, 2006, J IMMUNOL, V177, P5122, DOI 10.4049/jimmunol.177.8.5122; Romagnani S, 2002, MOL IMMUNOL, V38, P881, DOI 10.1016/S0161-5890(02)00013-5; Rommel C, 2007, NAT REV IMMUNOL, V7, P191, DOI 10.1038/nri2036; Somoza JR, 2015, J BIOL CHEM, V290, P8439, DOI 10.1074/jbc.M114.634683; Soond DR, 2010, BLOOD, V115, P2203, DOI 10.1182/blood-2009-07-232330; Stuebner P, 2006, ANN ALLERG ASTHMA IM, V96, P37, DOI 10.1016/S1081-1206(10)61038-1; Sugawara N, 2002, ALLERGY, V57, P180, DOI 10.1034/j.1398-9995.2002.1n3503.x; Uguccioni M, 1997, J CLIN INVEST, V100, P1137, DOI 10.1172/JCI119624; Wolanczyk-Medrala A, 2009, J INVEST ALLERG CLIN, V19, P465; Yanai M, 2007, CLIN IMMUNOL, V125, P291, DOI 10.1016/j.clim.2007.08.002; Zieglmayer P, 2008, CURR MED RES OPIN, V24, P1833, DOI 10.1185/03007990802155792	35	23	23	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2016	137	6					1733	1741		10.1016/j.jaci.2015.12.1313	http://dx.doi.org/10.1016/j.jaci.2015.12.1313			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DO1GT	26915677	Bronze			2022-12-18	WOS:000377527200013
J	Kucuk, ZY; Bleesing, JJ; Marsh, R; Zhang, KJ; Davies, S; Filipovich, AH				Kucuk, Zeynep Yesim; Bleesing, Jack J.; Marsh, Rebecca; Zhang, Kejian; Davies, Stella; Filipovich, Alexandra H.			A challenging undertaking: Stem cell transplantation for immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							BONE-MARROW-TRANSPLANTATION; IMMUNODYSREGULATION		[Kucuk, Zeynep Yesim; Bleesing, Jack J.; Marsh, Rebecca; Davies, Stella; Filipovich, Alexandra H.] Cincinnati Childrens Hosp Med Ctr, Div Bone Marrow Transplantat & Immune deficiency, Cincinnati, OH 45229 USA; [Zhang, Kejian] Cincinnati Childrens Hosp Med Ctr, Div Human Genet, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center	Kucuk, ZY (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Bone Marrow Transplantat & Immune deficiency, Cincinnati, OH 45229 USA.	zeynep.kucuk@cchmc.org	zhang, ke/AAH-8217-2019					Barzaghi F, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00211; Baud O, 2001, NEW ENGL J MED, V344, P1758, DOI 10.1056/NEJM200106073442304; Bennett CL, 2001, NAT GENET, V27, P20, DOI 10.1038/83713; Burroughs LM, 2014, BIOL BLOOD MARROW TR, V20, P1996, DOI 10.1016/j.bbmt.2014.08.020; Burroughs LM, 2010, J ALLERGY CLIN IMMUN, V126, P1000, DOI 10.1016/j.jaci.2010.05.021; Marsh RA, 2010, BLOOD, V116, P5824, DOI 10.1182/blood-2010-04-282392; Nademi Z, 2014, BONE MARROW TRANSPL, V49, P310, DOI 10.1038/bmt.2013.181; Rao A, 2007, BLOOD, V109, P383, DOI 10.1182/blood-2006-05-025072; Wildin RS, 2002, J MED GENET, V39, P537, DOI 10.1136/jmg.39.8.537	9	23	26	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2016	137	3					953	955		10.1016/j.jaci.2015.09.030	http://dx.doi.org/10.1016/j.jaci.2015.09.030			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DG2LB	26559324	Bronze			2022-12-18	WOS:000371897500048
J	Parry, DA; Holmes, TD; Gamper, N; El-Sayed, W; Hettiarachchi, NT; Ahmed, M; Cook, GP; Logan, CV; Johnson, CA; Joss, S; Peers, C; Prescott, K; Savic, S; Inglehearn, CF; Mighell, AJ				Parry, David A.; Holmes, Tim D.; Gamper, Nikita; El-Sayed, Walid; Hettiarachchi, Nishani T.; Ahmed, Mushtaq; Cook, Graham P.; Logan, Clare V.; Johnson, Colin A.; Joss, Shelagh; Peers, Chris; Prescott, Katrina; Savic, Sinisa; Inglehearn, Chris F.; Mighell, Alan J.			A homozygous STIM1 mutation impairs store-operated calcium entry and natural killer cell effector function without clinical immunodeficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							SENSOR; ACTIVATION; IMMUNITY		[Parry, David A.; Johnson, Colin A.; Inglehearn, Chris F.; Mighell, Alan J.] Univ Leeds, St Jamess Univ Hosp, Sch Med, Sect Ophthalmol & Neurosci, Leeds, W Yorkshire, England; [Parry, David A.; Logan, Clare V.] Univ Leeds, St Jamess Univ Hosp, Sch Med, Genet Sect, Leeds, W Yorkshire, England; [Holmes, Tim D.; Cook, Graham P.] Univ Leeds, St Jamess Univ Hosp, Sch Med, Leeds Inst Canc & Pathol, Leeds, W Yorkshire, England; [Holmes, Tim D.] Karolinska Univ Hosp, Ctr Infect Med, Stockholm, Sweden; [Gamper, Nikita] Univ Leeds, Sch Biomed Sci, Leeds, W Yorkshire, England; [Mighell, Alan J.] Univ Leeds, Sch Dent, Leeds, W Yorkshire, England; [El-Sayed, Walid] Gulf Med Univ, Dept Oral Biol, Dent Collage, Ajman, U Arab Emirates; [Hettiarachchi, Nishani T.; Peers, Chris] Univ Leeds, Sch Med, Div Cardiovasc & Diabet Res, Leeds LS2 9JT, W Yorkshire, England; [Ahmed, Mushtaq; Prescott, Katrina] Leeds Teaching Hosp NHS Trust, Chapel Allerton Hosp, Clin Genet, Leeds, W Yorkshire, England; [El-Sayed, Walid; Joss, Shelagh] So Gen Hosp, Clin Genet, Glasgow G51 4TF, Lanark, Scotland; [Savic, Sinisa] Univ Leeds, St Jamess Univ Hosp, Leeds Teaching Hosp NHS Trust, Dept Clin Immunol & Allergy, Leeds, W Yorkshire, England	Saint James's University Hospital; University of Leeds; Saint James's University Hospital; University of Leeds; Saint James's University Hospital; University of Leeds; Karolinska Institutet; Karolinska University Hospital; University of Leeds; University of Leeds; University of Leeds; Chapel Allerton Hospital; University of Leeds; University of Glasgow; Saint James's University Hospital; University of Leeds	Mighell, AJ (corresponding author), Univ Leeds, St Jamess Univ Hosp, Sch Med, Sect Ophthalmol & Neurosci, Leeds, W Yorkshire, England.; Mighell, AJ (corresponding author), Univ Leeds, Sch Dent, Leeds, W Yorkshire, England.	a.j.mighell@leeds.ac.uk	Savic, Sinisa/Q-6217-2019; Inglehearn, Chris/GYD-9783-2022; Ahmed, Mushtaq/GSN-9818-2022	Savic, Sinisa/0000-0001-7910-0554; Johnson, Colin/0000-0002-2979-8234	The Sir Jules Thorn Charitable Trust [09JTA] Funding Source: researchfish	The Sir Jules Thorn Charitable Trust		Bohm J, 2013, AM J HUM GENET, V92, P271, DOI 10.1016/j.ajhg.2012.12.007; Fuchs S, 2012, J IMMUNOL, V188, P1523, DOI 10.4049/jimmunol.1102507; Liou J, 2005, CURR BIOL, V15, P1235, DOI 10.1016/j.cub.2005.05.055; Picard C, 2009, NEW ENGL J MED, V360, P1971, DOI 10.1056/NEJMoa0900082; Schaballie H, 2015, J ALLERGY CLIN IMMUN, V136, P816, DOI 10.1016/j.jaci.2015.03.009; Shaw PJ, 2014, J CLIN INVEST, V124, P4549, DOI 10.1172/JCI76602; Zhang H, 2014, BLOOD, V123, P2238, DOI 10.1182/blood-2012-08-450403	7	23	23	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2016	137	3					955	957		10.1016/j.jaci.2015.08.051	http://dx.doi.org/10.1016/j.jaci.2015.08.051			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DG2LB		hybrid, Green Published			2022-12-18	WOS:000371897500049
J	Silverberg, JI				Silverberg, Jonathan I.			Association between childhood eczema and headaches: An analysis of 19 US population-based studies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; eczema; headaches; atopy; sleep disturbance; sleepiness; insomnia; fatigue	QUALITY-OF-LIFE; ATOPIC-DERMATITIS; CHILDREN; SLEEP; MIGRAINE; COMORBIDITY; PREVALENCE; HEALTH; ADOLESCENTS; ASTHMA	Background: Atopic dermatitis (or eczema) is a chronic inflammatory disorder associated with sleep disturbances and quality-of-life impairment. Sleep disturbances have been shown to cause headaches in childhood. However, an association between eczema and headaches is not well established. Objectives: We sought to determine whether childhood eczema is associated with increased headaches and whether such association is related to fatigue or sleep disturbance. Methods: We analyzed data from 401,002 children and adolescents in 19 US population-based cross-sectional studies from the National Survey of Children's Health 2003/2004 and 2007/2008 and the National Health Interview Survey 1997-2013. Results: In multivariate models controlling for age, sex, race/ethnicity, household income, highest level of education in the family, insurance coverage, number of persons in the household, birthplace in the United States, ever history of asthma, hay fever, and food allergy, eczema was found to be associated with headaches in 14 of 19 studies. In a pooled analysis of all 19 studies, children with eczema compared with those without eczema had a significantly higher prevalence (10.7% [95% CI, 10.3% to 11.0%] vs 5.4% [95% CI, 5.3% to 5.5%]) and odds (1.52 [95% CI, 1.45-1.59]) of headaches. Mild (1.79 [95% CI, 1.07-2.98]) and severe (2.72 [95% CI, 1.33-5.57]) eczema were associated with significantly higher odds of headaches. In particular, eczema associated with atopy, fatigue, excessive daytime sleepiness, insomnia, and only 0 to 3 nights of sufficient sleep had even higher odds of headache than eczema alone. Conclusions: Eczema is associated with increased headaches in childhood, particularly in patients with severe disease accompanied by atopy, fatigue, and sleep disturbances.	[Silverberg, Jonathan I.] Northwestern Univ, Feinberg Sch Med, Dept Dermatol, Suite 1600,676 N St Clair St, Chicago, IL 60611 USA; [Silverberg, Jonathan I.] Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, Chicago, IL 60611 USA; [Silverberg, Jonathan I.] Northwestern Univ, Feinberg Sch Med, Dept Med Social Sci, Chicago, IL 60611 USA; [Silverberg, Jonathan I.] Northwestern Med Multidisciplinary Eczema Ctr, Chicago, IL USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine	Silverberg, JI (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Dermatol, Suite 1600,676 N St Clair St, Chicago, IL 60611 USA.	JonathanISilverberg@Gmail.com	silverberg, jonathan/ABH-2765-2021	silverberg, jonathan/0000-0003-3686-7805	Agency for Healthcare Research and Quality [K12HS023011]; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [K12HS023011] Funding Source: NIH RePORTER	Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)	This publication was made possible with support from the Agency for Healthcare Research and Quality (grant no. K12HS023011).	Barloese M, 2015, CEPHALALGIA; Beattie PE, 2006, BRIT J DERMATOL, V155, P1249, DOI 10.1111/j.1365-2133.2006.07525.x; Beikert FC, 2014, ARCH DERMATOL RES, V306, P279, DOI 10.1007/s00403-013-1402-1; Bellini B, 2013, J HEADACHE PAIN, V14, DOI 10.1186/1129-2377-14-79; Bender BG, 2003, J ALLERGY CLIN IMMUN, V111, P598, DOI 10.1067/mai.2003.174; Bockowski L, 2010, PHARMACOL REP, V62, P287; Davey G, 2002, BRIT J GEN PRACT, V52, P723; Evers S, 2014, CEPHALALGIA, V34, P723, DOI 10.1177/0333102414543504; Fivenson David, 2002, J Manag Care Pharm, V8, P333; Flohr C, 2009, BRIT J DERMATOL, V161, P846, DOI 10.1111/j.1365-2133.2009.09261.x; Garcia-Aymerich J, 2015, ALLERGY, V70, P973, DOI 10.1111/all.12640; Garg N, 2015, JAMA DERMATOL, V151, P33, DOI 10.1001/jamadermatol.2014.2098; Garg N, 2014, ANN ALLERG ASTHMA IM, V112, P525, DOI 10.1016/j.anai.2014.03.006; Gazerani P, 2003, SCAND J IMMUNOL, V57, P286, DOI 10.1046/j.1365-3083.2003.01216.x; HEATLEY RV, 1982, CLIN ALLERGY, V12, P145, DOI 10.1111/j.1365-2222.1982.tb01633.x; Holland PR, 2014, CEPHALALGIA, V34, P725, DOI 10.1177/0333102414541687; Hon KLE, 2008, CLIN EXP DERMATOL, V33, P705, DOI 10.1111/j.1365-2230.2008.02853.x; Kramer U, 1998, BRIT J DERMATOL, V139, P1040; Lateef TM, 2009, J CHILD NEUROL, V24, P536, DOI 10.1177/0883073808327831; Laughter D, 2000, J AM ACAD DERMATOL, V43, P649, DOI 10.1067/mjd.2000.107773; Lund N, 2014, CEPHALALGIA, V34, P833, DOI 10.1177/0333102414543332; Magin PJ, 2011, INT J DERMATOL, V50, P1486, DOI 10.1111/j.1365-4632.2011.04883.x; MORTIMER MJ, 1993, HEADACHE, V33, P427, DOI 10.1111/j.1526-4610.1993.hed3308427.x; Munno I, 2001, HEADACHE, V41, P764, DOI 10.1046/j.1526-4610.2001.01140.x; Powers SW, 2003, PEDIATRICS, V112, pE1, DOI 10.1542/peds.112.1.e1; Rains JC, 2015, CURR NEUROL NEUROSCI, V15, DOI 10.1007/s11910-014-0520-2; Ricci G, 2007, PEDIATR ALLERGY IMMU, V18, P245, DOI 10.1111/j.1399-3038.2006.00502.x; Rocha PAS, 2014, HEADACHE, V54, P1194, DOI 10.1111/head.12394; Rosario D, 2014, J CLIN DIAGN RES, V8, P57, DOI 10.7860/JCDR/2014/7516.4007; Shaw TE, 2011, J INVEST DERMATOL, V131, P67, DOI 10.1038/jid.2010.251; Silverberg JI, 2015, JAMA DERMATOL, V151, P401, DOI 10.1001/jamadermatol.2014.3432; Silverberg JI, 2015, J ALLERGY CLIN IMMUN, V135, P721, DOI 10.1016/j.jaci.2014.11.023; Silverberg JI, 2015, J INVEST DERMATOL, V135, P56, DOI 10.1038/jid.2014.325; Silverberg JI, 2013, PEDIAT ALLERG IMM-UK, V24, P476, DOI 10.1111/pai.12095; Skalland Benjamin J, 2012, Vital Health Stat 2, P1; Stark CD, 2015, CURR PAIN HEADACHE R, V19, DOI 10.1007/s11916-014-0468-6; SUSITAIVAL P, 1995, SCAND J WORK ENV HEA, V21, P30, DOI 10.5271/sjweh.5; Yaghmaie P, 2013, J ALLERGY CLIN IMMUN, V131, P428, DOI 10.1016/j.jaci.2012.10.041	38	23	24	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2016	137	2					492	+		10.1016/j.jaci.2015.07.020	http://dx.doi.org/10.1016/j.jaci.2015.07.020			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DC5BN	26329510	Green Accepted, Bronze			2022-12-18	WOS:000369235500018
J	Wegienka, G; Havstad, S; Zoratti, EM; Kim, H; Ownby, DR; Johnson, CC				Wegienka, Ganesa; Havstad, Suzanne; Zoratti, Edward M.; Kim, Haejin; Ownby, Dennis R.; Johnson, Christine Cole			Association between vitamin D levels and allergy-related outcomes vary by race and other factors	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Vitamin D; allergy; eczema; asthma; IgE; racial differences	SERUM 25-HYDROXYVITAMIN D; ATOPIC-DERMATITIS; CIRCULATING VITAMIN-D-3; MID-PREGNANCY; CHILDHOOD; ASTHMA; CHILDREN; DISEASE; RISK; MICROBIOTA	Background: Allergy-related studies that include biological measurements of vitamin D preceding well-measured outcomes are needed. Objective: We sought to examine the associations between early-life vitamin D levels and the development of allergy-related outcomes in the racially diverse Wayne County Health, Environment, Allergy, and Asthma Longitudinal Study birth cohort. Methods: 25-Hydroxyvitamin D (25[OH] D) levels were measured in stored blood samples from pregnancy, cord blood, and age 2 years. Logistic regression models were used to calculate odds ratios (ORs) with 95% CIs for a 5 ng/mL increase in 25(OH) D levels for the following outcomes at age 2 years: eczema, skin prick tests (SPTs), increased allergen-specific IgE level (>= 0.35 IU/mL), and doctor's diagnosis of asthma (3-6 years). Results: Prenatal 25(OH) D levels were inversely associated with eczema (OR, 0.85; 95% CI, 0.75-0.96). The association was stronger in white children (white children: OR, 0.79; 95% CI, 0.57-1.09; black children: OR, 0.96; 95% CI, 0.82-1.12), although this was not statistically significant. Cord blood 25(OH) D levels were inversely associated with having 1 or more positive SPT responses and aeroallergen sensitization. Both associations were statistically significant in white children (positive SPT response: OR, 0.50; 95% CI, 0.32-0.80; >= 1 aeroallergen sensitization: OR, 0.50; 95% CI, 0.28-0.92) in contrast with black children (positive SPT response: OR, 0.88; 95% CI, 0.68-1.14; >= 1 aeroallergen sensitization: OR, 0.85; 95% CI, 0.65-1.11). 25(OH) D levels measured concurrently with outcome assessment were inversely associated with aeroallergen sensitization (OR, 0.79; 95% CI, 0.66-0.96) only among black children (white children: OR, 1.21; 95% CI, 0.87-1.69). Conclusions: Prenatal and cord blood 25(OH) D levels were associated with some allergy-related outcomes, with a general pattern indicating that children with higher 25(OH) D levels tend to have fewer allergy-related outcomes.	[Wegienka, Ganesa; Havstad, Suzanne; Johnson, Christine Cole] Henry Ford Hosp, Dept Publ Hlth Sci, Detroit, MI 48202 USA; [Zoratti, Edward M.; Kim, Haejin] Henry Ford Hosp, Dept Internal Med, Div Allergy, Detroit, MI 48202 USA; [Ownby, Dennis R.] Georgia Regents Univ, Dept Pediat, Augusta, GA USA	Henry Ford Health System; Henry Ford Hospital; Henry Ford Health System; Henry Ford Hospital; University System of Georgia; Augusta University	Wegienka, G (corresponding author), 1 Ford Pl,3E, Detroit, MI 48202 USA.	gwegien1@hfhs.org			National Institutes of Health [HL113010, AI051598, AI089473]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL113010] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI051598, R01AI050681, P01AI089473, R01AI110450] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the National Institutes of Health (HL113010, AI051598, and AI089473).	Aichbhaumik N, 2008, CLIN EXP ALLERGY, V38, P1787, DOI 10.1111/j.1365-2222.2008.03079.x; Ananthakrishnan AN, 2012, GASTROENTEROLOGY, V142, P482, DOI 10.1053/j.gastro.2011.11.040; Anto JM, 2012, J ALLERGY CLIN IMMUN, V129, P943, DOI 10.1016/j.jaci.2012.01.047; Bacharier LB, 2014, J ALLERGY CLIN IMMUN, V133, P154, DOI 10.1016/j.jaci.2013.07.034; Baiz N, 2014, J ALLERGY CLIN IMMUN, V133, P147, DOI 10.1016/j.jaci.2013.05.017; Binkley N, 2008, J CLIN ENDOCR METAB, V93, P1804, DOI 10.1210/jc.2007-2340; Binkley N, 2010, CLIN CHIM ACTA, V411, P1976, DOI 10.1016/j.cca.2010.08.018; Binkley N, 2009, J CLIN DENSITOM, V12, P417, DOI 10.1016/j.jocd.2009.06.001; Binkley Neil, 2008, Curr Osteoporos Rep, V6, P95, DOI 10.1007/s11914-008-0017-5; Camargo CA, 2007, AM J CLIN NUTR, V85, P788, DOI 10.1093/ajcn/85.3.788; Camargo CA, 2011, PEDIATRICS, V127, pE180, DOI 10.1542/peds.2010-0442; Cantorna MT, 2014, EXP BIOL MED, V239, P1524, DOI 10.1177/1535370214523890; Gale CR, 2008, EUR J CLIN NUTR, V62, P68, DOI 10.1038/sj.ejcn.1602680; Gentschew L, 2012, MOL NUTR FOOD RES, V56, P524, DOI 10.1002/mnfr.201100630; Gergen PJ, 2013, AM J CLIN NUTR, V97, P1228, DOI 10.3945/ajcn.112.046961; Heaney RP, 2008, AM J CLIN NUTR, V87, P1738, DOI 10.1093/ajcn/87.6.1738; Heimbeck I, 2013, ALLERGY, V68, P906, DOI 10.1111/all.12167; Hollis BW, 2007, J STEROID BIOCHEM, V103, P631, DOI 10.1016/j.jsbmb.2006.12.066; Jones AP, 2012, PEDIATRICS, V130, pE1128, DOI 10.1542/peds.2012-1172; Lensmeyer GL, 2006, CLIN CHEM, V52, P1120, DOI 10.1373/clinchem.2005.064956; Ly NP, 2011, J ALLERGY CLIN IMMUN, V127, P1087, DOI 10.1016/j.jaci.2011.02.015; Magnus MC, 2013, PAEDIATR PERINAT EP, V27, P532, DOI 10.1111/ppe.12080; Maslova E, 2013, BMC PREGNANCY CHILDB, V13, DOI 10.1186/1471-2393-13-199; Noh S, 2014, J ALLERGY CLIN IMMUN, V133, P1767, DOI 10.1016/j.jaci.2014.02.038; Pike KC, 2012, THORAX, V67, P950, DOI 10.1136/thoraxjnl-2012-201888; Prescott SL, 2013, J ALLERGY CLIN IMMUN, V131, P23, DOI 10.1016/j.jaci.2012.11.019; Rothers J, 2011, J ALLERGY CLIN IMMUN, V128, pe1, DOI DOI 10.1016/J.JACI.2011.07.015; Rothers J, 2011, J ALLERGY CLIN IMMUN, V128, P1093, DOI 10.1016/j.jaci.2011.07.015; Rothman K, 2010, MODERN EPIDEMIOLOGY; Searing DA, 2010, IMMUNOL ALLERGY CLIN, V30, P397, DOI 10.1016/j.iac.2010.05.005; van der Mei IAF, 2007, J NEUROL, V254, P581, DOI 10.1007/s00415-006-0315-8; Wang SS, 2014, PEDIAT ALLERG IMM-UK, V25, P30, DOI 10.1111/pai.12167; Wegienka G, 2012, CLIN EXP ALLERGY, V42, P909, DOI 10.1111/j.1365-2222.2011.03946.x; Wegienka G, 2012, J ALLERGY CLIN IMMUN, V130, P657, DOI 10.1016/j.jaci.2012.06.024; Weisse K, 2013, ALLERGY, V68, P220, DOI 10.1111/all.12081; Willers SM, 2007, THORAX, V62, P773, DOI 10.1136/thx.2006.074187; Wills AK, 2013, CLIN EXP ALLERGY, V43, P1180, DOI 10.1111/cea.12172; Yang CL, 2011, BMC PULM MED, V11, DOI 10.1186/1471-2466-11-52	38	23	28	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2015	136	5					1309	+		10.1016/j.jaci.2015.04.017	http://dx.doi.org/10.1016/j.jaci.2015.04.017			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CW1YE	26078105	Green Accepted			2022-12-18	WOS:000364787200021
J	Chou, J; Badran, YR; Yee, CSK; Bainter, W; Ohsumi, TK; Al-Hammadi, S; Pai, SY; Feske, S; Geha, RS				Chou, Janet; Badran, Yousef R.; Yee, Christina S. K.; Bainter, Wayne; Ohsumi, Toshiro K.; Al-Hammadi, Suleiman; Pai, Sung-Yun; Feske, Stefan; Geha, Raif S.			A novel mutation in ORAI1 presenting with combined immunodeficiency and residual T-cell function	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							LYMPHOCYTE FUNCTION		[Chou, Janet; Badran, Yousef R.; Yee, Christina S. K.; Bainter, Wayne; Geha, Raif S.] Childrens Hosp, Div Immunol, Boston, MA 02115 USA; [Chou, Janet; Badran, Yousef R.; Yee, Christina S. K.; Bainter, Wayne; Geha, Raif S.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; [Ohsumi, Toshiro K.] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA; [Ohsumi, Toshiro K.] Harvard Univ, Sch Med, Boston, MA USA; [Al-Hammadi, Suleiman] United Arab Emirates Univ, Dept Pediat, Al Ain, U Arab Emirates; [Pai, Sung-Yun] Boston Childrens Hosp, Div Hematol Oncol, Boston, MA USA; [Pai, Sung-Yun] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; [Feske, Stefan] NYU, Dept Pathol, Langone Med Ctr, New York, NY 10016 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; United Arab Emirates University; Harvard University; Boston Children's Hospital; Harvard University; Dana-Farber Cancer Institute; New York University; NYU Langone Medical Center	Chou, J (corresponding author), Childrens Hosp, Div Immunol, 300 Longwood Ave, Boston, MA 02115 USA.	raif.geha@childrens.harvard.edu	Pai, Sung-Yun/AAH-7762-2019; Feske, stefan/ABB-3554-2021	Pai, Sung-Yun/0000-0002-0158-8147; Feske, stefan/0000-0001-5431-8178	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI076210, T32AI007512, R01AI097302, R03AI094017] Funding Source: NIH RePORTER; NIAID NIH HHS [R03 AI094017, AI-094017, P01 AI076210, T32 AI007512, R01 AI097302] Funding Source: Medline; PHS HHS [UO1AIO67854] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Chou J, 2015, J ALLERGY CLIN IMMUN, V136, P794, DOI 10.1016/j.jaci.2014.12.1940; Feske S, 2012, NAT REV IMMUNOL, V12, P532, DOI 10.1038/nri3233; Feske S, 2010, CLIN IMMUNOL, V135, P169, DOI 10.1016/j.clim.2010.01.011; Gwack Y, 2008, MOL CELL BIOL, V28, P5209, DOI 10.1128/MCB.00360-08; Gwack Y, 2007, J BIOL CHEM, V282, P16232, DOI 10.1074/jbc.M609630200; JOLLIFF CR, 1982, CLIN CHEM, V28, P126; Maul-Pavicic A, 2011, P NATL ACAD SCI USA, V108, P3324, DOI 10.1073/pnas.1013285108; McCarl CA, 2009, J ALLERGY CLIN IMMUN, V124, P1311, DOI 10.1016/j.jaci.2009.10.007; Morbach H, 2010, CLIN EXP IMMUNOL, V162, P271, DOI 10.1111/j.1365-2249.2010.04206.x; Shaw PJ, 2014, J CLIN INVEST, V124, P4549, DOI 10.1172/JCI76602; Shaw PJ, 2012, J PHYSIOL-LONDON, V590, P4157, DOI 10.1113/jphysiol.2012.233221; Shearer WT, 2003, J ALLERGY CLIN IMMUN, V112, P973, DOI 10.1016/j.jaci.2003.07.003	12	23	24	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2015	136	2					479	+		10.1016/j.jaci.2015.03.050	http://dx.doi.org/10.1016/j.jaci.2015.03.050			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CO2RS	26070885	Green Accepted			2022-12-18	WOS:000359004900031
J	Chawes, BLK; Stockholm, J; Bonnelykke, K; Brix, S; Bisgaard, H				Chawes, Bo L. K.; Stockholm, Jakob; Bonnelykke, Klaus; Brix, Susanne; Bisgaard, Hans			Neonates with reduced neonatal lung function have systemic low-grade inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; children; high-sensitivity C-reactive protein; proinflammatory cytokines; spirometry	C-REACTIVE PROTEIN; CHILDHOOD ASTHMA; CYSTIC-FIBROSIS; YOUNG INFANTS; BIRTH COHORT; TNF-ALPHA; SENSITIVITY; AIRWAY; ASSOCIATION; POPULATION	Background: Children and adults with asthma and impaired lung function have been reported to have low-grade systemic inflammation, but it is unknown whether this inflammation starts before symptoms and in particular whether low-grade inflammation is present in asymptomatic neonates with reduced lung function. Objective: We sought to investigate the possible association between neonatal lung function and biomarkers of systemic inflammation. Methods: Plasma levels of high-sensitivity C-reactive protein (hs-CRP), IL-1b, IL-6, TNF-alpha, and CXCL8 (IL-8) were measured at age 6 months in 300 children of the Copenhagen Prospective Study on Asthma in Childhood(2000) birth cohort who had completed neonatal lung function testing at age 4 weeks. Associations between neonatal lung function indices and inflammatory biomarkers were investigated by conventional statistics and unsupervised principal component analysis. Results: The neonatal forced expiratory volume at 0.5 seconds was inversely associated with hs-CRP (beta-coefficient, -0.12; 95% CI, -0.21 to -0.04; P < .01) and IL-6 (beta-coefficient, -0.10; 95% CI, -0.18 to -0.01; P = .03) levels. The multivariate principal component analysis approach, including hs-CRP, IL-6, TNF-alpha, and CXCL8, confirmed a uniform upregulated inflammatory profile in children with reduced forced expiratory volume at 0.5 seconds (P = .02). Adjusting for body mass index at birth, maternal smoking, older children in the home, neonatal bacterial airway colonization, infections 14 days before, and asthmatic symptoms, as well as virus-induced wheezing, at any time before biomarker assessment at age 6 months did not affect the associations. Conclusion: Diminished neonatal lung function is associated with upregulated systemic inflammatory markers, such as hs-CRP.	[Chawes, Bo L. K.; Stockholm, Jakob; Bonnelykke, Klaus; Bisgaard, Hans] Univ Copenhagen, Copenhagen Prospect Studies Asthma Childhood Hlth, DK-2820 Gentofte, Denmark; [Chawes, Bo L. K.; Stockholm, Jakob; Bonnelykke, Klaus; Bisgaard, Hans] Univ Copenhagen, Gentofte Hosp, Danish Pediat Asthma Ctr, DK-2820 Gentofte, Denmark; [Brix, Susanne] Tech Univ Denmark, Dept Syst Biol, Ctr Biol Sequence Anal, Copenhagen, Denmark; [Stockholm, Jakob] Naestved Hosp, Dept Pediat, Naestved, Denmark	University of Copenhagen; University of Copenhagen; Herlev & Gentofte Hospital; Technical University of Denmark; Naestved Hospital	Bisgaard, H (corresponding author), Univ Copenhagen, Copenhagen Prospect Studies Asthma Childhood Hlth, DK-2820 Gentofte, Denmark.	bisgaard@copsac.com	Pedersen, Susanne Brix/B-3484-2009; Bisgaard, Hans/N-4761-2016	Pedersen, Susanne Brix/0000-0001-8951-6705; Bisgaard, Hans/0000-0003-4131-7592; Chawes, Bo/0000-0001-6846-6243; Stokholm, Jakob/0000-0003-4989-9769; Bonnelykke, Klaus/0000-0003-2003-1018	Lundbeck Foundation [R16-A1694]; Danish State Budget [0903516]; Danish Strategic Research Council [0603-00280B]; Danish Medical Research Council [10-082884, 271-08-0815]; Lundbeck Foundation [R16-2007-1694] Funding Source: researchfish	Lundbeck Foundation(Lundbeckfonden); Danish State Budget; Danish Strategic Research Council(Danske Strategiske Forskningsrad (DSF)); Danish Medical Research Council(Danish Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Lundbeck Foundation(Lundbeckfonden)	COPSAC is funded by private and public research funds listed on www.copsac.com. The Lundbeck Foundation (R16-A1694), the Danish State Budget (0903516), the Danish Strategic Research Council (0603-00280B), and the Danish Medical Research Council (10-082884 & 271-08-0815) provided the core support for COPSAC research center. The funding agencies did not have any role in design and conduct of the study; collection, management, and interpretation of the data; or preparation, review, or approval of the manuscript.	[Anonymous], 2005, AM J RESP CRIT CARE, V172, P1463; Bisgaard H, 2004, ANN ALLERG ASTHMA IM, V93, P381, DOI 10.1016/S1081-1206(10)61398-1; Bisgaard H, 2006, NEW ENGL J MED, V354, P1998, DOI 10.1056/NEJMoa054692; Bisgaard H, 2007, NEW ENGL J MED, V357, P1487, DOI 10.1056/NEJMoa052632; Bisgaard H, 2012, AM J RESP CRIT CARE, V185, P1183, DOI 10.1164/rccm.201110-1922OC; Bisgaard H, 2011, J ALLERGY CLIN IMMUN, V127, P1155, DOI 10.1016/j.jaci.2011.02.007; Bisgaard H, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c4978; Bisgaard H, 2009, J ALLERGY CLIN IMMUN, V123, P651, DOI 10.1016/j.jaci.2008.11.036; Bisgaard H, 2009, AM J RESP CRIT CARE, V179, P179, DOI 10.1164/rccm.200809-1436OC; Chawes BLK, 2010, AM J RESP CRIT CARE, V182, P138, DOI 10.1164/rccm.200909-1377OC; de Jager W, 2009, BMC IMMUNOL, V10, DOI 10.1186/1471-2172-10-52; Deraz TE, 2012, PEDIATR PULM, V47, P220, DOI 10.1002/ppul.21539; Doganci A, 2005, CLIN REV ALLERG IMMU, V28, P257, DOI 10.1385/CRIAI:28:3:257; Fogarty AW, 2007, THORAX, V62, P515, DOI 10.1136/thx.2006.066969; Folsgaard NV, 2012, AM J RESP CRIT CARE, V185, P275, DOI 10.1164/rccm.201108-1471OC; Hardyman MA, 2013, J ALLERGY CLIN IMMUN, V132, P665, DOI 10.1016/j.jaci.2013.03.005; Hung MJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077655; Jackman RP, 2011, CLIN VACCINE IMMUNOL, V18, P318, DOI 10.1128/CVI.00465-10; Kohidai L, 1998, CYTOKINE, V10, P481, DOI 10.1006/cyto.1997.0328; Kony S, 2004, THORAX, V59, P892, DOI 10.1136/thx.2003.015768; Loland L, 2006, CHEST, V129, P669, DOI 10.1378/chest.129.3.669; Loland L, 2008, CHEST, V133, P115, DOI 10.1378/chest.07-1328; McDade TW, 2012, P NATL ACAD SCI USA, V109, P17281, DOI 10.1073/pnas.1202244109; Melbye H, 2004, BRIT J GEN PRACT, V54, P653; Nappo A, 2013, J AM HEART ASSOC, V2, DOI 10.1161/JAHA.113.000101; Navratil M, 2009, J ASTHMA, V46, P822, DOI 10.3109/02770900903159718; Pepys MB, 2003, J CLIN INVEST, V111, P1805, DOI 10.1172/JCI200318921; Pillarisetti N, 2011, AM J RESP CRIT CARE, V184, P75, DOI 10.1164/rccm.201011-1892OC; Ranganathan SC, 2004, AM J RESP CRIT CARE, V169, P928, DOI 10.1164/rccm.200309-1344OC; Rifai N, 1999, CLIN CHEM, V45, P2136; Sabatine MS, 2007, CIRCULATION, V115, P1528, DOI 10.1161/CIRCULATIONAHA.106.649939; Shaaban R, 2006, RESP MED, V100, P2112, DOI 10.1016/j.rmed.2006.03.027; Soferman R, 2008, PEDIATR INT, V50, P12, DOI 10.1111/j.1442-200X.2007.02517.x; Takemura M, 2006, EUR RESPIR J, V27, P908, DOI 10.1183/09031936.06.00114405; Thomsen M, 2013, JAMA-J AM MED ASSOC, V309, P2353, DOI 10.1001/jama.2013.5732; Voleti B, 2005, J IMMUNOL, V175, P3386, DOI 10.4049/jimmunol.175.5.3386	36	23	23	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2015	135	6					1450	U90		10.1016/j.jaci.2014.11.020	http://dx.doi.org/10.1016/j.jaci.2014.11.020			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CK0ZC	25579483	Green Published, Bronze, Green Submitted			2022-12-18	WOS:000355933400006
J	Kracker, S; Di Virgilio, M; Schwartzentruber, J; Cuenin, C; Forveille, M; Deau, MC; McBride, KM; Majewski, J; Gazumyan, A; Seneviratne, S; Grimbacher, B; Kutukculer, N; Herceg, Z; Cavazzana, M; Jabado, N; Nussenzweig, MC; Fischer, A; Durandy, A				Kracker, Sven; Di Virgilio, Michela; Schwartzentruber, Jeremy; Cuenin, Cyrille; Forveille, Monique; Deau, Marie-Celine; McBride, Kevin M.; Majewski, Jacek; Gazumyan, Anna; Seneviratne, Suranjith; Grimbacher, Bodo; Kutukculer, Necil; Herceg, Zdenko; Cavazzana, Marina; Jabado, Nada; Nussenzweig, Michel C.; Fischer, Alain; Durandy, Anne			An inherited immunoglobulin class-switch recombination deficiency associated with a defect in the INO80 chromatin remodeling complex	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chromatin remodeling; class-switch recombination defect; CSR synapse; cohesin	ACTIVATION-INDUCED DEAMINASE; STRAND BREAK REPAIR; GENE-EXPRESSION; HUMAN-CELLS; HYPER-IGM; DNA; TRANSCRIPTION; COHESIN; AID; YY1	Background: Immunoglobulin class-switch recombination defects (CSR-D) are rare primary immunodeficiencies characterized by impaired production of switched immunoglobulin isotypes and normal or elevated IgM levels. They are caused by impaired T:B cooperation or intrinsic B cell defects. However, many immunoglobulin CSR-Ds are still undefined at the molecular level. Objective: This study's objective was to delineate new causes of immunoglobulin CSR-Ds and thus gain further insights into the process of immunoglobulin class-switch recombination (CSR). Methods: Exome sequencing in 2 immunoglobulin CSR-D patients identified variations in the INO80 gene. Functional experiments were performed to assess the function of INO80 on immunoglobulin CSR. Results: We identified recessive, nonsynonymous coding variations in the INO80 gene in 2 patients affected by defective immunoglobulin CSR. Expression of wild-type INO80 in patients' fibroblastic cells corrected their hypersensitivity to high doses of gamma-irradiation. In murine CH12-F3 cells, the INO80 complex accumulates at Sa and Em regions of the IgH locus, and downregulation of INO80 as well as its partners Reptin and Pontin impaired CSR. In addition, Reptin and Pontin were shown to interact with activation-induced cytidine deaminase. Finally, an abnormal separation of sister chromatids was observed upon INO80 downregulation in CH12-F3 cells, pinpointing its role in cohesin activity. Conclusion: INO80 deficiency appears to be associated with defective immunoglobulin CSR. We propose that the INO80 complex modulates cohesin function that may be required during immunoglobulin switch region synapsis.	[Kracker, Sven; Deau, Marie-Celine; Cavazzana, Marina; Fischer, Alain; Durandy, Anne] INSERM, UMR 1163, Human Lymphohematopoiesis Lab, Paris, France; [Kracker, Sven; Deau, Marie-Celine; Cavazzana, Marina; Fischer, Alain; Durandy, Anne] Paris Descartes Sorbonne Paris Cite Univ, Imagine Inst, Paris, France; [Di Virgilio, Michela; McBride, Kevin M.; Gazumyan, Anna; Nussenzweig, Michel C.] Rockefeller Univ, Howard Hughes Med Inst, Lab Mol Immunol, New York, NY 10021 USA; [Schwartzentruber, Jeremy; Majewski, Jacek] McGill Univ, Dept Human Genet, Montreal, PQ, Canada; [Schwartzentruber, Jeremy; Majewski, Jacek] Genome Quebec Innovat Ctr, Montreal, PQ, Canada; [Cuenin, Cyrille; Herceg, Zdenko] Int Agcy Res Canc, F-69008 Lyon, France; [Forveille, Monique] Hop Necker Enfants Malad, Ctr Primary Immunodeficiencies, F-75015 Paris, France; [Seneviratne, Suranjith; Grimbacher, Bodo] Royal Free London NHS Fdn Tust, UCL Inst Immun & Transplantat, London, England; [Grimbacher, Bodo] Univ Med Ctr Freiburg, Ctr Chron Immunodeficiency, D-79106 Freiburg, Germany; [Grimbacher, Bodo] Univ Freiburg, D-79106 Freiburg, Germany; [Kutukculer, Necil] Ege Univ, Fac Med, Dept Pediat Immunol, TR-35100 Izmir, Turkey; [Cavazzana, Marina] Hop Necker Enfants Malad, AP HP, Dept Biotherapy, F-75015 Paris, France; [Cavazzana, Marina] AP HP, INSERM, Clin Invest Ctr CIC Biotherapy GHU Ouest, Paris, France; [Jabado, Nada] McGill Univ, Dept Pediat, Montreal, PQ H3A 2T5, Canada; [Jabado, Nada] McGill Univ, Ctr Hlth, Montreal, PQ, Canada; [Fischer, Alain; Durandy, Anne] Hop Necker Enfants Malad, Dept Immunol & Hematol, F-75015 Paris, France; [Fischer, Alain] Coll France, F-75231 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Howard Hughes Medical Institute; Rockefeller University; McGill University; World Health Organization; International Agency for Research on Cancer (IARC); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; University of London; University College London; Royal Free London NHS Foundation Trust; University of Freiburg; University of Freiburg; Ege University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; McGill University; McGill University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; College de France	Durandy, A (corresponding author), INSERM, U1163, Imagine Inst, 24 Blvd Montparnasse, F-75015 Paris, France.	anne.durandy@inserm.fr	Durandy, Anne/H-7475-2017; Di Virgilio, Michela/AAE-9298-2022; Nussenzweig, Michel/AAE-7292-2019; Jabado, Nada/AAN-4026-2020; Kracker, Sven/H-3681-2017	Durandy, Anne/0000-0001-7706-8466; Kracker, Sven/0000-0003-4543-8236; Cavazzana, Marina/0000-0002-0264-0891; DEAU, Marie-Celine/0000-0003-3954-0584; Schwartzentruber, Jeremy/0000-0002-6183-2092; Di Virgilio, Michela/0000-0001-5189-0793	National Institute of Health and Medical Research; le fonds de recherche clinique du Ministere de la Sante; European Union (EUROPAD) [201549]; European Union (ERC advanced grant PID-IMMUNE) [249816]; Association Contre Le Cancer; Fondation pour la Recherche Medicale [ING20130526624]; la Ligue Contre le Cancer (Comite de Paris); Agence Nationale de la Recherche [2010-CSRD]; French Agence Nationale de la Recherche as part of the Investments for the Future program [ANR-10-IAHU-01]; La Ligue National contre le Cancer (France); Fondation ARC, France; Institut National du Cancer (INCA), France; German Federal Ministry of Education and Research [BMBF 01 EO 0803]; Canadian Gene Cure Foundation and Finding of Rare Disease Genes (FORGE) Canada; National Institutes of Health [AI037526]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI037526, R01AI037526] Funding Source: NIH RePORTER	National Institute of Health and Medical Research; le fonds de recherche clinique du Ministere de la Sante; European Union (EUROPAD); European Union (ERC advanced grant PID-IMMUNE); Association Contre Le Cancer; Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); la Ligue Contre le Cancer (Comite de Paris); Agence Nationale de la Recherche(French National Research Agency (ANR)); French Agence Nationale de la Recherche as part of the Investments for the Future program(French National Research Agency (ANR)); La Ligue National contre le Cancer (France); Fondation ARC, France; Institut National du Cancer (INCA), France(Institut National du Cancer (INCA) France); German Federal Ministry of Education and Research(Federal Ministry of Education & Research (BMBF)); Canadian Gene Cure Foundation and Finding of Rare Disease Genes (FORGE) Canada; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This study was supported by the National Institute of Health and Medical Research, le fonds de recherche clinique du Ministere de la Sante, the European Union's Seventh Research and Technological Development Framework Programme (EUROPAD contract 201549 and ERC advanced grant PID-IMMUNE contract 249816), Association Contre Le Cancer, the Fondation pour la Recherche Medicale (grant number: ING20130526624), la Ligue Contre le Cancer (Comite de Paris) and the Agence Nationale de la Recherche (grant: 2010-CSRD) and a government grant managed by the French Agence Nationale de la Recherche as part of the Investments for the Future program (ANR-10-IAHU-01). This work in the Epigenetics group at the International Agency for Research on Cancer was supported by the La Ligue National contre le Cancer (France), Fondation ARC, France, and Institut National du Cancer (INCA), France. This study was also funded by the German Federal Ministry of Education and Research (grant: BMBF 01 EO 0803) and by the Canadian Gene Cure Foundation and Finding of Rare Disease Genes (FORGE) Canada. This work was supported in part by National Institutes of Health grant AI037526 to M.C.N. M.C.N. is a Howard Hughes Medical Institute investigator. S.K. is a Centre National de la Recherche Scientifique researcher.	Basu U, 2011, CELL, V144, P353, DOI 10.1016/j.cell.2011.01.001; Cai Y, 2007, NAT STRUCT MOL BIOL, V14, P872, DOI 10.1038/nsmb1276; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Chatterjee S, 2011, J BIOL CHEM, V286, P29303, DOI 10.1074/jbc.M111.243543; Chaudhuri J, 2003, NATURE, V422, P726, DOI 10.1038/nature01574; Conaway RC, 2009, TRENDS BIOCHEM SCI, V34, P71, DOI 10.1016/j.tibs.2008.10.010; Dorsett D, 2012, CURR BIOL, V22, pR240, DOI 10.1016/j.cub.2012.02.046; Downs JA, 2007, NATURE, V447, P951, DOI 10.1038/nature05980; Durandy Anne, 2007, Adv Immunol, V94, P275, DOI 10.1016/S0065-2776(06)94009-7; Enervald E, 2013, J EXP MED, V210, P2503, DOI 10.1084/jem.20130168; Franco S, 2006, MOL CELL, V21, P201, DOI 10.1016/j.molcel.2006.01.005; Gospodinov A, 2011, MOL CELL BIOL, V31, P4735, DOI 10.1128/MCB.06182-11; Green MR, 2011, P NATL ACAD SCI USA, V108, P2873, DOI 10.1073/pnas.1019537108; Imai K, 2003, NAT IMMUNOL, V4, P1023, DOI 10.1038/ni974; Jiang YJ, 2010, P NATL ACAD SCI USA, V107, P17274, DOI 10.1073/pnas.1008388107; Kagey MH, 2010, NATURE, V467, P430, DOI 10.1038/nature09380; KORTHAUER U, 1993, NATURE, V361, P539, DOI 10.1038/361539a0; Kracker S, 2010, P NATL ACAD SCI USA, V107, P22225, DOI 10.1073/pnas.1012591108; Kuang FL, 2009, P NATL ACAD SCI USA, V106, P5288, DOI 10.1073/pnas.0901368106; Li H, 2009, BIOINFORMATICS, V25, P2078, DOI 10.1093/bioinformatics/btp352; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Lusser A, 2003, BIOESSAYS, V25, P1192, DOI 10.1002/bies.10359; McBride KM, 2006, P NATL ACAD SCI USA, V103, P8798, DOI 10.1073/pnas.0603272103; McBride KM, 2004, J EXP MED, V199, P1235, DOI 10.1084/jem.20040373; Min JN, 2013, CELL RES, V23, P1396, DOI 10.1038/cr.2013.113; Morrison AJ, 2009, NAT REV MOL CELL BIO, V10, P373, DOI 10.1038/nrm2693; Neumann FR, 2012, GENE DEV, V26, P369, DOI 10.1101/gad.176156.111; Ogiwara H, 2007, CELL CYCLE, V6, P1090, DOI 10.4161/cc.6.9.4130; Oka Y, 2011, BIOCHEM BIOPH RES CO, V411, P762, DOI 10.1016/j.bbrc.2011.07.021; Pan Q, 2002, EUR J IMMUNOL, V32, P1300, DOI 10.1002/1521-4141(200205)32:5<1300::AID-IMMU1300>3.0.CO;2-L; Pan-Hammarstrom Q, 2005, J EXP MED, V201, P189, DOI 10.1084/jem.20040772; Park EJ, 2010, BIOCHEM J, V431, P179, DOI 10.1042/BJ20100988; Pavri R, 2010, CELL, V143, P122, DOI 10.1016/j.cell.2010.09.017; Peron S, 2008, J EXP MED, V205, P2465, DOI 10.1084/jem.20080789; Ramachandran S, 2010, P NATL ACAD SCI USA, V107, P809, DOI 10.1073/pnas.0913790107; Revy P, 2000, CELL, V102, P565, DOI 10.1016/S0092-8674(00)00079-9; Sabouri S, 2014, P NATL ACAD SCI USA, V111, P2253, DOI 10.1073/pnas.1324057111; Schotta G, 2008, GENE DEV, V22, P2048, DOI 10.1101/gad.476008; Seitan VC, 2011, NATURE, V476, P467, DOI 10.1038/nature10312; Shen XT, 2000, NATURE, V406, P541, DOI 10.1038/35020123; Stanlie A, 2010, P NATL ACAD SCI USA, V107, P22190, DOI 10.1073/pnas.1016923108; Stewart GS, 2009, CELL, V136, P420, DOI 10.1016/j.cell.2008.12.042; Ta VT, 2003, NAT IMMUNOL, V4, P843, DOI 10.1038/ni964; Thomas-Claudepierre AS, 2013, J EXP MED, V210, P2495, DOI 10.1084/jem.20130166; Venteicher AS, 2008, CELL, V132, P945, DOI 10.1016/j.cell.2008.01.019; Vuong BQ, 2009, NAT IMMUNOL, V10, P420, DOI 10.1038/ni.1708; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603; Wuerffe R, 2007, IMMUNITY, V27, P711, DOI 10.1016/j.immuni.2007.09.007; Zaprazna K, 2012, MOL CELL BIOL, V32, P1542, DOI 10.1128/MCB.05989-11	49	23	24	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2015	135	4					998	+		10.1016/j.jaci.2014.08.030	http://dx.doi.org/10.1016/j.jaci.2014.08.030			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CF0MQ	25312759	Green Accepted, Green Published, hybrid			2022-12-18	WOS:000352238600023
J	Roca, A; Afolabi, MO; Saidu, Y; Kampmann, B				Roca, Anna; Afolabi, Muhammed O.; Saidu, Yauba; Kampmann, Beate			Ebola: A holistic approach is required to achieve effective management and control	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Ebola virus disease; viral hemorrhagic fever; containment; holistic; West Africa	HEMORRHAGIC-FEVER; VIRUS DISEASE; TRANSMISSION; INFECTION; IDENTIFICATION; PATHOGENESIS; FAVIPIRAVIR; EMERGENCY; RESPONSES; DYNAMICS	The current Ebola outbreak in West Africa has already caused substantial mortality and dire human and economic consequences. It continues to represent an alarming public health threat in the region and beyond and jeopardizes the provision of health care and other services in the affected countries. The scale of the epidemic has accelerated research efforts for diagnostics, treatment, and prevention galvanized through increased availability of funding. Our knowledge relating to the virus, disease pathogenesis, risk factors, dynamics of transmission, and epidemic control is increasing, and sociocultural factors have emerged as critical determinants for the success and failure of control efforts. However, there is a long way to go. In this review we summarize the current knowledge, examine the sociocultural context in West Africa, and outline priority areas for future research.	[Roca, Anna; Afolabi, Muhammed O.; Saidu, Yauba; Kampmann, Beate] MRC, Med Res Unit, Fajara, Gambia; [Kampmann, Beate] Univ London Imperial Coll Sci Technol & Med, London SW7 2AZ, England	University of London; London School of Hygiene & Tropical Medicine; Imperial College London	Kampmann, B (corresponding author), Med Res Unit, Vaccinol Theme, Atlantic Rd, Fajara, Gambia.	bkampmann@mrc.gm		Afolabi, Muhammed/0000-0002-9967-6419; Kampmann, Beate/0000-0002-6546-4709	Medical Research Council Unit Core; Wellcome Trust; Bill & Melinda Gates Foundation; European Respiratory Society; European & Developing Countries Clinical Trial Partnership; MRC [MC_EX_MR/K011944/1, MC_UP_A900_1122] Funding Source: UKRI; Medical Research Council [MC_EX_MR/K011944/1, MC_UP_A900_1122] Funding Source: researchfish	Medical Research Council Unit Core(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome TrustEuropean Commission); Bill & Melinda Gates Foundation(Bill & Melinda Gates FoundationCGIAR); European Respiratory Society; European & Developing Countries Clinical Trial Partnership; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	B. Kampmann has received research support from the Medical Research Council Unit Core, the Wellcome Trust, and the Bill & Melinda Gates Foundation and has received payment for development of educational presentations from the European Respiratory Society. A. Roca has received travel support from the World Health Organization. M. Afolabi has received research support from the European & Developing Countries Clinical Trial Partnership. Y. Saidu declares no relevant conflicts of interest.	Adebamowo C, 2014, LANCET, V384, P1423, DOI 10.1016/S0140-6736(14)61734-7; [Anonymous], 1978, Bull World Health Organ, V56, P247; Ascenzi P, 2008, MOL ASPECTS MED, V29, P151, DOI 10.1016/j.mam.2007.09.005; Aylward B, 2014, NEW ENGL J MED, V371, P1481, DOI 10.1056/NEJMoa1411100; Bah EI, 2015, NEW ENGL J MED, V372, P40, DOI 10.1056/NEJMoa1411249; Baize S, 2002, CLIN EXP IMMUNOL, V128, P163, DOI 10.1046/j.1365-2249.2002.01800.x; Baize S, 2014, NEW ENGL J MED, V371, P1418, DOI 10.1056/NEJMoa1404505; Bharat TAM, 2012, P NATL ACAD SCI USA, V109, P4275, DOI 10.1073/pnas.1120453109; Bishop BM, 2015, ANN PHARMACOTHER, V49, P196, DOI 10.1177/1060028014561227; Bornholdt ZA, 2013, CELL, V154, P763, DOI 10.1016/j.cell.2013.07.015; Bray M., EPIDEMIOLOGY PATHOGE; Breman JG, 2014, NEW ENGL J MED, V371, P1663, DOI 10.1056/NEJMp1410540; Briand S, 2014, NEW ENGL J MED, V371, P1180, DOI 10.1056/NEJMp1409858; Brown C. A., 2006, BMC MED RES METHODOL, V6, P54, DOI [DOI 10.1186/1471-2288-6-54, 10.1186/1471--2288-6---54, DOI 10.1186/1471--2288-6---54]; Burke J, 1978, B WORLD HEALTH ORGAN, V56, P271; Burki TK, 2011, LANCET, V378, P389, DOI 10.1016/S0140-6736(11)61194-X; Camacho A, 2014, EPIDEMICS-NETH, V9, P70, DOI 10.1016/j.epidem.2014.09.003; Centers for Disease Control and Prevention, TRANSM EB EB VIR DIS; Chan M, 2014, NEW ENGL J MED, V371, P1183, DOI 10.1056/NEJMp1409859; Chowell G, 2014, BMC MED, V12, DOI 10.1186/s12916-014-0196-0; Clark DV, 2012, VIRUSES-BASEL, V4, P1668, DOI 10.3390/v4091668; Dowell SF, 1999, J INFECT DIS, V179, pS87, DOI 10.1086/514284; Edwards SJL, 2013, AM J BIOETHICS, V13, P3, DOI 10.1080/15265161.2013.813597; Farrar JJ, 2014, NEW ENGL J MED, V371, P1545, DOI 10.1056/NEJMe1411471; Fauci AS, 2014, NEW ENGL J MED, V371, P1084, DOI 10.1056/NEJMp1409494; Feldmann H, 2011, LANCET, V377, P849, DOI 10.1016/S0140-6736(10)60667-8; FISHERHOCH SP, 1985, J INFECT DIS, V152, P887, DOI 10.1093/infdis/152.5.887; Food and Agricultural Organisation, BATS BUSHM IMPL GLOB; Furuta Y, 2013, ANTIVIR RES, V100, P446, DOI 10.1016/j.antiviral.2013.09.015; Geisbert TW, 2000, LAB INVEST, V80, P171, DOI 10.1038/labinvest.3780021; Geisbert TW, 2003, AM J PATHOL, V163, P2347, DOI 10.1016/S0002-9440(10)63591-2; Gire SK, 2014, SCIENCE, V345, P1369, DOI 10.1126/science.1259657; Gonzalez JP, 2000, MICROBES INFECT, V2, P39, DOI 10.1016/S1286-4579(00)00287-2; Gostin LO, 2014, LANCET, V384, pE49, DOI 10.1016/S0140-6736(14)61345-3; Groseth A, 2007, TRENDS MICROBIOL, V15, P408, DOI 10.1016/j.tim.2007.08.001; Heffernan RT, 2005, J INFECT DIS, V191, P964, DOI 10.1086/427994; Hewlett BS, 2003, EMERG INFECT DIS, V9, P1242; Hussey MA, 2007, CONTEMP CLIN TRIALS, V28, P182, DOI 10.1016/j.cct.2006.05.007; Kanapathipillai R, 2014, NEW ENGL J MED, V371, P2249, DOI 10.1056/NEJMp1412166; Kinsman J, 2012, GLOBALIZATION HEALTH, V8, DOI 10.1186/1744-8603-8-15; Kortepeter MG, 2011, J INFECT DIS, V204, pS810, DOI 10.1093/infdis/jir299; Kucharski AJ, 2014, LANCET, V384, P1260, DOI 10.1016/S0140-6736(14)61706-2; Ledgerwood JE, 2017, NEW ENGL J MED, V376, P928, DOI [10.1056/NEJMoa1410863, 10.1056/nejmoa1410863]; Lefebvre A, 2014, MED MALADIES INFECT, V44, P412, DOI 10.1016/j.medmal.2014.08.005; Legrand J, 2007, EPIDEMIOL INFECT, V135, P610, DOI 10.1017/S0950268806007217; Leroy EM, 2000, LANCET, V355, P2210, DOI 10.1016/S0140-6736(00)02405-3; Leroy EM, 2005, NATURE, V438, P575, DOI 10.1038/438575a; Leroy EM, 2009, VECTOR-BORNE ZOONOT, V9, P723, DOI 10.1089/vbz.2008.0167; Maganga GD, 2014, NEW ENGL J MED, V371, P2083, DOI 10.1056/NEJMoa1411099; Modrof J, 2001, VIROLOGY, V287, P171, DOI 10.1006/viro.2001.1027; Nanbo A, 2013, SCI REP-UK, V3, DOI 10.1038/srep01206; Noda T, 2006, PLOS PATHOG, V2, P864, DOI 10.1371/journal.ppat.0020099; Nossiter A, FEAR EBOLA BREEDS TE; Oestereich L, 2014, ANTIVIR RES, V105, P17, DOI 10.1016/j.antiviral.2014.02.014; Omaswa F, LANCET GLOBAL HLTH; Painter W, 2012, ANTIMICROB AGENTS CH, V56, P2726, DOI 10.1128/AAC.05983-11; Pandey A, 2014, SCIENCE, V346, P991, DOI 10.1126/science.1260612; Prewitt KC., WHY LIBERIANS RAIDED; Reith C, 2013, NEW ENGL J MED, V369, P1061, DOI 10.1056/NEJMsb1300760; Rid A, 2014, LANCET, V384, P1896, DOI 10.1016/S0140-6736(14)61315-5; Saijo M, 2006, CLIN VACCINE IMMUNOL, V13, P444, DOI 10.1128/CVI.13.4.444-451.2006; Sanchez A, 2004, J VIROL, V78, P10370, DOI 10.1128/JVI.78.19.10370-10377.2004; SANCHEZ A, 1987, VIROLOGY, V157, P414, DOI 10.1016/0042-6822(87)90283-2; Sanchez A, 2007, FIELDS VIROLOGY, V1, P1409; Sanchez A, 2007, J INFECT DIS, V196, pS329, DOI 10.1086/520588; Schieffelin JS, 2014, NEW ENGL J MED, V371, P2092, DOI 10.1056/NEJMoa1411680; Schopper D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000115; Schulte-Herbruggen B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072807; Shaw D, 2014, LANCET, V384, P1667, DOI 10.1016/S0140-6736(14)61735-9; Skolnik R, 2008, GLOBAL HLTH, V101, P120; Sobarzo A, 2013, J INFECT DIS, V208, P299, DOI 10.1093/infdis/jit162; Takada A, 2001, TRENDS MICROBIOL, V9, P506, DOI 10.1016/S0966-842X(01)02201-6; The Rockefeller Foundation, LESS PREV EB OUTBR I; Towner JS, 2004, J VIROL, V78, P4330, DOI 10.1128/JVI.78.8.4330-4341.2004; Villinger F, 1999, J INFECT DIS, V179, pS188, DOI 10.1086/514283; WHO, WHAT DO WE KNOW TRAM; Wolf T, 2015, LANCET, V385, P1428, DOI 10.1016/S0140-6736(14)62384-9; World Health Organisation, UNPR NUM MED STAFF I; World Health Organization, 2007, EV BUS STRENGTH HLTH	79	23	24	0	43	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2015	135	4					856	867		10.1016/j.jaci.2015.02.015	http://dx.doi.org/10.1016/j.jaci.2015.02.015			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CF0MQ	25843598	Green Published, Green Accepted, hybrid			2022-12-18	WOS:000352238600002
J	Deshane, JS; Redden, DT; Zeng, M; Spell, ML; Zmijewski, JW; Anderson, JT; Deshane, RJ; Gaggar, A; Siegal, GP; Abraham, E; Dransfield, MT; Chaplin, DD				Deshane, Jessy S.; Redden, David T.; Zeng, Meiqin; Spell, Marion L.; Zmijewski, Jaroslaw W.; Anderson, John T.; Deshane, Rohit J.; Gaggar, Amit; Siegal, Gene P.; Abraham, Edward; Dransfield, Mark T.; Chaplin, David D.			Subsets of airway myeloid-derived regulatory cells distinguish mild asthma from chronic obstructive pulmonary disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Myeloid cell; macrophage; nitric oxide; superoxide regulatory T cell	SUPPRESSOR-CELLS; NITRIC-OXIDE; NITRATIVE STRESS; INFLAMMATION; ARGINASE; POPULATION; MECHANISMS; BALANCE	Background: Subsets of myeloid-derived regulatory cells (MDRCs), which are phenotypically similar to the myeloid-derived suppressor cells found in patients with cancer, have recently been appreciated as critical regulators of airway inflammation in mouse models of asthma. Objective: We test the hypothesis that subsets of airway MDRCs contribute differentially to the inflammatory milieu in human asthma and chronic obstructive pulmonary disease (COPD). Methods: We used bronchoalveolar lavage to identify and characterize human airway MDRCs from 10 healthy subjects, 9 patients with mild asthma, and 8 patients with COPD, none of whom were treated with inhaled or systemic corticosteroids. We defined subsets of airway MDRCs using flow cytometry, the molecular mediators they produce, and their abilities to regulate proliferation of polyclonally activated autologous T lymphocytes. Results: We found substantial differences in the functional potential of MDRC subsets in healthy subjects, patients with asthma, and patients with COPD, with these differences regulated by the nitrosative and oxidative free radicals and cytokines they produced. Nitric oxide-producing MDRCs suppressed and superoxide-producing MDRCs enhanced proliferation of polyclonally activated autologous CD4 T cells. HLA-DR(+)CD11(+)CD11c(+)CD163(-) superoxide-producing MDRCs, which stimulated proliferation of autologous T cells, comprised a high fraction of MDRCs in the airways of patients with mild asthma or COPD but not those of healthy control subjects. CD11b(+)CD14(+)CD16(-) HLA-DR- nitric oxide-producing MDRCs, which suppressed T-cell proliferation, were present in high numbers in airways of patients with mild asthma but not patients with COPD or healthy control subjects. Conclusion: Subsets of airway MDRCs conclusively discriminate patients with mild asthma, patients with COPD, and healthy subjects from each other. The distinctive activities of these MDRCs in patients with asthma or COPD might provide novel targets for new therapeutics for these common disorders.	[Deshane, Jessy S.; Spell, Marion L.; Zmijewski, Jaroslaw W.; Anderson, John T.; Gaggar, Amit; Abraham, Edward; Dransfield, Mark T.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA; [Deshane, Jessy S.; Zeng, Meiqin; Deshane, Rohit J.; Chaplin, David D.] Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA; [Redden, David T.] Univ Alabama Birmingham, Dept Biostat, Birmingham, AL 35294 USA; [Siegal, Gene P.] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA; [Gaggar, Amit; Siegal, Gene P.] Univ Alabama Birmingham, Dept Cell Dev & Integrat Biol, Birmingham, AL 35294 USA; [Siegal, Gene P.] Univ Alabama Birmingham, Dept Surg, Birmingham, AL 35294 USA; [Deshane, Jessy S.; Zmijewski, Jaroslaw W.; Abraham, Edward; Chaplin, David D.] Univ Alabama Birmingham, Ctr Free Radical Biol, Birmingham, AL 35294 USA; [Deshane, Jessy S.; Redden, David T.; Chaplin, David D.] Univ Alabama Birmingham, Comprehens Arthrit Musculoskeletal & Autoimmun Ct, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Deshane, JS (corresponding author), Univ Alabama Birmingham, Dept Med, Div Pulm Allergy & Crit Care Med, 1900 Univ Blvd, Birmingham, AL 35294 USA.	treena@uab.edu; dchaplin@uab.edu		Chaplin, David/0000-0002-1354-3069	Flight Attendant Medical Research Institute (Young Clinical Scientist faculty award) [YCSA2010]; Parker B. Francis Family Foundation; University of Alabama at Birmingham (UAB) Lung Health Center; UAB Center for Free Radical Biology; UAB Comprehensive Arthritis, Musculoskeletal, and Autoimmunity Center; National Institutes of Health [F32HL095341-01A1]; UAB Center for Clinical and Translational Science [UL1TR00165]; UAB Multidisciplinary Clinical Research Center [P60AR048095, P60AR064172];  [P01HL073907];  [P30AR046031];  [R01HL102371];  [R01HL107585];  [R01HL062221]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000165, UL1TR001417] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL102371, R01HL062221, P01HL073907, R01HL107585, F32HL095341] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007051] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR064172, P30AR046031, P60AR048095, P30AR048311] Funding Source: NIH RePORTER	Flight Attendant Medical Research Institute (Young Clinical Scientist faculty award); Parker B. Francis Family Foundation; University of Alabama at Birmingham (UAB) Lung Health Center; UAB Center for Free Radical Biology; UAB Comprehensive Arthritis, Musculoskeletal, and Autoimmunity Center; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); UAB Center for Clinical and Translational Science; UAB Multidisciplinary Clinical Research Center; ; ; ; ; ; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	Supported by grants from the Flight Attendant Medical Research Institute (Young Clinical Scientist faculty award [YCSA2010] to J.S.D.); a fellowship from the Parker B. Francis Family Foundation (to J.S.D.); grants from the University of Alabama at Birmingham (UAB) Lung Health Center, UAB Center for Free Radical Biology, and UAB Comprehensive Arthritis, Musculoskeletal, and Autoimmunity Center (to D.D.C.); and National Institutes of Health grants F32HL095341-01A1 (to J.S.D.); UL1TR00165 (UAB Center for Clinical and Translational Science; to D.D.C.), P60AR048095 and P60AR064172 (UAB Multidisciplinary Clinical Research Center; to D.T.R. and D.D.C.); P01HL073907 (to D.D.C.), P30AR046031 (to G.P.S.), R01HL102371 (to A.G.), R01HL107585 (to J.W.Z.), and R01HL062221 (to E.A.).	Anderson JT, 2011, FREE RADICAL BIO MED, V50, P1679, DOI 10.1016/j.freeradbiomed.2011.03.015; Andreadis AA, 2003, FREE RADICAL BIO MED, V35, P213, DOI 10.1016/S0891-5849(03)00278-8; Arora M, 2010, MUCOSAL IMMUNOL, V3, P578, DOI 10.1038/mi.2010.41; BOUSHEY HA, 1995, ENVIRON HEALTH PERSP, V103, P229, DOI 10.2307/3432378; CALHOUN WJ, 1992, AM REV RESPIR DIS, V145, P317, DOI 10.1164/ajrccm/145.2_Pt_1.317; Chioda M, 2011, CANCER METAST REV, V30, P27, DOI 10.1007/s10555-011-9268-1; Choi J, 2012, TUMOR BIOL, V33, P121, DOI 10.1007/s13277-011-0254-6; Deshane J, 2011, MUCOSAL IMMUNOL, V4, P503, DOI 10.1038/mi.2011.16; Dolcetti L, 2008, CANCER LETT, V267, P216, DOI 10.1016/j.canlet.2008.03.012; Durante W, 2007, CLIN EXP PHARMACOL P, V34, P906, DOI 10.1111/j.1440-1681.2007.04638.x; Feng Songqing, 2013, Nan Fang Yi Ke Da Xue Xue Bao, V33, P550; Fernandes PD, 2007, INT IMMUNOPHARMACOL, V7, P96, DOI 10.1016/j.intimp.2006.09.004; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; Ghosh S, 2011, BBA-GEN SUBJECTS, V1810, P1008, DOI 10.1016/j.bbagen.2011.06.009; Goedegebuure P, 2011, CURR CANCER DRUG TAR, V11, P734, DOI 10.2174/156800911796191024; Greten TF, 2011, INT IMMUNOPHARMACOL, V11, P802, DOI 10.1016/j.intimp.2011.01.003; Kasic T, 2011, EUR J IMMUNOL, V41, P1843, DOI 10.1002/eji.201040868; Kelly EAB, 2009, J IMMUNOL, V182, P1404, DOI 10.4049/jimmunol.182.3.1404; Maarsingh H, 2008, N-S ARCH PHARMACOL, V378, P171, DOI 10.1007/s00210-008-0286-7; Matangkasombut P, 2009, J ALLERGY CLIN IMMUN, V123, P1181, DOI 10.1016/j.jaci.2009.02.013; Nagaraj S, 2007, ADV EXP MED BIOL, V601, P213; Nagaraj Srinivas, 2009, Cancer Res, V69, P7503, DOI 10.1158/0008-5472.CAN-09-2152; Osoata GO, 2009, CHEST, V135, P1513, DOI 10.1378/chest.08-2105; Ostrand-Rosenberg S, 2009, J IMMUNOL, V182, P4499, DOI 10.4049/jimmunol.0802740; Petersen BC, 2012, NAT MED, V18, P751, DOI 10.1038/nm.2735; Puckett JL, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-47; Puckett JL, 2010, PEDIATR PULM, V45, P174, DOI 10.1002/ppul.21172; Raychaudhuri B, 2011, NEURO-ONCOLOGY, V13, P591, DOI 10.1093/neuonc/nor042; Ricciardolo FLM, 2006, EUR J PHARMACOL, V533, P240, DOI 10.1016/j.ejphar.2005.12.057; Rodriguez PC, 2008, IMMUNOL REV, V222, P180, DOI 10.1111/j.1600-065X.2008.00608.x; Rodriguez PC, 2005, J EXP MED, V202, P931, DOI 10.1084/jem.20050715; Short PM, 2011, LUNG, V189, P493, DOI 10.1007/s00408-011-9328-x; Solito S, 2011, BLOOD, V118, P2254, DOI 10.1182/blood-2010-12-325753; Srivastava MK, 2010, CANCER RES, V70, P68, DOI 10.1158/0008-5472.CAN-09-2587; Sugiura H, 2008, ANTIOXID REDOX SIGN, V10, P785, DOI 10.1089/ars.2007.1937; Sugiura H, 2011, NITRIC OXIDE-BIOL CH, V25, P138, DOI 10.1016/j.niox.2011.03.079; Sun J, 2010, ARCH BIOCHEM BIOPHYS, V494, P130, DOI 10.1016/j.abb.2009.11.019; Tadie JM, 2008, AM J PHYSIOL-LUNG C, V294, pL489, DOI 10.1152/ajplung.00109.2007; WILCOXON F, 1946, J ECON ENTOMOL, V39, P269, DOI 10.1093/jee/39.2.269; Youn JI, 2010, EUR J IMMUNOL, V40, P2969, DOI 10.1002/eji.201040895; Zeyrek D, 2008, ALLERGY ASTHMA PROC, V29, P468, DOI 10.2500/aap.2008.29.3154; Zhang YL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063775; Zweier JL, 2011, ANTIOXID REDOX SIGN, V14, P1769, DOI 10.1089/ars.2011.3904	43	23	24	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2015	135	2					413	U569		10.1016/j.jaci.2014.08.040	http://dx.doi.org/10.1016/j.jaci.2014.08.040			27	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CB1FL	25420684	Green Accepted			2022-12-18	WOS:000349372300013
J	Huffaker, M; Phipatanakul, W				Huffaker, Michelle; Phipatanakul, Wanda			Introducing an environmental assessment and intervention program in inner-city schools	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Environmental intervention; school-based environmental intervention; pediatric asthma	INDOOR AIR-QUALITY; MOUSE ALLERGEN EXPOSURE; FEL-D-I; COCKROACH ALLERGEN; PEDIATRIC ASTHMA; MOISTURE-DAMAGE; ENDOTOXIN EXPOSURE; RESPIRATORY HEALTH; AIRBORNE ALLERGENS; PUBLIC PLACES	Home-based environmental interventions have demonstrated clinical benefit for children with asthma. Although much is known about school-based exposures, few studies have comprehensively examined the role the school environment plays in asthma and how effectively changing the environment might reduce morbidity when adjusting for exposures in the home. This review summarizes the importance and common challenges of school-based environmental assessment and intervention studies linked to health effects. We focus on the key components of study development and the challenges and benefits to implementation.	[Huffaker, Michelle] Brigham & Womens Hosp, Boston, MA 02115 USA; [Huffaker, Michelle; Phipatanakul, Wanda] Boston Childrens Hosp, Boston, MA 02115 USA; [Huffaker, Michelle; Phipatanakul, Wanda] Harvard Univ, Sch Med, Cambridge, MA 02138 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Boston Children's Hospital; Harvard University	Phipatanakul, W (corresponding author), Boston Childrens Hosp, Div Immunol, 300 Longwood Ave,Fegan 6, Boston, MA 02115 USA.	wanda.phipatanakul@childrens.harvard.edu			National Institutes of Health [R01AI 073964, K24 AI 106822, U10HL098102]; Harvard Catalyst/the Harvard Clinical and Translational Science Center (NIH) [UL1 TR001102]; Harvard University; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001102] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U10HL098102] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI073964, K24AI106822] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Harvard Catalyst/the Harvard Clinical and Translational Science Center (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Harvard University; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the National Institutes of Health (grant nos. R01AI 073964, K24 AI 106822, and U10HL098102). This work was also conducted with support from Harvard Catalyst/the Harvard Clinical and Translational Science Center (NIH Award no. UL1 TR001102) and financial contributions from Harvard University and its affiliated academic health care centers. The content is solely the responsibility of the authors and does not necessarily represent the official views of Harvard Catalyst, Harvard University and its affiliated academic health care centers, the National Center for Research Resources, or the National Institutes of Health.	Abubucker S, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002358; Ahluwalia SK, 2013, J ALLERGY CLIN IMMUN, V132, P830, DOI 10.1016/j.jaci.2013.05.005; Amr S, 2003, ANN ALLERG ASTHMA IM, V90, P34, DOI 10.1016/S1081-1206(10)63611-3; Arbes SJ, 2005, ENVIRON HEALTH PERSP, V113, P665, DOI 10.1289/ehp.7648; Batterman S, 2013, AIR QUAL ATMOS HLTH, V6, P759, DOI 10.1007/s11869-013-0216-9; Baxi SN, 2013, PEDIAT ALLERG IMM-UK, V24, P697, DOI 10.1111/pai.12127; Baxi SN, 2011, ANN ALLERG ASTHMA IM, V107, P371, DOI 10.1016/j.anai.2011.08.007; Bernstein JA, 2005, INDOOR AIR, V15, P402, DOI 10.1111/j.1600-0668.2005.00379.x; Borras-Santos A, 2013, OCCUP ENVIRON MED, V70, P681, DOI 10.1136/oemed-2012-101286; Bryant-Stephens T, 2009, J ALLERGY CLIN IMMUN, V123, P1199, DOI 10.1016/j.jaci.2009.04.030; Burge HA, 2000, ENVIRON HEALTH PERSP, V108, P653, DOI 10.2307/3454401; Butz AM, 2011, ARCH PEDIAT ADOL MED, V165, P741, DOI 10.1001/archpediatrics.2011.111; CALL RS, 1992, J PEDIATR-US, V121, P862, DOI 10.1016/S0022-3476(05)80329-4; Chen CH, 2014, CHEST, V146, P123, DOI 10.1378/chest.13-2129; Chew GL, 2005, INDOOR AIR, V15, P228, DOI 10.1111/j.1600-0668.2005.00363.x; Crain EF, 2002, ENVIRON HEALTH PERSP, V110, P939, DOI 10.1289/ehp.02110939; Curtin-Brosnan J, 2010, J OCCUP ENVIRON HYG, V7, P726, DOI 10.1080/15459624.2010.530906; Custis NJ, 2003, CLIN EXP ALLERGY, V33, P986, DOI 10.1046/j.1365-2222.2003.01706.x; Custovic A, 1996, CLIN EXP ALLERGY, V26, P1246, DOI 10.1111/j.1365-2222.1996.tb00521.x; Delfino RJ, 2011, ENVIRON HEALTH-GLOB, V10, DOI 10.1186/1476-069X-10-69; Dotterud LK, 1997, CLIN EXP ALLERGY, V27, P252, DOI 10.1111/j.1365-2222.1997.tb00703.x; Du L, 2011, BUILD ENVIRON, V46, P2303, DOI 10.1016/j.buildenv.2011.05.012; DUNGY CI, 1986, ANN ALLERGY, V56, P218; DYBENDAL T, 1992, CLIN EXP ALLERGY, V22, P1100, DOI 10.1111/j.1365-2222.1992.tb00136.x; Eggleston PA, 1998, J ALLERGY CLIN IMMUN, V102, P563, DOI 10.1016/S0091-6749(98)70272-6; Gern James E, 2009, BMC Pulm Med, V9, P17, DOI 10.1186/1471-2466-9-17; Godwin C, 2007, INDOOR AIR, V17, P109, DOI 10.1111/j.1600-0668.2006.00459.x; Green BJ, 2003, J ALLERGY CLIN IMMUN, V111, P285, DOI 10.1067/mai.2003.57; Gruchalla RS, 2005, J ALLERGY CLIN IMMUN, V115, P478, DOI 10.1016/j.jaci.2004.12.006; Gruchalla RS, 2003, ANN ALLERG ASTHMA IM, V90, P491, DOI 10.1016/S1081-1206(10)61842-X; Jacobs JH, 2014, INDOOR AIR, V24, P148, DOI 10.1111/ina.12064; Jacobs J, 2014, OCCUP ENVIRON MED, V71, P704, DOI 10.1136/oemed-2014-102246; Jassal MS, 2013, J ASTHMA, V50, P672, DOI 10.3109/02770903.2013.792351; Joseph CLM, 1996, J PEDIATR-US, V129, P735, DOI 10.1016/S0022-3476(96)70158-0; Karlsson AS, 2004, J ALLERGY CLIN IMMUN, V113, P1172, DOI 10.1016/j.jaci.2003.12.590; Karlsson AS, 2004, ALLERGY, V59, P661, DOI 10.1111/j.1398-9995.2004.00519.x; Kattan M, 1997, PEDIATR PULM, V24, P253, DOI 10.1002/(SICI)1099-0496(199710)24:4<253::AID-PPUL4>3.0.CO;2-L; Knorr RS, 2004, ENVIRON HEALTH PERSP, V112, P1424, DOI 10.1289/ehp.7146; Lanphear BP, 2011, PEDIATRICS, V127, P93, DOI 10.1542/peds.2009-2312; Lee K, 1998, J AIR WASTE MANAGE, V48, P736, DOI 10.1080/10473289.1998.10463717; Lignell U, 2007, J ENVIRON MONITOR, V9, P225, DOI 10.1039/b615459j; Meklin T, 2005, INDOOR AIR, V15, P40, DOI 10.1111/j.1600-0668.2005.00357.x; Mendell MJ, 2005, INDOOR AIR, V15, P27, DOI 10.1111/j.1600-0668.2004.00320.x; Mitchell H, 1997, PEDIATR PULM, V24, P237; Moonie SA, 2006, J SCHOOL HEALTH, V76, P18, DOI 10.1111/j.1746-1561.2006.00062.x; Morgan WJ, 2004, NEW ENGL J MED, V351, P1068, DOI 10.1056/NEJMoa032097; Muilenberg ML, 2003, IMMUNOL ALLERGY CLIN, V23, P337, DOI 10.1016/S0889-8561(03)00030-4; MUNIR AKM, 1993, J ALLERGY CLIN IMMUN, V91, P1067, DOI 10.1016/0091-6749(93)90221-Z; Munir AKM, 1996, ALLERGY, V51, P36; Oeder S, 2012, INDOOR AIR, V22, P148, DOI 10.1111/j.1600-0668.2011.00743.x; Ownby DR, 2013, J ALLERGY CLIN IMMUN, V132, P836, DOI 10.1016/j.jaci.2013.06.046; Peitzsch M, 2012, J ENVIRON MONITOR, V14, P2044, DOI 10.1039/c2em30195d; Permaul P, 2012, PEDIAT ALLERG IMM-UK, V23, P543, DOI 10.1111/j.1399-3038.2012.01327.x; Perzanowski MS, 1999, J ALLERGY CLIN IMMUN, V103, P1018, DOI 10.1016/S0091-6749(99)70173-9; Phipatanakul W, 2004, ANN ALLERG ASTHMA IM, V92, P420, DOI 10.1016/S1081-1206(10)61777-2; Phipatanakul W, 2000, J ALLERGY CLIN IMMUN, V106, P1070, DOI 10.1067/mai.2000.110796; Phipatanakul W, 2000, J ALLERGY CLIN IMMUN, V106, P1075, DOI 10.1067/mai.2000.110795; Phipatanakul W, 2011, J ASTHMA, V48, P1007, DOI 10.3109/02770903.2011.624235; Pilotto LS, 2004, INT J EPIDEMIOL, V33, P208, DOI 10.1093/ije/dyh018; Platts-Mills JA, 2005, J ALLERGY CLIN IMMUN, V116, P384, DOI 10.1016/j.jaci.2005.05.012; Platts-Mills JA, 2005, CONTEMP TOP LAB ANIM, V44, P12; Platts-Mills TAE, 2008, J ALLERGY CLIN IMMUN, V122, P694, DOI 10.1016/j.jaci.2008.07.045; Pongracic JA, 2008, ANN ALLERG ASTHMA IM, V101, P35, DOI 10.1016/S1081-1206(10)60832-0; Pongracic JA, 2010, J ALLERGY CLIN IMMUN, V125, P593, DOI 10.1016/j.jaci.2009.10.036; Redline S, 2003, ANN ALLERG ASTHMA IM, V90, P516, DOI 10.1016/S1081-1206(10)61845-5; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Salo PM, 2009, J ALLERGY CLIN IMMUN, V124, P185, DOI 10.1016/j.jaci.2009.05.012; Sarpong SB, 1997, J ALLERGY CLIN IMMUN, V99, P486, DOI 10.1016/S0091-6749(97)70074-5; Sarpong SB, 1996, J ALLERGY CLIN IMMUN, V97, P1393, DOI 10.1016/S0091-6749(96)70209-9; Segata N, 2012, NAT METHODS, V9, P811, DOI [10.1038/NMETH.2066, 10.1038/nmeth.2066]; Senturia YD, 1998, CONTROL CLIN TRIALS, V19, P544, DOI 10.1016/S0197-2456(98)00032-4; Sheehan WJ, 2012, ANN ALLERG ASTHMA IM, V108, P418, DOI 10.1016/j.anai.2012.04.003; Sheehan WJ, 2009, ANN ALLERG ASTHMA IM, V102, P125, DOI 10.1016/S1081-1206(10)60242-6; Silverstein MD, 2001, J PEDIATR-US, V139, P278, DOI 10.1067/mpd.2001.115573; Smedje G, 1997, CLIN EXP ALLERGY, V27, P1270, DOI 10.1111/j.1365-2222.1997.tb01171.x; Smedje G, 2000, ARCH ENVIRON HEALTH, V55, P18, DOI 10.1080/00039890009603380; Stranger M, 2008, INDOOR AIR, V18, P454, DOI 10.1111/j.1600-0668.2008.00545.x; Strickland MJ, 2010, AM J RESP CRIT CARE, V182, P307, DOI 10.1164/rccm.200908-1201OC; Sublett JL, 2011, CURR ALLERGY ASTHM R, V11, P395, DOI 10.1007/s11882-011-0208-5; Sublett JL, 2010, J ALLERGY CLIN IMMUN, V125, P32, DOI 10.1016/j.jaci.2009.08.036; Tortolero SR, 2002, J SCHOOL HEALTH, V72, P33, DOI 10.1111/j.1746-1561.2002.tb06509.x; Tovey ER, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069900; Wickens K, 1997, J ALLERGY CLIN IMMUN, V99, P587, DOI 10.1016/S0091-6749(97)70017-4; Zook PM, 2010, CLIN TRIALS, V7, P400, DOI 10.1177/1740774510373798; Zota A, 2005, INDOOR AIR, V15, P393, DOI 10.1111/j.1600-0668.2005.00375.x	85	23	23	1	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2014	134	6					1232	1237		10.1016/j.jaci.2014.09.010	http://dx.doi.org/10.1016/j.jaci.2014.09.010			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AW1UG	25441649	Green Accepted			2022-12-18	WOS:000346075400002
J	Brandt, S; Perez, L; Kunzli, N; Lurmann, F; Wilson, J; Pastor, M; McConnell, R				Brandt, Sylvia; Perez, Laura; Kuenzli, Nino; Lurmann, Fred; Wilson, John; Pastor, Manuel; McConnell, Rob			Cost of near-roadway and regional air pollution-attributable childhood asthma in Los Angeles County	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Air pollution; asthma; cost of illness; urban growth; vehicle emissions; willingness to pay	CHRONIC COUGH; CALIFORNIA COMMUNITIES; ACUTE BRONCHITIS; CHILDREN; CARE; EXACERBATIONS; ANTIBIOTICS; INFECTIONS; MANAGEMENT; EXPOSURES	Background: Emerging evidence suggests that near-roadway air pollution (NRP) exposure causes childhood asthma. The associated costs are not well documented. Objective: We estimated the cost of childhood asthma attributable to residential NRP exposure and regional ozone (O-3) and nitrogen dioxide (NO2) levels in Los Angeles County. We developed a novel approach to apportion the costs between these exposures under different pollution scenarios. Methods: We integrated results from a study of willingness to pay to reduce the burden of asthma with results from studies of health care use and charges to estimate the costs of an asthma case and exacerbation. We applied those costs to the number of asthma cases and exacerbations caused by regional pollution in 2007 and to hypothetical scenarios of a 20% reduction in regional pollution in combination with a 20% reduction or increase in the proportion of the total population living within 75 m of a major roadway. Results: Cost of air pollution-related asthma in Los Angeles County in 2007 was $441 million for O-3 and $202 million for NO2 in 2010 dollars. Cost of routine care (care in absence of exacerbation) accounted for 18% of the combined NRP and O-3 cost and 39% of the combined NRP and NO2 cost; these costs were not recognized in previous analyses. NRP-attributable asthma accounted for 43% (O-3) to 51% (NO2) of the total annual cost of exacerbations and routine care associated with pollution. Hypothetical scenarios showed that costs from increased NRP exposure might offset savings from reduced regional pollution. Conclusions: Our model disaggregates the costs of regional pollution and NRP exposure and illustrates how they might vary under alternative exposure scenarios. The cost of air pollution is a substantial burden on families and an economic loss for society.	[Brandt, Sylvia] Univ Massachusetts, Ctr Publ Policy & Adm, Amherst, MA 01002 USA; [Brandt, Sylvia] Univ Massachusetts, Dept Resource Econ, Amherst, MA 01002 USA; [Perez, Laura; Kuenzli, Nino] Univ Basel, Basel, Switzerland; [Perez, Laura; Kuenzli, Nino] Swiss Trop & Publ Hlth Inst, Dept Epidemiol & Publ Hlth, Basel, Switzerland; [Lurmann, Fred] Sonoma Technol, Petaluma, CA USA; [Wilson, John] Univ So Calif, Spatial Sci Inst, Los Angeles, CA USA; [Pastor, Manuel] Univ So Calif, Program Environm & Reg Equ, Los Angeles, CA USA; [McConnell, Rob] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA	University of Massachusetts System; University of Massachusetts Amherst; University of Massachusetts System; University of Massachusetts Amherst; University of Basel; University of Basel; Swiss Tropical & Public Health Institute; University of Southern California; University of Southern California; University of Southern California	Brandt, S (corresponding author), Univ Massachusetts, Ctr Publ Policy & Adm, 205 Stockbridge Hall, Amherst, MA 01002 USA.	sylvbrandt@gmail.com	Kuenzli, Nino/F-7195-2014	Kuenzli, Nino/0000-0001-8360-080X; Brandt, Sylvia/0000-0001-8399-5514	South Coast Air Quality Management District; California state regulatory agency; National Institute of Environmental Health Sciences [R01 ES016535, P01ES011627, P30ES007048, P01ES009581, 5R01ES014447]; U.S. Environmental Protection Agency [R826708, RD831861, R831845]; Hastings Foundation; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES016535, P01ES009581, P30ES007048, P01ES011627, R01ES014447] Funding Source: NIH RePORTER	South Coast Air Quality Management District; California state regulatory agency; National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); U.S. Environmental Protection Agency(United States Environmental Protection Agency); Hastings Foundation; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported by the South Coast Air Quality Management District, a California state regulatory agency, with funds from a settlement with BP for violation of air quality regulations; National Institute of Environmental Health Sciences grants R01 ES016535, P01ES011627, P30ES007048, P01ES009581, and 5R01ES014447; U.S. Environmental Protection Agency grants R826708, RD831861, and R831845; and the Hastings Foundation.	American Academy of Pediatricians (AAP), 2007, AAP MED REIMB SURV 2; Anderson DJ, 2002, AM ECON REV, V92, P354, DOI 10.1257/000282802320191606; Anderson HR, 2013, AIR QUAL ATMOS HLTH, V6, P47, DOI 10.1007/s11869-011-0144-5; [Anonymous], 2004, HC089 MEPS FULL YEAR; [Anonymous], 2007, HC112 MEPS MED COND; Arrow K., 1993, FED REGISTER, V58, P4601; Assessor, COUNTY LOS ANG ANN R, P40; BenMAP, 2010, ENV BEN MAPP AN PROG; Bisgaard H, 2007, PEDIATR PULM, V42, P723, DOI 10.1002/ppul.20644; Bosson J, 2007, RESP MED, V101, P1140, DOI 10.1016/j.rmed.2006.11.010; Brandt S, 2012, VALUE HEALTH, V15, P1077, DOI 10.1016/j.jval.2012.07.006; Brandt SJ, 2012, EUR RESPIR J, V40, P363, DOI 10.1183/09031936.00157811; Bureau of Labor Statistics (BLS), CPI INF CALC; Cabana MD, 2006, PEDIATRICS, V117, P2149, DOI 10.1542/peds.2005-1055; California Health Interview Survey (CHIS), 2009, CHIS 2009 AD CHILD P; Chang AB, 2010, TRIALS, V11, DOI 10.1186/1745-6215-11-103; Chang AB, 2006, CHEST, V129, p260S, DOI 10.1378/chest.129.1_suppl.260S; Clark NA, 2010, ENVIRON HEALTH PERSP, V118, P284, DOI 10.1289/ehp.0900916; Coco A, 2005, ARCH PEDIAT ADOL MED, V159, P1145, DOI 10.1001/archpedi.159.12.1145; Evertsen J, 2010, PRIM CARE RESP J, V19, P237, DOI 10.4104/pcrj.2010.00024; Gauderman WJ, 2004, NEW ENGL J MED, V351, P1057, DOI 10.1056/NEJMoa040610; Gonzales R, 2000, ANN INTERN MED, V133, P981, DOI 10.7326/0003-4819-133-12-200012190-00014; Greek AA, 2006, J ASTHMA, V43, P61, DOI 10.1080/02770900500448639; Grupp-Phelan J, 2001, J ASTHMA, V38, P363, DOI 10.1081/JAS-100001492; Hall JV, 2008, J ENVIRON MANAGE, V88, P1003, DOI 10.1016/j.jenvman.2007.05.002; Hanemann M, 2003, P VALUING ENV HLTH R; HAZUCHA MJ, 1994, AM J RESP CRIT CARE, V150, P642, DOI 10.1164/ajrccm.150.3.8087332; HEI, 2009, TRAFF REL AIR POLL C; HEI, 2010, TRAFF REL AIR POLL C; Hubbell BJ, 2009, AIR QUAL ATMOS HLTH, V2, P99, DOI 10.1007/s11869-009-0037-z; Jackson DJ, 2011, J ALLERGY CLIN IMMUN, V128, P1165, DOI 10.1016/j.jaci.2011.10.024; Kattan M, 2005, J ALLERGY CLIN IMMUN, V116, P1058, DOI 10.1016/j.jaci.2005.07.032; Kunzli N, 2008, EPIDEMIOLOGY, V19, P179, DOI 10.1097/EDE.0b013e3181633c2f; Landrigan PJ, 2012, EUR RESPIR J, V40, P286, DOI 10.1183/09031936.00006112; Lavarreda S. A., 2012, STATE HLTH INSURANCE; Levy JI, 2010, ENVIRON HEALTH-GLOB, V9, DOI 10.1186/1476-069X-9-65; MacGillvary J, 2011, EC IMPACTS EARLY CAR; Machlin S, 2005, COMPUTING STANDARD E; Marchant JM, 2008, CHEST, V134, P303, DOI 10.1378/chest.07-2236; McConnell R, 2006, ENVIRON HEALTH PERSP, V114, P766, DOI 10.1289/ehp.8594; McConnell R, 2003, AM J RESP CRIT CARE, V168, P790, DOI 10.1164/rccm.200304-466OC; McCurdy T, 2005, MED EXPENDITURES HIS; Milet M, 2007, BURDEN ASTHMA CALIFO; Niska RW, 2008, NATL HLTH STAT REPOR; Nyquist AC, 1998, JAMA-J AM MED ASSOC, V279, P875, DOI 10.1001/jama.279.11.875; OECD, 2006, EC VAL ENV HLTH RISK, DOI 10.1787/9789264013988-en; Oeffinger KC, 1997, J FAM PRACTICE, V45, P402; Ostro BD, 2006, J AIR WASTE MANAGE, V56, P1007, DOI 10.1080/10473289.2006.10464511; Perez L, 2012, ENVIRON HEALTH PERSP, V120, P1619, DOI 10.1289/ehp.1104785; Perez Laura, 2009, Am J Public Health, V99 Suppl 3, pS622, DOI 10.2105/AJPH.2008.154955; Peters JM, 1999, AM J RESP CRIT CARE, V159, P768, DOI 10.1164/ajrccm.159.3.9804144; Salam MT, 2008, CURR OPIN PULM MED, V14, P3, DOI 10.1097/MCP.0b013e3282f1987a; SCAQMD, 2013, FIN 2012 AIR QUAL MA; Steinman MA, 2003, ANN INTERN MED, V138, P525, DOI 10.7326/0003-4819-138-7-200304010-00008; Sullivan PW, 2013, J ASTHMA, V50, P891, DOI 10.3109/02770903.2013.813035; U. S. Census Bureau, STAT COUNT QUICKF 20; US Census Bureau, 2006, CURR HOUS REP; Zhou FJ, 2008, J INFECT DIS, V197, pS156, DOI 10.1086/522135	58	23	23	3	33	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2014	134	5					1028	1035		10.1016/j.jaci.2014.09.029	http://dx.doi.org/10.1016/j.jaci.2014.09.029			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AT4UN	25439228	Green Accepted, Bronze			2022-12-18	WOS:000344938900005
J	Hwang, SL; Lu, Y; Li, X; Kim, YD; Cho, YS; Jahng, Y; Son, JK; Lee, YJ; Kang, WK; Taketomi, Y; Murakami, M; Moon, TC; Chang, HW				Hwang, Seung-Lark; Lu, Yue; Li, Xian; Kim, Yong Deuk; Cho, You Sook; Jahng, Yurndong; Son, Jong-Keun; Lee, Youn Ju; Kang, Wonku; Taketomi, Yoshitaka; Murakami, Makoto; Moon, Tae Chul; Chang, Hyeun Wook			ERK1/2 antagonize AMPK-dependent regulation of Fc epsilon RI-mediated mast cell activation and anaphylaxis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Mast cell; AMPK; ERK1/2; anaphylaxis	PROTEIN-KINASE; DEGRANULATION; PATHWAYS; RESPONSES; RECEPTOR; ROLES	Background: Extracellular signal-regulated kinases 1/2 (ERK1/2) make important contributions to allergic responses via their regulation of degranulation, eicosanoid production, and cytokine expression by mast cells, yet the mechanisms underlying their positive effects on Fc epsilon RI-dependent signaling are not fully understood. Recently, we reported that mast cell activation and anaphylaxis are negatively regulated by AMP-activated protein kinase (AMPK). However, little is known about the relationship between ERK1/2-mediated positive and the AMPK-mediated negative regulation of Fc epsilon RI signaling in mast cells. Objective: We investigated possible interactions between ERK1/2 and AMPK in the modulation of mast cell signaling and anaphylaxis. Methods: Wild-type or AMPK alpha 2(-/-) mice, or bone marrow-derived mast cells obtained from these mice, were treated with either chemical agents or small interfering RNAs that modulated the activity or expression of ERK1/2 or AMPK to evaluate the functional interplay between ERK1/2 and AMPK in Fc epsilon RI-dependent signaling. Results: The ERK1/2 pathway inhibitor U0126 and the AMPK activator 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside similarly inhibited Fc epsilon RI-mediated mast cell signals in vitro and anaphylaxis in vivo. ERK1/2-specific small interfering RNA also mimicked this effect on FceRI signals. Moreover, AMPK alpha 2 knockdown or deficiency led to increased Fc epsilon RI-mediated mast cell activation and anaphylaxis that were insensitive to U0126 or activator 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside, suggesting that the suppression of Fc epsilon RI signals by the inhibition of the ERK1/2 pathway relies largely on AMPK activation. ERK1/2 controlled AMPK activity by regulating its subcellular translocation. Conclusions: ERK1/2 ablated the AMPK-dependent negative regulatory axis, thereby activating FceRI signals in mast cells.	[Hwang, Seung-Lark; Lu, Yue; Li, Xian; Kim, Yong Deuk; Jahng, Yurndong; Son, Jong-Keun; Chang, Hyeun Wook] Yeungnam Univ, Coll Pharm, Gyongsan 712749, South Korea; [Lu, Yue] Shanghai Univ Tradit Chinese Med, Sch Pharm, Shanghai, Peoples R China; [Cho, You Sook] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Allergy & Clin Immunol, Seoul, South Korea; [Lee, Youn Ju] Catholic Univ Daegu, Sch Med, Dept Pharmacol, Taegu, South Korea; [Kang, Wonku] Chung Ang Univ, Coll Pharm, Seoul 156756, South Korea; [Taketomi, Yoshitaka; Murakami, Makoto] Tokyo Metropolitan Inst Med Sci, Lipid Metab Project, Tokyo, Japan; [Moon, Tae Chul] Univ Alberta, Dept Med, Pulm Res Grp, Edmonton, AB, Canada	Yeungnam University; Shanghai University of Traditional Chinese Medicine; University of Ulsan; Asan Medical Center; Catholic University of Daegu; Chung Ang University; Tokyo Metropolitan Institute of Medical Science; University of Alberta	Chang, HW (corresponding author), Yeungnam Univ, Coll Pharm, Gyongsan 712749, South Korea.	hwchang@yu.ac.kr	Lu, Yue/AAD-5889-2020		Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education, Science and Technology [NRF 2012R1A2A2A01013681]; NRF-Japan Society for the Promotion of Science (JSPS) Bilateral Joint Project [2012K2A2A4014189, FY2012]; Grants-in-Aid for Scientific Research [22116005] Funding Source: KAKEN	Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education, Science and Technology; NRF-Japan Society for the Promotion of Science (JSPS) Bilateral Joint Project; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	S.-L. Hwang, Y. Lu, X. Li, and H. W. Chang were supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (grant no. NRF 2012R1A2A2A01013681) and H.W. Chang and M. Murakami were supported in part by the NRF (grant no. 2012K2A2A4014189)-Japan Society for the Promotion of Science (JSPS) Bilateral Joint Project FY2012.	Barker SA, 1999, J LEUKOCYTE BIOL, V65, P321, DOI 10.1002/jlb.65.3.321; Bischoff SC, 2007, NAT REV IMMUNOL, V7, P93, DOI 10.1038/nri2018; Geest CR, 2009, BLOOD, V114, P3402, DOI 10.1182/blood-2008-08-175141; Gibbs BF, 2005, INT ARCH ALLERGY IMM, V136, P329, DOI 10.1159/000084226; Gilfillan AM, 2009, IMMUNOL REV, V228, P149, DOI 10.1111/j.1600-065X.2008.00742.x; Gilfillan AM, 2006, NAT REV IMMUNOL, V6, P218, DOI 10.1038/nri1782; Hawley SA, 1996, J BIOL CHEM, V271, P27879, DOI 10.1074/jbc.271.44.27879; HendricksTaylor LR, 1997, J BIOL CHEM, V272, P1363, DOI 10.1074/jbc.272.2.1363; Hwang SL, 2013, J ALLERGY CLIN IMMUN, V132, P729, DOI 10.1016/j.jaci.2013.02.018; Hwang SL, 2013, BRIT J PHARMACOL, V169, P69, DOI 10.1111/bph.12124; Jager J, 2011, DIABETOLOGIA, V54, P180, DOI 10.1007/s00125-010-1944-0; Kimata M, 2000, BIOCHEM PHARMACOL, V60, P589, DOI 10.1016/S0006-2952(00)00354-3; Kimata M, 2000, BIOCH PHRAM, P60589; Lage R, 2008, TRENDS MOL MED, V14, P539, DOI 10.1016/j.molmed.2008.09.007; Lu Y, 2011, BIOCHEM PHARMACOL, V82, P1700, DOI 10.1016/j.bcp.2011.08.022; Meares GP, 2013, J IMMUNOL, V190, P372, DOI 10.4049/jimmunol.1202390; Metcalfe DD, 2008, BLOOD, V112, P946, DOI 10.1182/blood-2007-11-078097; Parravicini V, 2002, NAT IMMUNOL, V3, P741, DOI 10.1038/ni817; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Richards JD, 2001, J IMMUNOL, V166, P3855, DOI 10.4049/jimmunol.166.6.3855; Sag D, 2008, J IMMUNOL, V181, P8633, DOI 10.4049/jimmunol.181.12.8633; Takayama G, 2013, INT IMMUNOL, V25, P215, DOI 10.1093/intimm/dxs105; Tang X, 2011, ACTA PHARMACOL SIN, V32, P1138, DOI 10.1038/aps.2011.75; Viollet B, 2003, J CLIN INVEST, V111, P91, DOI 10.1172/JCI200316567; Yamada E, 2010, CELL METAB, V11, P113, DOI 10.1016/j.cmet.2009.12.010; Yamasaki S, 2004, BLOOD, V103, P3093, DOI 10.1182/blood-2003-08-2944; Yang ZG, 2010, J BIOL CHEM, V285, P19051, DOI 10.1074/jbc.M110.123620; Zhang J, 1996, J EXP MED, V184, P71, DOI 10.1084/jem.184.1.71	28	23	23	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2014	134	3					714	+		10.1016/j.jaci.2014.05.001	http://dx.doi.org/10.1016/j.jaci.2014.05.001			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AO5GR	24948367				2022-12-18	WOS:000341372400026
J	Malka, J; Mauger, DT; Covar, R; Rabinovitch, N; Lemanske, RF; Spahn, JD; Strunk, RC; Zeiger, RS; Morgan, WJ; Szefler, SJ				Malka, Jonathan; Mauger, David T.; Covar, Ronina; Rabinovitch, Nathan; Lemanske, Robert F., Jr.; Spahn, Joseph D.; Strunk, Robert C.; Zeiger, Robert S.; Morgan, Wayne J.; Szefler, Stanley J.			Eczema and race as combined determinants for differential response to step-up asthma therapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							BRONCHODILATOR RESPONSIVENESS; INHALED CORTICOSTEROIDS; LEUKOTRIENE PATHWAY; UNCONTROLLED ASTHMA; CHILDREN		[Malka, Jonathan; Covar, Ronina; Rabinovitch, Nathan; Spahn, Joseph D.; Szefler, Stanley J.] Natl Jewish Hlth, Dept Pediat, Denver, CO 80206 USA; [Malka, Jonathan; Covar, Ronina; Rabinovitch, Nathan; Spahn, Joseph D.; Szefler, Stanley J.] Univ Colorado, Denver Sch Med, Denver, CO 80202 USA; [Malka, Jonathan] Pediat Associates, Lauderdale Lakes, FL USA; [Mauger, David T.] Penn State Univ, Dept Hlth Evaluat Sci, Hershey, PA USA; [Lemanske, Robert F., Jr.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA; [Strunk, Robert C.] Washington Univ, Sch Med, Dept Pediat, Div Allergy Immunol & Pulm Med, St Louis, WA USA; [Zeiger, Robert S.] Kaiser Permanente, Dept Allergy, San Diego, CA USA; [Zeiger, Robert S.] Univ Calif San Diego, Dept Pediat, San Diego, CA 92103 USA; [Morgan, Wayne J.] Univ Arizona, Arizona Resp Ctr, Tucson, AZ USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University of Wisconsin System; University of Wisconsin Madison; Kaiser Permanente; University of California System; University of California San Diego; University of Arizona	Malka, J (corresponding author), Natl Jewish Hlth, Dept Pediat, Denver, CO 80206 USA.	szeflers@njhealth.org		Szefler, Stanley/0000-0002-6911-3199; Zeiger, Robert/0000-0001-5788-5063	NCATS NIH HHS [UL1 TR001082, UL1 TR000154, UL1 TR000448, UL1 TR000427] Funding Source: Medline; NCRR NIH HHS [UL1-RR025011, UL1 RR025011, UL1 RR024992, M01-RR00036, M01-RR03186, UL1-RR024992, UL1 RR025780] Funding Source: Medline; NHLBI NIH HHS [HL064313, HL064288, HL064295, HL064287, U10 HL064313, HL064307, HL064305, U10 HL064288] Funding Source: Medline; NIAID NIH HHS [T32AI007635] Funding Source: Medline; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000448, UL1TR000154, UL1TR000427, UL1TR001082] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR003186, M01RR000036, UL1RR025011, UL1RR024992, UL1RR025780] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U10HL064305, U10HL064295, U10HL064307, U10HL064313, U10HL064288, U10HL064287] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007635] Funding Source: NIH RePORTER	NCATS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Chan MTS, 1998, J ALLERGY CLIN IMMUN, V101, P594, DOI 10.1016/S0091-6749(98)70165-4; Drazen JM, 1999, NEW ENGL J MED, V340, P197, DOI 10.1056/NEJM199901213400306; Federico MJ, 2005, CHEST, V127, P571, DOI 10.1378/chest.127.2.571; Lemanske RF, 2010, NEW ENGL J MED, V362, P975, DOI 10.1056/NEJMoa1001278; Lima JJ, 2006, AM J RESP CRIT CARE, V173, P379, DOI 10.1164/rccm.200509-1412OC; Naqvi M, 2008, ANN ALLERG ASTHMA IM, V100, P551, DOI 10.1016/S1081-1206(10)60055-5; Naqvi M, 2007, J ASTHMA, V44, P639, DOI 10.1080/02770900701554441; Rabinovitch N, 2014, J ALLERGY CLIN IMMUN, V133, P350, DOI 10.1016/j.jaci.2013.07.039	8	23	23	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2014	134	2					483	485		10.1016/j.jaci.2014.03.039	http://dx.doi.org/10.1016/j.jaci.2014.03.039			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AO5GB	24835502	Green Accepted			2022-12-18	WOS:000341370800033
J	Pham, D; Sehra, S; Sun, X; Kaplan, MH				Pham, Duy; Sehra, Sarita; Sun, Xin; Kaplan, Mark H.			The transcription factor Etv5 controls T(H)17 cell development and allergic airway inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						T(H)17 cells; transcription factor; Etv5; epigenetic modifications; allergic inflammation	T-HELPER-CELLS; ROR-GAMMA-T; T-H-17 CELLS; TH17 CELLS; SELF-RENEWAL; C-MAF; MOUSE; IL-17; DIFFERENTIATION; EXPRESSION	Background: The differentiation of T(H)17 cells, which promote pulmonary inflammation, requires the cooperation of a network of transcription factors. Objectives: We sought to define the role of Etv5, an Ets-family transcription factor, in T(H)17 cell development and function. Methods: T(H)17 development was examined in primary mouse T cells wherein Etv5 expression was altered by retroviral transduction, small interfering RNA targeting a specific gene, and mice with a conditional deletion of Etv5 in T cells. The direct function of Etv5 on the Il17 locus was tested with chromatin immunoprecipitation and reporter assays. The house dust mite-induced allergic inflammation model was used to test the requirement for Etv5-dependent T(H)17 functions in vivo. Results: We identify Etv5 as a signal transducer and activator of transcription 3-induced positive regulator of T(H)17 development. Etv5 controls T(H)17 differentiation by directly promoting Il17a and Il17f expression. Etv5 recruits histone-modifying enzymes to the Il17a-Il17f locus, resulting in increased active histone marks and decreased repressive histone marks. In a model of allergic airway inflammation, mice with Etv5-deficient T cells have reduced airway inflammation and IL-17A/F production in the lung and bronchoalveolar lavage fluid compared with wild-type mice, without changes in T(H)2 cytokine production. Conclusions: These data define signal transducer and activator of transcription 3-dependent feed-forward control of T(H)17 cytokine production and a novel role for Etv5 in promoting T cell-dependent airway inflammation.	[Pham, Duy; Sehra, Sarita; Kaplan, Mark H.] Indiana Univ, Sch Med, Dept Pediat, Herman B Wells Ctr Pediat Res, Indianapolis, IN 46202 USA; [Pham, Duy; Kaplan, Mark H.] Indiana Univ, Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA; [Sun, Xin] Univ Wisconsin Madison, Genet Lab, Madison, WI USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; University of Wisconsin System; University of Wisconsin Madison	Kaplan, MH (corresponding author), Indiana Univ, Dept Pediat, Wells Ctr, 1044 West Walnut St,Rm 202, Indianapolis, IN 46202 USA.	mkaplan2@iupui.edu		Kaplan, Mark/0000-0002-2923-8245	Public Health Service [AI045515];  [T32 HL007910]; NATIONAL CANCER INSTITUTE [P30CA082709] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007910] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045515, R56AI045515] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U54DK106846] Funding Source: NIH RePORTER	Public Health Service(United States Department of Health & Human ServicesUnited States Public Health Service); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Supported by Public Health Service grants AI045515 (to M. H. K.). D. P. was supported by T32 HL007910.	Abraham C, 2009, INFLAMM BOWEL DIS, V15, P1090, DOI 10.1002/ibd.20894; Al-Ramli W, 2009, J ALLERGY CLIN IMMUN, V123, P1185, DOI 10.1016/j.jaci.2009.02.024; Bauquet AT, 2009, NAT IMMUNOL, V10, P167, DOI 10.1038/ni.1690; Brackett CM, 2013, J IMMUNOL, V191, P4348, DOI 10.4049/jimmunol.1103621; Brustle A, 2007, NAT IMMUNOL, V8, P958, DOI 10.1038/ni1500; Call DR, 2001, SHOCK, V15, P278, DOI 10.1097/00024382-200115040-00005; Chen K, 2011, IMMUNITY, V35, P997, DOI 10.1016/j.immuni.2011.10.018; Ciofani M, 2012, CELL, V151, P289, DOI 10.1016/j.cell.2012.09.016; de Boer JD, 2013, AM J RESP CELL MOL, V48, P382, DOI 10.1165/rcmb.2012-0331OC; Durant L, 2010, IMMUNITY, V32, P605, DOI 10.1016/j.immuni.2010.05.003; Pham D, 2012, J IMMUNOL, V189, P832, DOI 10.4049/jimmunol.1200854; Gregory LG, 2009, CLIN EXP ALLERGY, V39, P1597, DOI 10.1111/j.1365-2222.2009.03302.x; Harrington LE, 2005, NAT IMMUNOL, V6, P1123, DOI 10.1038/ni1254; Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035; Jojic V, 2013, NAT IMMUNOL, V14, P633, DOI 10.1038/ni.2587; Khader SA, 2007, NAT IMMUNOL, V8, P369, DOI 10.1038/ni1449; Korn T, 2009, ANNU REV IMMUNOL, V27, P485, DOI 10.1146/annurev.immunol.021908.132710; Kotake S, 1999, J CLIN INVEST, V103, P1345, DOI 10.1172/JCI5703; Kudo M, 2012, NAT MED, V18, P547, DOI 10.1038/nm.2684; Laan M, 1999, J IMMUNOL, V162, P2347; Lajoie S, 2010, NAT IMMUNOL, V11, P928, DOI 10.1038/ni.1926; Langrish CL, 2005, J EXP MED, V201, P233, DOI 10.1084/jem.20041257; Manel N, 2008, NAT IMMUNOL, V9, P641, DOI 10.1038/ni.1610; Mathur AN, 2007, J IMMUNOL, V178, P4901, DOI 10.4049/jimmunol.178.8.4901; Mathur AN, 2006, BLOOD, V108, P1595, DOI 10.1182/blood-2006-04-015016; Moreira AP, 2011, J CLIN INVEST, V121, P4420, DOI 10.1172/JCI44999; Nakae S, 2002, IMMUNITY, V17, P375, DOI 10.1016/S1074-7613(02)00391-6; Niu ZY, 2011, P NATL ACAD SCI USA, V108, P12740, DOI 10.1073/pnas.1109987108; Oh S, 2012, BBA-REV CANCER, V1826, P1, DOI 10.1016/j.bbcan.2012.02.002; Ouyang W, 1999, P NATL ACAD SCI USA, V96, P3888, DOI 10.1073/pnas.96.7.3888; Pandiyan P, 2011, IMMUNITY, V34, P422, DOI 10.1016/j.immuni.2011.03.002; Phipps S, 2009, AM J RESP CRIT CARE, V179, P883, DOI 10.1164/rccm.200806-974OC; Schnyder-Candrian S, 2006, J EXP MED, V203, P2715, DOI 10.1084/jem.20061401; Schraml BU, 2009, NATURE, V460, P405, DOI 10.1038/nature08114; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; Stritesky GL, 2011, IMMUNITY, V34, P39, DOI 10.1016/j.immuni.2010.12.013; Thieu VT, 2008, IMMUNITY, V29, P679, DOI 10.1016/j.immuni.2008.08.017; van Rijt LS, 2004, J IMMUNOL METHODS, V288, P111, DOI 10.1016/j.jim.2004.03.004; Weaver CT, 2007, ANNU REV IMMUNOL, V25, P821, DOI 10.1146/annurev.immunol.25.022106.141557; Wu X, 2011, BIOL REPROD, V85, P1114, DOI 10.1095/biolreprod.111.091793; Xu JN, 2009, J IMMUNOL, V182, P6226, DOI 10.4049/jimmunol.0900123; Yang XP, 2011, NAT IMMUNOL, V12, P247, DOI 10.1038/ni.1995; Yang XXO, 2008, J EXP MED, V205, P1063, DOI 10.1084/jem.20071978; Zhang Z, 2009, J CLIN INVEST, V119, P1899, DOI 10.1172/JCI36731; Zhang Z, 2010, DEVELOPMENT, V137, P3417, DOI 10.1242/dev.051789; Zhang Z, 2009, DEV CELL, V16, P607, DOI 10.1016/j.devcel.2009.02.008; Zhou LA, 2007, NAT IMMUNOL, V8, P967, DOI 10.1038/ni1488	47	23	24	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2014	134	1					204	+		10.1016/j.jaci.2013.12.021	http://dx.doi.org/10.1016/j.jaci.2013.12.021			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AL2BH	24486067	Green Accepted, Green Published			2022-12-18	WOS:000338930300026
J	Simon, KL; Anderson, SM; Garabedian, EK; Moratto, D; Sokolic, RA; Candotti, F				Simon, Karen L.; Anderson, Stacie M.; Garabedian, Elizabeth K.; Moratto, Daniele; Sokolic, Robert A.; Candotti, Fabio			Molecular and phenotypic abnormalities of B lymphocytes in patients with Wiskott-Aldrich syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							COMMON VARIABLE IMMUNODEFICIENCY; CELLS; AUTOIMMUNITY; DEFICIENCY		[Simon, Karen L.; Anderson, Stacie M.; Garabedian, Elizabeth K.; Moratto, Daniele; Sokolic, Robert A.; Candotti, Fabio] NHGRI, Genet & Mol Biol Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Simon, KL (corresponding author), NHGRI, Genet & Mol Biol Branch, NIH, Bethesda, MD 20892 USA.	fabio@nhgri.nih.gov	Sokolic, Robert/E-6224-2017	Sokolic, Robert/0000-0002-3399-7893; Candotti, Fabio/0000-0001-6399-6042	Intramural NIH HHS [Z99 HG999999, ZIA HG000121-15] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [ZIAHG000121] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Albert MH, 2011, CURR OPIN HEMATOL, V18, P42, DOI 10.1097/MOH.0b013e32834114bc; Becker-Herman S, 2011, J EXP MED, V208, P2033, DOI 10.1084/jem.20110200; Catucci M, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00209; Dorner T, 2005, CLIN EXP MED, V4, P159, DOI 10.1007/s10238-004-0051-2; Dupuis-Girod S, 2003, PEDIATRICS, V111, pE622, DOI 10.1542/peds.111.5.e622; Park JY, 2005, CLIN EXP IMMUNOL, V139, P297, DOI 10.1111/j.1365-2249.2005.02693.x; Rakhmanov M, 2009, P NATL ACAD SCI USA, V106, P13451, DOI 10.1073/pnas.0901984106; Recher M, 2012, BLOOD, V119, P2819, DOI 10.1182/blood-2011-09-379412; Vlkova M, 2010, J IMMUNOL, V185, P6431, DOI 10.4049/jimmunol.0903876; Wang XW, 2000, J IMMUNOL METHODS, V244, P217, DOI 10.1016/S0022-1759(00)00260-X; Warnatz K, 2002, BLOOD, V99, P1544, DOI 10.1182/blood.V99.5.1544; Wehr C, 2004, CLIN IMMUNOL, V113, P161, DOI 10.1016/j.clim.2004.05.010	12	23	24	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2014	133	3					896	899		10.1016/j.jaci.2013.08.050	http://dx.doi.org/10.1016/j.jaci.2013.08.050			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC3EK	24210885	Green Accepted			2022-12-18	WOS:000332397600039
J	Bafunno, V; Divella, C; Sessa, F; Tiscia, GL; Castellano, G; Gesualdo, L; Margaglione, M; Montinaro, V				Bafunno, Valeria; Divella, Chiara; Sessa, Francesco; Tiscia, Giovanni Luca; Castellano, Giuseppe; Gesualdo, Loreto; Margaglione, Maurizio; Montinaro, Vincenzo			De novo homozygous mutation of the C1 inhibitor gene in a patient with hereditary angioedema	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							EDEMA		[Bafunno, Valeria; Sessa, Francesco; Margaglione, Maurizio] Univ Foggia, Dept Clin & Expt Med, Foggia, Italy; [Divella, Chiara; Castellano, Giuseppe; Gesualdo, Loreto; Montinaro, Vincenzo] Univ Aldo Moro Bari, Azienda Osped Univ Consorziale Policlin, Div Nephrol, Bari, Italy; [Divella, Chiara; Castellano, Giuseppe; Gesualdo, Loreto; Montinaro, Vincenzo] Univ Aldo Moro Bari, Azienda Osped Univ Consorziale Policlin, Ctr Diag & Treatment Hereditary Angioedema, Dept Emergency & Organ Transplantat, Bari, Italy; [Tiscia, Giovanni Luca] IRCCS Casa Sollievo Sofferenza, Thrombosis & Haemostasis Unit, Foggia, Italy	University of Foggia; Universita degli Studi di Bari Aldo Moro; Universita degli Studi di Bari Aldo Moro; IRCCS Casa Sollievo Della Sofferenza	Bafunno, V (corresponding author), Univ Foggia, Dept Clin & Expt Med, Foggia, Italy.	vincenzo.montinaro1@gmail.com	Divella, Chiara/K-2783-2016; montinaro, vincenzo/H-3674-2019; Sessa, Francesco/G-1754-2018; Tiscia, Giovanni/AAC-8788-2019; Castellano, Giuseppe/H-1626-2012; Gesualdo, Loreto/K-7751-2016	Divella, Chiara/0000-0003-2717-3158; Sessa, Francesco/0000-0003-0357-8791; Tiscia, Giovanni/0000-0001-5896-2024; Castellano, Giuseppe/0000-0002-0153-3795; Gesualdo, Loreto/0000-0002-4861-0911; montinaro, vincenzo/0000-0003-4018-0221; MARGAGLIONE, MAURIZIO/0000-0001-5627-9221				Blanch A, 2006, J ALLERGY CLIN IMMUN, V118, P1330, DOI 10.1016/j.jaci.2006.07.035; CARTER PE, 1991, EUR J BIOCHEM, V197, P301, DOI 10.1111/j.1432-1033.1991.tb15911.x; Cicardi M, 2003, MEDICINE, V82, P274, DOI 10.1097/00005792-200307000-00006; DAVIS AE, 1986, P NATL ACAD SCI USA, V83, P3161, DOI 10.1073/pnas.83.10.3161; Iwamoto K, 2012, CLIN EXP DERMATOL, V37, P20, DOI 10.1111/j.1365-2230.2011.04138.x; Longhurst H, 2012, LANCET, V379, P474, DOI 10.1016/S0140-6736(11)60935-5; Lopez-Lera A, 2010, J ALLERGY CLIN IMMUN, V126, P1307, DOI 10.1016/j.jaci.2010.07.037; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Nagy N, 2010, AUSTRALAS J DERMATOL, V51, P157, DOI 10.1111/j.1440-0960.2010.00649.x; Nosaeid MH, 2009, CLIN BIOCHEM, V42, P1291, DOI 10.1016/j.clinbiochem.2009.04.016; Pappalardo E, 2000, J ALLERGY CLIN IMMUN, V106, P1147, DOI 10.1067/mai.2000.110471; Roche O, 2005, HUM MUTAT, V26, P135, DOI 10.1002/humu.20197; Tosi M, 1998, IMMUNOBIOLOGY, V199, P358, DOI 10.1016/S0171-2985(98)80040-5	13	23	24	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2013	132	3					748	+		10.1016/j.jaci.2013.04.006	http://dx.doi.org/10.1016/j.jaci.2013.04.006			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	207OS	23688413				2022-12-18	WOS:000323612000032
J	Fischer, J; Teufel, M; Feidt, A; Giel, KE; Zipfel, S; Biedermann, T				Fischer, Joerg; Teufel, Martin; Feidt, Alexandra; Giel, Katrin Elisabeth; Zipfel, Stephan; Biedermann, Tilo			Tolerated wasp sting challenge improves health-related quality of life in patients allergic to wasp venom	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							IMMUNOTHERAPY		[Fischer, Joerg; Feidt, Alexandra; Biedermann, Tilo] Univ Tubingen, Fac Med, Dept Dermatol, Allergy Unit, Tubingen, Germany; [Teufel, Martin; Feidt, Alexandra; Giel, Katrin Elisabeth; Zipfel, Stephan] Univ Tubingen, Fac Med, Dept Internal Med, Psychosomat Med & Psychotherapy Unit, Tubingen, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital	Fischer, J (corresponding author), Univ Tubingen, Fac Med, Dept Dermatol, Allergy Unit, Tubingen, Germany.	tilo.biedermann@med.uni-tuebingen.de		Biedermann, Tilo/0000-0002-5352-5105; Zipfel, Stephan/0000-0003-1659-4440				Angermeyer M.C., 2000, HDB DTSCH VERSION WH; Elberink JNGO, 2002, J ALLERGY CLIN IMMUN, V110, P174, DOI 10.1067/mai.2002.125827; Elberink JNGO, 2003, CURR OPIN ALLERGY CL, V3, P287, DOI [10.1097/00130832-200308000-00009, 10.1097/01.all.0000083957.99396.b7]; Fischer J, 2011, J DTSCH DERMATOL GES, V9, P379, DOI 10.1111/j.1610-0387.2011.07622.x; JUNIPER EF, 1994, J CLIN EPIDEMIOL, V47, P81, DOI 10.1016/0895-4356(94)90036-1; Oude Elberink JNG, 2009, CLIN EXP ALLERGY, V39, P883, DOI 10.1111/j.1365-2222.2009.03230.x; Rueff F, 2001, J ALLERGY CLIN IMMUN, V108, P1027, DOI 10.1067/mai.2001.119154	7	23	23	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2013	132	2					489	490		10.1016/j.jaci.2013.03.010	http://dx.doi.org/10.1016/j.jaci.2013.03.010			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	194KL	23639308				2022-12-18	WOS:000322631700033
J	Abraham, RS; Recher, M; Giliani, S; Walter, JE; Lee, YN; Frugoni, F; Maddox, DE; Kirmani, S; Notarangelo, LD				Abraham, Roshini S.; Recher, Mike; Giliani, Silvia; Walter, Jolan E.; Lee, Yu Nee; Frugoni, Francesco; Maddox, Daniel E.; Kirmani, Salman; Notarangelo, Luigi D.			Adult-onset manifestation of idiopathic T-cell lymphopenia due to a heterozygous RAG1 mutation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							IMMUNODEFICIENCY		[Abraham, Roshini S.; Walter, Jolan E.] Mayo Clin, Dept Lab Med & Pathol, Cellular & Mol Immunol Lab, Rochester, MN 55905 USA; [Maddox, Daniel E.] Mayo Clin, Div Allerg Dis, Rochester, MN USA; [Kirmani, Salman] Mayo Clin, Dept Med Genet, Rochester, MN USA; [Recher, Mike; Lee, Yu Nee; Frugoni, Francesco; Notarangelo, Luigi D.] Harvard Univ, Childrens Hosp, Boston, MA 02115 USA; [Giliani, Silvia] Univ Brescia, Brescia, Italy; [Walter, Jolan E.] Massachusetts Gen Hosp Children, Dept Immunol, Boston, MA USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Harvard University; Boston Children's Hospital; University of Brescia	Abraham, RS (corresponding author), Mayo Clin, Dept Lab Med & Pathol, Cellular & Mol Immunol Lab, Rochester, MN 55905 USA.	abraham.roshini@mayo.edu	Giliani, Silvia/AAX-8843-2020; Notarangelo, Luigi D/F-9718-2016; Lee, Yu Nee/T-2360-2017	Giliani, Silvia/0000-0001-8137-4642; Notarangelo, Luigi D/0000-0002-8335-0262; Recher, Mike/0000-0002-9121-6936; Lee, Yu Nee/0000-0001-8648-5253; Frugoni, Francesco/0000-0002-1769-8121; Maddox, Daniel/0000-0001-8097-8794	NIAID NIH HHS [K08 AI103035, P01 AI076210] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI076210, K08AI103035] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Avila EM, 2010, PEDIATRICS, V126, pE1248, DOI 10.1542/peds.2009-3171; De Ravin SS, 2010, BLOOD, V116, P1263, DOI 10.1182/blood-2010-02-267583; Giblin W, 2009, BLOOD, V113, P2965, DOI 10.1182/blood-2008-07-165167; Kuijpers TW, 2011, BLOOD, V117, P5892, DOI 10.1182/blood-2011-01-329052; Santagata S, 2000, P NATL ACAD SCI USA, V97, P14572, DOI 10.1073/pnas.97.26.14572; SHOVLIN CL, 1994, J IMMUNOL, V153, P2331; Villa A, 2008, J ALLERGY CLIN IMMUN, V122, P1082, DOI 10.1016/j.jaci.2008.09.037	7	23	23	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2013	131	5					1421	1423		10.1016/j.jaci.2012.09.016	http://dx.doi.org/10.1016/j.jaci.2012.09.016			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	144AU	23122631	Green Accepted			2022-12-18	WOS:000318912200022
J	Farkas, H; Csuka, D; Zotter, Z; Szabo, E; Czaller, I; Varga, L; Fejes, J; Fust, G; Harmat, G				Farkas, Henriette; Csuka, Dorottya; Zotter, Zsuzsanna; Szabo, Erika; Czaller, Ibolya; Varga, Lilian; Fejes, Janos; Fuest, George; Harmat, George			Treatment of attacks with plasma-derived C1-inhibitor concentrate in pediatric hereditary angioedema patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							THERAPY		[Farkas, Henriette; Csuka, Dorottya; Zotter, Zsuzsanna; Szabo, Erika; Czaller, Ibolya; Varga, Lilian; Fuest, George] Semmelweis Univ, Dept Internal Med 3, H-1085 Budapest, Hungary; [Fejes, Janos; Harmat, George] Heim Pal Childrens Hosp, Budapest, Hungary	Semmelweis University	Farkas, H (corresponding author), Semmelweis Univ, Dept Internal Med 3, H-1085 Budapest, Hungary.	farkash@kut.sote.hu	Csuka, Dorottya/F-2224-2010; Czaller, Ibolya/R-4526-2018	Csuka, Dorottya/0000-0003-3610-9852; Farkas, Henriette/0000-0003-2929-1721; Varga, Lilian/0000-0002-5484-364X				Agostoni A, 2004, J ALLERGY CLIN IMMUN, V114, pS51, DOI 10.1016/j.jaci.2004.06.047; Bowen Tom, 2010, Allergy Asthma Clin Immunol, V6, P24, DOI 10.1186/1710-1492-6-24; Craig TJ, 2009, J ALLERGY CLIN IMMUN, V124, P801, DOI 10.1016/j.jaci.2009.07.017; Farkas H, 2007, J ALLERGY CLIN IMMUN, V120, P941, DOI 10.1016/j.jaci.2007.06.026; Farkas Henriette, 2010, Allergy Asthma Clin Immunol, V6, P18, DOI 10.1186/1710-1492-6-18; Kreuz W, 2012, TRANSFUSION, V52, P100, DOI 10.1111/j.1537-2995.2011.03240.x; Krishnamurthy A, 2008, CLIN REV ALLERG IMMU, V34, P250, DOI 10.1007/s12016-007-8037-y; O'Bier AO, 2005, PEDIATR EMERG CARE, V21, P27, DOI 10.1097/01.pec.0000150985.81109.0d; Varga L, 2007, MOL IMMUNOL, V44, P1454, DOI 10.1016/j.molimm.2006.04.020; Wahn V, 2012, EUR J PEDIATR, V171, P1339, DOI 10.1007/s00431-012-1726-4	10	23	23	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2013	131	3					909	+		10.1016/j.jaci.2012.08.036	http://dx.doi.org/10.1016/j.jaci.2012.08.036			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	098ZM	23063583				2022-12-18	WOS:000315587800038
J	Park, SJ; Kim, TH; Jun, YJ; Lee, SH; Ryu, HY; Jung, KJ; Jung, JY; Hwang, GH; Lee, SH				Park, Se Jin; Kim, Tae Hoon; Jun, Young Joon; Lee, Seung Hoon; Ryu, Hyei Yul; Jung, Kwang Jin; Jung, Jong Yoon; Hwang, Gyu Ho; Lee, Sang Hag			Chronic rhinosinusitis with polyps and without polyps is associated with increased expression of suppressors of cytokine signaling 1 and 3	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						SOCS1; SOCS3; chronic rhinosinusitis with nasal polyps; chronic rhinosinusitis without nasal polyps; cytokines	NEGATIVE REGULATION; IMMUNE-RESPONSES; IFN-GAMMA; SOCS; AIRWAY; IL-13	Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) or without nasal polyps (CRSsNP) is associated with expression of various cytokines. Suppressors of cytokine signaling (SOCS) regulate cytokine activity in a variety of cells, modulating inflammatory responses. Objective: We analyzed the expression and distribution pattern of SOCS1 and SOCS3 in CRSwNP and CRSsNP, and their cytokine-driven expression regulation in sinus mucosa. In addition, the expression levels of various cytokines were evaluated in CRSwNP and CRSsNP. Methods: The expression levels of SOCS1 and SOCS3 in CRSwNP and CRSsNP and in control samples were assessed by using real-time PCR, Western blot, and immunohistochemistry. Nasal epithelial cell culture was used to elucidate the effect of IL-4, IL-5, IL-6, IL-10, IL-13, IFN-gamma, TNF-alpha, and TGF-beta 1 on SOCS1 and SOCS3 expression in sinus mucosa. The expression levels of these cytokines were also evaluated in normal and inflammatory sinus mucosa by using real-time PCR and Western blot. Results: The expression levels of SOCS1 and SOCS3 were increased in CRS, irrespective of the presence of nasal polyp, and they were distributed in superficial epithelium, submucosal glands, and vascular endothelium in sinus mucosa. SOCS1 was induced by IL-4, IL-13, IFN-gamma, and TNF-alpha, while SOCS3 expression was upregulated by IL-6, IL-13, IFN-gamma, and TNF-alpha. IL-4 and IL-13 levels were increased in CRSwNP, while IL-4, IFN-gamma, TNF-alpha, and TGF-beta 1 levels were increased in CRSsNP. Conclusion: SOCS1 and SOCS3 are increased in CRS, irrespective of nasal polyp presence. This may be a response to elevated levels of various cytokines increasingly expressed in inflammatory sinus mucosa. (J Allergy Clin Immunol 2013;131:772-80.)	[Park, Se Jin; Kim, Tae Hoon; Jun, Young Joon; Lee, Seung Hoon; Ryu, Hyei Yul; Jung, Kwang Jin; Jung, Jong Yoon; Hwang, Gyu Ho; Lee, Sang Hag] Korea Univ, Coll Med, Dept Otorhinolaryngol Head & Neck Surg, 126-1,5 Ka, Seoul 136705, South Korea	Korea University; Korea University Medicine (KU Medicine)	Lee, SH (corresponding author), Korea Univ, Coll Med, Dept Otorhinolaryngol Head & Neck Surg, 126-1,5 Ka, Seoul 136705, South Korea.	sanghag@kumc.or.kr	LEE, Seung Hoon/GLN-6169-2022; Jun, Young Joon/AAP-7026-2020	Jun, Young Joon/0000-0002-3687-2367	Communication Disorders Center, Korea University, South Korea; Korea University grant, South Korea; Basic Science Research Program through the National Research Foundation of Korea; Ministry of Education, Science and Technology [2010-0004094]	Communication Disorders Center, Korea University, South Korea; Korea University grant, South Korea; Basic Science Research Program through the National Research Foundation of Korea(National Research Foundation of Korea); Ministry of Education, Science and Technology(Ministry of Education, Science & Technology (MEST), Republic of Korea)	This work was supported by a Grant-in-Aid for Scientific Research from the Communication Disorders Center, Korea University, South Korea, and The Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Education, Science and Technology (2010-0004094). This research was also supported by a Korea University grant, South Korea.	Ahmed CM, 2009, J VIROL, V83, P1402, DOI 10.1128/JVI.01138-08; Alexander WS, 2002, NAT REV IMMUNOL, V2, P410, DOI 10.1038/nri818; Bachert C, 2000, AM J RHINOL, V14, P279, DOI 10.2500/105065800781329573; Bachert Claus, 2002, Curr Allergy Asthma Rep, V2, P252, DOI 10.1007/s11882-002-0027-9; Baker BJ, 2009, TRENDS IMMUNOL, V30, P392, DOI 10.1016/j.it.2009.07.001; Benninger MS, 2003, OTOLARYNG HEAD NECK, V129, pS1, DOI 10.1016/S0194-5998(03)01397-4; Brook Itzhak, 2011, Proc Am Thorac Soc, V8, P90, DOI 10.1513/pats.201006-038RN; Cassel SL, 2009, ADV IMMUNOL, V103, P49, DOI 10.1016/S0065-2776(09)03003-X; Daegelmann C, 2008, CLIN EXP ALLERGY, V38, P438, DOI 10.1111/j.1365-2222.2007.02913.x; Federici M, 2002, J IMMUNOL, V169, P434, DOI 10.4049/jimmunol.169.1.434; Fokkens WJ, 2012, RHINOLOGY, V50, P1, DOI 10.4193/Rhin20.600; Foreman A, 2011, ALLERGY, V66, P1449, DOI 10.1111/j.1398-9995.2011.02678.x; Fukuyama S, 2009, AM J RESP CRIT CARE, V179, P992, DOI 10.1164/rccm.200806-992OC; Garlet GP, 2006, J PERIODONTAL RES, V41, P580, DOI 10.1111/j.1600-0765.2006.00908.x; Greenhalgh CJ, 2002, GASTROENTEROLOGY, V123, P2064, DOI 10.1053/gast.2002.37068; HAMILOS DL, 1995, J ALLERGY CLIN IMMUN, V96, P537, DOI 10.1016/S0091-6749(95)70298-9; Harada M, 2007, AM J RESP CELL MOL, V36, P491, DOI 10.1165/rcmb.2006-0090OC; Hernandez-Vargas P, 2005, J AM SOC NEPHROL, V16, P1673, DOI 10.1681/ASN.2004050374; Horino J, 2008, INT IMMUNOL, V20, P753, DOI 10.1093/intimm/dxn033; Hunter SE, 1999, OTOLARYNG HEAD NECK, V120, P884, DOI 10.1016/S0194-5998(99)70331-1; Kern RC, 2008, AM J RHINOL, V22, P549, DOI 10.2500/ajr.2008.22.3228; Kim TH, 2012, INT ARCH ALLERGY IMM, V158, P387, DOI 10.1159/000333103; Kramer MF, 2000, LARYNGOSCOPE, V110, P1056, DOI 10.1097/00005537-200006000-00031; Kubo M, 2003, NAT IMMUNOL, V4, P1169, DOI 10.1038/ni1012; Lanza VJ, 1997, OTLARYNGOL HEAD NECK, V117, P1; Lu XA, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-28; Lund VJ, 1997, OTOLARYNG HEAD NECK, V117, pS35, DOI 10.1016/S0194-5998(97)70005-6; Meltzer Eli O, 2004, J Allergy Clin Immunol, V114, P155, DOI 10.1016/j.jaci.2004.09.029; Moynihan BJ, 2008, RESP RES, V9, DOI 10.1186/1465-9921-9-84; Nell MJ, 2003, ANN OTO RHINOL LARYN, V112, P461, DOI 10.1177/000348940311200514; Otto BA, 2008, CURR OPIN OTOLARYNGO, V16, P270, DOI 10.1097/MOO.0b013e3282fb2885; Piccirillo JF, 2002, OTOLARYNG HEAD NECK, V126, P41, DOI 10.1067/mhn.2002.121022; Ramanathan M, 2007, OTOLARYNG HEAD NECK, V136, P348, DOI 10.1016/j.otohns.2006.11.011; Rao VLR, 2002, J NEUROCHEM, V83, P1072, DOI 10.1046/j.1471-4159.2002.01208.x; Seki Y, 2003, NAT MED, V9, P1047, DOI 10.1038/nm896; Shin SH, 2004, J ALLERGY CLIN IMMUN, V114, P1369, DOI 10.1016/j.jaci.2004.08.012; Suzuki A, 2001, J EXP MED, V193, P471, DOI 10.1084/jem.193.4.471; Van Bruaene N, 2008, J ALLERGY CLIN IMMUN, V121, P1435, DOI 10.1016/j.jaci.2008.02.018; Van Zele T, 2006, ALLERGY, V61, P1280, DOI 10.1111/j.1398-9995.2006.01225.x; Yasukawa H, 2000, ANNU REV IMMUNOL, V18, P143, DOI 10.1146/annurev.immunol.18.1.143; Yoshimura A, 2005, ARTHRITIS RES THER, V7, P100, DOI 10.1186/ar1741	41	23	23	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2013	131	3					772	780		10.1016/j.jaci.2012.12.671	http://dx.doi.org/10.1016/j.jaci.2012.12.671			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	098ZM	23375208				2022-12-18	WOS:000315587800019
J	Ducruet, T; Levasseur, MC; Des Roches, A; Kafal, A; Dicaire, R; Haddad, E				Ducruet, Thierry; Levasseur, Marie-Claude; Des Roches, Anne; Kafal, Ayman; Dicaire, Renee; Haddad, Elie			Pharmacoeconomic advantages of subcutaneous versus intravenous immunoglobulin treatment in a Canadian pediatric center	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							PRIMARY ANTIBODY DEFICIENCIES; IGG SELF-INFUSIONS; QUALITY-OF-LIFE; REPLACEMENT THERAPY; PRIMARY IMMUNODEFICIENCY; SAFETY; EFFICACY; DISEASES; CHILDREN; ADULTS		[Ducruet, Thierry] Univ Montreal, CHU St Justine, Ctr Rech, URCA, Montreal, PQ, Canada; [Levasseur, Marie-Claude; Des Roches, Anne; Dicaire, Renee; Haddad, Elie] Univ Montreal, Dept Pediat, Ctr Rech, CHU St Justine, Montreal, PQ H3C 3J7, Canada; [Kafal, Ayman] CSL Behring, Ottawa, ON, Canada; [Haddad, Elie] Univ Montreal, Dept Microbiol & Immunol, Ctr Rech, CHU St Justine, Montreal, PQ H3C 3J7, Canada	Universite de Montreal; Centre Hospitalier Universitaire Sainte-Justine; Universite de Montreal; Centre Hospitalier Universitaire Sainte-Justine; CSL; Universite de Montreal; Centre Hospitalier Universitaire Sainte-Justine	Ducruet, T (corresponding author), Univ Montreal, CHU St Justine, Ctr Rech, URCA, Montreal, PQ, Canada.	elie.haddad@umontreal.ca	Haddad, Elie/AAQ-4971-2020	Haddad, Elie/0000-0003-2446-6879				Beaute J, 2010, CLIN EXP IMMUNOL, V160, P240, DOI 10.1111/j.1365-2249.2009.04079.x; Chapel HM, 2000, J CLIN IMMUNOL, V20, P94, DOI 10.1023/A:1006678312925; Gardulf A, 2004, J ALLERGY CLIN IMMUN, V114, P936, DOI 10.1016/j.jaci.2004.06.053; GARDULF A, 1995, LANCET, V345, P365; Gardulf A, 2006, J CLIN IMMUNOL, V26, P177, DOI 10.1007/s10875-006-9002-x; Hagan JB, 2010, J CLIN IMMUNOL, V30, P734, DOI 10.1007/s10875-010-9423-4; Hogy Barbara, 2005, Eur J Health Econ, V6, P24, DOI 10.1007/s10198-004-0250-5; Jolles S, 2011, CLIN IMMUNOL, V141, P90, DOI 10.1016/j.clim.2011.06.002; Membe SK, 2008, IMMUNOL ALLERGY CLIN, V28, P861, DOI 10.1016/j.iac.2008.06.008; Nicolay U, 2006, J CLIN IMMUNOL, V26, P65, DOI 10.1007/s10875-006-8905-x; Notarangelo LD, 2009, J ALLERGY CLIN IMMUN, V124, P1161, DOI 10.1016/j.jaci.2009.10.013; Ochs HD, 2006, J CLIN IMMUNOL, V26, P265, DOI 10.1007/s10875-006-9021-7	12	23	23	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2013	131	2					585	587		10.1016/j.jaci.2012.08.022	http://dx.doi.org/10.1016/j.jaci.2012.08.022			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	086CT	23040368	Bronze			2022-12-18	WOS:000314661500041
J	Okupa, AY; Lemanske, RF; Jackson, DJ; Evans, MD; Wood, RA; Matsui, EC				Okupa, Adesua Y.; Lemanske, Robert F., Jr.; Jackson, Daniel J.; Evans, Michael D.; Wood, Robert A.; Matsui, Elizabeth C.			Early-life folate levels are associated with incident allergic sensitization	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CHILDHOOD RESPIRATORY HEALTH; FOLIC-ACID SUPPLEMENTS; PREGNANCY; ASTHMA; ATOPY		[Okupa, Adesua Y.; Lemanske, Robert F., Jr.; Jackson, Daniel J.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI 53706 USA; [Evans, Michael D.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Biostat & Med Informat, Madison, WI USA; [Wood, Robert A.; Matsui, Elizabeth C.] Johns Hopkins Sch Med, Div Pediat Allergy & Immunol, Baltimore, MD USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Johns Hopkins University; Johns Hopkins Medicine	Okupa, AY (corresponding author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI 53706 USA.	ematsui1@jhmi.edu		Evans, Michael/0000-0001-7449-3993; Matsui, Elizabeth/0000-0001-8134-5593	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000427] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025011, M01RR003186] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL070831, R01HL061879] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007635, R01AI070630] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P50ES015903, P01ES018176] Funding Source: NIH RePORTER; NCATS NIH HHS [UL1 TR000427] Funding Source: Medline; NCRR NIH HHS [1UL1RR025011, M01 RR003186, M01 RR03186, UL1 RR025011] Funding Source: Medline; NHLBI NIH HHS [R01 HL061879, P01 HL70831, R01 HL61879, P01 HL070831] Funding Source: Medline; NIAID NIH HHS [5R01AI070630, R01 AI070630, T32 AI007635] Funding Source: Medline; NICHD NIH HHS [R01 HD061879] Funding Source: Medline; NIEHS NIH HHS [P50 ES015903, 5P50ES015903, P01 ES018176] Funding Source: Medline; NIMH NIH HHS [R01 MH061879] Funding Source: Medline	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCATS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Bekkers MBM, 2012, EUR RESPIR J, V39, P1468, DOI 10.1183/09031936.00094511; Haberg SE, 2009, ARCH DIS CHILD, V94, P180, DOI 10.1136/adc.2008.142448; Haberg S. E., 2011, J ALLERGY CLIN IMMUN, V127; Haberg SE, 2011, J ALLERGY CLIN IMMUN, V127, P262, DOI 10.1016/j.jaci.2010.10.004; Hollingsworth JW, 2008, J CLIN INVEST, V118, P3462, DOI 10.1172/JCI34378; Magdelijns FJH, 2011, PEDIATRICS, V128, pE135, DOI 10.1542/peds.2010-1690; Matsui EC, 2009, J ALLERGY CLIN IMMUN, V123, P1253, DOI 10.1016/j.jaci.2009.03.007; Nadeau K, 2010, J ALLERGY CLIN IMMUN, V126, P845, DOI 10.1016/j.jaci.2010.08.008; Whitrow MJ, 2009, AM J EPIDEMIOL, V170, P1486, DOI 10.1093/aje/kwp315	9	23	24	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2013	131	1								10.1016/j.jaci.2012.08.015	http://dx.doi.org/10.1016/j.jaci.2012.08.015			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	062YR	23040888	Green Accepted			2022-12-18	WOS:000312961200031
J	Sicherer, SH; Leung, DYM				Sicherer, Scott H.; Leung, Donald Y. M.			Advances in allergic skin disease, anaphylaxis, and hypersensitivity reactions to foods, drugs, and insects in 2012	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Dermatology; skin disease; urticaria; atopic dermatitis; anaphylaxis; allergy; hypersensitivity disorders; food; drug; insect venom	INDUCED ENTEROCOLITIS SYNDROME; THYMIC STROMAL LYMPHOPOIETIN; BASOPHIL ACTIVATION TEST; EOSINOPHILIC ESOPHAGITIS; ATOPIC-DERMATITIS; PEANUT ALLERGY; MURINE MODEL; VENOM IMMUNOTHERAPY; ORAL IMMUNOTHERAPY; STRATUM-CORNEUM	This review highlights some of the research advances in anaphylaxis; hypersensitivity reactions to foods, drugs, and insects; and allergic skin diseases that were reported in the Journal in 2012. Studies support an increase in peanut allergy prevalence in children and exposure to the antibacterial agent triclosan and having filaggrin (FLG) loss-of-function mutations as risk factors for food sensitization. The role of specific foods in causing eosinophilic esophagitis is elucidated by several studies, and microRNA analysis is identified as a possible noninvasive disease biomarker. Studies on food allergy diagnosis emphasize the utility of component testing and the possibility of improved diagnosis through stepped approaches, epitope-binding analysis, and bioinformatics. Treatment studies of food allergy show promise for oral immunotherapy, but tolerance induction remains elusive, and additional therapies are under study. Studies on anaphylaxis suggest an important role for platelet-activating factor and its relationship to the need for prompt treatment with epinephrine. Insights on the pathophysiology and diagnosis of non-IgE-mediated drug allergy are offered, with novel data regarding the interaction of drugs with HLA molecules. Numerous studies support influenza vaccination of persons with egg allergy using modest precautions. Evidence continues to mount that there is cross-talk between skin barrier defects and immune responses in patients with atopic dermatitis. Augmentation of the skin barrier with reduction in skin inflammatory responses will likely lead to the most effective intervention in patients with this common skin disease. (J Allergy Clin Immunol 2013;131:55-66.)	[Sicherer, Scott H.] Mt Sinai Sch Med, Dept Pediat, Elliot & Roslyn Jaffe Food Allergy Inst, Div Allergy & Immunol, New York, NY USA; [Leung, Donald Y. M.] Natl Jewish Hlth, Div Pediat Allergy Immunol, Dept Pediat, Denver, CO USA	Icahn School of Medicine at Mount Sinai; National Jewish Health	Sicherer, SH (corresponding author), Mt Sinai Hosp, Div Allergy Immunol, Box 1198,1 Gustave L Levy Pl, New York, NY 10029 USA.	scott.sicherer@mssm.edu			National Institutes of Health/National Institute of Allergy and Infectious Diseases	National Institutes of Health/National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Disclosure of potential conflict of interest: S. H. Sicherer has received grants from the National Institutes of Health/National Institute of Allergy and Infectious Diseases and has consulted for the Food Allergy Initiative. D. Y. M. Leung declares that he has no relevant conflicts of interest.	Ahrens B, 2012, J ALLERGY CLIN IMMUN, V130, P549, DOI 10.1016/j.jaci.2012.05.045; Asarnoj A, 2012, J ALLERGY CLIN IMMUN, V130, P468, DOI 10.1016/j.jaci.2012.05.019; Baptist AP, 2012, J ALLERGY CLIN IMMUN, V130, P263, DOI 10.1016/j.jaci.2012.03.029; Ben-Shoshan M, 2012, J ALLERGY CLIN IMMUN, V129, P1401, DOI 10.1016/j.jaci.2012.01.078; Beyer K, 2012, J ALLERGY CLIN IMMUN, V129, P1179, DOI 10.1016/j.jaci.2012.03.037; Bin LH, 2012, J ALLERGY CLIN IMMUN, V130, P683, DOI 10.1016/j.jaci.2012.06.019; Bohme M, 2012, J ALLERGY CLIN IMMUN, V129, P1153, DOI 10.1016/j.jaci.2011.11.032; Bonadonna P, 2012, J ALLERGY CLIN IMMUN, V130, P547, DOI 10.1016/j.jaci.2012.04.048; Bork K, 2012, J ALLERGY CLIN IMMUN, V130, P692, DOI 10.1016/j.jaci.2012.05.055; Boyman O, 2012, J ALLERGY CLIN IMMUN, V129, P160, DOI 10.1016/j.jaci.2011.10.046; Brown SGA, 2012, J ALLERGY CLIN IMMUN, V130, P162, DOI 10.1016/j.jaci.2012.02.022; Burks AW, 2012, J ALLERGY CLIN IMMUN, V129, P906, DOI 10.1016/j.jaci.2012.02.001; Campbell RL, 2012, J ALLERGY CLIN IMMUN, V129, P748, DOI 10.1016/j.jaci.2011.09.030; Caubet JC, 2012, J ALLERGY CLIN IMMUN; Caubet JC, 2012, J ALLERGY CLIN IMMUN, V129, P739, DOI 10.1016/j.jaci.2011.11.053; Chiang WC, 2012, J ALLERGY CLIN IMMUN; Chinuki Y, 2012, J ALLERGY CLIN IMMUN, V129, P1404, DOI 10.1016/j.jaci.2012.02.049; Choy DF, 2012, J ALLERGY CLIN IMMUN; Confino-Cohen R, 2012, J ALLERGY CLIN IMMUN, V129, P1307, DOI 10.1016/j.jaci.2012.01.043; Cornelissen C, 2012, J ALLERGY CLIN IMMUN, V129, P426, DOI 10.1016/j.jaci.2011.10.042; Dang TD, 2012, J ALLERGY CLIN IMMUN, V129, P1056, DOI 10.1016/j.jaci.2012.01.056; Des Roches A, 2012, J ALLERGY CLIN IMMUN, V130, P1213, DOI 10.1016/j.jaci.2012.07.046; Diemert DJ, 2012, J ALLERGY CLIN IMMUN, V130, P169, DOI 10.1016/j.jaci.2012.04.027; Dizier MH, 2012, J ALLERGY CLIN IMMUN, V129, P1547, DOI 10.1016/j.jaci.2012.04.010; Eberlein B, 2012, J ALLERGY CLIN IMMUN, V130, P155, DOI 10.1016/j.jaci.2012.02.008; Fernandes BN, 2012, J ALLERGY CLIN IMMUN, V130, P1199, DOI 10.1016/j.jaci.2012.06.017; Fiorentino R, 2012, J ALLERGY CLIN IMMUN, V130, P613, DOI 10.1016/j.jaci.2012.07.011; Ford LS, 2012, J ALLERGY CLIN IMMUN; Fukutomi Y, 2012, J ALLERGY CLIN IMMUN, V129, P860, DOI 10.1016/j.jaci.2012.01.031; Fung I, 2012, J ALLERGY CLIN IMMUN, V129, P1157, DOI 10.1016/j.jaci.2011.11.038; Gao ZS, 2012, J ALLERGY CLIN IMMUN; Girard-Madoux MJH, 2012, J ALLERGY CLIN IMMUN, V129, P143, DOI 10.1016/j.jaci.2011.08.032; Gittler JK, 2012, J ALLERGY CLIN IMMUN; Gupta P, 2012, J ALLERGY CLIN IMMUN, V129, P571, DOI 10.1016/j.jaci.2011.09.033; Gupta RS, 2012, J ALLERGY CLIN IMMUN; Guttman-Yassky E, 2011, J ALLERGY CLIN IMMUN, V127, P1420, DOI 10.1016/j.jaci.2011.01.054; Guttman-Yassky E, 2011, J ALLERGY CLIN IMMUN, V127, P1110, DOI 10.1016/j.jaci.2011.01.053; Hancock DB, 2012, J ALLERGY CLIN IMMUN, V129, P1673, DOI 10.1016/j.jaci.2012.03.012; Haneda Y, 2012, J ALLERGY CLIN IMMUN, V129, P1681, DOI 10.1016/j.jaci.2012.03.041; Henderson CJ, 2012, J ALLERGY CLIN IMMUN, V129, P1570, DOI 10.1016/j.jaci.2012.03.023; Hopper J, 2012, J ALLERGY CLIN IMMUN, V130; Hsu P, 2012, J ALLERGY CLIN IMMUN; Huang F, 2012, J ALLERGY CLIN IMMUN, V129, P162, DOI 10.1016/j.jaci.2011.09.018; Illi S, 2012, J ALLERGY CLIN IMMUN, V129, P1470, DOI 10.1016/j.jaci.2012.03.013; Jacobsen RC, 2012, J ALLERGY CLIN IMMUN, V129, P1143, DOI 10.1016/j.jaci.2011.10.007; Javaloyes G, 2012, J ALLERGY CLIN IMMUN; Jensen MP, 2012, J ALLERGY CLIN IMMUN, V130, P1209, DOI 10.1016/j.jaci.2012.07.018; Kawasaki H, 2012, J ALLERGY CLIN IMMUN, V129, P1538, DOI 10.1016/j.jaci.2012.01.068; Keet CA, 2012, J ALLERGY CLIN IMMUN, V130, P1207, DOI 10.1016/j.jaci.2012.07.020; Keet CA, 2012, J ALLERGY CLIN IMMUN, V129, P448, DOI 10.1016/j.jaci.2011.10.023; Keet CA, 2012, J ALLERGY CLIN IMMUN, V129, P169, DOI 10.1016/j.jaci.2011.10.002; Kelso JM, 2012, J ALLERGY CLIN IMMUN, V130, P25, DOI 10.1016/j.jaci.2012.04.003; Kezic S, 2012, J ALLERGY CLIN IMMUN, V129, P1031, DOI 10.1016/j.jaci.2011.12.989; Kirkpatrick CH, 2012, J ALLERGY CLIN IMMUN, V130, P988, DOI 10.1016/j.jaci.2012.05.017; Klemans RJ, 2012, J ALLERGY CLIN IMMUN; Koplin JJ, 2012, J ALLERGY CLIN IMMUN, V129, P1145, DOI 10.1016/j.jaci.2011.09.044; Korosec P, 2012, J ALLERGY CLIN IMMUN, V129, P1406, DOI 10.1016/j.jaci.2011.12.975; Krueger JG, 2012, J ALLERGY CLIN IMMUN, V130, P145, DOI 10.1016/j.jaci.2012.04.024; Kucuk ZY, 2012, J ALLERGY CLIN IMMUN, V129, P1343, DOI 10.1016/j.jaci.2012.03.004; Kulis M, 2012, J ALLERGY CLIN IMMUN, V129, P1159, DOI 10.1016/j.jaci.2011.11.045; Kulis M, 2012, J ALLERGY CLIN IMMUN, V130, P716, DOI 10.1016/j.jaci.2012.05.044; Lack G, 2012, J ALLERGY CLIN IMMUN, V129, P1187, DOI 10.1016/j.jaci.2012.02.036; Lau S, 2012, J ALLERGY CLIN IMMUN, V129, P1040, DOI 10.1016/j.jaci.2012.02.005; Leonard SA, 2012, J ALLERGY CLIN IMMUN, V130, P473, DOI 10.1016/j.jaci.2012.06.006; Leonard SA, 2012, J ALLERGY CLIN IMMUN, V129, P1579, DOI 10.1016/j.jaci.2012.04.009; Lieberman JA, 2012, J ALLERGY CLIN IMMUN, V129, P1682, DOI 10.1016/j.jaci.2012.04.007; Lin J, 2012, J ALLERGY CLIN IMMUN, V129, P1321, DOI 10.1016/j.jaci.2012.02.012; Lu TX, 2012, J ALLERGY CLIN IMMUN, V129, P1064, DOI 10.1016/j.jaci.2012.01.060; MacGlashan DW, 2012, J ALLERGY CLIN IMMUN, V130, P1130, DOI 10.1016/j.jaci.2012.05.038; Margolis DJ, 2012, J ALLERGY CLIN IMMUN, V130, P912, DOI 10.1016/j.jaci.2012.07.008; Maslova E, 2012, J ALLERGY CLIN IMMUN, V130, P724, DOI 10.1016/j.jaci.2012.05.014; Menikou S, 2012, J ALLERGY CLIN IMMUN, V129, P1398, DOI 10.1016/j.jaci.2011.10.049; Milliken SVI, 2012, J ALLERGY CLIN IMMUN, V129, P1554, DOI 10.1016/j.jaci.2012.03.001; Molina-Infante J, 2012, J ALLERGY CLIN IMMUN, V130, P1200, DOI 10.1016/j.jaci.2012.06.027; Morizane S, 2012, J ALLERGY CLIN IMMUN, V130, P259, DOI 10.1016/j.jaci.2012.03.006; Mullins RJ, 2012, J ALLERGY CLIN IMMUN, V129, P1334, DOI 10.1016/j.jaci.2012.02.038; Murota H, 2012, J ALLERGY CLIN IMMUN, V130, P671, DOI 10.1016/j.jaci.2012.05.027; Nakajima S, 2012, J ALLERGY CLIN IMMUN, V129, P1048, DOI 10.1016/j.jaci.2012.01.063; Niggemann B, 2012, J ALLERGY CLIN IMMUN, V130, P261, DOI 10.1016/j.jaci.2012.03.021; Novak N, 2012, J ALLERGY CLIN IMMUN, V130, P925, DOI 10.1016/j.jaci.2012.08.004; Novak N, 2012, J ALLERGY CLIN IMMUN, V129, P879, DOI 10.1016/j.jaci.2012.01.062; Oh SH, 2012, J ALLERGY CLIN IMMUN, V129, P151, DOI 10.1016/j.jaci.2011.09.008; Ohtsuka Y, 2012, J ALLERGY CLIN IMMUN, V129, P1676, DOI 10.1016/j.jaci.2012.01.042; Osborne NJ, 2012, J ALLERGY CLIN IMMUN, V129, P865, DOI 10.1016/j.jaci.2012.01.037; Oyoshi MK, 2011, J ALLERGY CLIN IMMUN, V128, P890, DOI 10.1016/j.jaci.2011.06.042; Patil SU, 2012, J ALLERGY CLIN IMMUN, V129, P443, DOI 10.1016/j.jaci.2011.10.010; Pongracic JA, 2012, J ALLERGY CLIN IMMUN, V129, P564, DOI 10.1016/j.jaci.2011.09.024; Posthumus J, 2012, J ALLERGY CLIN IMMUN, V130, P814, DOI 10.1016/j.jaci.2012.04.037; Price JB, 2012, J ALLERGY CLIN IMMUN, V129, P863, DOI 10.1016/j.jaci.2012.01.034; Raedler D, 2012, J ALLERGY CLIN IMMUN; Rebane A, 2012, J ALLERGY CLIN IMMUN, V129, P1297, DOI 10.1016/j.jaci.2012.02.020; Rinaldi M, 2012, J ALLERGY CLIN IMMUN, V130, P945, DOI 10.1016/j.jaci.2012.07.042; Roduit C, 2012, J ALLERGY CLIN IMMUN, V130, P130, DOI 10.1016/j.jaci.2012.02.043; Romano A, 2012, J ALLERGY CLIN IMMUN, V129, P1166, DOI 10.1016/j.jaci.2011.12.995; Rudders SA, 2012, J ALLERGY CLIN IMMUN; Ruiter B, 2012, J ALLERGY CLIN IMMUN, V129, P921, DOI 10.1016/j.jaci.2012.01.080; Saffari H, 2012, J ALLERGY CLIN IMMUN, V130, P798, DOI 10.1016/j.jaci.2012.03.009; Sampson HA, J ALLERGY CLIN IMMUN; Sanchez-Garcia S, 2012, J ALLERGY CLIN IMMUN, V129, P1155, DOI 10.1016/j.jaci.2011.11.042; Sastre J, 2012, J ALLERGY CLIN IMMUN, V129, P566, DOI 10.1016/j.jaci.2011.09.028; Savage JH, 2012, J ALLERGY CLIN IMMUN, V130, P453, DOI 10.1016/j.jaci.2012.05.006; Savage JH, 2012, J ALLERGY CLIN IMMUN, V130; Schroeder S, 2012, J ALLERGY CLIN IMMUN, V129, P1419, DOI 10.1016/j.jaci.2012.03.007; Seppala U, 2012, J ALLERGY CLIN IMMUN, V129, P1314, DOI 10.1016/j.jaci.2011.10.014; Sicherer SH, 2012, J ALLERGY CLIN IMMUN, V129, P76, DOI 10.1016/j.jaci.2011.11.016; Simons FER, 2012, J ALLERGY CLIN IMMUN, V130, P597, DOI 10.1016/j.jaci.2012.06.035; Simpson EL, 2012, J ALLERGY CLIN IMMUN, V130, P137, DOI 10.1016/j.jaci.2012.01.075; Soller L, 2012, J ALLERGY CLIN IMMUN, V130, P986, DOI 10.1016/j.jaci.2012.06.029; Spergel JM, 2012, J ALLERGY CLIN IMMUN, V130, P461, DOI 10.1016/j.jaci.2012.05.021; Spergel JM, 2012, J ALLERGY CLIN IMMUN, V129, P456, DOI 10.1016/j.jaci.2011.11.044; Stoevesandt J, 2012, J ALLERGY CLIN IMMUN, V130, P698, DOI 10.1016/j.jaci.2012.03.024; Sugawara K, 2012, J ALLERGY CLIN IMMUN, V129, P726, DOI 10.1016/j.jaci.2011.11.009; Tan HT, 2012, J ALLERGY CLIN IMMUN, V130; Tan J, 2012, J ALLERGY CLIN IMMUN, V129, P873, DOI 10.1016/j.jaci.2011.12.1000; Tang TS, 2012, J ALLERGY CLIN IMMUN, V129, P1209, DOI 10.1016/j.jaci.2012.02.002; Cepeda ST, 2012, J ALLERGY CLIN IMMUN, V129, P1416, DOI 10.1016/j.jaci.2012.03.008; Thyssen JP, 2012, J ALLERGY CLIN IMMUN, V130; Tintle S, 2011, J ALLERGY CLIN IMMUN, V128, P583, DOI 10.1016/j.jaci.2011.05.042; Tunis MC, 2012, J ALLERGY CLIN IMMUN, V130, P705, DOI 10.1016/j.jaci.2012.04.011; Vadas P, 2012, J ALLERGY CLIN IMMUN; van der Velde JL, 2012, J ALLERGY CLIN IMMUN, V130, P1136, DOI 10.1016/j.jaci.2012.05.037; Varga EM, 2012, J ALLERGY CLIN IMMUN; Vasiadi M, 2012, J ALLERGY CLIN IMMUN, V129, P1410, DOI 10.1016/j.jaci.2012.01.041; Wang MQ, 2012, J ALLERGY CLIN IMMUN, V130, P932, DOI 10.1016/j.jaci.2012.07.032; Wei CY, 2012, J ALLERGY CLIN IMMUN, V129, P1562, DOI 10.1016/j.jaci.2011.12.990; Ziegler SF, 2012, J ALLERGY CLIN IMMUN, V130, P845, DOI 10.1016/j.jaci.2012.07.010	126	23	24	0	52	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2013	131	1					55	66		10.1016/j.jaci.2012.11.007	http://dx.doi.org/10.1016/j.jaci.2012.11.007			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	062YR	23199604				2022-12-18	WOS:000312961200007
J	Posch, W; Cardinaud, S; Hamimi, C; Fletcher, A; Muhlbacher, A; Loacker, K; Eichberger, P; Dierich, MP; Pancino, G; Lass-Florl, C; Moris, A; Saez-Cirion, A; Wilflingseder, D				Posch, Wilfried; Cardinaud, Sylvain; Hamimi, Chiraz; Fletcher, Adam; Muehlbacher, Annelies; Loacker, Klaus; Eichberger, Paul; Dierich, Manfred P.; Pancino, Gianfranco; Lass-Floerl, Cornelia; Moris, Arnaud; Saez-Cirion, Asier; Wilflingseder, Doris			Antibodies attenuate the capacity of dendritic cells to stimulate HIV-specific cytotoxic T lymphocytes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						HIV; IgG; opsonization; dendritic cells; cytotoxic T lymphocytes	IMMUNODEFICIENCY-VIRUS TYPE-1; CELLULAR IMMUNE-RESPONSES; NEUTRALIZING-ANTIBODY; ANTIGEN PRESENTATION; MONOCLONAL-ANTIBODY; DOUBLE-BLIND; INFECTION; VACCINE; CONTROLLERS; REPLICATION	Background: Control of HIV is suggested to depend on potent effector functions of the virus-specific CD8(+) T-cell response. Antigen opsonization can modulate the capture of antigen, its presentation, and the priming of specific CD8(+) T-cell responses. Objective: We have previously shown that opsonization of retroviruses acts as anendogenous adjuvant for dendritic cell (DC)mediated induction of specific cytotoxic T lymphocytes (CTLs). However, in some HIV-positive subjects, high levels of antibodies and low levels of complement fragments coat the HIV surface. Methods: Therefore we analyzed the effect of IgGopsonization on the antigen-presenting capacity of DCs by using CD8(+) T-cell proliferation assays after repeated prime boosting, by measuring the antiviral activity againstHIV-infected autologous CD4(+) T cells, and by determining IFN-gsecretion from HIV-specific CTL clones. Results: We find that DCs exposed to IgG-opsonized HIV significantly decreased the HIV-specific CD8(+) T-cell response compared with the earlier described efficient CD8(+) T-cell activation induced by DCs loaded with complement-opsonized HIV. DCs exposed to HIV bearing high surface IgG levels after incubation in plasma from HIV-infected subjects acted as weak stimulators for HIV-specific CTL clones. In contrast, HIV opsonized with plasma from patients exhibiting high complement and low IgG deposition on the viral surface favored significantly higher activation of HIV-specific CD8(+) T-cell clones. Conclusion: Our ex vivo and in vitro observations provide the first evidence that IgG opsonization of HIV is associated with a decreased CTL-stimulatory capacity of DCs. (J Allergy Clin Immunol 2012;130:1368-74.)	[Posch, Wilfried; Dierich, Manfred P.; Lass-Floerl, Cornelia; Wilflingseder, Doris] Innsbruck Med Univ, Div Hyg & Med Microbiol, A-6020 Innsbruck, Austria; [Muehlbacher, Annelies; Loacker, Klaus] Innsbruck Med Univ, Cent Inst Blood Transfus, A-6020 Innsbruck, Austria; [Muehlbacher, Annelies; Loacker, Klaus] Innsbruck Med Univ, Dept Immunol, A-6020 Innsbruck, Austria; [Eichberger, Paul] Innsbruck Med Univ, Dept Therapeut Radiol & Oncol, A-6020 Innsbruck, Austria; [Cardinaud, Sylvain; Moris, Arnaud] Univ Paris 06, INSERM, UMRS Infect & Immun 945, Hop La Pitie Salpetriere, Paris, France; [Hamimi, Chiraz; Pancino, Gianfranco; Saez-Cirion, Asier] Inst Pasteur, Unite Regulat Infect Retrovirales, Paris, France; [Fletcher, Adam] UCL, MRC UCL Ctr Med Mol Virol, Div Infect & Immun, London, England	Medical University of Innsbruck; Medical University of Innsbruck; Medical University of Innsbruck; Medical University of Innsbruck; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of London; University College London	Wilflingseder, D (corresponding author), Innsbruck Med Univ, Div Hyg & Med Microbiol, Fritz Pregl Str 3, A-6020 Innsbruck, Austria.	doris.wilflingseder@i-med.ac.at	Saez-Cirion, Asier/A-8640-2008; Posch, Wilfried/AAH-6845-2019; Lass-Flörl, Cornelia/AAA-8449-2020	Saez-Cirion, Asier/0000-0003-2406-7536; Posch, Wilfried/0000-0001-8955-7654; CARDINAUD, Sylvain/0000-0002-2650-1108; Wilflingseder, Doris/0000-0002-5888-5118; Lass-Florl, Cornelia/0000-0002-2946-7785; Moris, Arnaud/0000-0002-5052-1678	Tyrolean Science Fund; Austrian National Bank Fund; Sidaction; Gilead Sciences; MSD; Pfizer; Schering-Plough; Astellas Pharma; Sideaction/ANRS; MSF; Austrian Science Fund; Austrian Science Fund (FWF) [P 22165, P 24598] Funding Source: researchfish	Tyrolean Science Fund; Austrian National Bank Fund; Sidaction; Gilead Sciences(Gilead Sciences); MSD; Pfizer(Pfizer); Schering-Plough(Merck & CompanySchering Plough Corporation); Astellas Pharma(Astellas Pharmaceuticals); Sideaction/ANRS; MSF; Austrian Science Fund(Austrian Science Fund (FWF)); Austrian Science Fund (FWF)(Austrian Science Fund (FWF))	W. Posch has received research support from the Tyrolean Science Fund and the Austrian National Bank Fund. S. Cardinaud has received research support from Sidaction. C. Lass-Florl has received consultancy fees from Gilead Sciences, MSD, Pfizer, and Schering-Plough; has received research support from Astellas Pharma, Gilead Sciences, and Pfizer; has received lecture fees from Astellas Pharma, Pfizer, and MSD; and has received travel expenses from Gilead Sciences, MSD, Pfizer, and Astellas Pharma. A. Moris has received research support from Sideaction/ANRS. A. Saez-Cirion has received lecture fees from MSF. D. Wilflingseder has received research support from the Austrian Science Fund. The rest of the authors declare that they have no relevant conflicts of interest.	Andrieu JM, 2007, J INTERN MED, V261, P123, DOI 10.1111/j.1365-2796.2006.01738.x; Banki Z, 2005, AIDS, V19, P481, DOI 10.1097/01.aids.0000162336.20439.8d; Banki Z, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000891; Bar KJ, 2010, J VIROL, V84, P6241, DOI 10.1128/JVI.00077-10; BORROW P, 1994, J VIROL, V68, P6103, DOI 10.1128/JVI.68.9.6103-6110.1994; Bouhlal H, 2002, J IMMUNOL, V169, P3301, DOI 10.4049/jimmunol.169.6.3301; Buchbinder SP, 2008, LANCET, V372, P1881, DOI 10.1016/S0140-6736(08)61591-3; CAO YZ, 1995, NEW ENGL J MED, V332, P201, DOI 10.1056/NEJM199501263320401; Carrington M, 2003, ANNU REV MED, V54, P535, DOI 10.1146/annurev.med.54.101601.152346; Casartelli N, 2010, J EXP MED, V207, P39, DOI 10.1084/jem.20091933; Flynn MN, 2005, J INFECT DIS, V191, P654, DOI 10.1086/428404; Freeman GJ, 2006, J EXP MED, V203, P2223, DOI 10.1084/jem.20061800; Garcia E, 2005, TRAFFIC, V6, P488, DOI 10.1111/j.1600-0854.2005.00293.x; Goulder PJR, 2008, NAT REV IMMUNOL, V8, P619, DOI 10.1038/nri2357; Gray ES, 2011, J VIROL, V85, P7719, DOI 10.1128/JVI.00563-11; Haynes BF, 2011, TRENDS MOL MED, V17, P108, DOI 10.1016/j.molmed.2010.10.008; HEATH SL, 1995, NATURE, V377, P740, DOI 10.1038/377740a0; HEYMAN B, 1990, IMMUNOL TODAY, V11, P310, DOI 10.1016/0167-5699(90)90126-T; Holl V, 2006, J VIROL, V80, P6177, DOI 10.1128/JVI.02625-05; Jakubik JJ, 2000, J VIROL, V74, P552, DOI 10.1128/JVI.74.1.552-555.2000; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; Lambotte O, 2005, CLIN INFECT DIS, V41, P1053, DOI 10.1086/433188; Lambotte O, 2009, AIDS, V23, P897, DOI 10.1097/QAD.0b013e328329f97d; Lewis MJ, 2012, J VIROL, V86, P7459, DOI 10.1128/JVI.06724-11; Lutz MB, 1999, J IMMUNOL METHODS, V223, P77, DOI 10.1016/S0022-1759(98)00204-X; McElrath MJ, 2008, LANCET, V372, P1894, DOI 10.1016/S0140-6736(08)61592-5; McElrath MJ, 2010, IMMUNITY, V33, P542, DOI 10.1016/j.immuni.2010.09.011; McElrath MJ, 2010, J INFECT DIS, V202, pS323, DOI 10.1086/655658; McMichael AJ, 2001, NATURE, V410, P980, DOI 10.1038/35073658; Migueles SA, 2008, IMMUNITY, V29, P1009, DOI 10.1016/j.immuni.2008.10.010; Miura T, 2010, J VIROL, V84, P7581, DOI 10.1128/JVI.00286-10; Montefiori DC, 1996, J INFECT DIS, V173, P60, DOI 10.1093/infdis/173.1.60; Moog C, 1997, J VIROL, V71, P3734, DOI 10.1128/JVI.71.5.3734-3741.1997; Moris A, 2004, BLOOD, V103, P2648, DOI 10.1182/blood-2003-07-2532; Picker LJ, 2012, ANNU REV MED, V63, P95, DOI 10.1146/annurev-med-042010-085643; Pitisuttithum P, 2006, J INFECT DIS, V194, P1661, DOI 10.1086/508748; PURTSCHER M, 1994, AIDS RES HUM RETROV, V10, P1651, DOI 10.1089/aid.1994.10.1651; Rafiq K, 2002, J CLIN INVEST, V110, P71, DOI 10.1172/JCI200215640; Regnault A, 1999, J EXP MED, V189, P371, DOI 10.1084/jem.189.2.371; Rerks-Ngarm S, 2009, NEW ENGL J MED, V361, P2209, DOI 10.1056/NEJMoa0908492; Saez-Cirion A, 2007, TRENDS IMMUNOL, V28, P532, DOI 10.1016/j.it.2007.09.002; Saez-Cirion A, 2007, P NATL ACAD SCI USA, V104, P6776, DOI 10.1073/pnas.0611244104; Streeck H, 2009, J VIROL, V83, P7641, DOI 10.1128/JVI.00182-09; Tanaka Y, 2005, J IMMUNOL, V174, P1274, DOI 10.4049/jimmunol.174.3.1274; Tomaras GD, 2008, J VIROL, V82, P12449, DOI 10.1128/JVI.01708-08; Turley SJ, 2000, SCIENCE, V288, P522, DOI 10.1126/science.288.5465.522; Wilflingseder D, 2007, J IMMUNOL, V178, P7840, DOI 10.4049/jimmunol.178.12.7840	47	23	23	0	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2012	130	6					1368	+		10.1016/j.jaci.2012.08.025	http://dx.doi.org/10.1016/j.jaci.2012.08.025			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	044RP	23063584	Green Accepted, Bronze, Green Submitted			2022-12-18	WOS:000311641100018
J	Nair, P; Kraft, M				Nair, Parameswaran; Kraft, Monica			Serum periostin as a marker of T(H)2-dependent eosinophilic airway inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Asthma; eosinophils; biomarker; periostin	ASTHMA; PROTEIN; CORTICOSTEROIDS; IDENTIFICATION; BUDESONIDE; FIBROSIS; ADULTS; SPUTUM; BETA		[Nair, Parameswaran] McMaster Univ, Firestone Inst Resp Hlth, St Josephs Healthcare, Div Respirol, Hamilton, ON L8N 4A6, Canada; [Kraft, Monica] Duke Univ, Div Pulm & Crit Care, Durham, NC 27706 USA	McMaster University; Duke University	Nair, P (corresponding author), McMaster Univ, Firestone Inst Resp Hlth, St Josephs Healthcare, Div Respirol, 50 Charlton Ave E, Hamilton, ON L8N 4A6, Canada.	parames@mcmaster.ca						Barnes PJ, 2009, LANCET, V373, P1905, DOI 10.1016/S0140-6736(09)60326-3; Blanchard C, 2008, MUCOSAL IMMUNOL, V1, P289, DOI 10.1038/mi.2008.15; Castro M, 2011, AM J RESP CRIT CARE, V184, P1125, DOI 10.1164/rccm.201103-0396OC; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; Gordon ED, 2012, CLIN EXP ALLERGY, V42, P144, DOI 10.1111/j.1365-2222.2011.03840.x; Green RH, 2002, THORAX, V57, P875, DOI 10.1136/thorax.57.10.875; Horiuchi K, 1999, J BONE MINER RES, V14, P1239, DOI 10.1359/jbmr.1999.14.7.1239; Jia G, 2012, J ALLERGY CLIN IMMUN, V130; Kudo Y, 2007, HISTOL HISTOPATHOL, V22, P1167, DOI 10.14670/HH-22.1167; Litvin J, 2006, CARDIOVASC PATHOL, V15, P24, DOI 10.1016/j.carpath.2005.09.001; Masuoka M, 2012, J CLIN INVEST, V122, P2590, DOI 10.1172/JCI58978; Meijer RJ, 2002, CLIN EXP ALLERGY, V32, P1096, DOI 10.1046/j.1365-2222.2002.01412.x; Nair P, 2009, NEW ENGL J MED, V360, P985, DOI 10.1056/NEJMoa0805435; Pauwels RA, 1997, NEW ENGL J MED, V337, P1405, DOI 10.1056/NEJM199711133372001; Pauwels RA, 2003, LANCET, V361, P1071, DOI 10.1016/S0140-6736(03)12891-7; Sen K, 2011, AM J PATHOL, V179, P1756, DOI 10.1016/j.ajpath.2011.06.002; Sidhu SS, 2010, P NATL ACAD SCI USA, V107, P14170, DOI 10.1073/pnas.1009426107; Uchida M, 2012, AM J RESP CELL MOL, V46, P677, DOI 10.1165/rcmb.2011-0115OC; Walker JKL, 2011, BRIT J PHARMACOL, V163, P18, DOI 10.1111/j.1476-5381.2010.01178.x; Weiss ST, 2006, PHARMACOGENOMICS J, V6, P311, DOI 10.1038/sj.tpj.6500387; Woodruff PG, 2007, P NATL ACAD SCI USA, V104, P15858, DOI 10.1073/pnas.0707413104; Zhu M, 2010, GYNECOL ONCOL, V119, P337, DOI 10.1016/j.ygyno.2010.07.008	22	23	26	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2012	130	3					655	656		10.1016/j.jaci.2012.07.021	http://dx.doi.org/10.1016/j.jaci.2012.07.021			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	001LZ	22935590				2022-12-18	WOS:000308463500013
J	Twaroch, TE; Arcalis, E; Sterflinger, K; Stoger, E; Swoboda, I; Valenta, R				Twaroch, Teresa E.; Arcalis, Elsa; Sterflinger, Katja; Stoeger, Eva; Swoboda, Ines; Valenta, Rudolf			Predominant localization of the major Alternaria allergen Alt a 1 in the cell wall of airborne spores	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Twaroch, Teresa E.; Swoboda, Ines; Valenta, Rudolf] Med Univ Vienna, Christian Doppler Lab Allergy Res, Div Immunopathol, Dept Pathophysiol & Allergy Res,Ctr Pathophysiol, Vienna, Austria; [Arcalis, Elsa; Stoeger, Eva] Univ Nat Resources & Appl Life Sci, Inst Appl Genet & Cell Biol, Dept Biotechnol, Vienna, Austria; [Sterflinger, Katja] Univ Nat Resources & Appl Life Sci, Inst Appl Microbiol, Dept Biotechnol, Vienna, Austria	Medical University of Vienna; University of Natural Resources & Life Sciences, Vienna; University of Natural Resources & Life Sciences, Vienna	Twaroch, TE (corresponding author), Med Univ Vienna, Christian Doppler Lab Allergy Res, Div Immunopathol, Dept Pathophysiol & Allergy Res,Ctr Pathophysiol, Vienna, Austria.	rudolf.valenta@meduniwien.ac.at		Swoboda, Ines/0000-0002-9164-1721; Stoeger, Eva/0000-0002-7651-7992; Valenta, Rudolf/0000-0001-5944-3365; Sterflinger, Katja/0000-0002-0296-6728; Arcalis, Elsa/0000-0001-9883-465X				Aimanianda V, 2009, NATURE, V460, P1117, DOI 10.1038/nature08264; Breitenbach M, 2008, INT ARCH ALLERGY IMM, V145, P58, DOI 10.1159/000107578; Focke M, 2001, FASEB J, V15, P2042, DOI 10.1096/fj.01-0016fje; Grote M, 1999, INT ARCH ALLERGY IMM, V118, P1, DOI 10.1159/000024024; Ibarrola I, 2004, ANN ALLERG ASTHMA IM, V93, P589, DOI 10.1016/S1081-1206(10)61268-9; Mitakakis TZ, 2001, J ALLERGY CLIN IMMUN, V107, P388, DOI 10.1067/mai.2001.112602; PARIS S, 1991, J ALLERGY CLIN IMMUN, V88, P902, DOI 10.1016/0091-6749(91)90247-L; Rodriguez-Rajo FJ, 2005, MYCOL RES, V109, P497, DOI 10.1017/S0953756204001777; TARGONSKI PV, 1995, J ALLERGY CLIN IMMUN, V95, P955, DOI 10.1016/S0091-6749(95)70095-1	9	23	23	1	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2012	129	4					1148	1149		10.1016/j.jaci.2011.10.008	http://dx.doi.org/10.1016/j.jaci.2011.10.008			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	917AP	22078468				2022-12-18	WOS:000302144600033
J	Licciardi, PV; Balloch, A; Russell, FM; Burton, RL; Lin, JS; Nahm, MH; Mulholland, EK; Tang, MLK				Licciardi, Paul V.; Balloch, Anne; Russell, Fiona M.; Burton, Robert L.; Lin, Jisheng; Nahm, Moon H.; Mulholland, Edward K.; Tang, Mimi L. K.			Pneumococcal polysaccharide vaccine at 12 months of age produces functional immune responses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Pneumococcal polysaccharide vaccine; antibody; opsonophagocytosis; avidity; function; serotype; Pneumovax; 23-valent pneumococcal polysaccharide vaccine (Pneumovax)	CONJUGATE VACCINE; ANTIBODY-RESPONSE; IMMUNOGENICITY; INFANTS; OPSONOPHAGOCYTOSIS; PROTECTION; SCHEDULE; CHILDREN; AVIDITY	Background: Infections with Streptococcus pneumoniae (pneumococcus) are a cause of significant child mortality. Pneumococcal glycoconjugate vaccines are expensive and provide limited serotype coverage. The 23-valent pneumococcal polysaccharide vaccine (Pneumovax) might provide wider serotype coverage but is reported to be weakly immunogenic in children less than 2 years of age. We have previously reported that Pneumovax administered to healthy 12-month-old Fijian infants elicits significant serotype-specific IgG responses. However, the functional capacity of these responses in 12-month-old infants is not known. Objective: We sought to assess the functional, serotype-specific immune response of 12-month-old infants after immunization with Pneumovax. Methods: Functional responses of 12-month-old infants were assessed by using the opsonophagocytic and antibody avidity assay against 8 serotypes and 23 serotypes, respectively. Results: Seventy-one percent of infants produced strong opsonophagocytic activity against 4 of 8 serotypes, and 30% produced high-avidity serotype-specific IgG antibodies to 10 of 23 serotypes at 2 weeks after Pneumovax. Responses were protective for most serotypes that cause disease in Western countries, whereas responses to most of the epidemiologically relevant serotypes for developing countries were low. Conclusion: This is the first comprehensive study evaluating the functional antibody response to Pneumovax in 12-month-old infants. Pneumovax induced functional antibody responses to several serotypes causing disease in Western countries but induced poorer responses to serotypes that are responsible for the majority of disease in developing countries. Pneumovax might be of benefit in some populations, but further studies are required before this can be recommended in developing countries. (J Allergy Clin Immunol 2012;129:794-800.)	[Tang, Mimi L. K.] Royal Childrens Hosp, Dept Allergy & Immunol, Melbourne, Vic, Australia; [Licciardi, Paul V.; Balloch, Anne; Tang, Mimi L. K.] Murdoch Childrens Res Inst, Pneumococcal Lab, Melbourne, Vic, Australia; [Russell, Fiona M.] Murdoch Childrens Res Inst, Ctr Int Child Hlth, Melbourne, Vic, Australia; [Burton, Robert L.; Lin, Jisheng; Nahm, Moon H.] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA; [Burton, Robert L.; Lin, Jisheng; Nahm, Moon H.] Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA; [Mulholland, Edward K.] London Sch Hyg & Trop Med, London, England; [Tang, Mimi L. K.] Univ Melbourne, Dept Paediat, Melbourne, Vic 3010, Australia	Royal Children's Hospital Melbourne; Murdoch Children's Research Institute; Murdoch Children's Research Institute; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of London; London School of Hygiene & Tropical Medicine; University of Melbourne	Tang, MLK (corresponding author), Royal Childrens Hosp, Dept Allergy & Immunol, Melbourne, Vic, Australia.	mimi.tang@rch.org.au	Tang, Mimi/ABD-8350-2020	Tang, Mimi/0000-0002-3839-5293; Nahm, Moon/0000-0002-6922-1042	National Institute of Allergy and Infectious Diseases (NIAID) [2 U01 AI052337-05]; Australian National Health and Medical Research Council (NHMRC) [251648]; Victorian Government; National Institutes of Health [AI-30021]; Gates Foundation; Nestle Research Center; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI052337] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Australian National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); Victorian Government; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Gates Foundation(Bill & Melinda Gates Foundation); Nestle Research Center(Nestle SA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by grants from the National Institute of Allergy and Infectious Diseases (NIAID; 2 U01 AI052337-05), the Australian National Health and Medical Research Council (NHMRC grant no. 251648), and the Victorian Government's Operational Infrastructure Support Program. Pneumovax was kindly donated by CSL Biotherapies, Australia. M.H.N. is supported by National Institutes of Health contract AI-30021.; M. H. Nahm has consultant arrangements with Merck and receives research support from the National Institutes of Health. E. K. Mulholland receives research support from the National Institutes of Health and the Gates Foundation. M. L. K. Tang is a member of the Asia Pacific Medical Advisory Board for Nestle Nutrition Institute, is a member of the Medical Advisory Board for Wyeth, is a speaker for Danone, and receives research support from the Nestle Research Center. The rest of the authors declare that they have no relevant conflicts of interest.	Balloch A, 2010, VACCINE, V28, P1333, DOI 10.1016/j.vaccine.2009.11.011; Balloch A, 2008, 6 INT S PNEUM PNEUM; Balloch A, 2010, J ALLERGY CLIN IMMUN, V126, DOI 10.1016/j.jaci.2010.05.008; Breukels MA, 2005, SCAND J IMMUNOL, V61, P322, DOI 10.1111/j.1365-3083.2005.01584.x; Burton RL, 2006, CLIN VACCINE IMMUNOL, V13, P1004, DOI 10.1128/CVI.00112-06; Carey JB, 2008, J EXP MED, V205, P2043, DOI 10.1084/jem.20080559; DOUGLAS RM, 1983, J INFECT DIS, V148, P131, DOI 10.1093/infdis/148.1.131; Ekstrom N, 2005, INFECT IMMUN, V73, P369, DOI 10.1128/IAI.73.1.369-377.2005; Ekstrom N, 2007, INFECT IMMUN, V75, P1794, DOI 10.1128/IAI.01673-06; Goldblatt D, 2006, PEDIATR INFECT DIS J, V25, P312, DOI 10.1097/01.inf.0000207483.60267.e7; Goldblatt D, 2010, PEDIATR INFECT DIS J, V29, P401, DOI 10.1097/INF.0b013e3181c67f04; Hare ND, 2009, J ALLERGY CLIN IMMUN, V123, P195, DOI 10.1016/j.jaci.2008.09.021; Henckaerts I, 2007, VACCINE, V25, P2518, DOI 10.1016/j.vaccine.2006.09.029; Johnson HL, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000348; Kayhty H, 2005, PEDIATR INFECT DIS J, V24, P108, DOI 10.1097/01.inf.0000151022.92222.be; Kolibab Kris, 2005, Immun Ageing, V2, P10, DOI 10.1186/1742-4933-2-10; Laferriere C, 2011, VACCINE, V29, P6838, DOI 10.1016/j.vaccine.2011.07.097; Leach AJ, 2008, VACCINE, V26, P3885, DOI 10.1016/j.vaccine.2008.05.012; Licciardi PV, 2010, VACCINE, V28, P3793, DOI 10.1016/j.vaccine.2010.03.033; Licciardi PV, 2011, NAT REV DRUG DISCOV, V10, P394, DOI 10.1038/nrd3012-c1; Melin M, 2009, INFECT IMMUN, V77, P676, DOI 10.1128/IAI.01186-08; Morbach H, 2010, CLIN EXP IMMUNOL, V162, P271, DOI 10.1111/j.1365-2249.2010.04206.x; O'Brien KL, 2009, VACCINE, V27, P1863, DOI 10.1016/j.vaccine.2008.12.060; O'Grady KAF, 2010, CLIN INFECT DIS, V50, P970, DOI 10.1086/651079; Paris K, 2007, ANN ALLERG ASTHMA IM, V99, P462, DOI 10.1016/S1081-1206(10)60572-8; Park IH, 2007, J CLIN MICROBIOL, V45, P1225, DOI 10.1128/JCM.02199-06; Plotkin SA, 2010, CLIN VACCINE IMMUNOL, V17, P1055, DOI 10.1128/CVI.00131-10; PneumoADIP, 2008, PNEUM REG SER DISTR; Romero-Steiner S, 2006, CLIN VACCINE IMMUNOL, V13, P165, DOI 10.1128/CVI.13.2.165-169.2006; Russell FM, 2011, VACCINE, V29, P4499, DOI 10.1016/j.vaccine.2011.04.038; Russell FM, 2011, VACCINE, V29, P535, DOI 10.1016/j.vaccine.2010.10.046; Russell FM, 2010, CLIN VACCINE IMMUNOL, V17, P1970, DOI 10.1128/CVI.00117-10; Russell FM, 2010, VACCINE, V28, P3341, DOI 10.1016/j.vaccine.2010.02.087; Russell FM, 2010, VACCINE, V28, P3086, DOI 10.1016/j.vaccine.2010.02.065; Russell FM, 2009, VACCINE, V27, P5685, DOI 10.1016/j.vaccine.2009.06.098; Russell FM, 2010, PEDIATR INFECT DIS J, V29, P870, DOI 10.1097/INF.0b013e3181ec7ae2; Siber GR, 2007, VACCINE, V25, P3816, DOI 10.1016/j.vaccine.2007.01.119; Sorensen RU, 1998, J ALLERGY CLIN IMMUN, V102, P215, DOI 10.1016/S0091-6749(98)70089-2; Taillardet M, 2010, J INFECT DIS, V202, P470, DOI 10.1086/653739; Wardlaw TM, 2006, PNEUMONIA FORGOTTEN	40	23	23	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2012	129	3					794	U283		10.1016/j.jaci.2011.11.043	http://dx.doi.org/10.1016/j.jaci.2011.11.043			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	904IW	22305678	Green Accepted			2022-12-18	WOS:000301189300027
J	Cho, HJ; Lee, HJ; Kim, SC; Kim, K; Kim, YS; Kim, CH; Lee, JG; Yoon, JH; Choi, JY				Cho, Hyung-Ju; Lee, Hyun Jae; Kim, Sang Cheol; Kim, Kyubo; Kim, Yoo Suk; Kim, Chang-Hoon; Lee, Jeung-Gweon; Yoon, Joo-Heon; Choi, Jae Young			Protease-activated receptor 2-dependent fluid secretion from airway submucosal glands by house dust mite extract	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						House dust mites; submucosal gland; allergy; chronic rhinosinusitis; protease-activated receptor; nasal	VASOACTIVE-INTESTINAL-PEPTIDE; EPITHELIAL-CELLS; MUCUS SECRETION; EXPRESSION; IL-8; INFLAMMATION; RELEASE; VIVO	Background: The submucosal gland (SMG) is important in the control of airway surface fluid. Protease-activated receptor (PAR) 2 contributes to the pathophysiology of allergies in response to nonspecific allergens bearing proteases and anion secretion. House dust mites (HDMs) have abundant proteases that can activate PAR2, but little is known about the direct effect of HDM on SMG secretion. Objective: The aim of this study was to investigate the effect of HDMs on glandular secretion and its mechanism in allergic patients, patients with chronic rhinosinusitis (CRS), or both. Methods: Inferior nasal turbinates were harvested from 55 patients and classified into 4 groups (the control, allergic rhinitis [AR], CRS, and AR+CRS groups). A microscope attached to a digital camera was used to quantify mucus bubbles from individual SMGs while stimulated with HDM extract, PAR2-activating peptide, and carbachol. PAR2 expression in the SMG was determined by means of immunostaining with anti-PAR2 mAb. Results: HDM induced a significantly higher secretion rate and number of responding glands in the AR and AR+CRS groups than in the control group. Interestingly, patients in the CRS group, who had no HDM-specific IgE antibody, showed a higher response than the control group, and its response was suppressed by a PAR2-selective antagonist. The responses to PAR2-activating peptide were similar to those to HDM, and their secretion rates positively correlated with HDM responses. PAR2 was highly expressed in all 3 disease groups with immunostaining. Conclusions: HDM allergens can induce glandular secretion in patients with AR, CRS, or both, and PAR2 represents a possible mechanism for nonspecific hyperreactivity in inflammatory airway diseases. (J Allergy Clin Immunol 2012;129:529-35.)	[Lee, Hyun Jae; Kim, Sang Cheol; Kim, Yoo Suk; Kim, Chang-Hoon; Lee, Jeung-Gweon; Yoon, Joo-Heon; Choi, Jae Young] Yonsei Univ, Dept Otorhinolaryngol, Coll Med, Seoul 120752, South Korea; [Cho, Hyung-Ju; Kim, Kyubo] Hallym Univ, Dept Otorhinolaryngol, Kang Dong Sacred Heart Hosp, Coll Med, Seoul, South Korea; [Lee, Hyun Jae; Kim, Chang-Hoon; Yoon, Joo-Heon] Yonsei Univ, Coll Med, Res Ctr Human Nat Def Syst, Seoul 120752, South Korea; [Kim, Chang-Hoon; Yoon, Joo-Heon] Yonsei Univ, Airway Mucus Inst, Coll Med, Seoul 120752, South Korea; [Lee, Hyun Jae; Yoon, Joo-Heon; Choi, Jae Young] Yonsei Univ, Brain Korea Project Med Sci 21, Coll Med, Seoul 120752, South Korea	Yonsei University; Yonsei University Health System; Hallym University; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System	Choi, JY (corresponding author), Yonsei Univ, Dept Otorhinolaryngol, Coll Med, 134 Shinchon Dong, Seoul 120752, South Korea.	jhyoon@yuhs.ac; jychoi@yuhs.ac	Kim, Chang-Hoon/D-7205-2016; Lee, Hyun Jae/AAV-6015-2021; Yoon, Joo-Heon/E-5781-2016; rchnds, rchnds/D-7595-2016	Kim, Chang-Hoon/0000-0003-1238-6396; choi, jae young/0000-0001-9493-3458; Yoon, Joo-Heon/0000-0003-2404-7156	Korea Research Foundation; Korean Government (MOEHRD) [KRF-2007-313-E00337]; National Research Foundation of Korea; Ministry of Education, Science, and Technology [2011-0001168]	Korea Research Foundation(National Research Foundation of Korea); Korean Government (MOEHRD)(Ministry of Education & Human Resources Development (MOEHRD), Republic of KoreaKorean Government); National Research Foundation of Korea(National Research Foundation of Korea); Ministry of Education, Science, and Technology(Ministry of Education, Science & Technology (MEST), Republic of Korea)	Supported by a Korea Research Foundation Grant funded by the Korean Government (MOEHRD, Basic Research Promotion Fund [KRF-2007-313-E00337 to J.Y.C.]) and the National Research Foundation of Korea by the Ministry of Education, Science, and Technology (Basic Science Research Program, 2011-0001168 to J.-H.Y.).	[Anonymous], 1963, CLIN ASPECTS IMMUNOL; Cho HJ, 2010, J CELL BIOCHEM, V109, P1254, DOI 10.1002/jcb.22511; Choi JY, 2009, J CLIN INVEST, V119, P1189, DOI 10.1172/JCI37284; Dajani R, 2005, AM J RESP CELL MOL, V32, P548, DOI 10.1165/rcmb.2005-0059OC; ENGELHARDT JF, 1992, NAT GENET, V2, P240, DOI 10.1038/ng1192-240; Jenkins HA, 2003, CHEST, V124, P32, DOI 10.1378/chest.124.1.32; Joo NS, 2004, J BIOL CHEM, V279, P38854, DOI 10.1074/jbc.M407077200; Joo NS, 2002, J BIOL CHEM, V277, P50710, DOI 10.1074/jbc.M208826200; Joo NS, 2001, AM J PHYSIOL-LUNG C, V281, pL458, DOI 10.1152/ajplung.2001.281.2.L458; Joo NS, 2002, J BIOL CHEM, V277, P28167, DOI 10.1074/jbc.M202712200; Kauffman HF, 2000, J ALLERGY CLIN IMMUN, V105, P1185, DOI 10.1067/mai.2000.106210; Kawabata A, 2005, J PHARMACOL SCI, V97, P20, DOI 10.1254/jphs.FMJ04005X4; Kelso EB, 2006, J PHARMACOL EXP THER, V316, P1017, DOI 10.1124/jpet.105.093807; Kelso EB, 2007, ARTHRITIS RHEUM, V56, P765, DOI 10.1002/art.22423; Lee KE, 2007, CLIN EXP ALLERGY, V37, P1364, DOI 10.1111/j.1365-2222.2007.02797.x; Lee RJ, 2008, J GEN PHYSIOL, V132, P161, DOI 10.1085/jgp.200810017; Lim YS, 2007, ANN ALLERG ASTHMA IM, V98, P22, DOI 10.1016/S1081-1206(10)60855-1; Palmer ML, 2006, AM J PHYSIOL-CELL PH, V290, pC1189, DOI 10.1152/ajpcell.00464.2005; Rajan TV, 2003, TRENDS IMMUNOL, V24, P376, DOI 10.1016/S1471-4906(03)00142-X; Ramachandran R, 2006, AM J RESP CELL MOL, V35, P133, DOI 10.1165/rcmb.2005-0362OC; Risse PA, 2004, LIFE SCI, V75, P991, DOI 10.1016/j.lfs.2004.02.008; Roelandt T, 2008, J INVEST DERMATOL, V128, P1878, DOI 10.1038/jid.2008.168; Salinas D, 2004, FASEB J, V18, P431, DOI 10.1096/fj.04-2879fje; Sato S, 2005, BRIT J PHARMACOL, V146, P397, DOI 10.1038/sj.bjp.0706330; Schmidlin F, 2002, J IMMUNOL, V169, P5315, DOI 10.4049/jimmunol.169.9.5315; Tanaka Y, 2008, BIOCHEM BIOPH RES CO, V377, P622, DOI 10.1016/j.bbrc.2008.10.018; Vergnolle N, 1999, J IMMUNOL, V163, P5064; Verkman AS, 2003, AM J PHYSIOL-CELL PH, V284, pC2, DOI 10.1152/ajpcell.00417.2002; Wine JJ, 2011, METHODS MOL BIOL, V742, P93, DOI 10.1007/978-1-61779-120-8_6	29	23	23	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2012	129	2					529	U388		10.1016/j.jaci.2011.11.024	http://dx.doi.org/10.1016/j.jaci.2011.11.024			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	887TC	22196772				2022-12-18	WOS:000299951700033
J	Sedej, M; Schroder, R; Bell, K; Platzer, W; Vukoja, A; Kostenis, E; Heinemann, A; Waldhoer, M				Sedej, Miriam; Schroeder, Ralf; Bell, Kathrin; Platzer, Wolfgang; Vukoja, Anela; Kostenis, Evi; Heinemann, Akos; Waldhoer, Maria			D-type prostanoid receptor enhances the signaling of chemoattractant receptor-homologous molecule expressed on T(H)2 cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chemoattractant receptor-homologous molecule expressed on T(H)2 cells; eosinophils; prostaglandin D-2; Ca2+ flux; G protein-coupled receptor; D-type prostanoid receptor	PROSTAGLANDIN D-2 RECEPTOR; ALLERGIC INFLAMMATION; NASAL-MUCOSA; BONE-MARROW; T-CELLS; CRTH2; EOSINOPHILS; MIGRATION; ANTAGONIST; MODULATION	Background: Prostaglandin (PG) D-2 is substantially involved in allergic responses and signals through the 7 transmembrane-spanning/G protein-coupled receptors, chemoattractant receptor-homologous molecule expressed on T(H)2 cells (CRTH2), and D-type prostanoid (DP) receptor. Objective: Although the proinflammatory function of CRTH2 is well recognized and CRTH2 is hence considered an important emerging pharmacotherapeutic target, the role of the DP receptor in mediating the biological effects of PGD(2) in patients with allergic inflammation has remained unclear. Methods: The cross-talk of CRTH2 and DP receptors was investigated by using both a recombinant HEK293 cell model and human eosinophils in Ca2+ mobilization assays, coimmunoprecipitation, Western blotting, radioligand binding, and immunofluorescence. Results: We show that CRTH2 and DP receptors modulate one another's signaling properties and form CRTH2/DP heteromers without altering their ligand-binding capacities. We find that the DP receptor amplifies the CRTH2-induced Ca2+ release from intracellular stores and coincidentally forfeits its own signaling potency. Moreover, desensitization or pharmacologic blockade of the DP receptor hinders CRTH2-mediated signal transduction. However, CRTH2 internalization occurs independently of the DP receptor. In cells that express both receptors, pharmacologic blockade of G(aq/11) proteins abolishes the Ca2+ response to both CRTH2 and DP agonists, whereas inhibition of G(alpha i) proteins selectively attenuates the CRTH2-mediated response but not the DP signal. Conclusion: Our data demonstrate the capacity of DP receptors to amplify the biological response to CRTH2 activation. Therefore the CRTH2/DP heteromer might not only represent a functional signaling unit for PGD(2) but also a potential target for the development of heteromer-directed therapies to treat allergic diseases. (J Allergy Clin Immunol 2012;129:492-500.)	[Sedej, Miriam; Platzer, Wolfgang; Vukoja, Anela; Heinemann, Akos; Waldhoer, Maria] Med Univ Graz, Inst Expt & Clin Pharmacol, A-8010 Graz, Austria; [Schroeder, Ralf; Bell, Kathrin; Kostenis, Evi] Univ Bonn, Inst Pharmaceut Biol, Bonn, Germany; [Waldhoer, Maria] Hagedorn Res Inst, Gentofte, Denmark	Medical University of Graz; University of Bonn; Novo Nordisk; Hagedorn Research Institute	Heinemann, A (corresponding author), Med Univ Graz, Inst Expt & Clin Pharmacol, A-8010 Graz, Austria.	akos.heinemann@medunigraz.at	Waldhoer, Maria/HDO-0619-2022	Waldhoer, Maria/0000-0003-3534-1959; Heinemann, Akos/0000-0002-8554-2372	Austrian National Bank [12552, 13487]; Austrian Science Fund FWF [P18723, P19424-B05, P22521-B18]; Franz Lanyar Foundation [335, 343, 348]; Medical University of Graz; AstraZeneca; Almirall; AstraZeneca AB (Sweden); Austrian National Bank (Oe NB); Almirall SA (Spain); Lanyar Foundation (Graz, Austria); Austrian Science Fund (FWF) [P 22521] Funding Source: researchfish	Austrian National Bank; Austrian Science Fund FWF(Austrian Science Fund (FWF)); Franz Lanyar Foundation; Medical University of Graz; AstraZeneca(AstraZeneca); Almirall(Almirall); AstraZeneca AB (Sweden)(AstraZeneca); Austrian National Bank (Oe NB); Almirall SA (Spain)(Almirall); Lanyar Foundation (Graz, Austria); Austrian Science Fund (FWF)(Austrian Science Fund (FWF))	Supported by the Jubilaumsfonds of the Austrian National Bank (12552 and 13487), the Austrian Science Fund FWF (grants P18723, P19424-B05 and P22521-B18), and the Franz Lanyar Foundation (grants 335, 343 and 348). M.S. was supported by the PhD Program in Molecular Medicine of the Medical University of Graz. A.H. has received research support and consultancy fees from AstraZeneca and Almirall.; A. Heinemann has given lectures for AstraZeneca AB (Sweden) and has received research support from the Austrian Science Funds (FWF), the Jubilaumsfonds of the Austrian National Bank (Oe NB), AstraZeneca AB (Sweden), and Almirall SA (Spain). M. Waldhoer has received research support from the Austrian Science Funds (FWF), the Jubilaumsfonds of the Austrian National Bank (Oe NB), and the Lanyar Foundation (Graz, Austria). The rest of the authors declare that they have relevant no conflicts of interest.	Almishri W, 2005, J PHARMACOL EXP THER, V313, P64, DOI 10.1124/jpet.104.079079; Angeli V, 2001, J EXP MED, V193, P1135, DOI 10.1084/jem.193.10.1135; Arai I, 2004, EUR J PHARMACOL, V505, P229, DOI 10.1016/j.ejphar.2004.10.031; Arimura A, 2001, J PHARMACOL EXP THER, V298, P411; Barnes N, 2011, CLIN EXP ALLERGY; BOIE Y, 1995, J BIOL CHEM, V270, P18910, DOI 10.1074/jbc.270.32.18910; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; Chen YY, 2007, J IMMUNOL, V179, P2766, DOI 10.4049/jimmunol.179.5.2766; Gallant MA, 2007, EUR J PHARMACOL, V557, P115, DOI 10.1016/j.ejphar.2006.11.058; Gerashchenko D, 1998, J NEUROCHEM, V71, P937; Gervais FG, 2001, J ALLERGY CLIN IMMUN, V108, P982, DOI 10.1067/mai.2001.119919; Gosset P, 2003, J IMMUNOL, V170, P4943, DOI 10.4049/jimmunol.170.10.4943; Hammad H, 2003, J IMMUNOL, V171, P3936, DOI 10.4049/jimmunol.171.8.3936; Hammad H, 2007, J EXP MED, V204, P357, DOI 10.1084/jem.20061196; Hata AN, 2004, PHARMACOL THERAPEUT, V103, P147, DOI 10.1016/j.pharmthera.2004.06.003; Heinemann A, 2003, J IMMUNOL, V170, P4752, DOI 10.4049/jimmunol.170.9.4752; Hirai H, 2001, J EXP MED, V193, P255, DOI 10.1084/jem.193.2.255; HIRATA M, 1994, P NATL ACAD SCI USA, V91, P11192, DOI 10.1073/pnas.91.23.11192; Kostenis E, 2006, TRENDS MOL MED, V12, P148, DOI 10.1016/j.molmed.2006.02.005; Martini L, 2007, FASEB J, V21, P802, DOI 10.1096/fj.06-7132com; Matsuoka T, 2000, SCIENCE, V287, P2013, DOI 10.1126/science.287.5460.2013; Monneret G, 2001, BLOOD, V98, P1942, DOI 10.1182/blood.V98.6.1942; Nagata K, 1999, FEBS LETT, V459, P195, DOI 10.1016/S0014-5793(99)01251-X; Nantel F, 2004, PROSTAG OTH LIPID M, V73, P87, DOI 10.1016/j.prostaglandins.2003.12.002; Nesterov A, 2010, J BIOMOL SCREEN, V15, P518, DOI 10.1177/1087057110369702; Oka S, 2004, J LEUKOCYTE BIOL, V76, P1002, DOI 10.1189/jlb.0404252; Pettipher R, 2007, NAT REV DRUG DISCOV, V6, P313, DOI 10.1038/nrd2266; Prinster SC, 2005, PHARMACOL REV, V57, P289, DOI 10.1124/pr.57.3.1; Royer JF, 2008, EUR J CLIN INVEST, V38, P663, DOI 10.1111/j.1365-2362.2008.01989.x; Royer JF, 2007, ALLERGY, V62, P1401, DOI 10.1111/j.1398-9995.2007.01452.x; Rozenfeld R, 2010, TRENDS PHARMACOL SCI, V31, P124, DOI 10.1016/j.tips.2009.11.008; Schratl P, 2007, J IMMUNOL, V179, P4792, DOI 10.4049/jimmunol.179.7.4792; Schuligoi R, 2010, PHARMACOLOGY, V85, P372, DOI 10.1159/000313836; Schuligoi R, 2009, J LEUKOCYTE BIOL, V85, P136, DOI 10.1189/jlb.0608387; Shiraishi Y, 2005, J PHARMACOL EXP THER, V312, P954, DOI 10.1124/jpet.104.078212; Shirasaki H, 2009, ANN ALLERG ASTHMA IM, V102, P110, DOI 10.1016/S1081-1206(10)60239-6; Smith NJ, 2010, PHARMACOL REV, V62, P701, DOI 10.1124/pr.110.002667; Spik I, 2005, J IMMUNOL, V174, P3703, DOI 10.4049/jimmunol.174.6.3703; Sugimoto H, 2003, J PHARMACOL EXP THER, V305, P347, DOI 10.1124/jpet.102.046748; Tajima T, 2008, J PHARMACOL EXP THER, V326, P493, DOI 10.1124/jpet.108.137992; Tanaka K, 2004, BIOCHEM BIOPH RES CO, V316, P1009, DOI 10.1016/j.bbrc.2004.02.151; Torres D, 2008, J IMMUNOL, V180, P783, DOI 10.4049/jimmunol.180.2.783; Tschische P, 2010, TRAFFIC, V11, P660, DOI 10.1111/j.1600-0854.2010.1045.x; Ulven T, 2010, EXPERT OPIN THER PAT, V20, P1505, DOI 10.1517/13543776.2010.525506; van Rijn RM, 2010, CURR OPIN PHARMACOL, V10, P73, DOI 10.1016/j.coph.2009.09.007; Waldhoer M, 1998, MOL PHARMACOL, V53, P808; Waldhoer M, 2005, P NATL ACAD SCI USA, V102, P9050, DOI 10.1073/pnas.0501112102; Waldhoer M, 2004, ANNU REV BIOCHEM, V73, P953, DOI 10.1146/annurev.biochem.73.011303.073940; WHEELDON A, 1993, BRIT J PHARMACOL, V108, P1051, DOI 10.1111/j.1476-5381.1993.tb13504.x; Wright DH, 2000, BRIT J PHARMACOL, V131, P1537, DOI 10.1038/sj.bjp.0703688; Yoshimura-Uchiyama C, 2004, CLIN EXP ALLERGY, V34, P1283, DOI 10.1111/j.1365-2222.2004.02027.x	51	23	24	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2012	129	2					492	U327		10.1016/j.jaci.2011.08.015	http://dx.doi.org/10.1016/j.jaci.2011.08.015			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	887TC	21930295	Bronze			2022-12-18	WOS:000299951700029
J	Hernandez, M; Brickey, WJ; Alexis, NE; Fry, RC; Rager, JE; Zhou, BM; Ting, JPY; Zhou, HB; Peden, DB				Hernandez, Michelle; Brickey, Willie June; Alexis, Neil E.; Fry, Rebecca C.; Rager, Julia E.; Zhou, Baiming; Ting, Jenny P. Y.; Zhou, Haibo; Peden, David B.			Airway cells from atopic asthmatic patients exposed to ozone display an enhanced innate immune gene profile	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							MORTALITY		[Hernandez, Michelle; Alexis, Neil E.; Zhou, Haibo; Peden, David B.] Univ N Carolina, Gillings Sch Global Publ Hlth, Ctr Environm Med Asthma & Lung Biol, Chapel Hill, NC 27515 USA; [Hernandez, Michelle; Alexis, Neil E.; Peden, David B.] Univ N Carolina, Dept Pediat, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA; [Brickey, Willie June; Peden, David B.] Univ N Carolina, Dept Microbiol & Immunol, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Hernandez, M (corresponding author), Univ N Carolina, Gillings Sch Global Publ Hlth, Ctr Environm Med Asthma & Lung Biol, Chapel Hill, NC 27515 USA.	Michelle_Hernandez@med.unc.edu	ZHOU, Haibo/M-7373-2017	Fry, Rebecca/0000-0003-0899-9018; Peden, David/0000-0003-4526-4627	NCATS NIH HHS [KL2 TR001109] Funding Source: Medline; NCRR NIH HHS [KL2 RR025746, KL2 RR025746-05, KL2RR025746] Funding Source: Medline; NIAID NIH HHS [U19 AI077437, U19 AI077437-03S1, U19AI077437] Funding Source: Medline; NIEHS NIH HHS [P30 ES010126-01A1, P30 ES010126, P30ES010126] Funding Source: Medline; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [KL2TR001109] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [KL2RR025746] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI077437] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES010126] Funding Source: NIH RePORTER	NCATS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Alexis NE, 2008, ANN ALLERG ASTHMA IM, V100, P206, DOI 10.1016/S1081-1206(10)60444-9; Bell ML, 2004, JAMA-J AM MED ASSOC, V292, P2372, DOI 10.1001/jama.292.19.2372; Brickey WJ, 2011, J ALLERGY CLIN IMMUN, V128, P900, DOI 10.1016/j.jaci.2011.08.012; Chuang GC, 2009, AM J PHYSIOL-LUNG C, V297, pL209, DOI 10.1152/ajplung.00102.2009; Dudoit S, 2002, STAT SINICA, V12, P111; Faress JA, 2007, J APPL PHYSIOL, V103, P2077, DOI 10.1152/japplphysiol.00239.2007; Hernandez ML, 2010, J ALLERGY CLIN IMMUN, V126, P537, DOI 10.1016/j.jaci.2010.06.043; Jerrett M, 2009, NEW ENGL J MED, V360, P1085, DOI 10.1056/NEJMoa0803894; Stafoggia M, 2010, AM J RESP CRIT CARE, V182, P376, DOI 10.1164/rccm.200908-1269OC; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498	10	23	25	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2012	129	1					259	U378		10.1016/j.jaci.2011.11.007	http://dx.doi.org/10.1016/j.jaci.2011.11.007			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	869XT	22196529	Green Accepted, Green Published			2022-12-18	WOS:000298634000037
J	Schauberger, EM; Ewart, SL; Arshad, SH; Huebner, M; Karmaus, W; Holloway, JW; Friderici, KH; Ziegler, JT; Zhang, HM; Rose-Zerilli, MJ; Barton, SJ; Holgate, ST; Kilpatrick, JR; Harley, JB; Lajoie-Kadoch, S; Harley, ITW; Hamid, Q; Kurukulaaratchy, RJ; Seibold, MA; Avila, PC; Rodriguez-Cintron, W; Rodriguez-Santana, JR; Hu, DL; Gignoux, C; Romieu, I; London, SJ; Burchard, EG; Langefeld, CD; Wills-Karp, M				Schauberger, Eric M.; Ewart, Susan L.; Arshad, Syed H.; Huebner, Marianne; Karmaus, Wilfried; Holloway, John W.; Friderici, Karen H.; Ziegler, Julie T.; Zhang, Hongmei; Rose-Zerilli, Matthew J.; Barton, Sheila J.; Holgate, Stephen T.; Kilpatrick, Jeffrey R.; Harley, John B.; Lajoie-Kadoch, Stephane; Harley, Isaac T. W.; Hamid, Qutayba; Kurukulaaratchy, Ramesh J.; Seibold, Max A.; Avila, Pedro C.; Rodriguez-Cintron, William; Rodriguez-Santana, Jose R.; Hu, Donglei; Gignoux, Christopher; Romieu, Isabelle; London, Stephanie J.; Burchard, Esteban G.; Langefeld, Carl D.; Wills-Karp, Marsha			Identification of ATPAF1 as a novel candidate gene for asthma in children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; ATPAF1; children; gene; genetic; genome-wide association; purinergic; respiratory; single nucleotide polymorphism; SNP	GENOME-WIDE ASSOCIATION; PUERTO-RICAN; EXTRACELLULAR ATP; ASSEMBLY FACTORS; SUSCEPTIBILITY; LINKAGE; EXPRESSION; PHENOTYPES; VARIANTS; MEXICAN	Background: Asthma is a common disease of children with a complex genetic origin. Understanding the genetic basis of asthma susceptibility will allow disease prediction and risk stratification. Objective: We sought to identify asthma susceptibility genes in children. Methods: A nested case-control genetic association study of children of Caucasian European ancestry from a birth cohort was conducted. Single nucleotide polymorphisms (SNPs, n = 116,024) were genotyped in pools of DNA samples from cohort children with physician-diagnosed asthma (n = 112) and normal controls (n = 165). A genomic region containing the ATPAF1 gene was found to be significantly associated with asthma. Additional SNPs within this region were genotyped in individual samples from the same children and in 8 independent study populations of Caucasian, African American, Hispanic, or other ancestries. SNPs were also genotyped or imputed in 2 consortia control populations. ATPAF1 expression was measured in bronchial biopsies from asthmatic patients and controls. Results: Asthma was found to be associated with a cluster of SNPs and SNP haplotypes containing the ATPAF1 gene, with 2 SNPs achieving significance at a genome-wide level (P = 2.26 x 10(-5) to 2.2 x 10(-8)). Asthma severity was also found to be associated with SNPs and SNP haplotypes in the primary population. SNP and/or gene-level associations were confirmed in the 4 non-Hispanic populations. Haplotype associations were also confirmed in the non-Hispanic populations (P = .045-.0009). ATPAF1 total RNA expression was significantly (P < .01) higher in bronchial biopsies from asthmatic patients than from controls. Conclusion: Genetic variation in the ATPAF1 gene predisposes children of different ancestries to asthma. (J Allergy Clin Immunol 2011;128:753-60.)	[Ewart, Susan L.] Michigan State Univ, Vet Med Ctr G100, E Lansing, MI 48824 USA; [Arshad, Syed H.; Kurukulaaratchy, Ramesh J.] David Hide Asthma & Allergy Res Ctr, Isle Of Wight, England; [Arshad, Syed H.; Holloway, John W.; Rose-Zerilli, Matthew J.; Barton, Sheila J.; Holgate, Stephen T.; Kurukulaaratchy, Ramesh J.] Univ Southampton, Sch Med, Southampton SO9 5NH, Hants, England; [Karmaus, Wilfried; Zhang, Hongmei] Univ S Carolina, Columbia, SC 29208 USA; [Ziegler, Julie T.; Langefeld, Carl D.] Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA; [Kilpatrick, Jeffrey R.; Harley, John B.] JKA Genom, Oklahoma City, OK USA; [Harley, John B.] Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA; [Lajoie-Kadoch, Stephane; Harley, Isaac T. W.; Wills-Karp, Marsha] Cincinnati Childrens Hosp, Med Ctr, Cincinnati, OH USA; [Hamid, Qutayba] McGill Univ, Meakins Christie Lab, Montreal, PQ, Canada; [Seibold, Max A.] Natl Jewish Hlth, Denver, CO USA; [Avila, Pedro C.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA; [Rodriguez-Cintron, William] Vet Affairs Med Ctr, San Juan, PR USA; [Rodriguez-Santana, Jose R.] CSP, Ctr Neumol Pediatr, San Juan, PR USA; [Hu, Donglei; Gignoux, Christopher; Burchard, Esteban G.] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Romieu, Isabelle] Natl Inst Publ Hlth, Cuernevaca, Mexico; [London, Stephanie J.] NIEHS, NIH, Dept Hlth & Human Serv, Res Triangle Pk, NC 27709 USA	Michigan State University; University of Southampton; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; Wake Forest University; Wake Forest Baptist Medical Center; Oklahoma Medical Research Foundation; Cincinnati Children's Hospital Medical Center; McGill University; National Jewish Health; Northwestern University; Feinberg School of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; Instituto Nacional de Salud Publica; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Ewart, SL (corresponding author), Michigan State Univ, Vet Med Ctr G100, E Lansing, MI 48824 USA.	ewart@cvm.msu.edu	Schauberger, Eric/A-9213-2008; Holloway, John W/B-5424-2009; London, Stephanie/C-3734-2019; Huebner, Marianne/AAA-6882-2020	Schauberger, Eric/0000-0001-5069-7190; Holloway, John W/0000-0001-9998-0464; London, Stephanie/0000-0003-4911-5290; Rose-Zerilli, Matthew/0000-0002-1064-5350; Kurukulaaratchy, Ramesh/0000-0002-1588-2400; Barton, Sheila/0000-0003-4963-4242; Harley, Isaac/0000-0003-1282-5395; Huebner, Marianne/0000-0002-9694-9231	National Institutes of Health [R01 AI061471, R01 HL67736, P01 HL076383, T32GM063483]; Asthma UK [364]; Asthma, Allergy and Inflammation Research Charity; Richard and Edith Strauss Foundation of Canada; Robert Wood Johnson Foundation Amos Medical Faculty [HL078885, HL088133, AI077439, ES015794]; Flight Attendant Medical Research Institute (FAMRI); National Institutes of Health, National Institute of Environmental Health Sciences [Z01 ES49019]; National Council of Science and Technology, Mexico [26206-M]; National Center for Environmental Health at the Centers for Disease Control and Prevention; National Heart, Lung, and Blood Institute [NO1-HR-16044, NO1-HR-16045, NO1-HR-16046, NO1-HR-16047, NO1-HR-16048, NO1-HR-16049, NO1-HR-16050, NO1-HR-16051, NO1-HR-16052, HL071742-01, HL004519-04, 5U10HL064287, 5U10HL064288, 5U10HL064295, 5U10HL064307, 5U10HL064305, 5U10HL064313]; General Clinical Research Center; National Center for Research Resources [M01RR00051, M01RR0099718-24, M01RR02719-14, RR00036]; National Institutes of Health and the National Jewish Medical and Research Center [M01 RR00036, M01 RR00051]; MRC [G0800766, G19/34, MC_UP_A620_1017, G1001799] Funding Source: UKRI; DIVISION OF LUNG DISEASES [N01HR016046, N01HR016049, N01HR016051, N01HR016048, N01HR016052, N01HR016044, N01HR016050, N01HR016047, N01HR016045] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000036, M01RR002719, M01RR000051] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U10HL064287, U10HL064305, U10HL064313, R01HL078885, R01HL016052, U10HL064295, P01HL076383, U10HL064307, R01HL088133, U10HL064288, K30HL004519, R01HL067736, K08HL071742] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI077439, R37AI024717, R01AI024717, R01AI061471] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES015794, ZIAES049019, ZIAES025045, Z01ES049019] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM063483] Funding Source: NIH RePORTER; Medical Research Council [G0800766, G1001799, G19/34, MC_UP_A620_1017] Funding Source: researchfish; National Institute for Health Research [NF-SI-0510-10021] Funding Source: researchfish	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Asthma UK; Asthma, Allergy and Inflammation Research Charity; Richard and Edith Strauss Foundation of Canada; Robert Wood Johnson Foundation Amos Medical Faculty(Robert Wood Johnson Foundation (RWJF)); Flight Attendant Medical Research Institute (FAMRI); National Institutes of Health, National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); National Council of Science and Technology, Mexico(Consejo Nacional de Ciencia y Tecnologia (CONACyT)); National Center for Environmental Health at the Centers for Disease Control and Prevention; National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); General Clinical Research Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Institutes of Health and the National Jewish Medical and Research Center; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); DIVISION OF LUNG DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR))	This study was funded by the National Institutes of Health, grants R01 AI061471, R01 HL67736, P01 HL076383, and T32GM063483, Asthma UK (364), and the Asthma, Allergy and Inflammation Research Charity. The Wessex Family Cohort was originally recruited in collaboration with Genome Therapeutics Corporation and Schering-Plough. The Richard and Edith Strauss Foundation of Canada and Dr Ron Olivenstein supported the severe asthma program and collection of bronchial biopsies. The GALA studies were supported by grants HL078885, HL088133, AI077439, and ES015794, Robert Wood Johnson Foundation Amos Medical Faculty Development Program, Flight Attendant Medical Research Institute (FAMRI). The Mexico Childhood Asthma Study was supported by the Intramural Research Program of the National Institutes of Health, National Institute of Environmental Health Sciences (Z01 ES49019). Subject enrollment was also supported in part by the National Council of Science and Technology (grant 26206-M), Mexico. I. Romieu was supported in part by the National Center for Environmental Health at the Centers for Disease Control and Prevention. The CAMP study was supported by contracts with the National Heart, Lung, and Blood Institute (NO1-HR-16044, NO1-HR-16045, NO1-HR-16046, NO1-HR-16047, NO1-HR-16048, NO1-HR-16049, NO1-HR-16050, NO1-HR-16051, and NO1-HR-16052) and by General Clinical Research Center grants from the National Center for Research Resources (M01RR00051, M01RR0099718-24, M01RR02719-14, and RR00036). The CARE study was supported by grants (HL071742-01, HL004519-04, 5U10HL064287, 5U10HL064288, 5U10HL064295, 5U10HL064307, 5U10HL064305, and 5U10HL064313) from the National Heart, Lung, and Blood Institute. This study was carried out in part in the General Clinical Research Centers at Washington University School of Medicine (M01 RR00036) sponsored by the National Institutes of Health and the National Jewish Medical and Research Center (M01 RR00051). The data analyses for the CAMP, CARE, Wellcome Trust Case Control Consortium, and the Consortium for Systemic Lupus Erythematosus Genetics populations were supported by the Wake Forest School of Medicine Center for Public Health Genomics.	Affymetrix, 2007, GEN GEN AN SOFTW GTY; [Anonymous], DATABASE GENOTYPES P; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Beghe B, 2003, CLIN EXP ALLERGY, V33, P1111, DOI 10.1046/j.1365-2222.2003.01731.x; Blumenthal MN, 2004, HUM GENET, V114, P157, DOI 10.1007/s00439-003-1030-5; Bouzigon E, 2007, EUR RESPIR J, V30, P253, DOI 10.1183/09031936.00162206; Bouzigon E, 2004, HUM MOL GENET, V13, P3103, DOI 10.1093/hmg/ddh340; Burchard EG, 2004, AM J RESP CRIT CARE, V169, P386, DOI 10.1164/rccm.200309-1293OC; Burton PR, 2007, NATURE, V447, P661, DOI 10.1038/nature05911; CARTERPOKRAS OD, 1993, AM J PUBLIC HEALTH, V83, P580, DOI 10.2105/AJPH.83.4.580; Chen R, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-12-r170; Colilla S, 2003, J ALLERGY CLIN IMMUN, V111, P840, DOI 10.1067/mai.2003.170; David GL, 2003, AM J RESP CRIT CARE, V168, P1199, DOI 10.1164/rccm.200305-684OC; de Bakker PIW, 2005, NAT GENET, V37, P1217, DOI 10.1038/ng1669; De La Vega Francisco M, 2006, Pac Symp Biocomput, P487, DOI 10.1142/9789812701626_0045; Dizier MH, 2000, AM J RESP CRIT CARE, V162, P1812, DOI 10.1164/ajrccm.162.5.2002113; Eder W, 2006, NEW ENGL J MED, V355, P2226, DOI 10.1056/NEJMra054308; Foley SC, 2007, J ALLERGY CLIN IMMUN, V119, P863, DOI 10.1016/j.jaci.2006.12.665; Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168; Gonzalez JR, 2007, BIOINFORMATICS, V23, P644, DOI 10.1093/bioinformatics/btm025; Guilbert TW, 2004, CONTROL CLIN TRIALS, V25, P286, DOI 10.1016/j.cct.2004.03.002; Haagerup A, 2002, ALLERGY, V57, P680, DOI 10.1034/j.1398-9995.2002.23523.x; Hancock DB, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000623; Harley JB, 2008, NAT GENET, V40, P204, DOI 10.1038/ng.81; Himes BE, 2009, AM J HUM GENET, V84, P581, DOI 10.1016/j.ajhg.2009.04.006; Holloway JW, 2007, CURR OPIN ALLERGY CL, V7, P69, DOI 10.1097/ACI.0b013e328013d51b; Holloway JW, 2010, J ALLERGY CLIN IMMUN, V125, pS81, DOI 10.1016/j.jaci.2009.10.071; Homa DM, 2000, AM J RESP CRIT CARE, V161, P504, DOI 10.1164/ajrccm.161.2.9906025; Hudson CA, 2008, J LEUKOCYTE BIOL, V84, P631, DOI 10.1189/jlb.1207830; Idzko M, 2007, NAT MED, V13, P913, DOI 10.1038/nm1617; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; King DC, 2005, GENOME RES, V15, P1051, DOI 10.1101/gr.3642605; Kurukulaaratchy RJ, 2003, CLIN EXP ALLERGY, V33, P573, DOI 10.1046/j.1365-2222.2003.01657.x; Lake SL, 2003, HUM HERED, V55, P56, DOI 10.1159/000071811; Lange C, 2004, AM J HUM GENET, V74, P367, DOI 10.1086/381563; Li Y, 2010, GENET EPIDEMIOL, V34, P816, DOI 10.1002/gepi.20533; Mailman MD, 2007, NAT GENET, V39, P1181, DOI 10.1038/ng1007-1181; Marsh DG, 1997, NAT GENET, V15, P389; Mathias RA, 2001, GENET EPIDEMIOL, V20, P340, DOI 10.1002/gepi.5; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; National Center for Biotechnology Information, DAT GEN PHEN DBGAP; National Heart Lung and Blood Institute (NHLBI), 1998, GLOB IN ASTHM GINA; Pearce N, 2007, THORAX, V62, P758, DOI 10.1136/thx.2006.070169; Pickova A, 2005, PROTEINS, V59, P393, DOI 10.1002/prot.20452; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Rebhan M, 1997, TRENDS GENET, V13, P163, DOI 10.1016/S0168-9525(97)01103-7; Rogers AJ, 2009, AM J RESP CRIT CARE, V179, P1084, DOI 10.1164/rccm.200812-1860OC; Scheet P, 2006, AM J HUM GENET, V78, P629, DOI 10.1086/502802; Schnurr M, 2000, J IMMUNOL, V165, P4704, DOI 10.4049/jimmunol.165.8.4704; Shannon J, 2008, CHEST, V133, P420, DOI 10.1378/chest.07-1881; Sheluho D, 2001, J BIOL CHEM, V276, P39945, DOI 10.1074/jbc.M107252200; Su AI, 2004, P NATL ACAD SCI USA, V101, P6062, DOI 10.1073/pnas.0400782101; Szefler S, 2000, NEW ENGL J MED, V343, P1054; Team R. D. C., 2008, R LANG ENV STAT COMP; Thomas G, 2008, NAT GENET, V40, P310, DOI 10.1038/ng.91; Van Eerdewegh P, 2002, NATURE, V418, P426, DOI 10.1038/nature00878; Vercelli D, 2008, NAT REV IMMUNOL, V8, P169, DOI 10.1038/nri2257; Wang ZG, 2000, J BIOL CHEM, V275, P5767, DOI 10.1074/jbc.275.8.5767; Wang ZG, 2001, J BIOL CHEM, V276, P30773, DOI 10.1074/jbc.M104133200; Wu H, 2010, J ALLERGY CLIN IMMUN, V125, P321, DOI 10.1016/j.jaci.2009.09.007; Xu JF, 2001, AM J HUM GENET, V68, P1437, DOI 10.1086/320589; Yang HC, 2005, GENETICS, V169, P399, DOI 10.1534/genetics.104.032052	63	23	24	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2011	128	4					753	U415		10.1016/j.jaci.2011.04.058	http://dx.doi.org/10.1016/j.jaci.2011.04.058			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	841UA	21696813	Green Accepted			2022-12-18	WOS:000296538100008
J	Canonica, GW; Passalacqua, G				Canonica, Giorgio Walter; Passalacqua, Giovanni			Disease-modifying effect and economic implications of sublingual immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Sublingual immunotherapy; respiratory allergy; preventive effect; pharmacoeconomy	POLLEN-INDUCED RHINOCONJUNCTIVITIS; COST-EFFECTIVENESS; ASTHMA; ALLERGY; CHILDREN; PREVENTION; GRAZAX(R); EFFICACY; RHINITIS; UPDATE		[Canonica, Giorgio Walter; Passalacqua, Giovanni] Univ Genoa, Dept Internal Med, I-16132 Genoa, Italy	University of Genoa	Canonica, GW (corresponding author), Univ Genoa, Dept Internal Med, Lgo R Benzi 10, I-16132 Genoa, Italy.	canonica@unige.it	canonica, giorgio walter/ABF-2037-2020	canonica, giorgio walter/0000-0001-8467-2557				Bachert C, 2007, CLIN EXP ALLERGY, V37, P772, DOI 10.1111/j.1365-2222.2007.02706.x; Berto P, 2005, Eur Ann Allergy Clin Immunol, V37, P303; Berto P, 2008, CURR MED RES OPIN, V24, P261, DOI 10.1185/030079908X253726; Berto P, 2006, ANN ALLERG ASTHMA IM, V97, P615, DOI 10.1016/S1081-1206(10)61090-3; Berto P, 2008, CURR OPIN ALLERGY CL, V8, P585, DOI 10.1097/ACI.0b013e32831411e9; Bousquet PJ, 2007, CURR OPIN ALLERGY CL, V7, P561, DOI 10.1097/ACI.0b013e3282f1d6a4; Brozek JL, 2009, ALLERGY, V64, P669, DOI 10.1111/j.1398-9995.2009.01973.x; Canonica GW, 2007, RESP MED, V101, P1885, DOI 10.1016/j.rmed.2007.05.003; Canonica GW, 2009, ALLERGY, V64, P1, DOI 10.1111/j.1398-9995.2009.02309.x; Casale TB, 2009, J ALLERGY CLIN IMMUN, V124, P665, DOI 10.1016/j.jaci.2009.07.054; Di Rienzo V, 2003, CLIN EXP ALLERGY, V33, P206, DOI 10.1046/j.1365-2222.2003.01587.x; Durham SR, 2010, J ALLERGY CLIN IMMUN, V125, P131, DOI 10.1016/j.jaci.2009.10.035; Jacobsen L, 2007, ALLERGY, V62, P943, DOI 10.1111/j.1398-9995.2007.01451.x; James LK, 2008, CLIN EXP ALLERGY, V38, P1074, DOI 10.1111/j.1365-2222.2008.02976.x; JOHNSTONE DE, 1968, PEDIATRICS, V42, P793; Marogna M, 2008, ANN ALLERG ASTHMA IM, V101, P206, DOI 10.1016/S1081-1206(10)60211-6; Marogna M, 2010, J ALLERGY CLIN IMMUN, V126, P969, DOI 10.1016/j.jaci.2010.08.030; Novembre E, 2004, J ALLERGY CLIN IMMUN, V114, P851, DOI 10.1016/j.jaci.2004.07.012; Passalacqua G, 2007, J ALLERGY CLIN IMMUN, V119, P881, DOI 10.1016/j.jaci.2007.01.045; Tahamiler R, 2007, LARYNGOSCOPE, V117, P965, DOI 10.1097/MLG.0b013e31804f8141	20	23	24	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2011	127	1					44	45		10.1016/j.jaci.2010.09.037	http://dx.doi.org/10.1016/j.jaci.2010.09.037			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	702SY	21094517	Bronze			2022-12-18	WOS:000285917300006
J	Szefler, SJ				Szefler, Stanley J.			Advances in pediatric asthma in 2010: Addressing the major issues	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; asthma control; asthma impairment; asthma risk; asthma severity; early intervention in asthma; biomarkers; genetics; inhaled corticosteroids; leukotriene receptor antagonists; long-acting beta-adrenergic agonists; omalizumab; personalized medicine; therapeutics	EXHALED NITRIC-OXIDE; RESPIRATORY-TRACT INFECTIONS; GENOME-WIDE ASSOCIATION; STEP-UP THERAPY; INNER-CITY; AIRWAY HYPERRESPONSIVENESS; NATIONAL-INSTITUTES; NATURAL-HISTORY; CHILDREN; CHILDHOOD	Last year's "Advances in pediatric asthma'' concluded with the following statement: "If we can close these [remaining] gaps through better communication, improvements in the health care system and new insights into treatment, we will move closer to better methods to intervene early in the course of the disease and induce clinical remission as quickly as possible in most children.'' This year's summary will focus on recent advances in pediatric asthma that take steps moving forward as reported in Journal of Allergy and Clinical Immunology publications in 2010. Some of these recent reports show us how to improve asthma management through steps to better understand the natural history of asthma, individualize asthma care, reduce asthma exacerbations, and manage inner-city asthma and some potential new ways to use available medications to improve asthma control. It is clear that we have made many significant gains in managing asthma in children, but we have a ways to go to prevent asthma exacerbations, alter the natural history of the disease, and reduce health disparities in asthma care. Perhaps new directions in personalized medicine and improved health care access and communication will help maintain steady progress in alleviating the burden of this disease in children, especially young children. (J Allergy Clin Immunol 2011;127:102-15.)	[Szefler, Stanley J.] Natl Jewish Hlth, Div Pediat Clin Pharmacol & Allergy, Dept Pediat, Denver, CO 80206 USA; [Szefler, Stanley J.] Natl Jewish Hlth, Div Immunol, Dept Pediat, Denver, CO 80206 USA; [Szefler, Stanley J.] Univ Colorado, Sch Med, Dept Pediat, Denver, CO USA; [Szefler, Stanley J.] Univ Colorado, Sch Med, Dept Pharmacol, Denver, CO 80262 USA	National Jewish Health; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Szefler, SJ (corresponding author), Natl Jewish Hlth, Div Pediat Clin Pharmacol & Allergy, Dept Pediat, 1400 Jackson St,Rm J304,Molly Blank Bldg, Denver, CO 80206 USA.	szeflers@njhealth.org		Szefler, Stanley/0000-0002-6911-3199	Public Health Services Research [HR-16048, HL64288, HL 51834, AI-25496, HL081335, HL075416]; Colorado Cancer, Cardiovascular and Pulmonary Disease Program; National Institutes of Health (NIH) [1 UL1 RR025780]; National Center for Research Resources (NCRR); National Heart, Lung, and Blood Institute; National Institute of Allergy and Infectious Diseases; National Institute of Environmental Health Sciences/Environmental Protection Agency; GlaxoSmithKline; DIVISION OF LUNG DISEASES [N01HR016048] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025780] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL075416, R21HL087811, U10HL051834, U10HL064288, U01HL081335] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI025496] Funding Source: NIH RePORTER	Public Health Services Research(United States Department of Health & Human ServicesUnited States Public Health Service); Colorado Cancer, Cardiovascular and Pulmonary Disease Program; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Center for Research Resources (NCRR)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institute of Environmental Health Sciences/Environmental Protection Agency(United States Environmental Protection AgencyUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); GlaxoSmithKline(GlaxoSmithKline); DIVISION OF LUNG DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported in part by Public Health Services Research Grants HR-16048, HL64288, HL 51834, AI-25496, HL081335, and HL075416, and the Colorado Cancer, Cardiovascular and Pulmonary Disease Program. Also supported in part by Colorado CTSA grant 1 UL1 RR025780 from the National Institutes of Health (NIH) and the National Center for Research Resources (NCRR).; S. J. Szefler has consulted for GlaxoSmithKline, Genentech, Merck, Boehringer-Ingelheim, Novartis, and Schering-Plough and has received research support from the National Institutes of Health; National Heart, Lung, and Blood Institute; National Institute of Allergy and Infectious Diseases; National Institute of Environmental Health Sciences/Environmental Protection Agency; and GlaxoSmithKline.	Adkinson NF, 2010, J ALLERGY CLIN IMMUN, V126, P950, DOI 10.1016/j.jaci.2010.09.019; Amirav I, 2010, J ALLERGY CLIN IMMUN, V125, P1206, DOI 10.1016/j.jaci.2010.01.034; Andregnette-Roscigno V, 2010, J ALLERGY CLIN IMMUN, V126, P869, DOI 10.1016/j.jaci.2010.07.025; Apter AJ, 2010, J ALLERGY CLIN IMMUN, V125, P79, DOI 10.1016/j.jaci.2009.11.028; Bateman ED, 2010, J ALLERGY CLIN IMMUN, V125, P600, DOI 10.1016/j.jaci.2009.11.033; Baye TM, 2010, J ALLERGY CLIN IMMUN, V126, P425, DOI 10.1016/j.jaci.2010.05.025; Beebe A, 2010, J ALLERGY CLIN IMMUN, V126, P263, DOI 10.1016/j.jaci.2010.03.019; Bisgaard H, 2010, J ALLERGY CLIN IMMUN, V126, P187, DOI 10.1016/j.jaci.2010.07.011; Blumenthal D, 2010, NEW ENGL J MED, V363, P501, DOI 10.1056/NEJMp1006114; Bottema RWB, 2010, J ALLERGY CLIN IMMUN, V126, P338, DOI 10.1016/j.jaci.2010.04.024; Bousquet J, 2010, J ALLERGY CLIN IMMUN, V126, P926, DOI 10.1016/j.jaci.2010.07.019; Brasholt M, 2010, J ALLERGY CLIN IMMUN, V125, P1007, DOI 10.1016/j.jaci.2010.02.002; Brehm JM, 2010, J ALLERGY CLIN IMMUN, V126, P52, DOI 10.1016/j.jaci.2010.03.043; Breton MC, 2010, J ALLERGY CLIN IMMUN, V126, P772, DOI 10.1016/j.jaci.2010.08.018; Brozek JL, 2010, J ALLERGY CLIN IMMUN, V126, P466, DOI 10.1016/j.jaci.2010.06.047; Bush A, 2010, LANCET, V376, P814, DOI 10.1016/S0140-6736(10)61054-9; Busse WW, 2010, J ALLERGY CLIN IMMUN, V125, P529, DOI 10.1016/j.jaci.2010.01.036; Calvert J, 2010, J ALLERGY CLIN IMMUN, V125, P100, DOI 10.1016/j.jaci.2009.09.010; Castro-Rodriguez JA, 2010, J ALLERGY CLIN IMMUN, V126, P212, DOI 10.1016/j.jaci.2010.06.032; Chapman KR, 2010, J ALLERGY CLIN IMMUN, V125, P609, DOI 10.1016/j.jaci.2010.01.019; Chawes BLK, 2010, AM J RESP CRIT CARE, V182, P138, DOI 10.1164/rccm.200909-1377OC; Chawes BLK, 2010, J ALLERGY CLIN IMMUN, V126, P567, DOI 10.1016/j.jaci.2010.06.026; Cohen RT, 2010, J ALLERGY CLIN IMMUN, V126, P491, DOI 10.1016/j.jaci.2010.06.016; Covar R, 2010, CLIN EXP ALLERGY, V40, P1163, DOI 10.1111/j.1365-2222.2010.03523.x; Covar RA, 2010, J ALLERGY CLIN IMMUN, V125, P359, DOI 10.1016/j.jaci.2009.10.037; Debley JS, 2010, J ALLERGY CLIN IMMUN, V125, P1228, DOI 10.1016/j.jaci.2010.03.023; DeWan AT, 2010, J ALLERGY CLIN IMMUN, V126, P871, DOI 10.1016/j.jaci.2010.06.051; Deyton L, 2010, NEW ENGL J MED, V362, P1753, DOI 10.1056/NEJMp1004152; Dreger LC, 2010, J ALLERGY CLIN IMMUN, V125, P116, DOI 10.1016/j.jaci.2009.09.051; Dweik RA, 2010, AM J RESP CRIT CARE, V181, P1033, DOI 10.1164/rccm.200905-0695OC; FitzGerald JM, 2010, J ALLERGY CLIN IMMUN, V125, P307, DOI 10.1016/j.jaci.2009.12.978; Fitzpatrick AM, 2010, PEDIAT ALLER IMM PUL, V23, P131, DOI 10.1089/ped.2010.0021; Fitzpatrick AM, 2010, J ALLERGY CLIN IMMUN, V125, P851, DOI 10.1016/j.jaci.2010.01.048; Gamble C, 2010, J ALLERGY CLIN IMMUN, V126, P1149, DOI 10.1016/j.jaci.2010.08.049; Garcia-Marcos L, 2010, J ALLERGY CLIN IMMUN, V126, P489, DOI 10.1016/j.jaci.2010.06.037; Gerald JK, 2010, J ALLERGY CLIN IMMUN, V125, P643, DOI 10.1016/j.jaci.2009.12.984; Gern JE, 2010, J ALLERGY CLIN IMMUN, V125, P545, DOI 10.1016/j.jaci.2010.01.037; Ginde AA, 2010, J ALLERGY CLIN IMMUN, V126, P59, DOI 10.1016/j.jaci.2010.05.030; Gould W, 2010, J ALLERGY CLIN IMMUN, V126, P1131, DOI 10.1016/j.jaci.2010.08.002; Guilbert TW, 2010, J ALLERGY CLIN IMMUN, V126, P417, DOI 10.1016/j.jaci.2010.06.024; Hamburg MA, 2010, NEW ENGL J MED, V363, P301, DOI 10.1056/NEJMp1006304; Han JY, 2010, AM J RESP CRIT CARE, V182, P455, DOI 10.1164/rccm.200912-1811OC; Ho SM, 2010, J ALLERGY CLIN IMMUN, V126, P453, DOI 10.1016/j.jaci.2010.07.030; Holloway JW, 2010, J ALLERGY CLIN IMMUN, V126, P200, DOI 10.1016/j.jaci.2010.06.006; Holt PG, 2010, J ALLERGY CLIN IMMUN, V125, P963, DOI 10.1016/j.jaci.2010.02.011; Holt PG, 2010, J ALLERGY CLIN IMMUN, V125, P653, DOI 10.1016/j.jaci.2009.12.018; Horvat JC, 2010, J ALLERGY CLIN IMMUN, V125, P617, DOI 10.1016/j.jaci.2009.10.018; Jackson DJ, 2010, J ALLERGY CLIN IMMUN, V125, P1178, DOI 10.1016/j.jaci.2010.04.021; Jartti T, 2010, J ALLERGY CLIN IMMUN, V126, P1074, DOI 10.1016/j.jaci.2010.09.004; Jin Y, 2010, J ALLERGY CLIN IMMUN, V126, P618, DOI 10.1016/j.jaci.2010.06.007; Juhn YJ, 2010, J ALLERGY CLIN IMMUN, V125, P838, DOI 10.1016/j.jaci.2009.12.998; Kattan M, 2010, J ALLERGY CLIN IMMUN, V125, P584, DOI 10.1016/j.jaci.2010.01.053; Kazani S, 2010, J ALLERGY CLIN IMMUN, V125, P295, DOI 10.1016/j.jaci.2009.12.014; Kogan MD, 2010, NEW ENGL J MED, V363, P841, DOI 10.1056/NEJMsa0909994; Koh HK, 2010, NEW ENGL J MED, V362, P1653, DOI 10.1056/NEJMp1001601; Kull I, 2010, J ALLERGY CLIN IMMUN, V125, P1013, DOI 10.1016/j.jaci.2010.01.051; Lange NE, 2010, J ALLERGY CLIN IMMUN, V126, P250, DOI 10.1016/j.jaci.2010.05.009; Lemanske RF, 2010, J ALLERGY CLIN IMMUN, V126, P449, DOI 10.1016/j.jaci.2010.05.039; Lemanske RF, 2010, NEW ENGL J MED, V362, P975, DOI 10.1056/NEJMoa1001278; Leo HL, 2010, J ALLERGY CLIN IMMUN, V126, P166, DOI 10.1016/j.jaci.2010.03.040; Li XN, 2010, J ALLERGY CLIN IMMUN, V125, P328, DOI 10.1016/j.jaci.2009.11.018; Liu AH, 2010, J ALLERGY CLIN IMMUN, V126, P267, DOI 10.1016/j.jaci.2010.05.031; Majak P, 2010, J ALLERGY CLIN IMMUN, V125, P1220, DOI 10.1016/j.jaci.2010.02.034; Mathias RA, 2010, J ALLERGY CLIN IMMUN, V125, P336, DOI 10.1016/j.jaci.2009.08.031; McElligott S, 2010, J ALLERGY CLIN IMMUN, V125, P651, DOI 10.1016/j.jaci.2010.01.029; McFadden ER, 2010, J ALLERGY CLIN IMMUN, V126, P535, DOI 10.1016/j.jaci.2010.06.035; Melen E, 2010, J ALLERGY CLIN IMMUN, V126, P631, DOI 10.1016/j.jaci.2010.06.030; Meyers DA, 2010, J ALLERGY CLIN IMMUN, V126, P439, DOI 10.1016/j.jaci.2010.07.012; Mukhopadhyay S, 2010, J ALLERGY CLIN IMMUN, V126, P70, DOI 10.1016/j.jaci.2010.03.027; Munthe-Kaas MC, 2010, J ALLERGY CLIN IMMUN, V125, P1361, DOI 10.1016/j.jaci.2010.02.010; Nair P, 2010, J ALLERGY CLIN IMMUN, V126, DOI 10.1016/j.jaci.2010.05.032; Nelson H, 2010, J ALLERGY CLIN IMMUN, V125, P390, DOI 10.1016/j.jaci.2009.11.036; Olenec JP, 2010, J ALLERGY CLIN IMMUN, V125, P1001, DOI 10.1016/j.jaci.2010.01.059; Palmenberg AC, 2010, J ALLERGY CLIN IMMUN, V125, P1190, DOI 10.1016/j.jaci.2010.04.010; Perrin JM, 2010, NEW ENGL J MED, V363, P881, DOI 10.1056/NEJMe1007674; Peters SP, 2010, NEW ENGL J MED, V363, P1715, DOI 10.1056/NEJMoa1008770; Pfefferle PI, 2010, J ALLERGY CLIN IMMUN, V125, P108, DOI 10.1016/j.jaci.2009.09.019; Platts-Mills TAE, 2010, J ALLERGY CLIN IMMUN, V125, P106, DOI 10.1016/j.jaci.2009.10.068; Pongracic JA, 2010, J ALLERGY CLIN IMMUN, V125, P593, DOI 10.1016/j.jaci.2009.10.036; Rabinovitch N, 2010, J ALLERGY CLIN IMMUN, V126, P545, DOI 10.1016/j.jaci.2010.07.008; Raissy HH, 2010, J ALLERGY CLIN IMMUN, V126, DOI 10.1016/j.jaci.2010.05.007; Razi CH, 2010, J ALLERGY CLIN IMMUN, V126, P763, DOI 10.1016/j.jaci.2010.07.038; Rochat MK, 2010, J ALLERGY CLIN IMMUN, V126, P1170, DOI 10.1016/j.jaci.2010.09.008; Rosenthal LA, 2010, J ALLERGY CLIN IMMUN, V125, P1212, DOI 10.1016/j.jaci.2010.04.002; Roy SR, 2010, J ALLERGY CLIN IMMUN, V125, P636, DOI 10.1016/j.jaci.2009.11.046; Sachs-Olsen C, 2010, J ALLERGY CLIN IMMUN, V126, P859, DOI 10.1016/j.jaci.2010.07.015; Schnabel E, 2010, J ALLERGY CLIN IMMUN, V126, P1071, DOI 10.1016/j.jaci.2010.08.023; Searing DA, 2010, J ALLERGY CLIN IMMUN, V125, P995, DOI 10.1016/j.jaci.2010.03.008; Shaheen SO, 2010, J ALLERGY CLIN IMMUN, V126, P1141, DOI 10.1016/j.jaci.2010.08.047; Sheehan WJ, 2010, J ALLERGY CLIN IMMUN, V125, P575, DOI 10.1016/j.jaci.2010.01.023; Silverman RA, 2010, J ALLERGY CLIN IMMUN, V125, P367, DOI 10.1016/j.jaci.2009.10.061; Simoes EAF, 2010, J ALLERGY CLIN IMMUN, V126, P256, DOI 10.1016/j.jaci.2010.05.026; Simon MR, 2010, J ALLERGY CLIN IMMUN, V126, P527, DOI 10.1016/j.jaci.2010.05.016; Simpson A, 2010, AM J RESP CRIT CARE, V181, P1200, DOI 10.1164/rccm.200907-1101OC; Sly PD, 2010, J ALLERGY CLIN IMMUN, V125, P1202, DOI 10.1016/j.jaci.2010.01.024; Sonnappa S, 2010, J ALLERGY CLIN IMMUN, V126, P519, DOI 10.1016/j.jaci.2010.04.018; Strickland MJ, 2010, AM J RESP CRIT CARE, V182, P307, DOI 10.1164/rccm.200908-1201OC; Sun XG, 2010, J ALLERGY CLIN IMMUN, V126, P241, DOI 10.1016/j.jaci.2010.04.036; Sverrild A, 2010, J ALLERGY CLIN IMMUN, V126, P952, DOI 10.1016/j.jaci.2010.08.028; Szefler SJ, 2010, J ALLERGY CLIN IMMUN, V126, P939, DOI 10.1016/j.jaci.2010.09.018; Szefler SJ, 2010, J ALLERGY CLIN IMMUN, V125, P521, DOI 10.1016/j.jaci.2010.01.025; Szefler SJ, 2010, J ALLERGY CLIN IMMUN, V125, P285, DOI 10.1016/j.jaci.2009.10.026; Szefler SJ, 2010, J ALLERGY CLIN IMMUN, V125, P69, DOI 10.1016/j.jaci.2009.11.006; Tapiainen T, 2010, J ALLERGY CLIN IMMUN, V125, P751, DOI 10.1016/j.jaci.2009.11.039; Tcheurekdjian H, 2010, J ALLERGY CLIN IMMUN, V126, P853, DOI 10.1016/j.jaci.2010.06.048; Teague WG, 2010, J ALLERGY CLIN IMMUN, V125, P1235, DOI 10.1016/j.jaci.2010.04.012; Thomsen SF, 2010, J ALLERGY CLIN IMMUN, V126, P626, DOI 10.1016/j.jaci.2010.06.017; Toelle BG, 2010, J ALLERGY CLIN IMMUN, V126, P388, DOI 10.1016/j.jaci.2010.04.031; Togias A, 2010, J ALLERGY CLIN IMMUN, V125, P540, DOI 10.1016/j.jaci.2010.01.040; van de Kant KDG, 2010, J ALLERGY CLIN IMMUN, V126, P669, DOI 10.1016/j.jaci.2010.07.013; Van Muylem A, 2010, J ALLERGY CLIN IMMUN, V126, P730, DOI 10.1016/j.jaci.2010.06.019; Vink NM, 2010, J ALLERGY CLIN IMMUN, V126, P498, DOI 10.1016/j.jaci.2010.06.018; Weinberger M, 2010, J ALLERGY CLIN IMMUN, V126, P770, DOI 10.1016/j.jaci.2010.08.019; Williams LK, 2010, J ALLERGY CLIN IMMUN, V126, P225, DOI 10.1016/j.jaci.2010.03.034; Wright RJ, 2010, AM J RESP CRIT CARE, V182, P25, DOI 10.1164/rccm.200904-0637OC; Wu H, 2010, J ALLERGY CLIN IMMUN, V125, P321, DOI 10.1016/j.jaci.2009.09.007; Yao WG, 2010, J ALLERGY CLIN IMMUN, V126, P483, DOI 10.1016/j.jaci.2010.06.028; Zhang ZM, 2010, J ALLERGY CLIN IMMUN, V126, P1157, DOI 10.1016/j.jaci.2010.09.011; Zielen S, 2010, J ALLERGY CLIN IMMUN, V126, P942, DOI 10.1016/j.jaci.2010.06.002	119	23	23	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2011	127	1					102	115		10.1016/j.jaci.2010.11.018	http://dx.doi.org/10.1016/j.jaci.2010.11.018			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	702SY	21211645	Green Accepted, Bronze			2022-12-18	WOS:000285917300016
J	Wang, L; Hollenbeak, CS; Mauger, DT; Zeiger, RS; Paul, IM; Sorkness, CA; Lemanske, RF; Martinez, FD; Strunk, RC; Szefler, SJ; Taussig, LM				Wang, Li; Hollenbeak, Christopher S.; Mauger, David T.; Zeiger, Robert S.; Paul, Ian M.; Sorkness, Christine A.; Lemanske, Robert F., Jr.; Martinez, Fernando D.; Strunk, Robert C.; Szefler, Stanley J.; Taussig, Lynn M.		Natl Heart Lung Blood Inst	Cost-effectiveness analysis of fluticasone versus montelukast in children with mild-to-moderate persistent asthma in the Pediatric Asthma Controller Trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Cost-effectiveness analysis; childhood asthma; fluticasone; montelukast; Pediatric Asthma Controller Trial	EARLY INTERVENTION; PROPIONATE; BUDESONIDE; ADULTS; THERAPY; BUDESONIDE/FORMOTEROL; ADOLESCENTS; SALMETEROL; CARE	Background: Cost-effectiveness analyses of asthma controller regimens for adults exist, but similar evaluations exclusively for children are few. Objective: We sought to compare the cost-effectiveness of 2 commonly used asthma controllers, fluticasone and montelukast, with data from the Pediatric Asthma Controller Trial. Methods: We compared the cost-effectiveness of low-dose fluticasone with that of montelukast in a randomized, controlled, multicenter clinical trial in children with mild-to-moderate persistent asthma. Analyses were also conducted on subgroups based on phenotypic factors. Effectiveness measures included (1) the number of asthma-control days, (2) the percentage of participants with an increase over baseline of FEV1 of 12% or greater, and (3) the number of exacerbations avoided. Costs were analyzed from both a US health care payer's perspective and a societal perspective. Results: For all cost-effectiveness measures studied, fluticasone cost less and was more effective than montelukast. For example, fluticasone treatment cost $430 less in mean direct cost (P < .01) and resulted in 40 more asthma-control days (P < .01) during the 48-week study period. Considering sampling uncertainty, fluticasone cost less and was more effective at least 95% of the time. For the high exhaled nitric oxide (eNO) phenotypic subgroup (eNO >= 25 ppb) and more responsive PC20 subgroup (PC20 <2 mg/mL), fluticasone was cost-effective compared with montelukast for all cost-effectiveness measures, whereas not all the effectiveness measures were statistically different for the other 2 phenotypic subgroups. Conclusion: For children with mild-to-moderate persistent asthma, low-dose fluticasone had lower cost and higher effectiveness compared with montelukast, especially in those with more airway inflammation, as indicated by increased levels of eNO and more responsivity to methacholine. (J Allergy Clin Immunol 2011;127:161-6.)	[Wang, Li; Hollenbeak, Christopher S.; Mauger, David T.; Paul, Ian M.] Penn State Univ, Coll Med, Dept Publ Hlth Sci, Hershey, PA USA; [Hollenbeak, Christopher S.] Penn State Univ, Coll Med, Dept Surg, Hershey, PA USA; [Paul, Ian M.] Penn State Univ, Coll Med, Dept Pediat, Hershey, PA USA; [Zeiger, Robert S.] Univ Calif San Diego, Dept Pediat, San Diego, CA 92103 USA; [Zeiger, Robert S.] Kaiser Permanente So Calif, Dept Allergy, San Diego, CA USA; [Sorkness, Christine A.] Univ Wisconsin, Sch Pharm, Madison, WI 53706 USA; [Sorkness, Christine A.] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI USA; [Lemanske, Robert F., Jr.] Univ Wisconsin, Dept Pediat, Sch Med & Publ Hlth, Madison, WI USA; [Martinez, Fernando D.] Univ Arizona, Arizona Resp Ctr, Tucson, AZ USA; [Strunk, Robert C.] Washington Univ, Dept Pediat, St Louis, MO 63130 USA; [Szefler, Stanley J.; Taussig, Lynn M.] Univ Colorado, Denver Sch Med, Denver, CO 80202 USA; [Szefler, Stanley J.; Taussig, Lynn M.] Natl Jewish Hlth, Dept Pediat, Denver, CO USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University of California System; University of California San Diego; Kaiser Permanente; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Arizona; Washington University (WUSTL); University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; National Jewish Health	Wang, L (corresponding author), Penn State Coll Med, Dept Publ Hlth Sci, A210, Hershey, PA 17033 USA.	lwang@psu.edu	Paul, Ian/AAD-9813-2020; Hollenbeak, Christopher S./A-5309-2019; Wang, Li/C-6328-2013	Hollenbeak, Christopher S./0000-0002-3362-814X; Paul, Ian/0000-0002-6344-8609; Szefler, Stanley/0000-0002-6911-3199; Zeiger, Robert/0000-0001-5788-5063	National Heart, Lung, and Blood Institute [5U10HL064287, 5U10HL064288, 5U10HL064295, 5U10HL064307, 5U10HL0643055, 5U10HL064313]; General Clinical Research Centers at Washington University School of Medicine [M01 RR00036]; National Jewish Health and University of Colorado Denver School of Medicine from NCRR/HIH [M01RR00051, 1 UL1 RR025780]; GlaxoSmithKline; Aerocrine; Genentech; Merck; Schering-Plough; Pharmaxis; Sandoz/Compleware; National Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health; Novartis; Boehringer-Ingelheim; National Institutes of Health (NIH)/NHLBI; NHLBI's Childhood Asthma Research and Education; NIH/NHLBI's Asthma Clinical Research Network; NIH/NIAID's Inner City Asthma Consortium; NIH/NHLBI Asthma Met; National Institute of Environmental Health Sciences/US Environmental Protection Agency Childhood Environmental Health Center; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025780, M01RR000051, M01RR000036] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U10HL064305, U10HL064287, U10HL064288, U10HL064307, U10HL064313, U10HL064295] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); General Clinical Research Centers at Washington University School of Medicine(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Jewish Health and University of Colorado Denver School of Medicine from NCRR/HIH; GlaxoSmithKline(GlaxoSmithKline); Aerocrine; Genentech(Roche HoldingGenentech); Merck(Merck & Company); Schering-Plough(Merck & CompanySchering Plough Corporation); Pharmaxis; Sandoz/Compleware; National Heart, Lung, and Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Novartis(Novartis); Boehringer-Ingelheim(Boehringer Ingelheim); National Institutes of Health (NIH)/NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI's Childhood Asthma Research and Education(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIH/NHLBI's Asthma Clinical Research Network(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIH/NIAID's Inner City Asthma Consortium(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIH/NHLBI Asthma Met(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institute of Environmental Health Sciences/US Environmental Protection Agency Childhood Environmental Health Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by grants 5U10HL064287, 5U10HL064288, 5U10HL064295, 5U10HL064307, 5U10HL0643055, and 5U10HL064313 from the National Heart, Lung, and Blood Institute. This study was carried out in part in the General Clinical Research Centers at Washington University School of Medicine (M01 RR00036) and National Jewish Health and University of Colorado Denver School of Medicine (M01RR00051) under Colorado CTSA grant 1 UL1 RR025780 from NCRR/HIH.; D. T. Mauger has received research support from GlaxoSmithKline. R. S. Zeiger is a consultant for Aerocrine, AstraZeneca, Genentech, GlaxoSmithKline, MedImmune, Merck, and Sunovion and has received research support from Aerocrine, Genentech, GlaxoSmithKline, and Merck. C. A. Sorkness is a consultant for GlaxoSmithKline, AstraZeneca, and Novartis and has received research support from Schering-Plough, Pharmaxis, Sandoz/Compleware, and the National Heart, Lung, and Blood Institute (NHLBI). R. F. Lemanske is a speaker for Merck, Washington University, the Medicus Group, the Park Nicolet Institute, the ACAAI(American College of Allergy, Asthma & Immunology), the LAAllergy Society, the Michigan Allergy/Asthma Society, the Medical College of Wisconsin, the Fund for Medical Research and Education (Detroit), Children's Hospital of Minnesota, the Toronto Allergy Society, the AAAAI (American Academy of Allergy, Asthma & Immunology), Beaumont Hospital (Detroit), the University of Illinois, the Canadian Society of Allergy and Clinical Immunology, and New York Presbyterian; is a consultant and speaker for AstraZeneca; is a consultant for Map Pharmaceuticals, Gray Consulting, Smith Research, the Merck Childhood Asthma Network, Novartis, Quintiles/Innovax, RC Horowitz & Co, International Meetings and Science, and Scienomics; is the author of Up-to-Date; and is a textbook editor for Elsevier. F. D. Martinez is on the advisory board for and receives lecture fees from Merck; is a consultant for GlaxoSmithKline and MedImmune; receives lecture fees from Pfizer; and has received research support from the National Institutes of Health. S. J. Szefler is a consultant for GlaxoSmithKline, Genentech, Merck, Boehringer-Ingelheim, Novartis, and Schering-Plough and has received research support from the National Institutes of Health (NIH)/NHLBI's Childhood Management Program, the NHLBI's Childhood Asthma Research and Education, NIH/NHLBI's Asthma Clinical Research Network, the NIH/NIAID's Inner City Asthma Consortium, GlaxoSmithKline, NIH/NHLBI Asthma Met, and a National Institute of Environmental Health Sciences/US Environmental Protection Agency Childhood Environmental Health Center grant. The rest of the authors have declared that they have no conflict of interest.	Akazawa M, 2006, PHARMACOECONOMICS, V24, P971, DOI 10.2165/00019053-200624100-00005; [Anonymous], 2002, SUMMARY HLTH STAT 10; Asthma and Allergy Foundation of America, ASTHM FACTS FIG; Barnes NC, 1999, RESP MED, V93, P402, DOI 10.1053/rmed.1999.0577; Bisgaard H, 2001, CHEST, V120, P1835, DOI 10.1378/chest.120.6.1835; Borker R, 2005, ANN ALLERG ASTHMA IM, V95, P181, DOI 10.1016/S1081-1206(10)61209-4; Briggs AH, 2006, ALLERGY, V61, P531, DOI 10.1111/j.1398-9995.2006.01038.x; Bureau of Labor Statistics, CONS PRIC IND DAT; Buxton MJ, 2004, EUR RESPIR J, V24, P568, DOI 10.1183/09031936.04.00108703; Doull L, 2007, CURR MED RES OPIN, V23, P1147, DOI 10.1185/030079907X187982; Ericsson K, 2006, RESP MED, V100, P586, DOI 10.1016/j.rmed.2005.09.032; Feenstra TL, 2002, PEDIATR PULM, V34, P442, DOI 10.1002/ppul.10177; Haddix AC, 2003, PREVENTION EFFECTIVE; Johansson G, 1999, PHARMACOECONOMICS, V16, P15, DOI 10.2165/00019053-199916002-00003; Johansson G, 2006, PHARMACOECONOMICS, V24, P695, DOI 10.2165/00019053-200624070-00008; Knuffman JE, 2009, J ALLERGY CLIN IMMUN, V123, P411, DOI 10.1016/j.jaci.2008.11.016; Lundback B, 2000, RESP MED, V94, P724, DOI 10.1053/rmed.2000.0876; Miller E, 2008, J POPUL THER CLIN PH, V15, pE165; Murphy KR, 2003, J ALLERGY CLIN IMMUN, V111, P202, DOI 10.1067/mai.2003.50; O'Connor RD, 2004, PHARMACOECONOMICS, V22, P815, DOI 10.2165/00019053-200422120-00004; Pathak DS, 2002, PHARMACOTHERAPY, V22, P166, DOI 10.1592/phco.22.3.166.33548; Pieters Willem R, 2005, Treat Respir Med, V4, P129, DOI 10.2165/00151829-200504020-00007; Pieters WR, 1999, PHARMACOECONOMICS, V16, P29, DOI 10.2165/00019053-199916002-00005; RICE DP, 1967, AM J PUBLIC HEALTH N, V57, P424, DOI 10.2105/AJPH.57.3.424; Shepherd J, 2008, HEALTH TECHNOL ASSES, V12, pXI; Simonella L, 2006, INTERN MED J, V36, P244, DOI 10.1111/j.1445-5994.2006.01054.x; Sorkness CA, 2007, J ALLERGY CLIN IMMUN, V119, P64, DOI 10.1016/j.jaci.2006.09.042; Stempel DA, 2007, J PEDIATR-US, V150, P162, DOI 10.1016/j.jpeds.2006.10.069; Sullivan SD, 2003, J ALLERGY CLIN IMMUN, V112, P1229, DOI 10.1016/j.jaci.2003.09.025; *THOMS HEALTHC, 2003, DRUG TOP RED BOOK; Weiss K, 2006, PEDIAT ALLERG IMM-UK, V17, P21, DOI 10.1111/j.1600-5562.2006.00381.x	31	23	23	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2011	127	1					161	U258		10.1016/j.jaci.2010.10.035	http://dx.doi.org/10.1016/j.jaci.2010.10.035			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	702SY	21211651	Green Accepted			2022-12-18	WOS:000285917300023
J	Al-Sukaiti, N; Reid, B; Lavi, S; Al-Zaharani, D; Atkinson, A; Roifman, CM; Grunebaum, E				Al-Sukaiti, Nashat; Reid, Brenda; Lavi, Sasson; Al-Zaharani, Daifulah; Atkinson, Adelle; Roifman, Chaim M.; Grunebaum, Eyal			Safety and efficacy of measles, mumps, and rubella vaccine in patients with DiGeorge syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							LIVE VIRAL VACCINES; CHILDREN; IMMUNITY		[Al-Sukaiti, Nashat] Hosp Sick Children, Dept Peadiatr, Jeffrey Modell Res Lab Diag Primary Immunodeficie, Canadian Ctr Primary Immunodeficiency,Div Immunol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Al-Sukaiti, N (corresponding author), Hosp Sick Children, Dept Peadiatr, Jeffrey Modell Res Lab Diag Primary Immunodeficie, Canadian Ctr Primary Immunodeficiency,Div Immunol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	chaim.roifman@sickkids.ca						Aurpibul L, 2007, CLIN INFECT DIS, V45, P637, DOI 10.1086/520651; Azzari C, 2005, VACCINE, V23, P1668, DOI 10.1016/j.vaccine.2004.10.005; Davidkin I, 1998, VACCINE, V16, P2052, DOI 10.1016/S0264-410X(98)00081-4; JUNKER AK, 1995, J PEDIATR-US, V127, P231, DOI 10.1016/S0022-3476(95)70300-4; Moylett EH, 2004, CLIN IMMUNOL, V112, P106, DOI 10.1016/j.clim.2004.02.008; Perez EE, 2003, PEDIATRICS, V112, pE325, DOI 10.1542/peds.112.4.e325; Shinjoh M, 2008, VACCINE, V26, P6859, DOI 10.1016/j.vaccine.2008.09.076; Sullivan KE, 2004, CLIN IMMUNOL, V113, P3, DOI 10.1016/j.clim.2004.04.004; Watson J C, 1998, MMWR Recomm Rep, V47, P1	9	23	26	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2010	126	4					868	869		10.1016/j.jaci.2010.07.018	http://dx.doi.org/10.1016/j.jaci.2010.07.018			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	658SP	20810153				2022-12-18	WOS:000282510000027
J	Van Muylem, A; Kerckx, Y; Michils, A				Van Muylem, Alain; Kerckx, Yannick; Michils, Alain			Acinar effect of inhaled steroids evidenced by exhaled nitric oxide	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Exhaled nitric oxide; alveolar nitric oxide; asthma; inhaled corticosteroids; Asthma Control Questionnaire	AXIAL DIFFUSION; SMALL AIRWAYS; ALVEOLAR; ASTHMA; INFLAMMATION; EXCHANGE; LUNG; BUDESONIDE; SYMPTOMS; IMPACT	Background: The effects of inhaled corticosteroids (ICSs) on distal lung inflammation, as assessed by alveolar nitric oxide concentration (CANO), are a matter of debate. Recently, a theoretic study suggested that acinar airway obstruction that is relieved by ICS treatment and associated with a decrease in fraction of exhaled nitric oxide (FeNO) concentration might, paradoxically, increase CANO. This increase could be a hallmark effect of ICSs at the acinar level. Objective: In the light of this new hypothesis, we studied changes in CANO and FeNO after administration of ICSs. Methods: CANO and FeNO were measured before and after ICS treatment of 38 steroid-naive patients with uncontrolled asthma who showed clinical improvement after ICS therapy. Results: The average FeNO decreased from 78.3 to 28.9 ppb (P < .001); CANO decreased from 7.7 to 4.3 ppb (P = .009). In 14 subjects (low-slope group), slope (= Delta CANO/Delta FeNO) values (Delta = post-ICS - pre-ICS value) were less than the 95% normal CI (average Delta FeNO = -32.7 ppb and average Delta CANO= +2.9 ppb). In this group, baseline CANO was abnormally low when FeNO was taken into account. In 11 subjects (the high-slope group), the slope was above the normal interval (average Delta FeNO = -42.5 ppb and average Delta CANO = -14.7 ppb). Conclusion: Opposite patterns (one that was predicted) can indicate peripheral actions of ICSs; this difference might account for conflicting data reported from studies using CANO to determine the peripheral action of ICSs. We show that a low CANO does not preclude distal inflammation. (J Allergy Clin Immunol 2010;126:730-5.)	[Van Muylem, Alain; Kerckx, Yannick; Michils, Alain] Univ Libre Bruxelles, Clin Univ Erasme, Chest Dept, B-1070 Brussels, Belgium	Universite Libre de Bruxelles	Van Muylem, A (corresponding author), Univ Libre Bruxelles, Clin Univ Erasme, Chest Dept, 808 Route Lennik, B-1070 Brussels, Belgium.	avmuylem@ulb.ac.be			ESA; Novartis; AstraZeneca	ESA(European Space Agency); Novartis(Novartis); AstraZeneca(AstraZeneca)	Supported by a MAP project from ESA: Airway NO in microgravity.; Disclosure of potential conflict of interest: A. Michils receives consulting fees from Novartis and AstraZeneca. The rest of the authors have declared that they have no conflict of interest.	American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST; Balzar S, 2002, EUR RESPIR J, V20, P254, DOI 10.1183/09031936.02.00261102; Berry M, 2005, EUR RESPIR J, V25, P986, DOI 10.1183/09031936.05.00132404; Brindicci C, 2007, CHEST, V131, P1353, DOI 10.1378/chest.06-2531; CARROLL N, 1993, AM REV RESPIR DIS, V147, P405, DOI 10.1164/ajrccm/147.2.405; Condorelli P, 2007, J APPL PHYSIOL, V102, P417, DOI 10.1152/japplphysiol.00533.2006; Davison A., 1997, BOOTSTRAP METHODS TH, V94; Gelb AF, 2004, AM J RESP CRIT CARE, V170, P737, DOI 10.1164/rccm.200403-408OC; Gelb AF, 2006, CHEST, V129, P1492, DOI 10.1378/chest.129.6.1492; Juniper EF, 2006, RESP MED, V100, P616, DOI 10.1016/j.rmed.2005.08.012; Juniper EF, 2005, RESP MED, V99, P553, DOI 10.1016/j.rmed.2004.10.008; Kerckx Y, 2008, J APPL PHYSIOL, V104, P918, DOI 10.1152/japplphysiol.01032.2007; Kharitonov SA, 2002, THORAX, V57, P889, DOI 10.1136/thorax.57.10.889; Lehtimaki L, 2005, J ASTHMA, V42, P605, DOI 10.1080/02770900500294678; Lehtimaki L, 2002, EUR RESPIR J, V20, P841, DOI 10.1183/09031936.02.00202002; Lehtimaki L, 2001, EUR RESPIR J, V18, P635, DOI 10.1183/09031936.01.00000201; Martin GP, 2006, PHARM RES-DORDR, V23, P2210, DOI 10.1007/s11095-006-9056-8; Moore WC, 2007, J ALLERGY CLIN IMMUN, V119, P405, DOI 10.1016/j.jaci.2006.11.639; Paraskakis E, 2006, AM J RESP CRIT CARE, V174, P260, DOI 10.1164/rccm.200506-962OC; Pietropaoli AP, 1999, J APPL PHYSIOL, V87, P1532, DOI 10.1152/jappl.1999.87.4.1532; QUANJER PH, 1993, EUR RESPIR J, V6, P5, DOI 10.1183/09041950.005s1693; Shin HW, 2002, J APPL PHYSIOL, V93, P2070, DOI 10.1152/japplphysiol.00129.2002; Travers J, 2007, AM J RESP CRIT CARE, V176, P238, DOI 10.1164/rccm.200609-1346OC; Tsoukias NM, 1998, J APPL PHYSIOL, V85, P653, DOI 10.1152/jappl.1998.85.2.653; Van Muylem A, 2003, J APPL PHYSIOL, V94, P119, DOI 10.1152/japplphysiol.00044.2002; van Veen IH, 2006, EUR RESPIR J, V27, P951, DOI 10.1183/09031936.06.00087905; Verbanck S, 1999, AM J RESP CRIT CARE, V159, P1545, DOI 10.1164/ajrccm.159.5.9809017; Verbanck S, 2008, J APPL PHYSIOL, V104, P925, DOI 10.1152/japplphysiol.01019.2007; Weibel E.R., 1963, MORPHOMETRY HUMAN LU, DOI DOI 10.1007/978-3-642-87553-3; Wood LJ, 1999, AM J RESP CRIT CARE, V159, P1457, DOI 10.1164/ajrccm.159.5.9808123	30	23	23	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2010	126	4					730	U93		10.1016/j.jaci.2010.06.019	http://dx.doi.org/10.1016/j.jaci.2010.06.019			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	658SP	20709384	Bronze			2022-12-18	WOS:000282510000006
J	Prenner, BM; Lanier, BQ; Bernstein, DI; Shekar, T; Teper, A				Prenner, Bruce M.; Lanier, Bobby Q.; Bernstein, David I.; Shekar, Tulin; Teper, Ariel			Mometasone furoate nasal spray reduces the ocular symptoms of seasonal allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic rhinitis; intranasal corticosteroids; mometasone furoate nasal spray	QUALITY-OF-LIFE; OLOPATADINE HYDROCHLORIDE 0.1-PERCENT; INTRANASAL FLUTICASONE PROPIONATE; 2-PERCENT OPHTHALMIC SOLUTION; NEDOCROMIL SODIUM 2-PERCENT; RECEPTOR ANTAGONISTS; CARBON-DIOXIDE; CORTICOSTEROIDS; EFFICACY; CONJUNCTIVAL	Background: Mometasone furoate nasal spray (MFNS), a potent intranasal corticosteroid with proved efficacy in relieving nasal allergic rhinitis symptoms, has demonstrated effectiveness in improving ocular symptoms associated with seasonal allergic rhinitis (SAR) in retrospective analyses. Objective: We sought to evaluate prospectively the efficacy of MFNS in reducing total ocular symptom scores (TOSSs) and individual ocular symptoms in subjects with SAR. Methods: Subjects 12 years or older (n = 429) with moderate-to-severe baseline symptoms were randomized to MFNS, 200 mu g once daily, or placebo in this 15-day, double-blind, parallel-group study. Subjects evaluated morning instantaneous TOSSs and daily reflective TOSSs, total nasal symptom scores (TNSSs; both instantaneous TNSSs and reflective TNSSs, respectively), and individual ocular and nasal symptoms. Mean changes from baseline averaged over days 2 to 15 (instantaneous) and days 1 to 15 (reflective) were calculated. Quality of life was assessed by using the Rhinoconjunctivitis Quality of Life Questionnaire. Results: MFNS treatment yielded significant reductions from baseline versus placebo in instantaneous TOSSs (-0.34, P = .026, coprimary end point), instantaneous TNSSs (-0.88, P < .001, coprimary end point), reflective TOSSs (-0.44, P = .005), and reflective TNSSs (-1.06, P < .001). Significant decreases in all individual reflective ocular symptoms and instantaneous eye itching/burning and eye watering/tearing were observed for MFNS versus placebo (P < .05). Numeric improvements in instantaneous eye redness were seen but did not reach statistical significance. Improvements in Rhinoconjunctivitis Quality of Life Questionnaire total scores and individual symptom domains were achieved with MFNS treatment versus placebo (P < .001). MFNS was well tolerated. Conclusion: This prospective study demonstrates that MFNS significantly reduces ocular symptoms in subjects with SAR. (J Allergy Clin Immunol 2010;125:1247-53.)	[Prenner, Bruce M.] Allergy Associates Med Grp, San Diego, CA USA; [Lanier, Bobby Q.] Univ N Texas, N Texas Hlth Sci Ctr, Ft Worth, TX USA; [Bernstein, David I.] Univ Cincinnati, Dept Internal Med, Div Allergy Immunol, Cincinnati, OH 45221 USA; [Shekar, Tulin; Teper, Ariel] Merck Res Labs, Kenilworth, NJ USA	University of North Texas System; University of North Texas Health Science Center; University System of Ohio; University of Cincinnati; Merck & Company	Prenner, BM (corresponding author), UCSD Sch Med, Dept Pediat, 6386 Alvarado Ct 210, San Diego, CA 92120 USA.	prenner@aaamg.com			Schering-Plough Research Institute, a division of Schering Corporation; Abbot; Aerovent; Alcon; Amgen; Amphastar; Boehringer Ingelheim; Forrest; Genentech; GlaxoSmithKline; Map Pharmaceuticals; Meda; Novartis; Pharmaxis; Sanofi-Aventis; Schering-Plough Research Institute; Sepracor; Skyepharma; UCB; Wyeth; Schering Laboratories; Santofi; Schering-Plough; Alcon Labs	Schering-Plough Research Institute, a division of Schering Corporation(Merck & Company); Abbot; Aerovent; Alcon(Novartis); Amgen(Amgen); Amphastar; Boehringer Ingelheim(Boehringer Ingelheim); Forrest; Genentech(Roche HoldingGenentech); GlaxoSmithKline(GlaxoSmithKline); Map Pharmaceuticals; Meda; Novartis(Novartis); Pharmaxis; Sanofi-Aventis(Sanofi-Aventis); Schering-Plough Research Institute(Merck & Company); Sepracor; Skyepharma; UCB(UCB Pharma SA); Wyeth(Wyeth); Schering Laboratories; Santofi; Schering-Plough(Merck & CompanySchering Plough Corporation); Alcon Labs(Novartis)	Support was provided by Schering-Plough Research Institute, a division of Schering Corporation.; Disclosure of potential conflict of interest: B. M. Premier receives research support from Abbot, Aerovent, Alcon, Amgen, Amphastar, Boehringer Ingelheim, Forrest, Genentech, GlaxoSmithKline, Map Pharmaceuticals, Meda, Novartis, Pharmaxis, Sanofi-Aventis, the Schering-Plough Research Institute, Sepracor, Skyepharma, UCB, and Wyeth: has consultant arrangements with Abbott, Astellas, AstraZeneca, Dynavax, Critical Therapeutics, Genentech, GlaxoSmithKline, King Pharmaceuticals, Meda, Merck, Novartis, Protein Design Labs, Sanofi-Aventis, Schering-Plough, Sciele Pharma, Stallergenes, and Teva; and is on the speakers' bureau for Altana, Allergan, Astra Zeneca, Astellas, Genentech, GlaxoSmithKline, Meda, Merck. Novartis, Sanofi-Aventis, Sepracor, Schering-Plough, and Teva. B. Q. Lanier receives research support from Alcon Labs, Schering Laboratories, Novartis, and Santofi; has consulted for Alcon Laboratories on nasal antihistamine protocols; and is on the speakers' bureau for Novartis and Schering-Plough. D. I. Bernstein has consultant arrangements with Schering-Plough and receives research support from Schering-Plough. A. leper has financial interests with Schering-Plough. T. Shekar has declared that he has no conflict of interest.	Alexander M, 2000, ADV THER, V17, P140, DOI 10.1007/BF02853155; Andrews CP, 2009, ALLERGY ASTHMA PROC, V30, P128, DOI 10.2500/aap.2009.30.3204; Anolik R, 2008, INT ARCH ALLERGY IMM, V147, P323, DOI 10.1159/000144040; Anolik R, 2008, ANN ALLERG ASTHMA IM, V100, P264, DOI 10.1016/S1081-1206(10)60452-8; [Anonymous], LANDM SURV NAS ALL S; Bacon AS, 2000, J ALLERGY CLIN IMMUN, V106, P948, DOI 10.1067/mai.2000.110930; Baroody FM, 2008, ANN ALLERG ASTHMA IM, V100, P194, DOI 10.1016/S1081-1206(10)60442-5; Baroody FM, 2009, J ALLERGY CLIN IMMUN, V123, P1342, DOI 10.1016/j.jaci.2009.03.015; Bellamy JL, 2006, HEADACHE, V46, P24, DOI 10.1111/j.1526-4610.2006.00294.x; BENINCASA C, 1994, DRUG INVEST, V8, P225, DOI 10.1007/BF03258482; Berkowitz RB, 1999, ALLERGY, V54, P64, DOI 10.1034/j.1398-9995.1999.00713.x; Bernstein D, 2008, ALLERGY, V63, P87; Bernstein DI, 2004, CLIN EXP ALLERGY, V34, P952, DOI 10.1111/j.1365-2222.2004.01952.x; Bielory L, 2008, ANN ALLERG ASTHMA IM, V100, P272, DOI 10.1016/S1081-1206(10)60453-X; Bielory L, 2008, J ALLERGY CLIN IMMUN, V121, P538, DOI 10.1016/j.jaci.2007.10.013; Blaiss MS, 2008, CURR MED RES OPIN, V24, P821, DOI 10.1185/030079908X253780; BONINI S, 1990, J ALLERGY CLIN IMMUN, V86, P869, DOI 10.1016/S0091-6749(05)80148-4; Bonini S, 2006, CHEM IMMUNOL ALLERGY, V91, P110; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Bowen EJ, 2005, HEADACHE, V45, P808; Bronsky EA, 1997, ANN ALLERG ASTHMA IM, V79, P51, DOI 10.1016/S1081-1206(10)63084-0; Butrus S, 2000, CLIN THER, V22, P1462, DOI 10.1016/S0149-2918(00)83044-1; Canonica GW, 2007, ALLERGY, V62, P17, DOI 10.1111/j.1398-9995.2007.01549.x; Casale TB, 2008, J ALLERGY CLIN IMMUN, V121, P105, DOI 10.1016/j.jaci.2007.08.056; Cave A, 1999, PHARMACOL THERAPEUT, V83, P153, DOI 10.1016/S0163-7258(99)00019-4; COHEN AJ, LACRIMAL SYSTEM DIAG; DeWester J, 2003, ALLERGY ASTHMA PROC, V24, P331; Di Lorenzo G, 2004, CLIN EXP ALLERGY, V34, P259, DOI 10.1111/j.1365-2222.2004.01877.x; Fokkens WJ, 2007, ALLERGY, V62, P1078, DOI 10.1111/j.1398-9995.2007.01522.x; Frieri M, 1998, ANN ALLERG ASTHMA IM, V81, P431, DOI 10.1016/S1081-1206(10)63141-9; Friesen JHC, 2008, J ALLERGY CLIN IMMUN, V121, P265, DOI 10.1016/j.jaci.2007.07.060; Greiner JV, 2003, CLIN THER, V25, P1988, DOI 10.1016/S0149-2918(03)80200-X; Hebert J, 2007, J ALLERGY CLIN IMMUN, V119, pS61, DOI 10.1016/j.jaci.2006.11.263; Jacobs R, 2009, CURR MED RES OPIN, V25, P1393, DOI 10.1185/03007990902890512; Jacobson MR, 1999, CLIN EXP ALLERGY, V29, P1347; James IGV, 2003, CURR MED RES OPIN, V19, P313, DOI 10.1185/030079903125001785; Juniper EF, 1999, J ALLERGY CLIN IMMUN, V104, P364, DOI 10.1016/S0091-6749(99)70380-5; Juniper EF, 1996, J ALLERGY CLIN IMMUN, V98, P843, DOI 10.1016/S0091-6749(96)70135-5; Kaiser HB, 2007, J ALLERGY CLIN IMMUN, V119, P1430, DOI 10.1016/j.jaci.2007.02.022; Katelaris CH, 2002, CLIN THER, V24, P1561, DOI 10.1016/S0149-2918(02)80060-1; Keith PK, 2009, CURR MED RES OPIN, V25, P2021, DOI 10.1185/03007990903094106; Long AA, 2007, CLIN THER, V29, P342, DOI 10.1016/j.clinthera.2007.02.007; Martin BG, 2007, ALLERGY ASTHMA PROC, V28, P216, DOI 10.2500/aap.2007.28.2983; McNeill EJ, 2005, AM J RHINOL, V19, P588, DOI 10.1177/194589240501900610; Meltzer EO, 2001, ANN ALLERG ASTHMA IM, V86, P286, DOI 10.1016/S1081-1206(10)63300-5; Meltzer EO, 1999, J ALLERGY CLIN IMMUN, V104, P107, DOI 10.1016/S0091-6749(99)70121-1; NACLERIO RM, 1991, NEW ENGL J MED, V325, P860; Naclerio RM, 2008, ALLERGY ASTHMA PROC, V29, P24, DOI 10.2500/aap2008.29.3075; Naclerio RM, 2009, ALLERGY ASTHMA PROC, V30, P212, DOI 10.2500/aap.2009.30.3220; Ozturk F, 1998, Ear Nose Throat J, V77, P846; PHILIP G, 1994, J ALLERGY CLIN IMMUN, V94, P1035, DOI 10.1016/0091-6749(94)90122-8; PIPKORN U, 1987, NEW ENGL J MED, V316, P1506, DOI 10.1056/NEJM198706113162403; Pitt AD, 2004, OPHTHAL EPIDEMIOL, V11, P17, DOI 10.1076/opep.11.1.17.26437; Price David, 2006, Prim Care Respir J, V15, P58, DOI 10.1016/j.pcrj.2005.11.002; Ratner PH, 2008, ANN ALLERG ASTHMA IM, V100, P74, DOI 10.1016/S1081-1206(10)60408-5; Rosenwasser LJ, 2008, ALLERGY ASTHMA PROC, V29, P644, DOI 10.2500/aap.2008.29.3176; Scadding GK, 2008, CLIN EXP ALLERGY, V38, P19, DOI 10.1111/j.1365-2222.2007.02888.x; Schenkel E, 2007, ALLERGY CLIN IMMUNOL, V19, P50, DOI 10.1027/0838-1925.19.2.50; Skoner DR, 2001, J ALLERGY CLIN IMMUN, V108, pS2, DOI 10.1067/mai.2001.115569; Spangler DL, 2003, CLIN THER, V25, P2245, DOI 10.1016/S0149-2918(03)80217-5; Sussman G, 2007, J ALLERGY CLIN IMMUN, V119, pS61, DOI 10.1016/j.jaci.2006.11.261; Svensson C, 1998, ALLERGY, V53, P367, DOI 10.1111/j.1398-9995.1998.tb03907.x; Thompson AK, 2000, ANN ALLERG ASTHMA IM, V85, P338, DOI 10.1016/S1081-1206(10)62543-4; Undem Bradley J., 2000, Journal of Allergy and Clinical Immunology, V106, pS213; Vasar M, 2008, ALLERGY ASTHMA PROC, V29, P313, DOI 10.2500/aap.2008.29.3126; Weiner JM, 1998, BMJ-BRIT MED J, V317, P1624, DOI 10.1136/bmj.317.7173.1624; Wuthrich B, 1998, SCHWEIZ MED WSCHR, V128, P139; Yanez A, 2002, ANN ALLERG ASTHMA IM, V89, P479, DOI 10.1016/S1081-1206(10)62085-6	69	23	29	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2010	125	6					1247	1253		10.1016/j.jaci.2010.03.004	http://dx.doi.org/10.1016/j.jaci.2010.03.004			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	611PH	20434199				2022-12-18	WOS:000278831000011
J	Kelso, JM				Kelso, John M.			Administration of influenza vaccines to patients with egg allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Egg allergy; influenza vaccine; ovalbumin	VACCINATION; CHILDREN; SAFETY	Egg allergy influenza vaccine ovalbumin	Scripps Clin, Div Allergy Asthma & Immunol, San Diego, CA 92130 USA	Scripps Research Institute	Kelso, JM (corresponding author), Scripps Clin, Div Allergy Asthma & Immunol, 3811 Valley Ctr Dr, San Diego, CA 92130 USA.	kelso.john@scrippshealth.org						BIERMAN CW, 1977, J INFECT DIS, V136, pS652, DOI 10.1093/infdis/136.Supplement_3.S652; Bohlke K, 2003, PEDIATRICS, V112, P815, DOI 10.1542/peds.112.4.815; Erlewyn-Lajeunesse M, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b3680; James JM, 1998, J PEDIATR-US, V133, P624, DOI 10.1016/S0022-3476(98)70101-5; KELSO JM, 2009, UPTODATE; Kelso JM, 2008, MIDDLETONS ALLERGY P, P1189; LI JT, 2010, J ALLERGY C IN PRESS; Rank MA, 2009, J ALLERGY CLIN IMMUN, V124, P1123, DOI 10.1016/j.jaci.2009.09.028; RETAILLIAU HF, 1980, AM J EPIDEMIOL, V111, P270, DOI 10.1093/oxfordjournals.aje.a112896; Rona RJ, 2007, J ALLERGY CLIN IMMUN, V120, P638, DOI 10.1016/j.jaci.2007.05.026; Thompson WW, 2009, INFLUENZA OTHER RESP, V3, P37, DOI 10.1111/j.1750-2659.2009.00073.x; Vellozzi C, 2009, VACCINE, V27, P2114, DOI 10.1016/j.vaccine.2009.01.125; Waibel KH, 2010, J ALLERGY CLIN IMMUN, V125, P749, DOI 10.1016/j.jaci.2009.12.015; Zeiger RS, 2002, J ALLERGY CLIN IMMUN, V110, P834, DOI 10.1067/mai.2002.129372	14	23	26	1	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2010	125	4					800	802		10.1016/j.jaci.2010.02.013	http://dx.doi.org/10.1016/j.jaci.2010.02.013			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	584XP	20226505				2022-12-18	WOS:000276787900003
J	Uygungil, B; Bleesing, JJ; Risma, KA; McNeal, MM; Rothenberg, ME				Uygungil, Burcin; Bleesing, Jack J.; Risma, Kimberly A.; McNeal, Monica M.; Rothenberg, Marc E.			Persistent rotavirus vaccine shedding in a new case of severe combined immunodeficiency: A reason to screen	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							UNITED-STATES; HOSPITALIZATIONS; CHILDREN; GASTROENTERITIS; DIARRHEA; AGE		[Uygungil, Burcin; Bleesing, Jack J.; Risma, Kimberly A.; McNeal, Monica M.; Rothenberg, Marc E.] Cincinnati Childrens Hosp, Med Ctr, Cincinnati, OH USA	Cincinnati Children's Hospital Medical Center	Uygungil, B (corresponding author), Cincinnati Childrens Hosp, Med Ctr, Cincinnati, OH USA.	burcin.uygungil@cchmc.org	Risma, Kimberly/ABE-5905-2020	/0000-0003-0671-4859; McNeal, Monica/0000-0002-3784-9062				Bocchini JA, 2009, PEDIATRICS, V123, P1412, DOI 10.1542/peds.2009-0466; Charles MD, 2006, PEDIATR INFECT DIS J, V25, P489, DOI 10.1097/01.inf.0000215234.91997.21; Fischer TK, 2007, J INFECT DIS, V195, P1117, DOI 10.1086/512863; Malek MA, 2006, PEDIATRICS, V117, P1887, DOI 10.1542/peds.2005-2351; PATEL NC, 2009, J ALLERGY CLIN IMMUN; Payne DC, 2008, PEDIATRICS, V122, P1235, DOI 10.1542/peds.2007-3378; Rynn L., 2008, Morbidity and Mortality Weekly Report, V57, P1; Anonymous, 2006, Morbidity and Mortality Weekly Report, V55, P1; Tate JE, 2009, PEDIATRICS, V124, P465, DOI 10.1542/peds.2008-3528; Turcios RM, 2006, PEDIATR INFECT DIS J, V25, P451, DOI 10.1097/01.inf.0000214987.67522.78; Werther RL, 2009, J ALLERGY CLIN IMMUN, V124, P600, DOI 10.1016/j.jaci.2009.07.005	11	23	25	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2010	125	1					270	271		10.1016/j.jaci.2009.10.029	http://dx.doi.org/10.1016/j.jaci.2009.10.029			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	544MG	20109754				2022-12-18	WOS:000273660500036
J	Leb, VM; Jahn-Schmid, B; Kueng, HJ; Schmetterer, KG; Haiderer, D; Neunkirchner, A; Fischer, GF; Hartl, A; Thalhamer, J; Steinberger, P; Bohle, B; Seed, B; Pickl, WF				Leb, Victoria M.; Jahn-Schmid, Beatrice; Kueng, Hans J.; Schmetterer, Klaus G.; Haiderer, Daniela; Neunkirchner, Alina; Fischer, Gottfried F.; Hartl, Arnulf; Thalhamer, Josef; Steinberger, Peter; Bohle, Barbara; Seed, Brian; Pickl, Winfried F.			Modulation of allergen-specific T-lymphocyte function by virus-like particles decorated with HLA class II molecules	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Artificial APC; Art v 1; HLA class II; mugwort pollinosis; T-cell modulation; costimulation; TCR tg T cells; type I allergy; virus-like particles	MUGWORT POLLEN ALLERGEN; CELL-DERIVED EXOSOMES; ANTIGEN PRESENTATION; DENDRITIC CELLS; CLONAL ANERGY; LIPID RAFTS; IMMUNOTHERAPY; ACTIVATION; EXPRESSION; RECEPTOR	Background: T(H)2 lymphocytes play an important role in the induction and maintenance phase of type I allergy. Modulation of the responses of T(H)2 lymphocytes by novel forms of antigen-presenting platforms may help shape the immune response to allergen and palliate allergic diseases. Objective: To present HLA class II/allergen-peptide complexes on virus-like particles (VLPs) and to evaluate their potential to modulate allergen-specific T-cell responses. Methods: Virus-like particles that express the immunodominant T-cell epitope Art v 1(25-34) of the major mugwort pollen allergen in the context of HLA-DR1 and costimulatory molecules were produced by transfection of 293 cells. The effect of VLPs on IL-2 promoter activity, proliferation, and cytokine production of allergen-specific T cells derived from donors with and without mugwort pollen allergy was determined. Results: Flow-cytometric analyses showed that HLA class II molecules, invariant chain::Art v 1 fusion proteins, and costimulatory molecules were expressed on 293 cells. Biochemical analyses confirmed that these molecules were efficiently targeted to VLPs. The engineered VLPs activated Art v 1-specific T cells in a costimulation-dependent manner. VLPs lacking costimulators induced T-cell unresponsiveness, which was overcome by addition of exogenous IL-2. Costimulation could be provided by CD80, CD86, or CD58 and induced distinct cytokine profiles in allergen-specific T cells. Unlike the other costimulatory molecules, CD58 induced IL-10/IFN-gamma-secreting T cells. Conclusion: Virus-like particles represent a novel, modular, acellular antigen-presenting system able to modulate the responses of allergen-specific T cells in a costimulator-dependent fashion. Allergen-specific VLPs show promise as tools for specific immunotherapy of allergic diseases. (J Allergy Clin Immunol 2009;124:121-8.)	[Pickl, Winfried F.] Med Univ Vienna, Inst Immunol, Ctr Physiol Pathophysiol & Immunol, A-1090 Vienna, Austria; [Leb, Victoria M.; Kueng, Hans J.; Neunkirchner, Alina; Bohle, Barbara; Pickl, Winfried F.] Christian Doppler Lab Immunomodulat, Vienna, Austria; [Jahn-Schmid, Beatrice; Bohle, Barbara] Med Univ Vienna, Dept Pathophysiol, Ctr Physiol Pathophysiol & Immunol, A-1090 Vienna, Austria; [Fischer, Gottfried F.] Med Univ Vienna, Dept Blood Grp Serol, A-1090 Vienna, Austria; [Hartl, Arnulf] Paracelsus Med Univ, Inst Physiol & Pathophysiol, Salzburg, Austria; [Thalhamer, Josef] Salzburg Univ, Div Allergy Immunol, Dept Mol Biol, A-5020 Salzburg, Austria; [Seed, Brian] Harvard Univ, Sch Med, Ctr Computat & Integrat Biol, Boston, MA USA	Medical University of Vienna; Medical University of Vienna; Medical University of Vienna; Paracelsus Private Medical University; Salzburg University; Harvard University; Harvard Medical School	Pickl, WF (corresponding author), Med Univ Vienna, Inst Immunol, Ctr Physiol Pathophysiol & Immunol, Borschkegasse 8A, A-1090 Vienna, Austria.	winfried.pickl@meduniwien.ac.at	Pickl, Winfried F/E-5682-2011; Thalhamer, Josef/E-5787-2011	Thalhamer, Josef/0000-0003-2285-6400; Schmetterer, Klaus/0000-0001-9328-4871; Bohle, Barbara/0000-0002-5105-7985; Steinberger, Peter/0000-0001-6848-4097; Hartl, Arnulf/0000-0001-9626-6425; Pickl, Winfried F./0000-0003-0430-4952; Reichl, Victoria/0000-0001-7546-3438	Austrian Science Foundation (FWF) [SFB F1816-B13, F1807-B13, P20011-B09]; Osterreichische forschungsforderungsgesellschaft [812079]; Biomay AG; Christian Doppler Research Association (CDG)	Austrian Science Foundation (FWF)(Austrian Science Fund (FWF)); Osterreichische forschungsforderungsgesellschaft; Biomay AG; Christian Doppler Research Association (CDG)	Supported by grants SFB F1816-B13, F1807-B13 and P20011-B09 of the Austrian Science Foundation (FWF), Osterreichische forschungsforderungsgesellschaft #812079 (FFG), Biomay AG, and the Christian Doppler Research Association (CDG).	Admyre C, 2007, J ALLERGY CLIN IMMUN, V120, P1418, DOI 10.1016/j.jaci.2007.06.040; Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; Akdis M, 2007, J ALLERGY CLIN IMMUN, V119, P780, DOI 10.1016/j.jaci.2007.01.022; Ball JM, 1999, GASTROENTEROLOGY, V117, P40, DOI 10.1016/S0016-5085(99)70548-2; Bellinghausen I, 1997, EUR J IMMUNOL, V27, P1131, DOI 10.1002/eji.1830270513; Bohle B, 2007, J ALLERGY CLIN IMMUN, V120, P707, DOI 10.1016/j.jaci.2007.06.013; BRETSCHER P, 1970, SCIENCE, V169, P1042, DOI 10.1126/science.169.3950.1042; Derdak SV, 2006, P NATL ACAD SCI USA, V103, P13144, DOI 10.1073/pnas.0602283103; Ghani K, 2006, BIOTECHNOL BIOENG, V95, P653, DOI 10.1002/bit.20947; GIMMI CD, 1993, P NATL ACAD SCI USA, V90, P6586, DOI 10.1073/pnas.90.14.6586; Gollob JA, 1996, J IMMUNOL, V157, P1886; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Grgacic EVL, 2006, METHODS, V40, P60, DOI 10.1016/j.ymeth.2006.07.018; Groux H, 1997, NATURE, V389, P737, DOI 10.1038/39614; Hammad H, 2007, J EXP MED, V204, P357, DOI 10.1084/jem.20061196; Himly M, 2002, FASEB J, V16, P106, DOI 10.1096/fj.02-0472fje; Jahn-Schmid B, 2005, J ALLERGY CLIN IMMUN, V115, P399, DOI 10.1016/j.jaci.2004.10.010; Jahn-Schmid B, 2002, J IMMUNOL, V169, P6005, DOI 10.4049/jimmunol.169.10.6005; Jahn-Schmid B, 2008, J IMMUNOL, V181, P3636, DOI 10.4049/jimmunol.181.5.3636; JUTEL M, 1995, J IMMUNOL, V154, P4187; KIRNBAUER R, 1992, P NATL ACAD SCI USA, V89, P12180, DOI 10.1073/pnas.89.24.12180; Kundig TM, 2006, J ALLERGY CLIN IMMUN, V117, P1470, DOI 10.1016/j.jaci.2006.01.040; Kueng HJ, 2007, J VIROL, V81, P8666, DOI 10.1128/JVI.00682-07; LANIER LL, 1995, J IMMUNOL, V154, P97; Larche M, 2006, NAT REV IMMUNOL, V6, P761, DOI 10.1038/nri1934; Latham T, 2001, J VIROL, V75, P6154, DOI 10.1128/JVI.75.13.6154-6165.2001; Latouche JB, 2000, NAT BIOTECHNOL, V18, P405, DOI 10.1038/74455; Leb VM, 2008, J ALLERGY CLIN IMMUN, V121, P64, DOI 10.1016/j.jaci.2007.10.006; Lechner F, 2002, INTERVIROLOGY, V45, P212, DOI 10.1159/000067912; Manie SN, 2000, J VIROL, V74, P305, DOI 10.1128/JVI.74.1.305-311.2000; Maurer D, 1996, J IMMUNOL, V157, P607; MCALEER WJ, 1984, NATURE, V307, P178, DOI 10.1038/307178a0; MEUER SC, 1984, CELL, V36, P897, DOI 10.1016/0092-8674(84)90039-4; Montoya MC, 2002, IMMUNOL REV, V186, P68, DOI 10.1034/j.1600-065X.2002.18607.x; Nguyen DH, 2000, J VIROL, V74, P3264, DOI 10.1128/JVI.74.7.3264-3272.2000; Nissler K, 1998, BIOL CHEM, V379, P219, DOI 10.1515/bchm.1998.379.2.219; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; PARRA E, 1994, J IMMUNOL, V153, P2479; Pickl WF, 2001, J VIROL, V75, P7175, DOI 10.1128/JVI.75.15.7175-7183.2001; Raposo G, 1996, J EXP MED, V183, P1161, DOI 10.1084/jem.183.3.1161; Rocha N, 2008, EMBO J, V27, P1, DOI 10.1038/sj.emboj.7601945; Romagnani S, 2004, J ALLERGY CLIN IMMUN, V113, P395, DOI 10.1016/j.jaci.2003.11.025; Scheiffele P, 1999, J BIOL CHEM, V274, P2038, DOI 10.1074/jbc.274.4.2038; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SEKALY RP, 1986, J EXP MED, V164, P1490, DOI 10.1084/jem.164.5.1490; Steinman RM, 2007, NATURE, V449, P419, DOI 10.1038/nature06175; Thery C, 2002, NAT IMMUNOL, V3, P1156, DOI 10.1038/ni854; Thery C, 2002, NAT REV IMMUNOL, V2, P569, DOI 10.1038/nri855; Van Overtvelt L, 2008, J IMMUNOL, V180, P4514, DOI 10.4049/jimmunol.180.7.4514; vanBergen J, 1997, P NATL ACAD SCI USA, V94, P7499, DOI 10.1073/pnas.94.14.7499; Wakkach A, 2001, J IMMUNOL, V167, P3107, DOI 10.4049/jimmunol.167.6.3107; Yao QZ, 2003, VACCINE, V21, P638, DOI 10.1016/S0264-410X(02)00572-8; Zhang XW, 2001, MOL THER, V3, P787, DOI 10.1006/mthe.2001.0306; ZHOU J, 1991, VIROLOGY, V185, P251, DOI 10.1016/0042-6822(91)90772-4; Zitvogel L, 1998, NAT MED, V4, P594, DOI 10.1038/nm0598-594	56	23	25	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2009	124	1					121	128		10.1016/j.jaci.2009.04.008	http://dx.doi.org/10.1016/j.jaci.2009.04.008			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	469OR	19500826	Bronze			2022-12-18	WOS:000267909700015
J	Shao, ZF; Bharadwaj, AS; Mcgee, HS; Makinde, TO; Agrawal, DK				Shao, Zhifei; Bharadwaj, Arpita S.; McGee, Halvor S.; Makinde, Toluwalope O.; Agrawal, Devendra K.			Fms-like tyrosine kinase 3 ligand increases a lung DC subset with regulatory properties in allergic airway inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Adoptive transfer; airway hyperresponsiveness; asthma; dendritic cells; Flt3 ligand; mouse model; T-cell proliferation; regulatory dendritic cells	DENDRITIC CELL SUBSETS; FLT3 LIGAND; MOUSE MODEL; T-CELLS; IN-VIVO; CD8-ALPHA(+); MICE; ASTHMA; HYPERRESPONSIVENESS; CAPACITY	Background: Dendritic cell (DC) subsets display different functional roles in regulating immune responses and lead to various outcomes, including T(H)1 versus T(H)2 or regulatory versus immunologic responses. Administration of Fms-like tyrosine kinase 3 (Flt3) ligand prevents and reverses allergic airway inflammation and airway hyperresponsiveness in a mouse model. However, the underlying mechanisms are unclear. Objective: We characterized and examined the role of lung DC subsets in the therapeutic effect of Flt3 ligand. Methods: DCs were isolated from the lungs of ovalbumin (OVA)-sensitized and OVA-challenged mice treated with recombinant human Flt3 ligand. Two populations of CD11c(+) cells labeled with fluorochrome-conjugated antibodies were sorted. The ability of the purified cells to stimulate T-cell proliferation and cytokine secretion patterns by different DC subsets was examined. Also, DCs were adoptively transferred in mice to examine their effect on pulmonary function. Results: Two DC populations, CD11c(high)CD11b(low) and high CD11c(low)CD11b(high), were identified in the lungs of naive and OVA-sensitized and OVA-challenged mice with and without treatment with Flt3 ligand. The expression levels of CD8 alpha, B220, CD19, F4/80, MHC II, CCR7, CD40, programmed death ligand 1, programmed death ligand 2, CD80, and CD86 were distinctly different between the 2 DC populations, which supports the notion that CD11c(high)CD11b(low) and CD11c(low)CD11b(high) DCs potentially have regulatory and immunogenic properties, respectively. Administration of Flt3 ligand increased the DCs with regulatory potential in the lungs of antigen-sensitized mice, and CD11c(high)CD11b(low) DCs acquired a maximum degree of regulatory capacity after Flt3 ligand treatment. Conclusion: These data suggest that Flt3 ligand reverses airway hyperresponsiveness by regulating the function of lung DCs in a mouse model of allergic airway inflammation. (J Allergy Clin Immunol 2009;123:917-24.)	[Shao, Zhifei; McGee, Halvor S.; Makinde, Toluwalope O.; Agrawal, Devendra K.] Creighton Univ, Sch Med, Dept Biomed Sci, Omaha, NE 68178 USA; [Bharadwaj, Arpita S.; Agrawal, Devendra K.] Creighton Univ, Sch Med, Dept Med Microbiol & Immunol, Omaha, NE 68178 USA; [Agrawal, Devendra K.] Creighton Univ, Sch Med, Dept Internal Med, Omaha, NE 68178 USA	Creighton University; Creighton University; Creighton University	Agrawal, DK (corresponding author), Creighton Univ, Sch Med, Dept Biomed Sci, CRISS II Room 510,2500 Calif Plaza, Omaha, NE 68178 USA.	dkagr@creighton.edu	Agrawal, Devendra/GLR-3925-2022	Agrawal, Devendra/0000-0001-5445-0013	National Institutes of Health [R01 HL070885]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070885] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI075315] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health grant R01 HL070885.	Agrawal DK, 2001, INT IMMUNOPHARMACOL, V1, P2081, DOI 10.1016/S1567-5769(01)00122-9; Bharadwaj AS, 2007, CAN J PHYSIOL PHARM, V85, P686, DOI 10.1139/Y07-062; Bharadwaj AS, 2007, EXP MOL PATHOL, V83, P17, DOI 10.1016/j.yexmp.2006.09.007; Bilsborough J, 2003, IMMUNOLOGY, V108, P481, DOI 10.1046/j.1365-2567.2003.01606.x; Cai GF, 2004, CELL IMMUNOL, V230, P89, DOI 10.1016/j.cellimm.2004.09.004; Chong BTY, 1998, J PHARMACOL TOXICOL, V39, P163, DOI 10.1016/S1056-8719(98)00021-5; Cohn L, 2004, ANNU REV IMMUNOL, V22, P789, DOI 10.1146/annurev.immunol.22.012703.104716; de Heer HJ, 2004, J EXP MED, V200, P89, DOI 10.1084/jem.20040035; Edwan JH, 2007, IMMUNOL RES, V37, P147, DOI 10.1007/BF02685896; Edwan JH, 2005, INT IMMUNOPHARMACOL, V5, P345, DOI 10.1016/j.intimp.2004.10.002; Edwan JH, 2004, J IMMUNOL, V172, P5016, DOI 10.4049/jimmunol.172.8.5016; Fujita S, 2008, J ALLERGY CLIN IMMUN, V121, P95, DOI 10.1016/j.jaci.2007.08.038; Gilliland DG, 2002, BLOOD, V100, P1532, DOI 10.1182/blood-2002-02-0492; Glaab T, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-63; Gordon JR, 2005, J IMMUNOL, V175, P1516, DOI 10.4049/jimmunol.175.3.1516; Greenwald RJ, 2005, ANNU REV IMMUNOL, V23, P515, DOI 10.1146/annurev.immunol.23.021704.115611; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766, DOI 10.1164/ajrccm.156.3.9606031; Hammad H, 2004, CLIN EXP ALLERGY, V34, P1834, DOI 10.1111/j.1365-2222.2004.02133.x; Huang TJ, 2001, J IMMUNOL, V166, P207, DOI 10.4049/jimmunol.166.1.207; Karsunky H, 2003, J EXP MED, V198, P305, DOI 10.1084/jem.20030323; Kim HK, 2006, J LEUKOCYTE BIOL, V79, P686, DOI 10.1189/jlb.0805436; Maldonado-Lopez R, 2001, J IMMUNOL, V167, P4345, DOI 10.4049/jimmunol.167.8.4345; Martin P, 2002, BLOOD, V100, P383, DOI 10.1182/blood.V100.2.383; Miller G, 2003, J IMMUNOL, V170, P3554, DOI 10.4049/jimmunol.170.7.3554; Moser M, 2000, NAT IMMUNOL, V1, P199, DOI 10.1038/79734; Nakano H, 2001, J EXP MED, V194, P1171, DOI 10.1084/jem.194.8.1171; O'Keeffe M, 2002, BLOOD, V99, P2122, DOI 10.1182/blood.V99.6.2122; Rietz C, 2004, AM J TRANSPLANT, V4, P8, DOI 10.1046/j.1600-6143.2003.00303.x; Saunders PA, 2005, EUR J IMMUNOL, V35, P3561, DOI 10.1002/eji.200526347; Selenko-Gebauer N, 2003, J IMMUNOL, V170, P3637, DOI 10.4049/jimmunol.170.7.3637; Shortman K, 2002, NAT REV IMMUNOL, V2, P151, DOI 10.1038/nri746; Suda T, 1998, AM J RESP CELL MOL, V19, P728, DOI 10.1165/ajrcmb.19.5.3214; Swanson KA, 2004, J IMMUNOL, V173, P4875, DOI 10.4049/jimmunol.173.8.4875; Tattersfield AE, 2002, LANCET, V360, P1313, DOI 10.1016/S0140-6736(02)11312-2; Triccas JA, 2007, INFECT IMMUN, V75, P5368, DOI 10.1128/IAI.00322-07; Vermaelen K, 2005, AM J RESP CRIT CARE, V172, P530, DOI 10.1164/rccm.200410-1384SO; von Wulffen W, 2007, AM J RESP CRIT CARE, V176, P892, DOI 10.1164/rccm.200608-1068OC; Walzer T, 2005, J ALLERGY CLIN IMMUN, V115, P192, DOI 10.1016/j.jaci.2004.08.046; Wang HW, 2006, J IMMUNOL, V177, P2536, DOI 10.4049/jimmunol.177.4.2536; Waskow C, 2008, NAT IMMUNOL, V9, P676, DOI 10.1038/ni.1615; Wu L, 2007, IMMUNITY, V26, P741, DOI 10.1016/j.immuni.2007.06.006; Yasumi T, 2004, J IMMUNOL, V172, P4826, DOI 10.4049/jimmunol.172.8.4826	42	23	23	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2009	123	4					917	924		10.1016/j.jaci.2009.01.052	http://dx.doi.org/10.1016/j.jaci.2009.01.052			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	431JW	19348927	Green Accepted			2022-12-18	WOS:000265058600021
J	Krop, EJM; Heederik, DJJ; Lutter, R; De Meer, G; Aalberse, RC; Jansen, HM; van der Zee, JS				Krop, Esmeralda J. M.; Heederik, Dick J. J.; Lutter, Rene; De Meer, Gea; Aalberse, Rob C.; Jansen, Henk M.; van der Zee, Jaring S.			Associations between pre-employment immunologic and airway mucosal factors and the development of occupational allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Occupational allergy; atopy; IgE; laboratory animal allergy; sensitization	LABORATORY-ANIMAL WORKERS; BRONCHIAL RESPONSIVENESS; IGE; EXPOSURE; ASTHMA; ADENOSINE-5'-MONOPHOSPHATE; HYPERRESPONSIVENESS; SENSITIZATION; METHACHOLINE; APPRENTICES	Background: Sensitization to occupational allergens is frequently found in laboratory animal workers (LAWs) and can cause serious health problems. Atopy is a major risk factor for sensitization, but it is considered insufficient to advise against working with animals. Objective: We investigated whether immunologic measures, including serology and cytokine production profiles of blood cells, and parameters for airway inflammation are associated with the development of occupational sensitization. Methods: In a prospective cohort study 110 starting LAWS were followed for 2 years. At inclusion, results of health questionnaires, skin test results, lung function measures, methacholine threshold levels, and nasal lavage fluid were obtained. Blood was taken for measuring total IgE and allergen-specific IgE antibodies. Cytokine production profiles were measured in whole blood. Results: Twenty-two new cases of sensitization were identified during follow-up. In multivariate logistic regression analysis a model including atopy and total IgE level predicted sensitization best. This was corroborated in a separate validation cohort. Parameters for airway inflammation or cytokine production profiles did not further contribute to the prediction of sensitization. Based on these results, pre-employment counseling aimed at applicant LAWS with atopy and a total IgE level of greater than 100 IU/mL might be able to reduce occupational sensitization by up to 45% to 50% with less than 10% false-positive predictions. Conclusion: The combination of atopy and total IgE level offered the best model to predict development of occupational sensitization. other immunologic parameters and parameters of airway inflammation did not contribute significantly. (J Allergy Clin Immunol 2009;123:694-700.)	[Krop, Esmeralda J. M.; Lutter, Rene; Jansen, Henk M.; van der Zee, Jaring S.] Univ Amsterdam, Dept Pulmonol, Acad Med Ctr, NL-1100 DE Amsterdam, Netherlands; [Lutter, Rene] Univ Amsterdam, Dept Expt Immunol, Acad Med Ctr, NL-1100 DE Amsterdam, Netherlands; [Heederik, Dick J. J.; De Meer, Gea] Univ Utrecht, Inst Risk Assessment Sci, Utrecht, Netherlands; [De Meer, Gea] Municipal Hlth Serv Fryslan, Leeuwarden, Netherlands; [Aalberse, Rob C.] Sanquin Blood Supply Fdn, Dept Allergy, Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Utrecht University	van der Zee, JS (corresponding author), Univ Amsterdam, Dept Pulmonol, Acad Med Ctr, G5-247,POB 22700, NL-1100 DE Amsterdam, Netherlands.	j.s.vanderzee@amc.uva.nl	van der Zee, Jaring S/M-8462-2013; van der Zee, Jaring/HGU-9235-2022; van der Zee, Jaring/AAQ-6669-2021	van der Zee, Jaring S/0000-0002-8698-6039; Krop, Esmeralda/0000-0002-6009-1181; Heederik, Dick/0000-0002-4550-1437	Dutch Asthma Foundation [99-25]	Dutch Asthma Foundation	Supported by research grand no. 99-25 of the Dutch Asthma Foundation.	AALBERSE RC, 1981, J ALLERGY CLIN IMMUN, V68, P356, DOI 10.1016/0091-6749(81)90133-0; AOYAMA K, 1992, BRIT J IND MED, V49, P41; Burney P, 1997, J ALLERGY CLIN IMMUN, V99, P314, DOI 10.1016/S0091-6749(97)70048-4; de Meer G, 2003, CLIN EXP ALLERGY, V33, P789, DOI 10.1046/j.1365-2222.2003.01677.x; De Meer G, 2002, AM J RESP CRIT CARE, V165, P327, DOI 10.1164/ajrccm.165.3.2104066; De Meer G, 2001, THORAX, V56, P362, DOI 10.1136/thorax.56.5.362; Elliott L, 2005, Occup Environ Med, V62, P766, DOI 10.1136/oem.2004.018739; Gautrin D, 2000, AM J RESP CRIT CARE, V162, P1222, DOI 10.1164/ajrccm.162.4.2001023; Hollander A, 1997, AM J RESP CRIT CARE, V155, P562, DOI 10.1164/ajrccm.155.2.9032195; Hollander A, 1996, J ALLERGY CLIN IMMUN, V98, P545, DOI 10.1016/S0091-6749(96)70088-X; Hollander A, 1997, CLIN EXP ALLERGY, V27, P617; Kraan TCTMV, 1997, J IMMUNOL, V158, P5560; Lopuhaa CE, 2003, INT ARCH ALLERGY IMM, V130, P266, DOI 10.1159/000070213; Matsui EC, 2004, ANN ALLERG ASTHMA IM, V93, P171, DOI 10.1016/S1081-1206(10)61471-8; OBYRNE PM, 1987, AM REV RESPIR DIS, V136, pS35, DOI 10.1164/ajrccm/136.4_Pt_2.S35; Palmer KT, 2004, OCCUP ENVIRON MED, V61, P448, DOI 10.1136/oem.2002.005611; Seward JP, 1999, OCCUP MED-STATE ART, V14, P285; Spaan S, 2007, APPL ENVIRON MICROB, V73, P6134, DOI 10.1128/AEM.00851-07; STALLMAN PJ, 1977, INT ARCH ALLER A IMM, V54, P9, DOI 10.1159/000231803; VANDEGRAAF EA, 1991, AM REV RESPIR DIS, V143, P362, DOI 10.1164/ajrccm/143.2.362; [No title captured]	21	23	23	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2009	123	3					694	700		10.1016/j.jaci.2008.12.021	http://dx.doi.org/10.1016/j.jaci.2008.12.021			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	426TQ	19201013	Green Published			2022-12-18	WOS:000264731200033
J	Le, T; Tversky, J; Chichester, KL; Bienernan, AP; Huang, SK; Wood, RA; Schroeder, JT				Le, Trong; Tversky, Jody; Chichester, Kristin L.; Bienernan, Anja P.; Huang, Shau-Ku; Wood, Robert A.; Schroeder, John T.			Interferons modulate Fc is an element of RI-dependent production of autoregulatory IL-10 by circulating human monocytoid dendritic cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Dendritic cells; Fc is an element of RI; IL-10; IFN-alpha; TNF-alpha	EPSILON-RI; HUMAN BASOPHILS; IFN-ALPHA; IGE; EXPRESSION; DIFFERENTIATION; RESPONSES; SUBSETS	Background: Immature human blood monocytoid dendritic cells (mDCs) express high-affinity receptors for IgE (Fc is an element of RI), yet their exact function and regulation remain poorly understood. Objective: We sought to characterize Fc is an element of RI-dependent cytokine responses and their regulation in circulating human blood mDCs. Methods: Fc is an element of RI-dependent cytokine responses of circulating mDCs were studied by using anti-Fc is an element of RI alpha stimulation. Plasmacytoid dendritic cell (pDC) cross-regulation through Toll-like receptor 9 on these responses was investigated by examining the effects of exogenous IFN-alpha pretreatment and by coculturing pDCs and mDCs stimulated with CpG. Culture supernatants were analyzed by means of ELISA to determine cytokine levels. Cell markers were determined by means of flow cytometry. Results: mDCs express marked levels of Fc is an element of RI (net mean fluorescence intensity, 196 +/- 49; n = 4). After Fc is an element of RT-dependent activation in mDCs, TNF-alpha (2189 +/- 864 pg/10(6) mDCs, n = 3) levels were upregulated within 4 hours, whereas IL-10 (112 +/- 47 pg/106 mDCs, n = 3) levels were detectable only after 24 hours of incubation. After adding IL-10-neutralizing antibody, TNF-alpha Fc is an element of RI-dependent responses were significantly augmented (3903 197 pg/106 mDCs, P < .01, n = 3). Conversely, recombinant IL-10 dose-dependently inhibited Fc is an element of RI-mediated TNF-alpha responses up to 86% 3% (n = 3, P < .001). Pretreatment of mDCs with IFN-alpha (100 U/mL) enhanced Fc is an element of RI-dependent secretion of IL-10 by 3.2-fold (183 +/- 11 pg/106 mDCs, n = 4) compared with that seen in untreated cells (57 +/- 33 pg/10(6) mDCs, P < .001, n = 4). In pDC/mDC cocultures pretreated with CpG, Fc is an element of RI-dependent IL-10 secretion by mDCs was similarly augmented by 3-fold. Conclusions: Autocrine secretion of IL-10, a critical autoregulator of Fc is an element of RI-dependent proinflammatory responses in mDCs, is cross-regulated by IFN-alpha, a major product of Toll-like receptor 9 responses in pDCs that normally promotes T(H)1 immunity. (J Allergy Clin Immunol 2009;123:217-23.)	[Le, Trong; Wood, Robert A.] Johns Hopkins Asthma & Allergy Ctr, Dept Pediat, Baltimore, MD 21224 USA; [Tversky, Jody; Chichester, Kristin L.; Bienernan, Anja P.; Huang, Shau-Ku; Schroeder, John T.] Johns Hopkins Asthma & Allergy Ctr, Div Clin Immunol & Allergy, Dept Med, Baltimore, MD 21224 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Schroeder, JT (corresponding author), Johns Hopkins Asthma & Allergy Ctr, Unit Off 2, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.	schray@jhmi.edu	Huang, Shau-Ku/F-5509-2010		National Institutes of Health/National Institute or Allergy and Infectious Diseases; Asthma and Allergic Diseases Cooperative Research Centers [AI070345-01, R01AI42221, AI052468]; NIH/NIAID [AI07007]; Fudowond Foundation; Philip Morris Company; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042221, R01AI052468, U19AI070345, T32AI007007] Funding Source: NIH RePORTER	National Institutes of Health/National Institute or Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Asthma and Allergic Diseases Cooperative Research Centers; NIH/NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Fudowond Foundation; Philip Morris Company; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported in part by research funding from National Institutes of Health/National Institute or Allergy and Infectious Diseases grams: the Asthma and Allergic Diseases Cooperative Research Centers grants AI070345-01 (project 3: J.T.S), R01AI42221 (J.T.S), aid AI052468 (S.-K.H). T.L. was supported by NIH/NIAID training grant AI07007 and by the Fudowond Foundation (R.A.W.). Funding for S.-K.H. was also provided by the Philip Morris Company.	Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Blanco P, 2001, SCIENCE, V294, P1540, DOI 10.1126/science.1064890; Boruchov AM, 2005, J CLIN INVEST, V115, P2914, DOI 10.1172/JCI24772; Bratke K, 2007, THORAX, V62, P168, DOI 10.1136/thx.2006.067793; Cao W, 2006, J EXP MED, V203, P1399, DOI 10.1084/jem.20052454; Creticos PS, 2006, NEW ENGL J MED, V355, P1445, DOI 10.1056/NEJMoa052916; Duramad O, 2003, BLOOD, V102, P4487, DOI 10.1182/blood-2003-07-2465; Foster B, 2003, J ALLERGY CLIN IMMUN, V112, P1132, DOI 10.1016/j.jaci.2003.09.011; Fujita T, 2006, J CLIN IMMUNOL, V26, P512, DOI 10.1007/s10875-006-9043-1; Gillespie SR, 2004, J IMMUNOL, V172, P3181, DOI 10.4049/jimmunol.172.5.3181; Hammad H, 2006, J ALLERGY CLIN IMMUN, V118, P331, DOI 10.1016/j.jaci.2006.03.041; Jahnsen FL, 2000, J IMMUNOL, V165, P4062, DOI 10.4049/jimmunol.165.7.4062; Liu YJ, 2005, ANNU REV IMMUNOL, V23, P275, DOI 10.1146/annurev.immunol.23.021704.115633; Lommatzsch M, 2007, EUR RESPIR J, V30, P878, DOI 10.1183/09031936.00036307; Marshall JD, 2003, J LEUKOCYTE BIOL, V73, P781, DOI 10.1189/jlb.1202630; Masten BJ, 2006, J IMMUNOL, V177, P7784, DOI 10.4049/jimmunol.177.11.7784; Novak N, 2003, J ALLERGY CLIN IMMUN, V111, P38, DOI 10.1067/mai.2003.2; Novak N, 2001, J IMMUNOL, V167, P797, DOI 10.4049/jimmunol.167.2.797; Novak N, 2001, CURR OPIN IMMUNOL, V13, P721, DOI 10.1016/S0952-7915(01)00285-0; Prussin C, 2003, J ALLERGY CLIN IMMUN, V112, P1147, DOI 10.1016/j.jaci.2003.10.003; Schroeder JT, 2008, J ALLERGY CLIN IMMUN, V121, P486, DOI 10.1016/j.jaci.2007.09.049; Schroeder JT, 2005, J IMMUNOL, V175, P5724, DOI 10.4049/jimmunol.175.9.5724; SCHROEDER JT, 1994, J IMMUNOL, V153, P1808; Schroeder JT, 2002, J ALLERGY CLIN IMMUN, V109, P507, DOI 10.1067/mai.2002.122460; Siegal FP, 1999, SCIENCE, V284, P1835, DOI 10.1126/science.284.5421.1835; Simon HU, 2003, ALLERGY, V58, P1250, DOI 10.1046/j.1398-9995.2003.00424.x; Taniguchi T, 2001, NAT REV MOL CELL BIO, V2, P378, DOI 10.1038/35073080; Tilg H, 2004, EXPERT OPIN BIOL TH, V4, P469, DOI 10.1517/eobt.4.4.469.29791; Tversky JR, 2008, CLIN EXP ALLERGY, V38, P781, DOI 10.1111/j.1365-2222.2008.02954.x; van Rijt LS, 2005, J EXP MED, V201, P981, DOI 10.1084/jem.20042311	30	23	26	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2009	123	1					217	223		10.1016/j.jaci.2008.09.013	http://dx.doi.org/10.1016/j.jaci.2008.09.013			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	399IP	18845324	Green Accepted, Bronze			2022-12-18	WOS:000262793900035
J	Ono, E; Mita, H; Taniguchi, M; Higashi, N; Tsuburai, T; Hasegawa, M; Miyazaki, E; Kumamoto, T; Akiyama, K				Ono, Emiko; Mita, Haruhisa; Taniguchi, Masami; Higashi, Noritaka; Tsuburai, Takahiro; Hasegawa, Maki; Miyazaki, Eishi; Kumamoto, Toshihide; Akiyama, Kazuo			Increase in inflammatory mediator concentrations in exhaled breath condensate after allergen inhalation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						early asthmatic responses; exhaled breath condensate; cysteinyl leukotrienes; prostaglandin D-2; histamine; inflammatory mediators; mast cells	ASPIRIN-INDUCED ASTHMA; PROSTAGLANDIN D-2; URINARY-EXCRETION; GUINEA-PIGS; ANTIGEN; CHALLENGE; HISTAMINE; RECOMMENDATIONS; LEUKOTRIENES; METABOLISM		[Ono, Emiko; Mita, Haruhisa; Taniguchi, Masami; Higashi, Noritaka; Tsuburai, Takahiro; Hasegawa, Maki; Akiyama, Kazuo] Sagamihara Natl Hosp, Clin Res Ctr Allergy & Rheumatol, Natl Hosp Org, Kanagawa 2288522, Japan; [Ono, Emiko; Miyazaki, Eishi; Kumamoto, Toshihide] Oita Univ, Sch Med, Dept Internal Med 3, Oita 87011, Japan	Oita University	Ono, E (corresponding author), Sagamihara Natl Hosp, Clin Res Ctr Allergy & Rheumatol, Natl Hosp Org, Sakuradai 18-1, Kanagawa 2288522, Japan.	e-ono@sagamihra-hosp.gr.jp						Bayley DL, 2008, EUR RESPIR J, V31, P943, DOI 10.1183/09031936.00081707; Brichtling CE, 2000, AM J RESP CRIT CARE, V162, P878, DOI 10.1164/ajrccm.162.3.9909064; CHAI H, 1979, J ALLERGY CLIN IMMUN, V64, P575, DOI 10.1016/0091-6749(79)90015-0; Debley JS, 2007, J ALLERGY CLIN IMMUN, V120, P1216, DOI 10.1016/j.jaci.2007.06.029; Dworski R, 1998, CLIN EXP ALLERGY, V28, P1309; FICK RB, 1987, AM REV RESPIR DIS, V135, P1204; GLEICH GL, 1989, J ALLERGY CLIN IMMUN, V66, P295; Horvath I, 2005, EUR RESPIR J, V26, P523, DOI 10.1183/09031936.05.00029705; Jame AJ, 2007, CLIN EXP ALLERGY, V37, P880, DOI 10.1111/j.1365-2222.2007.02733.x; Kelly EAB, 2003, J ALLERGY CLIN IMMUN, V111, P79, DOI 10.1067/mai.2003.28; KUMLIN M, 1992, AM REV RESPIR DIS, V146, P96, DOI 10.1164/ajrccm/146.1.96; LINDSTROM EG, 1991, AGENTS ACTIONS, V33, P170, DOI 10.1007/BF01993158; Maciejewski-Lenoir D, 2006, J INVEST DERMATOL, V126, P2637, DOI 10.1038/sj.jid.5700586; MALTBY NH, 1990, J ALLERGY CLIN IMMUN, V85, P3, DOI 10.1016/0091-6749(90)90214-O; Mita H, 1997, J CHROMATOGR B, V692, P461, DOI 10.1016/S0378-4347(97)00006-6; Mita H, 2004, CLIN EXP ALLERGY, V34, P931, DOI 10.1111/j.1365-2222.2004.01968.x; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; NARASBHAT K, 1976, J ALLERGY CLIN IMMUN, V58, P647, DOI 10.1016/0091-6749(76)90176-7; *NAT ASTHM ED PREV, 1997, NIH PUBL; OSullivan S, 1996, J ALLERGY CLIN IMMUN, V98, P421, DOI 10.1016/S0091-6749(96)70167-7; Pierzchalska M, 2003, J ALLERGY CLIN IMMUN, V111, P1041, DOI 10.1067/mai.2003.1491; SCHWARTZ LB, 1989, J CLIN INVEST, V83, P1551, DOI 10.1172/JCI114051; Sekizawa K, 1995, J ALLERGY CLIN IMMUN, V96, P910, DOI 10.1016/S0091-6749(95)70228-8; Slutsky AS, 1999, AM J RESP CRIT CARE, V160, P2104; Tanaka K, 2000, J IMMUNOL, V164, P2277, DOI 10.4049/jimmunol.164.5.2277	25	23	23	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2008	122	4					768	773		10.1016/j.jaci.2008.06.009	http://dx.doi.org/10.1016/j.jaci.2008.06.009			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	359LU	18620744				2022-12-18	WOS:000259989000023
J	Trivedi, NN; Raymond, WW; Caughey, GH				Trivedi, Neil N.; Raymond, Wilfred W.; Caughey, George H.			Chimerism, point mutation, and truncation dramatically transformed mast cell delta-tryptases during primate evolution	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						tryptase; mast cells; comparative evolution; chimpanzee; gorilla; orangutan; macaque	ALPHA; ACTIVATION; BINDING; GENES; GAMMA; ANAPHYLAXIS; HISTIDINES; PROTEASES; TISSUES; FAMILY	Background: Tryptases are serine peptidases stored in mast cell granules. Rodents express 2 soluble tryptases, mast cell proteases (MCPs) 6 and 7. Human alpha- and beta-tryptases are orthologs of MCP-6. However, much of the ancestral MCP-7 ortholog was replaced by parts of other tryptases, creating chimeric delta-tryptase. Human delta-tryptase's limited activity is hypothesized to be due to truncation and processing mutations. Objective: We sought to probe the origins and consequences of mutations in primate delta-tryptases. Methods: Prosimian (lemur), monkey (macaque), great ape (orangutan, gorilla, and chimpanzee), and human delta-tryptase genes were identified by means of data mining and genomic sequencing. Resulting genes were analyzed phylogenetically and structurally. Results: The seminal conversion event generating the delta-tryptase chimera occurred early because all primates studied contain delta-tryptase genes. Truncation, resulting from a nonsense mutation of Trp206, occurred much later, after orangutans and other great apes last shared an ancestor. The Arg-3Gln propeptide mutation occurred most recently, being present in humans and chimpanzees but not in other primates. Surprisingly, the major active tryptase in monkeys is full-length delta-tryptase, not beta-tryptase, which is the main active tryptase in human subjects. Models of macaque delta-tryptase reveal that the segment truncated in human subjects contains antiparallel beta-strands coursing through the substrate-binding cleft, accounting for truncation's drastic effect on activity. Conclusions: Transformations in the ancestral MCP-7-like gene during primate evolution caused dramatic variations in function. Although delta-tryptases are nearly inactive in humans, they are active and dominant in monkeys.	[Trivedi, Neil N.; Raymond, Wilfred W.; Caughey, George H.] Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; [Trivedi, Neil N.; Caughey, George H.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; [Caughey, George H.] Vet Hlth Res Inst, San Francisco, CA USA; [Caughey, George H.] Vet Affairs Med Ctr, San Francisco, CA 94121 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Caughey, GH (corresponding author), Vet Adm Med Ctr 111D, 4150 Clement St, San Francisco, CA 94121 USA.	George.Caughey@ucsf.edu			NHLBI NIH HHS [HL024136, P01 HL024136] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL024136] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Caughey GH, 2007, IMMUNOL REV, V217, P141, DOI 10.1111/j.1600-065X.2007.00509.x; Caughey GH, 2006, J ALLERGY CLIN IMMUN, V117, P1411, DOI 10.1016/j.jaci.2006.02.026; Caughey GH, 2000, J IMMUNOL, V164, P6566, DOI 10.4049/jimmunol.164.12.6566; CLARK JM, 1995, AM J RESP CRIT CARE, V152, P2076, DOI 10.1164/ajrccm.152.6.8520778; Hallgren J, 2004, J IMMUNOL, V173, P1868, DOI 10.4049/jimmunol.173.3.1868; Huang CF, 1999, J BIOL CHEM, V274, P19670, DOI 10.1074/jbc.274.28.19670; Mann A, 1996, MOL PHYLOGENET EVOL, V5, P169, DOI 10.1006/mpev.1996.0011; Marquardt U, 2002, J MOL BIOL, V321, P491, DOI 10.1016/S0022-2836(02)00625-3; MATSUMOTO R, 1995, J BIOL CHEM, V270, P19524, DOI 10.1074/jbc.270.33.19524; Min HK, 2004, J ALLERGY CLIN IMMUN, V114, P48, DOI 10.1016/j.jaci.2004.04.008; Min HK, 2001, J ALLERGY CLIN IMMUN, V107, P315, DOI 10.1067/mai.2001.112130; Pallaoro M, 1999, J BIOL CHEM, V274, P3355, DOI 10.1074/jbc.274.6.3355; Pennisi E, 2007, SCIENCE, V316, P218, DOI 10.1126/science.316.5822.218; Pereira PJB, 1998, NATURE, V392, P306, DOI 10.1038/32703; Raaum RL, 2005, J HUM EVOL, V48, P237, DOI 10.1016/j.jhevol.2004.11.007; ROBINSON TL, 1997, COMP BIOCH PHYSL B, V188, P783; Sakaguchi M, 2000, JPN J PHARMACOL, V84, P375, DOI 10.1254/jjp.84.375; Sakai K, 1996, J CLIN INVEST, V97, P988, DOI 10.1172/JCI118523; SCHWARTZ LB, 1987, NEW ENGL J MED, V316, P1622, DOI 10.1056/NEJM198706253162603; Schwartz LB, 2003, J IMMUNOL, V170, P5667, DOI 10.4049/jimmunol.170.11.5667; Selwood T, 2002, BIOCHEMISTRY-US, V41, P3329, DOI 10.1021/bi015662v; Soto D, 2002, CLIN EXP ALLERGY, V32, P1000, DOI 10.1046/j.1365-2222.2002.01416.x; Trivedi NN, 2007, J IMMUNOL, V179, P6072, DOI 10.4049/jimmunol.179.9.6072; VANDERSLICE P, 1990, P NATL ACAD SCI USA, V87, P3811, DOI 10.1073/pnas.87.10.3811; Wang HW, 2002, J IMMUNOL, V169, P5145, DOI 10.4049/jimmunol.169.9.5145; Wong GW, 2002, J BIOL CHEM, V277, P41906, DOI 10.1074/jbc.M205868200; Wouters MA, 2003, MOL CELL, V12, P343, DOI 10.1016/S1097-2765(03)00308-3	27	23	23	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2008	121	5					1262	1268		10.1016/j.jaci.2008.01.019	http://dx.doi.org/10.1016/j.jaci.2008.01.019			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	302IJ	18325577				2022-12-18	WOS:000255961700028
J	Matheu, V; Franco, A; Perez, E; Hernandez, M; Barrios, Y				Matheu, Victor; Franco, Andres; Perez, Eva; Hernandez, Marta; Barrios, Yvelise			Omalizumab for drug allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Matheu, Victor] Lund Univ, Lund, Sweden; [Matheu, Victor; Perez, Eva] Hosp Univ NS Candelaria, Santa Cruz de Tenerife, Spain; [Franco, Andres; Hernandez, Marta; Barrios, Yvelise] Hosp Univ Canarias, San Cristobal la Laguna, Spain	Lund University; Universidad de la Laguna	Matheu, V (corresponding author), Lund Univ, Lund, Sweden.	Matheu@med.lu.se	Barrios, Yvelise/AGR-9501-2022; Matheu, Victor/AAU-3043-2020	Barrios, Yvelise/0000-0002-6994-2034; Matheu, Victor/0000-0002-0469-800X				Casale TB, 2006, J ALLERGY CLIN IMMUN, V117, P134, DOI 10.1016/j.jaci.2005.09.036; Chang TW, 2007, ADV IMMUNOL, V93, P63, DOI 10.1016/S0065-2776(06)93002-8; Lin H, 2004, J ALLERGY CLIN IMMUN, V113, P297, DOI 10.1016/j.jaci.2003.11.044; Mankad VS, 2005, CLIN REV ALLERG IMMU, V29, P17, DOI 10.1385/CRIAI:29:1:017; Matheu Victor, 2005, Clin Mol Allergy, V3, P16, DOI 10.1186/1476-7961-3-16	5	23	25	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2007	120	6					1471	1472		10.1016/j.jaci.2007.07.037	http://dx.doi.org/10.1016/j.jaci.2007.07.037			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	241JX	17854881	Bronze			2022-12-18	WOS:000251653800039
J	Mosnaim, GS; Sadowski, LS; Durazo-Arvizu, RA; Sharp, LK; Curtis, LM; Shalowitz, MU; Shannon, JJ; Weiss, KB				Mosnaim, Giselle S.; Sadowski, Laura S.; Durazo-Arvizu, Ramon A.; Sharp, Lisa K.; Curtis, Laura M.; Shalowitz, Madeleine U.; Shannon, John J.; Weiss, Kevin B.			Parental language and asthma among urban Hispanic children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Hispanic; asthma; pediatrics; language; school	HEALTH-CARE; CHILDHOOD ASTHMA; LATINO CHILDREN; PREVALENCE; IMPACT; VALIDATION; MANAGEMENT; INSURANCE; BARRIERS; SCREEN	Background: Many Hispanics in the United States have limited English proficiency and prefer communicating in Spanish. Language barriers are known to adversely affect health care quality and outcomes. Objective: We explored the relationship between parent language preference in a Hispanic population and the likelihood that a child with symptoms receives a diagnosis of asthma. Methods: We conducted a school-based survey in 105 Chicago public and Catholic schools. Our sample included 14,177 Hispanic children 6 to 12 years of age with a parent who completed an asthma survey. Outcomes of diagnosed asthma and possible asthma (asthma symptoms without diagnosis) were assessed by using the Brief Pediatric Asthma Screen Plus instrument. Results: Overall, 12.0 % of children had diagnosed asthma, and 12.7% had possible asthma. Parents of children at risk who completed the survey in English reported higher rates of asthma diagnosis compared with parents who completed it in Spanish (55.2% vs 36.3%, P <.001). Predictors of asthma diagnosis were child sex, parental language preference, parental asthma status, and other household members with asthma. Conclusions: Parental language preference might be an important characteristic associated with childhood asthma diagnosis. Whether language itself is the key factor or the fact that language is a surrogate for other attributes of acculturation needs to be explored. Clinical implications: Our findings suggest that estimates of asthma among Hispanic schoolchildren might be low because of underdiagnosis among children whose parents prefer communicating in Spanish.	Rush Med Coll, Dept Immunol & Microbiol, Chicago, IL 60612 USA; Rush Med Coll, Chicago, IL 60612 USA; Loyola Univ, Stritch Sch Med, Dept Prevent Med & Epidemiol, Maywood, IL 60153 USA; Univ Illinois, Sect Hlth Promot Res, Dept Med, Chicago, IL USA; Northwestern Univ, Inst Healthcare Studies, Evanston, IL 60208 USA; Northwestern Univ, Feinberg Sch Med, Evanston Northwestern Healthcare, Evanston, IL 60208 USA	Rush University; Rush University; Loyola University Chicago; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Northwestern University; NorthShore University Health System; Northwestern University; Feinberg School of Medicine	Mosnaim, GS (corresponding author), Rush Med Coll, Dept Immunol & Microbiol, 1725 W Harrison,Suite 117, Chicago, IL 60612 USA.	gmosnaim@rush.edu		Sharp, Lisa/0000-0002-7809-9042; Curtis, Laura/0000-0003-2380-2201	NHLBI NIH HHS [1-U01 HL 72496-1] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL072496] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akinbami LJ, 2002, PEDIATRICS, V110, P315, DOI 10.1542/peds.110.2.315; Akinbami LJ, 2002, AMBUL PEDIATR, V2, P382, DOI 10.1367/1539-4409(2002)002<0382:RAIDIC>2.0.CO;2; Bearison DJ, 2002, J PEDIATR PSYCHOL, V27, P385, DOI 10.1093/jpepsy/27.4.385; Berry CA, 2005, ANN ALLERG ASTHMA IM, V95, P53, DOI 10.1016/S1081-1206(10)61188-X; BLOOM B, 2005, 231 US DEP HHS; BLOOM B, 2004, FREQUENCIES AGE ADJU; CARR W, 1992, AM J PUBLIC HEALTH, V82, P59, DOI 10.2105/AJPH.82.1.59; CARTERPOKRAS OD, 1993, AM J PUBLIC HEALTH, V83, P580, DOI 10.2105/AJPH.83.4.580; Castro-Rodriguez JA, 2000, AM J RESP CRIT CARE, V162, P1403, DOI 10.1164/ajrccm.162.4.9912111; Chang PH, 1998, J HEALTH CARE POOR U, V9, pS5; *CHIC PUBL SCH, CPS GLANC; Farr JN, 1951, J APPL PSYCHOL, V35, P333, DOI 10.1037/h0062427; *FED INT FOR CHILD, 2005, AM CHILDR KEY NAT IN; FINKELSTEIN JA, 1995, PEDIATRICS, V95, P389; Flesch R, 1948, J APPL PSYCHOL, V32, P221, DOI 10.1037/h0057532; Flores G, 2002, JAMA-J AM MED ASSOC, V288, P82, DOI 10.1001/jama.288.1.82; Flores G, 1998, Fam Med, V30, P196; Flores G, 2000, J PEDIATR-US, V136, P14, DOI 10.1016/S0022-3476(00)90043-X; FORTIER MP, 2003, SETTING AGENDA RES C; Freeman NCG, 2003, AM J PUBLIC HEALTH, V93, P1316, DOI 10.2105/AJPH.93.8.1316; Granados G, 2001, AM J PUBLIC HEALTH, V91, P1806, DOI 10.2105/AJPH.91.11.1806; Guilbert TW, 2004, CONTROL CLIN TRIALS, V25, P286, DOI 10.1016/j.cct.2004.03.002; Guilbert TW, 2004, J ALLERGY CLIN IMMUN, V114, P1282, DOI 10.1016/j.jaci.2004.09.020; Hampers LC, 1999, PEDIATRICS, V103, P1253, DOI 10.1542/peds.103.6.1253; HOSMER DW, 1980, COMMUN STAT A-THEOR, V9, P1043, DOI 10.1080/03610928008827941; HU DJ, 1986, WESTERN J MED, V144, P490; Hunninghake GM, 2006, AM J RESP CRIT CARE, V173, P143, DOI 10.1164/rccm.200508-1232SO; Hunt LM, 2004, SOC SCI MED, V59, P973, DOI 10.1016/j.socscimed.2003.12.009; Kincaid JP., 1975, DERIVATION NEW READA, DOI [10.21236/ADA006655, DOI 10.21236/ADA006655]; Lara M, 2005, ANNU REV PUBL HEALTH, V26, P367, DOI 10.1146/annurev.publhealth.26.021304.144615; Ledogar RJ, 2000, AM J PUBLIC HEALTH, V90, P929, DOI 10.2105/AJPH.90.6.929; Mannino D M, 1998, MMWR CDC Surveill Summ, V47, P1; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Mikhail B I, 1994, West J Nurs Res, V16, P623, DOI 10.1177/019394599401600603; MILLS RJ, 2002, HLTH INSURANCE COVER; Mosnaim G, 2006, ANN ALLERG ASTHMA IM, V97, P477, DOI 10.1016/S1081-1206(10)60938-6; Newacheck PW, 2000, ARCH PEDIAT ADOL MED, V154, P287, DOI 10.1001/archpedi.154.3.287; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Ortega AN, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.1.e1; Pachter L M, 1992, Med Anthropol, V13, P285; Sarver J, 2000, J GEN INTERN MED, V15, P256, DOI 10.1046/j.1525-1497.2000.015004256.x; Schur CL, 1996, J HEALTH CARE POOR U, V7, P140; SHIN H, 2000, LANGUAGE USE ENGLISH; *STATACORP LP, 2006, STAT STAT STAT SOFTW; Thamer M, 1998, Ethn Health, V3, P19; *US CENS BUR, 2000, POP RAC HISP LAT OR; *US DEP AGR, SCH MEALS INC EL GUI; WASSERMAN RC, 1992, PEDIATRICS, V89, P834; Weiss KB, 1999, CHEST, V116, p183S, DOI 10.1378/chest.116.suppl_2.183S; WISSOW LS, 1988, AM J PUBLIC HEALTH, V78, P777, DOI 10.2105/AJPH.78.7.777; Wolf RL, 2003, ANN ALLERG ASTHMA IM, V90, P500, DOI 10.1016/S1081-1206(10)61843-1	51	23	23	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2007	120	5					1160	1165		10.1016/j.jaci.2007.08.040	http://dx.doi.org/10.1016/j.jaci.2007.08.040			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	231TZ	17983874	Bronze			2022-12-18	WOS:000250973400027
J	Nassenstein, C; Kammertoens, T; Veres, TZ; Uckert, W; Spies, E; Fuchs, B; Krug, N; Braun, A				Nassenstein, Christina; Kammertoens, Thomas; Veres, Tibor Zoltan; Uckert, Wolfgang; Spies, Emma; Fuchs, Barbara; Krug, Norbert; Braun, Armin			Neuroimmune crosstalk in asthma: Dual role of the neurotrophin receptor p75NTR	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						neuroimmune interaction; airway hyperreactivity; airway inflammation; sensory nerves; neurotrophin receptors; p75NTR; capsaicin; asthma; bone marrow; chimeras; neurotrophins	NERVE GROWTH-FACTOR; ALLERGIC AIRWAY INFLAMMATION; NEUROGENIC INFLAMMATION; SENSORY NEURONS; MURINE MODEL; MAST-CELLS; EOSINOPHIL; HYPERRESPONSIVENESS; CAPSAICIN; LUNG	Background: Neurotrophins have been implicated in the pathogenesis of asthma because of their ability to induce airway inflammation and to promote hyperreactivity of sensory neurons, which reflects an important mechanism in the pathogenesis of airway hyperreactivity. Neurotrophins use a dual-receptor system consisting of Trk-receptor tyrosine kinases and the structurally unrelated p75NTR. Previous studies revealed an important role of p75NTR in the pathogenesis of allergic asthma. Objectives: The aim of the study was to investigate the precise mechanisms of neurotrophins in neuroimmune interaction, which can lead to both airway inflammation and sensory nerve hyperreactivity in vivo. Methods: Mice selectively expressing p75NTR in immune cells or nerves, respectively, were generated. After sensitization and allergen provocation, hyperreactivity of sensory nerves was tested in response to capsaicin. Airway inflammation was analyzed on the basis of differential cell counts and cytokine levels in bronchoalveolar lavage fluids. Results: Allergic mice selectively expressing p75NTR in immune cells showed normal inflammation but no sensory nerve hyperreactivity, whereas mice selectively expressing p75NTR in nerve cells had a diminished inflammation and a distinct sensory nerve hyperreactivity. Conclusion: Our data indicate that p75NTR plays a dual role by promoting hyperreactivity of sensory nerves and airway inflammation. Additionally, our study provides experimental evidence that development of sensory nerve hyperreactivity depends on an established airway inflammation in asthma. In contrast, development of airway inflammation seems to be independent from sensory nerve hyperreactivity. Clinical implications: Because of its dual function, antagonization of p75NTR-mediated signals might be a novel approach in asthma therapy.	Fraunhofer Inst Toxicol & Expt Med, Dept Immunol Allergol & Immunotoxicol, D-30625 Hannover, Germany; Charite Campus Benjamin Franklin, Inst Immunol, Berlin, Germany; Max Delbruck Ctr Mol Med, Berlin, Germany; Humboldt Univ, Inst Biol, Berlin, Germany	Fraunhofer Gesellschaft; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Humboldt University of Berlin	Braun, A (corresponding author), Fraunhofer Inst Toxicol & Expt Med, Dept Immunol Allergol & Immunotoxicol, Nikolai Fuchs Str 1, D-30625 Hannover, Germany.	braun@item.fraunhofer.de	Braun, Armin/B-8750-2009	Braun, Armin/0000-0002-1142-1463; Kammertoens, Thomas/0000-0003-3309-5141				BARNES PJ, 1992, J ASTHMA, V29, P165, DOI 10.3109/02770909209099025; Barnes PJ, 1995, PULM PHARMACOL THER, V8, P151, DOI 10.1006/pulp.1995.1020; Barouch R, 2000, J NEUROIMMUNOL, V103, P112, DOI 10.1016/S0165-5728(99)00233-7; Bracci-Laudiero L, 2002, J NEUROIMMUNOL, V123, P58, DOI 10.1016/S0165-5728(01)00475-1; Braun A, 2004, BRIT J PHARMACOL, V141, P431, DOI 10.1038/sj.bjp.0705638; Braun A, 1998, EUR J IMMUNOL, V28, P3240, DOI 10.1002/(SICI)1521-4141(199810)28:10<3240::AID-IMMU3240>3.0.CO;2-U; Braun A, 2001, INT ARCH ALLERGY IMM, V124, P205, DOI 10.1159/000053711; Chavolla-Calderon M, 2003, J CLIN INVEST, V111, P973, DOI 10.1172/JCI200317458; Davies Dawn, 1994, Neuroimmunomodulation, V1, P308, DOI 10.1159/000097181; De Swert KO, 2006, EUR J PHARMACOL, V533, P171, DOI 10.1016/j.ejphar.2005.12.066; Evans CM, 1997, J CLIN INVEST, V100, P2254, DOI 10.1172/JCI119763; Fischer A, 1996, J CLIN INVEST, V98, P2284, DOI 10.1172/JCI119039; GOEDERT M, 1981, P NATL ACAD SCI-BIOL, V78, P5895, DOI 10.1073/pnas.78.9.5895; Hoyle GW, 1998, AM J RESP CELL MOL, V18, P149, DOI 10.1165/ajrcmb.18.2.2803m; JANISZEWSKI J, 1990, BRAIN BEHAV IMMUN, V4, P139, DOI 10.1016/0889-1591(90)90016-J; Kerzel S, 2003, AM J RESP CELL MOL, V28, P170, DOI 10.1165/rcmb.4811; Kingham PJ, 2003, PULM PHARMACOL THER, V16, P9, DOI 10.1016/S1094-5539(02)00093-7; Kradin R, 1997, AM J PATHOL, V150, P1735; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; LEE KF, 1992, CELL, V69, P737, DOI 10.1016/0092-8674(92)90286-L; Lee LY, 2001, J APPL PHYSIOL, V91, P1318, DOI 10.1152/jappl.2001.91.3.1318; Morgan RK, 2004, J IMMUNOL, V173, P5963, DOI 10.4049/jimmunol.173.10.5963; Nassenstein C, 2003, J EXP MED, V198, P455, DOI 10.1084/jem.20010897; Nassenstein C, 2006, EUR J PHARMACOL, V533, P195, DOI 10.1016/j.ejphar.2005.12.061; Nassenstein C, 2006, J ALLERGY CLIN IMMUN, V118, P597, DOI 10.1016/j.jaci.2006.04.052; NILSSON G, 1990, CELL TISSUE RES, V262, P125, DOI 10.1007/BF00327753; Obata K, 2006, J NEUROSCI, V26, P11974, DOI 10.1523/JNEUROSCI.3188-06.2006; Quarcoo D, 2004, CLIN EXP ALLERGY, V34, P1146, DOI 10.1111/j.1365-2222.2004.01993.x; Sanico AM, 1997, J ALLERGY CLIN IMMUN, V100, P632, DOI 10.1016/S0091-6749(97)70167-2; SARIA A, 1988, AM REV RESPIR DIS, V137, P1330, DOI 10.1164/ajrccm/137.6.1330; Sawatzky DA, 2003, AM J PHYSIOL-LUNG C, V285, pL1296, DOI 10.1152/ajplung.00107.2003; Tracey KJ, 2002, NATURE, V420, P853, DOI 10.1038/nature01321; Undem BJ, 1999, INT ARCH ALLERGY IMM, V118, P150, DOI 10.1159/000024053; Virchow JC, 1998, AM J RESP CRIT CARE, V158, P2002, DOI 10.1164/ajrccm.158.6.9803023	34	23	23	1	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2007	120	5					1089	1096		10.1016/j.jaci.2007.07.007	http://dx.doi.org/10.1016/j.jaci.2007.07.007			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	231TZ	17716721				2022-12-18	WOS:000250973400016
J	Sanka, M; Tangsinmankong, N; Loscalzo, M; Sleasman, JW; Dorsey, MJ				Sanka, Madhurima; Tangsinmankong, Nutthapong; Loscalzo, Melissa; Sleasman, John W.; Dorsey, Morna J.			Complete DiGeorge syndrome associated with CHD7 mutation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CHARGE SYNDROME; TRANSPLANTATION; UPDATE		Univ S Florida, Coll Med, All Childrens Hosp, Div Rheumatol Allergy & Immunol, St Petersburg, FL 33701 USA; Univ S Florida, Coll Med, All Childrens Hosp, Dept Pediat,Div Med Genet, St Petersburg, FL 33701 USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Sanka, M (corresponding author), Univ S Florida, Coll Med, All Childrens Hosp, Div Rheumatol Allergy & Immunol, St Petersburg, FL 33701 USA.	mdorsey@health.usf.edu	Dorsey, Morna/V-7270-2018	Dorsey, Morna/0000-0002-9432-3542	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047723] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI47723-04A1] Funding Source: Medline; PHS HHS [R60 MC 000003-01] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Aramaki M, 2006, J PEDIATR-US, V148, P410, DOI 10.1016/j.jpeds.2005.10.044; Blake KD, 1998, CLIN PEDIATR, V37, P159, DOI 10.1177/000992289803700302; de Lonlay-Debeney P, 1997, J MED GENET, V34, P986, DOI 10.1136/jmg.34.12.986; Delahaye A, 2007, CLIN GENET, V72, P112, DOI 10.1111/j.1399-0004.2007.00821.x; Devriendt K, 1998, J MED GENET, V35, P789, DOI 10.1136/jmg.35.9.789-a; Markert ML, 2007, BLOOD, V109, P4539, DOI 10.1182/blood-2006-10-048652; Markert ML, 1998, J PEDIATR-US, V132, P15, DOI 10.1016/S0022-3476(98)70478-0; Markert ML, 1999, NEW ENGL J MED, V341, P1180, DOI 10.1056/NEJM199910143411603; Sanlaville D, 2007, EUR J HUM GENET, V15, P389, DOI 10.1038/sj.ejhg.5201778; THEODOROPOULOS MD, 2002, CLIN MED RES, V1, P43; Verloes A, 2005, AM J MED GENET A, V133A, P306, DOI 10.1002/ajmg.a.30559; Vissers LELM, 2004, NAT GENET, V36, P955, DOI 10.1038/ng1407	12	23	23	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2007	120	4					952	954		10.1016/j.jaci.2007.08.013	http://dx.doi.org/10.1016/j.jaci.2007.08.013			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	220LH	17931565	Bronze			2022-12-18	WOS:000250157700034
J	Elkhal, A; Pichavant, M; He, R; Scott, J; Meyer, E; Goya, S; Geha, RS; Umetsu, DT				Elkhal, Abdallah; Pichavant, Muriel; He, Rui; Scott, Jordan; Meyer, Everett; Goya, Sho; Geha, Raif S.; Umetsu, Dale T.			CD1d restricted natural killer T cells are not required for allergic skin inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic dermatitis; allergic skin inflammation; NKT cells; T(H)2 cytokines; eosinophils	INDUCED AIRWAY HYPERREACTIVITY; V-ALPHA-14 NKT CELLS; GLYCOLIPID ANTIGENS; EXPERIMENTAL ASTHMA; ATOPIC-DERMATITIS; MURINE MODEL; MICE; IL-13; HYPERRESPONSIVENESS; EOSINOPHILIA	Background: Invariant T-cell receptor-positive natural killer (iNKT) cells have been shown to be essential for the development of allergen-induced airway hyperreactivity (AHR). Objective: We examined the role of iNKT cells in allergic skin inflammation using a murine model of atopic dermatitis (AD) elicited by epicutaneous sensitization with ovalbumin (OVA). Methods: Wild-type (WT) and natural killer T-cell-deficient CD1d(-/-) mice were epicutaneously sensitized with OVA or normal saline and challenged with aerosolized OVA. iNKT cells in skin and bronchoalveolar lavage fluid were analyzed by fluorescence-activated cell sorting, and cytokine mRNA levels were measured by quantitative RT-PCR. AHR to methacholine was measured after OVA inhalation. Results: Skin infiltration by eosinophils and CD4(+) cells and expression of mRNA encoding IL-4 and IL-13 in OVA-sensitized skin were similar in WT and CD1d(-/-) mice. No significant increase in iNKT cells was detectable in epicutaneously sensitized skin. In contrast, iNKT cells were found in the bronchoalveolar lavage fluid from OVA-challenged epicutaneously sensitized WT mice, but not CD1d(-/-) mice. Epicutaneously sensitized CD1d(-/-) mice had an impaired expression of IL-4, IL-5, and IL-13 mRNA in the lung and failed to develop AHR in response to airway challenge with OVA. Conclusion: These results demonstrate that iNKT cells are not required for allergic skin inflammation in a murine model of AD, in contrast with airway inflammation, in which iNKT cells are essential. Clinical implications: Understanding the potential role of iNKT cells in AD will allow us to have a more specific target for therapeutic use.	Childrens Hosp, Div Immunol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Geha, RS (corresponding author), Childrens Hosp, Div Immunol, Karp Bldg,1 Blackfan Circle, Boston, MA 02115 USA.	raif.geha@childrens.harvard.edu	He, Rui/P-7302-2019; Pichavant, Muriel/B-9036-2018	He, Rui/0000-0001-5288-9786; Pichavant, Muriel/0000-0002-1315-4397	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI031541, T32AI007290, U19AI031541] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-31541, T32 AI007290] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akbari O, 2003, CURR OPIN IMMUNOL, V15, P627, DOI 10.1016/j.coi.2003.09.012; Akbari O, 2003, NAT MED, V9, P582, DOI 10.1038/nm851; Bagley CJ, 1997, J ALLERGY CLIN IMMUN, V99, P725, DOI 10.1016/S0091-6749(97)80002-4; Behar SM, 1999, J EXP MED, V189, P1973, DOI 10.1084/jem.189.12.1973; Berzins SP, 2004, IMMUNOL CELL BIOL, V82, P269, DOI 10.1111/j.0818-9641.2004.01256.x; CAMAUD C, 1999, J IMMUNOL, V163, P4647; Chen YH, 1997, IMMUNITY, V6, P459, DOI 10.1016/S1074-7613(00)80289-7; Clark RA, 2005, J CLIN INVEST, V115, P3239, DOI 10.1172/JCI24731; Clark RA, 2006, J INVEST DERMATOL, V126, P1059, DOI 10.1038/sj.jid.5700199; Crowe NY, 2003, J IMMUNOL, V171, P4020, DOI 10.4049/jimmunol.171.8.4020; Cui JQ, 1999, J EXP MED, V190, P783, DOI 10.1084/jem.190.6.783; Godfrey DI, 2000, IMMUNOL TODAY, V21, P573, DOI 10.1016/S0167-5699(00)01735-7; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Johansson SGO, 2001, ALLERGY, V56, P813, DOI 10.1034/j.1398-9995.2001.t01-1-00001.x; Kaminishi K, 2002, J DERMATOL SCI, V29, P19, DOI 10.1016/S0923-1811(01)00174-8; Kawano T, 1998, P NATL ACAD SCI USA, V95, P5690, DOI 10.1073/pnas.95.10.5690; Kawano T, 1997, SCIENCE, V278, P1626, DOI 10.1126/science.278.5343.1626; Korsgren M, 1999, J EXP MED, V189, P553, DOI 10.1084/jem.189.3.553; Leung DYM, 2003, LANCET, V361, P151, DOI 10.1016/S0140-6736(03)12193-9; Lisbonne M, 2003, J IMMUNOL, V171, P1637, DOI 10.4049/jimmunol.171.4.1637; Ma W, 2002, J CLIN INVEST, V109, P621, DOI 10.1172/JCI200214097; Matsuda JL, 2000, J EXP MED, V192, P741, DOI 10.1084/jem.192.5.741; Mattner J, 2005, NATURE, V434, P525, DOI 10.1038/nature03408; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Rothenberg ME, 1998, NEW ENGL J MED, V338, P1592, DOI 10.1056/NEJM199805283382206; Smiley ST, 1997, SCIENCE, V275, P977, DOI 10.1126/science.275.5302.977; Spada FM, 1998, J EXP MED, V188, P1529, DOI 10.1084/jem.188.8.1529; Spergel JM, 1998, J CLIN INVEST, V101, P1614, DOI 10.1172/JCI1647; Spergel JM, 1999, J CLIN INVEST, V103, P1103, DOI 10.1172/JCI5669; STEVENS TL, 1988, NATURE, V334, P255, DOI 10.1038/334255a0; Walter DM, 2001, J IMMUNOL, V167, P4668, DOI 10.4049/jimmunol.167.8.4668; Webb DC, 2004, J IMMUNOL, V172, P1092, DOI 10.4049/jimmunol.172.2.1092; Wills-Karp M, 2004, IMMUNOL REV, V202, P175, DOI 10.1111/j.0105-2896.2004.00215.x; Wills-Karp M, 1999, ANNU REV IMMUNOL, V17, P255, DOI 10.1146/annurev.immunol.17.1.255; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; YOSHIMOTO T, 1994, J EXP MED, V179, P1285, DOI 10.1084/jem.179.4.1285; Zhou DP, 2004, SCIENCE, V306, P1786, DOI 10.1126/science.1103440	37	23	27	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2006	118	6					1363	1368		10.1016/j.jaci.2006.08.010	http://dx.doi.org/10.1016/j.jaci.2006.08.010			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	117NP	17157667	Bronze			2022-12-18	WOS:000242880300025
J	Carraro, S; Pasquale, MF; Da Fre, M; Rusconi, F; Bonetto, G; Zanconato, S; Baraldi, E				Carraro, Silvia; Pasquale, Maria Francesca; Da Fre, Monica; Rusconi, Franca; Bonetto, Gea; Zanconato, Stefania; Baraldi, Eugenio			Swimming pool attendance and exhaled nitric oxide in children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							AIRWAY INFLAMMATION; ASTHMA		Allergy & Resp Med Unit, Dept Pediat, Padua, Italy; Reg Hlth Agcy Tuscany, Epidemiol Unit, Florence, Italy; AOU Meyer, Dept Epidemiol, Florence, Italy	University of Florence; Azienda Ospedaliera Universitaria (AOU) MEYER	Carraro, S (corresponding author), Allergy & Resp Med Unit, Dept Pediat, Padua, Italy.		Rusconi, Franca/K-2346-2016; baraldi, eugenio/AAC-5233-2022	Rusconi, Franca/0000-0002-9544-6472; BARALDI, EUGENIO/0000-0002-1829-3652				ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Baraldi E, 2002, EUR RESPIR J, V20, P223, DOI 10.1183/09031936.02.00293102; Bernard A, 2005, TOXICOL APPL PHARM, V206, P185, DOI 10.1016/j.taap.2004.10.022; Bernard A, 2003, OCCUP ENVIRON MED, V60, P385, DOI 10.1136/oem.60.6.385; Berry MA, 2005, CLIN EXP ALLERGY, V35, P1175, DOI 10.1111/j.1365-2222.2005.02314.x; FITCH KD, 1976, ARCH DIS CHILD, V51, P190, DOI 10.1136/adc.51.3.190; Franklin PJ, 2003, THORAX, V58, P1048, DOI 10.1136/thorax.58.12.1048; GOODALL C, 1983, UNDERSTANDING ROBUST, P339; Helenius I, 2002, J ALLERGY CLIN IMMUN, V109, P962, DOI 10.1067/mai.2002.124769; Nemery B, 2002, EUR RESPIR J, V19, P790, DOI 10.1183/09031936.02.00308602; Silkoff PE, 2004, J ALLERGY CLIN IMMUN, V114, P1241, DOI 10.1016/j.jaci.2004.08.042; Strunk RC, 2003, J ALLERGY CLIN IMMUN, V112, P883, DOI 10.1016/j.jaci.2003.08.014	12	23	23	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2006	118	4					958	960		10.1016/j.jaci.2006.07.016	http://dx.doi.org/10.1016/j.jaci.2006.07.016			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	097GD	17030253				2022-12-18	WOS:000241434200029
J	Mastalerz, L; Sanak, M; Gawlewicz, A; Gielicz, A; Faber, J; Szczeklik, A				Mastalerz, Lucyna; Sanak, Marek; Gawlewicz, Agnieszka; Gielicz, Anna; Faber, Jacek; Szczeklik, Andrew			Different eicosanoid profile of the hypersensitivity reactions triggered by aspirin and celecoxib in a patient with sinusitis, asthma, and urticaria	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							EXCRETION		Jagiellonian Univ, Sch Med, Dept Med, Krakow, Poland	Jagiellonian University	Mastalerz, L (corresponding author), Jagiellonian Univ, Sch Med, Dept Med, Krakow, Poland.		Mastalerz, Lucyna/U-5974-2018; Sanak, Marek/A-2115-2008; Sanak, Marek/AAV-1628-2021	Mastalerz, Lucyna/0000-0002-8994-0036; Sanak, Marek/0000-0001-7635-8103				Baldassarre S, 2006, J ALLERGY CLIN IMMUN, V117, P215, DOI 10.1016/j.jaci.2005.10.021; Daffern PJ, 1999, J ALLERGY CLIN IMMUN, V104, P559, DOI 10.1016/S0091-6749(99)70324-6; Dahlen B, 1998, AM J RESP CRIT CARE, V157, P1187, DOI 10.1164/ajrccm.157.4.9707089; Dahlen B, 2001, NEW ENGL J MED, V344, P142, DOI 10.1056/NEJM200101113440215; Dahlen SE, 2004, THORAX, V59, P453, DOI 10.1136/thx.2004.026641; Grimm V, 2002, J ALLERGY CLIN IMMUN, V109, P370, DOI 10.1067/mai.2002.121315; Higashi N, 2004, J ALLERGY CLIN IMMUN, V113, P277, DOI 10.1016/j.jaci.2003.10.068; Stevenson DD, 2001, ANN ALLERG ASTHMA IM, V87, P177, DOI 10.1016/S1081-1206(10)62221-1; Viola M, 2005, INT ARCH ALLERGY IMM, V137, P145, DOI 10.1159/000085794; Warner TD, 1999, P NATL ACAD SCI USA, V96, P7563, DOI 10.1073/pnas.96.13.7563	10	23	25	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2006	118	4					957	958		10.1016/j.jaci.2006.06.028	http://dx.doi.org/10.1016/j.jaci.2006.06.028			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	097GD	17030252	Green Submitted			2022-12-18	WOS:000241434200028
J	Camargo, CA; Rifas-Shiman, SL; Litonjua, AA; Rich-Edwards, JW; Weiss, ST; Gold, DR; Gillman, MW				Camargo, CA; Rifas-Shiman, SL; Litonjua, AA; Rich-Edwards, JW; Weiss, ST; Gold, DR; Gillman, MW			Prospective study of maternal intake of vitamin D during pregnancy and risk of wheezing illnesses in children at age 2 years	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract	62nd Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology	MAR 03-07, 2006	Miami Beach, FL	Amer Acad Allergy, Asthma & Immunol					Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Harvard Medical School			Camargo, Carlos A./C-2145-2008	Camargo, Carlos A./0000-0002-5071-7654					0	23	23	0	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2006	117	3					721	722		10.1016/j.jaci.2006.01.024	http://dx.doi.org/10.1016/j.jaci.2006.01.024			2	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	025JY					2022-12-18	WOS:000236263100045
J	Cho, JY; Miller, M; McElwain, K; McElwain, S; Shim, JY; Raz, E; Broide, DH				Cho, JY; Miller, M; McElwain, K; McElwain, S; Shim, JY; Raz, E; Broide, DH			Remodeling associated expression of matrix metal loproteinase 9 but not tissue inhibitor of metal loproteinase 1 in airway epithelium: Modulation by immunostimulatory DNA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; remodeling; MMP-9; TIMP-1; ISS	METALLOPROTEINASE-1 RATIO; CPG OLIGODEOXYNUCLEOTIDES; ALVEOLAR MACROPHAGES; MURINE MODEL; MOUSE MODEL; ASTHMA; MATRIX-METALLOPROTEINASE-9; INFLAMMATION; HYPERRESPONSIVENESS; DEPOSITION	Background: Matrix metalloproteinase 9 (MMP-9) and its tissue inhibitor of metalloproteinase 1 (TIMP-1) are hypothesized to play a role in the pathogenesis of airway remodeling in asthma. Objective: We have used a mouse model of airway remodeling to determine the pattern of expression of MMP-9 and TIMP-1 in airway epithelium and peribronchial cells, and assess whether TIMP-1, an inhibitor of MMP-9, is expressed at the same sites in the airway. In addition, we have investigated whether immunostimulatory sequences (ISSs) of DNA modulate levels of expression of MMP-9, TIMP-1, and peribronchial fibrosis. Methods: Levels of lung MMP-9 and TIMP-1 were assessed by zymography, ELISA, and immunohistochemistry. Results: Repetitive ovalbumin challenge induced a significant increase in levels of MMP-9, TIMP-1, and peribronchial collagen deposition. The pattern of expression of MMP-9 and TIMP-1 in the remodeled airway was significantly different. MMP-9 but not MMP-1 was expressed in airway epithelium, whereas both MMP-9 and TIMP-1 were expressed in peribronchial inflammatory cells. ISS significantly reduced expression of MMP-9 in airway epithelium (which immunostained positive for Toll receptor 9), as well as in peribronchial inflammatory cells. lit vitro studies demonstrated that ISS inhibited bone marrow macrophage generation of MMP-9. Conclusion: Allergen-induced peribronchial fibrosis is associated with expression of MMP-9 and TIMP-1 at different anatomical sites in the remodeled airway. The ability of ISS to inhibit the expression of MMP-9 in airway epithelium (a site where its inhibitor TIMP-1 is not induced by allergen challenge) may be important in determining whether ISS contributes to reductions in airway remodeling by reducing levels of MMP-9. Clinical implications: Immunostimulatory sequences of DNA, which are being investigated as novel therapeutics in asthma, inhibit airway remodeling in mice as well as epithelial expression of MMP-9, an enzyme that degrades the extracellular matrix proteins surrounding the airway.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Sungkyunkwan Univ, Sch Med, Seoul, South Korea	University of California System; University of California San Diego; Sungkyunkwan University (SKKU)	Broide, DH (corresponding author), Univ Calif San Diego, Dept Med, Basic Sci Bldg,Room 5090,9500 Gilman Dr, La Jolla, CA 92093 USA.	dbroide@ucsd.edu		Broide, David/0000-0001-8405-9090	NIAID NIH HHS [AI 38425] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI038425, R01AI038425] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bosse M, 1999, AM J RESP CRIT CARE, V159, P596, DOI 10.1164/ajrccm.159.2.9802045; Broide D, 1998, J IMMUNOL, V161, P7054; Cataldo DD, 2002, AM J PATHOL, V161, P491, DOI 10.1016/S0002-9440(10)64205-8; Cho JY, 2004, J CLIN INVEST, V113, P551, DOI 10.1172/JCI200419133; Cho JY, 2004, AM J RESP CELL MOL, V30, P651, DOI 10.1165/rcmb.2003-0066OC; CHO JY, 2004, J IMMUNOL, V173, P7556; Corry DB, 2004, FASEB J, V18, P995, DOI 10.1096/fj.03-1412fje; Dahlen B, 1999, THORAX, V54, P590, DOI 10.1136/thx.54.7.590; Flood-Page P, 2003, J CLIN INVEST, V112, P1029, DOI 10.1172/JCI200317974; Hoshino M, 1999, J ALLERGY CLIN IMMUN, V104, P356, DOI 10.1016/S0091-6749(99)70379-9; Hoshino M, 1998, J ALLERGY CLIN IMMUN, V102, P783, DOI 10.1016/S0091-6749(98)70018-1; Kelly EAB, 2000, AM J RESP CRIT CARE, V162, P1157; KHERADMAND F, 2003, THERAPEUTIC TARGETS, V177, P749; Kline JN, 1998, J IMMUNOL, V160, P2555; Kumagai K, 1999, J IMMUNOL, V162, P4212; Lee YC, 2001, CLIN EXP ALLERGY, V31, P1623, DOI 10.1046/j.1365-2222.2001.01211.x; Lemjabbar H, 1999, AM J RESP CRIT CARE, V159, P1298, DOI 10.1164/ajrccm.159.4.9708080; Mautino G, 1997, AM J RESP CELL MOL, V17, P583, DOI 10.1165/ajrcmb.17.5.2562; Parks WC, 2001, RESP RES, V2, P10, DOI 10.1186/rr33; Sha Q, 2004, AM J RESP CELL MOL, V31, P358, DOI 10.1165/rcmb.2003-0388OC; SHAPIRO SD, 1991, J IMMUNOL, V146, P2724; Sur S, 1999, J IMMUNOL, V162, P6284; Tanaka H, 2000, J ALLERGY CLIN IMMUN, V105, P900, DOI 10.1067/mai.2000.105316; Vermaelen KY, 2003, J IMMUNOL, V171, P1016, DOI 10.4049/jimmunol.171.2.1016; Vignola AM, 1998, AM J RESP CRIT CARE, V158, P1945, DOI 10.1164/ajrccm.158.6.9803014	25	23	29	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2006	117	3					618	625		10.1016/j.jaci.2005.12.1324	http://dx.doi.org/10.1016/j.jaci.2005.12.1324			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	025JY	16522462				2022-12-18	WOS:000236263100018
J	Bender, BG; Leung, DYM				Bender, BG; Leung, DYM			Sleep disorders in patients with asthma, atopic dermatitis, and allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material							DOSE-RESPONSE; DEPRIVATION; RESTRICTION; PERFORMANCE; DISTURBANCE; CYTOKINES; MELATONIN; PATTERNS; CHILDREN; NEURONS		Natl Jewish Med & Res Ctr, Dept Pediat, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Dept Psychiat, Boulder, CO 80309 USA; Univ Colorado, Hlth Sci Ctr, Dept Pediat, Boulder, CO 80309 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Boulder; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Boulder	Bender, BG (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, 1400 Jackson St, Denver, CO 80206 USA.	benderb@njc.org						Alam MN, 2004, EUR J NEUROSCI, V20, P207, DOI 10.1111/j.1460-9568.2004.03469.x; Bass JL, 2004, PEDIATRICS, V114, P805, DOI 10.1542/peds.2004-0227; Belenky G, 2003, J SLEEP RES, V12, P1, DOI 10.1046/j.1365-2869.2003.00337.x; Bender BG, 2003, J ALLERGY CLIN IMMUN, V111, P598, DOI 10.1067/mai.2003.174; Bergeron C, 2005, J ALLERGY CLIN IMMUN, V116, P1393, DOI 10.1016/j.jaci.2005.10.008; BLAISS M, 2005, J ALLERGY CLIN IMMUN, V115, pS197, DOI 10.1016/j.jaci.2004.12.800; Bourgeois-Bougrine S, 2003, AVIAT SPACE ENVIR MD, V74, P1072; Craig TJ, 2004, J ALLERGY CLIN IMMUN, V114, pS139, DOI 10.1016/j.jaci.2004.08.044; Craig TJ, 2005, J ALLERGY CLIN IMMUN, V116, P1264, DOI 10.1016/j.jaci.2005.10.009; Drake CL, 2001, PSYCHOPHYSIOLOGY, V38, P979, DOI 10.1111/1469-8986.3860979; Durmer JS, 2005, SEMIN NEUROL, V25, P117, DOI 10.1055/s-0029-1237117; FOLKARD S, 1979, HUM FACTORS, V21, P483, DOI 10.1177/001872087902100410; Kleitman N., 1963, SLEEP WAKEFULNESS; Krouse HJ, 2002, OTOLARYNG HEAD NECK, V126, P607, DOI 10.1067/mhn.2002.125300; Krueger JM, 2001, ANN NY ACAD SCI, V933, P211; Kubota T, 2002, BRAIN RES, V932, P37, DOI 10.1016/S0006-8993(02)02262-X; LAVIE P, 1981, ACTA OTO-LARYNGOL, V92, P529, DOI 10.3109/00016488109133292; Leo HL, 2004, J ALLERGY CLIN IMMUN, V114, P691, DOI 10.1016/j.jaci.2004.05.037; Majde JA, 2005, J ALLERGY CLIN IMMUN, V116, P1188, DOI 10.1016/j.jaci.2005.08.005; Majde JA, 2002, TXB BIOL PSYCHIAT, P1247; Manfridi A, 2003, EUR J NEUROSCI, V18, P1041, DOI 10.1046/j.1460-9568.2003.02836.x; McCartt AT, 2000, ACCIDENT ANAL PREV, V32, P493, DOI 10.1016/S0001-4575(99)00067-6; Opp MR, 2005, SLEEP MED REV, V9, P355, DOI 10.1016/j.smrv.2005.01.002; Redwine L, 2000, J CLIN ENDOCR METAB, V85, P3597, DOI 10.1210/jc.85.10.3597; Reuveni H, 1999, ARCH PEDIAT ADOL MED, V153, P249; Steele MT, 1999, ACAD EMERG MED, V6, P1050, DOI 10.1111/j.1553-2712.1999.tb01191.x; Stuck BA, 2004, J ALLERGY CLIN IMMUN, V113, P663, DOI 10.1016/j.jaci.2003.12.589; Sutherland ER, 2003, J ALLERGY CLIN IMMUN, V112, P513, DOI 10.1067/mai.2003.1679; Sutherland ER, 2005, J ALLERGY CLIN IMMUN, V116, P1179, DOI 10.1016/j.jaci.2005.09.028; TURNERWARWICK M, 1988, AM J MED, V85, P6, DOI 10.1016/0002-9343(88)90231-8; Van Dongen HPA, 2003, SLEEP, V26, P117, DOI 10.1093/sleep/26.2.117; Vgontzas AN, 2004, J CLIN ENDOCR METAB, V89, P4409, DOI 10.1210/jc.2003-031929; Young T, 1997, J ALLERGY CLIN IMMUN, V99, P757	33	23	23	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2005	116	6					1200	1201		10.1016/j.jaci.2005.09.041	http://dx.doi.org/10.1016/j.jaci.2005.09.041			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IJ	16337445	Bronze			2022-12-18	WOS:000235687000003
J	Kaur, S; Gupta, VK; Shah, A; Thiel, S; Sarma, PU; Madan, T				Kaur, S; Gupta, VK; Shah, A; Thiel, S; Sarma, PU; Madan, T			Plasma mannan-binding lectin levels and activity are increased in allergic patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							BRONCHIAL-ASTHMA; RESPONSES; INNATE; MICE		Inst Genom & Integrat Biol, Delhi 110007, India; Kurukshetra Univ, Dept Biochem, Kurukshetra 132119, Haryana, India; Univ Delhi, Dept Resp Med, Delhi 110007, India; Aarhus Univ, Dept Med Microbiol & Immunol, Aarhus, Denmark	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Institute of Genomics & Integrative Biology (IGIB); Kurukshetra University; University of Delhi; Aarhus University	Kaur, S (corresponding author), Inst Genom & Integrat Biol, Mall Rd, Delhi 110007, India.		Kaur, Savneet/AAU-6681-2021	Kaur, Savneet/0000-0002-9863-2772; Thiel, Steffen/0000-0002-4817-155X				Hawlisch H, 2004, MOL IMMUNOL, V41, P123, DOI 10.1016/j.molimm.2004.03.019; Jousilahti P, 2002, ANN ALLERG ASTHMA IM, V89, P381, DOI 10.1016/S1081-1206(10)62039-X; Kilpatrick DC, 2002, TRANSFUSION MED, V12, P335, DOI 10.1046/j.1365-3148.2002.00408.x; KIRSCHFINK M, 1993, INT ARCH ALLERGY IMM, V100, P151, DOI 10.1159/000236402; Lipscombe R. J., 1992, Human Molecular Genetics, V1, P709, DOI 10.1093/hmg/1.9.709; Liu H, 2001, SCAND J IMMUNOL, V53, P489, DOI 10.1046/j.1365-3083.2001.00908.x; Madan T, 2001, J CLIN INVEST, V107, P467, DOI 10.1172/JCI10124; Petersen SV, 2001, J IMMUNOL METHODS, V257, P107, DOI 10.1016/S0022-1759(01)00453-7; Reading PC, 1997, J VIROL, V71, P8204, DOI 10.1128/JVI.71.11.8204-8212.1997; Takahashi K, 2002, MICROBES INFECT, V4, P773, DOI 10.1016/S1286-4579(02)01597-6	10	23	24	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2005	116	6					1381	1383		10.1016/j.jaci.2005.08.028	http://dx.doi.org/10.1016/j.jaci.2005.08.028			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IJ	16337475				2022-12-18	WOS:000235687000034
J	Whelan, GJ; Blumer, JL; Martin, RJ; Szefler, SJ				Whelan, GJ; Blumer, JL; Martin, RJ; Szefler, SJ		Asthma Clinical Res Network; Pediat Pharmacology Res Unit Netwo	Fluticasone propionate plasma concentration and systemic effect: Effect of delivery device and duration of administration	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						pharmacokinetics; fluticasone propionate; metered dose inhaler; dry powder inhaler; cortisol suppression; drug accumulation; steady state	METERED-DOSE INHALER; HEALTHY-VOLUNTEERS; TRIAMCINOLONE ACETONIDE; ADRENAL SUPPRESSION; LUNG DEPOSITION; ASTHMA; PHARMACOKINETICS; CORTICOSTEROIDS; BUDESONIDE; CHILDREN	Background: Inhaled corticosteroids are the preferred therapy in persistent asthma. Dry powder inhalers (DPIs) generate a larger particle size compared with metered-dose inhalers (MDIs), which affects pulmonary deposition, bioavailability, and subsequent systemic effects of fluticasone propionate (fluticasone). Objective: To examine the relationship of fluticasone pharmacokinetics and cortisol suppression for 2 fluticasone formulations (DPI and MDI) administered in adults over 1-week and 6-week treatment periods. Methods: Two previous studies conducted in adults by the Asthma Clinical Research Network examined relative efficacy and systemic effect of fluticasone from MDI and DPI. Sample sets (n = 33) were analyzed for fluticasone after administration of 352 mu g from the MDL and 400 mu g from the DPI formulation, twice daily, after a 1-week treatment period. The second study's sample sets (n = 9) were analyzed for fluticasone after 6 weeks therapy at 352 mu g twice daily from the MDI formulation, allowing achievement of steady state. Results: ANOVA revealed a significant trend of increasing fluticasone area under the curve from 0 to time t (AUC(0 -> t)) when comparing DPI with MDI for I week with MDI for 6 weeks (P < .0001). Similarly, ANOVA revealed increasing cortisol suppression between these groups (P = .007). Linear regression demonstrated that increasing fluticasone AUC(0 -> t) was significantly correlated with cortisol suppression (P < .0001; r(2) = 0.41). MDI for 6 weeks showed increasing fluticasone AUC (P = .0008, t test) compared with MDI for 1 week, suggesting accumulation. Conclusion: Fluticasone plasma concentrations are significantly greater after MDI compared with DPI, and cortisol suppression is associated with fluticasone plasma concentrations. Accumulation of fluticasone concentrations suggests that time to steady state exceeds 1 week of treatment with MDI.	Natl Jewish Med & Res Ctr, Dept Pediat, Denver, CO 80206 USA; Natl Jewish Med & Res Ctr, Div Pulm, Denver, CO 80206 USA; Natl Jewish Med & Res Ctr, Dept Med, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Denver, CO 80202 USA; Rainbow Babies & Childrens Hosp, Dept Pediat, Cleveland, OH 44106 USA	National Jewish Health; National Jewish Health; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Rainbow Babies & Children's Hospital	Whelan, GJ (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, 1400 Jackson St,Off J329, Denver, CO 80206 USA.	WhelanG@njc.org			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U01HD037237] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U10HL051831, U10HL051843, U10HL051845, U10HL051834, U10HL051810, U10HL056443, U10HL051823] Funding Source: NIH RePORTER; NHLBI NIH HHS [U10 HL-51823, U10 HL-51845, U10 HL-56443, U10 HL-51834, U10 HL-51831, U10 HL-51810, U10 HL-51843] Funding Source: Medline; NICHD NIH HHS [1-U01-HD37237, U10 HD 3123-11] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Agertoft L, 2000, NEW ENGL J MED, V343, P1064, DOI 10.1056/NEJM200010123431502; Argenti D, 1999, J CLIN PHARMACOL, V39, P695, DOI 10.1177/00912709922008335; Brindley C, 2000, CLIN PHARMACOKINET, V39, P1, DOI 10.2165/00003088-200039001-00001; Brutsche MH, 2000, LANCET, V356, P556, DOI 10.1016/S0140-6736(00)02581-2; Carlsen KH, 2002, EUR RESPIR J, V19, P985, DOI 10.1183/09031936.02.00308702; Chrystyn H, 1997, RESP MED, V91, P17, DOI 10.1016/S0954-6111(97)90100-1; Daley-Yates PT, 2000, CLIN PHARMACOKINET, V39, P39, DOI 10.2165/00003088-200039001-00006; DERENDORF H, 1995, J CLIN PHARMACOL, V35, P302, DOI 10.1002/j.1552-4604.1995.tb04064.x; Derendorf H, 1998, J ALLERGY CLIN IMMUN, V101, pS440, DOI 10.1016/S0091-6749(98)70156-3; Derom E, 1999, AM J RESP CRIT CARE, V160, P157, DOI 10.1164/ajrccm.160.1.9805106; DOULL IJM, 1995, AM J RESP CRIT CARE, V151, P1715, DOI 10.1164/ajrccm.151.6.7767512; Doull IJM, 1998, ARCH DIS CHILD, V78, P172, DOI 10.1136/adc.78.2.172; EBLING WF, 1984, J CHROMATOGR, V305, P271, DOI 10.1016/S0378-4347(00)83342-3; Falcoz C, 2000, CLIN PHARMACOKINET, V39, P9, DOI 10.2165/00003088-200039001-00002; Goldberg S, 1996, ANN ALLERG ASTHMA IM, V76, P234, DOI 10.1016/S1081-1206(10)63432-1; Kamin WES, 2002, J AEROSOL MED, V15, P65, DOI 10.1089/08942680252908593; Kelly HW, 1998, J ALLERGY CLIN IMMUN, V102, pS36, DOI 10.1016/S0091-6749(98)70004-1; Krishnaswami S, 2000, J PHARMACEUT BIOMED, V22, P123, DOI 10.1016/S0731-7085(99)00246-0; Leach CL, 2002, CHEST, V122, P510, DOI 10.1378/chest.122.2.510; Leach CL, 1998, EUR RESPIR J, V12, P1346, DOI 10.1183/09031936.98.12061346; Mackie AE, 2000, CLIN PHARMACOKINET, V39, P17, DOI 10.2165/00003088-200039001-00003; Mackie AE, 2000, CLIN PHARMACOKINET, V39, P23, DOI 10.2165/00003088-200039001-00004; Martin RJ, 2002, AM J RESP CRIT CARE, V165, P1377, DOI 10.1164/rccm.2105013; Mollmann H, 2001, J CLIN PHARMACOL, V41, P1329; Nagel MW, 2002, J AEROSOL MED, V15, P427, DOI 10.1089/08942680260473506; SHEN J, 2003, 51 ANN AM SOC MASS S; Szefler SJ, 2002, J ALLERGY CLIN IMMUN, V109, P410, DOI 10.1067/mai.2002.122635; THORSSON L, 1994, EUR RESPIR J, V7, P1839, DOI 10.1183/09031936.94.07101839; Thorsson L, 1997, BRIT J CLIN PHARMACO, V43, P155, DOI 10.1046/j.1365-2125.1997.d01-1425.x; Thorsson L, 2001, BRIT J CLIN PHARMACO, V52, P529, DOI 10.1046/j.0306-5251.2001.01493.x; Yiallouros PK, 1997, ARCH DIS CHILD, V76, P405, DOI 10.1136/adc.76.5.405	31	23	23	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2005	116	3					525	530		10.1016/j.jaci.2005.05.044	http://dx.doi.org/10.1016/j.jaci.2005.05.044			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IE	16159619	Bronze			2022-12-18	WOS:000235686500009
J	Vercelli, D				Vercelli, D			Genetic regulation of IgE responses: Achilles and the tortoise	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; genetics; single nucleotide polymorphisms; functional genomics; IL-13	IMMUNOGLOBULIN-E; ASTHMA; VARIANTS; ASSOCIATION; POLYMORPHISMS; POPULATIONS; ATOPY; CHILDREN; RECEPTOR	In the last few decades, basic biology and immunology have thrived, largely thanks to the use of model organisms that allow exploration of complex functions in ideal experimental conditions and genetically defined backgrounds. IgE regulation studies are no exception to this rule. The current challenge is to anchor what we are learning in test tubes and animals to mechanisms of disease in patients with allergy. With information about the human genome rapidly piling up, and strong associations between single nucleotide polymorphisms and disease phenotypes reported more and more often, it is becoming clear that such anchoring cannot occur without a robust integration between the biology of model systems and the biology of natural genetic variants. Here we will argue that an essential component of this integration is the functional analysis of the mechanisms through which natural variation affects pathways relevant to the pathogenesis of IgE-dependent inflammation.	Univ Arizona, Hlth Sci Ctr, Arizona Resp Ctr, Funct Genom Lab,Dept Cell Biol,Coll Med, Tucson, AZ 85724 USA; Univ Arizona, Grad Interdisciplinary Program Genet, Tucson, AZ 85721 USA	University of Arizona; University of Arizona Health Sciences; University of Arizona	Vercelli, D (corresponding author), Univ Arizona, Hlth Sci Ctr, Arizona Resp Ctr, Funct Genom Lab,Dept Cell Biol,Coll Med, 1501 N Campbell Ave,Rm 2349, Tucson, AZ 85724 USA.	donata@arc.arizona.edu						Baldini M, 1999, AM J RESP CELL MOL, V20, P976, DOI 10.1165/ajrcmb.20.5.3494; Basehore MJ, 2004, J ALLERGY CLIN IMMUN, V114, P80, DOI 10.1016/j.jaci.2004.05.035; Chen WG, 2004, J ALLERGY CLIN IMMUN, V114, P553, DOI 10.1016/j.jaci.2004.04.044; Eder W, 2004, J ALLERGY CLIN IMMUN, V113, P482, DOI 10.1016/j.jaci.2003.12.374; Geha RS, 2003, NAT REV IMMUNOL, V3, P721, DOI 10.1038/nri1181; Graves PE, 2000, J ALLERGY CLIN IMMUN, V105, P506, DOI 10.1067/mai.2000.104940; Heinzmann A, 2000, HUM MOL GENET, V9, P549, DOI 10.1093/hmg/9.4.549; Hinds DA, 2005, SCIENCE, V307, P1072, DOI 10.1126/science.1105436; Hobbs K, 1998, AM J RESP CRIT CARE, V158, P1958, DOI 10.1164/ajrccm.158.6.9804011; Hoffjan S, 2003, RESP RES, V4, DOI 10.1186/1465-9921-4-14; Howard TD, 2001, AM J RESP CELL MOL, V25, P377, DOI 10.1165/ajrcmb.25.3.4483; Hwang ES, 2005, SCIENCE, V307, P430, DOI 10.1126/science.1103336; MOSTECKI J, 2004, 12 INT C IMM MONTR C; Murphy KM, 2002, NAT REV IMMUNOL, V2, P933, DOI 10.1038/nri954; Oguma T, 2004, NEW ENGL J MED, V351, P1752, DOI 10.1056/NEJMoa031785; Pykalainen M, 2005, J ALLERGY CLIN IMMUN, V115, P80, DOI 10.1016/j.jaci.2004.10.006; Schedel M, 2004, J ALLERGY CLIN IMMUN, V114, P1100, DOI 10.1016/j.jaci.2004.07.048; SHIRAKAWA T, 1994, NAT GENET, V7, P125, DOI 10.1038/ng0694-125; Silverman ES, 2004, AM J RESP CRIT CARE, V169, P214, DOI 10.1164/rccm.200307-973OC; Stern Debra, 2004, Novartis Found Symp, V257, P25; Tantisira KG, 2004, P NATL ACAD SCI USA, V101, P18099, DOI 10.1073/pnas.0408532102; Traidl-Hoffmann C, 2005, J EXP MED, V201, P627, DOI 10.1084/jem.20041065; Vercelli D, 2004, J ALLERGY CLIN IMMUN, V113, P381, DOI 10.1016/j.jaci.2004.01.752; Vercelli D, 2003, CURR OPIN ALLERGY CL, V3, P343, DOI 10.1097/01.all.0000092603.76804.e4; Vladich FD, 2005, J CLIN INVEST, V115, P747, DOI 10.1172/JCI200522818	25	23	24	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2005	116	1					60	64		10.1016/j.jaci.2005.04.031	http://dx.doi.org/10.1016/j.jaci.2005.04.031			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IC	15990775				2022-12-18	WOS:000235686300010
J	Shearer, WT; Zhang, SJ; Reuben, JM; Lee, BN; Butel, JS				Shearer, WT; Zhang, SJ; Reuben, JM; Lee, BN; Butel, JS			Effects of radiation and latent virus on immune responses in a space flight model	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						space flight; radiation; polyoma virus injection; T lymphocytes; IFN-gamma; virus reactivation	BODY PROTON-IRRADIATION; EPSTEIN-BARR-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY; ANTARCTIC WINTER; DURATION MISSIONS; SPACEFLIGHT; SYSTEM; REACTIVATION; POPULATIONS; INFECTION	Background: The immunosuppressive effects of space flight radiation and reactivation of latent virus infections in human beings are largely unknown. Objective: To develop a murine model that can predict the adverse effects of space flight radiation and reactivation of latent virus infection for human beings. Methods: In experiment I, some BALB/c mice received whole-body gamma-irradiation (3 Gy) on day 0 and murine polyoma virus (PyV) on day 1. In experiment II, mice received irradiation (3 Gy) or none on days 0 and/or 49, and PyV or none on day 1: A1, 3 Gy/PyV/3 Gy; A2, 3 Gy/PyV/0 Gy; B1, 0 Gy/PyV/3 Gy; B2, 0 Gy/PyV/0 Gy; C, 3 Gy/0 PyV/0 Gy; and D, 0 Gy/0 PyV/0 Gy. Results: In experiment 1, PyV was detected by PCR more frequently in several host organs tested and for a longer period of time in irradiated than in control animals. In experiment II, PyV replication in the spleen was detected in A1 > B1 mice on days 10 and 20; both groups cleared PyV by day 49. After irradiation on day 49, reactivated PyV was detected in more B1 than A I mice. A I mice had lower spleen weights and cell counts than other groups at all time points. From 0 to 49 days, irradiation suppressed spleen cell proliferation to concanavalin A in all irradiated groups except in BI when the virus was cleared at day 20. PyV enhanced IFN-gamma production in all groups: B1 > A1 > C, D (0-49 days; all differences, P <.05). Conclusion: This small animal model or space flight suggests that the combined effects of radiation and virus replication will significantly affect T-Iymphocyte-mediated immunity that may lead to chronic viral infection and malignancy.	Baylor Coll Med, Dept Pediat, Sect Allergy & Immunol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center	Shearer, WT (corresponding author), Texas Childrens Hosp, 6621 Fannin St MC FC330-01, Houston, TX 77030 USA.	wtsheare@TexasChildrensHospital.org		Butel, Janet/0000-0002-6876-3245; Shearer, William/0000-0002-2483-2130				Arvin A, 2001, FIELDS VIROLOGY, P2731; Berke Z, 2000, ADV CANCER RES, V79, P249, DOI 10.1016/S0065-230X(00)79008-7; Butel JS, 2000, CARCINOGENESIS, V21, P405, DOI 10.1093/carcin/21.3.405; Croul S, 2003, J NEUROVIROL, V9, P173, DOI 10.1080/13550280390194055; Cucinotta FA, 2001, RADIAT RES, V156, P682, DOI 10.1667/0033-7587(2001)156[0682:SRCRAU]2.0.CO;2; Gridley DS, 2002, IMMUNOL LETT, V80, P55, DOI 10.1016/S0165-2478(01)00306-6; Harrington NP, 1997, CLIN EXP IMMUNOL, V107, P417, DOI 10.1111/j.1365-2249.1997.272-ce1158.x; Kajioka EH, 2000, RADIAT RES, V153, P587, DOI 10.1667/0033-7587(2000)153[0587:AEOWBP]2.0.CO;2; Kajioka EH, 1999, IN VIVO, V13, P525; Kajioka EH, 2000, IN VIVO, V14, P703; Karp JE, 1999, MICROBES AND MALIGNANCY, P131; KONSTANTINOVA IV, 1993, J LEUKOCYTE BIOL, V54, P189, DOI 10.1002/jlb.54.3.189; Lednicky JA, 2003, AIDS, V17, P801, DOI 10.1097/00002030-200304110-00004; Ling PD, 2003, CLIN INFECT DIS, V37, P1244, DOI 10.1086/378808; LUDLOW JW, 1987, J VIROL, V61, P509, DOI 10.1128/JVI.61.2.509-515.1987; Lukacher AE, 1999, J IMMUNOL, V163, P3369; Mehta SK, 2000, J MED VIROL, V61, P235, DOI 10.1002/(SICI)1096-9071(200006)61:2&lt;235::AID-JMV10&gt;3.0.CO;2-4; MOORE FD, 1992, FASEB J, V6, P2338, DOI 10.1096/fasebj.6.6.1544543; Moser JM, 2001, VIRAL IMMUNOL, V14, P199, DOI 10.1089/088282401753266738; *NATL RES COUNC CO, 1998, STRAT RES SPAC BIOL, P156; PAGANO JS, 1986, INFECT DIS MED MICRO, P470; PASS RF, 2001, FIELDS VIROLOGY, P2675; Payne DA, 1999, AVIAT SPACE ENVIR MD, V70, P1211; Pecaut MJ, 2002, IMMUNOL LETT, V80, P67, DOI 10.1016/S0165-2478(01)00307-8; PERKINS S, 2004, SCI NEWS, V166, P74; Schmitt DA, 1996, J INTERF CYTOK RES, V16, P151, DOI 10.1089/jir.1996.16.151; Shearer WT, 2002, J ALLERGY CLIN IMMUN, V109, P854, DOI 10.1067/mai.2002.123873; Shearer WT, 2001, J ALLERGY CLIN IMMUN, V107, P165, DOI 10.1067/mai.2001.112270; Shearer WT, 2001, J ALLERGY CLIN IMMUN, V107, P160, DOI 10.1067/mai.2001.112269; SHEARER WT, 2003, ENCY SPACE SCI TECHN, P810; Shirai T, 2003, J ALLERGY CLIN IMMUN, V111, P1353, DOI 10.1067/mai.2003.1504; Sonnenfeld Gerald, 2003, Rev Environ Health, V18, P1; Stowe RP, 2001, PSYCHOSOM MED, V63, P891, DOI 10.1097/00006842-200111000-00007; Stowe RP, 2001, AVIAT SPACE ENVIR MD, V72, P884; Taylor G R, 1997, Adv Space Biol Med, V6, P1, DOI 10.1016/S1569-2574(08)60076-3; TAYLOR GR, 1993, J LEUKOCYTE BIOL, V54, P202, DOI 10.1002/jlb.54.3.202; Tingate TR, 1997, IMMUNOL CELL BIOL, V75, P275, DOI 10.1038/icb.1997.42; Todd P, 1999, MUTAT RES-FUND MOL M, V430, P211, DOI 10.1016/S0027-5107(99)00132-3; Venkat S, 2001, J Environ Pathol Toxicol Oncol, V20, P165; Vilchez RA, 2002, LANCET, V359, P817, DOI 10.1016/S0140-6736(02)07950-3; Wilson JW, 2001, MATER DESIGN, V22, P541, DOI 10.1016/S0261-3069(01)00014-0; ZAIA JA, 2002, INFECT ORGAN TRANSPL, P79	42	23	23	1	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2005	115	6					1297	1303		10.1016/j.jaci.2005.03.003	http://dx.doi.org/10.1016/j.jaci.2005.03.003			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	935WZ	15940150				2022-12-18	WOS:000229815400030
J	Sood, A				Sood, A			Does obesity weigh heavily on the health of the human airway?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						asthma; obesity; bronchial hyperreactivity	ASTHMA; RESPONSES; CHILDREN		So Illinois Univ, Sch Med, Div Pulm & Crit Care Med, Springfield, IL 62794 USA	Southern Illinois University System; Southern Illinois University	Sood, A (corresponding author), So Illinois Univ, Sch Med, Div Pulm & Crit Care Med, 701 N 1st St,Room D434,POB 19636, Springfield, IL 62794 USA.	asood2@siumed.edu						Beckett WS, 2001, AM J RESP CRIT CARE, V164, P2045, DOI 10.1164/ajrccm.164.11.2004235; Brisbon N, 2005, J ALLERGY CLIN IMMUN, V115, P1024, DOI 10.1016/j.jaci.2005.02.020; Chinn S, 2003, THORAX, V58, P1008, DOI 10.1136/thorax.58.12.1008; Fantuzzi G, 2005, J ALLERGY CLIN IMMUN, V115, P911, DOI 10.1016/j.jaci.2005.02.023; Ford ES, 2005, J ALLERGY CLIN IMMUN, V115, P897, DOI 10.1016/j.jaci.2004.11.050; Hedley AA, 2004, JAMA-J AM MED ASSOC, V291, P2847, DOI 10.1001/jama.291.23.2847; Hill A.B., 1971, PRINCIPLES MED STAT; Lucas SR, 2005, J ALLERGY CLIN IMMUN, V115, P928, DOI 10.1016/j.jaci.2005.01.033; Mannino D M, 1998, MMWR CDC Surveill Summ, V47, P1; Shore SA, 2005, J ALLERGY CLIN IMMUN, V115, P925, DOI 10.1016/j.jaci.2005.01.064; Shore SA, 2003, J APPL PHYSIOL, V95, P938, DOI 10.1152/japplphysiol.00336.2003; Shore SA, 2005, J ALLERGY CLIN IMMUN, V115, P103, DOI 10.1016/j.jaci.2004.10.007; Tantisira KG, 2001, THORAX, V56, P64; von Mutius E, 2001, THORAX, V56, P835, DOI 10.1136/thorax.56.11.835; Weiss ST, 2004, AM J RESP CRIT CARE, V169, P963, DOI 10.1164/rccm.200303-403WS	15	23	24	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2005	115	5					921	924		10.1016/j.jaci.2005.02.033	http://dx.doi.org/10.1016/j.jaci.2005.02.033			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	925LR	15867845				2022-12-18	WOS:000229055100003
J	Bisgaard, H; Szefler, SJ				Bisgaard, H; Szefler, SJ			Understanding mild persistent asthma in children: The next frontier	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						children; adolescents; persistent asthma; mild	DOSE INHALED BUDESONIDE; EXERCISE-INDUCED BRONCHOSPASM; ONCE-DAILY THERAPY; CHILDHOOD ASTHMA; LUNG-FUNCTION; LEUKOTRIENE ANTAGONIST; RESPIRATORY SYMPTOMS; COMPARATIVE EFFICACY; AIRWAY-OBSTRUCTION; UNITED-STATES	Limitations in asthma prevalence studies and difficulties in diagnosing pediatric asthma lead to uncertainty over the full extent of mild persistent asthma in children and adolescents. Although recent surveys have reported that the majority of pediatric patients with asthma in the United States and Europe have symptoms consistent with mild disease, these surveys have limitations in design. Thus, the true prevalence of mild asthma remains unknown. It is unclear whether children with mild persistent asthma progress to more severe asthma, but the risk of severe asthma exacerbations seems to be unrelated to the symptom severity. Clinical studies restricted to pediatric patients with mild asthma are limited, but available data do suggest substantial morbidity of mild persistent asthma in this population and support inhaled corticosteroid intervention. There is a need for further investigation into the true prevalence of mild persistent asthma in children and adolescents, and optimal treatment.	Univ Copenhagen Hosp, Danish Paediat Asthma Ctr, Dept Paediat, DK-2900 Copenhagen, Denmark; Natl Jewish Ctr Immunol & Resp Med, Dept Pediat, Denver, CO 80206 USA	University of Copenhagen; National Jewish Health	Bisgaard, H (corresponding author), Univ Copenhagen Hosp, Danish Paediat Asthma Ctr, Dept Paediat, DK-2900 Copenhagen, Denmark.	Bisgaard@copsac.dk	Kronow, Joern/B-1054-2011; Bisgaard, Hans/N-4761-2016	Bisgaard, Hans/0000-0003-4131-7592				Adams RJ, 2002, J ALLERGY CLIN IMMUN, V110, P58, DOI 10.1067/mai.2002.125489; Arets HGM, 2002, EUR RESPIR J, V20, P1470, DOI 10.1183/09031936.02.00292702; AUERBACH I, 1993, THORAX, V48, P139, DOI 10.1136/thx.48.2.139; Bacharier LB, 2004, AM J RESP CRIT CARE, V170, P426, DOI 10.1164/rccm.200308-1178OC; BISGAARD H, 2004, EUR RESPIR J S45, V22, pS504; Busse WW, 2002, J ALLERGY CLIN IMMUN, V110, P703, DOI 10.1067/mai.2002.129368; Calhoun WJ, 2003, J ALLERGY CLIN IMMUN, V112, P1088, DOI 10.1016/j.jaci.2003.09.044; Cane RS, 2000, ARCH DIS CHILD, V82, P327, DOI 10.1136/adc.82.4.327; Cane RS, 2001, ARCH DIS CHILD, V84, P31, DOI 10.1136/adc.84.1.31; Coffey MJ, 2004, PEDIATRICS, V113, P87, DOI 10.1542/peds.113.1.87; Colice GL, 1999, AM J RESP CRIT CARE, V160, P1962, DOI 10.1164/ajrccm.160.6.9902112; Covar RA, 2004, AM J RESP CRIT CARE, V170, P234, DOI 10.1164/rccm.200308-1174OC; Dempsey OJ, 2002, J ALLERGY CLIN IMMUN, V109, P68, DOI 10.1067/mai.2002.120559; Fawcett WA, 2004, ANN ALLERG ASTHMA IM, V92, P129; FERGUSON AC, 1988, J ALLERGY CLIN IMMUN, V82, P19, DOI 10.1016/0091-6749(88)90045-0; Fuhlbrigge AL, 2002, AM J RESP CRIT CARE, V166, P1044, DOI 10.1164/rccm.2107057; Guyatt GH, 1997, PEDIATRICS, V99, P165, DOI 10.1542/peds.99.2.165; HABY MM, 1995, EUR RESPIR J, V8, P729; Hofstra WB, 2000, PEDIATR PULM, V29, P415, DOI 10.1002/(SICI)1099-0496(200006)29:6<415::AID-PPUL1>3.0.CO;2-7; Jonasson G, 1999, EUR RESPIR J, V14, P150, DOI 10.1034/j.1399-3003.1999.14a25.x; Jonasson G, 2000, ARCH DIS CHILD, V83, P330, DOI 10.1136/adc.83.4.330; Jonasson G, 2000, PEDIATR ALLERGY IMMU, V11, P120, DOI 10.1034/j.1399-3038.2000.00067.x; Jonasson G, 1998, EUR RESPIR J, V12, P1099, DOI 10.1183/09031936.98.12051099; Jonasson G, 2000, ALLERGY, V55, P740, DOI 10.1034/j.1398-9995.2000.00661.x; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; *NIH, 2003, PUBL; O'Byrne PM, 2001, AM J RESP CRIT CARE, V164, P1392, DOI 10.1164/ajrccm.164.8.2104102; Oswald H, 1997, PEDIATR PULM, V23, P14, DOI 10.1002/(SICI)1099-0496(199701)23:1<14::AID-PPUL2>3.0.CO;2-P; Panditi S, 2003, ARCH DIS CHILD, V88, P807, DOI 10.1136/adc.88.9.807; Pauwels RA, 2003, LANCET, V361, P1071, DOI 10.1016/S0140-6736(03)12891-7; PEDERSEN S, 1995, J ALLERGY CLIN IMMUN, V95, P29, DOI 10.1016/S0091-6749(95)70149-4; Rabe KF, 2000, EUR RESPIR J, V16, P802, DOI 10.1183/09031936.00.16580200; Rasmussen F, 2002, J ALLERGY CLIN IMMUN, V110, P220, DOI 10.1067/mai.2002.125295; RIEDLER J, 1994, AM J RESP CRIT CARE, V150, P1632, DOI 10.1164/ajrccm.150.6.7952626; ROBERTSON CF, 1992, PEDIATR PULM, V13, P95, DOI 10.1002/ppul.1950130207; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; Spahn JD, 2004, AM J RESP CRIT CARE, V169, P784, DOI 10.1164/rccm.200309-1234OE; Szefler S, 2000, NEW ENGL J MED, V343, P1054; Teeter JG, 1998, CHEST, V113, P272, DOI 10.1378/chest.113.2.272; Woodcock A, 2002, J AEROSOL MED, V15, P407, DOI 10.1089/08942680260473489; Yao TC, 2003, J ALLERGY CLIN IMMUN, V111, P1285, DOI 10.1067/mai.2003.1506; Yobo EODA, 1997, THORAX, V52, P161, DOI 10.1136/thx.52.2.161; Yurdakul AS, 2003, RESP MED, V97, P1313, DOI 10.1016/j.rmed.2003.07.007; Zeiger RS, 1999, J ALLERGY CLIN IMMUN, V103, P376, DOI 10.1016/S0091-6749(99)70460-4; Zhang J, 2002, EUR RESPIR J, V20, P1102, DOI 10.1183/09031936.02.02402001	45	23	23	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2005	115	4					708	713		10.1016/j.jaci.2004.11.018	http://dx.doi.org/10.1016/j.jaci.2004.11.018			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	916GM	15805988				2022-12-18	WOS:000228373400007
J	Subbarao, P; Dorman, SC; Rerecich, T; Watson, RM; Gauvreau, GM; O'Byrne, PM				Subbarao, P; Dorman, SC; Rerecich, T; Watson, RM; Gauvreau, GM; O'Byrne, PM			Protection by budesonide and fluticasone on allergen-induced airway responses after discontinuation of therapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						budesonide; fluticasone; steroids; asthma; allergen challenge; bronchial challenge test; sputum; eosinophils	LATE ASTHMATIC RESPONSES; INHALED BUDESONIDE; MOMETASONE FUROATE; BECLOMETHASONE; RESPONSIVENESS; INFLAMMATION; CHALLENGE; RETENTION; SPUTUM	Background: Treatment with inhaled steroids is an effective method of reducing bronchoconstriction and airway inflammation after allergen challenge. However, the duration of the protective effects of inhaled steroids after discontinuation of therapy has not been established. Objective: We sought to evaluate the protective effect of I week of inhaled steroid therapy against inhaled allergen challenge 12 hours after discontinuation of therapy. Methods: In this randomized, double-blind, placebo-controlled crossover trial, 26 asthmatic subjects (> 18 years old) not using inhaled steroids were administered 200 mu g of budesonide twice daily, 200 mu g of fluticasone twice daily, or placebo twice daily for 1 week. Twelve hours after discontinuation of therapy, subjects were administered an inhaled allergen challenge. Each treatment period was separated by a 3-week washout period. Results: When compared with placebo (26% +/- 14%), there was a slight but significant protection against the allergen-induced early response after fluticasone treatment (19% +/- 10%, P =.001) but not after budesonide treatment (23% +/- 13%, P =.08). However, when the area under the curve for the early airway response was examined, there was no difference between the 2 drugs in the amount of protection (P =.62). Partial protection was demonstrated against the late-response allergen-induced sputum eosinophilia with both treatments (P =.001). By contrast, no protection was observed against allergen-induced airway hyperresponsiveness for either treatment. Conclusions: The protective effects of inhaled steroids against allergen-induced early responses, airway eosinophilia, and allergen-induced airway hyperresponsiveness; are partially or completely lost as early as 12 hours after discontinuation of therapy.	St Josephs Hosp, Firestone Inst Resp Hlth, Hamilton, ON, Canada; McMaster Univ, Hamilton, ON, Canada	McGill University; McMaster University; McMaster University	Subbarao, P (corresponding author), Hosp Sick Children, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	padmaja.subbarao@sickkids.ca		Subbarao, Padmaja/0000-0003-0394-1933; O'Byrne, Paul/0000-0003-0979-281X				Asai K, 2003, CLIN EXP ALLERGY, V33, P595, DOI 10.1046/j.1365-2222.2003.01576.x; Bentley AM, 1996, CLIN EXP ALLERGY, V26, P909, DOI 10.1111/j.1365-2222.1996.tb00626.x; Boulet LP, 1999, CAN MED ASSOC J, V161, pS1; COCKCROFT DW, 1987, AM REV RESPIR DIS, V135, P264; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; COCKCROFT DW, 1987, J ALLERGY CLIN IMMUN, V79, P734, DOI 10.1016/0091-6749(87)90204-1; COCKCROFT DW, 1993, J ALLERGY CLIN IMMUN, V91, P1163, DOI 10.1016/0091-6749(93)90319-B; Edsbacker S, 1999, DRUGS, V58, P7, DOI 10.2165/00003495-199958004-00002; Gauvreau GM, 1996, AM J RESP CRIT CARE, V154, P1267, DOI 10.1164/ajrccm.154.5.8912734; Gibson PG, 2001, AM J RESP CRIT CARE, V163, P32, DOI 10.1164/ajrccm.163.1.9807061; INMAN MD, 1995, J ALLERGY CLIN IMMUN, V95, P1191, DOI 10.1016/S0091-6749(95)70075-7; Inman MD, 2001, AM J RESP CRIT CARE, V164, P569, DOI 10.1164/ajrccm.164.4.2007063; INMAN MD, 1999, AM J RESP CRIT CARE, V159, pA633; Johnson M, 1998, J ALLERGY CLIN IMMUN, V101, pS434, DOI 10.1016/S0091-6749(98)70155-1; Kelly EAB, 2000, AM J RESP CRIT CARE, V162, P883; Kemp JP, 2000, J ALLERGY CLIN IMMUN, V106, P485, DOI 10.1067/mai.2000.109431; Kidney JC, 1997, J ALLERGY CLIN IMMUN, V100, P65, DOI 10.1016/S0091-6749(97)70196-9; KUNA P, 2001, AM J RESP CRIT CARE, V163, pA517; Larsen BB, 2003, ALLERGY, V58, P207, DOI 10.1034/j.1398-9995.2003.00052.x; Leigh R, 2002, AM J RESP CRIT CARE, V166, P1212, DOI 10.1164/rccm.200206-509OC; Miller-Larsson A, 2000, AM J RESP CRIT CARE, V162, P1455, DOI 10.1164/ajrccm.162.4.9806112; Miller-Larsson A, 1998, DRUG METAB DISPOS, V26, P623; Noonan M, 2001, ANN ALLERG ASTHMA IM, V86, P36, DOI 10.1016/S1081-1206(10)62353-8; OBYRNE PM, 1987, AM REV RESPIR DIS, V136, P740, DOI 10.1164/ajrccm/136.3.740; Parameswaran K, 2000, Can Respir J, V7, P313; PEAT JK, 1994, J CLIN EPIDEMIOL, V47, P1099, DOI 10.1016/0895-4356(94)90096-5; Petersen H, 2001, BRIT J CLIN PHARMACO, V51, P159, DOI 10.1111/j.1365-2125.2001.01303.x; Pizzichini MMM, 1997, AM J RESP CRIT CARE, V155, P1501, DOI 10.1164/ajrccm.155.5.9154849; Swystun VA, 1998, J ALLERGY CLIN IMMUN, V102, P363, DOI 10.1016/S0091-6749(98)70121-6; Thio BJ, 2001, PEDIATR PULM, V32, P115; Thorsson L, 2001, BRIT J CLIN PHARMACO, V52, P529, DOI 10.1046/j.0306-5251.2001.01493.x; TOOGOOD JH, 1982, J ALLERGY CLIN IMMUN, V70, P288, DOI 10.1016/0091-6749(82)90065-3; Wolfe J, 2000, J ALLERGY CLIN IMMUN, V105, P1153, DOI 10.1067/mai.2000.107037; Wood LJ, 1999, AM J RESP CRIT CARE, V159, P1457, DOI 10.1164/ajrccm.159.5.9808123; ZuWallack R, 2000, CHEST, V118, P303, DOI 10.1378/chest.118.2.303	35	23	23	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2005	115	4					745	750		10.1016/j.jaci.2004.11.023	http://dx.doi.org/10.1016/j.jaci.2004.11.023			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	916GM	15805993				2022-12-18	WOS:000228373400012
J	James, SP				James, SP			Prototypic disorders of gastrointestinal mucosal immune function: Celiac disease and Crohn's disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Celiac disease; Crohn's disease; mucosal immunity; tolerance	INFLAMMATORY-BOWEL-DISEASE; GENETIC-VARIATION; STRUCTURAL BASIS; RESPONSES; PEPTIDES; GLUTENIN; CHILDREN; GLIADIN; SPRUE	Celiac disease is a disorder of the small intestine characterized by chronic inflammation of the mucosa and protean clinical manifestations caused by loss of tolerance to dietary antigens. Two strongly associated cofactors have been identified: the presence of HLA-DQ2 or HLA-DQ8 in the host and specific antigenic peptides in the diet that are present in wheat, rye, and barley. Most patients have complete remission after dietary elimination of these foods. Crohn's disease is characterized by chronic, relapsing, recurrent, focal, transmural inflammation of the gastrointestinal tract that can lead to multiple serious problems requiring chronic medical and surgical therapy. Crohn's disease is associated with multiple genetic mutations, at least one of which has been clearly implicated in innate immunity. Multiple lines of evidence suggest that the disease involves abnormal immune responses to gut microbial flora.	NIDDK, Div Digest Dis & Nutr, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	James, SP (corresponding author), NIDDK, Div Digest Dis & Nutr, 6707 Democracy Blvd,Room 677, Bethesda, MD 20892 USA.	Jamess@EXTRA.NIDDK.NIH.gov						Brant SR, 2004, INFLAMM BOWEL DIS, V10, P300, DOI 10.1097/00054725-200405000-00019; Darfeuille-Michaud A, 2004, GASTROENTEROLOGY, V127, P412, DOI 10.1053/j.gastro.2004.04.061; Dieckgraefe BK, 2002, LANCET, V360, P1478, DOI 10.1016/S0140-6736(02)11437-1; Farrell RJ, 2002, NEW ENGL J MED, V346, P180, DOI 10.1056/NEJMra010852; Hoffenberg EJ, 2003, J PEDIATR-US, V143, P308, DOI 10.1067/S0022-3476(03)00282-8; Kim CY, 2004, P NATL ACAD SCI USA, V101, P4175, DOI 10.1073/pnas.0306885101; Landers CJ, 2002, GASTROENTEROLOGY, V123, P689, DOI 10.1053/gast.2002.35379; Louka AS, 2003, TISSUE ANTIGENS, V61, P105, DOI 10.1034/j.1399-0039.2003.00017.x; Maki M, 2003, NEW ENGL J MED, V348, P2517, DOI 10.1056/NEJMoa021687; Molberg O, 1998, NAT MED, V4, P713, DOI 10.1038/nm0698-713; Molberg O, 2003, GASTROENTEROLOGY, V125, P337, DOI 10.1016/S0016-5085(03)00890-4; Naser SA, 2004, LANCET, V364, P1039, DOI 10.1016/S0140-6736(04)17058-X; *NIH, 2004, CONS DEV C CEL DIS J; Panaccione R, 2004, CAN J GASTROENTEROL, V18, P503, DOI 10.1155/2004/670161; Peltekova VD, 2004, NAT GENET, V36, P471, DOI 10.1038/ng1339; Podolsky DK, 2002, NEW ENGL J MED, V347, P417, DOI 10.1056/NEJMra0804647; Rioux JD, 2001, NAT GENET, V29, P223, DOI 10.1038/ng1001-223; Sandborn W, 2004, GASTROENTEROLOGY, V127, P332, DOI 10.1053/j.gastro.2004.05.009; Shan L, 2002, SCIENCE, V297, P2275, DOI 10.1126/science.1074129; Stoll M, 2004, NAT GENET, V36, P476, DOI 10.1038/ng1345; Strober W, 2002, ANNU REV IMMUNOL, V20, P495, DOI 10.1146/annurev.immunol.20.100301.064816; Vader W, 2002, GASTROENTEROLOGY, V122, P1729, DOI 10.1053/gast.2002.33606; van de Wal Y, 1999, EUR J IMMUNOL, V29, P3133, DOI 10.1002/(SICI)1521-4141(199910)29:10&lt;3133::AID-IMMU3133&gt;3.0.CO;2-G; Watanabe T, 2004, NAT IMMUNOL, V5, P800, DOI 10.1038/ni1092	24	23	25	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2005	115	1					25	30		10.1016/j.jaci.2004.11.011	http://dx.doi.org/10.1016/j.jaci.2004.11.011			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	886XS	15637543				2022-12-18	WOS:000226267000003
J	Chen, H; Katz, PP; Eisner, MD; Yelin, EH; Blanc, PD				Chen, H; Katz, PP; Eisner, MD; Yelin, EH; Blanc, PD			Health-related quality of life in adult rhinitis: The role of perceived control of disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						rhinitis; rhinosinusitis; quality of life; symptom score; perceived control; measurement; questionnaire; validation	ASTHMA; HELPLESSNESS; VALIDATION; ARTHRITIS	Background: Factors affecting health-related quality of life (HRQOL) in adult rhinitis have not been well described. Objective: To understand how symptom severity, physical functioning, psychological distress, and perceived control of disease relate to HRQOL in a population-based sample of adults with rhinitis. Methods: We conducted telephone interviews in 109 adults with rhinitis recruited via random digit dialing. We assessed HRQOL by using the Rhinosinusitis Disability Index, physical functioning by using the physical component score of the Short Form-12, and psychological distress by using the Center for Epidemiologic Studies Depression Scale. To evaluate the role of patient-perceived control of disease in rhinitis, we developed a new 8-item instrument, the Perceived Control of Rhinitis Questionnaire. Results: Lower HRQOL correlated with greater symptom severity (r = 0.57), poorer physical functioning (r = -0.41), greater psychological distress (r = 0.44), and less perceived control (r = -0.53). In a multivariate model, symptom severity (P < .001), psychological distress (P < .001), and perceived control (P < .001) were all independent predictors of HRQOL. Adding functional and psychosocial measures to a base model with demographics and disease severity explained an additional 26% of variance in HRQOL. Conclusions: Although disease severity is an important factor in HRQOL, psychosocial factors, such as perceived control of disease, explain a substantial amount of the variability in HRQOL among adults with rhinitis.	Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Inst Cardiovasc Res, San Francisco, CA 94143 USA; Univ Calif San Francisco, Inst Hlth Policy Studies, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Chen, H (corresponding author), 350 Parnassus Ave,Ste 609, San Francisco, CA 94143 USA.	hubertc@medicine.ucsf.edu		Chen, Hubert/0000-0002-6630-239X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007185] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32HL07185] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Benninger MS, 1997, ARCH OTOLARYNGOL, V123, P1175; Birch DS, 2001, RHINOLOGY, V39, P191; Blanc PD, 2001, J CLIN EPIDEMIOL, V54, P610, DOI 10.1016/S0895-4356(00)00349-8; Juniper EF, 1997, J ALLERGY CLIN IMMUN, V99, pS742, DOI 10.1016/S0091-6749(97)90000-2; Katz PP, 2002, ANN ALLERG ASTHMA IM, V89, P251, DOI 10.1016/S1081-1206(10)61951-5; Krouse JH, 2000, OTOLARYNG HEAD NECK, V123, P389, DOI 10.1067/mhn.2000.109476; NICASSIO PM, 1985, J RHEUMATOL, V12, P462; ORME JG, 1986, J CLIN PSYCHOL, V42, P28, DOI 10.1002/1097-4679(198601)42:1<28::AID-JCLP2270420104>3.0.CO;2-T; Pleis John R, 2003, Vital Health Stat 10, P1; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Rhee JS, 2003, LARYNGOSCOPE, V113, P1118, DOI 10.1097/00005537-200307000-00004; Senior BA, 2001, AM J RHINOL, V15, P15, DOI 10.2500/105065801781329428; STEIN MJ, 1988, ARTHRITIS RHEUM, V31, P876, DOI 10.1002/art.1780310708; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; Wasserfallen JB, 1997, J ALLERGY CLIN IMMUN, V100, P16, DOI 10.1016/S0091-6749(97)70189-1; WEISSMAN MM, 1977, AM J EPIDEMIOL, V106, P203, DOI 10.1093/oxfordjournals.aje.a112455	16	23	24	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2004	114	4					845	850		10.1016/j.jaci.2004.07.008	http://dx.doi.org/10.1016/j.jaci.2004.07.008			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	861SO	15480325				2022-12-18	WOS:000224439100019
J	Luo, ZH; Ronai, D; Scharff, MD				Luo, ZH; Ronai, D; Scharff, MD			The role of activation-induced cytidine deaminase in antibody diversification, immunodeficiency, and B-cell malignancies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						activation-induced cytidine deaminase; somatic hypermutation; class-switch recombination; immunodeficiency; lymphoma	CLASS-SWITCH RECOMBINATION; DOUBLE-STRAND BREAKS; AUTOSOMAL RECESSIVE FORM; HYPER-IGM SYNDROME; S-MU REGION; SOMATIC HYPERMUTATION; IMMUNOGLOBULIN GENES; NEGATIVE AUTOREGULATION; DNA DEAMINATION; VARIABLE REGION	Before exposure to antigen, antibodies with a wide diversity of antigen-binding sites are created by V(D)J rearrangement. After exposure to antigen, further diversification is accomplished by means of somatic hypermutation of the antibody variable region genes and class-switch recombination between the heavy-chain lit constant region and the downstream 7, E, and a constant region. The variable region mutations are responsible for the affinity maturation of the antibody response, whereas class-switch recombination enables the antibodies to be distributed throughout the body and to carry out different effector functions. Both somatic mutation and class switching require an enzyme called activation-induced cytidine deaminase (AID) that converts deoxycytidines to deoxyuracils on single-stranded DNA. Genetic defects of AID in human subjects result in hyper-IgM syndrome type 2. The analysis of both mutant mice and immunodeficient patients has led to a better understanding of the mechanism of action and role of AID in immunity, as well as in the malignant transformation of B cells.	Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Scharff, MD (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, 1300 Morris Pk Ave,Chanin 403, Bronx, NY 10461 USA.	Scharff@aecom.yu.edu			NCI NIH HHS [CA 102705, CA 72649] Funding Source: Medline; NIAID NIH HHS [AI 43937] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA102705, R01CA072649] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043937] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Albesiano E, 2003, BLOOD, V102, P3333, DOI 10.1182/blood-2003-05-1585; Babbage G, 2004, BLOOD, V103, P2795, DOI 10.1182/blood-2003-05-1632; Barreto V, 2003, MOL CELL, V12, P501, DOI 10.1016/S1097-2765(03)00309-5; Bransteitter R, 2003, P NATL ACAD SCI USA, V100, P4102, DOI 10.1073/pnas.0730835100; Bross L, 2000, IMMUNITY, V13, P589, DOI 10.1016/S1074-7613(00)00059-5; Capello D, 2000, BLOOD, V95, P651; Catalan N, 2003, J IMMUNOL, V171, P2504, DOI 10.4049/jimmunol.171.5.2504; Chaudhuri J, 2004, NATURE, V430, P992, DOI 10.1038/nature02821; Chaudhuri J, 2003, NATURE, V422, P726, DOI 10.1038/nature01574; Chaudhuri J, 2004, NAT REV IMMUNOL, V4, P541, DOI 10.1038/nri1395; Coker HA, 2003, J IMMUNOL, V171, P5602, DOI 10.4049/jimmunol.171.10.5602; Di Noia J, 2002, NATURE, V419, P43, DOI 10.1038/nature00981; Dickerson SK, 2003, J EXP MED, V197, P1291, DOI 10.1084/jem.20030481; Fagarasan S, 2004, CURR OPIN IMMUNOL, V16, P277, DOI 10.1016/j.coi.2004.03.005; Fagarasan S, 2002, SCIENCE, V298, P1424, DOI 10.1126/science.1077336; Faili A, 2002, NAT IMMUNOL, V3, P815, DOI 10.1038/ni826; Ferrari S, 2001, P NATL ACAD SCI USA, V98, P12614, DOI 10.1073/pnas.221456898; Fukita Y, 1998, IMMUNITY, V9, P105, DOI 10.1016/S1074-7613(00)80592-0; Fukuda T, 1997, J EXP MED, V186, P439, DOI 10.1084/jem.186.3.439; Gordon MS, 2003, P NATL ACAD SCI USA, V100, P4126, DOI 10.1073/pnas.0735266100; Greeve J, 2003, BLOOD, V101, P3574, DOI 10.1182/blood-2002-08-2424; Harada Y, 2003, J EXP MED, V197, P1779, DOI 10.1084/jem.20021457; Hein K, 1998, J EXP MED, V188, P2369, DOI 10.1084/jem.188.12.2369; Imai K, 2003, NAT IMMUNOL, V4, P1023, DOI 10.1038/ni974; JOHNSTON JM, 1992, LEUKEMIA LYMPHOMA, V8, P431, DOI 10.3109/10428199209051025; Jolly C J, 1996, Semin Immunol, V8, P159, DOI 10.1006/smim.1996.0020; Kelsoe G, 1996, Semin Immunol, V8, P179, DOI 10.1006/smim.1996.0022; Kenter AL, 2003, CURR OPIN IMMUNOL, V15, P190, DOI 10.1016/S0952-7915(03)00018-9; Kinoshita K, 2001, NAT REV MOL CELL BIO, V2, P493, DOI 10.1038/35080033; Kuppers R, 1999, NEW ENGL J MED, V341, P1520; Kuppers R, 1999, CURR TOP MICROBIOL, V246, P193; Lee CG, 2001, J EXP MED, V194, P365, DOI 10.1084/jem.194.3.365; Li ZQ, 2004, GENE DEV, V18, P1, DOI 10.1101/gad.1161904; Litinskiy MB, 2002, NAT IMMUNOL, V3, P822, DOI 10.1038/ni829; Liu YJ, 1996, IMMUNITY, V4, P603, DOI 10.1016/S1074-7613(00)80486-0; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.immunol.12.1.117; Mao CC, 2004, IMMUNITY, V20, P133, DOI 10.1016/S1074-7613(04)00019-6; Martin A, 2002, NAT REV IMMUNOL, V2, P605, DOI 10.1038/nri858; Martin A, 2002, NATURE, V415, P802, DOI 10.1038/nature714; McCarthy H, 2003, BLOOD, V101, P4903, DOI 10.1182/blood-2002-09-2906; Milstein C, 1998, P NATL ACAD SCI USA, V95, P8791, DOI 10.1073/pnas.95.15.8791; Minegishi Y, 2000, CLIN IMMUNOL, V97, P203, DOI 10.1006/clim.2000.4956; Mostoslavsky R, 2003, NAT IMMUNOL, V4, P603, DOI 10.1038/ni0703-603; Muramatsu M, 1999, J BIOL CHEM, V274, P18470, DOI 10.1074/jbc.274.26.18470; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Nagaoka H, 2002, J EXP MED, V195, P529, DOI 10.1084/jem.20012144; Nambu Y, 2003, SCIENCE, V302, P2137, DOI 10.1126/science.1092481; NAVARATNAM N, 1993, J BIOL CHEM, V268, P20709; Navaratnam N, 1998, J MOL BIOL, V275, P695, DOI 10.1006/jmbi.1997.1506; Okazaki I, 2003, J EXP MED, V197, P1173, DOI 10.1084/jem.20030275; Okazaki IM, 2002, NATURE, V416, P340, DOI 10.1038/nature727; Papavasiliou FN, 2002, CELL, V109, pS35, DOI 10.1016/S0092-8674(02)00706-7; Pasqualucci L, 2003, BLOOD, V101, P2914, DOI 10.1182/blood-2002-11-3387; Pasqualucci L, 2001, NATURE, V412, P341, DOI 10.1038/35085588; Pasqualucci L, 1998, P NATL ACAD SCI USA, V95, P11816, DOI 10.1073/pnas.95.20.11816; Peters A, 1996, IMMUNITY, V4, P57, DOI 10.1016/S1074-7613(00)80298-8; Petersen S, 2001, NATURE, V414, P660, DOI 10.1038/414660a; Petersen-Mahrt SK, 2002, NATURE, V418, P99, DOI 10.1038/nature00862; Pham P, 2003, NATURE, V424, P103, DOI 10.1038/nature01760; Poltoratsky V, 2000, J EXP MED, V192, pF27, DOI 10.1084/jem.192.10.F27; Quartier P, 2004, CLIN IMMUNOL, V110, P22, DOI 10.1016/j.clim.2003.10.007; Rada C, 1998, IMMUNITY, V9, P135, DOI 10.1016/S1074-7613(00)80595-6; Rada C, 2001, EMBO J, V20, P4570, DOI 10.1093/emboj/20.16.4570; Rada C, 2002, CURR BIOL, V12, P1748, DOI 10.1016/S0960-9822(02)01215-0; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; Reina-San-Martin B, 2003, J EXP MED, V197, P1767, DOI 10.1084/jem.20030569; Revy P, 2000, CELL, V102, P565, DOI 10.1016/S0092-8674(00)00079-9; Rogozin IB, 2004, J IMMUNOL, V172, P3382, DOI 10.4049/jimmunol.172.6.3382; ROGOZIN IB, 1992, BIOCHIM BIOPHYS ACTA, V1171, P11, DOI 10.1016/0167-4781(92)90134-L; Rush JS, 2004, INT IMMUNOL, V16, P549, DOI 10.1093/intimm/dxh057; Schrader CE, 2003, EMBO J, V22, P5893, DOI 10.1093/emboj/cdg550; Shen HM, 1998, SCIENCE, V280, P1750, DOI 10.1126/science.280.5370.1750; Shen HM, 2000, INT IMMUNOL, V12, P1085, DOI 10.1093/intimm/12.7.1085; Shinkura R, 2004, NAT IMMUNOL, V5, P707, DOI 10.1038/ni1086; Shinkura R, 2003, NAT IMMUNOL, V4, P435, DOI 10.1038/ni918; SISKIND GREGORY W., 1965, J IMMUNOL, V95, P436; Sohail A, 2003, NUCLEIC ACIDS RES, V31, P2990, DOI 10.1093/nar/gkg464; Stavnezer J, 2000, CURR TOP MICROBIOL, V245, P127; Storb U, 1998, IMMUNOL REV, V162, P153; Ta VT, 2003, NAT IMMUNOL, V4, P843, DOI 10.1038/ni964; Wang X, 2002, P NATL ACAD SCI USA, V99, P15018, DOI 10.1073/pnas.232581199; WEIGERT M, 1986, PROGR IMMUNOLOGY, V6, P138; WEIGERT MG, 1970, NATURE, V228, P1045, DOI 10.1038/2281045a0; William J, 2002, SCIENCE, V297, P2066, DOI 10.1126/science.1073924; Woo CJ, 2003, IMMUNITY, V19, P479, DOI 10.1016/S1074-7613(03)00261-9; Ye BH, 1997, NAT GENET, V16, P161, DOI 10.1038/ng0697-161; Yoshikawa K, 2002, SCIENCE, V296, P2033, DOI 10.1126/science.1071556; Yu KF, 2003, NAT IMMUNOL, V4, P442, DOI 10.1038/ni919; Zan H, 2003, IMMUNITY, V18, P727, DOI 10.1016/S1074-7613(03)00151-1; Zeng XM, 2001, NAT IMMUNOL, V2, P537, DOI 10.1038/88740; Zhang K, 2003, J LEUKOCYTE BIOL, V73, P323, DOI 10.1189/jlb.0702339; Zhou C, 2003, J IMMUNOL, V170, P1887, DOI 10.4049/jimmunol.170.4.1887; Zhu Yi, 2003, Journal of Medical and Dental Sciences, V50, P41	94	23	25	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2004	114	4					726	735		10.1016/j.jaci.2004.07.049	http://dx.doi.org/10.1016/j.jaci.2004.07.049			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	861SO	15480307				2022-12-18	WOS:000224439100002
J	Hendeles, L; Beaty, R; Ahrens, R; Stevens, G; Harman, EM				Hendeles, L; Beaty, R; Ahrens, R; Stevens, G; Harman, EM			Response to inhaled albuterol during nocturnal asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						bronchodilator agents; adrenergic beta-agonists; dose-response; bronchospasm	METERED-DOSE INHALER; HISTAMINE; SALBUTAMOL; BETA(2)-AGONISTS; TURBUHALER(R); EPINEPHRINE; EQUIVALENT; RECEPTORS; EFFICACY; POTENCY	Background: During conventional daytime studies of beta(2)-agonists, 1 puff of a metered-dose inhaler often produces a near maximum bronchodilator response. Consequently, the US Food and Drug Administration-approved dose of albuterol is only 1 to 2 puffs every 4 to 6 hours. Objective: To determine whether a higher dose of albuterol is required to normalize lung function during nocturnal asthma. Methods: Fifteen subjects (age, 18-37 years) were treated with albuterol metered-dose inhalers in a randomized crossover manner at the onset of nocturnal symptoms while sleeping in the Clinical Research Center and during the day when they were asymptomatic. The dose was doubled at 15-minute intervals to 16 cumulative puffs. Results: The mean +/- SD predose FEV1 was lower at night than during the day (44% +/- 12% vs 68% +/- 9% predicted; P = .0001). The maximum FEV1 achieved was also lower at night (84% +/- 15% vs 90% +/- 12%; P = .02). The nocturnal dose-response curve was shifted to the right. The median (25th, 75th percentiles) dose required to achieve 80% of the subject's personal best FEV1 was substantially higher at night (5 [1, 19] vs 0.4 [<0.25, 2] puffs; P = .02), and the median time to achieve this endpoint was longer (47 [21, 90] vs 10 [0.2, 42] minutes; P = .005). No significant systemic effects were observed. Conclusion: At night, the response was slower and required a higher dose because more severe airway obstruction was present on awakening. These results suggest that studies establishing the clinical dose of a beta(2)-agonist or assessing the equivalence of different formulations should be conducted in subjects with more severe reversible airway obstruction than is present during conventional daytime studies.	Univ Florida, Hlth Sci Ctr, Coll Pharm, Gainesville, FL 32610 USA; Univ Florida, Div Pulm, Dept Pediat, Gainesville, FL 32610 USA; Univ Florida, Dept Stat, Gainesville, FL 32610 USA; Univ Florida, Div Pulm & Crit Care Med, Dept Med, Gainesville, FL 32610 USA; Pul Associates SE, PC, Birmingham, AL USA; Univ Iowa, Dept Pediat, Pediat Allergy & Pulm Div, Iowa City, IA 52242 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; University of Iowa	Hendeles, L (corresponding author), Univ Florida, Hlth Sci Ctr, Coll Pharm, POB 100486,1600 SW Archer Rd,Room MG-57, Gainesville, FL 32610 USA.	hendeles@cop.ufl.edu			NCRR NIH HHS [M01 RR 00082] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000082] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AHRENS RC, 1987, J ALLERGY CLIN IMMUN, V79, P876, DOI 10.1016/0091-6749(87)90235-1; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; BARNES P, 1980, NEW ENGL J MED, V303, P263, DOI 10.1056/NEJM198007313030506; BARNES PJ, 1982, CLIN SCI, V62, P349, DOI 10.1042/cs0620349; BLAKE KV, 1992, CHEST, V101, P309, DOI 10.1378/chest.101.2.309; Bondesson E, 1998, RESP MED, V92, P325, DOI 10.1016/S0954-6111(98)90116-0; Carlsson LG, 1998, ALLERGY, V53, P712, DOI 10.1111/j.1398-9995.1998.tb03959.x; Creticos PS, 2002, J ALLERGY CLIN IMMUN, V110, P713, DOI 10.1067/mai.2002.129036; EKSTROM T, 1995, ANN ALLERG ASTHMA IM, V74, P328; FINNEY DJ, 1978, STAT METHODS BIOL AS, P211; Fishwick D, 2001, AM J RESP CRIT CARE, V163, P474, DOI 10.1164/ajrccm.163.2.2003027; HULTQUIST C, 1989, ALLERGY, V44, P467, DOI 10.1111/j.1398-9995.1989.tb04184.x; IDRIS AH, 1993, CHEST, V103, P665, DOI 10.1378/chest.103.3.665; JENNE JW, 1987, J APPL PHYSIOL, V63, P812, DOI 10.1152/jappl.1987.63.2.812; MARTIN RJ, 1991, AM REV RESPIR DIS, V143, P351, DOI 10.1164/ajrccm/143.2.351; Mellen A, 1999, AM J RESP CRIT CARE, V159, P1663, DOI 10.1164/ajrccm.159.5.9801061; MORRIS JF, 1971, AM REV RESPIR DIS, V103, P57; *NIH, 1997, NIH PUBL, P60; Parameswaran KN, 1999, AM J RESP CRIT CARE, V160, P354, DOI 10.1164/ajrccm.160.1.9812035; Roux FJ, 1996, AM J RESP CRIT CARE, V153, P1489, DOI 10.1164/ajrccm.153.5.8630591; *SAS I, 2000, SAS AN SYST VERS 8; SZEFLER SJ, 1991, CLIN PHARMACOL THER, V49, P59, DOI 10.1038/clpt.1991.11; WINDOM HH, 1990, NEW ZEAL MED J, V103, P205; 2001, PHYS DESK REFERENCE, P1680	24	23	23	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2004	113	6					1058	1062		10.1016/j.jaci.2004.03.046	http://dx.doi.org/10.1016/j.jaci.2004.03.046			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	829ZI	15208585				2022-12-18	WOS:000222091000009
J	Chinen, J; Puck, JM				Chinen, J; Puck, JM			Successes and risks of gene therapy in primary immunodeficiencies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						primary immunodeficiency; gene therapy; insertional mutagenesis; retroviral vector; LMO2; X-linked severe combined immunodeficiency; adenosine deaminase; severe combined immunodeficiency	WISKOTT-ALDRICH-SYNDROME; STEM-CELL TRANSPLANTATION; HEMATOPOIETIC PROGENITOR CELLS; CHRONIC GRANULOMATOUS-DISEASE; ADENOSINE-DEAMINASE; T-CELL; BONE-MARROW; SUSTAINED CORRECTION; DEFICIENT MICE; CD34(+) CELLS	Several primary immunodeficiencies are under consideration for gene therapy approaches because of limitations of current standard treatment. Many primary immunodeficiencies are caused by defects in single genes expressed in blood cells; thus addition of a correct copy of the gene to hematopoietic stem cells (HSCs) can generate immune cells with restored function. HSCs can be removed from a patient, treated outside the body, and reinfused. In the last decade, significant improvements have been made in transferring genes by means of retroviruses to HSCs in vitro, and gene therapy trials for patients with X-linked severe combined immunodeficiency (XSCID) and adenosine deaminase-deficient severe combined immunodeficiency have restored immune competence. Gene therapy is actively being pursued in other immunodeficiency disorders, including chronic granulomatous disease and Wiskott-Aldrich syndrome. However, enthusiasm for the correction of XSCID by means of gene therapy has been tempered by the occurrence of 2 cases of leukemia in gene therapy recipients caused by insertion of the retroviral vector in or near the oncogene LMO2. The likelihood of retroviral insertional mutagenesis was estimated to be very low in the past on the basis of theoretic calculations and the absence of observed malignancies in animal studies and early clinical trials. Emerging new findings on retroviral integration both in the patients with XSCID and experimental animals now indicate that the insertion of retroviral sequences into the genome carries significant risk. Understanding the magnitude of risk is now a priority so that safety can be improved for future gene therapy clinical trials.	NHGRI, Genet & Mol Biol Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Puck, JM (corresponding author), NHGRI, Genet & Mol Biol Branch, NIH, Bldg 49,Rm 4A14,49 Convent Dr, Bethesda, MD 20892 USA.				NATIONAL HUMAN GENOME RESEARCH INSTITUTE [Z01HG000010] Funding Source: NIH RePORTER	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Aiuti A, 2002, SCIENCE, V296, P2410, DOI 10.1126/science.1070104; Aiuti A, 2003, BLOOD, V102, p154A; Antoine C, 2003, LANCET, V361, P553, DOI 10.1016/S0140-6736(03)12513-5; Bauer TR, 2000, CURR OPIN MOL THER, V2, P383; BELMONT JW, 1986, NATURE, V322, P385, DOI 10.1038/322385a0; BLAESE RM, 1995, SCIENCE, V270, P475, DOI 10.1126/science.270.5235.475; BORDIGNON C, 1995, SCIENCE, V270, P470, DOI 10.1126/science.270.5235.470; Brenner S, 2003, BBA-MOL CELL RES, V1640, P1, DOI 10.1016/S0167-4889(03)00024-7; Brown MP, 1998, NAT MED, V4, P1253, DOI 10.1038/3233; Buckley RH, 1999, PRIMARY IMMUNODEFICIENCY DISEASES, P459; Buckley RH, 1999, NEW ENGL J MED, V340, P508, DOI 10.1056/NEJM199902183400703; Buckley RH, 1997, J PEDIATR-US, V130, P378, DOI 10.1016/S0022-3476(97)70199-9; Buckley RH, 2002, IMMUNOL REV, V185, P206, DOI 10.1034/j.1600-065X.2002.18517.x; Bunting KD, 2000, HUM GENE THER, V11, P2353, DOI 10.1089/104303400750038462; Candotti F, 1999, GENE THER, V6, P1170, DOI 10.1038/sj.gt.3300926; Candotti F, 1996, BLOOD, V87, P3097, DOI 10.1182/blood.V87.8.3097.bloodjournal8783097; Cavazzana-Calvo M, 2000, SCIENCE, V288, P669, DOI 10.1126/science.288.5466.669; Chapel H, 2003, CLIN EXP IMMUNOL, V132, P9, DOI 10.1046/j.1365-2249.2003.02110.x; Cooper Max D, 2003, Hematology Am Soc Hematol Educ Program, P314; Dadi HK, 2003, NEW ENGL J MED, V349, P1821, DOI 10.1056/NEJMoa031178; Dinauer MC, 1999, BLOOD, V94, P914, DOI 10.1182/blood.V94.3.914.415a11_914_922; Emery DW, 2000, P NATL ACAD SCI USA, V97, P9150, DOI 10.1073/pnas.160159597; Etzioni A, 1999, PRIMARY IMMUNODEFICIENCY DISEASES, P375; Filipovich AH, 2001, BLOOD, V97, P1598, DOI 10.1182/blood.V97.6.1598; Frank J, 1999, NATURE, V398, P473, DOI 10.1038/18997; Gaspar HB, 2003, GENE THER, V10, P1999, DOI 10.1038/sj.gt.3302150; GATTI RA, 1968, LANCET, V2, P1366; Hacein-Bey-Abina S, 2002, NEW ENGL J MED, V346, P1185, DOI 10.1056/NEJMoa012616; Hacein-Bey-Abina S, 2003, SCIENCE, V302, P415, DOI 10.1126/science.1088547; Hacein-Bey-Abina S, 2003, NEW ENGL J MED, V348, P255, DOI 10.1056/NEJM200301163480314; HaceinBey S, 1996, BLOOD, V87, P3108, DOI 10.1182/blood.V87.8.3108.bloodjournal8783108; Hay BN, 2002, BLOOD, V100, p464A; Heim DA, 2000, IMMUNOL REV, V178, P29, DOI 10.1034/j.1600-065X.2000.17802.x; HERSHFIELD MS, 1987, NEW ENGL J MED, V316, P589, DOI 10.1056/NEJM198703053161005; Hirschhorn R, 1999, PRIMARY IMMUNODEFICIENCY DISEASES, P121; Hoogerbrugge PM, 1996, GENE THER, V3, P179; Horwitz ME, 2001, NEW ENGL J MED, V344, P881, DOI 10.1056/NEJM200103223441203; KANTOFF PW, 1986, P NATL ACAD SCI USA, V83, P6563, DOI 10.1073/pnas.83.17.6563; KOHN DB, 1995, NAT MED, V1, P1017, DOI 10.1038/nm1095-1017; Kohn DB, 2003, MOL THER, V8, P180, DOI 10.1016/S1525-0016(03)00212-0; Kohn DB, 1998, NAT MED, V4, P775, DOI 10.1038/nm0798-775; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Liles WC, 2003, BLOOD, V102, P2728, DOI 10.1182/blood-2003-02-0663; MACCHI P, 1995, NATURE, V377, P65, DOI 10.1038/377065a0; Malech HL, 1997, P NATL ACAD SCI USA, V94, P12133, DOI 10.1073/pnas.94.22.12133; Mardiney M, 1997, BLOOD, V89, P2268, DOI 10.1182/blood.V89.7.2268; Muul LM, 2003, BLOOD, V101, P2563, DOI 10.1182/blood-2002-09-2800; Myers LA, 2002, BLOOD, V99, P872, DOI 10.1182/blood.V99.3.872; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; Notarangelo LD, 2003, CURR OPIN IMMUNOL, V15, P585, DOI 10.1016/S0952-7915(03)00112-2; Otsu M, 2000, MOL THER, V1, P145, DOI 10.1006/mthe.1999.0020; Patel DD, 2000, NEW ENGL J MED, V342, P1325, DOI 10.1056/NEJM200005043421804; Porpiglia AS, 2003, CLIN IMMUNOL, V107, P90, DOI 10.1016/S1521-6616(03)00044-5; PUCK JM, 1993, HUM MOL GENET, V2, P1099, DOI 10.1093/hmg/2.8.1099; PUCK JM, 1987, J CLIN INVEST, V79, P1395, DOI 10.1172/JCI112967; PUCK JM, 1990, BLOOD, V75, P2369; Puck JM, 1999, PRIMARY IMMUNODEFICIENCY DISEASES, P99; Quartier P, 1999, J PEDIATR-US, V134, P589, DOI 10.1016/S0022-3476(99)70246-5; Rabbitts TH, 1999, CANCER RES, V59, p1794S; REISNER Y, 1983, BLOOD, V61, P341; Ridanpaa M, 2001, CELL, V104, P195, DOI 10.1016/S0092-8674(01)00205-7; Rivella S, 2000, J VIROL, V74, P4679, DOI 10.1128/JVI.74.10.4679-4687.2000; Rohrer J, 1999, BLOOD, V94, P3358, DOI 10.1182/blood.V94.10.3358.422k04_3358_3365; Roos D, 1996, BLOOD, V87, P1663; Sacco MG, 2000, CANCER GENE THER, V7, P1299, DOI 10.1038/sj.cgt.0234; Schad M, 2002, BLOOD, V100, p319A; Schroder ARW, 2002, CELL, V110, P521, DOI 10.1016/S0092-8674(02)00864-4; Segal BH, 2000, MEDICINE, V79, P170, DOI 10.1097/00005792-200005000-00004; Sekhsaria S, 1996, BLOOD, V88, P1104; Smith CIE, 1999, PRIMARY IMMUNODEFICIENCY DISEASES, P3; Smogorzewska Elzbieta M., 2000, Archivum Immunologiae et Therapiae Experimentalis, V48, P111; Snapper SB, 1998, IMMUNITY, V9, P81, DOI 10.1016/S1074-7613(00)80590-7; Soudais C, 2000, BLOOD, V95, P3071, DOI 10.1182/blood.V95.10.3071.010k06_3071_3077; Stephan V, 1996, NEW ENGL J MED, V335, P1563, DOI 10.1056/NEJM199611213352104; Stiehm ER, 1999, PRIMARY IMMUNODEFICIENCY DISEASES, P448; Strom TS, 2003, GENE THER, V10, P803, DOI 10.1038/sj.gt.3301950; Taylor N, 1996, BLOOD, V87, P3103, DOI 10.1182/blood.V87.8.3103.bloodjournal8783103; Thomas CE, 2003, NAT REV GENET, V4, P346, DOI 10.1038/nrg1066; Tomaske M, 2003, BRIT J HAEMATOL, V121, P886, DOI 10.1046/j.1365-2141.2003.04390.x; Tsai EJ, 2002, BLOOD, V100, P72, DOI 10.1182/blood.V100.1.72; Tuschong L, 2002, HUM GENE THER, V13, P1605, DOI 10.1089/10430340260201699; Wada T, 2002, HUM GENE THER, V13, P1039, DOI 10.1089/104303402753812449; Wada T, 2001, P NATL ACAD SCI USA, V98, P8697, DOI 10.1073/pnas.151260498; Wu XL, 2003, SCIENCE, V300, P1749, DOI 10.1126/science.1083413; Yates F, 2002, BLOOD, V100, P3942, DOI 10.1182/blood-2002-03-0782	85	23	24	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2004	113	4					595	603		10.1016/j.jaci.2004.01.765	http://dx.doi.org/10.1016/j.jaci.2004.01.765			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	814DY	15100660	Green Published			2022-12-18	WOS:000220956600002
J	Kranke, B; Sturm, G; Aberer, W				Kranke, B; Sturm, G; Aberer, W			Negative venom skin test results and mastocytosis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							IMMUNOTHERAPY		Graz Univ, Dept Dermatol & Venereol, A-8036 Graz, Austria	University of Graz	Kranke, B (corresponding author), Graz Univ, Dept Dermatol & Venereol, Auenbruggerpl 8, A-8036 Graz, Austria.							Fricker M, 1997, J ALLERGY CLIN IMMUN, V100, P11, DOI 10.1016/S0091-6749(97)70188-X; Golden DBK, 2003, J ALLERGY CLIN IMMUN, V112, P495, DOI [10.1067/mai.2003.1606, 10.1016/S0091-6749(03)01537-9]; Rueff F, 2001, J ALLERGY CLIN IMMUN, V108, P1027, DOI 10.1067/mai.2001.119154; Schwartz LB, 1995, J CLIN INVEST, V96, P2702, DOI 10.1172/JCI118337	4	23	24	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2004	113	1					180	181		10.1016/j.jaci.2003.10.013	http://dx.doi.org/10.1016/j.jaci.2003.10.013			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	760MP	14713932				2022-12-18	WOS:000187837900031
J	Laaksonen, K; Junikka, M; Lahesmaa, R; Terho, EO; Savolainen, J				Laaksonen, K; Junikka, M; Lahesmaa, R; Terho, EO; Savolainen, J			In vitro allergen-induced mRNA expression of signaling lymphocytic activation molecule by PBMC of patients with allergic rhinitis is increased during specific pollen immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						specific immunotherapy; allergen-induced; SLAM; T-bet; IL-12R beta 2	T-CELL-ACTIVATION; CYTOKINE PRODUCTION; DENDRITIC CELLS; NASAL-MUCOSA; TH1; RESPONSES; EFFICACY; EOSINOPHILS; PATTERN; GAMMA	Background: Specific immunotherapy (SIT) acts by inducing ashift from T(H)2 to Till cell response on mucous membranes, reducing allergic inflammation. New genes expressed primarily in T(H)1-type cells have been found. Of these genes, signaling lymphocytic activation molecule (SLAM) promotes T-cell proliferation and IFN-gamma production. Nothing is known about its role in T(H)2-T(H)1 switch during SIT. Objective: We sought to analyze the mRNA expression of SLAM and other T(H)1-associated genes, interleukin-12 receptor beta2 (IL-12Rbeta2) and T-box expressed in T cells (T-bet), and compare them with the clinical outcome of the therapy. Methods: PBMC from 30 patients allergic to pollen undergoing SIT were collected during the therapy. Control PBMC were collected from 10 patients with allergic rhinitis not participating in SIT and from 10 nonallergic subjects. Cells were stimulated in vitro with pollen allergen extracts. SLAM, IL-12Rbeta2, and T-bet mRNA expressions were studied by real-time quantitative RT-PCR technique (Taqman). Symptom scoring and medication scoring were registered before commencement of SIT and after 1 year of the therapy. Results: Before the treatment in vitro allergen-induced SLAM mRNA expression in PBMC was significantly lower in the patients with allergic rhinitis than in the healthy control subjects. After 1 year of the treatment, SLAM mRNA expression was increased in the patients undergoing SIT and was associated with IFN-gamma mRNA expression and inversely associated with the symptom improvement. At the maintenance dose, an increase in SLAM mRNA expression was associated with the clinical symptom improvement at 1 year. No changes were seen in IL-12Rbeta(2) or T-bet mRNA expressions. Conclusions: SLAM mRNA expression in PBMC is modulated during the course of SIT, and an early and transient increase of SLAM mRNA expression is associated with clinical symptom improvement.	Turku Univ, Dept Pulm Dis & Clin Allergol Med, Turku 20520, Finland; Univ Turku, Turku Ctr Biotechnol, SF-20500 Turku, Finland; Abo Akad Univ, Turku, Finland	University of Turku; University of Turku; Abo Akademi University	Savolainen, J (corresponding author), Turku Univ, Dept Pulm Dis & Clin Allergol Med, Tykistokatu 6A, Turku 20520, Finland.		Savolainen, Johannes/D-2241-2011					Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Aversa G, 1997, IMMUNOL CELL BIOL, V75, P202, DOI 10.1038/icb.1997.30; Bleharski JR, 2001, J IMMUNOL, V167, P3174, DOI 10.4049/jimmunol.167.6.3174; BOUSQUET J, 1988, J ALLERGY CLIN IMMUN, V82, P439, DOI 10.1016/0091-6749(88)90017-6; Bousquet J, 1998, ALLERGY, V53, P4; Carballido JM, 1997, J IMMUNOL, V159, P4316; Castro AG, 1999, J IMMUNOL, V163, P5860; COCKS BG, 1995, NATURE, V376, P260, DOI 10.1038/376260a0; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Durham SR, 1996, J ALLERGY CLIN IMMUN, V97, P1356, DOI 10.1016/S0091-6749(96)70205-1; Ebner C, 1997, CLIN EXP ALLERGY, V27, P1007, DOI 10.1111/j.1365-2222.1997.tb01252.x; Ferrante P, 1998, J IMMUNOL, V160, P1514; Garcia VE, 2001, J IMMUNOL, V167, P5719, DOI 10.4049/jimmunol.167.10.5719; Hamalainen H, 2000, J IMMUNOL METHODS, V242, P9, DOI 10.1016/S0022-1759(00)00200-3; Hamalainen H, 2001, GENOME BIOL, V2; Hamid QA, 1997, J ALLERGY CLIN IMMUN, V99, P254, DOI 10.1016/S0091-6749(97)70106-4; Howie D, 2002, BLOOD, V100, P2899, DOI 10.1182/blood-2002-02-0445; Isomaki P, 1999, J ALLERGY CLIN IMMUN, V103, P114, DOI 10.1016/S0091-6749(99)70534-8; Isomaki P, 1997, J IMMUNOL, V159, P2986; Kruse M, 2001, J IMMUNOL, V167, P1989, DOI 10.4049/jimmunol.167.4.1989; Levizzani, 1998, METHODS AEROBIOLOGY, P47; Majori M, 2000, CLIN EXP ALLERGY, V30, P341, DOI 10.1046/j.1365-2222.2000.00701.x; Mavaddat N, 2000, J BIOL CHEM, V275, P28100; Meissner N, 1999, CLIN EXP ALLERGY, V29, P618; Mosmann TR, 1996, IMMUNOL TODAY, V17, P138, DOI 10.1016/0167-5699(96)80606-2; OBrien RM, 1997, CLIN EXP ALLERGY, V27, P46, DOI 10.1046/j.1365-2222.1997.d01-424.x; RANTIOLEHTIMAKI A, 1991, ALLERGY, V46, P68, DOI 10.1111/j.1398-9995.1991.tb00545.x; Rogge L, 1997, J EXP MED, V185, P825, DOI 10.1084/jem.185.5.825; ROMAGNANI S, 1995, J CLIN IMMUNOL, V15, P121, DOI 10.1007/BF01543103; Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3; Szabo SJ, 1997, J EXP MED, V185, P817, DOI 10.1084/jem.185.5.817; Van Bever HP, 1998, CLIN EXP ALLERGY, V28, P943; VARNEY VA, 1993, J CLIN INVEST, V92, P644, DOI 10.1172/JCI116633; Wachholz PA, 2002, IMMUNOLOGY, V105, P56, DOI 10.1046/j.1365-2567.2002.01338.x; WIERENGA EA, 1991, J IMMUNOL, V147, P2942; Wilson DR, 2001, J ALLERGY CLIN IMMUN, V107, P971, DOI 10.1067/mai.2001.115483; Winther L, 2000, ALLERGY, V55, P818, DOI 10.1034/j.1398-9995.2000.00367.x	37	23	25	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2003	112	6					1171	1177		10.1016/j.jaci.2003.08.043	http://dx.doi.org/10.1016/j.jaci.2003.08.043			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	752HC	14657878	Bronze			2022-12-18	WOS:000187154200021
J	Nakamura, H; Miyagawa, K; Ogino, K; Endo, T; Imai, T; Ozasa, K; Motohashi, Y; Matsuzaki, I; Sasahara, S; Hatta, K; Eboshida, A				Nakamura, H; Miyagawa, K; Ogino, K; Endo, T; Imai, T; Ozasa, K; Motohashi, Y; Matsuzaki, I; Sasahara, S; Hatta, K; Eboshida, A			High contribution contrast between the genes of eosinophil peroxidase and IL-4 receptor alpha-chain in Japanese cedar pollinosis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; association study; cedar pollinosis; eosinophil peroxidase; IgE; IL-4 receptor alpha-chain; odds ratio; onset; polymorphisms; sensitization	INTERLEUKIN-4 RECEPTOR; SIGNAL-TRANSDUCTION; ALLERGIC RHINITIS; ILE50VAL VARIANT; ATOPIC ECZEMA; IGE SYNTHESIS; ASSOCIATION; ASTHMA; POLYMORPHISMS; PREVALENCE	Background: Japanese cedar pollinosis is the most common form of hayfever in Japan in spring and has remarkably increased since 1960. Objective: We sought to clarify the candidate genes for cedar pollinosis using a case-control study. Methods: After diagnosing 351 subjects on the basis of an intradermal test, nasal provocation test, and questionnaire regarding nasal and conjunctival symptoms, we determined the blood-specific IgE values and genotypes of eosinophil peroxidase (EPO) and interleukin-4 receptor alpha-chain (IL4RA) in 145 patients with pollinosis and 206 healthy subjects, including 75 healthy subjects with higher specific IgE values. Results: We found significant differences in the frequencies of Pro358Leu in EPO and of Ile50Val and Glu375Ala in IL4RA between patients and healthy subjects. There was a significantly higher frequency of 358Leu in EPO in patients than in healthy subjects showing a higher specific IgE value. In contrast, we recognized significant changes in the prevalence of Ile50Val and Glu375Ala in IL4RA in healthy subjects with a normal IgE value compared with those in healthy subjects with a higher specific IgE value. The relationship between EPO polymorphisms and the onset of symptoms was exactly opposite that for IL4RA. Conclusions: These results suggest that Pro358Leu in EPO is strongly involved in the development of cedar pollinosis. Ile50Val and Glu375Ala in IL4RA seem to be related to cedar pollen sensitization. Subjects with Ile50 or Glu375 might develop cedar pollinosis with increased exposure to cedar pollen.	Kochi Med Sch, Dept Environm Med, Kochi, Japan; Hiroshima Univ, Dept Mol Pathol, Res Inst Radiat Biol & Med, Hiroshima 730, Japan; Kanazawa Univ, Dept Environm & Prevent Med, Grad Sch Med Sci, Kanazawa, Ishikawa 920, Japan; Jikei Univ, Dept Otorhinolaryngol, Sch Med, Tokyo, Japan; Kyoto Prefectural Univ Med, Dept Social Med & Cultural Sci, Res Inst Neurol Dis & Geriatr, Kyoto 602, Japan; Univ Tsukuba, Inst Community Med, Tsukuba, Ibaraki 305, Japan; Akita Univ, Sch Med, Dept Publ Hlth, Akita 010, Japan; Univ Tsukuba, Inst Community Med, Tsukuba, Ibaraki 305, Japan; Juntendo Univ, Sch Med, Dept Psychiat, Tokyo, Japan; Hiroshima Univ, Grad Sch Med & Pharmaceut Sci, Dept Publ Hlth, Hiroshima 730, Japan	Kochi University; Hiroshima University; Kanazawa University; Jikei University; Kyoto Prefectural University of Medicine; University of Tsukuba; Akita University; University of Tsukuba; Juntendo University; Hiroshima University	Nakamura, H (corresponding author), Kochi Med Univ, Dept Environm Med, Nanko Ku, Okoh 7838505, Japan.		Hatta, Kotaro/AAN-4791-2020; OZASA, Kotaro/ABF-3001-2020	OZASA, Kotaro/0000-0002-5637-1383				Caggana M, 1999, GENET MED, V1, P267; CAPRON M, 1989, CLIN EXP ALLERGY, V19, P3; Deichmann KA, 1998, CLIN EXP ALLERGY, V28, P151; Duguet A, 2001, AM J RESP CRIT CARE, V164, P1119, DOI 10.1164/ajrccm.164.7.2010085; Forrest S, 1999, J ALLERGY CLIN IMMUN, V104, P1066, DOI 10.1016/S0091-6749(99)70090-4; Haagerup A, 2001, ALLERGY, V56, P775, DOI 10.1034/j.1398-9995.2001.056008775.x; Hori T, 1996, TISSUE ANTIGENS, V47, P485, DOI 10.1111/j.1399-0039.1996.tb02590.x; ISHIZAKI T, 1987, ANN ALLERGY, V58, P265; Izuhara K, 1999, INT J MOL MED, V3, P3; Izuhara K, 2000, J ALLERGY CLIN IMMUN, V106, pS65, DOI 10.1067/mai.2000.106776; Kakinoki Y, 1998, ACTA OTO-LARYNGOL, P152; Kruse S, 1999, IMMUNOLOGY, V96, P365; Kruse S, 2003, J ALLERGY CLIN IMMUN, V111, P117, DOI 10.1067/mai.2003.43; Mitsuyasu H, 1998, NAT GENET, V19, P119, DOI 10.1038/472; Mitsuyasu H, 1999, J IMMUNOL, V162, P1227; Nagata H, 2001, HUM GENET, V109, P262, DOI 10.1007/s004390100561; Naito K, 1999, EUR ARCH OTO-RHINO-L, V256, P209, DOI 10.1007/s004050050142; Nakagawa H., 1996, Rhinology (Utrecht), V34, P201; Nakagawa T, 2001, Hum Mutat, V17, P235, DOI 10.1002/humu.10; Noguchi E, 1999, AM J RESP CRIT CARE, V160, P342, DOI 10.1164/ajrccm.160.1.9807130; Ober C, 2000, AM J HUM GENET, V66, P517, DOI 10.1086/302781; Oiso N, 2000, BRIT J DERMATOL, V142, P1003, DOI 10.1046/j.1365-2133.2000.03485.x; Ozasa Kotaro, 1999, Allergology International, V48, P69, DOI 10.1046/j.1440-1592.1999.00119.x; ROMANO M, 1994, P NATL ACAD SCI USA, V91, P12496, DOI 10.1073/pnas.91.26.12496; Romano M, 2000, EUR J BIOCHEM, V267, P3704, DOI 10.1046/j.1432-1327.2000.01403.x; SADANAGA Y, 1990, Auris Nasus Larynx, V17, P23; SAKAMAKI K, 1989, J BIOL CHEM, V264, P16828; Sakurai Y, 1998, PREV MED, V27, P617, DOI 10.1006/pmed.1998.0336; Shirakawa T, 2000, IMMUNOL TODAY, V21, P60, DOI 10.1016/S0167-5699(99)01492-9; Tanaka K, 2001, CLIN EXP ALLERGY, V31, P1522, DOI 10.1046/j.1365-2222.2001.01205.x; Tanihara S, 1999, J Epidemiol, V9, P20; YAMAGUCHI Y, 1994, J BIOL CHEM, V269, P19410	32	23	30	1	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2003	112	6					1127	1131		10.1016/j.jaci.2003.08.051	http://dx.doi.org/10.1016/j.jaci.2003.08.051			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	752HC	14657871	Bronze			2022-12-18	WOS:000187154200015
J	Sutton, SA; Assa'ad, AH; Steinmetz, C; Rothenberg, ME				Sutton, SA; Assa'ad, AH; Steinmetz, C; Rothenberg, ME			A negative, double-blind, placebo-controlled challenge to genetically modified corn	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									Childrens Hosp, Ctr Med, Div Allergy Immunol, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Sutton, SA (corresponding author), Childrens Hosp, Ctr Med, Div Allergy Immunol, Cincinnati, OH 45229 USA.							Bucchini L, 2002, ENVIRON HEALTH PERSP, V110, P5, DOI 10.1289/ehp.021105; *US EPA, 2001, SET SCI ISS BEING CO; 2000, KRAFT FOODS RECALLS; 2003, QUICKSTIX CRY9C BULK; 2001, CDC REPORT FDA  0611	5	23	24	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2003	112	5					1011	1012		10.1016/S0091-6749(03)02024-4	http://dx.doi.org/10.1016/S0091-6749(03)02024-4			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	743BV	14610498				2022-12-18	WOS:000186553300029
J	Watanabe, T; Katsukura, H; Shirai, Y; Yamori, M; Chiba, T; Kita, T; Wakatsuki, Y				Watanabe, T; Katsukura, H; Shirai, Y; Yamori, M; Chiba, T; Kita, T; Wakatsuki, Y			Helper CD4(+) T cells for IgE response to a dietary antigen develop in the liver	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						food allergy; IgE; IL-4; liver; apoptosis	MURINE MODEL; SYSTEMIC AUTOIMMUNITY; ORAL IMMUNIZATION; FOOD ALLERGY; IFN-GAMMA; B-CELL; DEATH; IL-4; MICE; INDUCTION	Background: Although T-cell responses to food antigens are normally inhibited either by deletion, active suppression, or both of antigen-specific T cells, T helper cells for IgE response to a food antigen still develop by unknown mechanisms in a genetically susceptible host. Objective: We determined the site at which those IgE helper T cells develop. Methods: We administered ovalbumin (OVA) orally to DO11.10 mice and studied CD4(+) T cells in Peyer's patches, the spleen, and the liver. Helper activity for IgE response was assessed by adoptively transferring those CD4(+) T cells to naive BALB/c mice, followed by systemic immunization with OVA. Results: OVA-specific CD4(+) T cells were deleted by cell death in the liver and Peyer's patches of DO11.10 mice fed OVA. OVA-specific CD4(+) T cells that survived apoptosis in the liver expressed Fas ligand and secreted IL-4, IL-10, and transforming growth factor beta(1). CD4(+) T cells producing IFN-gamma were deleted in the liver by repeated feeding of OVA. On transfer of CD4(+) T cells to naive mice and systemic immunization with OVA, a marked increase in OVA-specific IgE response developed only in the mice that received hepatic CD4(+) T cells from OVA-fed mice, the effect of which was not observed in the recipients of hepatic CD4+ T cells deficient in IL-4. In addition, significant suppression of delayed-type hypersensitivity and IgG(1)/IgG(2a) responses to OVA was observed in the recipients of hepatic CD4(+) T cells, and this suppression required Fas/Fas ligand interaction. Conclusion: Together, these results suggested that a food antigen might negatively select helper T cells for IgE response to the antigen by preferential deletion of T(H)1 cells in the liver. (J Allergy Clin Immunol 2003;111:1375-85.).	Kyoto Univ, Grad Sch Med, Dept Clin Bioregulatory Sci, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University; Kyoto University	Wakatsuki, Y (corresponding author), Kyoto Univ, Grad Sch Med, Dept Clin Bioregulatory Sci, Sakyo Ku, Shogoin Kawahara Cho 54, Kyoto 6068507, Japan.		Eckhardt, Erik/G-1567-2010; Watanabe, Tomohiro/ABA-4712-2021					Asai K, 2001, IMMUNITY, V14, P791, DOI 10.1016/S1074-7613(01)00157-1; CHEN YH, 1994, SCIENCE, V265, P1237, DOI 10.1126/science.7520605; CHEN YH, 1995, NATURE, V376, P177, DOI 10.1038/376177a0; COHEN PL, 1991, ANNU REV IMMUNOL, V9, P243, DOI 10.1146/annurev.iy.09.040191.001331; COHEN PL, 1992, IMMUNOL TODAY, V13, P427, DOI 10.1016/0167-5699(92)90066-G; Collins AM, 1999, CLIN EXP ALLERGY, V29, P262; Crispe IN, 1996, IMMUNOL TODAY, V17, P522, DOI 10.1016/S0167-5699(96)80906-6; CYCKE N, 1996, CURRENT PROTOCOLS IM; Faquim-Mauro EL, 1999, J IMMUNOL, V163, P3572; FINKELMAN FD, 1988, J IMMUNOL, V141, P2335; GILLIS S, 1978, J IMMUNOL, V120, P2027; Hayashi N, 1999, J IMMUNOL, V163, P6702; Helm RM, 2002, ANN NY ACAD SCI, V964, P139; HULI J, 1989, J IMMUNOL, V142, P800; IIKURA Y, 1995, INT ARCH ALLERGY IMM, V107, P189, DOI 10.1159/000236973; Ito K, 1997, EUR J IMMUNOL, V27, P3427, DOI 10.1002/eji.1830271243; Kayagaki N, 1997, P NATL ACAD SCI USA, V94, P3914, DOI 10.1073/pnas.94.8.3914; Khanna A, 2000, J IMMUNOL, V164, P1346, DOI 10.4049/jimmunol.164.3.1346; Knolle PA, 1999, GASTROENTEROLOGY, V116, P1428, DOI 10.1016/S0016-5085(99)70508-1; KRUISBECK AM, 1993, CURRENT PROTOCOLS IM; Kweon MN, 2000, J CLIN INVEST, V106, P199, DOI 10.1172/JCI8490; Legendre C, 1997, NEW ENGL J MED, V337, P822, DOI 10.1056/NEJM199709183371204; Li XM, 1999, J ALLERGY CLIN IMMUN, V103, P206, DOI 10.1016/S0091-6749(99)70492-6; Li XM, 2000, J ALLERGY CLIN IMMUN, V106, P150, DOI 10.1067/mai.2000.107395; MALOY KJ, 1995, EUR J IMMUNOL, V25, P2835, DOI 10.1002/eji.1830251019; Matsunaga Y, 2000, VACCINE, V19, P579, DOI 10.1016/S0264-410X(00)00120-1; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nishimura T, 1999, J IMMUNOL, V162, P6503; OKAMURA H, 1995, NATURE, V378, P88, DOI 10.1038/378088a0; Russell JQ, 1998, J EXP MED, V188, P1147, DOI 10.1084/jem.188.6.1147; Shirai Y, 2000, GASTROENTEROLOGY, V118, P749, DOI 10.1016/S0016-5085(00)70144-2; Sicherer SH, 2002, LANCET, V360, P701, DOI 10.1016/S0140-6736(02)09831-8; SNIDER DP, 1994, J IMMUNOL, V153, P647; Strober W, 1997, IMMUNOL TODAY, V18, P61, DOI 10.1016/S0167-5699(97)01000-1; Takahashi S, 1996, J CLIN INVEST, V97, P1597, DOI 10.1172/JCI118584; Usui T, 1997, J IMMUNOL, V158, P3197; Varadhachary AS, 1997, P NATL ACAD SCI USA, V94, P5778, DOI 10.1073/pnas.94.11.5778; Vella A, 1997, J EXP MED, V186, P325, DOI 10.1084/jem.186.2.325; Watanabe T, 2002, J IMMUNOL, V168, P2188, DOI 10.4049/jimmunol.168.5.2188; Yoshida M, 2001, INT IMMUNOL, V13, P1561, DOI 10.1093/intimm/13.12.1561; Zhang XH, 1997, J EXP MED, V185, P1837, DOI 10.1084/jem.185.10.1837	42	23	25	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2003	111	6					1375	1385		10.1067/mai.2003.1466	http://dx.doi.org/10.1067/mai.2003.1466			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	688FZ	12789242				2022-12-18	WOS:000183424700030
J	Rotrosen, D; Matthews, JB; Bluestone, JA				Rotrosen, D; Matthews, JB; Bluestone, JA			The immune tolerance network: A new paradigm for developing tolerance-inducing therapies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						immune tolerance; costimulation; anergy; autoimmunity; transplantation; asthma; allergy	DONOR BONE-MARROW; RENAL-ALLOGRAFT REJECTION; ANTIGEN-PRESENTING CELLS; TRANSPLANTATION TOLERANCE; PHASE-I; CHIMERISM; IMMUNOSUPPRESSION; IMMUNOTHERAPY; PROLIFERATION; MECHANISMS	Immune tolerance therapies are designed to reprogram immune cells in a highly specific fashion to eliminate pathogenic responses while preserving protective immunity. A concept that has tantalized immunologists for decades, the development of tolerance-inducing therapies, would revolutionize the management of a wide range of chronic and often debilitating diseases by obviating the need for lifelong immunosuppressive regimens. The advances of the past decade have provided a more detailed understanding of the molecular events associated with T-cell recognition and activation. Building on these advances, immunologists have demonstrated the feasibility of various tolerance-inducing approaches in small- and large-animal models of autoimmunity, allergy, and transplant graft rejection. Unprecedented opportunities to test these approaches in a variety of human diseases have now emerged. To capitalize on these advances, the National Institutes of Health recently established the Immune Tolerance Network (ITN), an international consortium of more than 70 basic and clinical immunologists dedicated to the evaluation of novel tolerance-inducing therapies and associated studies of immunologic mechanisms. By using a unique interactive approach to accelerate the development of clinical tolerance therapies, the ITN is partnering with the biotechnology and pharmaceutical industries to examine innovative tolerogenic approaches in a range of allergic and autoimmune diseases and to prevent graft rejection after transplantation. Two years since its inception, the ITN now has approximately 2 dozen clinical trials or tolerance assays studies ongoing or in later stages of protocol development. This report summarizes the rationale for emphasizing clinical research on immune tolerance and highlights the progress of the ITN.	Univ Calif San Francisco, Dept Med, Immune Tolerance Network, San Francisco, CA USA; NIAID, Bethesda, MD 20892 USA	Immune Tolerance Network; University of California System; University of California San Francisco; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Rotrosen, D (corresponding author), 6700-B Rockledge Dr,Room 5142,MSC 7640, Bethesda, MD 20817 USA.							BRENNAN DC, 1995, AM J KIDNEY DIS, V26, P701, DOI 10.1016/0272-6386(95)90432-8; Broide DH, 2001, J CLIN IMMUNOL, V21, P175, DOI 10.1023/A:1011078930363; Calne R, 2000, Nihon Geka Gakkai Zasshi, V101, P301; DeBenedette MA, 1997, J IMMUNOL, V158, P551; Devlin J, 1998, HEPATOLOGY, V27, P926, DOI 10.1002/hep.510270406; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Friend PJ, 1999, TRANSPLANTATION, V68, P1632, DOI 10.1097/00007890-199912150-00005; Golden DBK, 2000, J ALLERGY CLIN IMMUN, V105, P385, DOI 10.1016/S0091-6749(00)90092-7; Gudmundsdottir H, 2000, SEMIN NEPHROL, V20, P209; JENKINS MK, 1988, J IMMUNOL, V140, P3324; JENKINS MK, 1987, J EXP MED, V165, P302, DOI 10.1084/jem.165.2.302; Kenyon NS, 1999, DIABETES, V48, P1473, DOI 10.2337/diabetes.48.7.1473; KENYON NS, 2000, GRAFT, V96, P230; Kimikawa M, 1997, TRANSPLANTATION, V64, P709, DOI 10.1097/00007890-199709150-00008; Kirk AD, 1997, P NATL ACAD SCI USA, V94, P8789, DOI 10.1073/pnas.94.16.8789; Mazariegos GV, 1997, TRANSPLANTATION, V63, P243, DOI 10.1097/00007890-199701270-00012; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; ROSE SM, ADV INTERNAL MED, V47, P293; Shapiro AMJ, 2000, NEW ENGL J MED, V343, P230, DOI 10.1056/NEJM200007273430401; Spitzer TR, 1999, TRANSPLANTATION, V68, P480, DOI 10.1097/00007890-199908270-00006; STARZL TE, 1993, HEPATOLOGY, V17, P1127; Straus SE, 1999, ANN INTERN MED, V130, P591, DOI 10.7326/0003-4819-130-7-199904060-00020; Tamada K, 2000, J IMMUNOL, V164, P4105, DOI 10.4049/jimmunol.164.8.4105; Tamada K, 2000, NAT MED, V6, P283; Thomas JM, 1997, TRANSPLANTATION, V64, P124, DOI 10.1097/00007890-199707150-00022; Van Parijs L, 1999, IMMUNITY, V11, P281, DOI 10.1016/S1074-7613(00)80103-X; Veenstra DL, 1999, AM J KIDNEY DIS, V33, P829, DOI 10.1016/S0272-6386(99)70414-2; WEAVER CT, 1988, P NATL ACAD SCI USA, V85, P8181, DOI 10.1073/pnas.85.21.8181; Woodle ES, 1999, TRANSPLANTATION, V68, P608, DOI 10.1097/00007890-199909150-00003	29	23	23	0	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2002	110	1					17	23		10.1067/mai.2002.124258	http://dx.doi.org/10.1067/mai.2002.124258			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	574CF	12110811				2022-12-18	WOS:000176870300002
J	Shah, D; Hales, J; Cooper, D; Camp, R				Shah, D; Hales, J; Cooper, D; Camp, R			Recognition of pathogenically relevant house dust mite hypersensitivity in adults with atopic dermatitis: A new approach?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic dermatitis; IgE-facilitated allergen presentation; T lymphocytes; dermatophagoides; hypersensitivity; clinical relevance	EPSILON-CHAIN FRAGMENT; T-CELL RESPONSES; ALLERGEN PRESENTATION; DOUBLE-BLIND; CONTROLLED TRIAL; IN-SITU; LYMPHOCYTES; DERMATOPHAGOIDES; DISEASE; SKIN	Background: The pathogenic importance of the ubiquitous house dust mite, Dermatophagoides pteronyssinus (Dp), in atopic dermatitis is unclear. Objective: We aimed to explore the relevance of Dp hypersensitivity in adult patients with atopic dermatitis by using an in vivo topical challenge method and in vitro assays for T-cell reactivity. Methods: Dp and control skin prick test solutions were applied to the cubital fossae of 20 patients twice daily for 4 days; the severity of dermatitis and pruritus in the challenge sites were determined before and after testing. The same solutions were used in PBMC proliferation assays that included 10% fresh, autologous serum, the latter aimed at maximizing IgE-facilitated allergen presentation. Results: Although most patients had markedly elevated Dp-specific serum IgE levels, only 6 of 20 patients developed increases in cubital fossa dermatitis severity and pruritus scores that were greater at sites of application of Dp solution than at control sites. In addition, PBMC proliferation in response to Dp solution in the presence of autologous serum 4 was significantly greater in the in vivo challenge-positive patients than in those who did not respond to challenge. A subgroup of patients (7/20) also developed transient but pronounced contact urticaria at sites of Dp application. Conclusion: These finding suggest that hypersensitivity to Dp might be clinically relevant in approximately one third of the A adult atopic dermatitis population studied. They also point to methods of identifying patients who might respond to house dust avoidance measures.	Univ Leicester, Div Dermatol, Leicester LE1 9HN, Leics, England	University of Leicester	Camp, R (corresponding author), Univ Leicester, Div Dermatol, Maurice Shock Med Sci Bldg,Univ Rd, Leicester LE1 9HN, Leics, England.							BerthJones J, 1996, BRIT J DERMATOL, V135, P25, DOI 10.1111/j.1365-2133.1996.tb00706.x; COLLOFF MJ, 1989, BRIT J DERMATOL, V121, P199, DOI 10.1111/j.1365-2133.1989.tb01799.x; Darsow U, 2000, CLIN EXP DERMATOL, V25, P544, DOI 10.1046/j.1365-2230.2000.00695.x; GEHA RS, 1985, NATURE, V315, P577, DOI 10.1038/315577a0; Grewe M, 1998, IMMUNOL TODAY, V19, P359, DOI 10.1016/S0167-5699(98)01285-7; Gutgesell C, 2001, BRIT J DERMATOL, V145, P70, DOI 10.1046/j.1365-2133.2001.04283.x; HAMID Q, 1994, J CLIN INVEST, V94, P870, DOI 10.1172/JCI117408; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; HEWITT CRA, 1995, J EXP MED, V182, P1537, DOI 10.1084/jem.182.5.1537; Holden CA, 1998, TXB DERMATOLOGY, P681; ISHIZAKA T, 1986, P NATL ACAD SCI USA, V83, P8323, DOI 10.1073/pnas.83.21.8323; MAURER D, 1995, J IMMUNOL, V154, P6285; Maurer D, 1996, J IMMUNOL, V157, P607; NORRIS PG, 1988, BRIT J DERMATOL, V118, P435, DOI 10.1111/j.1365-2133.1988.tb02440.x; OHEHIR RE, 1989, IMMUNOLOGY, V66, P499; OHEHIR RE, 1993, J ALLERGY CLIN IMMUN, V92, P105, DOI 10.1016/0091-6749(93)90044-G; Rao WH, 2000, J IMMUNOL, V165, P4935, DOI 10.4049/jimmunol.165.9.4935; RAWLE FC, 1984, J IMMUNOL, V133, P195; Romagnani S, 2000, J ALLERGY CLIN IMMUN, V105, P399, DOI 10.1067/mai.2000.104575; SANDA T, 1992, J ALLERGY CLIN IMMUN, V89, P653, DOI 10.1016/0091-6749(92)90370-H; SHAH D, 2001, BR J DERMATOL S59, V145, P47; SOWDEN JM, 1991, LANCET, V338, P137, DOI 10.1016/0140-6736(91)90134-B; Tan BB, 1996, LANCET, V347, P15, DOI 10.1016/S0140-6736(96)91556-1; Thepen T, 1996, J ALLERGY CLIN IMMUN, V97, P828, DOI 10.1016/S0091-6749(96)80161-8; VANDERHEIJDEN FL, 1993, J IMMUNOL, V150, P3643; VANDERHEIJDEN FL, 1991, J INVEST DERMATOL, V97, P389, DOI 10.1111/1523-1747.ep12480966; VIRTANEN T, 1995, J ALLERGY CLIN IMMUN, V96, P411, DOI 10.1016/S0091-6749(95)70061-7; von Bubnoff D, 2001, J ALLERGY CLIN IMMUN, V108, P329, DOI 10.1067/mai.2001.117457; Werfel T, 1996, J INVEST DERMATOL, V107, P871, DOI 10.1111/1523-1747.ep12331164	29	23	23	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2002	109	6					1012	1018		10.1067/mai.2002.124654	http://dx.doi.org/10.1067/mai.2002.124654			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	566RU	12063533				2022-12-18	WOS:000176442700019
J	Latov, N; Chaudhry, V; Koski, CL; Lisak, RP; Apatoff, BR; Hahn, AF; Howard, JF				Latov, N; Chaudhry, V; Koski, CL; Lisak, RP; Apatoff, BR; Hahn, AF; Howard, JF			Use of intravenous gamma globulins in neuroimmunologic diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	IVIG Advisory Meeting	OCT 26-29, 2000	SANTA BARBARA, CA	Bayer Biol		intravenous gamma globulin; peripheral neuropathy; neuropathy; chronic inflammatory demyelinating polyneuropathy; Guillain-Barre syndrome; inflammatory neuropathy; neuroimmunology	MULTIFOCAL MOTOR NEUROPATHY; IMMUNOGLOBULIN TREATMENT; DOUBLE-BLIND; IMMUNE GLOBULIN; PLASMA-EXCHANGE; MULTIPLE-SCLEROSIS; IV IMMUNOGLOBULIN; CONTROLLED-TRIAL; DEMYELINATING NEUROPATHY; CLINICAL-TRIAL	Intravenous gamma globulin (IVIg) is used in the treatment of immunologic diseases that affect the entire neuroaxis, including the brain, spinal cord, peripheral nerves, muscles, and neuromuscular junction. The panel reviewed the available literature on the use of IVIg in order to evaluate the efficacy of this therapy in neuroimmunologic diseases. In prospective, rigorously controlled, double-blinded clinical trials, IVIg was found to have proven efficacy in the Guillain-Barre syndrome, chronic inflammatory demyelinating polyneuropathy, multifocal motor neuropathy, dermatomyositis, and Lambert-Eaton myasthenic syndrome. It was found to be probably effective in myasthenia gravis and polymyositis, and possibly effective in several other neuroimmunologic diseases. Further studies are needed to evaluate the use of IVIg for neuroimmunologic diseases in which its efficacy is suspected but not proven and to elucidate its mechanisms of action.	Columbia Univ, New York, NY USA	Columbia University	Latov, N (corresponding author), Peripheral Neuropathy Ctr, 635 Madison Ave,Sutie 400, New York, NY 10022 USA.			Howard, James/0000-0002-7136-8617				Achiron A, 1998, NEUROLOGY, V50, P398, DOI 10.1212/WNL.50.2.398; ACHIRON A, 1994, J NEUROL NEUROSUR PS, V57, P57, DOI 10.1136/jnnp.57.Suppl.57; Amato AA, 1997, MUSCLE NERVE, V20, P1303, DOI 10.1002/(SICI)1097-4598(199710)20:10<1303::AID-MUS13>3.0.CO;2-3; AZULAY JP, 1994, NEUROLOGY, V44, P429, DOI 10.1212/WNL.44.3_Part_1.429; Bain PG, 1996, NEUROLOGY, V47, P678, DOI 10.1212/WNL.47.3.678; BASTA M, 1994, J CLIN INVEST, V94, P1729, DOI 10.1172/JCI117520; BenDavid Y, 1996, CANCER-AM CANCER SOC, V78, P2153; Bentes C, 1999, Electromyogr Clin Neurophysiol, V39, P33; Bril V, 1996, NEUROLOGY, V46, P100, DOI 10.1212/WNL.46.1.100; Chaudhry V, 1998, SEMIN NEUROL, V18, P73, DOI 10.1055/s-2008-1040863; CHERIN P, 1994, J RHEUMATOL, V21, P1092; COOK D, 1990, NEUROLOGY, V40, P212, DOI 10.1212/WNL.40.2.212; Daaboul Y, 1998, NEUROL RES, V20, P85; DALAKAS MC, 1994, ARCH NEUROL-CHICAGO, V51, P861, DOI 10.1001/archneur.1994.00540210031010; Dalakas MC, 1996, ANN NEUROL, V40, P792, DOI 10.1002/ana.410400516; Dalakas MC, 1999, MUSCLE NERVE, V22, P1479, DOI 10.1002/(SICI)1097-4598(199911)22:11<1479::AID-MUS3>3.0.CO;2-B; DALAKAS MC, 1993, NEW ENGL J MED, V329, P1993, DOI 10.1056/NEJM199312303292704; Dalakas MC, 1997, NEUROLOGY, V48, P712, DOI 10.1212/WNL.48.3.712; DYCK PJ, 1994, ANN NEUROL, V36, P838, DOI 10.1002/ana.410360607; Ellis CM, 1999, J NEUROL NEUROSUR PS, V67, P15, DOI 10.1136/jnnp.67.1.15; Enders U, 1997, J NEUROIMMUNOL, V76, P112, DOI 10.1016/S0165-5728(97)00039-8; Fazekas F, 1997, LANCET, V349, P589, DOI 10.1016/S0140-6736(96)09377-4; Federico P, 2000, NEUROLOGY, V55, P1256, DOI 10.1212/WNL.55.9.1256; Gabriel CM, 1997, BRAIN, V120, P1533, DOI 10.1093/brain/120.9.1533; Gajdos P, 1997, ANN NEUROL, V41, P789, DOI 10.1002/ana.410410615; GORSON KC, 1995, ACTA NEUROL SCAND, V92, P376; Hahn AF, 1996, BRAIN, V119, P1067, DOI 10.1093/brain/119.4.1067; Hahn AF, 2000, CURR OPIN NEUROL, V13, P575, DOI 10.1097/00019052-200010000-00012; HART YM, 1994, NEUROLOGY, V44, P1030, DOI 10.1212/WNL.44.6.1030; Heafield MTE, 1996, LANCET, V347, P28, DOI 10.1016/S0140-6736(96)91559-7; Helveston WR, 1996, NEUROLOGY, V46, P584, DOI 10.1212/WNL.46.2.584; Huang CC, 1996, J NEUROL, V243, P726, DOI 10.1007/BF00873980; Hughes RAC, 1997, LANCET, V349, P225; ILLUM N, 1990, NEUROPEDIATRICS, V21, P87, DOI 10.1055/s-2008-1071468; KARLSON HW, 1994, ARTHRITIS RHEUM-US, V37, P915, DOI 10.1002/art.1780370621; Katirji B, 1997, NEUROLOGY, V48, P1690, DOI 10.1212/WNL.48.6.1690; KLEIMAN M, 1995, J CHILD NEUROL, V10, P481, DOI 10.1177/088307389501000612; Kubori T, 1999, No To Shinkei, V51, P127; KURODA Y, 1991, J NEUROL, V238, P309, DOI 10.1007/BF00315327; LEGER JM, 1994, J NEUROL NEUROSUR PS, V57, P46, DOI 10.1136/jnnp.57.Suppl.46; Lockwood CM, 1996, CLIN EXP IMMUNOL, V104, P77, DOI 10.1111/cei.1996.104.s1.77; Malik U, 1996, ANN NEUROL, V39, P136, DOI 10.1002/ana.410390121; Mariette X, 1997, J NEUROL NEUROSUR PS, V63, P28, DOI 10.1136/jnnp.63.1.28; Mendell JR, 2001, NEUROLOGY, V56, P445, DOI 10.1212/WNL.56.4.445; Mericle RA, 1997, J NEUROL NEUROSUR PS, V62, P529, DOI 10.1136/jnnp.62.5.529; Meucci N, 1996, J NEUROL, V243, P117, DOI 10.1007/BF02444000; MIIKE T, 1989, BRAIN DEV-JPN, V11, P134, DOI 10.1016/S0387-7604(89)80083-X; Miyagi F, 1997, J NEUROIMMUNOL, V78, P127, DOI 10.1016/S0165-5728(97)00090-8; Noseworthy JH, 2000, NEUROLOGY, V55, P1135, DOI 10.1212/WNL.55.8.1135; Pascual J, 1998, NEUROLOGY, V51, P650, DOI 10.1212/WNL.51.2.650-b; Pashov A, 1997, MULT SCLER, V3, P153, DOI 10.1177/135245859700300218; PASHOV A, 1997, MULT SCLER, V161, P153; Perlmutter SJ, 1999, LANCET, V354, P1153, DOI 10.1016/S0140-6736(98)12297-3; Pless M, 1996, NEUROLOGY, V46, P583, DOI 10.1212/WNL.46.2.583-a; Sharief MK, 1999, NEUROLOGY, V52, P1833, DOI 10.1212/WNL.52.9.1833; Smit AAJ, 1997, MAYO CLIN PROC, V72, P333, DOI 10.4065/72.4.333; Sorensen PS, 1997, MULT SCLER, V3, P145, DOI 10.1177/135245859700300216; Sorensen PS, 1998, NEUROLOGY, V50, P1273, DOI 10.1212/WNL.50.5.1273; Spellberg B, 1999, NEW ENGL J MED, V341, P57; Stangel M, 1998, J NEUROL SCI, V153, P203, DOI 10.1016/S0022-510X(97)00292-X; STURFELT G, 1990, ANN RHEUM DIS, V49, P939, DOI 10.1136/ard.49.11.939; Takeuchi H, 2000, NEUROLOGY, V54, P1008, DOI 10.1212/WNL.54.4.1008-a; Taylor CT, 1999, ANN PHARMACOTHER, V33, P1055, DOI 10.1345/aph.18439; Uchuya M, 1996, J NEUROL NEUROSUR PS, V60, P388, DOI 10.1136/jnnp.60.4.388; Van den Bergh PYK, 1998, NEUROLOGY, V50, P1514, DOI 10.1212/WNL.50.5.1514; van Doorn PA, 2000, NEUROLOGY, V55, P1246, DOI 10.1212/WNL.55.9.1246; vandenBerg LH, 1997, J NEUROL NEUROSUR PS, V63, P674, DOI 10.1136/jnnp.63.5.674; VANDENBERG LH, 1995, J NEUROL NEUROSUR PS, V59, P248, DOI 10.1136/jnnp.59.3.248; VANDERMECHE FGA, 1992, NEW ENGL J MED, V326, P1123, DOI 10.1056/NEJM199204233261705; VANRIJCKEVORSELHARMANT K, 1994, INT J CLIN LAB RES, V24, P162, DOI 10.1007/BF02592447; VERMA A, 1994, NEUROLOGY, V44, P248, DOI 10.1212/WNL.44.2.248; VERMEULEN M, 1995, J NEUROL NEUROSUR PS, V58, P383, DOI 10.1136/jnnp.58.3.383-a; WARRINGTON AE, 2000, P NATL ACAD SCI USA, V97, P6280; Yu ZY, 1999, NEW ENGL J MED, V340, P227, DOI 10.1056/NEJM199901213400311	74	23	26	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2001	108	4		S			S126	S132		10.1067/mai.2001.118300	http://dx.doi.org/10.1067/mai.2001.118300			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	487KL	11586280				2022-12-18	WOS:000171874200010
J	Tedeschi, A; Lorini, M; Asero, R				Tedeschi, A; Lorini, M; Asero, R			Anti-thyroid peroxidase IgE in patients with chronic urticaria	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							AUTOIMMUNITY		IRCCS, Osped Maggiore Policlin, Div Med 1, Allergy & Immunopharmacol Unit, I-20122 Milan, Italy; Osped Caduti Bollatesi, Allergy Unit, I-2021 Milan, Italy	IRCCS Ca Granda Ospedale Maggiore Policlinico	Tedeschi, A (corresponding author), IRCCS, Osped Maggiore Policlin, Div Med 1, Allergy & Immunopharmacol Unit, I-20122 Milan, Italy.							Asero R, 2000, J ALLERGY CLIN IMMUN, V105, pS268, DOI 10.1016/S0091-6749(00)91222-3; Bar-Sela S, 1999, J ALLERGY CLIN IMMUN, V103, P1216, DOI 10.1016/S0091-6749(99)70204-6; GRATTAN CEH, 1986, BRIT J DERMATOL, V114, P583, DOI 10.1111/j.1365-2133.1986.tb04065.x; Greaves M, 2000, J ALLERGY CLIN IMMUN, V105, P664, DOI 10.1067/mai.2000.105706; HIDE M, 1993, NEW ENGL J MED, V328, P1599, DOI 10.1056/NEJM199306033282204; LEZNOFF A, 1989, J ALLERGY CLIN IMMUN, V84, P66, DOI 10.1016/0091-6749(89)90180-2; Rumbyrt JS, 1995, J ALLERGY CLIN IMMUN, V96, P901, DOI 10.1016/S0091-6749(95)70226-1	7	23	25	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2001	108	3					467	468						2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	476FK	11544471				2022-12-18	WOS:000171215400023
J	Pedersen, S				Pedersen, S			Assessing the effect of intranasal steroids on growth	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						beclomethasone; dipropionate; budesonide; intranasal corticosteroids; mometasone furoate	SHORT-TERM; INHALED CORTICOSTEROIDS; MOMETASONE FUROATE; ALLERGIC RHINITIS; LINEAR GROWTH; CHILDREN; HEIGHT; ASTHMA; BECLOMETHASONE; RETARDATION	Several studies hake evaluated the effects of childhood use of corticosteroids on growth. In short-term studies, the budesonide (BUD) metered dose inhaler and methylprednisolone (injection) had significant effects on lower-leg growth, whereas terfenadine did not. When two doses of BUD (nasal inhaler, 200 or 400 mug once daily) were compared with placebo, only the 400-mug dose had a significant effect on short-term growth. Intranasal mometasone furoate (NIF) (100 and 200 mug) had no significant effect on short-term lower-leg growth. In intermediate studies of 1-year duration, intranasal beclomethasone dipropionate (84 mug twice daily) significantly affected growth rate, whereas in a Separate study, 100 mug intranasal MIT once daily did not. Long-term growth data come from retrospective studies of children with asthma. In these studies, no significant effect on growth has been demonstrated in children taking inhaled beclomethasone dipropionate or BUD. The reason for the discrepancy between intermediate and long-term studies is unclear and warrants further study. Variables in childhood growth including seasonal variations may make growth difficult to assess. However, because growth suppression has been reported in children receiving inhaled or intranasal corticosteroids, the low est effective dose of drug with a low systemic absorption ratio should always be used. Overall, there appears to be no growth suppression with 100 mug intranasal NIF used once daily in children.	Odense Univ, DK-6000 Kolding, Denmark; Kolding Cty Hosp, Dept Pediat, DK-6000 Kolding, Denmark	University of Southern Denmark; Kolding Hospital; University of Southern Denmark	Pedersen, S (corresponding author), Odense Univ, DK-6000 Kolding, Denmark.							Agertoft L, 1999, J ALLERGY CLIN IMMUN, V104, P948, DOI 10.1016/S0091-6749(99)70073-4; Agertoft L, 2000, NEW ENGL J MED, V343, P1064, DOI 10.1056/NEJM200010123431502; ALLEN DB, 1994, J ALLERGY CLIN IMMUN, V93, P967, DOI 10.1016/S0091-6749(94)70043-5; ARMENIO L, 1993, ARCH DIS CHILD, V68, P193, DOI 10.1136/adc.68.2.193; BALFOUR-LYNN L, 1987, Pediatrician, V14, P237; BALFOURLYNN L, 1986, ARCH DIS CHILD, V61, P1049, DOI 10.1136/adc.61.11.1049; Barnes PJ, 1998, AM J RESP CRIT CARE, V157, pS1, DOI 10.1164/ajrccm.157.3.157315; BUTLER GE, 1990, ANN HUM BIOL, V17, P177, DOI 10.1080/03014469000000952; Doull IJM, 1998, ARCH DIS CHILD, V78, P172, DOI 10.1136/adc.78.2.172; FERGUSON AC, 1982, J ALLERGY CLIN IMMUN, V69, P461, DOI 10.1016/0091-6749(82)90122-1; HAUSPIE R, 1977, J ALLERGY CLIN IMMUN, V59, P200, DOI 10.1016/0091-6749(77)90150-6; HAUSPIE R, 1976, HUM BIOL, V48, P271; KARLBERG J, 1994, ACTA PAEDIATR, V83, P777, DOI 10.1111/j.1651-2227.1994.tb13138.x; KARLBERG J, 1987, ACTA PAEDIATR SCAND, V76, P478, DOI 10.1111/j.1651-2227.1987.tb10503.x; KARLBERG J, 1993, ACTA PAEDIATR, V82, P631, DOI 10.1111/j.1651-2227.1993.tb18029.x; MARSHALL WA, 1971, ARCH DIS CHILD, V46, P414, DOI 10.1136/adc.46.248.414; MARTIN AJ, 1981, ACTA PAEDIATR SCAND, V70, P683, DOI 10.1111/j.1651-2227.1981.tb05768.x; McCowan C, 1998, BMJ-BRIT MED J, V316, P668, DOI 10.1136/bmj.316.7132.668; Pedersen S, 1997, ALLERGY, V52, P1, DOI 10.1111/j.1398-9995.1997.tb05047.x; Rachelefsky GS, 1998, J ALLERGY CLIN IMMUN, V101, pS236; Schenkel EJ, 2000, PEDIATRICS, V105, DOI 10.1542/peds.105.2.e22; Silverstein MD, 1997, J ALLERGY CLIN IMMUN, V99, P466, DOI 10.1016/S0091-6749(97)70072-1; SPROCK A, 1965, ANN ALLERGY, V23, P608; THOMAS BC, 1994, ACTA PAEDIATR, V83, P196, DOI 10.1111/j.1651-2227.1994.tb13050.x; Verberne AAPH, 1997, AM J RESP CRIT CARE, V156, P688, DOI 10.1164/ajrccm.156.3.9611067; VOSS LD, 1991, ARCH DIS CHILD, V66, P833, DOI 10.1136/adc.66.7.833; WOLTHERS OD, 1990, BRIT MED J, V301, P145, DOI 10.1136/bmj.301.6744.145; WOLTHERS OD, 1994, ALLERGY, V49, P96, DOI 10.1111/j.1398-9995.1994.tb00807.x; WOLTHERS OD, 1993, ACTA PAEDIATR, V82, P635, DOI 10.1111/j.1651-2227.1993.tb12780.x	29	23	26	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2001	108	1		S			S40	S44		10.1067/mai.2001.115565	http://dx.doi.org/10.1067/mai.2001.115565			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	459BU	11449205				2022-12-18	WOS:000170230600007
J	Dahl, M; Nordestgaard, BG; Lange, P; Tybjaerg-Hansen, A				Dahl, M; Nordestgaard, BG; Lange, P; Tybjaerg-Hansen, A			Fifteen-year follow-up of pulmonary function in individuals heterozygous for the cystic fibrosis phenylalanine-508 deletion	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cystic fibrosis heterozygosity; Delta F508 mutation; asthma; pulmonary function; genetic screening	ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; DELTA-F508 HETEROZYGOSITY; OBLIGATE HETEROZYGOTES; BRONCHIAL-ASTHMA; LUNG-FUNCTION; DISEASE; OBSTRUCTION; PREVALENCE; MUTATIONS	Background: In a cross-sectional study, we previously showed that cystic fibrosis phenylalanine-508 deletion (Delta F508) heterozygosity may be overrepresented among individuals with asthma. Objective: Using 15-year follow-up data from the Copenhagen City Heart Study, we now further explore this relationship. Methods: As part of 3 surveys in 1976 to 1978, 1981 to 1983, and 1991 to 1994, we measured pulmonary function and asked all participants about asthma and pulmonary risk factors. Results: There was no difference in annual decline in lung function between Delta F508 heterozygotes and noncarriers overall; however, among individuals with familial asthma, the annual declines in FEV1 and forced vital capacity (FVC) were 49 and 36 mt in Delta F508 heterozygotes versus 24 and 17 mt in noncarriers (P = .01 and P = .12, respectively). Cross-sectionally based on triple measurements, FEV1 and FVC in individuals aged 20 to 70 years were tower in heterozygous participants versus noncarriers (P = .02 and P = .004, respectively), The average reduction of FEV1 and FVC in Delta F508 heterozygotes versus noncarriers was 70 mt (P = .06) and 136 mt (P = .008). Finally, 10% of carriers reported asthma versus 7% of noncarriers (P = .02), resulting in an odds ratio of 2.0 (1.3-3.2) for asthma in Delta F508 heterozygotes, Conclusion: Cystic fibrosis Delta F508 heterozygotes may be overrepresented among individuals with asthma and may have poorer lung function than noncarriers. Furthermore, Delta F508 heterozygosity in context with familial predisposition to asthma may be associated with a greater annual FEV1 decline.	Univ Copenhagen Hosp, Copenhagen, Denmark; Glostrup Univ Hosp, Dept Clin Biochem, Copenhagen, Denmark; Herlev Univ Hosp, Dept Clin Biochem, Copenhagen, Denmark; Hvidovre Univ Hosp, Dept Resp Med, Copenhagen, Denmark; Bispebjerg Univ Hosp, Copenhagen City Heart Study, Copenhagen, Denmark	University of Copenhagen; University of Copenhagen; University of Copenhagen; Herlev & Gentofte Hospital; University of Copenhagen; University of Copenhagen; Bispebjerg Hospital	Tybjaerg-Hansen, A (corresponding author), Univ Copenhagen Hosp, Rigshosp, Dept Clin Biochem KB 3011, Blegdamsvej 9, DK-2100 Copenhagen O, Denmark.		Nordestgaard, Borge Gronne/ABF-1310-2020; Dahl, Morten/F-4219-2014	Dahl, Morten/0000-0002-6686-312X				Appleyard M., 1989, SCAND J SOC MED, V41, P1; BARKER DJP, 1991, BRIT MED J, V303, P671, DOI 10.1136/bmj.303.6804.671; Becker JW, 1996, CHEST, V109, P1536, DOI 10.1378/chest.109.6.1536; BOULET LP, 1994, CHEST, V105, P1024, DOI 10.1378/chest.105.4.1024; BURROWS B, 1990, MED CLIN N AM, V74, P547, DOI 10.1016/S0025-7125(16)30539-9; BYARD PJ, 1988, AM REV RESPIR DIS, V138, P312, DOI 10.1164/ajrccm/138.2.312; COUNAHAN R, 1975, ARCH DIS CHILD, V50, P477, DOI 10.1136/adc.50.6.477; Crater Scott E., 1998, Current Opinion in Pediatrics, V10, P594; Cropp GJ, 1996, AM J MED, V100, pS19, DOI 10.1016/S0002-9343(96)80049-0; Dahl M, 1998, LANCET, V351, P1911, DOI 10.1016/S0140-6736(97)11419-2; Davis PB, 1996, AM J RESP CRIT CARE, V154, P1229, DOI 10.1164/ajrccm.154.5.8912731; DAVIS PB, 1984, AM REV RESPIR DIS, V129, P911; DAVIS PB, 1987, THORAX, V42, P120, DOI 10.1136/thx.42.2.120; Estivill X, 1997, HUM MUTAT, V10, P135, DOI 10.1002/(SICI)1098-1004(1997)10:2<135::AID-HUMU6>3.3.CO;2-P; GASPARINI P, 1992, MOL CELL PROBE, V6, P1, DOI 10.1016/0890-8508(92)90064-5; Griesenbach U, 1999, THORAX, V54, pS19, DOI 10.1136/thx.54.2008.S19; HALLETT WY, 1965, AM REV RESPIR DIS, V90, P714; JENSEN G, 1984, ACTA MED SCAND S, V602, P1; Kauppi P, 1998, RESP MED, V92, P1281, DOI 10.1016/S0954-6111(98)90229-3; LANGE P, 1989, J INTERN MED, V226, P25, DOI 10.1111/j.1365-2796.1989.tb01349.x; Lowenfels AB, 1998, LANCET, V352, P985, DOI 10.1016/S0140-6736(05)61538-3; Miller PW, 1996, AM J HUM GENET, V59, P45; Murray CJL, 1997, LANCET, V349, P1436, DOI 10.1016/S0140-6736(96)07495-8; ORZALESI MM, 1963, ACTA PAEDIATR, V52, P267, DOI 10.1111/j.1651-2227.1963.tb03779.x; SCHROEDER SA, 1995, NAT MED, V1, P703, DOI 10.1038/nm0795-703; *SPSS INC, 1996, SPSS BAS 7 0 WIND US; Swift M, 1998, LANCET, V352, P984, DOI 10.1016/S0140-6736(98)00017-8; ULRIK CS, 1994, AM J RESP CRIT CARE, V150, P629, DOI 10.1164/ajrccm.150.3.8087330; Vollmer WM, 1998, AM J RESP CRIT CARE, V157, P1079, DOI 10.1164/ajrccm.157.4.9704140; WARNER JO, 1976, LANCET, V1, P990; Warner JO, 1996, PEDIATR ALLERGY IMMU, V7, P67, DOI 10.1111/j.1399-3038.1996.tb00399.x; Welsh MJ, 1995, METABOLIC MOL BASES, V3, P3799; Wills R, 1998, J PAEDIATR CHILD H, V34, P325, DOI 10.1046/j.1440-1754.1998.00197.x; WOOLCOCK AJ, 1994, TXB RESP MED, P1288	34	23	23	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2001	107	5					818	823		10.1067/mai.2001.114117	http://dx.doi.org/10.1067/mai.2001.114117			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	434JX	11344348	Bronze			2022-12-18	WOS:000168812300009
J	Creticos, PS; Balcer, SL; Schroeder, JT; Hamilton, RG; Chung, B; Norman, PS; Lichtenstein, LM; Eiden, JJ				Creticos, PS; Balcer, SL; Schroeder, JT; Hamilton, RG; Chung, B; Norman, PS; Lichtenstein, LM; Eiden, JJ			Initial immunotherapy trial to explore the safety, tolerability and immunogenicity of subcutaneous injections of an Amb a 1 immunostimulatory oligonucleotide conjugate [Aic] in ragweed allergic adults	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract									Johns Hopkins Univ, Sch Med, Johns Hopkins Asthma & Allergy Ctr, Baltimore, MD USA; Dynavax Technol Corp, Berkley, CA USA	Johns Hopkins University; Johns Hopkins Medicine									0	23	24	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2001	107	2		S		712	S216	S216						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	405RE					2022-12-18	WOS:000167172300708
J	Yawalkar, N; Karlen, S; Egli, F; Brand, U; Graber, HU; Pichler, WJ; Braathen, LR				Yawalkar, N; Karlen, S; Egli, F; Brand, U; Graber, HU; Pichler, WJ; Braathen, LR			Down-regulation of IL-12 by topical corticosteroids in chronic atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						skin; dendritic cells; cytokines; immunohistochemistry; quantitative reverse transcriptase; polymerase chain reaction	ANTIGEN-PRESENTING CELLS; MESSENGER-RNA; INTERFERON-GAMMA; EXPRESSION; INTERLEUKIN-12; GENE; P35; STIMULATION; EXOTOXINS; CYTOKINE	Background: Previous reports indicate that IL-12 may be involved in the development of chronic atopic dermatitis. However, the cellular source of this cytokine in the skin and its expression during successful treatment of the skin lesions are not known. Objective: Our purpose was to delineate the precise in situ localization of IL-12 and its modulation under topical treatment with corticosteroids. Methods: Skin biopsy specimens were obtained from nonlesional, lesional, and treated skin of patients with atopic dermatitis and from healthy skin of nonatopic control subjects. IL-12 was investigated by real-time quantitative reverse transcriptase-PCR and immunohistochemistry. Results: Expression of IL-12 p40 mRNA was significantly enhanced in lesional skin from atopic dermatitis and strongly down-regulated after treatment with topical corticosteroids for 9 to 10 days. In contrast, similar levels of IL-12 p35 transcripts were found in all the samples without any significant differences after treatment, In addition, a strong enhancement of IL-12 immunoreactivity was observed on the mononuclear cell infiltrate in the lesional skin samples, which was also markedly reduced after treatment. IL-12 immunoreactivity was mainly located in the cytoplasm of dermal dendritic cells and macrophages as well as some Langerhans cells. Conclusion: Our data suggest that the enhanced local production of IL-12 in dendritic cells and macrophages may be responsible for up-regulating production of IFN-gamma in chronic lesions and strengthen the idea that IL-12 may have a pivotal role in promoting inflammation in atopic dermatitis.	Univ Bern, Inselspital, Clin Rheumatol & Clin Immunol Allergol, CH-3010 Bern, Switzerland; Univ Bern, Inselspital, Dermatol Clin, CH-3010 Bern, Switzerland; Univ Bern, Inselspital, Dept Clin Res, CH-3010 Bern, Switzerland	University of Bern; University Hospital of Bern; University of Bern; University Hospital of Bern; University of Bern; University Hospital of Bern	Yawalkar, N (corresponding author), Univ Bern, Inselspital, Clin Rheumatol & Clin Immunol Allergol, CH-3010 Bern, Switzerland.			Pichler, Werner J./0000-0002-8117-359X				Beltrani VS, 1999, J ALLERGY CLIN IMMUN, V104, pS87, DOI 10.1016/S0091-6749(99)70050-3; BETTE M, 1994, EUR J IMMUNOL, V24, P2435, DOI 10.1002/eji.1830241026; Bunikowski R, 2000, J ALLERGY CLIN IMMUN, V105, P814, DOI 10.1067/mai.2000.105528; Bunikowski R, 1999, J ALLERGY CLIN IMMUN, V103, P119, DOI 10.1016/S0091-6749(99)70535-X; DANDREA A, 1993, J EXP MED, V178, P1041, DOI 10.1084/jem.178.3.1041; GREWE M, 1994, LANCET, V343, P25, DOI 10.1016/S0140-6736(94)90879-6; Grewe M, 1998, IMMUNOL TODAY, V19, P359, DOI 10.1016/S0167-5699(98)01285-7; GUBLER U, 1991, P NATL ACAD SCI USA, V88, P4143, DOI 10.1073/pnas.88.10.4143; Hamid Q, 1996, J ALLERGY CLIN IMMUN, V98, P225, DOI 10.1016/S0091-6749(96)70246-4; HAMID Q, 1994, J CLIN INVEST, V94, P870, DOI 10.1172/JCI117408; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; Kehren J, 1999, J EXP MED, V189, P779, DOI 10.1084/jem.189.5.779; KORC M, 1992, J CLIN INVEST, V90, P1352, DOI 10.1172/JCI116001; Kunz B, 1997, DERMATOLOGY, V195, P10, DOI 10.1159/000245677; Leung DYM, 2000, J ALLERGY CLIN IMMUN, V105, P860, DOI 10.1067/mai.2000.106484; LEUNG DYM, 1995, J EXP MED, V181, P747, DOI 10.1084/jem.181.2.747; Ma XJ, 1997, CHEM IMMUNOL, V68, P1; Ma XJ, 1996, J EXP MED, V183, P147, DOI 10.1084/jem.183.1.147; Maeda I, 1999, INT J CANCER, V81, P700, DOI 10.1002/(SICI)1097-0215(19990531)81:5<700::AID-IJC5>3.3.CO;2-4; Marth T, 1996, J IMMUNOL, V157, P2348; Maurer F, 1996, J BIOL CHEM, V271, P26074, DOI 10.1074/jbc.271.42.26074; MULLER G, 1994, J CLIN INVEST, V94, P1799, DOI 10.1172/JCI117528; Nomura I, 1999, J ALLERGY CLIN IMMUN, V104, P441, DOI 10.1016/S0091-6749(99)70390-8; Snijders A, 1996, J IMMUNOL, V156, P1207; STANLEY ER, 1994, STEM CELLS, V12, P15; Wang XY, 1998, LEUKEMIA, V12, P520, DOI 10.1038/sj.leu.2400975; WOLF SF, 1991, J IMMUNOL, V146, P3074; Yamane H, 1999, J IMMUNOL, V162, P6433; Yawalkar N, 1998, J INVEST DERMATOL, V111, P1053, DOI 10.1046/j.1523-1747.1998.00446.x; Yawalkar N, 1996, J INVEST DERMATOL, V106, P80, DOI 10.1111/1523-1747.ep12327985; Yawalkar N, 2000, CONTACT DERMATITIS, V42, P18, DOI 10.1034/j.1600-0536.2000.042001018.x; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219	32	23	25	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2000	106	5					941	947		10.1067/mai.2000.109825	http://dx.doi.org/10.1067/mai.2000.109825			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	417ZK	11080718				2022-12-18	WOS:000167865200020
J	Nurse, B; Puterman, AS; Haus, M; Berman, D; Weinberg, EG; Potter, PC				Nurse, B; Puterman, AS; Haus, M; Berman, D; Weinberg, EG; Potter, PC			PBMCs from both atopic asthmatic and nonatopic children show a T(H)2 cytokine response to house dust mite allergen	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopy; asthma; African; peripheral blood mononuclear cells; house dust mite; mycobacterial protein; IL-5; IFN-gamma	BLOOD MONONUCLEAR-CELLS; HUMAN T-CELLS; MESSENGER-RNA EXPRESSION; PERIPHERAL-BLOOD; IN-VITRO; INTERFERON-GAMMA; ENVIRONMENTAL ALLERGENS; SERUM IGE; INTERLEUKIN-5; PROLIFERATION	Background: The hypothesis that in atopic diseases the T-helper response is skewed toward a T(H)2-type cytokine response was based on studies with mitogen stimulation, T-cell clones, or both. Objective: Using primary cultures, we investigated (1) whether atopic asthmatic patients have a T(H)2 response and nonatopic subjects have a T(H)1 response to allergen and (2) whether atopic patients have a decreased ability to mount T(H)1 immune responses to mycobacterial antigens, Methods: The responses of PBMCs to allergen (house dust mite [HDM]) or purified protein derivative of Mycobacterium tuberculosis (PPD) stimulation from 10 severely and 14 moderately asthmatic patients (all allergic to HDM) were compared with those of 17 nonatopic healthy black (Xhosa) children. Results: HDM-stimulated proliferation, IL-5 release, and the IL-5/IFN-gamma ratio were significantly increased in subjects with atopic asthma, whereas IFN-gamma release was not significantly different. IL-4 levels were below the level of detection. PPD-stimulated proliferation, IL-5 release, IFN-gamma release, and the IL5/IFN-gamma ratio were not significantly different among the groups. Each group had a significantly higher IL-5/IFN-gamma ratio in response to HDM than to PPD (a T(H)1 stimulus). Conclusion: Our study, which used primary cultures to investigate the hypothesis that nonatopic subjects have a T(H)1 response to allergens, indicates that HDM stimulates a T(H)2 cytokine response in both atopic and nonatopic subjects but that the response is enhanced in atopic patients. Our results with PPD suggest that normal and atopic asthmatic subjects can have a T(H)1 cytokine response to mycobacteria, but there is a subgroup of atopic subjects that have a T(H)2 response.	Groote Schuur Hosp, Allergol Unit, Dept Immunol, ZA-7925 Cape Town, South Africa; Red Cross Childrens Hosp, Cape Town, South Africa; Univ Cape Town, Inst Child Hlth, ZA-7925 Cape Town, South Africa	University of Cape Town; University of Cape Town	Nurse, B (corresponding author), Groote Schuur Hosp, Dept Immunol, H53,Old Main Bldg, ZA-7925 Observatory, South Africa.							BARNES PJ, 1995, CLIN EXP ALLERGY, V25, P771, DOI 10.1111/j.1365-2222.1995.tb00016.x; Benjaponpitak S, 1999, J ALLERGY CLIN IMMUN, V103, P468, DOI 10.1016/S0091-6749(99)70473-2; BURASTERO SE, 1993, J ALLERGY CLIN IMMUN, V91, P1075, DOI 10.1016/0091-6749(93)90222-2; Chang JH, 1996, J ALLERGY CLIN IMMUN, V98, P922, DOI 10.1016/S0091-6749(96)80008-X; DELPRETE GF, 1991, J CLIN INVEST, V88, P346, DOI 10.1172/JCI115300; ELSON LH, 1995, J IMMUNOL, V154, P4294; Frew AJ, 1995, CLIN EXP ALLERGY, V25, P1143, DOI 10.1111/j.1365-2222.1995.tb03035.x; Gangur V, 1999, INT ARCH ALLERGY IMM, V118, P387, DOI 10.1159/000024144; HAUS M, 1990, S AFR MED J, V77, P7; Hoekstra MO, 1997, CLIN EXP ALLERGY, V27, P1254; Jung T, 1996, EUR J IMMUNOL, V26, P571, DOI 10.1002/eji.1830260311; Kimura M, 1998, J ALLERGY CLIN IMMUN, V101, P84, DOI 10.1016/S0091-6749(98)70197-6; Kimura M, 2000, J ALLERGY CLIN IMMUN, V105, P327, DOI 10.1016/S0091-6749(00)90083-6; Kimura M, 1998, J ALLERGY CLIN IMMUN, V102, P238, DOI 10.1016/S0091-6749(98)70092-2; Krug N, 1998, CLIN EXP ALLERGY, V28, P10; Laan MP, 1998, EUR CYTOKINE NETW, V9, P75; Lagging E, 1998, IMMUNOL LETT, V60, P45, DOI 10.1016/S0165-2478(97)00130-2; Lantero S, 1997, J ASTHMA, V34, P141, DOI 10.3109/02770909709075659; LOONEY RJ, 1994, J ALLERGY CLIN IMMUN, V93, P476, DOI 10.1016/0091-6749(94)90357-3; Meissner N, 1999, CLIN EXP ALLERGY, V29, P618; MICHAEL BN, 1994, CELL IMMUNOL, V158, P105, DOI 10.1006/cimm.1994.1260; Noma T, 1999, CLIN EXP ALLERGY, V29, P780, DOI 10.1046/j.1365-2222.1999.00584.x; Nurse B, 1997, J ALLERGY CLIN IMMUN, V100, P662, DOI 10.1016/S0091-6749(97)70171-4; O'Byrne PM, 1999, CLIN EXP ALLERGY, V29, P573; Ohashi Y, 1998, SCAND J IMMUNOL, V47, P596; OHEHIR RE, 1993, J ALLERGY CLIN IMMUN, V92, P105, DOI 10.1016/0091-6749(93)90044-G; Olivenstein R, 1999, J ALLERGY CLIN IMMUN, V103, P238, DOI 10.1016/S0091-6749(99)70497-5; PARRONCHI P, 1991, P NATL ACAD SCI USA, V88, P4538, DOI 10.1073/pnas.88.10.4538; Prescott SL, 1998, J IMMUNOL, V160, P4730; RAWLE FC, 1984, J IMMUNOL, V133, P195; ROMAGNANI S, 1994, ANNU REV IMMUNOL, V12, P227, DOI 10.1146/annurev.iy.12.040194.001303; Romagnani S, 1997, IMMUNOL TODAY, V18, P263, DOI 10.1016/S0167-5699(97)80019-9; Sawada K, 1997, CLIN EXP ALLERGY, V27, P225; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; Strannegard IL, 1998, ALLERGY, V53, P249, DOI 10.1111/j.1398-9995.1998.tb03884.x; Tang CB, 1998, J ALLERGY CLIN IMMUN, V102, P368, DOI 10.1016/S0091-6749(98)70122-8; Thepen T, 1996, J ALLERGY CLIN IMMUN, V97, P828, DOI 10.1016/S0091-6749(96)80161-8; Till S, 1997, J ALLERGY CLIN IMMUN, V99, P563, DOI 10.1016/S0091-6749(97)70085-X; Till SJ, 1998, AM J RESP CRIT CARE, V158, P404, DOI 10.1164/ajrccm.158.2.9705007; Umetsu DT, 1997, J ALLERGY CLIN IMMUN, V100, P1, DOI 10.1016/S0091-6749(97)70186-6; UPHAM JW, 1995, CLIN EXP ALLERGY, V25, P634, DOI 10.1111/j.1365-2222.1995.tb01111.x; Van Bever HP, 1998, CLIN EXP ALLERGY, V28, P943; Van der Veen MJ, 1999, CLIN EXP ALLERGY, V29, P217; Van Neerven RJJ, 1998, CLIN EXP ALLERGY, V28, P808; WARNER JO, 1997, P SAT S 16 INT C ALL; Weinberg EG, 2000, J ALLERGY CLIN IMMUN, V105, P224, DOI 10.1016/S0091-6749(00)90069-1; WIERENGA EA, 1991, J IMMUNOL, V147, P2942; Wurtzen PA, 1998, J ALLERGY CLIN IMMUN, V101, P241, DOI 10.1016/S0091-6749(98)70389-6	48	23	24	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2000	106	1	1				84	91		10.1067/mai.2000.107397	http://dx.doi.org/10.1067/mai.2000.107397			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	337ZH	10887310	Bronze			2022-12-18	WOS:000088393300012
J	Glare, EM; Divjak, W; Rolland, JM; Walters, EH				Glare, EM; Divjak, W; Rolland, JM; Walters, EH			Asthmatic airway biopsy specimens are more likely to express the IL-4 alternative splice variant IL-4 delta 2	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-4; IL-4 delta 2; splice variant; endobronchial biopsy; airway tissue; competitive PCR; nasal polyp; asthma; gene expression	MESSENGER-RNA EXPRESSION; ALLERGEN INHALATION CHALLENGE; BRONCHOALVEOLAR LAVAGE FLUID; COLONY-STIMULATING FACTOR; T-CELL PROLIFERATION; ATOPIC ASTHMA; HUMAN INTERLEUKIN-4; BRONCHIAL BIOPSIES; NASAL-MUCOSA; MAST-CELLS	Background: The human IL4 gene, has been shown to express the alternatively spliced messenger (m)RNA IL-4 delta 2. IL-4 delta 2 is missing the entire sequence from exon 2 and has been identified as an IL-4 receptor antagonist. Objective: We sought to distinguish IL-4 and IL-4 delta 2 mRNA in respiratory tract tissue for the first time. Methods: A novel competitive PCR assay was established with primers designed on either side of the alternative splice junction of the IL4 gene, allowing the simultaneous quantitation of both IL-4 and IL-4 delta 2 mRNA from one reaction. Results: IL-4 and IL-4 delta 2 were differentially expressed in 4 nasal polyps. No difference was seen in endobronchial biopsy specimens for IL-4 mRNA expression between control subjects (median, 2.8 x 10(2) copies/mu g RNA; range, 0-3.7 x 10(3) copies/mu g RNA) and asthmatic subjects (median, 1.4 x 10(2) copies/mu g RNA; range, 0-4.7 x 10(2) copies/mu g RNA), However, significantly more asthmatic subjects (6 of 9) than control subjects (1 of 7) expressed IL-4 delta 2 (P = .036), Expression of IL-4 variants was unaffected by atopic status. Conclusions: Given that IL-4 delta 2 is an IL-4 receptor antagonist, these results indicate that it is crucial to be able to distinguish IL-4 delta 2 from IL-4 when assessing IL4 gene expression. Increased expression of IL-4 delta 2 in stable asthmatic subjects suggests that the balance of IL-4 and IL-4 delta 2 may modulate asthmatic inflammation.	Alfred Hosp, Dept Resp Med, Melbourne, Vic 3181, Australia; Alfred Hosp, Dept Pathol & Immunol, Melbourne, Vic 3181, Australia; Monash Univ, Sch Med, Melbourne, Vic 3004, Australia	Florey Institute of Neuroscience & Mental Health; Florey Institute of Neuroscience & Mental Health; Monash University	Walters, EH (corresponding author), Alfred Hosp, Dept Resp Med, Melbourne, Vic 3181, Australia.		Rolland, Jennifer/E-7543-2011					Alms WJ, 1996, MOL IMMUNOL, V33, P361, DOI 10.1016/0161-5890(95)00154-9; ARAI N, 1989, J IMMUNOL, V142, P274; Arinobu Y, 1999, CELL IMMUNOL, V191, P161, DOI 10.1006/cimm.1998.1431; Atamas SP, 1996, J IMMUNOL, V156, P435; Ausubel F., 1999, CURRENT PROTOCOLS MO; Barata LT, 1998, J ALLERGY CLIN IMMUN, V101, P222, DOI 10.1016/S0091-6749(98)70387-2; BEACH JR, 1993, THORAX, V48, P239, DOI 10.1136/thx.48.3.239; BENTLEY AM, 1993, AM J RESP CELL MOL, V8, P35, DOI 10.1165/ajrcmb/8.1.35; Borish L, 1996, J ALLERGY CLIN IMMUN, V97, P719, DOI 10.1016/S0091-6749(96)80146-1; BRADDING P, 1994, AM J RESP CELL MOL, V10, P471, DOI 10.1165/ajrcmb.10.5.8179909; de Vries JE, 1998, J ALLERGY CLIN IMMUN, V102, P165, DOI 10.1016/S0091-6749(98)70080-6; Dolganov G, 1996, BLOOD, V87, P3316, DOI 10.1182/blood.V87.8.3316.bloodjournal8783316; DURHAM SR, 1992, J IMMUNOL, V148, P2390; GELDER CM, 1995, THORAX, V50, P1033, DOI 10.1136/thx.50.10.1033; Humbert M, 1996, AM J RESP CRIT CARE, V154, P1497, DOI 10.1164/ajrccm.154.5.8912771; Kelly EAB, 1997, AM J RESP CRIT CARE, V156, P1421, DOI 10.1164/ajrccm.156.5.9703054; Klein SC, 1996, CELL IMMUNOL, V167, P259, DOI 10.1006/cimm.1996.0034; MARINI M, 1992, CHEST, V102, P661, DOI 10.1378/chest.102.3.661; MOQBEL R, 1995, J IMMUNOL, V155, P4939; ROBINSON D, 1993, J ALLERGY CLIN IMMUN, V92, P313, DOI 10.1016/0091-6749(93)90175-F; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; ROBINSON DS, 1993, J ALLERGY CLIN IMMUN, V92, P397, DOI 10.1016/0091-6749(93)90118-Y; SORG RV, 1993, EXP HEMATOL, V21, P560; Tsytsikov VN, 1996, J BIOL CHEM, V271, P23055, DOI 10.1074/jbc.271.38.23055; Vener T, 1998, J CLIN MICROBIOL, V36, P1864, DOI 10.1128/JCM.36.7.1864-1870.1998; VIRCHOW JC, 1995, AM J RESP CRIT CARE, V151, P960; WALKER C, 1992, AM REV RESPIR DIS, V146, P109, DOI 10.1164/ajrccm/146.1.109; YING S, 1995, AM J RESP CELL MOL, V12, P477, DOI 10.1165/ajrcmb.12.5.7742012; YING S, 1994, IMMUNOLOGY, V82, P200; Zavyalov VP, 1997, IMMUNOL LETT, V58, P149, DOI 10.1016/S0165-2478(97)00083-7	30	23	28	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1999	104	5					978	982		10.1016/S0091-6749(99)70078-3	http://dx.doi.org/10.1016/S0091-6749(99)70078-3			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	257JH	10550742				2022-12-18	WOS:000083778400020
J	Fischer, B; Yawalkar, N; Brander, KA; Pichler, WJ; Helbling, A				Fischer, B; Yawalkar, N; Brander, KA; Pichler, WJ; Helbling, A			Coprinus comatus (shaggy cap) is a potential source of aeroallergen that may provoke atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						fungal spores; basidiomycetes; Coprinus comatus; aeroallergen; atopic dermatitis; atopy patch test; delayed-type reaction	PATCH TEST; BASIDIOMYCETE ALLERGY; SKIN; ASTHMA; CELLS; FREQUENCY; EUROPE; ECZEMA; IGE	Background: Basidiospores are universal components in the air and established as important causes of respiratory allergies. Recent reports indicate that aeroallergens may aggravate eczematous skin lesions in subjects with atopic dermatitis (AD), Objective: The aim of the study was to investigate whether spores of Coprinus comatus, a species of basidiomycetes, mag elicit delayed-type skin reactions in subjects with an atopic predilection, especially dermatitis. Methods: Sixty-six study subjects were categorized in groups having AD or respiratory allergy with regard to the skin prick test (SPT) reactivity to C comatus extract. Twenty nonatopic individuals served as control subjects. Atopy patch tests (APTs) were performed with extract of C comatus spore containing tissue at a concentration of 1.35 mg of protein per gram of petrolatum (Vaseline) and C comatus cap at a concentration of approximately 5 mg of protein per gram of petroleum jelly. APT reactions were evaluated after 48 and 72 hours. Results: Of the subjects with AD completing the study, 12 (32%) of 38 showed a positive APT reaction. with 8 (57%) also having a positive SPT response to C comatus. Only 1 (9%) of 11 subjects with asthma had a positive SPT and APT response to C comatus. No positive test reaction was observed in the nonatopic control subjects or in subjects with respiratory allergy and negative SPT responses to C comatus. Conclusion: Our results demonstrate that C comatus can induce delayed-type reactions in atopic individuals, particularly in those with AD. Because spores of Coprinus species are ubiquitous, basidiomycetes have to be considered as possible aeroallergens when investigating causes of eczematous skin lesions in AD.	Univ Hosp Bern, Inst Immunol & Allergol, CH-3010 Bern, Switzerland	University of Bern; University Hospital of Bern	Helbling, A (corresponding author), Univ Hosp Bern, Inst Immunol & Allergol, CH-3010 Bern, Switzerland.			Pichler, Werner J./0000-0002-8117-359X				ADINOFF AD, 1988, J ALLERGY CLIN IMMUN, V81, P736, DOI 10.1016/0091-6749(88)91047-0; Brander KA, 1999, J ALLERGY CLIN IMMUN, V104, P630, DOI 10.1016/S0091-6749(99)70335-0; BRUIJNZEELKOOM CAF, 1988, CLIN EXP IMMUNOL, V74, P137; BUTCHER BT, 1987, J ALLERGY CLIN IMMUN, V80, P803, DOI 10.1016/S0091-6749(87)80269-5; DAMATO G, 1995, ALLERGY, V50, P870, DOI 10.1111/j.1398-9995.1995.tb02492.x; Darsow U, 1996, BRIT J DERMATOL, V135, P182, DOI 10.1111/j.1365-2133.1996.tb01144.x; DARSOW U, 1995, J ALLERGY CLIN IMMUN, V95, P677, DOI 10.1016/S0091-6749(95)70172-9; DAVIS WE, 1988, CLIN ALLERGY, V18, P261, DOI 10.1111/j.1365-2222.1988.tb02868.x; Decco ML, 1998, MAYO CLIN PROC, V73, P225, DOI 10.4065/73.3.225; DIEPGEN TL, 1989, ACTA DRM VENEREO S S, V44, P50; Epton MJ, 1997, THORAX, V52, P528, DOI 10.1136/thx.52.6.528; Gfesser M, 1996, BRIT J DERMATOL, V135, P560, DOI 10.1046/j.1365-2133.1996.d01-1040.x; Gubler C. C., 1994, MYKOGENEN ALLERGIE P; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; Helbling A, 1998, J ALLERGY CLIN IMMUN, V102, P853, DOI 10.1016/S0091-6749(98)70028-4; Horner WE, 1998, ALLERGY, V53, P1114, DOI 10.1111/j.1398-9995.1998.tb03830.x; Horner WE, 1996, J ALLERGY CLIN IMMUN, V97, P153; LEHRER SB, 1994, ALLERGY, V49, P460, DOI 10.1111/j.1398-9995.1994.tb00840.x; LOPEZ M, 1989, J ALLERGY CLIN IMMUN, V84, P242, DOI 10.1016/0091-6749(89)90331-X; Malling HJ., 2003, ALLERGY, V48, P55; MAURER D, 1995, J INVEST DERMATOL, V104, P707, DOI 10.1111/1523-1747.ep12606958; MUDDE GC, 1990, IMMUNOLOGY, V69, P335; OROURKE MK, 1994, P 21 C AGR AER 1994; PLATTSMILLS T, 1993, HDB ATOPIC ECZEMA, P192; SAGER N, 1992, J ALLERGY CLIN IMMUN, V89, P801, DOI 10.1016/0091-6749(92)90434-4; SEIDENARI S, 1992, ANN ALLERGY, V69, P201; STALDER JF, 1993, DERMATOLOGY, V186, P23, DOI 10.1159/000247298; Thepen T, 1996, J ALLERGY CLIN IMMUN, V97, P828, DOI 10.1016/S0091-6749(96)80161-8; VANDERHEIJDEN FL, 1991, J INVEST DERMATOL, V97, P389, DOI 10.1111/1523-1747.ep12480966; VANREIJSEN FC, 1992, J ALLERGY CLIN IMMUN, V90, P184, DOI 10.1016/0091-6749(92)90070-I; WIEDMER E, 1994, THESIS U BERN; WILKINSON DS, 1970, ACTA DERM-VENEREOL, V50, P287	32	23	23	1	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1999	104	4	1				836	841		10.1016/S0091-6749(99)70295-2	http://dx.doi.org/10.1016/S0091-6749(99)70295-2			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	248NG	10518829				2022-12-18	WOS:000083281200016
J	Brander, KA; Borbely, P; Crameri, R; Pichler, WJ; Helbling, A				Brander, KA; Borbely, P; Crameri, R; Pichler, WJ; Helbling, A			IgE-binding proliferative responses and skin test reactivity to Cop c 1, the first recombinant allergen from the basidiomycete Coprinus comatus	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Basidiomycetes; mushrooms; Coprinus comatus; complementary DNA cloning; filamentous phage; recombinant allergens; airborne allergens	ASPERGILLUS-FUMIGATUS ALLERGENS; SYSTEM; ASTHMA; DISPLAY	Background: Basidiomycetes spores are ubiquitously distributed, found throughout the year in outdoor and indoor air, and represent relevant sources of aeroallergens associated with allergy and asthma, Objective: Cloning and characterization of Coprinus comatus (shaggy cap mushroom) allergens is essential to elucidate their molecular characteristics and to improve the diagnosis of allergy, Methods: A complementary DNA (cDNA) library of C comatus displayed on phage surface was screened with sera of basidiomycete-sensitized individuals. Subcloning and high-level expression of one of the enriched cDNAs allowed the isolation of a [His](6)-tagged recombinant protein formally termed rCop c 1. The allergenic properties of rCop c 1 were investigated in vitro by ELISA, inhibition experiments, immunoblots, and proliferation assays and in vivo by skin tests. Results: The rCop c 1-encoding cDNA spans 435 bp and contains an open reading frame of 246 bp, predicting a protein of 8.96 kd without significant sequence homology to known proteins, Immunoblots with [His](6)-rCop c 1 fusion protein show a background free IgE-binding band of the expected size that can be completely inhibited by crude C comatus extracts in ELISA, rCop c 1 induced specific proliferative responses in PBMCs of C comatus-sensitized individuals. The incidence of sensitization to rCop c 1 among 92 sera of basidiomycete-sensitized individuals tested in ELISA was 25%, indicating that Cop c 1 is an intermediate allergen. However, prick tests showed that less than 2 pmol of the rCop c 1 protein was able to induce strong specific skin reactions in sensitized individuals. Conclusions: rCop c 1, the first cloned allergen from the genus Coprinus, fulfills all the criteria required to be classified as a clinically relevant allergen. The data demonstrate at the molecular level the presence of sensitizing molecules among Basidiomycetes, the most important source contributing to the total spore load in the outdoor air.	Swiss Inst Allergy & Asthma Res, CH-7270 Davos, Switzerland; Univ Hosp Bern, Inst Immunol & Allergol, CH-3010 Bern, Switzerland	Swiss Institute of Allergy & Asthma Research; University of Bern; University Hospital of Bern	Helbling, A (corresponding author), Univ Hosp Bern, Inst Immunol & Allergol, Inselspital, CH-3010 Bern, Switzerland.			Pichler, Werner J./0000-0002-8117-359X				APPEL RD, 1994, TRENDS BIOCHEM SCI, V19, P258, DOI 10.1016/0968-0004(94)90153-8; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; Crameri R, 1996, INT ARCH ALLERGY IMM, V110, P41, DOI 10.1159/000237308; Crameri R, 1996, CLIN EXP ALLERGY, V26, P1411, DOI 10.1111/j.1365-2222.1996.tb00543.x; CRAMERI R, 1994, EUR J BIOCHEM, V226, P53, DOI 10.1111/j.1432-1033.1994.tb20025.x; DAMATO G, 1995, ALLERGY, V50, P870, DOI 10.1111/j.1398-9995.1995.tb02492.x; DAVIS WE, 1988, CLIN ALLERGY, V18, P261, DOI 10.1111/j.1365-2222.1988.tb02868.x; Epton MJ, 1997, THORAX, V52, P528, DOI 10.1136/thx.52.6.528; FLUCKIGER B, 1995, THESIS I MICROBIOLOG; Helbling A, 1998, J ALLERGY CLIN IMMUN, V102, P853, DOI 10.1016/S0091-6749(98)70028-4; Hemmann S, 1998, EUR J IMMUNOL, V28, P1155, DOI 10.1002/(SICI)1521-4141(199804)28:04&lt;1155::AID-IMMU1155&gt;3.0.CO;2-6; Hemmann S, 1997, AM J RESP CRIT CARE, V156, P1956, DOI 10.1164/ajrccm.156.6.9702087; Horner WE, 1998, ALLERGY, V53, P1114, DOI 10.1111/j.1398-9995.1998.tb03830.x; HORNER WE, 1995, CLIN MICROBIOL REV, V8, P161, DOI 10.1128/CMR.8.2.161; HORNER WE, 1995, INT ARCH ALLERGY IMM, V107, P298, DOI 10.1159/000237007; KING TP, 1995, ALLERGY, V50, P765, DOI 10.1111/j.1398-9995.1995.tb01222.x; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LOPEZ M, 1989, J ALLERGY CLIN IMMUN, V84, P242, DOI 10.1016/0091-6749(89)90331-X; Malling HJ., 2003, ALLERGY, V48, P55; MOSER M, 1994, J ALLERGY CLIN IMMUN, V93, P1, DOI 10.1016/0091-6749(94)90227-5; SALVAGGIO J, 1981, J ALLERGY CLIN IMMUN, V68, P327, DOI 10.1016/0091-6749(81)90131-7; Wang Guang-Li, 1993, Acta Botanica Sinica, V35, P547; WIEDMER E, 1998, KATALOG EUROPAISCHEN; ZHOU C, 1990, BIOTECHNIQUES, V8, P173	24	23	23	0	8	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1999	104	3	1				630	636		10.1016/S0091-6749(99)70335-0	http://dx.doi.org/10.1016/S0091-6749(99)70335-0			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	241EP	10482839	Bronze			2022-12-18	WOS:000082870000027
J	Kim, YK; Cho, SH; Koh, YY; Son, JW; Jee, YK; Lee, MH; Min, KU; Kim, YY				Kim, YK; Cho, SH; Koh, YY; Son, JW; Jee, YK; Lee, MH; Min, KU; Kim, YY			Skin reactivity to inhalant allergens, total serum IgE levels, and bronchial responsiveness to methacholine are increased in parents of nonatopic asthmatic children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						nonatopic; asthma; skin reactivity; bronchial responsiveness; total serum IgE	INTRINSIC ASTHMA; SYMPTOMS; DISEASE; BIOPSIES; TWINS	Background:Family studies suggest that asthma has an increased familial occurrence, but the hypothesis of a genetic predisposition to IgE response and bronchial hyperresponsiveness (BHR) on the expression of nonatopic asthma is controversial. Objective: The aim of this study was to evaluate familial predisposition to IgE response and BHR on expression of nonatopic asthma. Methods: One hundred four parents of nonatopic asthmatic children, 154 parents of atopic asthmatic children, 78 parents of atopic nonasthmatic control children, and 80 parents of nonatopic control children provided questionnaire data and underwent allergy skin prick tests with 10 inhalant allergens and methacholine bronchial provocation tests. Total serum IgE levels were determined in 352 parents (134 with atopic asthmatic children, 87 with nonatopic asthmatic children, 65 with atopic control children, and 66 with nonatopic control children). Results: Prevalence of asthma, based on questionnaire data and on BHR to methacholine, was higher among parents of nonatopic asthmatic children (10.6%) and atopic asthmatic children (9.1%) than among those of nonatopic control children (1.3%). BHR to methacholine was higher among parents of nonatopic asthmatic children (19.2%) and atopic asthmatic children (16.2%) than among those of atopic and nonatopic control children (5.1% and 1.3%, respectively). The percentage of positive skin test responses to 10 inhalant allergens was higher among parents of atopic asthmatic children (43.9%), nonatopic asthmatic children (39.4%), and atopic control children (38.5%) than among those of nonatopic control children (23.7%). Geometric means (IU/mL + SEM) of total serum IgE were higher among parents of atopic and nonatopic control children than among those of nonatopic control children (2.11 +/- 0.05 vs 2.20 +/- 0.06 vs 2.09 +/- 0.07 vs 1.92 +/- 0.06). Conclusion: Nonatopic asthma runs in families. The prevalence of positive skin test responses to inhalant allergens, BHR to methacholine, and total serum IgE levels is higher among the parents of nonatopic and atopic asthmatic children than among those of nonatopic control children.	Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 110744, South Korea; Seoul Natl Univ, Med Res Ctr, Inst Allergy & Clin Immunol, Seoul, South Korea; Seoul Natl Univ, Coll Med, Dept Pediat, Seoul 110744, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU)	Kim, YY (corresponding author), Seoul Natl Univ, Coll Med, Dept Internal Med, 28 Youngun Dong, Seoul 110744, South Korea.		Cho, Sang Heon/J-2793-2012; Min, Kyung-Up/J-5468-2012; Koh, Young Yull/J-5368-2012; Koh, Young Yull/D-6059-2012	Jee, Young-Koo/0000-0001-5800-8038				AAS K, 1969, ARCH DIS CHILD, V44, P1, DOI 10.1136/adc.44.233.1; [Anonymous], 1959, Thorax, V14, P286, DOI 10.1136/thx.14.4.286; Boulet LP, 1997, CLIN EXP ALLERGY, V27, P52, DOI 10.1111/j.1365-2222.1997.tb00672.x; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BURROWS B, 1992, J ALLERGY CLIN IMMUN, V90, P376, DOI 10.1016/S0091-6749(05)80018-1; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; Charpin J, 1971, Poumon Coeur, V27, P111; CLIFFORD RD, 1987, ARCH DIS CHILD, V62, P66, DOI 10.1136/adc.62.1.66; DORWARD AJ, 1988, THORAX, V43, P98, DOI 10.1136/thx.43.2.98; DUFFY DL, 1990, AM REV RESPIR DIS, V142, P1351, DOI 10.1164/ajrccm/142.6_Pt_1.1351; EDFORSLUBS ML, 1971, ACTA ALLERGOL, V26, P249, DOI 10.1111/j.1398-9995.1971.tb01300.x; HOPP RJ, 1988, ANN ALLERGY, V61, P184; HOPP RJ, 1984, J ALLERGY CLIN IMMUN, V73, P265, DOI 10.1016/S0091-6749(84)80018-4; HOPP RJ, 1990, AM REV RESPIR DIS, V141, P2, DOI 10.1164/ajrccm/141.1.2; Humbert M, 1996, AM J RESP CRIT CARE, V153, P1931, DOI 10.1164/ajrccm.153.6.8665058; Humbert M, 1996, AM J RESP CRIT CARE, V154, P1497, DOI 10.1164/ajrccm.154.5.8912771; Jenkins M A, 1993, Paediatr Perinat Epidemiol, V7, P67, DOI 10.1111/j.1365-3016.1993.tb00602.x; KONIG P, 1973, ARCH DIS CHILD, V48, P513, DOI 10.1136/adc.48.7.513; LOFFUS BG, 1986, CLIN ALLERGY, V16, P251; MENEELY GR, 1962, AM REV RESPIR DIS, V85, P762; MOLINA C, 1977, CLIN ALLERGY, V7, P137, DOI 10.1111/j.1365-2222.1977.tb01434.x; *NAT HEART LUNG BL, 1992, 923091 PUBL; OCONNOR GT, 1989, AM REV RESPIR DIS, V140, P225, DOI 10.1164/ajrccm/140.1.225; OSTERGAARD PA, 1985, ACTA PAEDIATR SCAND, V74, P713, DOI 10.1111/j.1651-2227.1985.tb10019.x; PEAT JK, 1991, AM REV RESPIR DIS, V144, P663, DOI 10.1164/ajrccm/144.3_Pt_1.663; PEPYS J, 1973, CLIN ALLERGY, V3, P491, DOI 10.1111/j.1365-2222.1973.tb03057.x; PIRSON F, 1991, ALLERGY, V46, P367, DOI 10.1111/j.1398-9995.1991.tb00600.x; RACKEMANN FM, 1947, AM J MED, V3, P601, DOI 10.1016/0002-9343(47)90204-0; Rackemann FM, 1918, ARCH INTERN MED, V22, P517; SCHWARTZ M, 1952, HEREDITY BRONCHIAL A; SIBBALD B, 1980, THORAX, V35, P671, DOI 10.1136/thx.35.9.671; SIBBALD B, 1986, SEMIN RESPIR MED, V7, P307, DOI 10.1055/s-2007-1012626; SIBBALD B, 1979, THORAX, V34, P322; TOELLE BG, 1992, AM REV RESPIR DIS, V146, P633, DOI 10.1164/ajrccm/146.3.633; WILLIAMS H, 1969, BRIT MED J, V4, P321, DOI 10.1136/bmj.4.5679.321	37	23	25	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1999	104	2	1				311	316		10.1016/S0091-6749(99)70372-6	http://dx.doi.org/10.1016/S0091-6749(99)70372-6			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	232HH	10452750				2022-12-18	WOS:000082364800021
J	Fernandez-Anaya, S; Crespo, JF; Rodriguez, JR; Daroca, P; Carmona, E; Herraez, L; Lopez-Rubio, A				Fernandez-Anaya, S; Crespo, JF; Rodriguez, JR; Daroca, P; Carmona, E; Herraez, L; Lopez-Rubio, A			Beer anaphylaxis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							URTICARIA		Hosp Univ Doce Octubre, Sch Med, Serv Alergia Hosp, Div Allergy, Madrid 28041, Spain	Hospital Universitario 12 de Octubre	Fernandez-Anaya, S (corresponding author), Hosp Univ Doce Octubre, Sch Med, Serv Alergia Hosp, Div Allergy, Ctra Andalucia,Km 5-400, Madrid 28041, Spain.							Gutgesell C, 1995, CONTACT DERMATITIS, V33, P436, DOI 10.1111/j.1600-0536.1995.tb02088.x; KELLER K, 1994, CONTACT DERMATITIS, V30, P44, DOI 10.1111/j.1600-0536.1994.tb00731.x; Santucci B, 1996, CONTACT DERMATITIS, V34, P368, DOI 10.1111/j.1600-0536.1996.tb02229.x; VANKETEL WG, 1980, CONTACT DERMATITIS, V6, P297, DOI 10.1111/j.1600-0536.1980.tb04946.x; VIDAL C, 1995, ANN ALLERG ASTHMA IM, V75, P121	5	23	23	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1999	103	5	1				959	960		10.1016/S0091-6749(99)70449-5	http://dx.doi.org/10.1016/S0091-6749(99)70449-5			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	199FP	10329839				2022-12-18	WOS:000080470200040
J	Tarlo, SM				Tarlo, SM			Diisocyanate sensitization and antibody production	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material							INDUCED OCCUPATIONAL ASTHMA; ISOCYANATE-INDUCED ASTHMA; WORKERS; SERUM; MDI; IGE		Toronto Hosp, Western Div, Div Resp, Toronto, ON M5T 2S8, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto	Tarlo, SM (corresponding author), Toronto Hosp, Western Div, Div Resp, Edith Cavell Wing,Suite 4-009,399 Bathurst St, Toronto, ON M5T 2S8, Canada.			Tarlo, Susan/0000-0002-4746-5310				Aul DJ, 1999, J ALLERGY CLIN IMMUN, V103, P749, DOI 10.1016/S0091-6749(99)70415-X; BANKS DE, 1989, CHEST, V95, P414, DOI 10.1378/chest.95.2.414; BENTLEY AM, 1992, J ALLERGY CLIN IMMUN, V89, P821, DOI 10.1016/0091-6749(92)90437-7; CARTIER A, 1989, J ALLERGY CLIN IMMUN, V84, P507, DOI 10.1016/0091-6749(89)90364-3; FABBRI LM, 1994, CLIN EXP ALLERGY, V24, P628, DOI 10.1111/j.1365-2222.1994.tb00966.x; Leroyer C, 1998, THORAX, V53, P152, DOI 10.1136/thx.53.2.152; Lummus ZL, 1998, J ALLERGY CLIN IMMUN, V102, P265, DOI 10.1016/S0091-6749(98)70095-8; Lushniak BD, 1998, AM J IND MED, V33, P471, DOI 10.1002/(SICI)1097-0274(199805)33:5<471::AID-AJIM6>3.0.CO;2-V; MALO JL, 1990, CHEST, V98, pS236, DOI 10.1378/chest.98.5.236S; MATTE TD, 1990, CHEST, V98, pS173, DOI 10.1378/chest.98.5_Supplement.173S; MEREDITH SK, 1991, BRIT J IND MED, V48, P292; Son Minsik, 1998, Journal of Korean Medical Science, V13, P147; Tarlo S M, 1998, Can Respir J, V5, P289; TARLO SM, 1989, CHEST, V96, P297, DOI 10.1378/chest.96.2.297; Tarlo SM, 1997, OCCUP ENVIRON MED, V54, P756, DOI 10.1136/oem.54.10.756; Tee RD, 1998, J ALLERGY CLIN IMMUN, V101, P709, DOI 10.1016/S0091-6749(98)70181-2; VANDENPLAS O, 1993, AM REV RESPIR DIS, V147, P338, DOI 10.1164/ajrccm/147.2.338; VANDENPLAS O, 1992, J ALLERGY CLIN IMMUN, V89, P1183, DOI 10.1016/0091-6749(92)90303-J; WASS U, 1989, J ALLERGY CLIN IMMUN, V83, P126, DOI 10.1016/0091-6749(89)90487-9	19	23	23	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1999	103	5	1				739	741		10.1016/S0091-6749(99)70413-6	http://dx.doi.org/10.1016/S0091-6749(99)70413-6			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	199FP	10329803				2022-12-18	WOS:000080470200003
J	Eggleston, PA; Creticos, PS; Lockey, R; Platts-Mills, TAE; Sheffer, A; Taggart, VS; Shapas, TJ; Clobes, A; Scheuttenberg, W; Shapas, TJ				Eggleston, PA; Creticos, PS; Lockey, R; Platts-Mills, TAE; Sheffer, A; Taggart, VS; Shapas, TJ; Clobes, A; Scheuttenberg, W; Shapas, TJ		Ad Hoc Working Grp Environm Allergens	Environmental allergen avoidance in allergic asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material							DUST MITE ALLERGEN; INNER-CITY CHILDREN; HOUSE-DUST; CONTROLLED TRIAL; BRONCHIAL HYPERRESPONSIVENESS; COCKROACH ALLERGEN; CHANGING PATTERNS; FELIS-DOMESTICUS; PARTICLE-SIZE; RISK-FACTORS		Amer Acad Allergy Asthma & Immunol, Execut Off, Milwaukee, WI 53202 USA; NHLBI, Bethesda, MD USA; Allergy Control Prod Inc, Bethesda, MD USA; Honeywell Inc, Minneapolis, MN 55408 USA; Clorox Co, Oakland, CA USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Honeywell	Eggleston, PA (corresponding author), Amer Acad Allergy Asthma & Immunol, Execut Off, 611 E Wells St, Milwaukee, WI 53202 USA.			Platts-Mills, Thomas/0000-0002-1263-329X				ANTO JM, 1989, NEW ENGL J MED, V320, P1097, DOI 10.1056/NEJM198904273201701; BRYANT DH, 1976, MED J AUSTRALIA, V1, P918, DOI 10.5694/j.1326-5377.1976.tb141170.x; BURGE HA, 1989, IMMUNOL ALLERGY CLIN, V9, P307; BURR ML, 1980, THORAX, V35, P506, DOI 10.1136/thx.35.7.506; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; CABRERA P, 1995, J ALLERGY CLIN IMMUN, V95, P635, DOI 10.1016/S0091-6749(95)70328-4; CALL RS, 1992, J PEDIATR-US, V121, P862, DOI 10.1016/S0022-3476(05)80329-4; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; Custovic A, 1997, AM J RESP CRIT CARE, V155, P94, DOI 10.1164/ajrccm.155.1.9001295; DIETEMANN A, 1993, J ALLERGY CLIN IMMUN, V91, P738, DOI 10.1016/0091-6749(93)90193-J; DOWSE GK, 1985, J ALLERGY CLIN IMMUN, V75, P75, DOI 10.1016/0091-6749(85)90016-8; EGGLESTON PA, 1992, AM REV RESPIR DIS, V45, P213; EHNERT B, 1992, J ALLERGY CLIN IMMUN, V90, P135, DOI 10.1016/S0091-6749(06)80024-2; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573, DOI 10.1164/ajrccm/147.3.573; GERGEN PJ, 1990, JAMA-J AM MED ASSOC, V264, P1688, DOI 10.1001/jama.264.13.1688; GERRITSEN J, 1990, J ALLERGY CLIN IMMUN, V85, P116, DOI 10.1016/0091-6749(90)90232-S; HAYDEN ML, 1992, J ALLERGY CLIN IMMUN, V89, P536, DOI 10.1016/0091-6749(92)90320-2; HUSS K, 1992, J ALLERGY CLIN IMMUN, V89, P836, DOI 10.1016/0091-6749(92)90439-9; KNIEST FM, 1991, CLIN EXP ALLERGY, V21, P39, DOI 10.1111/j.1365-2222.1991.tb00802.x; KORSGAARD J, 1982, AM REV RESPIR DIS, V125, P80; LUCZYNSKA CM, 1990, AM REV RESPIR DIS, V141, P361, DOI 10.1164/ajrccm/141.2.361; MCDONALD LG, 1992, J ALLERGY CLIN IMMUN, V90, P599, DOI 10.1016/0091-6749(92)90132-L; MURRAY AB, 1983, PEDIATRICS, V71, P418; *NAT ASTHM ED PROG, 1997, DHHS NIH PUB; Nelson RP, 1996, J ALLERGY CLIN IMMUN, V98, P258, DOI 10.1016/S0091-6749(96)70148-3; OHOLLAREN MT, 1991, NEW ENGL J MED, V324, P359, DOI 10.1056/NEJM199102073240602; PEAT JK, 1987, CLIN ALLERGY, V17, P291, DOI 10.1111/j.1365-2222.1987.tb02017.x; PERONI DG, 1994, AM J RESP CRIT CARE, V149, P1442, DOI 10.1164/ajrccm.149.6.8004296; PLATTSMILLS TAE, 1993, AM REV RESPIR DIS, V148, P553, DOI 10.1164/ajrccm/148.3.553; PLATTSMILLS TAE, 1982, LANCET, V2, P675; POLLART SM, 1989, J ALLERGY CLIN IMMUN, V83, P875, DOI 10.1016/0091-6749(89)90100-0; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Sarpong SB, 1996, ANN ALLERG ASTHMA IM, V76, P257, DOI 10.1016/S1081-1206(10)63437-0; SHEFFER AL, 1992, EUR RESPIR J, V5, P601; SOLOMON WR, 1993, ALLERGY PRINCIPLES P, P469; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; STEWART GA, 1995, ASTHMA RHINITIS, P898; TOVEY ER, 1981, AM REV RESPIR DIS, V124, P630; VANMETRE TE, 1986, J ALLERGY CLIN IMMUN, V78, P62, DOI 10.1016/0091-6749(86)90116-8; WALSHAW MJ, 1986, Q J MED, V58, P199; WEISS KB, 1990, JAMA-J AM MED ASSOC, V264, P1683, DOI 10.1001/jama.264.13.1683; WEITZMAN, 1992, JAMA-J AM MED ASSOC, V268, P3673; WISSOW LS, 1988, AM J PUBLIC HEALTH, V78, P777, DOI 10.2105/AJPH.78.7.777; WOOD RA, 1989, J ALLERGY CLIN IMMUN, V83, P730, DOI 10.1016/0091-6749(89)90006-7; 1990, MMWR MORB MORTAL WKL, V39, P493	45	23	23	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1999	103	2	1				203	205						3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	167JW					2022-12-18	WOS:000078630100004
J	Simons, FER				Simons, FER			Benefits and risks of inhaled glucocorticoids in children with persistent asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Festschrift Meeting in Honor of Jerry Dolovich	MAY 24, 1997	HAMILTON, CANADA	McMaster Univ, Fac Hlth Sci, Astra Canada			LONG-TERM TREATMENT; BECLOMETHASONE DIPROPIONATE; CHILDHOOD ASTHMA; FLUTICASONE PROPIONATE; CORTICOSTEROID BUDESONIDE; PREPUBERTAL CHILDREN; GROWTH-RETARDATION; COLLAGEN TURNOVER; BRONCHIAL-ASTHMA; ADRENAL-FUNCTION	In children, an inhaled glucocorticoid is currently the medication of choice for the long-term control of persistent asthma, Inhaled glucocorticoids are significantly more effective than nonsteroidal medications on all outcome measures of asthma treatment. They reduce the frequency of symptoms and of acute asthma exacerbations, decrease the need for "rescue" medications, improve airway patency, and reduce airway hyperresponsiveness. These considerable long-term benefits are worth the minimal risks of clinically significant local ol systemic adverse effects. An inhaled glucocorticoid should be used in the lowest dose that prevents symptoms and eliminates the need for supplemental courses of ingested glucocorticoids, Pulmonary function and height velocity of children receiving an inhaled glucocorticoid should be monitored at regular intervals.	Univ Manitoba, Dept Pediat & Child Hlth, Winnipeg, MB R3T 2N2, Canada	University of Manitoba	Simons, FER (corresponding author), Childrens Hosp Winnipeg, 820 Sherbrook St, Winnipeg, MB, Canada.							Adkinson NF, 1997, NEW ENGL J MED, V336, P324, DOI 10.1056/NEJM199701303360502; AGERTOFT L, 1994, RESP MED, V88, P373, DOI 10.1016/0954-6111(94)90044-2; Agertoft L, 1998, AM J RESP CRIT CARE, V157, P178, DOI 10.1164/ajrccm.157.1.9707072; ALLEN DB, 1994, J ALLERGY CLIN IMMUN, V93, P967, DOI 10.1016/S0091-6749(94)70043-5; Allen DB, 1998, J PEDIATR-US, V132, P472, DOI 10.1016/S0022-3476(98)70023-X; BALFOURLYNN L, 1986, ARCH DIS CHILD, V61, P1049, DOI 10.1136/adc.61.11.1049; Barnes PJ, 1996, EUR RESPIR J, V9, pS154; BARNES PJ, 1997, ALLERGY ALLERGIC DIS, P619; Bender B, 1997, ANN ALLERG ASTHMA IM, V79, P177, DOI 10.1016/S1081-1206(10)63001-3; Birkebaek NH, 1995, ARCH DIS CHILD, V73, P524, DOI 10.1136/adc.73.6.524; BISGAARD H, 1988, J ALLERGY CLIN IMMUN, V81, P1088, DOI 10.1016/0091-6749(88)90874-3; Bisgaard H, 1998, AM J RESP CRIT CARE, V157, P518, DOI 10.1164/ajrccm.157.2.9705025; BISGAARD H, 1994, EUR RESPIR J, V7, P740, DOI 10.1183/09031936.94.07040740; CHOONG K, 1995, PEDIATR INFECT DIS J, V14, P809; CONNETT G, 1991, LANCET, V338, P634, DOI 10.1016/0140-6736(91)90646-7; CROWLEY S, 1995, J PEDIATR-US, V126, P297, DOI 10.1016/S0022-3476(95)70566-X; Donahue JG, 1997, JAMA-J AM MED ASSOC, V277, P887, DOI 10.1001/jama.277.11.887; DOULL IJM, 1995, AM J RESP CRIT CARE, V151, P1715, DOI 10.1164/ajrccm.151.6.7767512; Doull IJM, 1998, ARCH DIS CHILD, V78, P172, DOI 10.1136/adc.78.2.172; FERGUSON AC, 1982, J ALLERGY CLIN IMMUN, V69, P461, DOI 10.1016/0091-6749(82)90122-1; GODFREY S, 1974, ARCH DIS CHILD, V49, P591, DOI 10.1136/adc.49.8.591; GROSS G, 1997, AM J RESP CRIT CARE, V155, pA666; GUSTAFSSON P, 1993, ARCH DIS CHILD, V69, P206, DOI 10.1136/adc.69.2.206; HOPP RJ, 1995, PEDIATR PULM, V20, P189, DOI 10.1002/ppul.1950200311; HUNT GJJ, 1994, THORAX, V49, pP399; Inoue T, 1995, Arerugi, V44, P678; JAKOBSSON T, 1994, ALLERGY, V49, P413, DOI 10.1111/j.1398-9995.1994.tb00833.x; Kamada AK, 1996, AM J RESP CRIT CARE, V153, P1739, DOI 10.1164/ajrccm.153.6.8665030; KATZ Y, 1996, AM J RESP CRIT CAR S, V156, pA74; KERREBIJN KF, 1987, J ALLERGY CLIN IMMUN, V79, P653, DOI 10.1016/S0091-6749(87)80163-X; Knorr B, 1998, JAMA-J AM MED ASSOC, V279, P1181, DOI 10.1001/jama.279.15.1181; KONIG P, 1993, J PEDIATR-US, V122, P219, DOI 10.1016/S0022-3476(06)80116-2; Konig P, 1996, J ALLERGY CLIN IMMUN, V98, P1103, DOI 10.1016/S0091-6749(96)80198-9; LANDWEHR LP, 1995, CLIN IMMUNOTHER, V4, P124, DOI 10.1007/BF03259077; LEBOURGEOIS M, 1995, J ALLERGY CLIN IMMUN, V96, P565, DOI 10.1016/S0091-6749(95)70305-5; LEBOURGEOIS M, 1993, AM REV RESPIR DIS, V147, pA265; LITTLEWOOD JM, 1988, LANCET, V1, P115; LLANGOVAN P, 1993, ARCH DIS CHILD, V68, P356; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; MELTZER EO, 1982, PEDIATRICS, V69, P340; MERKUS PJFM, 1993, PEDIATRICS, V91, P1121; MURPHY S, 1997, NIH PUBLICATION; NASSIF E, 1987, J ALLERGY CLIN IMMUN, V80, P518, DOI 10.1016/0091-6749(87)90002-9; NICOLAIZIK WH, 1994, AM J RESP CRIT CARE, V150, P624, DOI 10.1164/ajrccm.150.3.8087329; PEDERSEN S, 1995, J ALLERGY CLIN IMMUN, V95, P29, DOI 10.1016/S0091-6749(95)70149-4; Pedersen S, 1997, ALLERGY, V52, P1, DOI 10.1111/j.1398-9995.1997.tb05047.x; PEDERSEN S, 1995, AM J RESP CRIT CARE, V151, pS27, DOI 10.1164/ajrccm/151.2_Pt_2.S27; PHILLIP M, 1992, PEDIATR PULM, V12, P84, DOI 10.1002/ppul.1950120205; PRAHL P, 1991, CLIN EXP ALLERGY, V21, P145, DOI 10.1111/j.1365-2222.1991.tb00817.x; Price JF, 1997, PEDIATR PULM, V24, P178; RAO R, 1997, AM J RESP CRIT CARE, V155, pA267; Saha MT, 1997, ACTA PAEDIATR, V86, P138, DOI 10.1111/j.1651-2227.1997.tb08854.x; SCHLEIMER RP, 1997, TOPICAL GLUCOCORTICO, P203; SHAPIRO GG, 1991, J ALLERGY CLIN IMMUN, V88, P742, DOI 10.1016/0091-6749(91)90181-M; Silverstein MD, 1997, J ALLERGY CLIN IMMUN, V99, P466, DOI 10.1016/S0091-6749(97)70072-1; Simons FER, 1997, PEDIATRICS, V99, P655, DOI 10.1542/peds.99.5.655; Simons FER, 1997, NEW ENGL J MED, V337, P1659, DOI 10.1056/NEJM199712043372304; SIMONS FER, 1993, LANCET, V342, P776, DOI 10.1016/0140-6736(93)91541-S; SIMONS FER, 1996, HISTAMINE H1 RECEPTO, P329; TABACHNIK E, 1991, J PEDIATR-US, V118, P294, DOI 10.1016/S0022-3476(05)80506-2; THOMAS BC, 1994, ACTA PAEDIATR, V83, P196, DOI 10.1111/j.1651-2227.1994.tb13050.x; TINKELMAN DG, 1993, PEDIATRICS, V92, P64; Todd G, 1996, LANCET, V348, P27, DOI 10.1016/S0140-6736(96)03339-9; TONASCIA J, 1999, INPRESS CONTROL CLIN; TURPEINEN M, 1991, J ALLERGY CLIN IMMUN, V88, P384, DOI 10.1016/0091-6749(91)90101-S; VANESSENZANDVLIET EE, 1994, EUR RESPIR J, V7, P63, DOI 10.1183/09031936.94.07010063; VANESSENZANDVLIET EE, 1992, AM REV RESPIR DIS, V146, P547, DOI 10.1164/ajrccm/146.3.547; Verberne AAPH, 1997, AM J RESP CRIT CARE, V156, P688, DOI 10.1164/ajrccm.156.3.9611067; VOLOVITZ B, 1993, NEW ENGL J MED, V329, P1703, DOI 10.1056/NEJM199312023292305; WAALKENS HJ, 1993, AM REV RESPIR DIS, V148, P1252, DOI 10.1164/ajrccm/148.5.1252; WAALKENS HJ, 1991, THORAX, V46, P499, DOI 10.1136/thx.46.7.499; WALES JKH, 1991, LANCET, V338, P1535, DOI 10.1016/0140-6736(91)92362-6; Wennergren G, 1996, ACTA PAEDIATR, V85, P183, DOI 10.1111/j.1651-2227.1996.tb13989.x; White AJ, 1997, J ALLERGY CLIN IMMUN, V99, P1330; Wolthers OD, 1997, PEDIATR RES, V41, P44, DOI 10.1203/00006450-199701000-00007; Wolthers OD, 1996, EUR RESPIR J, V9, P821, DOI 10.1183/09031936.96.09040821; ZWAAN CM, 1992, LANCET, V340, P1289, DOI 10.1016/0140-6736(92)92991-N	77	23	25	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1998	102	5					S77	S84		10.1016/S0091-6749(98)70035-1	http://dx.doi.org/10.1016/S0091-6749(98)70035-1			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	139MR	9819313	Bronze			2022-12-18	WOS:000077033400031
J	Rancinan, C; Morlat, P; Chene, G; Guez, S; Baquey, A; Beylot, J; Salamon, R				Rancinan, C; Morlat, P; Chene, G; Guez, S; Baquey, A; Beylot, J; Salamon, R			IgE serum level: A prognostic marker for AIDS in HIV-infected adults?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							ELEVATION		Univ Bordeaux 2, INSERM, U 330, F-33076 Bordeaux, France; Hop St Andre, Serv Med Interne & Malad Infect, Bordeaux, France; Hop Pellegrin Tripode, Serv Informat Med, Bordeaux, France; Hop Pellegrin Tripode, Serv Med Interne, Bordeaux, France; Hop Pellegrin Tripode, Immunol Lab, Bordeaux, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; CHU Bordeaux; CHU Bordeaux; CHU Bordeaux; CHU Bordeaux	Rancinan, C (corresponding author), Univ Bordeaux 2, INSERM, U 330, 146 Rue Leo Saignat, F-33076 Bordeaux, France.		chene, genevieve/H-8665-2014	chene, genevieve/0000-0002-8368-6460				Gascan H, 1991, Clin Exp Allergy, V21 Suppl 1, P162, DOI 10.1111/j.1365-2222.1991.tb01721.x; ISRAELBIET D, 1992, J ALLERGY CLIN IMMUN, V89, P68, DOI 10.1016/S0091-6749(05)80042-9; LUCEY DR, 1990, AIDS RES HUM RETROV, V6, P427, DOI 10.1089/aid.1990.6.427; Rancinan C, 1997, REV MED INTERNE, V18, P691, DOI 10.1016/S0248-8663(97)83747-2; VIGANO A, 1995, J ALLERGY CLIN IMMUN, V95, P627, DOI 10.1016/S0091-6749(95)70326-8	5	23	24	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1998	102	2					329	330		10.1016/S0091-6749(98)70107-1	http://dx.doi.org/10.1016/S0091-6749(98)70107-1			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	113EH	9723683				2022-12-18	WOS:000075537100032
J	Shah, S; Cawley, M; Gleeson, R; O'Connor, J; McGeady, S				Shah, S; Cawley, M; Gleeson, R; O'Connor, J; McGeady, S			Latex allergy and latex sensitization in children and adolescents with meningomyelocele	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						latex; clinical allergy sensitization; age; surgical procedures; atopic status; skin prick test; Ala STAT rest	SPINA-BIFIDA PATIENTS; RISK-FACTORS; IGE; HYPERSENSITIVITY; PREVALENCE; REACTIVITY; HEALTH; SKIN; ANAPHYLAXIS; PERSONNEL	Background: The high prevalence of clinical latex allergy and latex sensitization in children with meningomyelocele has been widely reported. It has also been noted that these same children have a higher than expected prevalence of atopic disease. It would be useful to have a safe, sensitive, and specific skin test to detect latex sensitivity and to know how web this test compares with available in vitro tests. It would likewise be helpful to know as fully as possible the characteristics ties of the individual and to evaluate the relative importance of factors suspected to contribute to clinical latex allergy and latex sensitization in this population. Methods: A group of 116 children and adolescents 1 to 20 years of age were recruited for the study, An extensive history of latex allergy, atopic diseases, and surgical procedures was taken on all subjects. Each subject had either a latex skin test or an in vitro study for latex-specific IgE, and 67 subjects had both tests simultaneously. Eighty-five subjects had epicutaneous skin tests to a panel of environmental allergens. Results: Overall, 25 of 116 (21.5%) subjects had a history of clinical latex allergy, and 51 of 116 (44%) were sensitized to latex. The sensitivity and specificity of skin tests for clinical latex allergy were slightly greater than for the in vitro test (100% vs 95.8% and 82.3% vs 68.9%, respectively). The positive predictive value and negative predictive value of skin testing for clinical latex allergy were also greater (67.6% vs 50% and 100% vs 98.1%, respectively). Age was found to be a significant variable for both latex allergy and latex sensitization. The number of surgical procedures undergone and the presence of positive skin test responses to environmental allergens were significantly correlated with latex sensitization but not with clinical allergy to latex. Conclusions: A sensitive, specific, and safe skin test for latex sensitivity appears superior to in vitro testing for latex allergy. Age, number of surgical procedures, and the presence of positive allergen skin test responses are significantly correlated with latex sensitization. Age alone is significantly correlated with clinical allergy to latex.	Thomas Jefferson Univ, Philadelphia, PA 19107 USA; duPont Hosp Children, Nemours Fdn, Alfred I Dupont Inst, Wilmington, DE 19801 USA	Jefferson University; Nemours Alfred I. duPont Hospital for Children	McGeady, S (corresponding author), 2B-29,1600 Rockland Rd, Wilmington, DE 19899 USA.							ALENIUS H, 1993, INT ARCH ALLERGY IMM, V102, P61, DOI 10.1159/000236551; BRADDING P, 1992, J EXP MED, V176, P1381, DOI 10.1084/jem.176.5.1381; BUBAK ME, 1992, MAYO CLIN PROC, V67, P1075, DOI 10.1016/S0025-6196(12)61122-7; CAPRILESHULETT A, 1995, ANN ALLERG ASTHMA IM, V75, P62; ELLSWORTH PI, 1993, J UROLOGY, V150, P691, DOI 10.1016/S0022-5347(17)35587-8; FISHER AA, 1992, J ALLERGY CLIN IMMUN, V90, P729, DOI 10.1016/0091-6749(92)90095-J; Friday GA, 1995, PEDIATR ASTHMA ALLER, V9, P189, DOI 10.1089/pai.1995.9.189; FUCHS D, 1997, J ALLERGY CLIN IMMUN, V100, P356; GERGEN PJ, 1987, J ALLERGY CLIN IMMUN, V80, P669, DOI 10.1016/0091-6749(87)90286-7; GOLD M, 1991, J ALLERGY CLIN IMMUN, V87, P662, DOI 10.1016/0091-6749(91)90385-2; Hamilton RG, 1996, J ALLERGY CLIN IMMUN, V98, P872, DOI 10.1016/S0091-6749(96)80003-0; Hollander A, 1996, J ALLERGY CLIN IMMUN, V98, P545, DOI 10.1016/S0091-6749(96)70088-X; Holt PG, 1996, J EXP MED, V183, P1297, DOI 10.1084/jem.183.4.1297; KELLY KJ, 1994, J ALLERGY CLIN IMMUN, V94, P53, DOI 10.1016/0091-6749(94)90071-X; KELLY KJ, 1993, J ALLERGY CLIN IMMUN, V91, P1140, DOI 10.1016/0091-6749(93)90316-8; KJELLMAN NIM, 1977, ACTA PAEDIATR SCAND, V66, P465, DOI 10.1111/j.1651-2227.1977.tb07928.x; KONZ KR, 1995, J ALLERGY CLIN IMMUN, V95, P950, DOI 10.1016/S0091-6749(95)70094-3; LUTSKY II, 1983, J OCCUP ENVIRON MED, V25, P372; MONERETVAUTRIN DA, 1993, J ALLERGY CLIN IMMUN, V92, P668, DOI 10.1016/0091-6749(93)90009-5; Nieto A, 1996, J ALLERGY CLIN IMMUN, V98, P501, DOI 10.1016/S0091-6749(96)70082-9; NYUGEN DH, 1991, J UROLOGY, V146, P578; OGARRA A, 1994, CURR OPIN IMMUNOL, V6, P458, DOI 10.1016/0952-7915(94)90128-7; Ownby DR, 1996, J ALLERGY CLIN IMMUN, V97, P1188, DOI 10.1016/S0091-6749(96)70183-5; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; PEARSON ML, 1994, DEV MED CHILD NEUROL, V36, P64, DOI 10.1111/j.1469-8749.1994.tb11767.x; ROSS BD, 1992, J ALLERGY CLIN IMMUN, V90, P409, DOI 10.1016/S0091-6749(05)80023-5; SCHROEDER JT, 1994, J IMMUNOL, V153, P1808; SCHUMACHER MJ, 1981, J ALLERGY CLIN IMMUN, V68, P310, DOI 10.1016/0091-6749(81)90157-3; SLATER JE, 1989, NEW ENGL J MED, V320, P1126, DOI 10.1056/NEJM198904273201707; SLATER JE, 1991, J UROLOGY, V146, P578, DOI 10.1016/S0022-5347(17)37860-6; SUSSMAN GL, 1991, JAMA-J AM MED ASSOC, V265, P2844, DOI 10.1001/jama.265.21.2844; TARLO SM, 1990, J ALLERGY CLIN IMMUN, V85, P626, DOI 10.1016/0091-6749(90)90103-B; TOSI LL, 1993, J PEDIATR ORTHOPED, V13, P709, DOI 10.1097/01241398-199311000-00003; TURJANMAA K, 1987, CONTACT DERMATITIS, V17, P270, DOI 10.1111/j.1600-0536.1987.tb01476.x; YASSIN MS, 1992, ANN ALLERGY, V69, P207; Yeang HY, 1996, J ALLERGY CLIN IMMUN, V98, P628, DOI 10.1016/S0091-6749(96)70097-0	36	23	23	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1998	101	6	1				741	746		10.1016/S0091-6749(98)70303-3	http://dx.doi.org/10.1016/S0091-6749(98)70303-3			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZW470	9648700				2022-12-18	WOS:000074414200005
J	Alibrahim, A; Lepore, M; Lierl, M; Filipovich, A; Assa'ad, A				Alibrahim, A; Lepore, M; Lierl, M; Filipovich, A; Assa'ad, A			Pneumocystis carinii pneumonia in an infant with X-linked agammaglobulinemia	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									Childrens Hosp, Med Ctr, Div Pulm Med, Cincinnati, OH 45229 USA; Childrens Hosp, Med Ctr, Div Clin Immunol & Allergy, Cincinnati, OH 45229 USA; Childrens Hosp, Med Ctr, Div Hematol & Oncol, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center	Assa'ad, A (corresponding author), Childrens Hosp, Med Ctr, Div Pulm Med, 3333 Burnet Ave, Cincinnati, OH 45229 USA.							BONAGURA VR, 1989, CLIN IMMUNOL IMMUNOP, V51, P216, DOI 10.1016/0090-1229(89)90021-4; JOSE DG, 1971, J PEDIATR-US, V79, P748, DOI 10.1016/S0022-3476(71)80386-4; LEDERMAN HM, 1985, MEDICINE, V64, P145, DOI 10.1097/00005792-198505000-00001; PANDU RC, 1983, J PEDIATR, V103, P410; STAUGAS REM, 1988, PEDIATR INFECT DIS J, V7, P724, DOI 10.1097/00006454-198810000-00012	5	23	23	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1998	101	4	1				552	553		10.1016/S0091-6749(98)70363-X	http://dx.doi.org/10.1016/S0091-6749(98)70363-X			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZH469	9564810	Bronze			2022-12-18	WOS:000073113500019
J	Norris, JG; Sullivan, TJ				Norris, JG; Sullivan, TJ			Leukotrienes and cytokines in steroid dependent chronic urticaria.	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	23	23	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1998	101	1	2			529	S128	S128						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YW339					2022-12-18	WOS:000071924800529
J	Kraneveld, AD; VanArk, I; VanderLinde, HJ; Fattah, D; Nijkamp, FP; VanOosterhout, AJM				Kraneveld, AD; VanArk, I; VanderLinde, HJ; Fattah, D; Nijkamp, FP; VanOosterhout, AJM			Antibody to very late activation antigen 4 prevents interleukin-5-induced airway hyperresponsiveness and eosinophil infiltration in the airways of guinea pigs	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						interleukin-5; airway hyperresponsiveness; eosinophil; very late activation antigen-4	INTEGRIN (CD11/18)-DEPENDENT MANNER; RECOMBINANT HUMAN INTERLEUKIN-5; COLONY-STIMULATING FACTOR; CELL-ADHESION MOLECULE-1; INVITRO ADHESION; MESSENGER-RNA; IL-5; ASTHMA; HYPERREACTIVITY; NEUTROPHILS	This study examines the effect of monoclonal antibody to very late activation antigen-4 (VLA-4) on IL5-induced airway hyperresponsiveness in vivo and eosinophil accumulation into guinea pig airways, IL5 has been shown to be important in the development of airway hyperresponsiveness and eosinophil accumulation in the guinea pig. Eosinophils, unlike neutrophils, express VLA-4 which mediates the adhesion to vascular cell adhesion molecule-1 on endothelial cells, Thus VLA-4 seems to be an important adhesion molecule in the infiltration of eosinophils from the vasculature into the airway tissue, In addition, it has been shown that IL5 activates VLA-4 on eosinophils to facilitate their adhesion, In the present study, IL5 (1 mu g, twice on one day) or vehicle were administered intranasally, Monoclonal antibody (mAb) to VLA-4 (HP1/2) or the isotype-matched control mAb (1E6) were injected 1 hour before each IL5 or vehicle treatment at a dose of 2.5 mg/kg body weight. The next day in vivo bronchial reactivity, eosinophil number in bronchoalveolar lavage (BAL) fluid, and eosinophil peroxidase (EPO) activity in cell-free BAL fluid were determined. IL5 induces an increase in bronchial reactivity to histamine, which is associated with an accumulation of eosinophils into BAL fluid (control: 12 (5 to 42) x 10(5) cells and IL5: 69 (11 to 99) x 10(5) cells, p < 0.05) and an increase of 35% +/- 14% in EPO activity in cell-free BAL fluid. Intravenous administration of anti-VLA-4 mAb, but not of the control antibody, completely inhibits the bronchial hyperresponsiveness as well as the airway eosinophilia found after intraairway application of IL5, HP1/2 also suppresses the IL5-induced increase in EPO activity in cell-free BAL fluid, In conclusion, for the development of IL5-induced airway hyperresponsiveness in the guinea pig, the VLA-4-dependent infiltration and activation of eosinophils in the bronchial tissue seems to be essential.	GLAXO GRP RES LTD,DEPT CELLULAR SCI,GREENFORD UB6 0HE,MIDDX,ENGLAND	GlaxoSmithKline	Kraneveld, AD (corresponding author), UNIV UTRECHT,DEPT PHARMACOL & PATHOPHYSIOL,UTRECHT INST PHARMACEUT SCI,POB 80-082,NL-3508 TB UTRECHT,NETHERLANDS.		Kraneveld, Aletta D/J-3351-2016	Kraneveld, Aletta D/0000-0001-9819-383X				AMDUR MO, 1958, AM J PHYSIOL, V192, P364, DOI 10.1152/ajplegacy.1958.192.2.364; ANWAR ARE, 1994, IMMUNOLOGY, V82, P222; CLUTTERBUCK EJ, 1989, BLOOD, V73, P1504; COFFMAN RL, 1989, SCIENCE, V245, P308, DOI 10.1126/science.2787531; CORRIGAN CJ, 1992, IMMUNOL TODAY, V13, P501, DOI 10.1016/0167-5699(92)90026-4; DAS AM, 1995, IMMUNOLOGY, V84, P41; DOBRINA A, 1991, J CLIN INVEST, V88, P20, DOI 10.1172/JCI115278; FATTAH D, 1994, AM REV RESPIR DIS, V149, pA834; FUJISAWA T, 1990, J IMMUNOL, V144, P642; GARSSEN J, 1991, AM REV RESPIR DIS, V144, P931, DOI 10.1164/ajrccm/144.4.931; GERBLICH AA, 1991, AM REV RESPIR DIS, V143, P533, DOI 10.1164/ajrccm/143.3.533; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; HORIE S, 1994, J IMMUNOL, V152, P5457; KAY AB, 1991, J ALLERGY CLIN IMMUN, V87, P893, DOI 10.1016/0091-6749(91)90408-G; KAY AB, 1991, J EXP MED, V173, P775, DOI 10.1084/jem.173.3.775; LOPEZ AF, 1988, J EXP MED, V167, P219, DOI 10.1084/jem.167.1.219; MAUSER PJ, 1993, AM REV RESPIR DIS, V148, P1623, DOI 10.1164/ajrccm/148.6_Pt_1.1623; MIGITA M, 1991, CELL IMMUNOL, V133, P484, DOI 10.1016/0008-8749(91)90120-Z; NAKAJIMA H, 1994, J EXP MED, V179, P1145, DOI 10.1084/jem.179.4.1145; NEELEY SP, 1993, AM J RESP CELL MOL, V8, P633, DOI 10.1165/ajrcmb/8.6.633; OBYRNE PM, 1988, J ALLERGY CLIN IMMUN, V81, P119, DOI 10.1016/0091-6749(88)90230-8; OHKAWARA Y, 1995, AM J RESP CELL MOL, V12, P4, DOI 10.1165/ajrcmb.12.1.7529029; PRETOLANI M, 1994, AM J RESP CRIT CARE, V149, P1167, DOI 10.1164/ajrccm.149.5.8173756; PRETOLANI M, 1994, J EXP MED, V180, P795, DOI 10.1084/jem.180.3.795; PRETOLANI M, 1992, BRIT J PHARMACOL, V106, P677, DOI 10.1111/j.1476-5381.1992.tb14394.x; PULIDO R, 1991, J BIOL CHEM, V266, P10241; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; SANDERSON CJ, 1992, BLOOD, V79, P3101, DOI 10.1182/blood.V79.12.3101.3101; SCHLEIMER RP, 1992, J IMMUNOL, V148, P1086; SIBILLE Y, 1990, AM REV RESPIR DIS, V141, P471, DOI 10.1164/ajrccm/141.2.471; STRATH M, 1985, J IMMUNOL METHODS, V83, P209, DOI 10.1016/0022-1759(85)90242-X; Teixeira MM, 1995, TRENDS PHARMACOL SCI, V16, P418; VANOOSTERHOUT AJM, 1990, LIFE SCI, V46, P1255, DOI 10.1016/0024-3205(90)90357-W; VANOOSTERHOUT AJM, 1993, EUR J PHARMACOL, V236, P379, DOI 10.1016/0014-2999(93)90475-W; VanOosterhout AJM, 1996, EUR RESPIR J, V9, P493, DOI 10.1183/09031936.96.09030493; VANOOSTERHOUT AJM, 1994, MEDIAT INFLAMM, V3, P53, DOI 10.1155/S0962935194000098; VANOOSTERHOUT AJM, 1995, J ALLERGY CLIN IMMUN, V96, P104, DOI 10.1016/S0091-6749(95)70039-0; VANOOSTERHOUT AJM, 1993, AM REV RESPIR DIS, V147, P548, DOI 10.1164/ajrccm/147.3.548; WALSH GM, 1991, INT ARCH ALLER A IMM, V94, P174, DOI 10.1159/000235355; WALSH GM, 1990, IMMUNOLOGY, V71, P258; WANG JM, 1989, EUR J IMMUNOL, V19, P701, DOI 10.1002/eji.1830190420; WARRINGA RAJ, 1992, AM J RESP CELL MOL, V7, P631, DOI 10.1165/ajrcmb/7.6.631; WEG VB, 1993, J EXP MED, V177, P561, DOI 10.1084/jem.177.2.561; WELLER PF, 1991, P NATL ACAD SCI USA, V88, P7403	44	23	24	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1997	100	2					242	250		10.1016/S0091-6749(97)70231-8	http://dx.doi.org/10.1016/S0091-6749(97)70231-8			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	XR351	9275147				2022-12-18	WOS:A1997XR35100016
J	Neukirch, F; LyonCaen, O; Clanet, M; Bousquet, J; Feingold, J; Druet, P				Neukirch, F; LyonCaen, O; Clanet, M; Bousquet, J; Feingold, J; Druet, P			Asthma, nasal allergies, and multiple sclerosis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter											Neukirch, F (corresponding author), UNIV PARIS 07,BP 416,F-75870 PARIS 18,FRANCE.		Bousquet, Jean/O-4221-2019					BURNEY PGJ, 1994, EUR RESPIR J, V7, P954, DOI 10.1183/09031936.94.07050954; NEUKIRCH F, 1995, RESP MED, V89, P685, DOI 10.1016/0954-6111(95)90136-1; ORO, 1996, J ALLERGY CLIN IMMUN, V97, P1402	3	23	23	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1997	99	2					270	271						2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WH831	9042063				2022-12-18	WOS:A1997WH83100028
J	DesRoches, A; Paradis, L; Menardo, JL; Bouges, S; Daures, JP; Bougeard, YH; Bousquet, J				DesRoches, A; Paradis, L; Menardo, JL; Bouges, S; Daures, JP; Bougeard, YH; Bousquet, J			Does specific immunotherapy to Dermatophagoides pteronyssinus prevents the onset of new sensitizations in monosensitized children?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract									DEPT ALLERGY & RESP DIS,MONTPELLIER,FRANCE; DEPT BIOSTAT & EPIDEMIOL,NIMES,FRANCE				Bousquet, Jean/O-4221-2019						0	23	23	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1997	99	1	2	S			524	524		10.1016/S0091-6749(96)70085-4	http://dx.doi.org/10.1016/S0091-6749(96)70085-4			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WH142					2022-12-18	WOS:A1997WH14200522
J	Kelly, KJ; Sussman, G; Fink, JN				Kelly, KJ; Sussman, G; Fink, JN			Stop the sensitization	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material							LATEX; ALLERGENS; WORKERS; CONTACT; GLOVES		MED COLL WISCONSIN,DIV ALLERGY IMMUNOL,MILWAUKEE,WI 53201; UNIV TORONTO,TORONTO,ON M5S 1A1,CANADA	Medical College of Wisconsin; University of Toronto				Kelly, Kevin/0000-0002-2954-6117				ALENIUS H, 1991, INT ARCH ALLER A IMM, V96, P376, DOI 10.1159/000235525; BEEZHOLD D, 1992, ARCH SURG-CHICAGO, V127, P1354; BUBAK ME, 1992, MAYO CLIN PROC, V67, P1075, DOI 10.1016/S0025-6196(12)61122-7; CHANYEUNG M, 1995, NEW ENGL J MED, V333, P107, DOI 10.1056/NEJM199507133330207; CHAROUS BL, 1994, J ALLERGY CLIN IMMUN, V94, P12, DOI 10.1016/0091-6749(94)90065-5; EGHARISABET S, 1993, J RESPIR DIS, V14, P473; *FDA PUBL HLTH ADV, 1996, MED WATCH       0627; FISHER AA, 1992, J ALLERGY CLIN IMMUN, V90, P729, DOI 10.1016/0091-6749(92)90095-J; Gehring L. L., 1996, Journal of Allergy and Clinical Immunology, V97, P186, DOI 10.1016/S0091-6749(96)80231-4; KURUP VP, 1995, LATEX ALLERGY, P45; OWNBY DR, 1991, AM J ROENTGENOL, V156, P903, DOI 10.2214/ajr.156.5.2017949; Siu S. R., 1996, Journal of Allergy and Clinical Immunology, V97, P325, DOI 10.1016/S0091-6749(96)80787-1; SUSSMAN GL, 1991, JAMA-J AM MED ASSOC, V265, P2844, DOI 10.1001/jama.265.21.2844; SWANSON MC, 1994, J ALLERGY CLIN IMMUN, V94, P445, DOI 10.1016/0091-6749(94)90199-6; TARLO SM, 1994, J ALLERGY CLIN IMMUN, V93, P585; TURJANMAA K, 1990, LANCET, V336, P1588, DOI 10.1016/0140-6736(90)93372-V; YUNGINGER JW, 1994, J ALLERGY CLIN IMMUN, V93, P836, DOI 10.1016/0091-6749(94)90374-3; Zeldin R. K., 1996, Journal of Allergy and Clinical Immunology, V97, P429, DOI 10.1016/S0091-6749(96)81205-X	18	23	23	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1996	98	5	1				857	858		10.1016/S0091-6749(96)80001-7	http://dx.doi.org/10.1016/S0091-6749(96)80001-7			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VU764	8939148				2022-12-18	WOS:A1996VU76400001
J	Caffarelli, C; Cavagni, G; Giordano, S; Terzi, V; Perrone, F				Caffarelli, C; Cavagni, G; Giordano, S; Terzi, V; Perrone, F			Reduced pulmonary function in multiple food-induced, exercise-related episodes of anaphylaxis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV BRESCIA,DEPT PEDIAT,BRESCIA,ITALY	University of Brescia	Caffarelli, C (corresponding author), UNIV PARMA,PEDIAT CLIN,DEPT PEDIAT,VIA GRAMSCI,14,I-43100 PARMA,ITALY.		Caffarelli, Carlo/AAC-2488-2022					DOHI M, 1991, J ALLERGY CLIN IMMUN, V87, P34, DOI 10.1016/0091-6749(91)90210-F; MAULITZ RM, 1979, J ALLERGY CLIN IMMUN, V63, P433, DOI 10.1016/0091-6749(79)90218-5; NOVEY HS, 1983, J ALLERGY CLIN IMMUN, V71, P498, DOI 10.1016/0091-6749(83)90468-2; SHEFFER AL, 1984, J ALLERGY CLIN IMMUN, V73, P699, DOI 10.1016/0091-6749(84)90309-9; WADE JP, 1989, PROGR CLIN BIOL RES, P175	5	23	24	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1996	98	4					762	765		10.1016/S0091-6749(96)70125-2	http://dx.doi.org/10.1016/S0091-6749(96)70125-2			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VM665	8876552				2022-12-18	WOS:A1996VM66500009
J	Horak, F; Berger, U; Menapace, R; Schuster, N				Horak, F; Berger, U; Menapace, R; Schuster, N			Quantification of conjunctival vascular reaction by digital imaging	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						conjunctival provocation test; conjunctival allergic inflammation; vascular reaction; video equipment; red density	PROVOCATION TEST	Background: No objective evaluation of the conjunctival provocation test (CPT) was possible until now. Objective: The aim of this study was to develop a tool that would enable us to monitor conjunctival allergic inflammation by objective measurements. Methods: Twenty-four patients allergic to grass pollen were challenged by a CPT with grass pollen and genuine grass pollen in the ''Vienna Challenge Chamber.'' Patients were randomized to treatment with placebo or topical application of an H1-receptor antagonist (azelastine). Vascular reaction of the conjunctiva was repeatedly monitored by special video equipment. The signal was sent to a digital frame grabber, and digital image analysis was done with the aid of the WCUE-3 program (Olympus Optical Co., Hamburg, Germany). Results: The CPT led to an immediate increase of the red density. This extension was linear within the first 15 minutes. During the long-term challenge, the increasing vascular effect lasted 2 hours. During active treatment a consistent reaction pattern was obvious; however, the corresponding levels were statistically lower (p = 0.022). Conclusion: The calculation of red density of the conjunctiva by digital analysis proved to be a sensitive tool for measuring the conjunctival allergic reaction. It is possible to overcome the insufficient subjective evaluation of the CPT by objective measurements of the vascular reaction.	UNIV VIENNA, EYE CLIN B, VIENNA, AUSTRIA; OLYMPUS OPT CO EUROPE, HAMBURG, GERMANY	University of Vienna; Olympus Corporation	Horak, F (corresponding author), UNIV VIENNA, EAR NOSE & THROAT CLIN, WAHRINGER GURTEL 18-20, A-1090 VIENNA, AUSTRIA.							CARTIER A, 1989, J ALLERGY CLIN IMMUN, V84, P823, DOI 10.1016/0091-6749(89)90346-1; CIPRANDI G, 1993, ALLERGY, V48, P421, DOI 10.1111/j.1398-9995.1993.tb00740.x; CIPRANDI G, 1991, INT ARCH ALLER A IMM, V96, P344, DOI 10.1159/000235519; CIPRANDI G, 1992, ALLERGY, V47, P309, DOI 10.1111/j.1398-9995.1992.tb02059.x; DREBORG S, 1993, ALLERGY, V48, P49, DOI 10.1111/j.1398-9995.1993.tb04756.x; Escudero A I, 1993, Allergol Immunopathol (Madr), V21, P153; HILLIER K, 1980, Drugs of the Future, V5, P123; HORAK F, 1987, WIEN KLIN WOCHENSCHR, V99, P509; HORAK F, 1994, ZENTRALBLATT HNO, V144, P768; JAGER S, 1988, ALLERGY, V43, P56; LEONARDI A, 1993, EYE, V7, P461, DOI 10.1038/eye.1993.93; *MAN GAL PD LTD, 1994, CUE SER OLYMP; *OLYMP OPT CO, 1994, JQ, V19; RIMAS M, 1992, ALLERGY, V47, P324, DOI 10.1111/j.1398-9995.1992.tb02062.x; Salzano F. A., 1992, Rhinology (Utrecht), V30, P265	15	23	24	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1996	98	3					495	500		10.1016/S0091-6749(96)70081-7	http://dx.doi.org/10.1016/S0091-6749(96)70081-7			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VJ428	8828525				2022-12-18	WOS:A1996VJ42800004
J	Su, SN; Shu, P; Lau, GX; Yang, SY; Huang, SW; Lee, YC				Su, SN; Shu, P; Lau, GX; Yang, SY; Huang, SW; Lee, YC			Immunologic and physicochemical studies of Bermuda grass pollen antigen BG60	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						pollen; allergen; purification; carbohydrate	CYNODON-DACTYLON POLLEN; CYN-D-I; CROSS-ALLERGENICITY; IGE ANTIBODIES; MONOCLONAL-ANTIBODIES; GLYCOPROTEIN ALLERGEN; CARBOHYDRATE EPITOPE; MAJOR ALLERGEN; LINKED GLYCANS; N-GLYCANS	Background: In a previous study we showed that antigen BG60 of Bermuda grass pollen contains isoallergens. Because the yield of purified isoallergens was low when a chromatofocusing technique was used, it was difficult to carry out further studies, such as determination of carbohydrate composition and structure. Objective: The aim of this study was to establish a procedure to purify antigen BG60 proteins as a group and to characterize this group's physicochemical and immunologic properties. Methods: A combination of chromatographic techniques (ion-exchange, gel filtration, blue gel affinity, and reverse-phase high-performance liquid chromatography) was used for the purification of BG60. Immunoblot and ELISA techniques were used to study BG60-specific IgE and IgG antibodies in patients' sera. The role of the carbohydrate moiety in antigenicity and allergenicity was examined with monoclonal antibodies and allergic sera by using periodate-treated BG60. Its carbohydrate composition was analyzed by high-performance anion-exchange chromatography with a pulsed amperometric detector. Results: Homogeneity of BG60 was demonstrated by a single sharp peak in reverse-phase high-performance liquid chromatography, a single band in sodium dodecylsulfate-polyacrylamide gel electrophoresis, and only one band stained by anti-BG60 monoclonal antibody. BG60-specific IgE and IgG antibodies wee shown to be present in allergic sera. Six plant lectins were found to react with BG60. On periodate treatment, BG60 reduced binding toward its monoclonal antibody and human IgE and IgG. Carbohydrate composition analysis showed that BG60 contains three kinds of sugars: mannose, N-acetylglucosamine, and fucose (in a ratio of approximately 3:2:1) and a minute amount of xylose. The carbohydrate content is approximately 7.5%, and peptide content is about 92.5%. Conclusion: A procedure was established for the purification of a large quantity of the BG60 antigen. The results suggest that the carbohydrate moiety of antigen BG60 may play an important role in the immune response.	JOHNS HOPKINS UNIV, DEPT BIOL, BALTIMORE, MD 21218 USA; UNIV FLORIDA, DEPT PEDIAT, DIV IMMUNOL & ALLERGY, GAINESVILLE, FL USA	Johns Hopkins University; State University System of Florida; University of Florida	Su, SN (corresponding author), VET GEN HOSP, DEPT MED RES, TAIPEI 112, TAIWAN.							AALBERSE RC, 1981, INT ARCH ALLER A IMM, V66, P259, DOI 10.1159/000232913; AUGUSTIN R, 1959, IMMUNOLOGY, V2, P230; BALDO BA, 1982, PROG ALLERGY, V30, P1; BERNSTEIN IL, 1976, J ALLERGY CLIN IMMUN, V57, P141, DOI 10.1016/0091-6749(76)90033-6; Chang HN, 1984, CLIN MED J, V34, P376; FAN JQ, 1994, ANAL BIOCHEM, V219, P375, DOI 10.1006/abio.1994.1280; FAYE L, 1993, ANAL BIOCHEM, V209, P104, DOI 10.1006/abio.1993.1088; FAYE L, 1988, GLYCOCONJUGATE J, V5, P245, DOI 10.1007/BF01049085; FORD SA, 1987, J ALLERGY CLIN IMMUN, V79, P711, DOI 10.1016/0091-6749(87)90201-6; HAAVIK S, 1987, INT ARCH ALLER A IMM, V83, P231, DOI 10.1159/000234302; HAN SH, 1993, J ALLERGY CLIN IMMUN, V92, P549, DOI 10.1016/0091-6749(93)90079-U; HANSEN MY, 1994, ALLERGY, V49, P235, DOI 10.1111/j.1398-9995.1994.tb02655.x; HARBOE N, 1983, SCAND J IMMUNOL S, V10, P345; KARLSTAM B, 1982, J IMMUNOL METHODS, V54, P119, DOI 10.1016/0022-1759(82)90120-X; KOSHTE VL, 1989, J ALLERGY CLIN IMMUN, V84, P174, DOI 10.1016/0091-6749(89)90322-9; KUROSAKA A, 1991, J BIOL CHEM, V266, P4168; LAEMMLI VK, 1975, NATURE, V227, P680; LAINE AC, 1991, FEBS LETT, V295, P179, DOI 10.1016/0014-5793(91)81413-3; LAURIERE M, 1989, PLANT PHYSIOL, V90, P1182, DOI 10.1104/pp.90.3.1182; LEE YC, 1990, ANAL BIOCHEM, V189, P151, DOI 10.1016/0003-2697(90)90099-U; LEIFERMAN KM, 1976, J ALLERGY CLIN IMMUN, V58, P129, DOI 10.1016/0091-6749(76)90148-2; LIU TY, 1989, ANAL BIOCHEM, V182, P383, DOI 10.1016/0003-2697(89)90612-X; MARSH DG, 1966, INT ARCH ALLER A IMM, V29, P521, DOI 10.1159/000229739; MARSH DG, 1970, J ALLERGY, V46, P107, DOI 10.1016/0021-8707(70)90078-X; MARTIN BG, 1985, ANN ALLERGY, V54, P99; MARTIN BG, 1980, J ALLERGY CLIN IMMUN, V65, P229; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MATTHIESEN F, 1989, J ALLERGY CLIN IMMUN, V83, P1124, DOI 10.1016/0091-6749(89)90456-9; MATTHIESEN F, 1991, J ALLERGY CLIN IMMUN, V88, P763, DOI 10.1016/0091-6749(91)90184-P; MEYERS RL, 1971, J ALLERGY, V47, P100; ORREN A, 1975, INT ARCH ALLER A IMM, V49, P814, DOI 10.1159/000231465; ORREN A, 1977, S AFR MED J, V51, P586; PAZUR JH, 1986, CARBOHYDRATE ANAL PR, P55; RAMIREZSOTO D, 1991, CARBOHYD RES, V213, P27, DOI 10.1016/S0008-6215(00)90595-0; SCHUMACHER M J, 1982, Journal of Allergy and Clinical Immunology, V69, P145; SCHUMACHER MJ, 1985, ANN ALLERGY, V55, P584; SHEN HD, 1988, CLIN ALLERGY, V18, P401, DOI 10.1111/j.1365-2222.1988.tb02888.x; SINGH MB, 1990, MONOGR ALLERGY, V28, P101; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SU S-N, 1986, Chinese Journal of Microbiology and Immunology (Taipei), V19, P263; SU S-N, 1990, Proceedings of the National Science Council Republic of China Part B Life Sciences, V14, P85; SU SN, 1994, J ALLERGY CLIN IMMUN, V93, P190; SU SN, 1991, CLIN EXP ALLERGY, V21, P449, DOI 10.1111/j.1365-2222.1991.tb01685.x; SWARDNORDMO M, 1988, INT ARCH ALLER A IMM, V85, P295, DOI 10.1159/000234520; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRETTER V, 1993, INT ARCH ALLERGY IMM, V102, P259, DOI 10.1159/000236534; TRINCA JC, 1962, MED J AUSTRALIA, V1, P969, DOI 10.5694/j.1326-5377.1962.tb27045.x; Voller A, 1986, MANUAL CLIN LABORATO, P99; WEBER A, 1987, ALLERGY, V42, P464, DOI 10.1111/j.1398-9995.1987.tb00364.x	49	23	25	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1996	98	3					486	494		10.1016/S0091-6749(96)70080-5	http://dx.doi.org/10.1016/S0091-6749(96)70080-5			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VJ428	8828524	hybrid			2022-12-18	WOS:A1996VJ42800003
J	Kraft, M; Pak, J; Borish, L; Martin, RJ				Kraft, M; Pak, J; Borish, L; Martin, RJ			Theophylline's effect on neutrophil function and the late asthmatic response	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; theophylline; late asthmatic response; adenosine	EXHIBIT DIMINISHED RESPONSIVENESS; AIRWAY RESPONSIVENESS; ALLERGEN; ADENOSINE	Background: The decrement in lung function associated with the late asthmatic response after allergen challenge is believed to be mediated by an inflammatory response in the airways. Theophylline has been shown to inhibit the late asthmatic response, but the mechanisms are not clear. Objective: The study was designed to determine whether theophylline would inhibit the late asthmatic response by reducing neutrophil activation and subsequent superoxide production. Methods: Twelve subjects with asthma underwent treatment in this double-blind, randomized, crossover study. Each subject received theophylline and placebo in random order in two treatment periods of 3 weeks each. Each treatment period was followed by an allergen challenge and blood neutrophil function analysis. Results: At therapeutic levels theophylline increased FEV(1) at baseline and during the allergen challenge and increased the percentage suppression of neutrophil superoxide production by adenosine. Conclusion: Theophylline improved pulmonary function at baseline and during an allergen challenge, in part perhaps, by increasing the neutrophil's response to feedback inhibition by adenosine. However, theophylline did not decrease the severity and duration of the late asthmatic response.	UNIV COLORADO, HLTH SCI CTR, DIV PULM & CRIT CARE, DENVER, CO USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Kraft, M (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED, DEPT MED, 1400 JACKSON ST, ROOM J106, DENVER, CO 80206 USA.							ANDERSSON P, 1985, EXCERPTA MED, P187; [Anonymous], 1987, AM REV RESPIR DIS, V136, P225; COCKCROFT DW, 1989, J ALLERGY CLIN IMMUN, V83, P913, DOI 10.1016/0091-6749(89)90105-X; Cohen J., 1988, STAT POWER ANAL BEHA; CRESCIOLI S, 1991, ANN ALLERGY, V66, P245; Cushley M J, 1983, Agents Actions Suppl, V13, P109; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; HENDELES L, 1995, J ALLERGY CLIN IMMUN, V95, P505, DOI 10.1016/S0091-6749(95)70312-8; Jones B., 1989, DESIGN ANAL CROSS OV, P16; JOSEPH BZ, 1992, INFLAMMATION, V16, P101, DOI 10.1007/BF00918951; MANN JS, 1983, CLIN SCI, V65, pP22; MAPP C, 1987, AM REV RESPIR DIS, V136, P1403, DOI 10.1164/ajrccm/136.6.1403; METZGER WJ, 1986, CHEST, V89, P477, DOI 10.1378/chest.89.4.477; NELSON S, 1985, AM REV RESPIR DIS, V131, P923; NIELSON CP, 1988, AM REV RESPIR DIS, V137, P25, DOI 10.1164/ajrccm/137.1.25; OBYRNE PM, 1987, AM REV RESPIR DIS, V136, P740, DOI 10.1164/ajrccm/136.3.740; PAUWELS R, 1985, J ALLERGY CLIN IMMUN, V76, P583, DOI 10.1016/0091-6749(85)90779-1; PERSSON C G A, 1988, Journal of Allergy and Clinical Immunology, V81, P615, DOI 10.1016/0091-6749(88)90203-5; PERSSON CGA, 1986, J ALLERGY CLIN IMMUN, V78, P780, DOI 10.1016/0091-6749(86)90061-8; SCHMEICHEL CJ, 1987, J IMMUNOL, V138, P1896; SCHRIER DJ, 1986, J IMMUNOL, V137, P3284; STEIN SK, 1977, CALCULUS ANAL GEOMET, P423; STYRT B, 1988, J ALLERGY CLIN IMMUN, V81, P20, DOI 10.1016/0091-6749(88)90215-1; SUSTIEL AM, 1989, AM REV RESPIR DIS, V140, P1556, DOI 10.1164/ajrccm/140.6.1556; WARD AJM, 1993, AM REV RESPIR DIS, V147, P518, DOI 10.1164/ajrccm/147.3.518	25	23	23	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1996	98	2					251	257		10.1016/S0091-6749(96)70147-1	http://dx.doi.org/10.1016/S0091-6749(96)70147-1			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VC995	8757200				2022-12-18	WOS:A1996VC99500002
J	Kuwata, S; Yanagisawa, M; Saeki, H; Nakagawa, H; Etoh, T; Tokunaga, K; Juji, T; Shibata, Y				Kuwata, S; Yanagisawa, M; Saeki, H; Nakagawa, H; Etoh, T; Tokunaga, K; Juji, T; Shibata, Y			Lack of primary association between transporter associated with antigen processing genes and atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	New Trends in Immunopharmacology 1994 Conference	JUL   23, 1994	TOKYO, JAPAN	Sandoz Pharm Ltd		TAP; HLA; PCR; PCR-RFLP; mismatch PCR-RFLP; atopic dermatitis; haplotype; linkage disequilibrium; Japanese	CLASS-II REGION; MHC; TAP2; HLA; POLYMORPHISM; HAPLOTYPES; ALLELES; DISEASE; DNA	We examined polymorphisms of transporter associated with antigen processing (TRP) genes in 37 Japanese patients with atopic dermatitis and 52 control subjects. We have evaluated again, the specificity polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method since our previous report and have also developed a mismatch PCR-RFLP method for discriminating two dimorphic sites of TAP1 gene and four dimorphic sites of TAP2 gene. Amplified products from genomic DNA were digested with restriction endonucleases: Sau3A1 for TAP1 codon 333 (Ile-Val), AccI for TAP1 codon 637 (Asp-Gly), and BfaI for TAP2 codon 687 (Stop-Gln). The other sites of TAP2 gene were analyzed by mismatch PCR-RFLP: AccII for TAP2 codon 379 (Val-Ile), RsaI for codon 565 (Ala-Thr), and MspI for codon 665 (Thr-Ala). We observed three TAP1 alleles and six TAP2 alleles. infrequent allele TRP1 C was observed in one patient and one control subject. We did not identify any differences in TAP allele frequencies between those patients with atopic dermatitis and Japanese control subjects. Analysis of TAP gene polymorphisms will provide better understanding of susceptibility loci in HLA class II-associated disease because TAP genes are located between HLA-DQB1 and HLA-DPB1 loci.	UNIV TOKYO,FAC MED,DEPT DERMATOL,TOKYO 113,JAPAN; JAPANESE RED CROSS,CENT BLOOD CTR,TOKYO,JAPAN	University of Tokyo; Japanese Red Cross Medical Center	Kuwata, S (corresponding author), UNIV TOKYO,FAC MED,DEPT TRANSFUS MED & IMMUNOHEMATOL,BUNKYO KU,HONGO 7-3-1,TOKYO 113,JAPAN.							ANDROLEWICZ MJ, 1994, P NATL ACAD SCI USA, V91, P12716, DOI 10.1073/pnas.91.26.12716; BECK S, 1992, J MOL BIOL, V228, P433, DOI 10.1016/0022-2836(92)90832-5; BIJVOET SM, 1992, HUM MOL GENET, V1, P541; BODMER JG, 1994, TISSUE ANTIGENS, V44, P1, DOI 10.1111/j.1399-0039.1994.tb02351.x; CARRINGTON M, 1993, IMMUNOGENETICS, V37, P266; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; DJILALI SI, 1994, HUM IMMUNOL, V40, P8; HILL A, 1995, P NATL ACAD SCI USA, V92, P341, DOI 10.1073/pnas.92.2.341; KELLARWOOD HF, 1994, TISSUE ANTIGENS, V43, P129, DOI 10.1111/j.1399-0039.1994.tb02313.x; KUWATA S, 1994, J ALLERGY CLIN IMMUN, V94, P565, DOI 10.1016/0091-6749(94)90132-5; MALNATI MS, 1992, NATURE, V357, P702, DOI 10.1038/357702a0; MARSH DG, 1989, COLD SPRING HARB SYM, V54, P459; MOMBURG F, 1994, J EXP MED, V179, P1613, DOI 10.1084/jem.179.5.1613; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; POWIS SH, 1993, IMMUNOGENETICS, V38, P345; POWIS SH, 1993, IMMUNOGENETICS, V37, P373, DOI 10.1007/BF00216802; POWIS SJ, 1992, NATURE, V357, P211, DOI 10.1038/357211a0; RONNINGEN KS, 1993, EUR J IMMUNOL, V23, P1050, DOI 10.1002/eji.1830230511; Saeki H, 1995, J ALLERGY CLIN IMMUN, V96, P1061, DOI 10.1016/S0091-6749(95)70191-5; SAEKI H, 1994, J ALLERGY CLIN IMMUN, V94, P575, DOI 10.1016/0091-6749(94)90133-3; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; SPURKLAND A, 1994, HUM IMMUNOL, V39, P299, DOI 10.1016/0198-8859(94)90273-9; SUGITA M, 1994, J EXP MED, V180, P2163, DOI 10.1084/jem.180.6.2163; SVEJGAARD A, 1983, IMMUNOL REV, V70, P193, DOI 10.1111/j.1600-065X.1983.tb00715.x; TIGHE MR, 1994, HUM IMMUNOL, V39, P9; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; VANENDERT PM, 1994, DIABETES, V43, P110, DOI 10.2337/diabetes.43.1.110	28	23	24	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1995	96	6	2	S			1051	1060		10.1016/S0091-6749(95)70190-7	http://dx.doi.org/10.1016/S0091-6749(95)70190-7			10	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TQ509	8543762				2022-12-18	WOS:A1995TQ50900001
J	EIGENMANN, PA; BELLI, DC; LUDI, F; KAHN, JM; POLLA, BS				EIGENMANN, PA; BELLI, DC; LUDI, F; KAHN, JM; POLLA, BS			IN-VITRO LYMPHOCYTE-PROLIFERATION WITH MILK AND A CASEIN WHEY-PROTEIN HYDROLYZED FORMULA IN CHILDREN WITH COWS MILK ALLERGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						MILK HYPERSENSITIVITY; INFANT NUTRITION; IMMUNE TOLERANCE; LYMPHOCYTE TRANSFORMATION	SENSITIVE ATOPIC-DERMATITIS; DIAGNOSTIC-VALUE; NATURAL-HISTORY; INTOLERANCE; HYPERSENSITIVITY; ANAPHYLAXIS; RESPONSES; INFANTS; TESTS	Discordant results have been reported about the role of lymphocyte proliferation assays in patients with cow's milk allergy. We studied the peripheral blood mononuclear cell response of 10 children with cow's milk allergy by means of a lymphocyte proliferation test to determine the diagnostic value of this assay, the clinical tolerance of a new therapeutic hydrolyzed formula, and the evolution of lymphocyte proliferation after 3 months of a cow's milk-fr ee diet with the hydrolyzed formula. The lymphocyte proliferation at the time of diagnosis in the patients with cow's milk allergy was not statistically different from the results in the control group. The proliferation test performed after 3 months of diet with the hydrolyzed formula and restriction of cow's milk protein showed that the cellular proliferation remained globally the same compared with the proliferation at the time of diagnosis. The hydrolyzed formula proteins induced a lower cellular proliferation than milk proteins in patients with cow's milk allergy Our results suggest that the lymphocyte proliferation test cannot be recommended for diagnostic purposes. However; in patients with cow's milk allergy the proliferation test affirmed the absence of immunogenicity of the hydrolyzed formula because it induced no significant T-cell activation.	UNIV HOSP GENEVA,PEDIAT CLIN,CH-1211 GENEVA 14,SWITZERLAND; UNIV HOSP GENEVA,ALLERGY UNIT,CH-1211 GENEVA 14,SWITZERLAND; SANDOZ NUTR,BERN,SWITZERLAND	University of Geneva; University of Geneva; Novartis; Sandoz			Eigenmann, Philippe/A-6569-2017	Eigenmann, Philippe/0000-0003-1738-1826				ALBANI S, 1989, ANN ALLERGY, V63, P489; BOCK SA, 1982, J ALLERGY CLIN IMMUN, V69, P173, DOI 10.1016/0091-6749(82)90096-3; BOCK SA, 1988, J ALLERGY CLIN IMMUN, V82, P986; CORDLE CT, 1991, J PEDIATR GASTR NUTR, V13, P270, DOI 10.1097/00005176-199110000-00006; EIGENMANN PA, 1994, ACI NEWS, V6, P7; ELLIS MH, 1991, J PEDIATR-US, V118, P74, DOI 10.1016/S0022-3476(05)81849-9; HOST A, 1990, ALLERGY, V45, P587, DOI 10.1111/j.1398-9995.1990.tb00944.x; JAKOBSSON I, 1979, ACTA PAEDIATR SCAND, V68, P853; KONDO N, 1993, J ALLERGY CLIN IMMUN, V91, P658, DOI 10.1016/0091-6749(93)90272-H; LEBENTHAL E, 1975, PEDIATR CLIN N AM, V22, P827; May C D, 1972, Clin Allergy, V2, P335, DOI 10.1111/j.1365-2222.1972.tb01298.x; MINOR JD, 1980, J ALLERGY CLIN IMMUN, V66, P314, DOI 10.1016/0091-6749(80)90027-5; MOWAT AM, 1987, IMMUNOL TODAY, V8, P93, DOI 10.1016/0167-5699(87)90853-X; RASANEN L, 1992, CLIN EXP ALLERGY, V22, P385, DOI 10.1111/j.1365-2222.1992.tb03100.x; SAMPSON HA, 1989, J PEDIATR-US, V115, P23, DOI 10.1016/S0022-3476(89)80323-3; SAMPSON HA, 1991, J PEDIATR-US, V118, P520, DOI 10.1016/S0022-3476(05)90001-2; SAYLOR JD, 1991, J PEDIATR-US, V118, P71, DOI 10.1016/S0022-3476(05)81848-7; SCHEINMANN P, 1976, CLIN ALLERGY, V6, P515, DOI 10.1111/j.1365-2222.1976.tb01936.x; SHINODA S, 1993, CLIN EXP ALLERGY, V23, P689, DOI 10.1111/j.1365-2222.1993.tb01795.x; STROBEL S, 1989, FOOD ALLERGY INFANCY, P157; TAINIO VM, 1990, ALLERGY, V45, P189, DOI 10.1111/j.1398-9995.1990.tb00482.x; VANSICKLE GJ, 1985, GASTROENTEROLOGY, V88, P1915, DOI 10.1016/0016-5085(85)90019-8; 1992, J PEDIATR GASTROENTE, V14, P108	23	23	23	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1995	96	4					549	557		10.1016/S0091-6749(95)70300-4	http://dx.doi.org/10.1016/S0091-6749(95)70300-4			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TA095	7560668	Bronze			2022-12-18	WOS:A1995TA09500017
J	FEIGENBAUM, BA; STEVENSON, DD; SIMON, RA				FEIGENBAUM, BA; STEVENSON, DD; SIMON, RA			HYDROCORTISONE SODIUM SUCCINATE DOES NOT CROSS-REACT WITH ASPIRIN IN ASPIRIN-SENSITIVE PATIENTS WITH ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ADVERSE REACTION; ASTHMA; ASPIRIN; ASPIRIN-SENSITIVE ASTHMA; ASPIRIN-SENSITIVE RESPIRATORY DISEASE; BRONCHOSPASM; CORTICOSTEROIDS; HYDROCORTISONE; METHYLPREDNISOLONE; SUCCINATE	METHYLPREDNISOLONE; ANAPHYLAXIS; ESTER	Background: Bronchospasm after intravenous hydrocortisone treatment has been r Objective: This study was designed to determine the prevalence of sensitivity to hydrocortisone among patients with aspirin-sensitive respiratory disease. Methods: We performed double-blind, placebo-controlled challenges with aspirin and 100 mg of hydrocortisone sodium succinate administered intravenously in 53 subjects. Results: Forty-five of the 53 subjects (85%) undergoing oral aspirin challenge experienced respiratory reactions to aspirin. Forty-four of these 45 patients had neither naso-ocular, cutaneous, nor respiratory reactions to hydrocortisone sodium succinate. One aspirin-sensitive subject had bronchospasm and a naso-ocular reaction to hydrocortisone sodium succinate and a naso-ocular reaction with minimal bronchospasm to methylprednisolone sodium succinate. After desensitization to aspirin, and while receiving maintenance aspirin therapy, this subject again reacted to hydrocortisone sodium succinate with bronchospasm and nasoocular reaction. Conclusion: We conclude that aspirin-sensitive patients with asthma ave not preferentially sensitive to hydrocortisone and that hydrocortisone sodium succinate does not cross-react or cross-desensitize with aspirin.	SCRIPPS CLIN & RES FDN, LA JOLLA, CA 92037 USA; SCRIPPS RES INST, LA JOLLA, CA USA	Scripps Research Institute; Scripps Research Institute					NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI032834] Funding Source: NIH RePORTER; NCRR NIH HHS [M0-1RR00833] Funding Source: Medline; NIAID NIH HHS [AI-32834] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALHABET SMH, 1989, BRIT J CLIN PHARMACO, V27, P285, DOI 10.1111/j.1365-2125.1989.tb05366.x; DAJANI BM, 1981, J ALLERGY CLIN IMMUN, V68, P201, DOI 10.1016/0091-6749(81)90184-6; DERENDORF H, 1985, CLIN PHARMACOL THER, V37, P502, DOI 10.1038/clpt.1985.79; FREEDMAN MD, 1981, JAMA-J AM MED ASSOC, V245, P607, DOI 10.1001/jama.245.6.607; FULCHER DA, 1991, MED J AUSTRALIA, V154, P210, DOI 10.5694/j.1326-5377.1991.tb121038.x; GOLDSTEIN DA, 1985, ANN ALLERGY, V55, P599; MANNING ME, 1992, IMMUNOL ALLERGY CLIN, V12, P611; MANSFIELD LE, 1986, J ASTHMA, V23, P81, DOI 10.3109/02770908609077478; MENDELSON LM, 1974, J ALLERGY CLIN IMMUN, V54, P125, DOI 10.1016/0091-6749(74)90049-9; PARTRIDGE MR, 1978, BRIT MED J, V1, P1521, DOI 10.1136/bmj.1.6126.1521; PLESKOW WW, 1982, J ALLERGY CLIN IMMUN, V69, P11, DOI 10.1016/0091-6749(82)90081-1; RODGER RSC, 1983, CLIN ALLERGY, V13, P499, DOI 10.1111/j.1365-2222.1983.tb02628.x; SETTIPANE RA, 1989, J ALLERGY CLIN IMMUN, V84, P26, DOI 10.1016/0091-6749(89)90174-7; STEVENSON DD, 1988, NEW ENGL REG ALLERGY, V9, P135; STEVENSON DD, 1990, J ALLERGY CLIN IMMUN, V86, P749, DOI 10.1016/S0091-6749(05)80179-4; SZCZEKLIK A, 1985, J ALLERGY CLIN IMMUN, V76, P530, DOI 10.1016/0091-6749(85)90771-7	16	23	23	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1995	96	4					545	548		10.1016/S0091-6749(95)70299-7	http://dx.doi.org/10.1016/S0091-6749(95)70299-7			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TA095	7560667				2022-12-18	WOS:A1995TA09500016
J	CLAYTON, MH; LEUNG, DYM; SURS, W; SZEFLER, SJ				CLAYTON, MH; LEUNG, DYM; SURS, W; SZEFLER, SJ			ALTERED GLUCOCORTICOID RECEPTOR-BINDING IN ATOPIC-DERMATITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note									UNIV COLORADO,HLTH SCI CTR,NATL JEWISH CTR IMMUNOL & RESP MED,DEPT PEDIAT,DIV ALLERGY IMMUNOL,DENVER,CO 80206; UNIV COLORADO,HLTH SCI CTR,DEPT PEDIAT,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,DEPT PHARMACOL,DENVER,CO 80262	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036577] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041256] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-36577] Funding Source: Medline; NIAMS NIH HHS [AR-41256] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		CRABTREE GR, 1981, METHODS HEMATOLOGY, V2, P252; HERRSCHER RF, 1992, J CLIN INVEST, V90, P596, DOI 10.1172/JCI115898; KAM JC, 1993, J IMMUNOL, V151, P3460; LEUNG DYM, 1992, SPRINGER SEMIN IMMUN, V13, P427; SHER ER, 1994, J CLIN INVEST, V93, P33, DOI 10.1172/JCI116963; WIERENGA EA, 1990, J IMMUNOL, V144, P4651	6	23	23	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1995	96	3					421	423		10.1016/S0091-6749(95)70062-5	http://dx.doi.org/10.1016/S0091-6749(95)70062-5			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RU660	7560645				2022-12-18	WOS:A1995RU66000015
J	KORNFELD, SJ; KRATZ, J; DIAMOND, F; DAY, NK; GOOD, RA				KORNFELD, SJ; KRATZ, J; DIAMOND, F; DAY, NK; GOOD, RA			SHWACHMAN-DIAMOND SYNDROME-ASSOCIATED WITH HYPOGAMMAGLOBULINEMIA AND GROWTH-HORMONE DEFICIENCY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							X-LINKED HYPOGAMMAGLOBULINEMIA; ZINC-DEFICIENCY; THYMULIN; AGAMMAGLOBULINEMIA	Shwachman-Diamond syndrome is a rare congenital disorder of unknown etiology. Characteristic abnormalities of this disease include pancreatic insufficiency, skeletal anomalies, growth retardation, recurrent infections, and hematologic abnormalities. Significant morbidity and mortality in these patients result from respiratory infections, which are not well explained on the basis of neutrophil defects. We have had the opportunity to perform an in-depth clinical immunologic and endocrinologic evaluation of a patient with this syndrome with recurrent respiratory tract infections. She was found to have profound humoral immunologic defects, and serum thymulin was absent. In addition, endocrinologic evaluation for growth retardation revealed growth hormone deficiency. The patient responded to treatment with supplemental growth hormone and intravenous gammaglobulin with accelerated growth and cessation of infections. This case is unique in that it links growth hormone deficiency and hypogammaglobulinemia in a non-X-linked manner and may provide the basis for treatment of other patients with this rare syndrome.	UNIV S FLORIDA,ALL CHILDRENS HOSP,DIV ENDOCRINOL,ST PETERSBURG,FL 33701	State University System of Florida; University of South Florida	KORNFELD, SJ (corresponding author), UNIV S FLORIDA,ALL CHILDRENS HOSP,DIV CLIN IMMUNOL & ALLERGY,801 6TH ST S,ST PETERSBURG,FL 33701, USA.				NIA NIH HHS [AG5628-10] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG005628, R37AG005628] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AGGETT PJ, 1979, J PEDIATR-US, V94, P391, DOI 10.1016/S0022-3476(79)80578-8; BRUETON MJ, 1977, ARCH DIS CHILD, V52, P76, DOI 10.1136/adc.52.1.76; BUZI F, 1994, ACTA PAEDIATR, V83, P99, DOI 10.1111/j.1651-2227.1994.tb12962.x; CONLEY ME, 1991, J PEDIATR-US, V119, P392, DOI 10.1016/S0022-3476(05)82051-7; DARDENNE M, 1989, ENDOCRINOLOGY, V125, P3, DOI 10.1210/endo-125-1-3; FLEISHER TA, 1980, NEW ENGL J MED, V302, P1429, DOI 10.1056/NEJM198006263022601; GOETEYN M, 1991, ARCH DERMATOL, V127, P225, DOI 10.1001/archderm.127.2.225; GOFF BL, 1987, CLIN EXP IMMUNOL, V68, P580; MONAFO V, 1991, ACTA PAEDIATR SCAND, V80, P563, DOI 10.1111/j.1651-2227.1991.tb11907.x; PRASAD AS, 1985, ANNU REV NUTR, V5, P341, DOI 10.1146/annurev.nu.05.070185.002013; PRASAD AS, 1988, J CLIN INVEST, V82, P1202, DOI 10.1172/JCI113717; REPO H, 1987, CLIN EXP IMMUNOL, V69, P204; ROOT AW, 1967, PEDIATRICS, V39, P844; ROSE NR, 1992, MANUAL CLIN LABORATO; SITZ KV, 1990, J PEDIATR-US, V116, P292, DOI 10.1016/S0022-3476(05)82896-3; THONG YH, 1978, AUST PAEDIATR J, V14, P34	16	23	24	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1995	96	2					247	250		10.1016/S0091-6749(95)70014-5	http://dx.doi.org/10.1016/S0091-6749(95)70014-5			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RQ001	7636061	Bronze			2022-12-18	WOS:A1995RQ00100014
J	SIMON, MR; COOPER, KD; NORRIS, RB; BLOK, B; KING, CL				SIMON, MR; COOPER, KD; NORRIS, RB; BLOK, B; KING, CL			ANTIGEN-PRESENTING CELL-INDEPENDENT CYTOKINE AND SPONTANEOUS IN-VITRO IGE PRODUCTION IN PATIENTS WITH ATOPIC-DERMATITIS - INCREASED INTERFERON-GAMMA PRODUCTION AND LACK OF EFFECTS OF IN-VIVO LOW-DOSE INTERFERON-GAMMA TREATMENT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ATOPIC DERMATITIS; IGE; IL-4; IL-5; INTERFERON-GAMMA	BLOOD MONONUCLEAR-CELLS; HUMAN B-CELLS; IMMUNOGLOBULIN-E; T-CELLS; IFN-GAMMA; FOOD HYPERSENSITIVITY; INVITRO PRODUCTION; LANGERHANS CELLS; INTERLEUKIN-4; LYMPHOCYTES	Atopic dermatitis is characterized by elevated serum IgE concentrations and dysregulation of T-lymphocyte function. To examine the pattern of cytokine production associated with elevated IgE levels phorbol ester plus ionomycin-stimulated production of interleukin (IL)-4, IL-5, and interferon-gamma (IFN-gamma) by blood mononuclear cells from 16 patients with atopic dermatitis was compared with that of 18 healthy subjects. Spontaneous in vitro IgE production was also studied longitudinally in patients receiving placebo or daily treatment with 0.05 mg/m(2) IFN-gamma. Spontaneous in vitro IgE production and mitogen-driven IL-4 and IFN-gamma synthesis did not differ when patients were receiving interferon treatment compared with no treatment. Furthermore, ionomycin plus phorbol ester-stimulated mononuclear cells from patients with atopic dermatitis produced less IL-4 and more IFN-gamma than did cells from healthy subjects. IL-5 production by cells from patients with atopic dermatitis did not differ from that of cells from healthy subjects. The ratio of IL-4 to IFN-gamma produced in vitro was significantly lower (p = 0.04) in the cells of patients with atopic dermatitis (0.9) as compared with those of healthy subjects (2.7). The findings suggest that when circulating T cells are stimulated under antigen presenting cell-independent conditions, atopic dermatitis is not characterized by the shift in the reciprocal relationship between IL-4 and IFN-gamma production, which has been postulated to explain the pathogenesis of IgE elevation and the therapeutic action of IFN-gamma in patients with atopic dermatitis.	WAYNE STATE UNIV,SCH MED,DEPT MED,DETROIT,MI 48201; WAYNE STATE UNIV,SCH MED,DEPT PEDIAT,DETROIT,MI 48201; UNIV MICHIGAN,SCH MED,DEPT DERMATOL,ANN ARBOR,MI; CASE WESTERN RESERVE UNIV,SCH MED,DEPT MED,CLEVELAND,OH 44106; VET AFFAIRS MED CTR,RES SERV,ALLEN PK,MI 48101; VET AFFAIRS MED CTR,DERMATOL SERV,ANN ARBOR,MI; VET AFFAIRS MED CTR,RES SERV,ANN ARBOR,MI; VET AFFAIRS MED CTR,MED SERV,CLEVELAND,OH; VET AFFAIRS MED CTR,RES SERV,CLEVELAND,OH	Wayne State University; Wayne State University; University of Michigan System; University of Michigan; Case Western Reserve University; US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center	SIMON, MR (corresponding author), VET AFFAIRS MED CTR,MED SERV,111F,ALLEN PK,MI 48101, USA.			Cooper, Kevin/0000-0002-1986-3602				ABRAMSON JS, 1982, J AM ACAD DERMATOL, V7, P105, DOI 10.1016/S0190-9622(82)80017-0; BOGUNIEWICZ M, 1990, AM J MED, V88, P365, DOI 10.1016/0002-9343(90)90490-5; BYRON KA, 1992, INT ARCH ALLERGY IMM, V99, P50, DOI 10.1159/000236335; CHAN SC, 1993, J IMMUNOL, V151, P3345; CHERWINSKI HM, 1987, J EXP MED, V166, P1229, DOI 10.1084/jem.166.5.1229; COOPER KD, 1994, J INVEST DERMATOL, V102, P128, DOI 10.1111/1523-1747.ep12371746; DELPRETE G, 1988, J IMMUNOL, V140, P4193; DELPRETE G, 1989, J CLIN INVEST, V84, P1830, DOI 10.1172/JCI114368; DUGAS B, 1993, EUR J IMMUNOL, V23, P1687, DOI 10.1002/eji.1830230743; FISER PM, 1979, J IMMUNOL, V123, P1788; FURUE M, 1991, J INVEST DERMATOL, V96, P468, DOI 10.1111/1523-1747.ep12470153; GAJEWSKI TF, 1988, J IMMUNOL, V140, P4245; GREWE M, 1994, J INVEST DERMATOL, V103, P426; HAMID Q, 1994, J CLIN INVEST, V94, P870, DOI 10.1172/JCI117408; HANIFIN JM, 1993, J AM ACAD DERMATOL, V28, P189, DOI 10.1016/0190-9622(93)70026-P; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; HASSNER A, 1983, J IMMUNOL, V130, P1567; HOFFMAN DR, 1975, J ALLERGY CLIN IMMUN, V55, P256, DOI 10.1016/0091-6749(75)90145-1; JUHLIN L, 1969, ARCH DERMATOL, V100, P12, DOI 10.1001/archderm.100.1.12; JUJO K, 1992, J ALLERGY CLIN IMMUN, V90, P323, DOI 10.1016/S0091-6749(05)80010-7; KAPSENBERG ML, 1991, J INVEST DERMATOL, V97, P389; KIEFFER M, 1990, J AM ACAD DERMATOL, V22, P739, DOI 10.1016/0190-9622(90)70100-V; KIMATA H, 1992, J EXP MED, V176, P1227, DOI 10.1084/jem.176.4.1227; KING CL, 1991, J IMMUNOL, V146, P1478; KING CL, 1989, P NATL ACAD SCI USA, V86, P10085, DOI 10.1073/pnas.86.24.10085; KING CL, 1990, J CLIN INVEST, V85, P1810, DOI 10.1172/JCI114639; KINIWA M, 1992, J CLIN INVEST, V90, P262, DOI 10.1172/JCI115846; LEUNG DYM, 1984, CLIN IMMUNOL IMMUNOP, V32, P339, DOI 10.1016/0090-1229(84)90277-0; LIMAYE AP, 1990, J EXP MED, V172, P399, DOI 10.1084/jem.172.1.399; MAGGI E, 1987, RES CLIN LAB, V17, P363; MITCHELL EB, 1986, BRIT J DERMATOL, V114, P65, DOI 10.1111/j.1365-2133.1986.tb02780.x; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; MUDDE GC, 1990, IMMUNOLOGY, V69, P335; MUDDE GC, 1992, J INVEST DERMATOL, V99, pS103, DOI 10.1111/1523-1747.ep12669981; NUTMAN TB, 1985, J IMMUNOL, V134, P1178; PARRONCHI P, 1991, INT J CLIN LAB RES, V21, P186; PELEMAN R, 1989, J EXP MED, V170, P1751, DOI 10.1084/jem.170.5.1751; PENE J, 1989, J CELL BIOCHEM, V39, P253, DOI 10.1002/jcb.240390305; PUNNONEN J, 1993, J IMMUNOL, V151, P1280; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; RAMBLINDHAUER C, 1991, ARCH DERMATOL RES, V283, P71, DOI 10.1007/BF00371611; REINHOLD U, 1990, CLIN EXP IMMUNOL, V79, P374; ROMAGNANI S, 1983, CLIN EXP IMMUNOL, V52, P85; ROMAGNANI S, 1980, CLIN EXP IMMUNOL, V42, P579; SAMPSON HA, 1984, NEW ENGL J MED, V311, P372, DOI 10.1056/NEJM198408093110605; SAMPSON HA, 1985, J PEDIATR-US, V107, P669, DOI 10.1016/S0022-3476(85)80390-5; SAMPSON HA, 1983, J ALLERGY CLIN IMMUN, V71, P473, DOI 10.1016/0091-6749(83)90464-5; SARYAN JA, 1983, J IMMUNOL, V130, P242; SAXON A, 1990, J ALLERGY CLIN IMMUN, V86, P333, DOI 10.1016/S0091-6749(05)80096-X; SEIKDENARI S, 1992, ANN ALLERGY, V69, P201; SHERR EH, 1987, J IMMUNOL, V138, P3836; VERCELLI D, 1990, J IMMUNOL, V144, P570; VERCELLI D, 1989, J CLIN IMMUNOL, V9, P75, DOI 10.1007/BF00916934; WALSH GA, 1981, J CLIN MICROBIOL, V13, P1046, DOI 10.1128/JCM.13.6.1046-1048.1981; WELBOURN E, 1976, BRIT J DERMATOL, V94, P619, DOI 10.1111/j.1365-2133.1976.tb05161.x; WU CY, 1992, CLIN IMMUNOL IMMUNOP, V62, P277, DOI 10.1016/0090-1229(92)90103-U	57	23	23	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1995	96	1					84	91		10.1016/S0091-6749(95)70036-6	http://dx.doi.org/10.1016/S0091-6749(95)70036-6			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RK383	7622767				2022-12-18	WOS:A1995RK38300011
J	QUARRE, JP; LECOMTE, J; LAUWERS, D; GILBERT, P; THIRIAUX, J				QUARRE, JP; LECOMTE, J; LAUWERS, D; GILBERT, P; THIRIAUX, J			ALLERGY TO LATEX AND PAPAIN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CONTACT				QUARRE, JP (corresponding author), HOP CIVIL CHARLEROI,DEPT PNEUMOL,BD P JANSON 92,B-6000 CHARLEROI,BELGIUM.							BAUR X, 1993, LANCET, V342, P1148, DOI 10.1016/0140-6736(93)92127-F; BAUR X, 1979, CLIN ALLERGY, V9, P451, DOI 10.1111/j.1365-2222.1979.tb02508.x; FISHER AA, 1992, J ALLERGY CLIN IMMUN, V90, P729, DOI 10.1016/0091-6749(92)90095-J; LEVY DA, 1992, ALLERGY, V47, P579, DOI 10.1111/j.1398-9995.1992.tb02378.x; NUTTER AF, 1979, BRIT J DERMATOL, V101, P597, DOI 10.1111/j.1365-2133.1979.tb15107.x	5	23	24	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1995	95	4					922	922		10.1016/S0091-6749(95)70144-3	http://dx.doi.org/10.1016/S0091-6749(95)70144-3			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QT468	7722179				2022-12-18	WOS:A1995QT46800026
J	NATHAN, RA; GLASS, M; SNADER, L				NATHAN, RA; GLASS, M; SNADER, L			EFFECTS OF 13 WEEKS OF TREATMENT WITH ICI-204,219 (ACCOLATET(TM)) OR CROMOLYN SODIUM (INTAL(R)) IN PATIENTS WITH MILD-TO-MODERATE ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	23	23	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1995	95	1	2				388	388						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QE854					2022-12-18	WOS:A1995QE85400988
J	NORMAN, PS; OHMAN, JL; LONG, AA; CRETICOS, PS; GEFTER, ML; SHAKED, Z; WOOD, RA; EGGLESTON, PA; LICHTENSTEIN, LM; JONES, NH; NICODEMUS, CF				NORMAN, PS; OHMAN, JL; LONG, AA; CRETICOS, PS; GEFTER, ML; SHAKED, Z; WOOD, RA; EGGLESTON, PA; LICHTENSTEIN, LM; JONES, NH; NICODEMUS, CF			FOLLOW ON STUDY OF THE FIRST CLINICAL-TRIAL WITH T-CELL DEFINED PEPTIDES FROM CAT ALLERGEN FEL-D-1	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	23	23	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1995	95	1	2				259	259						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QE854					2022-12-18	WOS:A1995QE85400474
J	SCHROEDER, JT; MACGLASHAN, DW; KAGEYSOBOTKA, A; WHITE, JM; LICHTENSTEIN, LM				SCHROEDER, JT; MACGLASHAN, DW; KAGEYSOBOTKA, A; WHITE, JM; LICHTENSTEIN, LM			CYTOKINE GENERATION BY HUMAN BASOPHILS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							MAST-CELL LINES; NON-T CELLS; CROSS-LINKAGE; IGE SYNTHESIS; FC-EPSILON; NON-B; PRODUCE INTERLEUKIN-4; LATE-PHASE; IL-4; ENDOTHELIUM				SCHROEDER, JT (corresponding author), JOHNS HOPKINS UNIV, SCH MED, JOHNS HOPKINS ASTHMA & ALLERGY CTR, 5501 HOPKINS BAYVIEW CIRCLE, BALTIMORE, MD 21224 USA.				NIAID NIH HHS [AI20253, AI07290] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020253] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABEHSIRAAMAR O, 1992, J IMMUNOL, V148, P3820; AROCK M, 1993, J IMMUNOL, V151, P1441; BASCOM R, 1988, J ALLERGY CLIN IMMUN, V81, P570, DOI 10.1016/0091-6749(88)90198-4; BENSASSON SZ, 1990, P NATL ACAD SCI USA, V87, P1421, DOI 10.1073/pnas.87.4.1421; BROWN MA, 1987, CELL, V50, P809, DOI 10.1016/0092-8674(87)90339-4; BRUNNER T, 1993, J EXP MED, V177, P605, DOI 10.1084/jem.177.3.605; CHARLESWORTH EN, 1989, J CLIN INVEST, V83, P1519, DOI 10.1172/JCI114047; CHUNG SW, 1986, BLOOD, V68, P1074; CONRAD DH, 1990, J EXP MED, V171, P1497, DOI 10.1084/jem.171.5.1497; DELPRETE G, 1988, J IMMUNOL, V140, P4193; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; GAGNON R, 1993, J ALLERGY CLIN IMMUN, V91, P950, DOI 10.1016/0091-6749(93)90353-H; GORDON JR, 1990, NATURE, V346, P274, DOI 10.1038/346274a0; GUO CB, 1994, AM J RESP CELL MOL, V10, P384, DOI 10.1165/ajrcmb.10.4.7510984; LEGROS G, 1990, J IMMUNOL, V145, P2500; MACGLASHAN D, 1994, J IMMUNOL, V152, P3006; MOSER R, 1992, J IMMUNOL, V149, P1432; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; OKUDA M, 1977, ARCH OTO-RHINO-LARYN, V214, P283, DOI 10.1007/BF00457469; PICCINNI MP, 1991, P NATL ACAD SCI USA, V88, P8656, DOI 10.1073/pnas.88.19.8656; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; SANDERSON CJ, 1988, IMMUNOL REV, V102, P29, DOI 10.1111/j.1600-065X.1988.tb00740.x; SCHLEIMER RP, 1992, J IMMUNOL, V148, P1086; SCHROEDER JT, 1994, J IMMUNOL, V153, P1808; SCHROEDER JT, 1994, J ALLERGY CLIN IMMUN, V93, P214; SEDER RA, 1991, P NATL ACAD SCI USA, V88, P2835, DOI 10.1073/pnas.88.7.2835; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; SWAIN SL, 1990, J IMMUNOL, V145, P3796; VERCELLI D, 1991, J ALLERGY CLIN IMMUN, V88, P285, DOI 10.1016/0091-6749(91)90087-5; VERCELLI D, 1989, J EXP MED, V169, P1295, DOI 10.1084/jem.169.4.1295; WODNARFILIPOWICZ A, 1989, NATURE, V339, P150, DOI 10.1038/339150a0	31	23	23	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1994	94	6	2	S			1189	1195		10.1016/0091-6749(94)90331-X	http://dx.doi.org/10.1016/0091-6749(94)90331-X			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QA020	7798559				2022-12-18	WOS:A1994QA02000011
J	TEPPER, RI				TEPPER, RI			THE EOSINOPHIL-MEDIATED ANTITUMOR-ACTIVITY OF INTERLEUKIN-4	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							TUMOR-NECROSIS-FACTOR; VASCULAR ENDOTHELIAL-CELLS; COLONY-STIMULATING FACTOR; GENE-TRANSFER; REDUCED TUMORIGENICITY; NEUTROPHIL ADHERENCE; ADHESION MOLECULE-1; INTERFERON-GAMMA; FACTOR-ALPHA; IFN-GAMMA				TEPPER, RI (corresponding author), MASSACHUSETTS GEN HOSP E,CTR CANC,TUMOR BIOL LAB,BOSTON,MA 02129, USA.							ANDERSON DC, 1985, J INFECT DIS, V152, P668, DOI 10.1093/infdis/152.4.668; ANDERSON DC, 1987, ANNU REV MED, V38, P175, DOI 10.1146/annurev.med.38.1.175; AOKI T, 1992, P NATL ACAD SCI USA, V89, P3850, DOI 10.1073/pnas.89.9.3850; ASHER AL, 1991, J IMMUNOL, V146, P3227; BEVILACQUA MP, 1985, J CLIN INVEST, V76, P2003, DOI 10.1172/JCI112200; BOCHNER BS, 1988, J CLIN INVEST, V81, P1355, DOI 10.1172/JCI113463; BROWN PO, 1987, CELL, V49, P347, DOI 10.1016/0092-8674(87)90287-X; BUBENIK J, 1990, IMMUNOL LETT, V23, P287, DOI 10.1016/0165-2478(90)90074-Z; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; CEPKO C, 1989, NEUROMETHODS, V16, P177; COFFMAN RL, 1989, SCIENCE, V245, P308, DOI 10.1126/science.2787531; COLOMBO MP, 1991, J EXP MED, V173, P889, DOI 10.1084/jem.173.4.889; CULVER KW, 1992, SCIENCE, V256, P1550, DOI 10.1126/science.1317968; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; DOBRINA A, 1989, IMMUNOLOGY, V67, P502; DOBRINA A, 1991, J CLIN INVEST, V36, P20; DRANOFF G, 1992, COMMUNICATION; DRANOFF G, 1993, COMMUNICATION; DUSTIN ML, 1986, J IMMUNOL, V137, P245; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; FEARON ER, 1990, CELL, V60, P397, DOI 10.1016/0092-8674(90)90591-2; GALLI SJ, 1993, COMMUNICATION; GAMBLE JR, 1985, P NATL ACAD SCI USA, V82, P8667, DOI 10.1073/pnas.82.24.8667; GANSBACHER B, 1990, CANCER RES, V50, P7820; GANSBACHER B, 1990, J EXP MED, V172, P1217, DOI 10.1084/jem.172.4.1217; GOILLOT E, 1992, UNPUB; GOLUMBEK PT, 1991, SCIENCE, V254, P713, DOI 10.1126/science.1948050; HOCK H, 1991, J EXP MED, V174, P1291, DOI 10.1084/jem.174.6.1291; JOSE PJ, 1994, J EXP MED, V179, P881, DOI 10.1084/jem.179.3.881; KITA H, 1991, J EXP MED, V174, P745, DOI 10.1084/jem.174.3.745; LAMAS AM, 1988, J IMMUNOL, V140, P1500; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LEWINSOHN DM, 1987, J IMMUNOL, V138, P4313; MAGGI E, 1991, J IMMUNOL, V146, P1169; MCBRIDE WH, 1992, CANCER RES, V52, P3931; MOQBEL R, 1991, J EXP MED, V174, P749, DOI 10.1084/jem.174.3.749; MOSER R, 1992, J IMMUNOL, V149, P1432; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; PENNLINE KJ, 1990, CYTOMETRY, V11, P283, DOI 10.1002/cyto.990110209; PICKER LJ, 1991, CELL, V66, P921, DOI 10.1016/0092-8674(91)90438-5; POBER JS, 1986, J IMMUNOL, V136, P1680; POHLMAN TH, 1986, J IMMUNOL, V136, P4548; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; SCHLEIMER RP, 1992, J IMMUNOL, V148, P1086; SPRY CJF, 1985, IMMUNOL TODAY, V6, P332, DOI 10.1016/0167-5699(85)90130-6; TENG MN, 1991, P NATL ACAD SCI USA, V88, P3535, DOI 10.1073/pnas.88.9.3535; TEPPER RI, 1990, CELL, V62, P457, DOI 10.1016/0092-8674(90)90011-3; TEPPER RI, 1992, BONE MARROW TRANSPL, V9, P177; TEPPER RI, 1989, CELL, V57, P503, DOI 10.1016/0092-8674(89)90925-2; TEPPER RI, 1992, SCIENCE, V257, P548, DOI 10.1126/science.1636093; THORNHILL MH, 1990, J IMMUNOL, V145, P865; THORNHILL MH, 1991, J IMMUNOL, V146, P592; VONANDRIAN UH, 1991, P NATL ACAD SCI USA, V8, P7538; WALSH GM, 1991, J IMMUNOL, V146, P3419; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; WANG LP, 1993, UNPUB; WATANABE Y, 1989, P NATL ACAD SCI USA, V86, P9456, DOI 10.1073/pnas.86.23.9456; WELLER PF, 1991, P NATL ACAD SCI USA, V88, P7430, DOI 10.1073/pnas.88.16.7430; WELLICOME SM, 1990, J IMMUNOL, V144, P2558; YU JS, 1993, CANCER RES, V53, P3125	61	23	23	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1994	94	6	2	S			1225	1231		10.1016/0091-6749(94)90336-0	http://dx.doi.org/10.1016/0091-6749(94)90336-0			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QA020	7798564	Bronze			2022-12-18	WOS:A1994QA02000016
J	[Anonymous]				[Anonymous]			THE USE OF EPINEPHRINE IN THE TREATMENT OF ANAPHYLAXIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material							FOOD											AUSTEN KF, 1974, NEW ENGL J MED, V291, P661, DOI 10.1056/NEJM197409262911306; BARACH EM, 1984, JAMA-J AM MED ASSOC, V251, P2118, DOI 10.1001/jama.251.16.2118; BARNARD JH, 1973, J ALLERGY CLIN IMMUN, V52, P259, DOI 10.1016/0091-6749(73)90044-4; BOCHNER BS, 1991, NEW ENGL J MED, V324, P1785, DOI 10.1056/NEJM199106203242506; BOCK SA, 1992, J ALLERGY CLIN IMMUN, V90, P683, DOI 10.1016/0091-6749(92)90143-P; FRAZIER CLAUDE A., 1964, SOUTHERN MED J, V57, P1028, DOI 10.1097/00007611-196409000-00006; HUTCHESON PS, 1990, ANN ALLERGY, V64, P306; PARRISH HM, 1963, AM J MED SCI, V245, P129; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; SMITH PL, 1980, J CLIN INVEST, V66, P1072, DOI 10.1172/JCI109936; VALENTINE MD, 1979, ANN INTERN MED, V90, P119, DOI 10.7326/0003-4819-90-1-119; YUNGINGER JW, 1988, JAMA-J AM MED ASSOC, V260, P1450, DOI 10.1001/jama.260.10.1450; 1990, PEDIATRICS, V86, P999	13	23	24	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1994	94	4					666	668						3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PM273					2022-12-18	WOS:A1994PM27300003
J	KUWATA, S; YANAGISAWA, M; SAEKI, H; NAKAGAWA, H; ETOH, T; TOKUNAGA, K; JUJI, T; SHIBATA, Y				KUWATA, S; YANAGISAWA, M; SAEKI, H; NAKAGAWA, H; ETOH, T; TOKUNAGA, K; JUJI, T; SHIBATA, Y			POLYMORPHISMS OF TRANSPORTER ASSOCIATED WITH ANTIGEN-PROCESSING GENES IN ATOPIC-DERMATITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	New Trends in Immunopharmacology 1993 Conference	JUL   17, 1993	TOKYO, JAPAN			TAP GENE; HLA; PCR; PCR-RFLP; ATOPIC DERMATITIS	CLASS-II REGION; DEPENDENT DIABETES-MELLITUS; MHC; HLA; ALLELES; TAP2; DNA; HAPLOTYPES; POLYMERASE; PEPTIDES	We investigated polymorphisms of transporter associated with antigen process (TAP) genes in atopic dermatitis. We developed a polymerase chain reaction-restriction fragment length polymorphism method for discriminating TAP alleles. Genomic DNA was obtained from 29 Japanese patients with atopic dermatitis and 35 control subjects. Dimorphic regions of TAP1 and TAP2 genes were amplified by polymerase chain reaction. Amplified products were digested with restriction endonucleases to determine TAP alleles: Sau3A1 for TAP1 codon 333 (Ile-Val), AccI for TAP1 codon 637 (Asp-Gly), and EcoRII for TAP2 codon 687(Gln-Stop). We observed foul alleles for TAP1 and dimorphism for TAP2 codon 687. Str of 35 controls had the TAP1 D allele, which has been reported to be a rare allele in Caucasian populations. Gene frequency of TAP1 637Asp exhibited a tendency to increase in the patients with atopic dermatitis. TAP1 637Asp and TAP1 A alleles were estimated to constitute a haplotype with DRB1*1302-DQB1*0604 and DRB1*0803-DQB1*0601 in the Japanese population. Because TAP1 and TAP2 genes are located between HLA-DQB1 and -DPB1 loci, analysis of TAP gene polymorphisms will be useful for a better understanding of susceptibility loci in HLA class II-associated disease.	UNIV TOKYO,FAC MED,DEPT DERMATOL,TOKYO 113,JAPAN; JAPANESE RED CROSS,CENT BLOOD CTR,TOKYO,JAPAN	University of Tokyo; Japanese Red Cross Medical Center	KUWATA, S (corresponding author), UNIV TOKYO,FAC MED,DEPT TRANSFUS MED & IMMUNOHEMATOL,BUNKYO KU,HONGO 7-3-1,TOKYO 113,JAPAN.							BECK S, 1992, J MOL BIOL, V228, P433, DOI 10.1016/0022-2836(92)90832-5; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BODMER JG, 1992, TISSUE ANTIGENS, V39, P161, DOI 10.1111/j.1399-0039.1992.tb01932.x; CARRINGTON M, 1993, IMMUNOGENETICS, V37, P266; COLONNA M, 1992, P NATL ACAD SCI USA, V89, P3932, DOI 10.1073/pnas.89.9.3932; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; IKEGAMI H, 1992, J CLIN ENDOCR METAB, V75, P1381, DOI 10.1210/jc.75.5.1381; Imanish T, 1992, HLA 1991, V1, P1065; INOKO H, 1990, TISSUE ANTIGENS, V36, P88, DOI 10.1111/j.1399-0039.1990.tb01806.x; Kimura A., 1991, HLA 1991 P 11 INT HI, VVolume 1, P397; Kuwata Shoji, 1993, Journal of the American Society of Nephrology, V4, P683; MAEDA M, 1989, TISSUE ANTIGENS, V34, P290, DOI 10.1111/j.1399-0039.1989.tb01745.x; MALNATI MS, 1992, NATURE, V357, P702, DOI 10.1038/357702a0; MANIATIS T, 1989, MOL CLONING LABORATO, P280; MITSUNAGA S, 1992, HUM IMMUNOL, V34, P203, DOI 10.1016/0198-8859(92)90113-2; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; POSIW SH, 1993, J AM SOC NEPHROL, V4, P687; POWIS SH, 1993, IMMUNOGENETICS, V38, P345; POWIS SH, 1993, IMMUNOGENETICS, V37, P480; POWIS SH, 1993, IMMUNOGENETICS, V37, P373, DOI 10.1007/BF00216802; POWIS SJ, 1992, NATURE, V357, P211, DOI 10.1038/357211a0; RONNINGEN KS, 1993, EUR J IMMUNOL, V23, P1050, DOI 10.1002/eji.1830230511; SAEKI H, 1994, J ALLERGY CLIN IMMUN, V94, P575, DOI 10.1016/0091-6749(94)90133-3; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; SVEJGAARD A, 1983, IMMUNOL REV, V70, P193, DOI 10.1111/j.1600-065X.1983.tb00715.x; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; UCHIGATA Y, 1992, LANCET, V339, P393, DOI 10.1016/0140-6736(92)90080-M	29	23	26	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1994	94	3	2	S			565	574		10.1016/0091-6749(94)90132-5	http://dx.doi.org/10.1016/0091-6749(94)90132-5			10	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PH235	7916022				2022-12-18	WOS:A1994PH23500001
J	SIRACUSA, A; BRUGNAMI, G; FIORDI, T; ARENI, S; SEVERINI, C; MARABINI, A				SIRACUSA, A; BRUGNAMI, G; FIORDI, T; ARENI, S; SEVERINI, C; MARABINI, A			TROLEANDOMYCIN IN THE TREATMENT OF DIFFICULT ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						DIFFICULT ASTHMA; CORTICOSTEROID-DEPENDENT ASTHMA; TROLEANDOMYCIN; METHYLPREDNISOLONE; STEROID-SPARING EFFECT; SIDE EFFECTS OF CORTICOSTEROIDS; BONE MINERAL CONTENT	CORTICOSTEROID-DEPENDENT ASTHMA; DOUBLE-BLIND; METHYLPREDNISOLONE ELIMINATION; METHOTREXATE; STEROIDS	Background: For difficult asthma, treatment is aimed at improving airway obstruction and minimizing adverse effects of systemic corticosteroids. The combination of troleandomycin (TAO) with methylprednisolone (MP) reportedly has a beneficial steroid-sparing effect on difficult asthma. Methods: To test the steroid-sparing effect of TAO, 14 subjects with severe corticosteroid-dependent asthma were studied before and during treatment with MP and TAO Results: Treatment with MP and TAO resulted in a clear reduction in respiratory symptoms, asthmatic attacks, corticosteroid and hospitalization requirements, improvement in pulmonary function tests, and a remarkable decrease in peak expiratory flow rate circadian variability when compared with the period before TAO treatment (with corticosteroids). Treatment with MP and TAO was fairly well tolerated. Only a reduction (-5.2%, p < 0.01) in bone mineral content and an increase in plasma glucose levels (from 81. 7 to 94.3 mg/dl, p < 0.05) were found, in comparison with pre-TAO values. One subject discontinued MP-TAO treatment because of a mild but persistent increase in serum alanine aminotransferase. In an evaluation of the clinical and pulmonary function test results, eight of the 14 subjects were responders and six were nonresponders. During follow-up three subjects discontinued TAO and consequently had an asthmatic attack after 4, 7, or 15 days, respectively. Conclusions: This study confirms that treatment with MP and TAO has a beneficial effect in a subgroups of severely steroid-dependent asthma patients.			SIRACUSA, A (corresponding author), UNIV PERUGIA,INST OCCUPAT MED,VIA E DAL POZZO,I-06100 PERUGIA,ITALY.							ALEXANDER E, 1991, AM REV RESPIR DIS, V143, P633; ALVAREZ J, 1992, J ALLERGY CLIN IMMUN, V89, P714, DOI 10.1016/0091-6749(92)90379-G; BAHOUS J, 1985, B EUR PHYSIOPATH RES, V21, P25; BARNES PJ, 1989, BRIT MED J, V299, P695, DOI 10.1136/bmj.299.6701.695; BERLOW BA, 1991, J ALLERGY CLIN IMMUN, V87, P710, DOI 10.1016/0091-6749(91)90393-3; BRENNER AM, 1991, IMMUNOL ALLERGY CLIN, V11, P91; CHAROUS BL, 1990, ANN ALLERGY, V65, P53; COTT GR, 1988, NEW ENGL J MED, V318, P634, DOI 10.1056/NEJM198803103181010; ERZURUM SC, 1991, ANN INTERN MED, V114, P353, DOI 10.7326/0003-4819-114-5-353; GREOS LS, 1990, AM REV RESPIR DIS, V141, P933; HIGGINS BG, 1989, AM REV RESPIR DIS, V140, P1368, DOI 10.1164/ajrccm/140.5.1368; ITKIN IH, 1970, J ALLERGY, V45, P146, DOI 10.1016/0021-8707(70)90124-3; KAPLAN MA, 1959, ANTIBIOTICS ANN 1958, P273; KLAUSTERMEYER WB, 1987, J ALLERGY CLIN IMMUN, V79, P720, DOI 10.1016/0091-6749(87)90202-8; MENZ G, 1990, ATEMW LUNGENKRKH S1, V16, P6; MULLARKEY MF, 1988, NEW ENGL J MED, V318, P603, DOI 10.1056/NEJM198803103181004; MURANAKA M, 1978, ANN ALLERGY, V40, P132; MURANAKA M, 1981, J ALLERGY CLIN IMMUN, V67, P560; RYAN G, 1982, THORAX, V37, P423, DOI 10.1136/thx.37.6.423; SCHWARZ YA, 1990, J ALLERGY CLIN IMMUN, V85, P578, DOI 10.1016/0091-6749(90)90096-M; SHAW LM, 1989, CLIN CHEM, V35, P1299; SHINER RJ, 1989, BRIT MED J, V299, P216, DOI 10.1136/bmj.299.6693.216; SHINER RJ, 1990, LANCET, V336, P137, DOI 10.1016/0140-6736(90)91659-X; SMITH R, 1990, THORAX, V45, P573, DOI 10.1136/thx.45.8.573; SPECTOR SL, 1974, J ALLERGY CLIN IMMUN, V54, P367, DOI 10.1016/0091-6749(74)90027-X; SZEFLER SJ, 1980, J ALLERGY CLIN IMMUN, V66, P447, DOI 10.1016/0091-6749(80)90004-4; SZEFLER SJ, 1982, CLIN PHARMACOL THER, V32, P166, DOI 10.1038/clpt.1982.143; TICKTIN HE, 1962, NEW ENGL J MED, V267, P964, DOI 10.1056/NEJM196211082671905; TRUHAN AP, 1989, ANN ALLERGY, V62, P375; WALD JA, 1986, J ALLERGY CLIN IMMUN, V78, P36, DOI 10.1016/0091-6749(86)90112-0; ZEIGER RS, 1980, J ALLERGY CLIN IMMUN, V66, P438, DOI 10.1016/0091-6749(80)90003-2	31	23	23	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1993	92	5					677	682		10.1016/0091-6749(93)90010-D	http://dx.doi.org/10.1016/0091-6749(93)90010-D			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MG982	8227858				2022-12-18	WOS:A1993MG98200008
J	ZEIGER, RS; HELLER, S				ZEIGER, RS; HELLER, S			DEVELOPMENT OF NASAL BASOPHILIC CELLS AND NASAL EOSINOPHILS FROM AGE 4 MONTHS THROUGH 4 YEARS IN CHILDREN OF ATOPIC PARENTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						BASOPHILS; EOSINOPHILS; ATOPY; IGE IGG FOOD ANTIBODIES	ALLERGIC RHINITIS; MAST-CELL; DIFFERENTIATION; HETEROGENEITY; INFANCY; SMOKING	Background: The importance of the inflammatory response in allergic disease has warranted investigation of two of the more integral cells in the pathogenesis of allergic rhinitis, namely, nasal basophilic cells (NBCs) and nasal eosinophils (NEs). In the present study the natural history of NBCs and NEs was studied from birth through 4 years of age in infants of atopic parents to better understand their relationship to the development of various atopic disorders. Methods: During a prospective, randomized, controlled trial of the effect of maternal and infant food avoidance on the development of atopic disorders in 288 infants of atopic parents, NBCs and NEs were determined semiquantitatively on Wright-Geimsa stained nasal mucosal scrapings and related to each other and to various atopic parameters. Results: In these infants who are at high risk NBCs developed in both those becoming atopic and those remaining nonatopic, but they occurred with increased frequency and quantity in those children in whom most allergic disorders and food or inhalant sensitization developed. NEs, rare at 4 months in all infants, increased in atopic children from 1 to 4 years, and remained infrequent and nominal in nonatopic children. Levels of NBCs and NEs (1) correlated with each other strongly, directly, and with increasing magnitude in children from ages 4 months to 4 years and (2) correlated with log serum IgE levels weakly and moderately in children from ages 2 to 4 years. Stepwise linear regression analyses revealed that allergic rhinitis accounted for most of the variance seen in the level of NBCs and NEs during early childhood, reaching 50% by age 4 years. Asthma, atopic dermatitis, food allergy, food and inhalant sensitization, serum IgE level, and IgG beta-lactoglobulin level accounted for a small proportion of the variance in NBCs and NEs from ages 4 months to 4 years. Conclusions: These findings help to elucidate the natural history of NBCs and NEs in infants at risk for atopic disorders and document the temporal association of these cells with the development of atopic disease, principally allergic rhinitis.	KAISER PERMANENTE MED CTR,DEPT ALLERGY,SAN DIEGO,CA	Kaiser Permanente				Zeiger, Robert/0000-0001-5788-5063				BENTLEY AM, 1992, J ALLERGY CLIN IMMUN, V89, P877, DOI 10.1016/0091-6749(92)90444-7; BIENENSTOCK J, 1982, J ALLERGY CLIN IMMUN, V70, P407, DOI 10.1016/0091-6749(82)90001-X; BOCK SA, 1978, J ALLERGY CLIN IMMUN, V62, P327, DOI 10.1016/0091-6749(78)90132-X; BORRES MP, 1991, PED ALLERGY IMMUNO S, V2, P1; BORRES MP, 1991, PEDIATR ALLERGY IMMU, V4, P184; CESKA M, 1972, IMMUNOCHEMISTRY, V9, P1021, DOI 10.1016/0019-2791(72)90112-7; COGSWELL JJ, 1987, ARCH DIS CHILD, V62, P338, DOI 10.1136/adc.62.4.338; COHEN GA, 1985, ANN ALLERGY, V54, P112; CRAWFORD LLOYD B., 1960, ANN ALLERGY, V18, P59; DENBURG JA, 1989, INT ARCH ALLER A IMM, V88, P126, DOI 10.1159/000234763; FRICK WE, 1988, J ALLERGY CLIN IMMUN, V82, P119, DOI 10.1016/0091-6749(88)90061-9; HANIFIN JM, 1977, ARCH DERMATOL, V113, P663, DOI 10.1001/archderm.113.5.663; IRANI AA, 1986, P NATL ACAD SCI USA, V83, P4464, DOI 10.1073/pnas.83.12.4464; JAMES JM, 1992, J PEDIATR-US, V121, P371, DOI 10.1016/S0022-3476(05)81788-3; KEMP AS, 1982, INT J PEDIATR OTORHI, V4, P293, DOI 10.1016/0165-5876(82)90041-6; KERSHAW CR, 1987, J ROY SOC MED, V80, P683, DOI 10.1177/014107688708001108; MATHESON A, 1957, J PEDIATR-US, V51, P502, DOI 10.1016/S0022-3476(57)80067-5; Meltzer EO, 1988, AM J RHINOL, V2, P47, DOI DOI 10.2500/105065888781693212; OHNISHI M, 1988, J ALLERGY CLIN IMMUN, V81, P1149, DOI 10.1016/0091-6749(88)90883-4; OKUDA M, 1989, ALLERGY PROC, V10, P23, DOI 10.2500/108854189778968533; OKUDA M, 1985, ANN ALLERGY, V54, P152; SHIODA H, 1966, J ALLERGY, V37, P321, DOI 10.1016/0021-8707(66)90131-6; ZEIGER RS, 1989, J ALLERGY CLIN IMMUN, V84, P72, DOI 10.1016/0091-6749(89)90181-4; ZEIGER RS, IN PRESS PEDIATR ALL; ZEIGER RS, 1989, AM J RHINOL, V3, P21	25	23	23	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1993	91	3					723	734		10.1016/0091-6749(93)90191-H	http://dx.doi.org/10.1016/0091-6749(93)90191-H			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KU203	8454794				2022-12-18	WOS:A1993KU20300004
J	KALLENBACH, J; BAYNES, R; FINE, B; DAJEE, D; BEZWODA, W				KALLENBACH, J; BAYNES, R; FINE, B; DAJEE, D; BEZWODA, W			PERSISTENT NEUTROPHIL ACTIVATION IN MILD ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note							CONSTITUENTS; LACTOFERRIN; LEUKOCYTES; RELEASE; PLASMA		JOHANNESBURG HOSP,DEPT MED,JOHANNESBURG,SOUTH AFRICA	University of Witwatersrand	KALLENBACH, J (corresponding author), UNIV WITWATERSRAND,SCH MED,DEPT MED,7 YORK RD,JOHANNESBURG 2193,SOUTH AFRICA.							BAYNES RD, 1986, SCAND J HAEMATOL, V36, P79; BENTWOOD BJ, 1980, J IMMUNOL, V124, P855; BEZWODA WR, 1985, CLIN CHIM ACTA, V151, P61, DOI 10.1016/0009-8981(85)90235-9; HENSON PM, 1971, J IMMUNOL, V107, P1547; KALLENBACH JM, 1988, CHEST, V93, P751, DOI 10.1378/chest.93.4.751; MAALLEM H, 1982, BRIT J HAEMATOL, V51, P201, DOI 10.1111/j.1365-2141.1982.tb08476.x; MARTIN RJ, 1991, AM REV RESPIR DIS, V143, P351, DOI 10.1164/ajrccm/143.2.351; SPITZNAGEL JK, 1974, LAB INVEST, V30, P774	8	23	23	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1992	90	2					272	274		10.1016/0091-6749(92)90084-F	http://dx.doi.org/10.1016/0091-6749(92)90084-F			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JJ423	1323589				2022-12-18	WOS:A1992JJ42300021
J	SUGIYAMA, H; OKADA, C; BEWTRA, AK; HOPP, RJ; TOWNLEY, RG				SUGIYAMA, H; OKADA, C; BEWTRA, AK; HOPP, RJ; TOWNLEY, RG			THE EFFECT OF FORMOTEROL ON THE LATE ASTHMATIC PHENOMENA IN GUINEA-PIGS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						FORMOTEROL; LONG-ACTING BETA-2-AGONIST; LATE ASTHMATIC RESPONSE; AIRWAY INFLAMMATION; INCREASED BRONCHIAL RESPONSIVENESS; GUINEA PIGS; BRONCHOALVEOLAR LAVAGE	LATE-PHASE BRONCHOCONSTRICTION; ALLERGEN-INDUCED INCREASE; INHALED FORMOTEROL; BRONCHIAL RESPONSIVENESS; BRONCHOALVEOLAR LAVAGE; LEUKOCYTE INFILTRATION; ANIMAL-MODEL; SALBUTAMOL; RESPONSES; CHALLENGE	We investigated the effects of formoterol, a new, long-acting, selective beta(2)-adrenoceptor agonist, on the antigen-induced late asthmatic response (LAR) and airway inflammation in guinea pigs. Animals were sensitized by exposure to aerosolized ovalbumin (2% in saline). After antigen challenge, preceded by administration of an H-1-receptor antagonist, specific airway conductance was measured with a two-chambered whole-body plethysmograph. An aerosolized solution of formoterol, isoproterenol, or saline was inhaled 15 minutes before challenge. Bronchoalveolar lavage (BAL) was performed 24 hours after challenge. The provocative concentrations of histamine required to decrease specific airway conductance by 50% were obtained before challenge, at 24 hours, and at 72 hours after challenge. The LAR (52.7% +/- 7.7% of the baseline; p < 0.02) was observed 6 to 8 hours after antigen challenge. An increased cellular influx in BAL (mainly eosinophils and macrophages) and an increased bronchial responsiveness to histamine occurred 24 hours after antigen challenge. Formoterol completely inhibited the LAR and the cellular increase in BAL; however, isoproterenol failed to prevent either the cellular infiltration or the LAR. Formoterol also decreased the antigen-induced increase in bronchial reactivity. These findings suggest that formoterol has inhibitory effects on the underlying inflammatory processes in antigen-induced asthma in addition to prolonged bronchodilation.			SUGIYAMA, H (corresponding author), CREIGHTON UNIV,CTR ALLERG DIS,2500 CALIF ST,OMAHA,NE 68178, USA.		Hopp, Russell/K-4578-2019					ABRAHAM WM, 1983, AM REV RESPIR DIS, V128, P839; BAKER AJ, 1990, AM REV RESPIR DIS, V141, P394; BECKER AB, 1989, J ALLERGY CLIN IMMUN, V84, P891, DOI 10.1016/0091-6749(89)90385-0; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; CHURCH MK, 1987, BRIT J PHARMACOL, V90, P421, DOI 10.1111/j.1476-5381.1987.tb08972.x; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; COCKCROFT DW, 1987, J ALLERGY CLIN IMMUN, V79, P734, DOI 10.1016/0091-6749(87)90204-1; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DURHAM SR, 1984, J ALLERGY CLIN IMMUN, V74, P49, DOI 10.1016/0091-6749(84)90086-1; EISER N, 1990, AM REV RESPIR DIS, V141, P874; GERLACH RF, 1989, J APPL TOXICOL, V9, P145, DOI 10.1002/jat.2550090303; GRAFFLONNEVIG V, 1990, CLIN EXP ALLERGY, V20, P429, DOI 10.1111/j.1365-2222.1990.tb02805.x; HUTSON PA, 1988, AM REV RESPIR DIS, V138, P1157, DOI 10.1164/ajrccm/138.5.1157; HUTSON PA, 1988, AM REV RESPIR DIS, V137, P548, DOI 10.1164/ajrccm/137.3.548; IIJIMA H, 1987, AM REV RESPIR DIS, V136, P922, DOI 10.1164/ajrccm/136.4.922; JOHNS K, 1990, AM REV RESPIR DIS, V142, P138, DOI 10.1164/ajrccm/142.1.138; KALLOS P, 1984, INT ARCH ALLER A IMM, V73, P77, DOI 10.1159/000233441; LOFDAHL CG, 1989, ALLERGY, V44, P264, DOI 10.1111/j.1398-9995.1989.tb01068.x; MAESEN FPV, 1990, CHEST, V97, P590, DOI 10.1378/chest.97.3.590; MALO JL, 1990, AM REV RESPIR DIS, V142, P1147, DOI 10.1164/ajrccm/142.5.1147; MCALPINE LG, 1990, RESP MED, V84, P293, DOI 10.1016/S0954-6111(08)80056-X; METZGER WJ, 1986, CHEST, V89, P477, DOI 10.1378/chest.89.4.477; MURPHY KR, 1986, AM REV RESPIR DIS, V134, P62; OBYRNE PM, 1987, AM REV RESPIR DIS, V136, P740, DOI 10.1164/ajrccm/136.3.740; PALMQVIST M, 1989, J ALLERGY CLIN IMMUN, V83, P244; PENNOCK BE, 1979, J APPL PHYSIOL, V46, P399, DOI 10.1152/jappl.1979.46.2.399; SHAMPAIN MP, 1982, AM REV RESPIR DIS, V126, P493; TWENTYMAN OP, 1990, LANCET, V336, P1338, DOI 10.1016/0140-6736(90)92894-N; VANBEVER HP, 1990, J ALLERGY CLIN IMMUN, V85, P700, DOI 10.1016/0091-6749(90)90186-8; VONBERG A, 1990, LUNG, V168, P90, DOI 10.1007/BF02718119	30	23	23	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1992	89	4					858	866		10.1016/0091-6749(92)90442-5	http://dx.doi.org/10.1016/0091-6749(92)90442-5			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HN860	1348516				2022-12-18	WOS:A1992HN86000012
J	CLAASSEN, JJ; LEVINE, AD; SCHIFF, SE; BUCKLEY, RH				CLAASSEN, JJ; LEVINE, AD; SCHIFF, SE; BUCKLEY, RH			MONONUCLEAR-CELLS FROM PATIENTS WITH THE HYPER-IGE SYNDROME PRODUCE LITTLE IGE WHEN THEY ARE STIMULATED WITH RECOMBINANT HUMAN INTERLEUKIN-4	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						HYPER-IGE SYNDROME; RECOMBINANT HUMAN INTERLEUKIN-4; IGE SYNTHESIS; ISOTYPE SWITCHING; ANTI-CD40	HUMAN B-CELLS; INTERFERON-GAMMA; HUMAN-LYMPHOCYTES; SYNTHESIS INVITRO; T-CELLS; IL-4; INFECTION; ANTIBODY; CLONES; ALPHA	To investigate whether B cells from patients with the hyper-IgE syndrome are more sensitive to the effects of interleukin-4 in vitro than B cells of normal or atopic individuals, we stimulated blood mononuclear cells (MNC) with varying doses of recombinant human interleukin 4 (rhIL-4) and measured supernatant IgE concentrations after 18 days of culture. Geometric mean spontaneous IgE synthesis after 18 days of culture without rhIL-4 was low (< 3 ng/ml) and similar for MNCs from nine patients with the hyper-IgE syndrome, nine atopic and nine normal subjects. As found in our previous studies, MNCs from the nine atopic and the nine normal donors produced significant and similar quantities of IgE (geometric mean maximum IgE, 25.2 and 18.7 ng/ml, respectively) when MNCs were stimulated with rhIL-4. MNCs from both donor groups had similar sensitivity to the concentration of IL-4 eliciting the IgE response. In striking contrast, MNCs from the nine patients with the hyper-IgE syndrome failed to produce significant IgE over that produced spontaneously when MNCs were stimulated by a wide range of rhIL-4 concentrations. Coculture of B cell-enriched subpopulations from patients with the hyper-IgE syndrome with T cell-enriched subpopulations from nonatopic and atopic donors failed to restore responsiveness to rhIL-4. The addition of anti-CD40 monoclonal antibody to MNC cultures did result in enhancement of rhIL-4 IgE synthesis by MNCs from patients with the hyper-IgE syndrome, but the concentration of anti-CD40 required to elicit this enhancement was tenfold higher than for control MNCs. These studies suggest that most blood B cells from patients with the hyper-IgE syndrome capable of producing IgE have been stimulated with sufficient IL-4 in vivo to induce isotype switching and, as a consequence, are no longer responsive to the effects of additional IL-4 in vitro.	DUKE UNIV,SCH MED,DEPT PEDIAT,DIV ALLERGY & IMMUNOL,DURHAM,NC 27706; DUKE UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,DURHAM,NC 27706; MONSANTO CO,DEPT BIOL SCI,ST LOUIS,MO 63166	Duke University; Duke University; Monsanto			Buckley, Rebecca/AAB-1578-2019		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI012026, R01AI028414] Funding Source: NIH RePORTER; NCRR NIH HHS [M01-RR-30] Funding Source: Medline; NIAID NIH HHS [AI12026, AI28414] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOGUNIEWICZ M, 1990, AM J MED, V88, P365, DOI 10.1016/0002-9343(90)90490-5; BUCKLEY RH, 1972, PEDIATRICS, V49, P59; BUCKLEY RH, 1981, CLIN IMMUNOLOGY UPDA, P147; CLAASSEN JL, 1990, J IMMUNOL, V144, P2123; CLAASSEN JL, 1990, J IMMUNOL METHODS, V126, P213, DOI 10.1016/0022-1759(90)90153-M; CLARK EA, 1986, P NATL ACAD SCI USA, V83, P4494, DOI 10.1073/pnas.83.12.4494; DELPRETE G, 1988, J IMMUNOL, V140, P4193; DELPRETE G, 1989, J CLIN INVEST, V84, P1830, DOI 10.1172/JCI114368; FINKELMAN FD, 1989, J IMMUNOL, V142, P403; FISER PM, 1979, J IMMUNOL, V123, P1788; GAMKRELIDZE A, 1990, J IMMUNOL METHODS, V130, P9, DOI 10.1016/0022-1759(90)90292-4; GLEICH GJ, 1971, J LAB CLIN MED, V77, P690; JABARA HH, 1990, J EXP MED, V172, P1861, DOI 10.1084/jem.172.6.1861; KING CL, 1991, J IMMUNOL, V146, P1478; KING CL, 1989, P NATL ACAD SCI USA, V86, P10085, DOI 10.1073/pnas.86.24.10085; LI JTC, 1990, J ALLERGY CLIN IMMUN, V85, P934, DOI 10.1016/0091-6749(90)90080-N; MASSICOT JG, 1986, J ALLERGY CLIN IMMUN, V77, P544, DOI 10.1016/0091-6749(86)90343-X; PAUL WE, 1987, ANNU REV IMMUNOL, V5, P429, DOI 10.1146/annurev.iy.05.040187.002241; PENE J, 1988, J IMMUNOL, V141, P1218; PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880; SAMPSON HA, 1981, J IMMUNOL, V127, P829; SAXON A, 1976, J IMMUNOL METHODS, V12, P285, DOI 10.1016/0022-1759(76)90050-8; SEETHARAM S, UNPUB CHARACTERIZATI; SNAPPER CM, 1988, IMMUNOL REV, V102, P51, DOI 10.1111/j.1600-065X.1988.tb00741.x; THYPHRONITIS G, 1989, P NATL ACAD SCI USA, V86, P5580, DOI 10.1073/pnas.86.14.5580; TURNER KJ, 1983, CLIN EXP IMMUNOL, V51, P387; VERCELLI D, 1989, J EXP MED, V169, P1295, DOI 10.1084/jem.169.4.1295; VERCELLI D, 1990, J CLIN INVEST, V85, P1666, DOI 10.1172/JCI114618; ZHANG K, 1991, J IMMUNOL, V146, P1836	29	23	23	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1991	88	5					713	721		10.1016/0091-6749(91)90177-P	http://dx.doi.org/10.1016/0091-6749(91)90177-P			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GQ452	1720150				2022-12-18	WOS:A1991GQ45200005
J	DRUCE, HM; SLAVIN, RG				DRUCE, HM; SLAVIN, RG			SINUSITIS - A CRITICAL NEED FOR FURTHER STUDY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							RECURRENT SINUSITIS; MAXILLARY SINUSITIS; NASAL; MANAGEMENT; CHILDREN; ALLERGY				DRUCE, HM (corresponding author), ST LOUIS UNIV,SCH MED,DIV ALLERGY & IMMUNOL,1402 S GRAND BLVD,ROOM R209,ST LOUIS,MO 63104, USA.							CARTER BL, 1988, OTOLARYNG CLIN N AM, V21, P395; DRUCE HM, 1991, ANN ALLERGY, V66, P132; DRUCE HM, 1984, J APPL PHYSIOL, V57, P1276, DOI 10.1152/jappl.1984.57.4.1276; DRUCE HM, 1990, OTOLARYNG HEAD NECK, V103, P880, DOI 10.1177/01945998901030S508; DRUCE HM, 1987, IMMUNOL ALLERGY CLIN, V7, P117; EVANS FO, 1975, NEW ENGL J MED, V293, P735, DOI 10.1056/NEJM197510092931502; GOLDENHERSH MJ, 1990, J ALLERGY CLIN IMMUN, V85, P1030, DOI 10.1016/0091-6749(90)90047-8; MCALISTER WH, 1989, AM J ROENTGENOL, V153, P1259, DOI 10.2214/ajr.153.6.1259; MELEN I, 1986, ACTA OTO-LARYNGOL, V101, P494, DOI 10.3109/00016488609108636; ROHR AS, 1986, J ALLERGY CLIN IMMUN, V78, P58, DOI 10.1016/0091-6749(86)90115-6; SELNER JC, 1985, ANN ALLERGY, V54, P479; STAMMBERGER H, 1986, ENDOSCOPY, V18, P213, DOI 10.1055/s-2007-1018382; WINTHER B, 1990, OTOLARYNG HEAD NECK, V103, P876, DOI 10.1177/01945998901030S507; ZINREICH SJ, 1990, OTOLARYNG HEAD NECK, V103, P863, DOI 10.1177/01945998901030S505; 1990, NIH DATA BOOK	15	23	24	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1991	88	4					675	677		10.1016/0091-6749(91)90161-G	http://dx.doi.org/10.1016/0091-6749(91)90161-G			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GL049	1918732				2022-12-18	WOS:A1991GL04900016
J	GHOSH, SK; DEVOS, C; MCILROY, I; PATEL, KR				GHOSH, SK; DEVOS, C; MCILROY, I; PATEL, KR			EFFECT OF CETIRIZINE ON HISTAMINE-INDUCED AND LEUKOTRIENE D4-INDUCED BRONCHOCONSTRICTION IN PATIENTS WITH ATOPIC ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							INHALED LEUKOTRIENE-D4; SUBSENSITIVITY; ANTAGONIST; POTENT	Cetirizine, a derivative of hydroxyzine, is a new compound with potent antihistaminic property without antiserotonin and anticholinergic activities. The effect of both a single dose (15 mg) and 7 days of treatment (15 mg twice daily) with cetirizine, a potent H1 antagonist on bronchoconstriction induced by histamine and leukotriene D4 (LTD4) has been examined in 10 patients with mild atopic asthma in a placebo-controlled, double-blind, crossover study. Cetirizine, after a single dose and 7 days of treatment with placebo, the geometric mean values of the provocative concentration of histamine causing a 20% fall in FEV1 (millimolars) were 1.60 (95% confidence interval, 0.82 to 3.11) and 1.67 (0.77 to 3.65), compared with 118.07 (77.22 to 180.54) (p < 0.0001) and 53.16 (20.50 to 137.84) after cetirizine administration (p < 0.0002). The mean inhibition after a single dose was twofold higher than after 1 week of treatment (p < 0.05). After a single dose and 7 days of treatment with placebo, the geometric mean values of the provocative concentration of LTD4 causing a 20% fall in FEV1 (micromolars) were 2.26 (1.74 to 2.94) and 2.37 (1.77 to 3.17), compared with 3.90 (2.60 to 5.86) (p < 0.05) and 3.21 (2.28 to 4.52) after cetirizine administration. This result suggests that cetirizine is a potent H-1 antagonist in the human airways. Diminished activity after 1 week of treatment suggests subsensitivity of H-1 receptors developing in human airways. The small protective effect after a single dose against LTD4-induced bronchoconstriction indicates a nonspecific rather than a specific receptor antagonism.	WESTERN INFIRM & ASSOCIATED HOSP,DEPT RESP MED,GLASGOW G11 6NT,SCOTLAND; UCB PHARMACEUT SECTOR,BRUSSELS,BELGIUM	UCB Pharma SA								ALBAZZAZ MK, 1988, THORAX, V43, P306, DOI 10.1136/thx.43.4.306; ARM JP, 1987, THORAX, V42, P220; BARNES N, 1987, J ALLERGY CLIN IMMUN, V79, P816, DOI 10.1016/0091-6749(87)90215-6; BOUDOULAS H, 1977, ANN INTERN MED, V87, P433, DOI 10.7326/0003-4819-87-4-433; CRETICOS PS, 1984, NEW ENGL J MED, V310, P1626, DOI 10.1056/NEJM198406213102502; DAHLEN SE, 1980, NATURE, V288, P484, DOI 10.1038/288484a0; DAHLEN SE, 1983, P NATL ACAD SCI-BIOL, V80, P1712, DOI 10.1073/pnas.80.6.1712; DAVIDSON AB, 1987, AM REV RESPIR DIS, V135, P333; HOLROYDE MC, 1981, LANCET, V2, P17; HOWARTH PH, 1985, J ALLERGY CLIN IMMUN, V75, P116; KERN R, 1986, AM REV RESPIR DIS, V133, P1127; KOPFERSCHMITTKU.MC, 1989, ALLERGOLOGIE, V21, P118; KUEHL FA, 1984, J ALLERGY CLIN IMMUN, V74, P378, DOI 10.1016/0091-6749(84)90134-9; LONG WF, 1985, J ALLERGY CLIN IMMUN, V76, P113, DOI 10.1016/0091-6749(85)90813-9; POPA VT, 1980, CHEST, V78, P447; RAFFERTY P, 1987, AM REV RESPIR DIS, V135, P181; SMITH LJ, 1985, AM REV RESPIR DIS, V131, P368; SNYDER SH, 1987, ANN ALLERGY, V59, P4; TAYLOR RJ, 1985, J ALLERGY CLIN IMMUN, V76, P103, DOI 10.1016/0091-6749(85)90811-5	19	23	23	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1991	87	5					1010	1013		10.1016/0091-6749(91)90424-M	http://dx.doi.org/10.1016/0091-6749(91)90424-M			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FM095	1673975				2022-12-18	WOS:A1991FM09500014
J	FRIERI, M; ANGADI, C; PAOLANO, A; OSTER, N; BLAU, SP; YANG, S; MELE, C; HAWRYLKO, E				FRIERI, M; ANGADI, C; PAOLANO, A; OSTER, N; BLAU, SP; YANG, S; MELE, C; HAWRYLKO, E			ALTERED T-CELL SUBPOPULATIONS AND LYMPHOCYTES EXPRESSING NATURAL-KILLER-CELL PHENOTYPES IN PATIENTS WITH PROGRESSIVE SYSTEMIC-SCLEROSIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							RHEUMATOID-ARTHRITIS; HELPER-INDUCER; MONOCLONAL-ANTIBODY; PERIPHERAL-BLOOD; SUB-POPULATIONS; NK-CELLS; SUPPRESSOR; ANTIGEN; SCLERODERMA; SUBSETS	Scleroderma (progressive systemic sclerosis [PSS]) is known to be associated with abnormal T cell immunoregulation. In the present study, we evaluated lymphocyte phenotypes in patients with PSS and normal control subjects by flow cytometry and monoclonal antibodies for total T (CD3), T suppressor (CD8), T helper (CD4), T helper-inducer (CDw29), T suppressor-inducer (CD45R), human leukocyte antigen, DR+B (CD19), DR+T, and natural killer subsets, HNK-1 (CD57) and NKH-1 (CD56) cells. Patients with PSS compared to normal subjects had significantly lower percentages of CD3+ (p < 0.005) and CD8+ (p < 0.05) (similar to several patients with rheumatoid arthritis also evaluated), as well as CD45R (p < 0.05), T+ DR+ (p < 0.05), and NKH-1 (CD56) (p < 0.0005) cells. Patients with PSS late-limited or generalized disease had lower percentages of CD8+, CD19, NKH-1 +, and CDw29, but higher percentages of CD4+, HNK-1, and CD45R cells compared to patients with early stage disease, but these results were not statistically significant. These unique alterations in patients with PSS may prove to be useful in monitoring the stage of disease activity for therapy and further define immunologic defects.	SUNY STONY BROOK,NASSAU CTY MED CTR,DEPT PATHOL,E MEADOW,NY; SUNY STONY BROOK,NASSAU CTY MED CTR,DEPT MED,E MEADOW,NY; LONG ISL COLL HOSP,DEPT ALLERGY & IMMUNOL,BROOKLYN,NY 11201	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Long Island College Hospital								ABO T, 1981, J IMMUNOL, V127, P1024; ALPERT SD, 1987, RHEUM DIS CLIN N AM, V13, P431; BOS JD, 1987, J INVEST DERMATOL, V88, P569, DOI 10.1111/1523-1747.ep12470172; EMERY P, 1987, ARTHRITIS RHEUM, V30, P849, DOI 10.1002/art.1780300802; Fotino M, 1971, Ann Clin Lab Sci, V1, P131; FRIERI M, 1988, J ALLERGY CLIN IMMUN, V81, P196, DOI 10.1016/0091-6749(88)90348-X; GOTO M, 1987, ARTHRITIS RHEUM, V30, P737, DOI 10.1002/art.1780300703; GUPTA S, 1979, CLIN EXP IMMUNOL, V38, P342; INOSHITA T, 1981, J LAB CLIN MED, V97, P264; JAMES SP, 1986, GASTROENTEROLOGY, V91, P1483, DOI 10.1016/0016-5085(86)90205-2; KEYSTONE EC, 1982, CLIN EXP IMMUNOL, V48, P443; KLUINNELEMANS HC, 1984, J RHEUMATOL, V11, P272; KONDO H, 1976, J CLIN INVEST, V58, P1388, DOI 10.1172/JCI108594; LANIER LL, 1981, J IMMUNOL METHODS, V47, P25, DOI 10.1016/0022-1759(81)90253-2; LANIER LL, 1983, J IMMUNOL, V131, P1789; LANIER LL, 1986, J IMMUNOL, V136, P4480; MILLER EB, 1988, ARTHRITIS RHEUM, V31, P1515, DOI 10.1002/art.1780311208; MORIMOTO C, 1987, NEW ENGL J MED, V316, P67, DOI 10.1056/NEJM198701083160202; MORIMOTO C, 1988, EUR J IMMUNOL, V18, P731, DOI 10.1002/eji.1830180512; MORIMOTO C, 1985, J IMMUNOL, V134, P1508; MORIMOTO C, 1985, J IMMUNOL, V134, P3762; PINCUS SH, 1985, ARTHRITIS RHEUM-US, V28, P8, DOI 10.1002/art.1780280103; POPES MW, 1958, B RHEUM DIS, V9, P175; Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee, 1980, ARTHRITIS RHEUM, V23, P581; QUEIROS MV, 1983, CLIN EXP IMMUNOL, V54, P509; SALTINI C, 1988, CLIN RES, V36, P446; SANDERS ME, 1988, IMMUNOL TODAY, V9, P195, DOI 10.1016/0167-5699(88)91212-1; SANDERS ME, 1988, J IMMUNOL, V140, P1401; SATO K, 1987, ARTHRITIS RHEUM, V30, P1407, DOI 10.1002/art.1780301212; SHARP GC, 1985, ARTHRITIS ALLIED CON; TALAL N, 1985, CLIN RHEUM DIS, P633; TAN EM, 1980, ARTHRITIS RHEUM, V23, P617, DOI 10.1002/art.1780230602; THEOFILAPOULOS AN, 1987, BASIC CLIN IMMUNOL, P147; UMEHARA H, 1988, ARTHRITIS RHEUM, V31, P401, DOI 10.1002/art.1780310312; UNANUE ER, 1984, J IMMUNOL, V132, P1; WHITESIDE TL, 1985, ARTHRITIS RHEUM, V28, P188, DOI 10.1002/art.1780280214; WHITESIDE TL, 1983, ARTHRITIS RHEUM, V26, P841, DOI 10.1002/art.1780260704; WRIGHT JK, 1982, ANN RHEUM DIS, V41, P409, DOI 10.1136/ard.41.4.409	38	23	24	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1991	87	4					773	779		10.1016/0091-6749(91)90121-4	http://dx.doi.org/10.1016/0091-6749(91)90121-4			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FG059	2013671				2022-12-18	WOS:A1991FG05900004
J	BERNSTEIN, JA; GREENBERGER, PA; PATTERSON, R; GLASS, M; KRELL, R; THYRUM, PT				BERNSTEIN, JA; GREENBERGER, PA; PATTERSON, R; GLASS, M; KRELL, R; THYRUM, PT			THE EFFECT OF THE ORAL LEUKOTRIENE ANTAGONIST, ICI 204,219, ON LEUKOTRIENE-D4 AND HISTAMINE-INDUCED CUTANEOUS VASCULAR REACTIONS IN MAN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							RECEPTOR ANTAGONIST; GUINEA-PIG; ANAPHYLAXIS; HUMANS; BRONCHOCONSTRICTION; PERMEABILITY; SUBSTANCE; AIRWAYS; LESIONS; ASTHMA	Eighteen normal male subjects were recruited for a double-blind, placebo-controlled, randomized, two-period crossover study to determine the effects of a new, potent, highly selective, oral peptide leukotriene antagonist (ICI 204,219) on cutaneous vasculature. Skin testing for leukotriene D4 (LTD4) and histamine was performed at three different time intervals after receiving ICI 204,219 or placebo. The LTD4 threshold dose responses were recorded in duplicate to verify reproducibility. These data confirm known remarkable dose-response variation of cutaneous vascular reactions to LTD4 since some subjects reacted to a dose as low as 0.001 fmol. Twelve subjects (67%) demonstrated a more than one-half log increase in their threshold response after receiving ICI 204,219. Five of these 12 subjects (28%) had > 1 log-dose response after ICI 204,219. Two of these subjects (11.1%) had a 5 or 10 log increase in their threshold response after receiving ICI 204,219. Given the role of leukotrienes as potentially important mediators in immediate-type reactions, our results raise the possibility for additional investigation of the antagonistic effect of ICI 204,219 in nonallergic and allergic cutaneous diseases.	NORTHWESTERN UNIV,SCH MED,DEPT MED,ALLERGY IMMUNOL SECT,303 E CHICAGO AVE,CHICAGO,IL 60611; ICI,PHARMACEUT GRP,WILMINGTON,DE	Northwestern University			Greenberger, Paul/L-2770-2019	Greenberger, Paul/0000-0003-3882-8498; Bernstein, Jonathan/0000-0002-3476-1196	NIAID NIH HHS [AI 11403] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011403] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHARONY D, 1988, ANN NY ACAD SCI, V524, P162; AUGSTEIN J, 1973, NATURE-NEW BIOL, V245, P215, DOI 10.1038/newbio245215a0; BARNES N, 1987, J ALLERGY CLIN IMMUN, V79, P816, DOI 10.1016/0091-6749(87)90215-6; BARNES NC, 1984, THORAX, V39, P500, DOI 10.1136/thx.39.7.500; BISGAARD H, 1985, BRIT MED J, V290, P1468, DOI 10.1136/bmj.290.6480.1468; BRAIN SD, 1985, PROSTAGLANDINS, V29, P611, DOI 10.1016/0090-6980(85)90084-X; COREY EJ, 1980, J AM CHEM SOC, V102, P1436, DOI 10.1021/ja00524a045; DRAZEN JM, 1987, AM REV RESPIR DIS, V136, P985, DOI 10.1164/ajrccm/136.4.985; FLEISCH JH, 1982, LIFE SCI, V31, P577, DOI 10.1016/0024-3205(82)90487-8; FLEISCH JH, 1985, J PHARMACOL EXP THER, V233, P148; GREENBERGER PA, 1986, J LAB CLIN MED, V108, P70; GRIFFIN M, 1983, NEW ENGL J MED, V308, P436, DOI 10.1056/NEJM198302243080807; HAY DWP, 1987, J PHARMACOL EXP THER, V243, P474; JONES TR, 1986, CAN J PHYSIOL PHARM, V64, P1068, DOI 10.1139/y86-183; KRELL RD, 1989, EUR J PHARMACOL, V159, P73, DOI 10.1016/0014-2999(89)90045-9; KRELL RD, 1990, AM REV RESPIR DIS, V141, P978, DOI 10.1164/ajrccm/141.4_Pt_1.978; KRELL RD, 1983, PROSTAGLANDINS, V25, P171, DOI 10.1016/0090-6980(83)90102-8; LEWIS RA, 1980, P NATL ACAD SCI-BIOL, V77, P3710, DOI 10.1073/pnas.77.6.3710; LEWIS RA, 1981, NATURE, V293, P103, DOI 10.1038/293103a0; RINKEMA LE, 1984, J PHARMACOL EXP THER, V230, P550; SMITH LJ, 1985, AM REV RESPIR DIS, V131, P368; SMITH LJ, 1987, J ALLERGY CLIN IMMUN, V80, P340, DOI 10.1016/0091-6749(87)90040-6; SOTER NA, 1983, J INVEST DERMATOL, V80, P115, DOI 10.1111/1523-1747.ep12531738; UENO A, 1981, PROSTAGLANDINS, V21, P637, DOI 10.1016/0090-6980(81)90012-5; WEISS JW, 1983, JAMA-J AM MED ASSOC, V249, P2814, DOI 10.1001/jama.249.20.2814; WONG E, 1984, BRIT J DERMATOL, V110, P653, DOI 10.1111/j.1365-2133.1984.tb04700.x	26	23	23	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1991	87	1	1				93	98		10.1016/0091-6749(91)90217-C	http://dx.doi.org/10.1016/0091-6749(91)90217-C			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EX985	1991926				2022-12-18	WOS:A1991EX98500012
J	MOHIUDDIN, AA; CORREN, J; HARBECK, RJ; TEAGUE, JL; VOLZ, M; GELFAND, EW				MOHIUDDIN, AA; CORREN, J; HARBECK, RJ; TEAGUE, JL; VOLZ, M; GELFAND, EW			UREAPLASMA-UREALYTICUM CHRONIC OSTEOMYELITIS IN A PATIENT WITH HYPOGAMMAGLOBULINEMIA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							MYCOPLASMA-HOMINIS; INFECTIONS; CULTURES; BLOOD; FEVER	Mycoplasma species are recognized as important pathogens in patients with hypogammaglobulinemia. In this article we describe, for the first time, a patient with hypogammaglobulinemia who developed osteomyelitis of the hip caused by Ureaplasma urealyticum. This article emphasizes the need for considering infection with Mycoplasma species in patients with antibody deficiency.	RAYMOND & BEVERLY SACKLER FDN,DENVER,CO; NATL JEWISH CTR IMMUNOL & RESP MED,DEPT MED,DENVER,CO 80206	National Jewish Health	GELFAND, EW (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED,DEPT PEDIAT,DIV BASIC SCI,1400 JACKSON ST,DENVER,CO 80206, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026490] Funding Source: NIH RePORTER; NIAID NIH HHS [AI26490] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BRUNNER H, 1974, ANN NY ACAD SCI, V225, P435; CHANOCK R, 1961, P NATL ACAD SCI USA, V47, P887, DOI 10.1073/pnas.47.6.887; FOY HM, 1973, J INFECT DIS, V127, P388, DOI 10.1093/infdis/127.4.388; MARDH PA, 1970, BRIT J VENER DIS, V46, P179; RAO RL, 1966, ARCH INTERN MED, V117, P520; ROIFFMAN CM, 1988, PEDIATR INFECT DIS J, V7, P92; ROIFMAN CM, 1986, AM J MED, V80, P590, DOI 10.1016/0002-9343(86)90812-0; SNELLER M, 1986, J INFECT DIS, V153, P174, DOI 10.1093/infdis/153.1.174; STEFFENSON DO, 1987, ANN INTERN MED, V106, P204, DOI 10.7326/0003-4819-106-2-204; STUCKEY M, 1978, LANCET, V2, P917, DOI 10.1016/S0140-6736(78)91632-X; TAYLORROBINSON D, 1977, Q J MED, V46, P309; THOMSEN AC, 1977, J CLIN MICROBIOL, V8, P84; TI TY, 1982, JAMA-J AM MED ASSOC, V247, P60, DOI 10.1001/jama.247.1.60; WALLACE RJ, 1978, OBSTET GYNECOL, V51, P181; WEBSTER ADB, 1978, BRIT MED J, V1, P478, DOI 10.1136/bmj.1.6111.478; WEBSTER ADB, 1976, BRIT MED J, P1314	16	23	23	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1991	87	1	1				104	107		10.1016/0091-6749(91)90219-E	http://dx.doi.org/10.1016/0091-6749(91)90219-E			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EX985	1991913				2022-12-18	WOS:A1991EX98500014
J	VANMETRE, TE; ADKINSON, NF; KAGEYSOBOTKA, A; MARSH, DG; NORMAN, PS; ROSENBERG, GL				VANMETRE, TE; ADKINSON, NF; KAGEYSOBOTKA, A; MARSH, DG; NORMAN, PS; ROSENBERG, GL			HOW SHOULD WE USE SKIN TESTING TO QUANTIFY IGE SENSITIVITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note									JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV CLIN IMMUNOL,BALTIMORE,MD 21205; JOHNS HOPKINS ASTHMA & ALLERGY CTR,BALTIMORE,MD	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI004866, R37AI004866] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 11936, AI 04866] Funding Source: Medline; PHS HHS [3 P50 AL 10304] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ATKINS PC, 1988, ANN ALLERGY, V60, P27; BOUSQUET J, 1988, J ALLERGY CLIN IMMUN, V82, P439, DOI 10.1016/0091-6749(88)90017-6; BOUSQUET J, 1985, J ALLERGY CLIN IMMUN, V76, P734, DOI 10.1016/0091-6749(85)90680-3; BOUSQUET J, 1987, J ALLERGY CLIN IMMUN, V80, P591, DOI 10.1016/0091-6749(87)90013-3; BOUSQUET J, 1988, ALLERGY PRINCIPLES P, P426; BRUCE CA, 1974, J ALLERGY CLIN IMMUN, V53, P230, DOI 10.1016/0091-6749(74)90085-2; DOLEVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38; DORFMAN R. I., 1938, JOUR ALLERGY, V9, P464, DOI 10.1016/S0021-8707(38)90552-0; HEDLIN G, 1986, J ALLERGY CLIN IMMUN, V77, P488, DOI 10.1016/0091-6749(86)90184-3; HORST M, 1990, J ALLERGY CLIN IMMUN, V85, P460, DOI 10.1016/0091-6749(90)90156-X; NELSON HS, 1981, J ALLERGY CLIN IMMUN, V67, P64, DOI 10.1016/0091-6749(81)90047-6; NORMAN PS, 1978, J ALLERGY CLIN IMMUN, V62, P314, DOI 10.1016/0091-6749(78)90164-1; NORMAN PS, 1973, J ALLERGY CLIN IMMUN, V52, P210, DOI 10.1016/0091-6749(73)90059-6; OHMAN JL, 1984, J ALLERGY CLIN IMMUN, V74, P230, DOI 10.1016/0091-6749(84)90251-3; PARKER WA, 1989, J ALLERGY CLIN IMMUN, V84, P667, DOI 10.1016/0091-6749(89)90294-7; PIENKOWSKI MM, 1985, J ALLERGY CLIN IMMUN, V76, P729, DOI 10.1016/0091-6749(85)90679-7; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; TAYLOR WW, 1978, J ALLERGY CLIN IMMUN, V61, P283, DOI 10.1016/0091-6749(78)90048-9; TURKELTAUB PC, 1982, J ALLERGY CLIN IMMUN, V70, P343, DOI 10.1016/0091-6749(82)90023-9; VANMETRE TE, 1982, J ALLERGY CLIN IMMUN, V69, P181, DOI 10.1016/0091-6749(82)90098-7; VANMETRE TE, 1988, J ALLERGY CLIN IMMUN, V82, P1055, DOI 10.1016/0091-6749(88)90144-3; VANMETRE TE, 1989, J ALLERGY CLIN IMMUN, V83, P888, DOI 10.1016/0091-6749(89)90102-4; VANMETRE TE, 1990, J ALLERGY CLIN IMMUN, V86, P587, DOI 10.1016/S0091-6749(05)80217-9	23	23	23	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1990	86	4	1				583	586		10.1016/S0091-6749(05)80216-7	http://dx.doi.org/10.1016/S0091-6749(05)80216-7			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EG454	2229818				2022-12-18	WOS:A1990EG45400020
J	SASTRE, J; BANKS, DE; LOPEZ, M; BARKMAN, HW; SALVAGGIO, JE				SASTRE, J; BANKS, DE; LOPEZ, M; BARKMAN, HW; SALVAGGIO, JE			NEUTROPHIL CHEMOTACTIC ACTIVITY IN TOLUENE DIISOCYANATE (TDI)-INDUCED ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									TULANE UNIV,SCH MED,DEPT MED,1430 TULANE AVE,RM 7209,NEW ORLEANS,LA 70112	Tulane University								AKIYAMA K, 1984, J LAB CLIN MED, V104, P391; ATKINS PC, 1977, ANN INTERN MED, V86, P415, DOI 10.7326/0003-4819-86-4-415; BARKMAN H W JR, 1985, Folia Allergologica et Immunologica Clinica, V32, P45; BERNSTEIN IL, 1982, J ALLERGY CLIN IMMUN, V70, P24, DOI 10.1016/0091-6749(82)90197-X; BUCHANAN D, 1987, J ALLERGY CLIN IMMUN, V79, P15; BUTCHER BT, 1977, AM REV RESPIR DIS, V116, P411, DOI 10.1164/arrd.1977.116.3.411; BUTCHER BT, 1979, J ALLERGY CLIN IMMUN, V64, P146, DOI 10.1016/0091-6749(79)90049-6; CENTER D M, 1980, American Review of Respiratory Disease, V121, P61; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; DANKS JM, 1981, CLIN ALLERGY, V11, P161, DOI 10.1111/j.1365-2222.1981.tb01580.x; DURHAM SR, 1984, J ALLERGY CLIN IMMUN, V74, P49, DOI 10.1016/0091-6749(84)90086-1; FABBRI LM, 1985, AM REV RESPIR DIS, V132, P1010; FALK W, 1980, J IMMUNOL METHODS, V33, P239, DOI 10.1016/S0022-1759(80)80014-7; HARVATH L, 1980, J IMMUNOL METHODS, V37, P39, DOI 10.1016/0022-1759(80)90179-9; HOLLINGSWORTH HM, 1984, AM REV RESPIR DIS, V130, P373; HOWARTH PH, 1985, AM REV RESPIR DIS, V132, P986; KAROL MH, 1979, J OCCUP ENVIRON MED, V21, P354; KELLY MT, 1971, J CLIN INVEST, V50, P1044, DOI 10.1172/JCI106575; LEE TH, 1982, J CLIN INVEST, V69, P889, DOI 10.1172/JCI110528; MACGLASHAN DW, 1983, FED PROC, V42, P2504; METZGER WJ, 1986, J ALLERGY CLIN IMMUN, V78, P282; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; ODRISCOLL BRC, 1983, J ALLERGY CLIN IMMUN, V72, P695, DOI 10.1016/0091-6749(83)90632-2; ORR TSC, 1980, CLIN ALLERGY, V10, P491, DOI 10.1111/j.1365-2222.1980.tb02163.x; SCHELEIMER RP, 1983, J CLIN INVEST, V71, P1830; SHAW RJ, 1985, ALLERGY, V40, P48, DOI 10.1111/j.1398-9995.1985.tb04154.x; WASSERMAN SI, 1977, J CLIN INVEST, V60, P180	27	23	23	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1990	85	3					567	572		10.1016/0091-6749(90)90094-K	http://dx.doi.org/10.1016/0091-6749(90)90094-K			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CU668	2155957				2022-12-18	WOS:A1990CU66800005
J	SCHWARTZ, SA; GORDON, KE; JOHNSTON, MV; GOLDSTEIN, GW				SCHWARTZ, SA; GORDON, KE; JOHNSTON, MV; GOLDSTEIN, GW			USE OF INTRAVENOUS IMMUNE GLOBULIN IN THE TREATMENT OF SEIZURE DISORDERS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV MICHIGAN,DEPT PEDIAT & COMMUNICABLE DIS,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan								AARLI JA, 1975, IMMUNOLOGY, V28, P171; AARLI JA, 1975, SCAND J IMMUNOL, V4, P391, DOI 10.1111/j.1365-3083.1975.tb02641.x; ARIIZUMI M, 1984, Nihon University Journal of Medicine, V26, P229; ARIIZUMI M, 1983, LANCET, V2, P162, DOI 10.1016/S0140-6736(83)90144-7; BEDINI R, 1985, EPILEPSIA, V26, P98, DOI 10.1111/j.1528-1157.1985.tb05194.x; BENSON M, 1987, ACTA PAEDIATR SCAND, V76, P147, DOI 10.1111/j.1651-2227.1987.tb10432.x; BOWEN FP, 1976, BRAIN RES, V102, P363, DOI 10.1016/0006-8993(76)90893-3; BOWEN FP, 1968, ARCH NEUROL-CHICAGO, V19, P398, DOI 10.1001/archneur.1968.00480040064006; Duse M, 1986, Monogr Allergy, V20, P128; ECHENNE B, 1987, NEUROPEDIATRICS, V18, P126; ERLENDSSON K, 1985, NEW ENGL J MED, V312, P351, DOI 10.1056/NEJM198502073120605; HEMACHUDHA T, 1987, NEW ENGL J MED, V316, P369, DOI 10.1056/NEJM198702123160703; JOHNSON RT, 1984, NEW ENGL J MED, V310, P137, DOI 10.1056/NEJM198401193100301; KARPIAK SE, 1976, SCIENCE, V194, P735, DOI 10.1126/science.982041; LAFFONT F, 1979, ANN MED INTERNE, V130, P307; LISAK RP, 1974, NEUROLOGY, V24, P514; MIHAILOV.LT, 1971, BRAIN RES, V32, P97, DOI 10.1016/0006-8993(71)90157-0; PECHADRE JC, 1977, REV EEG NEUROPHYSIOL, V7, P443, DOI 10.1016/S0370-4475(77)80049-X; PECHADRE JC, 1978, REV MED, V34, P1889; SANDSTEDT P, 1984, LANCET, V2, P1154; SEAGER J, 1975, LANCET, P632; WALKER AE, 1969, BASIC MECH EPILEPSIE, P812	22	23	23	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1989	84	4	2	S			603	607		10.1016/0091-6749(89)90197-8	http://dx.doi.org/10.1016/0091-6749(89)90197-8			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AZ398	2794301	Bronze			2022-12-18	WOS:A1989AZ39800006
J	VICHYANOND, P; NELSON, HS				VICHYANOND, P; NELSON, HS			CIRCADIAN VARIATION OF SKIN REACTIVITY AND ALLERGY SKIN-TESTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NATL JEWISH CTR IMMUNOL & RESP MED,1400 JACKSON ST,DENVER,CO 80206	National Jewish Health								DEVRIES K, 1962, INT ARCH ALLER A IMM, V20, P93, DOI 10.1159/000229248; DREBORG S, 1987, THESIS LINKOPING U M; LEE RE, 1977, ANN ALLERGY, V38, P231; OWNBY DR, 1982, J ALLERGY CLIN IMMUN, V69, P536, DOI 10.1016/0091-6749(82)90180-4; REINBERG A, 1969, J ALLERGY, V44, P292, DOI 10.1016/0021-8707(69)90034-3; REINBERG A, 1965, J ALLERGY, V36, P273, DOI 10.1016/0021-8707(65)90086-9; SPECTOR SL, 1983, PROVOCATIVE CHALLENG, V1, P161; SUSSMAN GL, 1982, ANN ALLERGY, V48, P75; TURKELTAUB PC, 1988, ALLERGY PRINCIPLES P, V1, P389; VANSELOW NA, 1967, MANUAL CLIN ALLERGY, P59; VOORHORST R, 1980, ALLERGY, V35, P247, DOI 10.1111/j.1398-9995.1980.tb01762.x	11	23	23	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1989	83	6					1101	1106		10.1016/0091-6749(89)90452-1	http://dx.doi.org/10.1016/0091-6749(89)90452-1			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC235	2732409				2022-12-18	WOS:A1989AC23500014
J	CRETICOS, PS				CRETICOS, PS			IMMUNOTHERAPY IN ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											CRETICOS, PS (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DIV CLIN IMMUNOL,5601 LOCH RAVE BLVD,SUITE 202 POB,BALTIMORE,MD 21239, USA.							AALBERSE RC, 1983, J IMMUNOL, V130, P722; AAS K, 1971, ACTA PAEDIATR SCAND, V60, P264, DOI 10.1111/j.1651-2227.1971.tb06655.x; AGARWAL MK, 1983, J ALLERGY CLIN IMMUN, V72, P40, DOI 10.1016/0091-6749(83)90050-7; ANDERSON MC, 1983, J ALLERGY CLIN IMMUN, V71, P105, DOI 10.1016/0091-6749(83)90191-4; [Anonymous], 1986, BMJ-BRIT MED J, V293, P948; BOUSQUET J, 1985, J ALLERGY CLIN IMMUN, V76, P734, DOI 10.1016/0091-6749(85)90680-3; CONNELL JT, 1969, J ALLERGY, V43, P33, DOI 10.1016/0021-8707(69)90018-5; CRETICOS P S, 1984, Journal of Allergy and Clinical Immunology, V73, P141; CRETICOS PS, 1984, J ALLERGY CLIN IMMUN, V73, P94, DOI 10.1016/0091-6749(84)90490-1; CRETICOS PS, 1985, J CLIN INVEST, V76, P2247, DOI 10.1172/JCI112233; CRETICOS PS, 1984, NEW ENGL J MED, V310, P1626, DOI 10.1056/NEJM198406213102502; CRETICOS PS, 1987, JAMA-J AM MED ASSOC, V258, P2874, DOI 10.1001/jama.258.20.2874; CRETICOS PS, 1986, CLIN REV ALLERG, V4, P355; FRANKLAND AW, 1954, LANCET, V1, P1055; GOLDEN DBK, 1988, J ALLERGY CLIN IMMUN, V81, P169; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; ISHIZAKA T, 1980, P NATL ACAD SCI-BIOL, V77, P1903, DOI 10.1073/pnas.77.4.1903; JOHNSTONE DE, 1957, AMA J DIS CHILD, V94, P1; LICHTENS.LM, 1968, AM J MED, V44, P514, DOI 10.1016/0002-9343(68)90052-1; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; LOCKEY RF, 1987, J ALLERGY CLIN IMMUN, V79, P660, DOI 10.1016/S0091-6749(87)80164-1; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; NORMAN PS, 1974, MED CLIN N AM, V58, P111, DOI 10.1016/S0025-7125(16)32181-2; NORMAN PS, 1968, J ALLERGY, V42, P93, DOI 10.1016/0021-8707(68)90139-1; NORMAN PS, 1971, J ALLERGY, V47, P273, DOI 10.1016/S0091-6749(71)80005-2; NORMAN PS, 1988, J ALLERGY CLIN IMMUN, V81, P294, DOI 10.1016/0091-6749(88)90737-3; NORMAN PS, 1978, J ALLERGY CLIN IMMUN, V61, P370, DOI 10.1016/0091-6749(78)90116-1; NORMAN PS, 1975, HOSP PRACT, V10, P41; OHMAN JL, 1984, J ALLERGY CLIN IMMUN, V74, P230, DOI 10.1016/0091-6749(84)90251-3; PATTERSON R, 1985, ALLERGIC DISEASES DI, P123; PLATTSMILLS TAE, 1976, J CLIN INVEST, V57, P1041, DOI 10.1172/JCI108346; PLATTSMILLS TAE, 1986, 12 P INT C ALL CLIN, P214; ROCKLIN RE, 1983, J ALLERGY CLIN IMMUN, V72, P323, DOI 10.1016/0091-6749(83)90492-X; ROCKLIN RE, 1980, NEW ENGL J MED, V302, P1213, DOI 10.1056/NEJM198005293022201; ROSENBERG GL, 1983, J ALLERGY CLIN IMMUN, V71, P302, DOI 10.1016/0091-6749(83)90084-2; SUNDIN B, 1986, J ALLERGY CLIN IMMUN, V77, P478, DOI 10.1016/0091-6749(86)90183-1; TAYLOR WW, 1978, J ALLERGY CLIN IMMUN, V61, P283, DOI 10.1016/0091-6749(78)90048-9; TURKELTAUB PC, 1982, J ALLERGY CLIN IMMUN, V70, P343, DOI 10.1016/0091-6749(82)90023-9; VALENTINE MD, 1987, JAMA-J AM MED ASSOC, V258, P2881, DOI 10.1001/jama.258.20.2881; VANDERZEE JS, 1986, J IMMUNOL, V137, P3566; VANMETRE TE, 1980, J ALLERGY CLIN IMMUN, V66, P500, DOI 10.1016/0091-6749(80)90012-3; WARNER JO, 1978, LANCET, V2, P912; WASSERMAN SI, 1983, J ALLERGY CLIN IMMUN, V72, P101, DOI 10.1016/0091-6749(83)90512-2	44	23	23	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1989	83	2	2				554	562		10.1016/0091-6749(89)90037-7	http://dx.doi.org/10.1016/0091-6749(89)90037-7			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	T4491	2645352	Bronze			2022-12-18	WOS:A1989T449100008
J	RICHARDSON, MA				RICHARDSON, MA			UPPER AIRWAY COMPLICATIONS OF CIGARETTE-SMOKING	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV WASHINGTON, SCH MED, DEPT OTOLARYNGOL, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle	RICHARDSON, MA (corresponding author), CHILDRENS ORTHOPED HOSP & MED CTR, DEPT OTOLARYNGOL HEAD & NECK SURG, 4800 SAND POINT WAY NE, SEATTLE, WA 98105 USA.							[Anonymous], 1986, PEDIATRICS, V77, P755; CARSON JL, 1985, NEW ENGL J MED, V312, P463, DOI 10.1056/NEJM198502213120802; COGGINS CRE, 1980, TOXICOLOGY, V16, P83, DOI 10.1016/0300-483X(80)90040-2; FERRIS BG, 1985, ENVIRON HEALTH PERSP, V62, P289, DOI 10.2307/3430127; FIELDING JE, 1985, NEW ENGL J MED, V313, P491, DOI 10.1056/NEJM198508223130807; FIELDING JE, 1985, NEW ENGL J MED, V313, P555, DOI 10.1056/NEJM198508293130906; KRAEMER MJ, 1983, JAMA-J AM MED ASSOC, V249, P1022, DOI 10.1001/jama.249.8.1022; NEWHOUSE M, 1976, NEW ENGL J MED, V295, P990, DOI 10.1056/NEJM197610282951805; PARK SS, 1977, AM REV RESPIR DIS, V115, P971; REIMER A, 1978, ACTA OTO-LARYNGOL, V355, P1; SADE J, 1979, INT J PEDIATR OTORHI, V1, P41, DOI 10.1016/0165-5876(79)90028-4; SADE J, 1967, ARCHIV OTOLARYNGOL, V86, P22; SAID G, 1978, J EPIDEMIOL COMMUN H, V32, P97, DOI 10.1136/jech.32.2.97; SORENSEN CH, 1981, INT J PEDIATR OTORHI, V3, P119, DOI 10.1016/0165-5876(81)90027-6; STECENKO A, 1986, PEDIATR RES, V20, P853, DOI 10.1203/00006450-198609000-00009; TEELE DW, 1980, ANN OTO RHINOL LARYN, V89, P5, DOI 10.1177/00034894800890S304; TOS M, 1979, ARCH OTOLARYNGOL, V105, P582; WEISS ST, 1983, AM REV RESPIR DIS, V128, P933; 1986, HLTH CONSEQUENCES IN, P1	19	23	24	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1988	81	5	2	S			1032	1035		10.1016/0091-6749(88)90175-3	http://dx.doi.org/10.1016/0091-6749(88)90175-3			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	N7037	3286730				2022-12-18	WOS:A1988N703700020
J	BLUMENTHAL, MN; SELCOW, J; SPECTOR, S; ZEIGER, RS; MELLON, M				BLUMENTHAL, MN; SELCOW, J; SPECTOR, S; ZEIGER, RS; MELLON, M			A MULTICENTER EVALUATION OF THE CLINICAL BENEFITS OF CROMOLYN SODIUM AEROSOL BY METERED-DOSE INHALER IN THE TREATMENT OF ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									KAISER PERMANENTE MED CTR,SAN DIEGO,CA; UNIV MINNESOTA,DEPT MED,ALLERGY SECT,MINNEAPOLIS,MN 55455; UNIV CONNECTICUT,SCH MED,DEPT PEDIAT,HARTFORD,CT 06112; UNIV CALIF LOS ANGELES,DEPT MED,ALLERGY SECT,LOS ANGELES,CA 90024; UNIV CALIF SAN DIEGO,DEPT ALLERGY,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT PEDIAT,LA JOLLA,CA 92093	Kaiser Permanente; University of Minnesota System; University of Minnesota Twin Cities; University of Connecticut; University of California System; University of California Los Angeles; University of California System; University of California San Diego; University of California System; University of California San Diego				Zeiger, Robert/0000-0001-5788-5063				BERNSTEIN L, 1985, J ALLERGY CLIN IMMUN, V76, P381; BLUMENTHAL MN, 1973, J ALLERGY CLIN IMMUN, V52, P105, DOI 10.1016/0091-6749(73)90082-1; BUNDGAARD A, 1982, CLIN ALLERGY, V12, P601, DOI 10.1111/j.1365-2222.1982.tb02559.x; ENGSTROM I, 1977, SCANDINAVIAN J RES S, V101, P49; Hobday J D, 1970, Aust Paediatr J, V6, P14; HOWELL JBL, 1967, LANCET, V2, P539; KOCH GG, 1982, BIOMETRICS, V38, P563, DOI 10.2307/2530041; LAL S, 1982, CLIN ALLERGY, V12, P197, DOI 10.1111/j.1365-2222.1982.tb01639.x; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; MUNROFORD R, 1969, MED J AUSTRALIA, V2, P537; SCHOEFFEL RE, 1983, AUST NZ J MED, V13, P157, DOI 10.1111/j.1445-5994.1983.tb02672.x; SHAPIRO GG, 1985, PHARMACOTHERAPY, V5, P156; SO SY, 1981, CLIN ALLERGY, V11, P479, DOI 10.1111/j.1365-2222.1981.tb01622.x	13	23	23	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1988	81	4					681	687		10.1016/0091-6749(88)91038-X	http://dx.doi.org/10.1016/0091-6749(88)91038-X			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	N0650	3128589				2022-12-18	WOS:A1988N065000007
J	WADEE, AA; RABSON, AR				WADEE, AA; RABSON, AR			DEVELOPMENT OF SPECIFIC IGE ANTIBODIES AFTER REPEATED EXPOSURE TO SNAKE-VENOM	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV WITWATERSRAND,JOHANNESBURG 2001,SOUTH AFRICA	University of Witwatersrand	WADEE, AA (corresponding author), S AFRICAN MRC,SCH PATHOL,DEPT IMMUNOL,MRC,HUMAN CELLULAR IMMUNOL,JOHANNESBURG 2000,SOUTH AFRICA.							ELLIS EF, 1965, J AMER MED ASSOC, V193, P401, DOI 10.1001/jama.1965.03090050077030; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MINTON SA, 1971, SNAKE VENOMS ENVENOM, P43; PARRISH HM, 1959, AM J MED SCI, V237, P277, DOI 10.1097/00000441-195903000-00001; SCHMUTZ J, 1985, LANCET, V2, P1306; ZOZAYA JOSE, 1930, BULL ANTIVENIN INST AMER, V3, P93	6	23	23	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1987	80	5					695	698		10.1016/0091-6749(87)90289-2	http://dx.doi.org/10.1016/0091-6749(87)90289-2			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	K9930	3680813				2022-12-18	WOS:A1987K993000009
J	MURPHY, GF; AUSTEN, KF; FONFERKO, E; SHEFFER, AL				MURPHY, GF; AUSTEN, KF; FONFERKO, E; SHEFFER, AL			MORPHOLOGICALLY DISTINCTIVE FORMS OF CUTANEOUS MAST-CELL DEGRANULATION INDUCED BY COLD AND MECHANICAL STIMULI - AN ULTRASTRUCTURAL-STUDY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									BRIGHAM & WOMENS HOSP, DEPT RHEUMATOL & IMMUNOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	MURPHY, GF (corresponding author), BRIGHAM & WOMENS HOSP, DEPT PATHOL, DIV DERMATOPATHOL, 75 FRANCIS ST, BOSTON, MA 02115 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI023401, R37AI022531, R01AI022531] Funding Source: NIH RePORTER; NIADDK NIH HHS [AM-07530] Funding Source: Medline; NIAID NIH HHS [AI-22531, AI-23401] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BEHRENDT H, 1978, INT ARCH ALLER A IMM, V56, P188, DOI 10.1159/000232022; BOSWELL RN, 1978, J IMMUNOL, V120, P15; CAULFIELD JP, 1980, J CELL BIOL, V85, P299, DOI 10.1083/jcb.85.2.299; CHIU H, 1972, HISTOCHEM J, V4, P135, DOI 10.1007/BF01004972; CLAMAN HN, 1985, CELL IMMUNOL, V94, P73, DOI 10.1016/0008-8749(85)90086-3; CLARK RAF, 1975, J EXP MED, V142, P1462, DOI 10.1084/jem.142.6.1462; DVORAK AM, 1976, J IMMUNOL, V116, P687; DVORAK AM, 1986, LAB INVEST, V54, P663; DVORAK AM, 1976, LAB INVEST, V34, P179; GLEICH GJ, 1986, ADV IMMUNOLOGY, V39, P177; GOMORI G, 1953, J HISTOCHEM CYTOCHEM, V1, P469, DOI 10.1177/1.6.469; IRANI AA, 1986, P NATL ACAD SCI USA, V83, P4464, DOI 10.1073/pnas.83.12.4464; KAY AB, 1971, J IMMUNOL, V107, P899; LEWIS RA, 1981, NATURE, V293, P103, DOI 10.1038/293103a0; PARWARESCH MR, 1985, PATHOL RES PRACT, V179, P439, DOI 10.1016/S0344-0338(85)80184-9; POWELL R, 1986, BYTE, V11, P145; SAGE H, 1979, J BIOL CHEM, V254, P9893; SCHWARTZ LB, 1984, PROG ALLERGY, V34, P271; STEVENS RL, 1986, J IMMUNOL, V137, P291; VANLOVEREN H, 1984, EUR J IMMUNOL, V14, P40, DOI 10.1002/eji.1830140108; WASSERMAN SI, 1982, CLIN EXP IMMUNOL, V47, P570; YEN A, 1976, J INVEST DERMATOL, V66, P131, DOI 10.1111/1523-1747.ep12481678	22	23	23	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1987	80	4					603	611		10.1016/0091-6749(87)90015-7	http://dx.doi.org/10.1016/0091-6749(87)90015-7			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	K5224	3668125	Bronze			2022-12-18	WOS:A1987K522400015
J	SPEIZER, FE				SPEIZER, FE			HISTORICAL PERSPECTIVES - THE EPIDEMIC OF ASTHMA DEATHS IN THE UNITED-KINGDOM IN THE 1960S	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HARVARD UNIV, SCH MED, CHANNING LAB, DEPT MED, 180 LONGWOOD AVE, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT MED, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital								ALEXANDER HL, 1963, J ALLERGY, V34, P305, DOI 10.1016/0021-8707(63)90039-X; BURNEY PGJ, 1986, LANCET, V2, P323; DOLL R, 1967, BRIT MED J, V1, P756, DOI 10.1136/bmj.1.5542.756-a; Fraser P M, 1971, Br J Dis Chest, V65, P71; INMAN WHW, 1969, LANCET, V2, P279; MAIMONIDES M, 1963, TREATISE ASTHMA; OSLER W, 1950, APHORISMS HIS BEDSID; OSLER W, 1901, PRINCIPLES PRACTICE; SPEIZER FE, 1968, BRIT MED J, V1, P339, DOI 10.1136/bmj.1.5588.339; SPEIZER FE, 1968, BRIT MED J, V3, P245, DOI 10.1136/bmj.3.5612.245; STOLLEY PD, 1978, PREV MED, V7, P519, DOI 10.1016/0091-7435(78)90265-7; 1969, EXCERPTS CLASSICS AL	12	23	23	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1987	80	3	2	S			368	372		10.1016/0091-6749(87)90051-0	http://dx.doi.org/10.1016/0091-6749(87)90051-0			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	K1037	3305666				2022-12-18	WOS:A1987K103700003
J	BECKER, AB; CHUNG, KF; MCDONALD, DM; LAZARUS, SC; FRICK, OL; GOLD, WM				BECKER, AB; CHUNG, KF; MCDONALD, DM; LAZARUS, SC; FRICK, OL; GOLD, WM			CUTANEOUS MAST-CELL HETEROGENEITY - RESPONSE TO ANTIGEN IN ATOPIC DOGS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,DEPT MED,1327-M,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PEDIAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT ANAT,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco			Chung, Kian Fan/B-1872-2012; Chung, Kian Fan/I-8456-2019	Chung, Kian Fan/0000-0001-7101-1426; Chung, Kian Fan/0000-0001-7101-1426	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL024136] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015233] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-24136] Funding Source: Medline; NIAID NIH HHS [R01 AI15233] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLANSMITH R, 1980, INVEST OPHTH VIS SCI, V19, P1521; BECKER AB, 1985, ANAT REC, V213, P477, DOI 10.1002/ar.1092130402; BEFUS AD, 1982, J IMMUNOL, V128, P2475; BIENENSTOCK J, 1982, J ALLERGY CLIN IMMUN, V70, P407, DOI 10.1016/0091-6749(82)90001-X; CARLSSON SA, 1969, ACTA PHYSIOL SCAND, V77, P449, DOI 10.1111/j.1748-1716.1969.tb04589.x; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; ENERBACK L, 1966, ACTA PATHOL MIC SC, V66, P289, DOI 10.1111/apm.1966.66.3.289; FRICK OL, 1983, AM J VET RES, V44, P440; GOLD WM, 1977, J APPL PHYSIOL, V43, P271, DOI 10.1152/jappl.1977.43.2.271; LEDER L-D, 1979, American Journal of Dermatopathology, V1, P39; LUNA LG, 1968, MANUAL HISTOLOGIC ST, P164; MICHELS NA, 1963, ANN NY ACAD SCI, V103, P1; PEARCE FL, 1984, J ALLERGY CLIN IMMUN, V73, P819, DOI 10.1016/0091-6749(84)90453-6; SHANAHAN F, 1984, CAN J PHYSIOL PHARM, V62, P734, DOI 10.1139/y84-121; SMOLEN AJ, 1983, J NEUROCYTOL, V12, P739, DOI 10.1007/BF01258148; SOKAL RR, 1981, BIOMETRY, P565; WOODBURY RG, 1981, METHOD ENZYMOL, V80, P588	17	23	23	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1986	78	5	1				937	942		10.1016/0091-6749(86)90243-5	http://dx.doi.org/10.1016/0091-6749(86)90243-5			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	E9713	3782660				2022-12-18	WOS:A1986E971300018
J	HAVAS, TE; COLE, P; PARKER, L; OPRYSK, D; AYIOMAMITIS, A				HAVAS, TE; COLE, P; PARKER, L; OPRYSK, D; AYIOMAMITIS, A			THE EFFECTS OF COMBINED H-1 AND H-2 HISTAMINE-ANTAGONISTS ON ALTERATIONS IN NASAL AIR-FLOW RESISTANCE INDUCED BY TOPICAL HISTAMINE PROVOCATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV TORONTO,DEPT OTOLARYNGOL,AIRFLOW LABS,TORONTO M5S 1A1,ONTARIO,CANADA; GAGE RES INST,TORONTO M5T 1R4,ONTARIO,CANADA	University of Toronto								BROOKS CD, 1982, J ALLERGY CLIN IMMUN, V70, P373, DOI 10.1016/0091-6749(82)90027-6; COLE P, 1983, J OTOLARYNGOL, V12, P58; CONNELL JT, 1979, ANN ALLERGY, V42, P278; GOODMAN N, 1985, PHARM BASIS THERAPEU, P605; GRIFFIN PM, 1979, J APPL PHYSIOL, V47, P1127, DOI 10.1152/jappl.1979.47.5.1127; HARVEY RP, 1980, J ALLERGY CLIN IMMUN, V65, P136, DOI 10.1016/0091-6749(80)90198-0; MATSON CJ, 1978, ARCH INT PHARMACOD T, V232, P68; NIINIMAA V, 1979, J APPL PHYSIOL, V47, P1336, DOI 10.1152/jappl.1979.47.6.1336; SECHER C, 1982, J ALLERGY CLIN IMMUN, V70, P211, DOI 10.1016/0091-6749(82)90044-6; SMITH JA, 1980, J ALLERGY CLIN IMMUN, V65, P118, DOI 10.1016/0091-6749(80)90195-5; WILLIAMS HL, 1970, P AM ACADEMY OPHTHAL, P6; WONG L, 1981, J ALLERGY CLIN IMMUN, V67, P273	12	23	26	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1986	78	5	1				856	860		10.1016/0091-6749(86)90230-7	http://dx.doi.org/10.1016/0091-6749(86)90230-7			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	E9713	2878016				2022-12-18	WOS:A1986E971300005
J	OSTROM, NK; SWANSON, MC; AGARWAL, MK; YUNGINGER, JW				OSTROM, NK; SWANSON, MC; AGARWAL, MK; YUNGINGER, JW			OCCUPATIONAL ALLERGY TO HONEYBEE-BODY DUST IN A HONEY-PROCESSING PLANT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MAYO CLIN & MAYO FDN,ALLERG DIS RES LAB,406 GUGGENHEIM BLDG,ROCHESTER,MN 55905; MAYO GRAD SCH MED,DEPT PEDIAT,ROCHESTER,MN 55901; MAYO GRAD SCH MED,DEPT INTERNAL MED ALLERGY,ROCHESTER,MN 55901	Mayo Clinic; Mayo Clinic; Mayo Clinic					NIAID NIH HHS [AI-21398] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021398] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGARWAL MK, 1981, J ALLERGY CLIN IMMUN, V68, P194, DOI 10.1016/0091-6749(81)90183-4; BENSON RL, 1930, J ALLERGY, V1, P105; BOUSQUET J, 1985, J ALLERGY CLIN IMMUN, V75, P70, DOI 10.1016/0091-6749(85)90015-6; BUSSE WW, 1975, JAMA-J AM MED ASSOC, V231, P1154, DOI 10.1001/jama.231.11.1154; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; COHEN SH, 1979, J ALLERGY CLIN IMMUN, V64, P270, DOI 10.1016/0091-6749(79)90143-X; ELLIS RALPH V., 1932, JOUR ALLERGY, V3, P247, DOI 10.1016/S0021-8707(32)90340-2; FEINBERG AR, 1956, J ALLERGY, V27, P437, DOI 10.1016/0021-8707(56)90103-4; FRAZIER CA, 1969, INSECT ALLERGY, P393; HUNT KJ, 1978, J ALLERGY CLIN IMMUN, V61, P48, DOI 10.1016/0091-6749(78)90473-6; LICHTENSTEIN LM, 1979, J ALLERGY CLIN IMMUN, V64, P5, DOI 10.1016/0091-6749(79)90075-7; NORMAN PS, 1980, MANUAL CLIN IMMUNOLO, P789; PERLMAN F, 1958, J ALLERGY, V29, P302, DOI 10.1016/0021-8707(58)90037-6; REISMAN RE, 1983, J ALLERGY CLIN IMMUN, V71, P18, DOI 10.1016/0091-6749(83)90541-9; SHULMAN S, 1968, PROG ALLERGY, V12, P246, DOI 10.1159/000287268; SWANSON MC, 1985, J ALLERGY CLIN IMMUN, V76, P724, DOI 10.1016/0091-6749(85)90678-5; Yunginger J. W., 1980, MANUAL CLIN IMMUNOLO, P778; YUNGINGER JW, 1978, J ALLERGY CLIN IMMUN, V61, P93, DOI 10.1016/0091-6749(78)90231-2	18	23	24	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1986	77	5					736	740		10.1016/0091-6749(86)90420-3	http://dx.doi.org/10.1016/0091-6749(86)90420-3			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	C3903	3700899				2022-12-18	WOS:A1986C390300018
J	QUIE, PG				QUIE, PG			PHAGOCYTIC CELL DYSFUNCTION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											QUIE, PG (corresponding author), UNIV MINNESOTA,SCH MED,BOX 483,MAYO MEM BLDG,420 DELEWARE ST SE,MINNEAPOLIS,MN 55455, USA.							ABRAMSON JS, 1982, J AM ACAD DERMATOL, V7, P105, DOI 10.1016/S0190-9622(82)80017-0; ABRAMSON JS, 1981, J PEDIATR-US, V99, P887, DOI 10.1016/S0022-3476(81)80011-X; AFZELIUS BA, 1980, ACTA MED SCAND, V208, P145; AGGETT PJ, 1979, J PEDIATR-US, V94, P391, DOI 10.1016/S0022-3476(79)80578-8; ALPER CA, 1970, NEW ENGL J MED, V282, P349, DOI 10.1056/NEJM197002122820701; ALTMAN LC, 1974, J CLIN INVEST, V54, P486, DOI 10.1172/JCI107784; ANDERSON DC, 1981, J CLIN INVEST, V68, P863, DOI 10.1172/JCI110341; ANDERSON R, 1981, CLIN EXP IMMUNOL, V43, P180; ARNAOUT MA, 1982, NEW ENGL J MED, V306, P693, DOI 10.1056/NEJM198203253061201; BADWEY JA, 1980, ANNU REV BIOCHEM, V49, P695, DOI 10.1146/annurev.bi.49.070180.003403; BASSARIS HP, 1982, J INFECT DIS, V146, P52, DOI 10.1093/infdis/146.1.52; BERGER M, 1980, J IMMUNOL, V125, P2437; BLUME RS, 1968, NEW ENGL J MED, V279, P1009, DOI 10.1056/NEJM196811072791901; BOXER LA, 1974, NEW ENGL J MED, V291, P1093, DOI 10.1056/NEJM197411212912101; BOXER LA, 1976, NEW ENGL J MED, V295, P1041, DOI 10.1056/NEJM197611042951904; BRETONGORIUS J, 1980, AM J PATHOL, V99, P413; BUCKLEY RH, 1972, PEDIATRICS, V49, P59; BUCKLEY RH, 1979, PEDIATRIC IMMUNOLOGY, P219; BUESCHER ES, 1982, NEW ENGL J MED, V307, P800, DOI 10.1056/NEJM198209233071306; CARSON MJ, 1965, PEDIATRICS, V34, P405; CHRISTENSEN RD, 1982, PEDIATRICS, V70, P1; CLARK RA, 1973, ANN INTERN MED, V78, P515, DOI 10.7326/0003-4819-78-4-515; COHEN MS, 1981, AM J MED, V71, P59, DOI 10.1016/0002-9343(81)90259-X; CROWLEY CA, 1980, NEW ENGL J MED, V302, P1163, DOI 10.1056/NEJM198005223022102; DAMELIO R, 1980, CLIN IMMUNOL IMMUNOP, V16, P287, DOI 10.1016/0090-1229(80)90134-8; DAVIS AT, 1971, NEW ENGL J MED, V285, P789, DOI 10.1056/NEJM197109302851410; DAVIS SD, 1966, LANCET, V1, P1013; DESNICK RJ, 1976, PEDIATR RES, V10, P985, DOI 10.1203/00006450-197612000-00008; DONABEDIAN H, 1982, J CLIN INVEST, V69, P1155, DOI 10.1172/JCI110551; FOROOZANFAR N, 1983, CLIN EXP IMMUNOL, V41, P99; FOROOZONFAR N, 1977, Lancet, V1, P210; GALLIN JE, 1980, INFECTIONS IMMUNOCOM, P37; GALLIN JI, 1978, BLOOD, V51, P919; GALLIN JI, 1983, ANN INTERN MED, V99, P657, DOI 10.7326/0003-4819-99-5-657; GALLIN JI, 1981, REV INFECT DIS, V3, P1196; GINSBURG I, 1980, INFLAMMATION, V4, P301, DOI 10.1007/BF00915031; GMUNDER FK, 1981, PEDIATR RES, V13, P1533; HAYWARD AR, 1979, LANCET, V1, P1099; HILL HR, 1974, LANCET, V1, P183; HILL HR, 1976, ANN INTERN MED, V85, P39, DOI 10.7326/0003-4819-85-1-39; ISHIZAKA T, 1972, J IMMUNOL, V108, P513; JOHNSTON RB, 1982, NEW ENGL J MED, V307, P434, DOI 10.1056/NEJM198208123070709; JOHNSTON RB, 1975, LANCET, V1, P824; JOHNSTON RB, 1977, PEDIATR CLIN N AM, V24, P365; JOHNSTON RB, 1983, ADV HOST DEFENSE MEC, V3, P182; KOSTMAN R, 1956, ACTA PAEDIATR SC   S, V45, P105; LANDING BH, 1957, PEDIATRICS, V20, P431; MACFARLANE PS, 1967, LANCET, V1, P408; MILLER ME, 1971, PEDIATR RES, V5, P487, DOI 10.1203/00006450-197109000-00007; MILLER ME, 1971, LANCET, V1, P565; MILLER ME, 1975, J LAB CLIN MED, V82, P1; MILLS EL, 1980, J CLIN INVEST, V66, P332, DOI 10.1172/JCI109861; MOLECH H, 1979, CLIN RES, V27, pA290; NAJJAR VA, 1975, J PEDIATR-US, V87, P1121, DOI 10.1016/S0022-3476(75)80125-9; NEWBURGER PE, 1979, NEW ENGL J MED, V300, P178, DOI 10.1056/NEJM197901253000406; OLIVER JM, 1978, AM J PATHOL, V93, P221; OSKI FA, 1982, HEMATOLOGIC PROBLEMS, P112; PARRY MF, 1981, ANN INTERN MED, V95, P293, DOI 10.7326/0003-4819-95-3-293; PETERSON PK, 1981, INVESTIGATION PHAGOC, P38; PHILIPPART MI, 1972, PEDIATRICS, V30, P923; PINCUS SH, 1975, J PEDIATR, V87, P980; QUIE PG, 1967, J CLIN INVEST, V46, P668, DOI 10.1172/JCI105568; QUIE PG, 1978, LEUKOCYTE CHEMOTAXIS, P307; QUIE PG, 1982, ADV HOST DEFENSE MEC, V1, P163; RAPPEPORT JM, 1982, J PEDIATR-US, V101, P952, DOI 10.1016/S0022-3476(82)80017-6; RAUBITSCHEK AA, 1973, PEDIATRICS, V51, P230; REGELMANN W, 1983, CHRONIC GRANULOMATOU, P3; ROBERTS R, 1983, ANN ALLERGY, V50, P330; ROOT RK, 1972, J CLIN INVEST, V51, P649, DOI 10.1172/JCI106854; ROSEN H, 1976, J CLIN INVEST, V58, P50, DOI 10.1172/JCI108458; ROSENFELD SI, 1976, J CLIN INVEST, V57, P1626, DOI 10.1172/JCI108433; SCHOPFER K, 1979, NEW ENGL J MED, V300, P835, DOI 10.1056/NEJM197904123001506; SEAY AR, 1979, J NEUROL SCI, V44, P13, DOI 10.1016/0022-510X(79)90219-3; SNYDERMAN R, 1977, J ALLERGY CLIN IMMUN, V60, P121, DOI 10.1016/0091-6749(77)90037-9; STJERNHOLM RL, 1973, INFECT IMMUN, V7, P313, DOI 10.1128/IAI.7.2.313-314.1973; STOSSEL TP, 1978, ANN INTERN MED, V89, P398, DOI 10.7326/0003-4819-89-3-398; TYGSTRUP I, 1979, PEDIATRICS, V64, P935; VANEPPS DE, 1978, LEUKOCYTE CHEMOTAXIS, P237; VIRELIZIER JL, 1982, NEW ENGL J MED, V306, P1055; WARD PA, 1969, LANCET, V2, P344; WEENING RS, 1983, J PEDIATR-US, V103, P127, DOI 10.1016/S0022-3476(83)80798-7; WINDHORST DB, 1968, J CLIN INVEST, V47, P1026, DOI 10.1172/JCI105792; WOLFSON JJ, 1968, RADIOLOGY, V91, P37, DOI 10.1148/91.1.37; WOLFSON JJ, 1969, J BONE JOINT SURG AM, VA 51, P1573, DOI 10.2106/00004623-196951080-00007; WRIGHT WC, 1975, PEDIATRICS, V56, P579; YOMTOVIAN R, 1981, TRANSFUSION, V21, P739, DOI 10.1046/j.1537-2995.1981.21682085767.x	86	23	23	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1986	77	3					387	398		10.1016/0091-6749(86)90169-7	http://dx.doi.org/10.1016/0091-6749(86)90169-7			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	A5367	3512661				2022-12-18	WOS:A1986A536700001
J	SUEZ, D; SZEFLER, SJ				SUEZ, D; SZEFLER, SJ			EXCESSIVE ACCUMULATION OF MUCUS IN CHILDREN WITH ASTHMA - A POTENTIAL ROLE FOR ERYTHROMYCIN - A CASE DISCUSSION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV COLORADO,HLTH SCI CTR,SCH MED,DEPT PHARMACOL,DENVER,CO 80262; NATL JEWISH CTR IMMUNOL & RESP MED,DENVER,CO	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; National Jewish Health	SUEZ, D (corresponding author), UNIV COLORADO,HLTH SCI CTR,SCH MED,DEPT PEDIAT,DENVER,CO 80262, USA.				NHLBI NIH HHS [HL-30513] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CUMMINS LH, 1977, PEDIATRICS, V59, P144; FOX JL, 1961, PENN MED J, V64, P634; ITKIN IH, 1970, J ALLERGY, V45, P146, DOI 10.1016/0021-8707(70)90124-3; KALINER M, 1984, J ALLERGY CLIN IMMUN, V73, P318, DOI 10.1016/0091-6749(84)90403-2; KAPLAN MA, 1959, ANTIBIOTICS ANN 1958, P273; KEAL EE, 1975, NEW DIRECTIONS ASTHM, P223; KELLAWAY I W, 1973, Journal of Pharmacy and Pharmacology, V25, P167; LAFORCE CF, 1983, J ALLERGY CLIN IMMUN, V72, P34, DOI 10.1016/0091-6749(83)90049-0; LAFORCE CF, 1981, J PEDIATR-US, V99, P153, DOI 10.1016/S0022-3476(81)80983-3; LIEBERMA.J, 1970, AM J MED, V49, P1, DOI 10.1016/S0002-9343(70)80107-3; LOPEZVIDRIERO M, 1975, THORAX, V30, P624, DOI 10.1136/thx.30.6.624; LOPEZVIDRIERO MT, 1978, BRIT MED BULL, V34, P63, DOI 10.1093/oxfordjournals.bmb.a071461; MARIOTT C, 1975, BIORHEOLOGY, V12, P391; PAVIA D, 1983, EUR J RESPIR DIS, V64, P304; SPECTOR SL, 1974, J ALLERGY CLIN IMMUN, V54, P867; SZEFLER SJ, 1980, J ALLERGY CLIN IMMUN, V66, P447, DOI 10.1016/0091-6749(80)90004-4; SZEFLER SJ, 1982, CLIN PHARMACOL THER, V32, P166, DOI 10.1038/clpt.1982.143; SZEFLER SJ, 1982, J ALLERGY CLIN IMMUN, V69, P455, DOI 10.1016/0091-6749(82)90121-X; WANNER A, 1983, J ALLERGY CLIN IMMUN, V72, P347, DOI 10.1016/0091-6749(83)90498-0; WEINBERGER M, 1977, J ALLERGY CLIN IMMUN, V59, P228, DOI 10.1016/0091-6749(77)90154-3	20	23	23	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1986	77	2					330	334		10.1016/S0091-6749(86)80113-0	http://dx.doi.org/10.1016/S0091-6749(86)80113-0			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	A0899	3944384				2022-12-18	WOS:A1986A089900011
J	ALLANSMITH, MR; RADL, J; HAAIJMAN, JJ; MESTECKY, J				ALLANSMITH, MR; RADL, J; HAAIJMAN, JJ; MESTECKY, J			MOLECULAR-FORMS OF TEAR IGA AND DISTRIBUTION OF IGA SUBCLASSES IN HUMAN LACRIMAL GLANDS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HARVARD UNIV,SCH MED,BOSTON,MA 02115; TNO,REP,INST EXPTL GERONTOL,RIJSWIJK,NETHERLANDS; UNIV ALABAMA,DEPT MICROBIOL,BIRMINGHAM,AL	Harvard University; Harvard Medical School; Netherlands Organization Applied Science Research; University of Alabama System; University of Alabama Birmingham	ALLANSMITH, MR (corresponding author), RETINA FDN,EYE RES INST,20 STANIFORD ST,BOSTON,MA 02114, USA.				NATIONAL EYE INSTITUTE [R01EY002882] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI018745, R01AI010854] Funding Source: NIH RePORTER; NEI NIH HHS [EY-02882] Funding Source: Medline; NIAID NIH HHS [AI-10854, AI-18745] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLANSMITH M, 1973, International Ophthalmology Clinics, V13, P47, DOI 10.1097/00004397-197301310-00006; ALLANSMITH MR, 1980, AM J OPHTHALMOL, V89, P353, DOI 10.1016/0002-9394(80)90004-5; ALLANSMITH MR, 1982, INFECT IMMUN, V35, P202, DOI 10.1128/IAI.35.1.202-204.1982; ALLANSMITH MR, 1980, AM J OPHTHALMOL, V90, P719, DOI 10.1016/S0002-9394(14)75144-X; BRANDTZAEG P, 1981, CLIN EXP IMMUNOL, V44, P221; BRANDTZAEG P, 1979, J IMMUNOL, V122, P504; CRAGO SS, 1979, J IMMUNOL, V122, P906; CRAGO SS, 1984, J IMMUNOL, V132, P16; DAHLGREN U, 1981, SCAND J IMMUNOL, V14, P95, DOI 10.1111/j.1365-3083.1981.tb00188.x; DELACROIX DL, 1982, IMMUNOLOGY, V47, P383; DELACROIX DL, 1982, J CLIN INVEST, V70, P230, DOI 10.1172/JCI110610; FRANKLIN RM, 1973, J IMMUNOL, V110, P984; JOSEPHSON AS, 1968, J IMMUNOL, V100, P1080; JOSEPHSON AS, 1964, J IMMUNOL, V93, P532; KESSLER SW, 1976, J IMMUNOL, V117, P1482; KUTTEH WH, 1982, GASTROENTEROLOGY, V82, P184; Mancini G, 1965, Immunochemistry, V2, P235, DOI 10.1016/0019-2791(65)90004-2; Mandel I D, 1978, Adv Exp Med Biol, V107, P839; MESTECKY J, 1978, J CLIN INVEST, V61, P731, DOI 10.1172/JCI108986; MONTGOMERY PC, 1983, ANN NY ACAD SCI, V409, P428, DOI 10.1111/j.1749-6632.1983.tb26887.x; MORO I, 1984, J ORAL PATHOL MED, V13, P97, DOI 10.1111/j.1600-0714.1984.tb01405.x; RUSSELL MW, 1982, MOL IMMUNOL, V19, P677, DOI 10.1016/0161-5890(82)90369-8; WOLMAN M, 1952, EXP CELL RES, V3, P619, DOI 10.1016/0014-4827(52)90110-9	23	23	23	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	4					569	576		10.1016/0091-6749(85)90777-8	http://dx.doi.org/10.1016/0091-6749(85)90777-8			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ATH66	3932498	Bronze			2022-12-18	WOS:A1985ATH6600008
J	BARDANA, EJ				BARDANA, EJ			RECENT DEVELOPMENTS IN IMMUNOMODULATORY THERAPY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review											BARDANA, EJ (corresponding author), OREGON HLTH SCI UNIV, DIV IMMUNOL ALLERGY & RHEUMATOL, L-329, 3181 SW SAM JACKSON PK RD, PORTLAND, OR 97201 USA.							AIUTI F, 1983, CLIN IMMUNOL ALLERGY, V3, P187; AMMANN AJ, 1982, CLIN IMMUNOL IMMUNOP, V22, P60, DOI 10.1016/0090-1229(82)90022-8; ANDERSON MJ, 1984, ANN INTERN MED, V100, P829, DOI 10.7326/0003-4819-100-6-829; ARALACHAVES MP, 1978, IMMUNOLOGICAL ENG, P35; ATRAH HI, 1984, LANCET, V2, P810; BACH FH, 1968, LANCET, V2, P1364; BARANDUN S, 1962, VOX SANG, V7, P157, DOI 10.1111/j.1423-0410.1962.tb03240.x; BARDANA EJ, 1981, MED CLIN N AM, V65, P959, DOI 10.1016/S0025-7125(16)31483-3; BASTEN A, 1978, IMMUNOLOGICAL ENG, P83; Behring EKS., 1890, DEUT MED WOCHENSCHR, V16, P1113, DOI [10.1055/s-0029-1207589, DOI 10.1055/S-0029-1207589]; BERGER M, 1982, JAMA-J AM MED ASSOC, V247, P2824, DOI 10.1001/jama.247.20.2824; BEVERIDGE T, 1984, LANCET, V1, P788, DOI 10.1016/S0140-6736(84)91293-5; BIERLING P, 1982, NEW ENGL J MED, V307, P1150; BLOMGREN H, 1982, INT J IMMUNOPHARMACO, V4, P360, DOI 10.1016/0192-0561(82)90373-3; BOREL JF, 1977, IMMUNOLOGY, V32, P1017; BORTIN MM, 1977, JAMA-J AM MED ASSOC, V238, P591, DOI 10.1001/jama.238.7.591; BRADSHAW LJ, 1977, ANN NY ACAD SCI, V284, P190, DOI 10.1111/j.1749-6632.1977.tb21950.x; BUCKLEY RH, 1982, J CLIN IMMUNOL, V2, pS15, DOI 10.1007/BF00918362; BUSSEL J, 1983, BLOOD, V62, P398; CANTELL K, 1977, TEX REP BIOL MED, V35, P138; CHAMBERLAND ME, 1984, ANN INTERN MED, V101, P617, DOI 10.7326/0003-4819-101-5-617; CLIFT RA, 1979, TRANSPLANTATION, V28, P235, DOI 10.1097/00007890-197909000-00016; COHEN DJ, 1984, ANN INTERN MED, V101, P667, DOI 10.7326/0003-4819-101-5-667; CONDIE RM, 1982, DEV BIOLOGICALS, V52, P501; CUNNINGHAMRUNDLES C, 1984, ANN INTERN MED, V101, P435, DOI 10.7326/0003-4819-101-4-435; Dau P C, 1983, J Clin Apher, V1, P104, DOI 10.1002/jca.2920010207; DAY NK, 1984, AM J MED, V76, P25, DOI 10.1016/0002-9343(84)90316-4; DEVATHASAN G, 1984, LANCET, V2, P809; DWYER JM, 1984, AM J MED, V76, P46; EIBL M, 1980, USDHHS FDA809005 PUB, P23; Erlich P, 1897, KLIN JB JENA, V6, P299; FATEHMOGHADAM A, 1984, LANCET, V1, P848; FEHR J, 1982, NEW ENGL J MED, V306, P1254, DOI 10.1056/NEJM198205273062102; FIELD AK, 1967, P NATL ACAD SCI USA, V58, P1004, DOI 10.1073/pnas.58.3.1004; FRIDMAN H, 1980, INT J IMMUNOPHARMACO, V2, P194, DOI 10.1016/0192-0561(80)90123-X; FURUSHO K, 1984, LANCET, V2, P1055; GASCON P, 1984, ANN INTERN MED, V100, P173, DOI 10.7326/0003-4819-100-2-173; GOEDDEL DV, 1980, NATURE, V287, P411, DOI 10.1038/287411a0; GOOD RA, 1962, J EXP MED, V116, P773, DOI 10.1084/jem.116.5.773; GREEN JA, 1969, SCIENCE, V164, P1415, DOI 10.1126/science.164.3886.1415; GRIECO MH, 1984, ANN INTERN MED, V101, P206, DOI 10.7326/0003-4819-101-2-206; HANSON LA, 1982, LANCET, V1, P396; HIRSCH MS, 1983, NEW ENGL J MED, V309, P963; HO M, 1964, SCIENCE, V146, P1472, DOI 10.1126/science.146.3650.1472; HOLDER IA, 1984, AM J MED, V76, P161, DOI 10.1016/0002-9343(84)90336-X; IMBACH P, 1981, LANCET, V1, P1228; INCEFY GS, 1983, CLIN IMMUNOL ALLERGY, V3, P95; IPPOLITI G, 1984, LANCET, V2, P809; ISAACS D, 1981, LANCET, V2, P950; Janeway CA, 1970, IMMUNOGLOBULINS BIOL, P3; JETT JR, 1983, ANN INTERN MED, V99, P621, DOI 10.7326/0003-4819-99-5-621; KATZ P, 1984, ADV INTERNAL MED, V29, P167; KENNY AB, 1979, EUR J PEDIATR, V131, P155, DOI 10.1007/BF00538940; Kiprov D D, 1983, J Clin Apher, V1, P57, DOI 10.1002/jca.2920010202; LAWRENCE HS, 1955, J CLIN INVEST, V34, P219, DOI 10.1172/JCI103075; LEVER AML, 1984, LANCET, V2, P1062; MARKER SC, 1981, SURGERY, V89, P660; McKhann CF, 1933, J INFECT DIS, V52, P268, DOI 10.1093/infdis/52.2.268; MEASE PJ, 1981, NEW ENGL J MED, V304, P1278, DOI 10.1056/NEJM198105213042107; MERIGAN TC, 1978, NEW ENGL J MED, V298, P981, DOI 10.1056/NEJM197805042981801; MEYERS JD, 1980, J INFECT DIS, V141, P555, DOI 10.1093/infdis/141.5.555; MONTANARO A, 1984, AM J MED, V76, P67, DOI 10.1016/0002-9343(84)90322-X; MORTON DL, 1970, ANN SURG, V172, P740, DOI 10.1097/00000658-197010000-00018; MUNSTER AM, 1970, ANN SURG, V172, P965, DOI 10.1097/00000658-197012000-00006; MURRAY HW, 1984, NEW ENGL J MED, V310, P883, DOI 10.1056/NEJM198404053101404; NICHOLLS AJ, 1983, LANCET, V1, P532; NOLTE MT, 1979, CLIN EXP IMMUNOL, V36, P237; NOLTE MT, 1975, J ALLERGY CLIN IMMUN, V55, P114; OCHS HD, 1982, J CLIN IMMUNOL, V2, pS22, DOI 10.1007/BF00918363; OCHS HD, 1984, AM J MED, V76, P78, DOI 10.1016/0002-9343(84)90324-3; Ordman CW, 1944, J CLIN INVEST, V23, P541, DOI 10.1172/JCI101519; Petersen E A, 1979, Ann N Y Acad Sci, V332, P216, DOI 10.1111/j.1749-6632.1979.tb47115.x; PIKE MC, 1977, CELL IMMUNOL, V32, P234, DOI 10.1016/0008-8749(77)90198-8; PIROFSKY B, 1982, J CLIN IMMUNOL, V2, pS7, DOI 10.1007/BF00918361; PIROFSKY B, 1984, AM J MED, V76, P53, DOI 10.1016/0002-9343(84)90320-6; PIROFSKY B, 1977, MED CLIN N AM, V61, P419, DOI 10.1016/S0025-7125(16)31342-6; PIROFSKY B, 1980, USDHHS FDA809005 PUB, P15; POSTIC B, 1984, Henry Ford Hospital Medical Journal, V32, P116; PRUITT BA, 1984, AM J MED, V76, P146, DOI 10.1016/0002-9343(84)90334-6; QUESADA JR, 1984, NEW ENGL J MED, V310, P15, DOI 10.1056/NEJM198401053100104; RAMSAY NKC, 1982, NEW ENGL J MED, V306, P392, DOI 10.1056/NEJM198202183060703; RAPPEPORT JM, 1980, AM J MED, V68, P605, DOI 10.1016/0002-9343(80)90312-5; ROMER J, 1982, VOX SANG, V42, P74; ROMER J, 1982, VOX SANG, V42, P62; ROUSELL RH, 1984, AM J MED, V76, P40, DOI 10.1016/0002-9343(84)90318-8; SCHULTZE HE, 1962, DEUT MED WOCHENSCHR, V87, P1643, DOI 10.1055/s-0028-1113997; SGOURIS JT, 1967, VOX SANG, V13, P71; SHARMA MK, 1979, CLIN IMMUNOL IMMUNOP, V12, P183, DOI 10.1016/0090-1229(79)90007-2; SHIRANI KZ, 1984, AM J MED, V76, P175, DOI 10.1016/0002-9343(84)90338-3; SILVERGLEID AJ, 1983, ANNU REV MED, V34, P69, DOI 10.1146/annurev.me.34.020183.000441; SMITH CI, 1983, J INFECT DIS, V148, P907, DOI 10.1093/infdis/148.5.907; SMITH GN, 1972, LANCET, V1, P1208; SORENSEN RU, 1984, AM J MED, V76, P83, DOI 10.1016/0002-9343(84)90325-5; SPITLER LE, 1979, AM J MED, V67, P59, DOI 10.1016/0002-9343(79)90074-3; STEPHAN W, 1971, VOX SANG, V20, P442, DOI 10.1111/j.1423-0410.1971.tb01819.x; STIEHM ER, 1966, BLOOD-J HEMATOL, V28, P918, DOI 10.1182/blood.V28.6.918.918; SULTAN Y, 1984, LANCET, V2, P765; SYMOENS J, 1977, J RETICULOENDOTH SOC, V21, P175; TOURAINE JL, 1979, TRANSPLANT P, V11, P494; TSANG KY, 1984, NEW ENGL J MED, V310, P987; Uhr J W, 1968, Adv Immunol, V8, P81, DOI 10.1016/S0065-2776(08)60465-4; WALDMANN TA, 1969, PROG ALLERGY, V13, P1, DOI 10.1159/000287491; WALLACE DJ, 1984, DISEASE MONTH, V30; WARA DW, 1983, CLIN IMMUNOL ALLERGY, V3, P169; WARRIER I, 1984, AM J MED, V76, P193, DOI 10.1016/0002-9343(84)90341-3; WELLS J V, 1972, Clinical Research, V20, P521; WILSON GB, 1979, J ALLERGY CLIN IMMUN, V64, P56, DOI 10.1016/0091-6749(79)90084-8; WILSON GB, 1981, THYMUS, V2, P257; WILSON GB, 1983, IMMUNOL TODAY, V4, P157, DOI 10.1016/0167-5699(83)90002-6; WINKELSTEIN A, 1984, J RHEUMATOL, V11, P162; WINSTON DJ, 1982, J CLIN IMMUNOL, V2, pS42, DOI 10.1007/BF00918366; WINSTON DJ, 1984, AM J MED, V76, P128, DOI 10.1016/0002-9343(84)90331-0; WINSTON DJ, 1982, ANN INTERN MED, V97, P11, DOI 10.7326/0003-4819-97-1-11; WOODS VL, 1984, BLOOD, V63, P368; WRIGHT JK, 1978, BIOCHEM BIOPH RES CO, V83, P1284, DOI 10.1016/0006-291X(78)91360-8; Wybran J., 1982, ADV PHARMACOL THER, V6, P123; YAMANAKA T, 1979, VOX SANG, V37, P14, DOI 10.1111/j.1423-0410.1979.tb02263.x; 1978, WHO TECHNICAL REPORT, V630, P3	118	23	24	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	75	4					423	437		10.1016/S0091-6749(85)80011-7	http://dx.doi.org/10.1016/S0091-6749(85)80011-7			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AFY44	2579994	Bronze			2022-12-18	WOS:A1985AFY4400001
J	CUSS, FM; BARNES, PJ				CUSS, FM; BARNES, PJ			THE EFFECT OF INHALED NIFEDIPINE ON BRONCHIAL REACTIVITY TO HISTAMINE IN MAN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											CUSS, FM (corresponding author), HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT MED,LONDON W12 0HS,ENGLAND.			Barnes, Peter/0000-0002-5122-4018				BARNES PJ, 1981, THORAX, V36, P726, DOI 10.1136/thx.36.10.726; BARNES PJ, 1983, THORAX, V38, P481, DOI 10.1136/thx.38.7.481; BRUGMAN TM, 1983, AM REV RESPIR DIS, V127, P14, DOI 10.1164/arrd.1983.127.1.14; CERRINA J, 1981, AM REV RESPIR DIS, V123, P156; CHENG JB, 1983, ARCH INT PHARMACOD T, V263, P228; COBURN RF, 1977, J PHARMACOL EXP THER, V201, P276; CORRIS PA, 1983, AM REV RESPIR DIS, V128, P991; COTES JE, 1975, LUNG FUNCTION ASSESS; CUSS FMC, 1985, CLIN SCI, V68, pP5; DANNELL M, 1982, AM REV RESPIR DIS, V125, P782; DEANFIELD J, 1983, BRIT MED J, V286, P1467, DOI 10.1136/bmj.286.6376.1467; DRAZEN JM, 1983, BRIT J PHARMACOL, V78, P687, DOI 10.1111/j.1476-5381.1983.tb09421.x; EISER NM, 1983, B EUR PHYSIOPATH RES, V19, P495; ELLULMICALLEF R, 1982, AM REV RESPIR DIS, V125, P63; FANTA CH, 1982, AM REV RESPIR DIS, V125, P61; FARLEY JM, 1977, J PHARMACOL EXP THER, V201, P199; FARLEY JM, 1978, J PHARMACOL EXP THER, V207, P340; FOSTER RW, 1984, BRIT J PHARMACOL, V81, P499, DOI 10.1111/j.1476-5381.1984.tb10103.x; GONZALEZ JM, 1983, AM REV RESPIR DIS, V127, P155; HENDERSON AF, 1983, THORAX, V38, P512, DOI 10.1136/thx.38.7.512; HENDERSON AF, 1983, AM REV RESPIR DIS, V127, P549, DOI 10.1164/arrd.1983.127.5.549; JAKOBSEN P, 1979, J CHROMATOGR, V162, P81, DOI 10.1016/S0378-4347(00)82066-6; KANNO T, 1973, CAN J PHYSIOL PHARM, V51, P1001, DOI 10.1139/y73-153; KIRKPATRICK CT, 1975, CLIN EXP PHARMACOL P, V2, P559, DOI 10.1111/j.1440-1681.1975.tb01861.x; KITAMURA S, 1980, ARZNEIMITTEL-FORSCH, V30-2, P1088; KNEUSSL M, 1983, AM REV RESPIR DIS, V127, P108; LEWIS RA, 1982, AM REV RESPIR DIS, V125, P94; MALIK S, 1982, THORAX, V32, P230; MALO PE, 1982, J PHARMACOL EXP THER, V221, P410; MARIN MG, 1982, J APPL PHYSIOL, V52, P198, DOI 10.1152/jappl.1982.52.1.198; MATTHEWS JI, 1983, AM REV RESPIR DIS, V127, P108; MCINTYRE E, 1983, J ALLERGY CLIN IMMUN, V71, P375, DOI 10.1016/0091-6749(83)90065-9; MIADONNA A, 1983, ANN ALLERGY, V51, P201; MIDDLETON E, 1983, EUR J RESPIR DIS, V64, P123; MIDDLETON E, 1980, J PHARM SCI-US, V69, P243, DOI 10.1002/jps.2600690244; MORICE RC, 1983, AM REV RESPIR DIS, V127, P144; NADEL JA, 1984, ANNU REV MED, V35, P451, DOI 10.1146/annurev.med.35.1.451; PATEL KR, 1981, BRIT MED J, V282, P932, DOI 10.1136/bmj.282.6268.932; PATEL KR, 1981, CLIN ALLERGY, V11, P429, DOI 10.1111/j.1365-2222.1981.tb01615.x; PATEL KR, 1983, CLIN ALLERGY, V13, P119, DOI 10.1111/j.1365-2222.1983.tb02578.x; PATEL KR, 1982, BR MED J, V284, P1926; POPA VT, 1983, AM REV RESPIR DIS, V127, P675; RAEBURN D, 1983, BR J PHARM S, pP330; REES PJ, 1982, THORAX, V37, P417, DOI 10.1136/thx.37.6.417; SOLWAY J, 1983, AM REV RESPIR DIS, V127, P92; THURINGER G, 1976, SCAND J RESPIR DIS, V57, P17; TRIGGLE DJ, 1983, ALLERGY, V38, P1, DOI 10.1111/j.1398-9995.1983.tb00849.x; VANBREEMEN C, 1980, CHEST, V78, P157, DOI 10.1378/chest.78.1.157; WALLER DG, 1984, BRIT J CLIN PHARMACO, V18, P951, DOI 10.1111/j.1365-2125.1984.tb02569.x; WILLIAMS DO, 1981, BRIT MED J, V283, P348, DOI 10.1136/bmj.283.6287.348	50	23	23	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	5					718	723		10.1016/0091-6749(85)90677-3	http://dx.doi.org/10.1016/0091-6749(85)90677-3			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AUU34	4056256	Bronze			2022-12-18	WOS:A1985AUU3400011
J	DOYLE, WJ; INGRAHAM, AS; FIREMAN, P				DOYLE, WJ; INGRAHAM, AS; FIREMAN, P			THE EFFECTS OF INTRANASAL HISTAMINE CHALLENGE ON EUSTACHIAN-TUBE FUNCTION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CHILDRENS HOSP,DEPT ALLERGY & IMMUNOL,PITTSBURGH,PA 15213; CHILDRENS HOSP,DEPT PEDIAT,PITTSBURGH,PA 15213; UNIV PITTSBURGH,SCH MED,PITTSBURGH,PA 15261	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	DOYLE, WJ (corresponding author), CHILDRENS HOSP,DEPT OTOLARYNGOL,125 DESOTO ST,PITTSBURGH,PA 15213, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019262] Funding Source: NIH RePORTER; NIAID NIH HHS [1-RO1-AI 19262] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACKERMAN MN, 1984, J ALLERGY CLIN IMMUN, V73, P604, DOI 10.1016/0091-6749(84)90519-0; BERNSTEIN JM, 1983, AM J OTOL, V5, P66; BLUESTONE CD, 1981, ANN OTO RHINOL LARYN, V90, P552, DOI 10.1177/000348948109000608; BLUESTONE CD, 1978, PEDIATRICS, V61, P753; BLUESTONE CD, 1977, LARYNGOSCOPE, V87, P493; BYLANDER A, 1983, ACTA OTO-LARYNGOL, V96, P255, DOI 10.3109/00016488309132898; BYLANDER A, ACTA OTOLARYNGOL STO; CANTEKIN EI, 1984, RECENT ADV OTITIS ME, P45; DOYLE WJ, 1984, ARCH OTOLARYNGOL, V110, P508; DOYLE WJ, 1984, RECENT ADV OTITIS ME, P59; DOYLE WJ, 1984, ACTA OTOLARYNGOL S S, V414, P52; FRIEDMAN PA, 1983, J ALLERGY CLIN IMMUN, V71, P442; JONSON B, 1969, ACTA OTO-LARYNGOL, V68, P271, DOI 10.3109/00016486909121565; NATHANSON SE, 1976, ANN OTO RHINOL LARYN, V85, P83, DOI 10.1177/000348947608500114; PAPARELLA M M, 1970, Annals of Otology Rhinology and Laryngology, V79, P766; PAYAN DG, 1984, J IMMUNOL, V132, P1601; RANKIN JD, 1970, ARCHIV OTOLARYNGOL, V92, P14	17	23	23	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	4					551	556		10.1016/0091-6749(85)90774-2	http://dx.doi.org/10.1016/0091-6749(85)90774-2			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ATH66	4056243	Bronze			2022-12-18	WOS:A1985ATH6600005
J	GERSHWIN, ME; OUGH, C; BOCK, A; FLETCHER, MP; NAGY, SM; TUFT, DS				GERSHWIN, ME; OUGH, C; BOCK, A; FLETCHER, MP; NAGY, SM; TUFT, DS			GRAND ROUNDS - ADVERSE REACTIONS TO WINE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Discussion									UNIV CALIF DAVIS,DEPT ENOL & VITICULTURE,DAVIS,CA 95616; UNIV CALIF DAVIS,SCH MED,DIV ALLERGY,DAVIS,CA 95616	University of California System; University of California Davis; University of California System; University of California Davis	GERSHWIN, ME (corresponding author), UNIV CALIF DAVIS,DEPT INTERNAL MED,DIV RHEUMATOL ALLERGY,TB 192,DAVIS,CA 95616, USA.				NIAID NIH HHS [AI 00193] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMERINE MA, 1980, METHODS ANAL MUSTS W, P217; BAKER GJ, 1981, MED J AUSTRALIA, V2, P614, DOI 10.5694/j.1326-5377.1981.tb113018.x; BAKER GJ, 1982, THOR SOC AUST, V12, P213; BOCK SA, 1978, J ALLERGY CLIN IMMUN, V62, P327, DOI 10.1016/0091-6749(78)90132-X; BOCK SA, 1983, ALLERGY PRINCIPLES P, P1415; BRESLIN A B X, 1973, Clinical Allergy, V3, P71, DOI 10.1111/j.1365-2222.1973.tb01311.x; CERRUTTI G, 1981, RISCERA ESQUITA CON, V34, P145; CHAYTOR JP, 1975, J SCI FOOD AGR, V26, P593, DOI 10.1002/jsfa.2740260505; CLAYTON DE, 1980, CLIN ALLERGY, V10, P341, DOI 10.1111/j.1365-2222.1980.tb02116.x; DALE HH, 1909, J PHYSIOL-LONDON, V34, P25; FREEDMAN BJ, 1980, BRIT J DIS CHEST, V74, P128, DOI 10.1016/0007-0971(80)90023-6; GEPPERT EF, 1978, AM REV RESPIR DIS, V118, P135; GONG H, 1981, CHEST, V80, P167, DOI 10.1378/chest.80.2.167; KOENIG JQ, 1982, J ALLERGY CLIN IMMUN, V69, P339, DOI 10.1016/0091-6749(82)90143-9; MARINKOVICH VA, 1983, B SOC MED FRIENDS WI, V1; MARINKOVICH VA, 1981, WINE HLTH SOC S SAN, P72; MURPHREE HB, 1967, FED PROC, V26, P1468; OUGH CS, 1982, J FOOD SCI, V47, P825, DOI 10.1111/j.1365-2621.1982.tb12724.x; OUGH CS, 1983, SULFUR DIOXIDE SULFI, P117; PRENNER BM, 1976, ANN ALLERGY, V37, P180; SANDLER M, 1974, NATURE, V250, P335, DOI 10.1038/250335a0; SHEPPARD D, 1980, AM REV RESPIR DIS, V122, P173; SHREIER P, 1979, CRC CRIT REV FOOD SC, V12, P59; SMITH I, 1970, Headache, V10, P43, DOI 10.1111/j.1526-4610.1970.hed1002043.x; STEVENSON DD, 1981, J ALLERGY CLIN IMMUN, V68, P26, DOI 10.1016/0091-6749(81)90119-6; TWAROG FJ, 1982, JAMA-J AM MED ASSOC, V248, P2030, DOI 10.1001/jama.248.16.2030; WALTS DA, 1981, J FOOD SCI, V46, P681	27	23	23	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	75	3					411	420		10.1016/0091-6749(85)90080-6	http://dx.doi.org/10.1016/0091-6749(85)90080-6			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AEB46	3973315				2022-12-18	WOS:A1985AEB4600014
J	ASAI, S; KRZANOWSKI, JJ; LOCKEY, RF; ANDERSON, WH; MARTIN, DF; POLSON, JB; BUKANTZ, SC; SZENTIVANYI, A				ASAI, S; KRZANOWSKI, JJ; LOCKEY, RF; ANDERSON, WH; MARTIN, DF; POLSON, JB; BUKANTZ, SC; SZENTIVANYI, A			THE SITE OF ACTION OF PTYCHODISCUS-BREVIS TOXIN WITHIN THE PARASYMPATHETIC AXONAL SODIUM CHANNEL-H GATE IN AIRWAY SMOOTH-MUSCLE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV S FLORIDA, COLL MED, DEPT PHARMACOL & THERAPEUT, TAMPA, FL 33612 USA; UNIV S FLORIDA, COLL NAT SCI, CHEMS CTR, DEPT CHEM, TAMPA, FL 33620 USA; JAMES A HALEY VET ADM MED CTR, DEPT INTERNAL MED, ALLERGY & IMMUNOL SECT, TAMPA, FL 33612 USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; US Department of Veterans Affairs; Veterans Health Administration (VHA); James A. Haley Veterans Hospital	ASAI, S (corresponding author), UNIV S FLORIDA, COLL MED, DEPT INTERNAL MED, DIV ALLERGY & IMMUNOL, TAMPA, FL 33612 USA.				NHLBI NIH HHS [HL 23658] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON WH, 1979, N-S ARCH PHARMACOL, V308, P717; ASAI S, 1982, J ALLERGY CLIN IMMUN, V69, P418, DOI 10.1016/0091-6749(82)90116-6; Brydon G A, 1971, Environ Lett, V1, P235; CATTERALL WA, 1980, ANNU REV PHARMACOL, V20, P15, DOI 10.1146/annurev.pa.20.040180.000311; CATTERALL WA, 1981, MOL PHARMACOL, V19, P345; CATTERALL WA, 1975, P NATL ACAD SCI USA, V72, P1782, DOI 10.1073/pnas.72.5.1782; DOIG MT, 1972, ENVIRON LETT, V3, P279, DOI 10.1080/00139307209435474; HEMMERT WH, 1975, 1ST P INT C TOX DIN, P489; HILLE B, 1977, J GEN PHYSIOL, V69, P497, DOI 10.1085/jgp.69.4.497; IIZUKA S, 1975, B PLANKTON SOC JPN, V21, P45; IIZUKA S, 1977, STUDIES TOXIC PHYTOP, P14; MARTIN DF, 1976, J CHEM EDUC, V53, P614, DOI 10.1021/ed053p614; McFARREN E. F., 1965, TOXICON, V3, P111, DOI 10.1016/0041-0101(65)90005-X; Music S I, 1973, JFMA, V60, P27; NARAHASHI T, 1972, FED PROC, V31, P1124; Quick J.A. Jr., 1974, P85; QUICK JA, 1975, 1ST P INT C TOX DIN, P414; SNEDECOR GW, 1956, STATISTICAL METHODS; Steidinger K.A., 1979, P435; STEIDINGER KA, 1978, J PHYCOL, V14, P72, DOI 10.1111/j.1529-8817.1978.tb00634.x; STEPHENS N, 1970, AIRWAY DYNAMICS PHYS, P191; TAYLOR HF, 1917, 848 US COMM FISH DOC, P5; WOODCOCK AH, 1948, J MAR RES, V7, P56	23	23	25	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	6					824	828		10.1016/0091-6749(84)90454-8	http://dx.doi.org/10.1016/0091-6749(84)90454-8			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SV829	6327792				2022-12-18	WOS:A1984SV82900010
J	SINDEL, LJ; BUCKLEY, RH; SCHIFF, SE; WARD, FE; MICKEY, GH; HUANG, AT; NASPITZ, C; KOREN, H				SINDEL, LJ; BUCKLEY, RH; SCHIFF, SE; WARD, FE; MICKEY, GH; HUANG, AT; NASPITZ, C; KOREN, H			SEVERE COMBINED IMMUNODEFICIENCY WITH NATURAL KILLER-CELL PREDOMINANCE - ABROGATION OF GRAFT-VERSUS-HOST DISEASE AND IMMUNOLOGICAL RECONSTITUTION WITH HLA-IDENTICAL BONE-MARROW CELLS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									DUKE UNIV,SCH MED,DEPT PEDIAT,DURHAM,NC 27706; DUKE UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,DURHAM,NC 27706; DUKE UNIV,SCH MED,DEPT MED & SURG,DURHAM,NC 27706; ESCOLA PAULISTA MED,DEPT PEDIAT,BR-04023 SAO PAULO,SP,BRAZIL	Duke University; Duke University; Duke University; Universidade Federal de Sao Paulo (UNIFESP)			Buckley, Rebecca/AAB-1578-2019		NCI NIH HHS [CA 23354] Funding Source: Medline; NIAID NIH HHS [AI18613] Funding Source: Medline; NIGMS NIH HHS [GM 10356] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018613, R37AI018613] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM010356] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABO T, 1981, J IMMUNOL, V127, P1024; BORTIN MM, 1977, JAMA-J AM MED ASSOC, V238, P591, DOI 10.1001/jama.238.7.591; BUCKLEY RH, 1976, J CLIN INVEST, V58, P130, DOI 10.1172/JCI108441; BUCKLEY RH, 1975, J CLIN INVEST, V55, P157, DOI 10.1172/JCI107906; BUCKLEY RH, 1968, PEDIATRICS, V41, P600; BUCKLEY RH, 1977, PEDIATR CLIN N AM, V24, P313; BUCKLEY RH, 1968, J ALLERGY, V40, P294; FLOMENBERG N, 1983, J IMMUNOL, V130, P2635; GEHA RS, 1980, J ALLERGY CLIN IMMUN, V66, P78, DOI 10.1016/0091-6749(80)90142-6; HAYNES BF, 1981, IMMUNOL REV, V57, P127, DOI 10.1111/j.1600-065X.1981.tb00445.x; Hirschhorn R, 1977, Prog Clin Immunol, V3, P67; KOREN HS, 1978, J IMMUNOL, V120, P796; LIPINSKI M, 1980, EUR J IMMUNOL, V10, P246, DOI 10.1002/eji.1830100405; LOPEZ C, 1979, LANCET, V2, P1103; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; ORTALDO JR, 1981, J IMMUNOL, V127, P2401; PAHWA SG, 1980, J CLIN INVEST, V66, P543, DOI 10.1172/JCI109886; PERUSSIA B, 1983, J IMMUNOL, V130, P2133; PHILLIPS JH, 1983, IMMUNOL LETT, V6, P143, DOI 10.1016/0165-2478(83)90096-2; REINHERZ EL, 1979, NEW ENGL J MED, V300, P1061, DOI 10.1056/NEJM197905103001901; REINHERZ EL, 1980, NEW ENGL J MED, V303, P370, DOI 10.1056/NEJM198008143030704; SANAL SO, 1978, J CLIN INVEST, V61, P1, DOI 10.1172/JCI108907; SCHIFF RI, 1974, J IMMUNOL, V112, P376; SULLIVAN JL, 1980, SCIENCE, V210, P543, DOI 10.1126/science.6158759; TIMONEN T, 1981, J EXP MED, V153, P569, DOI 10.1084/jem.153.3.569; TOURAINE JL, 1981, BONE MARROW TRANSPLA, V2, P209; VOSSEN JM, 1981, BONE MARROW TRANSPL, V2, P218	27	23	23	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	6					829	836		10.1016/0091-6749(84)90455-X	http://dx.doi.org/10.1016/0091-6749(84)90455-X			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SV829	6233355				2022-12-18	WOS:A1984SV82900011
J	SULLIVAN, TJ				SULLIVAN, TJ			ALLERGIC REACTIONS TO ANTIMICROBIAL AGENTS - A REVIEW OF REACTIONS TO DRUGS NOT IN THE BETA LACTAM ANTIBIOTIC CLASS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV TEXAS,HLTH SCI CTR,DEPT MICROBIOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas	SULLIVAN, TJ (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT INTERNAL MED,DALLAS,TX 75235, USA.							ABRAMOWICZ M, 1982, HDB ANTIMICROBIAL TH, P48; ARNDT KA, 1976, JAMA-J AM MED ASSOC, V235, P918, DOI 10.1001/jama.235.9.918; BALL AP, 1978, ANTIBACTERIAL DRUGS, P1; CALDWELL JR, 1974, JAMA-J AM MED ASSOC, V230, P77, DOI 10.1001/jama.230.1.77; GANOD LP, 1973, ANTIBIOTIC CHEMOTHER, P12; JICK H, 1970, J AMER MED ASSOC, V213, P1455, DOI 10.1001/jama.213.9.1455; LASSER EC, 1983, J ALLERGY CLIN IMMUN, V72, P83, DOI 10.1016/0091-6749(83)90056-8; NAGY L, 1982, NEW ENGL J MED, V306, P497, DOI 10.1056/NEJM198203043060901; NEWFIELD P, 1979, ANN INTERN MED, V91, P581, DOI 10.7326/0003-4819-91-4-581; PARKER CW, 1975, NEW ENGL J MED, V292, P957, DOI 10.1056/NEJM197505012921806; PARKER CW, 1975, NEW ENGL J MED, V292, P511, DOI 10.1056/NEJM197503062921006; PARKER CW, 1975, NEW ENGL J MED, V292, P732, DOI 10.1056/NEJM197504032921407; PARKER CW, 1980, CLIN IMMUNOLOGY, P1219; ROBERTS LJ, 1980, NEW ENGL J MED, V303, P1400, DOI 10.1056/NEJM198012113032405; ROLLO IM, 1980, PHARMACOL BASIS THER, P1013; SANDE MA, 1980, PHARMACOL BASIS THER, P1080; SCHAAD UB, 1980, J PEDIATR-US, V96, P119; SULLIVAN TJ, 1982, J ALLERGY CLIN IMMUN, V69, P500, DOI 10.1016/0091-6749(82)90174-9; SULLIVAN TJ, 1982, J ALLERGY CLIN IMMUN, V69, P260, DOI 10.1016/S0091-6749(82)80002-X; SULLIVAN TJ, 1983, CURRENT THERAPY ALLE, P62; VANARSDEL PP, 1982, JAMA-J AM MED ASSOC, V247, P2576, DOI 10.1001/jama.247.18.2576; VANARSDEL PP, 1981, MED CLIN N AM, V65, P1089, DOI 10.1016/S0025-7125(16)31492-4; WAGNER JL, ANAL BIOCH; WARREN K, 1983, J ALLERGY CLIN IMMUN, V71, P206, DOI 10.1016/0091-6749(83)90101-X	24	23	24	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	4					594	599		10.1016/0091-6749(84)90112-X	http://dx.doi.org/10.1016/0091-6749(84)90112-X			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TQ163	6491106				2022-12-18	WOS:A1984TQ16300009
J	WESTCOTT, JY; CLAY, KL; MURPHY, RC				WESTCOTT, JY; CLAY, KL; MURPHY, RC			DECOMPOSITION OF LEUKOTRIENE-C4	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV COLORADO,SCH MED,DEPT PHARMACOL C236,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver			Murphy, Robert/AAO-5349-2020	Murphy, Robert/0000-0002-9430-6515	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL025785, R37HL025785] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 25785] Funding Source: Medline; NIAAA NIH HHS [AA05193] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ANDERSON FS, 1983, ANAL CHEM, V55, P1837, DOI 10.1021/ac00261a052; BACH MK, 1977, PROSTAGLANDINS, V14, P21, DOI 10.1016/0090-6980(77)90154-X; BROCKLEHURST WE, 1976, J PHARM PHARMACOL, V28, P361, DOI 10.1111/j.2042-7158.1976.tb04180.x; CHAKRAVARTY N, 1959, THESIS KAROLINSKA I; CLAY KL, 1983, BIOMED MASS SPECTROM, V10, P489, DOI 10.1002/bms.1200100902; HENDERSON WR, 1983, BIOCH BIOPHYS RES CO, V110, P226; Kellaway CH, 1940, Q J EXP PHYSIOL CMS, V30, P121; LEE CW, 1982, P NATL ACAD SCI-BIOL, V79, P4166, DOI 10.1073/pnas.79.13.4166; MATHEWS WR, 1981, ANAL BIOCHEM, V118, P96, DOI 10.1016/0003-2697(81)90162-7; MURPHY RC, 1979, P NATL ACAD SCI USA, V76, P4275, DOI 10.1073/pnas.76.9.4275; MURPHY RC, 1982, PROSTAGLANDINS, V23, P201, DOI 10.1016/0090-6980(82)90046-6; Orange R P, 1969, Adv Immunol, V10, P105, DOI 10.1016/S0065-2776(08)60416-2	12	23	23	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	3					363	368		10.1016/0091-6749(84)90131-3	http://dx.doi.org/10.1016/0091-6749(84)90131-3			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TQ633	6470366				2022-12-18	WOS:A1984TQ63300011
J	CARPENTER, GB; BUNKERSOLER, AL; NELSON, HS				CARPENTER, GB; BUNKERSOLER, AL; NELSON, HS			EVALUATION OF COMBINED H-1-RECEPTOR AND H-2-RECEPTOR BLOCKING-AGENTS IN THE TREATMENT OF SEASONAL ALLERGIC RHINITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									FITZSIMONS ARMY MED CTR,ALLERGY IMMUNOL SERV,AURORA,CO 80045									COHEN SH, 1980, J ALLERGY CLIN IMMUN, V65, P189; COMMENS CA, 1978, BRIT J DERMATOL, V99, P675, DOI 10.1111/j.1365-2133.1978.tb07062.x; COOK J, 1979, BRIT J DERMATOL, V101, P21; DAVIES MG, 1979, ARCH DERMATOL RES, V266, P117, DOI 10.1007/BF00694619; Elliott J, 1979, JAMA, V242, P13, DOI 10.1001/jama.242.1.13; FINKELSTEIN W, 1978, NEW ENGL J MED, V299, P992; GERRARD JW, 1979, J PEDIATR, V94, P834; GOODWIN JE, 1957, FED PROC, V16, P628; GURNEY CW, 1955, J ALLERGY, V26, P533, DOI 10.1016/0021-8707(55)90094-0; HARVEY RP, 1980, J ALLERGY CLIN IMMUN, V65, P136, DOI 10.1016/0091-6749(80)90198-0; HARVEY RP, 1980, J ALLERGY CLIN IMMUN, V65, P190; HUTCHCROFT BJ, 1979, J ALLERGY CLIN IMMUN, V63, P376, DOI 10.1016/0091-6749(79)90209-4; KALINER M, 1982, J ALLERGY CLIN IMMUN, V69, P283, DOI 10.1016/S0091-6749(82)80005-5; KALINER M, 1981, J ALLERGY CLIN IMMUN, V68, P365, DOI 10.1016/0091-6749(81)90134-2; MARKS R, 1980, BRIT J DERMATOL, V102, P240, DOI 10.1111/j.1365-2133.1980.tb05702.x; MARKS R, 1977, BRIT J CLIN PHARMACO, V4, P367, DOI 10.1111/j.1365-2125.1977.tb00725.x; MATTHEWS CNA, 1979, BRIT J DERMATOL, V101, P57, DOI 10.1111/j.1365-2133.1979.tb15293.x; MCGUIGAN JE, 1981, GASTROENTEROLOGY, V80, P181; MYGIND N, 1977, CLIN ALLERGY, V7, P69, DOI 10.1111/j.1365-2222.1977.tb01426.x; NATHAN RA, 1981, J ALLERGY CLIN IMMUN, V67, P171, DOI 10.1016/0091-6749(81)90057-9; PELIKAN Z, 1978, ANN ALLERGY, V41, P37; PEPYS J, 1975, AM REV RESPIR DIS, V112, P829; PHANUPHAK P, 1978, CLIN ALLERGY, V8, P429, DOI 10.1111/j.1365-2222.1978.tb01493.x; PLAUT M, 1979, J ALLERGY CLIN IMMUN, V63, P371, DOI 10.1016/0091-6749(79)90208-2; POOTHULLIL J, 1976, J ALLERGY CLIN IMMUN, V57, P164, DOI 10.1016/0091-6749(76)90035-X; ROBERTS LJ, 1979, NEW ENGL J MED, V300, P236, DOI 10.1056/NEJM197902013000506; SECHER C, 1982, J ALLERGY CLIN IMMUN, V70, P211, DOI 10.1016/0091-6749(82)90044-6; SHAIKH W, 1977, J ALLERGY CLIN IMMUN, V60, P242, DOI 10.1016/0091-6749(77)90138-5; SMITH JA, 1980, J ALLERGY CLIN IMMUN, V65, P118, DOI 10.1016/0091-6749(80)90195-5; SUMMERS R, 1981, J ALLERGY CLIN IMMUN, V67, P456, DOI 10.1016/0091-6749(81)90099-3; TAYLOR G, 1973, CLIN ALLERGY, V3, P639, DOI 10.1111/j.1365-2222.1973.tb03067.x; WYLLIE JH, 1972, LANCET, V2, P1117	32	23	23	1	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	71	4					412	417		10.1016/0091-6749(83)90071-4	http://dx.doi.org/10.1016/0091-6749(83)90071-4			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QL121	6131914				2022-12-18	WOS:A1983QL12100010
J	PAPAGEORGIOU, N; LEE, TH; NAGAKURA, T; CROMWELL, O; WRAITH, DG; KAY, AB				PAPAGEORGIOU, N; LEE, TH; NAGAKURA, T; CROMWELL, O; WRAITH, DG; KAY, AB			NEUTROPHIL CHEMOTACTIC ACTIVITY IN MILK-INDUCED ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									BROMPTON HOSP,INST CARDIOTHORAC,DEPT ALLERGY & CLIN IMMUNOL,LONDON SW3 6HP,ENGLAND; ST THOMAS HOSP & MED SCH,DEPT IMMUNOL,LONDON SE1 7EH,ENGLAND	Royal Brompton Hospital; University of London; King's College London			Lee, Tak/AAA-9526-2020	Lee, Tak/0000-0002-7554-4059				ASHKENAZI A, 1980, PEDIATRICS, V66, P399; ATKINS PC, 1977, ANN INTERN MED, V86, P415, DOI 10.7326/0003-4819-86-4-415; ATKINS PC, 1981, J ALLERGY CLIN IMMUN, V68, P286, DOI 10.1016/0091-6749(81)90153-6; CHANG TT, 1981, 37TH P ANN M AM AC A; CUNNINGHAMRUNDLES C, 1981, CLIN EXP IMMUNOL, V45, P299; DAHL R, 1978, ALLERGY, V33, P120, DOI 10.1111/j.1398-9995.1978.tb01520.x; DAHL R, 1981, ALLERGY, V36, P161, DOI 10.1111/j.1398-9995.1981.tb01831.x; DIXON M, 1980, BRIT J PHARMACOL, V70, P11, DOI 10.1111/j.1476-5381.1980.tb10898.x; FLINT FJ, 1962, BRIT MED J, V2, P1231; LEE TH, 1982, J CLIN INVEST, V69, P889, DOI 10.1172/JCI110528; MARTIN LE, 1974, CLIN PHARMACOL THER, V15, P267; MAY CD, 1982, CLIN ALLERGY, V12, P229, DOI 10.1111/j.1365-2222.1982.tb02523.x; MAY CD, 1978, ALLERGY, V33, P166, DOI 10.1111/j.1398-9995.1978.tb01532.x; MAY CD, 1982, J ALLERGY CLIN IMMUN, V69, P255, DOI 10.1016/S0091-6749(82)80001-8; MAY CD, 1976, J ALLERGY CLIN IMMUN, V58, P500, DOI 10.1016/0091-6749(76)90194-9; MINOR JD, 1980, J ALLERGY CLIN IMMUN, V66, P314, DOI 10.1016/0091-6749(80)90027-5; MOSS GF, 1971, TOXICOL APPL PHARM, V20, P147, DOI 10.1016/0041-008X(71)90041-X; NAGY L, 1982, NEW ENGL J MED, V306, P497, DOI 10.1056/NEJM198203043060901; PAGANELLI R, 1979, LANCET, V1, P1270; PEPYS J, 1975, AM REV RESPIR DIS, V112, P829; RITCHIE B, 1962, LANCET, V2, P271; ROY AC, 1974, BIOCHEM PHARMACOL, V23, P917, DOI 10.1016/0006-2952(74)90223-8; RYO UY, 1976, JAMA-J AM MED ASSOC, V236, P927; SOTER NA, 1980, NEW ENGL J MED, V302, P604, DOI 10.1056/NEJM198003133021104; SOTER NA, 1979, J INVEST DERMATOL, V72, P282; WASSERMAN SI, 1977, J CLIN INVEST, V60, P189, DOI 10.1172/JCI108756	26	23	23	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	72	1					75	82		10.1016/0091-6749(83)90055-6	http://dx.doi.org/10.1016/0091-6749(83)90055-6			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QZ198	6406587				2022-12-18	WOS:A1983QZ19800010
J	SHELHAMER, JH; MAROM, Z; KALINER, M				SHELHAMER, JH; MAROM, Z; KALINER, M			ABNORMAL BETA-ADRENERGIC RESPONSIVENESS IN ALLERGIC SUBJECTS .2. THE ROLE OF SELECTIVE BETA2-ADRENERGIC HYPOREACTIVITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											SHELHAMER, JH (corresponding author), NIAID,CLIN INVEST LAB,CIENCIAS MED SECT,BLDG 10,ROOM 11C215,BETHESDA,MD 20205, USA.							BURGES RA, 1972, NATURE-NEW BIOL, V235, P249, DOI 10.1038/newbio235249a0; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CONOLLY ME, 1976, J CLIN INVEST, V58, P1307, DOI 10.1172/JCI108586; COOKSON DU, 1963, AM REV RESPIR DIS, V88, P636; FIREMAN P, 1973, INT ARCH ALLER A IMM, V45, P123, DOI 10.1159/000231014; FIREMAN P, 1970, J ALLERGY, V45, P117; GALANT SP, 1978, NEW ENGL J MED, V299, P933, DOI 10.1056/NEJM197810262991707; GREICO MH, 1968, AM J MED, V44, P863; HAGY GW, 1976, J ALLERGY CLIN IMMUN, V58, P330, DOI 10.1016/0091-6749(76)90139-1; INOUE S, 1967, J ALLERGY, V40, P337, DOI 10.1016/0021-8707(67)90023-8; JENNE JW, 1977, J ALLERGY CLIN IMMUN, V60, P346, DOI 10.1016/0091-6749(77)90065-3; KALINER M, 1976, J ALLERGY CLIN IMMUN, V58, P308, DOI 10.1016/0091-6749(76)90136-6; KRZANOWSKI JJ, 1979, CLIN EXP PHARMACOL P, V6, P111, DOI 10.1111/j.1440-1681.1979.tb00013.x; LANDS AM, 1964, P SOC EXP BIOL MED, V116, P331; LANDS AM, 1967, NATURE, V214, P597, DOI 10.1038/214597a0; LANG P, 1978, J ALLERGY CLIN IMMUN, V61, P248, DOI 10.1016/0091-6749(78)90199-9; LOCKEY SD, 1967, J ALLERGY, V40, P349, DOI 10.1016/0021-8707(67)90024-X; LOGSDON PJ, 1972, J ALLERGY CLIN IMMUN, V50, P45, DOI 10.1016/0091-6749(72)90078-4; MAKINO S, 1970, J ALLERGY, V46, P178, DOI 10.1016/0021-8707(70)90096-1; MAKINO S, 1977, J ALLERGY CLIN IMMUN, V59, P348, DOI 10.1016/0091-6749(77)90016-1; MASELLI R, 1970, J ALLERGY, V45, P117; MIDDLETON E, 1968, J ALLERGY, V42, P288, DOI 10.1016/0021-8707(68)90022-1; MORRIS HG, 1978, J ALLERGY CLIN IMMUN, V61, P294, DOI 10.1016/0091-6749(78)90050-7; ORANGE RP, 1971, FED PROC, V30, P1725; PARKER CW, 1973, J CLIN INVEST, V52, P48, DOI 10.1172/JCI107173; PARKER CW, 1973, J CLIN INVEST, V52, P1336, DOI 10.1172/JCI107305; SCHWARTZ HJ, 1973, J ALLERGY CLIN IMMUN, V51, P88, DOI 10.1016/S0091-6749(73)80024-7; SHELHAMER JH, 1980, J ALLERGY CLIN IMMUN, V66, P52, DOI 10.1016/0091-6749(80)90138-4; SMITH LJ, 1980, J ALLERGY CLIN IMMUN, V66, P374, DOI 10.1016/0091-6749(80)90116-5; SOKOL WN, 1975, J ALLERGY CLIN IMMUN, V55, P310, DOI 10.1016/0091-6749(75)90003-2; SZENTIVANYI A, 1968, J ALLERGY, V42, P203, DOI 10.1016/S0021-8707(68)90117-2	31	23	23	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	71	1					57	61		10.1016/0091-6749(83)90547-X	http://dx.doi.org/10.1016/0091-6749(83)90547-X			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PZ461	6130109				2022-12-18	WOS:A1983PZ46100009
J	CHIARAMONTE, LT; PRABHU, SL				CHIARAMONTE, LT; PRABHU, SL			COMPARATIVE-EVALUATION OF 5 PEAK FLOW DEVICES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											CHIARAMONTE, LT (corresponding author), LONG ISL COLL HOSP,DEPT ALLERGY & IMMUNOL,BROOKLYN,NY 11201, USA.							CHAI H, 1968, J ALLERGY, V41, P23, DOI 10.1016/0021-8707(68)90005-1; CHIARAMONTE LT, 1981, ANN ALLERGY, V47, P95; HAYDU SP, 1976, LANCET, V2, P1225; MACKLEM PT, 1963, AM REV RESPIR DIS, V87, P47; NIE NH, 1975, STATISTICAL PACKAGE; PERKS WH, 1979, THORAX, V34, P79, DOI 10.1136/thx.34.1.79; ROBERTSON DG, 1969, BMJ-BRIT MED J, V1, P552, DOI 10.1136/bmj.1.5643.552; STRART RD, 1977, BEHAVIORAL SELF MANA; WRIGHT BM, 1959, BRIT MED J, V2, P1041, DOI 10.1136/bmj.2.5159.1041; WRIGHT BM, 1978, BRIT MED J, V2, P1627, DOI 10.1136/bmj.2.6152.1627	10	23	23	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	69	6					509	515		10.1016/0091-6749(82)90175-0	http://dx.doi.org/10.1016/0091-6749(82)90175-0			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NT025	7076991				2022-12-18	WOS:A1982NT02500006
J	KANG, B; VERESTHORNER, C; HEREDIA, R; CHA, E; BOSE, S; SCHWARTZ, M				KANG, B; VERESTHORNER, C; HEREDIA, R; CHA, E; BOSE, S; SCHWARTZ, M			SUCCESSFUL TREATMENT OF FAR-ADVANCED PROGRESSIVE SYSTEMIC-SCLEROSIS BY D-PENICILLAMINE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MT SINAI HOSP,MED CTR,DEPT PATHOL,CHICAGO,IL 60608; MT SINAI HOSP,MED CTR,DEPT RADIOL,CHICAGO,IL 60608		KANG, B (corresponding author), MT SINAI HOSP,MED CTR,DEPT MED,CHICAGO,IL 60608, USA.							ABRUZZO ZL, 1979, ANN INTERN MED, V90, P117; ASBOEHANSEN G, 1976, PENICILLAMINE RES RH, P284; BENNETT R, 1971, ANN RHEUM DIS, V30, P581, DOI 10.1136/ard.30.6.581; BINNICK SA, 1977, ARCH DERMATOL, V113, P1398, DOI 10.1001/archderm.113.10.1398; BLUESTONE R, 1970, ANN RHEUM DIS, V29, P153, DOI 10.1136/ard.29.2.153; BROLL H, 1976, WIEN KLIN WOCHENSCHR, V88, P292; CAMPBELL P M, 1975, Seminars in Arthritis and Rheumatism, V4, P351, DOI 10.1016/0049-0172(75)90017-7; CLEMENTS PJ, 1978, ARTHRITIS RHEUM, V21, P62, DOI 10.1002/art.1780210111; DAVIS P, 1976, BRIT J DERMATOL, V94, P705, DOI 10.1111/j.1365-2133.1976.tb05174.x; FAULK DL, 1978, GASTROENTEROLOGY, V74, P922; FULGHUM DD, 1968, ARCH DERMATOL, V98, P51, DOI 10.1001/archderm.98.1.51; HALVERSON P, 1978, JAMA, V240, P1850; HARRIS ED, 1966, LANCET, V2, P707, DOI 10.1016/S0140-6736(66)92976-X; HARRIS ED, 1966, LANCET, V2, P966; HENKIN RI, 1969, ANN INTERN MED, V71, P791, DOI 10.7326/0003-4819-71-4-791; HERBERT CM, 1974, LANCET, V1, P187, DOI 10.1016/S0140-6736(74)92494-5; JAYSON MIV, 1976, PENICILLAMINE RES RH, P105; JIMENEZ SA, 1980, GASTROENTEROLOGY, V79, P155; KEANE WF, 1976, ANN INTERN MED, V85, P199, DOI 10.7326/0003-4819-85-2-199; LAM M, 1978, ANN INTERN MED, V89, P642, DOI 10.7326/0003-4819-89-5-642; MASI AT, 1978, ARTHRITIS RHEUM, V215, P576; METZGER TA, 1971, ANN INTERN MED, V75, P369; MOYNAHAN EJ, 1974, POSTGRAD MED J, V50, P39; MUERS M, 1976, BRIT HEART J, V38, P864; POIRIER TJ, 1972, AM J GASTROENTEROL, V58, P30; RODNAN GP, 1972, ARTHRITIS ALLIED CON, P962; SMILEY JD, 1967, ARTHRITIS RHEUM, V10, P313; SMITH JW, 1979, AM J MED, V66, P28, DOI 10.1016/0002-9343(79)90478-9; WASNER C, 1978, NEW ENGL J MED, V299, P873, DOI 10.1056/NEJM197810192991607; WINKLEMAN PK, 1976, MAYO CLIN P, V46, P128; YUN RYO, 1976, J NUCL MED, V17, P564; 1979, N ENGL J MED, V301, P929	32	23	26	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	69	3					297	305		10.1016/S0091-6749(82)80007-9	http://dx.doi.org/10.1016/S0091-6749(82)80007-9			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NF697	7061771				2022-12-18	WOS:A1982NF69700007
J	GOREVIC, PD; LEVINE, BB				GOREVIC, PD; LEVINE, BB			DESENSITIZATION OF ANAPHYLACTIC HYPERSENSITIVITY SPECIFIC FOR THE PENICILLOATE MINOR DETERMINANT OF PENICILLIN AND CARBENICILLIN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NYU,SCH MED,DEPT MED,DIV ALLERGY,NEW YORK,NY 10003	New York University								ADKINSON NF, 1971, NEW ENGL J MED, V285, P22, DOI 10.1056/NEJM197107012850104; Beaven MA., 1975, HDB PSYCHOPHARMACOLO, V1, P253; BOREL Y, 1976, NATURE, V261, P49, DOI 10.1038/261049a0; BOSOMBA A, 1978, CLIN ALLERGY, V8, P341; CHIORAZZI N, 1976, P NATL ACAD SCI USA, V73, P2091, DOI 10.1073/pnas.73.6.2091; Corcoran AC, 1938, AM J MED SCI, V196, P359, DOI 10.1097/00000441-193809000-00008; Dewdney JM, 1977, ANTIGENS, V4, P73; DEWECK AL, 1976, CHEMOTHERAPY, V4, P345; DROBIS JD, 1976, J IMMUNOL, V117, P1049; FELLNER MJ, 1970, J ALLERGY, V45, P55, DOI 10.1016/0021-8707(70)90017-1; GILLMAN S A, 1972, Clinical Allergy, V2, P63, DOI 10.1111/j.1365-2222.1972.tb01268.x; GLEICH GJ, 1971, J LAB CLIN MED, V77, P690; GRAYBILL JR, 1974, SOUTH MED J, V67, P62, DOI 10.1097/00007611-197401000-00017; GREEN GR, 1977, J ALLERGY CLIN IMMUN, V60, P339, DOI 10.1016/0091-6749(77)90064-1; GREEN GR, 1967, ANN INTERN MED, V67, P235, DOI 10.7326/0003-4819-67-2-235; HAMILTONMILLER JM, 1970, BIOCHEM J, V116, P371, DOI 10.1042/bj1160371; Hugli T E, 1978, Adv Immunol, V26, P1, DOI 10.1016/S0065-2776(08)60228-X; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; ISHIZAKA K, 1968, J IMMUNOL, V101, P68; ISHIZAKA T, 1970, J IMMUNOL, V104, P854; LAURELL CB, 1967, IMMUNOLOGY, V12, P313; LAWLEY TJ, 1980, J INVEST DERMATOL, V75, P297, DOI 10.1111/1523-1747.ep12530883; LEVINE BB, 1969, J ALLERGY, V43, P231, DOI 10.1016/0021-8707(69)90066-5; LEVINE BB, 1967, ANN NY ACAD SCI, V145, P298, DOI 10.1111/j.1749-6632.1967.tb50227.x; LEVINE BB, 1968, J CLIN INVEST, V47, P556, DOI 10.1172/JCI105752; LEVINE BB, 1969, INT ARCH ALLERGY APP, V35, P455; LEVINE BB, 1973, J INFECT DIS, V128, P5364; LEVINE BB, 1976, MANUAL CLIN IMMUNOLO, P637; LIEBERMAN P, 1971, J AMER MED ASSOC, V215, P1106; MATTSON JR, 1975, ARCH INTERN MED, V135, P818, DOI 10.1001/archinte.135.6.818; MOHAMMED I, 1977, J CLIN PATHOL, V30, P308, DOI 10.1136/jcp.30.4.308; PECK SM, 1948, JAMA-J AM MED ASSOC, V138, P631, DOI 10.1001/jama.1948.02900090005002; PEDERSEN.J, 1969, ACTA ALLERGOL, V24, P333, DOI 10.1111/j.1398-9995.1969.tb03748.x; PETZ LD, 1978, J INFECT DIS, V137, P574; RATNER B, 1943, ALLERGY BALTIMORE; REDMOND AP, 1967, J ALLERGY, V39, P51, DOI 10.1016/0021-8707(67)90127-X; REISMAN RE, 1962, J ALLERGY, V33, P178, DOI 10.1016/0021-8707(62)90007-2; ROSSEN RD, 1977, J NATL CANCER I, V58, P1205, DOI 10.1093/jnci/58.5.1205; SHER A, 1977, J IMMUNOL, V119, P722; SIEGEL BB, 1964, J ALLERGY, V35, P488, DOI 10.1016/0021-8707(64)90080-2; SMITH PL, 1980, J CLIN INVEST, V66, P1072, DOI 10.1172/JCI109936; SOBOTKA AK, 1979, J IMMUNOL, V122, P511; SULLIVAN TJ, 1980, J ALLERGY CLIN IMMUN, V65, P195; TANNENBAUM H, 1975, J ALLERGY CLIN IMMUN, V56, P226, DOI 10.1016/0091-6749(75)90094-9; VANDELLEN RG, 1970, MED CLIN N AM, V54, P997, DOI 10.1016/S0025-7125(16)32617-7; WITTERS LA, 1977, AM J MED, V63, P703, DOI 10.1016/0002-9343(77)90155-3; ZOLOV D, 1967, J ALLERGY, V39, P107	47	23	23	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	68	4					267	272		10.1016/0091-6749(81)90150-0	http://dx.doi.org/10.1016/0091-6749(81)90150-0			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ML525	6169752				2022-12-18	WOS:A1981ML52500004
J	TING, S; ZWEIMAN, B; LAVKER, R; DUNSKY, EH				TING, S; ZWEIMAN, B; LAVKER, R; DUNSKY, EH			HISTAMINE SUPPRESSION OF INVIVO EOSINOPHIL ACCUMULATION AND HISTAMINE-RELEASE IN HUMAN ALLERGIC REACTIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV PENN, SCH MED, DEPT MED, ALLERGY & IMMUNOL SECT, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DEPT DERMATOL, PHILADELPHIA, PA 19104 USA	University of Pennsylvania; University of Pennsylvania					NIAID NIH HHS [R01 AI 14332, AI 07031] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI014332] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOURNE HR, 1971, SCIENCE, V173, P743, DOI 10.1126/science.173.3998.743; BOURNE HR, 1972, J IMMUNOL, V108, P695; BRYANT DH, 1977, CLIN ALLERGY, V7, P211, DOI 10.1111/j.1365-2222.1977.tb01445.x; CHAKRIN LW, 1974, AGENTS ACTIONS, V4, P297, DOI 10.1007/BF01964930; CLARK RAF, 1975, J EXP MED, V142, P1462, DOI 10.1084/jem.142.6.1462; DUNSKY EH, 1978, J ALLERGY CLIN IMMUN, V62, P127, DOI 10.1016/0091-6749(78)90091-X; HORAKOVA Z, 1978, J ALLERGY CLIN IMMUN, V61, P350; KALINER M, 1978, AM REV RESPIR DIS, V118, P1015; KARNOVSKY MJ, 1965, J CELL BIOL, V27, pA137; KIISTALA U, 1964, LANCET, V1, P1444; LEVY DA, 1973, J LAB CLIN MED, V81, P291; LICHTENSTEIN LM, 1973, NATURE, V244, P287, DOI 10.1038/244287a0; LUFT JH, 1961, J BIOPHYS BIOCHEM CY, V9, P409, DOI 10.1083/jcb.9.2.409; MARTIN C, 1978, J PHARMACOL EXP THER, V204, P183; NARASBHAT K, 1976, J ALLERGY CLIN IMMUN, V58, P647, DOI 10.1016/0091-6749(76)90176-7; PALADE GE, 1952, J EXP MED, V95, P285, DOI 10.1084/jem.95.3.285; TING S, 1980, J ALLERGY CLIN IMMUN, V66, P417, DOI 10.1016/0091-6749(80)90122-0; TING S, 1980, CLIN RES, V28, pA362; TURNBULL LW, 1976, IMMUNOLOGY, V31, P797; VENABLE JH, 1965, J CELL BIOL, V25, P407, DOI 10.1083/jcb.25.2.407; VONWILLEBRAND E, 1978, CLIN IMMUNOL IMMUNOP, V11, P445, DOI 10.1016/0090-1229(78)90172-1; YAMAMOTO S, 1973, IMMUNOLOGY, V24, P77; YAMAMOTO S, 1976, J INVEST DERMATOL, V67, P696, DOI 10.1111/1523-1747.ep12598572	23	23	23	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	68	1					65	71		10.1016/0091-6749(81)90125-1	http://dx.doi.org/10.1016/0091-6749(81)90125-1			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LY101	6165750				2022-12-18	WOS:A1981LY10100011
J	SNAPPER, JR; BRAASCH, PS; INGRAM, RH; LORING, SH; DRAZEN, JM				SNAPPER, JR; BRAASCH, PS; INGRAM, RH; LORING, SH; DRAZEN, JM			INVIVO EFFECT OF CIMETIDINE ON CANINE PULMONARY RESPONSIVENESS TO AEROSOL HISTAMINE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									PETER BENT BRIGHAM HOSP, DEPT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT PHYSIOL, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health								BEAVEN MA, 1976, NEW ENGL J MED, V294, P320, DOI 10.1056/NEJM197602052940608; BEAVEN MA, 1976, NEW ENGL J MED, V294, P30, DOI 10.1056/NEJM197601012940108; BLACK JW, 1972, NATURE, V236, P385, DOI 10.1038/236385a0; DOUGLAS JS, 1973, J PHARMACOL EXP THER, V184, P169; DRAZEN JM, 1976, J APPL PHYSIOL, V41, P388, DOI 10.1152/jappl.1976.41.3.388; DRAZEN JM, 1979, CLIN RES, V27, pA396; DURANT GJ, 1977, CIMETIDINE, P1; EYRE P, 1977, ASTHMA PHYSL IMMUNOP, P169; IRVIN CG, 1978, RESP PHYSIOL, V35, P161, DOI 10.1016/0034-5687(78)90019-1; MAENGWYNDAVIES GD, 1968, J PHARM PHARMACOL, V20, P572, DOI 10.1111/j.2042-7158.1968.tb09810.x; NADEL JA, 1967, INHALED PARTICLES VA, V2, P55; OKPAKO DT, 1972, BRIT J PHARMACOL, V45, P311, DOI 10.1111/j.1476-5381.1972.tb08085.x; PARSONS ME, 1977, CIMETIDINE, P13; SNAPPER JR, 1978, J APPL PHYSIOL, V44, P738, DOI 10.1152/jappl.1978.44.5.738; SNAPPER JR, 1979, J APPL PHYSIOL, V47, P13, DOI 10.1152/jappl.1979.47.1.13; TAYLOR DC, 1977, DRUG METAB DISPOS, V6, P21; VONNEERGAARD K, 1927, Z KLIN MED, V105, P51; YAMATAKE Y, 1977, JPN J PHARMACOL, V27, P791, DOI 10.1254/jjp.27.791	18	23	23	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	66	1					70	74		10.1016/0091-6749(80)90140-2	http://dx.doi.org/10.1016/0091-6749(80)90140-2			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JZ541	6103907				2022-12-18	WOS:A1980JZ54100010
J	BUTCHER, BT				BUTCHER, BT			INHALATION CHALLENGE TESTING WITH TOLUENE DIISOCYANATE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											BUTCHER, BT (corresponding author), TULANE UNIV,MED CTR,DEPT MED,CLIN IMMUNOL SECT,NEW ORLEANS,LA 70112, USA.							BUTCHER BT, 1977, AM REV RESPIR DIS, V116, P411, DOI 10.1164/arrd.1977.116.3.411; BUTCHER BT, 1979, J ALLERGY CLIN IMMUN, V64, P146, DOI 10.1016/0091-6749(79)90049-6; BUTCHER BT, 1976, J ALLERGY CLIN IMMUN, V58, P89, DOI 10.1016/0091-6749(76)90110-X; DAVIES RJ, 1977, J ALLERGY CLIN IMMUN, V60, P223, DOI 10.1016/0091-6749(77)90134-8	4	23	23	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	64	6					655	657		10.1016/0091-6749(79)90031-9	http://dx.doi.org/10.1016/0091-6749(79)90031-9			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HX843	229144				2022-12-18	WOS:A1979HX84300019
J	GOREVIC, P; KAPLAN, AP				GOREVIC, P; KAPLAN, AP			CONTRAST AGENTS AND ANAPHYLACTIC-LIKE REACTIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											KAPLAN, AP (corresponding author), SUNY STONY BROOK,DEPT MED,DIV ALLERGY RHEUMATOL & CLIN IMMUNOL,STONY BROOK,NY 11794, USA.							ARROYAVE CM, 1976, J IMMUNOL, V117, P1866; Friedberger E, 1910, Z IMMUNITATSFORSCH, V4, P636; Hugli T E, 1978, Adv Immunol, V26, P1, DOI 10.1016/S0065-2776(08)60228-X; ISHIZAKA K, 1974, JOHNS HOPKINS MED J, V135, P67; LASSER EC, 1974, RADIOLOGY, V110, P49, DOI 10.1148/110.1.49; LEPOW IH, 1970, AM J PATHOL, V61, P13; LIEBERMAN P, 1978, J ALLERGY CLIN IMMUN, V62, P174, DOI 10.1016/0091-6749(78)90103-3; MANN MR, 1961, P ROY SOC MED, V54, P473; MILLER WL, 1975, J ALLERGY CLIN IMMUN, V56, P291, DOI 10.1016/0091-6749(75)90103-7; ROCKOFF SD, 1972, INVEST RADIOL, V7, P177; SZCZEKLIK A, 1976, J ALLERGY CLIN IMMUN, V58, P10, DOI 10.1016/0091-6749(76)90102-0; YECIES LW, CLIN IMMUNOLOGY; 1970, INVEST RADIOL, V5, P373	13	23	23	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	63	4					225	227		10.1016/0091-6749(79)90105-2	http://dx.doi.org/10.1016/0091-6749(79)90105-2			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GR842	429701				2022-12-18	WOS:A1979GR84200001
J	PATTERSON, R; SUSZKO, IM; BACAL, E; ZEISS, CR; KELLY, JF; PRUZANSKY, JJ				PATTERSON, R; SUSZKO, IM; BACAL, E; ZEISS, CR; KELLY, JF; PRUZANSKY, JJ			REDUCED ALLERGENICITY OF HIGH MOLECULAR-WEIGHT RAGWEED POLYMERS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											PATTERSON, R (corresponding author), NORTHWESTERN UNIV,SCH MED,DEPT MED,ALLERGY IMMUNOL SECT,CHICAGO,IL 60611, USA.							KING TP, 1964, BIOCHEMISTRY-US, V3, P458, DOI 10.1021/bi00891a026; LEVINE BB, 1965, J IMMUNOL, V94, P121; LIDD D, 1962, J ALLERGY, V33, P45, DOI 10.1016/0021-8707(62)90062-X; METZGER WJ, 1976, NEW ENGL J MED, V295, P1160, DOI 10.1056/NEJM197611182952103; PATTERSON R, 1974, J IMMUNOL, V112, P1855; PATTERSON R, 1978, J ALLERGY CLIN IMMUN, V61, P28, DOI 10.1016/0091-6749(78)90470-0; PATTERSON R, 1977, J ALLERGY CLIN IMMUN, V59, P314, DOI 10.1016/0091-6749(77)90053-7; PATTERSON R, 1973, J IMMUNOL, V110, P1413; PATTERSON R, 1976, 9 EXC MED INT C ALL, P492	9	23	24	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	63	1					47	50		10.1016/0091-6749(79)90161-1	http://dx.doi.org/10.1016/0091-6749(79)90161-1			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GE110	102675	Bronze			2022-12-18	WOS:A1979GE11000007
J	YUNGINGER, JW				YUNGINGER, JW			STING - REVISITED	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											YUNGINGER, JW (corresponding author), MAYO CLIN & MAYO FDN,ALLERG DIS RES LAB,ROCHESTER,MN 55901, USA.							GOLDEN D, 1979, J ALLERGY CLIN IMMUN, V63, P180; LICHTENSTEIN LM, 1979, J ALLERGY CLIN IMMUN, V63, P5; YUNGINGER JW, 1979, J ALLERGY CLIN IMMUN, V63, P340, DOI 10.1016/0091-6749(79)90129-5; YUNGINGER JW, 1978, J ALLERGY CLIN IMMUN, V61, P93, DOI 10.1016/0091-6749(78)90231-2	4	23	23	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	64	1					1	2		10.1016/0091-6749(79)90073-3	http://dx.doi.org/10.1016/0091-6749(79)90073-3			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HC424	447946				2022-12-18	WOS:A1979HC42400001
J	MORRIS, HG; RUSNAK, SA; SELNER, JC; BARZENS, K; BARNES, J				MORRIS, HG; RUSNAK, SA; SELNER, JC; BARZENS, K; BARNES, J			COMPARATIVE EFFECTS OF EPHEDRINE ON ADRENERGIC RESPONSIVENESS IN NORMAL AND ASTHMATIC SUBJECTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											MORRIS, HG (corresponding author), NATL JEWISH HOSP & RES CTR,DENVER,CO 80206, USA.							ALSTON WC, 1974, BRIT MED J, V1, P90, DOI 10.1136/bmj.1.5898.90; BROSTROM CO, 1974, ANAL BIOCHEM, V58, P459, DOI 10.1016/0003-2697(74)90214-0; CONOLLY ME, 1976, J CLIN INVEST, V58, P1307, DOI 10.1172/JCI108586; COOKSON DU, 1963, AM REV RESPIR DIS, V88, P636; DEGUCHI T, 1973, P NATL ACAD SCI USA, V70, P2411, DOI 10.1073/pnas.70.8.2411; DROSTE PL, 1974, P SOC EXP BIOL MED, V146, P352; ELLULMIC.R, 1974, CLIN SCI MOL MED, V47, P105, DOI 10.1042/cs0470105; ELLULMICALLEF R, 1975, LANCET, V2, P1269; FIREMAN P, 1970, J ALLERGY, V45, P117; FISHER RA, 1954, STATISTICAL METHODS; FLEISCH JH, 1972, J PHARMACOL EXP THER, V181, P425; FRANKLIN TJ, 1973, NATURE-NEW BIOL, V246, P146, DOI 10.1038/newbio246146a0; FRANKLIN TJ, 1975, MOL PHARMACOL, V11, P485; GILMAN AG, 1970, P NATL ACAD SCI USA, V67, P305, DOI 10.1073/pnas.67.1.305; JENNE JW, 1977, J ALLERGY CLIN IMMUN, V59, P383, DOI 10.1016/0091-6749(77)90023-9; Kanner R.E., 1975, CLIN PULMONARY FUNCT; KARETZKY MS, 1974, AM J MED SCI, V267, P213, DOI 10.1097/00000441-197404000-00002; KUMAR L, 1971, J PEDIATR-US, V79, P955, DOI 10.1016/S0022-3476(71)80190-7; LARSSON S, 1977, J ALLERGY CLIN IMMUN, V59, P93, DOI 10.1016/0091-6749(77)90209-3; LOCKEY SD, 1967, J ALLERGY, V40, P349, DOI 10.1016/0021-8707(67)90024-X; LOGSDON PJ, 1972, J ALLERGY CLIN IMMUN, V50, P45, DOI 10.1016/0091-6749(72)90078-4; MATHE AA, 1969, NEW ENGL J MED, V281, P234, DOI 10.1056/NEJM196907312810503; MCFADDEN ER, 1973, NEW ENGL J MED, V288, P221, DOI 10.1056/NEJM197302012880501; MCFADDEN ER, 1975, NEW DIRECTIONS ASTHM, P339; MICKEY J, 1975, J BIOL CHEM, V250, P5727; MORRIS HG, 1977, CLIN PHARMACOL THER, V22, P352; MORRIS HG, 1977, J CYCLIC NUCL PROT, V3, P439; MORRIS HG, 1974, J ALLERGY CLIN IMMUN, V54, P350, DOI 10.1016/0091-6749(74)90025-6; MORRIS HG, 1974, J PEDIATR-US, V85, P248, DOI 10.1016/S0022-3476(74)80406-3; MORRIS HG, 1974, J ALLERGY CLIN IMMUN, V53, P98; MORRIS HG, 1971, J PEDIATR-US, V79, P480, DOI 10.1016/S0022-3476(71)80163-4; MORRIS HG, CHEST; MORRIS HP, UNPUBLISHED; MUKHERJEE C, 1975, P NATL ACAD SCI USA, V72, P1945, DOI 10.1073/pnas.72.5.1945; MURPHY BEP, 1967, J CLIN ENDOCR METAB, V27, P973, DOI 10.1210/jcem-27-7-973; NELSON HS, 1975, J ALLERGY CLIN IMMUN, V55, P299, DOI 10.1016/0091-6749(75)90002-0; PARKER CW, 1973, J CLIN INVEST, V52, P48, DOI 10.1172/JCI107173; SZENTIVANYI A, 1968, J ALLERGY, V42, P203, DOI 10.1016/S0021-8707(68)90117-2; WILLIAMS LT, 1976, J CLIN INVEST, V57, P149, DOI 10.1172/JCI108254; WILSON AF, 1976, J ALLERGY CLIN IMMUN, V58, P204, DOI 10.1016/0091-6749(76)90156-1; WOOLCOCK AJ, 1965, LANCET, V2, P1323; BECKMAN GLUCOSE OPER	42	23	23	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	61	5					294	302		10.1016/0091-6749(78)90050-7	http://dx.doi.org/10.1016/0091-6749(78)90050-7			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EY714	205566				2022-12-18	WOS:A1978EY71400004
J	RUBIN, JL; GRIFFITHS, RW; HILL, HR				RUBIN, JL; GRIFFITHS, RW; HILL, HR			ALLERGEN-INDUCED DEPRESSION OF NEUTROPHIL CHEMOTAXIS IN ALLERGIC INDIVIDUALS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV UTAH,MED CTR,DIV CLIN IMMUNOL,SALT LAKE CITY,UT 84132; UNIV UTAH,DEPT PEDIAT,DIV CLIN IMMUNOL,SALT LAKE CITY,UT 84132; UNIV UTAH,DEPT MED,DIV CLIN IMMUNOL,SALT LAKE CITY,UT 84132; UNIV UTAH,DEPT PATHOL,SALT LAKE CITY,UT 84132	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah								ATKINS PC, 1977, ANN INTERN MED, V86, P415, DOI 10.7326/0003-4819-86-4-415; BURROWS B, 1976, ANN INTERN MED, V84, P134, DOI 10.7326/0003-4819-84-2-134; CLARK AF, 1978, LEUKOCYTE CHEMOTAXIS, P195; CLARK RA, 1973, ANN INTERN MED, V78, P515, DOI 10.7326/0003-4819-78-4-515; EVANS R, 1976, J CLIN INVEST, V57, P1378, DOI 10.1172/JCI108406; HILL HR, 1974, J PEDIATR-US, V84, P55, DOI 10.1016/S0022-3476(74)80553-6; HILL HR, 1974, LANCET, V2, P617; HILL HR, 1974, LANCET, V1, P183; HILL HR, 1977, AM J DIS CHILD, V131, P433, DOI 10.1001/archpedi.1977.02120170059011; HILL HR, 1975, METABOLISM, V24, P447, DOI 10.1016/0026-0495(75)90124-9; HILL HR, 1974, J CLIN INVEST, V53, P996, DOI 10.1172/JCI107666; HILL HR, 1975, J LAB CLIN MED, V86, P703; HILL HR, 1976, J LAB CLIN MED, V88, P796; HILL HR, 1976, ANN INTERN MED, V85, P39, DOI 10.7326/0003-4819-85-1-39; HILL HR, 1974, J INFECT DIS, V129, P322, DOI 10.1093/infdis/129.3.322; HILL HR, 1974, PHAGOCYTIC CELL HOST, P249; JACOBS JC, 1977, PEDIATR RES, V11, P732, DOI 10.1203/00006450-197706000-00007; JENSEN JA, 1975, NATURE, V256, P213, DOI 10.1038/256213a0; MILES AA, 1957, BRIT J EXP PATHOL, V38, P79; MILES AA, 1964, INJURY INFLAMMATION, P162; ORGEL HA, 1975, J ALLERGY CLIN IMMUN, V56, P296, DOI 10.1016/0091-6749(75)90104-9; PINCUS SH, 1975, J PEDIATR-US, V87, P908, DOI 10.1016/S0022-3476(75)80903-6; RIVKIN I, 1972, Federation Proceedings, V31, P657; VANSCOY RE, 1975, ANN INTERN MED, V82, P766, DOI 10.7326/0003-4819-82-6-766	24	23	23	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	62	5					301	308		10.1016/0091-6749(78)90162-8	http://dx.doi.org/10.1016/0091-6749(78)90162-8			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FW432	701666				2022-12-18	WOS:A1978FW43200008
J	CROWLE, AJ; ATKINS, A; MAY, M				CROWLE, AJ; ATKINS, A; MAY, M			INDUCTION OF DELAYED-HYPERSENSITIVITY TO PROTEIN ANTIGENS IN MICE WITHOUT FREUND ADJUVANTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV COLORADO,SCH MED,DEPT MICROBIOL & IMMUNOL,DENVER,CO 80220; UNIV COLORADO,WEBB WARING LUNG INST,DENVER,CO 80220	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Denver								ALLISON AC, 1973, IMMUNOPOTENTIATION, P73; ASHERSON GL, 1968, IMMUNOLOGY, V15, P405; BECK F, 1967, SCIENCE, V157, P1180, DOI 10.1126/science.157.3793.1180; BECK F., 1966, ADVANCE TERATOLOGY, V1, P131; BOROS DL, 1971, NATURE, V229, P200, DOI 10.1038/229200a0; CASTRO JE, 1973, IMMUNOPOTENTIATION, P237; CHANMOUGAN D, 1966, J EXP MED, V124, P364; CLARK C, 1976, CELL IMMUNOL, V26, P228, DOI 10.1016/0008-8749(76)90367-1; Crowle A J, 1975, Adv Immunol, V20, P197, DOI 10.1016/S0065-2776(08)60209-6; CROWLE AJ, 1968, J ALLERGY, V42, P140, DOI 10.1016/0021-8707(68)90087-7; CROWLE AJ, 1967, INT ARCH ALLER A IMM, V31, P123, DOI 10.1159/000229861; CROWLE AJ, 1976, CELL IMMUNOL, V22, P234, DOI 10.1016/0008-8749(76)90026-5; CROWLE AJ, 1962, DELAYED HYPERSENSITI; Dienes L, 1929, J IMMUNOL, V17, P531; DIETRICH FM, 1970, INT ARCH ALLER A IMM, V38, P246, DOI 10.1159/000230278; DVORAK HF, 1974, LAB INVEST, V31, P111; GOTTLIEB AA, 1972, CRC CRIT R MICROBIOL, V1, P321; HILGERT I, 1974, J IMMUNOGENET, V1, P153; HOYER JR, 1962, J EXP MED, V116, P679, DOI 10.1084/jem.116.5.679; JACOBS BB, 1975, P SOC EXP BIOL MED, V149, P146; KATZ SP, 1976, INFECT IMMUN, V14, P509, DOI 10.1128/IAI.14.2.509-521.1976; KERCKHAERT JA, 1974, ANN INST PASTEUR IMM, VC125, P415; KERCKHAERT JA, 1974, J IMMUNOL, V113, P1801; KONG YCM, 1966, J BACTERIOL, V91, P876, DOI 10.1128/JB.91.2.876-883.1966; KREJCI J, 1973, IMMUNOLOGY, V25, P875; LEE J W, 1970, International Archives of Allergy and Applied Immunology, V39, P609; LEVINE S, 1970, J IMMUNOL, V105, P1530; MIZUSHIMA Y, 1974, INT ARCH ALLER A IMM, V46, P731, DOI 10.1159/000231173; MUNOZ J, 1974, Z IMMUNITATSFORSCH, V146, P443; NELSON DS, 1964, INT ARCH ALLER A IMM, V25, P279, DOI 10.1159/000229529; OHMICHI Y, 1976, IMMUNOLOGY, V31, P101; SALVAGGIO J, 1970, P SOC EXP BIOL MED, V134, P1116; SALVAGGIO JE, 1965, J IMMUNOL, V95, P846; SCHEN RJ, 1967, CLIN CHIM ACTA, V16, P445, DOI 10.1016/0009-8981(67)90314-2; SCHWARTZ A, 1977, J IMMUNOL, V118, P159; SEEGER RC, 1972, J IMMUNOL, V109, P244; TURK JL, 1976, BRIT MED BULL, V32, P165, DOI 10.1093/oxfordjournals.bmb.a071350; TURK JL, 1964, NATURE, V202, P713, DOI 10.1038/202713a0; VALDUTIU AO, 1971, SCIENCE, V174, P1137; VONLICHTENBERG F, 1971, NATURE, V229, P199, DOI 10.1038/229199a0; WALLRAFF EB, 1964, J IMMUNOL, V93, P625; ZEMBALA M, 1974, IMMUNOLOGY, V26, P465; 1976, WHO595 TECH REP SER	43	23	23	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	60	1					14	26		10.1016/0091-6749(77)90078-1	http://dx.doi.org/10.1016/0091-6749(77)90078-1			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DN224	874206				2022-12-18	WOS:A1977DN22400003
J	JENNE, JW; CHICK, TW; STRICKLAND, RD; WALL, FJ				JENNE, JW; CHICK, TW; STRICKLAND, RD; WALL, FJ			COMPARISON OF BETA-ADRENERGIC FUNCTION IN ASTHMA AND CHRONIC-BRONCHITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV NEW MEXICO,SCH MED,ALBUQUERQUE,NM 87131; VET ADM HOSP,ALBUQUERQUE,NM 87108	University of New Mexico								ALSTON WC, 1974, BRIT MED J, V1, P90, DOI 10.1136/bmj.1.5898.90; BALL JH, 1972, J CLIN INVEST, V51, P2124, DOI 10.1172/JCI107019; Bollinger A., 1936, MED J AUST, V2, P818; BRUCE CA, 1975, J ALLERGY CLIN IMMUN, V56, P331, DOI 10.1016/0091-6749(75)90126-8; BUSSE W, 1976, J ALLERGY CLIN IMMUN, V57, P234; CONNOLLY ME, 1976, J CLIN INVEST, V58, P1307; COOKSON DU, 1963, AM REV RESPIR DIS, V88, P636; DOUGLAS JS, 1976, LUNG CELLS DISEASE, P245; FIREMAN P, 1973, INT ARCH ALLER A IMM, V45, P123, DOI 10.1159/000231014; FISH JE, 1976, AM REV RESPIR DIS, V113, P579; GILLESPIE E, 1974, J ALLERGY CLIN IMMUN, V53, P27, DOI 10.1016/0091-6749(74)90096-7; INOUE S, 1967, J ALLERGY, V40, P337, DOI 10.1016/0021-8707(67)90023-8; JENNE JW, 1977, J ALLERGY CLIN IMMUN, V59, P383, DOI 10.1016/0091-6749(77)90023-9; JONES RS, 1972, THORAX, V27, P572, DOI 10.1136/thx.27.5.572; Kendall M. G., 1962, RANK CORRELATION MET; LOCKEY SD, 1967, J ALLERGY, V40, P349, DOI 10.1016/0021-8707(67)90024-X; LOGSDON PJ, 1972, J ALLERGY CLIN IMMUN, V50, P45, DOI 10.1016/0091-6749(72)90078-4; MAKINO S, 1970, J ALLERGY, V46, P178, DOI 10.1016/0021-8707(70)90096-1; MCCULLOCH MW, 1967, EUR J PHARMACOL, V2, P214, DOI 10.1016/0014-2999(67)90090-8; MIDDLETON E, 1968, J ALLERGY, V42, P288, DOI 10.1016/0021-8707(68)90022-1; MORRIS HG, 1977, CLIN PHARMACOL THER, V22, P352; MORRIS HG, 1977, MAR AM C ALL IMM NEW; NELSON HS, 1975, J ALLERGY CLIN IMMUN, V55, P299, DOI 10.1016/0091-6749(75)90002-0; NELSON HS, IN PRESS; ORANGE RP, 1971, FED PROC, V30, P1725; Oser B.L., 1965, HAWKS PHYSIOLOGICAL; PARKER CW, 1973, J CLIN INVEST, V52, P48, DOI 10.1172/JCI107173; PARKER CW, 1973, J CLIN INVEST, V52, P1336, DOI 10.1172/JCI107305; PATERSON JW, 1968, LANCET, V2, P426; PATTERSON R, 1976, J CLIN INVEST, V57, P586, DOI 10.1172/JCI108314; PIERSON RN, 1969, AM REV RESPIR DIS, V100, P533; RANDOLPH TG, 1944, AM J CLIN PATHOL, V8, P48; RYO UY, 1976, J ALLERGY CLIN IMMUN, V57, P12, DOI 10.1016/0091-6749(76)90074-9; SCHACK JA, 1949, J PHARMACOL EXP THER, V97, P283; SCHWARTZ HJ, 1973, J ALLERGY CLIN IMMUN, V51, P88, DOI 10.1016/S0091-6749(73)80024-7; SPAULDING HS, 1975, J ALLERGY CLIN IMMUN, V55, P97; STEINER AL, 1969, P NATL ACAD SCI USA, V64, P367, DOI 10.1073/pnas.64.1.367; SVEDMYR NLV, 1976, CHEST, V69, P479, DOI 10.1378/chest.69.4.479; SZENTIVANYI A, 1968, J ALLERGY, V42, P203, DOI 10.1016/S0021-8707(68)90117-2; TOWNLEY RG, 1976, J ALLERGY CLIN IMMUN, V57, P358, DOI 10.1016/0091-6749(76)90093-2; TOWNLEY RG, 1975, J ALLERGY CLIN IMMUN, V56, P429; TROUT DL, 1960, J LIPID RES, V1, P199	42	23	23	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	60	6					346	356		10.1016/0091-6749(77)90065-3	http://dx.doi.org/10.1016/0091-6749(77)90065-3			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ED834	200639				2022-12-18	WOS:A1977ED83400003
J	SMITH, LJ; SLAVIN, RG				SMITH, LJ; SLAVIN, RG			DRUGS CONTAINING TARTRAZINE DYE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ST LOUIS UNIV,SCH MED,DEPT INTERN MED,ALLERGY & IMMUNOL SECT,ST LOUIS,MO 63104	Saint Louis University								CHAFEE FH, 1974, J ALLERGY CLIN IMMUN, V53, P193, DOI 10.1016/0091-6749(74)90080-3; DOEGLAS HMG, 1975, BRIT J DERMATOL, V93, P135, DOI 10.1111/j.1365-2133.1975.tb06732.x; FALLIERS CJ, 1973, J ALLERGY CLIN IMMUN, V52, P141, DOI 10.1016/0091-6749(73)90030-4; JUHLIN L, 1972, J ALLERGY CLIN IMMUN, V50, P92, DOI 10.1016/0091-6749(72)90004-8; LOCKEY STEPHEN D., 1959, ANN ALLERGY, V17, P719; MCDONALD JR, 1972, J ALLERGY CLIN IMMUN, V50, P198, DOI 10.1016/0091-6749(72)90014-0; RACHELEFSKY GS, 1975, PEDIATRICS, V56, P343; SAMTER M, 1968, ANN INTERN MED, V68, P975, DOI 10.7326/0003-4819-68-5-975; SAMTER M, 1967, J ALLERGY, V40, P281, DOI 10.1016/0021-8707(67)90076-7; SAMTER M, 1973, HOSP PRACT, V8, P85; SETTIPANE GA, 1975, J ALLERGY CLIN IMMUN, V56, P215, DOI 10.1016/0091-6749(75)90092-5; VANESLOW NA, 1967, ANN INTERN MED, V66, P568	12	23	23	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	58	4					456	470		10.1016/0091-6749(76)90189-5	http://dx.doi.org/10.1016/0091-6749(76)90189-5			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CH210	972214				2022-12-18	WOS:A1976CH21000002
J	KRAM, JA; BOURNE, HR; MAIBACH, HI; MELMON, KL				KRAM, JA; BOURNE, HR; MAIBACH, HI; MELMON, KL			CUTANEOUS IMMEDIATE HYPERSENSITIVITY IN MAN - EFFECTS OF SYSTEMICALLY ADMINISTERED ADRENERGIC DRUGS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CALIF,DEPT MED,SAN FRANCISCO,CA; UNIV CALIF,DEPT DERMATOL,SAN FRANCISCO,CA; UNIV CALIF,CARDIOVASC RES INST,SAN FRANCISCO,CA; UNIV CALIF,MED CTR,DIV CLIN PHARMACOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco								BOURNE HR, 1972, J IMMUNOL, V108, P695; GALANT SP, 1973, J ALLERGY CLIN IMMUN, V51, P245, DOI 10.1016/0091-6749(73)90144-9; KALINER M, 1972, J EXP MED, V136, P556, DOI 10.1084/jem.136.3.556; LICHTENS.LM, 1968, SCIENCE, V161, P902, DOI 10.1126/science.161.3844.902; MUELLER PS, 1962, J LIPID RES, V3, P251; NOETHER G, 1971, INTRO STATISTICS FIR, P113; ORANGE RP, 1971, J EXP MED          S, V134, P1367; ORANGE RP, 1971, FED P, V30, P1723; PERPER RJ, 1972, INT ARCH ALLER A IMM, V43, P837, DOI 10.1159/000230901; ROBISON GA, 1971, CYCLIC AMP, P224; SHELDON J M, 1951, Ann Allergy, V9, P45; SHEREFF RH, 1973, J ALLERGY CLIN IMMUN, V52, P328, DOI 10.1016/0091-6749(73)90091-2; TAYLOR WA, 1974, INT ARCH ALLER A IMM, V46, P104, DOI 10.1159/000231116; YAMAMOTO S, 1973, IMMUNOLOGY, V24, P77	14	23	23	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1975	56	5					387	392		10.1016/0091-6749(75)90132-3	http://dx.doi.org/10.1016/0091-6749(75)90132-3			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AW330	241760	Bronze			2022-12-18	WOS:A1975AW33000008
J	PATTERSON, R; TALBOT, C				PATTERSON, R; TALBOT, C			COMPARISON OF IMMEDIATE-TYPE RESPIRATORY REACTIONS TO IMMUNOLOGICAL AND PHARMACOLOGIC AGENTS IN RHESUS-MONKEYS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		COLEBATCH HJ, 1966, J APPL PHYSIOL, V21, P379, DOI 10.1152/jappl.1966.21.2.379; COLLIER HOJ, 1966, J PHYSIOL-LONDON, V185, pP71; COLLIER HOJ, 1963, ANN NY ACAD SCI, V104, P290, DOI 10.1111/j.1749-6632.1963.tb17674.x; HERXHEIMER H, 1961, J PHYSIOL-LONDON, V158, pP38; JOHNSON AR, 1969, FED PROC, V28, P1716; MIYAMOTO T, 1968, AM REV RESPIR DIS, V97, P76; PATTERSON R, 1969, J LAB CLIN MED, V73, P924; PATTERSON R, 1971, J IMMUNOL, V106, P1274; PATTERSON R, 1970, AM REV RESPIR DIS, V102, P412; PATTERSON R, 1971, J ALLERGY CLIN IMMUN, V40, P361; Patterson Richard W., IN PRESS; SLAVIN RG, 1968, P SOC EXP BIOL MED, V128, P146	12	23	23	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1972	49	5					292	+		10.1016/0091-6749(72)90097-8	http://dx.doi.org/10.1016/0091-6749(72)90097-8			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	M4215	4623126				2022-12-18	WOS:A1972M421500005
J	Roy, S; Ayudhya, CCN; Thapaliya, M; Deepak, V; Ali, H				Roy, Saptarshi; Ayudhya, Chalatip Chompunud Na; Thapaliya, Monica; Deepak, Vishwa; Ali, Hydar			Multifaceted MRGPRX2: New insight into the role of mast cells in health and disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						G protein-coupled receptor; host defense peptides; MRGPRX2; MrgprB2; mast cells; neurogenic inflammation; single nucleotide polymorphisms	PROTEIN-COUPLED RECEPTOR; ATOPIC-DERMATITIS; PSEUDOMONAS-AERUGINOSA; ANTIMICROBIAL PEPTIDES; SURFACE EXPRESSION; SKIN INFLAMMATION; RESTING BASOPHILS; HOST-DEFENSE; SUBSTANCE-P; GENE X2	Cutaneous mast cells (MCs) express Mas-related G protein- coupled receptor-X2 (MRGPRX2; mouse ortholog MrgprB2), which is activated by an ever-increasing number of cationic ligands. Antimicrobial host defense peptides (HDPs) generated by keratinocytes contribute to host defense likely by 2 mechanisms, one involving direct killing of microbes and the other via MC activation through MRGPRX2. However, its inappropriate activation may cause pseudoallergy and likely contribute to the pathogenesis of rosacea, atopic dermatitis, allergic contact dermatitis, urticaria, and mastocytosis. Gain and loss-of-function missense single nucleotide polymorphisms in MRGPRX2 have been identified. The ability of certain ligands to serve as balanced or G protein-biased agonists has been defined. Small-molecule HDP mimetics that display both direct antimicrobial activity and activate MCs via MRGPRX2 have been developed. In addition, antibodies and reagents that modulate MRGPRX2 expression and signaling have been generated. In this article, we provide a comprehensive update on MrgprB2 and MRGPRX2 biology. We propose that harnessing MRGPRX2's host defense function by small molecule HDP mimetics may provide a novel approach for the treatment of antibiotic-resistant cutaneous infections. In contrast, MRGPRX2-specific antibodies and inhibitors could be used for the modulation of allergic and inflammatory diseases that are mediated via this receptor. (J Allergy Clin Immunol 2021;148:293-308.)	[Roy, Saptarshi; Ayudhya, Chalatip Chompunud Na; Thapaliya, Monica; Deepak, Vishwa; Ali, Hydar] Univ Penn, Sch Dent Med, Dept Basic & Translat Sci, 240 South 40th St, Philadelphia, PA 19104 USA	University of Pennsylvania	Ali, H (corresponding author), Univ Penn, Sch Dent Med, Dept Basic & Translat Sci, 240 South 40th St, Philadelphia, PA 19104 USA.	alih@upenn.edu	Roy, Saptarshi/ABB-3263-2021	Roy, Saptarshi/0000-0002-4649-0741; Chompunud Na Ayudhya, Chalatip/0000-0003-0170-1047	National Institutes of Health [R01AI124182, R01AI143185, R01-AI149487]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by the National Institutes of Health (grant nos. R01AI124182, R01AI143185, and R01-AI149487 to H.A.) .	Ahn CS, 2018, DERMATOL CLIN, V36, P81, DOI 10.1016/j.det.2017.11.001; Alkanfari I, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8040311; Alkanfari I, 2018, J IMMUNOL, V201, P343, DOI 10.4049/jimmunol.1701793; An J, 2020, ALLERGY, V75, P959, DOI 10.1111/all.14084; Ardal C, 2020, NAT REV MICROBIOL, V18, P267, DOI 10.1038/s41579-019-0293-3; ARIDOR M, 1993, SCIENCE, V262, P1569, DOI 10.1126/science.7504324; Arifuzzaman M, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aav0216; Aroni K, 2008, ARCH DERMATOL RES, V300, P125, DOI 10.1007/s00403-007-0816-z; Aubdool AA, 2011, J INVEST DERM SYMP P, V15, P33, DOI 10.1038/jidsymp.2011.8; Aung G, 2011, IMMUNOLOGY, V132, P527, DOI 10.1111/j.1365-2567.2010.03395.x; Ayudhya CCN, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20215247; Azimi Ehsan, 2017, Itch (Phila), V2, DOI 10.1097/itx.0000000000000005; Babina M, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10010102; Babina M, 2021, J INVEST DERMATOL, V141, P1286, DOI 10.1016/j.jid.2020.09.017; Beckloff N, 2007, ANTIMICROB AGENTS CH, V51, P4125, DOI 10.1128/AAC.00208-07; Berroa F, 2014, CLIN EXP ALLERGY, V44, P270, DOI 10.1111/cea.12237; Bom A, 2002, ANGEW CHEM INT EDIT, V41, P266; BOST K L, 1992, Regional Immunology, V4, P105; Browne K, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21197047; Bunikowski R, 2000, J ALLERGY CLIN IMMUN, V105, P814, DOI 10.1067/mai.2000.105528; Cahill TJ, 2017, P NATL ACAD SCI USA, V114, P2562, DOI 10.1073/pnas.1701529114; Callahan BN, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00703; Cavalcante MCM, 2002, J STRUCT BIOL, V137, P313, DOI 10.1016/S1047-8477(02)00007-2; Cavalcante MCM, 2000, J BIOL CHEM, V275, P36189, DOI 10.1074/jbc.M005830200; Che DL, 2018, CELL IMMUNOL, V332, P121, DOI 10.1016/j.cellimm.2018.08.005; Che DL, 2018, INT IMMUNOPHARMACOL, V62, P244, DOI 10.1016/j.intimp.2018.07.020; Chen E, 2021, GASTROENTEROLOGY, V160, P1709, DOI 10.1053/j.gastro.2020.12.076; Chen Y, 2017, J INVEST DERMATOL, V137, P801, DOI 10.1016/j.jid.2016.12.013; Choi JE, 2019, J DERMATOL SCI, V93, P58, DOI 10.1016/j.jdermsci.2018.12.004; Choi JE, 2018, SEMIN IMMUNOPATHOL, V40, P249, DOI 10.1007/s00281-018-0675-z; Choi S, 2009, P NATL ACAD SCI USA, V106, P6968, DOI 10.1073/pnas.0811818106; Ayudhya CCN, 2020, J DENT RES, V99, P882, DOI 10.1177/0022034520919107; Ayudhya CCN, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10010156; Corbiere A, 2021, EXP DERMATOL, V30, P193, DOI 10.1111/exd.14222; Crivellato E, 2015, METHODS MOL BIOL, V1220, P11, DOI 10.1007/978-1-4939-1568-2_2; Dayan SH, 2017, J DRUGS DERMATOL, V16, P549; Dossel J, 2012, CELL MICROBIOL, V14, P1364, DOI 10.1111/j.1462-5822.2012.01801.x; Dondalska A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.559589; Dudeck A, 2011, IMMUNITY, V34, P973, DOI 10.1016/j.immuni.2011.03.028; Dwyer DF, 2016, NAT IMMUNOL, V17, P878, DOI 10.1038/ni.3445; Ebo DG, 2021, BRIT J ANAESTH, V126, pE27, DOI 10.1016/j.bja.2020.10.006; Ekkelenkamp MB, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.01541-19; Elst J, J INVESTIG ALLERGOL; Elst J, 2020, BRIT J ANAESTH, V125, pE448, DOI 10.1016/j.bja.2020.08.035; Fernandopulle NA, 2021, CLIN EXP ALLERGY, V51, P685, DOI 10.1111/cea.13801; Florvaag E, 2005, ACTA ANAESTH SCAND, V49, P437, DOI 10.1111/j.1399-6576.2004.00591.x; Forsythe P, 2019, TRENDS NEUROSCI, V42, P43, DOI 10.1016/j.tins.2018.09.006; Fujisawa D, 2014, J ALLERGY CLIN IMMUN, V134, P622, DOI 10.1016/j.jaci.2014.05.004; Galli SJ, 2020, ANNU REV IMMUNOL, V38, P49, DOI 10.1146/annurev-immunol-071719-094903; Gaudenzio N, 2016, J CLIN INVEST, V126, P3981, DOI 10.1172/JCI85538; Gaudenzio N, 2015, JOVE-J VIS EXP, DOI 10.3791/52753; Giavina-Bianchi P, 2020, J ALLER CL IMM-PRACT, V8, P426, DOI 10.1016/j.jaip.2019.09.035; Giavina-Bianchi P, 2019, J ALLER CL IMM-PRACT, V7, P2089, DOI 10.1016/j.jaip.2019.01.059; Green DP, 2019, NEURON, V101, P412, DOI 10.1016/j.neuron.2019.01.012; Grimes J, 2019, PHARMACOL RES PERSPE, V7, DOI 10.1002/prp2.547; Groneberg DA, 2005, ALLERGY, V60, P90, DOI 10.1111/j.1398-9995.2004.00628.x; Gupta K, 2017, INFECT IMMUN, V85, DOI 10.1128/IAI.00246-17; Gupta K, 2015, ONCOTARGET, V6, P28573, DOI 10.18632/oncotarget.5611; Gurevich VV, 2020, PHARMACOL THERAPEUT, V211, DOI 10.1016/j.pharmthera.2020.107540; Gurevich VV, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00125; Hamamura-Yasuno E, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-72819-5; Hao Y, 2020, INT IMMUNOPHARMACOL, V81, DOI 10.1016/j.intimp.2020.106258; Harder J, 2010, J INVEST DERMATOL, V130, P1355, DOI 10.1038/jid.2009.432; Hartmann K, 2016, J ALLERGY CLIN IMMUN, V137, P35, DOI 10.1016/j.jaci.2015.08.034; Hasbak P, 2006, BASIC CLIN PHARMACOL, V99, P162, DOI 10.1111/j.1742-7843.2006.pto_465.x; Hauser AS, 2018, CELL, V172, P41, DOI 10.1016/j.cell.2017.11.033; Hausmann O, 2012, CHEM IMMUNOL ALLERGY, V97, P32, DOI 10.1159/000335614; Helfrich YR, 2015, JAMA DERMATOL, V151, P825, DOI 10.1001/jamadermatol.2014.4728; Ishikawa T, 2009, J DERMATOL SCI, V56, P121, DOI 10.1016/j.jdermsci.2009.07.012; Jabbour JF, 2020, CURR OPIN INFECT DIS, V33, P146, DOI 10.1097/QCO.0000000000000635; Jarvikallio A, 2003, ARCH DERMATOL RES, V295, P2, DOI 10.1007/s00403-002-0378-z; Johansson SGO, 2010, ALLERGY, V65, P498, DOI 10.1111/j.1398-9995.2009.02193.x; Kanda N, 2010, BIOCHEM PHARMACOL, V79, P982, DOI 10.1016/j.bcp.2009.11.012; Katritch V, 2013, ANNU REV PHARMACOL, V53, P531, DOI 10.1146/annurev-pharmtox-032112-135923; Kelso JM, 2020, J ALLER CL IMM-PRACT, V8, P426, DOI 10.1016/j.jaip.2019.09.038; Kostner L, 2017, IMMUNOL ALLERGY CLIN, V37, P141, DOI 10.1016/j.iac.2016.08.014; Kuhn H, 2021, J ALLERGY CLIN IMMUN, V147, P456, DOI 10.1016/j.jaci.2020.08.027; Lansu K, 2017, NAT CHEM BIOL, V13, P529, DOI [10.1038/NCHEMBIO.2334, 10.1038/nchembio.2334]; Laxminarayan R, 2013, LANCET INFECT DIS, V13, P1057, DOI 10.1016/S1473-3099(13)70318-9; Lewis K, 2007, NAT REV MICROBIOL, V5, P48, DOI 10.1038/nrmicro1557; Leysen J, 2013, CYTOM PART B-CLIN CY, V84B, P65, DOI 10.1002/cyto.b.21074; Lister PD, 2009, CLIN MICROBIOL REV, V22, P582, DOI 10.1128/CMR.00040-09; Liu R, 2019, INT IMMUNOPHARMACOL, V70, P417, DOI 10.1016/j.intimp.2019.02.001; Lorentz A, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00143; Magana M, 2020, LANCET INFECT DIS, V20, pE216, DOI 10.1016/S1473-3099(20)30327-3; Manorak W, 2018, RESP RES, V19, DOI 10.1186/s12931-017-0698-3; MARSHALL JS, 1995, CLIN EXP ALLERGY, V25, P102, DOI 10.1111/j.1365-2222.1995.tb01013.x; Mascarenhas NL, 2017, J INVEST DERMATOL, V137, P972, DOI 10.1016/j.jid.2016.10.046; McLachlan JB, 2008, NAT MED, V14, P536, DOI 10.1038/nm1757; McNeil BD, 2021, NEUROSCI LETT, V751, DOI 10.1016/j.neulet.2021.135746; McNeil BD, 2015, NATURE, V519, P237, DOI 10.1038/nature14022; Meixiong J, 2020, TRENDS NEUROSCI, V43, P130, DOI 10.1016/j.tins.2020.01.001; Meixiong J, 2019, IMMUNITY, V50, P1163, DOI 10.1016/j.immuni.2019.03.013; Mencarelli A, 2020, J LEUKOCYTE BIOL, V107, P797, DOI 10.1002/JLB.3MA1219-210RR; Motakis E, 2014, BLOOD, V123, pE58, DOI 10.1182/blood-2013-02-483792; Muto Y, 2014, J INVEST DERMATOL, V134, P2728, DOI 10.1038/jid.2014.222; Nattkemper LA, 2018, J INVEST DERMATOL, V138, P1311, DOI 10.1016/j.jid.2017.12.029; Navines-Ferrer A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29965-8; Niyonsaba F, 2002, INT IMMUNOL, V14, P421, DOI 10.1093/intimm/14.4.421; Niyonsaba F, 2001, EUR J IMMUNOL, V31, P1066, DOI 10.1002/1521-4141(200104)31:4<1066::AID-IMMU1066>3.0.CO;2-#; Niyonsaba F, 2010, J IMMUNOL, V184, P3526, DOI 10.4049/jimmunol.0900712; Occhiuto CJ, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.03143; Ogasawara H, 2020, BIOCHEM BIOPHYS REP, V21, DOI 10.1016/j.bbrep.2019.100719; Ogasawara H, 2019, J LEUKOCYTE BIOL, V106, P1069, DOI 10.1002/JLB.2AB1018-405R; Okamura Y, 2017, ALLERGOL INT, V66, pS9, DOI 10.1016/j.alit.2017.03.002; Ommori R, 2013, MICROB PATHOGENESIS, V56, P35, DOI 10.1016/j.micpath.2012.11.005; Oskeritzian CA, 2005, J ALLERGY CLIN IMMUN, V115, P1162, DOI 10.1016/j.jaci.2005.02.022; Plum T, 2020, IMMUNITY, V52, P404, DOI 10.1016/j.immuni.2020.01.012; Porebski G, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03027; Pundir P, 2019, CELL HOST MICROBE, V26, P114, DOI 10.1016/j.chom.2019.06.003; Rasmussen SGF, 2011, NATURE, V477, P549, DOI 10.1038/nature10361; Ray P, 2018, PAIN, V159, P1325, DOI 10.1097/j.pain.0000000000001217; Reddy VB, 2017, J ALLERGY CLIN IMMUN, V140, P1726, DOI 10.1016/j.jaci.2017.05.046; Rouzaire P, 2013, J ALLER CL IMM-PRACT, V1, P273, DOI 10.1016/j.jaip.2013.02.007; Roy S, 2019, J ALLERGY CLIN IMMUN, V144, P603, DOI 10.1016/j.jaci.2019.04.024; Roy S, 2019, J IMMUNOL, V202, P1229, DOI 10.4049/jimmunol.1801227; Sabato V, 2020, ALLERGY, V75, P2421, DOI 10.1111/all.14252; Scala Jacopo, 2019, Open Access Maced J Med Sci, V7, P2985, DOI 10.3889/oamjms.2019.784; Schwab VD, 2011, J INVEST DERM SYMP P, V15, P53, DOI 10.1038/jidsymp.2011.6; Scott RW, 2017, CURR TOP MED CHEM, V17, P576, DOI 10.2174/1568026616666160713130452; Serhan N, 2019, NAT IMMUNOL, V20, P1435, DOI 10.1038/s41590-019-0493-z; Serra R, 2015, EXPERT REV ANTI-INFE, V13, P605, DOI 10.1586/14787210.2015.1023291; Shelley JR, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01176; Shtessel M, 2021, J INVEST DERMATOL, V141, P678, DOI 10.1016/j.jid.2020.06.030; Silva ON, 2020, P NATL ACAD SCI USA, V117, P26936, DOI 10.1073/pnas.2012379117; Simpson EL, 2019, J AM ACAD DERMATOL, V80, P1013, DOI 10.1016/j.jaad.2018.11.059; Sorensen OE, 2014, J CLIN INVEST, V124, P4539, DOI 10.1172/JCI76009; Spoerl D, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061223; Spoerl D, 2016, INT ARCH ALLERGY IMM, V169, P256, DOI 10.1159/000446182; Steinhoff M, 2003, J NEUROSCI, V23, P6176; Subramanian H, 2016, J ALLERGY CLIN IMMUN, V138, P700, DOI 10.1016/j.jaci.2016.04.051; Subramanian H, 2013, J IMMUNOL, V191, P345, DOI 10.4049/jimmunol.1300023; Subramanian H, 2011, J BIOL CHEM, V286, P44739, DOI 10.1074/jbc.M111.277152; SUGIURA H, 1992, ACTA DERM-VENEREOL, P74; Suzuki Y, 2020, BRIT J ANAESTH, V125, pE446, DOI 10.1016/j.bja.2020.05.046; Suzuki Y, 2020, EUR J PHARMACOL, V878, DOI 10.1016/j.ejphar.2020.173104; Tatemoto K, 2006, BIOCHEM BIOPH RES CO, V349, P1322, DOI 10.1016/j.bbrc.2006.08.177; Thapaliya M, 2021, CURR ALLERGY ASTHM R, V21, DOI 10.1007/s11882-020-00979-5; Toyoda M, 1998, ACTA DERM-VENEREOL, V78, P321; Tummler Burkhard, 2019, F1000Res, V8, DOI 10.12688/f1000research.19509.1; Valent P, 2018, J ALLERGY CLIN IMMUN, V142, P1008, DOI 10.1016/j.jaci.2018.06.004; Van Gasse AL, 2017, ALLERGY, V72, P2039, DOI 10.1111/all.13236; Van Gasse AL, 2019, J ALLER CL IMM-PRACT, V7, P998, DOI 10.1016/j.jaip.2018.09.034; Varricchi G, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00299; Venkatakrishnan AJ, 2016, NATURE, V536, P484, DOI 10.1038/nature19107; Venkatakrishnan AJ, 2013, NATURE, V494, P185, DOI 10.1038/nature11896; Vibhuti A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019585; Visser MJ, 2014, CONTACT DERMATITIS, V70, P139, DOI 10.1111/cod.12139; Wang F, 2020, J INVEST DERMATOL, V140, P945, DOI 10.1016/j.jid.2019.12.011; Wang Lian, 2019, Front Med (Lausanne), V6, P324, DOI 10.3389/fmed.2019.00324; Wang Z, 2020, EXP DERMATOL, V29, P1104, DOI 10.1111/exd.14182; Wedi B, 2020, ALLERGY, V75, P2424, DOI 10.1111/all.14446; Wedi B, 2020, ALLERGY, V75, P2229, DOI 10.1111/all.14213; Weidinger S, 2016, LANCET, V387, P1109, DOI 10.1016/S0140-6736(15)00149-X; WEINSTOCK JV, 1990, CELL IMMUNOL, V125, P380, DOI 10.1016/0008-8749(90)90092-6; Weller K, 2006, FASEB J, V20, P2366, DOI 10.1096/fj.06-5837fje; Wingler LM, 2020, TRENDS CELL BIOL, V30, P736, DOI 10.1016/j.tcb.2020.06.002; Xing YY, 2020, J INVEST DERMATOL, V140, P2041, DOI 10.1016/j.jid.2020.03.935; Yamasaki K, 2007, NAT MED, V13, P975, DOI 10.1038/nm1616; Yang B, 2017, J INVEST DERMATOL, V137, P1166, DOI 10.1016/j.jid.2017.01.010; Yang S, 2005, GENE, V352, P30, DOI 10.1016/j.gene.2005.03.001; Zhang L, 2019, J ALLERGY CLIN IMMUN, V143, P1960, DOI 10.1016/j.jaci.2019.01.013; Zhang Y, 2017, NATURE, V546, P248, DOI 10.1038/nature22394; Zhou XE, 2017, CELL, V170, P457, DOI 10.1016/j.cell.2017.07.002; Zimmermann C, 2019, P NATL ACAD SCI USA, V116, P20500, DOI 10.1073/pnas.1908816116	165	22	22	6	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2021	148	2					293	308		10.1016/j.jaci.2021.03.049	http://dx.doi.org/10.1016/j.jaci.2021.03.049		AUG 2021	16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TZ7BX	33957166	Green Accepted			2022-12-18	WOS:000684625700004
J	Zaid, Y; Dore, E; Dubuc, I; Archambault, AS; Flamand, O; Laviolette, M; Flamand, N; Boilard, E; Flamand, L				Zaid, Younes; Dore, Etienne; Dubuc, Isabelle; Archambault, Anne-Sophie; Flamand, Olivier; Laviolette, Michel; Flamand, Nicolas; Boilard, Eric; Flamand, Louis			Chemokines and eicosanoids fuel the hyperinflammation within the lungs of patients with severe COVID-19	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						SARS-CoV-2; COVID-19; ARDS; inflammatory cytokines; lipid mediators of inflammation; chemokines; eicosanoids	RESPIRATORY SYNDROME CORONAVIRUS; DISTRESS-SYNDROME; CYTOKINE; POTENT; ACTIVATION; INDUCTION; PLATELETS; MIGRATION; TRIGGERS; RELEASE	Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection can lead to a variety of clinical outcomes, ranging from the absence of symptoms to severe acute respiratory disease and ultimately death. A feature of patients with severe coronavirus disease 2019 (COVID-19) is the abundance of inflammatory cytokines in the blood. Elevated levels of cytokines are predictive of infection severity and clinical outcome. In contrast, studies aimed at defining the driving forces behind the inflammation in lungs of subjects with severe COVID-19 remain scarce. Objective: Our aim was to analyze and compare the plasma and bronchoalveolar lavage (BAL) fluids of patients with severe COVID-19 (n = 45) for the presence of cytokines and lipid mediators of inflammation (LMIs). Methods: Cytokines were measured by using Luminex multiplex assay, and LMIs were measured by using liquid chromatography-tandem mass spectrometry. Results: We revealed high concentrations of numerous cytokines, chemokines, and LMIs in the BAL fluid of patients with severe COVID-19. Of the 13 most abundant mediators in BAL fluid, 11 were chemokines, with CXCL1 and CXCL8 being 200 times more abundant than IL-6 and TNF-alpha. Eicosanoid levels were also elevated in the lungs of subjects with severe COVID-19. Consistent with the presence chemotactic molecules, BAL fluid samples were enriched for neutrophils, lymphocytes, and eosinophils. Inflammatory cytokines and LMIs in plasma showed limited correlations with those present in BAL fluid, arguing that circulating inflammatory molecules may not be a reliable proxy of the inflammation occurring in the lungs of patients with severe COVID-19. Conclusions: Our findings indicate that hyperinflammation of the lungs of patients with severe COVID-19 is fueled by excessive production of chemokines and eicosanoids. Therapeutic strategies to dampen inflammation in patients with COVID-19 should be tailored accordingly.	[Zaid, Younes] Mohammed Univ Rabat, Dept Biol, Fac Sci, Rabat, Morocco; [Zaid, Younes] Abulcasis Univ Hlth Sci, Cheikh Zaid Hosp, Rabat, Morocco; [Dore, Etienne; Dubuc, Isabelle; Flamand, Olivier; Boilard, Eric; Flamand, Louis] Ctr Hospitalier Univ Quebec Univ Laval, Axe Malad Infectieuses & Immunitaires, Ctr Rech, Laval, PQ, Canada; [Dore, Etienne; Boilard, Eric] Ctr Rech Arthrite, Laval, PQ, Canada; [Archambault, Anne-Sophie; Laviolette, Michel; Flamand, Nicolas] Inst Univ Cardiol & Pneumol Quebec, Ctr Rech, Fac Med, Dept Med, Quebec City, PQ, Canada; [Archambault, Anne-Sophie; Flamand, Nicolas] Microbiome Endocannabinoidome Axis Metab Hlth, Canada Res Excellence, Quebec City, PQ, Canada; [Boilard, Eric; Flamand, Louis] Univ Laval, Dept Microbiol Infectiol & dImmunol, Quebec City, PQ, Canada	Mohammed V University in Rabat; Laval University; Laval University	Flamand, L (corresponding author), CHU CHUL, Ctr Rech, 2705 Laurier Blvd,Off T1-49, Quebec City, PQ G1V 4G2, Canada.	louis.flamand@crchudequebec.ulaval.ca	Flamand, Nicolas/H-5823-2019; Zaid, Younes/AAU-4035-2021	Flamand, Nicolas/0000-0001-5944-7200; Zaid, Younes/0000-0001-8750-9106; Flamand, Louis/0000-0001-5010-4586; Archambault, Anne-Sophie/0000-0001-7243-7445	Cheikh Zaid Foundation; Canadian New Frontier Research Fund [NFRN-2019-00004]; CIHR [VR3_172632]; Canadian Institutes of Health Research; Fonds de Recherche du Quebec en Sante	Cheikh Zaid Foundation; Canadian New Frontier Research Fund; CIHR(Canadian Institutes of Health Research (CIHR)); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Fonds de Recherche du Quebec en Sante(Fonds de la Recherche en Sante du Quebec)	Supported by the Cheikh Zaid Foundation (to Y.Z.) and grants from the Canadian New Frontier Research Fund (NFRN-2019-00004) and CIHR (VR3_172632) (to L.F. [principal investigator], E.B. [coprincipal investigator], and N.F. [coprincipal investigator]). A.S.A. received a doctoral award from the Canadian Institutes of Health Research. E.D. and E.B. are, respectively, recipients of doctoral and senior awards from the Fonds de Recherche du Quebec en Sante.	Allaoui A, 2021, SEMIN THROMB HEMOST, V47, P419, DOI 10.1055/s-0041-1726033; Alosaimi B, 2020, CYTOKINE, V126, DOI 10.1016/j.cyto.2019.154895; Archambault AS, 2021, FASEB J, V35, DOI 10.1096/fj.202100540R; Barnes BJ, 2020, J EXP MED, V217, DOI 10.1084/jem.20200652; BECKER S, 1994, AM J PHYSIOL, V266, pL278, DOI 10.1152/ajplung.1994.266.3.L278; Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026; Borst O, 2012, CIRC RES, V111, P1297, DOI 10.1161/CIRCRESAHA.112.276444; Calfee CS, 2018, LANCET RESP MED, V6, P691, DOI 10.1016/S2213-2600(18)30177-2; Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7; Chi Y, 2020, J INFECT DIS, V222, P746, DOI 10.1093/infdis/jiaa363; Del Valle D.M., 2020, NAT MED, V26, P1636, DOI DOI 10.1038/s41591-020-1051-9; Estella A, 2011, J INFECT DEV COUNTR, V5, P540, DOI 10.3855/jidc.1618; Famous KR, 2017, AM J RESP CRIT CARE, V195, P331, DOI 10.1164/rccm.201603-0645OC; Flamand L, 2004, J INFECT DIS, V189, P2001, DOI 10.1086/386374; Flamand L, 2007, J IMMUNOL, V178, P8036, DOI 10.4049/jimmunol.178.12.8036; FORDHUTCHINSON AW, 1980, NATURE, V286, P264, DOI 10.1038/286264a0; Garofalo R, 1996, J VIROL, V70, P8773, DOI 10.1128/JVI.70.12.8773-8781.1996; Gleissner CA, 2008, ARTERIOSCL THROM VAS, V28, P1920, DOI 10.1161/ATVBAHA.108.169417; Grant RA, 2021, NATURE, V590, P635, DOI 10.1038/s41586-020-03148-w; Guo XZJ, 2017, SEMIN IMMUNOPATHOL, V39, P541, DOI 10.1007/s00281-017-0636-y; Gupta A, 2020, NAT MED, V26, P1017, DOI 10.1038/s41591-020-0968-3; Hadjadj J, 2020, SCIENCE, V369, P718, DOI 10.1126/science.abc6027; Han H, 2020, CLIN CHEM LAB MED, V58, P1116, DOI 10.1515/cclm-2020-0188; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2022926, 10.1056/NEJMoa2021436]; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Kalil AC, 2021, NEW ENGL J MED, V384, P795, DOI 10.1056/NEJMoa2031994; Kapur R, 2015, J IMMUNOL, V194, P5579, DOI 10.4049/jimmunol.1500259; Koh YY, 2007, CHEST, V131, P1454, DOI 10.1378/chest.06-0188; Lau SKP, 2013, J GEN VIROL, V94, P2679, DOI 10.1099/vir.0.055533-0; Lei XB, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17665-9; Leng L, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00355-9; Liao MF, 2020, NAT MED, V26, P842, DOI 10.1038/s41591-020-0901-9; MALMSTEN CL, 1980, ACTA PHYSIOL SCAND, V110, P449, DOI 10.1111/j.1748-1716.1980.tb06696.x; Mella C, 2013, J INFECT DIS, V207, P564, DOI 10.1093/infdis/jis721; Metzemaekers M, 2020, CELL MOL IMMUNOL, V17, P433, DOI 10.1038/s41423-020-0412-0; Min CK, 2016, SCI REP-UK, V6, DOI 10.1038/srep25359; Muller KAL, 2015, THROMB HAEMOSTASIS, V114, P498, DOI 10.1160/TH14-11-0947; Pandolfi L, 2020, BMC PULM MED, V20, DOI 10.1186/s12890-020-01343-z; Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248; Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669; Reghunathan R, 2005, BMC IMMUNOL, V6, DOI 10.1186/1471-2172-6-2; Schutyser E, 2003, CYTOKINE GROWTH F R, V14, P409, DOI 10.1016/S1359-6101(03)00049-2; Schwarz B, 2021, J IMMUNOL, V206, P329, DOI 10.4049/jimmunol.2001025; Singh A, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.561366; Sinha P, 2018, INTENS CARE MED, V44, P1859, DOI 10.1007/s00134-018-5378-3; STEINBERG KP, 1994, AM J RESP CRIT CARE, V150, P113, DOI 10.1164/ajrccm.150.1.8025736; Tang N, 2020, J THROMB HAEMOST, V18, P844, DOI 10.1111/jth.14768; Turcotte C, 2020, FASEB J, V34, P4253, DOI 10.1096/fj.201902916R; Williams AE, 2017, THORAX, V72, P66, DOI 10.1136/thoraxjnl-2016-208597; Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994; Wu F, 2020, NATURE, V580, pE7, DOI 10.1038/s41586-020-2202-3; Xia HJ, 2020, CELL REP, V33, DOI 10.1016/j.celrep.2020.108234; Xie GG, 2021, ALLERGY, V76, P471, DOI 10.1111/all.14465; Zaid Y, 2021, BLOOD ADV, V5, P635, DOI 10.1182/bloodadvances.2020003513; Zaid Y, 2020, CIRC RES, V127, P1404, DOI 10.1161/CIRCRESAHA.120.317703; Zhang HL, 2020, ANN INTERN MED, V172, P629, DOI 10.7326/M20-0533; Zhou J, 2014, J INFECT DIS, V209, P1331, DOI 10.1093/infdis/jit504	58	22	23	2	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2021	148	2					368	+		10.1016/j.jaci.2021.05.032	http://dx.doi.org/10.1016/j.jaci.2021.05.032		AUG 2021	16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TZ7BX	34111453	Green Published, hybrid			2022-12-18	WOS:000684625700015
J	Lemarquis, A; Campbell, T; Aranda-Guillen, M; Hennings, V; Brodin, P; Kampe, O; Blennow, K; Zetterberg, H; Wenneras, C; Eriksson, K; Landegren, N; Bryceson, Y; Berg, S; Ekwall, O				Lemarquis, Andri; Campbell, Tessa; Aranda-Guillen, Maribel; Hennings, Viktoria; Brodin, Petter; Kampe, Olle; Blennow, Kaj; Zetterberg, Henrik; Wenneras, Christine; Eriksson, Kristina; Landegren, Nils; Bryceson, Yenan; Berg, Stefan; Ekwall, Olov			Severe COVID-19 in an APS1 patient with interferon autoantibodies treated with plasmapheresis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Lemarquis, Andri; Hennings, Viktoria; Berg, Stefan; Ekwall, Olov] Univ Gothenburg, Dept Pediat, Inst Clin Sci, Gothenburg, Sweden; [Lemarquis, Andri; Hennings, Viktoria; Eriksson, Kristina; Ekwall, Olov] Univ Gothenburg, Dept Rheumatol & Inflammat Res, Inst Med, Sahlgrenska Acad, Gothenburg, Sweden; [Campbell, Tessa; Bryceson, Yenan] Karolinska Inst, Ctr Hematol & Regenerat Med, Dept Med, Stockholm, Sweden; [Campbell, Tessa; Bryceson, Yenan] Karolinska Univ Hosp, Div Clin Immunol & Transfus Med, Stockholm, Sweden; [Aranda-Guillen, Maribel; Kampe, Olle; Landegren, Nils] Karolinska Inst, Ctr Mol Med, Dept Med Solna, Stockholm, Sweden; [Brodin, Petter] Karolinska Inst, Sci Life Lab, Dept Womens & Childrens Hlth, Solna, Sweden; [Blennow, Kaj; Zetterberg, Henrik] Univ Gothenburg, Dept Psychiat & Neurochem, Inst Neurosci & Physiol, Sahlgrenska Acad, Gothenburg, Sweden; [Blennow, Kaj; Zetterberg, Henrik] Sahlgrens Univ Hosp, Clin Neurochem Lab, Molndal, Sweden; [Zetterberg, Henrik] UCL Queen Sq Inst Neurol, Dept Neurodegenerat Dis, London, England; [Zetterberg, Henrik] UK Dementia Res Inst UCL, London, England; [Wenneras, Christine] Univ Gothenburg, Dept Infect Dis, Inst Biomed, Sahlgrenska Acad, Gothenburg, Sweden; [Wenneras, Christine] Sahlgrens Univ Hosp, Dept Clin Microbiol, Gothenburg, Sweden; [Landegren, Nils] Uppsala Univ, Dept Med Biochem & Microbiol, Uppsala, Sweden; [Bryceson, Yenan] Univ Bergen, Broegelmann Res Lab, Dept Clin Sci, Bergen, Norway; [Berg, Stefan] Sahlgrens Univ Hosp, Dept Pediat, Queen Silvia Childrens Hosp, Gothenburg, Sweden	University of Gothenburg; University of Gothenburg; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska Institutet; University of Gothenburg; Sahlgrenska University Hospital; University of London; University College London; University of London; University College London; University of Gothenburg; Sahlgrenska University Hospital; Uppsala University; University of Bergen; Queen Silvia Children's Hospital; Sahlgrenska University Hospital	Lemarquis, A (corresponding author), Univ Gothenburg, Dept Pediat, Inst Clin Sci, Gothenburg, Sweden.; Lemarquis, A (corresponding author), Univ Gothenburg, Dept Rheumatol & Inflammat Res, Inst Med, Sahlgrenska Acad, Gothenburg, Sweden.	andri.lemarquis@gu.se; olov.ekwall@gu.se	Lemarquis, Andri Leó/AAO-5044-2021; Brodin, Petter/C-3317-2011	Ekwall, Olov/0000-0002-4506-9955; Campbell, Tessa Mollie/0000-0002-7737-2123; Brodin, Petter/0000-0002-8103-0046	Swedish Research Council [201802752]; Swedish government [76800, 76210]; Swedish county councils, the ALF-agreement [76800, 76210]	Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish government; Swedish county councils, the ALF-agreement	This study was supported by grants from the Swedish Research Council (grant no. 201802752) and from the Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement (grant nos. 76800 and 76210).	Bastard P, 2020, SCIENCE, V370, P423, DOI 10.1126/science.abd4585; Fernandez-Zarzoso M, 2019, TRANSFUS APHER SCI, V58, P247, DOI 10.1016/j.transci.2019.04.007; Hadjadj J, 2020, SCIENCE, V369, P718, DOI 10.1126/science.abc6027; Meager A, 2006, PLOS MED, V3, P1152, DOI 10.1371/journal.pmed.0030289; Zhang Q, 2020, SCIENCE, V370, DOI 10.1126/science.abd4570	5	22	22	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2021	148	1					96	98		10.1016/j.jaci.2021.03.034	http://dx.doi.org/10.1016/j.jaci.2021.03.034		JUL 2021	3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TE3IE	33892926	Green Published, Green Submitted, Bronze			2022-12-18	WOS:000669906700017
J	Wang, CW; Tassaneeyakul, W; Chen, CB; Chen, WT; Teng, YC; Huang, CY; Sukasem, C; Lu, CW; Lee, YS; Choon, SE; Nakkam, N; Hui, RCY; Huang, YH; Chang, YC; Lin, YYW; Chang, CJ; Chiu, TM; Chantratita, W; Konyoung, P; Lee, CN; Klaewsongkram, J; Rerkpattanapipat, T; Amornpinyo, W; Saksit, N; Rerknimitr, P; Huang, YH; Lin, SH; Hsu, CK; Chan, CC; Lin, YJ; Hung, SI; Chung, WH				Wang, Chuang-Wei; Tassaneeyakul, Wichittra; Chen, Chun-Bing; Chen, Wei-Ti; Teng, Yu-Chuan; Huang, Cheng-Yang; Sukasem, Chonlaphat; Lu, Chun-Wei; Lee, Yun-Shien; Choon, Siew-Eng; Nakkam, Nontaya; Hui, Rosaline Chung-Yee; Huang, Yen-Hua; Chang, Ya-Ching; Lin, Yang Yu-Wei; Chang, Chee-Jen; Chiu, Tsu-Man; Chantratita, Wasun; Konyoung, Parinya; Lee, Chaw-Ning; Klaewsongkram, Jettanong; Rerkpattanapipat, Ticha; Amornpinyo, Warayuwadee; Saksit, Niwat; Rerknimitr, Pawinee; Huang, Yu Huei; Lin, Shang-Hung; Hsu, Chao-Kai; Chan, Cheng-Chi; Lin, Yu-, Jr.; Hung, Shuen-Iu; Chung, Wen-Hung		Taiwan Asian Severe	Whole genome sequencing identifies genetic variants associated with co-trimoxazole hypersensitivity in Asians	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Co-trimoxazole; HLA-B*13:01; severe hypersensitivity reactions; sulfonamide; whole-genome sequencing	STEVENS-JOHNSON-SYNDROME; TOXIC EPIDERMAL NECROLYSIS; CUTANEOUS ADVERSE-REACTIONS; TRIMETHOPRIM-SULFAMETHOXAZOLE; DRUG-REACTIONS; RESTRICTED ACTIVATION; CONTROLLED-TRIAL; HLA-B; DAPSONE; HLA-B-ASTERISK-1301	Background: Co-trimoxazole, a sulfonamide antibiotic, is used to treat a variety of infections worldwide, and it remains a common first-line medicine for prophylaxis against Pneumocystis jiroveci pneumonia. However, it can cause severe cutaneous adverse reaction (SCAR), including Stevens-Johnson syndrome, toxic epidermal necrolysis, and drug reaction with eosinophilia and systemic symptoms. The pathomechanism of co-trimoxazole-induced SCAR remains unclear. Objective: We aimed to investigate the genetic predisposition of co-trimoxazole-induced SCAR. Methods: We conducted a multicountry case-control association study that included 151 patients with of co-trimoxazole-induced SCAR and 4631 population controls from Taiwan, Thailand, and Malaysia, as well as 138 tolerant controls from Taiwan. Whole-genome sequencing was performed for the patients and population controls from Taiwan; it further validated the results from Thailand and Malaysia. Results: The whole-genome sequencing study (43 case patients vs 507 controls) discovered that the single-nucleotide polymorphism rs41554616, which is located between the HLA-B and MICA loci, had the strongest association with cotrimoxazole-induced SCAR (P = 8.2 x 10(-9); odds ratio [OR] = 7.7). There were weak associations of variants in cotrimoxazole-related metabolizing enzymes (CYP2D6, GSTP1, GCLC, N-acetyltransferase [NAT2], and CYP2C8). A replication study using HLA genotyping revealed that HLA-B*13:01 was strongly associated with co-trimoxazole-induced SCAR (the combined sample comprised 91 case patients vs 2545 controls [P = 7.2 x 10(-21); OR = 8.7]). A strong HLA association was also observed in the case patients from Thailand (P = 3.2 x 10(-5); OR = 3.6) and Malaysia (P = .002; OR = 12.8), respectively. A meta-analysis and phenotype stratification study further indicated a strong association between HLA-B*13:01 and co-trimoxazole-induced drug reaction with eosinophilia and systemic symptoms (P = 4.2 x 10(-23); OR = 40.1). Conclusion: This study identified HLA-B*13:01 as an important genetic factor associated with co-trimoxazole-induced SCAR in Asians.	[Wang, Chuang-Wei; Chen, Chun-Bing; Chen, Wei-Ti; Teng, Yu-Chuan; Lu, Chun-Wei; Hui, Rosaline Chung-Yee; Chang, Ya-Ching; Lin, Yang Yu-Wei; Huang, Yu Huei; Chung, Wen-Hung] Chang Gung Mem Hosp, Dept Dermatol, Drug Hypersensit Clin & Res Ctr, Linkou, Taiwan; [Wang, Chuang-Wei; Chen, Chun-Bing; Chen, Wei-Ti; Teng, Yu-Chuan; Lu, Chun-Wei; Hui, Rosaline Chung-Yee; Chang, Ya-Ching; Lin, Yang Yu-Wei; Huang, Yu Huei; Chung, Wen-Hung] Chang Gung Mem Hosp, Dept Dermatol, Drug Hypersensit Clin & Res Ctr, Taipei, Taiwan; [Wang, Chuang-Wei; Chen, Chun-Bing; Chen, Wei-Ti; Teng, Yu-Chuan; Lu, Chun-Wei; Hui, Rosaline Chung-Yee; Chang, Ya-Ching; Lin, Yang Yu-Wei; Huang, Yu Huei; Chung, Wen-Hung] Chang Gung Mem Hosp, Dept Dermatol, Drug Hypersensit Clin & Res Ctr, Keelung, Taiwan; [Wang, Chuang-Wei; Chen, Chun-Bing; Chan, Cheng-Chi; Hung, Shuen-Iu; Chung, Wen-Hung] Chang Gung Mem Hosp, Canc Vaccine & Immune Cell Therapy Core Lab, Linkou, Taiwan; [Chen, Chun-Bing; Lu, Chun-Wei; Chung, Wen-Hung] Chang Gung Mem Hosp, Immune Oncol Ctr Excellence, Linkou, Taiwan; [Chen, Chun-Bing; Chung, Wen-Hung] Chang Gung Mem Hosp, Genom Med Core Lab, Linkou, Taiwan; [Wang, Chuang-Wei; Chen, Chun-Bing; Chung, Wen-Hung] Chang Gung Mem Hosp, Chang Gung Immunol Consortium, Taoyuan, Taiwan; [Wang, Chuang-Wei; Chen, Chun-Bing; Chung, Wen-Hung] Chang Gung Univ, Taoyuan, Taiwan; [Wang, Chuang-Wei; Chen, Chun-Bing; Chen, Wei-Ti; Lu, Chun-Wei; Chung, Wen-Hung] Xiamen Chang Gung Hosp, Dept Dermatol, Xiamen, Peoples R China; [Tassaneeyakul, Wichittra; Nakkam, Nontaya] Khon Kaen Univ, Fac Med, Dept Pharmacol, Khon Kaen, Thailand; [Chen, Chun-Bing; Lu, Chun-Wei; Chung, Wen-Hung] Chang Gung Univ, Grad Inst Clin Med Sci, Taoyuan, Taiwan; [Chen, Chun-Bing; Chen, Wei-Ti; Lu, Chun-Wei; Huang, Yu Huei; Chung, Wen-Hung] Chang Gung Univ, Coll Med, Taoyuan, Taiwan; [Chang, Chee-Jen; Lin, Yu-, Jr.] Chang Gung Univ, Res Serv Ctr Hlth Informat, Taoyuan, Taiwan; [Chen, Chun-Bing; Teng, Yu-Chuan; Hui, Rosaline Chung-Yee; Chung, Wen-Hung] Chang Gung Mem Hosp, Whole Genome Res Core Lab Human Dis, Keelung, Taiwan; [Huang, Cheng-Yang; Huang, Yen-Hua] Chung Shan Med Univ, Sch Biomed Sci, Taichung, Taiwan; [Huang, Cheng-Yang] Chung Shan Med Univ, Dept Med Res, Taichung, Taiwan; [Chiu, Tsu-Man] Chung Shan Med Univ, Sch Med, Taichung, Taiwan; [Sukasem, Chonlaphat] Mahidol Univ, Ramathibodi Hosp, Fac Med, Div Pharmacogen & Personalized Med,Dept Pathol, Bangkok, Thailand; [Chantratita, Wasun] Mahidol Univ, Ramathibodi Hosp, Fac Med, Ctr Med Genom, Bangkok, Thailand; [Rerkpattanapipat, Ticha] Mahidol Univ, Ramathibodi Hosp, Fac Med, Div Allergy Immunol & Rheumatol,Dept Med, Bangkok, Thailand; [Sukasem, Chonlaphat] Ramathibodi Hosp, Somdech Phra Debaratana Med Ctr, Lab Pharmacogen, Bangkok, Thailand; [Sukasem, Chonlaphat; Klaewsongkram, Jettanong; Rerkpattanapipat, Ticha; Rerknimitr, Pawinee] Thai Severe Cutaneous Adverse Drug React Res Grp, Bangkok, Thailand; [Lee, Yun-Shien] Ming Chuan Univ, Dept Biotechnol, Taoyuan, Taiwan; [Choon, Siew-Eng] Monash Univ, Jeffrey Cheah Sch Med & Hlth Sci, Clin Sch Johor Bahru, Hosp Sultanah Aminah, Subang Jaya, Selangor, Malaysia; [Chiu, Tsu-Man] Changhua Christian Hosp, Dept Dermatol, Changhua, Taiwan; [Chiu, Tsu-Man] Chung Yuan Christian Univ, Dept Biomed Engn, Taoyuan, Taiwan; [Konyoung, Parinya] Udon Thani Hosp, Pharm Unit, Udon Thani, Thailand; [Lee, Chaw-Ning] Natl Cheng Kung Univ Hosp, Coll Med, Dept Dermatol, Tainan, Taiwan; [Hsu, Chao-Kai] Natl Cheng Kung Univ, Int Ctr Wound Repair & Regenerat, Tainan, Taiwan; [Klaewsongkram, Jettanong] Chulalongkorn Univ, Fac Med, Skin & Allergy Res Unit, Div Allergy & Clin Immunol, Bangkok, Thailand; [Rerknimitr, Pawinee] Chulalongkorn Univ, Fac Med, Skin & Allergy Res Unit, Div Dermatol,Dept Med, Bangkok, Thailand; [Klaewsongkram, Jettanong] Thai Red Cross Soc, King Chulalongkorn Mem Hosp, Bangkok, Thailand; [Amornpinyo, Warayuwadee] Khon Kaen Hosp, Dept Internal Med, Div Dermatol, Khon Kaen, Thailand; [Lin, Shang-Hung] Kaohsiung Chang Gung Mem Hosp, Dept Dermatol, Kaohsiung, Taiwan; [Lin, Shang-Hung] Chang Gung Univ, Coll Med, Kaohsiung, Taiwan; [Hung, Shuen-Iu] Natl Yang Ming Univ, Infect & Immun Res Ctr, Sch Med, Dept & Inst Pharmacol, Taipei, Taiwan; [Chung, Wen-Hung] Tsinghua Univ, Sch Clin Med, Beijing Tsinghua Chang Gung Hosp, Dept Dermatol, Beijing, Peoples R China; [Chung, Wen-Hung] Shanghai Jiao Tong Univ, Sch Med, Shanghai, Peoples R China	Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung University; Khon Kaen University; Chang Gung University; Chang Gung University; Chang Gung University; Chang Gung Memorial Hospital; Chung Shan Medical University; Chung Shan Medical University; Chung Shan Medical University; Mahidol University; Mahidol University; Mahidol University; Mahidol University; Ming Chuan University; Monash University; Monash University Sunway; Changhua Christian Hospital; Chung Yuan Christian University; National Cheng Kung University; National Cheng Kung University Hospital; National Cheng Kung University; Chulalongkorn University; Chulalongkorn University; Chulalongkorn University; Thai Red Cross Society; Chang Gung Memorial Hospital; Chang Gung University; National Yang Ming Chiao Tung University; Tsinghua University; Shanghai Jiao Tong University	Hung, SI (corresponding author), Chang Gung Mem Hosp, Chang Gung Immunol Consortium, Canc Vaccine & Immune Cell Therapy Core Lab, 5,Fusing St, Taoyuan 333, Taiwan.; Chung, WH (corresponding author), Chang Gung Mem Hosp, Drug Hypersensit Clin & Res Ctr, Dept Dermatol, 5,Fusing St, Taoyuan 333, Taiwan.	sihung@cgmh.org.tw; wenhungchung@yahoo.com	Hung, Shuen-Iu/ABB-2139-2021; CHOON, SIEW ENG/AAU-8192-2021; Chen, Wei-Ti/O-7180-2019	Hung, Shuen-Iu/0000-0001-6531-5538; CHOON, SIEW ENG/0000-0002-7796-5746; Chen, Wei-Ti/0000-0002-1929-4008; Nakkam, Nontaya/0000-0003-1631-3178; Tassaneeyakul, Wichittra/0000-0001-6722-8796	Ministry of Science and Technology, Taiwan [MOST 103-2321-B-182-001, 104-2314-B-182A-148-MY3, 104-2325-B-182A-006, MOST 106-2314-B-182A-037-MY3, 108-2320-B-182A-023-MY3, 108-2622-B-182A-003-CC2, 108-2314-B-182A-104-MY3, 108-2320-B-182A-024-MY2, 108-2314-B-182A-006-MY3, 109-2320-B-182A-008 -MY3]; Chang Gung Memorial Hospital [BMRPG-290011, CIRPG3I0021-2, CIRPG3I0041-2, CLRPG2 E0051-3, CORPG3F0041-3, OMRPG3E0041-3, CMRPG1F0111-3, CMRPG2H 0081, CMRPG3I0381-2, CMRPG2J0221, CIROG2I0011, CORPG3F0061-3, CORPG3J0321-3, CMRPG3K0561]; Thailand Center of Excellence for Life Sciences [TC-12/63]; International Research Network-The Thailand Research Fund [IRN60W003]; Royal Golden Jubilee Ph.D. Program [PHD/0153/2559]; Newton Fund - PhD Placements for Scholars	Ministry of Science and Technology, Taiwan(Ministry of Science and Technology, Taiwan); Chang Gung Memorial Hospital(Chang Gung Memorial Hospital); Thailand Center of Excellence for Life Sciences; International Research Network-The Thailand Research Fund; Royal Golden Jubilee Ph.D. Program(Thailand Research Fund (TRF)); Newton Fund - PhD Placements for Scholars	Supported in part by grants from the Ministry of Science and Technology, Taiwan (MOST 103-2321-B-182-001, 104-2314-B-182A-148-MY3, 104-2325-B-182A-006, MOST 106-2314-B-182A-037-MY3, 108-2320-B-182A-023-MY3, 108-2622-B-182A-003-CC2, 108-2314-B-182A-104-MY3, 108-2320-B-182A-024-MY2, 108-2314-B-182A-006-MY3, and 109-2320-B-182A-008 -MY3), Chang Gung Memorial Hospital (BMRPG-290011, CIRPG3I0021-2, CIRPG3I0041-2, CLRPG2 E0051-3, CORPG3F0041-3, OMRPG3E0041-3, CMRPG1F0111-3, CMRPG2H 0081, CMRPG3I0381-2, CMRPG2J0221, CIROG2I0011, CORPG3F0061-3, CORPG3J0321-3, and CMRPG3K0561) and grants from the Thailand Center of Excellence for Life Sciences (TC-12/63), the International Research Network-The Thailand Research Fund (IRN60W003), the Royal Golden Jubilee Ph.D. Program (PHD/0153/2559) and Newton Fund - PhD Placements for Scholars.	Alfirevic A, 2009, PHARMACOGENOMICS, V10, P531, DOI 10.2217/PGS.09.6; ALONSO MD, 1992, ALLERGY, V47, P340, DOI 10.1111/j.1398-9995.1992.tb02067.x; Auquier-Dunant A, 2002, ARCH DERMATOL, V138, P1019, DOI 10.1001/archderm.138.8.1019; Avgeri SG, 2009, INT J ANTIMICROB AG, V33, P394, DOI 10.1016/j.ijantimicag.2008.09.010; BASTUJIGARIN S, 1993, ARCH DERMATOL, V129, P92, DOI 10.1001/archderm.129.1.92; Bianco C, 2019, P NATL ACAD SCI USA, V116, P22583, DOI 10.1073/pnas.1909143116; Cacoub P, 2011, AM J MED, V124, P588, DOI 10.1016/j.amjmed.2011.01.017; Castrejon JL, 2010, J ALLERGY CLIN IMMUN, V125, P411, DOI 10.1016/j.jaci.2009.10.031; Chen WT, 2018, J INVEST DERMATOL, V138, P1546, DOI 10.1016/j.jid.2018.02.004; Chessman D, 2008, IMMUNITY, V28, P822, DOI 10.1016/j.immuni.2008.04.020; Chung WH, 2016, J DERMATOL, V43, P758, DOI 10.1111/1346-8138.13430; Chung WH, 2015, J INVEST DERMATOL, V135, P2237, DOI 10.1038/jid.2015.165; Chung WH, 2014, JAMA-J AM MED ASSOC, V312, P525, DOI 10.1001/jama.2014.7859; Chung WH, 2008, NAT MED, V14, P1343, DOI 10.1038/nm.1884; Chung WH, 2004, NATURE, V428, P486, DOI 10.1038/428486a; Frey N, 2018, J INVEST DERMATOL, V138, P1207, DOI 10.1016/j.jid.2017.12.015; Fuster DG, 2014, PFLUG ARCH EUR J PHY, V466, P61, DOI 10.1007/s00424-013-1408-8; Genin E, 2014, PHARMACOGENOMICS J, V14, P281, DOI 10.1038/tpj.2013.40; Goldman JL, 2015, DRUG METAB DISPOS, V43, P1372, DOI 10.1124/dmd.115.065193; Hetherington S, 2002, LANCET, V359, P1121, DOI 10.1016/S0140-6736(02)08158-8; Hung SL, 2005, P NATL ACAD SCI USA, V102, P4134, DOI 10.1073/pnas.0409500102; Kardaun SH, 2013, BRIT J DERMATOL, V169, P1071, DOI 10.1111/bjd.12501; Kongpan T, 2015, PHARMACOGENET GENOM, V25, P402, DOI 10.1097/FPC.0000000000000153; Korbila IP, 2009, CAN FAM PHYSICIAN, V55, P60; Li YJ, 2021, HEPATOLOGY, V73, P268, DOI 10.1002/hep.31258; Lonjou C, 2008, PHARMACOGENET GENOM, V18, P99, DOI 10.1097/FPC.0b013e3282f3ef9c; Mallal S, 2008, NEW ENGL J MED, V358, P568, DOI 10.1056/NEJMoa0706135; MEDINA I, 1990, NEW ENGL J MED, V323, P776, DOI 10.1056/NEJM199009203231202; Mockenhaupt M, 2019, ALLERGY, V74, P2227, DOI 10.1111/all.13821; Nakamura R, 2020, J INVEST DERMATOL, V140, P1659, DOI 10.1016/j.jid.2019.12.025; NARANJO CA, 1981, CLIN PHARMACOL THER, V30, P239, DOI 10.1038/clpt.1981.154; Ogese MO, 2015, CLIN EXP ALLERGY, V45, P1305, DOI 10.1111/cea.12546; Ozkaya-Bayazit E, 2001, J AM ACAD DERMATOL, V45, P712, DOI 10.1067/mjd.2001.117854; Pan RY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11396-2; Reinhart JM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156000; Roujeau JC, 2005, TOXICOLOGY, V209, P123, DOI 10.1016/j.tox.2004.12.022; ROUJEAU JC, 1994, NEW ENGL J MED, V331, P1272, DOI 10.1056/NEJM199411103311906; ROUJEAU JC, 1995, NEW ENGL J MED, V333, P1600, DOI 10.1056/NEJM199512143332404; Salentin S, 2015, NUCLEIC ACIDS RES, V43, pW443, DOI 10.1093/nar/gkv315; Sassolas B, 2010, CLIN PHARMACOL THER, V88, P60, DOI 10.1038/clpt.2009.252; Tempark T, 2017, PHARMACOGENET GENOM, V27, P429, DOI 10.1097/FPC.0000000000000306; Vogel C, 2000, CURR DRUG METAB, V1, P391, DOI 10.2174/1389200003338884; Vyas PM, 2006, J PHARMACOL EXP THER, V319, P497, DOI 10.1124/jpet.106.105874; Walmsley SL, 1998, J ACQ IMMUN DEF SYND, V19, P498, DOI 10.1097/00042560-199812150-00009; Wang CW, 2018, J CLIN INVEST, V128, P985, DOI 10.1172/JCI93349; Wang CW, 2013, J ALLERGY CLIN IMMUN, V132, P713, DOI 10.1016/j.jaci.2013.04.036; Wang D, 2012, BMC MED GENOMICS, V5, DOI 10.1186/1755-8794-5-32; Wang YH, 2019, CLIN PHARMACOL THER, V105, P112, DOI 10.1002/cpt.1071; Watanabe H, 2017, J DERMATOL SCI, V88, P320, DOI 10.1016/j.jdermsci.2017.08.007; Watkins S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076211; Wei CY, 2012, J ALLERGY CLIN IMMUN, V129, P1562, DOI 10.1016/j.jaci.2011.12.990; Weinborn M, 2016, INT J DERMATOL, V55, P1225, DOI 10.1111/ijd.13350; WOLKENSTEIN P, 1995, ARCH DERMATOL, V131, P544, DOI 10.1001/archderm.131.5.544; Yang FP, 2014, PHARMACOGENOMICS, V15, P1461, DOI [10.2217/PGS.14.69, 10.2217/pgs.14.69]; Zhang FR, 2013, NEW ENGL J MED, V369, P1620, DOI 10.1056/NEJMoa1213096	55	22	22	2	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2021	147	4					1402	1412		10.1016/j.jaci.2020.08.003	http://dx.doi.org/10.1016/j.jaci.2020.08.003		APR 2021	11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RX3VK	32791162				2022-12-18	WOS:000647154500005
J	Stevens, WW; Staudacher, AG; Hulse, KE; Carter, RG; Winter, DR; Abdala-Valencia, H; Kato, A; Suh, L; Norton, JE; Huang, JLH; Peters, AT; Grammer, LC; Price, CPE; Conley, DB; Shintani-Smith, S; Tan, BK; Welch, KC; Kern, RC; Schleimer, RP				Stevens, Whitney W.; Staudacher, Anna G.; Hulse, Kathryn E.; Carter, Roderick G.; Winter, Deborah R.; Abdala-Valencia, Hiam; Kato, Atsushi; Suh, Lydia; Norton, James E.; Huang, Julia H.; Peters, Anju T.; Grammer, Leslie C.; Price, Caroline P. E.; Conley, David B.; Shintani-Smith, Stephanie; Tan, Bruce K.; Welch, Kevin C.; Kern, Robert C.; Schleimer, Robert P.			Activation of the 15-lipoxygenase pathway in aspirin-exacerbated respiratory disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chronic sinusitis; nasal polyps; CRSwNP; AERD; aspirin-exacerbated respiratory disease; 15-lipoxygenase; ALOX15; 15-oxo-eicosatetraenoic acid; hydroxyprostaglandin dehydrogenase		Background: Aspirin-exacerbated respiratory disease (AERD) is characterized by asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and an intolerance of medications that inhibit cyclooxygenase-1. Patients with AERD have more severe upper and lower respiratory tract disease than do aspirin-tolerant patients with CRSwNP. A dysregulation in arachidonic acid metabolism is thought to contribute to the enhanced sinonasal inflammation in AERD. Objective: Our aim was to utilize an unbiased approach investigating arachidonic acid metabolic pathways in AERD. Methods: Single-cell RNA sequencing (103 Genomics, Pleasanton, Calif) was utilized to compare the transcriptional profile of nasal polyp (NP) cells from patients with AERD and patients with CRSwNP and map differences in the expression of select genes among identified cell types. Findings were confirmed by traditional real-time PCR. Lipid mediators in sinonasal tissue were measured by mass spectrometry. Localization of various proteins within NPs was assessed by immunofluorescence. Results: The gene encoding for 15-lipooxygenase (15-LO), ALOX15, was significantly elevated in NPs of patients with AERD compared to NPs of patients with CRSwNP (P<.05) or controls (P<.001). ALOX15 was predominantly expressed by epithelial cells. Expression levels significantly correlated with radiographic sinus disease severity (r = 0.56; P<.001) and were associated with asthma. The level of 15-oxo-eicosatetraenoic acid (15-Oxo-ETE), a downstream product of 15-LO, was significantly elevated in NPs from patients with CRSwNP (27.93 pg/mg of tissue) and NPs from patients with AERD (61.03 pg/mg of tissue) compared to inferior turbinate tissue from controls (7.17 pg/mg of tissue [P<.001]). Hydroxyprostaglandin dehydrogenase, an enzyme required for 15-Oxo-ETE synthesis, was predominantly expressed in mast cells and localized near 15-LO+ epithelium in NPs from patients with AERD. Conclusions: Epithelial and mast cell interactions, leading to the synthesis of 15-Oxo-ETE, may contribute to the dysregulation of arachidonic acid metabolism via the 15-LO pathway and to the enhanced sinonasal disease severity observed in AERD.	[Stevens, Whitney W.; Staudacher, Anna G.; Hulse, Kathryn E.; Carter, Roderick G.; Kato, Atsushi; Suh, Lydia; Norton, James E.; Peters, Anju T.; Grammer, Leslie C.; Schleimer, Robert P.] Northwestern Univ, Feinberg Sch Med, Dept Med, Div Allergy & Immunol, Chicago, IL USA; [Stevens, Whitney W.; Huang, Julia H.; Peters, Anju T.; Price, Caroline P. E.; Conley, David B.; Shintani-Smith, Stephanie; Tan, Bruce K.; Welch, Kevin C.; Kern, Robert C.; Schleimer, Robert P.] Northwestern Univ, Feinberg Sch Med, Dept Otolaryngol, Chicago, IL USA; [Winter, Deborah R.] Northwestern Univ, Feinberg Sch Med, Div Rheumatol, Dept Med, Chicago, IL USA; [Abdala-Valencia, Hiam] Northwestern Univ, Feinberg Sch Med, Div Pulm & Crit Care Med, Dept Med, Chicago, IL USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine	Stevens, WW (corresponding author), Div Allergy Immunol, 211 E Ontario St,Suite 1000, Chicago, IL 60611 USA.	whitney-stevens@northwestern.edu	Smith, Stephanie Shintani/AAY-4854-2020	Smith, Stephanie Shintani/0000-0002-0605-3993; Winter, Deborah/0000-0003-1806-673X; /0000-0002-9590-7419	National Institutes of Health [KL2 TR001424, K23 AI141694, R01 AI104733, U19 AI106683, P01 145818]; Parker B. Francis Fellowship Foundation; HOPE APFED/AAAAI Pilot Grant Award; Ernest S. Bazley Foundation	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Parker B. Francis Fellowship Foundation; HOPE APFED/AAAAI Pilot Grant Award; Ernest S. Bazley Foundation	Supported in part by the grants from the National Institutes of Health (grants KL2 TR001424, K23 AI141694, R01 AI104733, U19 AI106683, and P01 145818), grants from the Parker B. Francis Fellowship Foundation, the HOPE APFED/AAAAI Pilot Grant Award, and the Ernest S. Bazley Foundation.	Atherton HC, 2003, AM J PHYSIOL-LUNG C, V285, pL730, DOI 10.1152/ajplung.00089.2003; Bankova LG, 2016, P NATL ACAD SCI USA, V113, P6242, DOI 10.1073/pnas.1605957113; Batra PS, 2013, LARYNGOSCOPE, V123, pS1, DOI 10.1002/lary.24418; Bhattacharyya N, 2019, LARYNGOSCOPE, V129, P1969, DOI 10.1002/lary.27852; Booth BW, 2001, AM J RESP CELL MOL, V25, P739, DOI 10.1165/ajrcmb.25.6.4659; Cahill KN, 2016, AM J RESP CELL MOL, V54, P34, DOI 10.1165/rcmb.2014-0486OC; Cahill KN, 2015, J ALLERGY CLIN IMMUN, V135, P245, DOI 10.1016/j.jaci.2014.07.031; CHRISTIE PE, 1991, AM REV RESPIR DIS, V143, P1025, DOI 10.1164/ajrccm/143.5_Pt_1.1025; Chu H. W., 2002, Clinical and Experimental Allergy, V32, P1558, DOI 10.1046/j.1365-2222.2002.01477.x; DAHLEN SE, 1983, P NATL ACAD SCI-BIOL, V80, P1712, DOI 10.1073/pnas.80.6.1712; Gulliksson M, 2007, BBA-MOL CELL BIOL L, V1771, P1156, DOI 10.1016/j.bbalip.2007.06.001; Hajek AR, 2008, J ALLERGY CLIN IMMUN, V122, P633, DOI 10.1016/j.jaci.2008.06.021; HAMBERG M, 1980, ACTA PHYSIOL SCAND, V110, P219, DOI 10.1111/j.1748-1716.1980.tb06656.x; HENKE D, 1988, ARCH BIOCHEM BIOPHYS, V267, P426, DOI 10.1016/0003-9861(88)90048-3; Jerschow E, 2017, J ALLER CL IMM-PRACT, V5, P998, DOI 10.1016/j.jaip.2016.11.021; JUNG TTK, 1987, LARYNGOSCOPE, V97, P184; Kowalski ML, 2003, J ALLERGY CLIN IMMUN, V112, P505, DOI 10.1067/mai.2003.1678; Kowalski ML, 2000, AM J RESP CRIT CARE, V161, P391, DOI 10.1164/ajrccm.161.2.9902034; Kristjansson RP, 2019, NAT GENET, V51, P267, DOI 10.1038/s41588-018-0314-6; KUMLIN M, 1990, ARCH BIOCHEM BIOPHYS, V282, P254, DOI 10.1016/0003-9861(90)90114-E; Laidlaw TM, 2016, NEW ENGL J MED, V374, P484, DOI 10.1056/NEJMcibr1514013; Li ZP, 2019, J ALLERGY CLIN IMMUN, V144, P1228, DOI 10.1016/j.jaci.2019.06.037; Lin DC, 2011, AM J RHINOL ALLERGY, V25, P205, DOI 10.2500/ajra.2011.25.3613; MAROM ZVI, 1982, AM REV RESPIR DIS, V126, P449; Mastalerz L, 2012, J Allergy (Cairo), V2012, P696792, DOI 10.1155/2012/696792; Mastalerz L, 2014, ALLERGY, V69, P1550, DOI 10.1111/all.12512; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; Ordovas-Montanes J, 2018, NATURE, V560, P649, DOI 10.1038/s41586-018-0449-8; Perez-Novo CA, 2005, J ALLERGY CLIN IMMUN, V115, P1189, DOI 10.1016/j.jaci.2005.02.029; PICADO C, 1991, ADV PROSTAG THROMB L, V21, P501; Powell WS, 2013, PROG LIPID RES, V52, P651, DOI 10.1016/j.plipres.2013.09.001; Promsopa C, 2016, INT FORUM ALLERGY RH, V6, P373, DOI 10.1002/alr.21674; Rajan JP, 2015, J ALLERGY CLIN IMMUN, V135, P676, DOI 10.1016/j.jaci.2014.08.020; Roca-Ferrer J, 2011, J ALLERGY CLIN IMMUN, V128, P66, DOI 10.1016/j.jaci.2011.01.065; Seshadri S, 2013, J ALLERGY CLIN IMMUN, V132, P1227, DOI 10.1016/j.jaci.2013.05.042; SLADEK K, 1994, AM J RESP CRIT CARE, V149, P940, DOI 10.1164/ajrccm.149.4.8143059; Stevens WW, 2017, J ALLER CL IMM-PRACT, V5, P1061, DOI 10.1016/j.jaip.2016.12.027; Stevens WW, 2015, AM J RESP CRIT CARE, V192, P682, DOI 10.1164/rccm.201412-2278OC; Takabayashi T, 2012, J ALLERGY CLIN IMMUN, V130, P410, DOI 10.1016/j.jaci.2012.02.046; ten Brinke A, 2002, J ALLERGY CLIN IMMUN, V109, P621, DOI 10.1067/mai.2002.122458; Van Bruaene N, 2008, J ALLERGY CLIN IMMUN, V121, P1435, DOI 10.1016/j.jaci.2008.02.018; Zhang Y, 2019, ALLERGY, V74, P131, DOI 10.1111/all.13489; Zhao JM, 2017, AM J RESP CELL MOL, V57, P692, DOI 10.1165/rcmb.2017-0031OC; Zhao JM, 2009, AM J RESP CRIT CARE, V179, P782, DOI 10.1164/rccm.200811-1744OC	44	22	23	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2021	147	2					600	612		10.1016/j.jaci.2020.04.031	http://dx.doi.org/10.1016/j.jaci.2020.04.031		FEB 2021	13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QF1NF	32371071	Green Accepted, Bronze			2022-12-18	WOS:000616665800022
J	Canna, SW; Cron, RQ				Canna, Scott W.; Cron, Randy Q.			Highways to hell: Mechanism-based management of cytokine storm syndromes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Cytokine storm; hemophagocytic lymphohistiocytosis; macrophage activation syndrome; cytokine release syndrome	MACROPHAGE ACTIVATION SYNDROME; JUVENILE IDIOPATHIC ARTHRITIS; FAMILIAL HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; ELEVATED SERUM-LEVELS; NATURAL-KILLER-CELLS; INTERFERON-GAMMA; T-CELLS; FREE INTERLEUKIN-18; RELEASE SYNDROME; GENE-EXPRESSION	Since the first textbook devoted to cytokine storm syndromes (CSSs) was published in 2019, the world has changed dramatically and the term's visibility has broadened. Herein, we define CSSs broadly to include life/organ-threatening systemic inflammation and immunopathology regardless of the context in which it occurs, recognizing that the indistinct borders of such a definition limit its utility. Nevertheless, we are focused on the pathomechanisms leading to CSSs, including impairment of granule-mediated cytotoxicity, specific viral infections, excess IL-18, and chimeric antigen receptor T-cell therapy. These mechanisms are often reflected in distinct clinical features, functional tests, and/or biomarker assessments. Moreover, these mechanisms often indicate specific, definitive treatments. This mechanism-focused organization is vital to both advancing the field and understanding the complexities in individual patients. However, increasing evidence suggests that these mechanisms interact and overlap. Likewise, the utility of a broad term such as "cytokine storm'' is that it reflects a convergence on a systemic inflammatory phenotype that, regardless of cause or context, may be amenable to "inflammo-stabilization.'' CSS research must improve our appreciation of its various mechanisms and their interactions and treatments, but it must also identify the signs and interventions that may broadly prevent CSS-induced immunopathology.	[Canna, Scott W.] Univ Pittsburgh, UPMC Childrens Hosp Pittsburgh, Pittsburgh, PA USA; [Cron, Randy Q.] Univ Alabama Birmingham, Birmingham Childrens Alabama, Birmingham, AL USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Alabama System; University of Alabama Birmingham	Canna, SW (corresponding author), 8124 Rangos,530 45th St, Pittsburgh, PA 15201 USA.	Scott.canna@chp.edu			RK Mellon Institute for Pediatric Research [R01 R01HD098428]	RK Mellon Institute for Pediatric Research	S.W.C. was supported by R01 R01HD098428 and the RK Mellon Institute for Pediatric Research.	Anft M, 2020, CELL MOL IMMUNOL, V17, P347, DOI 10.1038/s41423-019-0277-2; Avcin T, 2006, J PEDIATR-US, V148, P683, DOI 10.1016/j.jpeds.2005.12.070; Balamuth NJ, 2007, J PEDIAT HEMATOL ONC, V29, P569, DOI 10.1097/MPH.0b013e3180f61be3; Behrens EM, 2007, J RHEUMATOL, V34, P1133; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; Borgia RE, 2018, ARTHRITIS RHEUMATOL, V70, P616, DOI 10.1002/art.40417; Burn TN, 2020, ARTHRITIS RHEUMATOL, V72, P335, DOI 10.1002/art.41076; Canna SW, 2020, BLOOD, V135, P1332, DOI 10.1182/blood.2019000936; Canna SW, 2017, J ALLERGY CLIN IMMUN, V139, P1698, DOI 10.1016/j.jaci.2016.10.022; Canna SW, 2014, NAT GENET, V46, P1140, DOI 10.1038/ng.3089; Carcillo JA, 2017, PEDIATR CRIT CARE ME, V18, P513, DOI 10.1097/PCC.0000000000001122; Castillo L, 2009, PEDIATR CRIT CARE ME, V10, P387, DOI 10.1097/PCC.0b013e3181a1ae08; Chellapandian D, 2013, BRIT J HAEMATOL, V162, P376, DOI 10.1111/bjh.12386; Cron RQ, 2015, J RHEUMATOL, V42, P1078, DOI 10.3899/jrheum.150108; Delsing CE, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-166; Ehl S, 2018, J ALLER CL IMM-PRACT, V6, P1508, DOI 10.1016/j.jaip.2018.05.031; Eloseily EM, 2020, ARTHRITIS RHEUMATOL, V72, P326, DOI 10.1002/art.41103; Eloseily Esraa M A, 2019, ACR Open Rheumatol, V1, P345, DOI 10.1002/acr2.11048; Fardet L, 2014, ARTHRITIS RHEUMATOL, V66, P2613, DOI 10.1002/art.38690; Feldmann J, 2003, CELL, V115, P461, DOI 10.1016/S0092-8674(03)00855-9; Fitzsimmons L, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9110339; Gabay C, 2018, ANN RHEUM DIS, V77, P840, DOI 10.1136/annrheumdis-2017-212608; Gavand PE, 2017, AUTOIMMUN REV, V16, P743, DOI 10.1016/j.autrev.2017.05.010; Gernez Y, 2019, J ALLERGY CLIN IMMUN, V144, P1122, DOI 10.1016/j.jaci.2019.06.017; Girard C, 2016, RHEUMATOLOGY, V55, P2237, DOI 10.1093/rheumatology/kew300; Girard-Guyonvarc'h C, 2018, BLOOD, V131, P1430, DOI 10.1182/blood-2017-06-789552; Gloude NJ, 2020, J CLIN IMMUNOL, V40, P699, DOI 10.1007/s10875-020-00789-4; Goldstein Brahm, 2005, Pediatr Crit Care Med, V6, P2; Gorelik M, 2013, J RHEUMATOL, V40, P1191, DOI 10.3899/jrheum.121131; Group RC, N ENGL J MED; Grupp SA, 2013, NEW ENGL J MED, V368, P1509, DOI 10.1056/NEJMoa1215134; Henderson LA, ARTHRITIS RHEUMATOL; Henderson LA, 2020, ARTHRITIS RHEUMATOL, V72, P1059, DOI 10.1002/art.41285; Henter JI, 2007, PEDIATR BLOOD CANCER, V48, P124, DOI 10.1002/pbc.21039; Henter JI, 2002, BLOOD, V100, P2367, DOI 10.1182/blood-2002-01-0172; Hill GE, 1998, J CARDIOTHOR VASC AN, V12, P21; Hotchkiss RS, 2019, CRIT CARE MED, V47, P632, DOI 10.1097/CCM.0000000000003685; Hotchkiss RS, 2013, LANCET INFECT DIS, V13, P260, DOI 10.1016/S1473-3099(13)70001-X; House IG, 2015, IMMUNOL CELL BIOL, V93, P575, DOI 10.1038/icb.2015.1; Jenkins MR, 2015, J EXP MED, V212, P307, DOI 10.1084/jem.20140964; Jessen B, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00448; Jordan MB, 2004, BLOOD, V104, P735, DOI 10.1182/blood-2003-10-3413; Jordan MB, 2019, PEDIATR BLOOD CANCER, V66, DOI 10.1002/pbc.27929; Kasahara Y, 2002, CRIT REV ONCOL HEMAT, V44, P283, DOI 10.1016/S1040-8428(02)00119-1; Kaufman KM, 2014, ARTHRITIS RHEUMATOL, V66, P3486, DOI 10.1002/art.38793; Kawashima M, 2001, ARTHRITIS RHEUM-US, V44, P550, DOI 10.1002/1529-0131(200103)44:3<550::AID-ANR103>3.0.CO;2-5; Kyriazopoulou E, 2017, BMC MED, V15, DOI 10.1186/s12916-017-0930-5; La Rosee P, 2019, BLOOD, V133, P2465, DOI 10.1182/blood.2018894618; Lam MT, 2019, J EXP MED, V216, P2778, DOI 10.1084/jem.20190147; Lee DW, 2019, BIOL BLOOD MARROW TR, V25, P625, DOI 10.1016/j.bbmt.2018.12.758; Locatelli F, 2020, NEW ENGL J MED, V382, P1811, DOI 10.1056/NEJMoa1911326; Lucas C, 2020, NATURE, V584, P463, DOI 10.1038/s41586-020-2588-y; Lykens JE, 2011, BLOOD, V118, P618, DOI 10.1182/blood-2010-12-324533; Mace EM, 2019, IMMUNOL REV, V287, P202, DOI 10.1111/imr.12725; Maeno N, 2002, ARTHRITIS RHEUM, V46, P2539, DOI 10.1002/art.10389; Marsh RA, 2010, BLOOD, V116, P1079, DOI 10.1182/blood-2010-01-256099; Maude SL, 2014, NEW ENGL J MED, V371, P1507, DOI 10.1056/NEJMoa1407222; Meisel C, 2009, AM J RESP CRIT CARE, V180, P640, DOI 10.1164/rccm.200903-0363OC; Michels M, 2015, CLIN VACCINE IMMUNOL, V22, P650, DOI 10.1128/CVI.00147-15; Milone MC, 2005, BLOOD, V105, P994, DOI 10.1182/blood-2004-07-2965; Minoia F, 2019, ANN RHEUM DIS, V78, P1357, DOI 10.1136/annrheumdis-2019-215211; Minoia F, 2017, J PEDIATR-US, V189, P72, DOI 10.1016/j.jpeds.2017.06.005; Minoia F, 2014, ARTHRITIS RHEUMATOL, V66, P3160, DOI 10.1002/art.38802; Netter P, 2017, J IMMUNOL, V199, P2528, DOI 10.4049/jimmunol.1700394; Novick D, 2010, J AUTOIMMUN, V34, P121, DOI 10.1016/j.jaut.2009.08.002; Pagano JS, 2018, CANCERS, V10, DOI 10.3390/cancers10060197; Pasquier B, 2005, J EXP MED, V201, P695, DOI 10.1084/jem.20042432; Payen D, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4526-x; Put K, 2017, ARTHRITIS RHEUMATOL, V69, P213, DOI 10.1002/art.39933; Raith EP, 2017, JAMA-J AM MED ASSOC, V317, P290, DOI 10.1001/jama.2016.20328; Ravelli A, 2012, GENES IMMUN, V13, P289, DOI 10.1038/gene.2012.3; Ravelli A, 2016, ARTHRITIS RHEUMATOL, V68, P566, DOI 10.1002/art.39332; Romberg N, 2017, CURR OPIN ALLERGY CL, V17, P398, DOI 10.1097/ACI.0000000000000396; Romberg N, 2014, NAT GENET, V46, P1135, DOI 10.1038/ng.3066; Rood JE, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02642; Rood JE, 2016, BLOOD, V127, P426, DOI 10.1182/blood-2015-07-659813; Schmid JP, 2010, IMMUNOL REV, V235, P10, DOI 10.1111/j.0105-2896.2010.00890.x; Schmid JP, 2011, BLOOD, V117, P1522, DOI 10.1182/blood-2010-07-298372; Schulert GS, 2018, INT IMMUNOL, V30, P195, DOI 10.1093/intimm/dxy012; Schulert GS, 2018, ARTHRIT CARE RES, V70, P409, DOI 10.1002/acr.23277; Schulert GS, 2016, J INFECT DIS, V213, P1180, DOI 10.1093/infdis/jiv550; Sebastio G, 2011, AM J MED GENET C, V157C, P54, DOI 10.1002/ajmg.c.30287; Sepulveda FE, 2015, BLOOD, V125, P1427, DOI 10.1182/blood-2014-09-602946; Shah NN, 2020, J CLIN ONCOL, V38, P1938, DOI 10.1200/JCO.19.03279; Shakoory B, 2016, CRIT CARE MED, V44, P275, DOI 10.1097/CCM.0000000000001402; Shimizu M, 2019, CLIN IMMUNOL, V207, P36, DOI 10.1016/j.clim.2019.07.005; Shimizu M, 2015, CLIN IMMUNOL, V160, P277, DOI 10.1016/j.clim.2015.06.005; Shimizu M, 2012, CYTOKINE, V58, P287, DOI 10.1016/j.cyto.2012.02.006; Shimizu M, 2010, RHEUMATOLOGY, V49, P1645, DOI 10.1093/rheumatology/keq133; Snow AL, 2009, J CLIN INVEST, V119, P2976, DOI 10.1172/JCI39518; Suntharalingam G, 2006, NEW ENGL J MED, V355, P1018, DOI 10.1056/NEJMoa063842; Tan HY, 2015, AIDS, V29, P421, DOI 10.1097/QAD.0000000000000557; Taylor Matthew D, 2018, Immunohorizons, V2, P67, DOI 10.4049/immunohorizons.1800003; Teachey DT, 2016, CANCER DISCOV, V6, P664, DOI 10.1158/2159-8290.CD-16-0040; Teachey DT, 2013, BLOOD, V121, P5154, DOI 10.1182/blood-2013-02-485623; Terrell CE, 2013, BLOOD, V122, P2618, DOI 10.1182/blood-2013-06-508143; Tesi B, 2015, J ALLERGY CLIN IMMUN, V135, P1638, DOI 10.1016/j.jaci.2014.11.030; Trambas C, 2005, BLOOD, V106, P932, DOI 10.1182/blood-2004-09-3713; Tsoukas P, BLOOD; Ulloa-Gutierrez R, 2019, CYTOKINE STORM SYNDROME, P393, DOI 10.1007/978-3-030-22094-5_23; Wada T, 2014, CYTOKINE, V65, P74, DOI 10.1016/j.cyto.2013.09.007; Weiss ES, 2018, BLOOD, V131, P1442, DOI 10.1182/blood-2017-12-820852; Weiss SL, 2015, AM J RESP CRIT CARE, V191, P1147, DOI 10.1164/rccm.201412-2323OC; Wohlfarth P, 2019, J INTENSIVE CARE MED, V34, P723, DOI 10.1177/0885066617711386; Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994; Yasin S, 2020, RHEUMATOLOGY, V59, P442, DOI 10.1093/rheumatology/kez284; Yasin S, 2020, RHEUMATOLOGY, V59, P361, DOI 10.1093/rheumatology/kez282; Yin HL, 2019, MED MICROBIOL IMMUN, V208, P573, DOI 10.1007/s00430-018-0570-1; Zhang KJ, 2011, BLOOD, V118, P5794, DOI 10.1182/blood-2011-07-370148; Zhou T, 2020, NATURE, V583, P609, DOI 10.1038/s41586-020-2422-6; Zoller EE, 2011, J EXP MED, V208, P1203, DOI 10.1084/jem.20102538	111	22	23	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2020	146	5					949	959		10.1016/j.jaci.2020.09.016	http://dx.doi.org/10.1016/j.jaci.2020.09.016			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	OP5VH	33007328	Bronze, Green Published			2022-12-18	WOS:000588153700031
J	Muehling, LM; Heymann, PW; Wright, PW; Eccles, JD; Agrawal, R; Carper, HT; Murphy, DD; Workman, LJ; Word, CR; Ratcliffe, SJ; Capaldo, BJ; Platts-Mills, TAE; Turner, RB; Kwok, WW; Woodfolk, JA				Muehling, Lyndsey M.; Heymann, Peter W.; Wright, Paul W.; Eccles, Jacob D.; Agrawal, Rachana; Carper, Holliday T.; Murphy, Deborah D.; Workman, Lisa J.; Word, Carolyn R.; Ratcliffe, Sarah J.; Capaldo, Brian J.; Platts-Mills, Thomas A. E.; Turner, Ronald B.; Kwok, William W.; Woodfolk, Judith A.			Human T(H)1 and T(H)2 cells targeting rhinovirus and allergen coordinately promote allergic asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Rhinovirus; asthma; IFN; cytokines; T cells; T(H)1; T(H)2; tetramers; anti-IgE	BRONCHIAL EPITHELIAL-CELLS; THYMIC STROMAL LYMPHOPOIETIN; INNATE IMMUNE-RESPONSES; VIRUS-INDUCED ASTHMA; CD4(+) T-CELLS; TYPE-2 INFLAMMATION; RESPIRATORY ILLNESS; IFN-GAMMA; TH1 CELLS; EXPRESSION	Background: Allergic asthmatic subjects are uniquely susceptible to acute wheezing episodes provoked by rhinovirus. However, the underlying immune mechanisms and interaction between rhinovirus and allergy remain enigmatic, and current paradigms are controversial. Objective: We sought to perform a comprehensive analysis of type 1 and type 2 innate and adaptive responses in allergic asthmatic subjects infected with rhinovirus. Methods: Circulating virus-specific T(H)1 cells and allergenspecific T(H)2 cells were precisely monitored before and after rhinovirus challenge in allergic asthmatic subjects (total IgE, 133-4692 IU/mL; n = 28) and healthy nonallergic controls (n = 12) using peptide/MHCII tetramers. T cells were sampled for up to 11 weeks to capture steady-state and postinfection phases. T-cell responses were analyzed in parallel with 18 cytokines in the nose, upper and lower airway symptoms, and lung function. The influence of in vivo IgE blockade was also examined. Results: In uninfected asthmatic subjects, higher numbers of circulating virus-specific PD-1(+) T(H)1 cells, but not allergenspecific T(H)2 cells, were linked to worse lung function. Rhinovirus infection induced an amplified antiviral T(H)1 response in asthmatic subjects versus controls, with synchronized allergen-specific T(H)2 expansion, and production of type 1 and 2 cytokines in the nose. In contrast, T(H)2 responses were absent in infected asthmatic subjects who had normal lung function, and in those receiving anti-IgE. Across all subjects, early induction of a minimal set of nasal cytokines that discriminated high responders (G-CSF, IFN-gamma, TNF-alpha) correlated with both egress of circulating virus-specific T(H)1 cells and worse symptoms. Conclusions: Rhinovirus induces robust T(H)1 responses in allergic asthmatic subjects that may promote disease, even after the infection resolves.	[Muehling, Lyndsey M.; Wright, Paul W.; Eccles, Jacob D.; Agrawal, Rachana; Workman, Lisa J.; Platts-Mills, Thomas A. E.; Woodfolk, Judith A.] Univ Virginia, Sch Med, Dept Med, Charlottesville, VA 22908 USA; [Muehling, Lyndsey M.; Eccles, Jacob D.; Capaldo, Brian J.; Woodfolk, Judith A.] Univ Virginia, Sch Med, Dept Microbiol, Charlottesville, VA 22908 USA; [Heymann, Peter W.; Carper, Holliday T.; Murphy, Deborah D.; Word, Carolyn R.; Turner, Ronald B.] Univ Virginia, Sch Med, Dept Pediat, Charlottesville, VA 22908 USA; [Ratcliffe, Sarah J.] Univ Virginia, Sch Med, Dept Publ Hlth Sci, Charlottesville, VA USA; [Kwok, William W.] Virginia Mason, Benaroya Res Inst, Seattle, VA USA	University of Virginia; University of Virginia; University of Virginia; University of Virginia; Benaroya Research Institute; Virginia Mason Medical Center	Woodfolk, JA (corresponding author), Univ Virginia Hlth Syst, Allergy Div, POB 801355, Charlottesville, VA 22908 USA.	jaw4m@virginia.edu	Ratcliffe, Sarah J/GYR-1110-2022	Ratcliffe, Sarah J/0000-0002-6644-8284; Platts-Mills, Thomas/0000-0002-1263-329X	Novartis Pharmaceuticals; National Institutes of Health/National Institute of Allergy and Infectious Diseases (NIH/NIAID) [U01 AI100799, R01 AI020565, U01 AI125056, T32 AI007496]	Novartis Pharmaceuticals(Novartis); National Institutes of Health/National Institute of Allergy and Infectious Diseases (NIH/NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by Novartis Pharmaceuticals and the National Institutes of Health/National Institute of Allergy and Infectious Diseases (NIH/NIAID) (grant nos. U01 AI100799, R01 AI020565, U01 AI125056, and T32 AI007496).	Agrawal R, 2014, CLIN EXP ALLERGY, V44, P1266, DOI 10.1111/cea.12390; Altman MC, 2019, NAT IMMUNOL, V20, P637, DOI 10.1038/s41590-019-0347-8; Altman MC, 2018, J ALLERGY CLIN IMMUN, V142, P451, DOI 10.1016/j.jaci.2017.10.004; Avice MN, 1998, J IMMUNOL, V161, P3408; Bangs SC, 2009, J IMMUNOL, V182, P1962, DOI 10.4049/jimmunol.0802596; Baumann C, 2015, P NATL ACAD SCI USA, V112, P4056, DOI 10.1073/pnas.1418549112; Bratke K, 2013, CLIN EXP ALLERGY, V43, P312, DOI 10.1111/cea.12064; Busse WW, 2011, NEW ENGL J MED, V364, P1005, DOI 10.1056/NEJMoa1009705; Byington CL, 2015, CLIN INFECT DIS, V61, P1217, DOI 10.1093/cid/civ486; Castanhinha S, 2015, J ALLERGY CLIN IMMUN, V136, P312, DOI 10.1016/j.jaci.2015.01.016; Celada LJ, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aar8356; Chakir H, 2003, EUR J IMMUNOL, V33, P1788, DOI 10.1002/eji.200323398; Contoli M, 2015, ALLERGY, V70, P910, DOI 10.1111/all.12627; Contoli M, 2006, NAT MED, V12, P1023, DOI 10.1038/nm1462; DeMore JP, 2009, J ALLERGY CLIN IMMUN, V124, P245, DOI 10.1016/j.jaci.2009.05.030; Dougherty RH, 2009, CLIN EXP ALLERGY, V39, P193, DOI 10.1111/j.1365-2222.2008.03157.x; Durrani SR, 2012, J ALLERGY CLIN IMMUN, V130, P489, DOI 10.1016/j.jaci.2012.05.023; Eccles JD, 2020, CELL REP, V30, P351, DOI 10.1016/j.celrep.2019.12.027; Fitzpatrick AM, 2010, J ALLERGY CLIN IMMUN, V125, P851, DOI 10.1016/j.jaci.2010.01.048; Fleming HE, 1999, AM J RESP CRIT CARE, V160, P100, DOI 10.1164/ajrccm.160.1.9808074; Geng Y, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.125326; Gern JE, 2000, AM J RESP CRIT CARE, V162, P2226, DOI 10.1164/ajrccm.162.6.2003019; Gill MA, 2018, J ALLERGY CLIN IMMUN, V141, P1735, DOI 10.1016/j.jaci.2017.07.035; Gill MA, 2010, J IMMUNOL, V184, P5999, DOI 10.4049/jimmunol.0901194; Griffith JW, 2014, ANNU REV IMMUNOL, V32, P659, DOI 10.1146/annurev-immunol-032713-120145; Gwaltney JM, 1996, CLIN INFECT DIS, V23, P1209, DOI 10.1093/clinids/23.6.1209; Hansel TT, 2017, EBIOMEDICINE, V19, P128, DOI 10.1016/j.ebiom.2017.03.033; Hansen G, 1999, J CLIN INVEST, V103, P175, DOI 10.1172/JCI5155; Hatchwell L, 2015, THORAX, V70, P854, DOI 10.1136/thoraxjnl-2014-205465; Heymann Peter W, 2005, Pediatr Infect Dis J, V24, pS217, DOI 10.1097/01.inf.0000188164.33856.f9; Heymann PW, 2020, J ALLERGY CLIN IMMUN, V146, P545, DOI 10.1016/j.jaci.2020.01.035; Heymann PW, 2004, J ALLERGY CLIN IMMUN, V114, P239, DOI 10.1016/j.jaci.2004.04.006; Hirai H, 2001, J EXP MED, V193, P255, DOI 10.1084/jem.193.2.255; Hou WQ, 2009, J EXP MED, V206, P313, DOI 10.1084/jem.20082030; Jackson DJ, 2014, AM J RESP CRIT CARE, V190, P1373, DOI 10.1164/rccm.201406-1039OC; JACKSON GG, 1959, J CLIN INVEST, V38, P762, DOI 10.1172/JCI103857; Jarjour NN, 2000, J ALLERGY CLIN IMMUN, V105, P1169, DOI 10.1067/mai.2000.106376; Kantor DB, 2016, J ALLERGY CLIN IMMUN, V138, P1467, DOI 10.1016/j.jaci.2016.04.044; Kennedy JL, 2014, AM J RESP CRIT CARE, V189, P532, DOI 10.1164/rccm.201310-1767OC; Kwok WW, 2010, J ALLERGY CLIN IMMUN, V125, P1407, DOI 10.1016/j.jaci.2010.03.037; Lynch JP, 2016, J ALLERGY CLIN IMMUN, V138, P1326, DOI 10.1016/j.jaci.2016.02.039; Message SD, 2008, P NATL ACAD SCI USA, V105, P13562, DOI 10.1073/pnas.0804181105; MONTO AS, 1974, JAMA-J AM MED ASSOC, V227, P164, DOI 10.1001/jama.227.2.164; Muehling LM, 2018, J INFECT DIS, V217, P381, DOI 10.1093/infdis/jix514; Muehling LM, 2016, J IMMUNOL, V197, P3214, DOI 10.4049/jimmunol.1600663; National Heart Lung and Blood Institute, 2007, 074051 NAT HEART LUN; Papadopoulos NG, 2002, CLIN EXP ALLERGY, V32, P537, DOI 10.1046/j.0954-7894.2002.01313.x; Patel DA, 2014, J ALLERGY CLIN IMMUN, V134, P1402, DOI 10.1016/j.jaci.2014.07.013; Portales-Cervantes L, 2020, J ALLERGY CLIN IMMUN, V146, P675, DOI 10.1016/j.jaci.2020.02.011; Prefontaine D, 2010, J ALLERGY CLIN IMMUN, V125, P752, DOI 10.1016/j.jaci.2009.12.935; Prefontaine D, 2009, J IMMUNOL, V183, P5094, DOI 10.4049/jimmunol.0802387; Rakes CP, 1999, AM J RESP CRIT CARE, V159, P785, DOI 10.1164/ajrccm.159.3.9801052; Randolph DA, 1999, J CLIN INVEST, V104, P1021, DOI 10.1172/JCI7631; Ravi A, 2019, J ALLERGY CLIN IMMUN, V143, P442, DOI 10.1016/j.jaci.2018.09.016; Schluns KS, 2003, NAT REV IMMUNOL, V3, P269, DOI 10.1038/nri1052; Schwantes EA, 2014, CLIN EXP ALLERGY, V44, P813, DOI 10.1111/cea.12269; Soto-Quiros M, 2012, J ALLERGY CLIN IMMUN, V129, P1499, DOI 10.1016/j.jaci.2012.03.040; Spergel JM, 2005, J ASTHMA, V42, P879, DOI 10.1080/02770900500371344; Stephens R, 2002, J IMMUNOL, V169, P5458, DOI 10.4049/jimmunol.169.10.5458; Sykes A, 2014, THORAX, V69, P240, DOI 10.1136/thoraxjnl-2012-202909; Sykes A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065921; Sykes A, 2012, J ALLERGY CLIN IMMUN, V129, P1506, DOI 10.1016/j.jaci.2012.03.044; Tough DF, 1997, J EXP MED, V185, P2089, DOI 10.1084/jem.185.12.2089; Uller L, 2010, THORAX, V65, P626, DOI 10.1136/thx.2009.125930; UNUTMAZ D, 1994, J EXP MED, V180, P1159, DOI 10.1084/jem.180.3.1159; Wambre E, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aam9171; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901; Werder RB, 2018, J ALLERGY CLIN IMMUN, V141, P1607, DOI 10.1016/j.jaci.2017.07.051; Wisniewski JA, 2018, J ALLERGY CLIN IMMUN, V141, P2048, DOI 10.1016/j.jaci.2017.08.020; Ying S, 2008, J IMMUNOL, V181, P2790, DOI 10.4049/jimmunol.181.4.2790; Zambrano JC, 2003, J ALLERGY CLIN IMMUN, V111, P1008, DOI 10.1067/mai.2003.1396; Zhu J, 2019, J ALLERGY CLIN IMMUN, V143, P114, DOI 10.1016/j.jaci.2018.04.003	72	22	22	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2020	146	3					555	570		10.1016/j.jaci.2020.03.037	http://dx.doi.org/10.1016/j.jaci.2020.03.037			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NO0HS	32320734	Green Accepted, Bronze			2022-12-18	WOS:000569168900009
J	Gudjonsson, JE; Kabashima, K; Eyerich, K				Gudjonsson, Johann E.; Kabashima, Kenji; Eyerich, Kilian			Mechanisms of skin autoimmunity: Cellular and soluble immune components of the skin	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Immune response pattern; autoimmunity; T cell; B cell; autoantigen	CHRONIC SPONTANEOUS URTICARIA; AUTOREACTIVE T-CELLS; PEMPHIGUS-VULGARIS; ALOPECIA-AREATA; AUTOANTIBODY PRODUCTION; ATOPIC-DERMATITIS; VITILIGO PATIENTS; PERIPHERAL-BLOOD; PSORIASIS; RESPONSES	Autoimmune diseases are driven by either T cells or antibodies reacting specifically to 1 or more self-antigens. Although a number of self-antigens associated with skin diseases have been identified, the causative antigen(s) remains unknown in the great majority of skin diseases suspected to be autoimmune driven. Model diseases such as pemphigus, dermatitis herpetiformis, and more recently psoriasis have added greatly to our understanding of skin autoimmunity. Depending on the dominant T- or B-cell phenotype, skin autoimmune diseases usually follow 1 of 6 immune response patterns: lichenoid, eczematous, bullous, psoriatic, fibrogenic, or granulomatous. Usually, skin autoimmunity develops as a consequence of several events-an altered microbiome, inherited dysfunctional immunity, antigens activating innate immunity, epigenetic modifications, sex predisposition, and impact of antigens either as neoantigen or through molecular mimicry. This review summarizes currently known antigens of skin autoimmune diseases and discusses mechanisms of skin autoimmunity.	[Gudjonsson, Johann E.] Univ Michigan, Dept Dermatol, Ann Arbor, MI 48109 USA; [Kabashima, Kenji] Kyoto Univ, Grad Sch Med, Dept Dermatol, Kyoto, Japan; [Eyerich, Kilian] Karolinska Inst, Dept Med Solna, Div Dermatol & Venereol, Stockholm, Sweden; [Eyerich, Kilian] Karolinska Inst, Ctr Mol Med, Stockholm, Sweden; [Eyerich, Kilian] Karolinska Univ Hosp, Unit Dermatol, Dept Dermatol & Venereol, Stockholm, Sweden; [Eyerich, Kilian] Tech Univ Munich, Dept Dermatol & Allergy, Munich, Germany	University of Michigan System; University of Michigan; Kyoto University; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Technical University of Munich	Eyerich, K (corresponding author), Karolinska Inst, S-17177 Stockholm, Sweden.	kilian.eyerich@ki.se			European Research Council (ERC) grant (Individualized Medicine in inflammatory Skin diseases [IMCIS]) [676858]; German Research Foundation [EY97/3-2]	European Research Council (ERC) grant (Individualized Medicine in inflammatory Skin diseases [IMCIS]); German Research Foundation(German Research Foundation (DFG))	K.E. is supported by a European Research Council (ERC) grant (Individualized Medicine in inflammatory Skin diseases [IMCIS], 676858) and the German Research Foundation (grant no. EY97/3-2).	Allenspach EJ, 2017, J ALLERGY CLIN IMMUN, V140, P616, DOI 10.1016/j.jaci.2017.02.017; Anzai A, 2019, INT IMMUNOL, V31, P439, DOI 10.1093/intimm/dxz039; Arakawa A, 2015, J EXP MED, V212, P2203, DOI 10.1084/jem.20151093; Auyeung P, 2016, J ALLERGY CLIN IMMUN, V138, P761, DOI 10.1016/j.jaci.2016.04.036; Baioumy SA, 2018, IMMUNOBIOLOGY, V223, P807, DOI 10.1016/j.imbio.2018.08.009; Baker BS, 2001, CLIN EXP IMMUNOL, V124, P516, DOI 10.1046/j.1365-2249.2001.01563.x; Balaji H, 2011, J ALLERGY CLIN IMMUN, V128, P92, DOI 10.1016/j.jaci.2011.02.043; Bieber T, 2008, NEW ENGL J MED, V358, P1483, DOI 10.1056/NEJMra074081; Billi AC, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.127291; Boniface K, 2018, J INVEST DERMATOL, V138, P355, DOI 10.1016/j.jid.2017.08.038; Bracken SJ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00627; Brown EM, 2019, ANNU REV IMMUNOL, V37, P599, DOI 10.1146/annurev-immunol-042718-041841; Cheuk S, 2017, IMMUNITY, V46, P287, DOI 10.1016/j.immuni.2017.01.009; Cheung KL, 2016, J EXP MED, V213, P2399, DOI 10.1084/jem.20160258; Cho MJ, 2016, J IMMUNOL, V197, P1065, DOI 10.4049/jimmunol.1600567; Collin P, 2017, ANN MED, V49, P23, DOI 10.1080/07853890.2016.1222450; de Jong A, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.121949; Dellacecca ER, 2020, J INVEST DERMATOL, V140, P676, DOI 10.1016/j.jid.2019.08.435; Deng QC, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00856; Dereure O, 2006, BRIT J DERMATOL, V154, P445, DOI 10.1111/j.1365-2133.2005.07044.x; Dharamsi JW, 2013, JAMA DERMATOL, V149, P1159, DOI 10.1001/jamadermatol.2013.4207; Dong YY, 2017, IMMUNOL LETT, V191, P1, DOI 10.1016/j.imlet.2017.09.003; Ellebrecht CT, 2016, SCIENCE, V353, P179, DOI 10.1126/science.aaf6756; Ellebrecht CT, 2016, J AUTOIMMUN, V68, P14, DOI 10.1016/j.jaut.2015.08.007; Emmanuel T, 2019, ACTA DERM-VENEREOL, V99, P909, DOI 10.2340/00015555-3233; Ewald DA, 2017, J ALLERGY CLIN IMMUN, V139, P562, DOI 10.1016/j.jaci.2016.08.029; Eyerich K, 2018, J EUR ACAD DERMATOL, V32, P692, DOI 10.1111/jdv.14673; Eyerich K, 2019, J ALLERGY CLIN IMMUN, V143, P36, DOI 10.1016/j.jaci.2018.10.033; Eyerich S, 2014, EUR J IMMUNOL, V44, P3475, DOI 10.1002/eji.201444891; Eyerich S, 2011, NEW ENGL J MED, V365, P231, DOI 10.1056/NEJMoa1104200; Feliciani C, 2019, GIORN ITAL DERMAT V, V154, P256, DOI 10.23736/S0392-0488.18.06153-9; Fiebiger E, 1995, J CLIN INVEST, V96, P2606, DOI 10.1172/JCI118325; Fink AL, 2018, CURR OPIN PHYSIOL, V6, P16, DOI 10.1016/j.cophys.2018.03.010; Fischer A, 2017, J ALLERGY CLIN IMMUN, V140, P1388, DOI 10.1016/j.jaci.2016.12.978; Freyschmidt-Paul P, 2006, BRIT J DERMATOL, V155, P515, DOI 10.1111/j.1365-2133.2006.07377.x; Garzorz-Stark N, 2018, J ALLERGY CLIN IMMUN, V141, P1320, DOI 10.1016/j.jaci.2017.07.045; Gilhar A, 2001, J INVEST DERMATOL, V117, P1357, DOI 10.1046/j.0022-202x.2001.01583.x; Gudjonsson JE, 2007, CLIN DERMATOL, V25, P535, DOI 10.1016/j.clindermatol.2007.08.007; Herre J, 2013, J IMMUNOL, V191, P1529, DOI 10.4049/jimmunol.1300284; Huang SL, 2019, SCAND J IMMUNOL, V90, DOI 10.1111/sji.12799; Irvine AD, 2011, NEW ENGL J MED, V365, P1315, DOI 10.1056/NEJMra1011040; Jarrett R, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad6833; Jin Y, 2015, PIGM CELL MELANOMA R, V28, DOI 10.1111/pcmr.12356; Johnston A, 2004, CLIN EXP IMMUNOL, V138, P83, DOI 10.1111/j.1365-2249.2004.00600.x; Joly P, 2007, NEW ENGL J MED, V357, P545, DOI 10.1056/NEJMoa067752; Joly P, 2017, LANCET, V389, P2031, DOI 10.1016/S0140-6736(17)30070-3; Khatri S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01487; Kim JH, 2016, NAT IMMUNOL, V17, P1159, DOI 10.1038/ni.3523; Klemann C, 2016, CLIN EXP IMMUNOL, V185, P1, DOI 10.1111/cei.12781; Kolkhir P, 2017, AUTOIMMUN REV, V16, P1196, DOI 10.1016/j.autrev.2017.10.003; Kreuter A, 2009, ARCH DERMATOL, V145, P1164, DOI 10.1001/archdermatol.2009.225; Kridin K, 2019, AUTOIMMUN REV, V18, P786, DOI 10.1016/j.autrev.2019.06.007; Lande R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6621; Lauffer F, 2018, J INVEST DERMATOL, V138, P1785, DOI 10.1016/j.jid.2018.02.034; Liang Y, 2017, NAT IMMUNOL, V18, P152, DOI 10.1038/ni.3643; Lin L, 2019, J ALLERGY CLIN IMMUN, V144, P720, DOI 10.1016/j.jaci.2019.04.020; Lu Q, 2007, J IMMUNOL, V179, P6352, DOI 10.4049/jimmunol.179.9.6352; Lu QJ, 2002, ARTHRITIS RHEUM, V46, P1282, DOI 10.1002/art.10234; Luksza M, 2017, NATURE, V551, P517, DOI 10.1038/nature24473; Mandelcorn-Monson RL, 2003, J INVEST DERMATOL, V121, P550, DOI 10.1046/j.1523-1747.2003.12413.x; Martini E, 2017, J INVEST DERMATOL, V137, P865, DOI 10.1016/j.jid.2016.11.033; Matos TR, 2017, J CLIN INVEST, V127, P4031, DOI 10.1172/JCI93396; McGranahan N, 2016, SCIENCE, V351, P1463, DOI 10.1126/science.aaf1490; Mikus M, 2019, CLIN TRANSL ALLERGY, V9, DOI 10.1186/s13601-019-0240-4; Miodovnik M, 2017, EXP DERMATOL, V26, P1221, DOI 10.1111/exd.13357; Nakajima K, 2018, J DERMATOL, V45, P252, DOI 10.1111/1346-8138.14112; Nishie W, 2019, J INVEST DERMATOL, V139, P755, DOI 10.1016/j.jid.2018.11.025; Nishimoto S, 2013, J IMMUNOL, V191, P3065, DOI 10.4049/jimmunol.1300348; Olivares M, 2015, GUT, V64, P406, DOI 10.1136/gutjnl-2014-306931; Palermo B, 2001, J INVEST DERMATOL, V117, P326, DOI 10.1046/j.1523-1747.2001.01408.x; Pan M, 2015, J DERMATOL, V42, P11, DOI 10.1111/1346-8138.12697; Petukhova L, 2010, NATURE, V466, P113, DOI 10.1038/nature09114; Purcell AW, 2019, DIABETES, V68, P879, DOI 10.2337/dbi18-0066; Qian Y, 2012, J IMMUNOL, V189, P1535, DOI 10.4049/jimmunol.1200842; Qiu JY, 2020, PROTEOM CLIN APPL, V14, DOI 10.1002/prca.201800114; Quaranta M, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008946; Rehman A, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1988-0; Roesner LM, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02128; Roesner LM, 2016, J IMMUNOL, V196, P3245, DOI 10.4049/jimmunol.1500351; Rojas M, 2018, J AUTOIMMUN, V95, P100, DOI 10.1016/j.jaut.2018.10.012; Rosenbaum JT, 2018, NAT REV RHEUMATOL, V14, P704, DOI 10.1038/s41584-018-0097-2; Ruff WE, 2019, CELL HOST MICROBE, V26, P100, DOI 10.1016/j.chom.2019.05.003; Ruiz-Romeu E, 2016, J ALLERGY CLIN IMMUN, V138, P491, DOI 10.1016/j.jaci.2016.02.008; Russell JT, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11460-x; Saschenbrecker S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01974; Scherm MG, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13587-3; Schmetzer O, 2018, J ALLERGY CLIN IMMUN, V142, P876, DOI 10.1016/j.jaci.2017.10.035; Schmid-Grendelmeier P, 2005, J ALLERGY CLIN IMMUN, V115, P1068, DOI 10.1016/j.jaci.2005.01.065; Schmidt E, 2019, LANCET, V394, P882, DOI 10.1016/S0140-6736(19)31778-7; Schmidt M, 2010, NAT IMMUNOL, V11, P814, DOI 10.1038/ni.1919; Schmidt T, 2018, J ALLERGY CLIN IMMUN, V142, P669, DOI 10.1016/j.jaci.2018.02.044; Selmi C, 2019, CLIN REV ALLERG IMMU, V56, P375, DOI 10.1007/s12016-019-08745-w; Serezal IG, 2019, J ALLERGY CLIN IMMUN, V143, P1444, DOI 10.1016/j.jaci.2018.08.048; Serezal IG, 2018, J INVEST DERMATOL, V138, P1754, DOI 10.1016/j.jid.2018.02.030; Shao S, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aav7561; Shen Z, 2005, J DERMATOL SCI, V38, P25, DOI 10.1016/j.jdermsci.2005.01.001; Silverman M, 2017, P NATL ACAD SCI USA, V114, P9671, DOI 10.1073/pnas.1712280114; Spindler V, 2018, J INVEST DERMATOL, V138, P32, DOI 10.1016/j.jid.2017.06.022; Srivastava A, 2017, J ALLERGY CLIN IMMUN, V139, P550, DOI 10.1016/j.jaci.2016.07.025; Takahashi H, 2019, INT IMMUNOL, V31, P431, DOI 10.1093/intimm/dxz030; Takahashi H, 2011, J CLIN INVEST, V121, P3677, DOI 10.1172/JCI57379; Takahashi H, 2009, J IMMUNOL, V182, P1740, DOI 10.4049/jimmunol.182.3.1740; Trompette A, 2009, NATURE, V457, P585, DOI 10.1038/nature07548; Tsoi LC, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15382; Veldman C, 2003, J IMMUNOL, V170, P635, DOI 10.4049/jimmunol.170.1.635; Verdelli A, 2019, J EUR ACAD DERMATOL, V33, P742, DOI 10.1111/jdv.15147; Wang YH, 2019, MED SCI MONITOR, V25, P1017, DOI 10.12659/MSM.914898; Weidinger S, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/s41572-018-0001-z; Wu ZW, 2013, J DERMATOL SCI, V71, P167, DOI 10.1016/j.jdermsci.2013.04.022; Xing LZ, 2014, NAT MED, V20, P1043, DOI 10.1038/nm.3645; Yi XL, 2018, MED SCI MONITOR, V24, P6489, DOI 10.12659/MSM.910515; Zhao M, 2015, INT J BIOCHEM CELL B, V67, P65, DOI 10.1016/j.biocel.2015.05.022; Zhao ZH, 2019, ANN RHEUM DIS, V78, P380, DOI 10.1136/annrheumdis-2018-214125; Zhu HQ, 2012, J CLIN IMMUNOL, V32, P114, DOI 10.1007/s10875-011-9597-4	115	22	22	2	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2020	146	1					8	16		10.1016/j.jaci.2020.05.009	http://dx.doi.org/10.1016/j.jaci.2020.05.009			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	OC5BB	32631499				2022-12-18	WOS:000579170500002
J	Branchett, WJ; Stolting, H; Oliver, RA; Walker, SA; Puttur, F; Gregory, LG; Gabrysova, L; Wilson, MS; O'Garra, A; Lloyd, CM				Branchett, William J.; Stolting, Helen; Oliver, Robert A.; Walker, Simone A.; Puttur, Franz; Gregory, Lisa G.; Gabrysova, Leona; Wilson, Mark S.; O'Garra, Anne; Lloyd, Clare M.			A T cell-myeloid IL-10 axis regulates pathogenic IFN-gamma-dependent immunity in a mouse model of type 2-low asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Severe asthma; type 2-low asthma; IL-10; immune regulation; T cell; macrophage; dendritic cell; IFN-gamma	INHIBITS CYTOKINE PRODUCTION; DENDRITIC CELLS; AIRWAY INFLAMMATION; INTERLEUKIN-10; MACROPHAGES; EXPRESSION; RECEPTOR; LIPOPOLYSACCHARIDE; HYPERREACTIVITY; LYMPHOCYTES	Background: Although originally defined as a type 2 (T2) immune-mediated condition, non-T2 cytokines, such as IFN-gamma and IL-17A, have been implicated in asthma pathogenesis, particularly in patients with severe disease. IL-10 regulates T-H cell phenotypes and can dampen T2 immunity to allergens, but its functions in controlling non-T2 cytokine responses in asthmatic patients are unclear. Objective: We sought to determine how IL-10 regulates the balance of T-H cell responses to inhaled allergen. Methods: Allergic airway disease was induced in wild-type, IL-10 reporter, and conditional IL-10 or IL-10 receptor a (IL-10Ra) knockout mice by means of repeated intranasal administration of house dust mite (HDM). IL-10 and IFN-gamma signaling were disrupted by using blocking antibodies. Results: Repeated HDM inhalation induced a mixed IL-13/IL-17A response and accumulation of IL-10-producing forkhead box P3-negative effector CD4(+) T cells in the lungs. Ablation of T cell-derived IL-10 increased the IFN-gamma and IL-17A response to HDM, reducing IL-13 levels and airway eosinophilia without affecting IgE levels or airway hyperresponsiveness. The increased IFN-gamma response could be recapitulated by IL-10R alpha deletion in CD11c(+) myeloid cells or local IL-10R alpha blockade. Disruption of the T cell-myeloid IL-10 axis resulted in increased pulmonary monocyte-derived dendritic cell numbers and increased IFN-gamma-dependent expression of CXCR3 ligands by airway macrophages, which is suggestive of a feedforward loop of TH1 cell recruitment. Augmented IFN-gamma responses in the HDM allergic airway disease model were accompanied by increased disruption of airway epithelium, which was reversed by therapeutic blockade of IFN-gamma. Conclusions: IL-10 from effector T cells signals to CD11c(+) myeloid cells to suppress an atypical and pathogenic IFN-gamma response to inhaled HDM.	[Branchett, William J.; Stolting, Helen; Oliver, Robert A.; Walker, Simone A.; Puttur, Franz; Gregory, Lisa G.; O'Garra, Anne; Lloyd, Clare M.] Natl Heart & Lung Inst, London, England; [Branchett, William J.; Stolting, Helen; Oliver, Robert A.; Walker, Simone A.; Puttur, Franz; Gregory, Lisa G.; Lloyd, Clare M.] Imperial Coll London, Asthma UK Ctr Allerg Mech Asthma, London, England; [Gabrysova, Leona; O'Garra, Anne] Immunoregulat & Infect Lab, London, England; [Wilson, Mark S.] Francis Crick Inst, Allergy & Antihelminth Immun Lab, London, England; [Wilson, Mark S.] Genentech Inc, San Francisco, CA USA	Imperial College London; Imperial College London; University of London; King's College London; Francis Crick Institute; Roche Holding; Genentech	Lloyd, CM (corresponding author), Sir Alexander Fleming Bldg, London SW7 2AZ, England.	c.lloyd@imperial.ac.uk	Branchett, William/AAC-3558-2019; Stoelting, Helen/GPS-8154-2022	Branchett, William/0000-0003-4353-4857; Stoelting, Helen/0000-0002-7830-2776; Lloyd, Clare/0000-0001-8977-6726; O'Garra, Anne/0000-0001-9845-6134	Wellcome Trust Senior Fellowship [107059/Z/15/Z]; Medical Research Council; Francis Crick Institute from Cancer Research UK [FC001126]; UK Medical Research Council [FC001126]; Wellcome Trust [FC001126]; Asthma UK PhD studentship; MRC [MC_U117565642] Funding Source: UKRI	Wellcome Trust Senior Fellowship(Wellcome Trust); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Francis Crick Institute from Cancer Research UK; UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); Asthma UK PhD studentship; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Supported by Wellcome Trust Senior Fellowship 107059/Z/15/Z (to C.M.L.). W.J.B. was supported by a Medical Research Council and Asthma UKPhD studentship during part of this work. A.O. and L.G. were supported by the Francis Crick Institute, which receives its core funding from Cancer Research UK (FC001126), the UK Medical Research Council (FC001126), and the Wellcome Trust (FC001126).	Abram CL, 2014, J IMMUNOL METHODS, V408, P89, DOI 10.1016/j.jim.2014.05.009; Al-Ramli W, 2009, J ALLERGY CLIN IMMUN, V123, P1185, DOI 10.1016/j.jaci.2009.02.024; Basinski TM, 2009, J ALLERGY CLIN IMMUN, V124, P74, DOI 10.1016/j.jaci.2009.04.019; Bedoret D, 2009, J CLIN INVEST, V119, P3723, DOI 10.1172/JCI39717; Branchett WJ, 2019, MUCOSAL IMMUNOL, V12, P589, DOI 10.1038/s41385-019-0158-0; Bullens DMA, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-135; Byrne AJ, 2017, MUCOSAL IMMUNOL, V10, P716, DOI 10.1038/mi.2016.92; Campbell JD, 2009, J EXP MED, V206, P1535, DOI 10.1084/jem.20082901; Caton ML, 2007, J EXP MED, V204, P1653, DOI 10.1084/jem.20062648; Cavani A, 2000, J INVEST DERMATOL, V114, P295, DOI 10.1046/j.1523-1747.2000.00881.x; Choy DF, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab3142; Coomes SM, 2017, MUCOSAL IMMUNOL, V10, P150, DOI 10.1038/mi.2016.47; Denney L, 2018, MUCOSAL IMMUNOL, V11, P523, DOI 10.1038/mi.2017.77; Dolch A, 2019, EUR J IMMUNOL, V49, P302, DOI 10.1002/eji.201847883; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; FIORENTINO DF, 1989, J EXP MED, V170, P2081, DOI 10.1084/jem.170.6.2081; FIORENTINO DF, 1991, J IMMUNOL, V147, P3815; FIORENTINO DF, 1991, J IMMUNOL, V146, P3444; Gauthier M, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.94580; Grommes J, 2011, MOL MED, V17, P293, DOI 10.2119/molmed.2010.00138; Groom JR, 2011, EXP CELL RES, V317, P620, DOI 10.1016/j.yexcr.2010.12.017; Gupta A, 2014, THORAX, V69, P508, DOI 10.1136/thoraxjnl-2013-203421; Hall SL, 2017, J ALLERGY CLIN IMMUN, V139, P462, DOI 10.1016/j.jaci.2016.04.037; Hammad H, 2009, NAT MED, V15, P410, DOI 10.1038/nm.1946; Hawrylowicz C, 2002, J ALLERGY CLIN IMMUN, V109, P369, DOI 10.1067/mai.2002.121455; Huber S, 2011, IMMUNITY, V34, P554, DOI 10.1016/j.immuni.2011.01.020; Hyun MH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053758; Irvin C, 2014, J ALLERGY CLIN IMMUN, V134, P1175, DOI 10.1016/j.jaci.2014.05.038; Islam SA, 2011, NAT IMMUNOL, V12, P167, DOI 10.1038/ni.1984; Jevnikar Z, 2019, J ALLERGY CLIN IMMUN, V143, P577, DOI 10.1016/j.jaci.2018.05.026; Kawano H, 2016, INT IMMUNOL, V28, P489, DOI 10.1093/intimm/dxw012; Kearley J, 2005, J EXP MED, V202, P1539, DOI 10.1084/jem.20051166; Krausgruber T, 2011, NAT IMMUNOL, V12, P231, DOI 10.1038/ni.1990; Lambrecht BN, 2015, NAT IMMUNOL, V16, P45, DOI 10.1038/ni.3049; Lee PP, 2001, IMMUNITY, V15, P763, DOI 10.1016/S1074-7613(01)00227-8; Lim S, 1998, LANCET, V352, P113, DOI 10.1016/S0140-6736(98)85018-6; Loser S, 2017, J ALLERGY CLIN IMMUN, V139, P1496, DOI 10.1016/j.jaci.2016.07.033; Maynard CL, 2007, NAT IMMUNOL, V8, P931, DOI 10.1038/ni1504; Meiler F, 2008, J EXP MED, V205, P2887, DOI 10.1084/jem.20080193; Menzies-Gow A, 2002, J IMMUNOL, V169, P2712, DOI 10.4049/jimmunol.169.5.2712; Misharin AV, 2013, AM J RESP CELL MOL, V49, P503, DOI 10.1165/rcmb.2013-0086MA; Modena BD, 2017, AM J RESP CRIT CARE, V195, P1449, DOI 10.1164/rccm.201607-1407OC; Molet S, 2001, J ALLERGY CLIN IMMUN, V108, P430, DOI 10.1067/mai.2001.117929; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; Moreira-Teixeira L, 2017, J IMMUNOL, V199, P613, DOI 10.4049/jimmunol.1601340; Nembrini C, 2009, J ALLERGY CLIN IMMUN, V123, P986, DOI 10.1016/j.jaci.2009.03.033; Ng THS, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00129; Nials AT, 2008, DIS MODEL MECH, V1, P213, DOI 10.1242/dmm.000323; Oh JW, 2002, J ALLERGY CLIN IMMUN, V110, P460, DOI 10.1067/mai.2002.127512; Oriss TB, 2017, JCI INSIGHT, V2; Palomares O, 2017, IMMUNOL REV, V278, P219, DOI 10.1111/imr.12555; Persson C, 2009, CLIN EXP ALLERGY, V39, P1626, DOI 10.1111/j.1365-2222.2009.03373.x; Peters MC, 2014, J ALLERGY CLIN IMMUN, V133, P388, DOI 10.1016/j.jaci.2013.07.036; Pils MC, 2010, EUR J IMMUNOL, V40, P443, DOI 10.1002/eji.200939592; Plantinga M, 2013, IMMUNITY, V38, P322, DOI 10.1016/j.immuni.2012.10.016; Puttur F, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aav7638; Raundhal M, 2015, J CLIN INVEST, V125, P3037, DOI 10.1172/JCI80911; Ray A, 2016, J CLIN INVEST, V126, P2394, DOI 10.1172/JCI84144; Roers A, 2004, J EXP MED, V200, P1289, DOI 10.1084/jem.20041789; Sabatel C, 2017, IMMUNITY, V46, P457, DOI 10.1016/j.immuni.2017.02.016; Saglani S, 2009, AM J RESP CELL MOL, V41, P281, DOI 10.1165/rcmb.2008-0396OC; Saraiva M, 2010, NAT REV IMMUNOL, V10, P170, DOI 10.1038/nri2711; Schneider C, 2014, NAT IMMUNOL, V15, P1026, DOI 10.1038/ni.3005; Snelgrove RJ, 2014, J ALLERGY CLIN IMMUN, V134, P583, DOI 10.1016/j.jaci.2014.02.002; Soyka MB, 2012, J ALLERGY CLIN IMMUN, V130, P1087, DOI 10.1016/j.jaci.2012.05.052; Sun J, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002173; Sun J, 2009, NAT MED, V15, P277, DOI 10.1038/nm.1929; Tournoy KG, 2000, CLIN EXP ALLERGY, V30, P775; VIEIRA P, 1991, P NATL ACAD SCI USA, V88, P1172, DOI 10.1073/pnas.88.4.1172; Wenzel SE, 2012, NAT MED, V18, P716, DOI 10.1038/nm.2678; Whitsett JA, 2015, NAT IMMUNOL, V16, P27, DOI 10.1038/ni.3045; Wilson RH, 2009, AM J RESP CRIT CARE, V180, P720, DOI 10.1164/rccm.200904-0573OC	72	22	26	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2020	145	2					666	+		10.1016/j.jaci.2019.08.006	http://dx.doi.org/10.1016/j.jaci.2019.08.006			22	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KK6ZG	31445933	Green Published			2022-12-18	WOS:000512887400028
J	Hayes, SM; Biggs, TC; Goldie, SP; Harries, PG; Walls, AF; Allan, RN; Pender, SLF; Salib, RJ				Hayes, Stephen M.; Biggs, Timothy C.; Goldie, Simon P.; Harries, Philip G.; Walls, Andrew F.; Allan, Raymond N.; Pender, Sylvia L. F.; Salib, Rami J.			Staphylococcus aureus internalization in mast cells in nasal polyps: Characterization of interactions and potential mechanisms	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chronic rhinosinusitis; chronic rhinosinusitis with nasal polyps; nasal polyps; intracellular bacteria; Staphylococcus aureus; mast cells; bacterial superantigens; staphylococcal enterotoxin B	CHRONIC RHINOSINUSITIS; BACTERIAL BIOFILMS; ENTEROTOXIN-B; SUPERANTIGENS; IGE; EPITHELIUM; INNATE	Background: Chronic rhinosinusitis (CRS) with nasal polyps is a common chronic condition. The exact cause of nasal polyps remains unknown. Recently, we made the novel observation of intracellular localization of Staphylococcus aureus within mast cells in nasal polyps. Objective: This follow-up study aimed to further characterize interactions between S aureus and mast cells in this setting and elucidate potential internalization mechanisms with particular emphasis on the role of staphylococcal enterotoxin B (SEB). Methods: A prospective study was performed using an explant tissue model with ex vivo inferior turbinate mucosa obtained from patients with chronic rhinosinusitis with nasal polyps (n = 7) and patients without CRS (n = 5). Immunohistochemistry was used to characterize S aureus uptake into mast cells and investigate the effects of SEB on this process. An in vitro cell-culture model was used to investigate mast cell-S aureus interactions by using a combination of fluorescent in situ hybridization, confocal laser scanning microscopy, scanning electron microscopy, transmission electron microscopy, and proliferation assays. Results: S aureus was captured by extracellular traps and entered mast cells through phagocytosis. Proliferating intracellular S aureus led to the expansion and eventual rupture of mast cells, resulting in release of viable S aureus into the extracellular space. The presence of SEB appeared to promote internalization of S aureus into mast cells. Conclusion: This study provides new insights into the interactions between S aureus and mast cells, including the internalization process, and demonstrates a prominent role for SEB in promoting uptake of the bacteria into these cells.	[Hayes, Stephen M.; Biggs, Timothy C.; Goldie, Simon P.; Walls, Andrew F.; Pender, Sylvia L. F.; Salib, Rami J.] Univ Southampton, Fac Med, Sch Clin & Expt Sci, Southampton, Hants, England; [Allan, Raymond N.] Univ Southampton, Fac Environm & Life Sci, Dept Biol Sci, Southampton, Hants, England; [Hayes, Stephen M.; Biggs, Timothy C.; Goldie, Simon P.; Salib, Rami J.] Univ Southampton, Southampton NIHR Resp Biomed Res Ctr, Southampton, Hants, England; [Hayes, Stephen M.; Biggs, Timothy C.; Goldie, Simon P.; Salib, Rami J.] Univ Hosp Southampton NHS Fdn Trust, Southampton, Hants, England; [Hayes, Stephen M.; Biggs, Timothy C.; Goldie, Simon P.; Harries, Philip G.; Salib, Rami J.] Univ Hosp Southampton NHS Fdn Trust, Dept Otorhinolaryngol Head & Neck Surg, Tremona Rd, Southampton SO16 6YD, Hants, England; [Hayes, Stephen M.; Biggs, Timothy C.; Goldie, Simon P.; Allan, Raymond N.; Salib, Rami J.] Univ Hosp Southampton NHS Fdn Trust, NIHR Wellcome Trust Clin Res Facil, Southampton, Hants, England	University of Southampton; University of Southampton; University of Southampton; University of Southampton; University Hospital Southampton NHS Foundation Trust; University of Southampton; University Hospital Southampton NHS Foundation Trust; University of Southampton; University Hospital Southampton NHS Foundation Trust	Salib, RJ (corresponding author), Univ Hosp Southampton NHS Fdn Trust, Dept Otorhinolaryngol Head & Neck Surg, Tremona Rd, Southampton SO16 6YD, Hants, England.; Salib, RJ (corresponding author), Univ Hosp Southampton NHS Fdn Trust, Sch Clin & Expt Sci, Tremona Rd, Southampton SO16 6YD, Hants, England.	R.J.Salib@soton.ac.uk	; Allan, Raymond/K-2494-2017	Walls, Andrew/0000-0003-4803-4595; Goldie, Simon/0000-0002-3912-9026; Allan, Raymond/0000-0001-7764-4849; Salib, Rami/0000-0002-6753-7844	Royal College of Surgeons of England; Southampton National Institute for Health Research (NIHR) Respiratory Biomedical Research Centre; NIHR Wellcome Trust Clinical Research Facility; MRC [G0500729] Funding Source: UKRI	Royal College of Surgeons of England; Southampton National Institute for Health Research (NIHR) Respiratory Biomedical Research Centre; NIHR Wellcome Trust Clinical Research Facility; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Supported by a surgical research fellowship grant from the Royal College of Surgeons of England (to S.M.H.) and a pump priming grant from the Royal College of Surgeons of England (to R.J.S.). This work was also supported in part by the Southampton National Institute for Health Research (NIHR) Respiratory Biomedical Research Centre and NIHR Wellcome Trust Clinical Research Facility.	Abel J, 2011, J INNATE IMMUN, V3, P495, DOI 10.1159/000327714; Abraham SN, 2010, NAT REV IMMUNOL, V10, P440, DOI 10.1038/nri2782; Al-Mutairi D, 2011, CURR OPIN ALLERGY CL, V11, P18, DOI 10.1097/ACI.0b013e3283423376; Bachert C, 2007, Chem Immunol Allergy, V93, P214, DOI 10.1159/000100897; Bachert C, 2003, CURR ALLERGY ASTHM R, V3, P523, DOI 10.1007/s11882-003-0065-y; Bachert C, 2000, AM J RHINOL, V14, P279, DOI 10.2500/105065800781329573; Bachert C, 2001, J ALLERGY CLIN IMMUN, V107, P607, DOI 10.1067/mai.2001.112374; Bachert C, 2008, CURR OPIN ALLERGY CL, V8, P34, DOI 10.1097/ACI.0b013e3282f4178f; Bachert Claus, 2002, Curr Allergy Asthma Rep, V2, P252, DOI 10.1007/s11882-002-0027-9; Bendouah Z, 2006, OTOLARYNG HEAD NECK, V134, P991, DOI 10.1016/j.otohns.2006.03.001; BENNINGER MS, 1992, AM J RHINOL, V6, P37, DOI 10.2500/105065892781874829; Blackwell Debra L, 2002, Vital Health Stat 10, P1; BRITTEN KM, 1993, BIOTECH HISTOCHEM, V68, P271, DOI 10.3109/10520299309105629; Clement S, 2005, J INFECT DIS, V192, P1023, DOI 10.1086/432735; Cohen M, 2009, AM J RHINOL ALLERGY, V23, P255, DOI 10.2500/ajra.2009.23.3319; Collins J G, 1997, Vital Health Stat 10, P1; DrakeLee A, 1997, J LARYNGOL OTOL, V111, P340, DOI 10.1017/S0022215100137260; DRAKELEE AB, 1982, INT ARCH ALLER A IMM, V69, P268, DOI 10.1159/000233182; Fokkens WJ, 2012, RHINOLOGY, V50, P1, DOI 10.4193/Rhin20.600; Fokkens W, 2007, RHINOLOGY, P1; Foreman A, 2010, LARYNGOSCOPE, V120, P1701, DOI 10.1002/lary.21024; Foreman A, 2010, LARYNGOSCOPE, V120, P427, DOI 10.1002/lary.20705; Foreman A, 2009, AM J RHINOL ALLERGY, V23, P556, DOI 10.2500/ajra.2009.23.3413; Garzoni C, 2009, TRENDS MICROBIOL, V17, P59, DOI 10.1016/j.tim.2008.11.005; Gevaert E, 2017, J ALLERGY CLIN IMMUN, V139, P1849, DOI 10.1016/j.jaci.2017.01.019; Hayes SM, 2015, J ALLERGY CLIN IMMUN, V135, P1648, DOI 10.1016/j.jaci.2014.12.1929; Holgate ST, 2007, J ALLERGY CLIN IMMUN, V120, P1233, DOI 10.1016/j.jaci.2007.10.025; Hunsaker DH, 2008, CURR OPIN OTOLARYNGO, V16, P237, DOI 10.1097/MOO.0b013e3282fdc6d5; Huvenne W, 2013, INT ARCH ALLERGY IMM, V161, P304, DOI 10.1159/000350329; Langier S, 2011, RHINOLOGY, V49, P570, DOI 10.4193/Rhino.11.090; Lund Valerie J., 1993, Rhinology (Utrecht), V31, P183; Novo CAP, 2010, CLIN EXP ALLERGY, V40, P1323, DOI 10.1111/j.1365-2222.2010.03577.x; Okano M, 2009, J ALLERGY CLIN IMMUN, V123, P868, DOI 10.1016/j.jaci.2009.01.047; Ooi EH, 2010, OTOLARYNG CLIN N AM, V43, P473, DOI 10.1016/j.otc.2010.02.020; Patou J, 2008, J ALLERGY CLIN IMMUN, V121, P110, DOI 10.1016/j.jaci.2007.08.059; Perez-Novo CA, 2008, J INFECT DIS, V197, P1036, DOI 10.1086/528989; Pescador DB, 2012, J INVEST ALLERG CLIN, V22, P331; Bezerra TFP, 2011, OTOLARYNG HEAD NECK, V144, P612, DOI 10.1177/0194599811399536; Ramsey MM, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.01230; Rocha-De-Souza CM, 2008, INFECT IMMUN, V76, P4489, DOI 10.1128/IAI.00270-08; Schleimer RP, 2007, J ALLERGY CLIN IMMUN, V120, P1279, DOI 10.1016/j.jaci.2007.08.046; Singhal D, 2011, LARYNGOSCOPE, V121, P1578, DOI 10.1002/lary.21805; Soyka MB, 2012, J ALLERGY CLIN IMMUN, V130, P1087, DOI 10.1016/j.jaci.2012.05.052; Stankiewicz J, 2011, INT FORUM ALLERGY RH, V1, P38, DOI 10.1002/alr.20008; Tan BK, 2017, J ALLERGY CLIN IMMUN, V139, P699, DOI 10.1016/j.jaci.2016.06.063; Tan NCW, 2012, AM J RHINOL ALLERGY, V26, P444, DOI 10.2500/ajra.2012.26.3822; Tan NCW, 2012, LARYNGOSCOPE, V122, P1655, DOI 10.1002/lary.23317; Tomassen P, 2016, J ALLERGY CLIN IMMUN, V137, P1449, DOI 10.1016/j.jaci.2015.12.1324; Van Zele T, 2004, J ALLERGY CLIN IMMUN, V114, P981, DOI 10.1016/j.jaci.2004.07.013; Wang MM, 2011, OTOLARYNG HEAD NECK, V145, P717, DOI 10.1177/0194599811413859; Wang XD, 2016, J ALLERGY CLIN IMMUN, V138, P1344, DOI 10.1016/j.jaci.2016.05.041	51	22	23	2	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2020	145	1					147	159		10.1016/j.jaci.2019.06.013	http://dx.doi.org/10.1016/j.jaci.2019.06.013			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KA1WZ	31254531	Green Accepted, Green Submitted, Bronze			2022-12-18	WOS:000505590800022
J	Sakurai, K; Dainichi, T; Garcet, S; Tsuchiya, S; Yamamoto, Y; Kitoh, A; Honda, T; Nomura, T; Egawa, G; Otsuka, A; Nakajima, S; Matsumoto, R; Nakano, Y; Otsuka, M; Iwakura, Y; Grinberg-Bleyer, Y; Ghosh, S; Sugimoto, Y; Guttman-Yassky, E; Krueger, JG; Kabashima, K				Sakurai, Kenji; Dainichi, Teruki; Garcet, Sandra; Tsuchiya, Soken; Yamamoto, Yosuke; Kitoh, Akihiko; Honda, Tetsuya; Nomura, Takashi; Egawa, Gyohei; Otsuka, Atsushi; Nakajima, Saeko; Matsumoto, Reiko; Nakano, Yuri; Otsuka, Masayuki; Iwakura, Yoichiro; Grinberg-Bleyer, Yenkel; Ghosh, Sankar; Sugimoto, Yukihiko; Guttman-Yassky, Emma; Krueger, James G.; Kabashima, Kenji			Cutaneous p38 mitogen-activated protein kinase activation triggers psoriatic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Psoriasis; p38 mitogen-activated protein kinase; anisomycin; IL-17	NF-KAPPA-B; SKIN INFLAMMATION; IL36RN MUTATIONS; T-CELLS; EXPRESSION; KERATINOCYTES; P38-ALPHA; RECEPTOR; DISEASE; MICE	Background: Psoriasis is a chronic inflammatory skin disease characterized by IL-17-mediated immune responses. p38 is known to be highly activated in the psoriatic epidermis; however, whether p38 is involved in the development of psoriasis is unclear. Objective: We sought to demonstrate that activation of p38 mitogen-activated protein kinase is sufficient to induce psoriatic inflammation in mice and that cutaneous p38 activities are the topical therapeutic targets for psoriasis. Methods: A p38 activator, anisomycin, was applied daily to murine skin. Transcriptomic analyses were performed to evaluate the similarities of the skin responses to those in human psoriasis and the existing animal model. BIRB796, a small-molecule inhibitor targeting p38 activities, was applied to the murine psoriatic models topically or to human psoriatic skin specimens ex vivo. Results: Topical treatment with anisomycin induced key signatures in psoriasis, such as epidermal thickening, neutrophil infiltration, and gene expression of Il1a, Il1b, Il6, Il24, Cxcl1, Il23a, and Il17a, in treated murine skin. These responses were fully abrogated by topical treatment with BIRB796, and were reduced in IL-17A-deficient mice. Transcriptomic analyses demonstrated the similarities of anisomycin-induced dermatitis to human psoriasis and imiquimod-induced murine psoriatic dermatitis. Furthermore, BIRB796 targeting of p38 activities reduced expression of psoriasis-related genes in both human keratinocytes stimulated with recombinant IL-17A in vitro and psoriatic skin specimens ex vivo. Conclusion: Therefore our findings suggest that cutaneous p38 activation can be a key event in patients with psoriasis and a potential topical therapeutic target of a small molecule.	[Sakurai, Kenji; Dainichi, Teruki; Yamamoto, Yosuke; Kitoh, Akihiko; Honda, Tetsuya; Nomura, Takashi; Egawa, Gyohei; Otsuka, Atsushi; Nakajima, Saeko; Matsumoto, Reiko; Nakano, Yuri; Otsuka, Masayuki; Kabashima, Kenji] Kyoto Univ, Dept Dermatol, Grad Sch Med, Kyoto, Japan; [Garcet, Sandra; Guttman-Yassky, Emma; Krueger, James G.] Rockefeller Univ, Lab Invest Dermatol, 1230 York Ave, New York, NY 10021 USA; [Tsuchiya, Soken; Sugimoto, Yukihiko] Kumamoto Univ, Grad Sch Pharmaceut Sci, Dept Pharmaceut Biochem, Kumamoto, Japan; [Iwakura, Yoichiro] Tokyo Univ Sci, Ctr Anim Dis Models, Res Inst Biomed Sci, Noda, Chiba, Japan; [Grinberg-Bleyer, Yenkel; Ghosh, Sankar] Columbia Univ, Coll Phys & Surg, Dept Microbiol & Immunol, New York, NY USA; [Guttman-Yassky, Emma] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY 10029 USA; [Guttman-Yassky, Emma] Icahn Sch Med Mt Sinai, Immunol Inst, New York, NY 10029 USA; [Kabashima, Kenji] ASTAR, Biopolis, Singapore Immunol Network SIgN, Singapore, Singapore; [Kabashima, Kenji] ASTAR, Biopolis, Skin Res Inst Singapore, Singapore, Singapore	Kyoto University; Rockefeller University; Kumamoto University; Tokyo University of Science; Columbia University; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Agency for Science Technology & Research (A*STAR); A*STAR - Singapore Immunology Network (SIgN); Agency for Science Technology & Research (A*STAR); Skin Research Institute of Singapore (SRIS)	Dainichi, T; Kabashima, K (corresponding author), Kyoto Univ, Dept Dermatol, Grad Sch Med, Sakyo Ku, 54 Kawahara Cho, Kyoto 6068507, Japan.	dainichi@kuhp.kyoto-u.ac.jp; kaba@kuhp.kyoto-u.ac.jp	Sugimoto, Yukihiko/AAV-6470-2021; Nakajima, Saeko/AAB-1577-2021; Dainichi, Teruki/AAL-5400-2020; YAMAMOTO, Yosuke/HCH-0666-2022	Sugimoto, Yukihiko/0000-0001-6973-932X; Dainichi, Teruki/0000-0002-9497-0029; Grinberg-Bleyer, Yenkel/0000-0002-3515-8305; Egawa, Gyohei/0000-0002-6101-4719; Otsuka, Atsushi/0000-0001-7365-947X; Nakajima, Saeko/0000-0003-0831-1447; Garcet, Sandra/0000-0002-4465-8547	JSPS KAKENHI [JP15H05790]	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	Supported by JSPS KAKENHI grant no. JP15H05790.	Afonina IS, 2016, EMBO REP, V17, P914, DOI 10.15252/embr.201642109; Anbunathan H, 2017, J INVEST DERMATOL, V137, pE113, DOI 10.1016/j.jid.2016.03.047; Andres RM, 2013, EXP DERMATOL, V22, P323, DOI 10.1111/exd.12128; Cai YH, 2011, IMMUNITY, V35, P596, DOI 10.1016/j.immuni.2011.08.001; Elder JT, 2010, J INVEST DERMATOL, V130, P1213, DOI 10.1038/jid.2009.319; Flutter B, 2013, EUR J IMMUNOL, V43, P3138, DOI 10.1002/eji.201343801; Grinberg-Bleyer Y, 2015, J IMMUNOL, V194, P2472, DOI 10.4049/jimmunol.1402608; Gudjonsson JE, 2009, J INVEST DERMATOL, V129, P635, DOI 10.1038/jid.2008.266; Hald A, 2013, BRIT J DERMATOL, V168, P302, DOI 10.1111/bjd.12049; Hawkes JE, 2017, J ALLERGY CLIN IMMUN, V140, P645, DOI 10.1016/j.jaci.2017.07.004; Hawkes JE, 2017, J INVEST DERMATOL, V137, P546, DOI 10.1016/j.jid.2016.10.024; Huang GH, 2012, NAT IMMUNOL, V13, P152, DOI 10.1038/ni.2207; Johansen C, 2005, BRIT J DERMATOL, V152, P37, DOI 10.1111/J.1365-2133.2004.06304.X; Jordan CT, 2012, AM J HUM GENET, V90, P796, DOI 10.1016/j.ajhg.2012.03.013; Kagami S, 2010, J INVEST DERMATOL, V130, P1373, DOI 10.1038/jid.2009.399; Katayama M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062231; Krueger JG, 2018, EXP DERMATOL, V27, P115, DOI 10.1111/exd.13467; Kumari S, 2013, IMMUNITY, V39, P899, DOI 10.1016/j.immuni.2013.10.009; Lee JS, 2015, IMMUNITY, V43, P727, DOI 10.1016/j.immuni.2015.09.003; Li BS, 2014, J INVEST DERMATOL, V134, P1828, DOI 10.1038/jid.2014.28; Lowes MA, 2014, ANNU REV IMMUNOL, V32, P227, DOI 10.1146/annurev-immunol-032713-120225; Lowes MA, 2013, TRENDS IMMUNOL, V34, P174, DOI 10.1016/j.it.2012.11.005; Mahil SK, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aan2514; Marrakchi S, 2011, NEW ENGL J MED, V365, P620, DOI 10.1056/NEJMoa1013068; Matsumoto R, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.121175; McGeachy MJ, 2009, NAT IMMUNOL, V10, P314, DOI 10.1038/ni.1698; McKenzie RC, 2003, EUR J DERMATOL, V13, P315; NAGPAL S, 1995, J BIOL CHEM, V270, P923, DOI 10.1074/jbc.270.2.923; Nakae S, 2002, IMMUNITY, V17, P375, DOI 10.1016/S1074-7613(02)00391-6; Nograles KE, 2008, BRIT J DERMATOL, V159, P1092, DOI 10.1111/j.1365-2133.2008.08769.x; Onoufriadis A, 2011, AM J HUM GENET, V89, P432, DOI 10.1016/j.ajhg.2011.07.022; Otkjaer K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008671; Perera GK, 2012, ANNU REV PATHOL-MECH, V7, P385, DOI 10.1146/annurev-pathol-011811-132448; Sano S, 2005, NAT MED, V11, P43, DOI 10.1038/nm1162; Sano Y, 2014, J INVEST DERMATOL, V134, P2231, DOI 10.1038/jid.2014.153; Seldin MF, 2015, J AUTOIMMUN, V64, P1, DOI 10.1016/j.jaut.2015.08.015; Shalom-Barak T, 1998, J BIOL CHEM, V273, P27467, DOI 10.1074/jbc.273.42.27467; Shim EJ, 2013, J IMMUNOL, V191, P2764, DOI 10.4049/jimmunol.1300908; Suarez-Farinas M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084634; Sugiura K, 2014, J DERMATOL SCI, V74, P187, DOI 10.1016/j.jdermsci.2014.02.006; Swindell WR, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00080; Takeichi T, 2010, J INVEST DERMATOL, V130, P2760, DOI 10.1038/jid.2010.203; Tauber M, 2016, J INVEST DERMATOL, V136, P1811, DOI 10.1016/j.jid.2016.04.038; Towne JE, 2004, J BIOL CHEM, V279, P13677, DOI 10.1074/jbc.M400117200; van der Fits L, 2009, J IMMUNOL, V182, P5836, DOI 10.4049/jimmunol.0802999; Volpe E, 2014, J ALLERGY CLIN IMMUN, V134, P373, DOI 10.1016/j.jaci.2014.04.022; Vukmanovic-Stejic M, 2018, J ALLERGY CLIN IMMUN, V142, P844, DOI 10.1016/j.jaci.2017.10.032; Walter A, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2566; Yang CA, 2015, J AUTOIMMUN, V61, P1, DOI 10.1016/j.jaut.2015.05.001; Zheng T, 2018, SCI SIGNAL, V13, P11	50	22	23	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2019	144	4					1036	1049		10.1016/j.jaci.2019.06.019	http://dx.doi.org/10.1016/j.jaci.2019.06.019			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JB8FZ	31378305	Green Submitted, Bronze			2022-12-18	WOS:000488803900019
J	de Wit, J; Totte, JEE; van Mierlo, MMF; van Veldhuizen, J; van Doom, MBA; Schuren, FHJ; Willemsen, SP; Pardo, LM; Pasmans, SGMA				de Wit, Jill; Totte, Joan E. E.; van Mierlo, Minke M. F.; van Veldhuizen, Joyce; van Doom, Martijn B. A.; Schuren, Frank H. J.; Willemsen, Sten P.; Pardo, Luba M.; Pasmans, Suzanne G. M. A.			Endolysin treatment against Staphylococcus aureus in adults with atopic dermatitis: A randomized controlled trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							GENOME-WIDE ASSOCIATION; ASTHMA; CHILDREN; ECZEMA		[de Wit, Jill; Totte, Joan E. E.; van Mierlo, Minke M. F.; van Veldhuizen, Joyce; van Doom, Martijn B. A.; Pardo, Luba M.; Pasmans, Suzanne G. M. A.] Erasmus MC Univ Med Ctr, Dept Dermatol, Rotterdam, Netherlands; [Willemsen, Sten P.] Erasmus MC Univ Med Ctr, Dept Biostat, Rotterdam, Netherlands; [Schuren, Frank H. J.] TNO, Microbiol & Syst Biol Grp, Zeist, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Netherlands Organization Applied Science Research	Pasmans, SGMA (corresponding author), Erasmus MC Univ Med Ctr, Dept Dermatol, Rotterdam, Netherlands.	s.pasmans@erasmusmc.nl	Pasmans, Suzanne/AAI-6016-2021; de Wit, Jill/X-6110-2019	Pasmans, Suzanne/0000-0003-1018-4475; de Wit, Jill/0000-0001-5080-1453	Micreos Human Health, The Netherlands	Micreos Human Health, The Netherlands(Netherlands Government)	The Department of Dermatology of the Erasmus MC University Medical Center Rotterdam received an unrestricted grant from Micreos Human Health, The Netherlands.	Altshuler DM, 2012, NATURE, V491, P56, DOI 10.1038/nature11632; Angelova-Fischer I, 2014, J EUR ACAD DERMATOL, V28, P9, DOI 10.1111/jdv.12479; Bath-Hextall FJ, 2010, BRIT J DERMATOL, V163, P12, DOI 10.1111/j.1365-2133.2010.09743.x; Bonnelykke K, 2016, J ALLERGY CLIN IMMUN, V137, P667, DOI 10.1016/j.jaci.2016.01.006; Caudri D, 2009, J ALLERGY CLIN IMMUN, V124, P903, DOI 10.1016/j.jaci.2009.06.045; Demenais F, 2018, NAT GENET, V50, P42, DOI 10.1038/s41588-017-0014-7; Ferreira MA, 2017, NAT GENET, V49, P1752, DOI 10.1038/ng.3985; Gonzalez ME, 2016, J AM ACAD DERMATOL, V75, P481, DOI 10.1016/j.jaad.2016.04.066; Hafkamp-de Groen E, 2013, J ALLERGY CLIN IMMUN, V132, P1303, DOI 10.1016/j.jaci.2013.07.007; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Harrell FE, 2015, SPRINGER SER STAT, DOI 10.1007/978-3-319-19425-7; Howie B, 2012, NAT GENET, V44, P955, DOI 10.1038/ng.2354; Melen E, 2013, CLIN EXP ALLERGY, V43, P463, DOI 10.1111/cea.12054; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Ng JPX, 2015, J EUR ACAD DERMATOL, V29, P854, DOI 10.1111/jdv.12864; Niebuhr M, 2008, EXP DERMATOL, V17, P953, DOI 10.1111/j.1600-0625.2008.00734.x; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Roduit C, 2009, THORAX, V64, P107, DOI 10.1136/thx.2008.100875; Scholtens S, 2015, INT J EPIDEMIOL, V44, P1172, DOI 10.1093/ije/dyu229; Totte JEE, 2016, BRIT J DERMATOL, V175, P687, DOI 10.1111/bjd.14566; Totte J, 2017, TRIALS, V18, DOI 10.1186/s13063-017-2118-x; Totte JEE, 2017, CASE REP DERMATOL, V9, P19, DOI 10.1159/000473872; Wickman M, 2002, PEDIATR ALLERGY IMMU, V13, P11, DOI 10.1034/j.1399-3038.13.s.15.10.x; Wijga AH, 2014, INT J EPIDEMIOL, V43, P527, DOI 10.1093/ije/dys231; Wong SM, 2013, J DERMATOL, V40, P874, DOI 10.1111/1346-8138.12265	25	22	22	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2019	144	3					860	+		10.1016/j.jaci.2019.05.020	http://dx.doi.org/10.1016/j.jaci.2019.05.020			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IW8CV	31145938	Bronze			2022-12-18	WOS:000485222300031
J	Elfeky, R; Shah, RM; Unni, MNM; Ottaviano, G; Rao, K; Chiesa, R; Amrolia, P; Worth, A; Flood, T; Abinun, M; Hambleton, S; Cant, AJ; Gilmour, K; Adams, S; Ahsan, G; Barge, D; Gennery, AR; Qasim, W; Slatter, M; Veys, P				Elfeky, Reem; Shah, Ravi M.; Unni, Mohamed N. M.; Ottaviano, Giorgio; Rao, Kanchan; Chiesa, Robert; Amrolia, Persis; Worth, Austen; Flood, Terry; Abinun, Mario; Hambleton, Sophie; Cant, Andrew J.; Gilmour, Kimberly; Adams, Stuart; Ahsan, Gul; Barge, Dawn; Gennery, Andrew R.; Qasim, Waseem; Slatter, Mary; Veys, Paul			New graft manipulation strategies improve the outcome of mismatched stem cell transplantation in children with primary immunodeficiencies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Mismatched stem cell transplantation; graft-versus-host disease; cord; T-cell receptor alpha beta/CD19; immune reconstitution	VERSUS-HOST-DISEASE; IMMUNE RECONSTITUTION; ALLOGENEIC TRANSPLANTATION; DEPLETION; CRITERIA; MARROW; DONORS	Background: Mismatched stem cell transplantation is associated with a high risk of graft loss, graft-versus-host disease (GvHD), and transplant-related mortality. Alternative graft manipulation strategies have been used over the last 11 years to reduce these risks. Objective: We investigated the outcome of using different graft manipulation strategies among children with primary immunodeficiencies. Methods: Between 2006 and 2017, 147 patients with primary immunodeficiencies received 155 mismatched grafts: 30 T-cell receptor (TCR) alpha beta/CD19 depleted grafts, 43 cord blood (CB) grafts (72% with no serotherapy), 17 CD34(+) selection with T-cell add-back grafts, and 65 unmanipulated grafts. Results: The estimated 8-year survival of the entire cohort was 79%, transplant-related mortality was 21.7%, and the graft failure rate was 6.7%. Posttransplantation viral reactivation, grade II to IV acute graft-versus-host disease (aGvHD), and chronic graft-versus-host disease (cGvHD) complicated 49.6%, 35%, and 15% of transplantations, respectively. Use of TCR alpha beta/CD19 depletion was associated with a significantly lower incidence of grade II to IV aGvHD (11.5%) and cGvHD (0%), although with a greater incidence of viral reactivation (70%) in comparison with other grafts. T-cell immune reconstitution was robust among CB transplants, although with a high incidence (56.7%) of grade II to IV aGvHD. Stable full donor engraftment was significantly greater at 80% among TCR alpha beta(+)/CD19(+)-depleted and CB transplants versus 40% to 60% among the other groups. Conclusions: Rapidly accessible CB and haploidentical grafts are suitable alternatives for patients with no HLA-matched donor. Cord transplantation without serotherapy and TCR alpha beta(+)/CD19(+)-depleted grafts produced comparable survival rates of around 80%, although with a high rate of aGvHD with the former and a high risk of viral reactivation with the latter that need to be addressed.	[Elfeky, Reem; Amrolia, Persis; Qasim, Waseem; Veys, Paul] Univ Coll London UCL Great Ormond St Inst Child H, Mol & Cellular Immunol Unit, London, England; [Elfeky, Reem] Ain Shams Univ, Dept Paediat Allergy & Immunol, Cairo, Egypt; [Shah, Ravi M.; Rao, Kanchan; Chiesa, Robert; Amrolia, Persis; Worth, Austen; Gilmour, Kimberly; Adams, Stuart; Ahsan, Gul; Veys, Paul] Great Ormond St Hosp Sick Children, Blood & Bone Marrow Transplant Unit, London, England; [Unni, Mohamed N. M.; Flood, Terry; Abinun, Mario; Hambleton, Sophie; Cant, Andrew J.; Barge, Dawn; Gennery, Andrew R.; Slatter, Mary] Great North Childrens Hosp, Host Def Unit, Newcastle Upon Tyne, Tyne & Wear, England; [Ottaviano, Giorgio] Univ Milano Bicocca, Dept Paediat, Fdn MBBM, Monza, Italy; [Shah, Ravi M.] Alberta Childrens Prov Gen Hosp, Dept Paediat Oncol & BMT, Calgary, AB, Canada	Egyptian Knowledge Bank (EKB); Ain Shams University; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of Milano-Bicocca; Alberta Childrens Hospital; University of Calgary	Elfeky, R (corresponding author), Great Ormond St Hosp Sick Children, Paediat Immunol & Bone Marrow Transplantat, Great Ormond St, London WC1N 3JH, England.	r.elfeky@ucl.ac.uk	Ottaviano, Giorgio/GPT-0120-2022	Ottaviano, Giorgio/0000-0003-3777-0394; QASIM, WASEEM/0000-0001-8353-4494; Hambleton, Sophie/0000-0001-7954-3267	Department of Health [RP-2014-05-007] Funding Source: Medline	Department of Health		Admiraal R, 2015, LANCET HAEMATOL, V2, pE194, DOI 10.1016/S2352-3026(15)00045-9; Algeri M, 2018, 44 ANN M EUR SOC BLO; Balashov D, 2015, BIOL BLOOD MARROW TR, V21, P1955, DOI 10.1016/j.bbmt.2015.07.008; Bertaina A, 2014, BLOOD, V124, P822, DOI 10.1182/blood-2014-03-563817; Booth C, 2016, EXPERT REV CLIN IMMU, V12, P713, DOI 10.1586/1744666X.2016.1150177; Bremm M, 2017, CYTOM PART B-CLIN CY, V92, P126, DOI 10.1002/cyto.b.21328; Chiesa R, 2012, BRIT J HAEMATOL, V156, P656, DOI 10.1111/j.1365-2141.2011.08994.x; Elfeky R, 2018, J ALLERGY CLIN IMMUN, V141, P2279, DOI 10.1016/j.jaci.2017.10.051; Escobedo-Cousin M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138623; Filipovich AH, 2005, BIOL BLOOD MARROW TR, V11, P945, DOI 10.1016/j.bbmt.2005.09.004; Finke J, 1996, BONE MARROW TRANSPL, V18, P1081; Gennery AR, 2010, J ALLERGY CLIN IMMUN, V126, P602, DOI 10.1016/j.jaci.2010.06.015; GLUCKSBERG H, 1974, TRANSPLANTATION, V18, P295, DOI 10.1097/00007890-197410000-00001; Gragert L, 2014, NEW ENGL J MED, V371, P339, DOI 10.1056/NEJMsa1311707; Handgretinger R, 2001, BONE MARROW TRANSPL, V27, P777, DOI 10.1038/sj.bmt.1702996; Heimall J, 2017, BLOOD, V130, P2718, DOI 10.1182/blood-2017-05-781849; Jaiswal SR, 2016, PEDIATR TRANSPLANT, V20, P675, DOI 10.1111/petr.12724; Jodele S, 2014, BLOOD, V124, P645, DOI 10.1182/blood-2014-03-564997; Kurt B, 2008, CANCER-AM CANCER SOC, V113, P376, DOI 10.1002/cncr.23563; Lane JR, 2014, BIOL BLOOD MARROW TR, V20, P243, DOI 10.1016/j.bbmt.2013.11.005; Lang P, 1999, BONE MARROW TRANSPL, V24, P583, DOI 10.1038/sj.bmt.1701961; Laskin BL, 2011, BLOOD, V118, P1452, DOI 10.1182/blood-2011-02-321315; Luznik L, 2001, BLOOD, V98, P3456, DOI 10.1182/blood.V98.12.3456; O'Donnell PV, 2002, BIOL BLOOD MARROW TR, V8, P377, DOI 10.1053/bbmt.2002.v8.pm12171484; Shah RM, 2018, J ALLERGY CLIN IMMUN, V141, P1417, DOI 10.1016/j.jaci.2017.07.008; Shenoy S, 2015, CURR OPIN PEDIATR, V27, P9, DOI 10.1097/MOP.0000000000000179; Tiercy JM, 2016, HAEMATOLOGICA, V101, P680, DOI 10.3324/haematol.2015.141119	27	22	22	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2019	144	1					280	293		10.1016/j.jaci.2019.01.030	http://dx.doi.org/10.1016/j.jaci.2019.01.030			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IF9SM	30731121	Bronze			2022-12-18	WOS:000473432800029
J	Suurmond, J; Atisha-Fregoso, Y; Marasco, E; Barlev, AN; Ahmed, N; Calderon, SA; Wong, MY; Mackay, MC; Aranow, C; Diamond, B				Suurmond, Jolien; Atisha-Fregoso, Yemil; Marasco, Emiliano; Barlev, Ashley N.; Ahmed, Naveed; Calderon, Silvia A.; Wong, Mei Yin; Mackay, Meggan C.; Aranow, Cynthia; Diamond, Betty			Loss of an IgG plasma cell checkpoint in patients with lupus	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Plasma cells; tolerance; autoimmunity; systemic lupus erythematosus	DNA B-CELLS; MEMORY B; MOUSE MODEL; MICE; LYMPHOCYTES; SELECTION; AUTOANTIBODIES; TOLERANCE; ELIMINATION; AFFINITY	Background: IgG antinuclear antibodies (ANAs) are a feature of several autoimmune diseases. These antibodies arise through defects in central or peripheral tolerance checkpoints. The specific checkpoints breached in patients with autoimmune disease are not fully understood. Objectives: We sought to study whether autoreactive plasma cells in lupus models and patients with systemic lupus erythematosus (SLE) arise as a consequence of defective antigen-specific selection or a global enhancement of IgG plasma cell differentiation. Methods: We optimized and validated a novel technique to detect naturally occurring ANA(+) B cells and plasma cells. Results: We observed a major checkpoint for generation of ANA(+) IgG(+) plasma cells in both nonautoimmune mice and healthy human subjects. Interestingly, we observed increased numbers of ANA(+) IgG(+) plasma cells despite normal tolerance checkpoints in immature and naive B cells of lupus-prone MRL/lpr and NZB/W mice, as well as patients with SLE. This increase was due to increased numbers of total IgG 1 plasma cells rather than lack of selection against ANA(+) plasma cells. Conclusion: Using a method that permits quick and accurate quantification of autoreactive B cells and plasma cells in vivo within a native B-cell repertoire in mice and human subjects, we demonstrate the importance of a checkpoint that restricts the generation of IgG plasma cells and protects against IgG ANAs. Our observations suggest a fundamentally revised understanding of SLE: that it is a disease of aberrant B-cell differentiation rather than a defect in antigen-specific B-cell tolerance.	[Suurmond, Jolien; Atisha-Fregoso, Yemil; Marasco, Emiliano; Barlev, Ashley N.; Ahmed, Naveed; Calderon, Silvia A.; Wong, Mei Yin; Mackay, Meggan C.; Aranow, Cynthia; Diamond, Betty] Northwell Hlth, Feinstein Inst Med Res, Ctr Autoimmune Musculoskeletal & Hematopoiet Dis, Manhasset, NY USA; [Atisha-Fregoso, Yemil] Tecnol Monterrey, Monterrey, Mexico; [Marasco, Emiliano] Osped Pediat Bambino Gesu IRCCS, Div Rheumatol, Rome, Italy; [Barlev, Ashley N.] Donald & Barbara Zucker Sch Med Hofstra Northwell, Manhasset, NY USA; [Ahmed, Naveed] New York Inst Technol, Coll Osteopath Med, Old Westbury, NY 11568 USA; [Wong, Mei Yin] Univ Cambridge, Sch Clin Med, Cambridge, England	Northwell Health; Tecnologico de Monterrey; IRCCS Bambino Gesu; New York Institute Technology; University of Cambridge	Diamond, B (corresponding author), Feinstein Inst Med Res, Ctr Autoimmune Musculoskeletal & Hematopoiet Dis, 350 Community Dr, Manhasset, NY 11030 USA.	bdiamond@northwell.edu	Marasco, Emiliano/J-3627-2016	Marasco, Emiliano/0000-0001-5346-3357; Suurmond, Jolien/0000-0002-4092-8925	Mallinckrodt Pharmaceuticals; American Autoimmune Related Disease Association; Newham US Committee Travel Bursary; National Institutes of Health [1P01 AI073693]; Lupus Research Institute; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI073693] Funding Source: NIH RePORTER	Mallinckrodt Pharmaceuticals; American Autoimmune Related Disease Association; Newham US Committee Travel Bursary; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Lupus Research Institute; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	J.S. received financial support from Mallinckrodt Pharmaceuticals and the American Autoimmune Related Disease Association. M.Y.W. was supported by the Newham US Committee Travel Bursary. This work was further supported by National Institutes of Health grant 1P01 AI073693 and the Lupus Research Institute.	BARBAS SM, 1995, P NATL ACAD SCI USA, V92, P2529, DOI 10.1073/pnas.92.7.2529; Bynoe MS, 1999, EUR J IMMUNOL, V29, P1304, DOI 10.1002/(SICI)1521-4141(199904)29:04<1304::AID-IMMU1304>3.0.CO;2-6; Cappione A, 2005, J CLIN INVEST, V115, P3205, DOI 10.1172/JCI24179; Chan TD, 2012, IMMUNITY, V37, P893, DOI 10.1016/j.immuni.2012.07.017; Chen C, 1997, IMMUNITY, V6, P97, DOI 10.1016/S1074-7613(00)80673-1; CHEN C, 1995, NATURE, V373, P252, DOI 10.1038/373252a0; Chen C, 2006, J IMMUNOL, V176, P5183, DOI 10.4049/jimmunol.176.9.5183; Dorner T, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3433; ERIKSON J, 1991, NATURE, V349, P331, DOI 10.1038/349331a0; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; HARTLEY SB, 1991, NATURE, V353, P765, DOI 10.1038/353765a0; Hochberg MC, 1997, ARTHRITIS RHEUM, V40, P1725, DOI 10.1002/art.1780400928; IZUI S, 1978, J IMMUNOL, V121, P2213; Julien S, 2002, J IMMUNOL, V169, P4198, DOI 10.4049/jimmunol.169.8.4198; Kench JA, 1998, J EXP MED, V188, P909, DOI 10.1084/jem.188.5.909; KLINMAN DM, 1987, J EXP MED, V165, P1755, DOI 10.1084/jem.165.6.1755; KLINMAN DM, 1990, J CLIN INVEST, V86, P1249, DOI 10.1172/JCI114831; Kouskoff V, 1998, J EXP MED, V188, P1453, DOI 10.1084/jem.188.8.1453; Li H, 2001, IMMUNITY, V15, P947, DOI 10.1016/S1074-7613(01)00251-5; Li YJ, 2002, J EXP MED, V196, P1543, DOI 10.1084/jem.20021560; Liang ZY, 2004, J EXP MED, V199, P381, DOI 10.1084/jem.20030132; Malkiel S, 2016, ARTHRITIS RHEUMATOL, V68, P2210, DOI 10.1002/art.39710; Mandik-Nayak L, 1999, J EXP MED, V189, P1799, DOI 10.1084/jem.189.11.1799; MandikNayak L, 1997, J EXP MED, V186, P1257, DOI 10.1084/jem.186.8.1257; Meyer-Bahlburg A, 2008, J EXP MED, V205, P155, DOI 10.1084/jem.20071088; Mietzner B, 2008, P NATL ACAD SCI USA, V105, P9727, DOI 10.1073/pnas.0803644105; Pewzner-Jung Y, 1998, J IMMUNOL, V161, P4634; Phan TG, 2006, J EXP MED, V203, P2419, DOI 10.1084/jem.20061254; Pugh-Bernard AE, 2001, J CLIN INVEST, V108, P1061, DOI 10.1172/JCI200112462; ROARK JH, 1995, J EXP MED, V181, P1157, DOI 10.1084/jem.181.3.1157; Sabouri Z, 2014, P NATL ACAD SCI USA, V111, pE2567, DOI 10.1073/pnas.1406974111; Sandel PC, 1999, IMMUNITY, V10, P289, DOI 10.1016/S1074-7613(00)80029-1; Scheid JF, 2011, P NATL ACAD SCI USA, V108, P18044, DOI 10.1073/pnas.1113395108; Shinnakasu R, 2016, NAT IMMUNOL, V17, P861, DOI 10.1038/ni.3460; STAROBINSKI M, 1989, J AUTOIMMUN, V2, P657, DOI 10.1016/S0896-8411(89)80005-8; Steeves MA, 2004, J IMMUNOL, V172, P6568, DOI 10.4049/jimmunol.172.11.6568; Suurmond J, 2015, J CLIN INVEST, V125, P2194, DOI 10.1172/JCI78084; Sweet RA, 2010, AUTOIMMUNITY, V43, P607, DOI 10.3109/08916930903567500; Tiller T, 2007, IMMUNITY, V26, P205, DOI 10.1016/j.immuni.2007.01.009; Tiller T, 2010, J EXP MED, V207, P2767, DOI 10.1084/jem.20100171; Tipton CM, 2015, NAT IMMUNOL, V16, P755, DOI 10.1038/ni.3175; Vas J, 2012, ARTHRITIS RHEUM-US, V64, P3388, DOI 10.1002/art.34537; Wardemann H, 2003, SCIENCE, V301, P1374, DOI 10.1126/science.1086907; Weisel FJ, 2016, IMMUNITY, V44, P116, DOI 10.1016/j.immuni.2015.12.004; Wellmann U, 2001, EUR J IMMUNOL, V31, P2800, DOI 10.1002/1521-4141(200109)31:9<2800::AID-IMMU2800>3.0.CO;2-E; Yachimovich-Cohen N, 2003, EUR J IMMUNOL, V33, P2469, DOI 10.1002/eji.200324025; Yurasov S, 2005, J EXP MED, V201, P703, DOI 10.1084/jem.20042251	47	22	22	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2019	143	4					1586	1597		10.1016/j.jaci.2018.10.041	http://dx.doi.org/10.1016/j.jaci.2018.10.041			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HR7QE	30439406	Green Accepted, Bronze			2022-12-18	WOS:000463348900032
J	Uttarkar, S; Brembilla, NC; Boehncke, WH				Uttarkar, Sagar; Brembilla, Nicolo Costantino; Boehncke, Wolf-Henning			Regulatory cells in the skin: Pathophysiologic role and potential targets for anti-inflammatory therapies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Inflammation; regulatory T cells; regulatory B cells; monocytes; macrophages; myeloid-derived suppressor cells; Langerhans cells; psoriasis; atopic dermatitis	DELTA-T-CELLS; SUPPRESSOR-CELLS; B-CELLS; CONTACT HYPERSENSITIVITY; PERIPHERAL-BLOOD; LANGERHANS CELLS; MOUSE MODEL; MACROPHAGE ACTIVATION; PSORIASIS; INNATE	Inflammation is a fundamental defense mechanism to protect the body from danger, which becomes potentially harmful if it turns chronic. Therapeutic strategies aimed at specifically blocking proinflammatory signals, particularly cytokines, such as IL-4, IL-6, IL-13, IL-17A, or TNF-alpha, have substantially improved our ability to effectively and safely treat chronic inflammatory diseases. Much less effort has been made to better understand the role of potential anti-inflammatory mechanisms. Here we summarize the current understanding of regulatory cell populations in the context of chronic inflammation, namely macrophages, Langerhans cells, myeloid-derived suppressor cells, and regulatory T and B lymphocytes. Emphasis is given to the skin because many different immune-related diseases occur in the skin. Development, phenotype, function, and evidence for their role in animal models of inflammation, as well as in the corresponding human diseases, are described. Finally, the feasibility of using regulatory cells as targets for potentially disease-modifying therapeutic strategies is discussed.	[Uttarkar, Sagar; Brembilla, Nicolo Costantino; Boehncke, Wolf-Henning] Univ Geneva, Fac Med, Dept Pathol & Immunol, Geneva, Switzerland; [Boehncke, Wolf-Henning] Geneva Univ Hosp & Sch Med, Div Dermatol & Venereol, Rue Gabrielle Perret Gentil 4, CH-1211 Geneva, Switzerland	University of Geneva; University of Geneva	Boehncke, WH (corresponding author), Geneva Univ Hosp & Sch Med, Div Dermatol & Venereol, Rue Gabrielle Perret Gentil 4, CH-1211 Geneva, Switzerland.	wolf-henning.boehncke@hcuge.ch			Swiss National Foundation [310030_175470/1]	Swiss National Foundation(Swiss National Science Foundation (SNSF))	Supported by a grant from the Swiss National Foundation (310030_175470/1).	Akitsu A, 2018, IMMUNOLOGY, V155, P418, DOI 10.1111/imm.12993; Atmatzidis DH, 2017, J EUR ACAD DERMATOL, V31, P1817, DOI 10.1111/jdv.14522; Bansback N, 2009, DERMATOLOGY, V219, P209, DOI 10.1159/000233234; Bennett CL, 2001, NAT GENET, V27, P20, DOI 10.1038/83713; Berings M, 2017, J ALLERGY CLIN IMMUN, V140, P1250, DOI 10.1016/j.jaci.2017.08.025; Bieber K, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01628; Bovenschen HJ, 2011, J INVEST DERMATOL, V131, P1853, DOI 10.1038/jid.2011.139; Cai YH, 2013, INT IMMUNOPHARMACOL, V16, P388, DOI 10.1016/j.intimp.2013.02.018; Cao LY, 2016, J INVEST DERMATOL, V136, P1801, DOI 10.1016/j.jid.2016.02.816; Collison LW, 2012, NAT IMMUNOL, V13, P290, DOI 10.1038/ni.2227; Coombes JL, 2007, J EXP MED, V204, P1757, DOI 10.1084/jem.20070590; Corrado A, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/945945; Dantas RL, 2016, J PATHOL, V240, P366, DOI 10.1002/path.4786; Dass S, 2007, ARTHRITIS RHEUM, V56, P2715, DOI 10.1002/art.22811; Desreumaux P, 2012, GASTROENTEROLOGY, V143, P1207, DOI 10.1053/j.gastro.2012.07.116; Egawa M, 2013, IMMUNITY, V38, P570, DOI 10.1016/j.immuni.2012.11.014; Ezzelarab Mohamed B, 2016, Curr Transplant Rep, V3, P265, DOI 10.1007/s40472-016-0114-9; Fuentes-Duculan J, 2010, J INVEST DERMATOL, V130, P2412, DOI 10.1038/jid.2010.165; Furuhashi T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054895; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; Gaspar K, 2015, ACTA DERM-VENEREOL, V95, P151, DOI 10.2340/00015555-1882; Girardi M, 2002, J EXP MED, V195, P855, DOI 10.1084/jem.20012000; Guan HB, 2002, J INVEST DERMATOL, V119, P137, DOI 10.1046/j.1523-1747.2002.01830.x; Haile LA, 2008, GASTROENTEROLOGY, V135, P871, DOI 10.1053/j.gastro.2008.06.032; Han HW, 2017, IMMUNOL REV, V278, P116, DOI 10.1111/imr.12546; Hartwig T, 2015, EUR J IMMUNOL, V45, P3022, DOI 10.1002/eji.201545883; Hawkes JE, 2017, J ALLERGY CLIN IMMUN, V140, P645, DOI 10.1016/j.jaci.2017.07.004; Hayashi M, 2016, J DERMATOL SCI, V81, P93, DOI 10.1016/j.jdermsci.2015.11.003; Heratizadeh A, 2016, ALLERGY, V71, P1666, DOI 10.1111/all.13065; Hristodorov D, 2015, MABS-AUSTIN, V7, P853, DOI 10.1080/19420862.2015.1066950; Huang B, 2006, CANCER RES, V66, P1123, DOI 10.1158/0008-5472.CAN-05-1299; Huang X, 2018, METHODS MOL BIOL, V1784, P119, DOI 10.1007/978-1-4939-7837-3_12; Hutchinson JA, 2011, J IMMUNOL, V187, P2072, DOI 10.4049/jimmunol.1100762; Igyarto BZ, 2009, J IMMUNOL, V183, P5085, DOI 10.4049/jimmunol.0901884; Ilkovitch D, 2008, EXP DERMATOL, V17, P977, DOI 10.1111/j.1600-0625.2008.00779.x; Ilkovitch D, 2016, MOL MED REP, V14, P3935, DOI 10.3892/mmr.2016.5685; Ito T, 2008, IMMUNITY, V28, P870, DOI 10.1016/j.immuni.2008.03.018; Kannan AK, 2017, J IMMUNOL, V198; Kaplan DH, 2005, IMMUNITY, V23, P611, DOI 10.1016/j.immuni.2005.10.008; Karamehic Jasenko, 2014, Med Arch, V68, P236, DOI 10.5455/medarh.2014.68.236-238; Kasraie S., 2013, MEDIAT INFLAMM, V2013, P15; Koch S, 2017, ALLERGY, V72, P1686, DOI 10.1111/all.13170; Krueger JG, 2015, J ALLERGY CLIN IMMUN, V136, P116, DOI 10.1016/j.jaci.2015.01.018; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; Kusmartsev SA, 2000, J IMMUNOL, V165, P779, DOI 10.4049/jimmunol.165.2.779; Lavin Y, 2015, NAT REV IMMUNOL, V15, P731, DOI 10.1038/nri3920; Lechner MG, 2010, J IMMUNOL, V185, P2273, DOI 10.4049/jimmunol.1000901; Li HQ, 2009, J IMMUNOL, V182, P240, DOI 10.4049/jimmunol.182.1.240; Li JQ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132173; Ma L, 2014, J EUR ACAD DERMATOL, V28, P1079, DOI 10.1111/jdv.12288; Malissen B, 2014, NAT REV IMMUNOL, V14, P417, DOI 10.1038/nri3683; Maniadakis N, 2018, ADV THER, V35, P1333, DOI 10.1007/s12325-018-0759-0; Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015; Melani C, 2007, CANCER RES, V67, P11438, DOI 10.1158/0008-5472.CAN-07-1882; Melnik BC, 2018, BRIT J DERMATOL, V179, pe102; Mills CD, 2000, J IMMUNOL, V164, P6166, DOI 10.4049/jimmunol.164.12.6166; Mizutani H, 1997, J DERMATOL SCI, V14, P145, DOI 10.1016/S0923-1811(96)00562-2; Montalban-Arques A, 2018, INFLAMM BOWEL DIS, V24, P1649, DOI 10.1093/ibd/izy177; Murray PJ, 2017, ANNU REV PHYSIOL, V79, P541, DOI 10.1146/annurev-physiol-022516-034339; Murray PJ, 2014, IMMUNITY, V41, P14, DOI 10.1016/j.immuni.2014.06.008; Ohkura N, 2013, IMMUNITY, V38, P414, DOI 10.1016/j.immuni.2013.03.002; Oka T, 2017, J IMMUNOL, V198, P3897, DOI 10.4049/jimmunol.1601607; Okubo Y, 1998, J DERMATOL SCI, V17, P223, DOI 10.1016/S0923-1811(98)00019-X; Palomares O, 2014, GENES IMMUN, V15, P511, DOI 10.1038/gene.2014.45; Papotto PH, 2018, J AUTOIMMUN, V87, P26, DOI 10.1016/j.jaut.2017.11.006; Pawlaczyk M, 2010, POSTEP DERM ALERGOL, V27, P25; Prinz I, 2015, EUR J IMMUNOL, V45, P2994, DOI 10.1002/eji.201546033; Roers A, 2004, J EXP MED, V200, P1289, DOI 10.1084/jem.20041789; Roesner LM, 2015, ALLERGY, V70, P1656, DOI 10.1111/all.12712; Saito C, 2009, J DERMATOL SCI, V53, P231, DOI 10.1016/j.jdermsci.2008.09.011; Scharschmidt TC, 2017, SCI TRANSL MED, V9; Senra L, 2016, J INVEST DERMATOL, V136, P1970, DOI 10.1016/j.jid.2016.06.009; Sharma A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00883; Shevach EM, 2014, IMMUNOL REV, V259, P88, DOI 10.1111/imr.12160; Shin D, 2018, TOXINS, V10, DOI 10.3390/toxins10040146; Singh K, 2013, J IMMUNOL, V190, P2544, DOI 10.4049/jimmunol.1202399; Sinha P, 2007, J IMMUNOL, V179, P977, DOI 10.4049/jimmunol.179.2.977; Skabytska Y, 2014, IMMUNITY, V41, P762, DOI 10.1016/j.immuni.2014.10.009; Smith AR, 2014, J LEUKOCYTE BIOL, V96, P361, DOI 10.1189/jlb.3CE0414-205R; Soler DC, 2016, J INVEST DERMATOL, V136, P1749, DOI 10.1016/j.jid.2016.04.029; Soler DC, 2016, J INVEST DERMATOL, V136, P798, DOI 10.1016/j.jid.2015.12.036; Soler DC, 2013, CLIN IMMUNOL, V149, P111, DOI 10.1016/j.clim.2013.06.007; Stanic B, 2015, J ALLERGY CLIN IMMUN, V135, P771, DOI 10.1016/j.jaci.2014.07.041; Stratis A, 2006, J CLIN INVEST, V116, P2094, DOI 10.1172/JCI27179; Stunova A, 2018, CYTOKINE GROWTH F R, V39, P137, DOI 10.1016/j.cytogfr.2018.01.003; Thomson AW, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00015; van de Veen W, 2016, J ALLERGY CLIN IMMUN, V138, P654, DOI 10.1016/j.jaci.2016.07.006; van der Vliet HJJ, 2007, CLIN DEV IMMUNOL, DOI 10.1155/2007/89017; Vely F, 2016, NAT IMMUNOL, V17, P1291, DOI 10.1038/ni.3553; Wang HL, 2008, J CLIN INVEST, V118, P2629, DOI 10.1172/JCI34916; Wang HL, 2006, J CLIN INVEST, V116, P2105, DOI 10.1172/JCI27180; Wang S, 2017, CELL, V171, P201, DOI 10.1016/j.cell.2017.07.027; Yanaba K, 2013, J LEUKOCYTE BIOL, V94, P563, DOI 10.1189/jlb.1112562; Yoshiki R, 2009, J INVEST DERMATOL, V129, P705, DOI 10.1038/jid.2008.304; Zhang JF, 2016, J IMMUNOL, V197, P2131, DOI 10.4049/jimmunol.1600446; Zhang L, 2016, SCAND J IMMUNOL, V83, P174, DOI 10.1111/sji.12404; Zhang L, 2010, CLIN IMMUNOL, V135, P108, DOI 10.1016/j.clim.2009.11.008; Zhao M, 2014, CLIN IMMUNOL, V150, P22, DOI 10.1016/j.clim.2013.10.009; Zhou LL, 2015, J CANCER, V6, P717, DOI 10.7150/jca.10865	99	22	23	2	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2019	143	4					1302	1310		10.1016/j.jaci.2018.12.1011	http://dx.doi.org/10.1016/j.jaci.2018.12.1011			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HR7QE	30664891	Bronze			2022-12-18	WOS:000463348900004
J	Rosace, D; Gomez-Casado, C; Fernandez, P; Perez-Gordo, M; Dominguez, MD; Vega, A; Belver, MT; Ramos, T; Vega, F; Marco, G; de Pedro, M; Sanchez, L; Arnas, MD; Santaolalla, M; Saez, MA; Benede, S; Fernandez-Rivas, M; Blanco, C; Alvarado, MI; Escribese, MM; Barber, D				Rosace, Domenico; Gomez-Casado, Cristina; Fernandez, Paloma; Perez-Gordo, Marina; del Carmen Dominguez, Maria; Vega, Angel; Teresa Belver, Maria; Ramos, Tania; Vega, Francisco; Marco, Guadalupe; de Pedro, Manuel; Sanchez, Leticia; de las Mercedes Arnas, Maria; Santaolalla, Marcela; Angel Saez, Miguel; Benede, Sara; Fernandez-Rivas, Montserrat; Blanco, Carlos; Isabel Alvarado, Maria; Escribese, Maria M.; Barber, Domingo			Profilin-mediated food-induced allergic reactions are associated with oral epithelial remodeling	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; inflammation; oral mucosa; epithelial remodeling; grass pollen; profilin	MAST-CELL CHYMASE; DENDRITIC CELLS; SERUM PERIOSTIN; SENSITIZATION; INFLAMMATION; ACTIVATION; IL-33; EXPOSURE; CLEAVAGE; FIBROSIS	Background: In areas of high exposure to grass pollen, allergic patients are frequently sensitized to profilin, and some experience severe profilin-mediated food-induced reactions. This specific population of patients is ideal to study the relationship between respiratory and food allergies. Objective: We sought to determine the role of oral mucosal epithelial barrier integrity in profilin-mediated allergic reactions. Methods: Thirty-eight patients with profilin allergy stratified into mild or severe according to their clinical history and response to a profilin challenge test and 6 nonallergic subjects were recruited. Oral mucosal biopsies were used for measurement of CD11c, CD3, CD4, tryptase, claudin-1, occludin, E-cadherin, and vascular endothelial growth factor A levels; Masson trichrome staining; and POSTN, IL33, TPSAB, TPSB, and CMA gene expression analysis by using quantitative RT-PCR. Blood samples were used for basophil activation tests. Results: Distinct features of the group with severe allergy included the following: (1) impaired epithelial integrity with reduced expression of claudin-1, occludin, and E-cadherin and decreased numbers of epithelial cells, which is indicative of acanthosis, higher collagen deposition, and angiogenesis; (2) inflammatory immune response in the mucosa, with an increased number of CD11c 1 and CD4 1 infiltrates and increased expression of the cytokine genes POSTN and IL33; and (3) a 10-fold increased sensitivity of basophils to profilin. Conclusions: Patients with profilin allergy present with significant damage to the oral mucosal epithelial barrier, which might allow profilin penetration into the oral mucosa and induction of local inflammation. Additionally, severely allergic patients presented with increased sensitivity of effector cells.	[Rosace, Domenico; Gomez-Casado, Cristina; Fernandez, Paloma; Escribese, Maria M.; Barber, Domingo] Grp Hosp Madrid, Inst Med Mol Aplicada, Madrid, Spain; [Perez-Gordo, Marina; Escribese, Maria M.] Univ San Pablo CEU, Fac Med, Dept Ciencias Med Basicas, Madrid, Spain; [del Carmen Dominguez, Maria; Vega, Angel; Isabel Alvarado, Maria] Hosp Virgen Puerto, Plasencia, Caceres, Spain; [Teresa Belver, Maria; Ramos, Tania; Vega, Francisco; Blanco, Carlos] Hosp Univ La Princesa, Inst Invest Sanitaria Princesa IP, Madrid, Spain; [Marco, Guadalupe; de Pedro, Manuel; Sanchez, Leticia; Fernandez-Rivas, Montserrat] Hosp Univ Clin San Carlos, Madrid, Spain; [de las Mercedes Arnas, Maria; Santaolalla, Marcela] Hosp HM Sanchinarro, Madrid, Spain; [Angel Saez, Miguel] Hosp Cent Def Gomez Ulla, Madrid, Spain; [Benede, Sara] Univ Complutense Madrid, Fac Ciencias Quim, Madrid, Spain	San Pablo CEU University; Complutense University of Madrid	Escribese, MM (corresponding author), Univ San Pablo CEE, CEU Univ, Fac Med, Dept Ciencias Med Basicas, Campus Monteprincipe,Crta Boadilla Monte Km 5-3, Madrid 28668, Spain.	mariamarta.escribesealonso@ceu.es	Gomez-Casado, Cristina/AAE-4826-2021; Blanco, Carlos/B-3895-2012; Gordo, Marina Perez/F-6817-2017; Barber, Domingo/Y-9516-2019; Benedé, Sara/H-6147-2013; Escribese, Maria M/F-4716-2012; Marco, Guadalupe/ABF-9192-2021; Gomez-Casado, Cristina/K-4031-2016	Blanco, Carlos/0000-0002-2893-6594; Gordo, Marina Perez/0000-0003-2003-4841; Barber, Domingo/0000-0002-5488-5700; Benedé, Sara/0000-0002-9288-9438; Escribese, Maria M/0000-0001-5057-5150; Marco, Guadalupe/0000-0003-1754-3274; Fernandez, Paloma/0000-0001-5941-8442; Saez, Miguel Angel/0000-0002-8389-258X; Gomez-Casado, Cristina/0000-0002-7707-6367	ISCIII [PI16/00249, PI15/02256]; FEDER [RD16/0006/0015, RD16/0006/0009]; FPI-CEU predoctoral fellowships	ISCIII(Instituto de Salud Carlos III); FEDER(European Commission); FPI-CEU predoctoral fellowships	Supported by ISCIII (project nos. PI16/00249 and PI15/02256) by ISCIII, which was cofounded by FEDER, for the thematic network and cooperative research centers ARADyAL (RD16/0006/0015 and RD16/0006/0009). D.R. was supported by FPI-CEU predoctoral fellowships.	Almeida ECS, 2013, PATHOL RES PRACT, V209, P399, DOI 10.1016/j.prp.2013.03.001; Alvarado MI, 2014, ALLERGY, V69, P1610, DOI 10.1111/all.12509; Amin K, 2012, RESP MED, V106, P9, DOI 10.1016/j.rmed.2011.09.007; Asano T, 2017, ANN AM THORAC SOC, V14, P667, DOI 10.1513/AnnalsATS.201609-720OC; Asero R, 2015, INT ARCH ALLERGY IMM, V168, P25, DOI 10.1159/000441222; Barber D, 2009, CLIN EXP ALLERGY, V39, P1764, DOI 10.1111/j.1365-2222.2009.03351.x; Barber D, 2015, CURR ALLERGY ASTHM R, V15, DOI 10.1007/s11882-014-0496-7; Berin MC, 2013, CURR BIOL, V23, pR389, DOI 10.1016/j.cub.2013.02.043; Bousquet J, 2012, ALLERGY, V67, P18, DOI 10.1111/j.1398-9995.2011.02728.x; Cutler CW, 2006, J DENT RES, V85, P678, DOI 10.1177/154405910608500801; Dodani K, 2012, J PERIODONTOL, V83, P1038, DOI 10.1902/jop.2011.110352; Golebski K, 2013, ALLERGY, V68, P152, DOI 10.1111/all.12080; Gurish MF, 2012, IMMUNITY, V37, P25, DOI 10.1016/j.immuni.2012.07.003; Hovav AH, 2014, MUCOSAL IMMUNOL, V7, P27, DOI 10.1038/mi.2013.42; Incorvaia C, 2007, RECENT PATENTS INFLA, V1, P35, DOI 10.2174/187221307779815129; Kakizoe E, 2001, J INVEST DERMATOL, V116, P118, DOI 10.1046/j.1523-1747.2001.00165.x; Kofford MW, 1997, J BIOL CHEM, V272, P7127, DOI 10.1074/jbc.272.11.7127; Konstantelou E, 2017, CYTOKINE, V93, P51, DOI 10.1016/j.cyto.2017.05.007; Lambrecht BN, 2014, J ALLERGY CLIN IMMUN, V134, P499, DOI 10.1016/j.jaci.2014.06.036; Leoni G, 2015, MUCOSAL IMMUNOL, V8, P959, DOI 10.1038/mi.2015.63; Lund G, 2018, ALLERGY, V73, P1013, DOI 10.1111/all.13351; Martinez-Gonzalez I, 2015, TRENDS IMMUNOL, V36, P189, DOI 10.1016/j.it.2015.01.005; Mastrorilli C, 2016, ALLERGY, V71, P1181, DOI 10.1111/all.12888; Masuoka M, 2012, J CLIN INVEST, V122, P2590, DOI 10.1172/JCI58978; McGowan EC, 2013, CURR ALLERGY ASTHM R, V13, P101, DOI 10.1007/s11882-012-0324-x; Moutsopoulos NM, 2018, TRENDS IMMUNOL, V39, P276, DOI 10.1016/j.it.2017.08.005; Ng MFY, 2010, INT WOUND J, V7, P55, DOI 10.1111/j.1742-481X.2009.00651.x; Novak N, 2008, TRENDS MOL MED, V14, P191, DOI 10.1016/j.molmed.2008.03.001; Porsbjerg C, 2016, CLIN EXP ALLERGY, V46, P564, DOI 10.1111/cea.12702; Rak GD, 2016, J INVEST DERMATOL, V136, P487, DOI 10.1038/JID.2015.406; Ruiz-Garcia M, 2011, J ALLERGY CLIN IMMUN, V128, P416, DOI 10.1016/j.jaci.2011.03.008; SAARINEN J, 1994, J BIOL CHEM, V269, P18134; Santos A, 2011, INT ARCH ALLERGY IMM, V155, P191, DOI 10.1159/000321178; Schmitz J, 2005, IMMUNITY, V23, P479, DOI 10.1016/j.immuni.2005.09.015; Schwanekamp JA, 2016, ARTERIOSCL THROM VAS, V36, P60, DOI 10.1161/ATVBAHA.115.306397; Shin K, 2006, ANNU REV CELL DEV BI, V22, P207, DOI 10.1146/annurev.cellbio.22.010305.104219; Steelant B, 2016, J ALLERGY CLIN IMMUN, V137, P1043, DOI 10.1016/j.jaci.2015.10.050; Takabayashi T, 2013, AM J RESP CRIT CARE, V187, P49, DOI 10.1164/rccm.201207-1292OC; Tsuchiya T, 2003, J ASTHMA, V40, P935, DOI 10.1081/JAS-120024594; Van Bruaene N, 2009, J ALLERGY CLIN IMMUN, V124, P253, DOI 10.1016/j.jaci.2009.04.013; van Deventer SJH, 1999, ANN RHEUM DIS, V58, P114; Waern I, 2013, MUCOSAL IMMUNOL, V6, P911, DOI 10.1038/mi.2012.129	42	22	22	0	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2019	143	2					681	+		10.1016/j.jaci.2018.03.013	http://dx.doi.org/10.1016/j.jaci.2018.03.013			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HK2DJ	29705246				2022-12-18	WOS:000457718700027
J	Ghosh, S; Carmo, M; Calero-Garcia, M; Ricciardelli, I; Ogando, JCB; Blundell, MP; Schambach, A; Ashton-Rickardt, PG; Booth, C; Ehl, S; Lehmberg, K; Thrasher, AJ; Gaspar, HB				Ghosh, Sujal; Carmo, Marlene; Calero-Garcia, Miguel; Ricciardelli, Ida; Ogando, Juan Carlos Bustamante; Blundell, Michael P.; Schambach, Axel; Ashton-Rickardt, Philip G.; Booth, Claire; Ehl, Stephan; Lehmberg, Kai; Thrasher, Adrian J.; Gaspar, H. Bobby			T-cell gene therapy for perforin deficiency corrects cytotoxicity defects and prevents hemophagocytic lymphohistiocytosis manifestations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Gene therapy; hemophagocytic lymphohistiocytosis; perforin deficiency; T cells	MURINE MODELS; STEM-CELLS; TRANSPLANTATION; MICE; CHIMERISM; DISORDER; GAMMA	Background: Mutations in the perforM 1 (PRF1) gene account for up to 58% of familial hemophagocytic lymphohistiocytosis syndromes. The resulting defects in effector cell cytotoxicity lead to hypercytokinemia and hyperactivation with inflammation in various organs. Objective: We sought to determine whether autologous gene corrected T cells can restore cytotoxic function, reduce disease activity, and prevent hemophagocytic lymphohistiocytosis (HLH) symptoms in in vivo models. Methods: We developed a gammaretroviral vector to transduce murine CD8 T cells in the Prfl(-/-) mouse model. To verify functional correction of Prfl(-/-) CD8 T cells in vivo, we used a lymphocytic choriomeningitis virus (LCMV) epitopetransfected murine lung carcinoma cell tumor model. Furthermore, we challenged gene-corrected and uncorrected mice with LCMV. One patient sample was transduced with a PRF1-encoding lentiviral vector to study restoration of cytotoxicity in human cells. Results: We demonstrated efficient engraftment and functional reconstitution of cytotoxicity after intravenous administration of gene-corrected Prfl(-/-) CD8 T cells into Prfl(-/-) mice. In the tumor model infusion of Prfl(-/-) gene-corrected CD8 T cells eliminated the tumor as efficiently as transplantation of wild type CD8 T cells. Similarly, mice reconstituted with gene corrected Prfl(-/-) CD8 T cells displayed complete protection from the HLH phenotype after infection with LCMV. Patients' cells showed correction of cytotoxicity in human CD8 T cells after transduction. Conclusion: These data demonstrate the potential application of T -cell gene therapy in reconstituting cytotoxic function and protection against HLH in the setting of perforM deficiency.	[Ghosh, Sujal; Carmo, Marlene; Calero-Garcia, Miguel; Ricciardelli, Ida; Ogando, Juan Carlos Bustamante; Blundell, Michael P.; Booth, Claire; Thrasher, Adrian J.; Gaspar, H. Bobby] UCL, Great Ormond St Inst Child Hlth, Infect Immun Inflammat Mol & Cellular Immunol Sec, 30 Guilford St, London WC1N 1EH, England; [Ghosh, Sujal] Heinrich Heine Univ, Ctr Child & Adolescent Hlth, Fac Med, Dept Pediat Oncol Hematol & Clin Immunol, Dusseldorf, Germany; [Schambach, Axel] Hannover Med Sch, Inst Expt Hematol, Hannover, Germany; [Ashton-Rickardt, Philip G.] Imperial Coll, Dept Med, Fac Med, Sect Immunobiol,Div Inflammat & Immunol, London, England; [Ehl, Stephan] Univ Freiburg, Univ Med Ctr, Ctr Chron Immunodeficiency, Freiburg, Germany; [Lehmberg, Kai] Univ Med Ctr Hamburg Eppendorf, Dept Paediat Haematol & Oncol, Div Paediat Stem Cell Transplantat & Immunol, Hamburg, Germany	University of London; University College London; Heinrich Heine University Dusseldorf; Hannover Medical School; Imperial College London; University of Freiburg; University of Hamburg; University Medical Center Hamburg-Eppendorf	Gaspar, HB (corresponding author), UCL, Great Ormond St Inst Child Hlth, Infect Immun Inflammat Mol & Cellular Immunol Sec, 30 Guilford St, London WC1N 1EH, England.	h.gaspar@ucl.ac.uk	Ehl, Stephan/AAM-6006-2020; Ricciardelli, Ida/ABC-8937-2020; Blundell, Michael P/M-1276-2015; Schambach, Axel/C-5491-2011; Booth, Claire/I-3667-2016	Calero-Garcia, Miguel/0000-0002-6921-9700; Ehl, Stephan/0000-0002-9265-2721; BUSTAMANTE-OGANDO, JUAN CARLOS/0000-0003-3409-6226; Thrasher, Adrian/0000-0002-6097-6115; Blundell, Michael/0000-0002-9179-6870; Booth, Claire/0000-0002-2626-5037	German Research Foundation-Deutsche Forschungsgemeinschaft [GH 154/1-1, SFB1160]; Histiocytosis Research Trust; UCLTherapeutics Innovation Fund; Wellcome Trust; DAAD; German Federal Ministry of Research and Education; European Commission's 7th Framework Program [261387]; Medical Research Council [MR/L012855/1]; Great Ormond Street Hospital Children's Charity; National Institute of Health Research Biomedical Research Centre at Great Ormond Street Hospital and University College London; MRC [MR/L012855/1] Funding Source: UKRI	German Research Foundation-Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Histiocytosis Research Trust; UCLTherapeutics Innovation Fund; Wellcome Trust(Wellcome Trust); DAAD(Deutscher Akademischer Austausch Dienst (DAAD)); German Federal Ministry of Research and Education; European Commission's 7th Framework Program; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Great Ormond Street Hospital Children's Charity; National Institute of Health Research Biomedical Research Centre at Great Ormond Street Hospital and University College London; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Supported by grants from the German Research Foundation-Deutsche Forschungsgemeinschaft (grant no. GH 154/1-1 to S.G. and SFB1160, TP1 to S.E.), the Histiocytosis Research Trust and UCLTherapeutics Innovation Fund (to M.C.), the Wellcome Trust (to A.J.T.), the DAAD and the German Federal Ministry of Research and Education (to A.S.), the European Commission's 7th Framework Program Contract 261387 (CELL-PID), and grant MR/L012855/1 from the Medical Research Council. The authors would like to acknowledge the support of Great Ormond Street Hospital Children's Charity (to H.B.G.). This study was also supported by the National Institute of Health Research Biomedical Research Centre at Great Ormond Street Hospital and University College London.	Abina SHB, 2015, JAMA-J AM MED ASSOC, V313, P1550, DOI 10.1001/jama.2015.3253; Bartholomae C, 2014, AM SOC GEN CELL THER; Biffi A, 2013, SCIENCE, V341, P864, DOI 10.1126/science.1233158; Carmo M, 2015, MOL THER, V23, P737, DOI 10.1038/mt.2014.242; Cavazzana M, 2014, 19 C EUR HEM ASS; Das R, 2016, BLOOD, V127, P1666, DOI 10.1182/blood-2015-12-684399; Gaspar HB, 2014, AM SOC GEN CELL THER; Gattinoni L, 2009, NAT MED, V15, P808, DOI 10.1038/nm.1982; Gholam C, 2011, CLIN EXP IMMUNOL, V163, P271, DOI 10.1111/j.1365-2249.2010.04302.x; Hacein-Bey-Abina S, 2014, NEW ENGL J MED, V371, P1407, DOI 10.1056/NEJMoa1404588; Hartz B, 2016, BLOOD, V127, P3281, DOI 10.1182/blood-2015-12-684498; Henter JI, 2007, PEDIATR BLOOD CANCER, V48, P124, DOI 10.1002/pbc.21039; Henter JI, 2002, BLOOD, V100, P2367, DOI 10.1182/blood-2002-01-0172; Janka GE, 2012, ANNU REV MED, V63, P233, DOI 10.1146/annurev-med-041610-134208; Johnson TS, 2014, J IMMUNOL, V192, P84, DOI 10.4049/jimmunol.1302282; Jordan MB, 2004, BLOOD, V104, P735, DOI 10.1182/blood-2003-10-3413; Jordan MB, 2011, BLOOD, V118, P4041, DOI 10.1182/blood-2011-03-278127; Katano H, 2005, BRIT J HAEMATOL, V128, P739, DOI 10.1111/j.1365-2141.2004.05305.x; Lee DW, 2015, LANCET, V385, P517, DOI 10.1016/S0140-6736(14)61403-3; Lehmberg K, 2014, HAEMATOLOGICA, V99, P180, DOI 10.3324/haematol.2013.094730; Mahlaoui N, 2007, PEDIATRICS, V120, pE622, DOI 10.1542/peds.2006-3164; Marsh RA, 2013, PEDIATR BLOOD CANCER, V60, P101, DOI 10.1002/pbc.24188; Marsh RA, 2011, BRIT J HAEMATOL, V154, P556, DOI 10.1111/j.1365-2141.2011.08785.x; Marsh RA, 2010, BLOOD, V116, P5824, DOI 10.1182/blood-2010-04-282392; Maschalidi S, 2016, BLOOD, V128, P60, DOI 10.1182/blood-2016-02-700013; Maude SL, 2014, NEW ENGL J MED, V371, P1507, DOI 10.1056/NEJMoa1407222; Nikiforow S, 2015, HEMATOL ONCOL CLIN N, V29, P943, DOI 10.1016/j.hoc.2015.06.011; Pachlopnik SJ, 2009, EMBO MOL MED, V1, P112, DOI DOI 10.1002/EMMM.200900009; Prevost-Blondel A, 2000, J IMMUNOL, V164, P3645, DOI 10.4049/jimmunol.164.7.3645; Risma K, 2012, CURR OPIN PEDIATR, V24, P9, DOI 10.1097/MOP.0b013e32834ec9c1; Rood JE, 2016, BLOOD, V127, P426, DOI 10.1182/blood-2015-07-659813; Schambach A, 2000, MOL THER, V2, P435, DOI 10.1006/mthe.2000.0191; Stepp SE, 1999, SCIENCE, V286, P1957, DOI 10.1126/science.286.5446.1957; Terrell CE, 2013, BLOOD, V122, P2618, DOI 10.1182/blood-2013-06-508143; Terrell CE, 2013, BLOOD, V121, P5184, DOI 10.1182/blood-2013-04-495309	35	22	22	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2018	142	3					904	+		10.1016/j.jaci.2017.11.050	http://dx.doi.org/10.1016/j.jaci.2017.11.050			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GS5RJ	29355678	Green Published, hybrid			2022-12-18	WOS:000443726500023
J	Heremans, J; Garcia-Perez, JE; Turro, E; Schlenner, SM; Casteels, I; Collin, R; de Zegher, F; Greene, D; Humblet-Baron, S; Lesage, S; Matthys, P; Penkett, CJ; Put, K; Stirrups, K; Thys, C; Van Geet, C; Van Nieuwenhove, E; Wouters, C; Meyts, I; Freson, K; Liston, A				Heremans, Jessica; Garcia-Perez, Josselyn E.; Turro, Ernest; Schlenner, Susan M.; Casteels, Ingele; Collin, Roxanne; de Zegher, Francis; Greene, Daniel; Humblet-Baron, Stephanie; Lesage, Sylvie; Matthys, Patrick; Penkett, Christopher J.; Put, Karen; Stirrups, Kathleen; Thys, Chantal; Van Geet, Chris; Van Nieuwenhove, Erika; Wouters, Carine; Meyts, Isabelle; Freson, Kathleen; Liston, Adrian		Natl Inst Hlth Res BioResource	Abnormal differentiation of B cells and megakaryocytes in patients with Roifman syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						B cells; platelets; RNA processing; Roifman syndrome	DISORDER MOPD I; DEVELOPMENTAL DISORDER; MINOR SPLICEOSOME; U4ATAC SNRNA; HERMANSKY-PUDLAK-SYNDROME-1 HPS1; BAFF-R; PLATELET; EXPRESSION; IMMUNODEFICIENCY; BIOGENESIS	Background: Roifman syndrome is a rare inherited disorder characterized by spondyloepiphyseal dysplasia, growth retardation, cognitive delay, hypogammaglobulinemia, and, in some patients, thrombocytopenia. Compound heterozygous variants in the small nuclear RNA gene RNU4ATAC, which is necessary for U12-type intron splicing, were identified recently as driving Roifman syndrome. Objective: We studied 3 patients from 2 unrelated kindreds harboring compound heterozygous or homozygous stem II variants in RNU4ATAC to gain insight into the mechanisms behind this disorder. Methods: We systematically profiled the immunologic and hematologic compartments of the 3 patients with Roifman syndrome and performed RNA sequencing to unravel important splicing defects in both cell lineages. Results: The patients exhibited a dramatic reduction in B-cell numbers, with differentiation halted at the transitional B-cell stage. Despite abundant B-cell activating factor availability, development past this B-cell activating factor-dependent stage was crippled, with disturbed minor splicing of the critical mitogen-activated protein kinase 1 signaling component. In the hematologic compartment patients with Roifman syndrome demonstrated defects in megakaryocyte differentiation, with inadequate generation of proplatelets. Platelets from patients with Roifman syndrome were rounder, with increased tubulin and actin levels, and contained increased a-granule and dense granule markers. Significant minor intron retention in 354 megakaryocyte genes was observed, including DIAPH1 and HPS1, genes known to regulate platelet and dense granule formation, respectively. Conclusion: Together, our results provide novel molecular and cellular data toward understanding the immunologic and hematologic features of Roifman syndrome.	[Heremans, Jessica; Thys, Chantal; Van Geet, Chris; Freson, Kathleen] Katholieke Univ Leuven, Ctr Mol & Vasc Biol, Dept Cardiovasc Sci, Leuven, Belgium; [Garcia-Perez, Josselyn E.; Schlenner, Susan M.; Humblet-Baron, Stephanie; Matthys, Patrick; Put, Karen; Van Nieuwenhove, Erika; Wouters, Carine; Meyts, Isabelle; Liston, Adrian] Katholieke Univ Leuven, Dept Microbiol & Immunol, Leuven, Belgium; [Garcia-Perez, Josselyn E.; Schlenner, Susan M.; Humblet-Baron, Stephanie; Van Nieuwenhove, Erika; Liston, Adrian] VIB Ctr Brain & Dis Res, Leuven, Belgium; [Turro, Ernest; Greene, Daniel; Penkett, Christopher J.; Stirrups, Kathleen] Univ Cambridge, Dept Hematol, Cambridge, England; [Turro, Ernest; Penkett, Christopher J.; Stirrups, Kathleen] Natl Hlth Serv Blood & Transplant, Cambridge, England; [Turro, Ernest] Cambridge Biomed Campus, MRC, Biostat Unit, Cambridge Inst Publ Hlth, Cambridge, England; [Turro, Ernest; Greene, Daniel; Penkett, Christopher J.; Stirrups, Kathleen] Cambridge Biomed Campus, Natl Inst Hlth Res BioResource Rare Dis, Cambridge Univ Hosp, Cambridge, England; [Casteels, Ingele] Univ Hosp Leuven, Div Ophthalmol, Leuven, Belgium; [de Zegher, Francis; Van Geet, Chris; Van Nieuwenhove, Erika; Wouters, Carine; Meyts, Isabelle] Univ Hosp Leuven, Dept Pediat, Leuven, Belgium; [Collin, Roxanne; Lesage, Sylvie] Maisonneuve Rosemont Hosp, Dept Immunol Oncol, Montreal, PQ, Canada; [Collin, Roxanne; Lesage, Sylvie] Univ Montreal, Dept Microbiol Infectiol & Immunol, Montreal, PQ, Canada	KU Leuven; KU Leuven; Flanders Institute for Biotechnology (VIB); University of Cambridge; NHS Blood & Transplant (NHSBT); MRC Biostatistics Unit; University of Cambridge; University of Cambridge; KU Leuven; University Hospital Leuven; KU Leuven; University Hospital Leuven; Universite de Montreal; Universite de Montreal	Freson, K (corresponding author), Univ Leuven, Dept Cardiovasc Sci, Ctr Mol & Vasc Biol, Herestr 49, B-3000 Leuven, Belgium.; Liston, A (corresponding author), Univ Leuven, Dept Microbiol & Immunol, VIB Ctr Brain & Dis Res, Herestr 49, B-3000 Leuven, Belgium.	kathleen.freson@med.kuleuve.be; adrian.liston@vib.be	Matthys, Patrick/B-4813-2018; Van Nieuwenhove, Erika/H-7445-2018; Meyts, Isabelle/Z-3295-2019; Schlenner, Susan/P-7905-2017	Matthys, Patrick/0000-0002-9685-6836; Van Nieuwenhove, Erika/0000-0001-9584-3198; Turro, Ernest/0000-0002-1820-6563; Schlenner, Susan/0000-0002-8553-3388; Collin, Roxanne/0000-0002-4776-8696; Lesage, Sylvie/0000-0002-0968-2795; freson, kathleen/0000-0002-4381-2442; Humblet-Baron, Stephanie/0000-0003-4684-069X; Wouters, Carine/0000-0002-6426-8845	National Institute for Health Research of England [RG65966]; Research Foundation-Flanders [1S00816N, 1272517N, 1S22716N, G.0B17.13N]; Research Council of the University of Leuven (BOF KU Leuven) [OT/14/098]; ERC [Immuno ERC-2010-StG_20091118]; MRC [MC_UU_00002/10, MC_UP_0801/1] Funding Source: UKRI	National Institute for Health Research of England; Research Foundation-Flanders(FWO); Research Council of the University of Leuven (BOF KU Leuven); ERC(European Research Council (ERC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Supported by the National Institute for Health Research of England (award no. RG65966 to NIHR BioResource-Rare Diseases), Research Foundation-Flanders (grant no. 1S00816N to J.H., 1272517N to S.H.-B., 1S22716N to E.V.N., and G.0B17.13N to K.F.), the Research Council of the University of Leuven (BOF KU Leuven, OT/14/098 to K.F.), and the ERC (Immuno ERC-2010-StG_20091118 to A.L.). C.V.G. is holder of the Bayer and Norbert Heimburger (CSL Behring) Chairs.	Abdel-Salam GMH, 2013, AM J MED GENET A, V161, P1875, DOI 10.1002/ajmg.a.36009; Albers CA, 2012, NAT GENET, V44, P435, DOI 10.1038/ng.1083; Alioto TS, 2007, NUCLEIC ACIDS RES, V35, pD110, DOI 10.1093/nar/gkl796; Barbosa RR, 2014, J CLIN IMMUNOL, V34, P573, DOI 10.1007/s10875-014-0047-y; Bogaert DJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02434-4; Cai H, 2016, SEMIN THROMB HEMOST, V42, P282, DOI 10.1055/s-0035-1564836; Canault M, 2014, J EXP MED, V211, P1346, DOI 10.1084/jem.20130477; Carmona-Rivera C, 2013, BBA-MOL CELL RES, V1833, P468, DOI 10.1016/j.bbamcr.2012.10.019; Carss KJ, 2017, AM J HUM GENET, V100, P75, DOI 10.1016/j.ajhg.2016.12.003; Chesarone MA, 2010, NAT REV MOL CELL BIO, V11, P62, DOI 10.1038/nrm2816; Chiang PW, 2003, J BIOL CHEM, V278, P20332, DOI 10.1074/jbc.M300090200; Corral J, 2004, HAEMATOLOGICA, V89, P325; Craxton A, 2005, J EXP MED, V202, P1363, DOI 10.1084/jem.20051283; Craxton A, 2007, EUR J IMMUNOL, V37, P2715, DOI 10.1002/eji.200737327; Dangwal S, 2012, THROMB HAEMOSTASIS, V108, P599, DOI 10.1160/TH12-03-0211; Darce JR, 2007, J IMMUNOL, V179, P7276, DOI 10.4049/jimmunol.179.11.7276; de Vries PJ, 2006, J INTELL DISABIL RES, V50, P690, DOI 10.1111/j.1365-2788.2006.00817.x; Di Michele M, 2011, J PROTEOMICS, V74, P902, DOI 10.1016/j.jprot.2011.03.007; Edelstein LC, 2013, J THROMB HAEMOST, V11, P340, DOI 10.1111/jth.12214; Edelstein LC, 2011, BLOOD, V117, P5289, DOI 10.1182/blood-2011-01-292011; Edery P, 2011, SCIENCE, V332, P240, DOI 10.1126/science.1202205; Fairchild HR, 2011, AM J MED GENET A, V155A, P2560, DOI 10.1002/ajmg.a.34215; Feng LJ, 2002, BLOOD, V99, P1651, DOI 10.1182/blood.V99.5.1651.h8001651_1651_1658; Freson K, 2001, BLOOD, V98, P85, DOI 10.1182/blood.V98.1.85; Freson K, 2008, BLOOD, V111, P1885, DOI 10.1182/blood-2007-06-098558; Gray PEA, 2011, INT J IMMUNOGENET, V38, P501, DOI 10.1111/j.1744-313X.2011.01041.x; Greene D, 2017, AM J HUM GENET, V101, P104, DOI 10.1016/j.ajhg.2017.05.015; He HL, 2011, SCIENCE, V332, P238, DOI 10.1126/science.1200587; Jafarifar F, 2014, RNA, V20, P1078, DOI 10.1261/rna.045187.114; Kreivi JP, 1996, CURR BIOL, V6, P802, DOI 10.1016/S0960-9822(02)00599-7; Lentaigne C, 2016, BLOOD, V127, P2814, DOI 10.1182/blood-2016-03-378588; Mackay F, 2009, NAT REV IMMUNOL, V9, P491, DOI 10.1038/nri2572; Merico D, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9718; Motulsky HJ, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-123; Opalinska JB, 2010, BLOOD, V116, pE128, DOI 10.1182/blood-2010-06-292920; Put K, 2017, ARTHRITIS RHEUMATOL, V69, P213, DOI 10.1002/art.39933; Rodeghiero F, 2009, BLOOD, V113, P2386, DOI 10.1182/blood-2008-07-162503; Roifman CM, 2003, CLIN GENET, V63, P522, DOI 10.1034/j.1399-0004.2003.00033.x; Roifman CM, 1999, CLIN GENET, V55, P103, DOI 10.1034/j.1399-0004.1999.550206.x; Rondina MT, 2015, J THROMB HAEMOST, V13, pS26, DOI 10.1111/jth.12965; Schejter YD, 2017, NPJ GENOM MED, V2, DOI 10.1038/s41525-017-0024-5; Schneider P, 1999, J EXP MED, V189, P1747, DOI 10.1084/jem.189.11.1747; Shukla GC, 2002, NUCLEIC ACIDS RES, V30, P4650, DOI 10.1093/nar/gkf609; Stritt S, 2016, BLOOD, V127, P2903, DOI 10.1182/blood-2015-10-675629; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; Tangye SG, 2006, SEMIN IMMUNOL, V18, P305, DOI 10.1016/j.smim.2006.04.004; Tarn WY, 1996, CELL, V84, P801, DOI 10.1016/S0092-8674(00)81057-0; Thompson JS, 2001, SCIENCE, V293, P2108, DOI 10.1126/science.1061965; Turro E, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad7666; Turunen JJ, 2013, WIRES RNA, V4, P61, DOI 10.1002/wrna.1141; Westmoreland D, 2016, J THROMB HAEMOST, V14, P839, DOI 10.1111/jth.13269; Yeo GW, 2007, PLOS GENET, V3, P814, DOI 10.1371/journal.pgen.0030085	52	22	22	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2018	142	2					630	646		10.1016/j.jaci.2017.11.061	http://dx.doi.org/10.1016/j.jaci.2017.11.061			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GP2LN	29391254	Bronze, Green Submitted, Green Accepted			2022-12-18	WOS:000440664400029
J	Fogel, O; Riviere, E; Seror, R; Nocturne, G; Boudaoud, S; Ly, B; Gottenberg, JE; Le Guern, V; Dubost, JJ; Nititham, J; Taylor, KE; Chanson, P; Dieude, P; Criswell, LA; Jagla, B; Thai, A; Mingueneau, M; Mariette, X; Miceli-Richard, C				Fogel, Olivier; Riviere, Elodie; Seror, Raphaele; Nocturne, Gaetane; Boudaoud, Saida; Ly, Bineta; Gottenberg, Jacques-Eric; Le Guern, Veronique; Dubost, Jean-Jacques; Nititham, Joanne; Taylor, Kimberly E.; Chanson, Philippe; Dieude, Philippe; Criswell, Lindsey A.; Jagla, Bernd; Thai, Alice; Mingueneau, Michael; Mariette, Xavier; Miceli-Richard, Corinne			Role of the IL-12/IL-35 balance in patients with Sjogren syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-35; IL-12; regulatory T cell; regulatory B cell; Sjogren syndrome	REGULATORY B-CELLS; EPSTEIN-BARR-VIRUS; T-CELLS; DENDRITIC CELLS; SALIVARY-GLANDS; FUNCTIONAL POLYMORPHISM; IMMUNE-RESPONSES; DISEASE-ACTIVITY; INTERLEUKIN-12; IL-12	Background: An interferon signature is involved in the pathogenesis of primary Sjogren syndrome (pSS), but whether the signature is type 1 or type 2 remains controversial. Mouse models and genetic studies suggest the involvement of T(H)1 and type 2 interferon pathways. Likewise, polymorphisms of the IL-12A gene (IL12A), which encodes for IL-12p35, have been associated with pSS. The IL-12p35 subunit is shared by 2 heterodimers: IL-12 and IL-35. Objective: We sought to confirm genetic association of the IL12A polymorphism and pSS and elucidate involvement of the IL-12/IL-35 balance in patients with pSS by using functional studies. Methods: The genetic study involved 673 patients with pSS from 2 French pSS cohorts and 585 healthy French control subjects. Functional studies were performed on sorted monocytes, irrespective of whether they were stimulated. IL12A mRNA expression and IL-12 and IL-35 protein levels were assessed by using quantitative RT-PCR and ELISA and a multiplex kit for IL-35 and IL-12, respectively. Results: We confirmed association of the IL12A rs485497 polymorphism and pSS and found an increased serum protein level of IL-12p70 in patients with pSS carrying the risk allele (P=.016). Serum levels of IL-12p70 were greater in patients than control subjects (P=.0001), especially in patients with more active disease (P=.05); conversely, IL-35 levels were decreased in patients (P=.0001), especially in patients with more active disease (P=.05). In blood cellular subsets both IL12p35 and EBV-induced gene protein 3 (EBI3) mRNAs were detected only in B cells, with a trend toward a lower level among patients with pSS. Conclusion: Our findings emphasize involvement of the IL-12/IL-35 balance in the pathogenesis of pSS. Serum IL-35 levels were associated with low disease activity, in contrast with serum IL-12p70 levels, which were associated with more active disease.	[Fogel, Olivier; Riviere, Elodie; Seror, Raphaele; Nocturne, Gaetane; Boudaoud, Saida; Ly, Bineta; Mariette, Xavier; Miceli-Richard, Corinne] Univ Paris Sud, Hop Univ Paris Sud, AP HP, Paris, France; [Fogel, Olivier; Riviere, Elodie; Seror, Raphaele; Nocturne, Gaetane; Boudaoud, Saida; Ly, Bineta; Mariette, Xavier; Miceli-Richard, Corinne] Ctr Immunol Viral Infect & Autoimmune Dis, Le Kremlin Bicetre, France; [Gottenberg, Jacques-Eric] Univ Strasbourg, Ctr Hosp Univ Strasbourg, Hop Hautepierre, Serv Rhumatol, Strasbourg, France; [Le Guern, Veronique] Hop Cochin, Serv Med Interne, Paris, France; [Dubost, Jean-Jacques] Hop Univ G Montpied, Serv Rhumatol, Clermont Ferrand, France; [Nititham, Joanne; Taylor, Kimberly E.; Criswell, Lindsey A.] Univ Calif San Francisco, Dept Med, Rosalind Russell Ephraim P Engleman Rheumatol Res, San Francisco, CA USA; [Chanson, Philippe] Hop Bicetre, AP HP, Serv Endocrinol & Malad Reprod, Le Kremlin Bicetre, France; [Chanson, Philippe] Univ Paris Sud, Fac Med Paris Sud, UMR S1185, Le Kremlin Bicetre, France; [Chanson, Philippe] INSERM, U1185, Le Kremlin Bicetre, France; [Dieude, Philippe] Univ Paris 07, Hop Bichat, AP HP, INSERM,Serv Rhumatol,U699, Paris, France; [Jagla, Bernd] C3BI Inst Pasteur, Technol Core & Hub Bioinformat & Biostat, CRT, Paris, France; [Thai, Alice; Mingueneau, Michael] Biogen, Immunol Res, Cambridge, MA USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; UDICE-French Research Universities; Universite Paris Saclay; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; CHU Clermont Ferrand; University of California System; University of California San Francisco; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Biogen	Miceli-Richard, C (corresponding author), Hop Cochin, Serv Rhumatol, 27 Rue Faubourg St Jacques, F-75014 Paris, France.; Mariette, X (corresponding author), Hop Bicetre, Serv Rhumatol, 78 Rue Gen Leclerc, F-94275 Le Kremlin Bicetre, France.	xavier.mariette@aphp.fr; corinne.miceli@aphp.fr	Fogel, Olivier/U-6578-2019; Mingueneau, Michael/O-5313-2019; Chanson, Philippe/F-8511-2013	Mingueneau, Michael/0000-0002-3873-7329; Chanson, Philippe/0000-0001-5096-5722; Riviere, Elodie/0000-0003-1010-3081; Nocturne, Gaetane/0000-0001-6809-0733	French Ministry of Health: PHRC - Direction de la Recherche Clinique, Assistance Publique-Hopitaux de Paris [2006-AOM06133, PHRC 2010-AOM10188]; French Ministry of Research [ANR-2010-BLAN-113301, ANR-10-LABX-LERMIT]; Fondation pour la Recherche Medicale [DEQ20150934719]; French Ministry of Health: annee-recherche; Arthritis Fondation Courtin, Arthritis RD [CIFRE 2016/1406]	French Ministry of Health: PHRC - Direction de la Recherche Clinique, Assistance Publique-Hopitaux de Paris; French Ministry of Research(Ministry of Research, FranceEuropean Commission); Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); French Ministry of Health: annee-recherche; Arthritis Fondation Courtin, Arthritis RD	Support was obtained from the French Ministry of Health: PHRC no. 2006-AOM06133, PHRC 2010-AOM10188 (ASSESS cohort sponsored by Direction de la Recherche Clinique, Assistance Publique-Hopitaux de Paris); the French Ministry of Research: ANR-2010-BLAN-113301 and ANR-10-LABX-LERMIT; and Fondation pour la Recherche Medicale DEQ20150934719: Sjogren's syndrome and Autoimmunity-associated Lymphomas (SAIL). O.F. received a grant from the French Ministry of Health: annee-recherche. E.R. is the recipient of a PhD fellowship from Arthritis Fondation Courtin, Arthritis R&D (CIFRE 2016/1406).	Airoldi I, 2010, ARTHRITIS RHEUM-US, V62, P2180, DOI 10.1002/art.27484; Anders S, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-10-r106; Arshanapalli A, 2015, CYTOKINE, V73, P319, DOI 10.1016/j.cyto.2014.11.026; Bardel E, 2008, J IMMUNOL, V181, P6898, DOI 10.4049/jimmunol.181.10.6898; Bouaziz JD, 2008, IMMUNOL REV, V224, P201, DOI 10.1111/j.1600-065X.2008.00661.x; Chiche L, 2014, ARTHRITIS RHEUMATOL, V66, P1583, DOI 10.1002/art.38628; Christodoulou MI, 2008, AM J PATHOL, V173, P1389, DOI 10.2353/ajpath.2008.080246; Collison LW, 2007, NATURE, V450, P566, DOI 10.1038/nature06306; Collison LW, 2012, NAT IMMUNOL, V13, P290, DOI 10.1038/ni.2227; Collison LW, 2010, NAT IMMUNOL, V11, P1093, DOI 10.1038/ni.1952; Devergne O, 1997, P NATL ACAD SCI USA, V94, P12041, DOI 10.1073/pnas.94.22.12041; Dieude P, 2009, ARTHRITIS RHEUM-US, V60, P225, DOI 10.1002/art.24183; Dixon KO, 2015, EUR J IMMUNOL, V45, P1736, DOI 10.1002/eji.201445217; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Emamian ES, 2009, GENES IMMUN, V10, P285, DOI 10.1038/gene.2009.20; Farrar JD, 2000, J BIOL CHEM, V275, P2693, DOI 10.1074/jbc.275.4.2693; Fillatreau S, 2002, NAT IMMUNOL, V3, P944, DOI 10.1038/ni833; Fox RI, 2005, LANCET, V366, P321, DOI 10.1016/S0140-6736(05)66990-5; Gestermann N, 2010, GENES IMMUN, V11, P432, DOI 10.1038/gene.2010.29; Gottenberg JE, 2006, P NATL ACAD SCI USA, V103, P2770, DOI 10.1073/pnas.0510837103; Gottenberg JE, 2005, J AUTOIMMUN, V24, P235, DOI 10.1016/j.jaut.2005.01.015; Hall JC, 2012, P NATL ACAD SCI USA, V109, P17609, DOI 10.1073/pnas.1209724109; Horiuchi M, 1999, J CLIN PATHOL, V52, P833, DOI 10.1136/jcp.52.11.833; Kano SI, 2008, NAT IMMUNOL, V9, P34, DOI 10.1038/ni1538; KOBAYASHI M, 1989, J EXP MED, V170, P827, DOI 10.1084/jem.170.3.827; Korman BD, 2008, GENES IMMUN, V9, P267, DOI 10.1038/gene.2008.1; KUBIN M, 1994, BLOOD, V83, P1847; Lawrence M, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003118; Lessard CJ, 2013, NAT GENET, V45, P1284, DOI 10.1038/ng.2792; Li XM, 2007, J RHEUMATOL, V34, P2438; Li XY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033628; Li Y, 2014, MEDIAT INFLAMM, V2014, DOI DOI 10.1155/2014/136329; Li YZ, 2013, NAT GENET, V45, P1361, DOI 10.1038/ng.2779; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; MACATONIA SE, 1995, J IMMUNOL, V154, P5071; Manoussakis MN, 2007, ARTHRITIS RHEUM-US, V56, P3977, DOI 10.1002/art.23073; Mauri C, 2012, ANNU REV IMMUNOL, V30, P221, DOI 10.1146/annurev-immunol-020711-074934; McGrath-Morrow S, 2006, AM J PHYSIOL-LUNG C, V291, pL837, DOI 10.1152/ajplung.00134.2006; Miceli-Richard C, 2007, ARTHRITIS RHEUM, V56, P3989, DOI 10.1002/art.23142; Mingueneau M, 2016, J ALLERGY CLIN IMMUN, V137, P1809, DOI 10.1016/j.jaci.2016.01.024; Nakano S, 2015, RHEUMATOLOGY, V54, P1498, DOI 10.1093/rheumatology/keu528; Niedbala W, 2007, EUR J IMMUNOL, V37, P3021, DOI 10.1002/eji.200737810; Nocturne G, 2016, ARTHRITIS RHEUMATOL, V68, P977, DOI 10.1002/art.39518; Nocturne G, 2013, NAT REV RHEUMATOL, V9, P544, DOI 10.1038/nrrheum.2013.110; Nordmark G, 2011, GENES IMMUN, V12, P100, DOI 10.1038/gene.2010.44; Nordmark G, 2009, GENES IMMUN, V10, P68, DOI 10.1038/gene.2008.94; Nutz A, 2015, REV RHUMATOL S, V82S, pA121; Ohyama Y, 1996, ARTHRITIS RHEUM, V39, P1376, DOI 10.1002/art.1780390816; Ouyang H, 2014, AM J MED SCI, V348, P156, DOI 10.1097/MAJ.0000000000000215; Price AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847; Rogge L, 1998, J IMMUNOL, V161, P6567; Rosser EC, 2015, IMMUNITY, V42, P607, DOI 10.1016/j.immuni.2015.04.005; Rusakiewicz S, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005727; Sarigul M, 2010, LUPUS, V19, P138, DOI 10.1177/0961203309348234; Seror R, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075-015-0750-y; Seror R, 2010, ANN RHEUM DIS, V69, P1103, DOI 10.1136/ard.2009.110619; Shen P, 2014, NATURE, V507, P366, DOI 10.1038/nature12979; SIEBURTH D, 1992, GENOMICS, V14, P59, DOI 10.1016/S0888-7543(05)80283-6; Szodoray P, 2005, CLIN IMMUNOL, V117, P168, DOI 10.1016/j.clim.2005.06.016; Tomcik M, 2015, RHEUMATOLOGY, V54, P2273, DOI 10.1093/rheumatology/kev260; Unutmaz D, 2008, NAT IMMUNOL, V9, P9, DOI 10.1038/ni0108-9; van Wanrooij RLJ, 2012, J AUTOIMMUN, V39, P359, DOI 10.1016/j.jaut.2012.06.002; Vitali C, 2002, ANN RHEUM DIS, V61, P554, DOI 10.1136/ard.61.6.554; Volchenkov R, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4294; Vosters JL, 2009, ARTHRITIS RHEUM-US, V60, P3633, DOI 10.1002/art.24980; Wang RX, 2014, NAT MED, V20, P633, DOI 10.1038/nm.3554; Yanagi K, 1996, CELL IMMUNOL, V168, P243, DOI 10.1006/cimm.1996.0072; Yang YH, 2014, HUM IMMUNOL, V75, P909, DOI 10.1016/j.humimm.2014.06.019	68	22	24	1	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2018	142	1					258	+		10.1016/j.jaci.2017.07.041	http://dx.doi.org/10.1016/j.jaci.2017.07.041			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GM1OC	28916184	Bronze			2022-12-18	WOS:000437837500028
J	Meesilpavikkai, K; Dik, WA; Schrijver, B; Nagtzaam, NMA; Posthumus-van Sluijs, SJ; van Hagen, PM; Dalm, VASH				Meesilpavikkai, Kornvalee; Dik, Willem A.; Schrijver, Benjamin; Nagtzaam, Nicole M. A.; Posthumus-van Sluijs, Sandra J.; van Hagen, P. Martin; Dalm, Virgil A. S. H.			Baricitinib treatment in a patient with a gain-of-function mutation in signal transducer and activator of transcription 1 (STAT1)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							CHRONIC MUCOCUTANEOUS CANDIDIASIS; ATOPIC-DERMATITIS		[Meesilpavikkai, Kornvalee; Dik, Willem A.; Schrijver, Benjamin; Nagtzaam, Nicole M. A.; Posthumus-van Sluijs, Sandra J.; van Hagen, P. Martin; Dalm, Virgil A. S. H.] Erasmus MC, Univ Med Ctr, Dept Immunol, Rotterdam, Netherlands; [Meesilpavikkai, Kornvalee; van Hagen, P. Martin; Dalm, Virgil A. S. H.] Erasmus MC, Univ Med Ctr, Dept Internal Med, Div Clin Immunol, Rotterdam, Netherlands; [Dik, Willem A.; Schrijver, Benjamin; Nagtzaam, Nicole M. A.; Posthumus-van Sluijs, Sandra J.] Erasmus MC, Univ Med Ctr, Lab Med Immunol, Rotterdam, Netherlands; [Meesilpavikkai, Kornvalee] Chulalongkorn Univ, Fac Med, Dept Microbiol, Bangkok, Thailand	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Chulalongkorn University	Dalm, VASH (corresponding author), Erasmus MC, Univ Med Ctr, Dept Immunol, Rotterdam, Netherlands.; Dalm, VASH (corresponding author), Erasmus MC, Univ Med Ctr, Dept Internal Med, Div Clin Immunol, Rotterdam, Netherlands.	v.dalm@erasmusmc.nl			Erasmus MC, University Medical Center Rotterdam, The Netherlands; Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand	Erasmus MC, University Medical Center Rotterdam, The Netherlands(Netherlands Government); Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand(Chulalongkorn University)	Supported by Erasmus MC, University Medical Center Rotterdam, The Netherlands, and the Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.	Chopra R, 2017, BRIT J DERMATOL, V177, P1316, DOI 10.1111/bjd.15641; Dhingra N, 2014, J ALLERGY CLIN IMMUN, V134, P362, DOI 10.1016/j.jaci.2014.03.009; Fichorova RN, 2008, ANAL CHEM, V80, P4741, DOI 10.1021/ac702628q; Higgins E, 2015, J ALLERGY CLIN IMMUN, V135, P551, DOI 10.1016/j.jaci.2014.12.1867; Hirahara K, 2010, CYTOKINE GROWTH F R, V21, P425, DOI 10.1016/j.cytogfr.2010.10.006; Khattri S, 2014, J ALLERGY CLIN IMMUN, V133, P1626, DOI 10.1016/j.jaci.2014.03.003; Markham A, 2017, DRUGS, V77, P697, DOI 10.1007/s40265-017-0723-3; Meesilpavikkai K, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00274; Noda S, 2015, J ALLERGY CLIN IMMUN, V136, P1254, DOI 10.1016/j.jaci.2015.08.015; Romberg N, 2013, J ALLERGY CLIN IMMUN, V131, P1691, DOI 10.1016/j.jaci.2013.01.004; Shi JG, 2014, J CLIN PHARMACOL, V54, P1354, DOI 10.1002/jcph.354; Toubiana J, 2016, BLOOD, V127, P3154, DOI 10.1182/blood-2015-11-679902; Ungar B, 2017, J INVEST DERMATOL, V137, P603, DOI 10.1016/j.jid.2016.09.037; van de Veerdonk FL, 2016, J INFECTION, V72, pS56, DOI 10.1016/j.jinf.2016.04.023; Zhang Y, 2017, J EXP MED, V214, P2523, DOI 10.1084/jem.20161427	15	22	22	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2018	142	1					328	330		10.1016/j.jaci.2018.02.045	http://dx.doi.org/10.1016/j.jaci.2018.02.045			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GM1OC	29729898	Bronze			2022-12-18	WOS:000437837500045
J	Gudmundsdottir, J; Soderling, J; Berggren, H; Oskarsdottir, S; Neovius, M; Stephansson, O; Ekwall, O				Gudmundsdottir, Judith; Soderling, Jonas; Berggren, Hakan; Oskarsdottir, Solveig; Neovius, Martin; Stephansson, Olof; Ekwall, Olov			Long-term clinical effects of early thymectomy: Associations with autoimmune diseases, cancer, infections, and atopic diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							CELL; ASTHMA		[Gudmundsdottir, Judith; Ekwall, Olov] Univ Gothenburg, Sahlgrenska Acad, Inst Med, Dept Rheumatol & Inflammat Res, Gothenburg, Sweden; [Gudmundsdottir, Judith] Univ Hosp Iceland, Childrens Med Ctr, Reykjavik, Iceland; [Soderling, Jonas; Neovius, Martin; Stephansson, Olof] Dept Med, Solna, Sweden; [Soderling, Jonas; Neovius, Martin; Stephansson, Olof] Karolinska Inst, Clin Epidemiol Unit, Stockholm, Sweden; [Berggren, Hakan] Univ Gothenburg, Sahlgrenska Acad, Dept Mol & Clin Med, Inst Clin Sci, Gothenburg, Sweden; [Oskarsdottir, Solveig; Ekwall, Olov] Univ Gothenburg, Sahlgrenska Acad, Dept Pediat, Inst Clin Sci, Gothenburg, Sweden; [Stephansson, Olof] Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA	University of Gothenburg; Landspitali National University Hospital; Karolinska Institutet; University of Gothenburg; University of Gothenburg; University of California System; University of California Berkeley	Gudmundsdottir, J (corresponding author), Univ Gothenburg, Sahlgrenska Acad, Inst Med, Dept Rheumatol & Inflammat Res, Gothenburg, Sweden.; Gudmundsdottir, J (corresponding author), Univ Hosp Iceland, Childrens Med Ctr, Reykjavik, Iceland.	judith.gudmundsdottir@gu.se		Neovius, Martin/0000-0003-2300-3055; Ekwall, Olov/0000-0002-4506-9955; Stephansson, Olof/0000-0003-1528-4563	Region Vastra Gotaland [ALFGBG-771712]; Marianne and Marcus Wallenberg Foundation [MMW2012.0052]; Swedish Heart-Lung Foundation [20140420]; Swedish Research Council [2013-2429]; Queen Silvia Jubilee Foundation; Swedish Child Diabetes Foundation	Region Vastra Gotaland; Marianne and Marcus Wallenberg Foundation; Swedish Heart-Lung Foundation(Swedish Heart-Lung Foundation); Swedish Research Council(Swedish Research CouncilEuropean Commission); Queen Silvia Jubilee Foundation; Swedish Child Diabetes Foundation	This research was funded by Region Vastra Gotaland (grant no. ALFGBG-771712), the Marianne and Marcus Wallenberg Foundation (grant no. MMW2012.0052), the Swedish Heart-Lung Foundation (grant no. 20140420), the Swedish Research Council (grant no. 2013-2429), the Queen Silvia Jubilee Foundation, and the Swedish Child Diabetes Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Goronzy JJ, 2015, J IMMUNOL, V194, P4073, DOI 10.4049/jimmunol.1500046; Gudmundsdottir J, 2017, J ALLERGY CLIN IMMUN, V140, P1743, DOI 10.1016/j.jaci.2017.08.002; Gudmundsdottir J, 2016, J ALLERGY CLIN IMMUN, V138, P1439, DOI 10.1016/j.jaci.2016.05.014; Kurobe H, 2013, J THORAC CARDIOV SUR, V145, P656, DOI 10.1016/j.jtcvs.2012.12.015; Ludvigsson JF, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-450; Matheson MC, 2017, J ASTHMA, V54, P616, DOI 10.1080/02770903.2016.1249284; Tanabe T, 2012, EXPERT REV RESP MED, V6, P705, DOI [10.1586/ERS.12.67, 10.1586/ers.12.67]; van den Broek T, 2017, EUR J IMMUNOL, V47, P1970, DOI 10.1002/eji.201746971; van den Broek T, 2016, J CLIN INVEST, V126, P1126, DOI 10.1172/JCI84997	9	22	22	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2018	141	6					2294	2297		10.1016/j.jaci.2018.01.037	http://dx.doi.org/10.1016/j.jaci.2018.01.037			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GI7SD	29454003				2022-12-18	WOS:000434701600040
J	Mincheva, R; Ekerljung, L; Bossios, A; Lundback, B; Lotvall, J				Mincheva, Roxana; Ekerljung, Linda; Bossios, Apostolos; Lundback, Bo; Lotvall, Jan			High prevalence of severe asthma in a large random population study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma severity; prevalence; population study; phenotypic diversity	OBSTRUCTIVE LUNG-DISEASE; ADULT-ONSET ASTHMA; QUALITY-OF-LIFE; NORTHERN SWEDEN; BARIATRIC SURGERY; RESPIRATORY HEALTH; ALLERGIC RHINITIS; CIGARETTE-SMOKING; RISK-FACTORS; QUESTIONNAIRE	Background: The prevalence of asthma severity is not well described at a population level. Objective: We sought to determine the prevalence of phenotypic signs of asthma severity among asthmatic patients in a general population and to describe risk factors for asthma severity. Methods: We performed an epidemiologic study conducted between 2008 and 2012 (West Sweden Asthma Study). A postal questionnaire was sent to a random population (n 5 30,000) in west Sweden, with 18,087 responses. A total of 2,006 subjects were carefully phenotyped. Only subjects with `` active asthma'' (symptoms or medication in the last year, n 5 744) were analyzed in this study to determine the degree of severity of the disease within an asthma cohort. Phenotypes of severity were calculated based on (1) multiple symptoms during the day despite ongoing use of asthma medications, (2) FEV1 of less than 70% of predicted value, (3) daily or almost daily use of rescue medications, (4) nighttime symptoms once a week or more, and (5) oral corticosteroid use/emergency department visits. Asthmatic patients were grouped as having nonsevere disease, 1 sign of severity, or 2 or more signs of severity. Results: A total of 36.2% of asthmatic patients expressed at least 1 sign of asthma severity, and 13.2% had 2 or more signs. The group with 2 or more signs was older in age and had higher body mass index, a higher rate of tobacco smoking, and lower lung function. Bronchial hyperreactivity, airway inflammation, and sensitization were significantly different among the 3 groups. At a population level, the prevalence of asthma severity was 3.1% for 1 sign and 1.3% for at least 2 signs. Conclusion: More than 1 in 3 asthmatic patients show at least 1 sign of asthma severity. The phenotypes of asthma severity are highly diverse, which is important to consider when implementing personalized medicine in asthmatic patients.	[Mincheva, Roxana; Ekerljung, Linda; Bossios, Apostolos; Lundback, Bo; Lotvall, Jan] Univ Gothenburg, Inst Med, Krefting Res Ctr, Gothenburg, Sweden	University of Gothenburg	Lotvall, J (corresponding author), Univ Gothenburg, Krefting Res Ctr, Box 424, SE-40530 Gothenburg, Sweden.	jan.lotvall@gu.se	Bossios, Apostolos/ABH-8262-2020	Bossios, Apostolos/0000-0002-0494-2690; Lotvall, Jan/0000-0001-9195-9249; Mincheva, Roxana/0000-0002-6072-2748; Ekerljung, Linda/0000-0001-5784-0041	Swedish Research Council [K2014-85x-22504-01-3, K2011-56K-20676-04-6]; VBG Group Herman Krefting Foundation for Asthma and Allergy Research [20141209, 20131212, 20121218]; Swedish Heart and Lung Foundation [20120528]	Swedish Research Council(Swedish Research CouncilEuropean Commission); VBG Group Herman Krefting Foundation for Asthma and Allergy Research; Swedish Heart and Lung Foundation(Swedish Heart-Lung Foundation)	Supported by the Swedish Research Council (K2014-85x-22504-01-3 [for 2014 and 2015] and K2011-56K-20676-04-6 [for 2013]), VBG Group Herman Krefting Foundation for Asthma and Allergy Research (20141209 [for 2015], 20131212 [for 2014], 20121218 [for 2013]), and the Swedish Heart and Lung Foundation (20120528 [for 2013, 2014, and 2015]).	Abraham B, 2003, EUR RESPIR J, V22, P470, DOI 10.1183/09031936.03.00261903; Ali Z, 2013, RESP MED, V107, P1287, DOI 10.1016/j.rmed.2013.03.019; Almqvist C, 2008, ALLERGY, V63, P47, DOI 10.1111/j.1398-9995.2007.01524.x; Amelink M, 2013, J ALLERGY CLIN IMMUN, V132, P336, DOI 10.1016/j.jaci.2013.04.052; Antonicelli L, 2013, RESP MED, V107, P23, DOI 10.1016/j.rmed.2012.09.023; Axelsson M, 2014, J AM ASSOC NURSE PRA, V26, P32, DOI 10.1002/2327-6924.12069; Bel EH, 2013, AM J RESP CRIT CARE, V187, P667, DOI 10.1164/rccm.201302-0333ED; Bell MC, 2013, J ALLER CL IMM-PRACT, V1, P110, DOI 10.1016/j.jaip.2013.01.005; Bender B, 2003, J ALLERGY CLIN IMMUN, V112, P489, DOI 10.1067/mai.2003.1680; Bender BG, 2006, J ALLERGY CLIN IMMUN, V118, P899, DOI 10.1016/j.jaci.2006.07.002; Boulet LP, 2012, CLIN CHEST MED, V33, P405, DOI 10.1016/j.ccm.2012.06.002; Bumbacea D, 2004, EUR RESPIR J, V24, P122, DOI 10.1183/09031936.04.00077803; Busse William W., 2000, Journal of Allergy and Clinical Immunology, V106, P1033; Cazzoletti L, 2010, INT ARCH ALLERGY IMM, V151, P70, DOI 10.1159/000232572; Chalmers GW, 2002, THORAX, V57, P226, DOI 10.1136/thorax.57.3.226; Chaudhuri R, 2003, AM J RESP CRIT CARE, V168, P1308, DOI 10.1164/rccm.200304-503OC; Chung KF, 2014, EUR RESPIR J, V43, P343, DOI 10.1183/09031936.00202013; Melo SMD, 2013, OBES SURG, V23, P372, DOI 10.1007/s11695-012-0776-z; de Marco R, 2006, J ALLERGY CLIN IMMUN, V117, P1249, DOI 10.1016/j.jaci.2006.03.019; DEMARCO R, 1994, EUR RESPIR J, V7, P2139, DOI 10.1183/09031936.94.07122139; Desai M, 2011, CURR ALLERGY ASTHM R, V11, P454, DOI 10.1007/s11882-011-0227-2; Ekerljung L, 2011, EUR RESPIR J, V38, P825, DOI 10.1183/09031936.00143710; Ekerljung L, 2010, INT J TUBERC LUNG D, V14, P764; Ekerljung L, 2014, RESP MED, V108, P685, DOI 10.1016/j.rmed.2014.02.016; Gaga M, 2005, CLIN EXP ALLERGY, V35, P954, DOI 10.1111/j.1365-2222.2005.02281.x; Gibeon D, 2013, CHEST, V143, P406, DOI 10.1378/chest.12-0872; Global Initiative for Asthma. Global strategy for asthma management and prevention, NAT HEAT LUNG BLOOD; Hasegawa K, 2015, J ALLERGY CLIN IMMUN, V136, P288, DOI 10.1016/j.jaci.2014.12.1931; Hekking PPW, 2015, J ALLERGY CLIN IMMUN, V135, P896, DOI 10.1016/j.jaci.2014.08.042; Juniper EF, 2006, RESP MED, V100, P616, DOI 10.1016/j.rmed.2005.08.012; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; Kandane-Rathnayake RK, 2009, THORAX, V64, P1025, DOI 10.1136/thx.2009.118430; Kotaniemi JT, 2001, EUR J EPIDEMIOL, V17, P809, DOI 10.1023/A:1015615130459; Lavoie KL, 2006, RESP MED, V100, P648, DOI 10.1016/j.rmed.2005.08.001; Lotvall J, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-94; LUNDBACK B, 1991, EUR RESPIR J, V4, P257; Lundback B, 2016, EXPERT REV RESP MED, V10, P39, DOI 10.1586/17476348.2016.1114417; Malinovschi A, 2012, RESP MED, V106, P794, DOI 10.1016/j.rmed.2012.02.009; McGarvey LP, 2014, J ALLERGY CLIN IMMUN, V133, P704, DOI 10.1016/j.jaci.2013.09.016; Melgert BN, 2007, CURR ALLERGY ASTHM R, V7, P143, DOI 10.1007/s11882-007-0012-4; Mincheva R, 2014, RESP RES, V15, DOI 10.1186/1465-9921-15-79; Nathan RA, 2004, J ALLERGY CLIN IMMUN, V113, P59, DOI 10.1016/j.jaci.2003.09.008; Nolte F, 2006, RESP MED, V100, P354, DOI 10.1016/j.rmed.2005.05.012; Pakhale S, 2015, CHEST, V147, P1582, DOI 10.1378/chest.14-3105; Pearce N, 1999, THORAX, V54, P268, DOI 10.1136/thx.54.3.268; Rao CK, 2013, CHEST, V143, P984, DOI 10.1378/chest.12-0973; Ronmark E, 2005, EUR RESPIR J, V25, P282, DOI 10.1183/09031936.05.00054304; Ronmark E, 1997, ALLERGY, V52, P1071, DOI 10.1111/j.1398-9995.1997.tb00178.x; Ronmark E, 1999, ALLERGY, V54, P926, DOI 10.1034/j.1398-9995.1999.00044.x; Ronmark EP, 2009, RESP MED, V103, P1807, DOI 10.1016/j.rmed.2009.07.014; Ronmark E, 2007, RESP MED, V101, P2370, DOI 10.1016/j.rmed.2007.06.011; Schatz M, 2003, ANN ALLERG ASTHMA IM, V91, P553, DOI 10.1016/S1081-1206(10)61533-5; Shaw DE, 2015, EUR RESPIR J, V46, P1308, DOI 10.1183/13993003.00779-2015; Sheehan WJ, 2015, CURR OPIN ALLERGY CL, V15, P397, DOI 10.1097/ACI.0000000000000195; Shore SA, 2008, J ALLERGY CLIN IMMUN, V121, P1087, DOI 10.1016/j.jaci.2008.03.004; Smith JA, 2010, CURR OPIN ALLERGY CL, V10, P77, DOI 10.1097/ACI.0b013e328334e75f; Thomson NC, 2013, J ALLERGY CLIN IMMUN, V131, P1008, DOI 10.1016/j.jaci.2012.12.1574; van Huisstede A, 2015, THORAX, V70, P659, DOI 10.1136/thoraxjnl-2014-206712; von Bulow A, 2014, J ALLER CL IMM-PRACT, V2, P759, DOI 10.1016/j.jaip.2014.05.005; von Mutius E, 2001, CLIN EXP ALLERGY, V31, P1651, DOI 10.1046/j.1365-2222.2001.01272.x; Wennergren G, 2013, PRIM CARE RESP J, V22, P214, DOI 10.4104/pcrj.2013.00043; Wenzel S E, 2005, Exp Lung Res, V31 Suppl 1, P22; Zein JG, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133490; Zein JG, 2015, CURR ALLERGY ASTHM R, V15, DOI 10.1007/s11882-015-0528-y; Zuberbier T, 2014, ALLERGY, V69, P1275, DOI 10.1111/all.12470	65	22	22	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2018	141	6					2256	+		10.1016/j.jaci.2017.07.047	http://dx.doi.org/10.1016/j.jaci.2017.07.047			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GI7SD	28939411				2022-12-18	WOS:000434701600029
J	Shefler, I; Salamon, P; Levi-Schaffer, F; Mor, A; Hershko, AY; Mekori, YA				Shefler, Irit; Salamon, Pazit; Levi-Schaffer, Francesca; Mor, Adam; Hershko, Alon Y.; Mekori, Yoseph A.			MicroRNA-4443 regulates mast cell activation by T cell-derived microvesicles	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						MicroRNA; mast cells; microvesicles; T cells	ENDOTHELIAL-CELLS; MEDIATED TRANSFER; GENE-EXPRESSION; CONTACT; DEPHOSPHORYLATION; MICROPARTICLES; PROLIFERATION; COMMUNICATION; INFLAMMATION; MECHANISM	Background: The mechanism by which mast cells (MCs) are activated in T cell-mediated inflammatory processes remains elusive. Recently, we have shown that microvesicles derived from activated T cells (mvT*s) can stimulate MCs to degranulate and release several cytokines. Objective: The aim of this study was to characterize the contribution of microRNAs (miRs) delivered by microvesicles to MC activation. Methods: miR profiling was performed with NanoString technology and validated by using real-time PCR. The biological role of mvT*miR was verified by overexpression of miRs in MCs using mimic or inhibitory molecules and analyzing the effect on their predicted targets. Results: mvT*s were found to downregulate the expression of the tyrosine phosphatase protein tyrosine phosphatase receptor type J (PTPRJ), a known extracellular signal-regulated kinase inhibitor. Bioinformatics analysis predicted that miR-4443 regulates the PTPRJ gene expression. Indeed, miR-4443, which was present in mvT*s, was also found to be overexpressed in humanMCs stimulated with theseMVs. a-Amanitin insensitivity confirmed that overexpression of miR-4443 was not due to transcriptional activation. The luciferase reporter assay indicated that the 39 untranslated region of PTPRJ was targeted by this miR. Transfection of MCs with mimic or inhibitor of miR-4443 resulted in decreased or enhanced PTPRJ expression, respectively. Furthermore, miR-4443 regulated extracellular signal-regulated kinase phosphorylation and IL-8 release inMCsactivated by mvT*s. Conclusion: These results support a scenario by which T cell-derived microvesicles act as intercellular carriers of functional miR-4443, which might exert heterotypic regulation of PTPRJ gene expression in MCs, leading to their activation in the context of T cell-mediated inflammatory processes.	[Shefler, Irit; Salamon, Pazit; Hershko, Alon Y.; Mekori, Yoseph A.] Herbert Mast Cell Disorders Ctr, Lab Allergy & Clin Immunol, Meir Med Ctr, IL-44281 Kefar Sava, Israel; [Levi-Schaffer, Francesca] Hebrew Univ Jerusalem, Sch Pharm, Pharmacol & Expt Therapeut Unit, Fac Med, Jerusalem, Israel; [Mor, Adam] NYU, Sch Med, Dept Med, New York, NY 10003 USA; [Hershko, Alon Y.; Mekori, Yoseph A.] Tel Aviv Univ, Sackler Sch Med, Tel Aviv, Israel; [Mekori, Yoseph A.] Tel Hai Coll, Qiryat Shemona, Israel	Tel Aviv University; Sackler Faculty of Medicine; Hebrew University of Jerusalem; New York University; Tel Aviv University; Sackler Faculty of Medicine; Tel Hai Academy College	Mekori, YA (corresponding author), Herbert Mast Cell Disorders Ctr, Lab Allergy & Clin Immunol, Meir Med Ctr, IL-44281 Kefar Sava, Israel.	ymekori@telhai.ac.il		Levi-Schaffer, Francesca/0000-0003-0620-2810	Tel Aviv University (TAU)	Tel Aviv University (TAU)	Supported in part by a grant from Tel Aviv University (TAU). Y.A.M. is the incumbent of the Argentina Chair of the Research of Allergic Diseases at TAU.	Baram D, 2001, J IMMUNOL, V167, P4008, DOI 10.4049/jimmunol.167.7.4008; Camussi G, 2010, KIDNEY INT, V78, P838, DOI 10.1038/ki.2010.278; Collino F, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011803; Galli SJ, 2005, ANNU REV IMMUNOL, V23, P749, DOI 10.1146/annurev.immunol.21.120601.141025; Geiss GK, 2008, NAT BIOTECHNOL, V26, P317, DOI 10.1038/nbt1385; Hulsmans M, 2013, CARDIOVASC RES, V100, P7, DOI 10.1093/cvr/cvt161; Ishizaki T, 2011, GENES CELLS, V16, P803, DOI 10.1111/j.1365-2443.2011.01529.x; Kalesnikoff J, 2008, NAT IMMUNOL, V9, P1215, DOI 10.1038/ni.f.216; Kirshenbaum AS, 2003, LEUKEMIA RES, V27, P677, DOI 10.1016/S0145-2126(02)00343-0; Kovalenko M, 2000, J BIOL CHEM, V275, P16219, DOI 10.1074/jbc.275.21.16219; Krzyworzeka MB, 2006, CANCER IMMUNOL IMMUN, V55, P808; Laffont B, 2013, BLOOD, V122, P253, DOI 10.1182/blood-2013-03-492801; Lampugnani MG, 2003, J CELL BIOL, V161, P793, DOI 10.1083/jcb.200209019; Li CCY, 2013, RNA BIOL, V10, P1333, DOI 10.4161/rna.25281; Li J, 2013, J BIOL CHEM, V288, P23586, DOI 10.1074/jbc.M113.489302; Mekori YA, 2004, J ALLERGY CLIN IMMUN, V114, P52, DOI 10.1016/j.jaci.2004.04.015; Mekori YA, 2016, EUR J PHARMACOL, V778, P84, DOI 10.1016/j.ejphar.2015.03.087; Mittelbrunn M, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1285; Mor A, 2010, INFLAMMATION, V33, P119, DOI 10.1007/s10753-009-9165-8; O'Connell RM, 2010, NAT REV IMMUNOL, V10, P111, DOI 10.1038/nri2708; Ostman A, 2006, NAT REV CANCER, V6, P307, DOI 10.1038/nrc1837; Paduano F, 2013, FEBS J, V280, P401, DOI 10.1111/j.1742-4658.2012.08624.x; Qayum AA, 2016, J IMMUNOL, V196, P4457, DOI 10.4049/jimmunol.1502240; Rebane A, 2013, J ALLERGY CLIN IMMUN, V132, P15, DOI 10.1016/j.jaci.2013.04.011; Russi AE, 2016, J AUTOIMMUN, V73, P100, DOI 10.1016/j.jaut.2016.06.015; Sacco F, 2009, J BIOL CHEM, V284, P22048, DOI 10.1074/jbc.M109.002758; Salamon P, 2008, J ALLERGY CLIN IMMUN, V121, P448, DOI 10.1016/j.jaci.2007.08.054; Shefler I, 2014, J ALLERGY CLIN IMMUN, V133, P217, DOI 10.1016/j.jaci.2013.04.035; Shefler I, 2010, J IMMUNOL, V185, P4206, DOI 10.4049/jimmunol.1000409; Shefler I, 2008, J ALLERGY CLIN IMMUN, V122, P1222, DOI 10.1016/j.jaci.2008.07.024; Tarcic G, 2009, CURR BIOL, V19, P1788, DOI 10.1016/j.cub.2009.09.048; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; Xu L, 2013, J CELL PHYSIOL, V228, P1713, DOI 10.1002/jcp.24344; Zhou Y, 2016, CURR ANAL CHEM, V12, P425, DOI 10.2174/1573411011666150903204210	34	22	23	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2018	141	6					2132	+		10.1016/j.jaci.2017.06.045	http://dx.doi.org/10.1016/j.jaci.2017.06.045			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GI7SD	28823811	Bronze			2022-12-18	WOS:000434701600019
J	Uto, T; Takagi, H; Fukaya, T; Nasu, J; Fukui, T; Miyanaga, N; Arimura, K; Nakamura, T; Choijookhuu, N; Hishikawa, Y; Sato, K				Uto, Tomofumi; Takagi, Hideaki; Fukaya, Tomohiro; Nasu, Junta; Fukui, Takehito; Miyanaga, Noriaki; Arimura, Keiichi; Nakamura, Takeshi; Choijookhuu, Narantsog; Hishikawa, Yoshitaka; Sato, Katsuaki			Critical role of plasmacytoid dendritic cells in induction of oral tolerance	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Mucosal immunity; oral tolerance; dendritic cells; regulatory T cells; allergy	REGULATORY T-CELLS; INFLAMMATION; INITIATION; MACROPHAGES; IMMUNITY; RECEPTOR; SUBSETS; PROTECT	Background: Exposure to dietary constituents through the mucosal surface of the gastrointestinal tract generates oral tolerance that prevents deleterious T cell-mediated immunity. Although oral tolerance is an active process that involves emergence of CD4(+) forkhead box p3 (Foxp3)(+) regulatory T (Treg) cells in gut-associated lymphoid tissues (GALTs) for suppression of effector T (Teff) cells, how antigen-presenting cells initiate this process remains unclear. Objective: We sought to determine the role of plasmacytoid dendritic cells (pDCs), which are known as unconventional antigen-presenting cells, in establishment of oral tolerance. Methods: GALT-associated pDCs inwild-typemicewere examined for their ability to induce differentiation of CD4(+) Teff cells and CD4(+) Foxp3(+) Treg cells in vitro. Wild-type and pDC-ablated mice were fed oral antigen to compare their intestinal generation of CD4(+) Foxp3(+) Treg cells and induction of oral tolerance to protect against Teff cell-mediated allergic inflammation. Results: GALT-associated pDCs preferentially generate CD4(+) Foxp3(+) Treg cells rather than CD4(+) Teff cells, and such generation requires an autocrine loop of TGF-b for its robust production. A deficiency of pDCs abrogates antigen-specific de novo generation of CD4(+) Foxp3(+) Treg cells occurring in GALT after antigenic feeding. Furthermore, the absence ofpDCs impairs development of oral tolerance, which ameliorates the progression of delayed-type hypersensitivity and systemic anaphylaxis, as well as allergic asthma, accompanied by an enhanced antigen-specific CD4(+) Teff cell response and antibody production. Conclusion: pDCs are required for establishing oral tolerance to prevent undesirable allergic responses, and they might serve a key role in maintaining gastrointestinal immune homeostasis.	[Uto, Tomofumi; Takagi, Hideaki; Fukaya, Tomohiro; Nasu, Junta; Fukui, Takehito; Miyanaga, Noriaki; Arimura, Keiichi; Nakamura, Takeshi; Sato, Katsuaki] Univ Miyazaki, Dept Infect Dis, Div Immunol, Fac Med, 5200 Kihara, Kiyotake, Miyazaki 8891692, Japan; [Nasu, Junta; Fukui, Takehito; Arimura, Keiichi] Univ Miyazaki, Dept Oral & Maxillofacial Surg, Fac Med, Miyazaki, Japan; [Miyanaga, Noriaki; Nakamura, Takeshi] Univ Miyazaki, Dept Otolaryngol Head & Neck Surg, Fac Med, Miyazaki, Japan; [Choijookhuu, Narantsog; Hishikawa, Yoshitaka] Univ Miyazaki, Fac Med, Dept Anat, Div Histochem & Cell Biol, Miyazaki, Japan; [Uto, Tomofumi; Takagi, Hideaki; Fukaya, Tomohiro; Sato, Katsuaki] Japan Agcy Med Res & Dev AMED, Tokyo, Japan	University of Miyazaki; University of Miyazaki; University of Miyazaki; University of Miyazaki	Sato, K (corresponding author), Univ Miyazaki, Dept Infect Dis, Div Immunol, Fac Med, 5200 Kihara, Kiyotake, Miyazaki 8891692, Japan.	katsuaki_sato@med.miyazaki-u.ac.jp	Hishikawa, Yoshitaka/AAH-5094-2020		Ministry of Education, Science and Culture of Japan; Project for Cancer Research and Therapeutic Evolution (P-CREATE) from the Japan Agency for Medical Research and development (AMED); Mochida Memorial Foundation for Medical and Pharmaceutical Research; Uehara Memorial Foundation; Takeda Science Foundation; Novartis Foundation (Japan) for the Promotion of Science; Kato Memorial Bioscience Foundation; Nagao Memorial Fund; Daiichi Sankyo Foundation of Life Science; Naito Foundation; GSK Japan Research Grant; Bristol-Myers Squibb Foundation	Ministry of Education, Science and Culture of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Project for Cancer Research and Therapeutic Evolution (P-CREATE) from the Japan Agency for Medical Research and development (AMED)(Japan Agency for Medical Research and Development (AMED)); Mochida Memorial Foundation for Medical and Pharmaceutical Research; Uehara Memorial Foundation(Uehara Memorial Foundation); Takeda Science Foundation(Takeda Science Foundation (TSF)); Novartis Foundation (Japan) for the Promotion of Science(Novartis); Kato Memorial Bioscience Foundation; Nagao Memorial Fund; Daiichi Sankyo Foundation of Life Science; Naito Foundation(Naito Memorial Foundation); GSK Japan Research Grant; Bristol-Myers Squibb Foundation(Bristol-Myers Squibb)	Supported by a Grant-in-Aid for Challenging Exploratory Research (to K.S.) and for Young Scientists (B; to T.U. T.F., and H.T.) from the Ministry of Education, Science and Culture of Japan; the Project for Cancer Research and Therapeutic Evolution (P-CREATE) from the Japan Agency for Medical Research and development (AMED; to K.S.); the Mochida Memorial Foundation for Medical and Pharmaceutical Research (to K.S.); the Uehara Memorial Foundation (to K.S. and H.T.); the Takeda Science Foundation (to H.T. and T.F.); the Novartis Foundation (Japan) for the Promotion of Science (to H.T.); the Kato Memorial Bioscience Foundation (to H.T.); the Nagao Memorial Fund (to H.T.); the Daiichi Sankyo Foundation of Life Science (to K.S.); the Naito Foundation (to K.S.); the GSK Japan Research Grant (to T.F. and H.T.); and Bristol-Myers Squibb Foundation Grants (to K.S.).	Arimura K, 2017, MUCOSAL IMMUNOL, V10, P957, DOI 10.1038/mi.2016.96; Burks AW, 2008, J ALLERGY CLIN IMMUN, V121, P1344, DOI 10.1016/j.jaci.2008.02.037; Dresch C, 2012, TRENDS IMMUNOL, V33, P381, DOI 10.1016/j.it.2012.04.009; Dubois B, 2009, GASTROENTEROLOGY, V137, P1019, DOI 10.1053/j.gastro.2009.03.055; Esterhazy D, 2016, NAT IMMUNOL, V17, P545, DOI 10.1038/ni.3408; Fujita S, 2008, J ALLERGY CLIN IMMUN, V121, P95, DOI 10.1016/j.jaci.2007.08.038; Fukaya T, 2010, BLOOD, V116, P2266, DOI 10.1182/blood-2009-10-250472; Gilliet M, 2008, NAT REV IMMUNOL, V8, P594, DOI 10.1038/nri2358; Glitzner E, 2014, EMBO MOL MED, V6, P1312, DOI 10.15252/emmm.201404114; Goubier A, 2008, IMMUNITY, V29, P464, DOI 10.1016/j.immuni.2008.06.017; Guilliams M, 2014, NAT REV IMMUNOL, V14, P571, DOI 10.1038/nri3712; Guilliams M, 2010, BLOOD, V115, P1958, DOI 10.1182/blood-2009-09-245274; Hildner K, 2008, SCIENCE, V322, P1097, DOI 10.1126/science.1164206; Kashiwagi I, 2015, IMMUNITY, V43, P65, DOI 10.1016/j.immuni.2015.06.010; Kornete M, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00165; Liao W, 2011, NAT IMMUNOL, V12, P551, DOI 10.1038/ni.2030; Manicassamy S, 2011, IMMUNOL REV, V241, P206, DOI 10.1111/j.1600-065X.2011.01015.x; Mazzini E, 2014, IMMUNITY, V40, P248, DOI 10.1016/j.immuni.2013.12.012; Nakamura Takeshi, 2017, Biochem Biophys Rep, V9, P29, DOI 10.1016/j.bbrep.2016.11.001; Ochando JC, 2006, NAT IMMUNOL, V7, P652, DOI 10.1038/ni1333; Rescigno M, 2011, CELL MICROBIOL, V13, P1312, DOI 10.1111/j.1462-5822.2011.01626.x; Round JL, 2009, NAT REV IMMUNOL, V9, P313, DOI 10.1038/nri2515; Rowland SL, 2014, J EXP MED, V211, P1977, DOI 10.1084/jem.20132620; Sisirak V, 2014, J EXP MED, V211, P1969, DOI 10.1084/jem.20132522; Takagi H, 2016, SCI REP-UK, V6, DOI 10.1038/srep24477; Takagi H, 2011, IMMUNITY, V35, P958, DOI 10.1016/j.immuni.2011.10.014; Terashima A, 2008, J EXP MED, V205, P2727, DOI 10.1084/jem.20080698; Tsuji NM, 2008, TRENDS IMMUNOL, V29, P532, DOI 10.1016/j.it.2008.09.002; Uto T, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11273; Vickery BP, 2011, J ALLERGY CLIN IMMUN, V127, P576, DOI 10.1016/j.jaci.2010.12.1116; Villadangos JA, 2007, NAT REV IMMUNOL, V7, P543, DOI 10.1038/nri2103; Watowich SS, 2010, IMMUNOL REV, V238, P76, DOI 10.1111/j.1600-065X.2010.00949.x; Yun TJ, 2016, CELL METAB, V23, P852, DOI 10.1016/j.cmet.2016.04.010	33	22	25	1	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2018	141	6					2156	+		10.1016/j.jaci.2017.11.048	http://dx.doi.org/10.1016/j.jaci.2017.11.048			21	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GI7SD	29477579	Bronze			2022-12-18	WOS:000434701600021
J	Doherty, TA; Broide, DH				Doherty, Taylor A.; Broide, David H.			Lipid regulation of group 2 innate lymphoid cell function: Moving beyond epithelial cytokines	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Group 2 innate lymphoid cells; prostaglandin E-2; cysteinyl leukotriene; prostaglandin D; eicosanoid; asthma; aspirin-exacerbated respiratory disease	EXACERBATED RESPIRATORY-DISEASE; PROSTAGLANDIN E-2; INFLAMMATION; RESISTANCE		[Doherty, Taylor A.; Broide, David H.] Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA	University of California System; University of California San Diego	Broide, DH (corresponding author), Univ Calif San Diego, Dept Med, Biomed Sci Bldg,Rm 5090,9500 Gilman Dr, La Jolla, CA 92093 USA.	dbroide@ucsd.edu		Broide, David/0000-0001-8405-9090	National Institutes of Health (NIH) [AI 114585, AI 70535, AI 107779, AI 38425, AI 72115]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI070535, R01AI107779, R01AI038425, R01AI072115, R01AI114585, R37AI038425] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health (NIH) grants AI 114585 and AI 70535 (to T.A.D.) and NIH grants AI 107779, AI 38425, AI 70535, and AI 72115 (to D.H.B.).	Barnig C, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3004812; Cahill KN, 2016, AM J RESP CELL MOL, V54, P34, DOI 10.1165/rcmb.2014-0486OC; Cavagnero K, 2017, J CYTOKINE BIOL, V2; Cephus JY, 2017, CELL REP, V21, P2487, DOI 10.1016/j.celrep.2017.10.110; Doherty TA, 2015, J LEUKOCYTE BIOL, V97, P455, DOI 10.1189/jlb.5BT0814-374R; Doherty TA, 2013, J ALLERGY CLIN IMMUN, V132, P205, DOI 10.1016/j.jaci.2013.03.048; Eastman JJ, 2017, J ALLERGY CLIN IMMUN, V140, P101, DOI 10.1016/j.jaci.2016.11.023; Krishnamoorthy N, 2015, J IMMUNOL, V194, P863, DOI 10.4049/jimmunol.1402534; Laffont S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01069; Laidlaw TM, 2014, J ALLERGY CLIN IMMUN, V133, P1692, DOI 10.1016/j.jaci.2013.12.1034; Lone AM, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00130; Lund SJ, 2017, J IMMUNOL, V199, P1096, DOI 10.4049/jimmunol.1601569; Maric J, 2018, J ALLERGY CLIN IMMUN, V141, P1761, DOI 10.1016/j.jaci.2017.09.050; Pace S, 2017, J CLIN INVEST, V127, P3167, DOI 10.1172/JCI92885; Schauberger E, 2016, CURR ALLERGY ASTHM R, V16, DOI 10.1007/s11882-016-0628-3; von Moltke J, 2017, J EXP MED, V214, P27, DOI 10.1084/jem.20161274; Woessner KM, 2017, CURR ALLERGY ASTHM R, V17, DOI 10.1007/s11882-017-0673-6; Zhou WS, 2016, AM J RESP CRIT CARE, V193, P31, DOI 10.1164/rccm.201410-1793OC	18	22	23	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2018	141	5					1587	1589		10.1016/j.jaci.2018.02.034	http://dx.doi.org/10.1016/j.jaci.2018.02.034			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GF7KX	29522852	Green Accepted, Bronze			2022-12-18	WOS:000432148200006
J	Samuchiwal, SK; Boyce, JA				Samuchiwal, Sachin K.; Boyce, Joshua A.			Role of lipid mediators and control of lymphocyte responses in type 2 immunopathology	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Innate type 2 immunopathology; allergic inflammation; asthma; eosinophilic esophagitis; aspirin-exacerbated respiratory disease; innate lymphoid cells; innate immune cells; eicosanoids; cysteinyl leukotrienes; prostaglandins; prostacyclins	EXACERBATED RESPIRATORY-DISEASE; CYSTEINYL LEUKOTRIENE RECEPTOR; RANDOMIZED CONTROLLED-TRIAL; ALLERGIC LUNG INFLAMMATION; PROSTAGLANDIN-D SYNTHASE; E-PROSTANOID 2; MOLECULAR-CLONING; 5-LIPOXYGENASE INHIBITOR; EOSINOPHILIC ESOPHAGITIS; CHRONIC RHINOSINUSITIS	Type 2 immunopathology is a cardinal feature of allergic diseases and involves cooperation between adaptive immunity and innate effector responses. Virtually all cell types relevant to this pathology generate leukotriene and/or prostaglandin mediators that derive from arachidonic acid, express receptors for such mediators, or both. Recent studies highlight prominent functions for these mediators in communication between the innate and adaptive immune systems, as well as amplification or suppression of type 2 effector responses. This review focuses on recent advances and insights, and highlights existing and potential therapeutic applications of drugs that target these mediators or their receptors, with a special emphasis on their regulation of the innate and adaptive lymphocytes relevant to type 2 immunopathology.	[Samuchiwal, Sachin K.; Boyce, Joshua A.] Brigham & Womens Hosp, Dept Med, Div Rheumatol Immunol & Allergy, 75 Francis St, Boston, MA 02115 USA; [Samuchiwal, Sachin K.; Boyce, Joshua A.] Harvard Med Sch, Dept Med, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Boyce, JA (corresponding author), Brigham & Womens Hosp, BTM Bldg,Rm 5002V,60 Fenwood Rd, Boston, MA 02115 USA.	jboyce@rics.bwh.harvard.edu	Samuchiwal, Sachin/AAL-2904-2021	SAMUCHIWAL, SACHIN/0000-0001-6232-5650	National Institutes of Health [AI078908, AI095219, AT002782, AI082369, HL111113, HL117945]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Supported by National Institutes of Health grants AI078908, AI095219, AT002782, AI082369, HL111113, and HL117945 and by generous contributions from the Vinik Family.	Bankova LG, 2016, P NATL ACAD SCI USA, V113, P6242, DOI 10.1073/pnas.1605957113; Barnig C, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3004812; Barrett NA, 2013, J ALLERGY CLIN IMMUN, V132, P214, DOI 10.1016/j.jaci.2013.05.019; BEASLEY CRW, 1987, J CLIN INVEST, V79, P978, DOI 10.1172/JCI112909; BEASLEY R, 1987, AM REV RESPIR DIS, V136, P1140, DOI 10.1164/ajrccm/136.5.1140; Beermann C, 2016, NUTRITION, V32, P1165, DOI 10.1016/j.nut.2016.04.004; Bjorklund AK, 2016, NAT IMMUNOL, V17, P451, DOI 10.1038/ni.3368; Bloodworth MH, 2016, J ALLERGY CLIN IMMUN, V137, pAB270, DOI 10.1016/j.jaci.2015.12.1021; Boniface K, 2009, J EXP MED, V206, P535, DOI 10.1084/jem.20082293; Boyce JA, 2003, PROSTAG LEUKOTR ESS, V69, P195, DOI 10.1016/S0952-3278(03)00081-4; Buchheit KM, 2016, J ALLERGY CLIN IMMUN, V137, P1566, DOI 10.1016/j.jaci.2015.10.020; Busse W, 2005, CHEST, V127, P1312, DOI 10.1378/chest.127.4.1312; Chiu CY, 2014, PLOS ONE, V9, P1; Claar D, 2015, EXPERT REV RESP MED, V9, P55, DOI 10.1586/17476348.2015.992783; Corrigan C, 2005, J ALLERGY CLIN IMMUN, V115, P316, DOI 10.1016/j.jaci.2004.10.051; Corrigan CJ, 2012, J ALLERGY CLIN IMMUN, V129, P1636, DOI 10.1016/j.jaci.2012.02.007; Coutinho DS, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00740; Dahlen B, 2000, AM J RESP CRIT CARE, V161, pS137, DOI 10.1164/ajrccm.161.supplement_1.ltta-27; Dahlen B, 1998, AM J RESP CRIT CARE, V157, P1187, DOI 10.1164/ajrccm.157.4.9707089; Dahlen SE, 2002, AM J RESP CRIT CARE, V165, P9, DOI 10.1164/ajrccm.165.1.2010080; Doherty TA, 2015, J ALLERGY CLIN IMMUN, V136, P792, DOI 10.1016/j.jaci.2015.05.048; Doherty TA, 2013, J ALLERGY CLIN IMMUN, V132, P205, DOI 10.1016/j.jaci.2013.03.048; Dorris SL, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/926968; DRAZEN JM, 1992, AM REV RESPIR DIS, V146, P104, DOI 10.1164/ajrccm/146.1.104; Duan YZ, 2014, BMB REP, V47, P45, DOI 10.5483/BMBRep.2014.47.1.089; Duffin R, 2016, SCIENCE, V351, P1333, DOI 10.1126/science.aad9903; Fajt ML, 2013, J ALLERGY CLIN IMMUN, V131, P1504, DOI 10.1016/j.jaci.2013.01.035; Feng CL, 2006, BLOOD, V107, P3243, DOI 10.1182/blood-2005-07-2772; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Gauvreau GM, 1999, AM J RESP CRIT CARE, V159, P31, DOI 10.1164/ajrccm.159.1.9804030; George L, 2016, THER ADV CHRONIC DIS, V7, P34, DOI 10.1177/2040622315609251; Giouleka P, 2011, EUR J CLIN INVEST, V41, P30, DOI 10.1111/j.1365-2362.2010.02371.x; HARDY CC, 1988, J APPL PHYSIOL, V64, P1567, DOI 10.1152/jappl.1988.64.4.1567; HARDY CC, 1984, NEW ENGL J MED, V311, P209, DOI 10.1056/NEJM198407263110401; Hartert TV, 2000, AM J RESP CRIT CARE, V162, P637, DOI 10.1164/ajrccm.162.2.9904038; Hayashi M, 2010, CLIN EXP ALLERGY, V40, P317, DOI 10.1111/j.1365-2222.2009.03418.x; Hirai H, 2001, J EXP MED, V193, P255, DOI 10.1084/jem.193.2.255; Israel E, 2002, J ALLERGY CLIN IMMUN, V110, P847, DOI 10.1067/mai.2002.129413; Israel E, 1996, JAMA-J AM MED ASSOC, V275, P931, DOI 10.1001/jama.275.12.931; Ivy DD, 2010, PEDIATR CRIT CARE ME, V11, pS41, DOI 10.1097/PCC.0b013e3181d10845; Jaffar Z, 2002, J IMMUNOL, V169, P5997, DOI 10.4049/jimmunol.169.10.5997; Jaffar Z, 2007, J IMMUNOL, V179, P6193, DOI 10.4049/jimmunol.179.9.6193; Jaffar Z, 2011, J IMMUNOL, V187, P5380, DOI 10.4049/jimmunol.1101261; Jandl K, 2017, PROSTAG OTH LIPID M, V133, P42, DOI 10.1016/j.prostaglandins.2017.08.006; Jia Y, 2016, AM J RESP CELL MOL, V55, P675, DOI 10.1165/rcmb.2016-0099OC; Kabata H, 2015, ALLERGOL INT, V64, P227, DOI 10.1016/j.alit.2015.03.004; Kalinski P, 2012, J IMMUNOL, V188, P21, DOI 10.4049/jimmunol.1101029; Kanaoka Y, 2013, J BIOL CHEM, V288, P10967, DOI 10.1074/jbc.C113.453704; Karta MR, 2016, CURR ALLERGY ASTHM R, V16, DOI 10.1007/s11882-015-0581-6; Kay LJ, 2006, BRIT J PHARMACOL, V147, P707, DOI 10.1038/sj.bjp.0706664; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Konya V, 2016, IMMUNOL LETT, V179, P36, DOI 10.1016/j.imlet.2016.07.006; Laidlaw TM, 2014, J ALLERGY CLIN IMMUN, V133, P1692, DOI 10.1016/j.jaci.2013.12.1034; Laidlaw TM, 2013, IMMUNOL ALLERGY CLIN, V33, P195, DOI 10.1016/j.iac.2012.11.006; LAITINEN LA, 1993, LANCET, V341, P989, DOI 10.1016/0140-6736(93)91073-U; Liu T, 2018, J IMMUNOL, V200, P915, DOI 10.4049/jimmunol.1700603; Liu T, 2015, J IMMUNOL, V195, P3537, DOI 10.4049/jimmunol.1500905; Liu T, 2013, P NATL ACAD SCI USA, V110, P16987, DOI 10.1073/pnas.1313185110; Lund SJ, 2017, J IMMUNOL, V199, P1096, DOI 10.4049/jimmunol.1601569; Luo M, 2004, J BIOL CHEM, V279, P41512, DOI 10.1074/jbc.M312568200; Lynch KR, 1999, NATURE, V399, P789; Machado-Carvalho L, 2016, J ALLERGY CLIN IMMUN, V137, P99, DOI 10.1016/j.jaci.2015.09.028; Maric J, 2017, J ALLERGY CLIN IMMUN; Martin V, 2001, BIOCHEM PHARMACOL, V62, P1193, DOI 10.1016/S0006-2952(01)00774-2; McGovern T, 2016, J IMMUNOL, V197, P266, DOI 10.4049/jimmunol.1501084; Mitson-Salazar A, 2016, J ALLERGY CLIN IMMUN, V137, P907, DOI 10.1016/j.jaci.2015.08.007; Mjosberg J, 2016, J ALLERGY CLIN IMMUN, V138, P1265, DOI 10.1016/j.jaci.2016.09.009; Nagao K, 2003, AM J RESP CELL MOL, V29, P314, DOI 10.1165/rcmb.2003-0035OC; Nantel F, 2004, PROSTAG OTH LIPID M, V73, P87, DOI 10.1016/j.prostaglandins.2003.12.002; Neill DR, 2010, NATURE, V464, P1367, DOI 10.1038/nature08900; Nothacker HP, 2000, MOL PHARMACOL, V58, P1601, DOI 10.1124/mol.58.6.1601; Peters-Golden M, 2007, NEW ENGL J MED, V357, P1841, DOI 10.1056/NEJMra071371; Pettipher R, 2008, BRIT J PHARMACOL, V153, pS191, DOI 10.1038/sj.bjp.0707488; Planaguma A, 2008, AM J RESP CRIT CARE, V178, P574, DOI 10.1164/rccm.200801-061OC; Price DB, 2003, THORAX, V58, P211, DOI 10.1136/thorax.58.3.211; Ricciotti E, 2011, ARTERIOSCL THROM VAS, V31, P986, DOI 10.1161/ATVBAHA.110.207449; Rodriguez M, 2014, MOL PHARMACOL, V85, P187, DOI 10.1124/mol.113.089573; Safholm J, 2015, J ALLERGY CLIN IMMUN, V136, P1232, DOI 10.1016/j.jaci.2015.04.002; Salimi M, 2017, J ALLERGY CLIN IMMUN, V140, P1090, DOI 10.1016/j.jaci.2016.12.958; Samuchiwal SK, 2017, J BIOL CHEM, V292, P8195, DOI 10.1074/jbc.M116.769422; Sarau HM, 1999, MOL PHARMACOL, V56, P657, DOI 10.1124/mol.56.3.657; Schauberger E, 2016, CURR ALLERGY ASTHM R, V16, DOI 10.1007/s11882-016-0628-3; SCHULMAN ES, 1981, AM REV RESPIR DIS, V124, P402; SCHULMAN ES, 1982, J APPL PHYSIOL, V53, P589, DOI 10.1152/jappl.1982.53.3.589; Sekioka T, 2015, ALLERGOL INT, V64, P351, DOI 10.1016/j.alit.2015.04.008; Shaw JL, 2013, AM J RESP CRIT CARE, V188, P432, DOI 10.1164/rccm.201212-2227OC; Shin IS, 2013, INT IMMUNOPHARMACOL, V17, P867, DOI 10.1016/j.intimp.2013.09.017; Shirasaki H, 2016, ADV OTO-RHINO-LARYNG, V77, P40, DOI 10.1159/000441871; SMITH JB, 1981, ACTA MED SCAND, P91; Sreeramkumar V, 2012, IMMUNOL CELL BIOL, V90, P579, DOI 10.1038/icb.2011.75; Sugimoto Y, 2007, J BIOL CHEM, V282, P11613, DOI 10.1074/jbc.R600038200; Takahashi Y, 2002, BRIT J PHARMACOL, V137, P315, DOI 10.1038/sj.bjp.0704872; Takasaki J, 2000, BIOCHEM BIOPH RES CO, V274, P316, DOI 10.1006/bbrc.2000.3140; Tanaka K, 2004, BIOCHEM BIOPH RES CO, V316, P1009, DOI 10.1016/j.bbrc.2004.02.151; von Moltke J, 2017, J EXP MED, V214, P27, DOI 10.1084/jem.20161274; Wambre E, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aam9171; Wechsler JB, 2014, GASTROENTEROL CLIN N, V43, P281, DOI 10.1016/j.gtc.2014.02.006; Xue LZ, 2015, J ALLERGY CLIN IMMUN, V135, P1358, DOI 10.1016/j.jaci.2014.09.006; Yoshimura Tsuyoshi, 2008, Allergol Int, V57, P429, DOI 10.2332 allergolint.O-08-545; Zhang S, 2014, DIS ESOPHAGUS, V27, P601, DOI 10.1111/dote.12118; Zhou WS, 2007, J LEUKOCYTE BIOL, V81, P809, DOI 10.1189/jlb.0606375; Zhou WS, 2016, AM J RESP CRIT CARE, V193, P31, DOI 10.1164/rccm.201410-1793OC	102	22	24	3	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2018	141	4					1182	1190		10.1016/j.jaci.2018.02.006	http://dx.doi.org/10.1016/j.jaci.2018.02.006			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GB6QV	29477727	Bronze			2022-12-18	WOS:000429197800002
J	Choi, GE; Yoon, SY; Kim, JY; Kang, DY; Jang, YJ; Kim, HS				Choi, Go Eun; Yoon, Seung-Yong; Kim, Ji-Yun; Kang, Do-Young; Jang, Yong Ju; Kim, Hun Sik			Autophagy deficiency in myeloid cells exacerbates eosinophilic inflammation in chronic rhinosinusitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chronic rhinosinusitis; autophagy; eosinophil; macro-phage; prostaglandin D-2	INNATE LYMPHOID-CELLS; NASAL POLYPS; PROSTAGLANDIN D-2; MAST-CELLS; RECEPTOR; EXPRESSION; ASTHMA; PATHOGENESIS; ACTIVATION; CHEMOKINE	Background: Eosinophilic inflammation is a major pathologic feature of chronic rhinosinusitis (CRS) and is frequently associated with severe refractory disease. Prostaglandin (PG) D-2 levels are increased in patients with CRS, and PGD(2) is an important contributing factor to eosinophilic inflammation. Autophagy has a pleiotropic effect on immune responses and disease pathogenesis. Recent studies suggest the potential involvement of autophagy in patients with CRS and the PG pathway. Objective: We sought to investigate whether altered function of autophagy is associated with eosinophilic inflammation and dysregulated production of PGD(2) in patients with CRS. Methods: We used myeloid cell-specific deletion of autophagy-related gene 7 (Atg7), which is vital for autophagy, and investigated the effects of impaired autophagy on eosinophilic inflammation in a murine model of eosinophilic chronic rhinosinusitis (ECRS). The effect of autophagy on PGD(2) production and gene expression profiles associated with allergy and the PG pathway were assessed. Results: We found that impaired autophagy in myeloid cells aggravated eosinophilia, epithelial hyperplasia, and mucosal thickening in mice with ECRS. This aggravation was associated with gene expression profiles that favor eosinophilic inflammation, T(H)2 response, mast cell infiltration, and PGD(2) dysregulation. Supporting this, PGD(2) production was also increased significantly by impaired autophagy. Among other myeloid cells, macrophages were associated with autophagy deficiency, leading to increased IL-1 beta levels. Macrophage depletion or blockade of IL-1 receptor led to alleviation of eosinophilic inflammation and sinonasal anatomic abnormalities associated with autophagy deficiency. Conclusion: Our results suggest that impaired autophagy in myeloid cells, particularly macrophages, has a causal role in eosinophilic inflammation and ECRS pathogenesis.	[Choi, Go Eun; Kim, Ji-Yun; Kim, Hun Sik] Univ Ulsan, Asan Inst Life Sci, Asan Med Ctr, Coll Med,Dept Biomed Sci, Seoul, South Korea; [Choi, Go Eun; Kang, Do-Young] Dong A Univ, Inst Convergence Bio Hlth, Busan, South Korea; [Yoon, Seung-Yong] Univ Ulsan, Coll Med, Asan Inst Life Sci, ADEL, Seoul, South Korea; [Jang, Yong Ju] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Otolaryngol, Seoul, South Korea; [Yoon, Seung-Yong] Univ Ulsan, Coll Med, Dept Brain Sci, Seoul, South Korea; [Yoon, Seung-Yong; Kim, Ji-Yun; Kim, Hun Sik] Univ Ulsan, Coll Med, Cellular Dysfunct Res Ctr, Seoul, South Korea; [Kim, Hun Sik] Univ Ulsan, Coll Med, Dept Microbiol, Seoul, South Korea; [Kang, Do-Young] Dong A Univ, Coll Med, Med Ctr, Dept Nucl Med, Busan, South Korea	University of Ulsan; Asan Medical Center; Dong A University; University of Ulsan; University of Ulsan; Asan Medical Center; University of Ulsan; University of Ulsan; University of Ulsan; Dong A University	Kim, HS (corresponding author), Univ Ulsan, Coll Med, Dept Biomed Sci, 88 Olymp Ro 43 Gil, Seoul 05505, South Korea.	hunkim@amc.seoul.kr			Intelligent Synthetic Biology Center of the Global Frontier Project - Ministry of Education, Science and Technology [2013-0073185]; Korea Healthy Technology R&D Project, Ministry of Health Welfare [HI17C0501]; National Research Foundation of Korea [2008-0062286, 2016R1A2B4010300]	Intelligent Synthetic Biology Center of the Global Frontier Project - Ministry of Education, Science and Technology; Korea Healthy Technology R&D Project, Ministry of Health Welfare; National Research Foundation of Korea(National Research Foundation of Korea)	Supported by the Intelligent Synthetic Biology Center of the Global Frontier Project funded by the Ministry of Education, Science and Technology (2013-0073185); grants from the Korea Healthy Technology R&D Project, Ministry of Health & Welfare (HI17C0501); and grants from the National Research Foundation of Korea (2008-0062286; 2016R1A2B4010300).	Akdis CA, 2013, J ALLERGY CLIN IMMUN, V131, P1479, DOI 10.1016/j.jaci.2013.02.036; Ashraf M, 1996, BIOCHEM J, V320, P965, DOI 10.1042/bj3200965; Ban GY, 2016, CLIN EXP ALLERGY, V46, P48, DOI 10.1111/cea.12585; Bhattacharya A, 2015, CELL REP, V12, P1731, DOI 10.1016/j.celrep.2015.08.019; Castillo EF, 2012, P NATL ACAD SCI USA, V109, pE3168, DOI 10.1073/pnas.1210500109; Chen JYF, 2015, INT FORUM ALLERGY RH, V5, P119, DOI 10.1002/alr.21456; Cheng S, 2004, J BIOL CHEM, V279, P22057, DOI 10.1074/jbc.M402828200; Cho MH, 2014, AUTOPHAGY, V10, P1761, DOI 10.4161/auto.29647; CHURUKIAN C J, 1981, Journal of Histotechnology, V4, P85; Claeys S, 2004, ALLERGY, V59, P606, DOI 10.1111/j.1398-9995.2004.00471.x; de Bruin AM, 2010, BLOOD, V116, P2559, DOI 10.1182/blood-2009-12-261339; Deretic V, 2015, J CLIN INVEST, V125, P75, DOI 10.1172/JCI73945; Di Lorenzo G, 2001, INT ARCH ALLERGY IMM, V125, P164, DOI 10.1159/000053811; Fujitani Y, 2002, J IMMUNOL, V168, P443, DOI 10.4049/jimmunol.168.1.443; Gevaert P, 2011, J ALLERGY CLIN IMMUN, V128, P989, DOI 10.1016/j.jaci.2011.07.056; Harris J, 2007, IMMUNITY, V27, P505, DOI 10.1016/j.immuni.2007.07.022; Hirai H, 2001, J EXP MED, V193, P255, DOI 10.1084/jem.193.2.255; Honda K, 2003, J EXP MED, V198, P533, DOI 10.1084/jem.20022218; Hultner L, 2000, J IMMUNOL, V164, P5556, DOI 10.4049/jimmunol.164.11.5556; Ilyas G, 2016, J HEPATOL, V64, P118, DOI 10.1016/j.jhep.2015.08.019; Kato A, 2015, ALLERGOL INT, V64, P121, DOI 10.1016/j.alit.2014.12.006; Kim JH, 2016, SCI REP-UK, V6, DOI 10.1038/srep27615; Kim JH, 2014, AM J RHINOL ALLERGY, V28, P465, DOI 10.2500/ajra.2014.28.4100; Kolaczkowska E, 2009, ARCH IMMUNOL THER EX, V57, P459, DOI 10.1007/s00005-009-0053-6; Kolbeck R, 2010, J ALLERGY CLIN IMMUN, V125, P1344, DOI 10.1016/j.jaci.2010.04.004; Krysko O, 2011, ALLERGY, V66, P396, DOI 10.1111/j.1398-9995.2010.02498.x; Lee HY, 2016, AUTOPHAGY, V12, P1390, DOI 10.1080/15548627.2016.1184799; Lee Stella, 2011, Curr Infect Dis Rep, V13, P159, DOI 10.1007/s11908-011-0166-z; Lindeman JHN, 2010, P NATL ACAD SCI USA, V107, P862, DOI 10.1073/pnas.0910312107; Lopez-Chacon M, 2015, CURR ALLERGY ASTHM R, V15, DOI 10.1007/s11882-015-0520-6; Ma YT, 2013, IMMUNITY, V39, P211, DOI 10.1016/j.immuni.2013.07.017; Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015; Martin LJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033454; Martinez FO, 2009, ANNU REV IMMUNOL, V27, P451, DOI 10.1146/annurev.immunol.021908.132532; Matsuwaki Y, 2008, INT ARCH ALLERGY IMM, V146, P77, DOI 10.1159/000126066; Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026; Mosca M, 2007, J LEUKOCYTE BIOL, V82, P320, DOI 10.1189/jlb.0906576; Muniz-Junqueira MI, 2013, ALLERGY, V68, P911, DOI 10.1111/all.12176; Nagarkar DR, 2013, J ALLERGY CLIN IMMUN, V132, P593, DOI 10.1016/j.jaci.2013.04.005; Odegaard JI, 2007, NATURE, V447, P1116, DOI 10.1038/nature05894; Okano M, 2006, CLIN EXP ALLERGY, V36, P1028, DOI 10.1111/j.1365-2222.2006.02528.x; Pavord ID, 1999, AM J RESP CRIT CARE, V160, P1905, DOI 10.1164/ajrccm.160.6.9903114; Pawankar Ruby, 2007, Clin Allergy Immunol, V20, P93; Payne SC, 2011, J ALLERGY CLIN IMMUN, V128, P710, DOI 10.1016/j.jaci.2011.05.022; Pecaric-Petkovic T, 2009, BLOOD, V113, P1526, DOI 10.1182/blood-2008-05-157818; Perez-Novo CA, 2005, J ALLERGY CLIN IMMUN, V115, P1189, DOI 10.1016/j.jaci.2005.02.029; Poon AH, 2012, J ALLERGY CLIN IMMUN, V129, P569, DOI 10.1016/j.jaci.2011.09.035; Poposki JA, 2011, J ALLERGY CLIN IMMUN, V128, P73, DOI 10.1016/j.jaci.2011.03.017; Radonjic-Hoesli S, 2017, J ALLERGY CLIN IMMUN; Saitoh T, 2008, NATURE, V456, P264, DOI 10.1038/nature07383; Schleimer RP, 2017, ANNU REV PATHOL-MECH, V12, P331, DOI 10.1146/annurev-pathol-052016-100401; Shah SA, 2016, J INFLAMM-LOND, V13, DOI 10.1186/s12950-016-0121-8; Shaw JL, 2013, AM J RESP CRIT CARE, V188, P432, DOI 10.1164/rccm.201212-2227OC; Shibutani ST, 2015, NAT IMMUNOL, V16, P1014, DOI 10.1038/ni.3273; Strakhova MI, 2009, BRIT J PHARMACOL, V157, P44, DOI 10.1111/j.1476-5381.2009.00236.x; Suzuki Y, 2016, J ALLERGY CLIN IMMUN, V137, P1382, DOI 10.1016/j.jaci.2015.09.033; THEPEN T, 1989, J EXP MED, V170, P499, DOI 10.1084/jem.170.2.499; Uller L, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-16; Van Crombruggen K, 2011, J ALLERGY CLIN IMMUN, V128, P728, DOI 10.1016/j.jaci.2011.07.049; Wang LF, 2015, RHINOLOGY, V53, P270, DOI [10.4193/Rhin14.232, 10.4193/Rhino14.232]; Xue LZ, 2014, J ALLERGY CLIN IMMUN, V133, P1184, DOI 10.1016/j.jaci.2013.10.056; Yoshimura Tsuyoshi, 2008, Allergol Int, V57, P429, DOI 10.2332 allergolint.O-08-545; Zuo KJ, 2014, EUR ARCH OTO-RHINO-L, V271, P2461, DOI 10.1007/s00405-014-2910-0	63	22	22	3	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2018	141	3					938	+		10.1016/j.jaci.2017.10.038	http://dx.doi.org/10.1016/j.jaci.2017.10.038			25	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FY6PR	29225084	Bronze			2022-12-18	WOS:000426974800014
J	Lugogo, N; Francisco, D; Addison, KJ; Manne, A; Pederson, W; Ingram, JL; Green, CL; Suratt, BT; Lee, JJ; Sunday, ME; Kraft, M; Ledford, JG				Lugogo, Njira; Francisco, Dave; Addison, Kenneth J.; Manne, Akarsh; Pederson, William; Ingram, Jennifer L.; Green, Cynthia L.; Suratt, Benjamin T.; Lee, James J.; Sunday, Mary E.; Kraft, Monica; Ledford, Julie G.			Obese asthmatic patients have decreased surfactant protein A levels: Mechanisms and implications	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Surfactant; surfactant protein A; obesity; asthma; eosinophils; TNF-alpha; eotaxin; IL-6; epithelial cells; lung function	SEGMENTAL ALLERGEN CHALLENGE; AIRWAY INFLAMMATION; BRONCHOALVEOLAR LAVAGE; TNF-ALPHA; EOSINOPHILIC INFLAMMATION; PULMONARY SURFACTANT; LEPTIN PLAY; SPUTUM; PHENOTYPES; ASSOCIATION	Background: Eosinophils are prominent in some patients with asthma and are increased in the submucosa in a subgroup of obese patients with asthma (OAs). Surfactant protein A (SP-A) modulates host responses to infectious and environmental insults. Objective: We sought to determine whether SP-A levels are altered in OAs compared with a control group and to determine the implications of these alterations in SP-A levels in asthmatic patients. Methods: Bronchoalveolar lavage fluid from 23 lean, 12 overweight, and 20 obese subjects were examined for SP-A. Mouse tracheal epithelial cells grown at an air-liquid interface were used for mechanistic studies. SP-A(-/-) mice were challenged in allergen models, and exogenous SP-A therapy was given after the last challenge. Eosinophils were visualized and quantitated in lung parenchyma by means of immunostaining. Results: Significantly less SP-A (P = .002) was detected in samples from OAs compared with those from control subjects. A univariable regression model found SP-A levels were significantly negatively correlated with body mass index (r = -0.33, P = .014), whereas multivariable modeling demonstrated that the correlation depended both on asthma status (P = .017) and the interaction of asthma and body mass index (P = .008). Addition of exogenous TNF-alpha to mouse tracheal epithelial cells was sufficient to attenuate SP-A and eotaxin secretion. Allergen-challenged SP-A(-/-) mice that received SP-A therapy had significantly less tissue eosinophilia compared with mice receiving vehicle. Conclusions: SP-A functions as an important mediator in resolving tissue and lavage fluid eosinophilia in allergic mouse models. Decreased levels of SP-A in OAs, which could be due to increased local TNF-alpha levels, might lead to impaired eosinophil resolution and could contribute to the eosinophilic asthma phenotype.	[Lugogo, Njira; Ingram, Jennifer L.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; [Green, Cynthia L.] Duke Univ, Med Ctr, Dept Biostat & Bioinformat, Durham, NC USA; [Sunday, Mary E.] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA; [Francisco, Dave; Addison, Kenneth J.; Manne, Akarsh; Pederson, William; Kraft, Monica; Ledford, Julie G.] Univ Arizona, Dept Med, Tucson, AZ USA; [Suratt, Benjamin T.] Univ Arizona, Dept Immunol, Tucson, AZ USA; [Lee, James J.] Univ Vermont, Dept Med, Burlington, VT USA; [Ledford, Julie G.] Mayo Clin Arizona, Dept Biochem & Mol Biol, Scottsdale, AZ USA	Duke University; Duke University; Duke University; University of Arizona; University of Arizona; University of Vermont; Mayo Clinic; Mayo Clinic Phoenix	Ledford, JG (corresponding author), 1657 E Helen St,Bio5 Keating Bldg, Tucson, AZ 85721 USA.	jledford@deptofmed.arizona.edu	, Ben/L-5749-2019	Francisco, Dave/0000-0003-1206-7424; Addison, Kenneth/0000-0002-8964-9628; Pederson, William/0000-0001-9253-1279	 [HL111151];  [HL125602];  [HL065228]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL125602, R01HL130234, R01HL065228, K99HL111151, R00HL111151] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI125357] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006694] Funding Source: NIH RePORTER	; ; ; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported by grants HL111151, HL125602, and HL065228.	BAUGHMAN RP, 1993, AM REV RESPIR DIS, V147, P653, DOI 10.1164/ajrccm/147.3.653; Boulet LP, 2008, CLIN INVEST MED, V31, pE386, DOI 10.25011/cim.v31i6.4926; Chen Xiao-Jian, 2015, Zhongguo Dang Dai Er Ke Za Zhi, V17, P698; Cheng G, 2000, EUR RESPIR J, V16, P831, DOI 10.1183/09031936.00.16583100; Desai D, 2013, AM J RESP CRIT CARE, V188, P657, DOI 10.1164/rccm.201208-1470OC; Dixon Anne E, 2010, Proc Am Thorac Soc, V7, P325, DOI 10.1513/pats.200903-013ST; Erpenbeck VJ, 2006, ALLERGY, V61, P598, DOI 10.1111/j.1398-9995.2006.01062.x; Grotta MB, 2013, BMC PULM MED, V13, DOI 10.1186/1471-2466-13-39; Hastie AT, 2013, J ALLERGY CLIN IMMUN, V132, P72, DOI 10.1016/j.jaci.2013.03.044; Hohlfeld JM, 1999, AM J RESP CRIT CARE, V159, P1803, DOI 10.1164/ajrccm.159.6.9806145; Holguin F, 2011, J ALLERGY CLIN IMMUN, V127, P1486, DOI 10.1016/j.jaci.2011.03.036; Holguin F, 2011, J ASTHMA, V48, P217, DOI 10.3109/02770903.2011.555033; Kato H, 2011, INT ARCH ALLERGY IMM, V155, P335, DOI 10.1159/000321195; Kim HG, 2008, AM J PHYSIOL-CELL PH, V295, pC432, DOI 10.1152/ajpcell.00085.2008; Kim JY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116540; Korfhagen TR, 1996, P NATL ACAD SCI USA, V93, P9594, DOI 10.1073/pnas.93.18.9594; KWONG MS, 1986, PEDIATRICS, V78, P767; Ledford JG, 2015, J IMMUNOL, V194, P6123, DOI 10.4049/jimmunol.1500104; Ledford JG, 2010, J IMMUNOL, V185, P3884, DOI 10.4049/jimmunol.1000387; Lemiere C, 2006, J ALLERGY CLIN IMMUN, V118, P1033, DOI 10.1016/j.jaci.2006.08.003; Mai XM, 2009, PEDIATR ALLERGY IMMU, V20, P207, DOI 10.1111/j.1399-3038.2008.00812.x; McIntosh JC, 1996, AM J PHYSIOL-LUNG C, V271, pL310, DOI 10.1152/ajplung.1996.271.2.L310; Miakotina OL, 2002, AM J PHYSIOL-LUNG C, V283, pL418, DOI 10.1152/ajplung.00470.2001; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; Ortega H, 2014, EUR RESPIR J, V44, P239, DOI 10.1183/09031936.00220413; Peters JI, 2011, ANN ALLERG ASTHMA IM, V106, P30, DOI 10.1016/j.anai.2010.10.015; Sims MW, 2008, RESP RES, V9, DOI 10.1186/1465-9921-9-13; Stelts D, 1998, AM J RESP CELL MOL, V18, P463, DOI 10.1165/ajrcmb.18.4.2957; Sutherland ER, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036631; Sutherland TJT, 2008, AM J RESP CRIT CARE, V178, P469, DOI 10.1164/rccm.200802-301OC; Takeda M, 2012, INT ARCH ALLERGY IMM, V158, P87, DOI 10.1159/000337799; Todd DC, 2007, CLIN EXP ALLERGY, V37, P1049, DOI 10.1111/j.1365-2222.2007.02748.x; van der Wiel E, 2014, AM J RESP CRIT CARE, V189, P1281, DOI 10.1164/rccm.201310-1841LE; van Veen IH, 2008, ALLERGY, V63, P570, DOI 10.1111/j.1398-9995.2007.01597.x; VANDEGRAAF EA, 1992, J LAB CLIN MED, V120, P252; Wang Y, 2011, AM J PHYSIOL-LUNG C, V301, pL598, DOI 10.1152/ajplung.00381.2010; Westerhof GA, 2015, EUR RESPIR J, V46, P688, DOI 10.1183/09031936.00012415; WHITSETT JA, 1992, AM J PHYSIOL, V262, pL688, DOI 10.1152/ajplung.1992.262.6.L688; WISPE JR, 1990, J CLIN INVEST, V86, P1954, DOI 10.1172/JCI114929; Wong CK, 2007, EUR J IMMUNOL, V37, P2337, DOI 10.1002/eji.200636866	40	22	22	1	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2018	141	3					918	+		10.1016/j.jaci.2017.05.028	http://dx.doi.org/10.1016/j.jaci.2017.05.028			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FY6PR	28624607	Green Accepted, Bronze			2022-12-18	WOS:000426974800012
J	Filep, S; Block, DS; Smith, BRE; King, EM; Commins, S; Kulis, M; Vickery, BP; Chapman, MD				Filep, Stephanie; Block, Denise S.; Smith, Bryan R. E.; King, Eva M.; Commins, Scott; Kulis, Michael; Vickery, Brian P.; Chapman, Martin D.			Specific allergen profiles of peanut foods and diagnostic or therapeutic allergenic products	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Peanut; peanut foods; peanut butter; peanut flour; peanut allergens; oral immunotherapy; allergen dosing; risk assessment; allergen standardization	ARA H 6; ORAL IMMUNOTHERAPY; IGE; CHILDREN; ARA-H-1; BINDING	Background: Generic immunoassays for peanut cannot discriminate between allergen levels in peanut-derived food products or therapeutics. Clinical trials of oral immunotherapy (OIT) are strengthened by using standardized peanut preparations with defined doses of major allergens. Objective: This article describes measurement of Ara h 1, Ara h 2, and Ara h 6 in peanut foods and in peanut flour extracts used for allergy diagnosis and OIT. Methods: Monoclonal antibody-based enzyme immunoassays for Ara h 1, Ara h 2, and Ara h 6 were used to compare allergen levels in peanut (n = 16) and tree nut (n = 16) butter, peanut flour (n = 11), oils (n = 8), extracts used for diagnosis and OIT (n = 5), and the National Institute for Standards and Technology Peanut Butter Standard Reference Material 2387. Results: Roasted peanut butters contained 991 to 21,406 mu g/g Ara h 1 and exceeded Ara h 2 and Ara h 6 levels by 2- to 4-fold. Similarly, National Institute for Standards and Technology Peanut Butter Standard Reference Material 2387 contained 11,275 mu g/g Ara h 1, 2,522 mu g/g Ara h 2, and 2,036 mu g/g Ara h 6. In contrast, peanut flours contained 787 to 14,631 mu g/g Ara h 2 and exceeded Ara h 1 levels by 2- to 20-fold. Flour extracts used for OIT contained 394 to 505 mu g/mL Ara h 1, 1,187 to 5,270 mu g/mL Ara h 2, and 1,104 to 8,092 mu g/mL Ara h 6. In most cases specific peanut allergens were not detected in tree nut butters or peanut oils. Conclusions: The results show marked differences in specific peanut allergen profiles in peanut butter and flour and peanut preparations for clinical use. Roasting can increase Ara h 1 levels in peanut butter. Variability in allergen levels could affect the outcome of clinical trials of peanut OIT, especially with respect to Ara h 1. Specific allergen measurements will improve standardization and provide accurate dosing of peanut preparations that are being used for OIT.	[Filep, Stephanie; Block, Denise S.; Smith, Bryan R. E.; King, Eva M.; Chapman, Martin D.] INDOOR Biotechnol, 700 Harris St, Charlottesville, VA 22903 USA; [Commins, Scott] Univ Virginia, Hlth Sci Ctr, Div Pediat Allergy, Charlottesville, VA USA; [Kulis, Michael; Vickery, Brian P.] Univ N Carolina, Sch Med, Dept Pediat Allergy, Chapel Hill, NC USA; [Commins, Scott] Univ N Carolina, Sch Med, Dept Med, Thurston Res Ctr, Chapel Hill, NC USA	INDOOR Biotechnologies; University of Virginia; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Chapman, MD (corresponding author), INDOOR Biotechnol, 700 Harris St, Charlottesville, VA 22903 USA.	mdc@inbio.com		Chapman, Martin/0000-0002-0845-3632; Vickery, Brian/0000-0002-7243-5543; Filep, Stephanie/0000-0003-2135-5161	National Institutes of Health/National Institute for Allergy and Infectious Diseases [1K23AI099083, 2R01AI068074]; European Union 7th Framework [FP7-KBBE-2012-6-312147]; INDOOR Biotechnologies; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI068074] Funding Source: NIH RePORTER	National Institutes of Health/National Institute for Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); European Union 7th Framework(European Commission); INDOOR Biotechnologies; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported in part by grants from the National Institutes of Health/National Institute for Allergy and Infectious Diseases (1K23AI099083 and 2R01AI068074), a grant from the European Union 7th Framework (FP7-KBBE-2012-6-312147), and INDOOR Biotechnologies.	Chruszcz M, 2011, J BIOL CHEM, V286, P39318, DOI 10.1074/jbc.M111.270132; du Toit G, 2016, J ALLERGY CLIN IMMUN, V137, P998, DOI 10.1016/j.jaci.2016.02.005; Filep S, 2012, J ALLERGY CLIN IMMUN, V129, P1408, DOI 10.1016/j.jaci.2011.12.978; Flinterman AE, 2007, CLIN EXP ALLERGY, V37, P1221, DOI 10.1111/j.1365-2222.2007.02764.x; Hindley JP, 2018, J ALLERGY CLIN IMMUN, V141, P780, DOI 10.1016/j.jaci.2017.05.050; Hourihane JO, 1997, BRIT MED J, V314, P1084, DOI 10.1136/bmj.314.7087.1084; Jayasena S, 2015, J AGR FOOD CHEM, V63, P1849, DOI 10.1021/jf504741t; Johnson PE, 2016, ANAL CHEM, V88, P5689, DOI 10.1021/acs.analchem.5b04466; Jones SM, 2009, J ALLERGY CLIN IMMUN, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Kim Edwin H, 2014, Curr Treat Options Allergy, V1, P48; Klemans RJB, 2014, ALLERGY, V69, P1112, DOI 10.1111/all.12424; Koid AE, 2014, J AGR FOOD CHEM, V62, P206, DOI 10.1021/jf4022509; Lack G, 2003, NEW ENGL J MED, V348, P977, DOI 10.1056/NEJMoa013536; Lack G, 2015, NEW ENGL J MED, V372, P2165, DOI 10.1056/NEJMc1504021; Maleki SJ, 2000, J ALLERGY CLIN IMMUN, V106, P763, DOI 10.1067/mai.2000.109620; Maleki SJ, 2004, CURR OPIN ALLERGY CL, V4, P241, DOI 10.1097/01.all.0000129458.34716.3b; Maloney JM, 2006, J ALLERGY CLIN IMMUN, V118, P719, DOI 10.1016/j.jaci.2006.05.017; Mueller GA, 2013, ALLERGY, V68, P1546, DOI 10.1111/all.12261; Mueller GA, 2011, ALLERGY, V66, P878, DOI 10.1111/j.1398-9995.2010.02532.x; NORDLEE JA, 1981, J ALLERGY CLIN IMMUN, V68, P376, DOI 10.1016/0091-6749(81)90136-6; Olszewski A, 1998, CLIN EXP ALLERGY, V28, P850, DOI 10.1046/j.1365-2222.1998.00325.x; Perry TT, 2004, J ALLERGY CLIN IMMUN, V113, P973, DOI 10.1016/j.jaci.2004.02.035; Pomes A, 2006, CLIN EXP ALLERGY, V36, P824, DOI 10.1111/j.1365-2222.2006.02490.x; Pomes A, 2004, J FOOD PROTECT, V67, P793, DOI 10.4315/0362-028X-67.4.793; Pomes A, 2003, J ALLERGY CLIN IMMUN, V111, P640, DOI 10.1067/mai.2003.118; TAYLOR SL, 1981, J ALLERGY CLIN IMMUN, V68, P372, DOI 10.1016/0091-6749(81)90135-4; Vickery BP, 2017, J ALLERGY CLIN IMMUN, V139, P173, DOI 10.1016/j.jaci.2016.05.027; Vickery BP, 2010, CURR OPIN PEDIATR, V22, P765, DOI 10.1097/MOP.0b013e32833f5fc0	28	22	22	1	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2018	141	2					626	+		10.1016/j.jaci.2017.05.049	http://dx.doi.org/10.1016/j.jaci.2017.05.049			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FV2PQ	28709968	Bronze			2022-12-18	WOS:000424410800019
J	Jog, NR; James, JA				Jog, Neelakshi R.; James, Judith A.			Biomarkers in connective tissue diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Connective tissue diseases; systemic lupus erythematosus; rheumatoid arthritis; systemic sclerosis; vasculitis; biomarkers	SYSTEMIC-LUPUS-ERYTHEMATOSUS; CYCLIC CITRULLINATED PEPTIDES; GROWTH-DIFFERENTIATION FACTOR-15; LYMPHOCYTE STIMULATOR LEVELS; EARLY RHEUMATOID-ARTHRITIS; AFRICAN-AMERICAN PATIENTS; PROTEIN ANTIBODIES; SERUM-LEVELS; MICROSCOPIC POLYANGIITIS; RADIOGRAPHIC PROGRESSION	Autoimmune connective tissue diseases are clinically variable, making biomarkers desirable for assessing future disease risk, supporting early and accurate diagnosis, monitoring disease activity and progression, selecting therapeutics, and assessing treatment response. Because of their correlations with specific clinical characteristics and often with disease progression, autoantibodies and other soluble mediators are considered potential biomarkers. Additional biomarkers might reflect downstream pathologic processes or appear because of ongoing inflammation and damage. Because of overlap between diseases, some biomarkers have limited specificity for a single autoimmune connective tissue disease. This review describes select current biomarkers that aid in the diagnosis and treatment of several major systemic autoimmune connective tissue disorders: systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis, and anti-neutrophil cytoplasmic antibody-associated vasculitides. Newly proposed biomarkers that target various stages in disease onset or progression are also discussed. Newer approaches to overcome the diversity observed in patients with these diseases and to facilitate personalized disease monitoring and treatment are also addressed.	[Jog, Neelakshi R.; James, Judith A.] Oklahoma Med Res Fdn, Arthrit & Clin Immunol, 825 NE 13th St, Oklahoma City, OK 73104 USA; [James, Judith A.] Univ Oklahoma, Hlth Sci Ctr, Oklahoma Clin & Translat Sci Inst, Oklahoma City, OK USA; [James, Judith A.] Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK USA; [James, Judith A.] Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, Oklahoma City, OK USA; [James, Judith A.] Univ Oklahoma, Hlth Sci Ctr, Dept Microbiol & Immunol, Oklahoma City, OK 73190 USA	Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center	James, JA (corresponding author), Oklahoma Med Res Fdn, Arthrit & Clin Immunol, 825 NE 13th St, Oklahoma City, OK 73104 USA.	jamesj@omrf.org		Jog, Neelakshi/0000-0002-2477-2211	National Institutes of Health [U54GM104938, U01AI101934, U19AI082714, P30GM103510, P30AR053483]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI082714, U01AI101934] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR053483] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM104938, P30GM103510] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Supported by the National Institutes of Health (grants U54GM104938, U01AI101934, U19AI082714, P30GM103510, and P30AR053483).	Arbuckle MR, 2003, NEW ENGL J MED, V349, P1526, DOI 10.1056/NEJMoa021933; Baechler EC, 2003, P NATL ACAD SCI USA, V100, P2610, DOI 10.1073/pnas.0337679100; Banchereau R, 2016, CELL, V165, P551, DOI 10.1016/j.cell.2016.03.008; BARDANA EJ, 1975, AM J MED, V59, P515; Bauer JW, 2006, PLOS MED, V3, P2274, DOI 10.1371/journal.pmed.0030491; Brennan FM, 2008, J CLIN INVEST, V118, P3537, DOI 10.1172/JCI36389; Briani C, 2009, J AUTOIMMUN, V32, P79, DOI 10.1016/j.jaut.2008.12.002; Brunner HI, 2012, ARTHRITIS RHEUM-US, V64, P2687, DOI 10.1002/art.34426; Choi IY, 2015, ANN RHEUM DIS, V74, P499, DOI 10.1136/annrheumdis-2013-203923; Cozzani E, 2014, AUTOIMMUN DIS, V2014, DOI 10.1155/2014/321359; Dallos T, 2010, ARTHRITIS RHEUM-US, V62, P3496, DOI 10.1002/art.27678; de Joode AAE, 2013, CLIN J AM SOC NEPHRO, V8, P1709, DOI 10.2215/CJN.01020113; De Lauretis A, 2013, J RHEUMATOL, V40, P435, DOI 10.3899/jrheum.120725; Deane KD, 2014, NAT REV RHEUMATOL, V10, P212, DOI 10.1038/nrrheum.2014.6; Deane KD, 2010, ARTHRITIS RHEUM-US, V62, P3161, DOI 10.1002/art.27638; Demoruelle MK, 2017, ARTHRITIS RHEUMATOL, V69, P1165, DOI 10.1002/art.40066; Denton CP, 2017, LANCET; England BR, 2017, CURR OPIN RHEUMATOL, V29, P57, DOI 10.1097/BOR.0000000000000356; Eriksson C, 2013, SCAND J RHEUMATOL, V42, P260, DOI 10.3109/03009742.2012.754937; Eriksson C, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3258; Farh KKH, 2015, NATURE, V518, P337, DOI 10.1038/nature13835; Fertig N, 2009, ARTHRIT RHEUM-ARTHR, V61, P958, DOI 10.1002/art.24586; Franssen CFM, 2000, KIDNEY INT, V57, P2195, DOI 10.1046/j.1523-1755.2000.00080.x; Fritzler MJ, 2016, AUTOIMMUN REV, V15, P272, DOI 10.1016/j.autrev.2015.12.002; Gan RW, 2015, J RHEUMATOL, V42, P572, DOI 10.3899/jrheum.140767; Gardette A, 2014, JOINT BONE SPINE, V81, P416, DOI 10.1016/j.jbspin.2014.06.001; Gottenberg JE, 2012, ANN RHEUM DIS, V71, P1815, DOI 10.1136/annrheumdis-2011-201109; Gourh P, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2821; Greco A, 2015, AUTOIMMUN REV, V14, P341, DOI 10.1016/j.autrev.2014.12.004; Hahn BH, 1998, NEW ENGL J MED, V338, P1359, DOI 10.1056/NEJM199805073381906; Henes FO, 2011, ANN RHEUM DIS, V70, P1926, DOI 10.1136/ard.2010.146456; Hesselstrand R, 2008, ANN RHEUM DIS, V67, P1242, DOI 10.1136/ard.2007.082099; Hesselstrand R, 2013, RESP MED, V107, P1079, DOI 10.1016/j.rmed.2013.03.015; Hochberg MC, 1997, ARTHRITIS RHEUM, V40, P1725, DOI 10.1002/art.1780400928; Jog NR, 2016, LUPUS, V25, P1551, DOI 10.1177/0961203316644331; Kallenberg CGM, 2014, NAT REV RHEUMATOL, V10, P484, DOI 10.1038/nrrheum.2014.104; Kalunian KC, 2012, ARTHRITIS RHEUM-US, V64, P4040, DOI 10.1002/art.34669; Kawai H, 2014, CLIN EXP NEPHROL, V18, P795, DOI 10.1007/s10157-013-0926-1; Kemna MJ, 2016, CLIN EXP IMMUNOL, V185, P141, DOI 10.1111/cei.12796; Kemna MJ, 2017, EBIOMEDICINE, V17, P108, DOI 10.1016/j.ebiom.2017.01.033; Kirou KA, 2005, ARTHRITIS RHEUM-US, V52, P1491, DOI 10.1002/art.21031; Koenig M, 2008, AUTOIMMUN REV, V7, P588, DOI 10.1016/j.autrev.2008.06.010; Lai YF, 2017, IMMUNOL INVEST, V46, P375, DOI 10.1080/08820139.2017.1288236; Lambrecht S, 2014, ARTHRITIS RHEUMATOL, V66, P418, DOI 10.1002/art.38241; Landolt-Marticorena C, 2009, ANN RHEUM DIS, V68, P1440, DOI 10.1136/ard.2008.093146; Leuchten N, 2017, ARTHRITIS CARE RES; Lu RF, 2016, J AUTOIMMUN, V74, P182, DOI 10.1016/j.jaut.2016.06.001; Ma WT, 2017, J AUTOIMMUN, V83, P95, DOI 10.1016/j.jaut.2017.07.003; Maijer KI, 2015, ANN RHEUM DIS, V74, P2097, DOI 10.1136/annrheumdis-2015-207911; McClain MT, 2004, ARTHRITIS RHEUM-US, V50, P1226, DOI 10.1002/art.20120; Meadows CA, 2011, CHEST, V139, P994, DOI 10.1378/chest.10-0302; Menard HA, 2000, ARTHRITIS RES, V2, P429, DOI 10.1186/ar122; Migliorini P, 2005, AUTOIMMUNITY, V38, P47, DOI 10.1080/08916930400022715; Moinzadeh P, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4486; Munroe ME, 2017, J AUTOIMMUN, V78, P70, DOI 10.1016/j.jaut.2016.12.005; Munroe ME, 2017, ARTHRITIS RHEUMATOL, V69, P630, DOI 10.1002/art.40004; Munroe ME, 2016, ANN RHEUM DIS, V75, P2014, DOI 10.1136/annrheumdis-2015-208140; Munroe ME, 2014, ARTHRITIS RHEUMATOL, V66, P1888, DOI 10.1002/art.38573; Navarro-Compa V, 2015, RHEUMATOLOGY, V54, P994, DOI 10.1093/rheumatology/keu413; Ng KP, 2006, ARTHRIT RHEUM-ARTHR, V55, P900, DOI 10.1002/art.22356; Niewold TB, 2007, GENES IMMUN, V8, P492, DOI 10.1038/sj.gene.6364408; Niklas Karolina, 2016, Reumatologia (Warsaw), V54, P165, DOI 10.5114/reum.2016.62470; Niklas Karolina, 2016, Reumatologia (Warsaw), V54, P122, DOI 10.5114/reum.2016.61212; Nishimura K, 2007, ANN INTERN MED, V146, P797, DOI 10.7326/0003-4819-146-11-200706050-00008; O'Dell JR, 2002, ARTHRITIS RHEUM, V46, P283, DOI 10.1002/art.10092; OKANO Y, 1990, ARTHRITIS RHEUM, V33, P1822, DOI 10.1002/art.1780331210; Oliver JE, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2825; Olsen NJ, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3927; Olson SW, 2013, CLIN J AM SOC NEPHRO, V8, P1702, DOI 10.2215/CJN.01910213; Patro PS, 2016, J RHEUMATOL, V43, P731, DOI 10.3899/jrheum.150998; Paul BJ, 2017, EUR J RHEUMATOL, V4, P161, DOI 10.5152/eurjrheum.2017.16006; Pepper RJ, 2017, ARTHRITIS RHEUMATOL, V69, P185, DOI 10.1002/art.39814; Petri M, 2009, LUPUS, V18, P980, DOI 10.1177/0961203309105529; Petri M, 2008, ARTHRITIS RHEUM, V58, P2453, DOI 10.1002/art.23678; Petri M, 2012, ARTHRITIS RHEUM-US, V64, P2677, DOI 10.1002/art.34473; Petri M, 2009, J RHEUMATOL, V36, P2476, DOI 10.3899/jrheum.090019; Petri MA, 2013, ARTHRITIS RHEUM-US, V65, P2143, DOI 10.1002/art.37995; Putterman C, 2016, J IMMUNOL METHODS, V429, P1, DOI 10.1016/j.jim.2015.12.003; Putterman C, 2014, LUPUS SCI MED, V1, DOI 10.1136/lupus-2014-000056; Ritterhouse LL, 2011, ARTHRITIS RHEUM-US, V63, P3931, DOI 10.1002/art.30598; Robinson WH, 2002, NAT MED, V8, P295, DOI 10.1038/nm0302-295; Sato S, 2001, J DERMATOL SCI, V27, P140, DOI 10.1016/S0923-1811(01)00128-1; Satoh M, 2012, ARTHRITIS RHEUM-US, V64, P2319, DOI 10.1002/art.34380; Schwartz N, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2816; Shah AA, 2017, ARTHRITIS RHEUMATOL, V69, P1306, DOI 10.1002/art.40065; Sharif R, 2011, J RHEUMATOL, V38, P1622, DOI 10.3899/jrheum.110071; Sharma R, 2017, ARTHRITIS RHEUMATOL; Shooshtari P, 2017, AM J HUM GENET, V101, P75, DOI 10.1016/j.ajhg.2017.06.001; Singh S, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3912; Steen VD, 2005, SEMIN ARTHRITIS RHEU, V35, P35, DOI 10.1016/j.semarthrit.2005.03.005; Steiner Gunter, 2002, Arthritis Res, V4 Suppl 2, pS1, DOI 10.1186/ar551; Svard A, 2011, J RHEUMATOL, V38, P1265, DOI 10.3899/jrheum.101086; SWAAK AJG, 1986, ANN RHEUM DIS, V45, P359, DOI 10.1136/ard.45.5.359; Szczeklik W, 2012, CLIN EXP ALLERGY, V42, P513, DOI 10.1111/j.1365-2222.2011.03943.x; Szczeklik W, 2017, EUR J IMMUNOL, V47, P724, DOI 10.1002/eji.201646810; Takakuwa Y, 2011, ARTHRITIS RHEUM-US, V63, P3613, DOI 10.1002/art.30560; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; Tedeschi SK, 2017, ARTHRITIS CARE RES; Tomasson G, 2012, RHEUMATOLOGY, V51, P100, DOI 10.1093/rheumatology/ker280; Tony HP, 2015, CLIN EXP RHEUMATOL, V33, P887; Too CL, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3813; Tseng CE, 2006, ARTHRITIS RHEUM-US, V54, P3623, DOI 10.1002/art.22198; Turesson C, 2007, ANN RHEUM DIS, V66, P59, DOI 10.1136/ard.2006.054445; Vaglio A, 2012, ANN RHEUM DIS, V71, P390, DOI 10.1136/ard.2011.155382; Valoes CCM, 2017, LUPUS, V26, P484, DOI 10.1177/0961203316676386; van Bon L, 2014, ANN RHEUM DIS, V73, P1585, DOI 10.1136/annrheumdis-2013-205013; van Bon L, 2014, NEW ENGL J MED, V370, P433, DOI 10.1056/NEJMoa1114576; van der Woude D, 2010, ANN RHEUM DIS, V69, P1110, DOI 10.1136/ard.2009.116384; van Gaalen FA, 2004, ARTHRITIS RHEUM, V50, P709, DOI 10.1002/art.20044; Vidal-Bralo L, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180144; Vossenaar ER, 2004, ARTHRITIS RES THER, V6, pR142, DOI 10.1186/ar1149; Wilde B, 2011, KIDNEY INT, V79, P599, DOI 10.1038/ki.2010.472; Williams MH, 2006, EUR HEART J, V27, P1485, DOI 10.1093/eurheartj/ehi891; Wu TF, 2013, MOL CELL PROTEOMICS, V12, P1170, DOI 10.1074/mcp.M112.021667; Wuhrer M, 2015, J PROTEOME RES, V14, P1657, DOI 10.1021/pr500780a; Xu X, 2013, CLIN RHEUMATOL, V32, P1501, DOI 10.1007/s10067-013-2305-4; Yanaba K, 2004, J RHEUMATOL, V31, P1112; Yanaba K, 2012, MOD RHEUMATOL, V22, P668, DOI 10.1007/s10165-011-0568-7; Yazdany J, 2013, ARTHRIT CARE RES, V65, P329, DOI 10.1002/acr.21930; Yoshimi R, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/606195; Zhao ZG, 2005, ARTHRITIS RHEUM-US, V52, P522, DOI 10.1002/art.20862; Zwerina J, 2011, RHEUMATOLOGY, V50, P1823, DOI 10.1093/rheumatology/keq445	122	22	25	1	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2017	140	6					1473	1484		10.1016/j.jaci.2017.10.003	http://dx.doi.org/10.1016/j.jaci.2017.10.003			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FO9KI	29221579	Green Accepted, Bronze			2022-12-18	WOS:000417206000001
J	Hofer, H; Asam, C; Hauser, M; Nagl, B; Laimer, J; Himly, M; Briza, P; Ebner, C; Lang, R; Hawranek, T; Bohle, B; Lackner, P; Ferreira, F; Wallner, M				Hofer, Heidi; Asam, Claudia; Hauser, Michael; Nagl, Birgit; Laimer, Josef; Himly, Martin; Briza, Peter; Ebner, Christof; Lang, Roland; Hawranek, Thomas; Bohle, Barbara; Lackner, Peter; Ferreira, Fatima; Wallner, Michael			Tackling Bet v 1 and associated food allergies with a single hybrid protein	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Birch pollen allergy; Bet v 1; birch pollen-associated food allergy; allergy vaccine candidate; molecular allergology	BIRCH POLLEN ALLERGEN; SITE-DIRECTED MUTAGENESIS; T-CELL EPITOPE; CROSS-REACTIVITY; POTENTIAL USE; IMMUNOTHERAPY; GENERATION; EFFICACY; VACCINES; ISOFORMS	Background: Allergy vaccines should be easily applicable, safe, and efficacious. For Bet v 1-mediated birch pollen and associated food allergies, a single wild-type allergen does not provide a complete solution. Objective: We aimed to combine immunologically relevant epitopes of Bet v 1 and the 2 clinically most important related food allergens from apple and hazelnut to a single hybrid protein, termed MBC4. Methods: After identification of T cell epitope-containing parts on each of the 3 parental allergens, the hybrid molecule was designed to cover relevant epitopes and evaluated in silico. Thereby a mutation was introduced into the hybrid sequence, which should alter the secondary structure without compromising the immunogenic properties of the molecule. Results: MBC4 and the parental allergens were purified to homogeneity. Analyses of secondary structure elements revealed substantial changes rendering the hybrid de facto nonreactive with patients' serum IgE. Nevertheless, the protein was monomeric in solution. MBC4 was able to activate T-cell lines from donors with birch pollen allergy and from mice immunized with the parental allergens. Moreover, on immunization of mice and rabbits, MBC4 induced cross-reactive IgG antibodies, which were able to block the binding of human serum IgE. Conclusion: Directed epitope rearrangements combined with a knowledge-based structural modification resulted in a protein unable to bind IgE from allergic patients. Still, properties to activate specific T cells or induce blocking antibodies were conserved. This suggests that MBC4 is a suitable vaccine candidate for the simultaneous treatment of Bet v 1 and associated food allergies.	[Hofer, Heidi; Asam, Claudia; Hauser, Michael; Laimer, Josef; Himly, Martin; Briza, Peter; Lackner, Peter; Ferreira, Fatima; Wallner, Michael] Univ Salzburg, Dept Mol Biol, Hellbrunnerstr 34, A-5020 Salzburg, Austria; [Nagl, Birgit; Bohle, Barbara] Med Univ Vienna, Dept Pathophysiol & Allergy Res, Vienna, Austria; [Nagl, Birgit; Bohle, Barbara] Med Univ Vienna, Christian Doppler Lab Immunomodulat, Vienna, Austria; [Ebner, Christof] Allergy Clin Reumannpl, Vienna, Austria; [Lang, Roland; Hawranek, Thomas] Paracelsus Med Univ, Dept Dermatol, Salzburg, Austria	Salzburg University; Medical University of Vienna; Medical University of Vienna; Paracelsus Private Medical University	Wallner, M (corresponding author), Univ Salzburg, Dept Mol Biol, Hellbrunnerstr 34, A-5020 Salzburg, Austria.	michael.wallner@sbg.ac.at	Lackner, Peter/L-2900-2015; Ferreira, Fatima/AAB-4321-2019; Laimer, Josef/H-3226-2016; Ferreira, Fatima/E-4889-2011; Briza, Peter/D-7309-2012; Hauser, Michael/P-6148-2017; Wallner, Michael/L-5437-2015; Himly, Martin/D-1568-2015	Lackner, Peter/0000-0003-4681-6307; Ferreira, Fatima/0000-0003-0989-2335; Laimer, Josef/0000-0001-6413-4268; Ferreira, Fatima/0000-0003-0989-2335; Briza, Peter/0000-0002-4941-6782; Hauser, Michael/0000-0001-6558-755X; Wallner, Michael/0000-0001-6568-7892; Himly, Martin/0000-0001-5416-085X; Bohle, Barbara/0000-0002-5105-7985	Austrian Science Fund (FWF) [L688]; Austrian National Bank (ONB) [12533]; priority program "Allergy-Cancer-BioNano Research Centre'' of the University of Salzburg	Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); Austrian National Bank (ONB); priority program "Allergy-Cancer-BioNano Research Centre'' of the University of Salzburg	Supported by the Austrian Science Fund (FWF) grant L688, the Austrian National Bank (ONB) grant 12533, and the priority program "Allergy-Cancer-BioNano Research Centre'' of the University of Salzburg.	Akdis M, 2014, J ALLERGY CLIN IMMUN, V133, P621, DOI 10.1016/j.jaci.2013.12.1088; Bauer R, 2006, J ALLERGY CLIN IMMUN, V118, P269, DOI 10.1016/j.jaci.2006.03.033; Bohle B, 2005, CLIN EXP ALLERGY, V35, P1392, DOI 10.1111/j.1365-2222.2005.02332.x; Bolhaar STHP, 2004, CLIN EXP ALLERGY, V34, P761, DOI 10.1111/j.1365-2222.2004.1939.x; Egger M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017278; Ferreira F, 1998, FASEB J, V12, P231, DOI 10.1096/fasebj.12.2.231; Ferreira F, 1996, J EXP MED, V183, P599, DOI 10.1084/jem.183.2.599; Ferreira F, 2014, YONSEI MED J, V55, P839, DOI 10.3349/ymj.2014.55.4.839; Geroldinger-Simic M, 2011, J ALLERGY CLIN IMMUN, V127, P616, DOI 10.1016/j.jaci.2010.10.027; Jahn-Schmid B, 2005, J ALLERGY CLIN IMMUN, V116, P213, DOI 10.1016/j.jaci.2005.04.019; Jutel M, 2015, J ALLERGY CLIN IMMUN, V136, P556, DOI 10.1016/j.jaci.2015.04.047; Kinaciyan T, 2007, J ALLERGY CLIN IMMUN, V119, P937, DOI 10.1016/j.jaci.2006.11.010; Kitzmuller C, 2015, J ALLERGY CLIN IMMUN, V136, P151, DOI 10.1016/j.jaci.2014.12.1928; Laimer J, 2015, BMC BIOINFORMATICS, V16, DOI 10.1186/s12859-015-0548-6; Mauro M, 2011, INT ARCH ALLERGY IMM, V156, P416, DOI 10.1159/000323909; Nony E, 2015, ALLERGY, V70, P795, DOI 10.1111/all.12622; Pauli G, 2008, J ALLERGY CLIN IMMUN, V122, P951, DOI 10.1016/j.jaci.2008.09.017; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Pichler U, 2014, CLIN EXP ALLERGY, V44, P438, DOI 10.1111/cea.12250; Pichler U, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/832404; Roulias A, 2014, ALLERGY, V69, P208, DOI 10.1111/all.12306; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Subbarayal B, 2013, ALLERGY, V68, P1377, DOI 10.1111/all.12236; Wallner M, 2011, J ALLERGY CLIN IMMUN, V127, P1571, DOI 10.1016/j.jaci.2011.01.064; Wallner M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008457	26	22	23	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2017	140	2					525	+		10.1016/j.jaci.2016.09.055	http://dx.doi.org/10.1016/j.jaci.2016.09.055			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FC5BK	27939703	Green Accepted, hybrid			2022-12-18	WOS:000406855500024
J	van den Heuvel, D; Jansen, MAE; Nasserinejad, K; Dik, WA; van Lochem, EG; Bakker-Jonges, LE; Bouallouch-Charif, H; Jaddoe, VWV; Hooijkaas, H; van Dongen, JJM; Moll, HA; van Zelm, MC				van den Heuvel, Diana; Jansen, Michelle A. E.; Nasserinejad, Kazem; Dik, Willem A.; van Lochem, Ellen G.; Bakker-Jonges, Liesbeth E.; Bouallouch-Charif, Halima; Jaddoe, Vincent W. V.; Hooijkaas, Herbert; van Dongen, Jacques J. M.; Moll, Henriette A.; van Zelm, Menno C.			Effects of nongenetic factors on immune cell dynamics in early childhood: The Generation R Study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Longitudinal leukocyte dynamics; interindividual immunologic variance; innate leukocytes; CD4(+) T cells; CD8(+) T cells; B cells; T-cell receptor gamma delta(+) T cells; nongenetic determinants	MEMORY B-CELLS; HELICOBACTER-PYLORI CAGA; CD8(+) T-CELLS; REFERENCE VALUES; LYMPHOCYTE SUBPOPULATIONS; INTERMEDIATE MONOCYTES; PERIPHERAL-BLOOD; SUBSETS; INFECTION; HEALTHY	Background: Numbers of blood leukocyte subsets are highly dynamic in childhood and differ greatly between subjects. Interindividual variation is only partly accounted for by genetic factors. Objective: We sought to determine which nongenetic factors affect the dynamics of innate leukocytes and naive and memory lymphocyte subsets. Methods: We performed 6-color flow cytometry and linear mixed-effects modeling to define the dynamics of 62 leukocyte subsets from birth to 6 years of age in 1182 children, with 1 to 5 measurements per subject. Subsequently, we defined the effect of prenatal maternal lifestyle-related or immune-mediated determinants, birth characteristics, and bacterial/viral exposure-related determinants on leukocyte subset dynamics. Results: Functionally similar leukocyte populations were grouped by using unbiased hierarchical clustering of patterns of age-related leukocyte dynamics. Innate leukocyte numbers were high at birth and predominantly affected by maternal low education level. Naive lymphocyte counts peaked around 1 year, whereas most memory lymphocyte subsets more gradually increased during the first 4 years of life. Dynamics of CD4(+) T cells were predominantly associated with sex, birth characteristics, and persistent infections with cytomegalovirus (CMV) or EBV. CD8(+) T cells were predominantly associated with CMV and EBV infections, and T-cell receptor gamma delta(+) T cells were predominantly associated with premature rupture of membranes and CMV infection. B-cell subsets were predominantly associated with sex, breast-feeding, and Helicobacter pylori carriership. Conclusions: Our study identifies specific dynamic patterns of leukocyte subset numbers, as well as nongenetic determinants that affect these patterns, thereby providing new insights into the shaping of the childhood immune system.	[van den Heuvel, Diana; Dik, Willem A.; van Lochem, Ellen G.; Bakker-Jonges, Liesbeth E.; Bouallouch-Charif, Halima; Hooijkaas, Herbert; van Dongen, Jacques J. M.; van Zelm, Menno C.] Erasmus MC, Univ Med Ctr, Dept Immunol, Rotterdam, Netherlands; [Jansen, Michelle A. E.; Jaddoe, Vincent W. V.] Erasmus MC, Univ Med Ctr, Generat Study Grp R, Rotterdam, Netherlands; [Nasserinejad, Kazem] Erasmus MC, Univ Med Ctr, Dept Biostat, Rotterdam, Netherlands; [Jansen, Michelle A. E.; Jaddoe, Vincent W. V.] Erasmus MC, Univ Med Ctr, Dept Epidemiol, Rotterdam, Netherlands; [Jaddoe, Vincent W. V.; Moll, Henriette A.] Erasmus MC Sophia, Dept Pediat, Rotterdam, Netherlands; [van Zelm, Menno C.] Monash Univ, Cent Clin Sch, Dept Immunol & Pathol, 89 Commercial Rd, Melbourne, Vic 3004, Australia	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Monash University	van Zelm, MC (corresponding author), Monash Univ, Cent Clin Sch, Dept Immunol & Pathol, 89 Commercial Rd, Melbourne, Vic 3004, Australia.	menno.vanzelm@monash.edu	van Zelm, Menno C/O-4404-2015; van den Heuvel, Diana/Q-5930-2017	van Zelm, Menno C/0000-0003-4161-1919; Nasserinejad, Kazem/0000-0002-5666-5015; van Dongen, Jacques J.M./0000-0002-3650-7087	Erasmus MC Fellowship	Erasmus MC Fellowship	Supported by an Erasmus MC Fellowship (to M.C.v.Z.).	Appay V, 2002, NAT MED, V8, P379, DOI 10.1038/nm0402-379; Appay V, 2008, CYTOM PART A, V73A, P975, DOI 10.1002/cyto.a.20643; Babcock GJ, 1998, IMMUNITY, V9, P395, DOI 10.1016/S1074-7613(00)80622-6; Bekker V, 2005, AIDS, V19, P1025, DOI 10.1097/01.aids.0000174448.25132.ad; Bekker V, 2006, PEDIATRICS, V118, pE315, DOI 10.1542/peds.2005-2616; Berkowska MA, 2011, BLOOD, V118, P2150, DOI 10.1182/blood-2011-04-345579; Bouthoorn SH, 2015, ACTA DIABETOL, V52, P445, DOI 10.1007/s00592-014-0668-x; BREIT TM, 1994, J IMMUNOL, V152, P2860; Brodin P, 2015, CELL, V160, P37, DOI 10.1016/j.cell.2014.12.020; Carr EJ, 2016, NAT IMMUNOL, V17, P461, DOI 10.1038/ni.3371; Chaganti S, 2009, BLOOD, V113, P6372, DOI 10.1182/blood-2008-08-175828; Chidrawar S, 2009, CLIN EXP IMMUNOL, V155, P423, DOI 10.1111/j.1365-2249.2008.03785.x; ComansBitter WM, 1997, J PEDIATR-US, V130, P388, DOI 10.1016/S0022-3476(97)70200-2; den Hollander WJ, 2015, GUT, V64, P1200, DOI 10.1136/gutjnl-2014-307689; Derhovanessian E, 2011, J GEN VIROL, V92, P2746, DOI 10.1099/vir.0.036004-0; Driessen GJ, 2013, HAEMATOLOGICA, V98, P1617, DOI 10.3324/haematol.2013.085076; Duchamp M, 2014, IMMUN INFLAMM DIS, V2, P131, DOI 10.1002/iid3.26; Duijts L, 2009, MATERN CHILD NUTR, V5, P199, DOI 10.1111/j.1740-8709.2008.00176.x; Flores KG, 1999, J CLIN INVEST, V104, P1031, DOI 10.1172/JCI7558; Hanson LA, 2003, ANN NY ACAD SCI, V987, P199, DOI 10.1111/j.1749-6632.2003.tb06049.x; Hanson LA, 2001, PEDIAT ALLERG IMM-UK, V12, P15, DOI 10.1034/j.1399-3038.2001.121404.x; Hawkes JS, 1999, PEDIATR RES, V45, P648, DOI 10.1203/00006450-199905010-00006; Helmin-Basa A, 2011, HELICOBACTER, V16, P27, DOI 10.1111/j.1523-5378.2010.00809.x; Hijdra D, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00339; Huck K, 2009, CLIN IMMUNOL, V131, P50, DOI 10.1016/j.clim.2008.11.008; Jackson KJL, 2014, IMMUNOL CELL BIOL, V92, P729, DOI 10.1038/icb.2014.44; Jaddoe VWV, 2012, EUR J EPIDEMIOL, V27, P739, DOI 10.1007/s10654-012-9735-1; Jansen MAE, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126019; Jansen MA, 2014, AM J CLIN NUTR, V100, P1095, DOI 10.3945/ajcn.114.090316; Jensen K, 2010, PEDIATR HEMAT ONCOL, V27, P31, DOI 10.3109/08880010903420687; Kalina T, 2012, LEUKEMIA, V26, P1986, DOI 10.1038/leu.2012.122; Kiefte-de Jong JC, 2013, GASTROENTEROLOGY, V144, P726, DOI 10.1053/j.gastro.2013.01.003; Kogut I, 2012, SEMIN IMMUNOL, V24, P342, DOI 10.1016/j.smim.2012.04.004; Korevaar TIM, 2013, J CLIN ENDOCR METAB, V98, P3678, DOI 10.1210/jc.2013-2005; Kruithof CJ, 2014, EUR J EPIDEMIOL, V29, P911, DOI 10.1007/s10654-014-9980-6; LEE CK, 1995, J INFECT DIS, V172, P161, DOI 10.1093/infdis/172.1.161; Lin WC, 2010, CANCER RES, V70, P5740, DOI 10.1158/0008-5472.CAN-09-4690; M'Rabet L, 2008, J NUTR, V138, p1782S, DOI 10.1093/jn/138.9.1782S; MANROE BL, 1979, J PEDIATR-US, V95, P89, DOI 10.1016/S0022-3476(79)80096-7; Mattsson A, 1998, INFECT IMMUN, V66, P2705, DOI 10.1128/IAI.66.6.2705-2712.1998; Morbach H, 2010, CLIN EXP IMMUNOL, V162, P271, DOI 10.1111/j.1365-2249.2010.04206.x; Ober C, 2008, NAT REV GENET, V9, P911, DOI 10.1038/nrg2415; Orru V, 2013, CELL, V155, P242, DOI 10.1016/j.cell.2013.08.041; Pabst HF, 1997, ACTA PAEDIATR, V86, P1291, DOI 10.1111/j.1651-2227.1997.tb14900.x; Piatosa B, 2010, CYTOM PART B-CLIN CY, V78B, P372, DOI 10.1002/cyto.b.20536; R-Core-Team, 2015, LANG ENV STAT COMP; Sagnia B, 2011, CLIN VACCINE IMMUNOL, V18, P790, DOI 10.1128/CVI.00483-10; Sallusto F, 2004, ANNU REV IMMUNOL, V22, P745, DOI 10.1146/annurev.immunol.22.012703.104702; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; Sandberg Y, 2006, LEUKEMIA, V20, P505, DOI 10.1038/sj.leu.2404112; Tosato F, 2015, CYTOM PART A, V87A, P81, DOI 10.1002/cyto.a.22520; Turner JD, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002817; Umehara S, 2003, ONCOGENE, V22, P8337, DOI 10.1038/sj.onc.1207028; van Gent R, 2009, CLIN IMMUNOL, V133, P95, DOI 10.1016/j.clim.2009.05.020; van Leeuwen EMM, 2004, J IMMUNOL, V173, P1834, DOI 10.4049/jimmunol.173.3.1834; Weinberger B, 2007, HUM IMMUNOL, V68, P86, DOI 10.1016/j.humimm.2006.10.019; Weller S, 2004, BLOOD, V104, P3647, DOI 10.1182/blood-2004-01-0346; Weller S, 2001, P NATL ACAD SCI USA, V98, P1166, DOI 10.1073/pnas.98.3.1166; Whitacre CC, 1999, SCIENCE, V283, P1277, DOI 10.1126/science.283.5406.1277; Winkler B, 2015, EUR J NUTR, V54, P129, DOI 10.1007/s00394-014-0693-0; Wong KL, 2011, BLOOD, V118, pE15, DOI 10.1182/blood-2010-12-326355; XANTHOU M, 1970, ARCH DIS CHILD, V45, P242, DOI 10.1136/adc.45.240.242; Ziegler-Heitbrock L, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00023	63	22	22	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2017	139	6					1923	+		10.1016/j.jaci.2016.10.023	http://dx.doi.org/10.1016/j.jaci.2016.10.023			29	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EW7VG	27913304	Bronze			2022-12-18	WOS:000402724600023
J	Gabrion, A; Hmitou, I; Moshous, D; Neven, B; Lefevre-Utile, A; Diana, JS; Suarez, F; Picard, C; Blanche, S; Fischer, A; Cavazzana, M; Touzot, F				Gabrion, Aurelie; Hmitou, Isabelle; Moshous, Despina; Neven, Benedicte; Lefevre-Utile, Alain; Diana, Jean-Sebastien; Suarez, Felipe; Picard, Capucine; Blanche, Stephane; Fischer, Alain; Cavazzana, Marina; Touzot, Fabien			Mammalian target of rapamycin inhibition counterbalances the inflammatory status of immune cells in patients with chronic granulomatous disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chronic granulomatous disease; inflammatory manifestations; mammalian target of rapamycin inhibition; autophagy; inflammasome; IL-17A; IL-1 beta	HEMATOPOIETIC STEM-CELLS; DENDRITIC CELLS; ALPHA BLOCKADE; ROR-GAMMA; AUTOPHAGY; HYPERINFLAMMATION; DIFFERENTIATION; ACTIVATION; MICE; INTERLEUKIN-17	Background: Chronic granulomatous disease (CGD) is a primary immunodeficiency caused by defective production of reactive oxygen species in phagocytic cells that results in lifethreatening infections and severe inflammatory manifestations. The treatment of inflammatory manifestations remains challenging because it can be associated with an increased risk of infections. Previous studies have shown that phagocytes from patients with CGD display a defect in autophagy and a reactive oxygen species-independent activation of the inflammasome. Objective: Because the intersections between autophagy and the inflammasome have been observed in patients with various diseases and microbial infections, we investigated the possible benefit of restoring the autophagy defect through rapamycin, a potent autophagy inducer, in the setting of CGD. Methods: We studied 15 patients given a diagnosis of CGD and followed in our institution. All patients were free of any active infection at the time of the study. Results: We show that patients with CGD present a consistent inflammatory phenotype defined by (1) increased nonclassical and intermediate monocytes, (2) a proinflammatory state of mononuclear phagocytes with increased IL-1 beta and TNF-alpha content, (3) a T(H)17 bias of CD4(+) T cells, (4) and an increase in IL-17A-secreting neutrophil numbers. We document the reversion of CGD inflammatory status by the mammalian target of rapamycin inhibitor rapamycin on the different immune cell subsets. We also provide evidence for the enhancement of rapamycin's inhibitory effect on IL-1 beta secretion by the IL-1 receptor antagonist anakinra in phagocytes of patients with CGD. Conclusion: Altogether, these data open new therapeutic approaches for CGD-related inflammatory manifestations.	[Gabrion, Aurelie; Hmitou, Isabelle; Cavazzana, Marina; Touzot, Fabien] Necker Enfants Malad Hosp, AP HP, Biotherapy Dept, Paris, France; [Moshous, Despina; Neven, Benedicte; Lefevre-Utile, Alain; Diana, Jean-Sebastien; Blanche, Stephane; Fischer, Alain] Necker Enfants Malad Hosp, AP HP, Dept Pediat Immunol Hematol & Rheumatol, Paris, France; [Suarez, Felipe] Necker Enfants Malad Hosp, AP HP, Dept Hematol, Paris, France; [Picard, Capucine] Necker Enfants Malad Hosp, AP HP, Ctr Etud Deficits Immunitaires, Paris, France; [Moshous, Despina; Neven, Benedicte; Suarez, Felipe; Picard, Capucine; Blanche, Stephane; Fischer, Alain; Cavazzana, Marina; Touzot, Fabien] Univ Paris 05, Sorbonne Paris Cite, Inst Imagine, Paris, France; [Moshous, Despina; Neven, Benedicte; Suarez, Felipe; Picard, Capucine; Fischer, Alain; Cavazzana, Marina; Touzot, Fabien] INSERM, UMR 1163, Paris, France; [Fischer, Alain] Coll France, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; College de France	Touzot, F (corresponding author), Necker Enfants Malad Hosp, Biotherapy Dept, 149 Rue Sevres, F-75015 Paris, France.	fabien.touzot@aphp.fr	GABRION, AURELIE/K-1812-2017; Picard, Capucine/H-3914-2017; Touzot, Fabien/T-7797-2018; Moshous, Despina/B-7507-2017; Hmitou, Isabelle/H-8341-2017	GABRION, AURELIE/0000-0002-1885-2071; Picard, Capucine/0000-0001-8788-5056; Touzot, Fabien/0000-0002-0889-4905; Moshous, Despina/0000-0001-6719-3693; Hmitou, Isabelle/0000-0001-7320-6075; Cavazzana, Marina/0000-0002-0264-0891	Assistance Publique des Hopitaux de Paris (AP-HP); Net4CGD consortium	Assistance Publique des Hopitaux de Paris (AP-HP); Net4CGD consortium	Supported by the Assistance Publique des Hopitaux de Paris (AP-HP) and the Net4CGD consortium.	Abdelaziz DHA, 2015, IMMUNOL REV, V265, P194, DOI 10.1111/imr.12288; Cobbold SP, 2013, IMMUNOLOGY, V140, P391, DOI 10.1111/imm.12162; de Luca A, 2014, P NATL ACAD SCI USA, V111, P3526, DOI 10.1073/pnas.1322831111; Deffert C, 2012, J PATHOL, V228, P341, DOI 10.1002/path.4061; Deffert C, 2011, J ALLERGY CLIN IMMUN, V128, P675, DOI 10.1016/j.jaci.2011.04.028; Fleetwood AJ, 2007, J IMMUNOL, V178, P5245, DOI 10.4049/jimmunol.178.8.5245; Fujino S, 2003, GUT, V52, P65, DOI 10.1136/gut.52.1.65; Gaffen SL, 2014, NAT REV IMMUNOL, V14, P585, DOI 10.1038/nri3707; George-Chandy A, 2008, EUR J IMMUNOL, V38, P1118, DOI 10.1002/eji.200737348; Hahn KJ, 2015, AM J GASTROENTEROL, V110, P938, DOI 10.1038/ajg.2015.135; Holland SM, 2013, HEMATOL ONCOL CLIN N, V27, P89, DOI 10.1016/j.hoc.2012.11.002; Horvath R, 2011, CLIN EXP IMMUNOL, V166, P26, DOI 10.1111/j.1365-2249.2011.04449.x; Huang J, 2012, NAT MED, V18, P1778, DOI 10.1038/nm.2984; Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035; Kawai T, 2013, CLIN IMMUNOL, V147, P122, DOI 10.1016/j.clim.2013.03.004; Kim YC, 2015, J CLIN INVEST, V125, P25, DOI 10.1172/JCI73939; Kurebayashi Y, 2012, CELL REP, V1, P360, DOI 10.1016/j.celrep.2012.02.007; Luo Y, 2014, TRANSPLANTATION, V97, P20, DOI 10.1097/TP.0b013e3182a7fcf8; Magnani A, 2014, J ALLERGY CLIN IMMUN, V134, P655, DOI 10.1016/j.jaci.2014.04.014; Meissner F, 2010, BLOOD, V116, P1570, DOI 10.1182/blood-2010-01-264218; Mukherjee R, 2015, SCI REP-UK, V5, DOI 10.1038/srep13886; Rey-Giraud F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042656; Sasaki CY, 2016, EUR J IMMUNOL, V46, P212, DOI 10.1002/eji.201445422; Segal BH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009631; Sehgal SN, 2003, TRANSPLANT P, V35, p7S, DOI 10.1016/S0041-1345(03)00211-2; Shi CS, 2012, NAT IMMUNOL, V13, P255, DOI 10.1038/ni.2215; Taylor PR, 2014, NAT IMMUNOL, V15, P143, DOI 10.1038/ni.2797; Touzot M, 2015, AUTOIMMUN REV, V14, P370, DOI 10.1016/j.autrev.2014.12.009; Tzartos JS, 2008, AM J PATHOL, V172, P146, DOI 10.2353/ajpath.2008.070690; Urien S, 2013, BMC PHARMACOL TOXICO, V14, DOI 10.1186/2050-6511-14-40; Uzel G, 2010, CLIN INFECT DIS, V51, P1429, DOI 10.1086/657308; van de Veerdonk FL, 2014, AUTOPHAGY, V10, P1141, DOI 10.4161/auto.28638; van de Veerdonk FL, 2010, P NATL ACAD SCI USA, V107, P3030, DOI 10.1073/pnas.0914795107; Weisser M, 2016, J ALLERGY CLIN IMMUN, V138, P219, DOI 10.1016/j.jaci.2015.11.028; Ziegler-Heitbrock L, 2010, BLOOD, V116, pE74, DOI 10.1182/blood-2010-02-258558	35	22	22	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2017	139	5					1641	+		10.1016/j.jaci.2016.08.033	http://dx.doi.org/10.1016/j.jaci.2016.08.033			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ET7HI	27702670				2022-12-18	WOS:000400465300025
J	Avershina, E; Rubio, RC; Lundgard, K; Martinez, GP; Collado, MC; Storro, O; Oien, T; Dotterud, CK; Johnsen, R; Rudi, K				Avershina, Ekaterina; Cabrera Rubio, Raul; Lundgard, Krister; Perez Martinez, Gaspar; Carmen Collado, Maria; Storro, Ola; Oien, Torbjorn; Dotterud, Christian Kvikne; Johnsen, Roar; Rudi, Knut			Effect of probiotics in prevention of atopic dermatitis is dependent on the intrinsic microbiota at early infancy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							GAMMA-AMINOBUTYRIC-ACID; DISEASE; SUPPLEMENTATION; TRIAL; ONSET		[Avershina, Ekaterina; Lundgard, Krister; Rudi, Knut] Univ Life Sci, Dept Chem Biotechnol & Food Sci, As, Norway; [Cabrera Rubio, Raul; Perez Martinez, Gaspar; Carmen Collado, Maria] Spanish Natl Res Council, Inst Agrochem & Food Technol, Dept Biotechnol, Valencia, Spain; [Storro, Ola; Oien, Torbjorn; Dotterud, Christian Kvikne; Johnsen, Roar] Norwegian Univ Sci & Technol, Dept Publ Hlth & Gen Practice, Trondheim, Norway; [Dotterud, Christian Kvikne] St Olavs Hosp, Dept Dermatol, Trondheim, Norway	Norwegian University of Life Sciences; Consejo Superior de Investigaciones Cientificas (CSIC); Instituto de Agroquimica y Tecnologia de los Alimentos (IATA); Norwegian University of Science & Technology (NTNU); Norwegian University of Science & Technology (NTNU)	Rudi, K (corresponding author), Univ Life Sci, Dept Chem Biotechnol & Food Sci, As, Norway.	knut.rudi@nmbu.no	COLLADO, MARIA CARMEN/H-4924-2012; Avershina, Ekaterina/AAO-7779-2020; Martinez, Gaspar Perez/H-4167-2012; Rudi, Knut/AAZ-9858-2020	COLLADO, MARIA CARMEN/0000-0002-6204-4864; Avershina, Ekaterina/0000-0001-9935-2804; Martinez, Gaspar Perez/0000-0003-3501-1626; 	Norwegian University of Life Sciences; Norwegian University of Science and Technology; EEA Coordinated Mobility of Researchers NILS Science and Sustainability Project [017-CM-01-2013]	Norwegian University of Life Sciences; Norwegian University of Science and Technology; EEA Coordinated Mobility of Researchers NILS Science and Sustainability Project	We thank Norwegian University of Life Sciences and Norwegian University of Science and Technology for the financial support. Travels and stays in Spain and Norway for this study were supported by EEA Coordinated Mobility of Researchers NILS Science and Sustainability Project 017-CM-01-2013.	Andriantsoanirina V, 2013, ANAEROBE, V21, P39, DOI 10.1016/j.anaerobe.2013.04.005; Avershina E, 2016, ENVIRON MICROBIOL, V18, P2226, DOI 10.1111/1462-2920.13248; Barrett E, 2012, J APPL MICROBIOL, V113, P411, DOI 10.1111/j.1365-2672.2012.05344.x; Bieber T, 2010, ANN DERMATOL, V22, P125, DOI 10.5021/ad.2010.22.2.125; Burdette DL, 2011, NATURE, V478, P515, DOI 10.1038/nature10429; Chia J, 2016, J AM ACAD DERMATOL, V74, P186, DOI 10.1016/j.jaad.2015.10.007; Choi M, 2009, P NATL ACAD SCI USA, V106, P19096, DOI 10.1073/pnas.0910672106; Devenny A, 2004, BMJ-BRIT MED J, V329, P489, DOI 10.1136/bmj.38139.666447.F7; Dotterud CK, 2010, BRIT J DERMATOL, V163, P616, DOI 10.1111/j.1365-2133.2010.09889.x; Dotterud CK, 2015, J PEDIATR GASTR NUTR, V61, P200, DOI 10.1097/MPG.0000000000000781; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Hokazono H, 2010, BIOSCI BIOTECH BIOCH, V74, P135, DOI 10.1271/bbb.90653; Jeremiah N, 2014, J CLIN INVEST, V124, P5516, DOI 10.1172/JCI79100; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; Liu Y, 2014, NEW ENGL J MED, V371, P507, DOI 10.1056/NEJMoa1312625; Munoz J, 2015, JAMA DERMATOL, V151, P872, DOI 10.1001/jamadermatol.2015.0251; Panduru M, 2015, J EUR ACAD DERMATOL, V29, P232, DOI 10.1111/jdv.12496; Pelucchi C, 2012, EPIDEMIOLOGY, V23, P402, DOI 10.1097/EDE.0b013e31824d5da2; Prud'homme GJ, 2015, AUTOIMMUN REV, V14, P1048, DOI 10.1016/j.autrev.2015.07.011; Seo J, 2015, J HUM GENET, V60, P213, DOI 10.1038/jhg.2015.2; Sievers F, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.75; Spergel JM, 2010, ANN ALLERG ASTHMA IM, V105, P117; Spergel JM., 2010, ANN ALLERG ASTHMA IM, V105, P107; Spergel JM, 2010, ANN ALLERG ASTHMA IM, V105, P99, DOI 10.1016/j.anai.2009.10.002; Storro O, 2013, CURR OPIN ALLERGY CL, V13, P257, DOI 10.1097/ACI.0b013e328360968b; Wold AE, 1998, ALLERGY, V53, P20, DOI 10.1111/j.1398-9995.1998.tb04953.x; Yi GH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077846	27	22	23	3	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2017	139	4					1399	+		10.1016/j.jaci.2016.09.056	http://dx.doi.org/10.1016/j.jaci.2016.09.056			25	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ER4LR	27931973	Green Submitted, Bronze			2022-12-18	WOS:000398771800042
J	Goldberg, MR; Elizur, A; Nachshon, L; Appel, MY; Levy, MB; Golobov, K; Goldberg, R; Stein, M; Rothenberg, ME; Katz, Y				Goldberg, Michael R.; Elizur, Arnon; Nachshon, Liat; Appel, Michael Y.; Levy, Michael B.; Golobov, Keren; Goldberg, Robert; Stein, Miguel; Rothenberg, Marc E.; Katz, Yitzhak			Oral immunotherapy-induced gastrointestinal symptoms and peripheral blood eosinophil responses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							NONSEDATING H1-ANTIHISTAMINES; ESOPHAGITIS; CLASSIFICATION; URTICARIA; OUTCOMES; DISEASE; DIET		[Goldberg, Michael R.; Elizur, Arnon; Nachshon, Liat; Appel, Michael Y.; Levy, Michael B.; Golobov, Keren; Katz, Yitzhak] Assaf Harofeh Med Ctr, Allergy Immunol & Pediat Pulm Inst, Zerifin, Israel; [Elizur, Arnon; Katz, Yitzhak] Tel Aviv Univ, Sackler Fac Med, Dept Pediat, Tel Aviv, Israel; [Goldberg, Robert] CUNY, Dept Comp Sci, New York, NY 10021 USA; [Stein, Miguel] E Wolfson Med Ctr, Allergy & Immunol Unit, Holon, Israel; [Rothenberg, Marc E.] Cincinnati Childrens Hosp Med Ctr, Div Allergy & Immunol, Cincinnati, OH 45229 USA	Shamir Medical Center (Assaf Harofeh); Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine; City University of New York (CUNY) System; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Goldberg, MR (corresponding author), Assaf Harofeh Med Ctr, Allergy Immunol & Pediat Pulm Inst, Zerifin, Israel.	goldbergsm@yahoo.com		Elizur, Arnon/0000-0001-8157-8143; Katz, Yitzhak/0000-0002-4255-1244; Appel, Michael/0000-0002-9089-9472	Kamea grant from the Ministry of Health, Israel; Leon Alcalay Chair in Pediatric Immunology, Tel Aviv University	Kamea grant from the Ministry of Health, Israel; Leon Alcalay Chair in Pediatric Immunology, Tel Aviv University	M.R.G. is funded by a Kamea grant from the Ministry of Health, Israel. Y.K. is supported by the Leon Alcalay Chair in Pediatric Immunology, Tel Aviv University.	Akoglu G, 2012, ARCH DERMATOL RES, V304, P257, DOI 10.1007/s00403-011-1203-3; Caldwell JM, 2014, J ALLERGY CLIN IMMUN, V134, P1114, DOI 10.1016/j.jaci.2014.07.026; Gimenez-Arnau A, 2009, J EUR ACAD DERMATOL, V23, P1088, DOI 10.1111/j.1468-3083.2009.03289.x; Gonsalves N, 2012, GASTROENTEROLOGY, V142, P1451, DOI 10.1053/j.gastro.2012.03.001; Guo AY, 2015, ARCH DERMATOL RES, V307, P183, DOI 10.1007/s00403-014-1525-z; Kapel RC, 2008, GASTROENTEROLOGY, V134, P1316, DOI 10.1053/j.gastro.2008.02.016; Konikoff MR, 2006, CLIN GASTROENTEROL H, V4, P1328, DOI 10.1016/j.cgh.2006.08.013; Levy MB, 2014, ANN ALLERG ASTHMA IM, V112, P58, DOI 10.1016/j.anai.2013.10.001; Liacouras CA, 2014, GASTROENTEROL CLIN N, V43, P219, DOI 10.1016/j.gtc.2014.02.012; Lucendo AJ, 2014, ANN ALLERG ASTHMA IM, V113, P624, DOI 10.1016/j.anai.2014.08.004; Mlynek A, 2008, ALLERGY, V63, P777, DOI 10.1111/j.1398-9995.2008.01726.x; Nachshon L, 2015, ANN ALLERG ASTHMA IM, V114, P510, DOI 10.1016/j.anai.2015.04.007; Stein ML, 2012, J ALLERGY CLIN IMMUN, V129, pAB29, DOI 10.1016/j.jaci.2011.12.769; Yan SY, 2014, J DERMATOL SCI, V76, P240, DOI 10.1016/j.jdermsci.2014.09.012; YOUDEN WJ, 1950, CANCER-AM CANCER SOC, V3, P32, DOI 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3; Zuberbier T, 2009, ALLERGY, V64, P1417, DOI 10.1111/j.1398-9995.2009.02179.x	16	22	22	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2017	139	4					1388	+		10.1016/j.jaci.2016.09.053	http://dx.doi.org/10.1016/j.jaci.2016.09.053			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ER4LR	27913305	Bronze			2022-12-18	WOS:000398771800038
J	Matsuki, A; Takatori, H; Makita, S; Yokota, M; Tamachi, T; Suto, A; Suzuki, K; Hirose, K; Nakajima, H				Matsuki, Ayako; Takatori, Hiroaki; Makita, Sohei; Yokota, Masaya; Tamachi, Tomohiro; Suto, Akira; Suzuki, Kotaro; Hirose, Koichi; Nakajima, Hiroshi			T-bet inhibits innate lymphoid cell-mediated eosinophilic airway inflammation by suppressing IL-9 production	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						T-bet; innate lymphoid cells; IL-9; eosinophils	TRANSCRIPTION FACTOR; INTERFERON-GAMMA; ASTHMA; DIFFERENTIATION; FATE; MAINTENANCE; INDUCTION; PROMOTES; ALPHA; T(H)2	Background: Innate lymphoid cells (ILCs) are emerging subsets of immune cells that produce large amounts of cytokines upon cytokine and/or alarmin stimulation. Recent studies have shown that T-bet plays pivotal roles in the development of ILC3s and type 1 ILCs; however, the roles of T-bet in lung type 2 innate lymphoid cells (ILC2s) remain unknown. Objective: We sought to determine the role of T-bet in ILC2-mediated airway inflammation. Methods: The expression of T-bet in lung ILCs (defined as Thy1.2(+) Lin(-) cells) was examined. The roles of T-bet in the development of lung ILC2s and airway inflammation induced by IL-33 administration were examined by using T-bet-deficient (T-bet(-/-)) mice. Gene expression profiles of T-bet(-/-) lung ILCs were analyzed by RNA sequencing. Results: T-bet was expressed in lung ILC2s (defined as Thy1.2(+) Lin(-) cells expressing ST2 or CD25) and IFN-gamma enhanced its expression. Although the development of lung ILC2s at steady-state conditions was normal in T-bet(-/-) mice, IL-33-induced accumulation of lung ILC2s and eosinophilic airway inflammation were exacerbated in T-bet(-/-) mice. The exacerbated accumulation of ILC2s and eosinophilic airway inflammation by the absence of T-bet were evident even in a RAG2(-/-) background, suggesting that T-bet expressed in non-T/non-B population is involved in the suppression of IL-33-induced eosinophilic airway inflammation. Transcriptome analysis revealed that IL-9 expression in IL-33-stimulated lung ILCs was upregulated in T-bet(-/-) mice compared with that in wild-type mice. Importantly, neutralization of IL-9 markedly attenuated IL-33-induced accumulation of lung ILC2s and eosinophilic inflammation in T-bet(-/-) mice. Conclusions: T-bet suppresses IL-9 production from lung ILC2s and thereby inhibits IL-33-induced eosinophilic airway inflammation.	[Matsuki, Ayako; Takatori, Hiroaki; Makita, Sohei; Yokota, Masaya; Tamachi, Tomohiro; Suto, Akira; Suzuki, Kotaro; Hirose, Koichi; Nakajima, Hiroshi] Chiba Univ, Grad Sch Med, Dept Allergy & Clin Immunol, 1-8-1 Inohana, Chiba, Chiba 2608670, Japan	Chiba University	Takatori, H (corresponding author), Chiba Univ, Grad Sch Med, Dept Allergy & Clin Immunol, 1-8-1 Inohana, Chiba, Chiba 2608670, Japan.	takatorih@faculty.chiba-u.jp; nakajimh@faculty.chiba-u.jp	Nakajima, Hiroshi/AFU-9313-2022; Hirose, Koichi/I-1506-2017; Tamachi, Tomohiro/I-1468-2017	Nakajima, Hiroshi/0000-0001-8595-9381; Hirose, Koichi/0000-0001-7498-9630; Tamachi, Tomohiro/0000-0001-8295-1472; Suto, Akira/0000-0002-2593-565X	Ministry of Education, Culture, Sports, Science and Technology (MEXT) [WG24390207, G26461486]; LGS (Leading Graduate School at Chiba University) Program, MEXT, Japan; Takeda Science Foundation, Japan; Grants-in-Aid for Scientific Research [26461184] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science and Technology (MEXT)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); LGS (Leading Graduate School at Chiba University) Program, MEXT, Japan; Takeda Science Foundation, Japan(Takeda Science Foundation (TSF)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported in part by Grants-in-Aids for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology (MEXT, WG24390207, G26461486), the LGS (Leading Graduate School at Chiba University) Program, MEXT, Japan, and the Takeda Science Foundation, Japan.	Barlow JL, 2012, J ALLERGY CLIN IMMUN, V129, P191, DOI 10.1016/j.jaci.2011.09.041; Chang HC, 2010, NAT IMMUNOL, V11, P527, DOI 10.1038/ni.1867; Djuretic IM, 2007, NAT IMMUNOL, V8, P145, DOI 10.1038/ni1424; Duerr CU, 2016, NAT IMMUNOL, V17, P65, DOI 10.1038/ni.3308; Ermann J, 2014, P NATL ACAD SCI USA, V111, pE2559, DOI 10.1073/pnas.1408540111; Finotto S, 2002, SCIENCE, V295, P336, DOI 10.1126/science.1065544; Fujiwara M, 2007, J ALLERGY CLIN IMMUN, V119, P662, DOI 10.1016/j.jaci.2006.12.643; Halim TYF, 2014, IMMUNITY, V40, P425, DOI 10.1016/j.immuni.2014.01.011; Halim TYF, 2012, IMMUNITY, V37, P463, DOI 10.1016/j.immuni.2012.06.012; Halim TYF, 2012, IMMUNITY, V36, P451, DOI 10.1016/j.immuni.2011.12.020; Hoyler T, 2012, IMMUNITY, V37, P634, DOI 10.1016/j.immuni.2012.06.020; Jabeen R, 2013, J CLIN INVEST, V123, P4641, DOI 10.1172/JCI69489; Kadota K, 2009, ALGORITHM MOL BIOL, V4, DOI 10.1186/1748-7188-4-7; Kim BS, 2013, CURR OPIN IMMUNOL, V25, P738, DOI 10.1016/j.coi.2013.07.013; Klose CSN, 2013, NATURE, V494, P261, DOI 10.1038/nature11813; Kudo F, 2016, IMMUNOLOGY, V147, P21, DOI 10.1111/imm.12537; Lambrecht BN, 2015, NAT IMMUNOL, V16, P45, DOI 10.1038/ni.3049; Lazarevic V, 2011, NAT IMMUNOL, V12, P597, DOI 10.1038/ni.2059; Licona-Limon P, 2013, NAT IMMUNOL, V14, P536, DOI 10.1038/ni.2617; Lighvani AA, 2001, P NATL ACAD SCI USA, V98, P15137, DOI 10.1073/pnas.261570598; Mirchandani AS, 2014, J IMMUNOL, V192, P2442, DOI 10.4049/jimmunol.1300974; Mohapatra A, 2016, MUCOSAL IMMUNOL, V9, P275, DOI 10.1038/mi.2015.59; Molofsky AB, 2015, IMMUNITY, V43, P161, DOI 10.1016/j.immuni.2015.05.019; Monticelli LA, 2011, NAT IMMUNOL, V12, P1045, DOI [10.1031/ni.2131, 10.1038/ni.2131]; Morita H, 2015, IMMUNITY, V43, P175, DOI 10.1016/j.immuni.2015.06.021; Moro K, 2016, NAT IMMUNOL, V17, P76, DOI 10.1038/ni.3309; Munthe-Kaas MC, 2008, J ALLERGY CLIN IMMUN, V121, P51, DOI 10.1016/j.jaci.2007.07.068; Neill DR, 2010, NATURE, V464, P1367, DOI 10.1038/nature08900; Possot C, 2011, NAT IMMUNOL, V12, P949, DOI 10.1038/ni.2105; Powell N, 2012, IMMUNITY, V37, P674, DOI 10.1016/j.immuni.2012.09.008; Raby BA, 2006, AM J RESP CRIT CARE, V173, P64, DOI 10.1164/rccm.200503-505OC; Rankin LC, 2013, NAT IMMUNOL, V14, P389, DOI 10.1038/ni.2545; Sanos SL, 2011, IMMUNOLOGY, V132, P453, DOI 10.1111/j.1365-2567.2011.03410.x; Sciume G, 2012, J EXP MED, V209, P2331, DOI 10.1084/jem.20122097; Serafini N, 2014, J EXP MED, V211, P199, DOI 10.1084/jem.20131038; Spits H, 2013, NAT REV IMMUNOL, V13, P145, DOI 10.1038/nri3365; Spits H, 2012, ANNU REV IMMUNOL, V30, P647, DOI 10.1146/annurev-immunol-020711-075053; Staudt V, 2010, IMMUNITY, V33, P192, DOI 10.1016/j.immuni.2010.07.014; Suttner K, 2009, J ALLERGY CLIN IMMUN, V123, P1062, DOI 10.1016/j.jaci.2009.02.025; Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3; Takatori H, 2005, J IMMUNOL, V174, P3734, DOI 10.4049/jimmunol.174.6.3734; Takatori H, 2009, J EXP MED, V206, P35, DOI 10.1084/jem.20072713; Tanaka S, 2014, J EXP MED, V211, P1857, DOI 10.1084/jem.20130791; Tantisira KG, 2004, P NATL ACAD SCI USA, V101, P18099, DOI 10.1073/pnas.0408532102; Turner JE, 2013, J EXP MED, V210, P2951, DOI 10.1084/jem.20130071; Veldhoen M, 2008, NAT IMMUNOL, V9, P1341, DOI 10.1038/ni.1659; Wilhelm C, 2011, NAT IMMUNOL, V12, P1071, DOI 10.1038/ni.2133; Wolterink RGJK, 2013, P NATL ACAD SCI USA, V110, P10240, DOI 10.1073/pnas.1217158110; Wolterink RGJK, 2012, EUR J IMMUNOL, V42, P1106, DOI 10.1002/eji.201142018; Wong SH, 2012, NAT IMMUNOL, V13, P229, DOI 10.1038/ni.2208; Yang Q, 2013, IMMUNITY, V38, P694, DOI 10.1016/j.immuni.2012.12.003; Yang XXO, 2013, NAT IMMUNOL, V14, P732, DOI 10.1038/ni.2633; Yu S, 2014, J ALLERGY CLIN IMMUN, V133, P943, DOI 10.1016/j.jaci.2014.02.015; Zhu JF, 2012, IMMUNITY, V37, P660, DOI 10.1016/j.immuni.2012.09.007	54	22	23	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2017	139	4					1355	+		10.1016/j.jaci.2016.08.022	http://dx.doi.org/10.1016/j.jaci.2016.08.022			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ER4LR	27670243				2022-12-18	WOS:000398771800030
J	Gudmundsdottir, J; Oskarsdottir, S; Skogberg, G; Lindgren, S; Lundberg, V; Berglund, M; Lundell, AC; Berggren, H; Fasth, A; Telemo, E; Ekwall, O				Gudmundsdottir, Judith; Oskarsdottir, Solveig; Skogberg, Gabriel; Lindgren, Susanne; Lundberg, Vanja; Berglund, Martin; Lundell, Anna-Carin; Berggren, Hakan; Fasth, Anders; Telemo, Esbjorn; Ekwall, Olov			Early thymectomy leads to premature immunologic ageing: An 18-year follow-up	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							T-CELL COMPARTMENT; NEONATAL THYMECTOMY; SUBSETS; VIRUS; PCR		[Gudmundsdottir, Judith; Skogberg, Gabriel; Lindgren, Susanne; Lundberg, Vanja; Berglund, Martin; Lundell, Anna-Carin; Telemo, Esbjorn; Ekwall, Olov] Univ Gothenburg, Sahlgrenska Acad, Inst Med, Dept Rheumatol & Inflammat Res, Gothenburg, Sweden; [Gudmundsdottir, Judith; Oskarsdottir, Solveig; Lindgren, Susanne; Lundberg, Vanja; Fasth, Anders; Ekwall, Olov] Univ Gothenburg, Sahlgrenska Acad, Inst Clin Sci, Dept Pediat, Gothenburg, Sweden; [Berggren, Hakan] Univ Gothenburg, Sahlgrenska Acad, Inst Med, Dept Mol & Clin Med, Gothenburg, Sweden; [Skogberg, Gabriel] AstraZeneca, Dept Biosci Resp Inflammat & Autoimmun IMED, Gothenburg, Sweden	University of Gothenburg; University of Gothenburg; University of Gothenburg; AstraZeneca	Skogberg, G (corresponding author), Univ Gothenburg, Sahlgrenska Acad, Inst Med, Dept Rheumatol & Inflammat Res, Gothenburg, Sweden.; Skogberg, G (corresponding author), AstraZeneca, Dept Biosci Resp Inflammat & Autoimmun IMED, Gothenburg, Sweden.	judith.gudmundsdottir@gu.se	Fasth, Anders/I-1109-2019	Fasth, Anders/0000-0002-0033-740X; Ekwall, Olov/0000-0002-4506-9955				Abernathy E, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-32; Cawthon RM, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.10.e47; Hummel KB, 2006, J VIROL METHODS, V132, P166, DOI 10.1016/j.jviromet.2005.10.006; Kimmig S, 2002, J EXP MED, V195, P789, DOI 10.1084/jem.20011756; Miyara M, 2009, IMMUNITY, V30, P899, DOI 10.1016/j.immuni.2009.03.019; Namuwulya P, 2014, J MED VIROL, V86, P2107, DOI 10.1002/jmv.23935; Perelygina L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133267; Perelygina L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073014; Prelog M, 2009, CLIN IMMUNOL, V130, P123, DOI 10.1016/j.clim.2008.08.023; Rota JS, 2013, CLIN VACCINE IMMUNOL, V20, P391, DOI 10.1128/CVI.00660-12; Schadenberg AWL, 2014, J ALLERGY CLIN IMMUN, V133, P277, DOI 10.1016/j.jaci.2013.08.030; Schatorje EJH, 2012, SCAND J IMMUNOL, V75, P436, DOI 10.1111/j.1365-3083.2012.02671.x; van den Broek T, 2016, J CLIN INVEST, V126, P1126, DOI 10.1172/JCI84997; van Gent R, 2011, BLOOD, V118, P627, DOI 10.1182/blood-2011-03-341396; WEI S, 1994, IMMUNOGENETICS, V40, P27, DOI 10.1007/BF00163961	15	22	22	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2016	138	5					1439	+		10.1016/j.jaci.2016.05.014	http://dx.doi.org/10.1016/j.jaci.2016.05.014			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EE4AA	27397107				2022-12-18	WOS:000389542700026
J	Hector, A; Chotirmall, SH; Lavelle, GM; Mirkovic, B; Horan, D; Eichler, L; Mezger, M; Singh, A; Ralhan, A; Berenbrinker, S; Mack, I; Ensenauer, R; Riethmuller, J; Graepler-Mainka, U; Murray, MA; Griese, M; McElvaney, NG; Hartl, D				Hector, Andreas; Chotirmall, Sanjay H.; Lavelle, Gillian M.; Mirkovic, Bojana; Horan, Deirdre; Eichler, Laura; Mezger, Markus; Singh, Anurag; Ralhan, Anjai; Berenbrinker, Sina; Mack, Ines; Ensenauer, Regina; Riethmueller, Joachim; Graepler-Mainka, Ute; Murray, Michelle A.; Griese, Matthias; McElvaney, N. Gerry; Hartl, Dominik			Chitinase activation in patients with fungus-associated cystic fibrosis lung disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Cystic fibrosis; lung disease; chitinases; chitotriosidase; fungi; Candida species; neutrophils; proteases	PHAGOCYTE-SPECIFIC CHITOTRIOSIDASE; OBSTRUCTIVE PULMONARY-DISEASE; ACIDIC MAMMALIAN CHITINASE; CIGARETTE-SMOKE; INNATE IMMUNITY; INFLAMMATION; NEUTROPHILS; PATHOGENESIS; CFTR; EXPRESSION	Background: Chitinases have recently gained attention in the field of pulmonary diseases, particularly in asthma and chronic obstructive pulmonary disease, but their potential role in patients with cystic fibrosis (CF)-associated lung disease remains unclear. Objective: The aim of this study was to assess chitinase activity systemically and in the airways of patients with CF and asthma compared with healthy subjects. Additionally, we assessed factors that regulate chitinase activity within the lungs of patients with CF. Methods: Chitinase activities were quantified in serum and bronchoalveolar lavage fluid from patients with CF, asthmatic patients, and healthy control subjects. Mechanistically, the role of CF airway proteases and genetic chitinase deficiency was assessed. Results: Chitinase activity was systemically increased in patients with CF compared with that in healthy control subjects and asthmatic patients. Further stratification showed that chitinase activity was enhanced in patients with CF colonized with Candida albicans compared with that in noncolonized patients. CF proteases degraded chitinases in the airway microenvironment of patients with CF. Genetic chitinase deficiency was associated with C albicans colonization in patients with CF. Conclusion: Patients with CF have enhanced chitinase activation associated with C albicans colonization. Therefore chitinases might represent a novel biomarker and therapeutic target for CF-associated fungal disease.	[Hector, Andreas; Eichler, Laura; Mezger, Markus; Singh, Anurag; Ralhan, Anjai; Berenbrinker, Sina; Riethmueller, Joachim; Graepler-Mainka, Ute; Hartl, Dominik] Univ Tubingen, Childrens Hosp, CF Ctr, Tubingen, Germany; [Chotirmall, Sanjay H.] Nanyang Technol Univ, Lee Kong Chian Sch Med, Singapore, Singapore; [Lavelle, Gillian M.; Mirkovic, Bojana; Horan, Deirdre; Murray, Michelle A.; McElvaney, N. Gerry] Royal Coll Surgeons Ireland, Dept Med, Resp Res Div, Dublin, Ireland; [Mack, Ines] Univ Basel, Dept Paediat, CH-4003 Basel, Switzerland; [Ensenauer, Regina] Univ Dusseldorf, Univ Childrens Hosp, Dept Gen Pediat Neonatol & Pediat Cardiol, Expt Pediat, Dusseldorf, Germany; [Ensenauer, Regina] Univ Munich, Res Ctr, Dr von Hauner Childrens Hosp, Munich, Germany; [Griese, Matthias] Univ Munich, Dr von Hauner Childrens Hosp, Munich, Germany; [Griese, Matthias] German Ctr Lung, Comprehens Pneumol Ctr Munich, Munich, Germany	Eberhard Karls University of Tubingen; TUBINGEN UNIVERSITY CHILDRENS HOSPITAL; Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; Royal College of Surgeons - Ireland; University of Basel; Heinrich Heine University Dusseldorf; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Munich; University of Munich	Hartl, D (corresponding author), Univ Tubingen, Childrens Hosp, Tubingen, Germany.; Hartl, D (corresponding author), Univ Tubingen, Interdisciplinary Ctr Infect Dis, Tubingen, Germany.	dominik.hartl@med.uni-tuebingen.de	Chotirmall, Sanjay Haresh/K-4127-2015; McElvaney, Noel/A-6809-2010	Chotirmall, Sanjay Haresh/0000-0003-0417-7607; Murray, Michelle/0000-0003-3730-8765; mcelvaney, Noel/0000-0002-0152-4370; Singh, Anurag/0000-0002-9370-1038; Mezger, Markus/0000-0002-0211-2343; Hector, Andreas/0000-0002-5745-4746	German Research Foundation (DFG) [HA 5274/3-1]; Fritz-Thyssen Foundation at Tubingen [CRC685]; Novartis Foundation; Asian-Pacific Society of Respirology Annual Meeting, Malaysia; Cystic Fibrosis Foundation	German Research Foundation (DFG)(German Research Foundation (DFG)); Fritz-Thyssen Foundation at Tubingen; Novartis Foundation(Novartis); Asian-Pacific Society of Respirology Annual Meeting, Malaysia; Cystic Fibrosis Foundation(Italian Cystic Fibrosis Research Foundation)	Supported by the German Research Foundation (DFG, Emmy Noether Programme HA 5274/3-1 to D.H.), the Fritz-Thyssen Foundation (to A.H. and D.H.) the CRC685 at Tubingen, and the Novartis Foundation (to D.H.).; Disclosure of potential conflict of interest: S.H. Chotirmall has received travel support from the Asian-Pacific Society of Respirology Annual Meeting 2015, Malaysia. G.M. Lavelle has received travel support from the Cystic Fibrosis Foundation. The rest of the authors declare that they have no relevant conflicts of interest.	Aerts JM, 2008, ACTA PAEDIATR, V97, P7, DOI 10.1111/j.1651-2227.2007.00641.x; American Thoracic Society, 1995, AM J RESP CRIT CARE, V152, P1107; BOOT RG, 1995, J BIOL CHEM, V270, P26252, DOI 10.1074/jbc.270.44.26252; Boot RG, 2001, J BIOL CHEM, V276, P6770, DOI 10.1074/jbc.M009886200; Boot RG, 1998, J BIOL CHEM, V273, P25680, DOI 10.1074/jbc.273.40.25680; Cantin AM, 2015, J CYST FIBROS, V14, P419, DOI 10.1016/j.jcf.2015.03.003; Cho SJ, 2015, ALLERGY ASTHMA IMMUN, V7, P14, DOI 10.4168/aair.2015.7.1.14; Chotirmall SH, 2014, INT J BIOCHEM CELL B, V52, P161, DOI 10.1016/j.biocel.2014.03.001; Chotirmall SH, 2010, CHEST, V138, P1186, DOI 10.1378/chest.09-2996; Elias JA, 2005, J ALLERGY CLIN IMMUN, V116, P497, DOI 10.1016/j.jaci.2005.06.028; Geraghty P, 2008, THORAX, V63, P621, DOI 10.1136/thx.2007.088559; Griese M, 2007, EUR RESPIR J, V29, P240, DOI 10.1183/09031936.00047306; Hartl D, 2012, J CYST FIBROS, V11, P363, DOI 10.1016/j.jcf.2012.07.003; Hartl D, 2006, J ALLERGY CLIN IMMUN, V117, P204, DOI 10.1016/j.jaci.2005.09.023; Hartl D, 2007, NAT MED, V13, P1423, DOI 10.1038/nm1690; Hartl D, 2009, CURR OPIN ALLERGY CL, V9, P60, DOI 10.1097/ACI.0b013e32831f8ee0; Hector A, 2013, AM J RESP CELL MOL, V48, P71, DOI 10.1165/rcmb.2012-0061OC; Hector A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024399; James AJ, 2016, AM J RESP CRIT CARE, V193, P131, DOI 10.1164/rccm.201504-0760OC; Kormann MSD, 2012, EUR RESPIR J, V39, P1385, DOI 10.1183/09031936.00130011; Lee CG, 2012, J IMMUNOL, V189, P2635, DOI 10.4049/jimmunol.1201115; Lee CG, 2011, ANNU REV PHYSIOL, V73, P479, DOI 10.1146/annurev-physiol-012110-142250; Lee CG, 2009, J EXP MED, V206, P1149, DOI 10.1084/jem.20081271; Lee CG, 2008, CURR OPIN IMMUNOL, V20, P684, DOI 10.1016/j.coi.2008.10.002; Letuve S, 2010, AM J PATHOL, V176, P638, DOI 10.2353/ajpath.2010.090455; Mall MA, 2014, EUR RESPIR J, V44, P1042, DOI 10.1183/09031936.00228013; Painter RG, 2008, J LEUKOCYTE BIOL, V83, P1345, DOI 10.1189/jlb.0907658; Painter RG, 2006, BIOCHEMISTRY-US, V45, P10260, DOI 10.1021/bi060490t; Rab A, 2013, AM J PHYSIOL-LUNG C, V305, pL530, DOI 10.1152/ajplung.00039.2013; Raju SV, 2013, AM J RESP CRIT CARE, V188, P1321, DOI 10.1164/rccm.201304-0733OC; Ratjen FA, 2009, RESP CARE, V54, P595, DOI 10.4187/aarc0427; Renkema GH, 1998, EUR J BIOCHEM, V251, P504, DOI 10.1046/j.1432-1327.1998.2510504.x; Sasieni PD, 1997, BIOMETRICS, V53, P1253, DOI 10.2307/2533494; Schoonhoven A, 2007, CLIN CHIM ACTA, V381, P136, DOI 10.1016/j.cca.2007.02.042; Seibold MA, 2008, J ALLERGY CLIN IMMUN, V122, P944, DOI 10.1016/j.jaci.2008.08.023; Sly PD, 2013, NEW ENGL J MED, V368, P1963, DOI 10.1056/NEJMoa1301725; Stoltz DA, 2015, NEW ENGL J MED, V372, P351, DOI 10.1056/NEJMra1300109; Tirouvanziam R, 2008, P NATL ACAD SCI USA, V105, P4335, DOI 10.1073/pnas.0712386105; Tirouvanziam R, 2006, DRUG NEWS PERSPECT, V19, P609, DOI 10.1358/dnp.2006.19.10.1068008; van Eijk M, 2005, INT IMMUNOL, V17, P1505, DOI 10.1093/intimm/dxh328; van Eijk M, 2007, FEBS LETT, V581, P5389, DOI 10.1016/j.febslet.2007.10.039; van Eijk M, 2010, FEBS LETT, V584, P3165, DOI 10.1016/j.febslet.2010.06.001; Vandevenne M, 2011, PROTEIN SCI, V20, P1451, DOI 10.1002/pro.676; Zhu Z, 2004, SCIENCE, V304, P1678, DOI 10.1126/science.1095336	44	22	22	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2016	138	4					1183	+		10.1016/j.jaci.2016.01.031	http://dx.doi.org/10.1016/j.jaci.2016.01.031			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DZ0AP	27056270	Bronze			2022-12-18	WOS:000385499400024
J	Oyoshi, MK; Venturelli, N; Geha, RS				Oyoshi, Michiko K.; Venturelli, Nicholas; Geha, Raif S.			Thymic stromal lymphopoietin and IL-33 promote skin inflammation and vaccinia virus replication in a mouse model of atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							GENOMEWIDE ASSOCIATION; ADULT ASTHMA; GENE; POLYMORPHISM; CELLS		[Geha, Raif S.] Harvard Med Sch, Boston Childrens Hosp, Div Immunol, Boston, MA 02115 USA; Harvard Med Sch, Dept Pediat, Boston, MA USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School	Geha, RS (corresponding author), Harvard Med Sch, Boston Childrens Hosp, Div Immunol, Boston, MA 02115 USA.	raif.geha@childrens.harvard.edu			NIAID NIH HHS [U19 AI117673, HHSN272201000020C, N01AI40030, HHSN272201000020I, U01 AI147462] Funding Source: Medline; NIDDK NIH HHS [P30 DK034854] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI117673] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034854] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Dimas AS, 2009, SCIENCE, V325, P1246, DOI 10.1126/science.1174148; Engler RJM, 2002, J ALLERGY CLIN IMMUN, V110, P357, DOI 10.1067/mai.2002.128052; Gao PS, 2010, J ALLERGY CLIN IMMUN, V125, P1403, DOI 10.1016/j.jaci.2010.03.016; Grundberg E, 2012, NAT GENET, V44, P1084, DOI 10.1038/ng.2394; Hammad H, 2015, IMMUNITY, V43, P29, DOI 10.1016/j.immuni.2015.07.007; Harada M, 2009, AM J RESP CRIT CARE, V180, P1048, DOI 10.1164/rccm.200905-0652OC; He R, 2008, P NATL ACAD SCI USA, V105, P11875, DOI 10.1073/pnas.0801532105; Hijikata M, 2011, HUM GENET, V129, P117, DOI 10.1007/s00439-010-0906-4; Hirota T, 2011, NAT GENET, V43, P893, DOI 10.1038/ng.887; Hizawa N, 2002, AM J RESP CRIT CARE, V166, P686, DOI 10.1164/rccm.200202-090OC; Howell MD, 2006, IMMUNITY, V24, P341, DOI 10.1016/j.immuni.2006.02.006; Keicho N, 2011, RESPIROLOGY, V16, P581, DOI 10.1111/j.1440-1843.2011.01946.x; Li Y, 2009, ANNU REV GENOM HUM G, V10, P387, DOI 10.1146/annurev.genom.9.081307.164242; Masuko H, 2011, INT J CHRONIC OBSTR, V6, P181, DOI 10.2147/COPD.S16383; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Morita H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134226; Nishimura M, 2012, AM J RESP CRIT CARE, V185, P44, DOI 10.1164/rccm.201106-0992OC; Noguchi E, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002170; Oyoshi MK, 2011, J ALLERGY CLIN IMMUN, V128, P890, DOI 10.1016/j.jaci.2011.06.042; Oyoshi MK, 2009, P NATL ACAD SCI USA, V106, P14954, DOI 10.1073/pnas.0904021106; Paul WE, 2010, NAT REV IMMUNOL, V10, P225, DOI 10.1038/nri2735; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Stranger BE, 2012, PLOS GENET, V8, P272, DOI 10.1371/journal.pgen.1002639; Taniguchi N, 2013, ANN ALLERG ASTHMA IM, V111, P376, DOI 10.1016/j.anai.2013.08.005; Vestbo J, 2013, AM J RESP CRIT CARE, V187, P347, DOI 10.1164/rccm.201204-0596PP; Xu R, 2004, J IMMUNOL, V172, P6265, DOI 10.4049/jimmunol.172.10.6265; Yang TP, 2010, BIOINFORMATICS, V26, P2474, DOI 10.1093/bioinformatics/btq452; Yatagai Y, 2014, CLIN EXP ALLERGY, V44, P1327, DOI 10.1111/cea.12415	28	22	25	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2016	138	1					283	286		10.1016/j.jaci.2015.12.1304	http://dx.doi.org/10.1016/j.jaci.2015.12.1304			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DR1IL	26830114	Green Accepted, Bronze			2022-12-18	WOS:000379659100032
J	Akdis, CA; Ballas, ZK				Akdis, Cezmi A.; Ballas, Zuhair K.			Precision medicine and precision health: Building blocks to foster a revolutionary health care model	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Allergy; asthma; personalized medicine; biomarkers; phenotypes; endotypes	CLINICAL IMMUNOLOGY; PRACTALL DOCUMENT; AMERICAN ACADEMY; EUROPEAN ACADEMY; ASTHMA; BIOMARKERS; ALLERGY; ENDOTYPES; DISEASES		[Akdis, Cezmi A.] Univ Zurich, Swiss Inst Allergy & Asthma Res, Christine Kuhne Ctr Allergy Res & Educ, CH-7270 Davos, Switzerland; [Ballas, Zuhair K.] Univ Iowa, Internal Med, Iowa City, IA USA; [Ballas, Zuhair K.] Iowa City VA Med Ctr, Iowa City, IA USA	Swiss Institute of Allergy & Asthma Research; University of Zurich; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System	Akdis, CA (corresponding author), Univ Zurich, Swiss Inst Allergy & Asthma Res, Christine Kuhne Ctr Allergy Res & Educ, CH-7270 Davos, Switzerland.	akdisac@siaf.uzh.ch	Akdis, Cezmi/AAV-4844-2020	Akdis, Cezmi/0000-0001-8020-019X; Knaack, Aaron/0000-0001-7712-1415; Ballas, Zuhair/0000-0001-5569-1230				Akdis CA, 2013, J ALLERGY CLIN IMMUN, V131, P1479, DOI 10.1016/j.jaci.2013.02.036; Alcais A, 2009, J CLIN INVEST, V119, P2506, DOI 10.1172/JCI38111; Anderson WC, 2015, J ALLERGY CLIN IMMUN, V136, P848, DOI 10.1016/j.jaci.2015.07.007; Berry A, 2016, J ALLERGY CLIN IMMUN, V137, P1317, DOI 10.1016/j.jaci.2016.03.009; Galli SJ, 2016, J ALLERGY CLIN IMMUN, V137, P1289, DOI 10.1016/j.jaci.2016.03.006; Jutel M, 2015, J ALLERGY CLIN IMMUN, V136, P556, DOI 10.1016/j.jaci.2015.04.047; Lewis T, 1944, LANCET, V1, P619; Lotvall J, 2011, J ALLERGY CLIN IMMUN, V127, P355, DOI 10.1016/j.jaci.2010.11.037; Martino D, 2015, J ALLERGY CLIN IMMUN, V135, P1319, DOI 10.1016/j.jaci.2014.12.1933; Mingueneau M, 2016, J ALLERGY CLIN IMMUN; Muraro A, 2016, J ALLERGY CLIN IMMUN, V137, P1347, DOI 10.1016/j.jaci.2016.03.010; Noon L, 1911, LANCET, V1, P1572; Skevaki C, 2016, J ALLERGY CLIN IMMUN, V137, P1302, DOI 10.1016/j.jaci.2016.03.012	13	22	26	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2016	137	5					1359	1361		10.1016/j.jaci.2016.03.020	http://dx.doi.org/10.1016/j.jaci.2016.03.020			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DM2MF	27155031	Bronze			2022-12-18	WOS:000376180200007
J	Andiappan, AK; Sio, YY; Lee, B; Suri, BK; Matta, SA; Lum, J; Foo, SH; Koh, G; Liu, JJ; Zolezzi, F; Poidinger, M; Wang, DY; Rotzschke, O; Chew, FT				Andiappan, Anand Kumar; Sio, Yang Yie; Lee, Bernett; Suri, Bani Kaur; Matta, Sri Anusha; Lum, Josephine; Foo, Shihui; Koh, Geraldine; Liu, Jianjun; Zolezzi, Francesca; Poidinger, Michael; Wang, De Yun; Rotzschke, Olaf; Chew, Fook Tim			Functional variants of 17q12-21 are associated with allergic asthma but not allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ORMDL3; 17q21; allergic asthma; allergic rhinitis; Singapore Chinese; IgE; eosinophil counts	GENOME-WIDE ASSOCIATION; GENETIC-VARIANTS; HAY-FEVER; ARIA 2008; FAMILY; METAANALYSIS; EXPRESSION; HEALTH; IDENTIFICATION; SENSITIZATION	Background: Allergic rhinitis (AR) and asthma are common allergic conditions with a shared genetic component to their cause. The 17q12-21 locus includes several genes that have been linked to asthma susceptibility, but the role of this locus in AR is unclear. Asthma and AR in adults of Chinese ethnicity in Singapore are predominately caused by sensitization against house dust mites with a nearly complete penetrance of the allergen, which presents a unique opportunity for accurately identifying genetic associations with allergic diseases. Objective: We sought to define the functional role of 17q12-21 in patients with AR and allergic asthma. Methods: We asked whether single nucleotide polymorphisms (SNPs) in the 17q12-21 locus were associated with AR or asthma in a cohort of 3460 ethnic Chinese subjects residing in Singapore (1435 in the discovery phase and 2025 in the validation phase). Full-blood mRNA gene expression data, plasma IgE levels, and immune cell frequencies in peripheral blood were tested against the tag SNP genotypes. Luciferase assays were used to measure the effect of putative promoter SNPs on expression of the asthma-associated orosomucoid-like 3 gene (ORMDL3). Results: Within 17q12-21, only the tag SNP rs8076131 was significantly associated with asthma (P = 8.53 x 10(-10); odds ratio, 0.6715), and AR status was independent of SNPs in this region. C-A alleles at rs8076131 resulted in significantly increased ORMDL3 expression in HEK293 cells in vitro relative to T-G alleles. Moreover, subjects with the risk genotype AA exhibited significantly higher total IgE levels and higher blood eosinophil counts than those with the lower-risk genotypes. Conclusion: The 17q12-21 locus has a strong genetic association with allergic asthma but not with AR. The polymorphic effect of this locus is attributed to the linkage set tagged by rs8076131, which affects the expression of ORMDL3, protein phosphatase 1, regulatory inhibitor subunit 1B (PPP1R1B), zona pellucida binding protein 2 (ZPBP2), and gasdermin B (GSDMB) and is correlated with high IgE levels and eosinophil counts in subjects bearing the risk genotype.	[Andiappan, Anand Kumar; Lee, Bernett; Lum, Josephine; Foo, Shihui; Koh, Geraldine; Zolezzi, Francesca; Poidinger, Michael; Rotzschke, Olaf] Singapore Immunol Network SIgN, 8A Biomed Grove 04-06,Immunos Bldg, Singapore 138648, Singapore; [Liu, Jianjun] ASTAR, GIS, Singapore, Singapore; [Andiappan, Anand Kumar; Sio, Yang Yie; Suri, Bani Kaur; Matta, Sri Anusha; Chew, Fook Tim] Natl Univ Singapore, Dept Biol Sci, Singapore 117548, Singapore; [Wang, De Yun] Natl Univ Singapore, Natl Univ Hlth System, Dept Otolaryngol, 1E Kent Ridge Rd, Singapore 119228, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Singapore Immunology Network (SIgN); Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS); National University of Singapore; National University of Singapore	Rotzschke, O (corresponding author), Singapore Immunol Network SIgN, 8A Biomed Grove 04-06,Immunos Bldg, Singapore 138648, Singapore.; Wang, DY (corresponding author), Natl Univ Singapore, Natl Univ Hlth System, Dept Otolaryngol, 1E Kent Ridge Rd, Singapore 119228, Singapore.; Chew, FT (corresponding author), Natl Univ Singapore, Allergy & Mol Immunol Lab, Lee Hiok Kwee Funct Genom Labs, Dept Biol Sci,Fac Sci, Block S2,Level 5,Sci Dr 4,Lower Kent Ridge Rd, Singapore 117543, Singapore.	entwdy@nus.edu.sg; olaf_rotzschke@immunol.a-star.edu.sg; dbscft@nus.edu.sg	Roetzschke, Olaf/GXH-0012-2022; Andiappan, Anand Kumar/AAT-2336-2021; Liu, Jianjun/AAK-4989-2020; Chew, Fook Tim/E-7259-2010	Liu, Jianjun/0000-0002-3255-3019; Chew, Fook Tim/0000-0003-1337-5146; Poidinger, Michael/0000-0002-1047-2277; Andiappan, Anand Kumar/0000-0002-8442-1544	Singapore Ministry of Education [R-154-000-404-112, R-154-000-553-112, R-154-000-565-112, R-154-000-630-112]; National Medical Research Council (NMRC; Singapore) [NMRC/1150/2008]; Singapore Immunology Network, Agency for Science, Technology and Research (A*STAR) Singapore [SIgN-06-006, SIgN-08-020, SIgN-10-029]	Singapore Ministry of Education(Ministry of Education, Singapore); National Medical Research Council (NMRC; Singapore)(National Medical Research Council, Singapore); Singapore Immunology Network, Agency for Science, Technology and Research (A*STAR) Singapore(Agency for Science Technology & Research (A*STAR))	Supported by the Singapore Ministry of Education Academic Research Fund (R-154-000-404-112, R-154-000-553-112, R-154-000-565-112, R-154-000-630-112), National Medical Research Council (NMRC; Singapore, NMRC/1150/2008), and Singapore Immunology Network, Agency for Science, Technology and Research (A*STAR) Singapore (SIgN-06-006, SIgN-08-020, and SIgN-10-029).	Adamko DJ, 2005, ALLERGY, V60, P13, DOI 10.1111/j.1398-9995.2005.00676.x; Andiappan AK, 2014, ALLERGY, V69, P501, DOI 10.1111/all.12364; Andiappan AK, 2015, J ALLERGY CLIN IMMUN, V135, P556, DOI 10.1016/j.jaci.2014.06.028; Andiappan AK, 2011, CYTOKINE, V56, P218, DOI 10.1016/j.cyto.2011.05.008; Andiappan AK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019719; Andiappan AK, 2010, BMC GENET, V11, DOI 10.1186/1471-2156-11-36; Arbes SJ, 2005, J ALLERGY CLIN IMMUN, V116, P377, DOI 10.1016/j.jaci.2005.05.017; Berlivet S, 2012, HUM GENET, V131, P1161, DOI 10.1007/s00439-012-1142-x; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Breslow DK, 2010, NATURE, V463, P1048, DOI 10.1038/nature08787; de Bakker PIW, 2005, NAT GENET, V37, P1217, DOI 10.1038/ng1669; Fagnani C, 2008, TWIN RES HUM GENET, V11, P121, DOI 10.1375/twin.11.2.121; Ferreira MAR, 2014, J ALLERGY CLIN IMMUN, V133, P1564, DOI 10.1016/j.jaci.2013.10.030; Fuertes E, 2015, J ALLERGY CLIN IMMUN, V135, P573, DOI 10.1016/j.jaci.2014.08.016; Ha SG, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3479; Hinds DA, 2013, NAT GENET, V45, P907, DOI 10.1038/ng.2686; Hjelmqvist L, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-6-research0027; Katoh M, 2003, INT J MOL MED, V12, P399; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Morgan B, 1997, EMBO J, V16, P2004, DOI 10.1093/emboj/16.8.2004; Ober C, 2011, IMMUNOL REV, V242, P10, DOI 10.1111/j.1600-065X.2011.01029.x; Pawankar Ruby, 2012, World Allergy Organ J, V5, pS212, DOI 10.1097/WOX.0b013e318201d831; Pawankar R, 2009, ASIAN PAC J ALLERGY, V27, P237; Pawankar R, 2008, WORLD ALLERGY ORGAN, V1, pS4, DOI 10.1097/1939-4551-1-S1-S1; Prussin Calman, 2003, Journal of Allergy and Clinical Immunology, V111, pS486; Ramasamy A, 2011, J ALLERGY CLIN IMMUN, V128, P996, DOI 10.1016/j.jaci.2011.08.030; Saeki N, 2009, GENE CHROMOSOME CANC, V48, P261, DOI 10.1002/gcc.20636; Sleiman PMA, 2010, NEW ENGL J MED, V362, P36, DOI 10.1056/NEJMoa0901867; Strachan David P., 2000, Thorax, V55, pS2, DOI 10.1136/thorax.55.suppl_1.S2; Szefler SJ, 2005, J ALLERGY CLIN IMMUN, V115, P233, DOI 10.1016/j.jaci.2004.11.014; Tamura M, 2007, GENOMICS, V89, P618, DOI 10.1016/j.ygeno.2007.01.003; Tomita K, 2013, ALLERGY, V68, P92, DOI 10.1111/all.12066; Torgerson DG, 2011, NAT GENET, V43, P887, DOI 10.1038/ng.888; Verlaan DJ, 2009, AM J HUM GENET, V85, P377, DOI 10.1016/j.ajhg.2009.08.007; Westra HJ, 2013, NAT GENET, V45, P1238, DOI 10.1038/ng.2756; Willemsen G, 2008, TWIN RES HUM GENET, V11, P132, DOI 10.1375/twin.11.2.132	37	22	23	0	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2016	137	3					758	+		10.1016/j.jaci.2015.08.038	http://dx.doi.org/10.1016/j.jaci.2015.08.038			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DG2LB	26483175	Bronze			2022-12-18	WOS:000371897500018
J	Spinner, MA; Ker, JP; Stoudenmire, CJ; Fadare, O; Mace, EM; Orange, JS; Hsu, AP; Holland, SM				Spinner, Michael A.; Ker, Jennifer P.; Stoudenmire, Charles J.; Fadare, Oluwole; Mace, Emily M.; Orange, Jordan S.; Hsu, Amy P.; Holland, Steven M.			GATA2 deficiency underlying severe blastomycosis and fatal herpes simplex virus-associated hemophagocytic lymphohistiocytosis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							MUTATIONS		[Spinner, Michael A.] Stanford Univ, Med Ctr, Dept Med, Stanford, CA 94305 USA; [Ker, Jennifer P.] Vanderbilt Univ, Med Ctr, Div Allergy Pulm & Crit Care Med, 221 Kirkland Hall, Nashville, TN 37235 USA; [Stoudenmire, Charles J.; Fadare, Oluwole] Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, 221 Kirkland Hall, Nashville, TN 37235 USA; [Mace, Emily M.; Orange, Jordan S.] Texas Childrens Hosp, Baylor Coll Med, Ctr Human Immunobiol, Houston, TX 77030 USA; [Hsu, Amy P.; Holland, Steven M.] NIAID, Lab Clin Infect Dis, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA	Stanford University; Vanderbilt University; Vanderbilt University; Baylor College of Medicine; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Holland, SM (corresponding author), NIAID, Lab Clin Infect Dis, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.	smh@nih.gov		Mace, Emily/0000-0003-0226-7393; orange, jordan/0000-0001-7117-7725; Hsu, Amy/0000-0001-6841-2122; Spinner, Michael/0000-0002-5013-4651	Intramural NIH HHS [Z01 AI000646-16] Funding Source: Medline; NIAID NIH HHS [Z01-AI-00647-25] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000647, ZIAAI000646, ZIAAI000647] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Faitelson Y, 2014, CLIN IMMUNOL, V155, P118, DOI 10.1016/j.clim.2014.09.008; Grossman J, 2014, BIOL BLOOD MARROW TR, V20, P1940, DOI 10.1016/j.bbmt.2014.08.004; Imran T, 2013, 15 INT C IMM MIL IT; Mace EM, 2013, BLOOD, V121, P2669, DOI 10.1182/blood-2012-09-453969; Parvaneh N, 2013, BRIT J HAEMATOL, V162, P573, DOI 10.1111/bjh.12422; Sampaio EP, 2013, J ALLERGY CLIN IMMUN, V131, P1624, DOI 10.1016/j.jaci.2013.01.052; Siderits RH, 2010, CYTOJOURNAL, V7, DOI 10.4103/1742-6413.67106; Spinner MA, 2014, BLOOD, V123, P809, DOI 10.1182/blood-2013-07-515528; Zerbe CS, 2005, CLIN INFECT DIS, V41, pE38, DOI 10.1086/432120	9	22	22	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2016	137	2					638	+		10.1016/j.jaci.2015.07.043	http://dx.doi.org/10.1016/j.jaci.2015.07.043			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DC5BN	26395816	Green Accepted			2022-12-18	WOS:000369235500043
J	Nermes, M; Endo, A; Aarnio, J; Salminen, S; Isolauri, E				Nermes, Merja; Endo, Akihito; Aarnio, Jasmin; Salminen, Seppo; Isolauri, Erika			Furry pets modulate gut microbiota composition in infants at risk for allergic disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							BIFIDOBACTERIA; PREGNANCY		[Nermes, Merja; Aarnio, Jasmin; Isolauri, Erika] Univ Turku, Turku Univ Hosp, Dept Pediat & Adolescent Med, Turku, Finland; [Nermes, Merja; Aarnio, Jasmin; Isolauri, Erika] Univ Turku, Fac Med, Dept Clin Med, Turku, Finland; [Endo, Akihito; Salminen, Seppo] Univ Turku, Dept Biochem & Food Chem, Funct Foods Forum, FIN-20014 Turku, Finland	University of Turku; University of Turku; University of Turku	Nermes, M (corresponding author), Univ Turku, Turku Univ Hosp, Dept Pediat & Adolescent Med, Turku, Finland.	merja.nermes@tyks.fi						Biavati B, 2006, PROKARYOTES: A HANDBOOK ON THE BIOLOGY OF BACTERIA, VOL 3, THIRD EDITION, P322, DOI 10.1007/0-387-30743-5_17; Collado MC, 2008, AM J CLIN NUTR, V88, P894, DOI 10.1093/ajcn/88.4.894; GAVINI F, 1991, INT J SYST BACTERIOL, V41, P548, DOI 10.1099/00207713-41-4-548; Heederik D, 2012, J ALLERGY CLIN IMMUN, V130, P44, DOI 10.1016/j.jaci.2012.01.067; Lamendella R, 2008, APPL ENVIRON MICROB, V74, P575, DOI 10.1128/AEM.01221-07; MITSUOKA T, 1976, ZBL BAKT-INT J MED M, V235, P485; Rautava S, 2012, J ALLERGY CLIN IMMUN, V130, P1355, DOI 10.1016/j.jaci.2012.09.003; von Mutius E, 2009, J ALLERGY CLIN IMMUN, V123, P3, DOI 10.1016/j.jaci.2008.10.046; von Mutius E, 2010, NAT REV IMMUNOL, V10, P861, DOI 10.1038/nri2871	9	22	23	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2015	136	6					1688	1690		10.1016/j.jaci.2015.07.029	http://dx.doi.org/10.1016/j.jaci.2015.07.029			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CX9RZ	26343452	Bronze			2022-12-18	WOS:000366044300034
J	Kim, S; Kim, J; Park, SY; Um, HY; Kim, K; Kim, Y; Park, Y; Baek, S; Yoon, SY; Kwon, HS; Cho, YS; Moon, HB; Kim, TB				Kim, Sujeong; Kim, Jinhee; Park, So Young; Um, Hye-Yeon; Kim, Kyoungjoo; Kim, Yuri; Park, Yunjin; Baek, Seunghee; Yoon, Sun-Young; Kwon, Hyouk-Soo; Cho, You Sook; Moon, Hee-Bom; Kim, Tae-Bum			Effect of pregnancy in asthma on health care use and perinatal outcomes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; health care; insurance claim review; pregnancy	MATERNAL ASTHMA; INHALED CORTICOSTEROIDS; SEVERITY; RISK; EXACERBATIONS; PREVALENCE; SYMPTOMS; WOMEN; PRESCRIPTION; ASSOCIATION	Background: It is generally known that pregnancy in asthmatic patients increases the risk of asthma exacerbations and poor perinatal outcomes. However, the effect of pregnancy in asthmatic patients on health care use is not known well. In addition, its effect on perinatal outcomes is still controversial because of study limitations caused by ethical issues. National Health Insurance claim data are an ideal resource for studying real-world health care use patterns of asthma. Objective: We sought to evaluate the effect of pregnancy on asthma in terms of asthma-related health care use and prescription patterns in concert with the effect of asthma exacerbations on adverse pregnancy outcomes. Methods: Among all asthmatic patients in the Korean National Health Insurance claim database from January 2009 to December 2013, pregnant women who delivered in 2011 with pre-existing asthma were enrolled. Analyses included asthma-related health care use and prescription patterns compared between pregnant asthmatic women and nonpregnant female asthmatic control subjects, as well as within the pregnant subjects from before pregnancy throughout postpartum periods. In addition, the association between asthma exacerbation during pregnancy and adverse pregnancy outcomes was assessed. Results: A total of 3,357 pregnant asthmatic patients were compared with 50,355 nonpregnant asthmatic patients, and 10,311 pregnant patients were included to determine the effect of asthma exacerbations on adverse pregnancy outcome in the study. Pregnant asthmatic patients underwent more asthma-related hospitalizations (1.3% vs 0.8%, P = .005) but had significantly fewer outpatient visits and prescriptions for most asthma medications than nonpregnant asthmatic patients. The proportion of patients ever hospitalized gradually increased throughout pregnancy (first trimester, 0.2%; second trimester, 0.5%; and third trimester, 0.7%; P = .018). The prevalence of asthma exacerbation during pregnancy was 5.3%, and the patients who had acute exacerbation during pregnancy had significantly higher asthma-related health care use in terms of hospitalization, intensive care unit admission, and emergency department and outpatient visits within 1 year before delivery than those who had not. However, asthma exacerbation during pregnancy was not significantly related to adverse perinatal outcomes, except for cesarean section (27.1% vs 18.9%, P <.001). All exacerbations were managed with systemic corticosteroids, and the patients who ever experienced acute exacerbations maintained asthma medications, including inhaled corticosteroid-based inhalers, throughout the pregnancy period. Conclusion: Pregnancy profoundly affects asthma-related health care use but to a different degree depending on whether the patient experienced an exacerbation. Asthma exacerbation during pregnancy is not associated with adverse pregnancy outcomes while managed appropriately with systemic corticosteroids. However, further studies are needed to clarify the effect of asthma control on perinatal outcome and delivery method.	[Kim, Sujeong; Park, So Young; Yoon, Sun-Young; Kwon, Hyouk-Soo; Cho, You Sook; Moon, Hee-Bom; Kim, Tae-Bum] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Allergy & Clin Immunol,Asthma Ctr, Seoul 138736, South Korea; [Kim, Sujeong] Kyungpook Natl Univ, Sch Med, Dept Internal Med, Daegu, South Korea; [Kim, Jinhee; Kim, Kyoungjoo; Kim, Yuri] Natl Evidence Based Healthcare Collaborating Agcy, Seoul, South Korea; [Kim, Jinhee] Chosun Univ, Coll Med, Dept Nursing, Gwangju, South Korea; [Um, Hye-Yeon] Korea Inst Drug Safety & Risk Management, Seoul, South Korea; [Park, Yunjin] Dongguk Univ, Dept Stat, Seoul, South Korea; [Baek, Seunghee] Asan Med Ctr, Dept Clin Epidemiol & Biostat, Seoul, South Korea	University of Ulsan; Asan Medical Center; Kyungpook National University; National Evidence-based Healthcare Collaborating Agency (NECA); Chosun University; Dongguk University; University of Ulsan; Asan Medical Center	Kim, TB (corresponding author), Univ Ulsan, Coll Med, Asan Med Ctr, Dept Allergy & Clin Immunol, 88 Olymp Ro 43 Gil, Seoul 138736, South Korea.	tbkim@amc.seoul.kr			Korea Healthcare Technology R&D Project, Ministry of Health and Welfare, Republic of Korea [HI14C1971, HI13C0776]	Korea Healthcare Technology R&D Project, Ministry of Health and Welfare, Republic of Korea	Supported by a grant of the Korea Healthcare Technology R&D Project, Ministry of Health and Welfare, Republic of Korea (grant nos. HI14C1971 and HI13C0776).	Baibergenova A, 2006, J ASTHMA, V43, P293, DOI 10.1080/02770900600622984; Bakhireva LN, 2008, ANN ALLERG ASTHMA IM, V101, P137, DOI 10.1016/S1081-1206(10)60201-3; Belanger K, 2010, OBSTET GYNECOL, V115, P559, DOI 10.1097/AOG.0b013e3181d06945; Blais L, 2014, J ASTHMA, V51, P391, DOI 10.3109/02770903.2013.879880; Bracken MB, 2003, OBSTET GYNECOL, V102, P739, DOI 10.1016/S0029-7844(03)00621-5; Breton MC, 2009, THORAX, V64, P101, DOI 10.1136/thx.2008.102970; Charlton RA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060247; Chun CB, 2009, HLTH SYST TRANSIT, V11, P1; Dombrowski MP, 2004, OBSTET GYNECOL, V103, P5, DOI 10.1097/01.AOG.0000103994.75162.16; Enriquez R, 2007, J ALLERGY CLIN IMMUN, V120, P625, DOI 10.1016/j.jaci.2007.05.044; George J, 2012, AM J RESP CRIT CARE, V185, P476, DOI 10.1164/rccm.201112-2249ED; Gluck JC, 2006, IMMUNOL ALLERGY CLIN, V26, P63, DOI 10.1016/j.iac.2005.10.008; Gluck LC, 2004, CLIN REV ALLERG IMMU, V26, P171, DOI 10.1385/CRIAI:26:3:171; Hansen C, 2013, MATERN CHILD HLTH J, V17, P1611, DOI 10.1007/s10995-012-1173-x; Juniper E, 1993, ASTHMA IMMUNOLOGICAL, P401; Kim S, 2013, ALLERGY, V68, P1435, DOI 10.1111/all.12256; Kircher S, 2002, ANN ALLERG ASTHMA IM, V89, P463, DOI 10.1016/S1081-1206(10)62082-0; Kwon HL, 2006, IMMUNOL ALLERGY CLIN, V26, P29, DOI 10.1016/j.iac.2005.11.002; Kwon HL, 2003, ANN EPIDEMIOL, V13, P317, DOI 10.1016/S1047-2797(03)00008-5; Liu SL, 2001, AM J OBSTET GYNECOL, V184, P90, DOI 10.1067/mob.2001.108073; Louik C, 2010, ANN ALLERG ASTHMA IM, V105, P110, DOI 10.1016/j.anai.2010.05.016; Martel MJ, 2005, BMJ-BRIT MED J, V330, P230, DOI 10.1136/bmj.38313.624352.8F; Mendola P, 2013, AM J OBSTET GYNECOL, V208, DOI 10.1016/j.ajog.2012.11.007; Murphy VE, 2011, BJOG-INT J OBSTET GY, V118, P1314, DOI 10.1111/j.1471-0528.2011.03055.x; Murphy VE, 2006, THORAX, V61, P169, DOI 10.1136/thx.2005.049718; Murphy VE, 2005, OBSTET GYNECOL, V106, P1046, DOI 10.1097/01.AOG.0000185281.21716.02; Murphy VE, 2005, EUR RESPIR J, V25, P731, DOI 10.1183/09031936.05.00085704; Namazy JA, 2013, EUR RESPIR J, V41, P1082, DOI 10.1183/09031936.00195111; Norjavaara E, 2003, J ALLERGY CLIN IMMUN, V111, P736, DOI 10.1067/mai.2003.1340; Olesen C, 2001, RESPIRATION, V68, P256, DOI 10.1159/000050507; Rocklin RE, 2011, REPROD TOXICOL, V32, P189, DOI 10.1016/j.reprotox.2011.05.023; Schatz M, 2005, ANN ALLERG ASTHMA IM, V95, P234, DOI 10.1016/S1081-1206(10)61219-7; Schatz M, 2003, J ALLERGY CLIN IMMUN, V112, P283, DOI 10.1067/mai.2003.1516; SCHATZ M, 1988, J ALLERGY CLIN IMMUN, V81, P495, DOI 10.1016/0091-6749(88)90187-X; Silverman M, 2005, ANN ALLERG ASTHMA IM, V95, P566, DOI 10.1016/S1081-1206(10)61020-4; SteniusAarniala BSM, 1996, THORAX, V51, P411, DOI 10.1136/thx.51.4.411; Triche EW, 2004, OBSTET GYNECOL, V104, P585, DOI 10.1097/01.AOG.0000136481.05983.91	37	22	23	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2015	136	5					1215	+		10.1016/j.jaci.2015.04.043	http://dx.doi.org/10.1016/j.jaci.2015.04.043			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CW1YE	26071938				2022-12-18	WOS:000364787200009
J	Szajewska, H; Shamir, R; Turck, D; van Goudoever, JB; Mihatsch, WA; Fewtrell, M				Szajewska, Hania; Shamir, Raanan; Turck, Dominique; van Goudoever, Johannes B.; Mihatsch, Walter A.; Fewtrell, Mary			Recommendations on probiotics in allergy prevention should not be based on pooling data from different strains	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							PLACEBO-CONTROLLED TRIAL; ATOPIC DISEASE; DOUBLE-BLIND; PREGNANCY		[Szajewska, Hania] Med Univ Warsaw, Dept Paediat, Warsaw, Poland; [Shamir, Raanan] Schneider Childrens Med Ctr Israel, Inst Gastroenterol Nutr & Liver Dis, Petah Tiqwa, Israel; [Shamir, Raanan] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel; [Turck, Dominique] Univ Lille, Childrens Hosp, Dept Pediat, Div Gastroenterol Hepatol & Nutr, Lille, France; [Turck, Dominique] Fac Med, Lille, France; [van Goudoever, Johannes B.] Emma Childrens Hosp AMC, Dept Pediat, Amsterdam, Netherlands; [van Goudoever, Johannes B.] Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands; [Mihatsch, Walter A.] Klinikum Harlaching, Klin Kinder & Jugendmed, Stadt Kliniken Munchen, Munich, Germany; [Fewtrell, Mary] UCL Inst Child Hlth, Childhood Nutr Res Ctr, London, England	Medical University of Warsaw; Tel Aviv University; Sackler Faculty of Medicine; Universite de Lille - ISITE; CHU Lille; Universite de Lille; Universite de Lille - ISITE; Universite de Lille; Emma Children's Hospital; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; Munchen Klinik; University of London; University College London	Szajewska, H (corresponding author), Med Univ Warsaw, Dept Paediat, Warsaw, Poland.	hania@ipgate.pl	van Goudoever, Johannes Bernard/Y-4520-2018; Turck, Dominique/S-2382-2018; Szajewska, Hania/M-4141-2018	Turck, Dominique/0000-0003-1370-4667; Szajewska, Hania/0000-0002-4596-2874; van Goudoever, Johannes (Hans)/0000-0003-3960-1703				Boyle RJ, 2011, ALLERGY, V66, P509, DOI 10.1111/j.1398-9995.2010.02507.x; Cuello-Garcia CA, 2015, J ALLERGY CLIN IMMUN, V136, P952, DOI [10.1016/j.jaci.2015.07.021, 10.1016/j.jaci.2015.04.031]; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; Kopp MV, 2008, PEDIATRICS, V121, pE850, DOI 10.1542/peds.2007-1492; Ou CY, 2012, CLIN EXP ALLERGY, V42, P1386, DOI 10.1111/j.1365-2222.2012.04037.x; Rautava S, 2002, J ALLERGY CLIN IMMUN, V109, P119, DOI 10.1067/mai.2002.120273	6	22	22	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2015	136	5					1422	1422		10.1016/j.jaci.2015.07.022	http://dx.doi.org/10.1016/j.jaci.2015.07.022			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CW1YE	26329511				2022-12-18	WOS:000364787200040
J	Castellucci, M; Rossato, M; Calzetti, F; Tamassia, N; Zeminian, S; Cassatella, MA; Bazzoni, F				Castellucci, Monica; Rossato, Marzia; Calzetti, Federica; Tamassia, Nicola; Zeminian, Stefano; Cassatella, Marco A.; Bazzoni, Flavia			IL-10 disrupts the Brd4-docking sites to inhibit LPS-induced CXCL8 and TNF-alpha expression in monocytes: Implications for chronic obstructive pulmonary disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-10; CXCL8; TNF-alpha; histone deacetylase 2; chronic obstructive pulmonary disease; transcriptional inhibition; Brd4-docking site; nuclear factor kappa B	NF-KAPPA-B; BROMODOMAIN PROTEIN BRD4; RNA-POLYMERASE-II; HISTONE DEACETYLASE ACTIVITY; P-TEFB; GENE-EXPRESSION; TRANSCRIPTIONAL ELONGATION; INFLAMMATORY RESPONSE; HUMAN NEUTROPHILS; PHOSPHORYLATION	Background: IL-10 is well known for its ability to block the expression and production of numerous proinflammatory cytokines, in this manner preventing the development of excessive or chronic immune activation. IL-10-induced transcriptional repression of CXCL8 and TNFA genes consists of 2 distinct phases: an early phase, occurring rapidly and in a protein synthesis-independent manner, followed by a second phase that is more delayed and dependent on protein synthesis. Objective: We sought to identify the mechanisms through which IL-10 rapidly and directly suppresses LPS-induced CXCL8 and TNF-alpha transcription, which might be defective under pathologic conditions. Methods: The molecular events triggered by IL-10 in LPS-activated monocytes at the CXCL8 and TNFA loci were investigated by using the chromatin immunoprecipitation assay. Results: Inhibition of LPS-induced CXCL8 and TNF-alpha expression by IL-10 proceeds through a common mechanism targeting LPS-induced phosphorylation of the nuclear factor kappa B p65 serine 276 residue (pS(276)p65). As a result, all the pS(276)p65-dependent events occurring at the CXCL8 and TNFA loci are consistently reduced, ultimately leading to a reduction in transcript elongation. Additionally, IL-10 selectively controls CXCL8 transcript elongation through histone deacetylase (HDAC) 2-dependent covalent chromatin modifications, disrupting the assembly of the transcriptional machinery. Remarkably, PBMCs from patients with acute-phase chronic obstructive pulmonary disease, which express negligible HDAC2 levels, are scarcely affected by IL-10 in terms of inhibition of CXCL8 expression. Conclusions: This study provides mechanistic evidence that IL-10 creates a chromatin environment that decreases the transcriptional rate of CXCL8 and TNF-alpha to Toll-like receptor 4-activating signals. Data identify novel molecular targets for therapeutic strategies aimed at dampening inflammation in pathologies such as chronic obstructive pulmonary disease, in which reduced intracellular HDAC2 levels have been described.	[Castellucci, Monica; Rossato, Marzia; Calzetti, Federica; Tamassia, Nicola; Cassatella, Marco A.; Bazzoni, Flavia] Univ Verona, Dept Pathol & Diagnost, Div Gen Pathol, I-37100 Verona, Italy; [Zeminian, Stefano] Osped San Pellegrino, Castiglione Delle Stivie, Mantova, Italy	University of Verona	Bazzoni, F (corresponding author), Univ Verona, Dept Pathol & Diagnost, Div Gen Pathol, Str Le Grazie 8, I-37100 Verona, Italy.	flavia.bazzoni@univr.it	Tamassia, Nicola/J-8621-2016; Cassatella, M A/B-8037-2013; Bazzoni, Flavia/AAB-7674-2019; Rossato, Marzia/AAB-7827-2019	Tamassia, Nicola/0000-0003-2990-3003; Cassatella, M A/0000-0001-7824-1806; Bazzoni, Flavia/0000-0001-6768-8012; Rossato, Marzia/0000-0002-6101-1550	Associazione Italiana per la Ricerca sul Cancro (AIRC) [IG-11782]; Ministero dell'Istruzione dell'Universita e della Ricerca (Programmi di Ricerca Scientifica di Rilevante Interesse Nazionale project) [200999KRFW_004]; Fondo Unico per la ricerca (FUR); FIRC Fellowship	Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Ministero dell'Istruzione dell'Universita e della Ricerca (Programmi di Ricerca Scientifica di Rilevante Interesse Nazionale project); Fondo Unico per la ricerca (FUR); FIRC Fellowship(Fondazione AIRC per la ricerca sul cancro)	Supported by grants from Associazione Italiana per la Ricerca sul Cancro (AIRC, IG-11782; to M.A.C.), by the Ministero dell'Istruzione dell'Universita e della Ricerca (Programmi di Ricerca Scientifica di Rilevante Interesse Nazionale project 200999KRFW_004), and by Fondo Unico per la ricerca (FUR) 2011, 2012 e 2013. N.T. is the recipient of an FIRC Fellowship.	Adcock IM, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-21; Barnes PJ, 2009, LANCET, V373, P1905, DOI 10.1016/S0140-6736(09)60326-3; Barnes PJ, 2009, ANNU REV PHYSIOL, V71, P451, DOI 10.1146/annurev.physiol.010908.163257; Berlato C, 2002, J IMMUNOL, V168, P6404, DOI 10.4049/jimmunol.168.12.6404; Brusselle GG, 2011, LANCET, V378, P1015, DOI 10.1016/S0140-6736(11)60988-4; CASSATELLA MA, 1990, J BIOL CHEM, V265, P20241; Chan CS, 2012, J BIOL CHEM, V287, DOI 10.1074/jbc.M112.348599; Chen LF, 2005, MOL CELL BIOL, V25, P7966, DOI 10.1128/MCB.25.18.7966-7975.2005; Chen Y, 2012, J INFLAMM-LOND, V9, DOI 10.1186/1476-9255-9-10; Chung KF, 2006, CURR DRUG TARGETS, V7, P675, DOI 10.2174/138945006777435263; Denys A, 2002, J IMMUNOL, V168, P4837, DOI 10.4049/jimmunol.168.10.4837; Dey A, 2003, P NATL ACAD SCI USA, V100, P8758, DOI 10.1073/pnas.1433065100; Diamant G, 2013, BBA-GENE REGUL MECH, V1829, P937, DOI 10.1016/j.bbagrm.2013.04.007; El Kasmi KC, 2007, J IMMUNOL, V179, P7215, DOI 10.4049/jimmunol.179.11.7215; Fabbri LM, 2007, LANCET, V370, P797, DOI 10.1016/S0140-6736(07)61383-X; Hargreaves DC, 2009, CELL, V138, P129, DOI 10.1016/j.cell.2009.05.047; Huang B, 2009, MOL CELL BIOL, V29, P1375, DOI 10.1128/MCB.01365-08; Ito K, 2005, NEW ENGL J MED, V352, P1967, DOI 10.1056/NEJMoa041892; Itzen F, 2014, NUCLEIC ACIDS RES, V42, P7577, DOI 10.1093/nar/gku449; Jang MK, 2005, MOL CELL, V19, P523, DOI 10.1016/j.molcel.2005.06.027; Kobayashi T, 2012, J IMMUNOL, V189, P1792, DOI 10.4049/jimmunol.1200042; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Medzhitov R, 2009, NAT REV IMMUNOL, V9, P692, DOI 10.1038/nri2634; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; Murray PJ, 2006, BIOCHEM SOC T, V34, P1028, DOI 10.1042/BST0341028; Murray PJ, 2005, P NATL ACAD SCI USA, V102, P8686, DOI 10.1073/pnas.0500419102; Nozell S, 2006, J IMMUNOL, V177, P822, DOI 10.4049/jimmunol.177.2.822; Pelletier M, 2010, BLOOD, V115, P335, DOI 10.1182/blood-2009-04-216085; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; Qu YQ, 2013, MOL BIOL REP, V40, P3995, DOI 10.1007/s11033-012-2477-z; Rossato M, 2007, EUR J IMMUNOL, V37, P3176, DOI 10.1002/eji.200737625; Schmeck B, 2008, J IMMUNOL, V181, P940, DOI 10.4049/jimmunol.181.2.940; Shakespear MR, 2011, TRENDS IMMUNOL, V32, P335, DOI 10.1016/j.it.2011.04.001; Smallie T, 2010, J EXP MED, V207, P2081, DOI 10.1084/jem.20100414; Szulakowski P, 2006, AM J RESP CRIT CARE, V174, P41, DOI 10.1164/rccm.200505-725OC; Tamassia N, 2007, J IMMUNOL, V178, P7344, DOI 10.4049/jimmunol.178.11.7344; Tamassia N, 2010, FASEB J, V24, P1365, DOI 10.1096/fj.09-145573; Venza I, 2012, EPIGENETICS-US, V7, P1315, DOI 10.4161/epi.22446; Yang ZY, 2005, MOL CELL, V19, P535, DOI 10.1016/j.molcel.2005.06.029; Yao HW, 2012, AM J PHYSIOL-LUNG C, V303, pL557, DOI 10.1152/ajplung.00175.2012; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	42	22	24	2	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2015	136	3					781	+		10.1016/j.jaci.2015.04.023	http://dx.doi.org/10.1016/j.jaci.2015.04.023			20	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CQ9EA	26044852	Bronze			2022-12-18	WOS:000360913300030
J	Clement, MC; Mahlaoui, N; Mignot, C; Le Bihan, C; Rabetrano, H; Hoang, L; Neven, B; Moshous, D; Cavazzana, M; Blanche, S; Fischer, A; Audrain, M; Durand-Zaleski, I				Clement, Marie Caroline; Mahlaoui, Nizar; Mignot, Cecile; Le Bihan, Christine; Rabetrano, Hasina; Hoang, Ly; Neven, Benedicte; Moshous, Despina; Cavazzana, Marina; Blanche, Stephane; Fischer, Alain; Audrain, Marie; Durand-Zaleski, Isabelle			Systematic neonatal screening for severe combined immunodeficiency and severe T-cell lymphopenia: Analysis of cost-effectiveness based on French real field data	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Primary immunodeficiency; severe combined immunodeficiency; severe T-cell lymphopenia; newborn screening; health economics; cost-effectiveness; health policy	TRANSPLANTATION; SURVIVAL; DISEASES	Background: The inclusion of severe combined immunodeficiency (SCID) in a Europe-wide screening program is currently debated. Objective: In making a case for inclusion in the French newborn screening program, we explored the costs incurred and potentially saved by early management of SCID. Methods: For test costs, a microcosting study documented the resources used in a laboratory piloting a newborn screening test on Guthrie cards using the T-cell receptor excision circle quantification method. For treatment costs, patients with SCID admitted to the national reference center for primary immunodeficiency in France between 2006 and 2010 were included. Costs of admission were estimated from actual national production costs. We estimated the costs for patients who underwent early versus delayed hematopoietic stem cell transplantation (HSCT; age, <= 3 vs >3 months, respectively). Results: The unit cost of the test varied between (sic)4 and (sic)6.79 for 33,800 samples per year, depending on equipment use and saturation. Of the 30 patients included, 27 underwent HSCT after age 3 months. At 1 year after HSCT, 10 of these had died, and all 3 patients undergoing early transplantation survived. The medical costs for HSCT after 3 months were (sic)195,776 (interquartile range, (sic)165,884-(sic)257,160) versus (sic)86,179 (range, (sic)59,014-(sic)272,577) when performed before 3 months of age. In patients undergoing late transplantation, active infection contributed to high cost and poor outcome. Conclusion: Early detection of SCID could reduce the cost of treatment by (sic)50,000-100,000 per case. Assuming a (sic)5 unit cost per test, the incidence required to break even is 1: 20,000; however, if the survival advantage of HSCT before 3 months is confirmed, universal screening is likely to be cost-effective.	[Clement, Marie Caroline; Rabetrano, Hasina; Hoang, Ly; Durand-Zaleski, Isabelle] Hop Hotel Dieu, AP HP, URC ECo Clin Res Unit Hlth Econ, F-75004 Paris, France; [Mahlaoui, Nizar; Neven, Benedicte; Moshous, Despina; Blanche, Stephane; Fischer, Alain] Necker Enfants Malades Univ Hosp, AP HP, Pediat Hematol Immunol & Rheumatol Unit, Paris, France; [Mahlaoui, Nizar; Mignot, Cecile; Neven, Benedicte; Moshous, Despina; Blanche, Stephane; Fischer, Alain] Necker Enfants Malades Univ Hosp, AP HP, CEREDIH French Natl Reference Ctr Primary Immune, Paris, France; [Le Bihan, Christine] Necker Enfants Malades Univ Hosp, AP HP, Med Informat Unit, Paris, France; [Mahlaoui, Nizar] INSERM, U1163, Necker Branch, Lab Human Genet Infect Dis, Paris, France; [Mahlaoui, Nizar; Neven, Benedicte; Moshous, Despina; Cavazzana, Marina; Blanche, Stephane; Fischer, Alain] Paris Descartes Univ, Sorbonne Paris Cite, Imagine Inst, Paris, France; [Cavazzana, Marina] Necker Childrens Univ Hosp, AP HP, Biotherapy Dept, Paris, France; [Cavazzana, Marina] Groupe Hosp Univ Ouest, INSERM, AP HP, Biotherapy Clin Invest Ctr, Paris, France; [Fischer, Alain] Coll France, F-75231 Paris, France; [Audrain, Marie] Nantes Univ Hosp, Immunol Lab, Nantes, France; [Durand-Zaleski, Isabelle] Hop Henri Mondor, INSERM, AP HP, UMR 1123,Publ Hlth Unit, F-94010 Creteil, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Nantes Universite; CHU de Nantes; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)	Durand-Zaleski, I (corresponding author), Hop Hotel Dieu, URCEco Ile France, 1 Pl Parvis Notre Dame, F-75004 Paris, France.	isabelle.durand-zaleski@hmn.aphp.fr	Mahlaoui, Nizar/J-7928-2017; MAHLAOUI, Nizar/AAH-6103-2020; Moshous, Despina/B-7507-2017	Mahlaoui, Nizar/0000-0002-0030-8094; MAHLAOUI, Nizar/0000-0002-0030-8094; Moshous, Despina/0000-0001-6719-3693; LE BIHAN-BENJAMIN, christine/0000-0002-1868-9358; Cavazzana, Marina/0000-0002-0264-0891	AP-HP Paris University hospital; Nantes Paris University hospital; Baxter Biosciences; French Association of Patients with Primary Immunodeficiencies (IRIS); French Ministry of Health; LFB; CSL Behring; GlaxoSmithKline; Pfizer; Octapharma; Orphan-Europe; French Association of Patients with PID (IRIS); International Patient Organisation for Primary Immunodeficiencies (IPOPI); head of the Social Worker Unit of Necker-Enfants Malades University Hospital	AP-HP Paris University hospital; Nantes Paris University hospital; Baxter Biosciences; French Association of Patients with Primary Immunodeficiencies (IRIS); French Ministry of Health; LFB; CSL Behring; GlaxoSmithKline(GlaxoSmithKline); Pfizer(Pfizer); Octapharma; Orphan-Europe; French Association of Patients with PID (IRIS); International Patient Organisation for Primary Immunodeficiencies (IPOPI); head of the Social Worker Unit of Necker-Enfants Malades University Hospital	The study was financed in part by Nantes and AP-HP Paris University hospitals and by an unrestricted grant from Baxter Biosciences to the Laboratory of Immunology of Nantes University Hospital for the estimation of the screening cost. CEREDIH is supported by the French Association of Patients with Primary Immunodeficiencies (IRIS) and is funded by the French Ministry of Health. It additionally received unrestricted educational grants from LFB, CSL Behring, Baxter Biosciences, GlaxoSmithKline, Pfizer, Octapharma, and Orphan-Europe. This study received support from the French Association of Patients with PID (IRIS), the International Patient Organisation for Primary Immunodeficiencies (IPOPI), and the head of the Social Worker Unit of Necker-Enfants Malades University Hospital (Mrs C. Maurey-Forquy).	Antoine C, 2003, LANCET, V361, P553, DOI 10.1016/S0140-6736(03)12513-5; Audrain M, 2014, CLIN IMMUNOL, V150, P137, DOI 10.1016/j.clim.2013.11.012; Barbouche MR, 2011, ANN NY ACAD SCI, V1238, P42, DOI 10.1111/j.1749-6632.2011.06260.x; Beaute J, 2010, CLIN IMMUNOL, V135, P264, DOI 10.1016/j.clim.2010.02.021; Borte S, 2013, CURR OPIN HEMATOL, V20, P48, DOI 10.1097/MOH.0b013e32835a9130; Brown L, 2011, BLOOD, V117, P3243, DOI 10.1182/blood-2010-08-300384; Buckley RH, 2012, J ALLERGY CLIN IMMUN, V129, P597, DOI 10.1016/j.jaci.2011.12.964; Buckley RH, 1999, NEW ENGL J MED, V340, P508, DOI 10.1056/NEJM199902183400703; Chan K, 2011, MOL GENET METAB, V104, P383, DOI 10.1016/j.ymgme.2011.07.007; Gaspar HB, 2014, J CLIN IMMUNOL, V34, P393, DOI 10.1007/s10875-014-0029-0; Gathmann B, 2009, CLIN EXP IMMUNOL, V157, P3, DOI 10.1111/j.1365-2249.2009.03954.x; Gennery AR, 2010, J ALLERGY CLIN IMMUN, V126, P602, DOI 10.1016/j.jaci.2010.06.015; Gennery AR, 2010, J ALLERGY CLIN IMMUN, V126, pe1; Joumard I, HLTH STATUS DETERMIN; Kubiak C, 2014, J ALLER CL IMM-PRACT, V2, P697, DOI 10.1016/j.jaip.2014.05.013; Kwan A, 2014, JAMA-J AM MED ASSOC, V312, P729, DOI 10.1001/jama.2014.9132; Kwan A, 2013, J ALLERGY CLIN IMMUN, V132, P140, DOI 10.1016/j.jaci.2013.04.024; Lipstein EA, 2010, PEDIATRICS, V125, pE1226, DOI 10.1542/peds.2009-1567; McGhee SA, 2005, J PEDIATR-US, V147, P603, DOI 10.1016/j.jpeds.2005.06.001; Myers LA, 2002, BLOOD, V99, P872, DOI 10.1182/blood.V99.3.872; Pai SY, 2014, NEW ENGL J MED, V371, P434, DOI 10.1056/NEJMoa1401177; Puck JM, 2011, CURR OPIN PEDIATR, V23, P667, DOI 10.1097/MOP.0b013e32834cb9b0; Railey MD, 2009, J PEDIATR-US, V155, P834, DOI 10.1016/j.jpeds.2009.07.049; Routes JM, 2009, JAMA-J AM MED ASSOC, V302, P2465, DOI 10.1001/jama.2009.1806; van der Burg M, 2011, EUR J PEDIATR, V170, P561, DOI 10.1007/s00431-011-1452-3; Verbsky JW, 2012, J CLIN IMMUNOL, V32, P82, DOI 10.1007/s10875-011-9609-4; Wilson JMG, 1968, PRINCIPLES PRACTICE	27	22	25	0	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2015	135	6					1589	1593		10.1016/j.jaci.2015.02.004	http://dx.doi.org/10.1016/j.jaci.2015.02.004			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CK0ZC	25840725				2022-12-18	WOS:000355933400022
J	Ghonim, MA; Pyakurel, K; Ju, J; Rodriguez, PC; Lammi, MR; Davis, C; Abughazleh, MQ; Mansy, MS; Naura, AS; Boulares, AH				Ghonim, Mohamed A.; Pyakurel, Kusma; Ju, Jihang; Rodriguez, Paulo C.; Lammi, Matthew R.; Davis, Christian; Abughazleh, Mohammad Q.; Mansy, Moselhy S.; Naura, Amarjit S.; Boulares, A. Hamid			DNA-dependent protein kinase inhibition blocks asthma in mice and modulates human endothelial and CD4(+) T-cell function without causing severe combined immunodeficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						DNA-dependent protein kinase; asthma; GATA-3; T(H)2 cytokines; adhesion molecules; eosinophilia; severe combined immunodeficiency disease; T-cell receptor	ALLERGIC AIRWAY INFLAMMATION; NF-KAPPA-B; POLY(ADP-RIBOSE) POLYMERASE; V(D)J RECOMBINATION; EXPRESSION; GROWTH; PK	Background: We reported that DNA-dependent protein kinase (DNA-PK) is critical for the expression of nuclear factor kappa B-dependent genes in TNF-alpha-treated glioblastoma cells, suggesting an involvement in inflammatory diseases. Objective: We sought to investigate the role of DNA-PK in asthma. Methods: Cell culture and ovalbumin (OVA)- or house dust mite-based murine asthma models were used in this study. Results: DNA-PK was essential for monocyte adhesion to TNF-alpha-treated endothelial cells. Administration of the DNA-PK inhibitor NU7441 reduced airway eosinophilia, mucus hypersecretion, airway hyperresponsiveness, and OVA-specific IgE production in mice prechallenged with OVA. Such effects correlated with a marked reduction in lung vascular cell adhesion molecule 1 expression and production of several cytokines, including IL-4, IL-5, IL-13, eotaxin, IL-2, and IL-12 and the chemokines monocyte chemoattractant protein 1 and keratinocyte-derived chemokine, with a negligible effect on IL-10/IFN-gamma production. DNA-PK inhibition by gene heterozygosity of the 450-kDa catalytic subunit of the kinase (DNA-PKcs(+/-)) also prevented manifestation of asthma-like traits. These results were confirmed in a chronic model of asthma by using house dust mite, a human allergen. Remarkably, such protection occurred without causing severe combined immunodeficiency. Adoptive transfer of T(H)2-skewed OT-II wild-type CD4(+) T cells reversed IgE and T(H)2 cytokine production but not airway hyperresponsiveness in OVA-challenged DNA-PKcs(+/-) mice. DNA-PK inhibition reduced IL-4, IL-5, IL-13, eotaxin, IL-8, and monocyte chemoattractant protein 1 production without affecting IL-2, IL-12, IFN-gamma, and interferon-inducible protein 10 production in CD3/CD28-stimulated human CD4(+) T cells, potentially by blocking expression of Gata3. These effects occurred without significant reductions in T-cell proliferation. In mouse CD4(+) T cells in vitro DNA-PK inhibition severely blocked CD3/CD28-induced Gata3 and T-bet expression in CD4(+) T cells and prevented differentiation of T(H)1 and T(H)2 cells under respective T(H)1- and T(H)2-skewing conditions. Conclusion: Our results suggest DNA-PK as a novel determinant of asthma and a potential target for the treatment of the disease.	[Ghonim, Mohamed A.; Pyakurel, Kusma; Ju, Jihang; Rodriguez, Paulo C.; Davis, Christian; Abughazleh, Mohammad Q.; Naura, Amarjit S.; Boulares, A. Hamid] LSU Hlth Sci Ctr, Stanley S Scott Canc Ctr, New Orleans, LA USA; [Lammi, Matthew R.] LSU Hlth Sci Ctr, Pulm & Crit Care Sect, New Orleans, LA USA; [Ghonim, Mohamed A.; Mansy, Moselhy S.] Al Azhar Univ, Fac Pharm, Cairo, Egypt	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Egyptian Knowledge Bank (EKB); Al Azhar University	Boulares, AH (corresponding author), 1700 Tulane Ave, New Orleans, LA 70112 USA.	anaura@pu.ac.in; hboulr@lsuhsc.edu	Rodríguez, Paulo/HDM-9539-2022; Ghonim, Mohamed A./AAT-3339-2021; Ghonim, Mohamed A./L-4757-2016	Ghonim, Mohamed A./0000-0001-9404-2698; Ghonim, Mohamed A./0000-0001-9404-2698; Rodriguez, Paulo/0000-0001-7480-6566	National Institutes of Health (NIH) [HL072889]; Louisiana Cancer Research Center (New Orleans, La); Egyptian Cultural and Educational Bureau (Egypt); NIH [P20GM103501]; American Heart Association [11POST8000008, 14PRE19630012]; LACaTS [NIH/U54 GM104940]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL072889] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM104940, P20GM103501] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Louisiana Cancer Research Center (New Orleans, La); Egyptian Cultural and Educational Bureau (Egypt)(Egyptian Cultural & Educational Bureau); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); LACaTS; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Supported in part by grant HL072889 from the National Institutes of Health (NIH) and funds from the Louisiana Cancer Research Center (New Orleans, La; to A.H.B.), by the Egyptian Cultural and Educational Bureau (Egypt), by P20GM103501 from the NIH (to A.S.N. program director: Dr A. Ochoa]), by postdoctoral fellowship 11POST8000008 (to J.J.) and predoctoral fellowship 14PRE19630012 (to K.P.) from the American Heart Association, and by a NIH/U54 GM104940 (LACaTS) Scholar grant to M.R.L.	Alt FW, 2013, CELL, V152, P417, DOI 10.1016/j.cell.2013.01.007; Das J, 2001, NAT IMMUNOL, V2, P45, DOI 10.1038/83158; De Alba J, 2010, EUR RESPIR J, V35, P1377, DOI 10.1183/09031936.00022908; Gao YJ, 1998, IMMUNITY, V9, P367, DOI 10.1016/S1074-7613(00)80619-6; Gu YS, 1997, IMMUNITY, V7, P653, DOI 10.1016/S1074-7613(00)80386-6; Hernandez CP, 2010, BLOOD, V115, P5214, DOI 10.1182/blood-2009-12-258822; Ju JH, 2010, J BIOL CHEM, V285, P41152, DOI 10.1074/jbc.M110.158352; Kelly M, 2007, J ALLERGY CLIN IMMUN, V120, P3, DOI 10.1016/j.jaci.2007.05.017; Kurimasa A, 1999, P NATL ACAD SCI USA, V96, P1403, DOI 10.1073/pnas.96.4.1403; Lloyd CM, 2013, J ALLERGY CLIN IMMUN, V131, P1267, DOI 10.1016/j.jaci.2013.02.016; Meek K, 2008, ADV IMMUNOL, V99, P33, DOI 10.1016/S0065-2776(08)00602-0; Naura AS, 2008, CLIN EXP ALLERGY, V38, P839, DOI 10.1111/j.1365-2222.2008.02943.x; Naura AS, 2013, J BIOL CHEM, V288, P1458, DOI 10.1074/jbc.M112.419580; Neal JA, 2011, MOL CELL BIOL, V31, P1719, DOI 10.1128/MCB.01298-10; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; Stevenson CS, 2011, PHARMACOL THERAPEUT, V130, P93, DOI 10.1016/j.pharmthera.2010.10.008; Woodbine L, 2013, J CLIN INVEST, V123, P2969, DOI 10.1172/JCI67349; Wright Jeffrey G, 2003, Am J Respir Med, V2, P211; Yang LY, 1998, J EXP MED, V188, P1739, DOI 10.1084/jem.188.9.1739; Zhao Y, 2006, CANCER RES, V66, P5354, DOI 10.1158/0008-5472.CAN-05-4275; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8	21	22	22	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2015	135	2					425	440		10.1016/j.jaci.2014.09.005	http://dx.doi.org/10.1016/j.jaci.2014.09.005			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CB1FL	25441643	Green Accepted			2022-12-18	WOS:000349372300014
J	Sirvent, S; Canto, B; Cuesta-Herranz, J; Gomez, F; Blanca, N; Canto, G; Blanca, M; Rodriguez, R; Villalba, M; Palomares, O				Sirvent, Sofia; Canto, Belen; Cuesta-Herranz, Javier; Gomez, Francisca; Blanca, Natalia; Canto, Gabriela; Blanca, Miguel; Rodriguez, Rosalia; Villalba, Mayte; Palomares, Oscar			Act d 12 and Act d 13: Two novel, masked, relevant allergens in kiwifruit seeds	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Sirvent, Sofia; Canto, Belen; Rodriguez, Rosalia; Villalba, Mayte; Palomares, Oscar] Univ Complutense Madrid, Sch Chem, Dept Biochem & Mol Biol, Madrid, Spain; [Cuesta-Herranz, Javier] Fdn Jimenez Diaz, Allergy Serv, E-28040 Madrid, Spain; [Gomez, Francisca; Blanca, Miguel] Hosp Carlos Haya, Allergy Serv, Malaga, Spain; [Blanca, Natalia; Canto, Gabriela] Hosp Infanta Leonor, Allergy Serv, Madrid, Spain	Complutense University of Madrid; Hospital Carlos Haya; Hospital Universitario Infanta Leonor	Sirvent, S (corresponding author), Univ Complutense Madrid, Sch Chem, Dept Biochem & Mol Biol, Madrid, Spain.	oscar.palomares@quim.ucm.es	Palomares, Oscar/ABG-5229-2020; Villalba, María Teresa/AAW-1067-2020; RODRIGUEZ, ROSALIA/K-4993-2014; Villalba, Mayte/K-5365-2014	Villalba, María Teresa/0000-0002-0042-9953; RODRIGUEZ, ROSALIA/0000-0002-4280-3691; Palomares, Oscar/0000-0003-4516-0369				Aleman A, 2004, J ALLERGY CLIN IMMUN, V113, P543, DOI 10.1016/j.jaci.2003.11.043; Bernardi ML, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027856; Beyer K, 2002, J ALLERGY CLIN IMMUN, V110, P154, DOI 10.1067/mai.2002.125487; Bublin M, 2013, ADV FOOD NUTR RES, V68, P321, DOI 10.1016/B978-0-12-394294-4.00018-3; Bublin M, 2010, J ALLERGY CLIN IMMUN, V125, P687, DOI 10.1016/j.jaci.2009.10.017; Le TM, 2013, J ALLERGY CLIN IMMUN, V131, P164, DOI 10.1016/j.jaci.2012.09.009; Palomares O, 2007, J ALLERGY CLIN IMMUN, V119, P1189, DOI 10.1016/j.jaci.2007.01.027; Vereda A, 2011, J ALLERGY CLIN IMMUN, V127, P1304, DOI 10.1016/j.jaci.2011.01.020; Wood RA, 2009, MIDDLETONS ALLERGY P, P1309	9	22	24	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2014	133	6					1765	1767		10.1016/j.jaci.2014.01.035	http://dx.doi.org/10.1016/j.jaci.2014.01.035			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AI2FI	24990823	Green Accepted			2022-12-18	WOS:000336672500035
J	Kinoshita, T; Baatjes, A; Smith, SG; Dua, B; Watson, R; Kawayama, T; Larche, M; Gauvreau, GM; O'Byrne, PM				Kinoshita, Takashi; Baatjes, Adrian; Smith, Steven G.; Dua, Benny; Watson, Richard; Kawayama, Tomotaka; Larche, Mark; Gauvreau, Gail M.; O'Byrne, Paul M.			Natural regulatory T cells in isolated early responders compared with dual responders with allergic asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic asthma; induced sputum; CD4(+) T cells; late asthmatic responses; regulatory T cells	AIRWAY HYPERRESPONSIVENESS; INFLAMMATION; FOXP3; HISTAMINE; REVERSAL; LUNG	Background: Natural regulatory T (Treg) cells are implicated in the regulation of the inflammatory response in patients with allergic asthma. Objectives: We sought to determine changes in Treg cell numbers in the airways and peripheral blood of isolated early responder (IER) versus dual responder (DR) subjects with mild allergic asthma before and after allergen challenge. Methods: Induced sputum was collected from 22 subjects with allergic asthma (10 IERs and 12 DRs) and peripheral blood collected from 8 DRs with allergic asthma at 0, 7, and 24 hours after allergen challenge. Treg cells were identified by using fluorescently labeled antibodies to CD4 and forkhead box protein 3 and enumerated by using flow cytometry. Results: There was a significant increase in the percentage of sputum CD4 1 cells 24 hours after allergen challenge in both IERs and DRs. The percentage of sputum Treg cells significantly decreased 24 hours after challenge in DRs but not IERs. This change was significantly correlated with the magnitude of the late asthmatic response. There was also a significant increase in the absolute number of sputum CD4 1 cells and Treg cells at 24 hours in DRs only. The ratio of the number of Treg cells to CD4 1 cells at 24 hours was significantly smaller in DRs compared with that in IERs. None of the above changes were observed in peripheral blood. Conclusions: DRs exhibit a diminished percentage of airway Treg cells after allergen challenge that is not observed in IERs and a significantly lower ratio of Treg cells to CD4 1 cells, which might contribute to the development of the late asthmatic response.	[Kinoshita, Takashi; Baatjes, Adrian; Smith, Steven G.; Dua, Benny; Watson, Richard; Larche, Mark; Gauvreau, Gail M.; O'Byrne, Paul M.] McMaster Univ, Firestone Inst Resp Hlth, Michael G DeGroote Sch Med, Hamilton, ON L8S 4K1, Canada; [Kinoshita, Takashi; Kawayama, Tomotaka] Kurume Univ, Dept Med, Div Respirol Neurol & Rheumatol, Fukuoka, Japan	McMaster University; Kurume University	O'Byrne, PM (corresponding author), McMaster Univ, Med Ctr, Rm 3W10,1280 Main St West, Hamilton, ON L8S 4K1, Canada.	obyrnep@mcmaster.ca		O'Byrne, Paul/0000-0003-0979-281X; Smith, Steven/0000-0001-9928-117X; Larche, Mark/0000-0002-1439-7593	Genentech; CSL; Asmacure; AstraZeneca; Amgen; Axikin; Novartis	Genentech(Roche HoldingGenentech); CSL; Asmacure; AstraZeneca(AstraZeneca); Amgen(Amgen); Axikin; Novartis(Novartis)	G. M. Gauvreau has consultancy arrangements with AIM Therapeutics, ONO Pharmaceuticals, Sterna Biologicals, and Merck and has received one or more grants from or has one or more grants pending with Genentech, CSL, and Asmacure. P. M. O'Byrne is a member of the Joint Oversight Board for the LABA safety study; has consultancy arrangements with AstraZeneca, GlaxoSmithKline, Merck, Boehringer, and Novartis; and has received one or more grants from or has one or more grants pending with AstraZeneca, Amgen, Genentech, Axikin, and Novartis. The rest of the authors declare that they have no relevant conflicts of interest.	Afshar R, 2013, J ALLERGY CLIN IMMUN, V131, P1644, DOI 10.1016/j.jaci.2013.03.002; Burchell JT, 2009, AM J PHYSIOL-LUNG C, V296, pL307, DOI 10.1152/ajplung.00521.2007; COCKCROFT DW, 1987, AM REV RESPIR DIS, V135, P264; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; Curiel TJ, 2004, NAT MED, V10, P942, DOI 10.1038/nm1093; Dieckmann D, 2002, J EXP MED, V196, P247, DOI 10.1084/jem.20020642; Ehrenstein MR, 2004, J EXP MED, V200, P277, DOI 10.1084/jem.20040165; Fontenot JD, 2017, J IMMUNOL, V198, P986, DOI 10.1038/ni904; Gauvreau GM, 1999, AM J RESP CRIT CARE, V160, P640, DOI 10.1164/ajrccm.160.2.9809130; Hartl D, 2007, J ALLERGY CLIN IMMUN, V119, P1258, DOI 10.1016/j.jaci.2007.02.023; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Kriegel MA, 2004, J EXP MED, V199, P1285, DOI 10.1084/jem.20032158; Martin H, 2012, J ALLERGY CLIN IMMUN, V129, P521, DOI 10.1016/j.jaci.2011.09.038; Matsumoto K, 2002, J ALLERGY CLIN IMMUN, V109, P281, DOI 10.1067/mai.2002.121144; Moniuszko M, 2008, EUR J CLIN INVEST, V38, P201, DOI 10.1111/j.1365-2362.2007.01920.x; OBYRNE PM, 1987, AM REV RESPIR DIS, V136, P740, DOI 10.1164/ajrccm/136.3.740; Pizzichini E, 1996, AM J RESP CRIT CARE, V154, P308, DOI 10.1164/ajrccm.154.2.8756799; Sjaheim TB, 2013, SCAND J IMMUNOL, V77, P398, DOI 10.1111/sji.12035; Smyth LJC, 2010, CHEST, V138, P905, DOI 10.1378/chest.09-3079; Soroosh P, 2013, J EXP MED, V210, P775, DOI 10.1084/jem.20121849; Strickland DH, 2006, J EXP MED, V203, P2649, DOI 10.1084/jem.20060155; Taams LS, 2002, EUR J IMMUNOL, V32, P1621, DOI 10.1002/1521-4141(200206)32:6<1621::AID-IMMU1621>3.0.CO;2-Q; Thunberg S, 2010, ALLERGY, V65, P311, DOI 10.1111/j.1398-9995.2009.02218.x; Workman CJ, 2009, CELL MOL LIFE SCI, V66, P2603, DOI 10.1007/s00018-009-0026-2; Yoshida M, 2005, J ALLERGY CLIN IMMUN, V115, P1004, DOI 10.1016/j.jaci.2005.02.003	25	22	25	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2014	133	3					696	703		10.1016/j.jaci.2013.08.025	http://dx.doi.org/10.1016/j.jaci.2013.08.025			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC3EK	24139499				2022-12-18	WOS:000332397600010
J	Chen, ZH; Wang, SZ; Erekosima, N; Li, YP; Hong, J; Qi, XP; Merkel, P; Nagabhushanam, V; Choo, E; Katial, R; Alam, R; Trikha, A; Chu, HW; Zhuang, YH; Jin, ML; Bai, CX; Huang, H				Chen, Zhihong; Wang, Shanze; Erekosima, Nkiruka; Li, Yapeng; Hong, Jessie; Qi, Xiaopeng; Merkel, Patricia; Nagabhushanam, Vijaya; Choo, Eugene; Katial, Rohit; Alam, Rafeul; Trikha, Anita; Chu, Hong Wei; Zhuang, Yonghua; Jin, Meiling; Bai, Chunxue; Huang, Hua			IL-4 confers resistance to IL-27-mediated suppression on CD4(+) T cells by impairing signal transducer and activator of transcription 1 signaling	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; T(H)2 stability; IL-4; signal transducer and activator of transcription 1 signaling; suppressor of cytokine signaling 3; IL-27	TH2 CELLS; IN-VIVO; IL-4-PRODUCING CELLS; LINEAGE COMMITMENT; IMMUNE-RESPONSES; GAMMA PRODUCTION; CUTTING EDGE; MICE LACKING; BET; EXPRESSION	Background: T(H)2 cells play a critical role in the pathogenesis of allergic asthma. Established T(H)2 cells have been shown to resist reprogramming into T-H+ cells. The inherent stability of T(H)2 cells poses a significant barrier to treating allergic diseases. Objective: We sought to understand the mechanisms by which CD4(+) T cells from asthmatic patients resist the IL-27-mediated inhibition. Methods: We isolated and cultured CD4(+) T cells from both healthy subjects and allergic asthmatic patients to test whether IL-27 can inhibit IL-4 production by the cultured CD4(+) T cells using ELISA. Culturing conditions that resulted in resistance to IL-27 were determined by using both murine and human CD4(+) T-cell culture systems. Signal transducer and activator of transcription (STAT) 1 phosphorylation was analyzed by means of Western blotting and flow cytometry. Suppressor of cytokine signaling (Socs) mRNA expression was measured by using quantitative PCR. The small interfering RNA method was used to knockdown the expression of Socs3 mRNA. Results: We demonstrated that CD4(+) T cells from asthmatic patients resisted the suppression of IL-4 production mediated by IL-27. We observed that repeated exposure to T(H)2-inducing conditions rendered healthy human CD4(+) T cells resistant to IL-27-mediated inhibition. Using an in vitro murine culture system, we further demonstrated that repeated or higher doses of IL-4 stimulation, but not IL-2 stimulation, upregulated Socs3 mRNA expression and impaired IL-27-induced STAT1 phosphorylation. The knockdown of Socs3 mRNA expression restored IL-27-induced STAT1 phosphorylation and IL-27-mediated inhibition of IL-4 production. Conclusions: Our findings demonstrate that differentiated T(H)2 cells can resist IL-27-induced reprogramming toward T(H)1 cells by downregulating STAT1 phosphorylation and likely explain why the CD4(+) T cells of asthmatic patients are resistant to IL-27-mediated inhibition.	[Chen, Zhihong; Wang, Shanze; Erekosima, Nkiruka; Li, Yapeng; Hong, Jessie; Qi, Xiaopeng; Choo, Eugene; Katial, Rohit; Alam, Rafeul; Trikha, Anita; Zhuang, Yonghua; Huang, Hua] Natl Jewish Hlth, Div Allergy & Immunol, Denver, CO 80206 USA; [Chu, Hong Wei] Natl Jewish Hlth, Dept Med, Div Pulm Crit Care & Sleep Med, Denver, CO 80206 USA; [Merkel, Patricia; Nagabhushanam, Vijaya] Natl Jewish Hlth, ADx Immunol Labs, Denver, CO 80206 USA; [Chen, Zhihong; Jin, Meiling; Bai, Chunxue] Fudan Univ, Zhangshan Hosp, Shanghai 200433, Peoples R China; [Huang, Hua] Univ Colorado, Sch Med, Integrated Dept Immunol, Denver, CO 80206 USA	National Jewish Health; National Jewish Health; National Jewish Health; Fudan University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Huang, H (corresponding author), Natl Jewish Hlth, Dept Med, 1400 Jackson St, Denver, CO 80206 USA.	huangh@njhealth.org	Zhuang, Yonghua/A-2946-2013	Zhuang, Yonghua/0000-0002-1822-2395; Bai, Chunxue/0000-0001-5798-3130; Huang, Hua/0000-0001-7317-8983	National Institutes of Health [RO1 AI068083, RO1AI083986]; National Jewish Health; National Science Foundation of China [81270078]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI068083, R01AI091614, R01AI083986] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Jewish Health; National Science Foundation of China(National Natural Science Foundation of China (NSFC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health RO1 grants AI068083 ARRA supplement (to H.H.) and RO1AI083986 (to H.H.), a fund provided by National Jewish Health (to H.H.), and a fund provided by National Science Foundation of China (no. 81270078; to Z.C. and C.B.).	Amadi-Obi A, 2007, NAT MED, V13, P711, DOI 10.1038/nm1585; Artis D, 2004, J IMMUNOL, V173, P5626, DOI 10.4049/jimmunol.173.9.5626; Canfield S, 2005, J IMMUNOL, V174, P2494, DOI 10.4049/jimmunol.174.5.2494; Cohney SJ, 1999, MOL CELL BIOL, V19, P4980; Croker BA, 2003, NAT IMMUNOL, V4, P540, DOI 10.1038/ni931; Dulek DE, 2011, BBA-GEN SUBJECTS, V1810, P1080, DOI 10.1016/j.bbagen.2011.01.012; Dupuis S, 2003, NAT GENET, V33, P388, DOI 10.1038/ng1097; Dupuis S, 2001, SCIENCE, V293, P300, DOI 10.1126/science.1061154; Elo LL, 2010, IMMUNITY, V32, P852, DOI 10.1016/j.immuni.2010.06.011; Finotto S, 2002, SCIENCE, V295, P336, DOI 10.1126/science.1065544; Fukushima A, 2005, IMMUNOGENETICS, V57, P337, DOI 10.1007/s00251-005-0805-3; Hida S, 2005, BLOOD, V106, P2011, DOI 10.1182/blood-2005-04-1344; Huang Hua, 2011, Front Biosci (Elite Ed), V3, P864; Huang Z, 2005, J IMMUNOL, V174, P1332, DOI 10.4049/jimmunol.174.3.1332; Huber JP, 2010, J IMMUNOL, V185, P813, DOI 10.4049/jimmunol.1000469; HuLi J, 1997, P NATL ACAD SCI USA, V94, P3189, DOI 10.1073/pnas.94.7.3189; Hunter CA, 2005, NAT REV IMMUNOL, V5, P521, DOI 10.1038/nri1648; KAM JC, 1993, J IMMUNOL, V151, P3460; Kaplan MH, 1996, NATURE, V382, P174, DOI 10.1038/382174a0; Kastelein RA, 2007, ANNU REV IMMUNOL, V25, P221, DOI 10.1146/annurev.immunol.22.012703.104758; Kraft M, 1998, AM J RESP CRIT CARE, V158, P998, DOI 10.1164/ajrccm.158.3.9711092; Kubo M, 2003, NAT IMMUNOL, V4, P1169, DOI 10.1038/ni1012; Le Gros G, 2008, J IMMUNOL, V181, P2943; LEGROS G, 1990, J EXP MED, V172, P921, DOI 10.1084/jem.172.3.921; Leung DYM, 2011, J ALLERGY CLIN IMMUN, V127, P965, DOI 10.1016/j.jaci.2011.02.010; Liang QL, 2010, J IMMUNOL, V185, P5704, DOI 10.4049/jimmunol.1000690; Lohoff M, 1997, IMMUNITY, V6, P681, DOI 10.1016/S1074-7613(00)80444-6; Lucas S, 2003, P NATL ACAD SCI USA, V100, P15047, DOI 10.1073/pnas.2536517100; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Messi M, 2003, NAT IMMUNOL, V4, P78, DOI 10.1038/ni872; Murphy E, 1996, J EXP MED, V183, P901, DOI 10.1084/jem.183.3.901; Neufert C, 2007, EUR J IMMUNOL, V37, P1809, DOI 10.1002/eji.200636896; O'Shea JJ, 2011, J IMMUNOL, V187, P5475, DOI 10.4049/jimmunol.1102913; Owaki T, 2006, J IMMUNOL, V177, P7579, DOI 10.4049/jimmunol.177.11.7579; Pecaric-Petkovic T, 2009, BLOOD, V113, P1526, DOI 10.1182/blood-2008-05-157818; Peebles R S Jr, 2000, Curr Opin Pulm Med, V6, P10, DOI 10.1097/00063198-200001000-00003; Qi XP, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.213389; Raby BA, 2006, AM J RESP CRIT CARE, V173, P64, DOI 10.1164/rccm.200503-505OC; Schmitz J, 2000, J BIOL CHEM, V275, P12848, DOI 10.1074/jbc.275.17.12848; Seki Y, 2003, NAT MED, V9, P1047, DOI 10.1038/nm896; Stritesky GL, 2011, IMMUNITY, V34, P39, DOI 10.1016/j.immuni.2010.12.013; Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3; Szabo SJ, 1997, J EXP MED, V185, P817, DOI 10.1084/jem.185.5.817; Szabo SJ, 2002, SCIENCE, V295, P338, DOI 10.1126/science.1065543; Taki S, 1997, IMMUNITY, V6, P673, DOI 10.1016/S1074-7613(00)80443-4; Usui T, 2006, J EXP MED, V203, P755, DOI 10.1084/jem.20052165; Usui T, 2003, IMMUNITY, V18, P415, DOI 10.1016/S1074-7613(03)00057-8; Villarino A, 2003, IMMUNITY, V19, P645, DOI 10.1016/S1074-7613(03)00300-5; Yoshimoto T, 2007, J IMMUNOL, V179, P4415, DOI 10.4049/jimmunol.179.7.4415; Zhu JF, 2012, IMMUNITY, V37, P660, DOI 10.1016/j.immuni.2012.09.007; Zhuang YH, 2009, IMMUNOLOGY, V128, P34, DOI 10.1111/j.1365-2567.2009.03049.x; Zhuang YH, 2009, J INTERF CYTOK RES, V29, P399, DOI 10.1089/jir.2008.0093	52	22	26	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2013	132	4					912	+		10.1016/j.jaci.2013.06.035	http://dx.doi.org/10.1016/j.jaci.2013.06.035			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	227FR	23958647	Bronze, Green Accepted			2022-12-18	WOS:000325096500019
J	de Roock, S; Stoppelenburg, AJ; Scholman, R; Hoeks, SBEA; Meerding, J; Prakken, BJ; Boes, M				de Roock, Sytze; Stoppelenburg, Arie J.; Scholman, Rianne; Hoeks, Sanne B. E. A.; Meerding, Jenny; Prakken, Berent J.; Boes, Marianne			Defective T(H)17 development in human neonatal T cells involves reduced RORC2 mRNA content	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							GENERATION; HELPER; BLOOD; CORD		[de Roock, Sytze; Stoppelenburg, Arie J.; Scholman, Rianne; Hoeks, Sanne B. E. A.; Meerding, Jenny; Prakken, Berent J.; Boes, Marianne] Univ Med Ctr Utrecht, Dept Pediat Immunol, CMCI, Wilhelmina Childrens Hosp, Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Wilhelmina Kinderziekenhuis	de Roock, S (corresponding author), Univ Med Ctr Utrecht, Dept Pediat Immunol, CMCI, Wilhelmina Childrens Hosp, Utrecht, Netherlands.	s.deroock@umcutrecht.nl	Stoppelenburg, Arie/AAR-4381-2020	Stoppelenburg, Arie/0000-0002-1969-6146; Boes, Marianne/0000-0003-2590-1692				Belderbos ME, 2009, CLIN IMMUNOL, V133, P228, DOI 10.1016/j.clim.2009.07.003; Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Cosmi L, 2008, J EXP MED, V205, P1903, DOI 10.1084/jem.20080397; de Roock S, 2011, J ALLERGY CLIN IMMUN, V128, P1369, DOI 10.1016/j.jaci.2011.08.006; Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035; Nitsche A, 2007, BMC IMMUNOL, V8, DOI 10.1186/1471-2172-8-18; Schaub B, 2008, ALLERGY, V63, P1438, DOI 10.1111/j.1398-9995.2008.01685.x; Unutmaz D, 2009, EUR J IMMUNOL, V39, P1452, DOI 10.1002/eji.200939540; van Beelen AJ, 2007, IMMUNITY, V27, P660, DOI 10.1016/j.immuni.2007.08.013; Wang GH, 2010, J IMMUNOL, V185, P71, DOI 10.4049/jimmunol.0903806	10	22	22	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2013	132	3					754	756		10.1016/j.jaci.2013.04.014	http://dx.doi.org/10.1016/j.jaci.2013.04.014			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	207OS	23726039				2022-12-18	WOS:000323612000034
J	Boguniewicz, M; Leung, DYM				Boguniewicz, Mark; Leung, Donald Y. M.			The ABC's of managing patients with severe atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							DISEASE; SKIN; ABNORMALITIES; COLONIZATION; FILAGGRIN; CHILDREN; BARRIER		Natl Jewish Hlth, Dept Pediat, Div Allergy Immunol, Denver, CO 80206 USA; Univ Colorado, Sch Med, Boulder, CO 80309 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Boulder	Leung, DYM (corresponding author), Natl Jewish Hlth, 1400 Jackson St,Rm K926i, Denver, CO 80206 USA.	leungd@njhealth.org			NIAID NIH HHS [HHSN272201000020C, U01 AI147462, HHSN272201000020I] Funding Source: Medline; NIAMS NIH HHS [AR41256, R01 AR041256] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041256] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Bergmann MM, 2013, J ALLER CL IMM-PRACT, V1, P22, DOI 10.1016/j.jaip.2012.11.005; Boguniewicz M, 2008, SEMIN CUTAN MED SURG, V27, P115, DOI 10.1016/j.sder.2008.05.001; Boguniewicz M, 2012, CHEM IMMUNOL ALLERGY, V96, P113, DOI 10.1159/000331910; Boguniewicz M, 2011, IMMUNOL REV, V242, P233, DOI 10.1111/j.1600-065X.2011.01027.x; Engelhardt KR, 2009, J ALLERGY CLIN IMMUN, V124, P1289, DOI 10.1016/j.jaci.2009.10.038; Fleischer DM, 2011, J PEDIATR-US, V158, P578, DOI 10.1016/j.jpeds.2010.09.027; Gittler JK, 2012, J ALLERGY CLIN IMMUN, V130, P1344, DOI 10.1016/j.jaci.2012.07.012; Hung SH, 2007, ANN ALLERG ASTHMA IM, V98, P51, DOI 10.1016/S1081-1206(10)60859-9; Irvine AD, 2011, NEW ENGL J MED, V365, P1315, DOI 10.1056/NEJMra1011040; Kuo IH, 2013, J ALLERGY CLIN IMMUN, V131, P266, DOI 10.1016/j.jaci.2012.12.1563; Lee JH, 2007, J EUR ACAD DERMATOL, V21, P1360, DOI 10.1111/j.1468-3083.2007.02277.x; Leung DYM, 2011, J ALLERGY CLIN IMMUN, V127, P965, DOI 10.1016/j.jaci.2011.02.010; McAleer MA, 2013, J ALLERGY CLIN IMMUN, V131, P280, DOI 10.1016/j.jaci.2012.12.668; Muehleisen B, 2013, J ALLERGY CLIN IMMUN, V131, P324, DOI 10.1016/j.jaci.2012.12.1562; Odhiambo JA, 2009, J ALLERGY CLIN IMMUN, V124, P1251, DOI 10.1016/j.jaci.2009.10.009; Schmitt J, 2011, BRIT J DERMATOL, V164, P415, DOI 10.1111/j.1365-2133.2010.10030.x; Schneider L, 2013, J ALLERGY CLIN IMMUN, V131, P295, DOI 10.1016/j.jaci.2012.12.672; Shemer A, 2013, J ALLERGY CLIN IMMUN, V131, P577, DOI 10.1016/j.jaci.2012.11.010; Suarez-Farinas M, 2011, J ALLERGY CLIN IMMUN, V127, P954, DOI 10.1016/j.jaci.2010.12.1124; Tintle S, 2011, J ALLERGY CLIN IMMUN, V128, P583, DOI 10.1016/j.jaci.2011.05.042	20	22	24	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2013	132	2					511	+		10.1016/j.jaci.2013.06.030	http://dx.doi.org/10.1016/j.jaci.2013.06.030			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	194KL	23905920	Green Accepted			2022-12-18	WOS:000322631700046
J	Henderson, LA; Frugoni, F; Hopkins, G; Al-Herz, W; Weinacht, K; Comeau, AM; Bonilla, FA; Notarangelo, LD; Pai, SY				Henderson, Lauren A.; Frugoni, Francesco; Hopkins, Gregory; Al-Herz, Waleed; Weinacht, Katja; Comeau, Anne Marie; Bonilla, Francisco A.; Notarangelo, Luigi D.; Pai, Sung-Yun			First reported case of Omenn syndrome in a patient with reticular dysgenesis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							SEVERE COMBINED IMMUNODEFICIENCY; ADENYLATE KINASE 2; SENSORINEURAL DEAFNESS; ALEUKOCYTOSIS		[Henderson, Lauren A.; Frugoni, Francesco; Bonilla, Francisco A.; Notarangelo, Luigi D.] Childrens Hosp Boston, Div Immunol, Boston, MA USA; [Hopkins, Gregory; Weinacht, Katja; Pai, Sung-Yun] Childrens Hosp Boston, Div Hematol & Oncol, Boston, MA USA; [Notarangelo, Luigi D.] Childrens Hosp Boston, Manton Ctr Orphan Dis Res, Boston, MA USA; [Al-Herz, Waleed] Kuwait Univ, Dept Pediat, Fac Med, Allergy & Clin Immunol Unit, Kuwait, Kuwait; [Weinacht, Katja; Pai, Sung-Yun] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; [Comeau, Anne Marie] Univ Massachusetts, Sch Med, New England Newborn Screening Program, Worcester, MA USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Kuwait University; Harvard University; Dana-Farber Cancer Institute; University of Massachusetts System; University of Massachusetts Worcester	Henderson, LA (corresponding author), Childrens Hosp Boston, Div Immunol, Boston, MA USA.	Sung-Yun.Pai@childrens.harvard.edu	Pai, Sung-Yun/AAH-7762-2019; Notarangelo, Luigi D/F-9718-2016	Pai, Sung-Yun/0000-0002-0158-8147; Notarangelo, Luigi D/0000-0002-8335-0262; Frugoni, Francesco/0000-0002-1769-8121	NIAID NIH HHS [U54AI082973, U54 AI082973] Funding Source: Medline; NCEH CDC HHS [1U01EH00362, U01 EH000362] Funding Source: Medline; NATIONAL CENTER FOR ENVIRONMENTAL HEALTH [U01EH000362] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U54AI082973] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCEH CDC HHS; NATIONAL CENTER FOR ENVIRONMENTAL HEALTH(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bulley SR, 2008, BIOL BLOOD MARROW TR, V14, P229, DOI 10.1016/j.bbmt.2007.10.027; ComansBitter WM, 1997, J PEDIATR-US, V130, P388, DOI 10.1016/S0022-3476(97)70200-2; DEVAAL OM, 1959, LANCET, V2, P1123; Gerstel-Thompson JL, 2010, CLIN CHEM, V56, P1466, DOI 10.1373/clinchem.2010.144915; Lagresle-Peyrou C, 2009, NAT GENET, V41, P106, DOI 10.1038/ng.278; Pannicke U, 2009, NAT GENET, V41, P101, DOI 10.1038/ng.265; Shearer WT, 2003, J ALLERGY CLIN IMMUN, V112, P973, DOI 10.1016/j.jaci.2003.07.003; Small TN, 1999, J PEDIATR-US, V135, P387, DOI 10.1016/S0022-3476(99)70141-1; Straathof KC, 2009, LANCET, V374, P912, DOI 10.1016/S0140-6736(09)60945-4; Villa A, 2008, J ALLERGY CLIN IMMUN, V122, P1082, DOI 10.1016/j.jaci.2008.09.037	10	22	22	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2013	131	4					1227	1230		10.1016/j.jaci.2012.07.045	http://dx.doi.org/10.1016/j.jaci.2012.07.045			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	120QT	23014587	Green Accepted			2022-12-18	WOS:000317187200034
J	Mazerolles, F; Picard, C; Kracker, S; Fischer, A; Durandy, A				Mazerolles, Fabienne; Picard, Capucine; Kracker, Sven; Fischer, Alain; Durandy, Anne			Blood CD4(+)CD45RO(+)CXCR5(+) T cells are decreased but partially functional in signal transducer and activator of transcription 3 deficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Human; T cells; signal transducer and activator of transcription 3 deficiency; cell activation; naive B cells	CXC CHEMOKINE RECEPTOR-5; FOLLICULAR-HELPER-CELLS; COMMON GAMMA-CHAIN; HYPER-IGE SYNDROME; MEMORY B-CELLS; CUTTING EDGE; IL-21 RECEPTOR; HUMAN NAIVE; ANTIBODY-RESPONSES; STAT3	Background: The generation of high-affinity antibodies requires the presence of a population of CD4(+) T cells (follicular T-H [T-FH] cells) in the lymph node follicles. These cells differ from T(H)1, T(H)2, and T(H)17 effector cells in that they strongly express activation markers and the chemokine receptor CXCR5 and secrete large amounts of IL-21 and CXCL13. Small numbers of nonactivated CD4(+)CD45RO(+)CXCR5(+) T cells are also found in the blood. Objective: We sought to obtain in vitro a population close to the TFH cells and to study the presence of this cell population among patients with autosomal dominant hyper-IgE syndrome carrying heterozygous signal transducer and activator of transcription 3 (STAT3) mutations that impair the IL-21 signaling required for B-cell differentiation. Methods: CD4(+)CD45RO(+)CXCR5(+) T cells were isolated from blood and activated by CD3/T-cell receptor. Results: We found that CD4(+)CD45RO(+)CXCR5(+) activated T cells corresponding to circulating bona fide memory TFH cells and that STAT3-deficient patients have abnormally low numbers of "TFH-like'' blood T cells. However, STAT3-deficient TFH cells have much the same phenotypic and functional characteristics as TFH cells from healthy control subjects. The ability of STAT3-deficient TFH cells to produce IL-21 on CD28/T-cell receptor activation and to proliferate did not differ from that observed for control TFH cells in vitro. Although the STAT3deficient TFH cells were also able to help control B cells to produce IgG and IgA, induction of IgG production by naive B cells was impaired. Conclusion: Heterozygous mutations in STAT3 lead to reduced numbers of circulating TFH-like cells, a finding that might account (at least in part) for the observed defect in antibody production. (J Allergy Clin Immunol 2013; 131:1146-56.)	[Mazerolles, Fabienne; Kracker, Sven; Fischer, Alain; Durandy, Anne] INSERM, U768, Paris, France; [Mazerolles, Fabienne; Picard, Capucine; Kracker, Sven; Fischer, Alain; Durandy, Anne] Univ Sorbonne Paris Cite, Inst Imagine, Necker Med Fac, Paris, France; [Picard, Capucine] Necker Med Sch, Necker Div, Lab Human Genet Infect Dis, INSERM,U980, Paris, France; [Picard, Capucine; Fischer, Alain] Hop Necker Enfants Malad, AP HP, Pediat Hematol & Immunol Unit, Paris, France; [Picard, Capucine; Durandy, Anne] Necker Enfants Malad Hosp, Immunodeficiency Study Ctr, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite	Mazerolles, F (corresponding author), Bat Pasteur Necker Enfants Malad Hosp, Inst Natl Sante & Rech Med, U768, 149 Rue Sevres, F-75015 Paris, France.	fabienne.mazerolles@inserm.fr	Kracker, Sven/H-3681-2017; Picard, Capucine/H-3914-2017; Durandy, Anne/H-7475-2017	Kracker, Sven/0000-0003-4543-8236; Picard, Capucine/0000-0001-8788-5056; Durandy, Anne/0000-0001-7706-8466; MAZEROLLES, Fabienne/0000-0002-5991-614X	March of Dimes; Dana Foundation; INSERM; Institut National de la Sante et de la Recherche Medicale; European Union [201549]; Association Contre Le Cancer; ANR Blanc; EUROPAD	March of Dimes(March of Dimes); Dana Foundation; INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Institut National de la Sante et de la Recherche Medicale(Institut National de la Sante et de la Recherche Medicale (Inserm)); European Union(European Commission); Association Contre Le Cancer; ANR Blanc(French National Research Agency (ANR)); EUROPAD	The Laboratory of Human Genetics of Infectious Diseases was funded by the March of Dimes, the Dana Foundation, and INSERM. This work was funded by grants from Institut National de la Sante et de la Recherche Medicale, the European Union's 7th RTD Framework Programme (EUROPAD contract no. 201549), Association Contre Le Cancer, and ANR Blanc 2010-CSR.; Disclosure of potential conflict of interest: S. Kracker, A. Fischer, and A. Durandy have received grants from EUROPAD and ANR Blanc. The rest of the authors declare that they have no relevant conflicts of interest.	Allen CDC, 2007, IMMUNITY, V27, P190, DOI 10.1016/j.immuni.2007.07.009; Amft N, 2001, ARTHRITIS RHEUM-US, V44, P2633, DOI 10.1002/1529-0131(200111)44:11<2633::AID-ART443>3.0.CO;2-9; Ansel KM, 1999, J EXP MED, V190, P1123, DOI 10.1084/jem.190.8.1123; Asao H, 2001, J IMMUNOL, V167, P1, DOI 10.4049/jimmunol.167.1.1; Avery DT, 2008, BLOOD, V112, P1784, DOI 10.1182/blood-2008-02-142745; Avery DT, 2008, J IMMUNOL, V181, P1767, DOI 10.4049/jimmunol.181.3.1767; Avery DT, 2010, J EXP MED, V207, P155, DOI 10.1084/jem.20091706; Baumjohann D, 2011, J IMMUNOL, V187, P2089, DOI 10.4049/jimmunol.1101393; Breitfeld D, 2000, J EXP MED, V192, P1545, DOI 10.1084/jem.192.11.1545; Bryant VL, 2007, J IMMUNOL, V179, P8180, DOI 10.4049/jimmunol.179.12.8180; Chandesris MO, 2012, MEDICINE, V91, pE1, DOI 10.1097/MD.0b013e31825f95b9; Chevalier N, 2011, J IMMUNOL, V186, P5556, DOI 10.4049/jimmunol.1002828; Chtanova T, 2004, J IMMUNOL, V173, P68, DOI 10.4049/jimmunol.173.1.68; de Beaucoudrey L, 2008, J EXP MED, V205, P1543, DOI 10.1084/jem.20080321; Dong C, 2001, J IMMUNOL, V166, P3659, DOI 10.4049/jimmunol.166.6.3659; Eddahri F, 2009, BLOOD, V113, P2426, DOI 10.1182/blood-2008-04-154682; Erazo A, 2007, IMMUNITY, V26, P191, DOI 10.1016/j.immuni.2006.12.006; Ettinger R, 2005, J IMMUNOL, V175, P7867, DOI 10.4049/jimmunol.175.12.7867; Ettinger R, 2008, IMMUNOL REV, V223, P60, DOI 10.1111/j.1600-065X.2008.00631.x; Fazilleau N, 2009, IMMUNITY, V30, P324, DOI 10.1016/j.immuni.2009.03.003; Garside P, 1998, SCIENCE, V281, P96, DOI 10.1126/science.281.5373.96; Habib T, 2002, BIOCHEMISTRY-US, V41, P8725, DOI 10.1021/bi0202023; Haynes NM, 2007, J IMMUNOL, V179, P5099, DOI 10.4049/jimmunol.179.8.5099; He B, 2007, IMMUNITY, V26, P812, DOI 10.1016/j.immuni.2007.04.014; Johnston RJ, 2009, SCIENCE, V325, P1006, DOI 10.1126/science.1175870; Kim CH, 2004, BLOOD, V104, P1952, DOI 10.1182/blood-2004-03-1206; Kim CH, 2001, J EXP MED, V193, P1373, DOI 10.1084/jem.193.12.1373; King C, 2008, ANNU REV IMMUNOL, V26, P741, DOI 10.1146/annurev.immunol.26.021607.090344; LEUNG DYM, 1988, J ALLERGY CLIN IMMUN, V81, P1082, DOI 10.1016/0091-6749(88)90873-1; Liu YJ, 1996, IMMUNITY, V4, P241, DOI 10.1016/S1074-7613(00)80432-X; Ma CS, 2008, J EXP MED, V205, P1551, DOI 10.1084/jem.20080218; Ma CS, 2012, BLOOD, V119, P3997, DOI 10.1182/blood-2011-11-392985; Ma CS, 2009, IMMUNOL CELL BIOL, V87, P590, DOI 10.1038/icb.2009.64; Milner JD, 2008, NATURE, V452, P773, DOI 10.1038/nature06764; Minegishi Y, 2007, NATURE, V448, P1058, DOI 10.1038/nature06096; Morita R, 2011, IMMUNITY, V34, P108, DOI 10.1016/j.immuni.2010.12.012; Nurieva RI, 2008, IMMUNITY, V29, P138, DOI 10.1016/j.immuni.2008.05.009; Nurieva RI, 2009, SCIENCE, V325, P1001, DOI 10.1126/science.1176676; Ozaki K, 2002, SCIENCE, V298, P1630, DOI 10.1126/science.1077002; Pene J, 2004, J IMMUNOL, V172, P5154, DOI 10.4049/jimmunol.172.9.5154; Schaerli P, 2000, J EXP MED, V192, P1553, DOI 10.1084/jem.192.11.1553; Schmitt N, 2009, IMMUNITY, V31, P158, DOI 10.1016/j.immuni.2009.04.016; Shuai K, 2003, NAT REV IMMUNOL, V3, P900, DOI 10.1038/nri1226; Siegel AM, 2011, IMMUNITY, V35, P806, DOI 10.1016/j.immuni.2011.09.016; Speckmann C, 2008, CLIN IMMUNOL, V129, P448, DOI 10.1016/j.clim.2008.08.002; Suto A, 2002, BLOOD, V100, P4565, DOI 10.1182/blood-2002-04-1115; Tangye SG, 2009, J IMMUNOL, V182, P21, DOI 10.4049/jimmunol.182.1.21; Vogelzang A, 2008, IMMUNITY, V29, P127, DOI 10.1016/j.immuni.2008.06.001; Warnatz K, 2006, BLOOD, V107, P3045, DOI 10.1182/blood-2005-07-2955; Yu D, 2009, IMMUNITY, V31, P457, DOI 10.1016/j.immuni.2009.07.002	50	22	22	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2013	131	4					1146	+		10.1016/j.jaci.2012.12.1519	http://dx.doi.org/10.1016/j.jaci.2012.12.1519			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	120QT	23403044				2022-12-18	WOS:000317187200025
J	Al-Alwan, LA; Chang, Y; Baglole, CJ; Risse, PA; Halayko, AJ; Martin, JG; Eidelman, DH; Hamid, Q				Al-Alwan, Laila A.; Chang, Ying; Baglole, Carolyn J.; Risse, Paul-Andre; Halayko, Andrew J.; Martin, James G.; Eidelman, David H.; Hamid, Qutayba			Autocrine-regulated airway smooth muscle cell migration is dependent on IL-17-induced growth-related oncogenes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; airway remodeling; IL-17; airway smooth muscle cells; migration; growth-related oncogenes	NF-KAPPA-B; EPITHELIAL-CELLS; TNF-ALPHA; INTERLEUKIN-8 RELEASE; BRONCHIAL-ASTHMA; CXC CHEMOKINES; MESSENGER-RNA; EXPRESSION; ACTIVATION; IL-17A	Background: Airway smooth muscle cell (ASMC) migration is one of the proposed mechanisms underlying the increased airway smooth muscle mass seen in airway remodeling of patients with severe asthma. IL-17-related cytokines are a new subgroup of inflammatory mediators that have been suggested to play a role in regulating smooth muscle function. We hypothesized that IL-17-induced chemokine production from smooth muscle cells can contribute to migration of additional smooth muscle cells in the airways of asthmatic patients. Objective: We sought to investigate the effect of IL-17 on smooth muscle-derived chemokines and to examine the mechanisms involved in their production and contribution to the increase in airway smooth muscle migration. Methods: The effect of IL-17-induced supernatants on human ASMC migration was investigated. IL-17-induced growth-related oncogene (GRO) production and mRNA expression was assessed by using ELISA and RT-PCR, respectively. The direct effect of GROs on ASMC migration and the involvement of the CXCR2 receptor were also examined. Results: IL-17-induced supernatants promoted ASMC migration. After IL-17 stimulation, GROs were the most abundant chemokines produced from ASMCs, and blocking their effect by using neutralizing antibodies significantly inhibited ASMC migration. In addition, a combination of recombinant human GRO-alpha, GRO-beta, and GRO-gamma was able to promote significant migration of ASMCs that was mediated through the CXCR2 receptor. Conclusion: These findings suggest that IL-17-induced GROs can be an important mediator of ASMC migration and therefore might contribute to the pathogenesis of airway remodeling in asthmatic patients. (J Allergy Clin Immunol 2012; 130:977-85.)	[Al-Alwan, Laila A.; Chang, Ying; Baglole, Carolyn J.; Risse, Paul-Andre; Martin, James G.; Eidelman, David H.; Hamid, Qutayba] McGill Univ, Meakins Christie Labs, Montreal, PQ H2X 2P2, Canada; [Al-Alwan, Laila A.; Chang, Ying; Baglole, Carolyn J.; Risse, Paul-Andre; Martin, James G.; Eidelman, David H.; Hamid, Qutayba] McGill Univ, Div Resp, Dept Med, Montreal, PQ H2X 2P2, Canada; [Halayko, Andrew J.] Univ Manitoba, Dept Physiol, Resp Hosp, Winnipeg, MB, Canada	McGill University; McGill University; University of Manitoba; Children's Hospital Research Institute of Manitoba	Hamid, Q (corresponding author), McGill Univ, Meakins Christie Labs, 3626 Rue St Urbain, Montreal, PQ H2X 2P2, Canada.	qutayba.hamid@mcgill.ca	Chang, Ying/I-1362-2012	Halayko, Andrew/0000-0002-7865-4552; Martin, James/0000-0001-7574-5363	Canadian Institutes of Health Research; American Thoracic Society; Costello Memorial Fund; McGill University Health Centre-Research Institute of Fonds de la Recherche en Sante Quebec; GlaxoSmithKline; Canadian Institute of Health Research; Genentech	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); American Thoracic Society; Costello Memorial Fund; McGill University Health Centre-Research Institute of Fonds de la Recherche en Sante Quebec; GlaxoSmithKline(GlaxoSmithKline); Canadian Institute of Health Research(Canadian Institutes of Health Research (CIHR)); Genentech(Roche HoldingGenentech)	Supported by the Canadian Institutes of Health Research, the American Thoracic Society, the Costello Memorial Fund, and the McGill University Health Centre-Research Institute of Fonds de la Recherche en Sante Quebec.; A.J. Halayko is an advisory board member for Novartis and receives research support from GlaxoSmithKline. J.G. Martin receives research support from the Canadian Institutes of Health Research and receives payment for lectures from Merck and Novartis. Q. Hamid receives research support from the Canadian Institute of Health Research and Genentech, has consultant arrangements with GlaxoSmithKline, has received payment for lectures from Merck USA, and is employed by the McGill University Health Centre Research Institute. The rest of the authors declare that they have no relevant conflicts of interest.	Agache I, 2010, RESP MED, V104, P1131, DOI 10.1016/j.rmed.2010.02.018; Ahuja SK, 1996, J BIOL CHEM, V271, P20545, DOI 10.1074/jbc.271.34.20545; Al-Ramli W, 2009, J ALLERGY CLIN IMMUN, V123, P1185, DOI 10.1016/j.jaci.2009.02.024; Awane M, 1999, J IMMUNOL, V162, P5337; Bentley J Kelley, 2008, Proc Am Thorac Soc, V5, P89, DOI 10.1513/pats.200705-063VS; Black JL, 2001, AM J RESP CRIT CARE, V164, pS63, DOI 10.1164/ajrccm.164.supplement_2.2106059; Bradley ME, 2009, BRIT J PHARMACOL, V158, P328, DOI 10.1111/j.1476-5381.2009.00182.x; Carroll N, 1996, EUR RESPIR J, V9, P709, DOI 10.1183/09031936.96.09040709; Chang Y, 2011, J ALLERGY CLIN IMMUN, V127, P1046, DOI 10.1016/j.jaci.2010.12.1117; Clarke DL, 2010, J BIOL CHEM, V285, P29101, DOI 10.1074/jbc.M109.0999952; Doe C, 2010, CHEST, V138, P1140, DOI 10.1378/chest.09-3058; Doll D, 2010, INT J COLORECTAL DIS, V25, P573, DOI 10.1007/s00384-010-0901-1; Fixman ED, 2007, EUR RESPIR J, V29, P379, DOI 10.1183/09031936.00053506; Goleva E, 2008, J ALLERGY CLIN IMMUN, V122, P550, DOI 10.1016/j.jaci.2008.07.007; Goncharova EA, 2006, NAT PROTOC, V1, P2933, DOI 10.1038/nprot.2006.434; Gordon RJ, 2009, MOL CELL NEUROSCI, V41, P219, DOI 10.1016/j.mcn.2009.03.001; HALAYKO AJ, 1994, CAN J PHYSIOL PHARM, V72, P1448, DOI 10.1139/y94-209; HASKILL S, 1990, P NATL ACAD SCI USA, V87, P7732, DOI 10.1073/pnas.87.19.7732; Henness S, 2006, AM J PHYSIOL-LUNG C, V290, pL1283, DOI 10.1152/ajplung.00367.2005; Hoshino M, 1998, THORAX, V53, P21, DOI 10.1136/thx.53.1.21; Huang F, 2007, J IMMUNOL, V179, P6504, DOI 10.4049/jimmunol.179.10.6504; Issa R, 2006, AM J PHYSIOL-LUNG C, V291, pL66, DOI 10.1152/ajplung.00384.2005; Iwakura Y, 2008, IMMUNOL REV, V226, P57, DOI 10.1111/j.1600-065X.2008.00699.x; Jarai G, 2004, EUR J PHARMACOL, V497, P255, DOI 10.1016/j.ejphar.2004.06.055; Kaur D, 2006, AM J RESP CRIT CARE, V174, P1179, DOI 10.1164/rccm.200603-394OC; Kelly E, 2008, BRIT J PHARMACOL, V153, pS379, DOI 10.1038/sj.bjp.0707604; Knobloch J, 2009, THORAX, V64, P1044, DOI 10.1136/thx.2008.111047; Kuo PL, 2012, BASIC CLIN PHARMACOL, V110, P178, DOI 10.1111/j.1742-7843.2011.00797.x; LAMBERT RK, 1993, J APPL PHYSIOL, V74, P2771, DOI 10.1152/jappl.1993.74.6.2771; Lazaar AL, 2005, J ALLERGY CLIN IMMUN, V116, P488, DOI 10.1016/j.jaci.2005.06.030; Minamitani C, 2008, MOL CELL ENDOCRINOL, V291, P27, DOI 10.1016/j.mce.2008.05.011; Minshall EM, 1997, AM J RESP CELL MOL, V17, P326, DOI 10.1165/ajrcmb.17.3.2733; Moran EM, 2011, ARTHRITIS RHEUM-US, V63, P3263, DOI 10.1002/art.30582; Munakata Mitsuru, 2006, Allergol Int, V55, P235, DOI 10.2332/allergolint.55.235; Olson TS, 2002, AM J PHYSIOL-REG I, V283, pR7, DOI 10.1152/ajpregu.00738.2001; Onishi RM, 2010, IMMUNOLOGY, V129, P311, DOI 10.1111/j.1365-2567.2009.03240.x; Parameswaran K, 2007, AM J RESP CELL MOL, V37, P240, DOI 10.1165/rcmb.2006-0172OC; Prause O, 2003, EUR J PHARMACOL, V462, P193, DOI 10.1016/S0014-2999(03)01341-4; Prefontaine D, 2009, J IMMUNOL, V183, P5094, DOI 10.4049/jimmunol.0802387; Rahman MS, 2005, CLIN IMMUNOL, V115, P268, DOI 10.1016/j.clim.2005.01.014; Rahman MS, 2006, J IMMUNOL, V177, P4064, DOI 10.4049/jimmunol.177.6.4064; Ramos-Barbon D, 2010, AM J RESP CRIT CARE, V182, P317, DOI 10.1164/rccm.200905-0745OC; Robins S, 2011, AM J RESP CELL MOL, V45, P984, DOI 10.1165/rcmb.2010-0450OC; Rudack C, 2003, J INTERF CYTOK RES, V23, P113, DOI 10.1089/107999003321455507; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; Takeda N, 2009, CLIN EXP ALLERGY, V39, P1018, DOI 10.1111/j.1365-2222.2009.03238.x; Vignola A M, 2002, Paediatr Respir Rev, V3, P41, DOI 10.1053/prrv.2001.0166; Vignola AM, 2003, CHEST, V123, p417S, DOI 10.1378/chest.123.3_suppl.417S; Wang Q, 2010, J IMMUNOL, V185, P834, DOI 10.4049/jimmunol.0901490; Wuyts WA, 2005, J HEART LUNG TRANSPL, V24, P875, DOI 10.1016/j.healun.2004.05.003; Xu WJ, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-14; Zaja-Milatovic S, 2008, HISTOL HISTOPATHOL, V23, P1399, DOI 10.14670/HH-23.1399	52	22	24	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2012	130	4					977	+		10.1016/j.jaci.2012.04.042	http://dx.doi.org/10.1016/j.jaci.2012.04.042			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017MT	22698519				2022-12-18	WOS:000309594800020
J	Wang, MQ; Okamoto, M; Domenico, J; Han, JY; Ashino, S; Shin, YS; Gelfand, EW				Wang, Meiqin; Okamoto, Masakazu; Domenico, Joanne; Han, Junyan; Ashino, Shigeru; Shin, Yoo Seob; Gelfand, Erwin W.			Inhibition of Pim1 kinase prevents peanut allergy by enhancing Runx3 expression and suppressing T(H)2 and T(H)17 T-cell differentiation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Pim1 kinase; Runx3; peanut; intestinal allergy; T(H)2; T(H)17	MEDIATED AIRWAY HYPERRESPONSIVENESS; TRANSCRIPTION FACTOR; HELPER TYPE-1; FAMILY; PROTEINS; RECEPTOR; LINEAGE; IL-13; ACTIVATION; CYTOKINE	Background: The provirus integration site for Moloney murine leukemia virus (Pim) 1 kinase is an oncogenic serine/threonine kinase implicated in cytokine-induced cell signaling, whereas Runt-related transcription factor (Runx) has been implicated in the regulation of T-cell differentiation. The interaction of Pim1 kinase and Runx3 in the pathogenesis of peanut allergy has not been defined. Objectives: We sought to determine the effects of Pim1 kinase modulation on Runx3 expression and T(H)2 and T(H)17 cell function in an experimental model of peanut allergy. Methods: A Pim1 kinase inhibitor was administered to peanut-sensitized and challenged wild-type and Runx3(+/-) mice. Symptoms, intestinal inflammation, and Pim1 kinase and Runx3 mRNA expression and protein levels were assessed. The effects of Pim1 kinase inhibition on T(H)1, T(H)2, and T(H)17 differentiation in vivo and in vitro were also determined. Results: Peanut sensitization and challenge resulted in accumulation of inflammatory cells and goblet cell metaplasia and increased levels of Pim1 kinase and T(H)2 and T(H)17 cytokine production but decreased levels of Runx3 mRNA and protein in the small intestines of wild-type mice. All of these findings were normalized with Pim1 kinase inhibition. In sensitized and challenged Runx3(+/-) mice, inhibition of Pim1 kinase had less effect on the development of the full spectrum of intestinal allergic responses. In vitro inhibition of Pim1 kinase attenuated T(H)2 and T(H)17 cell differentiation and expansion while maintaining Runx3 expression in T-cell cultures from wild-type mice; these effects were reduced in T-cell cultures from Runx3(+/-) mice. Conclusion: These data support a novel regulatory axis involving Pim1 kinase and Runx3 in the control of food-induced allergic reactions through the regulation of T(H)2 and T(H)17 differentiation. (J Allergy Clin Immunol 2012; 130:932-44.)	[Wang, Meiqin; Okamoto, Masakazu; Domenico, Joanne; Han, Junyan; Ashino, Shigeru; Shin, Yoo Seob; Gelfand, Erwin W.] Natl Jewish Hlth, Dept Pediat, Div Cell Biol, Denver, CO 80206 USA	National Jewish Health	Gelfand, EW (corresponding author), Natl Jewish Hlth, Dept Pediat, Div Cell Biol, 1400 Jackson St, Denver, CO 80206 USA.	gelfande@njhealth.org			National Institutes of Health [HL-36577, AI-77609]; Eugene F. and Easton M. Crawford Charitable Lead Unitrust; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036577] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI077609, R01AI077609] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Eugene F. and Easton M. Crawford Charitable Lead Unitrust; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health grants HL-36577 and AI-77609. M.W. was supported by a fellowship from the Eugene F. and Easton M. Crawford Charitable Lead Unitrust. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Heart, Lung, and Blood Institute or the National Institutes of Health.	Aho TL, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-21; Aho TLT, 2005, IMMUNOLOGY, V116, P82, DOI 10.1111/j.1365-2567.2005.02201.x; Ashino S, 2010, INT IMMUNOL, V22, P503, DOI 10.1093/intimm/dxq034; Aujla M, 2010, NAT REV CLIN ONCOL, V7, P3; Bachmann M, 2005, INT J BIOCHEM CELL B, V37, P726, DOI 10.1016/j.biocel.2004.11.005; Blumchen K, 2010, J ALLERGY CLIN IMMUN, V126, P83, DOI 10.1016/j.jaci.2010.04.030; Brault L, 2010, HAEMATOL-HEMATOL J, V95, P1004, DOI 10.3324/haematol.2009.017079; Brenner O, 2004, P NATL ACAD SCI USA, V101, P16016, DOI 10.1073/pnas.0407180101; CALABI F, 1995, GENOMICS, V26, P607, DOI 10.1016/0888-7543(95)80184-N; Christensen U, 2009, HUM GENET, V126, P549, DOI 10.1007/s00439-009-0692-z; Collins A, 2009, NAT REV IMMUNOL, V9, P106, DOI 10.1038/nri2489; DAUTRY F, 1988, J BIOL CHEM, V263, P17615; Djuretic IM, 2007, NAT IMMUNOL, V8, P145, DOI 10.1038/ni1424; Donaldson DD, 1998, J IMMUNOL, V161, P2317; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Eigenmann PA, 2002, PEDIAT ALLERG IMM-UK, V13, P162, DOI 10.1034/j.1399-3038.2002.01015.x; Fainaru O, 2005, P NATL ACAD SCI USA, V102, P10598, DOI 10.1073/pnas.0504787102; Fox CJ, 2005, J EXP MED, V201, P259, DOI 10.1084/jem.20042020; Friend DS, 1996, J CELL BIOL, V135, P279, DOI 10.1083/jcb.135.1.279; Haagerup A, 2002, ALLERGY, V57, P680, DOI 10.1034/j.1398-9995.2002.23523.x; Jackson LJ, 2009, J IMMUNOL, V182; Kohu K, 2009, J IMMUNOL, V183, P7817, DOI 10.4049/jimmunol.0802527; Kolls JK, 2004, IMMUNITY, V21, P467, DOI 10.1016/j.immuni.2004.08.018; Komine O, 2003, J EXP MED, V198, P51, DOI 10.1084/jem.20021200; Kweon MN, 2000, J CLIN INVEST, V106, P199, DOI 10.1172/JCI8490; Lajoie S, 2010, NAT IMMUNOL, V11, P928, DOI 10.1038/ni.1926; Lee SH, 2009, BIOCHEM BIOPH RES CO, V381, P214, DOI 10.1016/j.bbrc.2009.02.026; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; Li XM, 2000, J ALLERGY CLIN IMMUN, V106, P150, DOI 10.1067/mai.2000.107395; Matikainen S, 1999, BLOOD, V93, P1980, DOI 10.1182/blood.V93.6.1980.406k20_1980_1991; Miyahara S, 2006, J ALLERGY CLIN IMMUN, V118, P1110, DOI 10.1016/j.jaci.2006.06.014; Ohnishi H, 2008, J ALLERGY CLIN IMMUN, V121, P864, DOI 10.1016/j.jaci.2008.01.035; Okamoto K, 2010, NATURE, V464, P1381, DOI 10.1038/nature08922; Okamoto M, 2008, J EXP MED, V205, P1087, DOI 10.1084/jem.20072200; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Ouyang W, 1998, IMMUNITY, V9, P745, DOI 10.1016/S1074-7613(00)80671-8; Rainio EM, 2002, J IMMUNOL, V168, P1524, DOI 10.4049/jimmunol.168.4.1524; Shin YS, 2012, AM J RESP CELL MOL, V46, P488, DOI 10.1165/rcmb.2011-0190OC; Stout BA, 2004, J IMMUNOL, V173, P6409, DOI 10.4049/jimmunol.173.10.6409; Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3; Taniuchi I, 2002, CELL, V111, P621, DOI 10.1016/S0092-8674(02)01111-X; Taube C, 2006, J IMMUNOL, V176, P3157, DOI 10.4049/jimmunol.176.5.3157; Tesmer LA, 2008, IMMUNOL REV, V223, P87, DOI 10.1111/j.1600-065X.2008.00628.x; Tomkinson A, 2001, AM J RESP CRIT CARE, V163, P721, DOI 10.1164/ajrccm.163.3.2005010; Walter DM, 2001, J IMMUNOL, V167, P4668, DOI 10.4049/jimmunol.167.8.4668; Wang MQ, 2010, J ALLERGY CLIN IMMUN, V126, P306, DOI 10.1016/j.jaci.2010.05.017; Wang YH, 2010, J EXP MED, V207, P2479, DOI 10.1084/jem.20101376; Wingett D, 1996, J IMMUNOL, V156, P549; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8	49	22	37	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2012	130	4					932	+		10.1016/j.jaci.2012.07.032	http://dx.doi.org/10.1016/j.jaci.2012.07.032			25	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017MT	22944483	Green Accepted			2022-12-18	WOS:000309594800015
J	Torgerson, DG; Capurso, D; Ampleford, EJ; Li, XN; Moore, WC; Gignoux, CR; Hu, DL; Eng, C; Mathias, RA; Busse, WW; Castro, M; Erzurum, SC; Fitzpatrick, AM; Gaston, B; Israel, E; Jarjour, NN; Teague, WG; Wenzel, SE; Rodriguez-Santana, JR; Rodriguez-Cintron, W; Avila, PC; Ford, JG; Barnes, KC; Burchard, EG; Howard, TD; Bleecker, ER; Meyers, DA; Cox, NJ; Ober, C; Nicolae, DL				Torgerson, Dara G.; Capurso, Daniel; Ampleford, Elizabeth J.; Li, Xingnan; Moore, Wendy C.; Gignoux, Christopher R.; Hu, Donglei; Eng, Celeste; Mathias, Rasika A.; Busse, William W.; Castro, Mario; Erzurum, Serpil C.; Fitzpatrick, Anne M.; Gaston, Benjamin; Israel, Elliot; Jarjour, Nizar N.; Teague, W. Gerald; Wenzel, Sally E.; Rodriguez-Santana, Jose R.; Rodriguez-Cintron, William; Avila, Pedro C.; Ford, Jean G.; Barnes, Kathleen C.; Burchard, Esteban G.; Howard, Timothy D.; Bleecker, Eugene R.; Meyers, Deborah A.; Cox, Nancy J.; Ober, Carole; Nicolae, Dan L.			Genome-wide ancestry association testing identifies a common European variant on 6q14.1 as a risk factor for asthma in African American subjects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; population structure; genome-wide association study; admixture mapping; ancestry association testing; admixed populations; African American; Puerto Rican	RESEARCH-PROGRAM; POPULATION; LOCUS; STRATIFICATION; HERITABILITY; CONSORTIUM; PHENOTYPES; COMPONENTS; GENETICS; SCALE	Background: Genetic variants that contribute to asthma susceptibility might be present at varying frequencies in different populations, which is an important consideration and advantage for performing genetic association studies in admixed populations. Objective: We sought to identify asthma-associated loci in African American subjects. Methods: We compared local African and European ancestry estimated from dense single nucleotide polymorphism genotype data in African American adults with asthma and nonasthmatic control subjects. Allelic tests of association were performed within the candidate regions identified, correcting for local European admixture. Results: We identified a significant ancestry association peak on chromosome 6q. Allelic tests for association within this region identified a single nucleotide polymorphism (rs1361549) on 6q14.1 that was associated with asthma exclusively in African American subjects with local European admixture (odds ratio, 2.2). The risk allele is common in Europe (42% in the HapMap population of Utah residents with Northern and Western European ancestry from the Centre d'Etude du Polymorphisme Humain collection) but absent in West Africa (0% in the HapMap population of Yorubans in Ibadan, Nigeria), suggesting the allele is present in African American subjects because of recent European admixture. We replicated our findings in Puerto Rican subjects and similarly found that the signal of association is largely specific to subjects who are heterozygous for African and non-African ancestry at 6q14.1. However, we found no evidence for association in European American or Puerto Rican subjects in the absence of local African ancestry, suggesting that the association with asthma at rs1361549 is due to an environmental or genetic interaction. Conclusion: We identified a novel asthma-associated locus that is relevant to admixed populations with African ancestry and highlight the importance of considering local ancestry in genetic association studies of admixed populations. (J Allergy Clin Immunol 2012;130:622-9.)	[Nicolae, Dan L.] Univ Chicago, Med Genet Sect, Dept Med, Chicago, IL 60637 USA; [Torgerson, Dara G.; Capurso, Daniel; Ober, Carole] Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA; [Torgerson, Dara G.; Capurso, Daniel; Gignoux, Christopher R.; Hu, Donglei; Eng, Celeste; Burchard, Esteban G.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA; [Ampleford, Elizabeth J.; Li, Xingnan; Moore, Wendy C.; Howard, Timothy D.; Bleecker, Eugene R.; Meyers, Deborah A.] Wake Forest Sch Med, Ctr Genom & Personalized Med Res, Winston Salem, NC USA; [Mathias, Rasika A.; Barnes, Kathleen C.] Johns Hopkins Asthma & Allergy Ctr, Baltimore, MD USA; [Busse, William W.] Univ Wisconsin, Dept Med, Madison, WI USA; [Castro, Mario] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; [Castro, Mario] Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; [Erzurum, Serpil C.] Lerner Res Inst, Cleveland, OH USA; [Fitzpatrick, Anne M.] Emory Univ, Sch Med, Dept Pediat, Atlanta, GA USA; [Gaston, Benjamin; Teague, W. Gerald] Univ Virginia Hlth Syst, Dept Pediat, Charlottesville, VA USA; [Israel, Elliot] Harvard Univ, Brigham & Womens Hosp, Boston, MA 02115 USA; [Jarjour, Nizar N.] Univ Wisconsin Hosp & Clin, Dept Med, Madison, WI 53792 USA; [Jarjour, Nizar N.] Univ Wisconsin Hosp & Clin, Dept Publ Hlth Sci, Madison, WI 53792 USA; [Wenzel, Sally E.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA; [Rodriguez-Santana, Jose R.] Ctr Neumol Pediat, Caguas, PR USA; [Rodriguez-Cintron, William] VA Med Ctr, San Juan, PR USA; [Avila, Pedro C.] Northwestern Univ, Dept Med, Chicago, IL 60611 USA; [Ford, Jean G.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, New York, NY USA	University of Chicago; University of Chicago; University of California System; University of California San Francisco; Wake Forest University; Johns Hopkins University; Johns Hopkins Medicine; University of Wisconsin System; University of Wisconsin Madison; Washington University (WUSTL); Washington University (WUSTL); Cleveland Clinic Foundation; Emory University; University of Virginia; Harvard University; Brigham & Women's Hospital; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Northwestern University; Johns Hopkins University	Nicolae, DL (corresponding author), Univ Chicago, Med Genet Sect, Dept Med, 900 E 57th St,KCBD 3220, Chicago, IL 60637 USA.	nicolae@galton.uchicago.edu		Ober, Carole/0000-0003-4626-9809; Fitzpatrick, Anne/0000-0002-2933-5926; Wenzel, Sally/0000-0002-4242-0164; Nicolae, Dan/0000-0002-0918-4630	National Institutes of Health [U01 HL49596, R01 HL072414, R01 HL087665, RC2 HL101651, 2T32GM007546, 1RC2 HL101651, ES015794, U19 AI077439, HL088133, HL078885]; Flight Attendant Medical Research Institute (FAMRI); National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID); NIH/National Heart, Lung, and Blood Institute (NHLBI); Asthmatx; Amgen; Ception/Cephalon; Genentech; Medimmune; Merck; Novartis; NIH; GlaxoSmithKline; Severe Asthma Research Network (SARP); NIH/NHLBI; American Lung Association; Sirius Genomics, Inc.; National Heart, Lung, and Blood Institute; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000005] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024153] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL049596, R01HL072414, R01HL088133, R01HL078885, RC2HL101651, R01HL087665] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES015794] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007546] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Flight Attendant Medical Research Institute (FAMRI); National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIH/National Heart, Lung, and Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Asthmatx; Amgen(Amgen); Ception/Cephalon; Genentech(Roche HoldingGenentech); Medimmune(AstraZenecaMedimmune); Merck(Merck & Company); Novartis(Novartis); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); GlaxoSmithKline(GlaxoSmithKline); Severe Asthma Research Network (SARP); NIH/NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); American Lung Association; Sirius Genomics, Inc.; National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Supported by grants from the National Institutes of Health (U01 HL49596, R01 HL072414, R01 HL087665, RC2 HL101651, 2T32GM007546, 1RC2 HL101651, ES015794, U19 AI077439, HL088133, and HL078885) and the Flight Attendant Medical Research Institute (FAMRI).; C. R. Gignoux owns stock in 23 and Me, Inc. W. W. Busse is on the Advisory Board for Centocor and Merck; is a consultant for Amgen, AstraZeneca, Novartis, GlaxoSmithKline, MedImmune, and Genentech; has received research support from the National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID) and NIH/National Heart, Lung, and Blood Institute (NHLBI). M. Castro has given lectures for Asthmatx, Genentech, AstraZeneca, Merck, and GlaxoSmithKline; has consulted for Asthmatx; is on an advisory board for Genentech; and has received grants (given to his institution) from Asthmatx, Amgen, Ception/Cephalon, Genentech, Medimmune, Merck, Novartis, the NIH, and GlaxoSmithKline. B. Gaston has received research support from the Severe Asthma Research Network (SARP). W. G. Teague is a speaker for Merck and Genentech and has received research support from NIH/NHLBI and the American Lung Association. P. C. Avila has received research grants from Genentech and the NIH. J. G. Ford is a consultant for GlaxoSmithKline. K. C. Barnes has received research support from the NIH and Sirius Genomics, Inc. E. R. Bleecker and D. A. Meyers have received grants from the NIH. The rest of the authors declare that they have no relevant conflicts of interest.; We thank all of the participants in the CSGA, SARP, and GALA. SARP is a multicenter asthma research group funded by the National Heart, Lung, and Blood Institute and consisting of the following contributors (principal investigators are marked with asterisks): Brigham & Women's Hospital-Elliot Israel,* Bruce D. Levy, Michael E. Wechsler, Shamsah Kazani, and Gautham Marigowda; Cleveland Clinic-Serpil C. Erzurum,* Raed A. Dweik, Suzy A. A. Comhair, Emmea Cleggett-Mattox, Deepa George, Marcelle Baaklini, and Daniel Laskowski; Emory University-Anne M. Fitzpatrick, Denise Whitlock, and Shanae Wakefield; Imperial College School of Medicine-Kian Fan Chung,* Mark Hew, Patricia Macedo, Sally Meah, and Florence Chow; University of Iowa-Eric Hoffman* and Janice Cook-Granroth; University of Pittsburgh-Sally E. Wenzel,* Fernando Holguin, Silvana Balzar, and Jen Chamberlin; University of Texas-Medical Branch-William J. Calhoun* and Bill T. Ameredes; University of Virginia-Benjamin Gaston,* W. Gerald Teague,* and Denise Thompson-Batt; University of Wisconsin-William W. Busse,* Nizar Jarjour, Ronald Sorkness, Sean Fain, and Gina Crisafi; Wake Forest University-Eugene R. Bleecker,* Deborah Meyers, Wendy Moore, Stephen Peters, Rodolfo M. Pascual, Annette Hastie, Gregory Hawkins, Jeffrey Krings, and Regina Smith; Washington University in St Louis-Mario Castro,* Leonard Bacharier, and Jaime Tarsi; Data Coordinating Center-Douglas Curran-Everett,* Ruthie Knowles, Maura Robinson, and Lori Silveira; and the National Heart, Lung, and Blood Institute-Patricia Noel and Robert Smith. We thank Vito J. Mantese, BA.	Agudelo M, 2008, J NEUROIMMUNE PHARM, V3, P35, DOI 10.1007/s11481-007-9088-9; Alexander DH, 2009, GENOME RES, V19, P1655, DOI 10.1101/gr.094052.109; Altshuler D, 2010, NATURE, V467, P1061, DOI 10.1038/nature09534; Barnes Kathleen C, 2007, Proc Am Thorac Soc, V4, P58, DOI 10.1513/pats.200607-146JG; Boyko AR, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000083; Cheng CY, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000908; Cheng CY, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000490; Choudhry S, 2006, HUM GENET, V118, P652, DOI 10.1007/s00439-005-0071-3; Choudhry S, 2008, HUM GENET, V123, P455, DOI 10.1007/s00439-008-0495-7; Freedman ML, 2006, P NATL ACAD SCI USA, V103, P14068, DOI 10.1073/pnas.0605832103; Gamazon ER, 2010, BIOINFORMATICS, V26, P259, DOI 10.1093/bioinformatics/btp644; Hancock DB, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000623; Himes BE, 2009, AM J HUM GENET, V84, P581, DOI 10.1016/j.ajhg.2009.04.006; Howie BN, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000529; Huizinga TWJ, 2003, J RHEUMATOL, V30, P1904; Lester LA, 2001, J ALLERGY CLIN IMMUN, V108, P357, DOI 10.1067/mai.2001.117796; Li XN, 2010, J ALLERGY CLIN IMMUN, V125, P328, DOI 10.1016/j.jaci.2009.11.018; Marchini J, 2007, NAT GENET, V39, P906, DOI 10.1038/ng2088; Mathias RA, 2010, J ALLERGY CLIN IMMUN, V125, P336, DOI 10.1016/j.jaci.2009.08.031; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Moore WC, 2007, J ALLERGY CLIN IMMUN, V119, P405, DOI 10.1016/j.jaci.2006.11.639; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; Murray T, 2010, GENET EPIDEMIOL, V34, P561, DOI 10.1002/gepi.20512; Ober C, 2006, GENES IMMUN, V7, P95, DOI 10.1038/sj.gene.6364284; Patterson N, 2004, AM J HUM GENET, V74, P979, DOI 10.1086/420871; Patterson N, 2006, PLOS GENET, V2, P2074, DOI 10.1371/journal.pgen.0020190; Price AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847; Price AL, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000519; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Reich D, 2005, NAT GENET, V37, P1113, DOI 10.1038/ng1646; Sankararaman S, 2008, AM J HUM GENET, V82, P290, DOI 10.1016/j.ajhg.2007.09.022; Sleiman PMA, 2010, NEW ENGL J MED, V362, P36, DOI 10.1056/NEJMoa0901867; Su AI, 2004, P NATL ACAD SCI USA, V101, P6062, DOI 10.1073/pnas.0400782101; Thomsen SF, 2010, CLIN EXP ALLERGY, V40, P1054, DOI 10.1111/j.1365-2222.2010.03525.x; Willemsen G, 2008, TWIN RES HUM GENET, V11, P132, DOI 10.1375/twin.11.2.132; Zhu XF, 2011, HUM MOL GENET, V20, P2285, DOI 10.1093/hmg/ddr113	37	22	22	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2012	130	3					622	+		10.1016/j.jaci.2012.03.045	http://dx.doi.org/10.1016/j.jaci.2012.03.045			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	001LZ	22607992	Green Accepted			2022-12-18	WOS:000308463500008
J	Larson, D; Cooper, PJ; Hubner, MP; Reyes, J; Vaca, M; Chico, M; Kong, HH; Mitre, E				Larson, David; Cooper, Philip J.; Huebner, Marc P.; Reyes, Jorge; Vaca, Maritza; Chico, Martha; Kong, Heidi H.; Mitre, Edward			Helminth infection is associated with decreased basophil responsiveness in human beings	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Larson, David; Huebner, Marc P.; Mitre, Edward] Uniformed Serv Univ Hlth Sci, Dept Microbiol & Immunol, Bethesda, MD 20814 USA; [Cooper, Philip J.] Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England; [Cooper, Philip J.; Reyes, Jorge; Vaca, Maritza; Chico, Martha] Lab Invest FEPIS, Quininde, Esmeraldas Prov, Ecuador; [Cooper, Philip J.] Univ San Francisco Quito, Colegio Ciencias Salud, Quito, Ecuador; [Huebner, Marc P.] Univ Hosp Bonn, Inst Med Microbiol Immunol & Parasitol, Bonn, Germany; [Kong, Heidi H.] NCI, Dermatol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	Uniformed Services University of the Health Sciences - USA; Liverpool School of Tropical Medicine; University of Liverpool; University of Bonn; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Larson, D (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Microbiol & Immunol, Bethesda, MD 20814 USA.	edward.mitre@usuhs.edu	Hübner, Marc P/O-1684-2019; Kong, Heidi H/L-4856-2018; Hübner, Marc P/W-9529-2018	Hübner, Marc P/0000-0001-8885-418X; Kong, Heidi H/0000-0003-4424-064X; Hübner, Marc P/0000-0001-8885-418X; Reyes, Jorge A/0000-0002-5215-164X	NATIONAL CANCER INSTITUTE [ZIABC010938] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI076522] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI076522, R01AI076522] Funding Source: Medline; Wellcome Trust [088862, 072405/Z/03/Z] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Wellcome Trust(Wellcome TrustEuropean Commission)		Cooper PJ, 2009, CURR OPIN ALLERGY CL, V9, P29, DOI 10.1097/ACI.0b013e32831f44a6; Falcone FH, 2011, CLIN EXP ALLERGY, V41, P939, DOI 10.1111/j.1365-2222.2011.03781.x; Fallon PG, 2007, NAT REV IMMUNOL, V7, P220, DOI 10.1038/nri2039; Larson D, 2012, J IMMUNOL, V188, P4188, DOI 10.4049/jimmunol.1101859; Lee JJ, 2007, BLOOD, V109, P859, DOI 10.1182/blood-2006-06-027490; MacGlashan D, 2001, J LEUKOCYTE BIOL, V70, P207; Ohnmacht C, 2010, IMMUNITY, V33, P364, DOI 10.1016/j.immuni.2010.08.011; Sokol CL, 2010, MUCOSAL IMMUNOL, V3, P129, DOI 10.1038/mi.2009.137	8	22	23	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2012	130	1					270	272		10.1016/j.jaci.2012.04.017	http://dx.doi.org/10.1016/j.jaci.2012.04.017			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	977GN	22608572	Green Accepted			2022-12-18	WOS:000306644800041
J	Ueta, M; Tamiya, G; Tokunaga, K; Sotozono, C; Ueki, M; Sawai, H; Inatomi, T; Matsuoka, T; Akira, S; Narumiya, S; Tashiro, K; Kinoshita, S				Ueta, Mayumi; Tamiya, Gen; Tokunaga, Katsushi; Sotozono, Chie; Ueki, Masao; Sawai, Hiromi; Inatomi, Tsutomu; Matsuoka, Toshiyuki; Akira, Shizuo; Narumiya, Shuh; Tashiro, Kei; Kinoshita, Shigeru			Epistatic interaction between Toll-like receptor 3 (TLR3) and prostaglandin E receptor 3 (PTGER3) genes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							STEVENS-JOHNSON-SYNDROME; CONJUNCTIVAL EPITHELIUM; SUBTYPE EP3; POLYMORPHISMS; ASSOCIATION; JAPANESE		[Ueta, Mayumi; Sotozono, Chie; Inatomi, Tsutomu; Kinoshita, Shigeru] Kyoto Prefectural Univ Med, Dept Ophthalmol, Kyoto, Japan; [Ueta, Mayumi] Doshisha Univ, Res Ctr Inflammat & Regenerat Med, Fac Life & Med Sci, Kyoto 602, Japan; [Tashiro, Kei] Kyoto Prefectural Univ Med, Dept Genom Med Sci, Kyoto, Japan; [Tamiya, Gen; Ueki, Masao] Yamagata Univ, Adv Mol Epidemiol Res Inst, Fac Med, Yamagata 990, Japan; [Tokunaga, Katsushi; Sawai, Hiromi] Univ Tokyo, Dept Human Genet, Grad Sch Med, Tokyo, Japan; [Matsuoka, Toshiyuki] Tenri Yorozu Hosp, Nara, Japan; [Akira, Shizuo] Osaka Univ, Dept Host Def, Res Inst Microbial Dis, Osaka, Japan; [Narumiya, Shuh] Kyoto Univ, Dept Pharmacol, Kyoto, Japan; [Narumiya, Shuh] Kyoto Univ, Fac Med, Kyoto, Japan	Kyoto Prefectural University of Medicine; Doshisha University; Kyoto Prefectural University of Medicine; Yamagata University; University of Tokyo; Osaka University; Kyoto University; Kyoto University	Ueta, M (corresponding author), Kyoto Prefectural Univ Med, Dept Ophthalmol, Kyoto, Japan.	mueta@koto.kpu-m.ac.jp	Akira, Shizuo/C-3134-2009	Tamiya, Gen/0000-0002-0597-415X	Grants-in-Aid for Scientific Research [23659818] Funding Source: KAKEN	Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))		Cordell HJ, 2009, NAT REV GENET, V10, P392, DOI 10.1038/nrg2579; Sotozono C, 2007, OPHTHALMOLOGY, V114, P1294, DOI 10.1016/j.ophtha.2006.10.029; Stevens AM, 1922, AM J DIS CHILD, V24, P526, DOI 10.1001/archpedi.1922.04120120077005; Ueta M, 2007, J ALLERGY CLIN IMMUN, V120, P1457, DOI 10.1016/j.jaci.2007.07.048; Ueta M, 2007, BRIT J OPHTHALMOL, V91, P962, DOI 10.1136/bjo.2006.113449; Ueta M, 2007, AM J OPHTHALMOL, V143, P367, DOI 10.1016/j.ajo.2006.09.029; Ueta M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025209; Ueta M, 2011, BRIT J OPHTHALMOL, V95, P742, DOI 10.1136/bjo.2010.188748; Ueta M, 2011, BRIT J OPHTHALMOL, V95, P859, DOI 10.1136/bjo.2010.199679; Ueta M, 2010, J ALLERGY CLIN IMMUN, V126, P1218, DOI 10.1016/j.jaci.2010.08.007; Ueta M, 2009, J ALLERGY CLIN IMMUN, V123, P1187, DOI 10.1016/j.jaci.2009.03.008; Ueta M, 2009, J ALLERGY CLIN IMMUN, V123, P466, DOI 10.1016/j.jaci.2008.09.044	12	22	22	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2012	129	5					1413	1416		10.1016/j.jaci.2012.01.069	http://dx.doi.org/10.1016/j.jaci.2012.01.069			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	934CG	22421267				2022-12-18	WOS:000303418000038
J	Fung, I; Spergel, JM				Fung, Irene; Spergel, Jonathan M.			Administration of influenza vaccine to pediatric patients with egg-induced anaphylaxis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ALLERGY; SAFETY		[Fung, Irene; Spergel, Jonathan M.] Univ Penn, Childrens Hosp Philadelphia, Perelman Sch Med, Div Allergy & Immunol, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Fung, I (corresponding author), Univ Penn, Childrens Hosp Philadelphia, Perelman Sch Med, Div Allergy & Immunol, Philadelphia, PA 19104 USA.	Spergel@email.chop.edu		Spergel, Jonathan/0000-0002-4658-5353				Chung EY, 2010, PEDIATRICS, V125, pE1024, DOI 10.1542/peds.2009-2512; Gagnon R, 2010, J ALLERGY CLIN IMMUN, V126, P317, DOI 10.1016/j.jaci.2010.05.037; Greenhawt MJ, 2011, ANN ALLERG ASTHMA IM, V106, P11, DOI 10.1016/j.anai.2010.11.015; Greenhawt MJ, 2010, ANN ALLERG ASTHMA IM, V105, P387, DOI 10.1016/j.anai.2010.08.015; Howe LE, 2011, ANN ALLERG ASTHMA IM, V106, P446, DOI 10.1016/j.anai.2011.01.024; James JM, 1998, J PEDIATR-US, V133, P624, DOI 10.1016/S0022-3476(98)70101-5; Li JT, 2010, J ALLERGY CLIN IMMUN, V125, P1412, DOI 10.1016/j.jaci.2010.03.009; Owens G, 2011, J ALLERGY CLIN IMMUN, V127, P264, DOI 10.1016/j.jaci.2010.10.005; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Webb L, 2011, J ALLERGY CLIN IMMUN, V128, P218, DOI 10.1016/j.jaci.2011.02.013	10	22	22	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2012	129	4					1157	1159		10.1016/j.jaci.2011.11.038	http://dx.doi.org/10.1016/j.jaci.2011.11.038			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	917AP	22236726	Bronze			2022-12-18	WOS:000302144600038
J	Redhu, NS; Saleh, A; Lee, HC; Halayko, AJ; Ziegler, SF; Gounni, AS				Redhu, Naresh Singh; Saleh, Ali; Lee, Hai-Chon; Halayko, Andrew J.; Ziegler, Steven F.; Gounni, Abdelilah S.			IgE induces transcriptional regulation of thymic stromal lymphopoietin in human airway smooth muscle cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							FC-EPSILON-RI; EXPRESSION; RECEPTOR; ACTIVATION; APOPTOSIS		[Redhu, Naresh Singh; Saleh, Ali; Gounni, Abdelilah S.] Univ Manitoba, Fac Med, Dept Immunol, Winnipeg, MB R3E 0W3, Canada; [Halayko, Andrew J.] Univ Manitoba, Fac Med, Dept Physiol, Winnipeg, MB, Canada; [Lee, Hai-Chon; Ziegler, Steven F.] Benaroya Res Inst, Program Immunol, Seattle, WA USA	University of Manitoba; University of Manitoba; Benaroya Research Institute	Redhu, NS (corresponding author), Univ Manitoba, Fac Med, Dept Immunol, Winnipeg, MB R3E 0W3, Canada.	gounni@cc.umanitoba.ca	Gounni, Abdelilah Soussi/AAH-3456-2020	Halayko, Andrew/0000-0002-7865-4552; Soussi Gounni, Abdelilah/0000-0002-7282-0388; Gounni, Abdelilah/0000-0003-1265-6560	Canadian Institutes of Health Research Funding Source: Medline	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))		Allakhverdi Z, 2009, J ALLERGY CLIN IMMUN, V123, P958, DOI 10.1016/j.jaci.2009.01.059; Gould HJ, 2003, ANNU REV IMMUNOL, V21, P579, DOI 10.1146/annurev.immunol.21.120601.141103; Gounni AS, 2005, J IMMUNOL, V175, P2613, DOI 10.4049/jimmunol.175.4.2613; Hamann KJ, 2000, AM J PHYSIOL-LUNG C, V278, pL618, DOI 10.1152/ajplung.2000.278.3.L618; Kalesnikoff J, 2001, IMMUNITY, V14, P801, DOI 10.1016/S1074-7613(01)00159-5; Katoh N, 2000, J CLIN INVEST, V105, P183, DOI 10.1172/JCI6895; Kung SKP, 2000, J VIROL, V74, P3668, DOI 10.1128/JVI.74.8.3668-3681.2000; Lee HC, 2007, P NATL ACAD SCI USA, V104, P914, DOI 10.1073/pnas.0607305104; Matsubara S, 2006, AM J RESP CRIT CARE, V173, P56, DOI 10.1164/rccm.200503-361OC; Redhu NS, 2011, AM J PHYSIOL-LUNG C, V300, pL479, DOI 10.1152/ajplung.00301.2009; Redhu NS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006153; Rossi AB, 2006, J ALLERGY CLIN IMMUN, V118, P749, DOI 10.1016/j.jaci.2006.05.023; Roth M, 2010, ANN ALLERG ASTHMA IM, V104, P152, DOI 10.1016/j.anai.2009.11.022; Saffar AS, 2007, J IMMUNOL, V178, P2535, DOI 10.4049/jimmunol.178.4.2535; Shan LY, 2010, J IMMUNOL, V184, P7134, DOI 10.4049/jimmunol.0902515; Smelter DF, 2010, J IMMUNOL, V185, P3035, DOI 10.4049/jimmunol.1000252; Taussig LM, 2003, J ALLERGY CLIN IMMUN, V111, P661, DOI 10.1067/mai.2003.162; Tliba O, 2009, ANNU REV PHYSIOL, V71, P509, DOI 10.1146/annurev.physiol.010908.163227; Zhang KQ, 2007, AM J PHYSIOL-LUNG C, V293, pL375, DOI 10.1152/ajplung.00045.2007; Ziegler SF, 2010, CURR OPIN IMMUNOL, V22, P795, DOI 10.1016/j.coi.2010.10.020	20	22	24	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2011	128	4					892	+		10.1016/j.jaci.2011.06.045	http://dx.doi.org/10.1016/j.jaci.2011.06.045			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	841UA	21835441				2022-12-18	WOS:000296538100031
J	Pessach, IM; Notarangelo, LD				Pessach, Itai M.; Notarangelo, Luigi D.			Gene therapy for primary immunodeficiencies: Looking ahead, toward gene correction	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Primary immunodeficiencies; severe combined immunodeficiency; gene therapy; gene correction; locus-specific targeting; homing endonucleases; meganucleases; zinc finger nucleases; safe harbors; transposons	ACTIVATION; PROSPECTS	Allogeneic hematopoietic stem cell transplantation is the treatment of choice for severe primary immunodeficiencies (PIDs). For patients lacking an HLA-identical donor, gene therapy is an attractive therapeutic option. Approaches based on insertion of a functional gene by using viral vectors have provided proof of concept for the ability of gene therapy to cure PIDs. However, leukemic transformation as a result of insertional mutagenesis has been observed, prompting development of novel approaches based on introduction of DNA double-strand breaks into the endogenous locus to achieve gene correction, or into a safe genomic location ("safe harbor"). Homing endonucleases and zinc finger nucleases are target-specific endonucleases that induce site-specific DNA double-strand breaks, facilitating homologous recombination around their target sites to achieve gene correction or gene insertion into safe harbors. An alternative approach to achieve site-specific insertion of functional genes is based on transposons, DNA elements that spontaneously translocate from a specific chromosomal location to another. These novel tools may lead to efficient and safer strategies to achieve gene therapy for PIDs and other disorders. (J Allergy Clin Immunol 2011;127:1344-50.)	[Pessach, Itai M.] Safra Childrens Hosp, Sheba Med Ctr, Dept Pediat Crit Care, Tel Hashomer, Israel; [Pessach, Itai M.] Safra Childrens Hosp, Sheba Med Ctr, Talpiot Med Leadership Program, Tel Hashomer, Israel; [Pessach, Itai M.; Notarangelo, Luigi D.] Harvard Univ, Sch Med, Div Immunol, Boston, MA USA; [Notarangelo, Luigi D.] Childrens Hosp Boston, Manton Ctr Orphan Dis Res, Boston, MA 02115 USA	Chaim Sheba Medical Center; Chaim Sheba Medical Center; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital	Notarangelo, LD (corresponding author), Childrens Hosp Boston, Div Immunol, Karp Bldg,Room 9210,1 Blackfan Circle, Boston, MA 02115 USA.	luigi.notarangelo@childrens.harvard.edu	Notarangelo, Luigi D/F-9718-2016	Notarangelo, Luigi D/0000-0002-8335-0262	National Institutes of Health [1R03AI088352-01, 1R21AI089810-01]; March of Dimes [6-FY10-282]; Manton Foundation; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R03AI088352, R21AI089810] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); March of Dimes(March of Dimes); Manton Foundation; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health grants 1R03AI088352-01 and 1R21AI089810-01, March of Dimes grant 6-FY10-282, and the Manton Foundation.	BLAESE RM, 1995, SCIENCE, V270, P475, DOI 10.1126/science.270.5235.475; Bouuaert CC, 2010, GENETICA, V138, P473, DOI 10.1007/s10709-009-9391-x; Boztug K, 2010, NEW ENGL J MED, V363, P1918, DOI 10.1056/NEJMoa1003548; Buckley RH, 2004, ANNU REV IMMUNOL, V22, P625, DOI 10.1146/annurev.immunol.22.012703.104614; Cavazzana-Calvo M, 2010, NATURE, V467, P318, DOI 10.1038/nature09328; Ferrua F, 2010, CURR OPIN ALLERGY CL, V10, P551, DOI 10.1097/ACI.0b013e32833fea85; Fischer A, 2010, IMMUNOL ALLERGY CLIN, V30, P237, DOI 10.1016/j.iac.2010.02.002; Gennery AR, 2010, J ALLERGY CLIN IMMUN, V126, P602, DOI 10.1016/j.jaci.2010.06.015; GOSTISSA M, 2010, ANN REV IMMUNOL 0405; Hackett PB, 2010, MOL THER, V18, P674, DOI 10.1038/mt.2010.2; Lagresle-Peyrou C, 2006, BLOOD, V107, P63, DOI 10.1182/blood-2005-05-2032; Munoz IG, 2011, NUCLEIC ACIDS RES, V39, P729, DOI 10.1093/nar/gkq801; Nakayama M, 2010, DRUG DISCOV TODAY, V15, P198, DOI 10.1016/j.drudis.2010.01.006; Notarangelo LD, 2009, J ALLERGY CLIN IMMUN, V124, P1161, DOI 10.1016/j.jaci.2009.10.013; PESSACH IM, 2010, J ALLERGY CLIN  1223; Qasim W, 2009, GENE THER, V16, P1285, DOI 10.1038/gt.2009.127; Silva G, 2011, CURR GENE THER, V11, P11, DOI 10.2174/156652311794520111; Stein S, 2010, NAT MED, V16, P198, DOI 10.1038/nm.2088; Urnov FD, 2005, NATURE, V435, P646, DOI 10.1038/nature03556; VandenDriessche T, 2009, BLOOD, V114, P1461, DOI 10.1182/blood-2009-04-210427	20	22	23	1	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2011	127	6					1344	1350		10.1016/j.jaci.2011.02.027	http://dx.doi.org/10.1016/j.jaci.2011.02.027			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	769WH	21440291	Bronze, Green Accepted			2022-12-18	WOS:000291048500003
J	Crump, C; Sundquist, K; Sundquist, J; Winkleby, MA				Crump, Casey; Sundquist, Kristina; Sundquist, Jan; Winkleby, Marilyn A.			Gestational age at birth and risk of allergic rhinitis in young adulthood	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Antiallergic agents; gestational age; perennial allergic; seasonal allergic rhinitis; premature birth	HAY-FEVER; ATOPIC DISEASE; PRETERM BIRTH; FETAL-GROWTH; COHORT; ASTHMA; CHILDHOOD; ECZEMA; CHILDREN; WEIGHT	Background: Previous studies of the association between gestational age or birth weight and allergic rhinitis in later life have had various limitations, including the inability to estimate risk among subjects born extremely preterm or to examine specific contributions of gestational age and fetal growth. Objective: We sought to determine whether gestational age at birth independent of fetal growth is associated with allergic rhinitis medication prescription in a national cohort of young adults. Methods: We conducted a national cohort study of 630,090 infants born in Sweden from 1973 through 1979 including 27,953 born preterm (<37 weeks) and followed for prescription of nasal corticosteroids and oral antihistamines in 2005-2009 (age, 25.5-37.0 years). Medication data were obtained from all outpatient and inpatient pharmacies throughout Sweden. Results: The overall prevalence of nasal corticosteroid and oral antihistamine prescription was 16.3% and 16.8%, respectively, which is similar to the reported prevalence of allergic rhinitis in this population. Low gestational age at birth was associated with a decreased risk of nasal corticosteroid and oral antihistamine prescription in young adulthood after adjusting for fetal growth and other potential confounders. For subjects born extremely preterm (23-28 weeks), adjusted odds ratios were 0.70 (95% CI, 0.51-0.96) for nasal corticosteroid prescription and 0.45 (95% CI, 0.27-0.76) for both nasal corticosteroid and oral antihistamine prescription relative to those born at full term. Conclusion: These findings suggest that low gestational age at birth independent of fetal growth is associated with a decreased risk of allergic rhinitis in young adulthood, possibly because of a protective effect of earlier exposure to pathogens. (J Allergy Clin Immunol 2011;127:1173-9.)	[Crump, Casey] Stanford Univ, Dept Med, Palo Alto, CA 94304 USA; [Sundquist, Jan; Winkleby, Marilyn A.] Stanford Univ, Stanford Prevent Res Ctr, Palo Alto, CA 94304 USA; [Sundquist, Kristina; Sundquist, Jan] Lund Univ, Ctr Primary Hlth Care Res, Malmo, Sweden	Stanford University; Stanford University; Lund University	Crump, C (corresponding author), 211 Quarry Rd,Room N300,MC 5765, Palo Alto, CA 94304 USA.	kccrump@stanford.edu	Crump, Casey/AAO-8802-2021	Crump, Casey/0000-0002-2990-1166	National Institute of Child Health and Human Development [1R01HD052848-01]; Swedish Research Council [2008-3110, 2008-2638]; Swedish Council for Working Life and Social Research [2006-0386, 2007-1754, 2007-1962]; Lund, Sweden; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD052848] Funding Source: NIH RePORTER	National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Council for Working Life and Social Research(Swedish Research CouncilSwedish Research Council for Health Working Life & Welfare (Forte)); Lund, Sweden; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	Supported by the National Institute of Child Health and Human Development (1R01HD052848-01), the Swedish Research Council (2008-3110 and 2008-2638), the Swedish Council for Working Life and Social Research (2006-0386, 2007-1754, and 2007-1962), and an ALF project grant, Lund, Sweden.	Bolte G, 2004, CLIN EXP ALLERGY, V34, P381, DOI 10.1111/j.1365-2222.2004.01890.x; Braback L, 1998, CLIN EXP ALLERGY, V28, P936; Butland BK, 1997, BRIT MED J, V315, P717, DOI 10.1136/bmj.315.7110.717; Crump C, 2010, INT J EPIDEMIOL, V39, P1522, DOI 10.1093/ije/dyq103; Fergusson DM, 1997, CLIN EXP ALLERGY, V27, P1394, DOI 10.1046/j.1365-2222.1997.1430947.x; Katz KA, 2003, CLIN EXP ALLERGY, V33, P737, DOI 10.1046/j.1365-2222.2003.01670.x; Kiechl-Kohlendorfer U, 2007, ACTA PAEDIATR, V96, P1606, DOI 10.1111/j.1651-2227.2007.00449.x; Lundholm C, 2010, CLIN EXP ALLERGY, V40, P1044, DOI 10.1111/j.1365-2222.2010.03519.x; Mallen CD, 2008, J ASTHMA, V45, P309, DOI 10.1080/02770900801911194; Marsal K, 1996, ACTA PAEDIATR, V85, P843, DOI 10.1111/j.1651-2227.1996.tb14164.x; Nihlen U, 2006, ALLERGY, V61, P1299, DOI 10.1111/j.1398-9995.2006.01166.x; Pekkanen J, 2001, CLIN EXP ALLERGY, V31, P95, DOI 10.1046/j.1365-2222.2001.00930.x; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; Rasanen M, 2001, Twin Res, V4, P392; Shah PS, 2010, ACTA OBSTET GYN SCAN, V89, P862, DOI 10.3109/00016349.2010.486827; StataCorp, 2010, STAT STAT SOFTW REL; Strachan David P., 2000, Thorax, V55, pS2, DOI 10.1136/thorax.55.suppl_1.S2; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Strachan DP, 1997, J ALLERGY CLIN IMMUN, V99, P6, DOI 10.1016/S0091-6749(97)81038-X; WEGMANN TG, 1993, IMMUNOL TODAY, V14, P353, DOI 10.1016/0167-5699(93)90235-D; *WHO, 2010, METH CCFDS	21	22	22	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2011	127	5					1173	1179		10.1016/j.jaci.2011.02.023	http://dx.doi.org/10.1016/j.jaci.2011.02.023			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	756NG	21439628	Green Accepted			2022-12-18	WOS:000290018600011
J	Corren, J; Wood, RA; Patel, D; Zhu, J; Yegin, A; Dhillon, G; Fish, JE				Corren, Jonathan; Wood, Robert A.; Patel, Deepen; Zhu, Jin; Yegin, Ashley; Dhillon, Gitika; Fish, James E.			Effects of omalizumab on changes in pulmonary function induced by controlled cat room challenge	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Aeroallergen; cat allergy; dander; Fel d 1; omalizumab; IgE; asthma	SEVERE ALLERGIC-ASTHMA; PLACEBO-CONTROLLED TRIAL; LONG-TERM CONTROL; FEL-D-I; MONOCLONAL-ANTIBODY; CASCADE IMPACTOR; EXPOSURE; RESPONSES; SENSITIZATION; ZAFIRLUKAST	Background: Environmental exposure to cat allergen is common, and sensitization to cat allergens is strongly associated with asthma. Objective: We sought to examine the efficacy of omalizumab in preventing acute bronchoconstriction induced by environmental exposure to cat allergen. Methods: Patients with a history of cat allergen-induced asthma were randomized to treatment with omalizumab or placebo and exposed to cat allergen in a controlled chamber for up to 1 hour at baseline and after 16 weeks of treatment. The primary efficacy outcome was area under the curve for percentage decrease from prechallenge FEV(1) at week 16 for omalizumab-treated versus placebo-treated patients. FEV(1) was recorded before and every 10 minutes during the 1-hour challenge. Chest, nasal, and ocular symptoms were also monitored during cat chamber exposure as secondary end points. Results: The area under the curve for percentage decrease in FEV(1) was 15.2% per hour for omalizumab-treated patients (n 5 32) and 27.3% per hour for placebo-treated patients (n 5 33), reflecting 44% less reduction in FEV(1) and a treatment difference of -12.1% per hour (P = .0009; 95% CI, -19.0 to -5.2). Compared with placebo-treated patients, omalizumab-treated patients were also able to tolerate longer allergen exposure (P = .0006) and demonstrated significant reductions from prechallenge values in their chest symptom score (P < .0001) and nasal-ocular symptom score (P = .0002). Conclusions: The severity of acute airway reactions and symptoms caused by controlled cat room exposure to allergens was significantly reduced by treatment with omalizumab. (J Allergy Clin Immunol 2011;127:398-405.)	[Corren, Jonathan] Div Res, Allergy Med Clin, Los Angeles, CA 90025 USA; [Wood, Robert A.; Dhillon, Gitika] Johns Hopkins Univ, Sch Med, Baltimore, MD USA; [Patel, Deepen] Cetero Res, Mississauga, ON, Canada; [Zhu, Jin; Yegin, Ashley; Fish, James E.] Genentech Inc, San Francisco, CA 94080 USA	Johns Hopkins University; Roche Holding; Genentech	Corren, J (corresponding author), Div Res, Allergy Med Clin, 10780 Santa Monica Blvd,Suite 280, Los Angeles, CA 90025 USA.	jcorren@ucla.edu			Genentech, Inc.; Genentech; Novartis; National Institutes of Health	Genentech, Inc.(Roche HoldingGenentech); Genentech(Roche HoldingGenentech); Novartis(Novartis); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Supported by Genentech, Inc.; J. Corren has given talks for Genentech and has received research support from Genentech and Novartis. R. A. Wood has received research support from the National Institutes of Health and Genentech and is on the medical advisory board of the Food Allergy and Anaphylaxis Network. D. Patel is an employee of Cetero Research and has received research support from Genentech. J. Zhu, A. Yegin, and J. E. Fish are employees of Genentech. G. Dhillon has declared no conflict of interest.	[Anonymous], 2005, AM J RESP CRIT CARE, V171, P912; Arbes SJ, 2005, J ALLERGY CLIN IMMUN, V116, P377, DOI 10.1016/j.jaci.2005.05.017; Bollinger ME, 1998, J ALLERGY CLIN IMMUN, V101, P124, DOI 10.1016/S0091-6749(98)70203-9; Bollinger ME, 1996, J ALLERGY CLIN IMMUN, V97, P907, DOI 10.1016/S0091-6749(96)80064-9; Buhl R, 2002, EUR RESPIR J, V20, P73, DOI 10.1183/09031936.02.00278102; Busse W, 2001, J ALLERGY CLIN IMMUN, V108, P184, DOI 10.1067/mai.2001.117880; Chapman MD, 2001, J ALLERGY CLIN IMMUN, V107, pS414, DOI 10.1067/mai.2001.113672; Corren J, 2001, ANN ALLERG ASTHMA IM, V87, P211, DOI 10.1016/S1081-1206(10)62228-4; CRAPO RO, 1981, AM REV RESPIR DIS, V123, P659; DEBLAY F, 1991, AM REV RESPIR DIS, V143, P1334, DOI 10.1164/ajrccm/143.6.1334; Eckman JA, 2010, J ALLERGY CLIN IMMUN, V125, P889, DOI 10.1016/j.jaci.2009.09.012; Fahy JV, 1997, AM J RESP CRIT CARE, V155, P1828, DOI 10.1164/ajrccm.155.6.9196082; *GEN INC, 2008, XOL OM PACK INS; Gent JF, 2009, ENVIRON RES, V109, P768, DOI 10.1016/j.envres.2009.04.010; Gruchalla RS, 2005, J ALLERGY CLIN IMMUN, V115, P478, DOI 10.1016/j.jaci.2004.12.006; INGRAM JM, 1995, J ALLERGY CLIN IMMUN, V96, P449, DOI 10.1016/S0091-6749(95)70286-5; Lanier BQ, 2003, ANN ALLERG ASTHMA IM, V91, P154, DOI 10.1016/S1081-1206(10)62170-9; Lewis SA, 2002, AM J RESP CRIT CARE, V165, P961, DOI 10.1164/ajrccm.165.7.2103044; Lieutier-Colas F, 2003, AM J RESP CRIT CARE, V167, P1077, DOI 10.1164/rccm.2204037; LUCZYNSKA CM, 1990, AM REV RESPIR DIS, V141, P361, DOI 10.1164/ajrccm/141.2.361; Nelson HS, 1999, J ALLERGY CLIN IMMUN, V104, P775, DOI 10.1016/S0091-6749(99)70287-3; Perry TT, 2004, ANN ALLERG ASTHMA IM, V93, P431, DOI 10.1016/S1081-1206(10)61409-3; Phipatanakul W, 2000, J ALLERGY CLIN IMMUN, V105, P704, DOI 10.1067/mai.2000.105123; PLATTSMILLS TAE, 1986, J ALLERGY CLIN IMMUN, V77, P850, DOI 10.1016/0091-6749(86)90383-0; Soler M, 2001, EUR RESPIR J, V18, P254, DOI 10.1183/09031936.01.00092101; WOOD RA, 1995, AM J RESP CRIT CARE, V151, P315, DOI 10.1164/ajrccm.151.2.7842184; WOOD RA, 1993, CLIN EXP ALLERGY, V23, P733, DOI 10.1111/j.1365-2222.1993.tb00360.x; Wood RA, 1998, AM J RESP CRIT CARE, V158, P115, DOI 10.1164/ajrccm.158.1.9712110; Zeidler MR, 2006, J ALLERGY CLIN IMMUN, V118, P1075, DOI 10.1016/j.jaci.2006.06.042	29	22	22	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2011	127	2					398	405		10.1016/j.jaci.2010.09.043	http://dx.doi.org/10.1016/j.jaci.2010.09.043			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	714KH	21281870	Bronze			2022-12-18	WOS:000286808000013
J	Kulis, M; Li, YF; Lane, H; Pons, L; Burks, W				Kulis, Mike; Li, Yifan; Lane, Hannah; Pons, Laurent; Burks, Wesley			Single-tree nut immunotherapy attenuates allergic reactions in mice with hypersensitivity to multiple tree nuts	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food allergy; tree nut allergy; immunotherapy; cross-reactivity; cashew; walnut; pistachio	CROSS-REACTIVITY; CASHEW NUT; ORAL IMMUNOTHERAPY; MAST-CELLS; PEANUT; ANAPHYLAXIS; PISTACHIO; MECHANISMS; GLOBULIN	Background: Allergic reactions to tree nuts are often severe and are outgrown in less than 10% of diagnosed patients. Objectives: To determine whether treatment of underlying tree nut sensitization will prevent allergic reactions to cross-reacting tree nuts and to determine the effects of single-tree nut immunotherapy on true multi-tree nut sensitization. Methods: Cross-reactivity model: Cashew-sensitized mice underwent immunotherapy with cashew and were subsequently challenged with cashew and pistachio. Multisensitization model: Cashew plus walnut-sensitized mice were treated with cashew alone, walnut alone, or both cashew and walnut and then underwent challenges to cashew and walnut. Challenges were assessed on the basis of symptoms, changes in body temperature, and mouse mast cell protease-1 release. Results: In the cross-reactivity model, cashew immunotherapy completely prevented allergic reactions on challenges with cashew or the cross-reactive pistachio. In the multisensitization model, mice with cashew plus walnut allergy were significantly protected from anaphylactic reactions on cashew challenge in both the cashew-alone and walnut-alone immunotherapy groups. Results from the walnut challenge demonstrated significantly decreased allergic responses in the walnut immunotherapy group, whereas mice in the cashew immunotherapy group experienced significantly lower symptoms. In the cross-reactivity model, immunotherapy effectively decreased IL-4 and IL-5 production and increased IL-12 relative to placebo while also inducing a 5-fold increase in specific IgG(1). Conclusion: Single-tree nut immunotherapy can effectively decrease allergic responses in both the cross-reactivity and multisensitization mouse models. Further studies are needed to determine which single-tree nut immunotherapies will be most effective for specific multi-tree nut allergy profiles. (J Allergy Clin Immunol 2011;127:81-8.)	[Kulis, Mike; Li, Yifan; Lane, Hannah; Pons, Laurent; Burks, Wesley] Duke Univ, Med Ctr, Div Pediat Allergy & Immunol, Dept Pediat, Durham, NC 27710 USA	Duke University	Kulis, M (corresponding author), Duke Univ, Med Ctr, Div Pediat Allergy & Immunol, Dept Pediat, Box 2644, Durham, NC 27710 USA.	michael.kulis@duke.edu			Food Allergy Initiative; National Institutes of Health; Food Allergy and Anaphylaxis Network; Wallace Research Foundation	Food Allergy Initiative; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Food Allergy and Anaphylaxis Network; Wallace Research Foundation	M. Kulis receives research support from the Food Allergy Initiative and the National Institutes of Health. W. Burks is a consultant for ActoGeniX NV, Intelliject, McNeil Nutritionals, and Novartis; is on the advisory board for Dannon Co Probiotics; is on the expert panel for Nutricia; is a minority stockholder in Allertein and MastCell, Inc; receives research support from the National Institutes of Health, the Food Allergy and Anaphylaxis Network, and the Wallace Research Foundation; has provided expert witness testimony/legal consultation services in cases related to food allergy; is on the Medical Board of Directors for the Food Allergy and Anaphylaxis Network; is a Dermatological Allergy Committee member for the American College of Allergy, Asthma, and Immunology; is a study section member for the NIH HAI; is on the review board for the Journal of Allegy & Clinical Immunology; and is a member of the FDA. The rest of the authors have declared that they have no conflict of interest.	Ahn K, 2009, CLIN EXP ALLERGY, V39, P926, DOI 10.1111/j.1365-2222.2009.03259.x; Akdis M, 2007, J ALLERGY CLIN IMMUN, V119, P780, DOI 10.1016/j.jaci.2007.01.022; Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; Buchanan AD, 2007, J ALLERGY CLIN IMMUN, V119, P199, DOI 10.1016/j.jaci.2006.09.016; Clark AT, 2007, ALLERGY, V62, P913, DOI 10.1111/j.1398-9995.2007.01447.x; Clark AT, 2005, PEDIATR ALLERGY IMMU, V16, P507, DOI 10.1111/j.1399-3038.2005.00310.x; de Leon MP, 2003, CLIN EXP ALLERGY, V33, P1273, DOI 10.1046/j.1365-2222.2003.01761.x; Faquim-Mauro EL, 2003, IMMUNOBIOLOGY, V207, P169, DOI 10.1078/0171-2985-00231; Fernandez C, 1995, CLIN EXP ALLERGY, V25, P1254, DOI 10.1111/j.1365-2222.1995.tb03050.x; Finkelman FD, 2005, J ALLERGY CLIN IMMUN, V115, P449, DOI 10.1016/j.jaci.2004.12.1125; Fleischer DM, 2005, J ALLERGY CLIN IMMUN, V116, P1087, DOI 10.1016/j.jaci.2005.09.002; Goetz DW, 2005, ANN ALLERG ASTHMA IM, V95, P45, DOI 10.1016/S1081-1206(10)61187-8; Hasegawa Miki, 2009, Allergology International, V58, P209, DOI 10.2332/allergolint.08-OA-0010; Jones SM, 2009, J ALLERGY CLIN IMMUN, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Jones Stacie M, 2009, J Allergy Clin Immunol, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Kulis M, 2009, INT ARCH ALLERGY IMM, V148, P109, DOI 10.1159/000155741; Li XM, 2000, J ALLERGY CLIN IMMUN, V106, P150, DOI 10.1067/mai.2000.107395; Maloney JM, 2008, J ALLERGY CLIN IMMUN, V122, P145, DOI 10.1016/j.jaci.2008.04.014; Musio S, 2009, LAB INVEST, V89, P398, DOI 10.1038/labinvest.2009.4; Pons L, 2004, J ALLERGY CLIN IMMUN, V114, P915, DOI 10.1016/j.jaci.2004.06.049; Roux KH, 2003, INT ARCH ALLERGY IMM, V131, P234, DOI 10.1159/000072135; Sathe SK, 2009, J AGR FOOD CHEM, V57, P7846, DOI 10.1021/jf9016338; Sathe SK, 1997, J AGR FOOD CHEM, V45, P2854, DOI 10.1021/jf970153e; Sicherer SH, 2003, J ALLERGY CLIN IMMUN, V112, P1203, DOI 10.1016/S0091-6749(03)02026-8; Sicherer SH, 2001, J ALLERGY CLIN IMMUN, V108, P128, DOI 10.1067/mai.2001.115755; Silva SR, 2008, J IMMUNOL, V181, P8308, DOI 10.4049/jimmunol.181.12.8308; Skripak JM, 2008, J ALLERGY CLIN IMMUN, V122, P1154, DOI 10.1016/j.jaci.2008.09.030; Strait RT, 2002, J ALLERGY CLIN IMMUN, V109, P658, DOI 10.1067/mai.2002.123302; Teuber SS, 2002, J AGR FOOD CHEM, V50, P6543, DOI 10.1021/jf025757j; Willison LN, 2008, CLIN EXP ALLERGY, V38, P1229, DOI 10.1111/j.1365-2222.2008.02998.x	30	22	29	0	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2011	127	1					81	88		10.1016/j.jaci.2010.09.014	http://dx.doi.org/10.1016/j.jaci.2010.09.014			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	702SY	21093029				2022-12-18	WOS:000285917300012
J	Reefer, AJ; Hulse, KE; Lannigan, JA; Solga, MD; Wright, PW; Kelly, LA; Patrie, J; Chapman, MD; Woodfolk, JA				Reefer, Amanda J.; Hulse, Kathryn E.; Lannigan, Josephine A.; Solga, Michael D.; Wright, Paul W.; Kelly, Libby A.; Patrie, James; Chapman, Martin D.; Woodfolk, Judith A.			Flow cytometry imaging identifies rare T(H)2 cells expressing thymic stromal lymphopoietin receptor in a "proallergic" milieu	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						TSLP; TSLP receptor; atopic dermatitis; T(H)2 cells; flow cytometry imaging	HUMAN EPITHELIAL-CELLS; ATOPIC-DERMATITIS; DENDRITIC CELLS; T-CELLS; INFLAMMATION; ALLERGEN; TSLP; REVEALS; CLONING; MOUSE	Background: Thymic stromal lymphopoietin (TSLP) is expressed at sites of allergic inflammation, including eczematous skin. This cytokine has been reported to exert its T(H)2-inducing properties through dendritic cells. Expression of TSLP receptor on the surface of activated T(H)2 cells could amplify T(H)2 responses at inflamed sites through the direct actions of TSLP. Objective: To test rigorously whether T(H)2 cells induced by "proallergic" factors express TSLP receptor and characterize these cells using an experimental platform that combines flow cytometry with microscopic capabilities. Methods: CD4(+) T cells isolated from patients with atopic dermatitis or normal healthy controls were cocultured with autologous dendritic cells in the presence of T(H)2-promoting stimuli (TSLP +/- allergen and staphylococcal enterotoxin B +/- TSLP). Surface expression of TSLP receptor was analyzed by image-based flow cytometry, and responsiveness of purified T cells to TSLP was assessed by phosphorylation of signal transducer and activator of transcription-5 and cytokine secretion. Results: T(H)2-promoting stimuli induced a robust population of activated T(H)2 cells (CD25(+)IL-4(+)). Regardless of the nature of the stimulus, flow cytometry imaging confirmed that T cells expressing TSLP receptor were rare, constituting a minor fraction of the IL-4(+) T cell pool; however, TSLP responsiveness was nonetheless detectable. Analysis of cell size and nuclear morphology revealed preferential expression of TSLP receptor on IL-4-expressing cells undergoing mitosis. Analysis of lesional skin in atopic dermatitis supported the view that rare IL-4(+) T cells expressing TSLP receptor are present at inflamed sites. Conclusion: In a "proallergic" milieu, TSLP receptor is preferentially expressed on rare actively dividing T(H)2 cells. The direct action of TSLP on T cells could amplify T(H)2 responses at	[Woodfolk, Judith A.] Univ Virginia Hlth Syst, Div Allergy, Asthma & Allerg Dis Ctr, Charlottesville, VA 22908 USA; [Lannigan, Josephine A.; Solga, Michael D.] Univ Virginia Hlth Syst, Dept Microbiol, Charlottesville, VA 22908 USA; [Patrie, James] Univ Virginia Hlth Syst, Dept Publ Hlth Sci, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia	Woodfolk, JA (corresponding author), Univ Virginia Hlth Syst, Div Allergy, Asthma & Allerg Dis Ctr, POB 801355, Charlottesville, VA 22908 USA.	jaw4m@virginia.edu		Lannigan, Joanne/0000-0002-3981-8681; Chapman, Martin/0000-0002-0845-3632; Hulse, Kathryn/0000-0003-0969-999X	NIH [AI-052196, AI-070364]; National Institute of Allergy and Infectious Diseases; National Institute for Environmental Health Sciences; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052196, U19AI070364] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institute for Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by NIH grants AI-052196 and AI-070364.; J. A. Woodfolk has received research support and honoraria from the National Institute of Allergy and Infectious Diseases. M. D. Chapman is president, CEO, and owner of Indoor Biotechnologies Inc and has received research support from the National Institute for Environmental Health Sciences. The rest of the authors have declared that they have no conflict of interest.	Al-Shami A, 2005, J EXP MED, V202, P829, DOI 10.1084/jem.20050199; Allakhverdi Z, 2007, J EXP MED, V204, P253, DOI 10.1084/jem.20062211; Arima K, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000567; Ebner S, 2001, J IMMUNOL, V166, P633, DOI 10.4049/jimmunol.166.1.633; Eyerich K, 2009, J ALLERGY CLIN IMMUN, V123, P59, DOI 10.1016/j.jaci.2008.10.031; Fallon PG, 2009, NAT GENET, V41, P602, DOI 10.1038/ng.358; George TC, 2004, CYTOM PART A, V59A, P237, DOI 10.1002/cyto.a.20048; HANIFIN JM, 1980, ACTA DERM-VENEREOL, P44; Hanifin JM, 2009, J INVEST DERMATOL, V129, P320, DOI 10.1038/jid.2008.252; He R, 2008, P NATL ACAD SCI USA, V105, P11875, DOI 10.1073/pnas.0801532105; Hochrein H, 2000, J EXP MED, V192, P823, DOI 10.1084/jem.192.6.823; Hulse KE, 2010, J ALLERGY CLIN IMMUN, V125, P247, DOI 10.1016/j.jaci.2009.10.027; Ito T, 2005, J EXP MED, V202, P1213, DOI 10.1084/jem.20051135; Kunz B, 1997, DERMATOLOGY, V195, P10, DOI 10.1159/000245677; Liu WH, 2006, J EXP MED, V203, P1701, DOI 10.1084/jem.20060772; Lu N, 2009, J EXP MED, V206, P2111, DOI 10.1084/jem.20090153; Omori M, 2007, J IMMUNOL, V178, P1396, DOI 10.4049/jimmunol.178.3.1396; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Pandey A, 2000, NAT IMMUNOL, V1, P59, DOI 10.1038/76923; Park LS, 2000, J EXP MED, V192, P659, DOI 10.1084/jem.192.5.659; Reefer AJ, 2008, J ALLERGY CLIN IMMUN, V121, P415, DOI 10.1016/j.jaci.2007.11.003; Reefer AJ, 2007, J ALLERGY CLIN IMMUN, V120, P156, DOI 10.1016/j.jaci.2007.03.042; Rissoan MC, 1999, SCIENCE, V283, P1183, DOI 10.1126/science.283.5405.1183; Rochman I, 2007, J IMMUNOL, V178, P6720, DOI 10.4049/jimmunol.178.11.6720; Seddiki N, 2006, J EXP MED, V203, P1693, DOI 10.1084/jem.20060468; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; Tanaka J, 2009, CLIN EXP ALLERGY, V39, P89, DOI 10.1111/j.1365-2222.2008.03151.x; Vailes LD, 2002, J ALLERGY CLIN IMMUN, V110, P757, DOI 10.1067/mai.2002.129035; Werfel T, 2009, J INVEST DERMATOL, V129, P1878, DOI 10.1038/jid.2009.71; Yoo J, 2005, J EXP MED, V202, P541, DOI 10.1084/jem.20041503; Zhou BH, 2005, NAT IMMUNOL, V6, P1047, DOI 10.1038/ni1247	31	22	23	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2010	126	5					1049	U241		10.1016/j.jaci.2010.07.023	http://dx.doi.org/10.1016/j.jaci.2010.07.023			20	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	674HB	20888036	Green Accepted, Bronze			2022-12-18	WOS:000283727100023
J	Hasegawa, A; Hayashi, K; Kishimoto, H; Yang, M; Tofukuji, S; Suzuki, K; Nakajima, H; Hoffman, RM; Shirai, M; Nakayama, T				Hasegawa, Akihiro; Hayashi, Katsuhiro; Kishimoto, Hiroyuki; Yang, Meng; Tofukuji, Soichi; Suzuki, Kazuo; Nakajima, Hiroshi; Hoffman, Robert M.; Shirai, Mutsunori; Nakayama, Toshinori			Color-coded real-time cellular imaging of lung T-lymphocyte accumulation and focus formation in a mouse asthma model	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Real-time in vivo cellular imaging; cellular dynamics; T(H)2 cells; mouse model of asthma; focus formation; airway inflammation; GFP; ICAM-1; VCAM-1	ALLERGIC AIRWAY INFLAMMATION; DENDRITIC CELLS; IN-VIVO; NODES; MICE; TRAFFICKING; RECRUITMENT; ACTIVATION; DYNAMICS; PATHOGENESIS	Background: A critical role for CD4(+)T(H)2 cells in the pathogenesis of acute asthma has been demonstrated in the studies of human asthma as well as of animal models of asthma. T(H)2-cell migration into the lung is crucial for the initiation of asthma phenotype, but the dynamics of this process are poorly understood because it has been difficult to visualize this process. Objective: Our aim was to image the cellular dynamics of the migration of T(H)2 cells into the lung of living animals in a mouse model of asthma and identify the cellular processes required for the initiation of the asthma phenotype. Methods: We developed a color-coded real-time imaging model of cell migration into the lung using green fluorescent protein (GFP) and red fluorescent protein (RFP) transgenic CD4 T cells. Results: Selective accumulation of antigen-specific CD4 T cells in the lungs was quantitatively imaged in a mouse model of asthma. The inhibition of accumulation by dexamethasone was imaged. Accumulating GFP(+) T(H)2 cells formed foci in the lungs from 6 to 20 hours after antigen inhalation. This process was also inhibited by the administration of anti-intercellular adhesion molecule I or anti-vascular cell adhesion molecule 1 mAbs. Two days after inhalation of antigen, GFP(+) T(H)2 cells were detected in the area of eosinophil infiltration. Conclusion: Focus formation generated by accumulating antigen-specific T(H)2 cells in the lung appeared to be a critical process in the initiation of the asthma phenotype. This new model enables the study of in vivo cell biology of airway inflammation and novel drug discovery for lung inflammatory diseases. (J Allergy Clin Immunol 2010;125:461-8.)	[Hasegawa, Akihiro; Tofukuji, Soichi; Suzuki, Kazuo; Nakayama, Toshinori] Chiba Univ, Grad Sch Med, Dept Immunol, Chiba 2608670, Japan; [Nakajima, Hiroshi] Chiba Univ, Grad Sch Med, Dept Mol Genet, Chiba 2608670, Japan; [Hasegawa, Akihiro; Shirai, Mutsunori] Yamaguchi Univ, Sch Med, Dept Microbiol & Immunol, Ube, Yamaguchi 755, Japan; [Hasegawa, Akihiro; Hayashi, Katsuhiro; Kishimoto, Hiroyuki; Yang, Meng; Hoffman, Robert M.] AntiCanc Inc, San Diego, CA USA; [Hoffman, Robert M.] Univ Calif San Diego, Dept Surg, San Diego, CA 92103 USA	Chiba University; Chiba University; Yamaguchi University; AntiCancer, Inc.; University of California System; University of California San Diego	Nakayama, T (corresponding author), Chiba Univ, Grad Sch Med, Dept Immunol H3, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan.	tnakayama@faculty.chiba-u.jp	Nakayama, Toshinori/E-1067-2017; Nakajima, Hiroshi/AFU-9313-2022; Hayashi, K/C-4685-2015	Nakayama, Toshinori/0000-0002-1434-2007; Nakajima, Hiroshi/0000-0001-8595-9381; Hayashi, K/0000-0001-8665-2154; Tofukuji, Soichi/0000-0003-4599-4937	Monbukagakusho (MEXT), Japan; Ministry of education, Culture, Sports. Science and Technology (Japan); Grants-in-Aid for Scientific Research [21390255] Funding Source: KAKEN	Monbukagakusho (MEXT), Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Ministry of education, Culture, Sports. Science and Technology (Japan)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	Supported in part by the Global Center of Excellence (COE) program (Global Center for Education and Research in Immune System Regulation and Treatment), Monbukagakusho (MEXT), Japan, and grants from the Ministry of education, Culture, Sports. Science and Technology (Japan).	Bajenoff M, 2006, IMMUNITY, V25, P989, DOI 10.1016/j.immuni.2006.10.011; Barnden MJ, 1998, IMMUNOL CELL BIOL, V76, P34, DOI 10.1046/j.1440-1711.1998.00709.x; Bousso P, 2003, NAT IMMUNOL, V4, P579, DOI 10.1038/ni928; Busse WW, 2001, NEW ENGL J MED, V344, P350, DOI 10.1056/NEJM200102013440507; Catron DM, 2006, J EXP MED, V203, P1045, DOI 10.1084/jem.20051954; Cavanagh LL, 2005, NAT IMMUNOL, V6, P1029, DOI 10.1038/ni1249; Cohn L, 2004, ANNU REV IMMUNOL, V22, P789, DOI 10.1146/annurev.immunol.22.012703.104716; Cohn L, 1997, J EXP MED, V186, P1737, DOI 10.1084/jem.186.10.1737; Eder W, 2006, NEW ENGL J MED, V355, P2226, DOI 10.1056/NEJMra054308; Elias JA, 2003, J CLIN INVEST, V111, P291, DOI 10.1172/JCI200317748; Germain RN, 2006, NAT REV IMMUNOL, V6, P497, DOI 10.1038/nri1884; Hamelmann E, 2001, IMMUNOL REV, V179, P182, DOI 10.1034/j.1600-065X.2001.790118.x; Hansen G, 1999, J CLIN INVEST, V103, P175, DOI 10.1172/JCI5155; Hasegawa A, 2006, J IMMUNOL, V176, P2546, DOI 10.4049/jimmunol.176.4.2546; Hayashi K, 2007, CANCER RES, V67, P8223, DOI 10.1158/0008-5472.CAN-07-1237; Hirahara K, 2008, J ALLERGY CLIN IMMUN, V122, P512, DOI 10.1016/j.jaci.2008.06.004; Hoffman RM, 2005, NAT REV CANCER, V5, P796, DOI 10.1038/nrc1717; Hugues S, 2007, NAT IMMUNOL, V8, P921, DOI 10.1038/ni1495; Hutchison S, 2009, CLIN EXP IMMUNOL, V155, P107, DOI 10.1111/j.1365-2249.2008.03800.x; Ichimura H, 2006, AM J PHYSIOL-LUNG C, V291, pL596, DOI 10.1152/ajplung.00036.2006; Kamata T, 2003, J CLIN INVEST, V111, P109, DOI 10.1172/JCI200315719; Kaminuma O, 2001, EUR J IMMUNOL, V31, P2669, DOI 10.1002/1521-4141(200109)31:9<2669::AID-IMMU2669>3.0.CO;2-Y; Kohlmeier JE, 2006, CURR OPIN IMMUNOL, V18, P357, DOI 10.1016/j.coi.2006.03.012; Kuebler WM, 2007, J APPL PHYSIOL, V102, P1255, DOI 10.1152/japplphysiol.00786.2006; Lloyd CM, 2001, ADV IMMUNOL, V77, P263, DOI 10.1016/S0065-2776(01)77019-8; Mathew A, 2002, J IMMUNOL, V169, P651, DOI 10.4049/jimmunol.169.2.651; MCFADDEN ER, 1992, NEW ENGL J MED, V327, P1928, DOI 10.1056/NEJM199212313272708; Mempel TR, 2004, NATURE, V427, P154, DOI 10.1038/nature02238; Miller MJ, 2004, J EXP MED, V200, P847, DOI 10.1084/jem.20041236; Miller MJ, 2002, SCIENCE, V296, P1869, DOI 10.1126/science.1070051; NAKAJIMA H, 1994, J EXP MED, V179, P1145, DOI 10.1084/jem.179.4.1145; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; Schwickert TA, 2007, NATURE, V446, P83, DOI 10.1038/nature05573; Umetsu DT, 2006, IMMUNOL REV, V212, P238, DOI 10.1111/j.0105-2896.2006.00413.x; Vintersten K, 2004, GENESIS, V40, P241, DOI 10.1002/gene.20095; Wang WG, 2007, CANCER RES, V67, P3505, DOI 10.1158/0008-5472.CAN-06-3714; Wells JW, 2007, J ALLERGY CLIN IMMUN, V119, P226, DOI 10.1016/j.jaci.2006.09.004; Wills-Karp M, 2004, IMMUNOL REV, V202, P175, DOI 10.1111/j.0105-2896.2004.00215.x; Xu BH, 2003, J EXP MED, V197, P1255, DOI 10.1084/jem.20010685; Yamauchi K, 2006, CANCER RES, V66, P4208, DOI 10.1158/0008-5472.CAN-05-3927; Yang M, 2009, J CELL BIOCHEM, V106, P279, DOI 10.1002/jcb.21999	41	22	24	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2010	125	2					461	468		10.1016/j.jaci.2009.09.016	http://dx.doi.org/10.1016/j.jaci.2009.09.016			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	558RU	20031194				2022-12-18	WOS:000274764000026
J	Kazani, S; Wechsler, ME; Israel, E				Kazani, Shamsah; Wechsler, Michael E.; Israel, Elliot			The role of pharmacogenomics in improving the management of asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Pharmacogenomics; asthma; pharmacotherapy; genetics; beta(2)-adrenergic receptor; leukotrienes; corticosteroid; variability	BETA(2)-ADRENERGIC RECEPTOR POLYMORPHISMS; LEUKOTRIENE C-4 SYNTHASE; ALOX5 PROMOTER GENOTYPE; CLINICAL-RESPONSE; INHALED CORTICOSTEROIDS; PERSISTENT ASTHMA; BRONCHODILATOR RESPONSE; GENETIC POLYMORPHISMS; A(-444)C POLYMORPHISM; ASSOCIATION ANALYSIS	There is a large amount of interindividual variability in both therapeutic and adverse responses to asthma therapies. Genetic variability can account for 50% to 60% of this variability. Pharmacogenomics holds out the promise of allowing clinicians to prospectively choose therapies that have the greatest likelihood to be effective for individual patients and to avoid those that might have a high likelihood of producing adverse effects'. In this article we review the principles of pharmacogenomic investigation. We explore the data developed from the early pharmacogenomic studies with the most common asthma therapies. Furthermore, we explore the potential use of pharmacogenomics, as well as caveats in interpreting such information. (J Allergy Clin Immunol 2010;125:295-302.)	[Kazani, Shamsah; Wechsler, Michael E.; Israel, Elliot] Harvard Univ, Dept Med, Div Pulm & Crit Care, Brigham & Womens Hosp,Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Israel, E (corresponding author), Harvard Univ, Dept Med, Div Pulm & Crit Care, Brigham & Womens Hosp,Sch Med, 75 Francis St, Boston, MA 02115 USA.	eisrael@partners.org	Wechsler, Michael/AAC-5506-2019; Wechsler, Michael/B-3979-2013	Wechsler, Michael/0000-0003-3505-2946	National Heart, Lung, and Blood Institute/National Institutes of Health [U10 HL74227]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U10HL074227] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute/National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by National Heart, Lung, and Blood Institute/National Institutes of Health grant U10 HL74227.	Anderson W., 2008, AM J RESP CRIT CARE, V177; Asano K, 2002, PHARMACOGENETICS, V12, P565, DOI 10.1097/00008571-200210000-00009; Bleecker ER, 2008, J ALLERGY CLIN IMMUN, V121, pS143, DOI 10.1016/j.jaci.2007.12.1109; Bleecker ER, 2007, LANCET, V370, P2118, DOI 10.1016/S0140-6736(07)61906-0; Bleecker ER, 2006, J ALLERGY CLIN IMMUN, V118, P809, DOI 10.1016/j.jaci.2006.06.036; Burchard EG, 2003, NEW ENGL J MED, V348, P1170, DOI 10.1056/NEJMsb025007; Carroll CL, 2009, CHEST, V135, P1186, DOI 10.1378/chest.08-2041; Choudhry S, 2005, AM J RESP CRIT CARE, V171, P563, DOI 10.1164/rccm.200409-1286OC; Dijkstra A, 2008, J ALLERGY CLIN IMMUN, V121, P1510, DOI 10.1016/j.jaci.2008.04.015; Drazen JM, 1999, NAT GENET, V22, P168, DOI 10.1038/9680; GREEN SA, 1994, BIOCHEMISTRY-US, V33, P9414, DOI 10.1021/bi00198a006; GREEN SA, 1993, J BIOL CHEM, V268, P23116; GREEN SA, 1995, AM J RESP CELL MOL, V13, P25, DOI 10.1165/ajrcmb.13.1.7598936; Hall IP, 2006, LANCET, V368, P771, DOI 10.1016/S0140-6736(06)69287-8; Hansen NT, 2009, CLIN PHARMACOL THER, V86, P183, DOI 10.1038/clpt.2009.42; Hawkins GA, 2006, AM J RESP CRIT CARE, V174, P1101, DOI 10.1164/rccm.200509-1405OC; Himes BE, 2009, PHARMACOGENOMICS, V10, P1393, DOI 10.2217/PGS.09.93; Israel E, 2001, NEW ENGL J MED, V345, P941, DOI 10.1056/NEJMoa002304; Israel E, 2004, LANCET, V364, P1505, DOI 10.1016/S0140-6736(04)17273-5; Israel E, 2000, AM J RESP CRIT CARE, V162, P75, DOI 10.1164/ajrccm.162.1.9907092; Klotsman M, 2007, PHARMACOGENET GENOM, V17, P189, DOI 10.1097/FPC.0b013e3280120043; Lee DKC, 2004, BRIT J CLIN PHARMACO, V57, P68, DOI 10.1046/j.1365-2125.2003.01955.x; Lima JJ, 1999, CLIN PHARMACOL THER, V65, P519, DOI 10.1016/S0009-9236(99)70071-8; Lima JJ, 2006, AM J RESP CRIT CARE, V173, P379, DOI 10.1164/rccm.200509-1412OC; Litonjua AA, 2004, CHEST, V126, P66, DOI 10.1378/chest.126.1.66; Litonjua AA, 2008, AM J RESP CRIT CARE, V178, P688, DOI 10.1164/rccm.200709-1363OC; Malmstrom K, 1999, ANN INTERN MED, V130, P487, DOI 10.7326/0003-4819-130-6-199903160-00005; Martin AC, 2008, J ASTHMA, V45, P383, DOI 10.1080/02770900801971792; Martinez FD, 1997, J CLIN INVEST, V100, P3184, DOI 10.1172/JCI119874; McGraw DW, 1998, J CLIN INVEST, V102, P1927, DOI 10.1172/JCI4862; Mougey EB, 2009, PHARMACOGENET GENOM, V19, P129, DOI 10.1097/FPC.0b013e32831bd98c; Nelson HS, 2006, CHEST, V129, P15, DOI 10.1378/chest.129.1.15; Palmer CNA, 2006, THORAX, V61, P940, DOI 10.1136/thx.2006.059386; Palmer LJ, 2002, AM J RESP CRIT CARE, V165, P861, DOI 10.1164/ajrccm.165.7.2109096; Panebra A, 2008, AM J PHYSIOL-LUNG C, V294, pL190, DOI 10.1152/ajplung.00277.2007; Sampson AP, 2000, THORAX, V55, pS28, DOI 10.1136/thorax.55.suppl_2.S28; Sanak M, 2000, AM J RESP CELL MOL, V23, P290, DOI 10.1165/ajrcmb.23.3.4051; Sanak M, 1997, LANCET, V350, P1599, DOI 10.1016/S0140-6736(05)64015-9; Silverman EK, 2003, J ALLERGY CLIN IMMUN, V112, P870, DOI 10.1016/S0091-6749(03)02023-2; Stallings SC, 2006, PHARMACOGENOMICS, V7, P853, DOI 10.2217/14622416.7.6.853; Szefler SJ, 2002, J ALLERGY CLIN IMMUN, V109, P410, DOI 10.1067/mai.2002.122635; Szefler SJ, 2005, J ALLERGY CLIN IMMUN, V115, P233, DOI 10.1016/j.jaci.2004.11.014; Tantisira KG, 2007, J ALLERGY CLIN IMMUN, V120, P1285, DOI 10.1016/j.jaci.2007.09.005; Tantisira KG, 2004, HUM MOL GENET, V13, P1353, DOI 10.1093/hmg/ddh149; Tantisira KG, 2005, HUM MOL GENET, V14, P1671, DOI 10.1093/hmg/ddi175; Tantisira KG, 2004, P NATL ACAD SCI USA, V101, P18099, DOI 10.1073/pnas.0408532102; TANTISIRA KG, 2009, GENOMICS, V19, P244; Taylor DR, 2000, THORAX, V55, P762, DOI 10.1136/thorax.55.9.762; Taylor DR, 2005, AM J RESP CRIT CARE, V172, P700, DOI 10.1164/rccm.200501-092OC; Telleria JJ, 2008, RESP MED, V102, P857, DOI 10.1016/j.rmed.2008.01.011; Tsai HJ, 2006, HUM GENET, V119, P547, DOI 10.1007/s00439-006-0169-2; Van Eerdewegh P, 2002, NATURE, V418, P426, DOI 10.1038/nature00878; Wechsler ME, 2006, AM J RESP CRIT CARE, V173, P519, DOI 10.1164/rccm.200509-1519OC; Wechsler ME, 2009, LANCET, V374, P1754, DOI 10.1016/S0140-6736(09)61492-6; Weiss ST, 2006, PHARMACOGENOMICS J, V6, P311, DOI 10.1038/sj.tpj.6500387; Whelan GJ, 2003, PEDIATR PULM, V36, P413, DOI 10.1002/ppul.10385	56	22	24	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2010	125	2					295	302		10.1016/j.jaci.2009.12.014	http://dx.doi.org/10.1016/j.jaci.2009.12.014			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	558RU	20159237	Green Accepted			2022-12-18	WOS:000274764000002
J	Farcet, MR; Planitzer, CB; Stein, O; Modrof, J; Kreil, TR				Farcet, Maria R.; Planitzer, Christina B.; Stein, Oliver; Modrof, Jens; Kreil, Thomas R.			Hepatitis A virus antibodies in immunoglobulin preparations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Intravenous immunoglobulin; IGIV; immune globulin; antibody functionality; replacement therapy; hepatitis A incidence; seroprevalence; virus neutralization; human plasma pool	UNITED-STATES; SEROPREVALENCE; IMMUNIZATION; PERSISTENCE; POPULATION; US	Background: Persons with primary immune deficiency receive intravenous immunoglobulin (IVIG) as antibody replacement therapy. These patients depend on the presence of protective antibody levels against circulating pathogens in IVIG. Objectives: The incidence of hepatitis A virus (HAV) infections has been decreasing globally. We investigated whether this decrease in HAV incidence is reflected in human plasma pools and evaluated whether HAV antibody titers in IVIG preparations are still adequate for antibody replacement. Methods: By using ELISA, the HAV antibody titer of 3,953 plasma pools sourced from March 2003 through September 2008 in the European Union (EU) or United States (US) and of 169 IVIG lots manufactured from 2005 through 2007 was determined. The functionality of the HAV antibodies contained in IVIG was assessed by using a microneutralization assay. Results: The results confirm a decrease in HAV antibody titers in EU (-28%) and US (-41%) plasma. Furthermore, the mean HAV antibody content in EU (1.70 +/- 0.12 IU/mL) and US (0.82 +/- 0.09 IU/mL [mean +/- SEM]) plasma was significantly different (P = .0001). A significant difference (P < .0001) was also evident in the IVIG preparations KIOVIG (22.91 +/- 0.68 IU/mL) and Gammagard Liquid (14.60 +/- 0.48 IU/mL), respectively, made from EU or US plasma. In accordance with the ELISA results, there was a significant difference (P < .0001) in HAV neutralization titer 50% (NT50) values between IVIG produced from EU-sourced (2,477 +/- 265 NT50 [1:X]) or US-sourced (844 +/- 82 NT50 [1:X]) plasma. Conclusion: Although HAV antibody seroprevalence continues to decrease in Europe and the US, HAV antibody titers in IVIG lots appear to remain adequate for antibody replacement therapy. Q Allergy Clin Immunol 2010;125:198-202.)	[Farcet, Maria R.; Planitzer, Christina B.; Stein, Oliver; Modrof, Jens; Kreil, Thomas R.] Baxter BioSci, Global Pathogen Safety, A-1221 Vienna, Austria		Kreil, TR (corresponding author), Baxter BioSci, Global Pathogen Safety, Benatzkygasse 2-6, A-1221 Vienna, Austria.	thomas_kreil@baxter.com	Modrof, Jens/AAQ-8751-2020; Modrof, Jens/AAU-4681-2020	Modrof, Jens/0000-0001-8416-7681; 				Abraham B, 2002, ANTIVIR RES, V53, P63, DOI 10.1016/S0166-3542(01)00194-2; [Anonymous], EPIDEMIOLOGY PREVENT; Armstrong GL, 2002, PEDIATRICS, V109, P839, DOI 10.1542/peds.109.5.839; Audet S, 2006, J INFECT DIS, V194, P781, DOI 10.1086/506363; *BUND GES, 2008, IMPFPL 2009 OST EV B; *CDCP, 2006, MMWR-MORBID MORTAL W, V57, P1; Chlibek R., 2006, Epidemiologie Mikrobiologie Imunologie, V55, P99; Ehrlich HJ, 2008, NEW ENGL J MED, V358, P2573, DOI 10.1056/NEJMoa073121; *EUR DIR QUAL MED, 2008, HUM NORM IMM INTR AD; *EUR MED AG, 2004, CPMPBPWG85995 EUR ME; *EUVAC, 2009, NET VACC SCHED SURV; FABIANOVA K, 2008, EUROSURVEILLANCE, V13, P1; GOUBAU P, 1992, VACCINE, V10, pS114, DOI 10.1016/0264-410X(92)90561-W; Jacobsen KH, 2004, EPIDEMIOL INFECT, V132, P1005, DOI 10.1017/S0950268804002857; Lejtenyi D, 2008, J ALLERGY CLIN IMMUN, V121, P254, DOI 10.1016/j.jaci.2007.11.001; Maiwald H, 1997, VACCINE, V15, P346, DOI 10.1016/S0264-410X(97)00211-9; Matejtschuk P, 2002, VOX SANG, V83, P17, DOI 10.1046/j.1423-0410.2002.00186.x; Modrof J, 2008, TRANSFUSION, V48, P178, DOI 10.1111/j.1537-2995.2007.01503.x; Orange JS, 2006, J ALLERGY CLIN IMMUN, V117, pS525, DOI 10.1016/j.jaci.2006.01.015; PICKERING LK, 2006, RED BOOK 2006 REPORT, P326; Planitzer CB, 2007, J INFECT DIS, V196, P435, DOI 10.1086/519392; PRODINGER WM, 1994, INFECTION, V22, P53, DOI 10.1007/BF01780769; *R KOCH I, 2008, EP B R KOCH I, V30, P235; Rendi-Wagner P, 2007, VACCINE, V25, P927, DOI 10.1016/j.vaccine.2006.08.044; Anonymous, 2006, Morbidity and Mortality Weekly Report, V55, P1; Teschner W, 2007, VOX SANG, V92, P42, DOI 10.1111/j.1423-0410.2006.00846.x; Thierfelder W, 2001, EUR J EPIDEMIOL, V17, P429, DOI 10.1023/A:1013792013184; Wasley A, 2005, JAMA-J AM MED ASSOC, V294, P194, DOI 10.1001/jama.294.2.194; ZAAIJER HL, 1993, J MED VIROL, V40, P22, DOI 10.1002/jmv.1890400106; ZOON KC, 1993, DONOR SUITABILITY RE	30	22	23	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2010	125	1					198	202		10.1016/j.jaci.2009.09.008	http://dx.doi.org/10.1016/j.jaci.2009.09.008			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	544MG	19962745				2022-12-18	WOS:000273660500024
J	Khan, SH; Grayson, MH				Khan, Sadia Hayat; Grayson, Mitchell H.			Cross-linking IgE augments human conventional dendritic cell production of CC chemokine ligand 28	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ASTHMA; CCL28		[Khan, Sadia Hayat] Washington Univ, Sch Med, Dept Internal Med, Div Allergy & Immunol, St Louis, MO 63110 USA; [Grayson, Mitchell H.] Med Coll Wisconsin, Dept Pediat, Div Clin Immunol & Allergy, Milwaukee, WI 53226 USA	Washington University (WUSTL); Medical College of Wisconsin	Khan, SH (corresponding author), Washington Univ, Sch Med, Dept Internal Med, Div Allergy & Immunol, St Louis, MO 63110 USA.	wheeze@allergist.com	Grayson, Mitchell H/A-3693-2008; Grayson, Mitchell/AAX-3674-2020	Grayson, Mitchell H/0000-0002-4673-2122; Grayson, Mitchell/0000-0002-4673-2122	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL087778] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL087778, R01 HL087778-01A2, R01 HL087778] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ezzat MHM, 2009, INT J DERMATOL, V48, P822, DOI 10.1111/j.1365-4632.2009.04069.x; Foster B, 2003, J ALLERGY CLIN IMMUN, V112, P1132, DOI 10.1016/j.jaci.2003.09.011; Grayson MH, 2007, J EXP MED, V204, P2759, DOI 10.1084/jem.20070360; Lazarus NH, 2003, J IMMUNOL, V170, P3799, DOI 10.4049/jimmunol.170.7.3799; O'Gorman MT, 2005, CELL IMMUNOL, V238, P87, DOI 10.1016/j.cellimm.2006.02.003; Sigurs Nele, 2002, Paediatr Respir Rev, V3, P177, DOI 10.1016/S1526-0542(02)00191-4; Stensballe LG, 2009, J ALLERGY CLIN IMMUN, V123, P131, DOI 10.1016/j.jaci.2008.10.042; Wang W, 2000, J BIOL CHEM, V275, P22313, DOI 10.1074/jbc.M001461200	8	22	22	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2010	125	1					265	267		10.1016/j.jaci.2009.09.038	http://dx.doi.org/10.1016/j.jaci.2009.09.038			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	544MG	19962743	Green Accepted			2022-12-18	WOS:000273660500034
J	Farquhar, H; Crane, J; Mitchell, EA; Eyers, S; Beasley, R				Farquhar, Hamish; Crane, Julian; Mitchell, Edwin A.; Eyers, Sally; Beasley, Richard			The acetaminophen and asthma hypothesis 10 years on: A case to answer	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Asthma; acetaminophen; epidemiologic studies; risk factor	ADULT-ONSET ASTHMA; PARACETAMOL USE; GLUTATHIONE LEVELS; RISK-FACTOR; RHINOVIRUS ILLNESSES; PRENATAL EXPOSURE; CHILDREN; ASPIRIN; ASSOCIATION; CHILDHOOD		[Farquhar, Hamish; Eyers, Sally; Beasley, Richard] Med Res Inst New Zealand, Wellington 6143, New Zealand; [Crane, Julian] Univ Otago Wellington, Dept Med, Dunedin, New Zealand; [Mitchell, Edwin A.] Univ Auckland, Fac Med & Hlth Sci, Auckland 1, New Zealand; [Eyers, Sally; Beasley, Richard] Capital & Coast Dist Hlth Board, Wellington, New Zealand	Medical Research Institute Of New Zealand; University of Otago; University of Auckland	Beasley, R (corresponding author), Med Res Inst New Zealand, POB 10055, Wellington 6143, New Zealand.	Richard.Beasley@mrinz.ac.nz	Beasley, Richard/AAH-3908-2019	Beasley, Richard/0000-0003-0337-406X; Ioannides, Sally/0000-0002-7999-1198				BARNES PJ, 1990, FREE RADICAL BIO MED, V9, P235, DOI 10.1016/0891-5849(90)90034-G; Barr RG, 2008, LANCET, V372, P1011, DOI 10.1016/S0140-6736(08)61417-8; Barr RG, 2007, AM J RESP CRIT CARE, V175, P120, DOI 10.1164/rccm.200603-411OC; Barr RG, 2004, AM J RESP CRIT CARE, V169, P836, DOI 10.1164/rccm.200304-596OC; Beasley R, 2008, LANCET, V372, P1039, DOI 10.1016/S0140-6736(08)61445-2; Beasley R, 2009, LANCET, V373, P120, DOI 10.1016/S0140-6736(09)60031-3; Bertolini A, 2006, CNS DRUG REV, V12, P250, DOI 10.1111/j.1527-3458.2006.00250.x; Brandts CH, 1997, LANCET, V350, P704, DOI 10.1016/S0140-6736(97)02255-1; Davey G, 2005, J ALLERGY CLIN IMMUN, V116, P863, DOI 10.1016/j.jaci.2005.05.045; Dimova S, 2005, INT J BIOCHEM CELL B, V37, P1727, DOI 10.1016/j.biocel.2005.03.005; Eder W, 2006, NEW ENGL J MED, V355, P2226, DOI 10.1056/NEJMra054308; Garcia-Marcos L, 2009, INT ARCH ALLERGY IMM, V149, P33, DOI 10.1159/000176304; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; Koniman R, 2007, PEDIAT ALLERG IMM-UK, V18, P128, DOI 10.1111/j.1399-3038.2006.00484.x; Kurth T, 2008, THORAX, V63, P514, DOI 10.1136/thx.2007.091447; Lawrence J, 2009, LANCET, V373, P119, DOI 10.1016/S0140-6736(09)60029-5; Lemanske RF, 2005, J ALLERGY CLIN IMMUN, V116, P571, DOI 10.1016/j.jaci.2005.06.024; Lesko SM, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e20; Lowe A, 2009, LANCET, V373, P120, DOI 10.1016/S0140-6736(09)60030-1; McConnell R, 2002, LANCET, V359, P386, DOI 10.1016/S0140-6736(02)07597-9; McKeever TM, 2005, AM J RESP CRIT CARE, V171, P966, DOI 10.1164/rccm.200409-1269OC; MICHELI L, 1994, ENVIRON HEALTH PERSP, V102, P63, DOI 10.1289/ehp.94102s963; Newson RB, 2000, EUR RESPIR J, V16, P817, DOI 10.1183/09031936.00.16581700; Nuttall SL, 2003, J CLIN PHARM THER, V28, P251, DOI 10.1046/j.1365-2710.2003.00492.x; Pernerstorfer T, 1999, CLIN PHARMACOL THER, V66, P51, DOI 10.1016/S0009-9236(99)70053-6; Persky V, 2008, ANN ALLERG ASTHMA IM, V101, P271, DOI 10.1016/S1081-1206(10)60492-9; Perzanowski MS, 2008, J ALLERGY CLIN IMMUN, V121, pS231, DOI 10.1016/j.jaci.2007.12.914; Peterson JD, 1998, P NATL ACAD SCI USA, V95, P3071, DOI 10.1073/pnas.95.6.3071; Rebordosa C, 2008, INT J EPIDEMIOL, V37, P583, DOI 10.1093/ije/dyn070; Rubin RN, 2004, AM J RESP CRIT CARE, V169, P393, DOI 10.1164/rccm.200301-055OC; Shaheen S, 2008, EUR RESPIR J, V32, P1231, DOI 10.1183/09031936.00039208; Shaheen SO, 2005, CLIN EXP ALLERGY, V35, P18, DOI 10.1111/j.1365-2222.2005.02151.x; Shaheen SO, 2000, THORAX, V55, P266, DOI 10.1136/thorax.55.4.266; Shaheen SO, 2002, THORAX, V57, P958, DOI 10.1136/thorax.57.11.958; Shaheen SO, 2001, AM J RESP CRIT CARE, V164, P1823, DOI 10.1164/ajrccm.164.10.2104061; Singh M, 2009, LANCET, V373, P119, DOI 10.1016/S0140-6736(09)60028-3; Thomsen SF, 2008, J ASTHMA, V45, P675, DOI 10.1080/02770900802165998; Varner AE, 1998, ANN ALLERG ASTHMA IM, V81, P347, DOI 10.1016/S1081-1206(10)63127-4	39	22	22	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2009	124	4					649	651		10.1016/j.jaci.2009.07.037	http://dx.doi.org/10.1016/j.jaci.2009.07.037			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	506UV	19767081				2022-12-18	WOS:000270802800003
J	Hentges, F; Hilger, C; Kohnen, M; Gilson, G				Hentges, Francois; Hilger, Christiane; Kohnen, Marianne; Gilson, Georges			Angioedema and estrogen-dependent angioedema with activation of the contact system	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							MOLECULAR-WEIGHT KININOGEN; HEREDITARY ANGIOEDEMA; FACTOR-XII; NORMAL C1-INHIBITOR; PLASMA; WOMEN		[Hentges, Francois; Kohnen, Marianne] Ctr Hosp Luxembourg, Unit Immunol & Allergol, Luxembourg, Luxembourg; [Hentges, Francois; Hilger, Christiane] Ctr Hosp Luxembourg, Lab Immunogenet & Allergol, CRP Sante, Luxembourg, Luxembourg; [Gilson, Georges] Ctr Hosp Luxembourg, Lab Biochem & Immunopathol, Luxembourg, Luxembourg	Luxembourg Hospital Center; Luxembourg Hospital Center; Luxembourg Institute of Health; Luxembourg Hospital Center	Hentges, F (corresponding author), Ctr Hosp Luxembourg, Unit Immunol & Allergol, Luxembourg, Luxembourg.	hentges.francois@chl.lu		Hilger, Christiane/0000-0001-9455-5442				BERRETTINI M, 1986, BLOOD, V68, P455; BINKLEY K, 2004, J ALLERGY CLIN IMMUN, V114, pSLI; Binkley KE, 2000, J ALLERGY CLIN IMMUN, V106, P546; Bork K, 2000, LANCET, V356, P213, DOI 10.1016/S0140-6736(00)02483-1; Cichon S, 2006, AM J HUM GENET, V79, P1098, DOI 10.1086/509899; Dewald G, 2006, BIOCHEM BIOPH RES CO, V343, P1286, DOI 10.1016/j.bbrc.2006.03.092; HACK E, 2004, J ALLERGY CLIN IMMUN, V114, pS75; HENTGES F, 1994, B SOC SCI MED GRAND, V1321, P9; HOEM NO, 1991, THROMB RES, V64, P427, DOI 10.1016/0049-3848(91)90343-U	9	22	22	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2009	123	1					262	264		10.1016/j.jaci.2008.10.056	http://dx.doi.org/10.1016/j.jaci.2008.10.056			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	399IP	19130939				2022-12-18	WOS:000262793900042
J	Ohnishi, H; Takeda, K; Domenico, J; Lucas, JJ; Miyahara, N; Swasey, CH; Dakhama, A; Gelfand, EW				Ohnishi, Hiroshi; Takeda, Katsuyuki; Domenico, Joanne; Lucas, Joseph J.; Miyahara, Nobuaki; Swasey, Christina H.; Dakhama, Azzeddine; Gelfand, Erwin W.			Mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2-dependent pathways are essential for CD8(+) T cell-mediated airway hyperresponsiveness and inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; asthma; effector memory T cell; mitogen-activated protein kinase; signal transduction	SMOOTH-MUSCLE CELLS; LEUKOTRIENE B-4; EFFECTOR; EXPRESSION; DEGRANULATION; RECEPTOR-1; INHIBITOR; MIGRATION; RELEASE; ERK	Background: Ligation of the leukotriene B-4 (LTB4) receptor I on effector memory CD8(+) T cells by LTB4 is important for the recruitment of CD8(+) T cells into the airways, which appears central to the induction of airway hyperresponsiveness (AHR) and allergic inflammation. Phosphorylation of extracellular signal-regulated kinase (ERK) is important in activation and cytokine production from many cell types. Objective: The roles of ERKs in effector CD8(+) T-cell function and on CD8(+) T cell-mediated AHR were determined. Methods: Effector CD8(+) T cells were generated from OVA(257.264) (SIINFEKL) peptide-primed mononuclear cells from OT-1 mice. The effects of U0126, an ERK inhibitor, on effector CD8(+) T-cell function and on CD8(+) T cell-mediated AHR and allergic inflammation were examined. Results: Pretreatment of effector CD8(+) T cells with U0126 suppressed anti-CD3/anti-CD28-induced ERK1/2 phosphorylation and cytokine production, but did not affect LTB4-induced Ca2+ mobilization or chemotaxis. Adoptive transfer of U0126-treated CD8(+) T cells into sensitized mice before secondary allergen challenge resulted in significant decreases in AHR, eosinophilic inflammation, goblet cell metaplasia, and IL-5 and IL-13 levels in bronchoalveolar lavage fluid of recipient mice. The number of transferred CD8(+) T cells accumulating in bronchoalveolar lavage fluid or lungs was unaffected by treatment. Conclusion: ERK1/2-dependent pathways are essential for the effector functions of CD8(+) T cells, including T(H)2 cytokine production, allergic inflammation, and development of AHR. Inhibition of ERK1/2 signaling has potential therapeutic benefit in preventing CD8(+) T cell-mediated AHR. (J Allergy Clin Immunol 2009;123:249-57.)	[Ohnishi, Hiroshi; Takeda, Katsuyuki; Domenico, Joanne; Lucas, Joseph J.; Miyahara, Nobuaki; Swasey, Christina H.; Dakhama, Azzeddine; Gelfand, Erwin W.] Natl Jewish Hlth, Dept Pediat, Div Cell Biol, Denver, CO 80206 USA	National Jewish Health	Gelfand, EW (corresponding author), Natl Jewish Hlth, Dept Pediat, Div Cell Biol, 1400 Jackson St, Denver, CO 80206 USA.			Ohnishi, Hiroshi/0000-0002-7863-4519	National Institutes of Health [HL-36577, HL-61005]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061005, P01HL036577] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by National Institutes of Health grants HL-36577 and HL-61005.	AHL A, 2002, BRIT J PHARMACOL, V135, P1915; AMASHITA M, 1999, P NATL ACAD SCI USA, V96, P1024; Atherton HC, 2003, AM J PHYSIOL-LUNG C, V285, pL730, DOI 10.1152/ajplung.00089.2003; Berg NN, 1998, J IMMUNOL, V161, P2919; Boehme SA, 1999, J IMMUNOL, V163, P1611; Chialda L, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-36; DOWELL M, 2004, AM J RESP CRIT CARE, V169, pA28; DOWELL ML, 2005, AM J RESP CRIT CARE, V171, pA503; Duan W, 2004, J IMMUNOL, V172, P7053, DOI 10.4049/jimmunol.172.11.7053; Engedal N, 2003, J BIOL CHEM, V278, P10934, DOI 10.1074/jbc.M211556200; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Gelfand EW, 2006, J ALLERGY CLIN IMMUN, V117, P577, DOI 10.1016/j.jaci.2005.12.1340; Hamelmann E, 1999, AM J RESP CRIT CARE, V160, P934, DOI 10.1164/ajrccm.160.3.9806029; Hirst SJ, 2002, AM J RESP CRIT CARE, V165, P1161, DOI 10.1164/ajrccm.165.8.2107158; Ip WK, 2006, CLIN EXP IMMUNOL, V145, P162, DOI 10.1111/j.1365-2249.2006.03085.x; Kampen GT, 2000, BLOOD, V95, P1911, DOI 10.1182/blood.V95.6.1911; Kimata M, 2000, BIOCHEM PHARMACOL, V60, P589, DOI 10.1016/S0006-2952(00)00354-3; Koya T, 2007, J IMMUNOL, V179, P2787, DOI 10.4049/jimmunol.179.5.2787; Kumar A, 2003, FASEB J, V17, P1800, DOI 10.1096/fj.02-1148com; Langdon C, 2003, J IMMUNOL, V170, P548, DOI 10.4049/jimmunol.170.1.548; Manjunath N, 2001, J CLIN INVEST, V108, P871, DOI 10.1172/JCI200113296; MITCHELL RW, 2004, AM J RESP CRIT CARE, V169, pA447; Miyahara N, 2005, AM J RESP CRIT CARE, V172, P161, DOI 10.1164/rccm.200502-205OC; Miyahara N, 2005, J IMMUNOL, V174, P4979, DOI 10.4049/jimmunol.174.8.4979; Miyahara N, 2004, NAT MED, V10, P865, DOI 10.1038/nm1081; Moore PE, 2002, AM J PHYSIOL-LUNG C, V282, pL847, DOI 10.1152/ajplung.00245.2001; Nishibe T, 2001, BLOOD, V97, P692, DOI 10.1182/blood.V97.3.692; Ohnishi H, 2008, J ALLERGY CLIN IMMUN, V121, P864, DOI 10.1016/j.jaci.2008.01.035; Oshiba A, 1996, J CLIN INVEST, V97, P1398, DOI 10.1172/JCI118560; Ott VL, 2003, NAT IMMUNOL, V4, P974, DOI 10.1038/ni971; Pelaia G, 2005, J CELL PHYSIOL, V202, P642, DOI 10.1002/jcp.20169; Puente LG, 2000, J IMMUNOL, V165, P6865, DOI 10.4049/jimmunol.165.12.6865; Richards JD, 2001, J IMMUNOL, V166, P3855, DOI 10.4049/jimmunol.166.6.3855; Takeda K, 2005, EUR RESPIR J, V26, P577, DOI 10.1183/09031936.05.00090304; Takeda K, 1997, J EXP MED, V186, P449, DOI 10.1084/jem.186.3.449; Tan AHM, 2006, J BIOL CHEM, V281, P28666, DOI 10.1074/jbc.M604081200; Taube C, 2006, J IMMUNOL, V176, P3157, DOI 10.4049/jimmunol.176.5.3157; Tsukimoto M, 2006, J IMMUNOL, V177, P2842, DOI 10.4049/jimmunol.177.5.2842; van Rensen ELJ, 2005, AM J RESP CRIT CARE, V172, P837, DOI 10.1164/rccm.200504-619OC; Waiczies S, 2005, J IMMUNOL, V174, P5630, DOI 10.4049/jimmunol.174.9.5630; Weninger W, 2001, J EXP MED, V194, P953, DOI 10.1084/jem.194.7.953; Woo CH, 2003, J IMMUNOL, V170, P6273, DOI 10.4049/jimmunol.170.12.6273	42	22	22	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2009	123	1					249	257		10.1016/j.jaci.2008.10.054	http://dx.doi.org/10.1016/j.jaci.2008.10.054			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	399IP	19130938				2022-12-18	WOS:000262793900039
J	Kwiek, B; Peng, WM; Allam, JP; Langner, A; Bieber, T; Novak, N				Kwiek, Bartlomiej; Peng, Wen-Ming; Allam, Jean-Pierre; Langner, Andrzej; Bieber, Thomas; Novak, Natalija			Tacrolimus and TGF-beta act synergistically on the generation of Langerhans cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Langerhans cells; inflammatory dendritic epidermal cells; atopic dermatitis; TGF-beta; tacrolimus; TGF-beta receptor	GROWTH-FACTOR-BETA; FC-EPSILON-RI; DENDRITIC CELLS; ATOPIC-DERMATITIS; STEADY-STATE; LYMPH-NODES; EXPRESSION; TGF-BETA-1; FK506; DIFFERENTIATION	Background: The proportion of dendritic cell subpopulations in the skin is important for the severity of atopic dermatitis because topical treatment with tacrolimus leads to rapid depletion of inflammatory dendritic epidermal cells, whereas Langerhans cells (LCs) predominate in cured sites. Objectives: The effects of tacrolimus and TGF-beta 1 on LC differentiation and the idea of tacrolimus skewing the differentiation of epidermal precursors to LCs were evaluated. Methods: The presence of LC markers, MHC, and costimulatory molecules and stimulatory capacity toward T cells of monocyte-derived LCs were analyzed. Skin samples of patients with atopic dermatitis were assessed by means of immunofluorescence microscopy before and after tacrolimus treatment. TGF-beta production of skin cells was analyzed. Results: Tacrolimus and TGF-beta 1 act synergistically on the generation of LCs and the expression of CD40, CD80, CD86, CD83, and MHC II; stabilize TGF-beta receptor II expression; and decrease the stimulatory capacity of LCs toward T cells. In vivo the number of epidermal LCs in tacrolimus-treated skin increased. Conclusion: The synergism between TGF-beta 1 and tacrolimus leads to the generation of LCs, reduced expression of costimulatory and MHC II molecules, and reduced stimulatory activity. Shifting the balance of the dendritic cell population to LCs might be of major importance for the therapeutic effect of tacrolimus.	[Kwiek, Bartlomiej; Peng, Wen-Ming; Allam, Jean-Pierre; Bieber, Thomas; Novak, Natalija] Univ Bonn, Dept Dermatol & Allergol, D-53105 Bonn, Germany; [Kwiek, Bartlomiej; Langner, Andrzej] Med Univ Warsaw, Dept Dermatol, Warsaw, Poland	University of Bonn; Medical University of Warsaw	Novak, N (corresponding author), Univ Bonn, Dept Dermatol & Allergol, Sigmund Freud Str 25, D-53105 Bonn, Germany.	Natalija.Novak@ukb.uni-bonn.de	Kwiek, Bartlomiej/AAE-4835-2020; Peng, Wenming/GSD-3650-2022; Peng, PD Dr. rer. nat. Wenming/E-3708-2017	Peng, PD Dr. rer. nat. Wenming/0000-0003-0012-7389				BAKER BS, 1985, CLIN EXP IMMUNOL, V61, P526; BELSITO DV, 1982, J EXP MED, V155, P291, DOI 10.1084/jem.155.1.291; BIEBER T, 1988, BRIT J DERMATOL, V118, P385, DOI 10.1111/j.1365-2133.1988.tb02432.x; Bing P, 2006, TRANSPLANT P, V38, P2180, DOI 10.1016/j.transproceed.2006.06.102; Boguniewicz M, 2006, J ALLERGY CLIN IMMUN, V118, P40, DOI 10.1016/j.jaci.2006.04.044; Borkowski TA, 1997, J CLIN INVEST, V100, P575, DOI 10.1172/JCI119567; BUCKLEY CC, 1992, J INVEST DERMATOL, V99, P184, DOI 10.1111/1523-1747.ep12616813; Chen YG, 1997, EMBO J, V16, P3866, DOI 10.1093/emboj/16.13.3866; Geissmann F, 1998, J EXP MED, V187, P961, DOI 10.1084/jem.187.6.961; Geissmann F, 1999, J IMMUNOL, V162, P4567; Geissmann F, 2002, J EXP MED, V196, P417, DOI 10.1084/jem.20020018; GINBOUX F, 2006, NAT IMMUNOL, V7, P265; GRABBE S, 1995, J IMMUNOL, V155, P4207; Hoetzenecker W, 2005, J ALLERGY CLIN IMMUN, V115, P1276, DOI 10.1016/j.jaci.2005.02.011; Homey B, 1998, J IMMUNOL, V160, P5331; Kaplan DH, 2007, J EXP MED, V204, P2545, DOI 10.1084/jem.20071401; Khanna A, 2002, KIDNEY INT, V62, P2257, DOI 10.1046/j.1523-1755.2002.00668.x; Kissenpfennig A, 2006, TRENDS IMMUNOL, V27, P132, DOI 10.1016/j.it.2006.01.003; Lan CCE, 2004, BRIT J DERMATOL, V151, P679, DOI 10.1111/j.1365-2133.2004.06109.x; Matsue H, 2002, J IMMUNOL, V169, P3555, DOI 10.4049/jimmunol.169.7.3555; Merad M, 2002, NAT IMMUNOL, V3, P1135, DOI 10.1038/ni852; Novak N, 2005, CLIN EXP DERMATOL, V30, P160, DOI 10.1111/j.1365-2230.2005.01709.x; Novak N, 2004, J ALLERGY CLIN IMMUN, V113, P949, DOI 10.1016/j.jaci.2004.02.005; Novak N, 2002, J INVEST DERMATOL, V119, P842, DOI 10.1046/j.1523-1747.2002.00102.x; Novak N, 2001, J ALLERGY CLIN IMMUN, V108, P588, DOI 10.1067/mai.2001.118597; Novak N, 2001, J IMMUNOL, V167, P797, DOI 10.4049/jimmunol.167.2.797; Novak N, 2003, J ALLERGY CLIN IMMUN, V112, pS128, DOI DOI 10.1016/j.jaci.2003.09.032; Panhans-Gross A, 2001, J ALLERGY CLIN IMMUN, V107, P345, DOI 10.1067/mai.2001.112600; Probst HC, 2003, IMMUNITY, V18, P713, DOI 10.1016/S1074-7613(03)00120-1; Ruzicka T, 1997, NEW ENGL J MED, V337, P816, DOI 10.1056/NEJM199709183371203; Schuller E, 2004, J ALLERGY CLIN IMMUN, V114, P137, DOI 10.1016/j.jaci.2004.03.021; Simon D, 2005, ALLERGY, V60, P944, DOI 10.1111/j.1398-9995.2005.00798.x; Simon D, 2004, J ALLERGY CLIN IMMUN, V114, P887, DOI 10.1016/j.jaci.2004.05.066; Steinman RM, 2002, P NATL ACAD SCI USA, V99, P351, DOI 10.1073/pnas.231606698; Stoitzner P, 2005, J INVEST DERMATOL, V125, P116, DOI 10.1111/j.0022-202X.2005.23757.x; WANG TW, 1994, SCIENCE, V265, P674, DOI 10.1126/science.7518616; Wollenberg A, 1996, J INVEST DERMATOL, V106, P446, DOI 10.1111/1523-1747.ep12343596; Wollenberg A, 2000, CLIN EXP DERMATOL, V25, P530, DOI 10.1046/j.1365-2230.2000.00699.x; Wollenberg A, 2001, J ALLERGY CLIN IMMUN, V107, P519, DOI 10.1067/mai.2001.112942; Yao DY, 2000, J BIOL CHEM, V275, P13149, DOI 10.1074/jbc.275.17.13149	41	22	23	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2008	122	1					126	132		10.1016/j.jaci.2008.05.005	http://dx.doi.org/10.1016/j.jaci.2008.05.005			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	325RD	18547634				2022-12-18	WOS:000257605100021
J	Finkelman, FD				Finkelman, Fred D.			Use of unrestrained, single-chamber barometric plethysmography to evaluate sensitivity to cholinergic stimulation in mouse models of allergic airway disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material							BRONCHIAL HYPERRESPONSIVENESS; MICE; RESPONSIVENESS; INFLAMMATION; HYPERREACTIVITY; RHINITIS; ASTHMA; PENH		Cincinnati Vet Affairs Med Ctr, Dept Med, Cincinnati, OH 45220 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Cincinnati VA Medical Center	Finkelman, FD (corresponding author), Cincinnati Vet Affairs Med Ctr, Dept Med, 3200 Vine St, Cincinnati, OH 45220 USA.	ffinkelman@pol.net						Adler A, 2004, J APPL PHYSIOL, V97, P286, DOI 10.1152/japplphysiol.00821.2003; Akbari O, 2003, NAT MED, V9, P582, DOI 10.1038/nm851; Bates J, 2004, AM J RESP CELL MOL, V31, P373, DOI 10.1165/ajrcmb.31.3.1; Bryce PJ, 2003, J ALLERGY CLIN IMMUN, V112, P149, DOI 10.1067/mai.2003.1616; Cui JQ, 2005, J ALLERGY CLIN IMMUN, V115, P309, DOI 10.1016/j.jaci.2004.10.046; Drazen JM, 1999, ANNU REV PHYSIOL, V61, P593, DOI 10.1146/annurev.physiol.61.1.593; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766, DOI 10.1164/ajrccm.156.3.9606031; Krane CM, 2001, P NATL ACAD SCI USA, V98, P14114, DOI 10.1073/pnas.231273398; LEE CC, 2007, MOL THER; Lin CC, 2001, RESPIRATION, V68, P178, DOI 10.1159/000050489; Lomask M, 2006, EXP TOXICOL PATHOL, V57, P13, DOI 10.1016/j.etp.2006.02.014; Lundblad LKA, 2002, J APPL PHYSIOL, V93, P1198, DOI 10.1152/japplphysiol.00080.2002; Mehlhop PD, 2000, AM J RESP CELL MOL, V23, P646, DOI 10.1165/ajrcmb.23.5.3954; Mitzner W, 2003, J APPL PHYSIOL, V94, P828, DOI 10.1152/japplphysiol.00815.2002; Mitzner W, 2007, AM J RESP CRIT CARE, V176, P215, DOI 10.1164/ajrccm.176.2.215; Miyahara S, 2005, J ALLERGY CLIN IMMUN, V116, P1020, DOI 10.1016/j.jaci.2005.08.020; Nakae S, 2007, J ALLERGY CLIN IMMUN, V120, P48, DOI 10.1016/j.jaci.2007.02.046; Nakaya M, 2006, LAB INVEST, V86, P917, DOI 10.1038/labinvest.3700452; Petak F, 2001, J APPL PHYSIOL, V90, P2221, DOI 10.1152/jappl.2001.90.6.2221; Yamashita N, 2006, J ALLERGY CLIN IMMUN, V117, P1040, DOI 10.1016/j.jaci.2006.01.009	20	22	22	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2008	121	2					334	335		10.1016/j.jaci.2007.11.028	http://dx.doi.org/10.1016/j.jaci.2007.11.028			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	265CX	18177698				2022-12-18	WOS:000253337800007
J	Metz-Favre, C; Linhart, B; Focke-Tejkl, M; Purohit, A; de Blay, F; Valenta, R; Pauli, G				Metz-Favre, Carine; Linhart, Birgit; Focke-Tejkl, Margarete; Purohit, Ashok; de Blay, Frederic; Valenta, Rudolf; Pauli, Gabrielle			Skin test diagnosis of grass pollen allergy with a recombinant hybrid molecule	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; grass pollen; recombinant hybrid allergen; skin testing; diagnosis	PHLEUM-PRATENSE POLLEN; IMMUNOLOGICAL CHARACTERIZATION; BIRCH POLLEN; IGE; IMMUNOTHERAPY; SENSITIVITY; EXPULSION; RELEASE; EXTRACT; ASTHMA	Background: A recombinant hybrid molecule (HM) consisting of 4 major allergens from timothy grass (Phi p 1, 2, 5, and 6) was expressed in Escherichia coli, purified, and characterized regarding its immunologic properties. Objective: We sought to determine whether the recombinant HM can be used for the diagnosis of grass pollen allergy by means of skin testing. Methods: Skin prick testing was performed in 32 patients with grass pollen allergy and in 9 control individuals by using increasing concentrations (4, 12, 36, and 108 mu g/mL) of the HM and using commercial grass pollen extract. Specific IgE reactivities against the HM, grass pollen extract, and a panel of purified grass pollen allergens (recombinant Phi p 1, 2, 5, 6, 7, 12, and 13 and natural Phi p 4) were measured by means of ELISA, and timothy grass pollen-specific IgE levels were determined by using ImmunoCAP. Results: Grass pollen allergy was diagnosed in all patients by means of skin testing with the HM. No false-positive skin test responses were obtained in the control individuals. There was an excellent correlation between IgE levels obtained with the HM and natural grass pollen extract measured by means of ELISA (r = 0.98, P < .0001) and by means of ImmunoCAP (r = 0.98, P < .0001). Conclusions: The recombinant HM permitted accurate and specific in vivo diagnosis of grass pollen allergy in all tested patients. It can be considered a well-defined tool for the diagnosis and perhaps for immunotherapy of grass pollen allergy. Clinical implications: A recombinant HM can replace traditional allergen extracts for skin test-based diagnosis of grass pollen allergy.	Hop Univ Strasbourg, Dept Resp Dis, F-67091 Strasbourg, France; Med Univ Vienna, Ctr Physiol & Pathophysiol, Dept Pathophysiol,Div Immunopathol, Christian Doppler Lab Allergy Res, Vienna, Austria	CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Medical University of Vienna	Pauli, G (corresponding author), Hop Univ Strasbourg, Dept Resp Dis, BP 426, F-67091 Strasbourg, France.	Gabrielle.pauli@chru-strasbourg.fr		Linhart, Birgit/0000-0001-6857-3049; Valenta, Rudolf/0000-0001-5944-3365				Andersson K, 2003, INT ARCH ALLERGY IMM, V130, P87, DOI 10.1159/000069013; Esch Robert E, 2004, Clin Allergy Immunol, V18, P185; Grote M, 2000, J ALLERGY CLIN IMMUN, V105, P1140, DOI 10.1067/mai.2000.107044; Heiss S, 1999, J INVEST DERMATOL, V113, P830, DOI 10.1046/j.1523-1747.1999.00796.x; Jutel M, 2005, J ALLERGY CLIN IMMUN, V116, P608, DOI 10.1016/j.jaci.2005.06.004; Laffer S, 1996, J ALLERGY CLIN IMMUN, V98, P652, DOI 10.1016/S0091-6749(96)70099-4; Linhart B, 2005, J ALLERGY CLIN IMMUN, V115, P1010, DOI 10.1016/j.jaci.2004.12.1142; Linhart B, 2002, FASEB J, V16, P1301, DOI 10.1096/fj.01-1012fje; Mari A, 2003, CLIN EXP ALLERGY, V33, P43, DOI 10.1046/j.1365-2222.2003.01569.x; Marth K, 2004, J ALLERGY CLIN IMMUN, V113, P470, DOI 10.1016/j.jaci.2003.11.042; MARTH K, 2004, P 23 EAACI C AMST NE, P181; Martin S, 1997, ALLERGY, V52, P97, DOI 10.1111/j.1398-9995.1997.tb02552.x; Niederberger V, 1998, J ALLERGY CLIN IMMUN, V101, P258, DOI 10.1016/S0091-6749(98)70391-4; Niederberger V, 1999, FASEB J, V13, P843, DOI 10.1096/fasebj.13.8.843; Niederberger V, 2001, J INVEST DERMATOL, V117, P848, DOI 10.1046/j.0022-202x.2001.01470.x; Pauli G, 1996, J ALLERGY CLIN IMMUN, V97, P1100, DOI 10.1016/S0091-6749(96)70264-6; Purohit A, 2005, CLIN EXP ALLERGY, V35, P186, DOI 10.1111/j.1365-2222.2005.02156.x; STEWART GA, 2003, MIDDLETONS ALLERGY P, P585; Stumvoll S, 2002, BIOL CHEM, V383, P1383, DOI 10.1515/BC.2002.157; SUPHIOGLU C, 1992, LANCET, V339, P569, DOI 10.1016/0140-6736(92)90864-Y; Swoboda I, 2004, J IMMUNOL, V172, P6490, DOI 10.4049/jimmunol.172.10.6490; TANIZAKI Y, 1984, INT ARCH ALLER A IMM, V73, P141, DOI 10.1159/000233454; Taylor PE, 2002, J ALLERGY CLIN IMMUN, V109, P51, DOI 10.1067/mai.2002.120759; TURKELTAUB PC, 1982, J ALLERGY CLIN IMMUN, V70, P343, DOI 10.1016/0091-6749(82)90023-9; VALENTA R, 1992, INT ARCH ALLERGY IMM, V97, P287, DOI 10.1159/000236135; Valenta R, 1999, CLIN EXP ALLERGY, V29, P896; Vrtala S, 1996, J ALLERGY CLIN IMMUN, V97, P781, DOI 10.1016/S0091-6749(96)80156-4; Vrtala S, 1999, J IMMUNOL, V163, P5489; WESTRITSCHNIG K, 2006, P 25 EAACI C VIENN A, P39	29	22	24	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2007	120	2					315	321		10.1016/j.jaci.2007.03.046	http://dx.doi.org/10.1016/j.jaci.2007.03.046			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	198VF	17512042				2022-12-18	WOS:000248654900015
J	Jartti, T; Waris, M; Niesters, HGM; Allander, T; Ruitskanen, O				Jartti, Tuomas; Waris, Matti; Niesters, Hubert G. M.; Allander, Tobias; Ruitskanen, Olli			Respiratory viruses and acute asthma in children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									Turku Univ Hosp, Dept Pediat, FIN-20520 Turku, Finland; Turku Univ, Dept Virol, Turku, Finland; Univ Rotterdam, Ctr Med, Erasmus MC, Dept Virol, Rotterdam, Netherlands; Karolinska Univ Hosp, Dept Clin Microbiol, Stockholm, Sweden	University of Turku; University of Turku; Erasmus University Rotterdam; Erasmus MC; Karolinska Institutet; Karolinska University Hospital	Jartti, T (corresponding author), Turku Univ Hosp, Dept Pediat, FIN-20520 Turku, Finland.	tuomas.jartti@utu.fi	Waris, Matti E/A-6418-2008; Niesters, Hubert/AAH-6808-2019	Waris, Matti/0000-0002-6747-0889; Niesters, Hubert/0000-0002-1758-0430				Allander T, 2007, CLIN INFECT DIS, V44, P904, DOI 10.1086/512196; Jartti T, 2004, EMERG INFECT DIS, V10, P1095, DOI 10.3201/eid1006.030629; Jartti T, 2004, J MED VIROL, V72, P695, DOI 10.1002/jmv.20027; Khetsuriani N, 2007, J ALLERGY CLIN IMMUN, V119, P314, DOI 10.1016/j.jaci.2006.08.041	4	22	22	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2007	120	1					216	216		10.1016/j.jaci.2007.02.025	http://dx.doi.org/10.1016/j.jaci.2007.02.025			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	190NS	17399782	Green Published			2022-12-18	WOS:000248066400034
J	O'Byrne, PM				O'Byrne, Paul M.			Acute asthma intervention: Insights from the STAY study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; exacerbations; inhaled corticosteroids; budesonide; long-acting beta-agonists; formoterol	RELIEVER THERAPY; BUDESONIDE/FORMOTEROL MAINTENANCE; INHALED BUDESONIDE; SINGLE INHALER; FORMOTEROL; EXACERBATIONS; COMBINATION; SALMETEROL; SAFETY; TRIAL	In some patients, asthma control is improved by combining inhaled corticosteroids with long-acting O-2-agonists. However, fluctuating asthma control and exacerbations can still occur. The STAY study evaluated whether, in patients with moderate to severe asthma, replacing a short-acting O-2-agonist reliever with the combination of budesonide/formoterol as reliever would both provide rapid symptom relief and reduce asthma exacerbations. The study evaluated 2760 patients with asthma (4-80 years) randomized to budesonide 400 mu g twice daily (bid) and terbutaline as reliever, budesonide/formoterol 100/6 mu g bid and terbutaline as reliever, or budesonide/formoterol 100/6 mu g bid both as maintenance and reliever. Children (age 4-11 years) used a once-daily maintenance dose. Budesonide/ formoterol as maintenance and reliever significantly reduced severe exacerbation risk by 45% to 47% compared with the other 2 treatments and improved symptoms, awakenings, and lung function. The benefit was seen in patients of all ages. Subsequent studies have revealed that this beneficial effect of budesonide/formoterol as maintenance and reliever requires both components of the combination.	McMaster Univ, Firestone Inst Resp Hlth, St Josephs Healthcare, Dept Med, Hamilton, ON L8N 3Z5, Canada	McMaster University	O'Byrne, PM (corresponding author), McMaster Univ, Firestone Inst Resp Hlth, St Josephs Healthcare, Dept Med, 1200 Main St W, Hamilton, ON L8N 3Z5, Canada.	obyrnep@mcmaster.ca		O'Byrne, Paul/0000-0003-0979-281X				ANDERSON GP, 1993, LIFE SCI, V52, P2145, DOI 10.1016/0024-3205(93)90729-M; [Anonymous], 2006, NIH PUBLICATION; Balanag VM, 2006, PULM PHARMACOL THER, V19, P139, DOI 10.1016/j.pupt.2005.04.009; Bateman ED, 2004, AM J RESP CRIT CARE, V170, P836, DOI 10.1164/rccm.200401-033OC; Bisgaard H, 2003, PEDIATR PULM, V36, P391, DOI 10.1002/ppul.10381; Bisgaard H, 2006, CHEST, V130, P1733, DOI 10.1378/chest.130.6.1733; Duong M, 2007, J ALLERGY CLIN IMMUN, V119, P322, DOI 10.1016/j.jaci.2006.10.018; FitzGerald JM, 2004, THORAX, V59, P550, DOI 10.1136/thx.2003.014936; Harrison TW, 2004, LANCET, V363, P271, DOI 10.1016/S0140-6736(03)15384-6; Ind PW, 2003, RESP MED, V97, P555, DOI 10.1053/rmed.2003.1483; McIvor RA, 1998, AM J RESP CRIT CARE, V158, P924; O'Byrne PM, 2001, AM J RESP CRIT CARE, V164, P1392, DOI 10.1164/ajrccm.164.8.2104102; O'Byrne PM, 2005, AM J RESP CRIT CARE, V171, P129, DOI 10.1164/rccm.200407-884OC; Pauwels RA, 1997, NEW ENGL J MED, V337, P1405, DOI 10.1056/NEJM199711133372001; Pauwels RA, 2003, EUR RESPIR J, V22, P787, DOI 10.1183/09031936.03.00055803; Rabe KF, 2006, LANCET, V368, P744, DOI 10.1016/S0140-6736(06)69284-2; Scicchitano R, 2004, CURR MED RES OPIN, V20, P1403, DOI 10.1185/030079904X2051; Tattersfield AE, 1999, AM J RESP CRIT CARE, V160, P594, DOI 10.1164/ajrccm.160.2.9811100; Tattersfield AE, 2001, LANCET, V357, P257, DOI 10.1016/S0140-6736(00)03611-4; Vogelmeier C, 2005, EUR RESPIR J, V26, P819, DOI 10.1183/09031936.05.00028305; Woolcock A, 1996, AM J RESP CRIT CARE, V153, P1481, DOI 10.1164/ajrccm.153.5.8630590; Zetterstrom O, 2001, EUR RESPIR J, V18, P262, DOI 10.1183/09031936.01.00065801	22	22	22	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2007	119	6					1332	1336		10.1016/j.jaci.2007.03.007	http://dx.doi.org/10.1016/j.jaci.2007.03.007			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	178PO	17451803	Bronze			2022-12-18	WOS:000247232800007
J	Zhou, XX; Hu, HZ; Huynh, MLN; Kotaru, C; Balzar, S; Trudeau, JB; Wenzel, SE				Zhou, Xiuxia; Hu, Haizhen; Huynh, Mai-Lan N.; Kotaru, Chakradhar; Balzar, Silvana; Trudeau, John B.; Wenzel, Sally E.			Mechanisms of tissue inhibitor of metalloproteinase 1 augmentation by IL-13 on TGF-beta 1-stimulated primary human fibroblasts	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						TIMP-1; real-time PCR; Smad; dominant negative Smad-2,-3; PI3K-Akt; LY294002; MEK-ERK; U0126	HUMAN GINGIVAL FIBROBLASTS; GROWTH-FACTOR EXPRESSION; TGF-BETA; CROSS-TALK; INFLAMMATION; RECEPTOR; KINASES; ASTHMA; LUNG; P38	Background: TGF-beta induces expression of tissue inhibitor of metalloproteinase 1 (TIMP-1), a potent inhibitor of matrix metalloproteinases that controls extracellular matrix metabolism and deposition. IL-13 alone does not induce TIMP-1, but in combination with TGF-beta it augments TIMP-1 expression. Although these interactions have implications for remodeling in asthma, little is understood regarding the mechanisms controlling TIMP-1 product. Objective: To explore the role of Smads and mitogen-activated protein kinase kinase (MEK)-extracellular signal-regulated kinase (ERK) in the TIMP-1 augmentation by IL-13+TGF-beta I in primary human airway fibroblasts. Methods: Real-time PCR, Western blot, ELISA, and transient transfection were used to evaluate the mechanisms of TIMP-1 augmentation. Results: IL-13 enhanced TGF-beta 1-induced Smad-2 and Smad-3 phosphorylation, transient transfection with dominant-negative Smad-2 or Smad-3 decreased TIMP-1 mRNA expression in the presence of TGF-beta 1 and IL-13+TGF-beta 1 through inhibition of Smad-2 or Smad-3 phosphorylation. ERK phosphorylation was increased by IL-13 and IL-13+TGF-beta 1. MEK-ERK inhibition decreased TIMP-1 mRNA/protein to a greater degree after IL-13+TGF-beta 1 stimulation versus TGF-beta 1 alone. MEK-ERK inhibition also significantly increased Akt phosphorylation under all conditions and decreased Smad-3 phosphorylation in the presence of IL-13+TGF-beta 1. In contrast, phosphoinositde-3 kinase-Akt inhibition increased phosphorylation of ERK and Smads, leading to increased TIMP-1. Conclusion: These results indicate that IL-13 augments TGF01-induced TIMP-1 expression through increased Smad phosphorylation. These increases occur as TGF-beta 1 downregulates IL-13-induced phosphoinositde-3 kinase activation while leaving the positive effect of IL-13-induced ERK on Smad signaling. Clinical implications: This augmentation of TGF-beta 1-induced TIMP-1 by IL-13 could contribute to the fibrosis and airway remodeling seen in the presence of TH2 inflammation in asthma.	Univ Pittsburgh, Med Ctr, Pittsburgh, PA 15213 USA; Natl Jewish Med & Res Ctr, Denver, CO USA; Univ Colorado, Hlth Sci Ctr, Denver, CO USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Wenzel, SE (corresponding author), Univ Pittsburgh, Med Ctr, NW 628 Montefiore Hosp,3459 Fifth Ave, Pittsburgh, PA 15213 USA.	wenzelse@upmc.edu		Zhou, Xiuxia/0000-0003-1562-103X	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000005] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064087] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040600] Funding Source: NIH RePORTER; NCATS NIH HHS [UL1 TR000005] Funding Source: Medline; NCRR NIH HHS [RR-00051] Funding Source: Medline; NHLBI NIH HHS [HL-64087] Funding Source: Medline; NIAID NIH HHS [AI-40600] Funding Source: Medline	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCATS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Balzar S, 2005, J ALLERGY CLIN IMMUN, V115, P110, DOI 10.1016/j.jaci.2004.09.034; Batra V, 2004, CLIN EXP ALLERGY, V34, P437, DOI 10.1111/j.1365-2222.2004.01885.x; Blaeser F, 2003, J EXP MED, V198, P1189, DOI 10.1084/jem.20030471; Bridgewater DJ, 2005, KIDNEY INT, V67, P1308, DOI 10.1111/j.1523-1755.2005.00208.x; Chen QS, 2005, J IMMUNOL, V174, P2305, DOI 10.4049/jimmunol.174.4.2305; Choi WS, 2004, J RECEPT SIG TRANSD, V24, P67, DOI 10.1081/RRS-120034229; Choy L, 2000, J CELL BIOL, V149, P667, DOI 10.1083/jcb.149.3.667; Chu HW, 2004, AM J PATHOL, V165, P1097, DOI 10.1016/S0002-9440(10)63371-8; Cohn L, 2004, ANNU REV IMMUNOL, V22, P789, DOI 10.1146/annurev.immunol.22.012703.104716; Doucet C, 1998, J CLIN INVEST, V101, P2129, DOI 10.1172/JCI741; Hayashida T, 2003, FASEB J, V17, P1576, DOI 10.1096/fj.03-0037fje; Hoshino M, 1999, J ALLERGY CLIN IMMUN, V103, P1054, DOI 10.1016/S0091-6749(99)70179-X; Imamichi Y, 2005, BIOL CHEM, V386, P225, DOI 10.1515/BC.2005.028; Johnson SR, 2005, THORAX, V60, P617, DOI 10.1136/thx.2004.036475; Kaviratne M, 2004, J IMMUNOL, V173, P4020, DOI 10.4049/jimmunol.173.6.4020; Kotaru C, 2006, AM J RESP CRIT CARE, V173, P1208, DOI 10.1164/rccm.200508-1218OC; Kumagai K, 1999, J IMMUNOL, V162, P4212; Kumar RK, 2004, AM J RESP CRIT CARE, V170, P1043, DOI 10.1164/rccm.200405-681OC; Leigh R, 2004, AM J RESP CRIT CARE, V169, P860, DOI 10.1164/rccm.200305-706OC; Leivonen SK, 2002, J BIOL CHEM, V277, P46338, DOI 10.1074/jbc.M206535200; Lose F, 2005, THORAX, V60, P623, DOI 10.1136/thx.2004.026930; Marchand-Adam S, 2005, AM J RESP CELL MOL, V32, P470, DOI 10.1165/rcmb.2004-0205OC; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Qiu Q, 2004, REPRODUCTION, V128, P355, DOI 10.1530/rep.1.00234; Qureshi HY, 2005, J CELL PHYSIOL, V203, P345, DOI 10.1002/jcp.20228; Ravanti L, 1999, J BIOL CHEM, V274, P37292, DOI 10.1074/jbc.274.52.37292; Suzuki Ryujiro, 2004, Treat Respir Med, V3, P17, DOI 10.2165/00151829-200403010-00003; Tong L, 2004, CELL SIGNAL, V16, P1123, DOI 10.1016/j.cellsig.2004.03.003; Verrecchia F, 2002, J INVEST DERMATOL, V118, P211, DOI 10.1046/j.1523-1747.2002.01641.x; Wenzel SE, 2003, J ALLERGY CLIN IMMUN, V111, P1345, DOI 10.1067/mai.2003.1464; Wenzel SE, 2002, J IMMUNOL, V169, P4613, DOI 10.4049/jimmunol.169.8.4613; Xie SP, 2005, AM J PHYSIOL-LUNG C, V288, pL68, DOI 10.1152/ajplung.00156.2004; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yang GY, 2004, CYTOKINE, V28, P224, DOI 10.1016/j.cyto.2004.08.007; Zhou XX, 2005, AM J PHYSIOL-CELL PH, V288, pC435, DOI 10.1152/ajpcell.00035.2004	35	22	23	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2007	119	6					1388	1397		10.1016/j.jaci.2007.02.011	http://dx.doi.org/10.1016/j.jaci.2007.02.011			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	178PO	17418380				2022-12-18	WOS:000247232800014
J	Hagler, M; Smith-Norowitz, TA; Chicel, S; Wallner, SR; Viterbo, D; Mueller, CM; Gross, R; Nowakowski, M; Schulze, R; Zenilman, ME; Bluth, MH				Hagler, M.; Smith-Norowitz, T. A.; Chicel, S.; Wallner, S. R.; Viterbo, D.; Mueller, C. M.; Gross, R.; Nowakowski, M.; Schulze, R.; Zenilman, M. E.; Bluth, M. H.			Sophorolipids decrease IgE production in U266 cells by downregulation of BSAP (Pax5), TLR-2, STAT3 and IL-6	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract	63rd Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology	FEB 23-27, 2007	San Diego, CA	Amer Acad Allergy, Asthma & Immunol					[Hagler, M.; Smith-Norowitz, T. A.; Chicel, S.; Viterbo, D.; Gross, R.; Nowakowski, M.; Schulze, R.; Zenilman, M. E.; Bluth, M. H.] Suny Downstate Med Ctr, Brooklyn, NY 11203 USA; [Wallner, S. R.; Gross, R.] Polytech Univ, Brooklyn, NY 11201 USA	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; New York University; Polytechnic University Puerto Rico									0	22	28	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2007	119	1		1		1030	S263	S263		10.1016/j.jaci.2006.12.399	http://dx.doi.org/10.1016/j.jaci.2006.12.399			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	238PT					2022-12-18	WOS:000251460401413
J	Oryszczyn, MP; Bouzigon, E; Maccario, J; Siroux, V; Nadif, R; Wright, A; Kauffmann, F				Oryszczyn, Marie-Pierre; Bouzigon, Emmanuelle; Maccario, Jean; Siroux, Valerie; Nadif, Rachel; Wright, Anne; Kauffmann, Francine			Interrelationships of quantitative asthma-related phenotypes in the Epidemiological Study on the Genetics and Environment of Asthma, Bronchial Hyperresponsiveness, and Atopy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; asthma; eosinophils; epidemiology; sex; IgE; lung function	SKIN-TEST REACTIVITY; LUNG-FUNCTION; BLOOD EOSINOPHILIA; GENDER-DIFFERENCES; IMMUNOGLOBULIN-E; ALLERGY MARKERS; TOTAL IGE; EGEA; SEVERITY; ADULTS	Background: Delineating asthma subphenotypes is of interest to understand the cause of the disease. Few studies have addressed the interrelationships of quantitative asthma-related traits. Objective: We sought to study the interrelationships of allergy markers and FEV1 in relation to asthma and sex in children and adults. Methods: Total IgE levels, skin prick test (SPT) positivity, eosinophil counts, and FEV1 were assessed in 299 asthmatic cases (children and adults) recruited in chest clinics and 309 nonasthmatic population-based control subjects in the French Epidemiological Study on the Genetics and Environment of Asthma, Bronchial Hyperresponsiveness, and Atopy. Results: Allergy parameters were significantly higher in asthmatic cases than in control subjects for children and adults and for both sexes. Sex and age modified the pattern of concordance of high IgE levels, SPT positivity, and eosinophilia among asthmatic cases, with the greatest overlap in male children (64%) and the lowest in male adults (18%). Patterns of change over the lifespan of IgE levels, eosinophil counts, and FEV1/height(2) varied, with the acceleration of FEV1 decrease being particularly evident in asthmatic adults. In adult cases and control subjects, SPT positivity (particularly to indoor allergens) was significantly related to IgE levels but not to eosinophil counts. The association of eosinophil counts with IgE levels was evident only in children. Environmental factors (smoking, pets, and country living) did not alter the patterns observed. Conclusions: Each allergy-related phenotype showed a distinct relation with asthma, with the role for eosinophils being different than that for IgE levels and SPT responses. Clinical implications: Taking age and sex into account is essential for understanding the interrelationships of the various allergy-related phenotypes to asthma status.	INSERM U780, F-94807 Villejuif, France; Univ Paris Sud, IFR69, Villejuif, France; INSERM U794, Evry, France; Univ Evry, Evry, France; Univ Paris 05, Paris, France; INSERM U578, Grenoble, France; Arizona Resp Ctr, Tucson, AZ USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm)	Oryszczyn, MP (corresponding author), INSERM U780, 16 Ave Paul Vaillant Couturier, F-94807 Villejuif, France.	picot@vjv.inserm.fr	siroux, valerie/N-1865-2013; Bouzigon, Emmanuelle/L-2766-2017; Nadif, Rachel/R-2876-2016	siroux, valerie/0000-0001-7329-7237; Bouzigon, Emmanuelle/0000-0001-5756-4286; Nadif, Rachel/0000-0003-4938-9339				Alam R, 2004, J ALLERGY CLIN IMMUN, V113, P38, DOI 10.1016/j.jaci.2003.10.054; Arshad SH, 2005, J ALLERGY CLIN IMMUN, V116, P3, DOI 10.1016/j.jaci.2005.03.043; Baldacci S, 2001, EUR RESPIR J, V17, P773, DOI 10.1183/09031936.01.17407730; BARBEE RA, 1981, J ALLERGY CLIN IMMUN, V68, P106, DOI 10.1016/0091-6749(81)90167-6; Becklake MR, 1999, THORAX, V54, P1119, DOI 10.1136/thx.54.12.1119; Bouzigon E, 2004, EUR J HUM GENET, V12, P955, DOI 10.1038/sj.ejhg.5201241; Douwes J, 2002, THORAX, V57, P643, DOI 10.1136/thorax.57.7.643; FRETTE C, 1991, AM REV RESPIR DIS, V143, P987, DOI 10.1164/ajrccm/143.5_Pt_1.987; Frew AJ, 2005, J ALLERGY CLIN IMMUN, V115, P1197, DOI 10.1016/j.jaci.2005.03.006; Giembycz MA, 1999, PHARMACOL REV, V51, P213; Gottlieb DJ, 1996, AM J RESP CRIT CARE, V153, P561, DOI 10.1164/ajrccm.153.2.8564098; Heaton T, 2005, LANCET, V365, P142, DOI 10.1016/S0140-6736(05)17704-6; Hoffjan S, 2005, AM J HUM GENET, V76, P696, DOI 10.1086/429418; Jansen DF, 1999, AM J RESP CRIT CARE, V159, P924, DOI 10.1164/ajrccm.159.3.9804024; Kauffmann F, 2002, CLIN EXP ALLERGY, V32, P379, DOI 10.1046/j.1365-2222.2002.01325.x; Kauffmann F, 2001, REV EPIDEMIOL SANTE, V49, P343; KAUFFMANN F, 1997, AM J RESP CRIT CARE, V156, P123; Lapperre TS, 2004, AM J RESP CRIT CARE, V170, P499, DOI 10.1164/rccm.200401-112OC; Le Moual N, 2005, AM J RESP CRIT CARE, V172, P440, DOI 10.1164/rccm.200501-111OC; Lewis SA, 2001, CHEST, V119, P105, DOI 10.1378/chest.119.1.105; Maccario J, 2003, J ALLERGY CLIN IMMUN, V111, P750, DOI 10.1067/mai.2003.1386; Martinez FD, 2005, IMMUNOL ALLERGY CLIN, V25, P709, DOI 10.1016/j.iac.2005.09.001; Matricardi PM, 2000, BMJ-BRIT MED J, V320, P412, DOI 10.1136/bmj.320.7232.412; Miranda C, 2004, J ALLERGY CLIN IMMUN, V113, P101, DOI 10.1016/j.jaci.2003.10.041; Ober C, 2005, CURR OPIN IMMUNOL, V17, P670, DOI 10.1016/j.coi.2005.09.009; Oryszczyn MP, 2003, ALLERGY, V58, P1136, DOI 10.1046/j.1398-9995.2003.00314.x; Oryszczyn MP, 2000, AM J RESP CRIT CARE, V161, P1241, DOI 10.1164/ajrccm.161.4.9905027; ORYSZCZYN MP, 2006, P AM THORAC SOC, V3, pA473; Pascual RM, 2005, J ALLERGY CLIN IMMUN, V116, P477, DOI 10.1016/j.jaci.2005.07.011; Postma Dirkje S, 2004, Chest, V126, p96S, DOI 10.1378/chest.126.2_suppl_1.96S; Siroux V, 2004, REV MAL RESPIR, V21, P917; Siroux V, 2004, J ALLERGY CLIN IMMUN, V114, P491, DOI 10.1016/j.jaci.2004.05.027; Siroux V, 2003, CLIN EXP ALLERGY, V33, P746, DOI 10.1046/j.1365-2222.2003.01674.x; Strunk RC, 2003, J ALLERGY CLIN IMMUN, V112, P883, DOI 10.1016/j.jaci.2003.08.014; VANDELLEN RG, 1981, MAYO CLIN PROC, V56, P395; Varraso R, 2005, AM J RESP CRIT CARE, V171, P334, DOI 10.1164/rccm.200405-674OC; von Mutius E, 2004, J ALLERGY CLIN IMMUN, V113, P373, DOI 10.1016/j.jaci.2003.12.040; Williams TJ, 2004, J CLIN INVEST, V113, P507, DOI 10.1172/JCI200421073; Wills-Karp M, 2004, SCIENCE, V305, P1726, DOI 10.1126/science.1104134; Wright AL, 2006, PEDIATR PULM, V41, P318, DOI 10.1002/ppul.20373	40	22	24	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2007	119	1					57	63		10.1016/j.jaci.2006.09.026	http://dx.doi.org/10.1016/j.jaci.2006.09.026			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	127YL	17208586	Green Submitted			2022-12-18	WOS:000243622200010
J	McDonald, DR; Brown, D; Bonilla, FA; Geha, RS				McDonald, Douglas R.; Brown, Daniel; Bonilla, Francisco A.; Geha, Raif S.			Interleukin receptor-associated kinase-4 deficiency impairs Toll-like receptor-dependent innate antiviral immune responses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IRAK-4; Toll-like receptor; TNF-alpha; IFN-alpha; pneumoccocus; MyD88; TRIF	BACTERIAL-INFECTIONS; IRAK-4 DEFICIENCY; CELL-ACTIVATION; INDUCTION	Background: Engagement of all known Toll-like receptors (TLRs) causes the production of inflammatory cytokines, including TNF-alpha, whereas in humans, engagement of TLRs 3, 7, 8, and 9 also induces type I IFNs. IRAK-4 is a critical effector in signaling by TLRs and the IL-1 receptor, which share homology in their intracellular domain and recruit IRAK-4 via the adaptor myeloid differentiation factor 88 (MyD88). Patients with IRAK-4 deficiency are susceptible to invasive bacterial infections but have so far not been reported to be susceptible to viral infection. Blood cells from these patients are impaired in their ability to make TNF-alpha in response to activation by TLRs. A recent report has described concomitant impairment of type I IFN production after activation of TLRs 7, 8, and 9, but not TLR3. Objectives: We sought to evaluate the role of IRAK-4 in TLR-induced production of the type I IFN, IFN-alpha, in humans. Methods: We examined TLR-induced production of TNF-a and IFN-alpha in PBMCs from an IRAK-4-deficient patient, his heterozygous carrier parents, and normal controls. Results: TNF-alpha production in response to TLR agonists was severely impaired in the patient. IFN-alpha production induced by TLR7, TLR8, and TLR9, as well as TLR3 agonists, was low or absent. Conclusions: IRAK-4 plays an important role in the production of type I IFN, as well as TNF-a, induced by all TLRs, including TLR3. Clinical implications: IRAK-4 may play a broader role in human innate antiviral immunity than previously appreciated.	Childrens Hosp, Div Immunol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Geha, RS (corresponding author), Childrens Hosp, Div Immunol, New Res Bldg,1 Blackfan Circle, Boston, MA 02115 USA.	raif.geha@childrens.harvard.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI035714] Funding Source: NIH RePORTER; NIAID NIH HHS [T32AI0075512, P01 AI035714] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Beutler B, 2004, NATURE, V430, P257, DOI 10.1038/nature02761; Day N, 2004, J PEDIATR-US, V144, P524, DOI 10.1016/j.jpeds.2003.11.025; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; JANEWAY CA, 1994, CELL, V76, P275, DOI 10.1016/0092-8674(94)90335-2; Kawai T, 2004, NAT IMMUNOL, V5, P1061, DOI 10.1038/ni1118; Medvedev AE, 2003, J EXP MED, V198, P521, DOI 10.1084/jem.20030701; O'Neill LAJ, 2002, CURR TOP MICROBIOL, V270, P47; Picard C, 2003, SCIENCE, V299, P2076, DOI 10.1126/science.1081902; Sen G, 2005, J IMMUNOL, V175, P3084, DOI 10.4049/jimmunol.175.5.3084; Shinohara ML, 2006, NAT IMMUNOL, V7, P498, DOI 10.1038/ni1327; Sporri R, 2005, NAT IMMUNOL, V6, P163, DOI 10.1038/ni1162; Suzuki N, 2006, SCIENCE, V311, P1927, DOI 10.1126/science.1124256; Suzuki N, 2002, NATURE, V416, P750, DOI 10.1038/nature736; Takeuchi O, 2001, INT IMMUNOPHARMACOL, V1, P625, DOI 10.1016/S1567-5769(01)00010-8; West MA, 2004, SCIENCE, V305, P1153, DOI 10.1126/science.1099153; Yang K, 2005, IMMUNITY, V23, P465, DOI 10.1016/j.immuni.2005.09.016; Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087	17	22	22	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2006	118	6					1357	1362		10.1016/j.jaci.2006.08.006	http://dx.doi.org/10.1016/j.jaci.2006.08.006			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	117NP	17157666				2022-12-18	WOS:000242880300024
J	Lockey, RF				Lockey, Richard F.			Rhinitis medicamentosa and the stuffy nose	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						rhinitis medicamentosa; decongestants			Univ S Florida, Coll Med, Div Allergy Immunol, VA Hosp,Dept Internal Med, Tampa, FL 33612 USA; James A Haley Vet Adm Hosp, Tampa, FL USA	State University System of Florida; University of South Florida; US Department of Veterans Affairs; Veterans Health Administration (VHA); James A. Haley Veterans Hospital	Lockey, RF (corresponding author), Univ S Florida, Coll Med, Div Allergy Immunol, VA Hosp,Dept Internal Med, 13000 Bruce B Downs Blvd, Tampa, FL 33612 USA.	rlockey@hsc.usf.edu						BLACK MJ, 1980, CAN MED ASSOC J, V122, P881; Ferguson BJ, 2001, OTOLARYNG HEAD NECK, V125, P253, DOI 10.1067/mhn.2001.117717; Graf Peter, 2005, Treat Respir Med, V4, P21; Hallen H, 1997, CLIN EXP ALLERGY, V27, P552, DOI 10.1046/j.1365-2222.1997.d01-529.x; TOOHILL RJ, 1981, LARYNGOSCOPE, V91, P1614	5	22	29	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2006	118	5					1017	1018		10.1016/j.jaci.2006.06.018	http://dx.doi.org/10.1016/j.jaci.2006.06.018			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	137GY	17088123				2022-12-18	WOS:000244282300003
J	Kancherla, VS; Hanson, IC				Kancherla, Vikas S.; Hanson, I. Celine			Mumps resurgence in the United States	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						mumps; outbreak; mumps complications; parotitis; orchitis; incomplete immunization	LIVE ATTENUATED MEASLES; VIRUS VACCINE; ANTIBODY	The recent mumps epidemic in the central United States has generated a large amount of public concern. A total of 2597 mumps cases have been reported in the United States in 11 states since January 1, 2006, representing a marked resurgence of mumps in a single year. The majority of these recent cases have occurred in college students age 18 to 25 years. Most were vaccinated with 2 doses of measles, mumps, and rubella-containing vaccines. Such outbreaks provide an opportunity for clinicians to review the clinical presentation, diagnosis, and morbidity of vaccine-preventable infections and also to review immunologic mechanisms and practice guidelines that might contribute to poor vaccine responses. A review of mumps is provided with discussion of potential mechanisms for vaccine failure.	Baylor Coll Med, Childrens Hosp, Dept Pediat, Allergy Immunol Sect, Houston, TX 77030 USA	Baylor College of Medicine	Hanson, IC (corresponding author), 6621 Fannin,FC 330-01, Houston, TX 77030 USA.	ihanson@bcm.edu						*ADV COMM IMM PRAC, 2006, MMWR-MORBID MORTAL W, V55, P629; *ADV COMM IMM PRAC, 2003, MMWR MORB MORTAL, V52, P1023; *ADV COMM IMM PRAC, 2006, MMWR-MORBID MORTAL W, V54, pQ1; *ADV COMM IMM PRAC, 1998, MMWR-MORBID MORTAL W, V47, P8; COCHI SL, 1988, AM J DIS CHILD, V142, P499, DOI 10.1001/archpedi.1988.02150050037025; Gershman K., 2006, Morbidity and Mortality Weekly Report, V55, P559; HILLEMAN MR, 1967, NEW ENGL J MED, V276, P252, DOI 10.1056/NEJM196702022760501; KIMFARLEY R, 1985, AM J EPIDEMIOL, V121, P593, DOI 10.1093/oxfordjournals.aje.a114037; LITMAN N, 2005, PRINCIPLES PRACTICE, P2003; Ovsyannikova IG, 2005, IMMUNOGENETICS, V57, P828, DOI 10.1007/s00251-005-0061-6; Savage E., 2006, Morbidity and Mortality Weekly Report, V55, P173; SUGG WC, 1968, J PEDIATR-US, V72, P461, DOI 10.1016/S0022-3476(68)80334-8; WEIBEL RE, 1979, P SOC EXP BIOL MED, V162, P328, DOI 10.3181/00379727-162-40675; WEIBEL RE, 1967, NEW ENGL J MED, V276, P245, DOI 10.1056/NEJM196702022760501; WEIBEL RE, 1980, P SOC EXP BIOL MED, V165, P260, DOI 10.3181/00379727-165-40967; Willis Bayo C., 2005, Morbidity and Mortality Weekly Report, V54, P1	16	22	22	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2006	118	4					938	941		10.1016/j.jaci.2006.07.033	http://dx.doi.org/10.1016/j.jaci.2006.07.033			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	097GD	17030249				2022-12-18	WOS:000241434200024
J	Asero, R; Weber, B; Mistrello, G; Amato, S; Madonini, E; Cromwell, O				Asero, R; Weber, B; Mistrello, G; Amato, S; Madonini, E; Cromwell, O			Giant ragweed specific immunotherapy is not effective in a proportion of patients sensitized to short ragweed: Analysis of the allergenic differences between short and giant ragweed	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ragweed; allergy; cross-reactivity; specific immunotherapy; allergens	POLLEN; EFFICACY; HOMOLOG; NORTH; RA5G	Background: Short ragweed and giant ragweed pollen allergens are considered largely cross-reactive, and it is generally believed that I species is sufficient for skin testing and immunotherapy. However, in the area north of Milan (a zone widely invaded only by short ragweed), about 50% of patients submitted to injection specific immunotherapy with giant ragweed showed little or no clinical response, but showed an excellent outcome if they were shifted to short ragweed specific immunotherapy. Objective: To investigate allergenic differences between short and giant ragweed. Methods: IgE reactivity to short ragweed of sera from 16 patients allergic to ragweed was assessed by immunoblot before and after absorption with short and giant ragweed. Moreover, 41 ragweed-monosensitive patients underwent skin prick test with both ragweed species. Results: In several cases, preabsorption of sera with giant ragweed extract was unable to inhibit IgE reactivity fully against both a 43-kd allergen and other allergens at different molecular weights in short ragweed. On skin prick test, short ragweed induced larger wheals than giant ragweed in the majority of patients, and 6 of 41 (15%) patients were strongly short ragweed-positive but giant ragweed-negative. The immunoblot with the serum from I of these subjects showed a strong IgE reactivity to short ragweed at about 43 kd in the absence of any reactivity to giant ragweed. Conclusion: Short and giant ragweed are not allergenically equivalent. Allergenic differences involve both the major allergens Amb a 1-2/Amb t 1-2 and some minor allergens. In patients allergic to ragweed, both diagnosis in vivo and immunotherapy should always be performed by using the ragweed species present in that specific geographic area.	Clin San Carlo, Ambulatorio Allergol, I-20037 Paderno Gugnano, MI, Italy; Allergopharma, Reinbek, Italy; Lofarma SpA, Milan, Italy		Asero, R (corresponding author), Clin San Carlo, Ambulatorio Allergol, Via Osped 21, I-20037 Paderno Gugnano, MI, Italy.	r.asero@libero.it	Amato, Sandra/AAH-4430-2021	Amato, Sandra/0000-0002-3277-0662				Asero R, 2002, ALLERGY, V57, P1063, DOI 10.1034/j.1398-9995.2002.23766.x; ASERO R, 1998, GIORN IT ALLERGOL IM, V8, P241; BERNSTEIN IL, 1976, J ALLERGY CLIN IMMUN, V57, P141, DOI 10.1016/0091-6749(76)90033-6; BOTTERO P, 1990, Folia Allergologica et Immunologica Clinica, V37, P99; Bousquet J, 1998, ALLERGY, V53, P4; BOUSQUET J, 1988, J ALLERGY CLIN IMMUN, V82, P971, DOI 10.1016/0091-6749(88)90133-9; Chapoval SP, 1998, J IMMUNOL, V161, P2032; DREBORG S, 1993, ALLERGY, V48, P49, DOI 10.1111/j.1398-9995.1993.tb04756.x; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Esch R. E., 2003, ALLERGY PRINCIPLES P, P529; GOODFRIEND L, 1985, MOL IMMUNOL, V22, P899, DOI 10.1016/0161-5890(85)90076-8; HUANG SK, 1991, IMMUNOLOGY, V73, P363; Jacobsen L, 1997, ALLERGY, V52, P914, DOI 10.1111/j.1398-9995.1997.tb01251.x; LEIFERMAN KM, 1976, J ALLERGY CLIN IMMUN, V58, P140, DOI 10.1016/0091-6749(76)90149-4; MALLING HJ, 1993, ALLERGY, V48, P9; ROEBBER M, 1985, J IMMUNOL, V134, P3062; STEWART GA, 2003, ALLERGY PRINCIPLES P, P585; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Weber RW, 2003, J ALLERGY CLIN IMMUN, V112, P229, DOI 10.1067/mai.2003.1683; White JF, 2003, ANN ALLERG ASTHMA IM, V91, P425, DOI 10.1016/S1081-1206(10)61509-8; ZHU XJ, 1995, J IMMUNOL, V155, P5064	21	22	24	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2005	116	5					1036	1041		10.1016/j.jaci.2005.08.019	http://dx.doi.org/10.1016/j.jaci.2005.08.019			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IG	16275372				2022-12-18	WOS:000235686700013
J	Moylett, EH; Hanson, CI				Moylett, EH; Hanson, CI			Mechanistic actions of the risks and adverse events associated with vaccine administration	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						toxoid; live viral vaccine; vaccine allergy; vaccine adverse events; egg sensitivity; gelatin; thimerosal; aluminum; adjuvants; preservative	HEPATITIS-B VACCINATION; ACELLULAR PERTUSSIS VACCINES; INFLUENZA VACCINE; CHRONIC ARTHROPATHY; UNITED-STATES; MMR VACCINE; WHOLE-CELL; IMMUNIZATION; TETANUS; SAFETY	Vaccine-preventable disease levels in the United States are at or near record lows. Most parents today have never seen a case of diphtheria, measles, or other once commonly encountered infectious diseases now preventable by vaccine administration. As a result, some parents wonder why their children must receive shots for diseases that do not seem to exist. Myths and misinformation about vaccine safety abound and can confuse parents who are trying to make sound decisions about their children's health care. However, we cannot take continued high immunization coverage levels for granted. A successful vaccination program, like a successful society, depends on the cooperation of every individual to ensure the good of all. This review outlines for clinical allergists-immunologists the molecular basis for the risks and adverse events associated with vaccine administration so that they can be better informed as experts on vaccine-associated adverse reactions.	Texas Childrens Hosp, Baylor Coll Med, Dept Allergy & Immunol, Houston, TX 77030 USA	Baylor College of Medicine	Hanson, CI (corresponding author), Texas Childrens Hosp, Baylor Coll Med, Dept Allergy & Immunol, 6621 Fannin St MC-FC330-01, Houston, TX 77030 USA.	ichanson@texaschildrenshospital.org			NCRR NIH HHS [RR 0188] Funding Source: Medline; NHLBI NIH HHS [HL 72705] Funding Source: Medline; NIAID NIH HHS [AI 36211, AI 27551] Funding Source: Medline; NICHD NIH HHS [HD 41983] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U01HD041983] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL072705] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI036211, U01AI027551] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abramson JS, 2000, PEDIATRICS, V106, P367, DOI 10.1542/peds.106.2.367; [Anonymous], 1999, MMWR Recomm Rep, V48, P1; [Anonymous], 1991, MMWR Recomm Rep, V40, P1; [Anonymous], 2000, MMWR Recomm Rep, V49, P1; Ascherio A, 2001, NEW ENGL J MED, V344, P327, DOI 10.1056/NEJM200102013440502; Baker JP, 2003, VACCINE, V21, P4003, DOI 10.1016/S0264-410X(03)00302-5; Ball LK, 2001, PEDIATRICS, V107, P1147, DOI 10.1542/peds.107.5.1147; BEGHI E, 1985, ANN NEUROL, V18, P320, DOI 10.1002/ana.410180308; Black C, 2003, BRIT J CLIN PHARMACO, V55, P107, DOI 10.1046/j.1365-2125.2003.01790.x; Black S, 2004, VACCINE, V22, P766, DOI 10.1016/j.vaccine.2003.08.034; Braun MM, 2000, PEDIATRICS, V106, DOI 10.1542/peds.106.4.e51; Can D, 2003, J INVEST ALLERG CLIN, V13, P177; *CDCP, 2004, MMWR-MORBID MORTAL W, V53, P106; *CDCP, 1998, MMWR-MORBID MORTAL W, V47, P993; Center for Diseases Control and Prevention, 2002, MMWR-MORBID MORTAL W, V51, P989; Centers for Disease Control and Prevention (CDC), 2004, MMWR Morb Mortal Wkly Rep, V53, P532; Centers for Disease Control and Prevention (CDC), 2003, MMWR Morb Mortal Wkly Rep, V52, P203; Clarkson TW, 1997, CRIT REV CL LAB SCI, V34, P369, DOI 10.3109/10408369708998098; Classen JB, 2003, J PEDIATR ENDOCR MET, V16, P495; Classen JB, 2002, AUTOIMMUNITY, V35, P247, DOI 10.1080/08916930290028175; *COMM INF DIS, 2003, 2003 RED BOOK REP CO; Dayan G., 2004, Morbidity and Mortality Weekly Report, V53, P713; DeStefano F, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.6.e112; Donnelly S, 2001, INFECT IMMUN, V69, P4217, DOI 10.1128/IAI.69.7.4217-4223.2001; Duclos Philippe, 2003, Expert Opin Drug Saf, V2, P225, DOI 10.1517/14740338.2.3.225; Eckart RE, 2004, J AM COLL CARDIOL, V44, P201, DOI 10.1016/j.jacc.2004.05.004; Farooqi IS, 1998, THORAX, V53, P927, DOI 10.1136/thx.53.11.927; FAWCETT HA, 1984, ARCH DERMATOL, V120, P1318, DOI 10.1001/archderm.120.10.1318; Ferro Valerie A, 2002, Expert Rev Vaccines, V1, P443, DOI 10.1586/14760584.1.4.443; Friedrich F, 1996, ACTA VIROL, V40, P157; GARCIAPATOS V, 1995, ARCH DERMATOL, V131, P1421, DOI 10.1001/archderm.131.12.1421; Geier DA, 2004, BRAIN DEV-JPN, V26, P296, DOI 10.1016/S0387-7604(03)00169-4; Geier DA, 2002, ANN PHARMACOTHER, V36, P776, DOI 10.1345/aph.1A410; Geier MR, 2003, CLIN IMMUNOL, V107, P116, DOI 10.1016/S1521-6616(03)00046-9; Gherardi RK, 2003, IMMUNOL ALLERGY CLIN, V23, P699, DOI 10.1016/S0889-8561(03)00095-X; Gilboa E, 2004, NAT REV CANCER, V4, P401, DOI 10.1038/nrc1359; Halsell JS, 2003, JAMA-J AM MED ASSOC, V289, P3283, DOI 10.1001/jama.289.24.3283; Halsey NA, 2004, B WORLD HEALTH ORGAN, V82, P3; Kroger Andrew T., 2011, Morbidity and Mortality Weekly Report, V60, P3; HAUSEN BM, 1993, CONTACT DERMATITIS, V28, P149, DOI 10.1111/j.1600-0536.1993.tb03376.x; HERROELEN L, 1991, LANCET, V338, P1174, DOI 10.1016/0140-6736(91)92034-Y; Holden J M, 1965, N Z Med J, V64, P574; Hviid A, 2004, NEW ENGL J MED, V350, P1398, DOI 10.1056/NEJMoa032665; Hviid A, 2003, JAMA-J AM MED ASSOC, V290, P1763, DOI 10.1001/jama.290.13.1763; *IMM SAF REV COMM, 2004, IMM SAF REV VACC AUT, P17; JACOBS RL, 1982, JAMA-J AM MED ASSOC, V247, P40, DOI 10.1001/jama.247.1.40; James JM, 1998, J PEDIATR-US, V133, P624, DOI 10.1016/S0022-3476(98)70101-5; Kann Laura, 1996, Morbidity and Mortality Weekly Report, V45, P1; Karin N, 2004, CURR OPIN MOL THER, V6, P27; Kelso JM, 2003, IMMUNOL ALLERGY CLIN, V23, P635, DOI 10.1016/S0889-8561(03)00091-2; Kew OM, 2004, B WORLD HEALTH ORGAN, V82, P16; KWITTKEN PL, 1993, AM J DIS CHILD, V147, P128, DOI 10.1001/archpedi.1993.02160260018005; Lackner TE, 2003, J AM GERIATR SOC, V51, P240, DOI 10.1046/j.1532-5415.2003.51064.x; LEVINE L, 1981, J INFECT DIS, V144, P376, DOI 10.1093/infdis/144.4.376; Madaan A, 2003, IMMUNOL ALLERGY CLIN, V23, P555, DOI 10.1016/S0889-8561(03)00099-7; MCCOMB JA, 1961, NEW ENGL J MED, V265, P1152, DOI 10.1056/NEJM196112072652307; MILLER DL, 1981, BRIT MED J, V282, P1595, DOI 10.1136/bmj.282.6276.1595; Monteyne P, 2000, VACCINE, V18, P1994, DOI 10.1016/S0264-410X(99)00533-2; MORTIMER J, 1986, LANCET, V2, P1182; Mutsch M, 2004, NEW ENGL J MED, V350, P896, DOI 10.1056/NEJMoa030595; MYERS MG, 1982, JAMA-J AM MED ASSOC, V248, P2478, DOI 10.1001/jama.248.19.2478; Peter G, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.6.e67; Pichichero ME, 2002, LANCET, V360, P1737, DOI 10.1016/S0140-6736(02)11682-5; Piedra PA, 2002, PEDIATRICS, V110, P662, DOI 10.1542/peds.110.4.662; Pool V, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.6.e71; Ray P, 1997, JAMA-J AM MED ASSOC, V278, P551, DOI 10.1001/jama.278.7.551; Relihan M, 1969, J Ir Med Assoc, V62, P430; Rennels Margaret B, 2003, Semin Pediatr Infect Dis, V14, P196, DOI 10.1016/S1045-1870(03)00033-5; Rimaniol AC, 2004, VACCINE, V22, P3127, DOI 10.1016/j.vaccine.2004.01.061; Rock MT, 2004, J INFECT DIS, V189, P1401, DOI 10.1086/382510; Sakaguchi M, 2000, VACCINE, V18, P2055, DOI 10.1016/S0264-410X(99)00480-6; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; SHAPIRO ED, 1991, NEW ENGL J MED, V325, P1453, DOI 10.1056/NEJM199111213252101; SMITH RE, 1962, ANN ALLERGY, V20, P809; STRATTON K, 2002, MULTIPLE IMMUNIZATIO, P152; STRATTON KR, 1994, JAMA-J AM MED ASSOC, V271, P1602, DOI 10.1001/jama.271.20.1602; Sutter RW, 2000, PEDIATR CLIN N AM, V47, P287, DOI 10.1016/S0031-3955(05)70208-X; Torling J, 2003, VACCINE, V22, P96, DOI 10.1016/S0264-410X(03)00521-8; Tourbah A, 1999, NEUROLOGY, V53, P396, DOI 10.1212/WNL.53.2.396; Varricchio F, 2004, PEDIATR INFECT DIS J, V23, P287, DOI 10.1097/00006454-200404000-00002; WARDLAW AC, 1982, PHARMACOL THERAPEUT, V19, P1, DOI 10.1016/0163-7258(82)90041-9; WARRINGTON RJ, 1987, J ALLERGY CLIN IMMUN, V79, P605, DOI 10.1016/S0091-6749(87)80156-2; Weibel RE, 1996, ARTHRITIS RHEUM, V39, P1529, DOI 10.1002/art.1780390913; WHITE WG, 1973, J HYG-CAMBRIDGE, V71, P283, DOI 10.1017/S0022172400022750; *WHO, 2004, VACC IMM BIOL MEASL; Zangwill KM, 2003, VACCINE, V21, P1894, DOI 10.1016/S0264-410X(03)00013-6	86	22	26	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2004	114	5					1010	1020		10.1016/j.jaci.2004.09.007	http://dx.doi.org/10.1016/j.jaci.2004.09.007			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	870HI	15536401				2022-12-18	WOS:000225047800002
J	Shin, HD; Park, KS; Park, CS				Shin, HD; Park, KS; Park, CS			Lack of association of GPRA (G protein-coupled receptor for asthma susceptibility) haplotypes with high serum IgE or asthma in a Korean population	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							POLYMORPHISMS		SNP Genet Inc, Dept Gen Epidemiol, Seoul, South Korea; Seoul Natl Univ Hosp, Clin Res Inst, Genome Res Ctr Diabet & Endocrine Dis, Seoul 110744, South Korea; Soonchunhyang Univ Hosp, Asthma Genome Res Grp, Seoul, South Korea	SNP Genetics; Seoul National University (SNU); Seoul National University Hospital; Soonchunhyang University; Soonchunhyang University Hospital	Shin, HD (corresponding author), SNP Genet Inc, Dept Gen Epidemiol, Seoul, South Korea.		Park, Kyong Soo/C-2265-2008	Park, Kyong Soo/0000-0003-3597-342X; Park, Choon-Sik/0000-0003-2977-0255				Laitinen T, 2004, SCIENCE, V304, P300, DOI 10.1126/science.1090010; Lee JH, 2004, CLIN EXP ALLERGY, V34, P860, DOI 10.1111/j.1365-2222.2004.01977.x; Livak KJ, 1999, GENET ANAL-BIOMOL E, V14, P143, DOI 10.1016/S1050-3862(98)00019-9; Shin HD, 2004, DIABETES, V53, P847, DOI 10.2337/diabetes.53.3.847; Shin HD, 2004, HUM MOL GENET, V13, P397, DOI 10.1093/hmg/ddh036; Shin HD, 2003, J ALLERGY CLIN IMMUN, V112, P454, DOI 10.1067/mai.2003.1641; Shin HD, 2003, HUM MOL GENET, V12, P1279, DOI 10.1093/hmg/ddg142	7	22	25	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2004	114	5					1226	1227		10.1016/j.jaci.2004.08.003	http://dx.doi.org/10.1016/j.jaci.2004.08.003			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	870HI	15536436				2022-12-18	WOS:000225047800035
J	Sedgwick, JB; Vrtis, RF; Jansen, KJ; Kita, H; Bartemes, K; Busse, WW				Sedgwick, JB; Vrtis, RF; Jansen, KJ; Kita, H; Bartemes, K; Busse, WW			Peripheral blood eosinophils from patients with allergic asthma contain increased intracellular eosinophil-derived neurotoxin	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eosinophil; eosinophil-derived neurotosin; degranulation; asthma; allergic rhinitis; corticosteroids; hypereosinophilic syndrome	CATIONIC PROTEIN; GRANULE PROTEINS; SERUM-LEVELS; ANTIGEN CHALLENGE; AIRWAY; CELLS; RHINITIS; EXPRESSION; ALPHA	Background: One mechanism of the eosinophil's contribution to airway inflammation in asthma is through release of cationic granule proteins to cause airway injury. Differences in either the intracellular concentration of granule proteins or the extent of activated degranulation between eosinophils from healthy patients and those with allergy and asthma could, therefore, relate to fundamental differences in this cell's function. Objective: To identify phenotypic differences in eosinophil-derived neurotoxin (EDN) content and release in eosinophils from healthy patients, those with allergy, and those with allergy and asthma. Methods: Peripheral blood eosinophils were isolated by negative anti-CD16 selection. Total intracellular and cytokine-activated release of EDN protein was measured by radioimmunoassay. EDN mRNA was assessed by real-time PCR. Results: Eosinophils from patients with asthma contained significantly more EDN per cell than comparable cells from healthy patients, those with allergy but without asthma, or those with asthma treated with inhaled corticosteroids, but they had concentrations similar to airway eosinophils isolated from bronchoalveolar lavage fluid 48 hours after segmental bronchoprovocation with allergen. Furthermore, this increased granule protein was reflected in more EDN degranulation by IL-5- or GM-CSF-activated eosinophils when calculated as nanograms of protein secreted but not when calculated as a percentage of total EDN release. Levels of EDN mRNA were similar in all subject groups. Conclusions: These data suggest that peripheral blood eosinophils from subjects with untreated asthma have increased inflammatory capacity, as reflected by greater intracellular concentrations of EDN.	Univ Wisconsin, Dept Med, Madison, WI 53792 USA; Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA	University of Wisconsin System; University of Wisconsin Madison; Mayo Clinic	Sedgwick, JB (corresponding author), Univ Wisconsin, Dept Med, CSC-3244,H6-355 Allergy,600 Highland Ave, Madison, WI 53792 USA.	jxs@medicine.wisc.edu		Bartemes, Kathleen/0000-0003-4561-3233				ABUGHAZALEH RI, 1992, J LEUKOCYTE BIOL, V52, P611, DOI 10.1002/jlb.52.6.611; Al-Rabia MW, 2003, CLIN EXP ALLERGY, V33, P640, DOI 10.1046/j.1365-2222.2003.01639.x; CARLSON M, 1991, J ALLERGY CLIN IMMUN, V87, P27, DOI 10.1016/0091-6749(91)90209-7; CARLSON M, 1994, BRIT J HAEMATOL, V86, P41, DOI 10.1111/j.1365-2141.1994.tb03250.x; COYLE AJ, 1994, AM J RESP CRIT CARE, V150, pS63, DOI 10.1164/ajrccm/150.5_Pt_2.S63; Di Lorenzo G, 1999, ALLERGY ASTHMA PROC, V20, P119, DOI 10.2500/108854199778612590; DURHAM SR, 1989, J ALLERGY CLIN IMMUN, V84, P931, DOI 10.1016/0091-6749(89)90391-6; Erpenbeck VJ, 2003, CLIN EXP ALLERGY, V33, P331, DOI 10.1046/j.1365-2222.2003.01580.x; HANLON WA, 1991, J LEUKOCYTE BIOL, V50, P43, DOI 10.1002/jlb.50.1.43; Horie S, 1996, J ALLERGY CLIN IMMUN, V98, P371, DOI 10.1016/S0091-6749(96)70161-6; HUIZINGA TWJ, 1990, J IMMUNOL, V144, P1432; Krug N, 1999, CLIN EXP ALLERGY, V29, P1507; Liu LY, 2002, J IMMUNOL, V169, P6452, DOI 10.4049/jimmunol.169.11.6452; Matsumoto H, 2001, CLIN EXP ALLERGY, V31, P637, DOI 10.1046/j.1365-2222.2001.01034.x; Ohashi H, 1999, INT ARCH ALLERGY IMM, V118, P44, DOI 10.1159/000024030; Palma-Carlos A G, 2001, Allerg Immunol (Paris), V33, P237; Pronk-Admiraal CJ, 2001, SCAND J CLIN LAB INV, V61, P453, DOI 10.1080/00365510152567095; PronkAdmiraal CJ, 1997, EUR J CLIN CHEM CLIN, V35, P351; Rosenberg HF, 1996, EXP HEMATOL, V24, P888; SEDGWICK JB, 1992, J IMMUNOL, V149, P3710; SEDGWICK JB, 1991, AM REV RESPIR DIS, V144, P1274, DOI 10.1164/ajrccm/144.6.1274; Tomassini M, 1996, J ALLERGY CLIN IMMUN, V97, P1350, DOI 10.1016/S0091-6749(96)70204-X; Vignola AM, 2001, CLIN EXP ALLERGY, V31, P674, DOI 10.1046/j.1365-2222.2001.01115.x; *WORLD HLTH IN, 2001, ALL RHIN ITS IMP AST; Yamamoto H, 1998, J IMMUNOL, V161, P971	25	22	26	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2004	114	3					568	574		10.1016/j.jaci.2004.05.023	http://dx.doi.org/10.1016/j.jaci.2004.05.023			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	853AX	15356558				2022-12-18	WOS:000223799600015
J	Fleisher, TA; Oliveira, JB				Fleisher, TA; Oliveira, JB			Functional and molecular evaluation of lymphocytes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						lymphocytes; immune deficiency; diagnostic immunology	SEVERE COMBINED IMMUNODEFICIENCY; HYPER-IGM SYNDROME; B-CELL DEVELOPMENT; FLOW-CYTOMETRY; CYTOKINE PRODUCTION; T-CELLS; LINKED AGAMMAGLOBULINEMIA; BACTERIAL-INFECTIONS; IMMUNE-RESPONSE; MUTATIONS	The laboratory plays a central role in the evaluation of immune function and is critical in the diagnosis and treatment of immune deficiencies. The range of options available to evaluate lymphocyte function has expanded dramatically as our understanding of the immune system has expanded. As the choices of laboratory tests increase, so also does the need to choose testing in such a way as to appropriately direct the evaluation. Typically, this approach involves starting with screening tests and, on the basis of the results of these tests, deciding whether more sophisticated and expensive testing is warranted. The remarkable developments over the past decade leading to the identification of numerous gene defects underlying a variety of immune deficiencies has moved mutation analysis into the realm of the clinical laboratory. This information could be indispensable for immune deficiency diagnosis, prenatal screening, carrier detection, and family counseling. In this review a sequential approach to evaluating lymphocyte function is presented, starting with readily available screening tests and followed by more complex in vitro testing, including the application of newer assays. The various approaches are presented from the perspective of appropriate use and information garnered, whereas actual details of test procedures are not discussed but are referenced. The evolution of immune function testing suggests that it will continue to develop, and future assays are likely to provide even more insight into specific aspects of the immune response and be linked to immune deficiencies not yet defined.	NIH, Serv Immunol, Dept Lab Med, Ctr Clin,Dept Hlth & Human Serv, Bethesda, MD USA	National Institutes of Health (NIH) - USA; NIH Clinical Center (CC)	Fleisher, TA (corresponding author), 10 Cr Dr,MSC 1508, Bethesda, MD 20892 USA.	tfleisher@nih.gov						Agematsu K, 2000, IMMUNOL TODAY, V21, P204, DOI 10.1016/S0167-5699(00)01605-4; Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; Aziz N, 1999, CLIN DIAGN LAB IMMUN, V6, P89, DOI 10.1128/CDLI.6.1.89-95.1999; Bakker ABH, 2000, HUM IMMUNOL, V61, P18, DOI 10.1016/S0198-8859(99)00160-3; Ballow M, 2002, J ALLERGY CLIN IMMUN, V109, P581, DOI 10.1067/mai.2002.122466; Balmer P, 2003, CLIN EXP IMMUNOL, V133, P364, DOI 10.1046/j.1365-2249.2003.02232.x; BARRETT DJ, 1984, PEDIATR RES, V18, P1067, DOI 10.1203/00006450-198411000-00001; Biassoni R, 2003, J CELL MOL MED, V7, P376, DOI 10.1111/j.1582-4934.2003.tb00240.x; Binstadt BA, 2003, J ALLERGY CLIN IMMUN, V111, P697, DOI 10.1067/mai.2003.1380; Bleesing JJH, 2001, SEMIN HEMATOL, V38, P100, DOI 10.1053/shem.2001.21922; Buckley Rebecca H, 2002, Curr Allergy Asthma Rep, V2, P356, DOI 10.1007/s11882-002-0067-1; BUCKLEY RH, 1975, J CLIN INVEST, V55, P157, DOI 10.1172/JCI107906; Buckley RH, 2002, J ALLERGY CLIN IMMUN, V109, P747, DOI 10.1067/mai.2002.123617; BUCKLEY RH, 1968, PEDIATRICS, V41, P600; BURANDY A, 2004, ADV IMMUNOL, V82, P295; Cameron TO, 2002, J IMMUNOL METHODS, V268, P51, DOI 10.1016/S0022-1759(02)00200-4; CUNNINGHAMRUNDLES C, 1989, J CLIN IMMUNOL, V9, P22, DOI 10.1007/BF00917124; Currie AJ, 2004, J PEDIATR-US, V144, P512, DOI 10.1016/j.jpeds.2003.10.034; CURTIS JE, 1970, CLIN EXP IMMUNOL, V6, P473; Day CL, 2003, J CLIN INVEST, V112, P831, DOI 10.1172/JCI200318509; DERMAUR CA, 1993, TRANSFUSION, V33, P915; Douek DC, 1998, NATURE, V396, P690, DOI 10.1038/25374; Douek DC, 2000, LANCET, V355, P1875, DOI 10.1016/S0140-6736(00)02293-5; DURANDY A, 1993, EUR J IMMUNOL, V23, P2294, DOI 10.1002/eji.1830230936; ELSASSERBEILE U, 1991, J IMMUNOL METHODS, V139, P191, DOI 10.1016/0022-1759(91)90188-L; Ewen C, 2003, J IMMUNOL METHODS, V276, P89, DOI 10.1016/S0022-1759(03)00073-5; Fagarasan S, 2000, SCIENCE, V290, P89, DOI 10.1126/science.290.5489.89; FLETCHER MA, 1997, MANUAL CLIN LAB IMMU, P313; Fuss IJ, 1998, EUR J IMMUNOL, V28, P4275, DOI 10.1002/(SICI)1521-4141(199812)28:12<4275::AID-IMMU4275>3.0.CO;2-P; GORDON EH, 1983, J ALLERGY CLIN IMMUN, V72, P487, DOI 10.1016/0091-6749(83)90586-9; GORDON J, 1992, CLIN EXP ALLERGY, V22, P199, DOI 10.1111/j.1365-2222.1992.tb03073.x; Hein J, 2001, SCAND J IMMUNOL, V54, P285, DOI 10.1046/j.1365-3083.2001.00928.x; HIROHATA S, 1988, J IMMUNOL, V140, P3726; Hoppner M, 2002, J IMMUNOL METHODS, V267, P157, DOI 10.1016/S0022-1759(02)00167-9; Hugues S, 2002, J IMMUNOL METHODS, V268, P83, DOI 10.1016/S0022-1759(02)00202-8; Jain A, 2001, NAT IMMUNOL, V2, P223, DOI 10.1038/85277; Kita H, 2003, AUTOIMMUN REV, V2, P43, DOI 10.1016/S1568-9972(02)00124-6; LEDERMAN HM, 1985, MEDICINE, V64, P145, DOI 10.1097/00005792-198505000-00001; Letsch A, 2003, METHODS, V31, P143, DOI 10.1016/S1046-2023(03)00124-5; Longo NS, 2001, SPRINGER SEMIN IMMUN, V23, P367, DOI 10.1007/s281-001-8165-0; Lynn J, 2004, J ALLERGY CLIN IMMUN, V114, P409, DOI 10.1016/j.jaci.2004.02.033; Lyons AB, 2000, J IMMUNOL METHODS, V243, P147, DOI 10.1016/S0022-1759(00)00231-3; Maclsaac C, 2003, J IMMUNOL METHODS, V283, P9, DOI 10.1016/S0022-1759(03)00260-6; Maguire GA, 2002, ANN CLIN BIOCHEM, V39, P374, DOI 10.1258/000456302760042678; Maino VC, 1998, CYTOMETRY, V34, P207, DOI 10.1002/(SICI)1097-0320(19981015)34:5<207::AID-CYTO1>3.0.CO;2-J; Mardiney M, 1996, CYTOMETRY, V26, P305, DOI 10.1002/(SICI)1097-0320(19961215)26:4<305::AID-CYTO11>3.0.CO;2-V; Markert ML, 1999, NEW ENGL J MED, V341, P1180, DOI 10.1056/NEJM199910143411603; MASLANKA K, 1995, HUM IMMUNOL, V44, P28, DOI 10.1016/0198-8859(95)00056-A; Medvedev AE, 2003, J EXP MED, V198, P521, DOI 10.1084/jem.20030701; Mehta BA, 1997, J IMMUNOL METHODS, V208, P49, DOI 10.1016/S0022-1759(97)00127-0; Minegishi Y, 1999, J CLIN INVEST, V104, P1115, DOI 10.1172/JCI7696; Minegishi Y, 1999, SCIENCE, V286, P1954, DOI 10.1126/science.286.5446.1954; Minegishi Y, 1998, J EXP MED, V187, P71, DOI 10.1084/jem.187.1.71; Niemela JE, 2000, CLIN IMMUNOL, V95, P33, DOI 10.1006/clim.2000.4846; OCHS HD, 1987, ANNU REV MED, V38, P325, DOI 10.1146/annurev.me.38.020187.001545; OCHS HD, 1971, J CLIN INVEST, V50, P2559, DOI 10.1172/JCI106756; PAPADOPOULOS NG, 1994, J IMMUNOL METHODS, V177, P101, DOI 10.1016/0022-1759(94)90147-3; PATARCA R, 1997, MANUAL CLIN LAB IMMU, P296; Picard C, 2003, SCIENCE, V299, P2076, DOI 10.1126/science.1081902; Prussin C, 1997, J CLIN IMMUNOL, V17, P195, DOI 10.1023/A:1027350226435; Puck JM, 1997, HUM GENET, V99, P628, DOI 10.1007/s004390050418; Radaev S, 2003, ANNU REV BIOPH BIOM, V32, P93, DOI 10.1146/annurev.biophys.32.110601.142347; SARKAR G, 1992, GENOMICS, V13, P441, DOI 10.1016/0888-7543(92)90266-U; Schmid I, 2000, J IMMUNOL METHODS, V235, P121, DOI 10.1016/S0022-1759(99)00225-2; SHACKELFORD PG, 1990, PEDIATR RES, V27, P16, DOI 10.1203/00006450-199001000-00004; Shearer WT, 2003, J ALLERGY CLIN IMMUN, V112, P973, DOI 10.1016/j.jaci.2003.07.003; SHEFFIELD VC, 1993, GENOMICS, V16, P325, DOI 10.1006/geno.1993.1193; Villa A, 1999, J CLIN IMMUNOL, V19, P87, DOI 10.1023/A:1020550432126; WRIGHT PF, 1977, J PEDIATR-US, V91, P408, DOI 10.1016/S0022-3476(77)81309-7; WRIGHT PW, 1995, J FAM PRACTICE, V41, P59; Wu CJ, 2000, BLOOD, V95, P352	71	22	22	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2004	114	2					227	234		10.1016/j.jaci.2004.06.001	http://dx.doi.org/10.1016/j.jaci.2004.06.001			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	847OU	15316494				2022-12-18	WOS:000223405600002
J	Weidinger, S; Kramer, U; Dunemann, L; Mohrenschlager, M; Ring, J; Behrendt, H				Weidinger, S; Kramer, U; Dunemann, L; Mohrenschlager, M; Ring, J; Behrendt, H			Body burden of mercury is associated with acute atopic eczema and total IgE in children from southern Germany	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							AUTOIMMUNITY		Tech Univ Munich, Dept Dermatol & Allergy, D-80802 Munich, Germany; Tech Univ Munich, Res Ctr Environm & Hlth GSF, Div Environm Dermatol & Allerg, Dusseldorf, Germany; Inst Umweltmed Forsch, Dusseldorf, Germany	Technical University of Munich; Technical University of Munich	Weidinger, S (corresponding author), Tech Univ Munich, Dept Dermatol & Allergy, Biedersteiner St 29, D-80802 Munich, Germany.		Ring, Johannes/GLN-4341-2022; Weidinger, Stephan/C-8461-2011	Ring, Johannes/0000-0001-8236-3152; Weidinger, Stephan/0000-0003-3944-252X				Bagenstose LM, 1999, IMMUNOL RES, V20, P67, DOI 10.1007/BF02786508; Ewers U, 1999, INT ARCH OCC ENV HEA, V72, P255, DOI 10.1007/s004200050369; Fournie GJ, 2001, J AUTOIMMUN, V16, P319, DOI 10.1006/jaut.2000.0482; Han FXX, 2002, NATURWISSENSCHAFTEN, V89, P497, DOI 10.1007/s00114-002-0373-4; Kono DH, 1998, J IMMUNOL, V161, P234; Leung DYM, 2003, LANCET, V361, P151, DOI 10.1016/S0140-6736(03)12193-9; Marth E, 2001, Int J Occup Med Environ Health, V14, P375; POLLARD KM, 1997, MERCURY ITS EFFECTS; Schuppe HC, 1998, CLIN DERMATOL, V16, P149, DOI 10.1016/S0738-081X(97)00194-6; Strenzke N, 2001, TOXICOL APPL PHARM, V174, P257, DOI 10.1006/taap.2001.9223	10	22	22	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2004	114	2					457	459		10.1016/j.jaci.2004.04.011	http://dx.doi.org/10.1016/j.jaci.2004.04.011			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	847OU	15341030	Bronze			2022-12-18	WOS:000223405600042
J	Zeng, DW; Prosperini, G; Russo, C; Spicuzza, L; Cacciola, RR; Di Maria, GU; Polosa, R				Zeng, DW; Prosperini, G; Russo, C; Spicuzza, L; Cacciola, RR; Di Maria, GU; Polosa, R			Heparin attenuates symptoms and mast cell degranulation induced by AMP nasal provocation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						heparin; allergic rhinitis; histamine; tryptase; adenosine challenge	HISTAMINE-RELEASE; MEDIATED RESPONSES; ALLERGIC SUBJECTS; INHALED HEPARIN; ADENOSINE; ASTHMA; AIRWAY; INHIBITION; CHALLENGE; EXERCISE	Background: Previous studies have shown that inhaled heparin attenuated the airway responses to allergen, exercise, and AMP bronchial provocation, possibly through an inhibition of mast cell activation. Objective: The aim of this study was to provide the evidence of in vivo inhibition of human mast cell activation by heparin in a noninvasive model. Methods: Nine atopic and 6 nonatopic subjects received placebo and unfractionated heparin sodium (5000 IU/mL) 15 minutes before an AMP nasal provocation in a double-blind crossover study design. The nasal lavage was collected from these subjects before or 3, 5, 15, or 30 minutes after the AMP nasal challenge, and concentrations of histamine and tryptase in the nasal lavage were measured. Results: AMP nasal provocation produced considerable sneezing and induced a transient increase in histamine and tryptase release, with peak values achieved at 3 to 5 minutes after the challenge in all atopic subjects. Compared with placebo, inhaled heparin significantly attenuated the release of histamine and tryptase induced by AMP challenge (P = .012 and .004, respectively). Moreover, the AMP-induced sneezing was also inhibited by pretreatment with heparin (P = .016). In nonatopic subjects, AMP did not induce a significant increase in histamine and tryptase release on placebo-treated or heparin-treated days. Conclusion: These data suggest that AMP nasal provocation and AMP bronchial provocation cause mast cell mediator release in a similar fashion. In addition, the data support the hypothesis that inhaled heparin plays a protective role against AMP provocation by inhibition of mast cell activation.	Univ Catania, Dipartimento Med Interna & Specialist, Sez Ematol, I-95125 Catania, Italy; Univ Catania, Dipartimento Sci Biomed, Sez Ematol, I-95125 Catania, Italy; CV Therapeut Inc, Dept Drug Res & Pharmacol Sci, Palo Alto, CA USA	University of Catania; University of Catania; CV Therapeutics, Inc.	Polosa, R (corresponding author), Univ Catania, Dipartimento Med Interna & Specialist, Sez Ematol, Via Passo Gravina 187, I-95125 Catania, Italy.	polosa@unict.it	Spicuzza, Lucia/AAC-5892-2022	Spicuzza, Lucia/0000-0002-8246-8357				AHMED T, 1993, NEW ENGL J MED, V329, P90, DOI 10.1056/NEJM199307083290204; BOWLER SD, 1993, AM REV RESPIR DIS, V147, P160, DOI 10.1164/ajrccm/147.1.160; CASTELLOT JJ, 1985, J CELL PHYSIOL, V124, P21, DOI 10.1002/jcp.1041240105; CRIMI N, 1993, DRUG DEVELOP RES, V28, P322, DOI 10.1002/ddr.430280325; HOWARTH PH, 1985, AM REV RESPIR DIS, V132, P986; HUGHES PJ, 1984, BIOCHEM PHARMACOL, V33, P3847, DOI 10.1016/0006-2952(84)90050-9; LEE TH, 1983, LANCET, V1, P520; LUCIO J, 1992, J APPL PHYSIOL, V73, P1093, DOI 10.1152/jappl.1992.73.3.1093; Martinez-Salas J, 1998, J APPL PHYSIOL, V84, P222, DOI 10.1152/jappl.1998.84.1.222; Molinari JF, 1998, AM J RESP CRIT CARE, V157, P887, DOI 10.1164/ajrccm.157.3.9708027; Okajima K, 2001, IMMUNOL REV, V184, P258, DOI 10.1034/j.1600-065x.2001.1840123.x; Page C, 2000, J ALLERGY CLIN IMMUN, V105, pS518, DOI 10.1016/S0091-6749(00)90054-X; PEACHELL PT, 1988, AM REV RESPIR DIS, V138, P1143, DOI 10.1164/ajrccm/138.5.1143; Polosa R, 1999, THORAX, V54, P230, DOI 10.1136/thx.54.3.230; Polosa R, 1997, J ALLERGY CLIN IMMUN, V99, P338, DOI 10.1016/S0091-6749(97)70051-4; Polosa R, 2002, EUR RESPIR J, V20, P488, DOI 10.1183/09031936.02.01132002; POLOSA R, 1995, AM J RESP CRIT CARE, V151, P624; Roemisch J, 2002, BLOOD COAGUL FIBRIN, V13, P657, DOI 10.1097/00001721-200212000-00001; SAYAMA S, 1987, J BIOL CHEM, V262, P6808; SCHWARTZ LB, 1986, J BIOL CHEM, V261, P7372; SPIRCUZZA L, 2003, TRENDS PHARMACOL SCI, V24, P409; Vancheri C, 2001, J ALLERGY CLIN IMMUN, V108, P703, DOI 10.1067/mai.2001.118785; WRIGHT TC, 1985, J CELL PHYSIOL, V125, P499, DOI 10.1002/jcp.1041250320	23	22	27	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2004	114	2					316	320		10.1016/j.jaci.2004.05.026	http://dx.doi.org/10.1016/j.jaci.2004.05.026			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	847OU	15316509				2022-12-18	WOS:000223405600016
J	Hadjicharalambous, C; Dent, G; May, RD; Handy, RLC; Anderson, IK; Davies, DE; Djukanovic, R				Hadjicharalambous, C; Dent, G; May, RD; Handy, RLC; Anderson, IK; Davies, DE; Djukanovic, R			Measurement of eotaxin (CCL11) in induced sputum supernatants: Validation and detection in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eotaxin (CCL11); induced sputum; asthma; ELISA; dithioerythritol	INVESTIGATE AIRWAY INFLAMMATION; CELL COUNTS; DITHIOTHREITOL; EOSINOPHILS; MEDIATORS; CHEMOKINE	Background: Induced sputum is widely used in asthma research: however, for many mediators, the detection methods have not been validated. Objective: We sought to optimize the method of detection of eotaxin, an important chemokine acting through the CCR3 receptor on eosinophils, basophils, and T(H)2 cells. Methods: Induced sputum from normal and asthmatic subjects was processed with dithioerythritol (DTE) or PBS; recovery of eotaxin was assessed by means of ELISA before and after spiking with recombinant eotaxin. Furthermore, the effects of removing DTE by means of ultrafiltration or the addition of protease inhibitors and high-speed centrifugation on endogenous levels and spiking recovery of eotaxin were assessed. Results: Endogenous eotaxin was undetectable in DTE-processed samples, with a mean of only 30% (SD, 13%) spike recovery. DTE had no effect on the immunoassay capture antibody but dramatically reduced the detection of recombinant eotaxin. Removal of DTE from sputum before immunoassay did not improve detection, although it restored the recovery of a subsequent eotaxin spike. In contrast, PBS-processed sputum resulted in an eotaxin spike recovery of 101% (SD, 20%). Addition of protease inhibitors or high-speed centrifugation had no effect on eotaxin detection. By using this optimized protocol, eotaxin levels in PBS-processed sputum samples were found to be significantly increased in asthmatic sputum (P < .05). Conclusion: Measurement of eotaxin by means of immunoassay is adversely affected by DTE, possibly through irreversible denaturation of epitopes, which makes eotaxin undetectable by using the immunoassay antibody. Sputum samples should be processed into PBS for assessment of eotaxin, which is present at increased levels in asthmatic sputum.	Univ Southampton, Sch Med, Dept Resp Cell & Mol Biol, Div Infect Inflammat & Repair, Southampton, Hants, England; Cambridge Antibody Technol, Cambridge, England	University of Southampton; AstraZeneca	Djukanovic, R (corresponding author), Southampton Gen Hosp, Tremona Rd,Mail Pt 810, Southampton SO16 6YD, Hants, England.		Davies, Donna E/H-2993-2012; Dent, Gordon/O-3197-2013	Dent, Gordon/0000-0001-9419-2952; Davies, Donna/0000-0002-5117-2991; Djukanovic, Ratko/0000-0001-6039-5612; May, Richard/0000-0001-7825-2716; Hadjicharalambous, Chrystalleni/0000-0001-6830-974X				Conroy DM, 1997, MEM I OSWALDO CRUZ, V92, P183, DOI 10.1590/S0074-02761997000800024; Crump MP, 1998, J BIOL CHEM, V273, P22471, DOI 10.1074/jbc.273.35.22471; Culpitt SV, 1999, AM J RESP CRIT CARE, V160, P1635, DOI 10.1164/ajrccm.160.5.9811058; Cunningham S.J., 1997, EMERG PEDIAT, V10, P33; Efthimiadis A, 1997, EUR RESPIR J, V10, P1336, DOI 10.1183/09031936.97.10061336; Efthimiadis A, 2002, EUR RESPIR J, V20, p19S, DOI 10.1183/09031936.02.00001902; GarciaZepeda EA, 1996, NAT MED, V2, P449, DOI 10.1038/nm0496-449; Kelly MM, 2000, J ALLERGY CLIN IMMUN, V105, P1162, DOI 10.1067/mai.2000.106375; Kelly MM, 2002, EUR RESPIR J, V20, p24S, DOI 10.1183/09031936.02.00002402; Kelly MM, 2001, EUR RESPIR J, V18, P685, DOI 10.1183/09031936.01.00098501; Louis R, 1999, EUR RESPIR J, V13, P660, DOI 10.1183/09031936.99.13366099; Paggiaro PL, 2002, EUR RESPIR J, V20, p3S, DOI 10.1183/09031936.02.00000302; Palframan RT, 1998, BLOOD, V91, P2240, DOI 10.1182/blood.V91.7.2240.2240_2240_2248; Pavord ID, 1997, THORAX, V52, P498, DOI 10.1136/thx.52.6.498; PIN I, 1992, THORAX, V47, P25, DOI 10.1136/thx.47.1.25; Woolhouse IS, 2002, THORAX, V57, P667, DOI 10.1136/thorax.57.8.667; Yamada H, 1997, BIOCHEM BIOPH RES CO, V231, P365, DOI 10.1006/bbrc.1997.6100; Zeibecoglou K, 2000, ALLERGY, V55, P1042, DOI 10.1034/j.1398-9995.2000.00764.x	18	22	22	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2004	113	4					657	662		10.1016/j.jaci.2004.01.757	http://dx.doi.org/10.1016/j.jaci.2004.01.757			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	814DY	15100669				2022-12-18	WOS:000220956600011
J	D'ambrosio, C; Akin, C; Wu, YL; Magnusson, MK; Metcalfe, DD				D'ambrosio, C; Akin, C; Wu, YL; Magnusson, MK; Metcalfe, DD			Gene expression analysis in mastocytosis reveals a highly consistent profile with candidate molecular markers	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						mastocytosis; microarray; tryptase	BLOOD MONONUCLEAR-CELLS; C-KIT; MYELODYSPLASTIC SYNDROME; SYSTEMIC MASTOCYTOSIS; ACTIVATING MUTATION; HEMATOPOIETIC-CELLS; CATALYTIC DOMAIN; MAST-CELLS; APOPTOSIS; PROTEINS	Background: Mastocytosis is a rare clonal disorder that might be accompanied by non-mast-cell clonal hematologic disorders, such as myeloproliferative or myelodysplastic syndromes. Objective: Our aim was to further understand the pathologic basis of mastocytosis and to identify novel molecular markers of disease. Methods: Microarray analysis was performed on RNA preparations obtained from bone marrow mononuclear cells of patients with mastocytosis. Results were compared with gene expression profiles performed on bone marrow mononuclear cells of healthy subjects. Results: Analysis of gene expression in neoplastic bone marrow tissues revealed highly consistent profiles. One hundred four genes were significantly upregulated, and 64 genes were significantly downregulated in the bone marrow of patients with mastocytosis. The most prominent differentially expressed gene was alpha-tryptase (44.6-fold increase). Also upregulated were genes involved in cell proliferation, neoplastic transformation, and apoptosis. Both hierarchical and K-means clustering analyses identified an identical group of 10 genes highly coordinately overexpressed in patients with mastocytosis, including genes for the mast-cell-associated enzymes alpha- and beta-tryptase and carboxypeptidase A. The expression level of 3 of these 10 genes (alpha-tryptase, the activating transcription factor type 3, and the muscle aponeurotic fibrosarcoma type F oncogene) was significantly correlated with serum tryptase levels, a surrogate marker of disease. Conclusion: The data presented in this study reveal significant differences in gene expression in the bone marrow of patients with mastocytosis compared with healthy subjects, demonstrate highly coordinated genes that might contribute to pathology, and identify 3 genes as candidate molecular markers for systemic disease.	NIAID, NIH, LAD, Bethesda, MD 20892 USA; NHLBI, Hematol Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Metcalfe, DD (corresponding author), NIAID, NIH, LAD, Bldg 10,Room 11C205,10 Ctr Dr,MSC 1881, Bethesda, MD 20892 USA.			Magnusson, Magnus Karl/0000-0001-8593-4934; Akin, Cem/0000-0001-6301-4520	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000249, Z01AI000249] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akin C, 2000, EXP HEMATOL, V28, P140, DOI 10.1016/S0301-472X(99)00145-9; Azam N, 2001, J BIOL CHEM, V276, P2766, DOI 10.1074/jbc.M005626200; Baker SJ, 1998, ONCOGENE, V17, P3261, DOI 10.1038/sj.onc.1202568; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P9; CASTELLS MC, 1987, J IMMUNOL, V138, P2184; Elson A, 1999, ONCOGENE, V18, P7535, DOI 10.1038/sj.onc.1203098; Foster B, 2002, J ALLERGY CLIN IMMUN, V109, P287, DOI 10.1067/mai.2002.121454; FUJIWARA KT, 1993, ONCOGENE, V8, P2371; Gersuk GR, 1998, BRIT J HAEMATOL, V103, P176, DOI 10.1046/j.1365-2141.1998.00933.x; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; IRANI AA, 1986, P NATL ACAD SCI USA, V83, P4464, DOI 10.1073/pnas.83.12.4464; Ishiguro T, 2000, ONCOL RES, V12, P181; Kataoka K, 2001, J BIOL CHEM, V276, P819, DOI 10.1074/jbc.M007643200; Kaufmann D, 2002, CANCER RES, V62, P1503; LAHTI JM, 1995, MOL CELL BIOL, V15, P1; Li Y, 1999, CLIN EXP METASTAS, V17, P213, DOI 10.1023/A:1006617016451; Lin CW, 2002, LEUKEMIA RES, V26, P551, DOI 10.1016/S0145-2126(01)00170-9; Longley BJ, 1999, P NATL ACAD SCI USA, V96, P1609, DOI 10.1073/pnas.96.4.1609; Longley BJ, 1996, NAT GENET, V12, P312, DOI 10.1038/ng0396-312; Martin-Subero JI, 2002, BLOOD, V99, P1474, DOI 10.1182/blood.V99.4.1474; Mashima T, 2001, J CELL PHYSIOL, V188, P352, DOI 10.1002/jcp.1130; Muller S, 2000, HUM MOL GENET, V9, P757, DOI 10.1093/hmg/9.5.757; NAGATA H, 1995, P NATL ACAD SCI USA, V92, P10560, DOI 10.1073/pnas.92.23.10560; RAZA A, 1995, BLOOD, V86, P268, DOI 10.1182/blood.V86.1.268.bloodjournal861268; REYNOLDS DS, 1989, P NATL ACAD SCI USA, V86, P9480, DOI 10.1073/pnas.86.23.9480; ROBBINS PF, 1995, J IMMUNOL, V154, P5944; Sattler M, 2002, ONCOGENE, V21, P1423, DOI 10.1038/sj.onc.1205202; Schwartz LB, 1995, J CLIN INVEST, V96, P2702, DOI 10.1172/JCI118337; SCHWARTZ LB, 1987, J IMMUNOL, V138, P2611; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; Tang BL, 1998, BIOCHEM BIOPH RES CO, V242, P673, DOI 10.1006/bbrc.1997.8029; Tsai FY, 1997, BLOOD, V89, P3636, DOI 10.1182/blood.V89.10.3636.3636_3636_3643; Valent P, 2001, LEUKEMIA RES, V25, P603, DOI 10.1016/S0145-2126(01)00038-8; Valent P, 2001, LEUKEMIA RES, V25, P595, DOI 10.1016/S0145-2126(01)00040-6; Worobec AS, 1998, CANCER, V83, P2120, DOI 10.1002/(SICI)1097-0142(19981115)83:10<2120::AID-CNCR10>3.0.CO;2-C; Wu MY, 1999, J BIOL CHEM, V274, P11868, DOI 10.1074/jbc.274.17.11868; Xu SQ, 2000, BIOCHEM BIOPH RES CO, V269, P179, DOI 10.1006/bbrc.2000.2247; Yavuz AS, 2002, BLOOD, V100, P661, DOI 10.1182/blood-2002-01-0203; Yoshikawa K, 2000, INT J CANCER, V88, P28, DOI 10.1002/1097-0215(20001001)88:1<28::AID-IJC5>3.0.CO;2-4; Zang DY, 2001, BLOOD, V98, P3058, DOI 10.1182/blood.V98.10.3058; Zellweger T, 2001, NEOPLASIA, V3, P360, DOI 10.1038/sj.neo.7900174	41	22	23	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2003	112	6					1162	1170		10.1016/j.jaci.2003.07.008	http://dx.doi.org/10.1016/j.jaci.2003.07.008			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	752HC	14657877				2022-12-18	WOS:000187154200020
J	von Bubnoff, D; Hanau, D; Wenzel, J; Takikawa, O; Hall, B; Koch, S; Bieber, T				von Bubnoff, D; Hanau, D; Wenzel, J; Takikawa, O; Hall, B; Koch, S; Bieber, T			Indoleamine 2,3-dioxygenase-expressing antigen-presenting cells and peripheral T-cell tolerance: Another piece to the atopic puzzle?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						tryptophan degradation; T-cell suppression; Fc epsilon RI; immunoregulation; antigen-presenting cells	FC-EPSILON-RI; DENDRITIC CELLS; INTERFERON-GAMMA; TRYPTOPHAN DEGRADATION; TOXOPLASMA-GONDII; HUMAN-FIBROBLASTS; GENE INDUCTION; INHIBITION; PROLIFERATION; EXPRESSION	There is growing evidence that dendritic cells, the major antigen-presenting cells and T-cell activators, have a broad effect on peripheral T-cell tolerance and regulation of immunity. Very recently, a new feature of regulatory antigen-presenting cells was observed. Certain dendritic cells, monocytes, and macrophages express the enzyme indoleamine 2,3-dioxygenase, and thus because of enhanced degradation of the essential amino acid tryptophan, they modulate T-cell activity in specific local tissue environments. In this review we discuss the various and apparently disparate effects of indoleamine 2,3-dioxygenase induction in cells of the immune system. We place current knowledge about this mechanism in the context of atopy. We introduce the hypothesis that tryptophan degradation might add to the ability to control and downregulate allergen-specific T-cell responses in atopic individuals.	Univ Bonn, Dept Dermatol, D-53105 Bonn, Germany; Etablissement Francais Sang Alsace, Strasbourg, France; Mayo Clin, Rochester, MN USA; Hokkaido Univ, Dept Cell Pharmacol, Sapporo, Hokkaido, Japan	University of Bonn; Mayo Clinic; Hokkaido University	Bieber, T (corresponding author), Univ Bonn, Dept Dermatol, Sigmund Freud Str 25, D-53105 Bonn, Germany.		Wenzel, Jörg/AAX-2644-2020	Wenzel, Jörg/0000-0002-4744-5993				Akbari O, 2001, NAT IMMUNOL, V2, P725, DOI 10.1038/90667; AUNE TM, 1989, J CLIN INVEST, V84, P863, DOI 10.1172/JCI114247; Bodaghi B, 1999, J IMMUNOL, V162, P957; Bonney EA, 1998, NAT MED, V4, P1128, DOI 10.1038/2624; CARLIN JM, 1987, J IMMUNOL, V139, P2414; Chaves ACL, 2001, EUR J IMMUNOL, V31, P333, DOI 10.1002/1521-4141(200102)31:2&lt;333::AID-IMMU333&gt;3.0.CO;2-X; DERMOTT R, 2002, MOL BIOL CELL, V13, P317; Frumento G, 2002, J EXP MED, V196, P459, DOI 10.1084/jem.20020121; Fujigaki S, 2001, EUR J IMMUNOL, V31, P2313, DOI 10.1002/1521-4141(200108)31:8<2313::AID-IMMU2313>3.0.CO;2-S; Grohmann U, 2002, NAT IMMUNOL, V3, P1097, DOI 10.1038/ni846; Grohmann U, 2003, TRENDS MOL MED, V9, P133, DOI 10.1016/S1471-4914(03)00026-1; Grohmann U, 2003, TRENDS IMMUNOL, V24, P242, DOI 10.1016/S1471-4906(03)00072-3; HU BG, 1995, J INTERF CYTOK RES, V15, P617, DOI 10.1089/jir.1995.15.617; Hwu P, 2000, J IMMUNOL, V164, P3596, DOI 10.4049/jimmunol.164.7.3596; Kerschenlohr K, 2003, J ALLERGY CLIN IMMUN, V111, P869, DOI 10.1067/mai.2003.1347; Kluken H, 2003, ALLERGY, V58, P5, DOI 10.1034/j.1398-9995.2003.02162.x; Konan KV, 1996, J BIOL CHEM, V271, P19140, DOI 10.1074/jbc.271.32.19140; Leung DYM, 2003, LANCET, V361, P151, DOI 10.1016/S0140-6736(03)12193-9; MACKENZIE CR, 1999, TRYPTOPHAN SEROTONIN; MAURER D, 1995, J IMMUNOL, V154, P6285; Mellor AL, 1999, IMMUNOL TODAY, V20, P469, DOI 10.1016/S0167-5699(99)01520-0; Munn DH, 2002, SCIENCE, V297, P1867, DOI 10.1126/science.1073514; Munn DH, 1998, SCIENCE, V281, P1191, DOI 10.1126/science.281.5380.1191; Munn DH, 1999, J EXP MED, V189, P1363, DOI 10.1084/jem.189.9.1363; MUSSO T, 1994, BLOOD, V83, P1408; Novak N, 2003, J CLIN INVEST, V111, P1047, DOI 10.1172/JCI200315932; Novak N, 2003, J ALLERGY CLIN IMMUN, V111, P38, DOI 10.1067/mai.2003.2; Novak N, 2002, J INVEST DERMATOL, V119, P870, DOI 10.1046/j.1523-1747.2002.00191.x; Novak N, 2001, J IMMUNOL, V167, P797, DOI 10.4049/jimmunol.167.2.797; PFEFFERKORN ER, 1984, P NATL ACAD SCI-BIOL, V81, P908, DOI 10.1073/pnas.81.3.908; Qiang Y, 2003, J IMMUNOL, V170, P1473, DOI 10.4049/jimmunol.170.3.1473; TAYLOR MW, 1991, FASEB J, V5, P2516, DOI 10.1096/fasebj.5.11.1907934; Terness P, 2002, J EXP MED, V196, P447, DOI 10.1084/jem.20020052; Thompson CB, 1997, IMMUNITY, V7, P445, DOI 10.1016/S1074-7613(00)80366-0; vanKooten C, 1997, CURR OPIN IMMUNOL, V9, P330, DOI 10.1016/S0952-7915(97)80078-7; Von Bubnoff D, 2003, CLIN EXP IMMUNOL, V132, P247, DOI 10.1046/j.1365-2249.2003.02125.x; von Bubnoff D, 2002, J IMMUNOL, V169, P6170, DOI 10.4049/jimmunol.169.11.6170; von Bubnoff D, 2002, J IMMUNOL, V169, P1810, DOI 10.4049/jimmunol.169.4.1810; von Bubnoff D, 2001, J ALLERGY CLIN IMMUN, V108, P329, DOI 10.1067/mai.2001.117457; Weiss G, 1999, CLIN EXP IMMUNOL, V116, P435; WIDNER B, 2000, MOD ASP IMMUNOBIOL, V1, P105; YAMAZAKI F, 1985, BIOCHEM J, V230, P635, DOI 10.1042/bj2300635; YOSHIDA R, 1980, ARCH BIOCHEM BIOPHYS, V203, P343, DOI 10.1016/0003-9861(80)90185-X	43	22	23	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2003	112	5					854	860		10.1016/S0091-6749(03)02014-1	http://dx.doi.org/10.1016/S0091-6749(03)02014-1			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	743BV	14610470				2022-12-18	WOS:000186553300005
J	Brown, HC; Ballas, ZK				Brown, HC; Ballas, ZK			Acute associated with intravenous immunoglobulin infusion in antibody-deficient patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							MYOCARDIAL-INFARCTION; CEREBRAL VASOSPASM; THERAPY; ENCEPHALOPATHY		Univ Iowa, Dept Internal Med, Div Allergy Immunol, Iowa City, IA 52242 USA	University of Iowa	Brown, HC (corresponding author), Univ Iowa, Dept Internal Med, Div Allergy Immunol, C42-E13,GH, Iowa City, IA 52242 USA.			Knaack, Aaron/0000-0001-7712-1415; Ballas, Zuhair/0000-0001-5569-1230				DALAKAS MC, 1994, NEUROLOGY, V44, P223, DOI 10.1212/WNL.44.2.223; Elkayam O, 2000, ANN RHEUM DIS, V59, P77, DOI 10.1136/ard.59.1.77; Go RS, 2000, MAYO CLIN PROC, V75, P83, DOI 10.4065/75.1.83; Nydegger UE, 1996, CLIN EXP RHEUMATOL, V14, pS53; REINHART WH, 1992, LANCET, V339, P662, DOI 10.1016/0140-6736(92)90806-E; Rosenbaum JT, 1997, ARTHRITIS RHEUM, V40, P1732, DOI 10.1002/art.38; Sztajzel R, 1999, EUR NEUROL, V41, P153, DOI 10.1159/000008040; Turner B, 2000, J NEUROL NEUROSUR PS, V68, P790, DOI 10.1136/jnnp.68.6.790; Voltz R, 1996, NEUROLOGY, V46, P250, DOI 10.1212/WNL.46.1.250; Wolberg AS, 2000, AM J HEMATOL, V65, P30, DOI 10.1002/1096-8652(200009)65:1<30::AID-AJH5>3.0.CO;2-J	10	22	22	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2003	112	4					797	799		10.1016/S0091-6749(03)01780-9	http://dx.doi.org/10.1016/S0091-6749(03)01780-9			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	730LA	14564366	Bronze			2022-12-18	WOS:000185831200023
J	Gore, C; Peterson, CGB; Kissen, P; Simpson, BM; Lowe, LA; Woodcock, A; Custovic, A				Gore, C; Peterson, CGB; Kissen, P; Simpson, BM; Lowe, LA; Woodcock, A; Custovic, A		Natl Asthma Campaign Manchester As	Urinary eosinophilic protein X, atopy, and symptoms suggestive of allergic disease at 3 years of age	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						urinary eosinophilic protein X; asthma; atopy; cough; allergy	CATIONIC PROTEIN; RESPIRATORY SYMPTOMS; NASAL LAVAGE; CHILDREN; ASTHMA; DERMATITIS; INFLAMMATION; INFANTS; PARENTS; LIFE	Background: Urinary eosinophilic protein X (U-EPX) measurement is easy to perform in children. However, its use for prediction, diagnosis, and monitoring of asthma and atopy is unclear. Objective: We sought to investigate the relationship between U-EPX and clinical phenotypes suggestive of allergic diseases. Methods: U-EPX measurement (RIA), respiratory questionnaires, and skin testing were completed at age 3 years in 903 children followed prospectively from birth. Specific airway resistance was measured in 503 currently asymptomatic children by using whole-body plethysmography during tidal breathing. Results: Nonatopic children with wheezing or eczema had slightly increased U-EPX levels compared with nonatopic asymptomatic children. U-EPX levels (geometric mean EPX/creatinine ratio) were as follows: nonatopic asymptomatic children (n = 313), 61.3 mug/mmol (95% CI, 56.4-66.6 mug/mmol); nonatopic children with wheezing (n = 148), 71.2 mug/mmol (95% CI, 63.2-80.1 mug/mmol); nonatopic children with eczema (n = 90), 65.7 mug/mmol (95% CI, 56.7-76.2 mug/mmol); and nonatopic children with wheezing and eczema (n = 86), 79.7 mug/mmol (95% CI, 67.4-94.3 mug/mmol). Children who had persistent atopy early in life had significantly higher U-EPX levels at age 3 years (nonatopic at 1 and 3 years [n = 263], 63.4 mug/mmol [95% CI, 58.4-69.0 mug/mmol]; atopic at 1 but not 3 years [n = 24], 65.1 mug/mmol [95% CI, 43.8-96.7 mug/mmol]; nonatopic at 1 year and atopic at 3 years [n = 62], 90.0 mug/mmol [95% CI, 74.6-108.4 mug/mmol]; atopic at 1 and 3 years [n = 35], 111.5 mug/mmol [95% Cl, 89.2-139.3 mug/mmol]; P < .002). Atopy alone and with wheezing, eczema, or both was associated with significantly increased U-EPX levels (P < .0001). Wheezing appeared to be associated with higher U-EPX levels compared with eczema in both atopic and nonatopic children. The highest U-EPX level was found in atopic children with a history of wheezing and eczema (P < .0001). There was no relationship between U-EPX level and lung function. Conclusion: U-EPX level reflects the presence of atopy and associated symptoms and might be useful for monitoring the progression of allergic disease.	Wythenshawe Hosp, N W Lung Ctr, Manchester M23 9LT, Lancs, England; Pharmacia Diagnost AB, S-75182 Uppsala, Sweden	Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital; Pfizer; Pharmacia Corporation	Gore, C (corresponding author), Wythenshawe Hosp, N W Lung Ctr, Manchester M23 9LT, Lancs, England.		Custovic, Adnan/A-2435-2012	Custovic, Adnan/0000-0001-5218-7071; Woodcock, Ashley/0000-0002-5428-8578; Gore, Claudia/0000-0002-3626-5129				BRADLEY BL, 1991, J ALLERGY CLIN IMMUN, V88, P661, DOI 10.1016/0091-6749(91)90160-P; Breuer K, 2001, ALLERGY, V56, P780, DOI 10.1034/j.1398-9995.2001.056008780.x; Cane RS, 2000, ARCH DIS CHILD, V82, P327, DOI 10.1136/adc.82.4.327; CARLSEN KCL, 1995, EUR RESPIR J, V8, P1148, DOI 10.1183/09031936.95.08071148; Custovic A, 2001, LANCET, V358, P188, DOI 10.1016/S0140-6736(01)05406-X; Elphick HE, 2000, EUR RESPIR J, V16, P593, DOI 10.1034/j.1399-3003.2000.16d04.x; Frischer T, 2000, ALLERGY, V55, P773, DOI 10.1034/j.1398-9995.2000.00773.x; Halmerbauer G, 2000, ALLERGY, V55, P1121, DOI 10.1034/j.1398-9995.2000.00439.x; KHALIL KW, 2002, ALLERGOL IMMUNOPATH, V30, P225; Koller DY, 1999, CLIN EXP ALLERGY, V29, P786; Kristjansson S, 1996, J ALLERGY CLIN IMMUN, V97, P1179, DOI 10.1016/S0091-6749(96)70182-3; Labbe A, 2001, PEDIATR PULM, V31, P354, DOI 10.1002/ppul.1058; Lowe L, 2002, LANCET, V359, P1904, DOI 10.1016/S0140-6736(02)08781-0; Lugosi E, 1997, ALLERGY, V52, P584, DOI 10.1111/j.1398-9995.1997.tb02605.x; Majamaa H, 1999, CLIN EXP ALLERGY, V29, P1502, DOI 10.1046/j.1365-2222.1999.00666.x; Mattes J, 2002, PEDIATR RES, V51, P190, DOI 10.1203/00006450-200202000-00011; O'Sullivan S, 1999, CLIN EXP ALLERGY, V29, P1454; Oymar K, 2000, ALLERGY, V55, P964, DOI 10.1034/j.1398-9995.2000.00682.x; Oymar K, 2001, ACTA PAEDIATR, V90, P843, DOI 10.1080/08035250152509528; Oymar K, 2001, PEDIATR ALLERGY IMMU, V12, P34, DOI 10.1034/j.1399-3038.2001.012001034.x; PETERSON C, 1996, AM J RESP CRIT CARE, V153, pA201; PETERSON CGB, 1983, IMMUNOLOGY, V50, P19; Pucci N, 2000, J ALLERGY CLIN IMMUN, V105, P353, DOI 10.1016/S0091-6749(00)90087-3; Schosser M, 2001, ALLERGY, V56, P792, DOI 10.1034/j.1398-9995.2001.056008792.x; Tauber E, 2000, ALLERGY, V55, P647, DOI 10.1034/j.1398-9995.2000.00528.x; Wojnarowski C, 1999, CLIN EXP ALLERGY, V29, P926; Wojnarowski C, 2001, ALLERGY, V56, P883, DOI 10.1034/j.1398-9995.2001.00973.x	27	22	22	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2003	112	4					702	708		10.1016/S0091-6749(03)01886-4	http://dx.doi.org/10.1016/S0091-6749(03)01886-4			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	730LA	14564347				2022-12-18	WOS:000185831200008
J	Nguyen, B; Ghezzo, H; Malo, JL; Gautrin, D				Nguyen, B; Ghezzo, H; Malo, JL; Gautrin, D			Time course of onset of sensitization to common and occupational inhalants in apprentices	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IgE-mediated hypersensitivity; occupational exposure; occupational asthma; asthma	LONGITUDINAL CHANGES; LABORATORY-ANIMALS; HOST DETERMINANTS; TEST REACTIVITY; CAT ALLERGEN; FEL-DI; ASTHMA; POPULATION; CHILDREN	Background: Incident sensitization to common allergens in the setting of sensitization to an occupational allergen has not been described. Objective: Our aim was to determine the risk and timing of development of sensitization to common allergens in subjects with incident sensitization to a work-related allergen. Methods: Data from a cohort of 769 apprentices in animal-health technology, pastry making, and dental hygiene were used. Skin prick tests to work-related allergens (laboratory animal, flour, and latex) and common allergens (mites, molds, pets, and pollen) were administered at baseline and at up to 3 subsequent annual visits. Risk ratios (RRs) and 95% CIs were calculated. Results: Eighty-three subjects had sensitization to a work-related allergen. Four (4.8%) subjects became sensitized to common and then occupational allergens. Nine (10.8%) subjects had sensitization to a common allergen after sensitization to a work-related allergen. In 20 (24.1%) subjects new sensitizations to specific and common allergens were detected simultaneously. Fifty subjects remained free from new sensitization to occupational allergen during development of sensitization to common allergens. An increased risk of development of sensitization to molds (RR = 3.49) and pets (RR = 2.51) was found in subjects with incident sensitization to occupational allergens relative to the risk in subjects without sensitization. Conclusion: New sensitization to common aeroallergens is frequent in subjects not previously exposed to work-related allergens; it often occurs around the same time as sensitization to work-related agents. Subjects with new occupational sensitization are at a greater risk of development of sensitization to common aeroallergens than subjects without sensitization.	Hop Sacre Coeur, Dept Chest Med, Montreal, PQ H4J 1C5, Canada	Universite de Montreal	Gautrin, D (corresponding author), Hop Sacre Coeur, Dept Chest Med, 5400 Gouin Blvd W, Montreal, PQ H4J 1C5, Canada.							Almqvist C, 1999, J ALLERGY CLIN IMMUN, V103, P1012, DOI 10.1016/S0091-6749(99)70172-7; BALDO BA, 1982, CLIN ALLERGY, V12, P179, DOI 10.1111/j.1365-2222.1982.tb01637.x; BARBEE RA, 1987, J ALLERGY CLIN IMMUN, V79, P16, DOI 10.1016/S0091-6749(87)80010-6; BECKLAKE MR, 1999, ASTHMA WORKPLACE, P27; BERNSTEIN IL, 1999, ASTHMA WORKPLACE, P1; BOUSQUET J, 1988, ALLERGY PRINCIPLES P, P419; CHANYEUNG M, 1995, NEW ENGL J MED, V333, P107, DOI 10.1056/NEJM199507133330207; Gautrin D, 2000, AM J RESP CRIT CARE, V162, P1222, DOI 10.1164/ajrccm.162.4.2001023; Gautrin D, 2002, EUR RESPIR J, V19, P96, DOI 10.1183/09031936.02.00230202; Gautrin D, 1997, AM J RESP CRIT CARE, V155, P1841, DOI 10.1164/ajrccm.155.6.9196084; Gautrin D, 2001, AM J RESP CRIT CARE, V163, P899, DOI 10.1164/ajrccm.163.4.2008011; JOHNSTON SL, 1992, CLIN EXP ALLERGY, V22, P948, DOI 10.1111/j.1365-2222.1992.tb02069.x; KARN RC, 1994, BIOCHEM GENET, V32, P271, DOI 10.1007/BF00555830; Merrett TG, 1999, CLIN EXP ALLERGY, V29, P1572; MORGENSTERN JP, 1991, P NATL ACAD SCI USA, V88, P9690, DOI 10.1073/pnas.88.21.9690; ORYSZCZYN MP, 1995, AM J RESP CRIT CARE, V151, P663; PEPYS J, 1973, CLIN ALLERGY, V3, P491, DOI 10.1111/j.1365-2222.1973.tb03057.x; Silvestri M, 1999, ANN ALLERG ASTHMA IM, V83, P335, DOI 10.1016/S1081-1206(10)62674-9; ULRIK C, 2002, ANN ALLERG ASTHMA IM, V85, P293; Zureik M, 2002, BMJ-BRIT MED J, V325, P411, DOI 10.1136/bmj.325.7361.411	20	22	22	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2003	111	4					807	812		10.1067/mai.2003.1341	http://dx.doi.org/10.1067/mai.2003.1341			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	667WW	12704362				2022-12-18	WOS:000182258500022
J	Hori, H; Hattori, S; Inouye, S; Kimura, A; Irie, S; Miyazawa, H; Sakaguchi, M				Hori, H; Hattori, S; Inouye, S; Kimura, A; Irie, S; Miyazawa, H; Sakaguchi, M			Analysis of the major epitope of the alpha 2 chain of bovine type I collagen in children with bovine gelatin allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergen; anaphylaxis; gelatin; IgE; epitope	IMMEDIATE-TYPE REACTIONS; MONOCLONAL-ANTIBODIES; IGE ANTIBODY; MEASLES; VACCINES; PRODUCTS; MUMPS; ANAPHYLAXIS; REACTIVITY; SEQUENCE	Background: Anaphylaxis to measles, mumps, and rubella vaccines has been reported. It has been found that most of these reactions to live vaccines are caused by type I allergy with the bovine gelatin present in the vaccines as an allergen. Gelatin mainly includes denatured type I collagen, which consists of alpha1 and alpha2 chains. We previously reported that allergic reactions to gelatin are caused by the type I collagen alpha2 (alpha2[I]) chain. Objective: To aid in the development of gelatin that has little or no allergenicity in human subjects, we investigated epitopes of bovine alpha2(I) chain with use of IgE in gelatin-sensitive children. Methods: Serum samples were collected from 15 patients who had systemic allergic reactions to vaccines and high levels of specific IgE to bovine gelatin. Eleven overlapping recombinant proteins that cover bovine alpha2(I) were prepared with a bacterial expression vector. We examined IgE reactivity to these recombinant proteins by means of ELISA. Fifteen peptides covering a major reactive recombinant protein were synthesized. The IgE-reacting epitope was identified by means of IgE-ELISA inhibition with these synthetic peptides and pooled serum from the patients. Results: We found that of the 15 patients, 13 showed IgE reactivity to a recombinant protein (no. 3) spanning the central region of the collagenous domain ((418)Gly-(662)Pro). Furthermore, all 13 patients showed IgE reactivity to the 4-kd recombinant protein (no. 3a) spanning the region from (461)Pro to (500)Glu. In IgE-ELISA inhibition we found that a minimum IgE epitope of gelatin allergen was composed of the 10-amino-acid sequence (485)Ile-Pro-Gly-Glu-Phe-Gly-Leu-Pro-Gly-Pro(494). This sequence is not observed in the human type I collagen alpha1 and alpha2 chains, nor is it found in the bovine type I collagen alpha1 chain. Conclusions: We found that Ile-Pro-Gly-Glu-Phe-Gly-Leu-Pro-Gly-Pro is a major IgE epitope of the alpha2 chain of bovine type I collagen in patients with gelatin allergy. The degree of anaphylaxis to gelatin in vaccines might be reduced by digestion of this IgE-binding site in gelatin.	Natl Inst Infect Dis, Dept Immunol, Shinjuku Ku, Tokyo 1628640, Japan; Tokyo Med & Dent Univ, Div Adult Dis, Med Res Inst, Tokyo, Japan; Nippi Res Inst Biomatrix, Tokyo, Japan; Infect Dis Surveillance Ctr, Tokyo, Japan; Kyorin Univ, Dept Med Technol, Tokyo, Japan	National Institute of Infectious Diseases (NIID); Tokyo Medical & Dental University (TMDU); Kyorin University	Sakaguchi, M (corresponding author), Natl Inst Infect Dis, Dept Immunol, Shinjuku Ku, Toyama 1-23-1, Tokyo 1628640, Japan.		Kimura, Akinori/I-5989-2018; Inouye, Sharon/R-7216-2019	Kimura, Akinori/0000-0002-4933-2132; 				AUKRUST L, 1980, ALLERGY, V35, P581, DOI 10.1111/j.1398-9995.1980.tb01808.x; BERNARD MP, 1983, BIOCHEMISTRY-US, V22, P213; BUSINCO L, 1994, ANN ALLERGY, V72, P1; DEWET W, 1987, J BIOL CHEM, V262, P32; HORI H, 1992, MOL IMMUNOL, V29, P759; HORI H, 1994, J BIOCHEM-TOKYO, V116, P1212, DOI 10.1093/oxfordjournals.jbchem.a124666; JANTUNENBACKMAN K, 1987, AM J DIS CHILD, V141, P1103; KESLO JM, 1993, J ALLERGY CLIN IMMUN, V91, P867; Kumagai T, 1997, J ALLERGY CLIN IMMUN, V100, P130, DOI 10.1016/S0091-6749(97)70204-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Miller E. J., 1984, EXTRACELLULAR MATRIX, P41; Nakayama T, 1999, J ALLERGY CLIN IMMUN, V103, P321, DOI 10.1016/S0091-6749(99)70508-7; POLLOCK TM, 1983, LANCET, V1, P753; Sakaguchi M, 1999, J ALLERGY CLIN IMMUN, V104, P695, DOI 10.1016/S0091-6749(99)70344-1; Sakaguchi M, 2000, J ALLERGY CLIN IMMUN, V106, P579, DOI 10.1067/mai.2000.108499; Sakaguchi M, 1999, J ALLERGY CLIN IMMUN, V103, P349, DOI 10.1016/S0091-6749(99)70512-9; SAKAGUCHI M, 1995, J ALLERGY CLIN IMMUN, V96, P563, DOI 10.1016/S0091-6749(95)70304-7; Sakaguchi M, 1996, J ALLERGY CLIN IMMUN, V98, P1058, DOI 10.1016/S0091-6749(96)80191-6; Sakaguchi M, 2001, J ALLERGY CLIN IMMUN, V108, P1033, DOI 10.1067/mai.2001.119412; Saldanha J, 1996, BRIT J HAEMATOL, V93, P714, DOI 10.1046/j.1365-2141.1996.d01-1679.x; Shirai T, 1998, MATRIX BIOL, V17, P85, DOI 10.1016/S0945-053X(98)90076-2; TUTTLE J, 1996, MMWR-MORBID MORTAL W, V45, P1; WAHL R, 1989, CLIN EXP ALLERGY, V19, P77, DOI 10.1111/j.1365-2222.1989.tb02348.x	23	22	24	0	9	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2002	110	4					652	657		10.1067/mai.2002.127862	http://dx.doi.org/10.1067/mai.2002.127862			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	602JJ	12373276	Bronze			2022-12-18	WOS:000178501900018
J	Mita, H; Hasegawa, M; Higashi, N; Akiyama, K				Mita, H; Hasegawa, M; Higashi, N; Akiyama, K			Characterization of PGE(2) receptor subtypes in human eosinophils	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eosinophils; prostaglandin E; prostaglandin E receptors	PROSTANOID RECEPTORS; LEUKOTRIENE	Although previous pharmacologic studies have indicated that PGE receptors are expressed in human eosinophils, the exact distribution of the subtypes remains mostly unknown. By using a combination of genetic and conventional pharmacologic approaches, coexpression of mRNAs encoding the PGE receptor 2 (EP2) and EP4 was confirmed in eosinophils. Moreover, competitive PCR analysis of eosinophil RNA revealed that levels of the EP4 receptor mRNA were significantly higher than those of the EP2 receptor mRNA (P=.04). On the basis of the expression levels of mRNAs, an EP4 agonist, but not an EP2 agonist, was effective in inducing cyclic AMP production in eosinophils, suggesting that the EP4 receptor is of primary importance in eosinophil functions of PGE(2).	Natl Sagamihara Hosp, Clin Res Ctr, Kanagawa, Japan		Mita, H (corresponding author), 18-1 Sakuradai, Kanagawa 2288522, Japan.							Kiriyama M, 1997, BRIT J PHARMACOL, V122, P217, DOI 10.1038/sj.bjp.0701367; Mita H, 2001, CLIN EXP ALLERGY, V31, P1714, DOI 10.1046/j.1365-2222.2001.01184.x; Narumiya S, 1999, PHYSIOL REV, V79, P1193, DOI 10.1152/physrev.1999.79.4.1193; Nishigaki N, 1996, MOL PHARMACOL, V50, P1031; Peacock CD, 1999, J ALLERGY CLIN IMMUN, V104, P153, DOI 10.1016/S0091-6749(99)70127-2; Takahashi HK, 2002, J IMMUNOL, V168, P4446, DOI 10.4049/jimmunol.168.9.4446; Tenor H, 1996, BRIT J PHARMACOL, V118, P1727, DOI 10.1111/j.1476-5381.1996.tb15598.x	7	22	22	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2002	110	3					457	459		10.1067/mai.2002.127001	http://dx.doi.org/10.1067/mai.2002.127001			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	592KM	12209094	Bronze			2022-12-18	WOS:000177936900017
J	Szefler, SJ; Warner, J; Staab, D; Wahn, U; Le Bourgeois, M; van Essen-Zandvliet, EEM; Arora, S; Pedersen, S				Szefler, SJ; Warner, J; Staab, D; Wahn, U; Le Bourgeois, M; van Essen-Zandvliet, EEM; Arora, S; Pedersen, S		Pediat Study Grp	Switching from conventional to extrafine aerosol beclomethasone dipropionate therapy in children: A 6-month, open-label, randomized trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						children; asthma; inhaled corticosteroid; chlorofluorocarbon free; hydrofluoralkane-134a beclomethasone dipropionate	400 MU-G; EQUIVALENT ASTHMA CONTROL; FLUTICASONE PROPIONATE; ACUTE SAFETY; NON-CFC; EFFICACY; HFA-134A; FORMULATION; DEPOSITION; SYSTEM	Background: In adults with asthma, hydrofluoralkane-134a beclomethasone dipropionate (HFA-BDP) extrafine aerosol provides equivalent asthma control at half the daily dose of conventional chloronuorocarbon (CFC)-BDP. Objective: We sought to compare the efficacy and tolerability of switching from CFC-BDP to HFA-BDP at half the daily dose in children with stable asthma. Methods: This 6-month, open-label, randomized, multicenter study enrolled 520 children aged 5 to 11 years with well-controlled asthma receiving inhaled CFC-BDP or budesonide 200 to 800 mug/d x. (Four hundred fifty-two patients were using doses within the recommended range of 200-400 mug and were analyzed separately.) During a 4-week run-in period, patients used CFC-BDP plus a spacer (CFC-BDP+S) at approximately the same dose as they were using before study entry. Patients were then randomized in a 1:3 ratio to continue on CFCBDP+S or switch to HFA-BDP Autohaler at half the daily dose. Results: The change from baseline in morning peak expiratory flow was significantly greater in patients receiving 100-200 mug of HFA-BDP compared with those receiving 200-400 mug of CFC-BDP+S at weeks 7 to 8 (8.5 and 0.4 L/min, respectively; P =.014), with continuing improvement in both groups over 6 months (12.2 and 12.4 L/min, respectively, at month 6). There were no significant differences between treatments in mean change from baseline in FEV1, percentage of days or nights without asthma symptoms, and daily P-agonist use over the 6-month treatment period. The proportion of patients who had one or more asthma exacerbations, the incidence of adverse events, and the percentage change from baseline in 24-hour urinary free cortisol levels were similar in the 2 treatment groups. Conclusions: This study confirms that asthma control can be well maintained in children when switching from CFC-BDP+S to an HFA-BDP Autohaler at doses as low as 100 to 200 mug/d.	Kolding Sygehus, Paediat Afdeling, Kolding, Denmark; 3M Co, Pharmaceut, St Paul, MN 55144 USA; Asthma Ctr Heideheuvel, Hilversum, Netherlands; Grp Hosp Necker Enfants Malad, Serv Pneumol & Allergol Pediat, Paris, France; Humboldt Univ, Charite, Dept Pediat Pneumol & Immunol, Berlin, Germany; Southampton Gen Hosp, Dept Child Hlth, Southampton SO9 4XY, Hants, England; Natl Jewish Med & Res Ctr, Denver, CO 80206 USA	Kolding Hospital; 3M; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Southampton; National Jewish Health	Szefler, SJ (corresponding author), Natl Jewish Med & Res Ctr, 1400 Jackson St,Room B121, Denver, CO 80206 USA.							Ayres JG, 1999, RESP MED, V93, P27, DOI 10.1016/S0954-6111(99)90073-2; Boulet LP, 2001, J ALLERGY CLIN IMMUN, V107, pS103; Busse WW, 1999, J ALLERGY CLIN IMMUN, V104, P1215, DOI 10.1016/S0091-6749(99)70016-3; Davies RJ, 1998, RESP MED, V92, P23, DOI 10.1016/S0954-6111(98)90214-1; Demedts M, 1999, INT J CLIN PRACT, V53, P331; DOLOVICH MB, 2000, AM J RESP CRIT CARE, V161, pA33; DONNELL D, 1995, EUR J CLIN PHARMACOL, V48, P473; Ferguson AC, 1999, J PEDIATR-US, V134, P422, DOI 10.1016/S0022-3476(99)70198-8; Fireman P, 2001, ANN ALLERG ASTHMA IM, V86, P557, DOI 10.1016/S1081-1206(10)62905-5; Fitzgerald D, 1998, THORAX, V53, P656, DOI 10.1136/thx.53.8.656; Gross G, 1999, CHEST, V115, P343, DOI 10.1378/chest.115.2.343; GUSTAFSSON P, 1993, ARCH DIS CHILD, V69, P206, DOI 10.1136/adc.69.2.206; Harrison LI, 1996, J PHARM PHARMACOL, V48, P596, DOI 10.1111/j.2042-7158.1996.tb05980.x; *INT ASTHM MAN PRO, 1992, ALLERGY, V47, P1; JUNE DS, 1995, J AEROSOL MED, V8, P91; Leach C, 1999, J ALLERGY CLIN IMMUN, V104, pS250, DOI 10.1016/S0091-6749(99)70041-2; Leach C. L., 1997, European Respiratory Journal Supplement, V10, p236S; Leach CL, 1998, EUR RESPIR J, V12, P1346, DOI 10.1183/09031936.98.12061346; Magnussen H, 2000, RESP MED, V94, P549, DOI 10.1053/rmed.1999.0772; Matthys H, 1998, RESP MED, V92, P17, DOI 10.1016/S0954-6111(98)90213-X; OCALLAGHAN C, 1994, THORAX, V49, P961, DOI 10.1136/thx.49.10.961; Pedersen S, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.6.e92; Richards J, 2001, J AEROSOL MED, V14, P197, DOI 10.1089/08942680152484126; Soria I., 1997, European Respiratory Journal Supplement, V10, p237S; Thompson PJ, 1998, RESP MED, V92, P33, DOI 10.1016/S0954-6111(98)90215-3	25	22	24	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2002	110	1					45	50		10.1067/mai.2002.124771a	http://dx.doi.org/10.1067/mai.2002.124771a			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	574CF	12110818	Bronze			2022-12-18	WOS:000176870300010
J	Carvalho, LP; Bacellar, O; Neves, N; de Jesus, AR; Carvalho, EM				Carvalho, LP; Bacellar, O; Neves, N; de Jesus, AR; Carvalho, EM			Downregulation of IFN-gamma production in patients with recurrent vaginal candidiasis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						recurrent vaginal candidiasis; cytokines; immune regulation	INDUCED LYMPHOCYTE-PROLIFERATION; INHIBITS CYTOKINE PRODUCTION; WOMEN; SUSCEPTIBILITY; VAGINITIS; IMMUNITY; IL-10; MICE; CELL; CHALLENGE	Background: Recurrent vaginal candidiasis (RVC) is an important health problem with unknown pathogenesis. Although impairment of the T-cell response is associated with persistent or recurrent candidiasis, data on immunologic responses in patients with RVC are controversial. Objectives: To evaluate the T-cell response in patients with RVC and the ability of cytokines and cytokine antagonists to modulate IFN-gamma production in cultures stimulated with Candida albicans antigens. Methods: Participants in the study included 13 patients with RVC and 7 control women with sporadic candidiasis. Cytokines were determined by ELISA in supernatants of mononuclear cells with C albicans, purified protein derivative, or tetanus toxoid antigen. Results: IFN-gamma production was absent or low in 11 of 13 women (84.6%) with RVC. Absent or low IFN-gamma production was specific to C albicans antigens (189 +/- 389 pg/mL), because high IFN-gamma levels were found in cultures stimulated with purified protein derivative (739 +/- 774 pg/mL) or tetanus toxoid antigens (1085 +/- 546 pg/mL). Monoclonal antibody anti-IL-10 enhanced IFN-gamma levels (750 +/- 753 pg/mL), and IL-10 suppressed this cytokine production in patients with sporadic candidiasis. Conclusions: Mononuclear cells from patients with RVC stimulated with C albicans antigen have low or absent IFN-gamma production. IL-10 plays an important role in downregulation of the T-cell response in these patients.	Univ Fed Bahia, Hosp Univ Prof Edgard Santos, Serv Imunol, BR-40110160 Salvador, BA, Brazil	Universidade Federal da Bahia	Carvalho, EM (corresponding author), Univ Fed Bahia, Hosp Univ Prof Edgard Santos, Serv Imunol, 5 Andar,Rua Joao Botas S-N, BR-40110160 Salvador, BA, Brazil.		Carvalho, Lucas/J-6734-2012; Carvalho, Lucas/AAP-1844-2020					Araujo MI, 1996, EUR J IMMUNOL, V26, P1399, DOI 10.1002/eji.1830260633; Bomfim G, 1996, EXP PARASITOL, V84, P188, DOI 10.1006/expr.1996.0104; Corrigan EM, 1998, CLIN EXP IMMUNOL, V111, P574; Dahl KM, 1997, AIDS RES HUM RETROV, V13, P485, DOI 10.1089/aid.1997.13.485; DE WMR, 1991, J EXP MED, V174, P1209; Duerr A, 1997, OBSTET GYNECOL, V90, P252, DOI 10.1016/S0029-7844(97)00253-6; FIDEL PL, 1993, J INFECT DIS, V168, P1458, DOI 10.1093/infdis/168.6.1458; Fidel PL, 1997, J INFECT DIS, V176, P728, DOI 10.1086/514097; FIORENTINO DF, 1989, J EXP MED, V170, P2081, DOI 10.1084/jem.170.6.2081; FIORENTINO DF, 1991, J IMMUNOL, V147, P3815; FISCHER A, 1978, J CLIN INVEST, V62, P1005, DOI 10.1172/JCI109204; FLEURY F J, 1981, Clinical Obstetrics and Gynecology, V24, P407, DOI 10.1097/00003081-198106000-00008; Fulurija A, 1996, MICROBIOL-SGM, V142, P3487, DOI 10.1099/13500872-142-12-3487; HOBBS JR, 1977, P ROY SOC MED, V70, P11, DOI 10.1177/00359157770700S404; HURLEY R, 1977, P ROY SOC MED, V70, P1; KIRKPATRICK CH, 1989, EUR J CLIN MICROBIOL, V8, P448, DOI 10.1007/BF01964059; KUDELKO NM, 1971, ANN ALLERGY, V29, P266; LEE WM, 1986, AM J MED SCI, V292, P47, DOI 10.1097/00000441-198607000-00010; Lilic D, 1996, CLIN EXP IMMUNOL, V105, P205, DOI 10.1046/j.1365-2249.1996.d01-764.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALEFYT RD, 1991, J EXP MED, V174, P915; Moraes PSA, 1998, ANN ALLERG ASTHMA IM, V81, P165, DOI 10.1016/S1081-1206(10)62804-9; MORTON RS, 1977, P ROY SOC MED, V70, P3, DOI 10.1177/00359157770700S402; ODDS FC, 1979, CANDIDA CANDIDOSIS, P104; PALACIOS HJ, 1976, ANN ALLERGY, V37, P110; PUCCETTI P, 1995, TRENDS MICROBIOL, V3, P237, DOI 10.1016/S0966-842X(00)88931-3; ROMANI L, 1992, J EXP MED, V176, P19, DOI 10.1084/jem.176.1.19; ROMANI L, 1994, J IMMUNOL, V152, P3514; ROMANI L, 1993, J IMMUNOL, V150, P925; Sobel J D, 1988, Ann N Y Acad Sci, V544, P547, DOI 10.1111/j.1749-6632.1988.tb40450.x; SPACCAPELO R, 1995, J IMMUNOL, V155, P1349; VALDIMARSSON H, 1973, CELL IMMUNOL, V6, P348, DOI 10.1016/0008-8749(73)90035-X; WITKIN SS, 1989, J MED VET MYCOL, V27, P57; WITKIN SS, 1986, AM J OBSTET GYNECOL, V155, P790, DOI 10.1016/S0002-9378(86)80022-9; WITKIN SS, 1986, OBSTET GYNECOL, V68, P696	36	22	27	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2002	109	1					102	105		10.1067/mai.2002.120555	http://dx.doi.org/10.1067/mai.2002.120555			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	519RM	11799373				2022-12-18	WOS:000173739300016
J	Warrington, AE; Bieber, AJ; Ciric, B; Van Keulen, V; Pease, LR; Mitsunaga, Y; Soldan, MMP; Rodriguez, M				Warrington, AE; Bieber, AJ; Ciric, B; Van Keulen, V; Pease, LR; Mitsunaga, Y; Soldan, MMP; Rodriguez, M			Immunoglobulin-mediated CNS repair	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	IVIG Advisory Meeting	OCT 26-29, 2000	SANTA BARBARA, CALIFORNIA	Bayer Biol		IVIG; remyelination; demyelination; immunoglobulin; oligodendrocyte; Theiler's virus; multiple sclerosis; autoimmune response	CENTRAL-NERVOUS-SYSTEM; MULTIPLE-SCLEROSIS; SPINAL-CORD; AXON REGENERATION; REMYELINATION; MODEL; AUTOANTIBODIES; ANTIBODIES; THERAPY; DISEASE	Our view of the immune system continues to evolve from a system dedicated primarily to defense against pathogens to a system that monitors the integrity of the organism and aids in repair following damage. Repair following injury to the central nervous system (CNS) is facilitated by both cellular and Immoral components of the immune system Transfer of macrophages or T cells activated against CNS antigens promote axon regrowth and protect axons from further damage. Animals immunized with spinal cord antigens and subsequently challenged with demyelination or transection of the spinal cord demonstrate better repair than animals without prior immunization. In both experimental systems, antibodies are the biologically active immune component. Human mAbs reactive to oligodendrocytes that arise in the absence of neurologic injury promote remyelination. These data support the hypothesis that B-cell clones producing mAbs reactive to CNS epitopes are a normal part of the human antibody repertoire. They challenge the assertion that an immune response to CNS antigens is pathogenic. Treatment with CNS-reactive human mAbs following CNS disease may facilitate CNS regeneration.	Mayo Clin & Mayo Grad Sch Med, Dept Neurol, Rochester, MN 55905 USA; Mayo Clin & Mayo Grad Sch Med, Dept Immunol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Warrington, AE (corresponding author), Mayo Clin & Mayo Grad Sch Med, Dept Neurol, Rochester, MN 55905 USA.			Rodriguez, Moses/0000-0001-6328-6497; Paz Soldan, M. Mateo/0000-0003-0521-7789	NINDS NIH HHS [NS24180] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024180] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Asakura K, 1998, J NEUROSCI, V18, P7700; Bansal R, 1999, J NEUROSCI, V19, P7913; Chen MS, 2000, NATURE, V403, P434, DOI 10.1038/35000219; Cohen IR, 1999, J NEUROIMMUNOL, V100, P111, DOI 10.1016/S0165-5728(99)00190-3; Dalakas MC, 1997, ANN INTERN MED, V126, P721, DOI 10.7326/0003-4819-126-9-199705010-00008; Dawson MRL, 2000, J NEUROSCI RES, V61, P471, DOI 10.1002/1097-4547(20000901)61:5<471::AID-JNR1>3.0.CO;2-N; Filbin MT, 2000, CURR BIOL, V10, pR100, DOI 10.1016/S0960-9822(00)00302-X; FRAZEKAS F, 1999, INT MSJ, V6, P15; Huang DW, 1999, NEURON, V24, P639, DOI 10.1016/S0896-6273(00)81118-6; Hurez V, 1997, BLOOD, V90, P4004, DOI 10.1182/blood.V90.10.4004; Kasahara K, 2000, J BIOL CHEM, V275, P34701, DOI 10.1074/jbc.M003163200; Kuhlmann T, 1999, NEUROSCI LETT, V275, P191, DOI 10.1016/S0304-3940(99)00782-X; LINNINGTON C, 1992, J NEUROIMMUNOL EXP N, V40, P219; MILLER DJ, 1994, J NEUROSCI, V14, P6230; Noseworthy JH, 2000, NEW ENGL J MED, V343, P938, DOI 10.1056/NEJM200009283431307; PRINEAS JW, 1993, ANN NEUROL, V33, P137, DOI 10.1002/ana.410330203; RODRIGUEZ M, 1987, CRIT REV IMMUNOL, V7, P325; RODRIGUEZ M, 1987, J NEUROPATH EXP NEUR, V46, P84, DOI 10.1097/00005072-198701000-00008; Schwartz M, 1999, TRENDS NEUROSCI, V22, P295, DOI 10.1016/S0166-2236(99)01405-8; Stangel M, 2000, J NEUROIMMUNOL, V103, P195, DOI 10.1016/S0165-5728(99)00241-6; Steinman L, 1999, NEURON, V24, P511, DOI 10.1016/S0896-6273(00)81107-1; Warrington AE, 2000, P NATL ACAD SCI USA, V97, P6820, DOI 10.1073/pnas.97.12.6820	22	22	26	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2001	108	4		S			S121	S125		10.1067/mai.2001.118301	http://dx.doi.org/10.1067/mai.2001.118301			5	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	487KL	11586279				2022-12-18	WOS:000171874200009
J	Kumar, M; Behera, AK; Hu, JN; Lockey, RF; Mohapatra, SS				Kumar, M; Behera, AK; Hu, JN; Lockey, RF; Mohapatra, SS			IFN-gamma and IL-12 plasmid DNAs as vaccine adjuvant in a murine model of grass allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergen; adjuvant; cytokines; plasmids; T(H)1; T(H)2; inflammation; airway hyperresponsiveness	INDUCED AIRWAY HYPERRESPONSIVENESS; INTERFERON-GAMMA; T-CELLS; SENSITIZED MICE; GENE DELIVERY; INFLAMMATION; EXPRESSION; ACTIVATION; RESPONSES	Background: Plasmids encoding cytokines such as IFN-gamma and IL-12 are potential genetic adjuvants that might increase the effectiveness of allergen vaccines. Objective: The role of plasmids expressing the cytokines IFN-gamma (pIFN-gamma) and/or IL-12 (pIL-12) as adjuvants in modulating allergic immune responses, inflammation, and asthma was investigated in a murine model of Kentucky blue grass (KBG) allergy. Methods: Groups of naive B6D2F1 mice were vaccinated subcutaneously with KBG allergens and administered intramuscularly with pIFN-gamma, pIL-12, pIFN-gamma plus pIL-12, or a vector control. Mice were then sensitized with KBG allergens in alum (intraperitoneally) and later challenged intranasally. Mice were examined for modulation or specific immunity, prevention of the development of airway hyperresponsiveness, and inflammation. Results: Mice vaccinated with cytokine plasmid adjuvants had relatively lower levels of total serum IgE and higher levels of grass allergen-specific IgG2a in comparison with control mice. The lowest IgE and highest IgG2a levels were found in mice vaccinated with the combination of pIFN-gamma and pIL-12 as an adjuvant. The vaccination of mice with both pIFN-gamma and pIL-12 as an adjuvant induced the highest level of T(H)1 cytokines, IFN-gamma, and IL-2 in comparison with mice given either of the plasmids alone. The most profound decrease in airway hyperresponsiveness and pulmonary inflammation was observed in mice receiving both pIFN-gamma and pIL-12 as an adjuvant. Conclusion: These results demonstrate that pIFN-gamma and pIL-12 together provide an effective adjuvant to parenteral grass allergen vaccines and show that this adjuvant can significantly enhance the effectiveness of allergen immunotherapy in human beings.	Univ S Florida, Coll Med, Dept Internal Med,Div Allergy & Immunol, Joy McCann Culverhouse Airway Dis Ctr, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Med Microbiol & Immunol, Tampa, FL 33612 USA; VA Hosp, Tampa, FL USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Mohapatra, SS (corresponding author), Univ S Florida, Coll Med, Dept Internal Med,Div Allergy & Immunol, Joy McCann Culverhouse Airway Dis Ctr, 12901 Bruce B Downs Blvd, Tampa, FL 33612 USA.		Mohapatra, Shyam/C-2500-2012					Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; Bradley LM, 1996, J IMMUNOL, V157, P1350; Brusselle GG, 1997, AM J RESP CELL MOL, V17, P767, DOI 10.1165/ajrcmb.17.6.2820; Cao Y, 1997, IMMUNOLOGY, V90, P46, DOI 10.1046/j.1365-2567.1997.00132.x; Dow SW, 1999, HUM GENE THER, V10, P1905, DOI 10.1089/10430349950017266; GAVETT SH, 1995, J EXP MED, V182, P1527, DOI 10.1084/jem.182.5.1527; Hacker H, 1998, EMBO J, V17, P6230, DOI 10.1093/emboj/17.21.6230; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Hogan SP, 1998, EUR J IMMUNOL, V28, P413; Horner AA, 2000, J ALLERGY CLIN IMMUN, V106, P349, DOI 10.1067/mai.2000.107933; IWAMOTO I, 1993, J EXP MED, V177, P573, DOI 10.1084/jem.177.2.573; Kemp SF, 2000, IMMUNOL ALLERGY CLIN, V20, P571, DOI 10.1016/S0889-8561(05)70167-3; Kips JC, 1996, AM J RESP CRIT CARE, V153, P535, DOI 10.1164/ajrccm.153.2.8564093; Krieg AM, 1998, P NATL ACAD SCI USA, V95, P12631, DOI 10.1073/pnas.95.21.12631; Kumar M, 1999, VACCINE, V18, P558, DOI 10.1016/S0264-410X(99)00185-1; Li XM, 1996, J IMMUNOL, V157, P3216; Maecker HT, 2001, J IMMUNOL, V166, P959, DOI 10.4049/jimmunol.166.2.959; Matsuse H, 2000, J IMMUNOL, V164, P6583, DOI 10.4049/jimmunol.164.12.6583; MOHAPATRA SS, 1995, SCIENCE, V269, P1499, DOI 10.1126/science.7667628; Mohapatra SS, 2000, IMMUNOL ALLERGY CLIN, V20, P625, DOI 10.1016/S0889-8561(05)70170-3; Parronchi P, 1996, EUR J IMMUNOL, V26, P697, DOI 10.1002/eji.1830260328; Pasquini S, 1997, IMMUNOL CELL BIOL, V75, P397, DOI 10.1038/icb.1997.62; Peng ZK, 2001, INT IMMUNOL, V13, P3, DOI 10.1093/intimm/13.1.3; Roman M, 1997, NAT MED, V3, P849, DOI 10.1038/nm0897-849; Schwarze J, 1998, J ALLERGY CLIN IMMUN, V102, P86, DOI 10.1016/S0091-6749(98)70058-2; Sur S, 1996, J IMMUNOL, V157, P4173; Wenner CA, 1996, J IMMUNOL, V156, P1442; Wu CY, 2000, EUR J IMMUNOL, V30, P1364, DOI 10.1002/(SICI)1521-4141(200005)30:5<1364::AID-IMMU1364>3.0.CO;2-U; Yoshimoto T, 1997, P NATL ACAD SCI USA, V94, P3948, DOI 10.1073/pnas.94.8.3948	29	22	26	0	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2001	108	3					402	408		10.1067/mai.2001.117261	http://dx.doi.org/10.1067/mai.2001.117261			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	476FK	11544460	Bronze			2022-12-18	WOS:000171215400012
J	Frew, AJ; Plummeridge, MJ				Frew, AJ; Plummeridge, MJ			Alternative agents in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						asthma; asthma therapy; steroids; steroid-sparing agents	STEROID-DEPENDENT ASTHMA; DOSE INTRAVENOUS IMMUNOGLOBULIN; COLONY-STIMULATING FACTOR; MESSENGER-RNA EXPRESSION; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; AIRWAY INFLAMMATION; CYCLOSPORINE-A; FLUTICASONE PROPIONATE; ADHESION MOLECULE-1	Glucocorticosteroids are the backbone of asthma therapy and are administered mainly by the inhaled route. Patients with "difficult" asthma are not a single homogeneous group. Some are stable on high-dose steroid therapy but experience unacceptable side effects; others remain unstable despite receiving high doses of inhaled or oral steroids. Several different steroid-sparing and alternative agents have been tried, with varying degrees of success. Some success has been achieved with conventional immunosuppressants such as methotrexate, gold, and cyclosporin A, but these agents can be justified only in a limited range of cases. Leukotriene receptor antagonists have proved a useful addition to asthma therapy and have been shown to have a modest steroid-sparing effect. Although existing range of alternative agents has not proved to be particularly effective, several new therapeutic agents have been developed to target specific components of the inflammatory process in asthma. These include IgE antibodies, cytokines, chemokines, and vascular adhesion molecules. Future developments might include better forms of immunotherapy and strategies targeting the remodeling of structural elements of the airways.	Univ Southampton, Sch Med, Dept Med Specialties, Southampton, Hants, England; Frenchay Hosp, Dept Resp Med, Bristol BS16 1LE, Avon, England	University of Southampton	Frew, AJ (corresponding author), Southampton Gen Hosp, Mailpoint 810, Southampton SO16 6YD, Hants, England.		Kelly, Frank J/C-6125-2009	Kelly, Frank J/0000-0003-2558-8392				Aaron SD, 1998, RESP MED, V92, P1059, DOI 10.1016/S0954-6111(98)90355-9; Abramson M, 1999, ALLERGY, V54, P1022, DOI 10.1034/j.1398-9995.1999.00102.x; ALEXANDER AG, 1992, LANCET, V339, P324, DOI 10.1016/0140-6736(92)91646-P; ALLEN DB, 1994, J ALLERGY CLIN IMMUN, V93, P967, DOI 10.1016/S0091-6749(94)70043-5; BARNES NC, 1993, EUR RESPIR J, V6, P877; Barnes PJ, 1996, NEW ENGL J MED, V334, P531, DOI 10.1056/NEJM199602223340811; Bateman ED, 1995, ALLERGY S26, V50, P320; BERLOW BA, 1991, J ALLERGY CLIN IMMUN, V87, P710, DOI 10.1016/0091-6749(91)90393-3; Bernstein DI, 1999, RESP MED, V93, P603, DOI 10.1016/S0954-6111(99)90099-9; Bernstein IL, 1996, J ALLERGY CLIN IMMUN, V98, P317, DOI 10.1016/S0091-6749(96)70156-2; BOGUNIEWICZ M, 1993, CLIN EXP ALLERGY, V23, P785, DOI 10.1111/j.1365-2222.1993.tb00367.x; BORDLEY JE, 1949, B JOHNS HOPKINS HOSP, V85, P396; Borish LC, 1999, AM J RESP CRIT CARE, V160, P1816, DOI 10.1164/ajrccm.160.6.9808146; Boulet LP, 1997, AM J RESP CRIT CARE, V155, P1835, DOI 10.1164/ajrccm.155.6.9196083; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720, DOI 10.1164/ajrccm.161.5.9903102; Bryan SA, 2000, LANCET, V356, P2149, DOI 10.1016/S0140-6736(00)03497-8; Charous BL, 1998, J ALLERGY CLIN IMMUN, V102, P198, DOI 10.1016/S0091-6749(98)70086-7; Chen SH, 1998, J EXP MED, V188, P193, DOI 10.1084/jem.188.1.193; COFFEY MJ, 1994, CHEST, V105, P117, DOI 10.1378/chest.105.1.117; DURHAM SR, 1992, J IMMUNOL, V148, P2390; DYER PD, 1991, J ALLERGY CLIN IMMUN, V88, P208, DOI 10.1016/0091-6749(91)90330-Q; Erb KJ, 1998, J EXP MED, V187, P561, DOI 10.1084/jem.187.4.561; ERZURUM SC, 1991, ANN INTERN MED, V114, P353, DOI 10.7326/0003-4819-114-5-353; Fahy JV, 1997, AM J RESP CRIT CARE, V155, P1828, DOI 10.1164/ajrccm.155.6.9196082; Gonzalo JA, 1998, J EXP MED, V188, P157, DOI 10.1084/jem.188.1.157; GUNDEL RH, 1991, J CLIN INVEST, V88, P1407, DOI 10.1172/JCI115447; Hamelmann E, 1999, AM J RESP CRIT CARE, V160, P934, DOI 10.1164/ajrccm.160.3.9806029; Hamelmann E, 1999, AM J RESP CELL MOL, V21, P480, DOI 10.1165/ajrcmb.21.4.3659; Hedman J, 1996, EUR J CLIN PHARMACOL, V49, P347, DOI 10.1007/BF00203775; HODGES NG, 1971, THORAX, V26, P734, DOI 10.1136/thx.26.6.734; IND PW, 2000, EUR RESPIR REV, V10, P2; Iwamoto I, 1996, AM J RESP CRIT CARE, V154, P1257, DOI 10.1164/ajrccm.154.5.8912732; JAKOBSSON T, 1994, ALLERGY, V49, P413, DOI 10.1111/j.1398-9995.1994.tb00833.x; Khan LN, 2000, AM J RESP CRIT CARE, V162, P1377, DOI 10.1164/ajrccm.162.4.9911117; Kishiyama JL, 1999, CLIN IMMUNOL, V91, P126, DOI 10.1006/clim.1999.4714; KLAUSTERMEYER WB, 1987, J ALLERGY CLIN IMMUN, V79, P720, DOI 10.1016/0091-6749(87)90202-8; Kline JN, 1998, J IMMUNOL, V160, P2555; LACRONIQUE J, 1991, EUR RESPIR J, V4, P807; Laviolette M, 1999, AM J RESP CRIT CARE, V160, P1862, DOI 10.1164/ajrccm.160.6.9803042; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Lock SH, 1996, AM J RESP CRIT CARE, V153, P509, DOI 10.1164/ajrccm.153.2.8564089; LOFDAHL CG, 1999, BMJ-BRIT MED J, V319, P1; Marin MG, 1997, CHEST, V112, P29, DOI 10.1378/chest.112.1.29; MAUSER PJ, 1993, AM REV RESPIR DIS, V148, P1623, DOI 10.1164/ajrccm/148.6_Pt_1.1623; MAUSER PJ, 1995, AM J RESP CRIT CARE, V152, P467, DOI 10.1164/ajrccm.152.2.7633694; MAZER BD, 1991, J ALLERGY CLIN IMMUN, V87, P976, DOI 10.1016/0091-6749(91)90420-S; Milgrom H, 1999, NEW ENGL J MED, V341, P1966, DOI 10.1056/NEJM199912233412603; *MRC, 1979, BR J DIS CHEST, V73, P121; MULLARKEY MF, 1988, NEW ENGL J MED, V318, P603, DOI 10.1056/NEJM198803103181004; NELSON HS, 1993, AM REV RESPIR DIS, V147, P398, DOI 10.1164/ajrccm/147.2.398; Newman KB, 1997, J ALLERGY CLIN IMMUN, V99, P176, DOI 10.1016/S0091-6749(97)70092-7; Nickel R, 1999, J ALLERGY CLIN IMMUN, V104, P723, DOI 10.1016/S0091-6749(99)70281-2; NIEROP G, 1992, THORAX, V47, P349, DOI 10.1136/thx.47.5.349; NIZANKOWSKA E, 1995, EUR RESPIR J, V8, P1091, DOI 10.1183/09031936.95.08071091; OGIRALA RG, 1995, AM J RESP CRIT CARE, V152, P1461, DOI 10.1164/ajrccm.152.5.7582277; Roberts J A, 1988, Pulm Pharmacol, V1, P59, DOI 10.1016/0952-0600(88)90012-9; Robinson DS, 1996, AM J RESP CELL MOL, V14, P113, DOI 10.1165/ajrcmb.14.2.8630259; Salmun LM, 1999, J ALLERGY CLIN IMMUN, V103, P810, DOI 10.1016/S0091-6749(99)70424-0; SCHWARZ YA, 1990, J ALLERGY CLIN IMMUN, V85, P578, DOI 10.1016/0091-6749(90)90096-M; Shi HZ, 1998, AM J RESP CRIT CARE, V157, P1818, DOI 10.1164/ajrccm.157.6.9710023; Shi HZ, 1999, J ALLERGY CLIN IMMUN, V103, P463, DOI 10.1016/S0091-6749(99)70472-0; SHINER RJ, 1994, ALLERGY, V49, P565, DOI 10.1111/j.1398-9995.1994.tb01130.x; SHINER RJ, 1990, LANCET, V336, P137, DOI 10.1016/0140-6736(90)91659-X; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; Sihra BS, 1997, THORAX, V52, P447, DOI 10.1136/thx.52.5.447; Silverstein MD, 1997, J ALLERGY CLIN IMMUN, V99, P466, DOI 10.1016/S0091-6749(97)70072-1; SMITH MJ, 1983, LANCET, V1, P265, DOI 10.1016/S0140-6736(83)91686-0; Spahn JD, 1999, J ALLERGY CLIN IMMUN, V103, P421, DOI 10.1016/S0091-6749(99)70466-5; SPECTOR SL, 1974, J ALLERGY CLIN IMMUN, V54, P367, DOI 10.1016/0091-6749(74)90027-X; STEWART GE, 1994, J ALLERGY CLIN IMMUN, V94, P482, DOI 10.1016/0091-6749(94)90204-6; Strannegard IL, 1998, ALLERGY, V53, P249, DOI 10.1111/j.1398-9995.1998.tb03884.x; Sur S, 1999, J IMMUNOL, V162, P6284; SZEFLER SJ, 1982, CLIN PHARMACOL THER, V32, P166, DOI 10.1038/clpt.1982.143; Tamaoki J, 1997, AM J RESP CRIT CARE, V155, P1235, DOI 10.1164/ajrccm.155.4.9105060; TRIGG CJ, 1993, RESP MED, V87, P211, DOI 10.1016/0954-6111(93)90094-G; Virchow JC, 2000, AM J RESP CRIT CARE, V162, P578; Vrugt B, 2000, EUR RESPIR J, V15, P478, DOI 10.1034/j.1399-3003.2000.15.09.x; Vrugt B, 1997, THORAX, V52, P662, DOI 10.1136/thx.52.7.662; Walker SM, 2001, J ALLERGY CLIN IMMUN, V107, P87, DOI 10.1067/mai.2001.112027; Wechsler ME, 1998, JAMA-J AM MED ASSOC, V279, P455, DOI 10.1001/jama.279.6.455; WEGNER CD, 1990, SCIENCE, V247, P456, DOI 10.1126/science.1967851; WOLTHERS OD, 1993, ARCH DIS CHILD, V68, P673, DOI 10.1136/adc.68.5.673	82	22	23	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2001	108	1					3	10		10.1067/mai.2001.115758	http://dx.doi.org/10.1067/mai.2001.115758			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	458AN	11447376				2022-12-18	WOS:000170171200001
J	Asmus, MJ; Barros, MD; Liang, J; Chesrown, SE; Hendeles, L				Asmus, MJ; Barros, MD; Liang, J; Chesrown, SE; Hendeles, L			Pulmonary function response to EDTA, an additive in nebulized bronchodilators	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						EDTA; benzalkonium compounds; albuterol	BENZALKONIUM CHLORIDE; IPRATROPIUM BROMIDE; PRESERVATIVES; CALCIUM; RISKS	Background: Some nebulized bronchodilator solutions contain additives, such as EDTA, benzalkonium chloride (BAC), or bath. Objective: Although BAG-induced bronchoconstriction has been well documented in patients with asthma, there is no information on the effects of EDTA on FEV1 when inhaled in the amounts that would be administered during emergency department treatment of asthma, Methods: Eighteen subjects with stable asthma and airway responsiveness to methacholine were randomly assigned to inhale up to four 600-mug nebulized doses of EDTA, BAC (positive control), and normal saline (placebo) in a double-blind crossover manner on separate days. FEV1 was measured 15 minutes after each dose. Treatments were repeated every 20 minutes until FEV1 decreased by 20% or greater or a maximum of 4 doses were administered. Results: Mean +/- SD maximum percent decrease in FEV1 was 1.8% +/- 5.8% after EDTA, 16.6% +/- 13.9% after BAG, and 3.6% +/- 8.2% after placebo (P <.001); there was no significant difference between EDTA and placebo. Conclusion: The amount of EDTA contained in maximum recommended doses of nebulized bronchodilators does not induce bronchospasm. In contrast, BAC induces clinically important bronchospasm, which could decrease the efficacy of a bronchodilator during an emergency.	Univ Florida, Hlth Sci Ctr, Coll Pharm, Dept Pharm Practice,Asthma Res Lab, Gainesville, FL 32610 USA; Univ Florida, Hlth Sci Ctr, Coll Med, Div Pediat Pulm, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Asmus, MJ (corresponding author), Univ Florida, Hlth Sci Ctr, Coll Pharm, Dept Pharm Practice,Asthma Res Lab, Box 100486, Gainesville, FL 32610 USA.		Asmus, Michael J/U-8654-2019	Asmus, Michael J/0000-0002-5939-7802				[Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; Asmus MJ, 1999, J ALLERGY CLIN IMMUN, V104, pS53, DOI 10.1016/S0091-6749(99)70274-5; BEASLEY CRW, 1987, BRIT MED J, V294, P1197, DOI 10.1136/bmj.294.6581.1197-a; Beasley R, 1998, PHARMACOTHERAPY, V18, P130; Beasley R, 1999, PHARMACOTHERAPY, V19, P473, DOI 10.1592/phco.19.6.473.31043; BOUCHER M, 1992, ANN PHARMACOTHER, V26, P772, DOI 10.1177/106002809202600604; CRAPO RO, 1981, AM REV RESPIR DIS, V123, P659; DOWNES H, 1983, J APPL PHYSIOL, V55, P1496, DOI 10.1152/jappl.1983.55.5.1496; DOWNES H, 1985, J APPL PHYSIOL, V59, P92, DOI 10.1152/jappl.1985.59.1.92; KWONG T, 1990, NEW ZEAL MED J, V103, P457; LINDEMAN KS, 1991, J APPL PHYSIOL, V71, P1848, DOI 10.1152/jappl.1991.71.5.1848; MENENDEZ R, 1989, J ALLERGY CLIN IMMUN, V84, P272, DOI 10.1016/0091-6749(89)90336-9; MISZKIEL KA, 1988, BRIT J CLIN PHARMACO, V26, P295, DOI 10.1111/j.1365-2125.1988.tb05280.x; *NAT ASTHM ED PREV, 1997, NIH PUBL; Prince SJ, 1999, J PHARMACEUT BIOMED, V19, P877, DOI 10.1016/S0731-7085(98)00187-3; READ GW, 1979, J PHARMACOL EXP THER, V211, P711; Rosenthal RR, 1995, PROVOCATION TESTING, P215; ZHANG YG, 1990, AM REV RESPIR DIS, V141, P1405, DOI 10.1164/ajrccm/141.6.1405	18	22	31	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2001	107	1					68	72		10.1067/mai.2001.111591	http://dx.doi.org/10.1067/mai.2001.111591			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	394PW	11149993				2022-12-18	WOS:000166533300012
J	Gosset, P; Lamblin-Degros, C; Tillie-Leblond, I; Charbonnier, AS; Joseph, M; Wallaert, B; Kochan, JP; Tonnel, AB				Gosset, P; Lamblin-Degros, C; Tillie-Leblond, I; Charbonnier, AS; Joseph, M; Wallaert, B; Kochan, JP; Tonnel, AB			Modulation of high-affinity IgE receptor expression in blood monocytes: Opposite effect of IL-4 and glucocorticoids	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						monocyte; IgE receptor; IL-4; GM-CSF; corticoid; asthma; allergy	FC-EPSILON-RI; HUMAN MAST-CELLS; MONONUCLEAR PHAGOCYTES; INFLAMMATORY MEDIATORS; TRANSCRIPTION FACTORS; ALPHA; EOSINOPHILS; ASTHMA; GENE; CD23	Background: The expression of high-affinity IgE receptor (Fc epsilon RI) is increased in blood monocytes (BMs) from allergic patients compared with those of nonatopic subjects (NASs). Objective: We investigated the in vitro effect of cytokines involved in allergic diseases on the modulation of Fc epsilon RI expression in BMs from allergic asthmatic patients (AAPs) and NASs. The influence of in vitro and in vivo treatments with glucocorticoids (GCs) was also assessed. Methods: Fc epsilon RI alpha -chain expression on BMs evaluated by flow cytometry analysis was studied ex vivo in AAPs treated or not with GCs and in NASs. IgE receptor expression was also evaluated in vitro with or without stimulation by IL-4, IL-13, GM-CSF, and/or GCs, Messenger (m)RNA expression was also analyzed with RT-PCR. Results: The expression of the Fc epsilon RI alpha chain was significantly increased in BMs from untreated patients, with AAPs compared with NASs (P < .05). In steroid-treated AAPs Fc<epsilon>RI alpha -chain expression returned to the level found in BMs from NASs. In vitro addition of IL-1 induced a dose-dependent increase in Fc epsilon RI alpha -chain expression on BMs from NASs, and this effect was significantly enhanced with BMs from AAPs. Fc epsilon RI alpha -chain mRNA was significantly upregulated by IL-1, whereas the beta chain was always undetectable. The gamma chain was not modulated by IL-4. Similar findings were obtained with IL-13. In contrast with CDU expression, GM-CSF alone or in coincubation with IL-4 had no effect on Fc epsilon RI alpha -chain expression in BMs. Lastly, GCs significantly inhibited in vitro the IL-4-induced Fc epsilon RI alpha -chain expression (P < .05). Conclusion: Two different pathways by which Fc<epsilon>RI alpha -chain expression was modulated in BMs were identified: (1) the enhancing effect of IL-4 and IL-13 and (2) the inhibitory effect of GCs. Modulation of Fc epsilon RI alpha -chain expression on BMs may affect their capacity to regulate allergic inflammation.	Inst Pasteur, INSERM, U416, F-59019 Lille, France; CHR, Clin Malad Resp, Lille, France; Hoffmann La Roche Inc, Nutley, NJ 07110 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille - ISITE; CHU Lille; Roche Holding	Gosset, P (corresponding author), Inst Pasteur, INSERM, U416, BP 245, F-59019 Lille, France.		Gosset, Philippe/C-6174-2018	Gosset, Philippe/0000-0002-4043-6429				Barnes PJ, 1998, CLIN SCI, V94, P557, DOI 10.1042/cs0940557; Barnes PJ, 1998, PHARMACOL REV, V50, P515; BORISH L, 1991, J IMMUNOL, V146, P63; Braun CM, 1997, J ALLERGY CLIN IMMUN, V100, P400, DOI 10.1016/S0091-6749(97)70255-0; Chung KF, 1999, THORAX, V54, P825, DOI 10.1136/thx.54.9.825; ELLIOTT MJ, 1989, BLOOD, V74, P2349; ESPINAS ML, 1994, MOL CELL BIOL, V14, P4116, DOI 10.1128/MCB.14.6.4116; GOSSET P, 1992, AM REV RESPIR DIS, V146, P768, DOI 10.1164/ajrccm/146.3.768; Gosset P, 1999, J ALLERGY CLIN IMMUN, V103, P289, DOI 10.1016/S0091-6749(99)70504-X; GOUNNI AS, 1994, J ALLERGY CLIN IMMUN, V94, P1214, DOI 10.1016/0091-6749(94)90334-4; GOUNNI AS, 1994, NATURE, V367, P183, DOI 10.1038/367183a0; Humbert M, 1996, AM J RESP CRIT CARE, V153, P1931, DOI 10.1164/ajrccm.153.6.8665058; Joseph M, 1997, EUR J IMMUNOL, V27, P2212, DOI 10.1002/eji.1830270914; KOCHAN J, 1988, NUCLEIC ACIDS RES, V16, P3584, DOI 10.1093/nar/16.8.3584; KOHLER I, 1993, EUR J IMMUNOL, V23, P3066, DOI 10.1002/eji.1830231204; MacGlashan D, 1999, J ALLERGY CLIN IMMUN, V104, P492, DOI 10.1016/S0091-6749(99)70399-4; Marquardt DL, 2000, J ALLERGY CLIN IMMUN, V105, P500, DOI 10.1067/mai.2000.104942; Marshall LA, 1998, J IMMUNOL, V161, P6005; MAURER D, 1995, J IMMUNOL, V154, P6285; MAURER D, 1994, J EXP MED, V179, P745, DOI 10.1084/jem.179.2.745; MOSSALAYI MD, 1994, INT IMMUNOL, V6, P931, DOI 10.1093/intimm/6.7.931; Mozo L, 1998, J ALLERGY CLIN IMMUN, V102, P968, DOI 10.1016/S0091-6749(98)70335-5; NARAYFEJESTOTH A, 1985, IMMUNOLOGY, V56, P359; *NHLBI, 1995, LNHLBI WHO PUBL; Nishiyama C, 1999, J IMMUNOL, V163, P623; Palis J, 1999, DEVELOPMENT, V126, P5073; PAULEUGENE N, 1992, J IMMUNOL, V149, P3066; Profita M, 1999, J ALLERGY CLIN IMMUN, V103, P159, DOI 10.1016/S0091-6749(99)70540-3; Reischl IG, 1996, CLIN EXP ALLERGY, V26, P630, DOI 10.1046/j.1365-2222.1996.1047408.x; Ross IL, 1998, J BIOL CHEM, V273, P6662, DOI 10.1074/jbc.273.12.6662; TAKENAKA M, 1995, INT ARCH ALLERGY IMM, V108, P247, DOI 10.1159/000237160; Terada N, 1995, J ALLERGY CLIN IMMUN, V96, P1161, DOI 10.1016/S0091-6749(95)70201-6; Toru H, 1996, INT IMMUNOL, V8, P1367; Turner H, 1999, NATURE, V402, pB24, DOI 10.1038/35037021; van den Heuvel MM, 1998, J ALLERGY CLIN IMMUN, V101, P90, DOI 10.1016/S0091-6749(98)70198-8; WANG B, 1992, J EXP MED, V175, P1353, DOI 10.1084/jem.175.5.1353; Xia HZ, 1997, J IMMUNOL, V159, P2911	37	22	22	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2001	107	1					114	122		10.1067/mai.2001.111126	http://dx.doi.org/10.1067/mai.2001.111126			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	394PW	11150000				2022-12-18	WOS:000166533300020
J	Marone, G; Florio, G; Petraroli, A; de Paulis, A				Marone, G; Florio, G; Petraroli, A; de Paulis, A			Dysregulation of the IgE/Fc epsilon RI network in HIV-1 infection	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						AIDS; basophils; CCR3; chemokine; HIV-1; IL-4; IL-13; mast cells; Tat	HUMAN-IMMUNODEFICIENCY-VIRUS; HUMAN MAST-CELLS; CYTOKINE PRODUCTION; TAT PROTEIN; PERIPHERAL-BLOOD; SYNDROME MAIDS; T-CELLS; IL-4; DISEASE; EXPRESSION	Serum IgE levels are increased in adults and children with HIV-1 infection and could be a marker of poor prognosis. Allergic reactions and adverse reactions to drugs are also increased in HIV-1-infected individuals.,in imbalance between a T(H)1-like and a T(H)2-like cytokine profile has been documented in HIV-1 infection. we have found that HIV-1 gp120 from different clades is a potent stimulus for histamine and cytokine (IL-4 and IL-13) release from basophils. Gp120 acts as a viral superantigen, interacting with the V(H)3 region of IgE to induce mediator release from human Fc epsilon RI+ cells. Human basophils and mast cells express the chemokine receptor CCR3, which binds the chemokines eotaxin and RANTES. By interacting with the CCR3 receptor on Fc epsilon RI+ cells, HIV-1 Tat protein is a potent chemoattractant for human basophils and lung mast cells. Tat protein also induced IL-4 and IL-13 release from basophils, Preincubation of basophils with Tat protein upregulated the surface expression of the CCR3 receptor. Extracellular Tat can influence the directional migration of human Fc epsilon RI+ cells, the expression of chemokine receptor CCR3, and the release of T(H)2 cytokines, Because Tat protein is actively released by HIV-l-infected cells, our results indicate a novel mechanism by which Fc epsilon RI+ cells are rendered more susceptible to infection with CCR3-tropic HIV-1 isolates; that is, two HIV-1 proteins, gp120 and Tat, trigger the release of cytokines critical for T(H)2 polarization from Fc epsilon RI+ cells, and Tat upregulates beta -chemokine receptor CCR3 on these cells.	Univ Naples Federico II, Div Clin Immunol & Allergy, I-80131 Naples, Italy	University of Naples Federico II	Marone, G (corresponding author), Univ Naples Federico II, Div Clin Immunol & Allergy, Via S Pansini 5, I-80131 Naples, Italy.							Agarwal SK, 1998, HUM IMMUNOL, V59, P99, DOI 10.1016/S0198-8859(97)00261-9; Albini A, 1998, P NATL ACAD SCI USA, V95, P13153, DOI 10.1073/pnas.95.22.13153; Andrew DP, 1998, J IMMUNOL, V161, P5027; BARCELLINI W, 1994, AIDS, V8, P757, DOI 10.1097/00002030-199406000-00006; Beasley R, 2000, J ALLERGY CLIN IMMUN, V105, pS466, DOI 10.1016/S0091-6749(00)90044-7; BERBERIAN L, 1993, SCIENCE, V261, P1588, DOI 10.1126/science.7690497; Bonecchi R, 1998, BLOOD, V92, P2668, DOI 10.1182/blood.V92.8.2668.420k39_2668_2671; BRADDING P, 1992, J EXP MED, V176, P1381, DOI 10.1084/jem.176.5.1381; BURD PR, 1995, J EXP MED, V181, P1373, DOI 10.1084/jem.181.4.1373; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; CLERICI M, 1993, IMMUNOL TODAY, V14, P107, DOI 10.1016/0167-5699(93)90208-3; CLERICI M, 1993, J CLIN INVEST, V91, P759, DOI 10.1172/JCI116294; COOPMAN SA, 1993, NEW ENGL J MED, V328, P1670, DOI 10.1056/NEJM199306103282304; de Paulis A, 2000, J IMMUNOL, V165, P7171, DOI 10.4049/jimmunol.165.12.7171; Devouassoux G, 1999, J ALLERGY CLIN IMMUN, V104, P811, DOI 10.1016/S0091-6749(99)70292-7; Empson M, 1999, J ALLERGY CLIN IMMUN, V103, P833, DOI 10.1016/S0091-6749(99)70427-6; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; Fakoya A, 1997, AIDS, V11, P1445, DOI 10.1097/00002030-199712000-00008; Fauci AS, 1999, NEW ENGL J MED, V341, P1046, DOI 10.1056/NEJM199909303411406; Fauci AS, 1996, NATURE, V384, P529, DOI 10.1038/384529a0; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Florio C, 2000, AIDS, V14, P931, DOI 10.1097/00002030-200005260-00004; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; Galli G, 1998, EUR J IMMUNOL, V28, P3280, DOI 10.1002/(SICI)1521-4141(199810)28:10<3280::AID-IMMU3280>3.0.CO;2-M; GAYNOR RB, 1995, CURR TOP MICROBIOL, V193, P51; Genovese A, 2000, INFECT IMMUN, V68, P5517, DOI 10.1128/IAI.68.10.5517-5524.2000; GRAZIOSI C, 1994, SCIENCE, V265, P248, DOI 10.1126/science.8023143; ISRAELBIET D, 1992, J ALLERGY CLIN IMMUN, V89, P68, DOI 10.1016/S0091-6749(05)80042-9; KANAGAWA O, 1993, SCIENCE, V262, P240, DOI 10.1126/science.8211142; KAPLAN MH, 1987, J AM ACAD DERMATOL, V16, P485, DOI 10.1016/S0190-9622(87)70066-8; Karray S, 1997, P NATL ACAD SCI USA, V94, P1356, DOI 10.1073/pnas.94.4.1356; Klein SA, 1997, AIDS, V11, P1111, DOI 10.1097/00002030-199709000-00005; Koutsonikolis A, 1996, J ALLERGY CLIN IMMUN, V97, P692, DOI 10.1016/S0091-6749(96)70316-0; KOVACS JA, 1984, ANN INTERN MED, V100, P663, DOI 10.7326/0003-4819-100-5-663; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; LUCEY DR, 1990, AIDS RES HUM RETROV, V6, P427, DOI 10.1089/aid.1990.6.427; MAGGI E, 1994, SCIENCE, V265, P244, DOI 10.1126/science.8023142; Marone G, 1998, IMMUNOL TODAY, V19, P5, DOI 10.1016/S0167-5699(97)01187-0; Marone G., 2000, MAST CELLS BASOPHILS; Meroni L, 1996, AIDS, V10, P23, DOI 10.1097/00002030-199601000-00004; MEYAARD L, 1994, BLOOD, V84, P4262, DOI 10.1182/blood.V84.12.4262.bloodjournal84124262; MIADONNA A, 1990, CLIN IMMUNOL IMMUNOP, V54, P237, DOI 10.1016/0090-1229(90)90085-5; MORAWETZ RA, 1994, SCIENCE, V265, P264, DOI 10.1126/science.8023146; Patella V, 2000, J IMMUNOL, V164, P589, DOI 10.4049/jimmunol.164.2.589; Patella V, 1998, J IMMUNOL, V161, P5647; PATELLA V, 2000, MAST CELLS BASOPHILS, P397; Pawankar R, 1997, J CLIN INVEST, V99, P1492, DOI 10.1172/JCI119311; PEDERSEN M, 1991, ALLERGY, V46, P206, DOI 10.1111/j.1398-9995.1991.tb00572.x; Penn ML, 1999, P NATL ACAD SCI USA, V96, P663, DOI 10.1073/pnas.96.2.663; Prodeus AP, 1997, NATURE, V390, P172, DOI 10.1038/36586; Rancinan C, 1998, J ALLERGY CLIN IMMUN, V102, P329, DOI 10.1016/S0091-6749(98)70107-1; Romagnani P, 1999, AM J PATHOL, V155, P1195, DOI 10.1016/S0002-9440(10)65222-4; Romagnani S, 2000, J ALLERGY CLIN IMMUN, V105, P399, DOI 10.1067/mai.2000.104575; SCHNITTMAN SM, 1986, SCIENCE, V233, P1084, DOI 10.1126/science.3016902; SHORPOSNER G, 1995, J ALLERGY CLIN IMMUN, V95, P886, DOI 10.1016/S0091-6749(95)70133-8; VIGANO A, 1995, J ALLERGY CLIN IMMUN, V95, P627, DOI 10.1016/S0091-6749(95)70326-8; WRIGHT DN, 1990, J ALLERGY CLIN IMMUN, V85, P445, DOI 10.1016/0091-6749(90)90154-V; Zou W, 1997, AIDS, V11, P533	58	22	22	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2001	107	1					22	30		10.1067/mai.2001.111589	http://dx.doi.org/10.1067/mai.2001.111589			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	394PW	11149986				2022-12-18	WOS:000166533300005
J	Kranke, B; Kern, T				Kranke, B; Kern, T			Multilocalized fixed drug eruption to the antihistamine cetirizine	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									Graz Univ, Dept Dermatol & Venerol, A-8036 Graz, Austria	University of Graz	Kranke, B (corresponding author), Graz Univ, Dept Dermatol & Venerol, Auenbruggerpl 8, A-8036 Graz, Austria.							ALANKO K, 1987, BRIT J DERMATOL, V116, P561, DOI 10.1111/j.1365-2133.1987.tb05879.x; CAO M, 1989, J INVEST DERMATOL, V82, P391; Routledge PA, 1999, CLIN EXP ALLERGY, V29, P240, DOI 10.1046/j.1365-2222.1999.0290s3240.x; Stingeni L, 1997, CONTACT DERMATITIS, V37, P249, DOI 10.1111/j.1600-0536.1997.tb02456.x; WRIGHT S, 1983, BRIT MED J, V287, P463, DOI 10.1136/bmj.287.6390.463	5	22	22	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2000	106	5					988	988						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	417ZK	11080726				2022-12-18	WOS:000167865200028
J	Figueredo, E; Cuesta-Herranz, J; Minguez, A; Vidarte, L; Pastor, C; de las Heras, M; Vivanco, F; Lahoz, C				Figueredo, E; Cuesta-Herranz, J; Minguez, A; Vidarte, L; Pastor, C; de las Heras, M; Vivanco, F; Lahoz, C			Allergy to pumpkin and cross-reactivity to other Cucurbitaceae fruits	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						allergy; cross-reactivity; fruit			Fdn Jimenez Diaz, Serv Alergia, E-28040 Madrid, Spain; Fdn Jimenez Diaz, Serv Immunol, E-28040 Madrid, Spain		Cuesta-Herranz, J (corresponding author), Fdn Jimenez Diaz, Serv Alergia, Avda Reyes Catolicos 2, E-28040 Madrid, Spain.		Pastor Vargas, Carlos/B-4112-2010; Vivanco, Fernando/Q-6866-2016	Pastor Vargas, Carlos/0000-0002-4678-7967; 				ANDERSON LB, 1970, J ALLERGY, V45, P310, DOI 10.1016/0021-8707(70)90037-7; Cuesta-Herranz J, 1999, J ALLERGY CLIN IMMUN, V104, P688, DOI 10.1016/S0091-6749(99)70343-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Martinez A, 1997, ALLERGY, V52, P155, DOI 10.1111/j.1398-9995.1997.tb00969.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	5	22	23	0	5	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2000	106	2					402	403		10.1067/mai.2000.108109	http://dx.doi.org/10.1067/mai.2000.108109			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	343NH	10932088				2022-12-18	WOS:000088708100027
J	Mori, A; Kaminuma, O; Ogawa, K; Nakata, A; Egan, RW; Akiyama, K; Okudaira, H				Mori, A; Kaminuma, O; Ogawa, K; Nakata, A; Egan, RW; Akiyama, K; Okudaira, H			Control of IL-5 production by human helper T cells as a treatment for eosinophilic inflammation: Comparison of in vitro and in vivo effects between selective and nonselective cytokine synthesis inhibitors	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Meeting on New Trends in Immunopharmacology 1998	JUL 25, 1998	TOKYO, JAPAN			T cell; eosinophilic inflammation	MESSENGER-RNA EXPRESSION; BRONCHOALVEOLAR LAVAGE CELLS; COLONY-STIMULATING FACTOR; GENE-TRANSCRIPTION; CYCLOSPORINE-A; ATOPIC ASTHMA; AIRWAY HYPERRESPONSIVENESS; INTERLEUKIN-5 SYNTHESIS; PERIPHERAL-BLOOD; GUINEA-PIGS	Background: Helper T cells are involved in the pathophysiologic condition of asthma, so modulation of cytokine production may be effective therapy. Objective: We aimed to selectively control the synthesis of IL-5 by helper T cells and tested in vivo effects using a murine asthma model. Methods: The effect of dexamethasone, FK506, cyclosporin A, and nonactin (a macrolide compound produced by Streptomyces griseus) on cytokine production by allergen-specific T-cell clones was determined, The effect of these agents and an anti-IL-5 neutralizing antibody on airway eosinophilic inflammation was investigated in a murine asthma model. Results: Dexamethasone, FK506, and cyclosporin A suppressed the production of IL-2, IL-4, and IL-5 by human helper T cells, which shows a similar concentration-response relationship in each case, Cyclosporin A and dexamethasone inhibited airway eosinophilia in vivo. Nonactin suppressed IL-5 synthesis but not IL-2 or IL-4 synthesis, and it also significantly suppressed airway eosinophilia. Conclusion: Nonactin only suppressed IL-5 synthesis and was as effective against eosinophilia as cyclosporin A and dexamethasone, which indicates that IL-5 is a reasonable therapeutic target in allergic disorders that are accompanied by eosinophilic inflammation.	Natl Sagamihara Hosp, Clin Res Ctr Allergy & Rheumatol, Sagamihara, Kanagawa 228, Japan; Tanabe Seiyaku Co Ltd, Toda, Saitama, Japan; Schering Plough Res Inst, Kenilworth, NJ USA; Univ Tokyo, Fac Med, Dept Med & Phys Therapy, Tokyo 113, Japan	Mitsubishi Tanabe Pharma Corporation; Merck & Company; Schering-Plough Research Institute; University of Tokyo	Mori, A (corresponding author), Natl Sagamihara Hosp, Clin Res Ctr Allergy & Rheumatol, 18-1 Sakuradai, Sagamihara, Kanagawa 228, Japan.							ALEXANDER AG, 1992, LANCET, V339, P324, DOI 10.1016/0140-6736(92)91646-P; AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407, DOI 10.1164/ajrccm/142.6_Pt_1.1407; CHAND N, 1992, EUR J PHARMACOL, V211, P121, DOI 10.1016/0014-2999(92)90273-7; CORRIGAN CJ, 1993, AM REV RESPIR DIS, V147, P540, DOI 10.1164/ajrccm/147.3.540; CORRIGAN CJ, 1992, IMMUNOL TODAY, V13, P501, DOI 10.1016/0167-5699(92)90026-4; DeBie JJ, 1996, BRIT J PHARMACOL, V119, P1484; Eum SY, 1996, CLIN EXP ALLERGY, V26, P971, DOI 10.1111/j.1365-2222.1996.tb00635.x; GAVETT SH, 1994, AM J RESP CELL MOL, V10, P587, DOI 10.1165/ajrcmb.10.6.8003337; GLEICH GJ, 1986, ADV IMMUNOL, V39, P177; GLEICH GJ, 1990, J ALLERGY CLIN IMMUN, V85, P422, DOI 10.1016/0091-6749(90)90151-S; GULBENKIAN AR, 1992, AM REV RESPIR DIS, V146, P263, DOI 10.1164/ajrccm/146.1.263; Humbert M, 1997, AM J RESP CRIT CARE, V156, P704, DOI 10.1164/ajrccm.156.3.9610033; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P1745, DOI 10.1164/ajrccm/140.6.1745; Kaminuma O, 1997, AM J RESP CELL MOL, V16, P448, DOI 10.1165/ajrcmb.16.4.9115756; KAY AB, 1992, AM REV RESPIR DIS, V145, pS22, DOI 10.1164/ajrccm/145.2_Pt_2.S22; KAY AB, 1991, J EXP MED, V173, P775, DOI 10.1084/jem.173.3.775; KRISHNASWAMY G, 1993, AM J RESP CELL MOL, V9, P279, DOI 10.1165/ajrcmb/9.3.279; Lee JJ, 1997, J EXP MED, V185, P2143, DOI 10.1084/jem.185.12.2143; MAUSER PJ, 1993, AM REV RESPIR DIS, V148, P1623, DOI 10.1164/ajrccm/148.6_Pt_1.1623; MIZOGUCHI M, 1992, LANCET, V339, P1120, DOI 10.1016/0140-6736(92)90719-J; Mori A, 1999, J ALLERGY CLIN IMMUN, V103, pS429, DOI 10.1016/S0091-6749(99)70158-2; MORI A, 1995, INT ARCH ALLERGY IMM, V107, P366, DOI 10.1159/000237036; Mori A, 1997, J ALLERGY CLIN IMMUN, V100, pS56, DOI 10.1016/S0091-6749(97)70006-X; Mori A, 1996, INT IMMUNOL, V8, P1889, DOI 10.1093/intimm/8.12.1889; Mori A, 1997, BLOOD, V89, P2891, DOI 10.1182/blood.V89.8.2891; MORI A, 1995, INT IMMUNOL, V7, P449, DOI 10.1093/intimm/7.3.449; Mori A, 1997, J IMMUNOL, V158, P3659; MORI A, 1995, INT ARCH ALLERGY IMM, V107, P220, DOI 10.1159/000236983; MORI A, 1994, ENV DERMATOL, V1, P42; MORI A, 1995, J IMMUNOL, V156, P2391; NAGAI H, 1995, INT ARCH ALLERGY IMM, V108, P189, DOI 10.1159/000237138; NAKAGAWA H, 1994, LANCET, V344, P883, DOI 10.1016/S0140-6736(94)92855-X; NAKAJIMA H, 1992, AM REV RESPIR DIS, V146, P374, DOI 10.1164/ajrccm/146.2.374; Nakata A, 1998, BRIT J PHARMACOL, V124, P1425, DOI 10.1038/sj.bjp.0701982; OHNISHI T, 1993, AM REV RESPIR DIS, V147, P901, DOI 10.1164/ajrccm/147.4.901; Okudaira H, 1997, INT ARCH ALLERGY IMM, V113, P331, DOI 10.1159/000237592; OKUDAIRA H, 1994, ACI NEWS, V6, P19; RIEGEL JS, 1992, CHEM IMMUNOL, V51, P266; ROBINSON D, 1993, J ALLERGY CLIN IMMUN, V92, P313, DOI 10.1016/0091-6749(93)90175-F; ROBINSON DS, 1993, J ALLERGY CLIN IMMUN, V92, P397, DOI 10.1016/0091-6749(93)90118-Y; SCHLEIMER RP, 1990, AM REV RESPIR DIS, V141, pS59; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SNYDER DS, 1982, J IMMUNOL, V129, P1803; STAYNOV DZ, 1992, IMMUNOLOGY, V75, P196; VACCA A, 1990, J BIOL CHEM, V265, P8075; VANOOSTERHOUT AJM, 1993, AM REV RESPIR DIS, V147, P548, DOI 10.1164/ajrccm/147.3.548; WALKER C, 1992, AM REV RESPIR DIS, V146, P109, DOI 10.1164/ajrccm/146.1.109; YUUKI T, 1991, AGR BIOL CHEM TOKYO, V55, P1233, DOI 10.1080/00021369.1991.10870757	49	22	23	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2000	106	1	2	S			S58	S64		10.1067/mai.2000.106775	http://dx.doi.org/10.1067/mai.2000.106775			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	339NF	10887335				2022-12-18	WOS:000088482600008
J	Lemanske, RF				Lemanske, RF			Inflammatory events in asthma: An expanding equation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Conference on Advances in Allergic Diseases - An Update for the New Millennium	FEB   11, 1999	WASHINGTON, D.C.			adhesion molecule; cytokine; eosinophil; inflammation; leukotriene; macrophage	CHRONIC LUNG-DISEASE; CHILDHOOD ASTHMA; PREMATURE-INFANTS; BLOOD EOSINOPHILS; CHILDREN; AIRWAYS; THERAPY; SPUTUM; CELLS	Asthma is a chronic inflammatory disorder that can lead to progressive, potentially irreversible declines in lung function in some patients. Asthmatic inflammation develops when the sequential interaction of inflammatory cells with resident cells generates a cascade of events that contribute to the chronic inflammation and clinical manifestations associated with the disease, including further inflammation, airway smooth muscle spasm (bronchospasm), airway mucus secretion, airway edema and narrowing, and bronchial epithelial damage, Because of the chronic, progressive nature of asthmatic inflammation and the early age of onset, the ability to evaluate inflammation in children would be useful, Several procedures that quantify inflammatory mediators tin peripheral blood, induced sputum, bronchoalveolar lavage fluid, and bronchial biopsies) have shown potential usefulness in the evaluation of and the monitoring of disease severity in children (and, by extension, adults) with asthma, Further research needs to be devoted to the elucidation of when the inflammatory process starts and how it changes over time, to the determination of whether the inflammatory process is the same in all patients with wheezing, regardless of the stimulus, to the definition of the relationship between atopy and asthma, and to the establishment of the usefulness of testing for inflammatory markers to help identify individual asthmatic phenotypes, to evaluate disease severity, to measure therapeutic response, and/or to predict potential outcomes.	Univ Wisconsin, Sch Med, Dept Pediat, Madison, WI 53706 USA; Univ Wisconsin, Sch Med, Dept Med, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Lemanske, RF (corresponding author), Univ Wisconsin Hosp, 600 Highland Ave,H4-432, Madison, WI 53792 USA.							AZEVEDO I, 1995, AM J RESP CRIT CARE, V152, P1208, DOI 10.1164/ajrccm.152.4.7551372; BARNES PJ, 1988, J ALLERGY CLIN IMMUN, V81, P919, DOI 10.1016/0091-6749(88)90952-9; BARNES PJ, 1992, J INTERN MED, V231, P453, DOI 10.1111/j.1365-2796.1992.tb00960.x; BJORNSDOTTIR US, 1995, ASTHMA RHINITIS, P328; BOUSQUET J, 1992, ALLERGY, V47, P3, DOI 10.1111/j.1398-9995.1992.tb02242.x; BROIDE DH, 1992, J ALLERGY CLIN IMMUN, V89, P958, DOI 10.1016/0091-6749(92)90218-Q; CUTZ E, 1978, HISTOPATHOLOGY, V2, P407, DOI 10.1111/j.1365-2559.1978.tb01735.x; Doi S, 1996, J ALLERGY CLIN IMMUN, V97, P955, DOI 10.1016/S0091-6749(96)80070-4; Hoekstra MO, 1996, EUR RESPIR J, V9, P2231, DOI 10.1183/09031936.96.09112231; Holgate ST, 1996, J ALLERGY CLIN IMMUN, V98, P1, DOI 10.1016/S0091-6749(96)70220-8; LEFF AR, 1991, AM J PHYSIOL, V260, P189; LITTLE S, 1995, THORAX, V50, P1073, DOI 10.1136/thx.50.10.1073; Nagayama Y, 1995, PEDIATR ALLERGY IMMU, V6, P204, DOI 10.1111/j.1399-3038.1995.tb00286.x; SCHAUER U, 1994, ARCH DIS CHILD, V71, P506, DOI 10.1136/adc.71.6.506; SIEGEL SC, 1985, J ALLERGY CLIN IMMUN, V76, P1, DOI 10.1016/0091-6749(85)90795-X; Stevenson EC, 1997, CLIN EXP ALLERGY, V27, P1027, DOI 10.1111/j.1365-2222.1997.tb01254.x; Twaddell SH, 1996, EUR RESPIR J, V9, P2104, DOI 10.1183/09031936.96.09102104; VITTORI E, 1992, AM REV RESPIR DIS, V146, P1320, DOI 10.1164/ajrccm/146.5_Pt_1.1320; WIGGS BR, 1992, AM REV RESPIR DIS, V145, P1251, DOI 10.1164/ajrccm/145.6.1251; Yamamoto C, 1996, ACTA PAEDIATR, V85, P1232; ZIMMERMAN B, 1993, CLIN EXP ALLERGY, V23, P564, DOI 10.1111/j.1365-2222.1993.tb00895.x	21	22	24	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2000	105	6	2	S			S633	S636						4	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	328QU	10856170				2022-12-18	WOS:000087862200008
J	Patke, CL; Shearer, WT				Patke, CL; Shearer, WT			gp120- and TNF-alpha-induced modulation of human B cell function: Proliferation, cyclic AMP generation, Ig production, and B-cell receptor expression	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						gp120; TNF-alpha; B cells; cyclic AMP; B-cell receptor; CD79b; HIV-1 long terminal repeat	NECROSIS-FACTOR-ALPHA; PROTEIN-KINASE-A; ACQUIRED IMMUNODEFICIENCY SYNDROME; SUPERANTIGEN-BINDING-SITE; HIV-INFECTION; LYMPHOCYTES-B; ANTIGEN RECEPTOR; CROSS-LINKING; IN-VITRO; T-CELLS	Background: It is well known that HIV-1 infection induces profound alterations in the immune system, including hyperactivation of B cells. TNF-alpha induces HIV-1 replication and immunodysregulation, including polyclonal B-cell activation. Objective: We sought to determine the effects of surface-binding HIV-1 envelope glycoprotein (gp120) and TNF-alpha on human B-cell function. Methods: HIV-1 seronegative peripheral blood human B cells were purified and activated by CD40 mAb and IL-4. In vitro studies of B-cell proliferation, cyclic AMP (cAMP) generation, receptor expression, and Ig production were performed. Results: gp120, an Ig superantigen, stimulated HIV-1 seronegative and HIV-1 seropositive human B-cell cAMP generation, proliferation, and Ig production. These gp120-induced B-cell responses were demonstrated to be specific as evidenced by the abrogation of the stimulatory response in the presence of anti-gp120 mAb, blocking of CD4 resulting in no change on gp120-induced B-cell responses, and the binding of gp120 in these B cells. TNF-alpha also stimulated cAMP generation, proliferation, and Ig production in B cells, and the binding of gp120 to these B cells stimulated by TNF-alpha further enhanced cell proliferation, cAMP generation, and Ig production. Antigenic expression of the B-cell receptor CD79b was down-regulated by gp120 but was not altered by the addition of TNF-alpha. Conclusion: gp120 modulation of TNF-alpha-induccd B-cell receptor- and cAMP-mediated signal transduction events mag be involved in the B-cell abnormalities observed in HIV-1 infection.	Texas Childrens Hosp, Dept Allergy & Immunol, Houston, TX 77030 USA; Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; Baylor Coll Med, Dept Microbiol & Immunol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Patke, CL (corresponding author), Texas Childrens Hosp, Dept Allergy & Immunol, 6621 Fannin,MC 1-3291, Houston, TX 77030 USA.			Shearer, William/0000-0002-2483-2130	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI036211, R01AI039131] Funding Source: NIH RePORTER; NIAID NIH HHS [AI39131, AI36211] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aandahl EM, 1998, FASEB J, V12, P855, DOI 10.1096/fasebj.12.10.855; BERBERIAN L, 1994, J ACQ IMMUN DEF SYND, V7, P641; BERBERIAN L, 1993, SCIENCE, V261, P1588, DOI 10.1126/science.7690497; BOUSSIOTIS VA, 1994, P NATL ACAD SCI USA, V91, P7007, DOI 10.1073/pnas.91.15.7007; CHOWDHURY MIH, 1993, VIROLOGY, V194, P345, DOI 10.1006/viro.1993.1265; Conge AM, 1998, AIDS, V12, P1437, DOI 10.1097/00002030-199812000-00005; DALGLEISH AG, 1995, IMMUNOL TODAY, V16, P356, DOI 10.1016/0167-5699(95)80156-1; Fritsch L, 1998, VIROLOGY, V244, P542, DOI 10.1006/viro.1998.9120; FUNDERUD S, 1990, EUR J IMMUNOL, V20, P201, DOI 10.1002/eji.1830200129; GOODGLICK L, 1995, J IMMUNOL, V155, P5151; Gras G, 1996, VIROLOGY, V220, P309, DOI 10.1006/viro.1996.0319; HOFMANN B, 1993, P NATL ACAD SCI USA, V90, P6676, DOI 10.1073/pnas.90.14.6676; JELINEK DF, 1987, J IMMUNOL, V139, P2970; Juompan L, 1998, FASEB J, V12, P1473, DOI 10.1096/fasebj.12.14.1473; Karsten V, 1996, IMMUNOLOGY, V88, P55, DOI 10.1046/j.1365-2567.1996.d01-648.x; KEHRL JH, 1987, J EXP MED, V166, P786, DOI 10.1084/jem.166.3.786; LANE HC, 1985, ANNU REV IMMUNOL, V3, P477, DOI 10.1146/annurev.iy.03.040185.002401; Lapointe R, 1996, EUR J IMMUNOL, V26, P2376, DOI 10.1002/eji.1830261016; MACCHIA D, 1993, NATURE, V363, P464, DOI 10.1038/363464a0; MARUYAMA I, 1993, BIOCHEM BIOPH RES CO, V195, P1264, DOI 10.1006/bbrc.1993.2180; Nakamura T, 1996, INT J HEMATOL, V64, P39; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; Oyaizu N, 1996, BLOOD, V87, P2361, DOI 10.1182/blood.V87.6.2361.bloodjournal8762361; Patella V, 2000, J IMMUNOL, V164, P589, DOI 10.4049/jimmunol.164.2.589; PATKE CL, 1994, CLIN DIAGN LAB IMMUN, V4, P424; POLI G, 1990, P NATL ACAD SCI USA, V87, P782, DOI 10.1073/pnas.87.2.782; Rabbi MF, 1997, VIROLOGY, V237, P422, DOI 10.1006/viro.1997.8798; RASMUSSEN AM, 1992, J IMMUNOL METHODS, V146, P195, DOI 10.1016/0022-1759(92)90228-L; RIECKMANN P, 1991, J IMMUNOL, V147, P2922; RODRIGUEZ C, 1993, EUR J IMMUNOL, V23, P1160, DOI 10.1002/eji.1830230527; ROSENBERG ZF, 1990, IMMUNOL TODAY, V11, P176, DOI 10.1016/0167-5699(90)90070-P; SCHEURICH P, 1989, J EXP MED, V170, P947, DOI 10.1084/jem.170.3.947; SHIRAI A, 1992, J CLIN INVEST, V89, P561, DOI 10.1172/JCI115621; Van Kooten C, 1997, CLIN EXP IMMUNOL, V110, P509, DOI 10.1046/j.1365-2249.1997.4201436.x; YARCHOAN R, 1986, J CLIN INVEST, V78, P439, DOI 10.1172/JCI112595; YOKOTA S, 1988, J IMMUNOL, V140, P531	36	22	22	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2000	105	5					975	982		10.1067/mai.2000.105315	http://dx.doi.org/10.1067/mai.2000.105315			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	316TW	10808179	Bronze			2022-12-18	WOS:000087185000017
J	Sano, F; Cortez, GK; Sole, D; Naspitz, CK				Sano, F; Cortez, GK; Sole, D; Naspitz, CK			Inhaled budesonide for the treatment of acute wheezing and dyspnea in children up to 24 months old receiving intravenous hydrocortisone	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; budesonide; inhaled steroids; efficacy; infants	NEBULIZED BUDESONIDE; IPRATROPIUM BROMIDE; CONTROLLED TRIAL; ACUTE ASTHMA; ORAL PREDNISOLONE; YOUNG-CHILDREN; INFANTS; SUSPENSION; EFFICACY; SAFETY	Background: Inhaled corticosteroids are highly effective in the treatment of asthma at all ages, and their use in younger children is increasing. There are no data currently available on the treatment of infants with acute wheeze and dyspnea with nebulized budesonide. Objective: Our purpose was to assess the clinical effect of nebulized budesonide in infants with acute wheeze and dyspnea. Methods: A prospective study was performed comparing the addition of nebulized budesonide 0.25 mg every 6 hours (group A, n = 32) and nebulized ipratropium bromide 0.1 mg every 6 hours (group B, n = 39) with the normal treatment regimen with intravenous fluid, hydrocortisone, and nebulized fenoterol. A clinical score was made at admission and every 12 hours. The score included wheezing and costal retraction (0-6) and respiratory rate (counts per minute). Results: Seventy-one infants aged 3 to 24 months were studied (42 boys). A statistically significant reduction was seen in clinical score and respiratory rate in both groups 12 hours after admission. The children who received budesonide improved significantly faster than the children who received ipratropium bromide, and the hospitalization period was significantly lower in the budesonide group (66.4 hours) compared with the ipratropium bromide group (93 hours) (P <.01). Three patients from the budesonide group and 2 from the ipratropium bromide group were readmitted within the first 4 weeks. Conclusion: Treatment of infants with acute wheeze with nebulized budesonide is associated with faster clinical improvement and reduction in hospital stay period.	Univ Fed Sao Paulo, Hosp Nipobrasileiro, Sao Paulo, Brazil; Univ Fed Sao Paulo, Dept Pediat, Div Allergy & Clin Immunol & Rheumatol, Sao Paulo, Brazil	Universidade Federal de Sao Paulo (UNIFESP); Universidade Federal de Sao Paulo (UNIFESP)	Sano, F (corresponding author), Av Onze Junho 685,Apto 166, BR-04041900 Sao Paulo, Brazil.		Solé, Dirceu/D-7789-2013					Azevedo I, 1997, J INVEST ALLERG CLIN, V7, P346; Azevedo I, 1997, EUR RESPIR J, V10, P1767, DOI 10.1183/09031936.97.10081767; Barnes PJ, 1998, AM J RESP CRIT CARE, V157, pS1, DOI 10.1164/ajrccm.157.3.157315; BENEDICTIS FM, 1996, PEDIATR PULM, V21, P310; BENTUR L, 1992, PEDIATRICS, V89, P133; BENTUR L, 1990, ANN ALLERGY, V65, P122; CURTIS P, 1995, EUR RESP J S, V19, P4705; deBlic J, 1996, J ALLERGY CLIN IMMUN, V98, P14, DOI 10.1016/S0091-6749(96)70221-X; Ducharme FM, 1998, J PEDIATR-US, V133, P479, DOI 10.1016/S0022-3476(98)70054-X; Godden CW, 1997, ARCH DIS CHILD, V76, P155, DOI 10.1136/adc.76.2.155; GOODWIN A, 1995, BR J CLIN RES, V6, P113; HODGES IGC, 1981, ARCH DIS CHILD, V56, P729, DOI 10.1136/adc.56.9.729; ILANGOVAN P, 1993, ARCH DIS CHILD, V68, P356, DOI 10.1136/adc.68.3.356; JOHNSON D, 1997, AM J CHILD HLTH S, V3, pA214; KRAEMER R, 1991, AM REV RESPIR DIS, V144, P347, DOI 10.1164/ajrccm/144.2.347; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Mitchell C. A., 1995, European Respiratory Journal, V8, p490S; Morice AH, 1996, CLIN PHARMACOL THER, V60, P675, DOI 10.1016/S0009-9236(96)90216-7; NASPITZ CK, 1992, J ASTHMA, V29, P253, DOI 10.3109/02770909209048939; *NAT I HLTH, 1997, NAT I HLTH PUBL; Plotnick LH, 1998, BMJ-BRIT MED J, V317, P971, DOI 10.1136/bmj.317.7164.971; Qureshi F, 1998, NEW ENGL J MED, V339, P1030, DOI 10.1056/NEJM199810083391503; Reijonen T, 1996, ARCH PEDIAT ADOL MED, V150, P512, DOI 10.1001/archpedi.1996.02170300066013; Richter H, 1998, J PEDIATR-US, V132, P849, DOI 10.1016/S0022-3476(98)70316-6; RUBIN BK, 1996, AM J MED S1A, V100, P49; Shapiro G, 1998, J ALLERGY CLIN IMMUN, V102, P789, DOI 10.1016/S0091-6749(98)70019-3; TSANAKAS JN, 1994, PEDIAT RES S, V36, P53; Volovitz B, 1998, J ALLERGY CLIN IMMUN, V101, P464, DOI 10.1016/S0091-6749(98)70405-1; Volovitz B, 1998, J ALLERGY CLIN IMMUN, V102, P605, DOI 10.1016/S0091-6749(98)70276-3; Wennergren G, 1996, ACTA PAEDIATR, V85, P183, DOI 10.1111/j.1651-2227.1996.tb13989.x	30	22	24	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2000	105	4					699	703		10.1067/mai.2000.104784	http://dx.doi.org/10.1067/mai.2000.104784			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	306PB	10756218				2022-12-18	WOS:000086604100006
J	Cardaba, B; Cortegano, I; Florido, F; Arrieta, I; Aceituno, E; del Pozo, V; Gallardo, S; Rojo, M; Palomino, P; Lahoz, C				Cardaba, B; Cortegano, I; Florido, F; Arrieta, I; Aceituno, E; del Pozo, V; Gallardo, S; Rojo, M; Palomino, P; Lahoz, C			Genetic restrictions in olive pollen allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						olive pollen allergy; Ole e 1; Ole e 3; HLA class II; IgE high-affinity receptor; T-cell receptor and TNF polymorphisms	OLE-E-I; AMINO-ACID-SEQUENCE; FC-EPSILON-RI; IMMUNOGLOBULIN-E RESPONSES; MAJOR ALLERGEN; BETA-SUBUNIT; EUROPEA POLLEN; TREE POLLEN; MAST-CELLS; E RECEPTOR	Background: The major antigen of olive tree pollen, Ole e 1, produces an IgE response restricted by DQ2. Objective: Our purpose was to further analyze the genetic restrictions associated with IgE and IgG antibodies against Ole e 1 and IgE against the recently described antigen Ole e 3. Methods: Twenty-two nuclear olive pollen-allergic families (n = 88) were selected. DRB1 and DQB1, TCR-V alpha 8.1, the high-affinity receptor of IgE (Fc epsilon RI-beta) Rsa I exon 7 and intron 2 and TNF-beta (LT alpha-Nco I) polymorphisms were determined by PCR and analyzed for association with allergic traits by the multiallelic transmission disequilibrium test. Results: Significant associations were found among HLA-DQB1*0201 (n = 29) and high levels of IgG (P =.023) and IgE (P =.0136) antibodies to Ole el and,vith IgE specific to Ole e 3 (P =.0368). DRB1*0701 was associated with high levels of total serum IgE (P =.04) and IgG against Ole e 1 (P =.025). The Fc epsilon RI-beta Rsa I exon 7, allele 1 (n = 39), was associated with high levels of total serum IgE (P =.01), IgE antibodies against Olea europaea extract (P =.004), and specific antibodies to Ole e 1, IgG (P =.04), and IgE (P =.006). The Fc epsilon RI-beta Rsa I intron 2, allele 2 (n = 33), was associated with IgE antibodies to O europaea extract (P =.003) and specific antibodies to Ole e 1, IgG (P =.025), and IgE (P =.05). Conclusions: We found a new association between IgE antibody response to Ole e 3 and DQB1*0201 and verified the previously reported association between Ole e 1-specific response and DQB1*0201, Also, the association between Fc epsilon RI-beta and IgE antibodies against Ole e 1 was demonstrated.	Fdn Jimenez Diaz, Dept Immunol, E-28040 Madrid, Spain; Hosp Gen Especialidades Jaen, Serv Alergia, Madrid, Spain		Lahoz, C (corresponding author), Fdn Jimenez Diaz, Dept Immunol, Av Reyes Catolicos 2, E-28040 Madrid, Spain.		Cárdaba, Blanca/S-3772-2019; Cortegano, Isabel/AAE-1500-2020	Cardaba, Blanca/0000-0003-0142-9901				ANSARI AA, 1989, HUM IMMUNOL, V25, P59, DOI 10.1016/0198-8859(89)90070-0; Barnes KC, 1996, GENOMICS, V37, P41, DOI 10.1006/geno.1996.0518; Batanero E, 1997, FEBS LETT, V410, P293, DOI 10.1016/S0014-5793(97)00582-6; Batanero E, 1996, EUR J BIOCHEM, V241, P772, DOI 10.1111/j.1432-1033.1996.00772.x; Boluda L, 1998, J ALLERGY CLIN IMMUN, V101, P210, DOI 10.1016/S0091-6749(98)70385-9; BOUSQUET J, 1995, CLIN EXP ALLERGY, V15, P439; BRADDING P, 1992, J EXP MED, V176, P1381, DOI 10.1084/jem.176.5.1381; BROIDE DH, 1992, J ALLERGY CLIN IMMUN, V89, P958, DOI 10.1016/0091-6749(92)90218-Q; Cardaba B, 1996, CLIN EXP ALLERGY, V26, P316, DOI 10.1111/j.1365-2222.1996.tb00097.x; CARDABA B, 1993, HUM IMMUNOL, V38, P293, DOI 10.1016/0198-8859(93)90557-H; Cardaba B, 1998, CLIN EXP ALLERGY, V28, P413; Castro J, 1998, ALLERGY, V53, P1083, DOI 10.1111/j.1398-9995.1998.tb03819.x; COOKSON WOCM, 1989, LANCET, V1, P1292; CORNELIS F, 1993, EUR J IMMUNOL, V23, P1277, DOI 10.1002/eji.1830230613; Cox HE, 1998, BRIT J DERMATOL, V138, P182; Dombrowicz D, 1998, IMMUNITY, V8, P517, DOI 10.1016/S1074-7613(00)80556-7; FISCHER GF, 1992, HUM IMMUNOL, V33, P259, DOI 10.1016/0198-8859(92)90333-I; GAUCHAT JF, 1993, NATURE, V365, P340, DOI 10.1038/365340a0; George V, 1999, AM J HUM GENET, V65, P236, DOI 10.1086/302444; Hill MR, 1996, HUM MOL GENET, V5, P959, DOI 10.1093/hmg/5.7.959; Hiraoka S, 1999, INT IMMUNOL, V11, P199, DOI 10.1093/intimm/11.2.199; Hizawa N., 1997, Journal of Allergy and Clinical Immunology, V99, pS477; JACOB CO, 1990, P NATL ACAD SCI USA, V87, P1233, DOI 10.1073/pnas.87.3.1233; Kimura A., 1992, HLA 1991, P419; LAUZURICA P, 1988, MOL IMMUNOL, V25, P337, DOI 10.1016/0161-5890(88)90028-4; LAUZURICA P, 1988, MOL IMMUNOL, V25, P329, DOI 10.1016/0161-5890(88)90027-2; Ledesma A, 1998, ALLERGY, V53, P520, DOI 10.1111/j.1398-9995.1998.tb04090.x; MARSH DG, 1981, NEW ENGL J MED, V305, P1551, DOI 10.1056/NEJM198112243052603; MARSH DG, 1982, J EXP MED, V155, P1439, DOI 10.1084/jem.155.5.1439; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; Martinez A, 1999, ALLERGY, V54, P584, DOI 10.1034/j.1398-9995.1999.00073.x; MARTINOROZCO E, 1994, INT ARCH ALLERGY IMM, V104, P160, DOI 10.1159/000236725; MESSER G, 1991, J EXP MED, V173, P209, DOI 10.1084/jem.173.1.209; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MOFFATT F, 1994, LANCET, V343, P1597, DOI 10.1016/S0140-6736(94)93057-0; Moffatt MF, 1997, IMMUNOGENETICS, V46, P226, DOI 10.1007/s002510050266; Nickel R., 1997, Journal of Allergy and Clinical Immunology, V99, pS476; Palmer LJ, 1997, AM J HUM GENET, V61, P182, DOI 10.1086/513888; SANDFORD AJ, 1993, LANCET, V341, P332, DOI 10.1016/0140-6736(93)90136-5; Schuurman J, 1998, J ALLERGY CLIN IMMUN, V101, P404, DOI 10.1016/S0091-6749(98)70255-6; Shirakawa T, 1996, LANCET, V347, P394, DOI 10.1016/S0140-6736(96)90570-X; SHIRAKAWA T, 1994, NAT GENET, V7, P125, DOI 10.1038/ng0694-125; TAUTZ C, 1994, J ALLERGY CLIN IMMUN, V93, P918, DOI 10.1016/0091-6749(94)90386-7; VILLALBA M, 1990, BIOCHEM BIOPH RES CO, V172, P523, DOI 10.1016/0006-291X(90)90704-Q; VILLALBA M, 1994, J BIOL CHEM, V269, P15217; VILLALBA M, 1993, EUR J BIOCHEM, V216, P863, DOI 10.1111/j.1432-1033.1993.tb18208.x; VIRCHOW JC, 1995, AM J RESP CRIT CARE, V151, P960; WHEELER AW, 1990, MOL IMMUNOL, V27, P631, DOI 10.1016/0161-5890(90)90005-K; YOUNG RP, 1992, J MED GENET, V29, P236, DOI 10.1136/jmg.29.4.236	49	22	25	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2000	105	2	1				292	298		10.1016/S0091-6749(00)90079-4	http://dx.doi.org/10.1016/S0091-6749(00)90079-4			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	285RQ	10669850				2022-12-18	WOS:000085402200014
J	Asero, R; Bottazzi, G				Asero, R; Bottazzi, G			Hypersensitivity to molds in patients with nasal polyposis: A clinical study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Polyposis; allergic rhinitis; molds; Candida albicans; skin prick tests; hypersensitivity			Poliambulat Paderno Dugnano, Ambulatorio Allergol, I-20021 Bollate, MI, Italy; Poliambulat Paderno Dugnano, Ambulatorio Otorinolaryngol, ASL MI I, Paderno Dugnano, MI, Italy		Asero, R (corresponding author), Osped Caduti Bollatesi, Ambulat Allergolog, Via Piave 20, I-20021 Bollate, MI, Italy.							BOUSQUET J, 1988, ALLERGY PRINCIPLES P, P419; CAPLIN I., 1971, ANN ALLERGY, V29, P63; DRAKELEE AB, 1984, J ROY SOC MED, V77, P120, DOI 10.1177/014107688407700210; SLAVIN RG, 1993, ALLERGY PRINCIPLES P, P1455; SOLOMON WR, 1993, ALLERGY PRINCIPLES P, P469	5	22	24	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2000	105	1	1				186	188		10.1016/S0091-6749(00)90198-2	http://dx.doi.org/10.1016/S0091-6749(00)90198-2			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	278LW	10629472				2022-12-18	WOS:000084992100029
J	Mellon, M				Mellon, M		Budesonide Inhalation Suspension Study Grp	Efficacy of budesonide inhalation suspension in infants and young children with persistent asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	54th Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology	MAR 13-18, 1998	WASHINGTON, D.C.	Amer Acad Allergy Asthma & Immunol		budesonide; budesonide inhalation suspension; asthma; corticosteroid; pediatric; efficacy; pulmonary function	NEBULIZED BUDESONIDE; PULMONARY-FUNCTION; CHILDHOOD ASTHMA; STEROIDS	This paper reviews the results from 3 randomized, double-blind, placebo-controlled, multicenter studies that assessed the efficacy and safety of once- and twice-daily dosing of budesonide inhalation suspension (BIS) in infants and young children with persistent asthma. In children with mild persistent asthma that was previously treated with bronchodilators or noncorticosteroid anti-inflammatory agents (study A), nighttime and daytime asthma symptoms were significantly improved in 0.25-mg once daily, 0.5-mg once daily, and 1.0-mg once daily BIS treatment groups compared with placebo (P less than or equal to .05). Rescue medications were used significantly less in all BIS groups (approximately 2 days of every 14 days) compared with placebo (P < .05). The proportion of patients who discontinued this therapy because of worsening asthma was greater in the placebo group than in the BIS groups, with the difference between placebo (23%) and the 1.0-mg BIS group (13%) being statistically significant (P = .020). All BIS doses except 0.5 mg once daily showed nonsignificant numeric improvement in morning and evening peak expiratory flow (PEF) compared with placebo. In children with asthma that was previously treated with inhaled corticosteroids (study B), BIS doses of 0.25 mg, 0.5 mg, and 1.0 mg twice daily resulted in significant improvements in nighttime symptoms scores versus placebo (P less than or equal to .026). Rescue medications were used significantly less in all BIS groups (approximately 2.5 to 3.5 days of every 14 days) compared with placebo (P less than or equal to .032). The proportion of patients receiving placebo who discontinued therapy because of worsening asthma symptoms (36 %) was significantly greater compared with the BIS groups (9%; P less than or equal to .015). Morning PEF levels were significantly greater in each BIS group compared with placebo (P less than or equal to .03). For evening PEF levels, all BIS treatment groups showed numeric improvements compared with placebo; the 0.25-mg twice daily budesonide group showed statistically significant improvement (P < .05), In children with moderate persistent asthma that was previously maintained either on bronchodilators or inhaled corticosteroids (study C), nighttime asthma symptoms significantly improved in the 0.25-mg twice daily, 0.5-mg twice daily, and 1.0-mg once daily BIS groups compared with placebo (P < .01); there was a numeric improvement for the 0.25-mg once daily treatment group. Rescue medications were used significantly less in all BIS groups (approximately 2 to 3 days of every 14 days) compared with placebo (P < .01). The proportion of patients who discontinued treatment because of worsening of asthma symptoms was greater in the placebo group than in the BIS groups; the difference between 0.25-mg twice daily group (13%) and the placebo group (26%) was statistically significant (P = .029). All BIS doses showed numeric improvement in morning PEF levels, and statistically significant improvements were observed in the 0.25-mg twice daily, 0.5-mg twice daily, and 1.0-mg once dairy groups compared with placebo (P < .03). Significant improvements in evening PEF levels were observed for each BIS treatment group (P less than or equal to .034), except for the 1.0-mg once daily group. Overall, the 3 studies show that once- and twice-daily dosing of BIS effectively relieves asthma symptoms and improves pulmonary function in infants and young children with mild-to-severe persistent asthma.	Kaiser Permanente Med Off, Dept Allergy, San Diego, CA 92111 USA	Kaiser Permanente	Mellon, M (corresponding author), Kaiser Permanente Med Off, Dept Allergy, 5th Floor,7060 Clairemont Mesa Blvd, San Diego, CA 92111 USA.							AGERTOFT L, 1994, RESP MED, V88, P373, DOI 10.1016/0954-6111(94)90044-2; Baker JW, 1999, PEDIATRICS, V103, P414, DOI 10.1542/peds.103.2.414; Bush A, 1996, BRIT J HOSP MED, V55, P110; Calpin C, 1997, J ALLERGY CLIN IMMUN, V100, P452, DOI 10.1016/S0091-6749(97)70134-9; CLOUGH J, 1995, PRACTITIONER, V239, P198; deBlic J, 1996, J ALLERGY CLIN IMMUN, V98, P14, DOI 10.1016/S0091-6749(96)70221-X; Foucard T, 1996, ALLERGY, V51, P367, DOI 10.1111/j.1398-9995.1996.tb04631.x; GODFREY S, 1987, LANCET, V2, P851; Grimfeld A., 1994, European Respiratory Journal, V7, p27S; HAAHTELA T, 1994, NEW ENGL J MED, V331, P700, DOI 10.1056/NEJM199409153311103; HULTQUIST C, 1989, LANCET, V1, P380; ILANGOVAN P, 1993, ARCH DIS CHILD, V68, P356, DOI 10.1136/adc.68.3.356; Kemp JP, 1999, ANN ALLERG ASTHMA IM, V83, P231, DOI 10.1016/S1081-1206(10)62646-4; Lemanske RF, 1997, JAMA-J AM MED ASSOC, V278, P1855, DOI 10.1001/jama.278.22.1855; MARTINATI LC, 1995, ALLERGY, V50, P701, DOI 10.1111/j.1398-9995.1995.tb01210.x; MUELLER GA, 1992, PEDIATR CLIN N AM, V39, P1243; *NAT ASTHM ED PREV, 1997, NIH NAT HEART LUNG B; Paton J, 1996, PRACTITIONER, V240, P576; PEDERSEN S, 1989, EUR RESP J S8, V2, pS647; Pedersen S, 1997, AM J RESP CRIT CARE, V155, pA268; Powell CVE, 1998, DRUGS, V55, P237, DOI 10.2165/00003495-199855020-00005; SELROOS O, 1995, CHEST, V108, P1228, DOI 10.1378/chest.108.5.1228; Shapiro G, 1998, J ALLERGY CLIN IMMUN, V102, P789, DOI 10.1016/S0091-6749(98)70019-3; SLY PD, 1990, J ASTHMA, V27, P137, DOI 10.3109/02770909009073314; VikreJorgensen J, 1997, PEDIATR PULM, V23, P270, DOI 10.1002/(SICI)1099-0496(199704)23:4<270::AID-PPUL4>3.0.CO;2-Q; Wennergren G, 1996, ACTA PAEDIATR, V85, P183, DOI 10.1111/j.1651-2227.1996.tb13989.x; WILLIAMS PV, 1997, CLIN SCI, V49, P2	27	22	22	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1999	104	4	2				S191	S199		10.1016/S0091-6749(99)70061-8	http://dx.doi.org/10.1016/S0091-6749(99)70061-8			9	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	249RH	10518846				2022-12-18	WOS:000083345700006
J	Schwenger, GTF; Fournier, R; Hall, LM; Sanderson, CJ; Mordvinov, VA				Schwenger, GTF; Fournier, R; Hall, LM; Sanderson, CJ; Mordvinov, VA			Nuclear factor of activated T cells and YY1 combine to repress IL-5 expression in a human T-cell line	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-5; promoter; transcription; T cells; gene expression; YY1; nuclear factor of activated T cells	HUMAN INTERLEUKIN-5 GENE; TRANSCRIPTION FACTOR; BINDING-SITES; PROMOTER; IDENTIFICATION; PROTEINS; DISSECTION; ELEMENT; FAMILY; NFAT	Background: IL-5 is an inducible T-cell cytokine with the unique ability to induce eosinophilia without increases in other cell compartments. Regulation of IL-5 expression is controlled primarily at the level of transcription. The role of eosinophilia in allergic disorders indicates IL-5 as a target for therapy. Objective: This report aims to increase our understanding of IL-5 gene regulation by identifying distal control elements in the human (h) IL-5 promoter, determining the transcription factors that bind these elements and elucidating their role in control of hIL-5 gene expression, Methods: Methods used in this study include deoxyribonuclease I footprint analysis, electrophoretic mobility shift assay, and functional analysis by transfection of PER-117 cells with site-directed mutants of the hIL-5 promoter. Results: We have identified a protected region in the distal hIL-5 promoter that has sequence homology to the previously identified negative regulatory element within BR3, This protected region has not been previously reported and is shown to contain overlapping binding sites for YY1 and nuclear factor of activated cells. The binding sites exist between positions -447 and -459, and this sequence was named hPRE2-IL5, Substitution mutations that abolish binding of these proteins to hPRE2-IL5 result in a 2- to 3-fold increase in hIL-5 promoter activity in activated human T cells. Conclusion: We report the novel combination of YY1 and nuclear factor of activated T cells transcription factors binding to a distal hIL-5 promoter element where both factors are involved in down-regulation of hIL-5 gene expression in human T cell.	Curtin Univ Technol, Perth, WA 6001, Australia	Curtin University	Schwenger, GTF (corresponding author), Western Australian Inst Med Res, Mol Immunol Grp, Level 5,MRF Bldg,Rear 50 Murray St, Perth, WA 6000, Australia.		Mordvinov, Viatcheslav A/S-8277-2017	Mordvinov, Viatcheslav A/0000-0002-6173-0774				Blumenthal SG, 1999, J BIOL CHEM, V274, P12910, DOI 10.1074/jbc.274.18.12910; DEBOER ML, 1999, IN PRESS INT J BIOCH; GRUARTGOUILLEUX V, 1995, EUR J IMMUNOL, V25, P1431, DOI 10.1002/eji.1830250544; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; KARLEN S, 1993, J VIROL, V67, P4296, DOI 10.1128/JVI.67.7.4296-4306.1993; KEES UR, 1994, J IMMUNOL METHODS, V168, P1, DOI 10.1016/0022-1759(94)90202-X; LiWeber M, 1997, J IMMUNOL, V158, P1194; MORDVINOV V, 1999, IN PRESS J IMMUNOL M; Mordvinov VA, 1999, J ALLERGY CLIN IMMUN, V103, P1125, DOI 10.1016/S0091-6749(99)70188-0; Mori A, 1997, INT ARCH ALLERGY IMM, V113, P272, DOI 10.1159/000237570; NAORA H, 1994, BLOOD, V83, P3620; PRIESCHL EE, 1995, J IMMUNOL, V154, P6112; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; SANDERSON CJ, 1992, BLOOD, V79, P3101, DOI 10.1182/blood.V79.12.3101.3101; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Schwenger GTF, 1998, MOL IMMUNOL, V35, P149, DOI 10.1016/S0161-5890(98)00023-6; Shi Y, 1997, BBA-REV CANCER, V1332, pF49, DOI 10.1016/S0304-419X(96)00044-3; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; Sica A, 1997, J BIOL CHEM, V272, P30412, DOI 10.1074/jbc.272.48.30412; Stranick KS, 1997, J BIOL CHEM, V272, P16453, DOI 10.1074/jbc.272.26.16453; Sweetser MT, 1998, J BIOL CHEM, V273, P34775, DOI 10.1074/jbc.273.52.34775; YAMAGATA T, 1995, MOL CELL BIOL, V15, P3830; YANT SR, 1995, NUCLEIC ACIDS RES, V23, P4353, DOI 10.1093/nar/23.21.4353	24	22	22	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1999	104	4	1				820	827		10.1016/S0091-6749(99)70293-9	http://dx.doi.org/10.1016/S0091-6749(99)70293-9			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	248NG	10518827				2022-12-18	WOS:000083281200014
J	Zheng, XY; Knight, DA; Zhou, DY; Weir, TD; Peacock, C; Schellenberg, RR; Bai, TR				Zheng, XY; Knight, DA; Zhou, DY; Weir, TD; Peacock, C; Schellenberg, RR; Bai, TR			Leukemia inhibitory factor is synthesized and released by human eosinophils and modulates activation state and chemotaxis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cytokine; inflammation; asthma; CD69; substance P	COLONY-STIMULATING FACTOR; SUBSTANCE-P; IN-VITRO; SYMPATHETIC NEURONS; DE-GRANULATION; CYTOKINES; EXPRESSION; INDUCTION; CD69; INTERLEUKIN-6	Background: The cytokine leukemia inhibitory factor (LIF) is known to be produced by both inflamed peripheral autonomic nerves and several cell types involved in the regulation of the immune response, We have recently demonstrated that several structural cell types in human airways produce LIF in response to inflammatory stimuli and that LIF augments contractile responses to tachykinins in airway explants. Because the eosinophil is a major effector cell in asthma and often found adjacent to the nerves, we hypothesized that eosinophils produce LIF and that LIF primes and upregulates eosinophil recruitment and function, allowing bidirectional neuroimmune interactions and augmentation of eosinophil-mediated injury. Objective: The purpose of this study was to demonstrate that human eosinophils synthesize and release LIF, to determine the effects of LIF on eosinophil functions (ie, chemotaxis, granule protein release, expression of the activation marker CD69, and apoptosis), and to compare serum LIF levels between atopic and nonatopic individuals, Methods: Reverse-transcription PCR, ELISA, immunocytochemistry, chemotaxis assay, and flow cytometry were used, Results: Peripheral blood eosinophils express LIF and messenger RNA for LIF and LIF receptor, Serum LIF levels were higher in atopic patients with mild asthma than in nonatopic normal donors. Eosinophils from nonatopic donors were stimulated by calcium ionophore to release small amounts of LIF (from almost none to 5.3 +/- 1.8 pg/10(6) cells), Eosinophils from atopic donors showed a 10-fold increase (from 45.1 +/- 38.7 pg/10(6) cells to 414.5 +/- 189.9 pg/10(6) cells), Preincubation of eosinophils with LIF increased eosinophil peroxidase release 4-fold. LIF was not chemotactic for eosinophils but augmented chemotaxis mediated by substance P by 82% and by platelet-activating factor by 31%. LIF did not effect eosinophil apoptosis but increased CD69 expression. Conclusion: LIF has proinflammatory roles in eosinophil-dependent airway disorders.	Univ British Columbia, Pulm Res Lab, St Pauls Hosp, Vancouver, BC V6Z 1Y6, Canada; Univ Western Australia, Dept Med, Asthma & Allergy Res Unit, Nedlands, WA 6009, Australia	St. Paul's Hospital; University of British Columbia; University of Saskatchewan; University of Western Australia	Bai, TR (corresponding author), Univ British Columbia, Pulm Res Lab, St Pauls Hosp, 1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.							BAI TR, 1995, AM J PHYSIOL-LUNG C, V269, pL309, DOI 10.1152/ajplung.1995.269.3.L309; Bowden JJ, 1996, AM J PHYSIOL-LUNG C, V270, pL404, DOI 10.1152/ajplung.1996.270.3.L404; Bozic CR, 1996, SCIENCE, V273, P1722, DOI 10.1126/science.273.5282.1722; CORRDELL JL, 1984, J HISTOCHEM CYTOCHEM, V32, P219; CORRIGAN CJ, 1992, IMMUNOL TODAY, V13, P501, DOI 10.1016/0167-5699(92)90026-4; Costello RW, 1997, AM J PHYSIOL-LUNG C, V273, pL93, DOI 10.1152/ajplung.1997.273.1.L93; ELBON CL, 1995, AM J RESP CELL MOL, V12, P320, DOI 10.1165/ajrcmb.12.3.7873198; FUJISAWA T, 1990, J IMMUNOL, V144, P642; FUKUDA T, 1985, J IMMUNOL, V135, P1349; HAMID Q, 1992, BLOOD, V80, P1496; HARTNELL A, 1993, IMMUNOLOGY, V80, P281; HOM JT, 1993, CLIN IMMUNOL IMMUNOP, V68, P293, DOI 10.1006/clin.1993.1130; Jorens PG, 1996, CYTOKINE, V8, P873, DOI 10.1006/cyto.1996.9999; KESSLER JA, 1993, REGUL PEPTIDES, V46, P70, DOI 10.1016/0167-0115(93)90014-Y; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; Knight D, 1997, BRIT J PHARMACOL, V120, P883, DOI 10.1038/sj.bjp.0700965; Knight D, 1997, J LEUKOCYTE BIOL, V62, P465, DOI 10.1002/jlb.62.4.465; Knight DA, 1999, AM J RESP CELL MOL, V20, P834, DOI 10.1165/ajrcmb.20.4.3429; KROEGEL C, 1989, J IMMUNOL, V142, P3518; LAMKHIOUED B, 1995, INT ARCH ALLERGY IMM, V107, P122, DOI 10.1159/000236949; LEVISCHAFFER F, 1995, BLOOD, V85, P2579, DOI 10.1182/blood.V85.9.2579.bloodjournal8592579; LUDLAM WH, 1994, DEV BIOL, V164, P528, DOI 10.1006/dbio.1994.1221; Luttmann W, 1996, J IMMUNOL, V157, P1678; Martin LB, 1996, INT ARCH ALLERGY IMM, V109, P207, DOI 10.1159/000237239; MATSUNAGA Y, 1994, ARCH BIOCHEM BIOPHYS, V312, P67, DOI 10.1006/abbi.1994.1281; MELANI C, 1993, BLOOD, V81, P2744; Metcalf D, 1992, GROWTH FACTORS, V7, DOI 10.3109/08977199209046921; MOQBEL R, 1994, J ALLERGY CLIN IMMUN, V94, P1183, DOI 10.1016/0091-6749(94)90330-1; MOREAU JF, 1987, J IMMUNOL, V138, P3844; MUNOZ NM, 1994, J PHARMACOL EXP THER, V268, P139; MUSSO T, 1995, BLOOD, V86, P1961, DOI 10.1182/blood.V86.5.1961.bloodjournal8651961; NISHIKAWA K, 1992, J ALLERGY CLIN IMMUN, V90, P169, DOI 10.1016/0091-6749(92)90068-D; PATTERSON PH, 1994, P NATL ACAD SCI USA, V91, P7833, DOI 10.1073/pnas.91.17.7833; Shindo K, 1997, BIOCHEM BIOPH RES CO, V237, P146, DOI 10.1006/bbrc.1997.7098; STRATH M, 1985, J IMMUNOL METHODS, V83, P209, DOI 10.1016/0022-1759(85)90242-X; VILLIGER PM, 1993, J CLIN INVEST, V91, P1575, DOI 10.1172/JCI116363; WALKER BAM, 1989, LAB INVEST, V61, P515; Walsh GM, 1996, BLOOD, V87, P2815, DOI 10.1182/blood.V87.7.2815.bloodjournal8772815; WARDLAW AJ, 1994, POSTGRAD MED J, V70, P536, DOI 10.1136/pgmj.70.826.536; Wardlaw AJ, 1995, ADV IMMUNOL, V60, P151, DOI 10.1016/S0065-2776(08)60586-6; WARING P, 1992, J CLIN INVEST, V90, P2031, DOI 10.1172/JCI116083; WARRINGA RAJ, 1991, BLOOD, V77, P2694; WHITE SR, 1991, J IMMUNOL METHODS, V44, P257; WIEDERMANN FJ, 1993, ACTA HAEMATOL-BASEL, V89, P213	44	22	25	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1999	104	1					136	144		10.1016/S0091-6749(99)70125-9	http://dx.doi.org/10.1016/S0091-6749(99)70125-9			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	221QZ	10400851	Bronze			2022-12-18	WOS:000081738900020
J	Persi, L; Demoly, P; Harris, AG; Tisserand, B; Michel, FB; Bousquet, J				Persi, L; Demoly, P; Harris, AG; Tisserand, B; Michel, FB; Bousquet, J			Comparison between nasal provocation tests and skin tests in patients treated with loratadine and cetirizine	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						orchard grass; nasal provocation test; rhinitis; loratadine; cetirizine	PLACEBO-CONTROLLED IMMUNOTHERAPY; GRASS-POLLEN ALLERGOIDS; DOUBLE-BLIND; PHARMACOLOGICAL MODULATION; RUSH IMMUNOTHERAPY; HISTAMINE; TERFENADINE; EFFICACY; ASTEMIZOLE; SUPPRESSION	Background: The effect of H1-blockers may differ depending on the target organ. Objective: A double-blind, placebo-controlled study was carried out to compare the effect of a 7-day treatment with loratadine (10 mg daily) or cetirizine (10 mg daily) on nasal challenge with grass pollen grains and skin tests with allergen or histamine. Methods: Twenty-four patients were enrolled, but the analysis was carried out on 23, Nasal challenge was carried out by using 5-fold increasing numbers of pollen grains. Skin prick tests were done with serial concentrations of allergens and 1 concentration of histamine. Patients were tested in a cross-over design, with each treatment being administered for the previous 7 days and with a 2-week washout period. Results: By comparison with placebo, loratadine and cetirizine increased significantly the threshold number of pollen grains required to induce a positive nasal challenge (P < .001). There was no difference between loratadine and cetirizine, Skin test responses to allergen were significantly reduced by loratadine and cetirizine by comparison with placebo. Skin test responses to histamine were significantly decreased by the 2 H1-blockers, but they were more profoundly decreased by cetirizine than by loratadine. Conclusions: Both Hi-blockers reduced similarly allergen-induced skin test and nasal challenge responses. Cetirizine was more effective on histamine skin test responses.	Hop Arnaud de Villeneuve, F-34295 Montpellier 5, France; Integrated Therapeut Grp Inc, Kenilworth, NJ USA; ITEM, Verum, France	Universite de Montpellier; CHU de Montpellier	Bousquet, J (corresponding author), Hop Arnaud de Villeneuve, F-34295 Montpellier 5, France.		Bousquet, Jean/O-4221-2019; Demoly, Pascal/Y-9938-2019	Demoly, Pascal/0000-0001-7827-7964; Harris, Alan/0000-0002-6618-2092				BOUSQUET J, 1988, J ALLERGY CLIN IMMUN, V82, P439, DOI 10.1016/0091-6749(88)90017-6; BOUSQUET J, 1985, J ALLERGY CLIN IMMUN, V76, P734, DOI 10.1016/0091-6749(85)90680-3; BOUSQUET J, 1985, CLIN ALLERGY, V15, P29, DOI 10.1111/j.1365-2222.1985.tb02251.x; BOUSQUET J, 1989, J ALLERGY CLIN IMMUN, V84, P546, DOI 10.1016/0091-6749(89)90369-2; BOUSQUET J, 1990, J ALLERGY CLIN IMMUN, V85, P490, DOI 10.1016/0091-6749(90)90160-6; BOUSQUET J, 1988, J ALLERGY CLIN IMMUN, V82, P881, DOI 10.1016/0091-6749(88)90094-2; BOUSQUET J, 1991, J ALLERGY CLIN IMMUN, V88, P43, DOI 10.1016/0091-6749(91)90299-4; BOUSQUET J, 1985, CLIN ALLERGY, V15, P179, DOI 10.1111/j.1365-2222.1985.tb02272.x; BOUSQUET J, 1990, J ALLERGY CLIN IMMUN, V86, P248, DOI 10.1016/S0091-6749(05)80072-7; BOUSQUET J, 1992, THERAPEUTIC INDEX AN, P57; BOUSQUET J, 1996, HISTAMINE H1 RECEPTO, P91; BOUSQUET J, 1993, ALLERGY PRINCIPLES P, P573; FADEL R, 1990, J INT MED RES, V18, P366, DOI 10.1177/030006059001800504; Frossard N, 1997, ALLERGY, V52, P205, DOI 10.1111/j.1398-9995.1997.tb00976.x; GHYS L, 1989, J INT MED RES, V17, P24, DOI 10.1177/030006058901700103; HARIA M, 1994, DRUGS, V48, P617, DOI 10.2165/00003495-199448040-00009; Herman D, 1992, Allerg Immunol (Paris), V24, P270; HORST M, 1990, J ALLERGY CLIN IMMUN, V85, P460, DOI 10.1016/0091-6749(90)90156-X; HOWARTH PH, 1984, BRIT J CLIN PHARMACO, V18, P1; KONTOUFILI K, 1989, EUR J CLIN PHARMACOL, V36, P617, DOI 10.1007/BF00637746; LEBEL B, 1988, J ALLERGY CLIN IMMUN, V82, P869, DOI 10.1016/0091-6749(88)90092-9; LEVANDER S, 1991, EUR J CLIN PHARMACOL, V41, P435, DOI 10.1007/BF00626365; LEVER LR, 1992, SKIN PHARMACOL, V5, P29; LOBATON P, 1990, ANN ALLERGY, V65, P401; LURIA X, 1992, DRUGS TODAY SB, V28, P69; MCTAVISH D, 1990, DRUGS, V39, P552, DOI 10.2165/00003495-199039040-00006; Meltzer EO, 1996, J ALLERGY CLIN IMMUN, V97, P617, DOI 10.1016/S0091-6749(96)70307-X; PECHADRE JC, 1991, J INT MED RES, V19, P289, DOI 10.1177/030006059101900401; RIHOUX JP, 1990, ANN ALLERGY, V65, P139; RIHOUX JP, 1987, ANN ALLERGY, V59, P235; RIHOUX JP, 1992, DERMATOLOGY, V184, P111, DOI 10.1159/000247515; RIHOUX JP, 1989, DERMATOLOGICA, V179, P129, DOI 10.1159/000248338; ROMAN IJ, 1986, ANN ALLERGY, V57, P253; SIMONS FER, 1990, J ALLERGY CLIN IMMUN, V86, P540; SIMONS FER, 1994, NEW ENGL J MED, V330, P1663; SMALL P, 1992, ANN ALLERGY, V68, P30; VANNESTE D, 1993, DERMATOLOGY, V186, P281, DOI 10.1159/000247376	37	22	26	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1999	103	4					591	594		10.1016/S0091-6749(99)70229-0	http://dx.doi.org/10.1016/S0091-6749(99)70229-0			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	186HY	10200006				2022-12-18	WOS:000079723900009
J	Ohsaki, M; Tsutsumi, H; Kumagai, T; Yamanaka, T; Wataya, Y; Furukawa, H; Kojima, H; Saito, A; Yano, S; Chiba, S				Ohsaki, M; Tsutsumi, H; Kumagai, T; Yamanaka, T; Wataya, Y; Furukawa, H; Kojima, H; Saito, A; Yano, S; Chiba, S			The relevance of T-H1 and T-H2 cells in immediate and nonimmediate reactions to gelatin-containing vaccine	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						gelatin allergy; T-H1; T-H2; IL-4; IFN-gamma	BLOOD MONONUCLEAR-CELLS; IFN-GAMMA PRODUCTION; ATOPIC-DERMATITIS; IGE PRODUCTION; LYMPHOCYTE-RESPONSE; CYTOKINE PRODUCTION; INTERFERON-GAMMA; MESSENGER-RNA; CHILDREN; IL-13	Background: The immune mechanism of gelatin allergy, especially the participation of T-H1 and T-H2 cells and their cytokine secretion, has not been investigated. Objective: We investigated the characteristics of T lymphocytes from patients allergic to gelatin-containing vaccine by secondary in vitro stimulation of circulating mononuclear cells with gelatin. Methods: We studied 8 children with a history of immediate-type reactions and 8 with nonimmediate-type reactions after inoculation of gelatin-containing vaccine. The expression of IFN-gamma (T-H1), IL-2 (T-H1), IL-4 (T-H2), and IL-13 (T-H2) mRNA was examined semiquantitatively by using a reverse transcriptase PCR. IgE antibody to bovine gelatin was measured with the fluorometric ELISA system, and gelatin-specific T-cell responses were detected by an in vitro lymphocyte proliferation assay. Results: Patients with an immediate reaction all had gelatin-specific IgE antibody whereas others did not. However, all patients exhibited positive T-lymphocyte responses specific to gelatin, Lymphocytes from subjects with nonimmediate-type reactions generally expressed very weak or sometimes no IFN-gamma, IL-2, or IL-13 genes and especially no IL-4 gene. On the other hand, the lymphocytes of subjects with immediate-type reactions significantly expressed not only IL-4 and IL-13 but also IFN-gamma and IL-2 mRNA. Conclusion: Our observations suggest that both gelatin-specific T-H2 and T-H1 responses are involved in the pathogenesis of the immediate reaction to gelatin. The gelatin-specific IL-4 and/or IL-13 responses consistently observed in patients with an immediate reaction may be associated with the production of gelatin-specific IgE antibody.	Sapporo Med Univ, Sch Med, Dept Pediat, Chuo Ku, Sapporo, Hokkaido 0608543, Japan; Pediat Allergy & Infect Dis Soc Sapporo, Sapporo, Hokkaido, Japan; Hokkaido Inst Publ Hlth, Sapporo, Hokkaido, Japan	Sapporo Medical University	Tsutsumi, H (corresponding author), Sapporo Med Univ, Sch Med, Dept Pediat, Chuo Ku, S-1,W-16, Sapporo, Hokkaido 0608543, Japan.							BYRON KA, 1994, CLIN EXP ALLERGY, V24, P878, DOI 10.1111/j.1365-2222.1994.tb01810.x; Chang JH, 1996, J ALLERGY CLIN IMMUN, V98, P922, DOI 10.1016/S0091-6749(96)80008-X; DELPRETE G, 1988, J IMMUNOL, V140, P4193; DOLECEK C, 1995, CLIN EXP ALLERGY, V25, P879, DOI 10.1111/j.1365-2222.1995.tb00031.x; GAGNON R, 1993, J ALLERGY CLIN IMMUN, V91, P950, DOI 10.1016/0091-6749(93)90353-H; GAUCHAT JF, 1990, J EXP MED, V172, P463, DOI 10.1084/jem.172.2.463; HUANG SK, 1995, J IMMUNOL, V155, P2688; Katagiri K, 1997, CLIN EXP IMMUNOL, V108, P289, DOI 10.1046/j.1365-2249.1997.d01-1015.x; KELSO JM, 1993, J ALLERGY CLIN IMMUN, V91, P867, DOI 10.1016/0091-6749(93)90344-F; KONDO N, 1993, J ALLERGY CLIN IMMUN, V91, P658, DOI 10.1016/0091-6749(93)90272-H; KUBOTA Y, 1994, CONTACT DERMATITIS, V31, P217, DOI 10.1111/j.1600-0536.1994.tb01991.x; Kumagai T, 1997, J ALLERGY CLIN IMMUN, V100, P130, DOI 10.1016/S0091-6749(97)70204-5; Levy F, 1997, INT ARCH ALLERGY IMM, V112, P49, DOI 10.1159/000237431; Li Y, 1996, INT IMMUNOL, V8, P897, DOI 10.1093/intimm/8.6.897; MOCHIZUKI Y, 1995, J JPN PEDIAT SOC, V99, P873; Mosmann TR, 1996, IMMUNOL TODAY, V17, P138, DOI 10.1016/0167-5699(96)80606-2; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; Nakajima H, 1996, J ALLERGY CLIN IMMUN, V97, P1342, DOI 10.1016/S0091-6749(96)70203-8; OGURA H, 1995, INFECT IMMUN CHILD, V7, P115; Reekers R, 1996, BRIT J DERMATOL, V135, P935, DOI 10.1046/j.1365-2133.1996.d01-1098.x; Robinson DS, 1996, CHEM IMMUNOL, V63, P187; Romagnani S, 1996, CLIN IMMUNOL IMMUNOP, V80, P225, DOI 10.1006/clin.1996.0118; SAKAGUCHI M, 1995, J ALLERGY CLIN IMMUN, V96, P563, DOI 10.1016/S0091-6749(95)70304-7; SAKAGUCHI M, 1995, J ALLERGY CLIN IMMUN, V84, P246; Shinbara M, 1996, ANN ALLERG ASTHMA IM, V77, P60, DOI 10.1016/S1081-1206(10)63481-3; Takeuchi R, 1998, J VIROL, V72, P837, DOI 10.1128/JVI.72.1.837-840.1998; Tsai SL, 1996, CLIN EXP IMMUNOL, V103, P99, DOI 10.1046/j.1365-2249.1996.00871.x; Tsutsumi H, 1996, CLIN EXP IMMUNOL, V106, P442, DOI 10.1046/j.1365-2249.1996.d01-874.x; Umetsu DT, 1997, P SOC EXP BIOL MED, V215, P11; VanVoorhis WC, 1996, J INFECT DIS, V173, P491, DOI 10.1093/infdis/173.2.491; Werfel T, 1997, J ALLERGY CLIN IMMUN, V99, P124, DOI 10.1016/S0091-6749(97)81053-6	31	22	22	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1999	103	2	1				276	281		10.1016/S0091-6749(99)70502-6	http://dx.doi.org/10.1016/S0091-6749(99)70502-6			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	167JW	9949319	Bronze			2022-12-18	WOS:000078630100015
J	Ylitalo, L; Alenius, H; Turjanmaa, K; Palosuo, T; Reunala, T				Ylitalo, L; Alenius, H; Turjanmaa, K; Palosuo, T; Reunala, T			IgE antibodies to prohevein, hevein, and rubber elongation factor in children with latex allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						natural rubber latex; prohevein; hevein; rubber elongation factor; IgE antibodies; immunoblotting; ELISA; children; surgery	SPINA-BIFIDA; PROTEINS; GLOVES; IDENTIFICATION; PURIFICATION; HEV-B-5; CLONING; CLUSTER	Background: Prohevein (Hev b 6.01) and hevein (Hev b 6.02) have been shown to be major IgE-binding allergens in health care workers and other adult patients allergic to natural rubber latex (NRL). Rubber elongation factor (REP; Hev b 1) and the 23/27 kd NRL allergen (Hev b 3) are characteristic of children with latex allergy who have spina bifida and other children requiring multiple operations at an early age, In addition, there are children with latex allergy and no history of multiple operations in whom sensitizing allergens are not known. Objectives: We studied IgE antibodies to NRL allergens in children with latex allergy who had not undergone surgery and compared the findings with those in children with latex allergy and a history of multiple operations. Methods: Sera from 30 children with latex allergy who had not undergone surgery, 12 children with Latex allergy with a history of multiple operations, and 19 control children without evidence of NRL allergy were examined, Immunoblotting was used to study IgE binding to NRL proteins, and purified prohevein, hevein, and REP were used in ELISA to measure specific IgE antibodies. Results: In immunoblotting, sera from 21 (70%) children who had not undergone surgery and from 4 (33%) children with a history of multiple operations showed IgE binding to a 20-kd protein band (known to contain prohevein), and 9 (30%) and 8 (67%) sera, respectively, to a 14-kd protein band (known to contain REP). In ELISA, sera from 26 (86%) children who had not undergone surgery and from 7 (58%) children with a history of multiple operations had IgE antibodies to prohevein and 19 (63%) and 7 (58%) sera, respectively, to hevein. Eight (27%) sera from the children who had not undergone surgery had IgE antibodies to REP in contrast to 8 (67%) sera from children with a history of multiple operations. Conclusions: The IgE antibody pattern differs between children with Latex allergy who had not undergone surgery and those with a history of multiple operations. The major allergens in children with no history of surgery appear to be prohevein and hevein and not REF, a finding that agrees well with that reported for health care workers with allergy to latex.	Tampere Univ Hosp, Dept Dermatol, FIN-33521 Tampere, Finland; Natl Inst Occupat Hlth, Helsinki, Finland; Univ Tampere, Sch Med, FIN-33101 Tampere, Finland; Natl Publ Hlth Inst, Helsinki, Finland; Univ Helsinki, Hosp Skin & Allerg Dis, Helsinki, Finland	Tampere University; Tampere University Hospital; Tampere University; Finland National Institute for Health & Welfare; University of Helsinki	Ylitalo, L (corresponding author), Tampere Univ Hosp, Dept Dermatol, POB 2000, FIN-33521 Tampere, Finland.			Alenius, Harri/0000-0003-0106-8923				Akasawa A, 1996, J BIOL CHEM, V271, P25389, DOI 10.1074/jbc.271.41.25389; ALENIUS H, 1995, CLIN EXP ALLERGY, V25, P659, DOI 10.1111/j.1365-2222.1995.tb01114.x; Alenius H, 1996, INT ARCH ALLERGY IMM, V109, P362, DOI 10.1159/000237264; ALENIUS H, 1993, INT ARCH ALLERGY IMM, V102, P61, DOI 10.1159/000236551; ALENIUS H, 1994, J LAB CLIN MED, V123, P712; Alenius H, 1996, J IMMUNOL, V156, P1618; ALENIUS H, 1995, INT ARCH ALLERGY IMM, V106, P258, DOI 10.1159/000236851; AXELSSON I, 1998, ACTA PAEDIATR SCAND, V77, P14; Beezhold DH, 1996, CLIN EXP ALLERGY, V26, P416, DOI 10.1046/j.1365-2222.1996.d01-334.x; Chen ZP, 1997, J ALLERGY CLIN IMMUN, V100, P684, DOI 10.1016/S0091-6749(97)70174-X; Chen ZP, 1997, J ALLERGY CLIN IMMUN, V99, P402, DOI 10.1016/S0091-6749(97)70059-9; KELLY KJ, 1994, J ALLERGY CLIN IMMUN, V94, P53, DOI 10.1016/0091-6749(94)90071-X; LAGIER F, 1992, J ALLERGY CLIN IMMUN, V90, P319, DOI 10.1016/S0091-6749(05)80009-0; Liebke C, 1996, PEDIATR ALLERGY IMMU, V7, P103, DOI 10.1111/j.1399-3038.1996.tb00115.x; LU I, 1995, J IMMUNOL, V155, P2721; MIKKOLA K, 1997, J ALLERGY CLIN IMMUN, V99, P342; Palosuo T, 1998, ALLERGY, V53, P59, DOI 10.1111/j.1398-9995.1998.tb03774.x; SLATER JE, 1992, J ALLERGY CLIN IMMUN, V89, P673, DOI 10.1016/0091-6749(92)90373-A; SLATER JE, 1991, J UROLOGY, V146, P578, DOI 10.1016/S0022-5347(17)37860-6; Slater JE, 1996, J BIOL CHEM, V271, P25394, DOI 10.1074/jbc.271.41.25394; SORVA R, 1995, PEDIATR ALLERGY IMMU, V6, P36, DOI 10.1111/j.1399-3038.1995.tb00255.x; TURJANMAA K, 1988, CONTACT DERMATITIS, V19, P362, DOI 10.1111/j.1600-0536.1988.tb02953.x; Turjanmaa K, 1997, ALLERGY, V52, P41, DOI 10.1111/j.1398-9995.1997.tb02544.x; Turjanmaa K, 1996, ALLERGY, V51, P593, DOI 10.1111/j.1398-9995.1996.tb04678.x; TURJANMAA K, 1987, CONTACT DERMATITIS, V17, P270, DOI 10.1111/j.1600-0536.1987.tb01476.x; Yeang HY, 1996, J ALLERGY CLIN IMMUN, V98, P628, DOI 10.1016/S0091-6749(96)70097-0; Ylitalo L, 1997, J ALLERGY CLIN IMMUN, V100, P606, DOI 10.1016/S0091-6749(97)70163-5; YUNGINGER JW, 1994, J ALLERGY CLIN IMMUN, V93, P836, DOI 10.1016/0091-6749(94)90374-3	28	22	23	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1998	102	4	1				659	664		10.1016/S0091-6749(98)70284-2	http://dx.doi.org/10.1016/S0091-6749(98)70284-2			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	131XK	9802376				2022-12-18	WOS:000076600400018
J	Woodcock, A				Woodcock, A			Effects of inhaled corticosteroids on bone density and metabolism	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						inhaled corticosteroids; bone density; bone metabolism; fluticasone; propionate; beclomethasone dipropionate; asthma	BECLOMETHASONE DIPROPIONATE; MINERAL DENSITY; OSTEOPOROSIS; TERM	Oral corticosteroids have adverse effects on bone density and metabolism. With the increased use of inhaled corticosteroids together dth the use of higher doses for the treatment of asthma, the long-term effects of inhaled corticosteroids on bone metabolism and density must be evaluated. This article discusses the markers of bone resorption and formation together with techniques used to measure cortical and trabceular bone density, The effects of inhaled corticosteroids on bone density and metabolism as determined by these techniques are described in detail. Overall, inhaled corticosteroids are extremely safe, even at high doses, with the longterm risk of bone loss being extremely small compared with oral corticosteroids. In particular, fluticasone propionate at the recommended doses appears to be free of effects on bone density and metabolism. Finally, the use of inhaled corticosteroids results in the control of asthma, allowing patients to exercise, which itself improves bone density and protects against osteoporosis.	Wythenshawe Hosp, NW Lung Ctr, Lung Funct Unit, Manchester M23 9LT, Lancs, England	Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital	Woodcock, A (corresponding author), Wythenshawe Hosp, NW Lung Ctr, Lung Funct Unit, Southmoor Rd, Manchester M23 9LT, Lancs, England.			Woodcock, Ashley/0000-0002-5428-8578				Bootsma GP, 1996, AM J RESP CRIT CARE, V153, P924, DOI 10.1164/ajrccm.153.3.8630574; BOULET LP, 1994, J ALLERGY CLIN IMMUN, V94, P796, DOI 10.1016/0091-6749(94)90145-7; DEMPSTER DW, 1993, LANCET, V341, P797, DOI 10.1016/0140-6736(93)90570-7; EASTELL R, 1995, J INTERN MED, V237, P439, DOI 10.1111/j.1365-2796.1995.tb00868.x; EGAN J, 1995, THORAX S2, V50, P109; HANANIA NA, 1995, AM J MED, V98, P196, DOI 10.1016/S0002-9343(99)80404-5; HERRALA J, 1994, BONE, V15, P621, DOI 10.1016/8756-3282(94)90309-3; HOPP RJ, 1995, ANN ALLERG ASTHMA IM, V75, P143; HUGHES J, 1996, THORAX S3, V51, pA172; KERSTJENS HAM, 1994, THORAX, V49, P652, DOI 10.1136/thx.49.7.652; Packe GE, 1996, J ROY COLL PHYS LOND, V30, P128; PAUWELS RA, 1995, AM J RESP CRIT CARE, V151, pA276; PECK WA, 1993, AM J MED, V94, P646; POUW EM, 1991, BRIT MED J, V302, P627, DOI 10.1136/bmj.302.6777.627	14	22	22	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1998	101	4	2	S			S456	S459		10.1016/S0091-6749(98)70159-9	http://dx.doi.org/10.1016/S0091-6749(98)70159-9			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZK101	9563372	Bronze			2022-12-18	WOS:000073285000006
J	Umpierrez, A; Cuesta-Herranz, J; Heras, MD; Lluch-Bernal, M; Figueredo, E; Sastre, J				Umpierrez, A; Cuesta-Herranz, J; Heras, MD; Lluch-Bernal, M; Figueredo, E; Sastre, J			Successful desensitization of a fixed drug eruption caused by allopurinol	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									Fdn Jimenez Diaz, Serv Alergia, E-28040 Madrid, Spain		Sastre, J (corresponding author), Fdn Jimenez Diaz, Serv Alergia, Avda Reyes Catolicos 2,Ciudad Univ, E-28040 Madrid, Spain.							AUDICANA M, 1990, Clinical and Experimental Allergy, V20, P121; *BOST COLL DRUG SU, 1972, NEW ENGL J MED, V286, P505; GARCESM, 1995, ALLERGY S26, V50, P213; Kelso JM, 1996, J ALLERGY CLIN IMMUN, V97, P1171, DOI 10.1016/S0091-6749(96)70275-0; MEYRIER A, 1976, BRIT MED J, V2, P458, DOI 10.1136/bmj.2.6033.458	5	22	26	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1998	101	2	1				286	287		10.1016/S0091-6749(98)70396-3	http://dx.doi.org/10.1016/S0091-6749(98)70396-3			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YZ342	9500766	Bronze			2022-12-18	WOS:000072244800022
J	Toci, G; Shah, S; Al-Faqih, A; Beezold, D; McGeady, SJ				Toci, G; Shah, S; Al-Faqih, A; Beezold, D; McGeady, SJ			Oral latex desensitization of healthcare workers.	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract									Thomas Jefferson Univ, Philadelphia, PA 19107 USA	Jefferson University									0	22	22	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1998	101	1	2			665	S161	S161						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YW339					2022-12-18	WOS:000071924800665
J	Borgonovo, B; Casorati, G; Frittoli, E; Gaffi, D; Crimi, E; Burastero, SE				Borgonovo, B; Casorati, G; Frittoli, E; Gaffi, D; Crimi, E; Burastero, SE			Recruitment of circulating allergen-specific T lymphocytes to the lung on allergen challenge in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						T lymphocytes; migration; allergy; asthma; bronchial provocation tests	LOWER RESPIRATORY-TRACT; BRONCHOALVEOLAR LAVAGE; EPITHELIAL SURFACE; GENE-EXPRESSION; CELLS; ACTIVATION; INTERLEUKIN-5; MACROPHAGES; EXPOSURE; SYSTEM	Background: In allergic subjects with asthma, the migration of CD4(+) T cells to the lungs in the hours after allergen exposure may contribute to allergic inflammation in the target organ. Objective: We studied allergen-specific T cells from the peripheral blood and lungs of allergic subjects with asthma at baseline and after allergen challenge. Methods: In each patient, blood samples were taken 10 minutes before and 24 hours after the inhalation of a major sensitizing allergen. In vitro proliferation of peripheral blood CD4(+) T cells specific for the same allergen used in the in vivo challenge was assessed. In one patient two Dermatophagoides pteronyssinus-specific T-cell clones (TCCs) were derived from peripheral blood, and their T-cell receptors mere sequenced to determine their clonotypic determinants on the beta chains. The T-cell receptor determinants of the allergen-specific TCCs were sought in blood and bronchoalveolar lavage samples taken from this patient. Results: We found that allergen inhalation is followed by a decrement in the specific proliferation of peripheral CD4+ T cells to the same allergen used for bronchial provocation. In one patient the clonotypic determinants of two allergen-specific TCCs diminished in the peripheral blood, whereas they were simultaneously expanded in the lower respiratory tract. Conclusion: Our data suggest that allergen-specific T cells are recruited from the peripheral blood to the bronchial lumen after allergen challenge.	SAN RAFFAELE SCI INST,DIBIT,I-20132 MILAN,ITALY; UNIV GENOA,DIPARTIMENTO SCI MOTORIE & RIABIL,FAC MED & CHIRURG,GENOA,ITALY	University of Genoa			, Burastero/AAN-2425-2020; Casorati, Giulia/J-7141-2018	, Burastero/0000-0001-7302-6381; Casorati, Giulia/0000-0002-5102-4112				American Thoracic Society, 1987, AM REV RESPIR DIS, V136, P224; BABI LFS, 1995, J IMMUNOL, V154, P1543; Burastero SE, 1996, EUR RESPIR J, V9, P319, DOI 10.1183/09031936.96.09020319; BURASTERO SE, 1995, J IMMUNOL, V155, P5836; BUTCHER EC, 1986, CURR TOP MICROBIOL, V128, P85; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; CASANOVA JL, 1990, NUCLEIC ACIDS RES, V18, P4028, DOI 10.1093/nar/18.13.4028; CHOI Y, 1989, P NATL ACAD SCI USA, V243, P217; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Crimi E, 1997, J ALLERGY CLIN IMMUN, V99, P788, DOI 10.1016/S0091-6749(97)80013-9; DELPRETE GF, 1993, EUR J IMMUNOL, V23, P1445, DOI 10.1002/eji.1830230707; GENEVEE C, 1992, EUR J IMMUNOL, V22, P1261, DOI 10.1002/eji.1830220522; GERBLICH AA, 1984, NEW ENGL J MED, V310, P1349, DOI 10.1056/NEJM198405243102103; GERBLICH AA, 1991, AM REV RESPIR DIS, V143, P533, DOI 10.1164/ajrccm/143.3.533; HARMSEN AG, 1985, SCIENCE, V230, P1277, DOI 10.1126/science.4071052; HOLT PG, 1986, CLIN EXP IMMUNOL, V63, P261; LASALLE JM, 1992, J EXP MED, V176, P177, DOI 10.1084/jem.176.1.177; MCFADDEN ER, 1994, NEW ENGL J MED, V330, P1362, DOI 10.1056/NEJM199405123301907; *NAT ASTHM ED PROG, 1991, GUID TREATM MAN ASTH, V91, P3042; PABST R, 1992, IMMUNOL TODAY, V13, P119, DOI 10.1016/0167-5699(92)90106-H; QUANJER PH, 1983, B EUR PHYSIOPATH RES, V19, P1; RABBITTS TH, 1985, EMBO J, V4, P1461, DOI 10.1002/j.1460-2075.1985.tb03803.x; REYNOLDS HY, 1991, PHYSIOL REV, V71, P1117, DOI 10.1152/physrev.1991.71.4.1117; ROBINSON D, 1993, AM REV RESPIR DIS, V148, P401, DOI 10.1164/ajrccm/148.2.401; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; SALTINI C, 1988, CLIN IMMUNOL IMMUNOP, V46, P221, DOI 10.1016/0090-1229(88)90185-7; SALTINI C, 1990, J EXP MED, V171, P1123, DOI 10.1084/jem.171.4.1123; SCHONHEGRAD MA, 1991, J EXP MED, V173, P1345, DOI 10.1084/jem.173.6.1345; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; Sprent J, 1980, Monogr Allergy, V16, P233; Wack A, 1996, J IMMUNOL METHODS, V196, P181, DOI 10.1016/0022-1759(96)00114-7; WALLAERT B, 1995, J EXP MED, V182, P1897, DOI 10.1084/jem.182.6.1897; WANG AM, 1990, PCR PROTOCOLS GUIDE, V1; XIA WJ, 1995, J EXP MED, V181, P1275, DOI 10.1084/jem.181.4.1275; YSSEL H, 1994, CURR OPIN IMMUNOL, V6, P847, DOI 10.1016/0952-7915(94)90003-5; YSSEL H, 1992, J IMMUNOL, V148, P738	36	22	27	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1997	100	5					669	678		10.1016/S0091-6749(97)70172-6	http://dx.doi.org/10.1016/S0091-6749(97)70172-6			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YG202	9389298				2022-12-18	WOS:A1997YG20200015
J	Rautiainen, J; Rytkonen, M; Virtanen, T; Pentikainen, J; Zeiler, T; Mantyjarvi, R				Rautiainen, J; Rytkonen, M; Virtanen, T; Pentikainen, J; Zeiler, T; Mantyjarvi, R			BDA20, a major bovine dander allergen characterized at the sequence level, is Bos d 2	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											Rautiainen, J (corresponding author), UNIV KUOPIO,DEPT CLIN MICROBIOL,POB 1627,FIN-70211 KUOPIO,FINLAND.			Rytkonen-Nissinen, Marja/0000-0002-2014-8315				Mantyjarvi R, 1996, J ALLERGY CLIN IMMUN, V97, P1297, DOI 10.1016/S0091-6749(96)70198-7; MARSH DG, 1986, B WORLD HEALTH ORGAN, V64, P767; PRAHL P, 1982, INT ARCH ALLER A IMM, V67, P293, DOI 10.1159/000233036; Rautiainen J, 1996, ALLERGY, V51, P378, DOI 10.1111/j.1398-9995.1996.tb04633.x; YLONEN J, 1994, J ALLERGY CLIN IMMUN, V93, P851, DOI 10.1016/0091-6749(94)90377-8	5	22	22	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1997	100	2					251	252		10.1016/S0091-6749(97)70232-X	http://dx.doi.org/10.1016/S0091-6749(97)70232-X			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	XR351	9275148	Bronze			2022-12-18	WOS:A1997XR35100017
J	King, TP; Lu, G				King, TP; Lu, G			Hornet venom allergen antigen 5, Dol m 5: Its T-cell epitopes in mice and its antigenic cross-reactivity with a mammalian testis protein	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergen; antigen 5; hornet; yellow jacket; wasp	AMINO-ACID-SEQUENCES; MYELIN BASIC-PROTEIN; DUST MITE ALLERGEN; FIRE ANT VENOM; SOL-I-III; HYMENOPTERA VENOM; MOLECULAR-CLONING; RESPONSES; PEPTIDES; GENE	Background: A major venom allergen of white-faced hornet (Dolichovespula maculata) is antigen 5, Dol m 5. It is a 204-residue protein having 23% to 35% sequence identity with several proteins from diverse sources. The biologic function of antigen 5 and its sequence-related proteins is not known. Objective: This study mas dune to delineate the T-cell epitopes of Dol m 5 and to test their cross-reactivity with a sequence-related mouse testis protein, tpx. Methods: T-cell epitope mapping and cross-reactivity were studied with 15- or 20-residue peptides bf their stimulation of spleen cells from mice immunized with recombinant Dol m 5 or tpx fragments. Results: Three of 20 peptides studied were found to represent major T-cell epitopes of Dol m 5, being recognized by five or all of six mouse strains tested. One major epitope peptide. residue 176-195, showed cross-reactivity in BALB/c mice with the homologous antigen 5s from yellow jackets and wasps, as well as with mouse tpx. The cross reactivity of Dol m 5 and mouse tpx is not reciprocal because spleen cells from tpx-immunized mice mere stimulated by the hornet peptide, but cells from Dol m S-immunized mice mere not stimulated by the corresponding tpx peptides. Conclusion: Cross-reactivity of vespid antigen 5 and mouse tps mag be of importance in insect allergy because human and mouse testis proteins are highly homologous.			King, TP (corresponding author), ROCKEFELLER UNIV,1230 YORK AVE,NEW YORK,NY 10021, USA.				NIAID NIH HHS [AI-17021] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI017021] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Blaher B, 1996, J ALLERGY CLIN IMMUN, V98, P124, DOI 10.1016/S0091-6749(96)70234-8; BRINER TJ, 1993, P NATL ACAD SCI USA, V90, P7608, DOI 10.1073/pnas.90.16.7608; CARBALLIDO JM, 1993, J IMMUNOL, V150, P3582; CHANG JY, 1982, BIOCHEM J, V203, P803, DOI 10.1042/bj2030803; CORNELISSEN BJC, 1986, EMBO J, V5, P37, DOI 10.1002/j.1460-2075.1986.tb04174.x; EBNER C, 1995, J IMMUNOL, V154, P1932; FANG KSY, 1988, P NATL ACAD SCI USA, V85, P895, DOI 10.1073/pnas.85.3.895; FEHLNER PF, 1991, J IMMUNOL, V146, P799; GMACHL M, 1993, P NATL ACAD SCI USA, V90, P3569, DOI 10.1073/pnas.90.8.3569; Hawdon JM, 1996, J BIOL CHEM, V271, P6672, DOI 10.1074/jbc.271.12.6672; HOFFMAN DR, 1993, J ALLERGY CLIN IMMUN, V92, P707, DOI 10.1016/0091-6749(93)90014-7; HOFFMAN DR, 1994, INT ARCH ALLERGY IMM, V104, P184, DOI 10.1159/000236728; HOFFMAN DR, 1993, J ALLERGY CLIN IMMUN, V91, P71, DOI 10.1016/0091-6749(93)90298-T; HOYNE GF, 1993, J EXP MED, V178, P1783, DOI 10.1084/jem.178.5.1783; KASAHARA M, 1989, GENOMICS, V5, P527, DOI 10.1016/0888-7543(89)90019-0; KING TP, 1978, BIOCHEMISTRY-US, V17, P5165, DOI 10.1021/bi00617a016; KING TP, 1987, MOL IMMUNOL, V24, P857, DOI 10.1016/0161-5890(87)90188-X; KING TP, 1995, J IMMUNOL, V154, P577; King TP, 1996, J ALLERGY CLIN IMMUN, V98, P588, DOI 10.1016/S0091-6749(96)70093-3; KINT TP, 1994, WHO B, V72, P797; KRISTENSEN NM, UNPUB INDUCTION T CE; LIN Y, 1993, P NATL ACAD SCI USA, V90, P10071, DOI 10.1073/pnas.90.21.10071; LU G, 1993, J IMMUNOL, V150, P2823; LU G, 1995, J BIOL CHEM, V270, P4457, DOI 10.1074/jbc.270.9.4457; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; MIZUKI N, 1992, MAMM GENOME, V3, P274, DOI 10.1007/BF00292155; MORRISSETTE J, 1995, BIOPHYS J, V68, P2280, DOI 10.1016/S0006-3495(95)80410-8; MULLER UR, 1990, INSECT STING ALLERGY, P54; MURPHY EV, 1995, GENE, V159, P131, DOI 10.1016/0378-1119(95)00061-A; NORMAN PS, 1995, J ALLERGY CLIN IMMUN, V95, P259; OBRIEN RM, 1995, IMMUNOLOGY, V86, P176; OHEHIR RE, 1993, EUR J CLIN INVEST, V23, P763, DOI 10.1111/j.1365-2362.1993.tb00729.x; OKA K, 1991, BIOCHIM BIOPHYS ACTA, V1089, P13, DOI 10.1016/0167-4781(91)90078-Z; RUDENSKY AY, 1991, NATURE, V353, P622, DOI 10.1038/353622a0; SCHMIDT M, 1994, J ALLERGY CLIN IMMUN, V93, P223; SETTIPANE GA, 1980, CLIN ALLERGY, V10, P659, DOI 10.1111/j.1365-2222.1980.tb02149.x; SLOANLANCASTER J, 1995, CURR OPIN IMMUNOL, V7, P103, DOI 10.1016/0952-7915(95)80035-2; SOLDATOVA L, 1993, FEBS LETT, V320, P145, DOI 10.1016/0014-5793(93)80080-E; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; UPHAM JW, 1995, CLIN EXP ALLERGY, V25, P634, DOI 10.1111/j.1365-2222.1995.tb01111.x; WUCHERPFENNIG KW, 1995, CELL, V80, P695, DOI 10.1016/0092-8674(95)90348-8; WUCHERPFENNIG KW, 1994, J EXP MED, V179, P279, DOI 10.1084/jem.179.1.279	42	22	23	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1997	99	5					630	639		10.1016/S0091-6749(97)70025-3	http://dx.doi.org/10.1016/S0091-6749(97)70025-3			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WY600	9155830				2022-12-18	WOS:A1997WY60000011
J	Prenner, BM; Chervinsky, P; Hampel, FC; Howland, WC; Lawrence, M; Meltzer, EO; Munk, ZM; Ratner, PH; Seltzer, JM; Settipane, GA; Lorber, RR; Harrison, JE				Prenner, BM; Chervinsky, P; Hampel, FC; Howland, WC; Lawrence, M; Meltzer, EO; Munk, ZM; Ratner, PH; Seltzer, JM; Settipane, GA; Lorber, RR; Harrison, JE			Double-strength beclomethasone dipropionate (84 mu g/spray) aqueous nasal spray in the treatment of seasonal allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						seasonal allergic rhinitis; beclomethasone dipropionate; intranasal corticosteroids	CORTICOSTEROIDS; THERAPY; ASTHMA	Background: The use of intranasally administered corticosteroid sprays in an established treatment option for seasonal allergic rhinitis. Methods: In this double-blind, placebo-controlled, multicenter study, 438 patients with moderate to severe symptoms of seasonal allergic rhinitis were treated for 4 weeks with double-strength beclomethasone dipropionate (BDP) aqueous nasal spray (84 mu g/spray: BDP-ds), once daily; regular-strength BDP (42 mu g/spray: BDP-rs), twice daily; high-strength BDP (336 mu g/spray: BDP-hs), once daily; or placebo. BDP-hs was included as a safety comparison group. All treatments were given as two sprays per nostril. Results: Physician-rated nasal symptom scores were significantly improved in all three active treatment groups compared with those of the placebo group within the initial 3 days of treatment. Improvement was maintained throughout the 4-week treatment period. BDP-ds and BDP-rs were equivalent at all time points. The BDP-ds, BDP-rs, and BDP-hs groups had greater numbers of patients with a good or excellent therapeutic response at end point than the placebo group. All treatments were well-tolerated, and no unexpected adverse events were reported. no effects on laboratory evaluations or vital signs were evident for any treatment group. Conclusions: The results of this study show that BDP-ds given once a day and BDP-rs given twice a day in the same total daily dose are comparably safe and effective in the treatment of patients with seasonal allergic rhinitis.	ALLERGY ASSOCIATES MED GRP INC,SAN DIEGO,CA; NEW ENGLAND RES CTR INC,N DARTMOUTH,MA; CENT TEXAS HLTH RES,NEW BRAUNFELS,TX; HLTHQUEST THERAPY & RES INST INC,AUSTIN,TX; CLIN RES CTR,TAUNTON,MA; ALLERGY & ASTHMA MED GRP & RES CTR,SAN DIEGO,CA; BRECO RES,HOUSTON,TX; SYLVANA RES,SAN ANTONIO,TX; CLIN RES INST INC,SAN DIEGO,CA; ASTHMA NASAL DIS & ALLERGY RES CTR NEW ENGLAND,PROVIDENCE,RI; SCHERING PLOUGH RES INST,KENILWORTH,NJ	Merck & Company; Schering-Plough Research Institute								APTER AJ, 1994, J ALLERGY CLIN IMMUN, V94, P723; BRANNAN MD, 1995, CLIN THER, V17, P638; HORN CR, 1990, RESP MED, V84, P67, DOI 10.1016/S0954-6111(08)80097-2; JUNIPER EF, 1992, CAN MED ASSOC J, V147, P887; MABRY RL, 1992, OTOLARYNG HEAD NECK, V107, P855, DOI 10.1177/019459989210700608.2; MANN MC, 1992, CHEST, V102, P1342, DOI 10.1378/chest.102.5.1342; NACLERIO RM, 1991, NEW ENGL J MED, V325, P860; Nuutinen J, 1983, Rhinology, V21, P165; NUUTINEN J, 1987, Rhinology (Utrecht), V25, P121; PAUWELS R, 1986, CLIN ALLERGY, V16, P281, DOI 10.1111/j.1365-2222.1986.tb01959.x; RATNER P, 1993, J ALLERGY CLIN IMMUN, V91, P194; VANAS A, 1993, J ALLERGY CLIN IMMUN, V91, P1146, DOI 10.1016/0091-6749(93)90317-9; 1980, CLIN ALLERGY, V10, P239	13	22	25	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1996	98	2					302	308		10.1016/S0091-6749(96)70154-9	http://dx.doi.org/10.1016/S0091-6749(96)70154-9			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VC995	8757207				2022-12-18	WOS:A1996VC99500009
J	Shalit, M; Sekhsaria, S; Li, F; Mauhorter, S; Mahanti, S; Malech, HL				Shalit, M; Sekhsaria, S; Li, F; Mauhorter, S; Mahanti, S; Malech, HL			Early commitment to the eosinophil lineage by cultured human peripheral blood CD34(+) cells: Messenger RNA analysis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eosinophils; peripheral blood CD34(+) cells; mRNA; growth factors	COLONY-STIMULATING FACTOR; RESPIRATORY BURST; INTERFERON-GAMMA; MAST-CELLS; PROGENITOR CELLS; GROWTH-FACTORS; DIFFERENTIATION; EXPRESSION; PROTEIN; IL-3	Early hematopoietic progenitors expressing the CD34(+) phenotype can be harvested from the peripheral blood of normal individuals. We have optimized the liquid culture of human CD34(+) peripheral blood progenitors (PBPs) to achieve differentiation into a population of cells consisting almost entirely of eosinophil progenitors and maturing eosinophils. Growth of CD34(+) PBPs for 28 days in the presence of the combination of IL-3, granulocyte-macrophage colony-stimulating factor, and IL-5 resulted in an almost 250-fold increase in cell number, yielding a population that contained 83% maturing eosinophils. The residual population consisted of basophils and mast cells (3% by acidic toluidine blue staining, 15.2% by flow cytometric assay for binding to high-affinity IgE receptor) and immature cells. This provides an opportunity to examine the kinetics of the acquisition of specialized mature eosinophil characteristics during eosinophil differentiation. Several host-defense and bioactive proteins are found almost exclusively in eosinophil granules. In addition, stimulated eosinophils, like neutrophils, produce copious amounts of toxic oxygen radicals. We used our culture system and the sensitive technique of reverse-transcriptase polymerase chain reaction to analyze the kinetics of production of messenger RNA transcripts encoding several eosinophil proteins, including five eosinophil granule proteins and four subunit peptides of the superoxide-generating reduced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase in small numbers of differentiating eosinophils from peripheral blood CD34(+) cells. Freshly isolated CD34(+) PBPs contained transcripts for the ubiquitously present housekeeping protein phosphoglucokinase but contained no eosinophil granule protein transcripts and barely detectable amounts of some oxidase protein transcripts. On day 3 of culture, no cells recognizable by histochemical staining as eosinophils could be detected, but transcripts for all five eosinophil period. Similar kinetics were seen for all but one of the NADPH oxidase protein transcripts. However, transcripts for the p67(phox) NADPH oxidase protein were not detected until day 7, and functional oxidase activity did not appear until day 12. From that point, oxidase activity increased to the eosinophil lineage occurs very early, by day 3, but that further events in differentiation must take place before the appearance of histologically staining eosinophil granules and acquisition of functional oxidase capacity.	NIAID,HOST DEF LAB,NATL INST HLTH,BETHESDA,MD 20892; NIAID,PARASIT DIS LAB,NATL INST HLTH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)				Malech, Harry/0000-0001-5874-5775				BRUGGER W, 1993, BLOOD, V81, P2579; CASSATELLA MA, 1990, J BIOL CHEM, V265, P20241; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CLUTTERBUCK EJ, 1990, BLOOD, V75, P1774; EMA H, 1990, BLOOD, V76, P1956; FABIAN I, 1992, BLOOD, V80, P788; GABBIANELLI M, 1990, SCIENCE, V249, P1561, DOI 10.1126/science.2218497; GLEICH GJ, 1993, ANNU REV MED, V44, P85, DOI 10.1146/annurev.me.44.020193.000505; GRUART V, 1992, BLOOD, V79, P2592; HANSEL TT, 1991, J IMMUNOL METHODS, V145, P105, DOI 10.1016/0022-1759(91)90315-7; KARP CL, 1993, J CLIN INVEST, V91, P1644, DOI 10.1172/JCI116372; KIRSHENBAUM AS, 1989, J IMMUNOL, V142, P2424; KIRSHENBAUM AS, 1992, J IMMUNOL, V148, P772; LEVY R, 1990, J IMMUNOL, V145, P2595; MALECH HL, 1993, CURR OPIN HEMATOL, V1, P123; NILSSON G, 1993, IMMUNOLOGY, V79, P325; PETRECCIA DC, 1987, J LEUKOCYTE BIOL, V41, P283, DOI 10.1002/jlb.41.4.283; SAAVEDRADELGADO AMP, 1984, AGENTS ACTIONS, V14, P1, DOI 10.1007/BF01966825; SAITO H, 1988, P NATL ACAD SCI USA, V85, P2288, DOI 10.1073/pnas.85.7.2288; SEKHSARIA S, 1993, BLOOD, V81, P2125; SHALIT M, 1995, CELL IMMUNOL, V160, P50, DOI 10.1016/0008-8749(95)80008-7; TEN RM, 1991, CYTOKINE, V3, P350, DOI 10.1016/1043-4666(91)90505-8; WELLER PF, 1991, NEW ENGL J MED, V324, P1110; YAZDANBAKHSH M, 1987, J IMMUNOL, V138, P3443	24	22	22	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1996	98	2					344	354		10.1016/S0091-6749(96)70159-8	http://dx.doi.org/10.1016/S0091-6749(96)70159-8			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VC995	8757212				2022-12-18	WOS:A1996VC99500014
J	MorenoAncillo, A; MartinMunoz, F; MartinBarroso, JA; DiazPena, JM; Ojeda, JA				MorenoAncillo, A; MartinMunoz, F; MartinBarroso, JA; DiazPena, JM; Ojeda, JA			Anaphylaxis to 6-alpha-methylprednisolone in an eight-year-old child	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							CORTICOSTEROIDS; HYDROCORTISONE		HOSP LA PAZ,SERV CHILDHOOD ALLERGY,MADRID,SPAIN	Hospital Universitario La Paz								COOPMAN S, 1989, BRIT J DERMATOL, V121, P27, DOI 10.1111/j.1365-2133.1989.tb01396.x; DAJANI BM, 1981, J ALLERGY CLIN IMMUN, V68, P201, DOI 10.1016/0091-6749(81)90184-6; DOOMSGOOSSENS A, 1992, CONTACT DERMATITIS, V26, P182, DOI 10.1111/j.1600-0536.1992.tb00290.x; MENDELSON LM, 1974, J ALLERGY CLIN IMMUN, V54, P125, DOI 10.1016/0091-6749(74)90049-9; PELLER JS, 1985, ANN ALLERGY, V54, P302; PREUSS L, 1985, ANN ALLERGY, V55, P772; RASANEN L, 1993, BRIT J DERMATOL, V128, P407, DOI 10.1111/j.1365-2133.1993.tb00200.x; SZCZEKLIK A, 1985, J ALLERGY CLIN IMMUN, V76, P530, DOI 10.1016/0091-6749(85)90771-7	8	22	22	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1996	97	5					1169	1171		10.1016/S0091-6749(96)70274-9	http://dx.doi.org/10.1016/S0091-6749(96)70274-9			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	UL261	8626997	Bronze			2022-12-18	WOS:A1996UL26100020
J	SCHULTZ, RK				SCHULTZ, RK			DRUG-DELIVERY CHARACTERISTICS OF METERED-DOSE INHALERS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											SCHULTZ, RK (corresponding author), THREE M CO,PHARMACEUT,INHALAT TECHNOL LAB,ST PAUL,MN 55144, USA.							BALDWIN JL, 1993, J RESPIR DIS, V14, P1222; BERGNER A, 1993, JAMA-J AM MED ASSOC, V269, P1506, DOI 10.1001/jama.269.12.1506; CYR TD, 1991, PHARMACEUT RES, V8, P658, DOI 10.1023/A:1015825311750; KONIG P, 1985, CHEST, V88, P276, DOI 10.1378/chest.88.2.276; PADFIELD JM, 1987, DRUG DELIVERY RESPIR, P75	5	22	27	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1995	96	2					284	287		10.1016/S0091-6749(95)70207-5	http://dx.doi.org/10.1016/S0091-6749(95)70207-5			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RQ001	7636072				2022-12-18	WOS:A1995RQ00100027
J	WHITE, MV				WHITE, MV			MUSCARINIC RECEPTORS IN HUMAN AIRWAYS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						MUSCARINIC; ANTICHOLINERGIC; UPPER AIRWAYS; LOWER AIRWAYS; PHARMACOLOGY; ASTHMA; RHINITIS	HUMAN NASAL-MUCOSA; GUINEA-PIG; AUTORADIOGRAPHIC LOCALIZATION; SMOOTH-MUSCLE; SUBTYPES; CAT; LUNG; BRONCHOCONSTRICTION; METHACHOLINE; STIMULATION	Muscarinic receptors play a double role in airway disorders, mediating an increase in mucus secretion, as well as construction of smooth muscle. Cholinergic activity of the lung is more pronounced in large than in peripheral airways,. in the nose parasympathetic stimulation leads to hypersecretion and vasodilation. This article reviews the differences in muscarinic subreceptors in the upper and lower airways and discusses the effectiveness of anticholinergic agents in blocking parasympathetic stimulation at these sites.			WHITE, MV (corresponding author), INST ASTHMA & ALLERGY,106 IRVING ST NW,SUITE 108,WASHINGTON,DC 20010, USA.							Andersen, 1982, NOSE UPPER AIRWAY PH, P45; ANGGARD A, 1974, ACTA OTO-LARYNGOL, V78, P98, DOI 10.3109/00016487409126332; BARANIUK JN, 1992, AM J RHINOL, V6, P145, DOI 10.2500/105065892781874649; BARANIUK JN, 1990, J CLIN INVEST, V86, P825, DOI 10.1172/JCI114780; BARNES PJ, 1983, AM REV RESPIR DIS, V127, P758; BARNES PJ, 1988, TRENDS PHARMACOL SCI, V9, P412, DOI 10.1016/0165-6147(88)90069-7; BARNES PJ, 1983, AM REV RESPIR DIS, V134, P1289; BARNES PJ, 1987, AM REV RESPIR DIS S, V136, P42; Bonner TI, 1989, TRENDS PHARM SCI S, V10, P11; BORUM P, 1979, J ALLERGY CLIN IMMUN, V63, P253, DOI 10.1016/0091-6749(79)90109-X; BORUM P, 1979, ACTA OTOLARYNGOL S S, V360, P35; BORUM P, 1983, EUR J RESP DIS S, V128, P65; BROFELDT S, 1986, AM REV RESPIR DIS, V133, P1138; BUCKLEY NJ, 1989, MOL PHARMACOL, V35, P469; ECCLES R, 1974, J PHYSIOL-LONDON, V238, P549, DOI 10.1113/jphysiol.1974.sp010542; ECCLES R, 1985, CLIN REV ALLERG, V3, P501; ECCLES R, 1973, J PHYSIOL-LONDON, V230, P213, DOI 10.1113/jphysiol.1973.sp010184; FAULKNER D, 1986, BRIT J PHARMACOL, V88, P181, DOI 10.1111/j.1476-5381.1986.tb09485.x; GADLAGE R, 1975, ARCH OTOLARYNGOL, V101, P422; INGRAM RH, 1977, J CLIN INVEST, V59, P696, DOI 10.1172/JCI108688; KILBINGER H, 1980, NEUROSCIENCE, V5, P1331, DOI 10.1016/0306-4522(80)90205-5; KLASSEN A, 1988, ORL J OTORHINOLARYNG, V50, P32; LAMMERS JWJ, 1989, AM REV RESPIR DIS, V139, P446, DOI 10.1164/ajrccm/139.2.446; LUNDBERG JM, 1981, P NATL ACAD SCI-BIOL, V78, P5255, DOI 10.1073/pnas.78.8.5255; MACLAGAN J, 1989, TRENDS PHARM SCI S, V10, P88; MAK JCW, 1992, AM J RESP CELL MOL, V7, P344, DOI 10.1165/ajrcmb/7.3.344; MAK JCW, 1990, AM REV RESPIR DIS, V141, P1559, DOI 10.1164/ajrccm/141.6.1559; MALM L, 1973, ACTA OTO-LARYNGOL, V76, P277, DOI 10.3109/00016487309121509; MINETTE PA, 1990, AM REV RESPIR DIS, V141, pS162, DOI 10.1164/ajrccm/141.3_Pt_2.S162; MINETTE PAH, 1989, J APPL PHYSIOL, V67, P2461, DOI 10.1152/jappl.1989.67.6.2461; NOMURA Y, 1972, ACTA OTO-LARYNGOL, V73, P493, DOI 10.3109/00016487209138970; OKAYAMA M, 1993, AM J RESP CELL MOL, V8, P176, DOI 10.1165/ajrcmb/8.2.176; RICHARDSON JB, 1979, AM REV RESPIR DIS, V119, P785; WHITE MV, 1993, J ALLERGY CLIN IMMUN, V9, P278; WIDDICOMBE JG, 1990, ASTHAM ITS PATHOLOGY, P327; WIDDOP S, 1993, AM J RESP CELL MOL, V9, P541, DOI 10.1165/ajrcmb/9.5.541	36	22	26	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1995	95	5	2				1065	1068		10.1016/S0091-6749(95)70209-1	http://dx.doi.org/10.1016/S0091-6749(95)70209-1			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QY918	7751523				2022-12-18	WOS:A1995QY91800001
J	THAKUR, BK; MURALI, MR				THAKUR, BK; MURALI, MR			EMLA CREAM-INDUCED ALLERGIC CONTACT-DERMATITIS - A ROLE FOR PRILOCAINE AS AN IMMUNOGEN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note							SENSITIVITY; LIGNOCAINE		SUNY STONY BROOK,HLTH SCI CTR,DIV CLIN IMMUNOL & ALLERGY,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook				Thakur, Barun Kumar/0000-0002-1713-9186				BLACK RJ, 1990, CONTACT DERMATITIS, V23, P117, DOI 10.1111/j.1600-0536.1990.tb03237.x; CURLEY RK, 1986, ARCH DERMATOL, V122, P924, DOI 10.1001/archderm.122.8.924; DEWAARDVANDERSP.FB, 1992, PEDIATR DERMATOL, V9, P126; DUGGAN M, 1993, CONTACT DERMATITIS, V28, P190, DOI 10.1111/j.1600-0536.1993.tb03390.x; PINCELLI C, 1993, DERMATOLOGY, V187, P153, DOI 10.1159/000247232; STOW PJ, 1989, PAIN, V39, P301, DOI 10.1016/0304-3959(89)90044-4; VANDENHOVE J, 1994, CONTACT DERMATITIS, V30, P239, DOI 10.1111/j.1600-0536.1994.tb00652.x; WEHLE B, 1989, SCAND J UROL NEPHROL, V23, P299, DOI 10.3109/00365598909180341	8	22	23	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1995	95	3					776	778		10.1016/S0091-6749(95)70187-7	http://dx.doi.org/10.1016/S0091-6749(95)70187-7			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QM017	7897165				2022-12-18	WOS:A1995QM01700022
J	CALL, RS; WARD, G; JACKSON, S; PLATTSMILLS, TAE				CALL, RS; WARD, G; JACKSON, S; PLATTSMILLS, TAE			INVESTIGATING SEVERE AND FATAL ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						SEVERE ASTHMA; ANTIFUNGAL THERAPY; STEROIDS; ALLERGEN; DERMATOPHYTE	HOUSE DUST MITE; ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; CORTICOSTEROID-DEPENDENT ASTHMA; FEL-D-I; BRONCHIAL HYPERREACTIVITY; TRICHOPHYTON ASTHMA; RISK-FACTORS; CHILDREN; EXPOSURE; ANTIBODIES	Background: Severe asthma continues to present a major therapeutic problem despite advances in our understanding of the disease. Innovative ideas for investigating the underlying causes and treatment of severe asthma are few, and many patients still become dependent on oral steroids. We describe two separate studies: first, a prospective investigation measuring the responses of persons with severe asthma to an allergen-free environment; second, a retrospective analysis of factors associated with eight fatalities and one near fatality caused by asthma exacerbations. Methods: In the prospective study 17 persons with severe asthma were admitted to a hospital clinical research unit containing an allergen-free room for steroid dose reduction. Peak flow measurements treatment requirements, and evidence of infection were followed up. In the retrospective study, the cases of nine patients who had been evaluated for asthma and who subsequently died during an asthma attack were reviewed; where possible allergen levels in their house dust and specific IgE antibodies to common indoor allergens were measured. Results: Analysis of the patients in the prospective study revealed two categories of responses to steroid dose reduction: (1) asthmatic persons who either maintained or improved peak flow values on steroid reduction; these patients were predominantly allergic to indoor allergens; (2) asthmatic persons whose condition deteriorated; these patients were unable to tolerate reduction in steroid dose. The second group included persons with sensitization to fungal antigens who had asthmatic exacerbations in association with culture-documented fungal colonization. The retrospective study revealed that in five of the eight fatalities caused by asthma, exposure to a relevant allergen had occurred at home before death. Conclusion: Some steroid-dependent persons with severe asthma are allergic to inhalant allergens and may benefit from avoiding allergens. In some cases there is no evidence that antigen exposure from diet, inhalants fungal infections, or sinusitis is relevant to their disease. However, persons with severe asthma include individuals infected with and sensitized to fungal antigens. The results suggest that cases of severe asthma should be investigated to identify treatable causes.			CALL, RS (corresponding author), UNIV VIRGINIA, HLTH SCI CTR, CTR ASTHMA & ALLERG DIS, DIV ASTHMA ALLERG DIS & CLIN IMMUNOL, BOX 225, CHARLOTTESVILLE, VA 22908 USA.			Platts-Mills, Thomas/0000-0002-1263-329X	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000847] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020565, R01AI030840, R37AI020565] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-00847] Funding Source: Medline; NIAID NIH HHS [AI-30840, AI-20565] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALEXANDER AG, 1992, LANCET, V339, P324, DOI 10.1016/0140-6736(92)91646-P; ARSHAD SH, 1992, LANCET, V339, P1493, DOI 10.1016/0140-6736(92)91260-F; BALL BD, 1990, ANN ALLERGY, V65, P37; BERNSTEIN DI, 1988, J ALLERGY CLIN IMMUN, V81, P6, DOI 10.1016/0091-6749(88)90213-8; CALL RS, 1992, J PEDIATR-US, V121, P862, DOI 10.1016/S0022-3476(05)80329-4; CHAPMAN MD, 1988, J IMMUNOL, V140, P812; CORRIGAN CJ, 1992, NEW ENGL J MED, V326, P298; DEBLAY F, 1991, AM REV RESPIR DIS, V143, P1334, DOI 10.1164/ajrccm/143.6.1334; DENNING DW, 1991, CHEST, V100, P813, DOI 10.1378/chest.100.3.813; DEUELL B, 1991, J IMMUNOL, V147, P96; EHNERT B, 1992, J ALLERGY CLIN IMMUN, V90, P135, DOI 10.1016/S0091-6749(06)80024-2; FRICK WE, 1988, CLIN CHEST MED, V9, P539; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573, DOI 10.1164/ajrccm/147.3.573; GLEZEN WP, 1984, CLIN CHEST MED, V5, P635; HARGREAVE FE, 1986, EUR J RESPIR DIS, V69, P16; HUBER AL, 1991, JAMA-J AM MED ASSOC, V266, P2225, DOI 10.1001/jama.1991.03470160057032; ITKIN IH, 1970, J ALLERGY, V45, P146, DOI 10.1016/0021-8707(70)90124-3; KERREBIJN KF, 1970, BRONCHITIS, V3; LIU MC, 1991, AM REV RESPIR DIS, V144, P51, DOI 10.1164/ajrccm/144.1.51; LUCZYNSKA CM, 1989, J IMMUNOL METHODS, V118, P227, DOI 10.1016/0022-1759(89)90010-0; MULLARKEY MF, 1990, ANN INTERN MED, V112, P577, DOI 10.7326/0003-4819-112-8-577; MURRAY AB, 1983, PEDIATRICS, V71, P418; NEWMAN LJ, 1994, JAMA-J AM MED ASSOC, V271, P363, DOI 10.1001/jama.271.5.363; OHOLLAREN MT, 1991, NEW ENGL J MED, V324, P359, DOI 10.1056/NEJM199102073240602; PATTERSON R, 1987, J ALLERGY CLIN IMMUN, V80, P663, DOI 10.1016/0091-6749(87)90285-5; PLATTSMILLS TAE, 1982, LANCET, V2, P675; PLATTSMILLS TAE, 1989, J ALLERGY CLIN IMMUN, V83, P416, DOI 10.1016/0091-6749(89)90128-0; POLLART SM, 1989, J ALLERGY CLIN IMMUN, V83, P875, DOI 10.1016/0091-6749(89)90100-0; POLLART SM, 1991, J ALLERGY CLIN IMMUN, V87, P505, DOI 10.1016/0091-6749(91)90009-D; SMITH TF, 1985, J ALLERGY CLIN IMMUN, V76, P782, DOI 10.1016/0091-6749(85)90748-1; SORKNESS CA, 1991, J ALLERGY CLIN IMMUN, V87, pA298; STELZER J, 1986, J APPL PHYSIOL, V60, P1321; WALSHAW MJ, 1986, Q J MED, V58, P199; WARD GW, 1989, LANCET, V1, P859; WARD GW, 1993, J ALLERGY CLIN IMMUN, V91, P226; WEARY PE, 1967, ARCH DERMATOL, V95, P400, DOI 10.1001/archderm.95.4.400; WOOD RA, 1988, AM REV RESPIR DIS, V137, P358, DOI 10.1164/ajrccm/137.2.358; 1991, NIH913042 NAT HEART	38	22	22	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1994	94	6	1				1065	1072		10.1016/0091-6749(94)90125-2	http://dx.doi.org/10.1016/0091-6749(94)90125-2			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PY230	7798539				2022-12-18	WOS:A1994PY23000015
J	KARTASAMITA, CB; ROSMAYUDI, O; DEMEDTS, M				KARTASAMITA, CB; ROSMAYUDI, O; DEMEDTS, M			TOTAL SERUM IGE AND EOSINOPHIL COUNT IN CHILDREN WITH AND WITHOUT A HISTORY OF ASTHMA, WHEEZING, OR ATOPY IN AN URBAN-COMMUNITY IN INDONESIA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						SERUM IGE; EOSINOPHIL COUNT; PARASITE; ATOPY; ASTHMA		Aim: The objectives of the study were to assess total serum IgE and eosinophil count in a random supply of 20% of the children between 12 and 54 months old in a suburban community of Bandung, Indonesia, and to investigate a possible relationship between these values and atopy, asthma or wheezing and parasite infestation. Methods: Two hundred sixty-nine children were examined at the Integrated Primary Health Care Unit, and the parents or guardians were interviewed with the use of a standardized questionnaire. Results: The overall median value of IgE was 436 IU/ml (range, 18 to 9707 IU/ml); almost 94% of the children showed an IgE value of more than 100 IU/ml, and 29% showed a value of more than 1000 IU/ml. The median value for eosinophils was 580/mm(3) (range, 70 to 5090/mm(3)); only 31% of the children had less than 400 eosinophils/mm(3). IgE levels and eosinophilia were not related to age but showed a significant, although not high, correlation with each other (p < 0.05). In about 36% of the children parasites were demonstrated in a single stool sample; in those subjects eosinophilia and IgE values tended to be greater, but the difference was not significant. About 7% of the children had asthma, and in those subject the eosinophil counts and IgE levels were more increased (p < 0.001 and p approximate to 0.01), respectively). No difference was found in IgE or eosinophil count in relation to other forms of atopy in the child (milk-induced dermatitis, urticaria, eczema, rhinitis) or in relation to a history of asthma or atopy in other family members. Yet, the occurrence of asthma in the child was significantly related to a history of asthma in other family members. Conclusions: IgE values and eosinophilia are markedly increased in these children under 5 years of age in Bandung, Indonesia, and the highest values are found in the 7% with asthma.	CATHOLIC UNIV LEUVEN, FAC MED, PNEUMOL LAB, LOUVAIN, BELGIUM; PADJADJARAN STATE UNIV, FAC MED, BANDUNG, INDONESIA	KU Leuven; Universitas Padjadjaran								BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; CHAERULFATAH A, 1986, ASIAN PAEDIATRIC FED; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; GLEICH GJ, 1990, J ALLERGY CLIN IMMUN, V85, P422, DOI 10.1016/0091-6749(90)90151-S; JOHANSSON SG, 1968, LANCET, V1, P1118; KARTASASMITA CB, 1993, THESIS CATHOLIC U LE; KLINK M, 1990, J ALLERGY CLIN IMMUN, V85, P440, DOI 10.1016/0091-6749(90)90153-U; LUBIS A, 1985, MEDIKA, V6, P528; NINAN TK, 1992, BRIT MED J, V304, P873, DOI 10.1136/bmj.304.6831.873; ROBERTS TE, 1990, ALLERGY TODAY S1, V3, P1; SANTOSO H, 1984, MAJALAH KEDOKTERAN I, V34, P731; SEARS MR, 1991, NEW ENGL J MED, V325, P1067, DOI 10.1056/NEJM199110103251504; TURNER KJ, 1989, CIBA F SYMP, V147, P205; VANARSDEL PP, 1989, ANN INTERN MED, V110, P304, DOI 10.7326/0003-4819-110-4-304; VERSTRAETE M, 1989, DIAGNOSTISCHE THERAP; VONMUTIUS E, 1992, BMJ-BRIT MED J, V305, P1395, DOI 10.1136/bmj.305.6866.1395; WILSON NW, 1988, ANN ALLERGY, V61, P323; WING J S, 1991, American Review of Respiratory Disease, V143, pA272; 1983, MEASURING CHANGE NUT	19	22	23	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1994	94	6	1				981	988		10.1016/0091-6749(94)90116-3	http://dx.doi.org/10.1016/0091-6749(94)90116-3			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PY230	7798546				2022-12-18	WOS:A1994PY23000006
J	GAUTRIN, D; VANDENPLAS, O; DEWITTE, JD; LARCHEVEQUE, J; LEBLANC, C; TRUDEAU, C; PAULIN, C; ARNOUD, D; MORAND, S; COMTOIS, P; MALO, JL				GAUTRIN, D; VANDENPLAS, O; DEWITTE, JD; LARCHEVEQUE, J; LEBLANC, C; TRUDEAU, C; PAULIN, C; ARNOUD, D; MORAND, S; COMTOIS, P; MALO, JL			ALLERGENIC EXPOSURE, IGE-MEDIATED SENSITIZATION, AND RELATED SYMPTOMS IN LAWN CUTTERS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ENVIRONMENT; OCCUPATIONAL DISEASES; RHINITIS; ASTHMA	DUST; ASTHMA; MITE; QUESTIONNAIRE; POPULATION; DURATION	Aims: The aims of the study conducted on lawn cutters were: (I) to evaluate exposure to pollens and molds; and (2) to assess the prevalence rate of IgE sensitization and symptoms in I elation to exposure to pollens and molds. Methods: Environmental assessment was done with the we of personal samplers on eight workers. Our population consisted of Ist municipal park workers including 128 lawn cutters and 67 control subjects (blue-collar workers in the hospital). A questionnaire was administered as well as skin prick tests with seven common inhalants including pollens and eight gr ass molds. The main outcome variables were grass or mold sensitization (at least one of eight molds) and work-related rhinitis, conjunctivitis, and rhinoconjunctivitis. Atopy and exposure to park-related allergens, as well as sensitization to grass pollens, were considered as explanatory factors. Smoking was taken into consideration as a covariant. Both presence and duration of occupational exposure to park-related allergens were considered as parameters of exposure. Duration of exposure (months x years of exposure as lawn cutters) was used as a continuous or as a categorical variable. Results: Environmental monitoring showed that the concentration of pollens and molds decreased in magnitude from samples collected close to lawn cutters faces, short distance away in parks, and in the general environment. There was no difference in the prevalence rates for atopy between lawn cutters (32%) and control subjects (37%). Sensitization rates to grass pollen were also similar in lawn cutters (18%) and in control subjects (22%). However, there was a tendency for prevalence rates of sensitization to molds to be greater among lawn cutters (12% to Alternaria) compared with control subjects (5%). In the logistic model atopy was significantly related to grass sensitization (odds ratio [OR] = 7.2), mold sensitization (OR = 9.3), and sensitization to Alternaria (OR = 5.8). Grass sensitization was a significant risk factor for park-related rhinitis (OR = 5.8), conjunctivitis (OR = 5.0), and rhinoconjunctivitis (OR = 9.4). Exposure for 12 years or more was associated with rhinoconjunctivitis with an OR of 4.1 (95% confidence interval, 1.0-16.7). Smoking was not significantly related to any outcome. Conclusion: We conclude that among lawn cutters exposure to pollens and molds is higher than in the general population, atopy is the main determinant of sensitization to these aeroallergens, and sensitization and, to a much lesser extent, exposure to grass are determinants of symptoms.	HOP SACRE COEUR, DEPT CHEST MED, MONTREAL H4J 1C5, PQ, CANADA; UNIV MONTREAL, DEPT GEOG, MONTREAL H3C 3J7, PQ, CANADA	Universite de Montreal; Universite de Montreal								BARBEE RA, 1987, J ALLERGY CLIN IMMUN, V79, P16, DOI 10.1016/S0091-6749(87)80010-6; BLUMENTHAL MN, 1986, J ALLERGY CLIN IMMUN, V78, P962, DOI 10.1016/0091-6749(86)90286-1; BURGE HA, 1982, J ALLERGY CLIN IMMUN, V70, P101, DOI 10.1016/0091-6749(82)90236-6; BURNEY PGJ, 1989, EUR RESPIR J, V2, P940; BURNEY PGJ, 1989, INT J EPIDEMIOL, V18, P165, DOI 10.1093/ije/18.1.165; DESJARDINS A, 1993, J ALLERGY CLIN IMMUN, V91, P979, DOI 10.1016/0091-6749(93)90210-7; DOWSE GK, 1985, J ALLERGY CLIN IMMUN, V75, P75, DOI 10.1016/0091-6749(85)90016-8; ERNST P, 1989, THORAX, V44, P116, DOI 10.1136/thx.44.2.116; HAGY GW, 1971, J ALLERGY CLIN IMMUN, V48, P200, DOI 10.1016/0091-6749(71)90066-2; KORSGAARD J, 1983, AM REV RESPIR DIS, V128, P231; LAU S, 1989, J ALLERGY CLIN IMMUN, V84, P718, DOI 10.1016/0091-6749(89)90300-X; MCDONALD JL, 1975, J ALLERGY CLIN IMMUN, V55, P89; MUSK AW, 1989, BRIT J IND MED, V46, P636; PEPYS J, 1973, CLIN ALLERGY, V3, P491, DOI 10.1111/j.1365-2222.1973.tb03057.x; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V79, P781, DOI 10.1016/0091-6749(87)90211-9; SCHWARTZ B, 1987, INT ARCH ALLER A IMM, V82, P447, DOI 10.1159/000234250; SOLOMON WR, 1984, J ALLERGY CLIN IMMUN, V74, P449, DOI 10.1016/0091-6749(84)90376-2; SWANSON MC, 1991, J ALLERGY CLIN IMMUN, V87, P783, DOI 10.1016/0091-6749(91)90123-6; VEDAL S, 1986, ARCH ENVIRON HEALTH, V41, P179, DOI 10.1080/00039896.1986.9935774; [No title captured]	20	22	22	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1994	93	2					437	445		10.1016/0091-6749(94)90352-2	http://dx.doi.org/10.1016/0091-6749(94)90352-2			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MY581	8120271				2022-12-18	WOS:A1994MY58100004
J	NORMAN, PS; OHMAN, JL; LONG, AA; CRETICOS, PS; SHAKED, Z; WOOD, RA; EGGLESTON, PA; JONES, NH; NICODEMUS, CF				NORMAN, PS; OHMAN, JL; LONG, AA; CRETICOS, PS; SHAKED, Z; WOOD, RA; EGGLESTON, PA; JONES, NH; NICODEMUS, CF			EARLY CLINICAL-EXPERIENCE WITH T-CELL REACTIVE PEPTIDES FROM CAT ALLERGEN FEL D1	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	22	22	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1994	93	1	2				231	231						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MV317					2022-12-18	WOS:A1994MV31700411
